PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	CROSSLEY, M; TSANG, AP; BIEKER, JJ; ORKIN, SH				CROSSLEY, M; TSANG, AP; BIEKER, JJ; ORKIN, SH			REGULATION OF THE ERYTHROID KRUPPEL-LIKE FACTOR (EKLF) GENE PROMOTER BY THE ERYTHROID TRANSCRIPTION FACTOR GATA-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOX-BINDING-PROTEINS; DNA-BINDING; GLOBIN GENE; POSITIVE REGULATOR; MAMMALIAN-CELLS; CACCC ELEMENT; EXPRESSION; FAMILY; MOUSE; DIFFERENTIATION	Erythroid Kruppel-like factor (EKLF) is an erythroid-specific transcription factor that binds a CACCC motif found in the human beta-globin gene promoter. We have studied the promoter of the EKLF gene and identified binding sites for the transcription factors GATA-1 and CCAAT-binding Protein 1 (CP1). We show that both types of binding sites are required for full activity, and that the GATA motif at -60 is essential. The EKLF promoter can be directly activated in nonerythroid cells in col transfection experiments by forced expression of GATA-1. These results suggest that EKLF is dependent on GATA-1 for its expression and lies downsteam of, or coincident with, GATA-1 in a regulatory hierarchy in erythroid development.	HARVARD UNIV,CHILDRENS HOSP,SCH MED,DANA FARBER CANC INST,DEPT PEDIAT,DIV HEMATOL ONCOL,BOSTON,MA 02115; HOWARD HUGHES MED INST,NEW YORK,NY 10029; CUNY MT SINAI SCH MED,BROOKDALE CTR MOLEC BIOL,NEW YORK,NY 10029; CUNY MT SINAI SCH MED,DEPT BIOCHEM,NEW YORK,NY 10029	Harvard University; Boston Children's Hospital; Dana-Farber Cancer Institute; Harvard Medical School; Howard Hughes Medical Institute; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai			Crossley, Merlin/D-7888-2011	Crossley, Merlin/0000-0003-2057-3642				ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; APLAN PD, 1992, EMBO J, V11, P4073, DOI 10.1002/j.1460-2075.1992.tb05500.x; CROSSLEY M, 1990, NATURE, V345, P444, DOI 10.1038/345444a0; DAVIDSON I, 1988, CELL, V54, P931, DOI 10.1016/0092-8674(88)90108-0; DAYLOT N, 1993, NUCLEIC ACIDS RES, V21, P4031; DORFMAN DM, 1992, J BIOL CHEM, V267, P1279; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; EVANS T, 1989, CELL, V58, P877, DOI 10.1016/0092-8674(89)90940-9; FENG WC, 1994, J BIOL CHEM, V269, P1492; HARTZOG GA, 1993, MOL CELL BIOL, V13, P44, DOI 10.1128/MCB.13.1.44; KO LJ, 1993, MOL CELL BIOL, V13, P4011, DOI 10.1128/MCB.13.7.4011; MACLEOD K, 1991, MOL CELL BIOL, V11, P4324, DOI 10.1128/MCB.11.9.4324; MARTIN DIK, 1990, GENE DEV, V4, P1886, DOI 10.1101/gad.4.11.1886; Maxam A M, 1980, Methods Enzymol, V65, P499; MERIKA M, 1993, MOL CELL BIOL, V13, P3999, DOI 10.1128/MCB.13.7.3999; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; NISHIOKA Y, 1979, CELL, V18, P875, DOI 10.1016/0092-8674(79)90139-9; ORKIN SH, 1992, BLOOD, V80, P575; RAYMONDJEAN M, 1988, P NATL ACAD SCI USA, V85, P757, DOI 10.1073/pnas.85.3.757; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; SHEN SH, 1981, CELL, V26, P191, DOI 10.1016/0092-8674(81)90302-0; SPOSI NM, 1992, P NATL ACAD SCI USA, V89, P6353, DOI 10.1073/pnas.89.14.6353; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; TSAI SF, 1991, GENE DEV, V5, P919, DOI 10.1101/gad.5.6.919; VANHUIJSDUIJNEN RH, 1990, EMBO J, V9, P3119, DOI 10.1002/j.1460-2075.1990.tb07509.x; WATT P, 1990, NUCLEIC ACIDS RES, V18, P1339, DOI 10.1093/nar/18.6.1339; YAMAMOTO M, 1990, GENE DEV, V4, P1650, DOI 10.1101/gad.4.10.1650	30	101	103	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15440	15444						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	8195185				2022-12-25	WOS:A1994NP51300010
J	DMELLO, NP; CHILDRESS, AM; FRANKLIN, DS; KALE, SP; PINSWASDI, C; JAZWINSKI, SM				DMELLO, NP; CHILDRESS, AM; FRANKLIN, DS; KALE, SP; PINSWASDI, C; JAZWINSKI, SM			CLONING AND CHARACTERIZATION OF LAG1, A LONGEVITY-ASSURANCE GENE IN YEAST	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-DIPLOID FIBROBLASTS; SACCHAROMYCES-CEREVISIAE; LIFE-SPAN; DROSOPHILA-MELANOGASTER; MESSENGER-RNAS; PLASMID DNA; CELL-CYCLE; SENESCENCE; PROTEINS; MEMBRANE	The yeast Saccharomyces cerevisiae has a finite life span that is measured by the number of times the individual cell divides. The gene coding for one of several transcripts that are differentially expressed during the replicative life span has been cloned. The nucleotide sequence revealed an open reading frame capable of encoding a transmembrane protein of 411 amino acids that displays no significant similarities to any known proteins. Nevertheless, sequences similar to this gene were found in several mammals, including humans. The transcript levels decreased with replicative age of yeast cells. A gene deletion in haploid eels resulted in a pronounced increase (approximately 50%) in mean and in maximum life span. These results indicate that this gene, which we call LAG1, plays a role in determining yeast longevity.	LOUISIANA STATE UNIV,MED CTR,DEPT BIOCHEM & MOLEC BIOL,NEW ORLEANS,LA 70112; LOUISIANA STATE UNIV,MED CTR,CTR AGING,NEW ORLEANS,LA 70112	Louisiana State University System; Louisiana State University System								ANDREWS BJ, 1992, NATURE, V355, P393, DOI 10.1038/355393a0; ARCANGIOLI B, 1985, EMBO J, V4, P2627, DOI 10.1002/j.1460-2075.1985.tb03980.x; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BAIROCH A, 1993, NUCLEIC ACIDS RES, V21, P3997; BENNETZEN JL, 1982, J BIOL CHEM, V257, P3926; CHEN JB, 1990, MOL MICROBIOL, V4, P2081, DOI 10.1111/j.1365-2958.1990.tb00568.x; EGILMEZ NK, 1989, J BACTERIOL, V171, P37, DOI 10.1128/jb.171.1.37-42.1989; EGILMEZ NK, 1990, J GERONTOL, V45, pB9, DOI 10.1093/geronj/45.1.B9; EGILMEZ NK, 1989, J BIOL CHEM, V264, P14312; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; Finch CE, 1990, LONGEVITY SENESCENCE; FRIEDMAN DB, 1988, GENETICS, V118, P75; GAVEL Y, 1990, PROTEIN ENG, V4, P33, DOI 10.1093/protein/4.1.33; Guthrie C, 1991, GUIDE YEAST GENETICS; HAMILTON R, 1987, NUCLEIC ACIDS RES, V15, P3581, DOI 10.1093/nar/15.8.3581; HINNEBUSCH AG, 1983, P NATL ACAD SCI-BIOL, V80, P5374, DOI 10.1073/pnas.80.17.5374; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JAZWINSKI SM, 1990, MOL MICROBIOL, V4, P337, DOI 10.1111/j.1365-2958.1990.tb00601.x; JAZWINSKI SM, 1982, P NATL ACAD SCI-BIOL, V79, P3428, DOI 10.1073/pnas.79.11.3428; JOHNSON TE, 1987, P NATL ACAD SCI USA, V84, P3777, DOI 10.1073/pnas.84.11.3777; JOHNSTON RF, 1990, ELECTROPHORESIS, V11, P355, DOI 10.1002/elps.1150110503; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LUCKINBILL LS, 1984, EVOLUTION, V38, P996, DOI 10.1111/j.1558-5646.1984.tb00369.x; LUMPKIN CK, 1986, SCIENCE, V232, P393, DOI 10.1126/science.2421407; MORTIMER RK, 1959, NATURE, V183, P1751, DOI 10.1038/1831751a0; MULLER I, 1980, MECH AGEING DEV, V12, P47, DOI 10.1016/0047-6374(80)90028-7; NASMYTH KA, 1980, P NATL ACAD SCI-BIOL, V77, P2119, DOI 10.1073/pnas.77.4.2119; PILLUS L, 1989, CELL, V59, P637, DOI 10.1016/0092-8674(89)90009-3; RAO JKM, 1986, BIOCHIM BIOPHYS ACTA, V869, P197, DOI 10.1016/0167-4838(86)90295-5; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; ROSE MR, 1984, EVOLUTION, V38, P1004, DOI 10.1111/j.1558-5646.1984.tb00370.x; Sacher G. A., 1978, The genetics of aging., P151; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sherman F., 1986, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P9; STRUHL K, 1985, NUCLEIC ACIDS RES, V13, P8578; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WRIGHT WE, 1989, MOL CELL BIOL, V9, P3088, DOI 10.1128/MCB.9.7.3088; ZARET KS, 1982, CELL, V28, P563, DOI 10.1016/0092-8674(82)90211-2	41	187	195	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15451	15459						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	8195187				2022-12-25	WOS:A1994NP51300012
J	REDDY, ST; HERSCHMAN, HR				REDDY, ST; HERSCHMAN, HR			LIGAND-INDUCED PROSTAGLANDIN SYNTHESIS REQUIRES EXPRESSION OF THE TIS10/PGS-2 PROSTAGLANDIN SYNTHASE GENE IN MURINE FIBROBLASTS AND MACROPHAGES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SWISS 3T3 CELLS; MITOGEN-INDUCIBLE CYCLOOXYGENASE; ENDOPEROXIDE SYNTHASE; 5-LIPOXYGENASE-ACTIVATING PROTEIN; LEUKOTRIENE SYNTHESIS; ARACHIDONIC-ACID; DEXAMETHASONE; RELEASE; TIS10	Phospholipase activation has been considered rate-limiting for ligand-stimulated prostaglandin (PG) synthesis. Constitutive prostaglandin synthase EC 1.14.99.1 (PGS-1) has been thought to convert arachidonate released following ligand stimulation to PGH(2). However, a second prostaglandin synthase, TIS10/PGS-2, is inducible in many cell types, including fibroblasts and macrophages. We have used antisense oligonucleotide inhibition of TIS10/PGS-2 induction to investigate the role of this enzyme in ligand-induced prostaglandin production in fibroblasts and macrophages. Antisense TIS10/ PGS-2 oligonucleotides block mitogen-induced prostaglandin production and TIS10/PGS-2 protein synthesis in both Swiss 3T3 cells and murine embryo fibroblast cultures, without inhibiting either constitutive PGS-1 activity or mitogen stimulated arachidonic acid release. TIS10/PGS-2 antisense oligonucleotides also block production of PGE(2) from endogenous arachidonate following endotoxin stimulation of both RAW 264.7 macrophage cells and murine peritoneal macrophages. In contrast, the constitutive prostaglandin synthase present in macrophages is unable to convert arachidonate released following endotoxin stimulation into prostaglandin. TIS10/PGS-2 expression is necessary for both mitogen-induced prostaglandin production in murine fibroblasts and endotoxin-induced prostaglandin synthesis in macrophages. PGS-1 present in these cells cannot utilize arachidonic acid released in response to mitogen or endotoxin stimulation.	UNIV CALIF LOS ANGELES,CTR HLTH SCI,DEPT BIOL CHEM,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,CTR HLTH SCI,STRUCT BIOL & MOLEC MED LAB,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024797] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM24797] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARBOUR SE, 1993, J BIOL CHEM, V268, P21862; BENAV P, 1989, FEBS LETT, V259, P64, DOI 10.1016/0014-5793(89)81495-4; BUTLERGRALLA E, 1983, BIOCHEM BIOPH RES CO, V111, P194, DOI 10.1016/S0006-291X(83)80135-1; DEWITT DL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P121, DOI 10.1016/0005-2760(91)90032-D; DIXON RAF, 1990, NATURE, V343, P282, DOI 10.1038/343282a0; FREEMAN CP, 1966, J LIPID RES, V7, P324; GILBERT RS, 1994, J CELL PHYSIOL, V159, P67, DOI 10.1002/jcp.1041590110; HABENICHT AJR, 1985, ADV PROSTAG THROMB L, V13, P37; HABIB A, 1993, J BIOL CHEM, V268, P23448; HAMASAKI Y, 1993, ARCH BIOCHEM BIOPHYS, V304, P226, DOI 10.1006/abbi.1993.1343; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; KUJUBU DA, 1993, J BIOL CHEM, V268, P5425; KUJUBU DA, 1992, J BIOL CHEM, V267, P7991; LEE SH, 1992, J BIOL CHEM, V267, P25934; MASFERRER JL, 1990, J CLIN INVEST, V86, P1375, DOI 10.1172/JCI114850; MEADE EA, 1993, J BIOL CHEM, V268, P6610; MILLER DK, 1990, NATURE, V343, P278, DOI 10.1038/343278a0; OBANNION MK, 1991, J BIOL CHEM, V267, P23261; REDDY ST, 1994, J LEUKOCYTE BIOL, V55, P192, DOI 10.1002/jlb.55.2.192; REGIER MK, 1993, ARCH BIOCHEM BIOPHYS, V301, P439, DOI 10.1006/abbi.1993.1168; REID GK, 1990, J BIOL CHEM, V265, P19818; Rudnicki M.A., 1987, TERATOCARCINOMAS EMB; RYSECK RP, 1992, CELL GROWTH DIFFER, V3, P433; SIROIS J, 1992, J BIOL CHEM, V267, P6382; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692; YAMAGATA K, 1993, NEURON, V11, P371, DOI 10.1016/0896-6273(93)90192-T	26	249	251	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15473	15480						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	8195190				2022-12-25	WOS:A1994NP51300015
J	ZHEN, Z; GIORDANO, S; LONGATI, P; MEDICO, E; CAMPIGLIO, M; COMOGLIO, PM				ZHEN, Z; GIORDANO, S; LONGATI, P; MEDICO, E; CAMPIGLIO, M; COMOGLIO, PM			STRUCTURAL AND FUNCTIONAL DOMAINS CRITICAL FOR CONSTITUTIVE ACTIVATION OF THE HGF-RECEPTOR (MET)	ONCOGENE			English	Article							HEPATOCYTE GROWTH-FACTOR; SCATTER FACTOR-RECEPTOR; C-MET; TYROSINE KINASE; EPITHELIAL-CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; ONCOGENIC REARRANGEMENT; THYROID CARCINOMAS; TPR; PROTOONCOGENE	The MET gene, encoding the tyrosine kinase receptor for Hepatocyte Growth Factor, is a potentially harmful oncogene overexpressed ina significant fraction of human cancers. To study the molecular mechanisms responsible for oncogenic activation, the biochemical and biological properties of a number of MET constructs were analysed. The native heterodimeric receptor (alpha beta), the beta chain alone, as well as a kinase defective mutant did not transform rodent fibroblasts upon transfection. The cytoplasmic domain, truncated immediately below the transmembrane region, acquired constitutive tyrosine kinase activity in vivo, produced foci of transformation, and was tumorigenic in nude mice. Removal of the first 39 amino acids of the juxtamembrane domain resulted in loss of constitutive activation in vivo and transforming potential, without impairment of the in vitro kinase activity. Replacement of the juxtamembrane domain with 5' TPR sequences restored constitutive kinase activation and transforming properties. Site-directed mutagenesis of either of the two tyrosine residues involved in the positive regulation of the catalytic activity upon phosphorylation (Y-1234 or Y-1235 in the kinase domain of the HGF receptor), strongly impaired TPR-MET transforming potential. These data show that: (1) the truncated cytoplasmic HGF receptor has constitutive kinase activity and is oncogenic; (2) the first 39 amino acids of the juxtamembrane domain and (3) the regulatory tyrosines in the catalytic domain are required to unleash its transforming potential.	UNIV TURIN,SCH MED,DEPT BIOMED SCI & ONCOL,TURIN,ITALY; NATL CANC INST,DEPT EXPTL ONCOL E,MILAN,ITALY	University of Turin; Fondazione IRCCS Istituto Nazionale Tumori Milan			Giordano, Silvia/J-9858-2018; Medico, Enzo/AAC-3185-2021	Giordano, Silvia/0000-0003-1854-1086; Medico, Enzo/0000-0002-3917-2438; Comoglio, Paolo/0000-0002-7056-5328				BARDELLI A, 1992, ONCOGENE, V7, P1973; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; CAPETANAKI Y, 1990, ONCOGENE, V5, P645; COCHET C, 1988, J BIOL CHEM, V263, P3290; COMOGLIO PM, 1984, EMBO J, V3, P483, DOI 10.1002/j.1460-2075.1984.tb01834.x; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; DEAN M, 1987, MOL CELL BIOL, V7, P921, DOI 10.1128/MCB.7.2.921; DIFIORE PP, 1992, EMBO J, V11, P3927, DOI 10.1002/j.1460-2075.1992.tb05486.x; DIRENZO MF, 1991, ONCOGENE, V6, P1997; DIRENZO MF, 1992, ONCOGENE, V7, P2549; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; FERRACINI R, 1991, J BIOL CHEM, V266, P19558; GANDINO L, 1991, J BIOL CHEM, V266, P16098; GANDINO L, 1994, J BIOL CHEM, V269, P1815; GANDINO L, 1990, ONCOGENE, V5, P721; GIORDANO S, 1989, ONCOGENE, V4, P1383; GIORDANO S, 1993, P NATL ACAD SCI USA, V90, P649, DOI 10.1073/pnas.90.2.649; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; GONZATTIHACES M, 1988, P NATL ACAD SCI USA, V85, P21, DOI 10.1073/pnas.85.1.21; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; GRAZIANI A, 1993, J BIOL CHEM, V268, P9165; GRECO A, 1992, ONCOGENE, V7, P237; GREENFIELD C, 1989, EMBO J, V8, P4115, DOI 10.1002/j.1460-2075.1989.tb08596.x; HAMMACHER A, 1989, EMBO J, V8, P2489, DOI 10.1002/j.1460-2075.1989.tb08385.x; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; KHAZAIE K, 1988, EMBO J, V7, P3061, DOI 10.1002/j.1460-2075.1988.tb03171.x; KING HWS, 1988, ONCOGENE, V2, P617; LIU C, 1992, ONCOGENE, V7, P181; LONGATI P, 1994, ONCOGENE, V9, P49; MICHELIN S, 1993, ONCOGENE, V8, P1983; MITCHELL PJ, 1992, ONCOGENE, V7, P383; MITCHELL PJ, 1992, ONCOGENE, V7, P2329; MONDINO A, 1991, MOL CELL BIOL, V11, P6084, DOI 10.1128/MCB.11.12.6084; MONTESANO R, 1991, CELL, V66, P697, DOI 10.1016/0092-8674(91)90115-F; MORUZZI EV, 1993, J BIOL CHEM, V268, P18176; NALDINI L, 1991, MOL CELL BIOL, V11, P1793, DOI 10.1128/MCB.11.4.1793; NALDINI L, 1991, ONCOGENE, V6, P501; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; NATALI PG, 1993, BRIT J CANCER, V68, P746, DOI 10.1038/bjc.1993.422; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; PONZETTO C, 1993, MOL CELL BIOL, V13, P4600, DOI 10.1128/MCB.13.8.4600; PONZETTO C, 1991, ONCOGENE, V6, P553; PONZETTO C, 1994, IN PRESS CELL; PRAT M, 1991, INT J CANCER, V49, P323, DOI 10.1002/ijc.2910490302; QUI F, 1988, EMBO J, V7, P1003; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; SEGATTO O, 1991, MOL CELL BIOL, V11, P3191, DOI 10.1128/MCB.11.6.3191; SEIFERT RA, 1989, J BIOL CHEM, V264, P8771; SHOELSON SE, 1988, J BIOL CHEM, V263, P4852; SNYDER MA, 1985, MOL CELL BIOL, V5, P1772, DOI 10.1128/MCB.5.7.1772; SOMAN NR, 1991, P NATL ACAD SCI USA, V88, P4892, DOI 10.1073/pnas.88.11.4892; SOMAN NR, 1990, P NATL ACAD SCI USA, V87, P738, DOI 10.1073/pnas.87.2.738; TEMPEST PR, 1986, CARCINOGENESIS, V7, P2051, DOI 10.1093/carcin/7.12.2051; UEHARA Y, 1992, J CELL BIOL, V117, P889, DOI 10.1083/jcb.117.4.889; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1443, DOI 10.1021/bi00379a035; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1434, DOI 10.1021/bi00379a034	61	63	76	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1994	9	6					1691	1697						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NL815	8183564				2022-12-25	WOS:A1994NL81500021
J	RAPAPORT, D; SHAI, Y				RAPAPORT, D; SHAI, Y			INTERACTION OF FLUORESCENTLY LABELED ANALOGS OF THE AMINO-TERMINAL FUSION PEPTIDE OF SENDAI VIRUS WITH PHOSPHOLIPID-MEMBRANES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARTIFICIAL LIPID-MEMBRANES; INFLUENZA-VIRUS; ENERGY-TRANSFER; DEPENDENT FUSION; PARDAXIN ANALOGS; N-TERMINUS; PROTEIN; HEMAGGLUTININ; VESICLES; GLYCOPROTEIN	A peptide representing the NH2-terminal (33 amino acid residues) of the fusion protein (F) of Sendai virus, as well as its Gly(12) --> Ala(12) mutant, were synthesized, fluorescently labeled, and spectroscopically and functionally characterized. Peptide-induced vesicle fusion was demonstrated by a combination of increased visible absorbance, lipid mixing assay, and electron microscopy. Both peptides, with the mutant peptide being significantly more potent, were shown to induce membrane fusion and bilayer perturbation of negatively charged phospholipid vesicles. These results are consistent with a previous study that showed that a similar mutation in the homologous NH2-terminal segment of simian virus 5 greatly enhanced syncytium formation (Horvath, C. M., and Lamb, R. A. (1992) J. Virol. 66, 2443-2455). Circular dichroism spectroscopy revealed similar high alpha-helical contents of both peptides in methanol and in trifluoroethanol. Using fluorescently labeled peptide analogues we found that (i) the peptides' membrane partition coefficients are in the range of 10(5) M(-1); (ii) the NH2 terminus of the wild-type peptide is located within the lipid bilayer, whereas that of the variant peptide lies on the surface; and (iii) both peptides tend to self-associate in their membrane-bound state. The results support a model in which an alpha-helical secondary structure and self-aggregation of peptides are necessary conditions for membrane fusion. The observed differences in the peptides' fusogenic abilities are hypothesized to result from differences in the peptides' degree of penetration into the membrane, induction of membrane destabilization, and ability to cause vesicles to aggregate. The data support Sendai virus-cell fusion models in which the fusion peptide plays a crucial role in fusion induction by destabilizing the bilayer and by triggering the association of viral fusion protein molecules.	WEIZMANN INST SCI, DEPT MEMBRANE RES & BIOPHYS, IL-76100 REHOVOT, ISRAEL	Weizmann Institute of Science								BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BESCHIASCHVILI G, 1990, BIOCHEMISTRY-US, V29, P52, DOI 10.1021/bi00453a007; BLUMBERG BM, 1985, J GEN VIROL, V66, P317, DOI 10.1099/0022-1317-66-2-317; BLUMENTHAL R, 1987, CURR TOP MEMBR TRANS, V29, P203; BOSCH ML, 1989, SCIENCE, V244, P694, DOI 10.1126/science.2541505; BURGER KNJ, 1991, BIOCHIM BIOPHYS ACTA, V1065, P121, DOI 10.1016/0005-2736(91)90221-S; CHOPPIN PW, 1980, REV INFECT DIS, V2, P40; CRANE SE, 1991, VIROLOGY, V185, P488, DOI 10.1016/0042-6822(91)90805-L; DUZGUNES N, 1992, J MEMBRANE BIOL, V128, P71, DOI 10.1007/BF00231872; FREED EO, 1990, P NATL ACAD SCI USA, V87, P4650, DOI 10.1073/pnas.87.12.4650; FREED EO, 1992, P NATL ACAD SCI USA, V89, P70, DOI 10.1073/pnas.89.1.70; GAZIT E, 1993, BIOCHEMISTRY-US, V32, P12363, DOI 10.1021/bi00097a013; GETHING MJ, 1978, P NATL ACAD SCI USA, V75, P2737, DOI 10.1073/pnas.75.6.2737; GETHING MJ, 1986, J CELL BIOL, V102, P11, DOI 10.1083/jcb.102.1.11; GLUSHAKOVA SE, 1992, BIOCHIM BIOPHYS ACTA, V1110, P202, DOI 10.1016/0005-2736(92)90360-X; HOEKSTRA D, 1990, J BIOENERG BIOMEMBR, V22, P121, DOI 10.1007/BF00762943; HORVATH CM, 1992, J VIROL, V66, P2443, DOI 10.1128/JVI.66.4.2443-2455.1992; HSU MC, 1981, J BIOL CHEM, V256, P3557; LEAR JD, 1987, J BIOL CHEM, V262, P6500; LEE S, 1992, BIOCHIM BIOPHYS ACTA, V1103, P157, DOI 10.1016/0005-2736(92)90069-X; LELKES PI, 1984, LIPOSOME TECHNOLOGY, V1, P37; LI SC, 1992, INT J PEPT PROT RES, V40, P243; LOEW LM, 1983, BIOCHEMISTRY-US, V22, P837, DOI 10.1021/bi00273a020; LUCY JA, 1982, BIOL MEMBR, V4, P367; MARTIN I, 1991, BIOCHEM BIOPH RES CO, V175, P872, DOI 10.1016/0006-291X(91)91646-T; MERRIFIELD RB, 1982, BIOCHEMISTRY-US, V21, P5020, DOI 10.1021/bi00263a028; MURATA M, 1991, BIOCHEM BIOPH RES CO, V179, P1050, DOI 10.1016/0006-291X(91)91925-3; MURATA M, 1987, BIOCHEMISTRY-US, V26, P4056, DOI 10.1021/bi00387a047; NIR S, 1980, BIOCHEMISTRY-US, V19, P6030, DOI 10.1021/bi00567a013; NOVICK SL, 1988, P NATL ACAD SCI USA, V85, P7433, DOI 10.1073/pnas.85.20.7433; PARENTE RA, 1988, J BIOL CHEM, V263, P4724; POUNY Y, 1992, BIOCHEMISTRY-US, V31, P12416, DOI 10.1021/bi00164a017; RAFALSKI M, 1990, BIOCHEMISTRY-US, V29, P7917, DOI 10.1021/bi00486a020; RAFALSKI M, 1991, BIOCHEMISTRY-US, V30, P10211, DOI 10.1021/bi00106a020; RAJARATHNAM K, 1989, BIOCHEMISTRY-US, V28, P3168, DOI 10.1021/bi00434a009; RAPAPORT D, 1991, J BIOL CHEM, V266, P23769; RAPAPORT D, 1992, BIOCHEMISTRY-US, V31, P8868, DOI 10.1021/bi00152a025; RAPAPORT D, 1993, BIOCHEMISTRY-US, V32, P3291, DOI 10.1021/bi00064a011; RAPAPORT D, 1992, J BIOL CHEM, V267, P6502; RIZZO V, 1987, BIOCHEMISTRY-US, V26, P2751, DOI 10.1021/bi00384a015; SCHWARZ G, 1986, BIOCHIM BIOPHYS ACTA, V861, P141, DOI 10.1016/0005-2736(86)90412-8; SERRANO L, 1992, NATURE, V356, P453, DOI 10.1038/356453a0; SHAI Y, 1990, J BIOL CHEM, V265, P20202; SHAI Y, 1991, J BIOL CHEM, V266, P22346; SIMS PJ, 1974, BIOCHEMISTRY-US, V13, P3315, DOI 10.1021/bi00713a022; SLEPUSHKIN VA, 1990, BIOCHEM BIOPH RES CO, V172, P952, DOI 10.1016/0006-291X(90)90768-I; STEGMANN T, 1989, ANNU REV BIOPHYS BIO, V18, P187, DOI 10.1146/annurev.bb.18.060189.001155; STRUCK DK, 1981, BIOCHEMISTRY-US, V20, P4093, DOI 10.1021/bi00517a023; TAYLOR JW, 1987, METHOD ENZYMOL, V154, P473; WHARTON SA, 1988, J GEN VIROL, V69, P1847, DOI 10.1099/0022-1317-69-8-1847; WHITE JM, 1990, ANNU REV PHYSIOL, V52, P675, DOI 10.1146/annurev.ph.52.030190.003331; WILEY DC, 1987, ANNU REV BIOCHEM, V56, P365, DOI 10.1146/annurev.bi.56.070187.002053; WOLBER PK, 1979, BIOPHYS J, V28, P197, DOI 10.1016/S0006-3495(79)85171-1; YEAGLE PL, 1991, BIOCHIM BIOPHYS ACTA, V1065, P49, DOI 10.1016/0005-2736(91)90009-W; Yeagle PL, 1993, VIRAL FUSION MECHANI, P313; ZHONG LX, 1992, P NATL ACAD SCI USA, V89, P4462, DOI 10.1073/pnas.89.10.4462; ZIMMERBERG J, 1993, ANNU REV BIOPH BIOM, V22, P433, DOI 10.1146/annurev.bb.22.060193.002245	57	71	74	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					15124	15131						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195149				2022-12-25	WOS:A1994NP73800043
J	GOLDSMITH, MA; XU, WD; AMARAL, MC; KUCZEK, ES; GREENE, WC				GOLDSMITH, MA; XU, WD; AMARAL, MC; KUCZEK, ES; GREENE, WC			THE CYTOPLASMIC DOMAIN OF THE INTERLEUKIN-2 RECEPTOR-BETA CHAIN CONTAINS BOTH UNIQUE AND FUNCTIONALLY REDUNDANT SIGNAL-TRANSDUCTION ELEMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN T-CELLS; IL-2 RECEPTOR; TYROSINE PHOSPHORYLATION; ERYTHROPOIETIN RECEPTOR; LYMPHOCYTES-T; PROTEIN-KINASE; POINT MUTATION; ACTIVATION; EXPRESSION; ANTIGEN	Binding of interleukin-2 (IL-2) to the IL-2 receptor (IL-2R) triggers a series of intracellular events culminating in lymphocyte proliferation and differentiation. A novel transient assay of signal transduction leading to proliferation is now described which allows the rapid functional assessment of wild type and mutant receptors, including the IL-2R and other members of the cytokine receptor superfamily. This assay has been used to define domains and specific residues within the IL-2R beta intracellular region that contribute to growth signal transduction. In these studies, internal deletion of either the conserved ''Box 1'' or ''Box 2'' proximal cytokine receptor homology segments significantly impaired receptor function. Similarly, mutation of specific key residues within or between Box 1 and Box 2, or deletion of the C-terminal 94 residues of the IL-2R beta chain, impaired growth signaling. In contrast, either replacement of the transmembrane domain with that of the CD4 molecule or internal deletion of the 119 amino acids immediately downstream of Box 2 had no impact on growth signaling competence. These studies thus further define the functional architecture of the intracellular region of IL-2R beta, and reveal specific receptor domains that are dispensable, unique, or functionally redundant.	UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94141; UNIV CALIF SAN FRANCISCO,DEPT MICROBIOL & IMMUNOL,SAN FRANCISCO,CA 94141	University of California System; University of California San Francisco; University of California System; University of California San Francisco	GOLDSMITH, MA (corresponding author), UNIV CALIF SAN FRANCISCO,SAN FRANCISCO GEN HOSP,GLADSTONE INST VIROL & IMMUNOL,POB 419100,SAN FRANCISCO,CA 94141, USA.			Kuczek, Elizabeth/0000-0002-5412-5509	NIAID NIH HHS [AI 07395-04] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007395] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ARUFFO A, 1991, CURRENT PROTOCOLS MO; ASAO H, 1990, J EXP MED, V171, P637, DOI 10.1084/jem.171.3.637; CAO H, 1992, EMBO J, V11, P923, DOI 10.1002/j.1460-2075.1992.tb05131.x; COSSON P, 1991, NATURE, V351, P414, DOI 10.1038/351414a0; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DUKOVICH M, 1987, NATURE, V327, P518, DOI 10.1038/327518a0; FUNG MR, 1991, J IMMUNOL, V147, P1253; GANCHI PA, 1992, MOL BIOL CELL, V3, P1339, DOI 10.1091/mbc.3.12.1339; GARVIN AM, 1990, INT IMMUNOL, V2, P173, DOI 10.1093/intimm/2.2.173; GOLDSMITH MA, 1994, IN PRESS CYTOKINE HD; GRANELLIPIPERNO A, 1986, J EXP MED, V163, P922, DOI 10.1084/jem.163.4.922; GRAVES JD, 1992, J IMMUNOL, V148, P2417; HATAKEYAMA M, 1989, CELL, V59, P837, DOI 10.1016/0092-8674(89)90607-7; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HATAKEYAMA M, 1992, P NATL ACAD SCI USA, V89, P2022, DOI 10.1073/pnas.89.6.2022; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; IZUHARA K, 1993, BIOCHEM BIOPH RES CO, V190, P992, DOI 10.1006/bbrc.1993.1147; MERIDA I, 1990, J BIOL CHEM, V265, P5690; MICHIEL DF, 1991, CYTOKINE, V3, P428, DOI 10.1016/1043-4666(91)90047-H; MILLS GB, 1986, J IMMUNOL, V136, P3019; MILLS GB, 1990, J BIOL CHEM, V265, P3561; MINAMI Y, 1993, ANNU REV IMMUNOL, V11, P245, DOI 10.1146/annurev.immunol.11.1.245; MINAMI Y, 1993, EMBO J, V12, P759, DOI 10.1002/j.1460-2075.1993.tb05710.x; MIURA O, 1993, MOL CELL BIOL, V13, P1788, DOI 10.1128/MCB.13.3.1788; MORI H, 1991, INT IMMUNOL, V3, P149, DOI 10.1093/intimm/3.2.149; MORLA AO, 1988, MOL CELL BIOL, V8, P2214, DOI 10.1128/MCB.8.5.2214; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; NOGUCHI M, 1993, CELL, V73, P147, DOI 10.1016/0092-8674(93)90167-O; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; REED JC, 1987, ONCOGENE, V1, P223; ROBB RJ, 1984, J EXP MED, V160, P1126, DOI 10.1084/jem.160.4.1126; SALTZMAN EM, 1988, J BIOL CHEM, V263, P6956; SHARON M, 1989, J IMMUNOL, V143, P2530; SHIBUYA H, 1992, CELL, V70, P57, DOI 10.1016/0092-8674(92)90533-I; SIEGEL JP, 1987, SCIENCE, V238, P75, DOI 10.1126/science.3116668; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; STERN JB, 1986, SCIENCE, V233, P203, DOI 10.1126/science.3523754; TANIGUCHI T, 1993, CELL, V73, P5, DOI 10.1016/0092-8674(93)90152-G; TIGGES MA, 1989, SCIENCE, V243, P781, DOI 10.1126/science.2492678; TURNER B, 1991, P NATL ACAD SCI USA, V88, P1227, DOI 10.1073/pnas.88.4.1227; VALGE VE, 1988, CELL, V55, P101, DOI 10.1016/0092-8674(88)90013-X; WATOWICH SS, 1992, P NATL ACAD SCI USA, V89, P2140, DOI 10.1073/pnas.89.6.2140; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; YOSHIMURA A, 1990, NATURE, V348, P647, DOI 10.1038/348647a0; ZMUIDZINAS A, 1991, MOL CELL BIOL, V11, P2794, DOI 10.1128/MCB.11.5.2794	48	58	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14698	14704						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	8182077				2022-12-25	WOS:A1994NM06500062
J	GUARDIOLADIAZ, HM; BOSWELL, C; SEASHOLTZ, AF				GUARDIOLADIAZ, HM; BOSWELL, C; SEASHOLTZ, AF			THE CAMP-RESPONSIVE ELEMENT IN THE CORTICOTROPIN-RELEASING HORMONE GENE MEDIATES TRANSCRIPTIONAL REGULATION BY DEPOLARIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3',5'-CYCLIC ADENOSINE-MONOPHOSPHATE; RAT HYPOTHALAMUS INVITRO; DEPENDENT PROTEIN-KINASE; IMMEDIATE EARLY GENES; NERVE GROWTH-FACTOR; CYCLIC-AMP; MEMBRANE DEPOLARIZATION; MESSENGER-RNA; CELL-LINE; PREINITIATION COMPLEX	Membrane depolarization is a critical element of neuronal signaling, In this study, the biochemical and molecular mechanisms involved in transcriptional regulation of the corticotropin-releasing hormone (CRH) gene by depolarization were investigated. In PC-12 cells, potassium-induced membrane depolarization increased expression of a CRH-reporter construct in a cAMP-dependent manner. This synergistic activation was mediated via calcium influx, predominantly via L-type calcium channels, and calmodulin. RNase protection assays demonstrated increased levels of CRH-reporter transcripts in stably transfected cells after treatment with cAMP and potassium, with the induced transcripts initiating at the major transcription initiation site of the human CRH gene. At the genomic level, the CRH cAMP-responsive element conferred both positive cAMP and synergistic cAMP/depolarization regulation to a heterologous promoter. Additionally, DNase I protection assays demonstrated similar nuclear protein/DNA binding profiles across the cAMP-responsive element after treatment of PC-12 cells with potassium or potassium/cAMP. These results support a model in which the protein(s) binding to the cAMP-responsive element integrates signals initiated by multiple pathways (cAMP and calcium) and transmits that integrated signal to the basal transcription machinery, resulting in increased levels of gene expression.	UNIV MICHIGAN, MENTAL HLTH RES INST, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, DEPT BIOL CHEM, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK042730] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007544] Funding Source: NIH RePORTER; NIDDK NIH HHS [R29 DK42730] Funding Source: Medline; NIGMS NIH HHS [T32-GM07544] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADLER GK, 1988, J BIOL CHEM, V263, P5846; ADLER GK, 1990, MOL CELL ENDOCRINOL, V70, P165, DOI 10.1016/0303-7207(90)90156-3; Ausubel FM., 2006, ENZYMATIC MANIPULATI; BECK E, 1982, GENE, V19, P327, DOI 10.1016/0378-1119(82)90023-3; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLARKE MJO, 1987, NEUROENDOCRINOLOGY, V46, P147, DOI 10.1159/000124812; COMB M, 1988, EMBO J, V7, P3793, DOI 10.1002/j.1460-2075.1988.tb03264.x; COMB M, 1986, NATURE, V323, P353, DOI 10.1038/323353a0; DASH PK, 1991, P NATL ACAD SCI USA, V88, P5061, DOI 10.1073/pnas.88.11.5061; DORIN RI, 1989, MOL ENDOCRINOL, V3, P1537, DOI 10.1210/mend-3-10-1537; EMANUEL RL, 1990, ENDOCRINOLOGY, V126, P3016, DOI 10.1210/endo-126-6-3016; FRIM DM, 1988, J CLIN INVEST, V82, P287, DOI 10.1172/JCI113585; FUJIMOTO M, 1991, NEUROSCI LETT, V122, P9, DOI 10.1016/0304-3940(91)90180-2; Ginty D D, 1992, Curr Opin Neurobiol, V2, P312, DOI 10.1016/0959-4388(92)90121-Z; GINTY DD, 1991, J BIOL CHEM, V266, P17454; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; Guardiola-Diaz H., 1992, Society for Neuroscience Abstracts, V18, P753; HAI T, 1988, CELL, V54, P1043, DOI 10.1016/0092-8674(88)90119-5; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; HYMAN SE, 1988, MOL CELL BIOL, V8, P4225, DOI 10.1128/MCB.8.10.4225; KILBOURNE EJ, 1992, J BIOL CHEM, V267, P7563; KILBOURNE EJ, 1990, MOL BRAIN RES, V8, P121, DOI 10.1016/0169-328X(90)90056-J; KONGSAMUT S, 1986, P NATL ACAD SCI USA, V83, P2243, DOI 10.1073/pnas.83.7.2243; LIU F, 1993, J BIOL CHEM, V268, P6714; MAJZOUB J, 1988, INT CONGR SER, V798, P231; Maxam A M, 1980, Methods Enzymol, V65, P499; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; MURPHY TH, 1991, NEURON, V7, P625, DOI 10.1016/0896-6273(91)90375-A; OWENS MJ, 1991, PHARMACOL REV, V43, P425; PROST E, 1986, GENE, V45, P107, DOI 10.1016/0378-1119(86)90138-1; RITCHIE AK, 1979, J PHYSIOL-LONDON, V286, P541, DOI 10.1113/jphysiol.1979.sp012636; ROBINSON BG, 1989, MOL CELL ENDOCRINOL, V61, P175, DOI 10.1016/0303-7207(89)90128-7; SCHWANINGER M, 1993, J BIOL CHEM, V268, P5168; SCULPTOREANU A, 1993, NATURE, V364, P240, DOI 10.1038/364240a0; SEASHOLTZ AF, 1988, MOL ENDOCRINOL, V2, P1311, DOI 10.1210/mend-2-12-1311; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; SHIBAHARA S, 1983, EMBO J, V2, P775, DOI 10.1002/j.1460-2075.1983.tb01499.x; SMITH MA, 1986, ENDOCRINOLOGY, V118, P1997, DOI 10.1210/endo-118-5-1997; SPENGLER D, 1992, MOL ENDOCRINOL, V6, P1931, DOI 10.1210/me.6.11.1931; SUDA T, 1985, LIFE SCI, V37, P1499, DOI 10.1016/0024-3205(85)90181-X; TSAGARAKIS S, 1991, J MOL ENDOCRINOL, V7, P71, DOI 10.1677/jme.0.0070071; TSAGARAKIS S, 1988, ENDOCRINOLOGY, V123, P1962, DOI 10.1210/endo-123-4-1962; USOWICZ MM, 1990, J PHYSIOL-LONDON, V426, P95, DOI 10.1113/jphysiol.1990.sp018128; VANNGUYEN T, 1990, J NEUROSCI, V10, P2825; XIA ZG, 1991, NEURON, V6, P431, DOI 10.1016/0896-6273(91)90251-T	46	69	71	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14784	14791						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	8182084				2022-12-25	WOS:A1994NM06500074
J	LAVOIE, C; TAM, R; CLARK, M; LEE, H; SONENBERG, N; LASKO, P				LAVOIE, C; TAM, R; CLARK, M; LEE, H; SONENBERG, N; LASKO, P			SUPPRESSION OF A TEMPERATURE-SENSITIVE CDC33 MUTATION OF YEAST BY A MULTICOPY PLASMID EXPRESSING A DROSOPHILA RIBOSOMAL-PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAP-BINDING PROTEIN; HIGH-EFFICIENCY TRANSFORMATION; MESSENGER-RNA; SACCHAROMYCES-CEREVISIAE; INITIATION-FACTOR; ESCHERICHIA-COLI; TRANSLATION INITIATION; 5'-TERMINAL CAP; GENES; CLONING	The Saccharomyces cerevisiae cdc33ts4-2 mutant produces a temperature sensitive allele of the cap-binding subunit of eukaryotic initiation factor-4F (also termed eIF-4E). From a Drosophila cDNA library constructed in a multicopy yeast shuttle vector, a clone was isolated which restored the ability to grow at elevated temperature to cdc33ts4-2 cells. The rescuing Drosophila clone encodes a small ribosomal subunit protein, which we name S15a based on its molecular weight and similarity with the Brassica napus S15a ribosomal protein. Transcription of the Drosophila gene, RpS15a, occurs at all developmental stages and is enhanced during oogenesis. The ribosomal protein gene is capable of suppressing other alleles of cdc33 but not an inactivation mutation, suggesting that suppression is dependent upon the presence of the temperature-sensitive eIF-4E protein. Supporting this, Western blot analysis shows that far more eIF-4E protein is present in cdc33 yeast cells expressing the RpS15a gene than lacking it. Levels of other unrelated proteins are unaffected. We propose therefore that the expression of high levels of the Drosophila S15a ribosomal protein in the cdc33 yeast cells leads to a selective stabilization of the temperature-sensitive eIF-4E protein, which accounts for the suppression phenomenon.	MCGILL UNIV, DEPT BIOL, MONTREAL H3A 1B1, PQ, CANADA; MCGILL UNIV, DEPT BIOCHEM, MONTREAL H3A 1B1, PQ, CANADA	McGill University; McGill University			Lasko, Paul/C-6761-2014	Lasko, Paul/0000-0002-4037-3501				ALTMANN M, 1989, NUCLEIC ACIDS RES, V17, P5923, DOI 10.1093/nar/17.15.5923; ALTMANN M, 1989, MOL CELL BIOL, V9, P4467, DOI 10.1128/MCB.9.10.4467; ALTMANN M, 1989, J BIOL CHEM, V264, P12145; ALTMANN M, 1987, MOL CELL BIOL, V7, P998, DOI 10.1128/MCB.7.3.998; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ANGERER LM, 1992, DEV BIOL, V149, P27, DOI 10.1016/0012-1606(92)90261-E; ASHBURNER M, 1989, DROSOPHILA LABORATOR; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BANERJEE AK, 1980, MICROBIOL REV, V44, P175, DOI 10.1128/MMBR.44.2.175-205.1980; BECKER DM, 1991, P NATL ACAD SCI USA, V88, P1968, DOI 10.1073/pnas.88.5.1968; BECKER DM, 1991, METHOD ENZYMOL, V194, P182; BELHUMEUR P, 1993, MOL CELL BIOL, V13, P2152, DOI 10.1128/MCB.13.4.2152; BONHAMSMITH PC, 1992, PLANT MOL BIOL, V18, P909, DOI 10.1007/BF00019205; BRENNER C, 1988, MOL CELL BIOL, V8, P3556, DOI 10.1128/MCB.8.8.3556; BURNS DK, 1984, MOL CELL BIOL, V4, P2643, DOI 10.1128/MCB.4.12.2643; CERRETTI DP, 1983, NUCLEIC ACIDS RES, V11, P2599, DOI 10.1093/nar/11.9.2599; CHOOI WY, 1980, BIOCHEMISTRY-US, V19, P3469, DOI 10.1021/bi00556a010; EDERY I, 1988, GENE, V74, P517, DOI 10.1016/0378-1119(88)90184-9; FRANCOEUR AM, 1985, J IMMUNOL, V135, P2378; GRIFO JA, 1983, J BIOL CHEM, V258, P5804; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; JONES EW, 1991, METHOD ENZYMOL, V194, P428; LEER RJ, 1985, NUCLEIC ACIDS RES, V13, P701, DOI 10.1093/nar/13.3.701; LEJBKOWICZ F, 1992, P NATL ACAD SCI USA, V89, P9612, DOI 10.1073/pnas.89.20.9612; LEOPOLD P, 1991, CELL, V66, P1207, DOI 10.1016/0092-8674(91)90043-X; LINDER P, 1990, BIOESSAYS, V12, P519, DOI 10.1002/bies.950121103; LINDER P, 1989, NATURE, V337, P121, DOI 10.1038/337121a0; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; NISHI K, 1988, NATURE, V336, P496, DOI 10.1038/336496a0; POOLE SJ, 1985, CELL, V40, P37, DOI 10.1016/0092-8674(85)90306-X; PRINGLE JR, 1981, MOL BIOL YEAST SACCH, P97; REED SI, 1980, GENETICS, V95, P561; RHOADS RE, 1991, TRANSLATION EUKARYOT, P109; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; ROEMER T, 1993, MOL CELL BIOL, V13, P4039, DOI 10.1128/MCB.13.7.4039; SACHS AB, 1989, CELL, V58, P857, DOI 10.1016/0092-8674(89)90938-0; Sambrook J, 1989, MOL CLONING LABORATO; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SHATKIN AJ, 1985, CELL, V40, P223, DOI 10.1016/0092-8674(85)90132-1; SONENBERG N, 1978, P NATL ACAD SCI USA, V75, P4843, DOI 10.1073/pnas.75.10.4843; TBONE WM, 1991, J BACTERIOL, V173, P3291; THACH RE, 1992, CELL, V68, P177, DOI 10.1016/0092-8674(92)90461-K; WITTMANNLIEBOLD B, 1990, RIBOSOME, P598; [No title captured]	44	28	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14625	14630						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	8182070				2022-12-25	WOS:A1994NM06500051
J	HENDERSON, GB; HUGHES, TR; SAXENA, M				HENDERSON, GB; HUGHES, TR; SAXENA, M			FUNCTIONAL IMPLICATIONS FROM THE EFFECTS OF 1-CHLORO-2,4-DINITROBENZENE AND ETHACRYNIC-ACID ON EFFLUX ROUTES FOR METHOTREXATE AND CHOLATE IN L1210 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE S-CONJUGATE; ATP-DEPENDENT TRANSPORT; PLASMA-MEMBRANE VESICLES; ORGANIC ANION TRANSPORT; RAT-HEART SARCOLEMMA; HUMAN-ERYTHROCYTES; DINITROPHENYL GLUTATHIONE; MULTIDRUG-RESISTANCE; CYSTIC-FIBROSIS; CYCLIC-AMP	1-Chloro-2,4-dinitrobenzene (CDNB) and ethacrynic acid were examined for the ability to inhibit unidirectional efflux routes in L1210 cells that extrude both methotrexate and cholate (system I) and methotrexate alone (system II). These electrophiles were selected for study because of their known ability to undergo rapid intracellular conversion to glutathione conjugates. CDNB produced typical inhibitor kinetics and was a moderate inhibitor of both system I (IC50 = 4.8 mu m) and system II (IC50 = 7.5 mu m) with methotrexate as the substrate. However, a complex response was observed when cholate was employed as an alternative substrate for system I. Cholate efflux was stimulated initially at low levels of CDNB, but then slowed to a net inhibition as CDNB concentrations exceeded 10 mu m The latter characteristics for CDNB were not observed with ethacrynic acid, which produced a comparable inhibition of efflux system I regardless of the substrate employed (IC50 = 4.6 mu m). Efflux measurements in an L1210/C7 variant which lacks system I confirmed that CDNB stimulates the activity of a substantial and unique efflux activity for cholate (system III). The inhibition of system I and II by CDNB and ethacrynic acid was not reversed by a wash step but required inhibitor removal and subsequent incubation at 37 degrees C. This slow reversal was attributed to a time dependent clearance of inhibitory glutathione conjugates. A correlation between efflux systems for anions and anionic glutathione conjugates was demonstrated further by the ability of prostaglandin A, and indomethacin, two potent inhibitors of methotrexate and cholate efflux, to inhibit the efflux of 2,4-dinitrophenyl-S-glutathione. These results support the hypothesis that efflux systems for methotrexate and cholate in L1210 cells are part of a family of efflux pumps which function in vivo to extrude various anions and anionic glutathione conjugates.			HENDERSON, GB (corresponding author), SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, LA JOLLA, CA 92037 USA.				NATIONAL CANCER INSTITUTE [R01CA023970] Funding Source: NIH RePORTER; NCI NIH HHS [CA23970] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKERBOOM TPM, 1991, J BIOL CHEM, V266, P13147; AKERBOOM TPM, 1992, BIOCHIM BIOPHYS ACTA, V1103, P115, DOI 10.1016/0005-2736(92)90064-S; AWASTHI S, 1993, BIOCHIM BIOPHYS ACTA, V1164, P173, DOI 10.1016/0167-4838(93)90245-M; BOARD PG, 1981, FEBS LETT, V124, P163, DOI 10.1016/0014-5793(81)80127-5; BRADLEY G, 1988, BIOCHIM BIOPHYS ACTA, V948, P87, DOI 10.1016/0304-419X(88)90006-6; BRUNTON LL, 1979, J BIOL CHEM, V254, P9714; CHEER S, 1974, ANAL BIOCHEM, V60, P102, DOI 10.1016/0003-2697(74)90134-1; DIVIRGILIO F, 1988, J IMMUNOL, V140, P915; GORNALL AG, 1949, J BIOL CHEM, V177, P751; GOTTESMAN MM, 1988, J BIOL CHEM, V263, P12163; HEASLEY LE, 1985, J BIOL CHEM, V260, P1520; HENDERSON GB, 1993, BIOCHIM BIOPHYS ACTA, V1152, P91, DOI 10.1016/0005-2736(93)90235-R; HENDERSON GB, 1988, CANCER RES, V48, P5995; HENDERSON GB, 1990, BIOCHIM BIOPHYS ACTA, V1051, P60, DOI 10.1016/0167-4889(90)90174-C; HENDERSON GB, 1987, J BIOL CHEM, V262, P13571; HENDERSON GB, 1984, J BIOL CHEM, V259, P1526; HENDERSON GB, 1991, J BIOL CHEM, V266, P1641; HENDERSON GB, 1992, BIOCHIM BIOPHYS ACTA, V1110, P137, DOI 10.1016/0005-2736(92)90350-U; ISHIKAWA T, 1992, TRENDS BIOCHEM SCI, V17, P463, DOI 10.1016/0968-0004(92)90489-V; ISHIKAWA T, 1989, FEBS LETT, V246, P177, DOI 10.1016/0014-5793(89)80278-9; ISHIKAWA T, 1990, J BIOL CHEM, V265, P19279; ISHIKAWA T, 1989, FEBS LETT, V259, P95, DOI 10.1016/0014-5793(89)81503-0; ISHIKAWA T, 1989, J BIOL CHEM, V264, P17343; JURANKA PF, 1989, FASEB J, V3, P2583, DOI 10.1096/fasebj.3.14.2574119; KOBAYASHI K, 1990, J BIOL CHEM, V265, P7737; KONDO T, 1981, BIOCHIM BIOPHYS ACTA, V645, P132, DOI 10.1016/0005-2736(81)90520-4; LABELLE EF, 1986, BIOCHEM J, V238, P443, DOI 10.1042/bj2380443; LIPMAN BJ, 1990, J BIOL CHEM, V265, P2142; MANNERVIK B, 1988, CRC CR REV BIOCH MOL, V23, P283, DOI 10.3109/10409238809088226; QUINTON PM, 1990, FASEB J, V4, P2709, DOI 10.1096/fasebj.4.10.2197151; RINDLER MJ, 1978, J BIOL CHEM, V253, P5431; SCHLEMMER SR, 1992, J BIOL CHEM, V267, P14746; SCOTT RB, 1990, J LAB CLIN MED, V116, P674; SIROTNAK FM, 1981, CANCER RES, V41, P966; SIROTNAK FM, 1991, CANCER RES, V51, P1412; VINCE R, 1971, J MED CHEM, V14, P402, DOI 10.1021/jm00287a006; WIDDICOMBE JH, 1991, TRENDS BIOCHEM SCI, V16, P474, DOI 10.1016/0968-0004(91)90183-V; ZIMNIAK P, 1993, TRENDS BIOCHEM SCI, V18, P164, DOI 10.1016/0968-0004(93)90106-W	38	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13382	13389						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175768				2022-12-25	WOS:A1994NK18400051
J	KING, JS; FAIRLEY, CF; MORGAN, WF				KING, JS; FAIRLEY, CF; MORGAN, WF			BRIDGING THE GAP - JOINING OF NONHOMOLOGOUS ENDS BY DNA-POLYMERASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CHROMOSOMAL INSTABILITY; ESCHERICHIA-COLI; TRANSFECTED DNA; MAMMALIAN-CELLS; RECOMBINATION; ALPHA; INTEGRATION; GENE	DNA double strand breaks with noncomplementary ends can be joined by mechanisms of nonhomologous recombination. In some systems a DNA end with a 3'protruding single strand (PSS), which does not have a recessed 3'-hydroxyl that can allow for fill-in DNA synthesis, is joined to a blunt end with preservation of the 3'-PSS. It has been proposed that this process occurs via single strand ligation or is facilitated by an alignment protein. We were interested in testing the hypothesis that a DNA polymerase could function as this putative alignment protein. To characterize polymerase activities in this type of reaction, we incubated short double-stranded oligonucleotides that had an excess of one of the strands with an exonuclease-free Klenow fragment of Escherichia coli polymerase I, Tag DNA polymerase from Thermus aquaticus, or an exonuclease-free Stoffel fragment of Tag DNA polymerase. Products were analyzed by using biotinylated oligonucleotides separated by denaturing polyacrylamide gel electrophoresis. To further assess the effect of DNA polymerases on the joining of 3'-PSS ends to blunt ends, we incubated linear plasmid DNA with the polymerases and subjected the DNA to Southern blot and sequence analysis. We determined that these DNA polymerases can use a S'-PSS end as a template after priming off the S'-hydroxyl of a blunt end. This implies that the joining of noncomplementary ends in eukaryotic cells could proceed by a similar mechanism.	UNIV CALIF SAN FRANCISCO,DEPT RADIAT ONCOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	KING, JS (corresponding author), UNIV CALIF SAN FRANCISCO,RADIOBIOL & ENVIRONM HLTH LAB,CAMPUS BOX 0750,SAN FRANCISCO,CA 94143, USA.				NATIONAL CANCER INSTITUTE [T32CA009215] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007106] Funding Source: NIH RePORTER; NCI NIH HHS [CA 09215-12] Funding Source: Medline; NIEHS NIH HHS [5 T32 ES07106] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BEESE LS, 1993, SCIENCE, V260, P352, DOI 10.1126/science.8469987; CLARK JM, 1987, J MOL BIOL, V198, P123, DOI 10.1016/0022-2836(87)90462-1; CLARK JM, 1988, NUCLEIC ACIDS RES, V16, P9677, DOI 10.1093/nar/16.20.9677; CLARK JM, 1991, GENE, V104, P75, DOI 10.1016/0378-1119(91)90467-P; GERONDAKIS S, 1984, CELL, V36, P973, DOI 10.1016/0092-8674(84)90047-3; HULTMAN T, 1989, NUCLEIC ACIDS RES, V17, P4937, DOI 10.1093/nar/17.13.4937; KADHIM MA, 1992, NATURE, V355, P738, DOI 10.1038/355738a0; KING JS, 1993, NUCLEIC ACIDS RES, V21, P1055, DOI 10.1093/nar/21.5.1055; MARDER BA, 1993, MOL CELL BIOL, V13, P6667, DOI 10.1128/MCB.13.11.6667; MENDELMAN LV, 1990, J BIOL CHEM, V265, P2338; MORGAN WF, 1988, MOL CELL BIOL, V8, P4204, DOI 10.1128/MCB.8.10.4204; MURNANE JP, 1990, NUCLEIC ACIDS RES, V18, P2733, DOI 10.1093/nar/18.9.2733; PFEIFFER P, 1988, NUCLEIC ACIDS RES, V16, P907, DOI 10.1093/nar/16.3.907; Roth D., 1988, GENETIC RECOMBINATIO, P621; ROTH DB, 1985, MOL CELL BIOL, V5, P2599, DOI 10.1128/MCB.5.10.2599; ROTH DB, 1986, MOL CELL BIOL, V6, P4295, DOI 10.1128/MCB.6.12.4295; SABATIER L, 1992, NATURE, V357, P548, DOI 10.1038/357548a0; THODE S, 1990, CELL, V60, P921, DOI 10.1016/0092-8674(90)90340-K; WAKE CT, 1984, MOL CELL BIOL, V4, P387, DOI 10.1128/MCB.4.3.387; WEISS SJ, 1992, J BIOL CHEM, V267, P18520; WINDLE B, 1991, GENE DEV, V5, P160, DOI 10.1101/gad.5.2.160; WOLFF S, 1973, ADV RAD RES, P457; WOODSSAMUELS P, 1991, GENOMICS, V10, P94, DOI 10.1016/0888-7543(91)90489-2	23	24	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13061	13064						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175727				2022-12-25	WOS:A1994NK18400002
J	HAYSTEAD, CMM; GREGORY, P; SHIRAZI, A; FADDEN, P; MOSSE, C; DENT, P; HAYSTEAD, TAJ				HAYSTEAD, CMM; GREGORY, P; SHIRAZI, A; FADDEN, P; MOSSE, C; DENT, P; HAYSTEAD, TAJ			INSULIN ACTIVATES A NOVEL ADIPOCYTE MITOGEN-ACTIVATED PROTEIN-KINASE KINASE KINASE THAT SHOWS RAPID PHASIC KINETICS AND IS DISTINCT FROM C-RAF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST PHEROMONE RESPONSE; MAP KINASE; GROWTH-FACTOR; PHOSPHORYLATION; REQUIREMENT; PATHWAY; HOMOLOG	Treatment of adipocytes with insulin or phorbol 12-myristate 13-acetate (PMA) results in transient activation of mitogen-activated protein kinase kinase (MEK) (T-max = 90 s) and mitogen-activated protein kinase (MAPK) (T-max = 300 s). We have identified a novel insulin-stimulated MEK kinase (I-MEKK) in the 100,000 x g infranatant that shows rapid phasic kinetics that temporally precede that of MEK. Maximal activation of I-MEKK occurs within 20 +/- 5 s (S.D., n = 3) followed by complete inactivation by 30 +/- 10 s (S.D., n = 3). I-MEKK was characterized by anion-exchange and gel filtration chromatography and separated into two distinct activities of similar to 56 kDa that phosphorylated and activated MEK. I-MEKKs did not co-elute on anion exchange with c-Raf or 73-kDa MEK kinase (MEKK), suggesting they are distinct enzymes. Protein phosphatase 2A inactivated both I-MEKKs in vitro and in the intact cell okadaic acid blocked inactivation in the presence of insulin. These results suggest activation of I-MEKK involves phosphorylation on serine or threonine residues. I-MEKK was not activated by PMA, suggesting that in adipocytes the enzyme represents a divergence point between signal transduction pathways mediated by insulin and those activating protein kinase C.			HAYSTEAD, CMM (corresponding author), UNIV VIRGINIA,SCH MED,DEPT PHARMACOL,CHARLOTTESVILLE,VA 22908, USA.							ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BLINDER D, 1989, CELL, V56, P479, DOI 10.1016/0092-8674(89)90250-X; CONSIDINE RV, 1993, J CELL BIOCHEM, V52, P8, DOI 10.1002/jcb.240520103; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DENT P, 1994, IN PRESS BIOCH J; GARDNER AM, 1993, J BIOL CHEM, V268, P17896; GEER P, 1993, PROTEIN PHOSPHORYLAT, P31; HAYSTEAD CMM, 1993, EUR J BIOCHEM, V214, P459, DOI 10.1111/j.1432-1033.1993.tb17942.x; HAYSTEAD CMM, 1993, FEBS LETT, V317, P12, DOI 10.1016/0014-5793(93)81481-E; HAYSTEAD TAJ, 1986, BIOCHEM J, V240, P99, DOI 10.1042/bj2400099; HAYSTEAD TAJ, 1992, FEBS LETT, V306, P17, DOI 10.1016/0014-5793(92)80828-5; HAYSTEAD TAJ, 1990, J BIOL CHEM, V265, P16571; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HUANG WD, 1993, P NATL ACAD SCI USA, V90, P10947, DOI 10.1073/pnas.90.23.10947; KYRIAKIS JM, 1993, J BIOL CHEM, V268, P16009; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; LEE KS, 1993, MOL CELL BIOL, V13, P3067, DOI 10.1128/MCB.13.5.3067; LEE KS, 1992, MOL CELL BIOL, V12, P172, DOI 10.1128/MCB.12.1.172; LLOYD ED, 1992, J NEUROCHEM, V59, P1099, DOI 10.1111/j.1471-4159.1992.tb08352.x; MELOCHE S, 1992, MOL BIOL CELL, V3, P63, DOI 10.1091/mbc.3.1.63; MERRALL NW, 1993, BIOCHEM J, V295, P351, DOI 10.1042/bj2950351; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; NEBREDA AR, 1993, EMBO J, V12, P1979, DOI 10.1002/j.1460-2075.1993.tb05847.x; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; SANGHERA JS, 1992, MOL BIOL CELL, V3, P775, DOI 10.1091/mbc.3.7.775; SCHAAP D, 1993, J BIOL CHEM, V268, P20232; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; WHITE MF, 1994, J BIOL CHEM, V269, P1; WILLIAMS NG, 1993, P NATL ACAD SCI USA, V90, P5772, DOI 10.1073/pnas.90.12.5772; WU J, 1993, MOL CELL BIOL, V13, P4539, DOI 10.1128/MCB.13.8.4539; ZHENG CF, 1993, J BIOL CHEM, V268, P23933; ZHENG CF, 1993, J BIOL CHEM, V268, P11435	36	58	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12804	12808						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175693				2022-12-25	WOS:A1994NH71600067
J	HOFFMANN, K; SCHNEIDERSCHERZER, E; KLEINKAUF, H; ZOCHER, R				HOFFMANN, K; SCHNEIDERSCHERZER, E; KLEINKAUF, H; ZOCHER, R			PURIFICATION AND CHARACTERIZATION OF EUKARYOTIC ALANINE RACEMASE ACTING AS KEY ENZYME IN CYCLOSPORINE BIOSYNTHESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-STEAROTHERMOPHILUS; MULTIENZYME POLYPEPTIDE; PEPTIDE; INACTIVATION; SYNTHETASE; PROTEINS; ISOMERS	A specific alanine racemase, which is a key enzyme in the biosynthesis of the undecapeptide cyclosporin A, was purified to electrophoretic homogeneity from the fungus Tolypocladium niveum. This is the first enzyme of this kind isolated from a eucaryotic organism. The enzyme catalyzes the reversible racemization of alanine and requires pyridoxal phosphate as the exclusive cofactor. K-m values for L- and D-alanine were found to be 38 and 2 mM, respectively. Maximal reaction velocity was observed at 42 degrees C and pH 8.8 for the L to D direction. Molecular mass determinations of the denatured enzyme by SDS-polyacrylamide gel electrophoresis gave a value of 37 kDa, whereas gel filtration calibration studies yielded a value between 120 and 150 kDa, indicating an oligomeric native structure.	TECH UNIV BERLIN,INST BIOCHEM & MOLEK BIOL,W-1000 BERLIN 10,GERMANY; BIOCHEM GMBH,A-6330 KUFSTEIN SCHAFTENA,AUSTRIA; YALE UNIV,SCH MED,DEPT PHARMACOL,NEW HAVEN,CT 06510	Technical University of Berlin; Yale University								ADAMS E, 1976, ADV ENZYMOL RAMB, V44, P69; ADAMS E, 1972, ENZYMES, V6, P479; BADET B, 1985, BIOCHEMISTRY-US, V24, P1333, DOI 10.1021/bi00327a010; BADET B, 1986, BIOCHEMISTRY-US, V25, P3275, DOI 10.1021/bi00359a029; BILLICH A, 1987, J BIOL CHEM, V262, P17258; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BOREL JF, 1986, PROG ALLERGY, V38, P9; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; KLEINKAUF H, 1991, BIOMED BIOCHIM ACTA, V50, P219; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWEN A, 1990, J BIOL CHEM, V265, P11355; Lineweaver H, 1934, J AM CHEM SOC, V56, P658, DOI 10.1021/ja01318a036; NAGATA Y, 1985, ANAL BIOCHEM, V150, P238, DOI 10.1016/0003-2697(85)90465-8; OFFENZELLER M, 1993, J BIOL CHEM, V268, P26127; ROISE D, 1984, BIOCHEMISTRY-US, V23, P5195, DOI 10.1021/bi00317a017; ROSKOSKI R, 1970, BIOCHEMISTRY-US, V9, P4839; SCHMIDT B, 1992, FEBS LETT, V307, P355, DOI 10.1016/0014-5793(92)80712-P; Silverman R B, 1988, J Enzyme Inhib, V2, P73, DOI 10.3109/14756368809040714; SODA K, 1986, COENZYMES COFACTOR B, V1, P223; TOYAMA H, 1991, J BIOCHEM-TOKYO, V110, P279, DOI 10.1093/oxfordjournals.jbchem.a123571; VATER J, 1976, BIOCHIM BIOPHYS ACTA, V429, P1062, DOI 10.1016/0005-2744(76)90351-X; WALSH CT, 1992, J BIOL CHEM, V267, P13115; WALSH CT, 1989, J BIOL CHEM, V264, P2393; ZOCHER R, 1986, BIOCHEMISTRY-US, V25, P550, DOI 10.1021/bi00351a005	24	128	133	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12710	12714						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175682				2022-12-25	WOS:A1994NH71600054
J	KUMAR, TKS; SUBBIAH, V; RAMAKRISHNA, T; PANDIT, MW				KUMAR, TKS; SUBBIAH, V; RAMAKRISHNA, T; PANDIT, MW			TRICHLOROACETIC ACID-INDUCED UNFOLDING OF BOVINE PANCREATIC RIBONUCLEASE - EXISTENCE OF MOLTEN GLOBULE-LIKE STATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOLDING REACTIONS; SMALL PROTEINS; INTERMEDIATE; DENATURATION; MECHANISM; PATHWAY; CHAINS; FORM	The exposure of ribonuclease A to trichloroacetic acid was earlier shown to alter the conformation of the protein resulting in reduced enzymatic activity (Sagar, A.J., Subbiah, V., and Pandit, M.W. (1989) Biochim. Biophys. Acta 995, 144-150). We have studied the structure and enzymatic activity of ribonuclease A treated with trichloroacetic acid over a wide range of acid concentrations (0-40%). The far ultraviolet circular dichroism spectra of ribonuclease A, on exposure to acid concentrations less than 10%, indicated an exceptionally high degree of chiral structure. Exposure of ribonuclease A to acid concentrations between 10 and 30% resulted in the formation of a molecule with significant chiral structure (conventionally assigned to residual secondary structure) but reduced tertiary structure (characteristics very similar to those of molten globule). Increased binding of the hydrophobic probe 1-anilinonaphthalene-8-sulfonate to the enzyme treated with 15-30% acid, as compared with the untreated or completely unfolded protein, supported the existence of a state having characteristics of molten globule. Reversed phase high performance liquid chromatography corroborated the data obtained by circular dichroism as well as 1-anilino-naphthalene-8-sulfonate-binding studies. Beyond acid concentrations of 30%, the ribonuclease is completely denatured. The trichloroacetic acid-induced unfolding is shown to be completely reversible.	CTR CELLULAR & MOLEC BIOL,HYDERABAD 500007,INDIA	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Centre for Cellular & Molecular Biology (CCMB)			Kumar, Dr Suresh/HHZ-2615-2022; Kumar, Suresh Thallapuranam/R-5606-2016; KUMAR, P. SURESH/AAT-8951-2020	Kumar, Dr Suresh/0000-0002-2539-6553; Kumar, Suresh Thallapuranam/0000-0001-7262-1373; KUMAR, P. SURESH/0000-0003-3222-2604				ABRAHAM KA, 1963, J REPROD FERTIL, V5, P277, DOI 10.1530/jrf.0.0050277; ABRAHAM KA, 1963, INDIAN J CHEM, V1, P124; AHMAD F, 1979, J MOL BIOL, V131, P607, DOI 10.1016/0022-2836(79)90010-X; ALFRED G, 1971, INDIAN J BIOCHEM BIO, V8, P28; ALFRED G, 1971, INDIAN J BIOCHEM BIO, V8, P35; ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; AUNE KC, 1967, J BIOL CHEM, V242, P4486; BALDWIN RL, 1991, CHEMTRACTS BIOCH MOL, V2, P379; BRANDTS JF, 1967, J AM CHEM SOC, V89, P4826, DOI 10.1021/ja00995a002; CROOK EM, 1960, BIOCHEM J, V74, P234, DOI 10.1042/bj0740234; DENTON JB, 1982, BIOCHEMISTRY-US, V21, P5155, DOI 10.1021/bi00264a008; GAREL JR, 1973, P NATL ACAD SCI USA, V70, P3347, DOI 10.1073/pnas.70.12.3347; GOTO Y, 1990, BIOCHEMISTRY-US, V29, P3480, DOI 10.1021/bi00466a009; GOTO Y, 1990, P NATL ACAD SCI USA, V87, P573, DOI 10.1073/pnas.87.2.573; JAGANNADHAM MV, 1985, FEBS LETT, V188, P326, DOI 10.1016/0014-5793(85)80396-3; JANICKE R, 1987, PROG BIOPHYS MOL BIO, V49, P117; KALNITSKY G, 1959, ANN NY ACAD SCI, V31, P542; KIM PS, 1990, ANNU REV BIOCHEM, V59, P631, DOI 10.1146/annurev.biochem.59.1.631; KIM PS, 1982, ANNU REV BIOCHEM, V51, P459, DOI 10.1146/annurev.bi.51.070182.002331; KUWAJIMA K, 1989, PROTEINS, V6, P87, DOI 10.1002/prot.340060202; LABHARDT AM, 1982, J MOL BIOL, V157, P331, DOI 10.1016/0022-2836(82)90238-8; LATTMAN EE, 1993, P NATL ACAD SCI USA, V90, P439, DOI 10.1073/pnas.90.2.439; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; OHGUSHI M, 1983, FEBS LETT, V164, P21, DOI 10.1016/0014-5793(83)80010-6; PTITSYN OB, 1987, J PROTEIN CHEM, V6, P273; RAO MSN, 1965, INDIAN J BIOCHEM, V2, P47; ROBERTSON AD, 1991, BIOCHEMISTRY-US, V30, P9907, DOI 10.1021/bi00105a014; SAGAR AJ, 1983, BIOCHIM BIOPHYS ACTA, V743, P303, DOI 10.1016/0167-4838(83)90386-2; SAGAR AJ, 1989, BIOCHIM BIOPHYS ACTA, V995, P144, DOI 10.1016/0167-4838(89)90073-3; SAGAR AJ, 1972, INDIAN J BIOCHEM BIO, V9, P52; SAGAR KDA, 1969, INDIAN J BIOCH, V6, P161; SCATCHARD G, 1957, J AM CHEM SOC, V79, P12, DOI 10.1021/ja01558a003; SCHMID FX, 1978, P NATL ACAD SCI USA, V75, P4764, DOI 10.1073/pnas.75.10.4764; SCHMID FX, 1979, J MOL BIOL, V133, P285, DOI 10.1016/0022-2836(79)90536-9; SEMISOTNOV GV, 1991, BIOPOLYMERS, V31, P119, DOI 10.1002/bip.360310111; TANFORD C, 1955, J AM CHEM SOC, V77, P6421, DOI 10.1021/ja01629a003; Tsong T Y, 1970, Biochemistry, V9, P2666, DOI 10.1021/bi00815a015; UDGAONKAR JB, 1988, NATURE, V335, P694, DOI 10.1038/335694a0; VANDERGOOT FG, 1991, NATURE, V354, P408, DOI 10.1038/354408a0	39	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12620	12625						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175671				2022-12-25	WOS:A1994NH71600041
J	YANG, SH; JAYARAM, M				YANG, SH; JAYARAM, M			GENERALITY OF THE SHARED ACTIVE-SITE AMONG YEAST FAMILY SITE-SPECIFIC RECOMBINASES - THE ARG SITE-SPECIFIC RECOMBINASE FOLLOWS THE FLP PARADIGM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGIONAL SIMILARITIES; FUNCTIONAL-ANALYSIS; INTEGRASE FAMILY; DNA; MUTANTS; MUTAGENESIS; MECHANISM; TYROSINE; BINDING	Mutations of the invariant Int family tetrad residues, the RHR triad, and the active site tyrosine, within the Zygosaccharomyces rouxii site-specific recombinase ARg cause the same ''step-arrest'' phenotypes as they do in the Flp recombinase of Saccharomyces cerevisiae. In ''half-site'' recombinations, the ARg recombinase exhibits catalytic complementation between an RHR triad mutant and an active site tyrosine mutant. Strand cutting by R follows the ''trans'' DNA cleavage rule. These results are best explained by the assembly of a functional active site from partial active sites harbored by the ARg monomers. Complementation tests using single and double step-arrest ARg mutants verify critical predictions of the ''shared active site'' model. A wild type monomer paired with an RHR triad-Tyr(358) double mutant is a catalytically inactive combination. Pairwise combinations of a single or a double RHR mutant with R(Y358F) yield comparable levels of catalytic complementation. These results strongly imply conservation of the mechanism of active site assembly and the mode of substrate cleavage within the yeast family site specific recombinases, and perhaps within the larger Int family recombinases.	UNIV TEXAS,DEPT MICROBIOL,AUSTIN,TX 78712	University of Texas System; University of Texas Austin								ABREMSKI KE, 1992, PROTEIN ENG, V5, P87, DOI 10.1093/protein/5.1.87; ARGOS P, 1986, EMBO J, V5, P433, DOI 10.1002/j.1460-2075.1986.tb04229.x; BEAUCAGE SL, 1981, TETRAHEDRON LETT, V22, P1859, DOI 10.1016/S0040-4039(01)90461-7; CHEN JW, 1992, MOL CELL BIOL, V12, P3757, DOI 10.1128/MCB.12.9.3757; CHEN JW, 1993, J BIOL CHEM, V268, P14417; CHEN JW, 1992, CELL, V69, P647, DOI 10.1016/0092-8674(92)90228-5; CRAIG NL, 1988, ANNU REV GENET, V22, P77; FRIESEN H, 1992, J MOL BIOL, V225, P313, DOI 10.1016/0022-2836(92)90924-9; HAN YPW, 1993, EMBO J, V12, P4577, DOI 10.1002/j.1460-2075.1993.tb06146.x; KIM SH, 1990, CELL, V63, P773, DOI 10.1016/0092-8674(90)90143-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDY A, 1989, ANNU REV BIOCHEM, V58, P913, DOI 10.1146/annurev.biochem.58.1.913; LEE J, 1993, J BIOL CHEM, V268, P17564; LEE J, 1992, J MOL BIOL, V228, P1091, DOI 10.1016/0022-2836(92)90317-D; Maniatis T., 1982, MOL CLONING; PAN H, 1993, MOL CELL BIOL, V13, P3167; PAN H, 1992, J BIOL CHEM, V267, P12397; PARSONS RL, 1988, MOL CELL BIOL, V8, P3303, DOI 10.1128/MCB.8.8.3303; PARSONS RL, 1990, J BIOL CHEM, V265, P4527; SERRE MC, 1992, J MOL BIOL, V225, P621, DOI 10.1016/0022-2836(92)90390-6; UTATSU I, 1987, J BACTERIOL, V169, P5537, DOI 10.1128/jb.169.12.5537-5545.1987; WENTE SR, 1987, P NATL ACAD SCI USA, V84, P31, DOI 10.1073/pnas.84.1.31	22	26	26	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12789	12796						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175691				2022-12-25	WOS:A1994NH71600065
J	MILLAR, DG; SHORE, GC				MILLAR, DG; SHORE, GC			MITOCHONDRIAL MAS70P SIGNAL ANCHOR SEQUENCE - MUTATIONS IN THE TRANSMEMBRANE DOMAIN THAT DISRUPT DIMERIZATION BUT NOT TARGETING OR MEMBRANE INSERTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER-MEMBRANE; GOLGI RETENTION; PROTEIN IMPORT; RECEPTOR; OLIGOMERIZATION; ASSOCIATION; HELIX	Mas70p is an integral membrane protein in Saccharomyces cerevisiae that is targeted and inserted into the mitochondrial outer membrane in an N-in-C-cyto orientation by its NH2-terminal 29-amino acid signal anchor sequence. Recently, we demonstrated that the signal anchor was capable of mediating homo-oligomerization of a fusion protein, pOMD29, in the outer membrane in vitro (Millar, D. G., and Shore, G. C. (1992) J. Biol. Chem. 268, 18403-18406). Consistent with this finding, we show here that a synthetic peptide corresponding to the Mas70p signal anchor is capable of independent membrane insertion and dimerization with pOMD29. To further map the oligomerization domain in the signal anchor sequence, a deletion mutant of pOMD29 that lacks amino acids 2-10 was constructed. This protein, pOMD29 Delta 2-10, efficiently participated in dimer formation following import, indicating that dimerization was mediated by the putative membrane spanning segment (amino acids 11-29). This segment is predicted to form an alpha-helix that has an alanine-rich face and contains multiple copies of a pentapeptide dimerization motif that is widespread among members of the receptor tyrosine kinase family. Substitution of the alanine residues in one of these copies with isoleucine, producing a potentially bulkier contact surface, resulted in a protein which was targeted and inserted into the outer membrane but failed to assemble into dimers. Taken together, these results identify a structural feature of the signal anchor transmembrane domain that is important for oligomerization but is not required for targeting and membrane insertion.			MILLAR, DG (corresponding author), MCGILL UNIV,DEPT BIOCHEM,MCINTYRE MED SCI BLDG,3655 DRUMMOND ST,MONTREAL H3G 1Y6,PQ,CANADA.			Millar, Douglas/0000-0002-8640-7148				BORMANN BJ, 1989, J BIOL CHEM, V264, P4033; BORMANN BJ, 1992, ANNU REV BIOPH BIOM, V21, P223, DOI 10.1146/annurev.bb.21.060192.001255; CHOTHIA C, 1984, ANNU REV BIOCHEM, V53, P537; CHOTHIA C, 1981, J MOL BIOL, V145, P215, DOI 10.1016/0022-2836(81)90341-7; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; COSSON P, 1992, SCIENCE, V258, P659, DOI 10.1126/science.1329208; DEISENHOFER J, 1985, NATURE, V318, P618, DOI 10.1038/318618a0; HASE T, 1984, EMBO J, V3, P3157, DOI 10.1002/j.1460-2075.1984.tb02274.x; HINES V, 1993, J BIOL CHEM, V268, P449; HINES V, 1990, EMBO J, V9, P3191, DOI 10.1002/j.1460-2075.1990.tb07517.x; KEIL P, 1993, J BIOL CHEM, V268, P19177; KUHLBRANDT W, 1991, NATURE, V350, P130, DOI 10.1038/350130a0; LANDOLTMARTICORENA C, 1993, J MOL BIOL, V229, P602, DOI 10.1006/jmbi.1993.1066; LEMMON MA, 1992, J BIOL CHEM, V267, P7683; LEMMON MA, 1992, BIOCHEMISTRY-US, V31, P12719, DOI 10.1021/bi00166a002; LI JM, 1992, SCIENCE, V256, P1815, DOI 10.1126/science.1615327; LI JM, 1992, BIOCHIM BIOPHYS ACTA, V1106, P233, DOI 10.1016/0005-2736(92)90001-3; MARGOLESE L, 1993, J BIOL CHEM, V268, P17959; MCBRIDE HM, 1992, J CELL BIOL, V119, P1451, DOI 10.1083/jcb.119.6.1451; MILLAR DG, 1993, J BIOL CHEM, V268, P18403; NAKAI M, 1989, J BIOCHEM-TOKYO, V105, P513, DOI 10.1093/oxfordjournals.jbchem.a122698; NGUYEN M, 1993, J BIOL CHEM, V268, P25265; POPOT JL, 1990, BIOCHEMISTRY-US, V29, P4031, DOI 10.1021/bi00469a001; RAMAGE L, 1993, EMBO J, V12, P4115, DOI 10.1002/j.1460-2075.1993.tb06095.x; RUTLEDGE T, 1992, EMBO J, V11, P3245, DOI 10.1002/j.1460-2075.1992.tb05402.x; SHORE GC, 1992, MEMBRANE BIOGENESIS, P253; SINGER SJ, 1990, ANNU REV CELL BIOL, V6, P247, DOI 10.1146/annurev.cb.06.110190.001335; SMITH S, 1993, J CELL BIOL, V120, P631, DOI 10.1083/jcb.120.3.631; SOLLNER T, 1992, NATURE, V355, P84, DOI 10.1038/355084a0; SOLLNER T, 1990, CELL, V62, P107, DOI 10.1016/0092-8674(90)90244-9; STERNBERG MJE, 1990, PROTEIN ENG, V3, P245, DOI 10.1093/protein/3.4.245; STERNBERG MJE, 1989, NATURE, V339, P587, DOI 10.1038/339587a0; SWIFT AM, 1991, J CELL BIOL, V115, P19, DOI 10.1083/jcb.115.1.19; TEASDALE RD, 1992, J BIOL CHEM, V267, P4084; TREUTLEIN HR, 1992, BIOCHEMISTRY-US, V31, P12726, DOI 10.1021/bi00166a003; VONHEIJNE G, 1988, BIOCHIM BIOPHYS ACTA, V947, P307, DOI 10.1016/0304-4157(88)90013-5; WICKNER WT, 1985, SCIENCE, V230, P400, DOI 10.1126/science.4048938; WOZNIAK RW, 1992, J CELL BIOL, V119, P1441, DOI 10.1083/jcb.119.6.1441	38	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					12229	12232						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163528				2022-12-25	WOS:A1994NG37700084
J	YEH, YC; LIU, HF; ELLIS, CA; LU, AL				YEH, YC; LIU, HF; ELLIS, CA; LU, AL			MAMMALIAN TOPOISOMERASE-I HAS BASE MISMATCH NICKING ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC RECOMBINATION; ESCHERICHIA-COLI; BACTERIOPHAGE-LAMBDA; DNA TOPOISOMERASES; HUMAN-CELLS; NUCLEOTIDE-SEQUENCE; NUCLEAR EXTRACTS; PAIR MISMATCHES; ANTITUMOR DRUGS; CAMPTOTHECIN	The all-type nicking enzyme (ATE) from human HeLa cells or calf thymus can nick DNA at the first phosphodiester bond 5' to all 8 possible mismatched bases. The strand disparity of this nicking is influenced by the neighboring nucleotide sequences. After nicking, the ATE covalently binds to the 3' end of the DNA product to form a cleavable complex, whose formation is insensitive to camptothecin, a specific inhibitor of eukaryotic topoisomerase I (Topo-I). During the purification of ATE from calf thymus, a Mg2+-independent relaxation activity, characteristic of eukaryotic Topo-I, copurifies with the mismatch-nicking activity. The ATE from calf thymus may be a breakdown product of Topo-I. N-terminal amino acid analysis indicates that one of the polypeptides with ATE activity contains the C-terminal portion of Topo-I. Moreover, active human Topo-I, expressed as a fusion protein in Escherichia coli, is also capable of nicking all 8 base mispairs in the absence of Mg2+. This mismatch-specific nicking activity may be a novel property of the mammalian Topo-I.	UNIV MARYLAND,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21201	University System of Maryland; University of Maryland Baltimore					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035132] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 35132] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AU KG, 1988, P NATL ACAD SCI USA, V85, P9163, DOI 10.1073/pnas.85.23.9163; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Champoux JJ, 1990, DNA TOPOLOGY ITS BIO, P217; CHRISTMAN MF, 1988, CELL, V55, P413, DOI 10.1016/0092-8674(88)90027-X; DARPA P, 1990, CANCER RES, V50, P6919; DARPA P, 1988, P NATL ACAD SCI USA, V85, P2543, DOI 10.1073/pnas.85.8.2543; DELBINO G, 1991, EXP CELL RES, V193, P27, DOI 10.1016/0014-4827(91)90534-2; ENG WK, 1988, MOL PHARMACOL, V34, P755; FUJII H, 1989, J BIOL CHEM, V264, P10057; HABER LT, 1988, J BACTERIOL, V170, P197, DOI 10.1128/jb.170.1.197-202.1988; HONG YR, 1993, VIROLOGY, V194, P481, DOI 10.1006/viro.1993.1287; HORWITZ MS, 1971, BIOCHEM BIOPH RES CO, V45, P723; HSIANG YH, 1989, CANCER RES, V49, P5077; HSIANG YH, 1985, J BIOL CHEM, V260, P4873; JAVAHERIAN K, 1982, NUCLEIC ACIDS RES, V10, P6945, DOI 10.1093/nar/10.21.6945; JIRICNY J, 1988, P NATL ACAD SCI USA, V85, P8860, DOI 10.1073/pnas.85.23.8860; KIM RA, 1989, CELL, V57, P975, DOI 10.1016/0092-8674(89)90336-X; KOIWAI O, 1993, GENE, V125, P211, DOI 10.1016/0378-1119(93)90331-V; KUDINOV AR, 1992, FEBS LETT, V314, P267, DOI 10.1016/0014-5793(92)81486-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVIN NA, 1993, GENETICS, V133, P799; LI LH, 1972, CANCER RES, V32, P2643; LIEB M, 1986, GENETICS, V114, P1041; LIEB M, 1983, MOL GEN GENET, V191, P118, DOI 10.1007/BF00330898; LIM M, 1986, CELL BIOL TOXICOL, V2, P485, DOI 10.1007/BF00117850; LINTON JP, 1989, MOL CELL BIOL, V9, P3058, DOI 10.1128/MCB.9.7.3058; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; LIU LF, 1981, P NATL ACAD SCI-BIOL, V78, P3487, DOI 10.1073/pnas.78.6.3487; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; LIU LF, 1989, DNA TOPOLOGY ITS BIO, P371; LU AL, 1983, P NATL ACAD SCI-BIOL, V80, P4639, DOI 10.1073/pnas.80.15.4639; LU AL, 1988, GENETICS, V118, P593; MARTIN SR, 1983, METHOD ENZYMOL, V100, P137; Maxam A M, 1980, Methods Enzymol, V65, P499; MICHAELS ML, 1990, NUCLEIC ACIDS RES, V18, P3841, DOI 10.1093/nar/18.13.3841; NASH HA, 1987, P NATL ACAD SCI USA, V84, P4049, DOI 10.1073/pnas.84.12.4049; NASH HA, 1989, EMBO J, V8, P3523, DOI 10.1002/j.1460-2075.1989.tb08518.x; NITISS J, 1988, P NATL ACAD SCI USA, V85, P7501, DOI 10.1073/pnas.85.20.7501; PORTER SE, 1989, NUCLEIC ACIDS RES, V17, P8521, DOI 10.1093/nar/17.21.8521; RADICELLA JP, 1988, P NATL ACAD SCI USA, V85, P9674, DOI 10.1073/pnas.85.24.9674; RYAN AJ, 1991, NUCLEIC ACIDS RES, V19, P3295, DOI 10.1093/nar/19.12.3295; SCHMITT B, 1984, EUR J BIOCHEM, V144, P127, DOI 10.1111/j.1432-1033.1984.tb08440.x; SHEN CC, 1990, J MOL BIOL, V212, P67, DOI 10.1016/0022-2836(90)90305-6; Speicher D.W., 1989, TECHNIQUES PROTEIN C, P24; STEPHENSON C, 1989, J BIOL CHEM, V264, P21177; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SU SS, 1988, J BIOL CHEM, V263, P6829; TOBEY RA, 1972, CANCER RES, V32, P2720; TRASK DK, 1983, NUCLEIC ACIDS RES, V11, P2779, DOI 10.1093/nar/11.9.2779; TRICOLI JV, 1983, BIOCHEMISTRY-US, V22, P2025, DOI 10.1021/bi00277a045; TSAIWU JJ, 1992, P NATL ACAD SCI USA, V89, P8779, DOI 10.1073/pnas.89.18.8779; TSAIWU JYYJ, 1991, J BACTERIOL, V173, P1902, DOI 10.1128/jb.173.6.1902-1910.1991; TSAO YP, 1992, CANCER RES, V52, P1823; WIEBAUER K, 1989, NATURE, V339, P234, DOI 10.1038/339234a0; Yanagida M, 1990, DNA TOPOLOGY ITS BIO, P299; YEH YC, 1991, J BIOL CHEM, V266, P6480; ZHANG H, 1990, CANCER CELL-MON REV, V2, P23	57	58	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15498	15504						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	8195193				2022-12-25	WOS:A1994NP51300019
J	MA, D; COOK, DN; PON, NG; HEARST, JE				MA, D; COOK, DN; PON, NG; HEARST, JE			EFFICIENT ANCHORING OF RNA-POLYMERASE IN ESCHERICHIA-COLI DURING COUPLED TRANSCRIPTION-TRANSLATION OF GENES ENCODING INTEGRAL INNER MEMBRANE POLYPEPTIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOPOISOMERASE-I MUTANTS; CYTOPLASMIC MEMBRANE; DNA; PROTEINS; DOMAINS; INVIVO; TRANSLOCATION; RESISTANCE; PROMOTER; TEMPLATE	While it has been known that supercoliing of the DNA template can be induced by transcription, the mechanism and the efficiency of this process in vivo is not fully understood. We report here that transcription of genes encoding 16 S rRNA, a stable RNA species, or cytoplasmic polypeptides leads to very little or no detectable DNA supercoliing even under the optimum conditions in Escherichia coli. This indicates that hydrodynamic drag on the transcription complex (including RNA polymrase, nascent RNA, ribosomes, and nascent polypeptides) is not sufficient to anchor RNA polymerase during coupled transcription-translation. On the other hand, transcription of membrane-associated genes encoding integral inner membrane or exported periplasmic polypeptides leads to apparent DNA supercoliing. Transcription of genes encoding integral inner membrane polypeptides leads to significantly greater anchoring of RNA polymerase than does transcription of genes encoding periplasmic polypeptides. This may reflect differences in the coupling of transcription-translation with membrane association during expression of these two classes of polypeptides. Evidence is further presented to suggest that the anchoring of RNA polymerase is probably achieved through the interaction of nascent polypeptides with the cytoplasmic surface of the inner membrane during coupled transcription-translation. Moreover, transcription of a membrane-associated gene can, under certain circumstances, induce topological anchoring of an RNA polymerase transcribing a neighboring gene that ordinarily is not membrane-associated Finally, the potential biological consequences of our findings are discussed.	UNIV CALIF BERKELEY, DEPT CHEM, BERKELEY, CA 94720 USA; UNIV CALIF BERKELEY, LAWRENCE BERKELEY LAB, DIV STRUCT BIOL, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley				/0000-0002-6129-2938	NIGMS NIH HHS [R1 GM 41911A-03-NF-03/92] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041911] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BUJARD H, 1987, METHOD ENZYMOL, V155, P416; COOK DN, 1992, P NATL ACAD SCI USA, V89, P10603, DOI 10.1073/pnas.89.22.10603; COOK DN, 1994, NUCLEIC ACIDS MOL BI, V8; DEUSCHLE U, 1986, EMBO J, V5, P2987, DOI 10.1002/j.1460-2075.1986.tb04596.x; DINARDO S, 1982, CELL, V31, P43, DOI 10.1016/0092-8674(82)90403-2; FRENCH S, 1992, SCIENCE, V258, P1362, DOI 10.1126/science.1455232; GAMPER HB, 1982, CELL, V29, P81, DOI 10.1016/0092-8674(82)90092-7; LEE C, 1986, ANNU REV CELL BIOL, V2, P315, DOI 10.1146/annurev.cellbio.2.1.315; LILLEY DMJ, 1991, MOL MICROBIOL, V5, P779, DOI 10.1111/j.1365-2958.1991.tb00749.x; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; LODGE JK, 1989, J BACTERIOL, V171, P2181, DOI 10.1128/jb.171.4.2181-2187.1989; LYNCH AS, 1993, J BACTERIOL, V175, P1645, DOI 10.1128/JB.175.6.1645-1655.1993; MA D, 1993, J BACTERIOL, V175, P6299, DOI 10.1128/JB.175.19.6299-6313.1993; OKAZAKI R, 1974, METHOD MOL BIOL, V7, P1; PRUSS GJ, 1986, P NATL ACAD SCI USA, V83, P8952, DOI 10.1073/pnas.83.23.8952; PRUSS GJ, 1989, CELL, V56, P521, DOI 10.1016/0092-8674(89)90574-6; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; RANDALL LL, 1983, CELL, V33, P231, DOI 10.1016/0092-8674(83)90352-5; Sambrook J, 1989, MOL CLONING LABORATO; TRUCKSIS M, 1991, J BACTERIOL, V173, P5854, DOI 10.1128/jb.173.18.5854-5860.1991; WU HY, 1988, CELL, V53, P433, DOI 10.1016/0092-8674(88)90163-8	21	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					15362	15370						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195175				2022-12-25	WOS:A1994NP73800076
J	HOSTEN, CM; SULLIVAN, AM; PALANIAPPAN, V; FITZGERALD, MM; TERNER, J				HOSTEN, CM; SULLIVAN, AM; PALANIAPPAN, V; FITZGERALD, MM; TERNER, J			RESONANCE RAMAN-SPECTROSCOPY OF THE CATALYTIC INTERMEDIATES AND DERIVATIVES OF CHLOROPEROXIDASE FROM CALDARIOMYCES-FUMAGO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PI-CATION RADICALS; ELECTRON-PARAMAGNETIC RESONANCE; HORSERADISH-PEROXIDASE COMPOUND; PORPHYRIN FORCE-FIELD; NUCLEAR MAGNETIC-RESONANCE; CYTOCHROME-C PEROXIDASE; HEME-LINKED IONIZATION; THIOLATE LIGATION; ACTIVE-SITE; NICKEL OCTAETHYLPORPHYRIN	Near-ultraviolet resonance Raman spectra of chloroperoxidase derivatives and high valent intermediates show frequencies that can be systematically assigned. In accord with previous observations of low nu(4) frequencies for the ferric enzyme, and quite low nu(4) frequencies for the ferrous enzyme, low nu(4) frequencies are observed for ferryl compound II and several ferric derivatives. Resonance Raman spectra of chloroperoxidase compound I feature upshifted nu(2), nu(11), and nu(37) frequencies and other characteristics that argue for a (2)A(1u) in preference to a (2)A(2u) ground state for the porphyrin pi-cation radical. A moderately intense anomalously polarized band is observed at a frequency typical for octaethylporphyrin pi-cation radicals, which have been previously assigned as the (2)A(1u) radical type. Similar resonance Raman spectral attributes are observed for horseradish peroxidase compound I, supporting a (2)A(1u) symmetry state assignment for this species also. A (2)A(1u) symmetry state assignment for chloroperoxidase and horseradish peroxidase compounds I is consistent with the beta pyrrole substituent pattern of the protoporphyrin hemes found in these enzymes.	VIRGINIA COMMONWEALTH UNIV,DEPT CHEM,RICHMOND,VA 23284	Virginia Commonwealth University					NIGMS NIH HHS [GM34443-06S1A1, GM48758] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [S15GM048758, R01GM034443] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABE M, 1978, J CHEM PHYS, V69, P4526, DOI 10.1063/1.436450; Anderson LA, 1990, STRUCT BOND, V74, P1; ANZENBACHER P, 1989, INORG CHEM, V28, P4491, DOI 10.1021/ic00324a013; Ballou D. P., 1971, THESIS U MICHIGAN; BANGCHAROENPAURPONG O, 1986, BIOCHEMISTRY-US, V25, P2374, DOI 10.1021/bi00357a011; BILL E, 1990, HYPERFINE INTERACT, V58, P2343, DOI 10.1007/BF02398341; BILL E, 1990, EUR J BIOCHEM, V188, P665, DOI 10.1111/j.1432-1033.1990.tb15448.x; BLANKE SR, 1989, BIOTECHNOL LETT, V11, P769, DOI 10.1007/BF01026094; BLANKE SR, 1989, THESIS U MICHIGAN AN; BORG DC, 1970, P NATL ACAD SCI USA, V67, P813, DOI 10.1073/pnas.67.2.813; BOSO B, 1983, J CHEM PHYS, V79, P1122, DOI 10.1063/1.445913; BOSSHARD HR, 1991, PEROXIDASES CHEM BIO, V2, P51; CHAMPION PM, 1976, BIOCHIM BIOPHYS ACTA, V446, P486, DOI 10.1016/0005-2795(76)90015-5; CHAMPION PM, 1978, J AM CHEM SOC, V100, P3743, DOI 10.1021/ja00480a015; CHAMPION PM, 1973, BIOCHEMISTRY-US, V12, P426, DOI 10.1021/bi00727a011; CHAMPION PM, 1975, BIOCHEMISTRY-US, V14, P4159, DOI 10.1021/bi00690a002; CHAMPION PM, 1988, BIOL APPLICATIONS RA, V3, P249; CHOI S, 1982, J AM CHEM SOC, V104, P4337, DOI 10.1021/ja00380a005; CHOI S, 1982, J AM CHEM SOC, V104, P4345, DOI 10.1021/ja00380a006; CHOI SH, 1983, J AM CHEM SOC, V105, P3683, DOI 10.1021/ja00349a056; CHUANG WJ, 1992, J BIOL CHEM, V267, P13293; CRAMER SP, 1978, J AM CHEM SOC, V100, P7282, DOI 10.1021/ja00491a027; CZERNUSZEWICZ RS, 1989, J AM CHEM SOC, V111, P3860, DOI 10.1021/ja00193a017; DAWSON JH, 1992, NEW J CHEM, V16, P577; DAWSON JH, 1988, SCIENCE, V240, P433, DOI 10.1126/science.3358128; DAWSON JH, 1976, J AM CHEM SOC, V98, P3709, DOI 10.1021/ja00428a055; DAWSON JH, 1987, CHEM REV, V87, P1255, DOI 10.1021/cr00081a015; DEMONTELLANO PRO, 1987, J BIOL CHEM, V262, P11641; DEMONTELLANO PRO, 1992, ANNU REV PHARMACOL, V32, P89, DOI 10.1146/annurev.pharmtox.32.1.89; DINELLO RK, 1981, J BIOL CHEM, V256, P6903; DINELLO RK, 1979, BIOCHEM BIOPH RES CO, V86, P190, DOI 10.1016/0006-291X(79)90399-1; DOLPHIN D, 1971, P NATL ACAD SCI USA, V68, P614, DOI 10.1073/pnas.68.3.614; DOLPHIN D, 1973, ANN NY ACAD SCI, V206, P177, DOI 10.1111/j.1749-6632.1973.tb43211.x; DOLPHIN D, 1974, ACCOUNTS CHEM RES, V7, P26, DOI 10.1021/ar50073a005; DUGAD LB, 1992, BIOCHEMISTRY-US, V31, P1651, DOI 10.1021/bi00121a011; Dunford H. B., 1982, BIOL CHEM IRON, P337; EGAWA T, 1992, FEBS LETT, V305, P206, DOI 10.1016/0014-5793(92)80668-7; FELTON RH, 1976, BIOCHIM BIOPHYS ACTA, V434, P82, DOI 10.1016/0005-2795(76)90037-4; FUHROP JH, 1969, J AM CHEM SOC, V91, P4174, DOI 10.1021/ja01043a027; FUJII H, 1993, J AM CHEM SOC, V115, P4641, DOI 10.1021/ja00064a027; FUJITA E, 1985, J AM CHEM SOC, V107, P7665, DOI 10.1021/ja00311a073; FUJITA I, 1983, J AM CHEM SOC, V105, P3296, DOI 10.1021/ja00348a056; GANS P, 1986, J AM CHEM SOC, V108, P1223, DOI 10.1021/ja00266a017; GODZIELA GM, 1986, J AM CHEM SOC, V108, P2237, DOI 10.1021/ja00269a019; GRIFFIN BW, 1991, PEROXIDASES CHEM BIO, V2, P85; HAGER LP, 1972, J AM CHEM SOC, V94, P4364, DOI 10.1021/ja00767a068; HANSON LK, 1981, J AM CHEM SOC, V103, P663, DOI 10.1021/ja00393a028; HASHIMOTO S, 1991, J AM CHEM SOC, V113, P6542, DOI 10.1021/ja00017a027; HASHIMOTO S, 1986, J BIOL CHEM, V261, P1110; HOLLENBERG PF, 1973, J BIOL CHEM, V248, P2630; HOLLENBERG PF, 1980, J BIOL CHEM, V255, P4801; HU SZ, 1993, J BIOL CHEM, V268, P6189; KASHIWAGI H, 1981, INT J QUANTUM CHEM, V20, P843, DOI 10.1002/qua.560200408; KITAGAWA T, 1976, J AM CHEM SOC, V98, P5169, DOI 10.1021/ja00433a019; Klebanoff S.J., 1991, PEROXIDASES CHEM BIO, P1; LAMAR GN, 1989, J BIOL CHEM, V264, P5428; LI XY, 1990, J PHYS CHEM-US, V94, P47, DOI 10.1021/j100364a008; LI XY, 1989, J AM CHEM SOC, V111, P7012, DOI 10.1021/ja00200a018; LI XY, 1990, J PHYS CHEM-US, V94, P31, DOI 10.1021/j100364a007; MACOR KA, 1990, INORG CHEM, V29, P1996, DOI 10.1021/ic00335a044; MANDON D, 1992, INORG CHEM, V31, P4404, DOI 10.1021/ic00047a031; Marnett L.J., 1986, CYTOCHROME P 450 STR, P29; McMurry T. J., 1986, CYTOCHROME P450 STRU, P1; MORISHIMA I, 1984, J AM CHEM SOC, V106, P7666, DOI 10.1021/ja00337a002; NAKASHIMA S, 1990, INORG CHEM, V29, P5207, DOI 10.1021/ic00351a014; Neidleman S.L., 1986, BIOHALOGENATION PRIN; OERTLING WA, 1988, BIOCHEMISTRY-US, V27, P3331, DOI 10.1021/bi00409a032; OERTLING WA, 1987, J PHYS CHEM-US, V91, P5887, DOI 10.1021/j100307a016; OERTLING WA, 1989, J PHYS CHEM-US, V93, P1311, DOI 10.1021/j100341a028; OZAKI Y, 1976, J BIOCHEM-TOKYO, V80, P1447, DOI 10.1093/oxfordjournals.jbchem.a131420; PAENG KJ, 1988, J AM CHEM SOC, V110, P7913, DOI 10.1021/ja00231a073; PALANIAPPAN V, 1989, J BIOL CHEM, V264, P16046; PALANIAPPAN V, 1992, SPRINGER P PHYSICS, V68, P32; PALANIAPPAN V, 1991, SPECTROSCOPY BIOL MO, P419; PALCIC MM, 1980, BIOCHEM BIOPH RES CO, V94, P1123, DOI 10.1016/0006-291X(80)90535-5; PALMER G, 1983, IRON PORPHYRINS 2, P43; PARTHASARATHI N, 1987, J AM CHEM SOC, V109, P3865, DOI 10.1021/ja00247a009; PICKARD MA, 1981, CAN J MICROBIOL, V27, P1298, DOI 10.1139/m81-199; PRENDERGAST K, 1991, J PHYS CHEM-US, V95, P9728, DOI 10.1021/j100177a025; RAKHIT G, 1976, BIOCHEM BIOPH RES CO, V71, P803, DOI 10.1016/0006-291X(76)90902-5; RECZEK CM, 1989, J MOL STRUCT, V214, P27, DOI 10.1016/0022-2860(89)80004-3; REMBA RD, 1979, BIOCHEMISTRY-US, V18, P2280, DOI 10.1021/bi00578a023; ROBERTS JE, 1981, J AM CHEM SOC, V103, P7654, DOI 10.1021/ja00415a044; ROBERTS JE, 1981, J BIOL CHEM, V256, P2118; RUTTER R, 1983, BIOCHEMISTRY-US, V22, P4769, DOI 10.1021/bi00289a024; RUTTER R, 1984, BIOCHEMISTRY-US, V23, P6809, DOI 10.1021/bi00321a082; RUTTER R, 1982, J BIOL CHEM, V257, P7958; SAGE JT, 1991, BIOCHEMISTRY-US, V30, P1227, DOI 10.1021/bi00219a010; SAMOKYSZYN VM, 1991, BIOCHEMISTRY-US, V30, P11646, DOI 10.1021/bi00114a006; SANDUSKY PO, 1991, J PHYS CHEM-US, V95, P4300, DOI 10.1021/j100164a024; SANDUSKY PO, 1989, J AM CHEM SOC, V111, P6437, DOI 10.1021/ja00198a074; SCHULZ CE, 1984, BIOCHEMISTRY-US, V23, P4743, DOI 10.1021/bi00315a033; SCHULZ CE, 1979, FEBS LETT, V103, P102, DOI 10.1016/0014-5793(79)81259-4; SITTER AJ, 1988, J BIOL CHEM, V263, P13032; SITTER AJ, 1985, J BIOL CHEM, V260, P7515; SKILLMAN AG, 1992, J AM CHEM SOC, V114, P9538, DOI 10.1021/ja00050a037; SONO M, 1991, BIOCHIM BIOPHYS ACTA, V1078, P351, DOI 10.1016/0167-4838(91)90156-T; SPELLANE PJ, 1980, INORG CHEM, V19, P386, DOI 10.1021/ic50204a021; Spiro T.G., 1983, IRON PORPHYRINS P2, P89; SPIRO TG, 1976, J AM CHEM SOC, V98, P5482, DOI 10.1021/ja00434a013; SPIRO TG, 1985, ADV PROTEIN CHEM, V37, P111, DOI 10.1016/S0065-3233(08)60064-9; Spiro TG, 1988, BIOL APPL RAMAN SPEC, V3, P1; TERNER J, 1984, BIOCHIM BIOPHYS ACTA, V789, P80, DOI 10.1016/0167-4838(84)90064-5; THOMAS JA, 1970, J BIOL CHEM, V245, P3129; WOLBERG A, 1970, J AM CHEM SOC, V92, P2982, DOI 10.1021/ja00713a010	105	57	57	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					13966	13978						13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188677				2022-12-25	WOS:A1994NL60600040
J	LI, S; ROSEN, JM				LI, S; ROSEN, JM			DISTAL REGULATORY ELEMENTS REQUIRED FOR RAT WHEY ACIDIC PROTEIN GENE-EXPRESSION IN TRANSGENIC MICE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR FACTOR-I; HIGH-LEVEL EXPRESSION; DNA-BINDING PROTEINS; TISSUE-SPECIFIC EXPRESSION; HUMAN CYTOMEGALO-VIRUS; HYPERSENSITIVE SITES; MAMMARY-GLAND; CASEIN GENE; MYC GENE; PROMOTER	Previous studies have demonstrated that a 3.0-kilobase, rat whey acidic protein (WAP) transgene containing 949 base pairs (bp) 5' and 70 bp 3'-flanking DNA is expressed specifically in the mammary gland of transgenic mice in a copy number dependent, position-independent manner (1). In order to localize the critical regulatory elements important for tissue-specific, high level WAP gene expression, DNase I hypersensitivity mapping studies of WAP transgenes were performed in nuclei isolated from mammary gland and liver. Two regions of DNase I hypersensitivity located at approximately -150 and -800 bp from the site of transcription initiation, respectively, were detected only in nuclei isolated from the lactating mammary gland. Within the distal hypersensitive region several binding sites for members of the CTF/NFI family of transcription factors were identified using in vitro DNase I and dimethyl sulfate interference footprinting and electrophoretic mobility shift assays. Genomic footprinting established that such protein-DNA interactions occur preferentially in the lactating mammary gland. The analysis of several 5' deletion constructs identified the region between -853 and -729 bp as essential for WAP transgene expression. These results suggest that the distal DNase I hypersensitive region contains binding sites for CTF/NFI and plays a critical role in the regulation of WAP gene expression in transgenic mice.	BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030	Baylor College of Medicine					NATIONAL CANCER INSTITUTE [R01CA016303, R37CA016303] Funding Source: NIH RePORTER; NCI NIH HHS [CA16303] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLEN ND, 1990, CELL, V61, P853, DOI 10.1016/0092-8674(90)90195-K; ALSHAWI R, 1990, MOL CELL BIOL, V10, P1192, DOI 10.1128/MCB.10.3.1192; AUSUBEL FM, 1987, CURRENT PROTOCALS MO, V1; BAYNA EM, 1990, NUCLEIC ACIDS RES, V18, P2977, DOI 10.1093/nar/18.10.2977; BECKER PB, 1987, CELL, V51, P435, DOI 10.1016/0092-8674(87)90639-8; BORGMEYER U, 1984, NUCLEIC ACIDS RES, V12, P4295, DOI 10.1093/nar/12.10.4295; BOYER BB, 1991, MOL CELL BIOL, V11, P4147, DOI 10.1128/MCB.11.8.4147; BUETTI E, 1986, J MOL BIOL, V190, P379, DOI 10.1016/0022-2836(86)90009-4; BURDON T, 1991, J BIOL CHEM, V266, P6909; CHAMBERLAIN JW, 1991, MOL CELL BIOL, V11, P3564, DOI 10.1128/MCB.11.7.3564; CHEN LH, 1989, CELL REGUL, V1, P45, DOI 10.1091/mbc.1.1.45; CORDINGLEY MG, 1987, CELL, V48, P261, DOI 10.1016/0092-8674(87)90429-6; DALE TC, 1992, MOL CELL BIOL, V12, P905, DOI 10.1128/MCB.12.3.905; DENTE L, 1988, GENE DEV, V2, P259, DOI 10.1101/gad.2.2.259; DEVRIES E, 1987, EMBO J, V6, P161, DOI 10.1002/j.1460-2075.1987.tb04734.x; DOPPLER W, 1991, MOL ENDOCRINOL, V5, P1624, DOI 10.1210/mend-5-11-1624; ELGIN SCR, 1988, J BIOL CHEM, V263, P19259; EPHRUSSI A, 1985, SCIENCE, V227, P134, DOI 10.1126/science.3917574; GIL G, 1988, P NATL ACAD SCI USA, V85, P8963, DOI 10.1073/pnas.85.23.8963; GOYAL N, 1990, MOL CELL BIOL, V10, P1041, DOI 10.1128/MCB.10.3.1041; GRAVES RA, 1991, GENE DEV, V5, P428, DOI 10.1101/gad.5.3.428; GREAVES DR, 1989, CELL, V56, P979, DOI 10.1016/0092-8674(89)90631-4; GREWAL T, 1992, MOL CELL BIOL, V12, P2339, DOI 10.1128/MCB.12.5.2339; GRONOSTAJSKI RM, 1985, MOL CELL BIOL, V5, P964, DOI 10.1128/MCB.5.5.964; GRONOSTAJSKI RM, 1986, NUCLEIC ACIDS RES, V14, P9117, DOI 10.1093/nar/14.22.9117; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; GUNZBURG WH, 1991, MOL ENDOCRINOL, V5, P123, DOI 10.1210/mend-5-1-123; HENNIGHAUSEN L, 1985, NATURE, V314, P289, DOI 10.1038/314289a0; HENNIGHAUSEN L, 1986, EMBO J, V5, P1367, DOI 10.1002/j.1460-2075.1986.tb04368.x; HENNIGHAUSEN L, 1990, Protein Expression and Purification, V1, P3, DOI 10.1016/1046-5928(90)90037-Y; HOBBS AA, 1982, J BIOL CHEM, V257, P3598; IVANOV V I, 1990, Molekulyarnaya Biologiya (Moscow), V24, P1605; JEANG KT, 1987, J VIROL, V61, P1559, DOI 10.1128/JVI.61.5.1559-1570.1987; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; LEE KF, 1988, NUCLEIC ACIDS RES, V16, P1027, DOI 10.1093/nar/16.3.1027; LICHTSTEINER S, 1987, CELL, V51, P963, DOI 10.1016/0092-8674(87)90583-6; LUBON H, 1987, NUCLEIC ACIDS RES, V15, P2103, DOI 10.1093/nar/15.5.2103; LUO XN, 1991, J BIOL CHEM, V266, P21004; MCKENZIE RM, 1978, J DAIRY SCI, V61, P723, DOI 10.3168/jds.S0022-0302(78)83639-X; MEISTERERNST M, 1989, BIOCHEMISTRY-US, V28, P8191, DOI 10.1021/bi00446a034; MINK S, 1992, MOL CELL BIOL, V12, P4906, DOI 10.1128/MCB.12.11.4906; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; NAGATA K, 1982, P NATL ACAD SCI-BIOL, V79, P6438, DOI 10.1073/pnas.79.21.6438; NITSCH D, 1990, MOL CELL BIOL, V10, P3334, DOI 10.1128/MCB.10.7.3334; PAONESSA G, 1988, EMBO J, V7, P3115, DOI 10.1002/j.1460-2075.1988.tb03178.x; RAUGHT B, 1994, MOL CELL BIOL, V14, P1752, DOI 10.1128/MCB.14.3.1752; RIGAUD G, 1991, CELL, V67, P977, DOI 10.1016/0092-8674(91)90370-E; ROSENFELD PJ, 1987, MOL CELL BIOL, V7, P875, DOI 10.1128/MCB.7.2.875; ROSSI P, 1988, CELL, V52, P405, DOI 10.1016/S0092-8674(88)80033-3; Sambrook J, 1989, MOL CLONING LABORATO; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SHAUL Y, 1986, EMBO J, V5, P1967, DOI 10.1002/j.1460-2075.1986.tb04451.x; SIEBENLIST U, 1984, CELL, V37, P381, DOI 10.1016/0092-8674(84)90368-4; SPIEGELMAN BM, 1993, J BIOL CHEM, V268, P6823; WATSON CJ, 1991, NUCLEIC ACIDS RES, V19, P6603, DOI 10.1093/nar/19.23.6603; YANG BS, 1993, MOL CELL BIOL, V13, P3093, DOI 10.1128/MCB.13.5.3093; ZIMMERMAN K, 1990, MOL CELL BIOL, V10, P2096, DOI 10.1128/MCB.10.5.2096	58	45	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					14235	14243						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188706				2022-12-25	WOS:A1994NL60600077
J	STENBERG, L; OTOOLE, PW; MESTECKY, J; LINDAHL, G				STENBERG, L; OTOOLE, PW; MESTECKY, J; LINDAHL, G			MOLECULAR CHARACTERIZATION OF PROTEIN SIR, A STREPTOCOCCAL CELL-SURFACE PROTEIN THAT BINDS BOTH IMMUNOGLOBULIN-A AND IMMUNOGLOBULIN-G	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP-A STREPTOCOCCI; GROUP-B STREPTOCOCCI; CLOSELY LINKED GENES; IGA-RECEPTOR; NUCLEOTIDE-SEQUENCES; ESCHERICHIA-COLI; CLONING VECTORS; FC-RECEPTOR; IDENTIFICATION; PURIFICATION	Cell surface proteins that bind to the Fc part of immunoglobulin (Ig) A and/or IgG are expressed by many strains of the group A Streptococcus, an important human pathogen. Two extensively characterized proteins in this group of molecules are protein Arp that preferentially binds IgA and protein H that binds IgG. In addition, recent work has shown that many group A strep streptococcal strains express a novel type of Fc-binding protein, designated protein Sir, that binds both IgA and IgG. Protein Sir22, the molecule expressed by a strain of serotype M22, has now been purified and characterized after expression of the cloned gene in Escherichia coli. Dot-blot analysis with a large number of purified monoclonal Igs showed that protein Sir22 reacted with 19 out of 20 IgA proteins and with 19 out of 24 IgG proteins. The affinity constants for the reactions between protein Sir22 and Ig were determined to be 7.0 x 10(8) M(-1) for serum IgA, 2.4 x 10(8) M(-1) for secretory IgA, and 7.8 x 10(8) M(-1) for IgG. Inhibition experiments showed that the bindings of IgA and IgG to protein Sir22 were mutually exclusive, indicating shared or contiguous binding sites. Analysis of the sequence of the sir22 gene indicated a gene product with 365 amino acid residues, including a 41-residue signal peptide. The processed form of the protein, 324 residues, has a calculated M(r) of 37,186. Deletion analysis of the sir22 gene showed that a 156-residue NH2-terminal fragment of protein Sir22 retained the ability to bind both IgA and IgG. The overall organization of protein Sir22 is similar to that of the IgA-binding protein Arp and the IgG-binding protein H. All three of these proteins are members of the M protein family and have a central repeat region of the C type.	LUND UNIV,DEPT MED MICROBIOL,S-22362 LUND,SWEDEN; UNIV ALABAMA,DEPT MICROBIOL,BIRMINGHAM,AL 35294	Lund University; University of Alabama System; University of Alabama Birmingham			O'Toole, Paul W/G-1593-2012	O'Toole, Paul W/0000-0001-5377-0824	NIDDK NIH HHS [DK-28537] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028537] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKERSTROM B, 1991, MOL IMMUNOL, V28, P349, DOI 10.1016/0161-5890(91)90147-C; AKERSTROM B, 1992, J IMMUNOL, V148, P3238; AKERSTROM B, 1994, IN PRESS MOL IMMUNOL; AKESSON P, 1990, MOL IMMUNOL, V27, P523, DOI 10.1016/0161-5890(90)90071-7; AKESSON P, 1994, IN PRESS BIOCH J; ANRAKU Y, 1967, J BIOL CHEM, V242, P2561; BESSEN DE, 1992, INFECT IMMUN, V60, P124, DOI 10.1128/IAI.60.1.124-135.1992; BJORCK L, 1984, J IMMUNOL, V133, P969; BOYLE MDP, 1990, BACTERIAL IMMUNOGLOB, V1; FISCHETTI VA, 1989, CLIN MICROBIOL REV, V2, P285, DOI 10.1128/CMR.2.3.285-314.1989; FISCHETTI VA, 1984, J EXP MED, V159, P1083, DOI 10.1084/jem.159.4.1083; FORSGREN A, 1966, J IMMUNOL, V97, P822; FRICK IM, 1994, IN PRESS MOL MICROBI; FRITHZ E, 1989, MOL MICROBIOL, V3, P1111, DOI 10.1111/j.1365-2958.1989.tb00261.x; GOMI H, 1990, J IMMUNOL, V144, P4046; HAANES EJ, 1992, J BACTERIOL, V174, P4967, DOI 10.1128/JB.174.15.4967-4976.1992; HEATH DG, 1989, P NATL ACAD SCI USA, V86, P4741, DOI 10.1073/pnas.86.12.4741; HEDEN LO, 1991, EUR J IMMUNOL, V21, P1481, DOI 10.1002/eji.1830210623; HEDEN LO, 1993, J GEN MICROBIOL, V139, P2067, DOI 10.1099/00221287-139-9-2067; HOLLINGSHEAD SK, 1986, J BIOL CHEM, V261, P1677; JEPPSON H, 1992, FEMS MICROBIOL LETT, V92, P139, DOI 10.1016/0378-1097(92)90502-F; JERLSTROM PG, 1991, MOL MICROBIOL, V5, P843, DOI 10.1111/j.1365-2958.1991.tb00757.x; KEHOE MA, 1994, NEW COMPR BIOCH, V27, P217; LINDAHL G, 1989, MOL MICROBIOL, V3, P239, DOI 10.1111/j.1365-2958.1989.tb01813.x; LINDAHL G, 1990, EUR J IMMUNOL, V20, P2241, DOI 10.1002/eji.1830201013; LINDAHL G, 1989, MOL GEN GENET, V216, P372, DOI 10.1007/BF00334378; LINDAHL G, 1990, EPIDEMIOL INFECT, V105, P87, DOI 10.1017/S0950268800047683; LINDAHL G, 1991, GENETICS AND MOLECULAR BIOLOGY OF STREPTOCOCCI, LACTOCOCCI, AND ENTEROCOCCI, P155; MALISZEWSKI CR, 1990, J EXP MED, V172, P1665, DOI 10.1084/jem.172.6.1665; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MESTECKY J, 1985, METHOD ENZYMOL, V116, P37; MICHAELSEN TE, 1977, J BIOL CHEM, V252, P883; MISRA TK, 1985, GENE, V34, P263, DOI 10.1016/0378-1119(85)90135-0; MYHRE EB, 1983, INFECT IMMUN, V40, P29, DOI 10.1128/IAI.40.1.29-34.1983; OTOOLE P, 1992, P NATL ACAD SCI USA, V89, P8661, DOI 10.1073/pnas.89.18.8661; PRIDMORE RD, 1987, GENE, V56, P309, DOI 10.1016/0378-1119(87)90149-1; RAEDER R, 1992, J CLIN MICROBIOL, V30, P3074, DOI 10.1128/JCM.30.12.3074-3081.1992; RETNONINGRUM DS, 1993, J IMMUNOL, V150, P2332; Sambrook J, 1989, MOL CLONING LABORATO; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; STENBERG L, 1992, MOL MICROBIOL, V6, P1185, DOI 10.1111/j.1365-2958.1992.tb01557.x; VANDEWINKEL JGJ, 1993, IMMUNOL TODAY, V14, P215, DOI 10.1016/0167-5699(93)90166-I; VANLOGHEM E, 1982, SCAND J IMMUNOL, V15, P275; WHATMORE AM, 1994, MOL MICROBIOL, V11, P363, DOI 10.1111/j.1365-2958.1994.tb00316.x; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	45	88	92	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13458	13464						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175778				2022-12-25	WOS:A1994NK18400061
J	WU, XR; LIN, JH; WALZ, T; HANER, M; YU, J; AEBI, UL; SUN, TT				WU, XR; LIN, JH; WALZ, T; HANER, M; YU, J; AEBI, UL; SUN, TT			MAMMALIAN UROPLAKINS - A GROUP OF HIGHLY CONSERVED UROTHELIAL DIFFERENTIATION-RELATED MEMBRANE-PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT URINARY-BLADDER; TRANSITIONAL EPITHELIAL-CELLS; EXPANSION-CONTRACTION CYCLE; LUMINAL MEMBRANE; 3-DIMENSIONAL STRUCTURE; POLYACRYLAMIDE GELS; MOLECULAR-CLONING; PLASMA-MEMBRANE; CD9 ANTIGEN; SURFACE	The asymmetric unit membrane (AUM) forms the apical plaques of mammalian urothelium and is believed to play a role in strengthening the urothelial apical surface thus preventing the cells from rupturing during bladder distention. We have shown previously that purified bovine AUMs contain four major integral membrane proteins: the uroplakins Ia (27 kDa), Ib (28 kDa), II (15 kDa), and III (47 kDa). This contradicts some previous reports indicating that some of these proteins are absent in AUMs of several species. Using an improved procedure, we isolated AUMs from, in addition to cattle, eight mammalian species (human, monkey, sheep, pig, dog, rabbit, rat, and mouse). The AUMs of these species appear morphologically similar bearing crystalline patches of 12-nm protein particles with a center-to center spacing of 16.5 nm. Using antibodies raised against synthetic oligopeptides or individual bovine uroplakins, we established by immunoblotting that the four uroplakins are present in AUMs of all these species. The DNA-deduced amino acid sequences of bovine and mouse uroplakin II revealed 83% identity. These results indicate that uroplakins Ia, Ib, II, and m are the major protein components of probably all mammalian urothelial plaques, and that the sequence and three-dimensional structure of uroplakin molecules are highly conserved during mammalian evolution.	NYU, SCH MED, RONALD O PERELMAN DEPT DERMATOL, EPITHELIAL BIOL UNIT, NEW YORK, NY 10016 USA; NYU, KAPLAN COMPREHENS CANC CTR, SCH MED, DEPT PHARMACOL, NEW YORK, NY 10016 USA; UNIV BASEL, BIOCTR, MAURICE E MULLER INST HIGH RESOLUT ELECTRON M, CH-4056 BASEL, SWITZERLAND	New York University; New York University; University of Basel			Sun, Tung-Tien/J-4425-2015; 郑, 征/C-8514-2011	Sun, Tung-Tien/0000-0002-6841-1063; Walz, Thomas/0000-0003-2606-2835; Wu, Xue-Ru/0000-0001-6058-6291	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR039749] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047529, R01DK039753] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR39749] Funding Source: Medline; NIDDK NIH HHS [DK47529, DK39753] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AEBI U, 1973, Journal of Supramolecular Structure, V1, P498, DOI 10.1002/jss.400010606; AMIOT M, 1990, J IMMUNOL, V145, P4322; BOUCHEIX C, 1991, J BIOL CHEM, V266, P117; BRADBURY LE, 1992, J IMMUNOL, V149, P2841; BRISSON A, 1983, J MOL BIOL, V166, P21, DOI 10.1016/S0022-2836(83)80048-5; CARUTHERS JS, 1977, J CELL BIOL, V73, P382, DOI 10.1083/jcb.73.2.382; CHLAPOWSKI FJ, 1972, J CELL BIOL, V53, P92, DOI 10.1083/jcb.53.1.92; CLASSON BJ, 1990, J EXP MED, V172, P1007, DOI 10.1084/jem.172.3.1007; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EICHNER R, 1984, J CELL BIOL, V98, P1388, DOI 10.1083/jcb.98.4.1388; FIRTH JA, 1973, J ANAT, V116, P31; HICKS RM, 1970, J CELL BIOL, V45, P542, DOI 10.1083/jcb.45.3.542; HICKS RM, 1969, NATURE, V224, P1304, DOI 10.1038/2241304a0; HICKS RM, 1965, J CELL BIOL, V26, P25, DOI 10.1083/jcb.26.1.25; HOTTA H, 1988, CANCER RES, V48, P2955; KALLIN B, 1991, MOL CELL BIOL, V11, P5338, DOI 10.1128/MCB.11.10.5338; KNUTTON S, 1976, J CELL SCI, V22, P355; KOSS LG, 1969, LAB INVEST, V21, P154; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN JH, 1994, J BIOL CHEM, V269, P1775; MERRIL CR, 1981, ANAL BIOCHEM, V110, P201, DOI 10.1016/0003-2697(81)90136-6; METZELAAR MJ, 1991, J BIOL CHEM, V266, P3239; MINSKY BD, 1978, J CELL BIOL, V77, P685, DOI 10.1083/jcb.77.3.685; MITAMURA T, 1992, J CELL BIOL, V118, P1389, DOI 10.1083/jcb.118.6.1389; PARSONS CL, 1980, SCIENCE, V208, P605, DOI 10.1126/science.6154316; PAULI BU, 1983, PATHOLOGY BLADDER CA, P42; PORTER KR, 1963, INTRO FINE STRUCTURE; ROBERTSON JD, 1980, J CELL BIOL, V86, P514, DOI 10.1083/jcb.86.2.514; RUGGIERI MR, 1992, J UROLOGY, V148, P173, DOI 10.1016/S0022-5347(17)36547-3; RYAN AM, 1993, MAMM GENOME, V4, P656, DOI 10.1007/BF00360903; SAMBROOK J, 1989, MOLCLONING LABORATOR; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARIKAS SN, 1986, CELL TISSUE RES, V246, P109; SARIKAS SN, 1989, CELL TISSUE RES, V258, P393; SAXTON WO, 1979, ULTRAMICROSCOPY, V4, P343, DOI 10.1016/S0304-3991(79)80044-3; SAXTON WO, 1982, J MICROSC-OXFORD, V127, P127, DOI 10.1111/j.1365-2818.1982.tb00405.x; SEVERS NJ, 1979, J ULTRA MOL STRUCT R, V69, P279, DOI 10.1016/S0022-5320(79)90117-5; STAEHELIN LA, 1972, J CELL BIOL, V53, P73, DOI 10.1083/jcb.53.1.73; STUBBS CD, 1979, BIOCHIM BIOPHYS ACTA, V558, P58, DOI 10.1016/0005-2736(79)90315-8; STUBBS CD, 1975, BIOCHEM SOC T, V3, P759, DOI 10.1042/bst0030759; SURYA B, 1990, J CELL SCI, V97, P419; TAKAHASHI S, 1990, J IMMUNOL, V145, P2207; TAYLOR KA, 1984, J ULTRA MOL STRUCT R, V87, P23, DOI 10.1016/S0022-5320(84)90113-8; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VERGARA J, 1974, J CELL BIOL, V61, P83, DOI 10.1083/jcb.61.1.83; WALKER BE, 1960, J ULTRA MOL STRUCT R, V3, P345, DOI 10.1016/S0022-5320(60)90014-9; WARREN RC, 1970, NATURE, V227, P280, DOI 10.1038/227280b0; WOODCOCKMITCHELL J, 1982, J CELL BIOL, V95, P580, DOI 10.1083/jcb.95.2.580; WU XR, 1993, J CELL SCI, V106, P31; WU XR, 1990, J BIOL CHEM, V265, P19170; YU J, 1990, J CELL BIOL, V111, P1207, DOI 10.1083/jcb.111.3.1207; YU J, 1994, IN PRESS J CELL BIOL	52	243	265	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13716	13724						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175808				2022-12-25	WOS:A1994NK18400096
J	BRANDT, U; URIBE, S; SCHAGGER, H; TRUMPOWER, BL				BRANDT, U; URIBE, S; SCHAGGER, H; TRUMPOWER, BL			ISOLATION AND CHARACTERIZATION OF QCR10, THE NUCLEAR GENE ENCODING THE 8.5-KDA SUBUNIT-10 OF THE SACCHAROMYCES-CEREVISIAE CYTOCHROME BC(1), COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								We have cloned and sequenced QCR10, the nuclear gene encoding an 8.5-kDa protein proposed to be a subunit of the cytochrome bc(1) complex of Saccharomyces cerevisiae. QCR10 includes a 231-base pair open reading frame capable of encoding a protein of 77 amino acids with a predicted molecular mass of 8492 Da. The codons for the amino-terminal methionine and alanine are separated from the remainder of the open reading frame by a 63-base pair intron that contains 5'-donor, 3'-acceptor, and TACTAAC sequences known to be necessary for splicing. The deduced amino acid sequence of the 8.5-kDa yeast protein is 28% identical to that of the 6.4-kDa subunit 11 from the bovine heart cytochrome be, complex, and the predicted secondary structures of the two proteins are very similar. Deletion of the chromosomal copy of QCR10 did not affect the growth of yeast on nonfermentable carbon sources. However, deletion of QCR10 synergistically contributes to the temperature-dependent phenotype resulting from deletion of QCR6, the gene for subunit 6 of the cytochrome bc(1) complex. In addition, ubiquinol-cytochrome c oxidoreductase activity was reduced 40% in mitochondrial membranes from the QCR10 deletion strain, and the Rieske iron-sulfur protein was lost when the cytochrome bc(1) complex lacking the 8.5-kDa protein was purified. We conclude that the 8.5-kDa protein encoded by QCR10 is a subunit of the yeast cytochrome bc(1) complex and that the presence of this subunit during assembly is required for stable association of the iron-sulfur protein with the complex.	DARTMOUTH COLL SCH MED, DEPT BIOCHEM, HANOVER, NH 03755 USA; UNIV FRANKFURT KLINIKUM, ZENTRUM BIOL CHEM, D-60596 FRANKFURT, GERMANY	Dartmouth College; Goethe University Frankfurt; Goethe University Frankfurt Hospital			Brandt, Ulrich/C-4406-2008	Brandt, Ulrich/0000-0003-1869-6811	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM020379, R01GM020379] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 20379] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BECKMANN JD, 1987, J BIOL CHEM, V262, P8901; BRANDT U, 1993, J BIOL CHEM, V268, P8387; CAI MJ, 1990, CELL, V61, P437, DOI 10.1016/0092-8674(90)90525-J; DELLASETA F, 1990, J BIOL CHEM, V265, P15168; ELBLE R, 1992, BIOTECHNIQUES, V13, P18; FORSBURG SL, 1988, MOL CELL BIOL, V8, P647, DOI 10.1128/MCB.8.2.647; GEIER BM, 1992, EUR J BIOCHEM, V208, P375, DOI 10.1111/j.1432-1033.1992.tb17197.x; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; Johnson D. A., 1984, Gene Analysis Techniques, V1, P3, DOI 10.1016/0735-0651(84)90049-9; JONES JS, 1990, YEAST, V6, P363, DOI 10.1002/yea.320060502; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAMARCHE AEP, 1992, J BIOL CHEM, V267, P22473; LJUNGDAHL O, 1987, BIOCHIM BIOPHYS ACTA, V891, P227; PHILLIPS JD, 1990, J BIOL CHEM, V265, P20813; RYMOND BC, 1992, MOL CELLULAR BIOL YE, V2, P143; Sambrook J, 1989, MOL CLONING LABORATO; SCHAGGER H, 1990, EUR J BIOCHEM, V190, P123, DOI 10.1111/j.1432-1033.1990.tb15554.x; SCHAGGER H, 1985, FEBS LETT, V190, P89, DOI 10.1016/0014-5793(85)80434-8; SCHAGGER H, 1986, METHOD ENZYMOL, V126, P224; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; SCHNEIDER JC, 1991, MOL CELL BIOL, V11, P4934, DOI 10.1128/MCB.11.10.4934; SHERMAN F, 1991, METHOD ENZYMOL, V194, P21; SIEDOW JN, 1978, J BIOL CHEM, V253, P2392; SIKORSKI RS, 1989, GENETICS, V122, P19; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TRECO DA, 1989, CURRENT PROTOCOLS MO; TRUMPOWER BL, 1990, MICROBIOL REV, V54, P101, DOI 10.1128/MMBR.54.2.101-129.1990; YANG MJ, 1994, J BIOL CHEM, V269, P1270; YANG XH, 1986, J BIOL CHEM, V261, P2282; ZHOU C, 1990, BIOTECHNIQUES, V8, P172; 1991, PROGRAM MANUAL GCG P	32	69	71	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12947	12953						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175712				2022-12-25	WOS:A1994NH71600087
J	ERNST, F; HOFFSCHULTE, HK; THOMEKROMER, B; SWIDERSKY, UE; WERNER, PK; MULLER, M				ERNST, F; HOFFSCHULTE, HK; THOMEKROMER, B; SWIDERSKY, UE; WERNER, PK; MULLER, M			PRECURSOR-SPECIFIC REQUIREMENTS FOR SECA, SECB, AND DELTA-MU(H+) DURING PROTEIN EXPORT OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								We compare translocation into inside-out plasma membrane vesicles (INV) of the in vitro synthesized outer membrane proteins LamB and OmpA and the periplasmic protein Skp of Escherichia coli and demonstrate a precursor-specific dependence on the export factors SecA, SecB, and the proton-motive force (Delta mu(H+)). A partial reduction in soluble SecA caused a 50% decrease in translocation of preLamB. In contrast, removal of INV-bound SecA by urea extraction was required to see a decrease in translocation of preOmpA and preSkp, with 8% of preSkp still being translocated into ureatreated INV. Translocation of the three precursors into INV showed a corresponding differential sensitivity toward dissipation of Delta mu(H+) following removal of the F-1- ATPase from the INV. While depletion of both F-1 and SecA or simply lowering of the reaction temperature resulted in an inhibition of complete transmembrane translocation, it interfered less severely with signal sequence cleavage, indicating the formation of translocation intermediates under these conditions. The relative amounts of intermediate obtained were also different for the three preproteins correlating a low requirement for SecA and Delta mu(H+) with a facilitated initiation of translocation. Whereas preSkp was translocated independently of SecB, preLamB was not even targeted to the INV in its absence. Functional targeting of preOmpA required the presence of SecB during incubation of the precursor with INV and not during its synthesis. SecB, exogenously added during the period of synthesis, did not prevent the formation of translocation-incompetent preLamB. The latter results are consistent with an important targeting function of SecB, which so far has mostly been described as a molecular chaperone. The findings are discussed with respect to current models of bacterial protein export usually derived from the analysis of a single precursor.	UNIV MUNICH, INST PHYS BIOCHEM, D-80366 MUNICH, GERMANY	University of Munich								AKIMARU J, 1991, P NATL ACAD SCI USA, V88, P6545, DOI 10.1073/pnas.88.15.6545; ALTMAN E, 1991, EMBO J, V10, P239, DOI 10.1002/j.1460-2075.1991.tb07943.x; BASSILANA M, 1992, J BIOL CHEM, V267, P25246; BIEKER KL, 1990, J BIOENERG BIOMEMBR, V22, P291, DOI 10.1007/BF00763169; BIEKER KL, 1990, CELL, V61, P833, DOI 10.1016/0092-8674(90)90193-I; BRUNDAGE L, 1990, CELL, V62, P649, DOI 10.1016/0092-8674(90)90111-Q; CHEN L, 1985, J BACTERIOL, V161, P973, DOI 10.1128/JB.161.3.973-980.1985; COLLIER DN, 1988, CELL, V53, P273, DOI 10.1016/0092-8674(88)90389-3; CROOKE E, 1988, EMBO J, V7, P1831, DOI 10.1002/j.1460-2075.1988.tb03015.x; CROOKE E, 1987, P NATL ACAD SCI USA, V84, P5216, DOI 10.1073/pnas.84.15.5216; CUNNINGHAM K, 1989, EMBO J, V8, P955, DOI 10.1002/j.1460-2075.1989.tb03457.x; DECOCK H, 1992, MOL MICROBIOL, V6, P599; FREUDL R, 1985, EMBO J, V4, P3593, DOI 10.1002/j.1460-2075.1985.tb04122.x; GELLER BL, 1989, J BIOL CHEM, V264, P16465; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; HOFFSCHUTE HK, 1994, J BIOL CHEM, V269, P12833; ITO K, 1992, MOL MICROBIOL, V6, P2423; JOLY JC, 1993, EMBO J, V12, P255, DOI 10.1002/j.1460-2075.1993.tb05651.x; KUMAMOTO CA, 1988, J BIOL CHEM, V263, P11554; KUMAMOTO CA, 1990, J BIOENERG BIOMEMBR, V22, P337, DOI 10.1007/BF00763171; KUMAMOTO CA, 1985, J BACTERIOL, V163, P267, DOI 10.1128/JB.163.1.267-274.1985; KUMAMOTO CA, 1993, J BACTERIOL, V175, P2184, DOI 10.1128/JB.175.8.2184-2188.1993; KUSTERS R, 1989, J BIOL CHEM, V264, P20827; LEE CA, 1986, J BACTERIOL, V166, P878, DOI 10.1128/jb.166.3.878-883.1986; LIU GP, 1989, P NATL ACAD SCI USA, V86, P9213, DOI 10.1073/pnas.86.23.9213; MIZUSHIMA S, 1990, J BIOENERG BIOMEMBR, V22, P389, DOI 10.1007/BF00763174; MULLER M, 1984, P NATL ACAD SCI-BIOL, V81, P7421, DOI 10.1073/pnas.81.23.7421; MULLER M, 1987, EMBO J, V6, P3855, DOI 10.1002/j.1460-2075.1987.tb02723.x; NISHIYAMA K, 1993, EMBO J, V12, P3409, DOI 10.1002/j.1460-2075.1993.tb06015.x; OLIVER DB, 1982, CELL, V30, P311, DOI 10.1016/0092-8674(82)90037-X; RANDALL LL, 1986, CELL, V46, P921, DOI 10.1016/0092-8674(86)90074-7; RHOADS DB, 1984, J BACTERIOL, V159, P63, DOI 10.1128/JB.159.1.63-70.1984; SCHATZ PJ, 1990, ANNU REV GENET, V24, P215, DOI 10.1146/annurev.ge.24.120190.001243; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; SWIDERSKY UE, 1990, EMBO J, V9, P1777, DOI 10.1002/j.1460-2075.1990.tb08302.x; SWIDERSKY UE, 1992, EUR J BIOCHEM, V207, P803, DOI 10.1111/j.1432-1033.1992.tb17111.x; TANI K, 1989, J BIOL CHEM, V264, P18582; THOME BM, 1990, FEBS LETT, V269, P113, DOI 10.1016/0014-5793(90)81132-8; THOME BM, 1991, MOL MICROBIOL, V5, P2815, DOI 10.1111/j.1365-2958.1991.tb01990.x; WATANABE M, 1989, P NATL ACAD SCI USA, V86, P2728, DOI 10.1073/pnas.86.8.2728; WATANABE M, 1990, P NATL ACAD SCI USA, V87, P1960, DOI 10.1073/pnas.87.5.1960; WATANABE M, 1993, P NATL ACAD SCI USA, V90, P9011, DOI 10.1073/pnas.90.19.9011; WEISS JB, 1988, P NATL ACAD SCI USA, V85, P8978, DOI 10.1073/pnas.85.23.8978; WICKNER W, 1991, ANNU REV BIOCHEM, V60, P101, DOI 10.1146/annurev.bi.60.070191.000533; YAMADA H, 1989, J BIOL CHEM, V264, P1723	45	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12840	12845						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175698				2022-12-25	WOS:A1994NH71600072
J	FLICK, KE; GONZALEZ, L; HARRISON, CJ; NELSON, HCM				FLICK, KE; GONZALEZ, L; HARRISON, CJ; NELSON, HCM			YEAST HEAT-SHOCK TRANSCRIPTION FACTOR CONTAINS A FLEXIBLE LINKER BETWEEN THE DNA-BINDING AND TRIMERIZATION DOMAINS - IMPLICATIONS FOR DNA-BINDING BY TRIMERIC PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								All heat shock transcription factors (HSFs) share two regions of homology, identified as the DNA binding and trimerization regions. The DNA binding region consists of two parts, an 89-amino-acid minimal DNA-binding domain and an additional 21 amino acids which are not necessary for specific DNA binding of a monomeric DNA-binding domain. These 21 amino acids may act as a flexible linker between the DNA-binding and trimerization domains. Saccharomyces cerevisiae HSF has an additional 52 amino acids between the proposed flexible linker and the trimerization domain. Deletion of this unique region has no effect on the structural integrity or essential in vivo functions of HSF. To investigate the role of the 21-amino-acid proposed linker a series of internal deletions was created in fragments containing the DNA-binding and trimerization domains. The deletions have no effect on the structural integrity of the protein as assayed by circular dichroism spectroscopy. However, alterations of the linker do affect affinity of trimeric HSF binding to its target DNA In addition, deletion of part or all of the proposed linker from full-length yeast HSF, an essential protein, disrupts growth of yeast.	UNIV CALIF BERKELEY, DEPT MOLEC & CELLULAR BIOL, DIV BIOCHEM & MOLEC BIOL, STANLEY DONNER ASU, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley			Gonzalez, Lino/E-4102-2012	Gonzalez, Lino/0000-0003-3817-6450	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007232, R01GM044086] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-44086, GM-07232] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMIN J, 1988, MOL CELL BIOL, V8, P3761, DOI 10.1128/MCB.8.9.3761; BIENZ M, 1987, ADV GENET, V24, P31, DOI 10.1016/S0065-2660(08)60006-1; BOORSTEIN WR, 1990, J BIOL CHEM, V265, P18912; CANTOR CR, 1980, BIOPHYSICAL CHEM 2, P409; CLOS J, 1990, CELL, V63, P1085, DOI 10.1016/0092-8674(90)90511-C; GALLO GJ, 1993, MOL CELL BIOL, V13, P749, DOI 10.1128/MCB.13.2.749; GROSS DS, 1990, J MOL BIOL, V216, P611, DOI 10.1016/0022-2836(90)90387-2; GUBLER M, 1991, EMBO J, V10, P951, DOI 10.1002/j.1460-2075.1991.tb08029.x; HARRISON CJ, 1994, SCIENCE, V263, P224, DOI 10.1126/science.8284672; JAKOBSEN BK, 1991, EMBO J, V10, P369, DOI 10.1002/j.1460-2075.1991.tb07958.x; LIS J, 1993, CELL, V74, P1, DOI 10.1016/0092-8674(93)90286-Y; Maxam A M, 1980, Methods Enzymol, V65, P499; MORIMOTO RI, 1992, J BIOL CHEM, V267, P21987; NAKAI A, 1993, MOL CELL BIOL, V13, P1983, DOI 10.1128/MCB.13.4.1983; OERTELBUCHHEIT P, 1993, J MOL BIOL, V229, P1, DOI 10.1006/jmbi.1993.1001; PERISIC O, 1989, CELL, V59, P797, DOI 10.1016/0092-8674(89)90603-X; PETERANDERL R, 1992, BIOCHEMISTRY-US, V31, P12272, DOI 10.1021/bi00163a042; RABINDRAN SK, 1991, P NATL ACAD SCI USA, V88, P6906, DOI 10.1073/pnas.88.16.6906; RADFORD SE, 1989, J BIOL CHEM, V264, P767; REECE RJ, 1993, SCIENCE, V261, P909, DOI 10.1126/science.8346441; RYE HS, 1993, J BIOL CHEM, V268, P25229; SARGE KD, 1991, GENE DEV, V5, P1902, DOI 10.1101/gad.5.10.1902; SAXENA VP, 1971, P NATL ACAD SCI USA, V68, P969, DOI 10.1073/pnas.68.5.969; SCHARF KD, 1990, EMBO J, V9, P4495, DOI 10.1002/j.1460-2075.1990.tb07900.x; SCHUETZ TJ, 1991, P NATL ACAD SCI USA, V88, P6911, DOI 10.1073/pnas.88.16.6911; SHEN H, 1991, J BIOL CHEM, V266, P11335; SHORE D, 1987, CELL, V51, P721, DOI 10.1016/0092-8674(87)90095-X; SORGER PK, 1990, CELL, V62, P793, DOI 10.1016/0092-8674(90)90123-V; SORGER PK, 1989, CELL, V59, P807, DOI 10.1016/0092-8674(89)90604-1; SORGER PK, 1988, CELL, V54, P855, DOI 10.1016/S0092-8674(88)91219-6; STARK MJR, 1987, GENE, V51, P255, DOI 10.1016/0378-1119(87)90314-3; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; VUISTER GW, 1994, BIOCHEMISTRY-US, V33, P10, DOI 10.1021/bi00167a002; WIEDERRECHT G, 1988, CELL, V54, P841, DOI 10.1016/S0092-8674(88)91197-X; XIAO H, 1988, SCIENCE, V239, P1139, DOI 10.1126/science.3125608	35	55	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12475	12481						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175654				2022-12-25	WOS:A1994NH71600019
J	KELLEHER, DJ; GILMORE, R				KELLEHER, DJ; GILMORE, R			THE SACCHAROMYCES-CEREVISIAE OLIGOSACCHARYLTRANSFERASE IS A PROTEIN COMPLEX COMPOSED OF WBP1P, SWP1P, AND 4 ADDITIONAL POLYPEPTIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								Asparagine linked glycosylation of proteins in the lumen of the endoplasmic reticulum is catalyzed by the oligosaccharyltransferase. Previously, the mammalian oligosaccharyltransferase was shown to co-purify with a protein complex consisting of three integral membrane proteins: ribophorin I and ribophorin II and a nonglycosylated 48-kDa polypeptide designated OST48. Here, we describe the purification of the oligosaccharyltransferase from Saccharomyces cerevisiae. The yeast oligosaccharyltransferase complex is composed of six subunits (alpha, beta, gamma, delta, epsilon, and zeta). The alpha subunit of the yeast oligosaccharyltransferase complex is a heterogeneously glycosylated protein with three glycoforms of 64, 62, and 60 kDa that contain, respectively, four, three, and two asparagine-linked oligosaccharide chains. The beta and delta subunits were shown to correspond to the 45-kDa Wbp1 glycoprotein and the 30-kDa Swp1 protein, respectively. The Wbp1 and Swp1 proteins were previously shown to be essential for asparagine-linked glycosylation in vivo. The nonglycosylated gamma, epsilon, and zeta subunits have apparent molecular masses of 34, 16, and 9 kDa. Homology between the yeast and mammalian oligosaccharyltransferase complexes first became evident when the 48-kDa subunit of the mammalian enzyme was found to be 25% identical in sequence with the Wbp1 protein. Here we present an alignment between the Swp1 protein and the carboxyl-terminal half of human ribophorin II that reveals that these two proteins are related gene products.			KELLEHER, DJ (corresponding author), UNIV MASSACHUSETTS, SCH MED, DEPT BIOCHEM & MOLEC BIOL, WORCESTER, MA 01655 USA.				NIGMS NIH HHS [GM 43768] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043768] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AMARCOSTESEC A, 1984, J CELL BIOL, V99, P2247, DOI 10.1083/jcb.99.6.2247; BADET J, 1988, CARBOHYD RES, V178, P49, DOI 10.1016/0008-6215(88)80101-0; CHAIT BT, 1992, SCIENCE, V257, P1885, DOI 10.1126/science.1411504; CRIMAUDO C, 1987, EMBO J, V6, P75, DOI 10.1002/j.1460-2075.1987.tb04721.x; DESHAIES RJ, 1991, NATURE, V349, P806, DOI 10.1038/349806a0; GAVEL Y, 1990, PROTEIN ENG, V3, P433, DOI 10.1093/protein/3.5.433; HARLOW E, 1988, ANTIBODIES LABORATOR; HARNIKORT V, 1987, J CELL BIOL, V104, P855, DOI 10.1083/jcb.104.4.855; HEESEN ST, 1992, EMBO J, V11, P2071, DOI 10.1002/j.1460-2075.1992.tb05265.x; HEESEN ST, 1993, EMBO J, V12, P279, DOI 10.1002/j.1460-2075.1993.tb05654.x; HEESEN ST, 1991, EUR J CELL BIOL, V56, P8; HIRSCHBERG CB, 1987, ANNU REV BIOCHEM, V56, P63, DOI 10.1146/annurev.bi.56.070187.000431; HUFFAKER TC, 1983, P NATL ACAD SCI-BIOL, V80, P7466, DOI 10.1073/pnas.80.24.7466; JONES EW, 1991, METHOD ENZYMOL, V194, P428; KELLEHER DJ, 1992, CELL, V69, P55, DOI 10.1016/0092-8674(92)90118-V; KUKURUZINSKA MA, 1987, ANNU REV BIOCHEM, V56, P915, DOI 10.1146/annurev.biochem.56.1.915; MARCANTONIO EE, 1984, J CELL BIOL, V99, P2254, DOI 10.1083/jcb.99.6.2254; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; SHARMA C, 1981, EUR J BIOCHEM, V116, P101, DOI 10.1111/j.1432-1033.1981.tb05306.x; SILBERSTEIN S, 1992, J BIOL CHEM, V267, P23658; Smith EL, 1940, P NATL ACAD SCI USA, V26, P272, DOI 10.1073/pnas.26.4.272; SPIRO MJ, 1979, J BIOL CHEM, V254, P7668; Steele J C Jr, 1978, Methods Enzymol, V48, P11; TRIMBLE RB, 1984, ANAL BIOCHEM, V141, P515, DOI 10.1016/0003-2697(84)90080-0; TRIMBLE RB, 1980, J BIOL CHEM, V255, P1892; Turco SJ, 1977, P NATL ACAD SCI USA, V74, P4410; VEROSTEK MF, 1993, J BIOL CHEM, V268, P12095; VEROSTEK MF, 1991, J BIOL CHEM, V266, P5547; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683	32	90	98	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12908	12917						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175708				2022-12-25	WOS:A1994NH71600082
J	LAPPI, DA; YING, WB; BARTHELEMY, I; MARTINEAU, D; PRIETO, I; BENATTI, L; SORIA, M; BAIRD, A				LAPPI, DA; YING, WB; BARTHELEMY, I; MARTINEAU, D; PRIETO, I; BENATTI, L; SORIA, M; BAIRD, A			EXPRESSION AND ACTIVITIES OF A RECOMBINANT BASIC FIBROBLAST GROWTH FACTOR-SAPORIN FUSION PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								A fusion protein containing the full-length sequences of the mitogen, basic fibroblast growth factor (FGF-2), and the ribosome inactivating protein, saporin (SAP), has been expressed in E. coli. As expected, it binds with high affinity to heparin-Sepharose like FGF-2 and can displace the binding of radiolabeled FGF-2 to its high affinity receptor. In contrast, the fusion protein only has much lower ribosome-inactivating activity than free saporin, although full ribosome-inactivating protein activity can be generated by proteolytic removal of the FGF-2 moiety. Cytotoxicity experiments with B16-F10 mouse melanoma cells establish that the fusion protein is active as a chemical conjugate against these intact cells. Presumably these cells have the ability to activate the SAP component of the fusion protein through an intracellular metabolism of the fusion protein. Because we also show the fusion protein has tumor growth inhibition properties and antimetastatic activity in in vivo models of melanoma, the findings support the hypothesis that FGF-based ligand-mediated cytotoxicity can serve to target cytotoxic agents in vivo.	FARMITALIA CARLO ERBA LTD, I-20014 NERVIANO, ITALY; IST SCI SAN RAFFAELE, DIPARTIMENTO BIOTECNOL, I-20132 MILAN, ITALY	Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele	LAPPI, DA (corresponding author), WHITTIER INST DIABET & ENDOCRINOL, DEPT MOLEC & CELLULAR GROWTH BIOL, LA JOLLA, CA 92037 USA.			Lappi, Douglas/0000-0003-4239-7387; Baird, Andrew/0000-0003-0027-9905	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK018811] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK18811] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAHAM JA, 1986, EMBO J, V5, P2523, DOI 10.1002/j.1460-2075.1986.tb04530.x; BACHA P, 1988, J EXP MED, V167, P612, DOI 10.1084/jem.167.2.612; BAIRD A, 1987, BIOCHEM BIOPH RES CO, V142, P428, DOI 10.1016/0006-291X(87)90292-0; BARRA D, 1991, BIOTECHNOL APPL BIOC, V13, P48; BARTHELEMY I, 1993, J BIOL CHEM, V268, P6541; Battey, 1986, BASIC METHODS MOL BI; BEATTIE GM, 1991, J CLIN ENDOCR METAB, V73, P93, DOI 10.1210/jcem-73-1-93; BEATTIE GM, 1990, DIABETES, V39, P1002, DOI 10.2337/diabetes.39.8.1002; BEITZ JG, 1992, CANCER RES, V52, P227; BENARDI MA, 1992, INT J CANCER S, V7, P73; BIRO S, 1992, CIRC RES, V71, P640, DOI 10.1161/01.RES.71.3.640; BRINKMANN U, 1992, P NATL ACAD SCI USA, V89, P3065, DOI 10.1073/pnas.89.7.3065; CASE JP, 1989, P NATL ACAD SCI USA, V86, P287, DOI 10.1073/pnas.86.1.287; CASSCELLS W, 1992, P NATL ACAD SCI USA, V89, P7159, DOI 10.1073/pnas.89.15.7159; CHAUDHARY VK, 1989, NATURE, V339, P394, DOI 10.1038/339394a0; CHAUDHARY VK, 1988, NATURE, V335, P369, DOI 10.1038/335369a0; DAVID T, 1992, J CELL PHYSIOL, V153, P483, DOI 10.1002/jcp.1041530307; ESCH F, 1992, ANAL BIOCHEM, V136, P39; FALINI B, 1992, LANCET, V339, P1195, DOI 10.1016/0140-6736(92)91135-U; GOLDIN A, 1985, INVEST NEW DRUG, V3, P3; GRISWOLD DP, 1972, CANCER CHEMOTH REP 2, V3, P315; Hill G J 2nd, 1971, J Surg Oncol, V3, P1, DOI 10.1002/jso.2930030104; ISACCHI A, 1991, P NATL ACAD SCI USA, V88, P2628, DOI 10.1073/pnas.88.7.2628; JEAN LFL, 1993, PROTEIN ENG, V6, P305, DOI 10.1093/protein/6.3.305; KASTURI S, 1992, J BIOL CHEM, V267, P23427; KELLEY VE, 1988, P NATL ACAD SCI USA, V85, P3980, DOI 10.1073/pnas.85.11.3980; KIYOKAWA T, 1991, ANN NY ACAD SCI, V636, P331, DOI 10.1111/j.1749-6632.1991.tb33463.x; KREITMAN RJ, 1990, P NATL ACAD SCI USA, V87, P8291, DOI 10.1073/pnas.87.21.8291; LAPPI DA, 1989, BIOCHEM BIOPH RES CO, V160, P917, DOI 10.1016/0006-291X(89)92522-9; LAPPI DA, 1993, ANAL BIOCHEM, V212, P446, DOI 10.1006/abio.1993.1353; LAPPI DA, 1985, BIOCHEM BIOPH RES CO, V129, P934, DOI 10.1016/0006-291X(85)91981-3; LAPPI DA, 1991, J CELL PHYSIOL, V147, P17, DOI 10.1002/jcp.1041470104; LAPPI DA, 1991, PROG GROWTH FACTOR R, V2, P223; LINDNER V, 1991, CIRC RES, V68, P106, DOI 10.1161/01.RES.68.1.106; LORBERBOUMGALSKI H, 1988, J BIOL CHEM, V263, P18650; LORBERBOUMGALSKI H, 1989, P NATL ACAD SCI USA, V86, P1008, DOI 10.1073/pnas.86.3.1008; MARAS B, 1990, BIOCHEM INT, V21, P831; MERWIN JR, 1992, CANCER RES, V52, P4995; MOSCATELLI D, 1987, J CELL PHYSIOL, V131, P123, DOI 10.1002/jcp.1041310118; MURATA J, 1989, JPN J CANCER RES, V80, P866, DOI 10.1111/j.1349-7006.1989.tb01728.x; MURPHY JR, 1986, P NATL ACAD SCI USA, V83, P8258, DOI 10.1073/pnas.83.21.8258; MURPHY JR, 1987, BIOCHEM SOC SYMP, P9; OELTMANN TN, 1991, FASEB J, V5, P2334, DOI 10.1096/fasebj.5.10.1676688; OGATA M, 1989, P NATL ACAD SCI USA, V86, P4215, DOI 10.1073/pnas.86.11.4215; OHARE M, 1990, FEBS LETT, V273, P200, DOI 10.1016/0014-5793(90)81084-2; PASTAN I, 1989, J BIOL CHEM, V264, P15157; PRIETO I, 1991, ANN NY ACAD SCI, V638, P434, DOI 10.1111/j.1749-6632.1991.tb49062.x; SANTORO MG, 1977, CANCER RES, V37, P3774; SIEGALL CB, 1989, FASEB J, V3, P2647, DOI 10.1096/fasebj.3.14.2556314; SIEGALL CB, 1988, P NATL ACAD SCI USA, V85, P9738, DOI 10.1073/pnas.85.24.9738; SIEGALL CB, 1991, FASEB J, V5, P2843, DOI 10.1096/fasebj.5.13.1717336; Soria M R, 1992, Targeted Diagn Ther, V7, P193; STIRPE F, 1983, BIOCHEM J, V216, P617, DOI 10.1042/bj2160617; STOPPELLI MP, 1985, P NATL ACAD SCI USA, V82, P4939, DOI 10.1073/pnas.82.15.4939; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; THEUER CP, 1993, J UROLOGY, V149, P1626, DOI 10.1016/S0022-5347(17)36464-9; UCKUN FM, 1993, LEUKEMIA, V7, P341; VANDERSPEK JC, 1993, J BIOL CHEM, V268, P12077; VLODAVSKY I, 1991, J CELL BIOCHEM, V45, P167, DOI 10.1002/jcb.240450208; WALICKE PA, 1991, J NEUROSCI, V11, P2249; WILEY RG, 1991, BRAIN RES, V562, P149, DOI 10.1016/0006-8993(91)91199-B	61	54	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12552	12558						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175664				2022-12-25	WOS:A1994NH71600031
J	POST, PL; TRYBUS, KM; TAYLOR, DL				POST, PL; TRYBUS, KM; TAYLOR, DL			A GENETICALLY-ENGINEERED, PROTEIN-BASED OPTICAL BIOSENSOR OF MYOSIN-II REGULATORY LIGHT-CHAIN PHOSPHORYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								Myosin II is an important motor in the contraction of smooth and striated muscle as well as in a variety of nonmuscle cell motile events including cytokinesis, cortical contractions during migration of fibroblasts, and capping of receptors. Phosphorylation of the 20-kDa light chain by myosin light chain kinase is part of the regulation of smooth muscle and mammalian nonmuscle myosin II. We designed, characterized, and tested the use of a protein-based optical biosensor to monitor this phosphorylation ''switch.'' A regulatory light chain was genetically engineered to contain a single cysteine at amino acid position 18. The mutant light chain (Cys(18).LC(20)), reacted with the fluorophore acrylodan, responded to phosphorylation of serine 19 with a fluorescence emission quenching of 60% and a 28-nm red-shift. When the acrylodan-labeled mutant light chain (AC-Cys(18).LC(20)) was exchanged into turkey gizzard myosin II, it exhibited a 25% fluorescence emission quenching and a 10-nm red-shift upon phosphorylation of serine 19. The myosin II optical biosensor exhibited nearly control levels of the rate of phosphorylation, K(+)ATPase activity, and in vitro motility. The acrylodan-labeled light chain was exchanged into the A-bands of chicken pectoralis myofibrils in situ to demonstrate the localization and activity of the biosensor in a highly ordered contractile system. Fluorometry and quantitative fluorescence microscopic imaging experiments demonstrated that AC-Cys(18). LC(20) exchanged myofibrils expressed a phosphorylation-dependent fluorescence change. Labeled light chains were also incorporated into stress fibers of living fibroblasts and smooth muscle cells. This general approach of combining molecular biology and fluorescence spectroscopy to create novel protein-based optical biosensors should provide valuable tools for investigations with model systems and solution studies and ultimately yield important information about temporal-spatial chemical and molecular changes in live cells.	CARNEGIE MELLON UNIV, DEPT BIOL SCI, PITTSBURGH, PA 15213 USA; BRANDEIS UNIV, ROSENSTIEL BASIC MED SCI RES CTR, WALTHAM, MA 02254 USA	Carnegie Mellon University; Brandeis University	POST, PL (corresponding author), CARNEGIE MELLON UNIV, CTR LIGHT MICROSCOPE IMAGING & BIOTECHNOL, PITTSBURGH, PA 15213 USA.			Taylor, D. Lansing/0000-0001-6947-1343	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL038113, R01HL038113] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR032461, R01AR032461] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL38113] Funding Source: Medline; NIAMS NIH HHS [AR32461] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ABUGHAZALEH RI, 1992, J MEMBRANE BIOL, V128, P153; ADAMS SR, 1991, NATURE, V349, P694, DOI 10.1038/349694a0; ADELSTEIN RS, 1981, J BIOL CHEM, V256, P7501; AMATO PA, 1983, J CELL BIOL, V96, P750, DOI 10.1083/jcb.96.3.750; BENNETT JP, 1988, J CELL BIOL, V107, P2623, DOI 10.1083/jcb.107.6.2623; BOWMAN BF, 1990, BIOPHYS J, V57, pA152; CLARK ID, 1988, ARCH BIOCHEM BIOPHYS, V260, P595, DOI 10.1016/0003-9861(88)90486-9; COLE HA, 1985, FEBS LETT, V180, P165, DOI 10.1016/0014-5793(85)81064-4; DEBIASIO RL, 1988, J CELL BIOL, V107, P2631, DOI 10.1083/jcb.107.6.2631; GIULIANO KA, 1990, CELL MOTIL CYTOSKEL, V16, P14, DOI 10.1002/cm.970160104; GIULIANO KA, 1992, MOL BIOL CELL, V3, P1037, DOI 10.1091/mbc.3.9.1037; HAHN K, 1992, NATURE, V359, P736, DOI 10.1038/359736a0; HAHN KM, 1990, J BIOL CHEM, V265, P20335; HAHN KM, 1993, FLUORESCENT LUMINESC, P349; IKEBE M, 1991, J BIOL CHEM, V266, P21339; IKEBE M, 1985, J BIOL CHEM, V260, P27; KEMP BE, 1983, P NATL ACAD SCI-BIOL, V80, P7471, DOI 10.1073/pnas.80.24.7471; KNIGHT PJ, 1982, METHOD ENZYMOL, V85, P9; KOLEGA J, 1993, MOL BIOL CELL, V4, P819, DOI 10.1091/mbc.4.8.819; Kolega J., 1993, Bioimaging, V1, P136, DOI 10.1002/1361-6374(199309)1:3<136::AID-BIO2>3.3.CO;2-4; KOLEGA J, 1991, J CELL BIOL, V114, P993, DOI 10.1083/jcb.114.5.993; KRON SJ, 1986, P NATL ACAD SCI USA, V83, P6272, DOI 10.1073/pnas.83.17.6272; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMB NJC, 1988, J CELL BIOL, V106, P1955, DOI 10.1083/jcb.106.6.1955; MARSH DJ, 1980, BIOCHEMISTRY-US, V19, P774, DOI 10.1021/bi00545a025; NGAI PK, 1984, BIOCHEM J, V218, P863, DOI 10.1042/bj2180863; PEARSON RB, 1986, J BIOL CHEM, V261, P25; PRENDERGAST FG, 1983, J BIOL CHEM, V258, P7541; RAJASEKHARAN KN, 1991, ARCH BIOCHEM BIOPHYS, V288, P584, DOI 10.1016/0003-9861(91)90240-J; REID SW, 1993, ARCH BIOCHEM BIOPHYS, V302, P31, DOI 10.1006/abbi.1993.1176; RICHIERI GV, 1992, J BIOL CHEM, V267, P23495; Sellers JR, 1991, CURR OPIN CELL BIOL, V3, P98, DOI 10.1016/0955-0674(91)90171-T; SELLERS JR, 1981, J BIOL CHEM, V256, P3137; Sellers JR, 1987, ENZYMES, V18, ppp381, DOI 10.1016/S1874-6047(08)60264-4; STAFFORD WF, 1983, BIOPHYS J, V41, pA93; TAN JL, 1992, ANNU REV BIOCHEM, V61, P721, DOI 10.1146/annurev.bi.61.070192.003445; TAYLOR DL, 1980, NATURE, V284, P405, DOI 10.1038/284405a0; TAYLOR DL, 1992, AM SCI, V80, P322; TAYLOR DL, 1978, P NATL ACAD SCI USA, V75, P857, DOI 10.1073/pnas.75.2.857; TRYBUS KM, 1993, J BIOL CHEM, V268, P4412; TRYBUS KM, 1984, J BIOL CHEM, V259, P8564; TRYBUS KM, 1991, CELL MOTIL CYTOSKEL, V18, P81, DOI 10.1002/cm.970180202; TSIEN RY, 1989, METHOD CELL BIOL, V30, P127; TSIEN RY, 1980, BIOCHEMISTRY-US, V19, P2396, DOI 10.1021/bi00552a018; WARRICK HM, 1987, ANNU REV CELL BIOL, V3, P379, DOI 10.1146/annurev.cb.03.110187.002115; WYSOLMERSKI RB, 1991, AM J PHYSIOL, V261, pC32, DOI 10.1152/ajpcell.1991.261.1.C32; [No title captured]	47	44	54	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12880	12887						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175704				2022-12-25	WOS:A1994NH71600078
J	TANG, MS; PAO, A; ZHANG, XS				TANG, MS; PAO, A; ZHANG, XS			REPAIR OF BENZO(A)PYRENE DIOL EPOXIDE-INDUCED AND UV-INDUCED DNA-DAMAGE IN DIHYDROFOLATE-REDUCTASE AND ADENINE PHOSPHORIBOSYLTRANSFERASE GENES OF CHO CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; DIPLOID HUMAN FIBROBLASTS; MAMMALIAN-CELLS; TRANSCRIBED STRAND; LINEAR DICHROISM; EXCISION REPAIR; N-METHYLPURINES; DHFR GENE; HPRT GENE; BENZO<A>PYRENE	Using Uvr proteins we have quantified benzo(a)pyrene diol epoxide (BPDE)-DNA adduct formation and repair at the dihydrofolate reductase (DHFR) and adenine phosphoribosyltransferase (APRT) genes in two Chinese hamster ovary cell lines: B-11 cells, which are 50-fold amplified for DHFR, and AT3-2 cells, which are diploid for DHFR. We have found that: 1) BPDE-DNA adduct formation in different regions of the DHFR gene is proportional to the concentration of BPDE. 2) There is no significant difference in the repair of BPDE-DNA adducts between the coding and noncoding regions in either amplified or nonamplified DHFR gene domains. 3) Repair in the nonamplified DHFR gene is more efficient (30-40%) than in the amplified DHFR genes. 4) There are no significant differences of repair in the transcribed or nontranscribed strands of the DHFR gene. 5) BPDE-DNA adduct formation and repair in the APRT gene in B-11 and AT3-2 cells are the same. These results contrast those for the repair of cyclobutane pyrimidine dimers, which occurs preferentially in the transcribed strand of the DHFR gene and in which gene amplification appears to play no role,			TANG, MS (corresponding author), UNIV TEXAS,MD ANDERSON CANC CTR,DIV SCI PK RES,SMITHVILLE,TX 78957, USA.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES003124] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES03124] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BELAND FA, 1989, PATHOBIOLOGY NEOPLAS, P57; BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; BOHR VA, 1991, CARCINOGENESIS, V12, P1983, DOI 10.1093/carcin/12.11.1983; BOHR VA, 1986, P NATL ACAD SCI USA, V83, P3830, DOI 10.1073/pnas.83.11.3830; CAROTHERS AM, 1991, P NATL ACAD SCI USA, V88, P5749, DOI 10.1073/pnas.88.13.5749; CHEN RH, 1990, P NATL ACAD SCI USA, V87, P8680, DOI 10.1073/pnas.87.21.8680; CHEN RH, 1992, P NATL ACAD SCI USA, V89, P5413, DOI 10.1073/pnas.89.12.5413; COHN SM, 1984, P NATL ACAD SCI-BIOL, V81, P4828, DOI 10.1073/pnas.81.15.4828; Friedberg E C, 1980, Methods Enzymol, V65, P191; GEACINTOV NE, 1978, BIOCHEMISTRY-US, V17, P5256, DOI 10.1021/bi00617a027; HARVEY RG, 1981, ACCOUNTS CHEM RES, V14, P218, DOI 10.1021/ar00067a004; HARVEY RG, 1988, ACCOUNTS CHEM RES, V21, P66, DOI 10.1021/ar00146a004; KAUFMAN RJ, 1981, MOL CELL BIOL, V1, P1069, DOI 10.1128/MCB.1.12.1069; MACLEOD MC, 1982, CARCINOGENESIS, V3, P1031, DOI 10.1093/carcin/3.9.1031; MACLEOD MC, 1988, MUTAT RES, V199, P243, DOI 10.1016/0027-5107(88)90252-7; Maniatis T., 1982, MOL CLONING; MELCHIOR W B JR, 1992, Proceedings of the American Association for Cancer Research Annual Meeting, V33, P175; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; MENICHINI P, 1991, MUTAT RES, V251, P143, DOI 10.1016/0027-5107(91)90224-C; PELKONEN O, 1982, PHARMACOL REV, V34, P189; ROSS J, 1985, ANAL BIOCHEM, V144, P212, DOI 10.1016/0003-2697(85)90108-3; SANCAR A, 1993, PHOTOCHEM PHOTOBIOL, V57, P905, DOI 10.1111/j.1751-1097.1993.tb09233.x; SCICCHITANO DA, 1989, P NATL ACAD SCI USA, V86, P3050, DOI 10.1073/pnas.86.9.3050; SCICCHITANO DA, 1990, MUTAT RES, V233, P31, DOI 10.1016/0027-5107(90)90148-W; SEEBERG E, 1983, MUTAT RES, V112, P139, DOI 10.1016/0167-8817(83)90036-6; SNYDERWINE EG, 1992, CANCER RES, V52, P4183; TANG MS, 1992, BIOCHEMISTRY-US, V31, P8429, DOI 10.1021/bi00151a006; TANG MS, 1989, J BIOL CHEM, V264, P14455; THOMAS DC, 1988, P NATL ACAD SCI USA, V85, P3723, DOI 10.1073/pnas.85.11.3723; UNDEMAN O, 1983, CANCER RES, V43, P1851; VRIELING H, 1992, MUTAT RES, V274, P147, DOI 10.1016/0921-8777(92)90061-7; VRIELING H, 1989, MOL CELL BIOL, V9, P1277, DOI 10.1128/MCB.9.3.1277; WASSERMANN K, 1990, J BIOL CHEM, V265, P13906; WEINSTEIN IB, 1981, J SUPRAMOL STR CELL, V17, P99, DOI 10.1002/jsscb.380170202; YANG LL, 1982, MUTAT RES, V94, P435, DOI 10.1016/0027-5107(82)90306-2	35	35	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12749	12754						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175687				2022-12-25	WOS:A1994NH71600059
J	KANEIISHII, C; YASUKAWA, T; MORIMOTO, RI; ISHII, S				KANEIISHII, C; YASUKAWA, T; MORIMOTO, RI; ISHII, S			C-MYB-INDUCED TRANSACTIVATION MEDIATED BY HEAT-SHOCK ELEMENTS WITHOUT SEQUENCE-SPECIFIC DNA-BINDING OF C-MYB	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN HSP70 PROMOTER; TRANSCRIPTION FACTOR; LEUCINE-ZIPPER; V-MYB; HEMATOPOIETIC-CELLS; MOLECULAR-CLONING; ONCOGENE PRODUCT; PROTO-ONCOGENE; GENE; EXPRESSION	The c-myb proto-oncogene product (c-Myb) can transactivate the human hsp70 promoter in a transient cotransfection assay. The present studies have demonstrated that the heat shock element (HSE) in the hsp7O promoter mediates trans-activation by c-Myb. Mutagenesis of the DNA sequence in HSE indicated that the NGAAN motif is necessary for not only the heat shock response but also the c-Myb-induced trans-activation. The HSE in the hsp70 promoter does not contain a c-Myb-binding site, implying that the sequence-specific DNA binding of c-Myb is not required for the HSE-dependent trans-activation by c-Myb. We had demonstrated that a disruption of the leucine zipper motif in the central portion of the c-Myb molecule increased the degree of c-Myb-induced trans-activation of the promoter containing c-Myb-binding sites, suggesting that a putative inhibitor binds to c-Myb through this leucine zipper (Kanie-Ishii, C., MacMillan, E. M., Nomura, T., Sarai, A., Ramsay, R. G., Aimoto, S., Ishii, S., and Gonda, T J. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 3088-3092). However, disruption of the leucine zipper in c-Myb abolished the HSE-dependent trans-activation by c-Myb, whereas deletion of the transcriptional activation domain containing acidic amino acids in c-Myb did not abolish the HSE-dependent trans-activation by c-Myb. These results suggest that c-Myb can activate transcription of the gene containing HSEs by interacting with unidentified trans-acting factor(s) but not by a direct binding to the promoter through its DNA-binding domain.	UNIV TSUKUBA, INST BASIC MED SCI, TSUKUBA, IBARAKI 305, JAPAN; NORTHWESTERN UNIV, DEPT BIOCHEM MOLEC BIOL & CELL BIOL, EVANSTON, IL 60208 USA	University of Tsukuba; Northwestern University	KANEIISHII, C (corresponding author), INST PHYS & CHEM RES, TSUKUBA LIFE SCI CTR, MOLEC GENET LAB, TSUKUBA, IBARAKI 305, JAPAN.		Ishii, Shunsuke/A-5271-2016	Ishii, Shunsuke/0000-0002-6530-2478				ABRAVAYA K, 1991, MOL CELL BIOL, V11, P586, DOI 10.1128/MCB.11.1.586; AMIN J, 1988, MOL CELL BIOL, V8, P3761, DOI 10.1128/MCB.8.9.3761; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; CLOS J, 1990, CELL, V63, P1085, DOI 10.1016/0092-8674(90)90511-C; DUPREY SP, 1985, P NATL ACAD SCI USA, V82, P6937, DOI 10.1073/pnas.82.20.6937; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; FOOS G, 1993, ONCOGENE, V8, P1775; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GODENBERG CJ, 1988, J BIOL CHEM, V263, P19734; GONDA TJ, 1989, EMBO J, V8, P1777, DOI 10.1002/j.1460-2075.1989.tb03571.x; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HIGUCHI R, 1990, PCR TECHNOLOGY PRINC, P61; HU YL, 1991, ONCOGENE, V6, P1549; JAKOBSEN BK, 1991, EMBO J, V10, P369, DOI 10.1002/j.1460-2075.1991.tb07958.x; KANEIISHII C, 1992, P NATL ACAD SCI USA, V89, P3088, DOI 10.1073/pnas.89.7.3088; KLEMPNAUER KH, 1989, GENE DEV, V3, P1582, DOI 10.1101/gad.3.10.1582; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; LAIMINS LA, 1984, J VIROL, V49, P183, DOI 10.1128/JVI.49.1.183-189.1984; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; MORGAN WD, 1987, MOL CELL BIOL, V7, P1129, DOI 10.1128/MCB.7.3.1129; MORIMOTO RI, 1992, J BIOL CHEM, V267, P21987; MOSSER DD, 1988, MOL CELL BIOL, V8, P4736, DOI 10.1128/MCB.8.11.4736; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NAKAGOSHI H, 1990, J BIOL CHEM, V265, P3479; NAKAI A, 1993, MOL CELL BIOL, V13, P1983, DOI 10.1128/MCB.13.4.1983; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NISHINA Y, 1989, NUCLEIC ACIDS RES, V17, P107, DOI 10.1093/nar/17.1.107; NOMURA T, 1993, J BIOL CHEM, V268, P21914; PARKER CS, 1984, CELL, V37, P273, DOI 10.1016/0092-8674(84)90323-4; PELHAM HRB, 1982, CELL, V30, P517, DOI 10.1016/0092-8674(82)90249-5; PERISIC O, 1989, CELL, V59, P797, DOI 10.1016/0092-8674(89)90603-X; RABINDRAN SK, 1991, P NATL ACAD SCI USA, V88, P6906, DOI 10.1073/pnas.88.16.6906; RABINDRAN SK, 1993, SCIENCE, V259, P230, DOI 10.1126/science.8421783; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SARGE KD, 1991, GENE DEV, V5, P1902, DOI 10.1101/gad.5.10.1902; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; SCHARF KD, 1990, EMBO J, V9, P4495, DOI 10.1002/j.1460-2075.1990.tb07900.x; SCHUETZ TJ, 1991, P NATL ACAD SCI USA, V88, P6911, DOI 10.1073/pnas.88.16.6911; SISTONEN L, 1992, MOL CELL BIOL, V12, P4104, DOI 10.1128/MCB.12.9.4104; SORGER PK, 1987, EMBO J, V6, P3035, DOI 10.1002/j.1460-2075.1987.tb02609.x; SORGER PK, 1989, CELL, V59, P807, DOI 10.1016/0092-8674(89)90604-1; SORGER PK, 1988, CELL, V54, P855, DOI 10.1016/S0092-8674(88)91219-6; TANIKAWA J, 1993, P NATL ACAD SCI USA, V90, P9320, DOI 10.1073/pnas.90.20.9320; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; WESTWOOD JT, 1991, NATURE, V353, P822, DOI 10.1038/353822a0; WIEDERRECHT G, 1988, CELL, V54, P841, DOI 10.1016/S0092-8674(88)91197-X; WILLIAMS GT, 1990, MOL CELL BIOL, V10, P3125, DOI 10.1128/MCB.10.6.3125; WU B, 1985, MOL CELL BIOL, V5, P330, DOI 10.1128/MCB.5.2.330; WU BJ, 1986, P NATL ACAD SCI USA, V83, P629, DOI 10.1073/pnas.83.3.629; WU C, 1987, SCIENCE, V238, P1247, DOI 10.1126/science.3685975; XIAO H, 1988, SCIENCE, V239, P1139, DOI 10.1126/science.3125608	54	38	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15768	15775						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	8195231				2022-12-25	WOS:A1994NP51300059
J	STRUM, JC; SMALL, GW; PAUIG, SB; DANIEL, LW				STRUM, JC; SMALL, GW; PAUIG, SB; DANIEL, LW			1-BETA-D-ARABINOFURANOSYLCYTOSINE STIMULATES CERAMIDE AND DIGLYCERIDE FORMATION IN HL-60 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; PROTEIN-KINASE-C; MYELOID-LEUKEMIA CELLS; SIGNAL-TRANSDUCTION; SPHINGOMYELIN TURNOVER; DIPHOSPHATE CHOLINE; GENE-EXPRESSION; FACTOR-ALPHA; FREE SYSTEM	The effect of 1-beta-D-arabinofuranosylcytosine (ara-C) on phospholipid metabolism was investigated in HL-60 cells. Treatment of cells with ara-C resulted in a time- and dose-dependent increase in the mass of ceramide and diglyceride. When cells were treated with 10 mu M ara-C, an increase in the mass of ceramide and diglyceride was detectable at 5 min and reached a plateau at 30 min with a 2-fold increase compared to control cells. Treatment of cells with 10 mu M ara-C resulted in the activation of neutral sphingomyelinase with a peak at 30 min that represented a S-fold increase in specific activity. ara-C also increased expression of the transcription factor NF-B-kappa which is related to the control of monocyte differentiation. These findings suggest that ara C activates phospholipid hydrolytic pathways to generate second messengers that control gene expression and differentiation in the HL-60 cell line,	WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT BIOCHEM,WINSTON SALEM,NC 27157	Wake Forest University; Wake Forest Baptist Medical Center				, George/0000-0002-7585-7258	NCI NIH HHS [CA-12197, CA-43297, CA-48995] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043297, R01CA048995, P30CA012197] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AANEN C, 1985, SEMIN ONCOL, V12, P120; ARIMA N, 1992, J IMMUNOL, V149, P83; AUSUBEL FM, 1989, SHORT PORTOCOLS MOL; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRACH MA, 1992, MOL PHARMACOL, V41, P60; CAPIZZI RL, 1988, YALE J BIOL MED, V61, P11; CHEDID M, 1991, J IMMUNOL, V147, P867; DALY PF, 1990, CANCER RES, V50, P552; DBAIBO GS, 1993, J BIOL CHEM, V268, P17762; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOBROWSKY RT, 1992, J BIOL CHEM, V267, P5045; DRESSLER KA, 1992, SCIENCE, V255, P1715, DOI 10.1126/science.1313189; FREI E, 1969, CANCER RES, V29, P1325; FURTH JJ, 1968, CANCER RES, V28, P2061; GALE RP, 1979, NEW ENGL J MED, V300, P1189, DOI 10.1056/NEJM197905243002105; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GRIFFIN GE, 1989, NATURE, V339, P70, DOI 10.1038/339070a0; GRIFFIN J, 1982, EXP HEMATOL, V10, P774; HOHMANN HP, 1991, MOL CELL BIOL, V11, P259, DOI 10.1128/MCB.11.1.259; KALEN A, 1992, BIOCHIM BIOPHYS ACTA, V1125, P90, DOI 10.1016/0005-2760(92)90160-W; KAUFMAN PA, 1992, J CLIN INVEST, V90, P121, DOI 10.1172/JCI115824; KHARBANDA S, 1991, BIOCHEMISTRY-US, V30, P7947, DOI 10.1021/bi00246a011; KIM MY, 1991, J BIOL CHEM, V266, P484; KUCERA GL, 1992, CANCER RES, V52, P3886; KUFE DW, 1980, J BIOL CHEM, V255, P8997; LAUZON GJ, 1978, CANCER RES, V38, P1723; LAUZON GJ, 1978, CANCER RES, V38, P1730; MATHIAS S, 1993, SCIENCE, V259, P519, DOI 10.1126/science.8424175; MEICHLE A, 1990, J BIOL CHEM, V265, P8339; MERRILL AH, 1990, BIOCHIM BIOPHYS ACTA, V1044, P1, DOI 10.1016/0005-2760(90)90211-F; MICHALEWICZ R, 1984, LEUKEMIA RES, V8, P783, DOI 10.1016/0145-2126(84)90099-7; NICULESCU F, 1993, J IMMUNOL, V150, P214; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; PINTO A, 1988, MED ONCOL TUMOR PHAR, V5, P91; PREISS J, 1986, J BIOL CHEM, V261, P8597; RAO BG, 1976, J LIPID RES, V17, P506; SCHRECKER AW, 1970, CANCER RES, V30, P632; SHIRAKAWA F, 1989, MOL CELL BIOL, V9, P2424, DOI 10.1128/MCB.9.6.2424; VOELKER DR, 1982, BIOCHEMISTRY-US, V21, P2753, DOI 10.1021/bi00540a027; YANG JL, 1986, ACTA PHARMACOL SINIC, V4, P368; YANG ZH, 1993, J BIOL CHEM, V268, P20520	41	154	168	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15493	15497						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	8195192				2022-12-25	WOS:A1994NP51300018
J	GUO, XD; WATTANAPERMPOOL, J; PALMITER, KA; MURPHY, AM; SOLARO, RJ				GUO, XD; WATTANAPERMPOOL, J; PALMITER, KA; MURPHY, AM; SOLARO, RJ			MUTAGENESIS OF CARDIAC TROPONIN-I - ROLE OF THE UNIQUE NH2-TERMINAL PEPTIDE IN MYOFILAMENT ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; 2 ADJACENT PHOSPHOSERINES; SKELETAL-MUSCLE; RAT-HEART; BIOLOGICAL-ACTIVITY; ISOFORM EXPRESSION; RABBIT; BINDING; BOVINE; PHOSPHORYLATION	Phosphorylation of Ser residues in the NH2-terminal extension unique to cardiac troponin I (cTnI) is known to occur through protein kinase A and to alter myofilament Ca2+ activation (Robertson, S. P., Johnson, J. D., Holroyde, M. J., Kranias, E. G., Potter, J. D., and Solaro, R. J. (1982) J. Biol. Chem. 257, 260-263). Yet, how the NH2-terminal extension may itself affect thin filament Ca2+ signaling is unknown. To approach this question we have used molecular cloning, mutagenesis, and bacterial synthesis of a full-length cTnI: and a truncated mutant (cTnI/NH2) missing the 32 amino acids. Using reconstituted preparations we could show no differences between cTnI and cTnI/NH2 either in inhibition of actomyosin ATPase activity, in Ca2+-reversible inhibitory activity, or in the relation between pCa and Ca2+ binding to the regulatory site of cTnC at either pH 7.0 or 6.5. There were also no significant differences at either pH in the pCa-MgATPase activity relation of myofibrils into which the various species of TnI had been exchanged. Our results indicate: 1) that phosphorylation most likely induces a new state of TnI activity rather than altering an intrinsic effect of the NH2-terminal peptide on Ca2+ activation; and 2) that domains outside the NH2-terminal extension are important with regard to differences in effects of acidic pH on Ca2+ activation on cardiac and skeletal myofilaments.	UNIV ILLINOIS, COLL MED, DEPT PHYSIOL & BIOPHYS, CHICAGO, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL022231, R29HL050184, T32HL007692] Funding Source: NIH RePORTER; NHLBI NIH HHS [R29-HL-50184, T32 HL-07692, R01-HL-22231] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARTER SG, 1982, J BIOCHEM BIOPH METH, V7, P7, DOI 10.1016/0165-022X(82)90031-8; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; ELSALEH SC, 1988, J BIOL CHEM, V263, P3274; ENDOH M, 1988, CIRC RES, V62, P247, DOI 10.1161/01.RES.62.2.247; GRAND RJA, 1976, BIOCHEM J, V159, P633, DOI 10.1042/bj1590633; HASTINGS KEM, 1991, J BIOL CHEM, V266, P19659; HATAKENAKA M, 1992, EUR J BIOCHEM, V205, P985, DOI 10.1111/j.1432-1033.1992.tb16865.x; HOLROYDE MJ, 1979, BIOCHIM BIOPHYS ACTA, V586, P63, DOI 10.1016/0304-4165(79)90405-7; HUNKELER NM, 1991, CIRC RES, V69, P1409, DOI 10.1161/01.RES.69.5.1409; JOHNSON JD, 1980, J BIOL CHEM, V255, P9635; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEAVIS PC, 1987, CRIT REV BIOCH, V16, P233; LESZYK J, 1988, BIOCHEMISTRY-US, V27, P2821, DOI 10.1021/bi00408a024; LIAO R, 1990, THESIS U ALABAMA BIR; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maniatis T., 1982, MOL CLONING; MARTIN AF, 1991, CIRC RES, V69, P1244, DOI 10.1161/01.RES.69.5.1244; MITTMANN K, 1990, FEBS LETT, V273, P41, DOI 10.1016/0014-5793(90)81046-Q; MURPHY AM, 1991, BIOCHEMISTRY-US, V30, P707, DOI 10.1021/bi00217a018; PAGANI ED, 1983, AM J PHYSIOL, V245, pH713, DOI 10.1152/ajpheart.1983.245.5.H713; PAN BS, 1987, J BIOL CHEM, V262, P7839; POTTER JD, 1982, METHOD ENZYMOL, V85, P241; ROBERTSON SP, 1982, J BIOL CHEM, V257, P260; SABRY MA, 1989, J MUSCLE RES CELL M, V10, P85, DOI 10.1007/BF01739858; SAGGIN L, 1989, J BIOL CHEM, V264, P16299; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHENG Z, 1993, BIOPHYS J, V64, pA136; SOLARO RJ, 1976, NATURE, V262, P615, DOI 10.1038/262615a0; SOLARO RJ, 1986, CIRC RES, V58, P721, DOI 10.1161/01.RES.58.5.721; SOLARO RJ, 1993, MODULATION CARDIAC C, P160; SOLARO RJ, 1988, PHYSL PATHOPHYSIOLOG, P291; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SWIDEREK K, 1988, EUR J BIOCHEM, V176, P335, DOI 10.1111/j.1432-1033.1988.tb14286.x; SYSKA H, 1976, BIOCHEM J, V153, P375, DOI 10.1042/bj1530375; TALBOT JA, 1981, J BIOL CHEM, V256, P2374; TAO T, 1990, SCIENCE, V247, P1339, DOI 10.1126/science.2138356; WILKINSON JM, 1978, NATURE, V271, P31, DOI 10.1038/271031a0; ZOT AS, 1987, ANNU REV BIOPHYS BIO, V16, P535	40	85	89	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					15210	15216						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195157				2022-12-25	WOS:A1994NP73800054
J	TAOUIS, M; LEVYTOLEDANO, R; ROACH, P; TAYLOR, SI; GORDEN, P				TAOUIS, M; LEVYTOLEDANO, R; ROACH, P; TAYLOR, SI; GORDEN, P			STRUCTURAL BASIS BY WHICH A RECESSIVE MUTATION IN THE ALPHA-SUBUNIT OF THE INSULIN-RECEPTOR AFFECTS INSULIN BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH FACTOR-I; HIGH-AFFINITY; BETA-SUBUNIT; PLASMA-MEMBRANE; LIGAND-BINDING; KINASE; CELLS; AUTOPHOSPHORYLATION; RESISTANCE; ANTIBODIES	Recently, a mutation substituting Leu for Ser(323) in the alpha-subunit of the human insulin receptor has been identified in an insulin-resistant patient. The Leu(323) mutation leads to a severe impairment in insulin binding without significantly altering the processing or cell surface expression of the receptor. In order to study how alpha beta half-receptors interact to form the insulin-binding site, we cotransfected NIH-3T3 cells with two insulin receptor cDNA constructs: a truncated insulin receptor lacking the C-terminal 43 amino acids (Delta 43) and the full-length Leu(323) mutant receptor. A clonal cell line from cotransfected cells expresses a hybrid receptor consisting of a Leu(323) half-receptor and a Delta 43 half-receptor. We demonstrate that the Leu(323)-Delta 43 hybrid receptor binds insulin with high affinity. Furthermore, by cross-linking I-125-insulin to immobilized hybrid receptors, we show that only the alpha beta(Delta) half of the hybrid receptor binds insulin. Since the isolated half-insulin receptor has low affinity for insulin, this suggests that the addition of even a non-binding alpha-subunit can result in high affinity binding to the holoreceptor (alpha alpha(mut)beta(Delta)beta). Both beta and beta(Delta)-subunits of the Leu(323)-Delta 43 hybrid receptor are phosphorylated in vivo and in vitro in an insulin-dependent manner, suggesting an intramolecular transphosphorylation mechanism and that the presence of the Leu(323) mutant receptor that lacks an intrinsic high affinity binding site does not prevent the associated beta-subunit from functioning either as a tyrosine kinase or as a phosphate acceptor in the hybrid insulin receptor molecule (alpha alpha(mut)beta(Delta)beta). Furthermore, we show that the hybrid receptor can phosphorylate insulin receptor substrate-1 (IRS-1) in response to insulin and can be coimmunoprecipitated together with IRS-1 by anti-IRS-1 antibody.	NIDDK,DIABET BRANCH,BETHESDA,MD 20892; INRA,RECH AVICOLES STN,F-37380 NOUZILLY,FRANCE	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); INRAE			Taouis, Mohammed/CAA-1797-2022	Taouis, Mohammed/0000-0002-4101-691X				ACCILI D, 1989, EMBO J, V8, P2509, DOI 10.1002/j.1460-2075.1989.tb08388.x; BACKER JM, 1993, J BIOL CHEM, V268, P8204; BONISCHNETZLER M, 1987, J BIOL CHEM, V262, P8395; CAMA A, 1988, DIABETES, V37, P982, DOI 10.2337/diabetes.37.7.982; CAMA A, 1992, J BIOL CHEM, V267, P8383; CAMA A, 1991, J CLIN ENDOCR METAB, V73, P894, DOI 10.1210/jcem-73-4-894; DEMEYTS P, 1973, BIOCHEM BIOPH RES CO, V55, P154, DOI 10.1016/S0006-291X(73)80072-5; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; FRATTALI AL, 1993, J BIOL CHEM, V268, P7393; FRATTALI AL, 1992, J BIOL CHEM, V267, P19521; KADOWAKI T, 1988, SCIENCE, V240, P787, DOI 10.1126/science.2834824; LEE JS, 1993, J BIOL CHEM, V268, P4092; LEVYTOLEDANO R, 1994, EMBO J, V13, P835, DOI 10.1002/j.1460-2075.1994.tb06326.x; MAEGAWA H, 1988, J BIOL CHEM, V263, P12629; MYERS MG, 1991, J BIOL CHEM, V266, P10616; PANG DT, 1983, J BIOL CHEM, V258, P2514; PANG DT, 1984, J BIOL CHEM, V259, P8589; PILCH PF, 1979, J BIOL CHEM, V254, P3375; SHOELSON SE, 1993, J BIOL CHEM, V268, P4085; SOOS MA, 1993, BIOCHEM J, V290, P419, DOI 10.1042/bj2900419; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SWEET LJ, 1987, J BIOL CHEM, V262, P6939; TAOUIS M, 1993, MOL CELL ENDOCRINOL, V96, P113, DOI 10.1016/0303-7207(93)90101-O; TAYLOR SI, 1984, J CLIN ENDOCR METAB, V58, P182, DOI 10.1210/jcem-58-1-182; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; YIP CC, 1992, J BIOL CHEM, V267, P13131; ZHANG B, 1991, P NATL ACAD SCI USA, V88, P9858, DOI 10.1073/pnas.88.21.9858	28	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					14912	14918						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195122				2022-12-25	WOS:A1994NP73800013
J	HORWITZ, EM; MALONEY, KA; LEY, TJ				HORWITZ, EM; MALONEY, KA; LEY, TJ			A HUMAN PROTEIN CONTAINING A COLD SHOCK DOMAIN BINDS SPECIFICALLY TO H-DNA UPSTREAM FROM THE HUMAN GAMMA-GLOBIN GENES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA+ HEREDITARY PERSISTENCE; STAGE-SPECIFIC EXPRESSION; POINT MUTATION 5'; FETAL HEMOGLOBIN; TRANSGENIC MICE; Y-BOX; CHROMOSOMAL LOCALIZATION; FUNCTIONAL-ANALYSIS; PROMOTER ELEMENT; ESCHERICHIA-COLI	We previously determined that a region between positions -228 and -189 upstream from the human gamma-globin genes can form an intramolecular tripler (H-DNA) in supercoiled plasmids. To identify proteins that might interact with this DNA structure, we performed expression cloning using an adult bone marrow cDNA library and the single-stranded region of the H-DNA structure as a probe. We cloned molecules very similar to two previously identified cDNAs, dbpA and dbpB. The dbpB-like protein (called BP-8 in this study) interacts specifically (R(D) similar to 4 nM) with two homopyrimidine ''half-sites'' in the single-stranded gamma-228 to -189 probe, but binds to double-stranded DNA containing the same sequence with 100-fold less affinity. We have also shown that supercoiled plasmids containing the gamma-228 to -189 region contain a high affinity binding site for BP-8 that is stabilized by factors that stabilize H-DNA; two HPFH point mutations (-202 C --> G or C --> T) that destabilize the secondary DNA structure abolish the high affinity binding site. Collectively, these data show that dbpB/BP-8 binds specifically to homopyrimidine half-sites in single-stranded DNA, and that it also binds to H-DNA structures that contain homopyrimidine tracts in the single-stranded and triple-stranded regions.	ST LOUIS CHILDRENS HOSP,DEPT PEDIAT,DIV BONE MARROW TRANSPLANTAT & STEM CELL BIOL,ST LOUIS,MO 63110; ST LOUIS CHILDRENS HOSP,DEPT MED,ST LOUIS,MO 63110; ST LOUIS CHILDRENS HOSP,DEPT GENET,ST LOUIS,MO 63110; WASHINGTON UNIV,JEWISH HOSP ST LOUIS,MED CTR,ST LOUIS,MO 63110	St. Louis Children's Hospital; Washington University (WUSTL); St. Louis Children's Hospital; Washington University (WUSTL); St. Louis Children's Hospital; Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL)					NCI NIH HHS [CA-49712, CA-01704] Funding Source: Medline; NIDDK NIH HHS [DK-38682] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA049712, K12CA001704] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK038682, R01DK038682] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CATALA F, 1989, NUCLEIC ACIDS RES, V17, P3811, DOI 10.1093/nar/17.10.3811; CHADA K, 1986, NATURE, V319, P685, DOI 10.1038/319685a0; COLLIER DA, 1990, J BIOL CHEM, V265, P10652; COLLINS FS, 1984, BLOOD, V64, P1292; DIDIER DK, 1988, P NATL ACAD SCI USA, V85, P7322, DOI 10.1073/pnas.85.19.7322; DILLON N, 1991, NATURE, V350, P252, DOI 10.1038/350252a0; FIRULLI AB, 1992, BIOCHEM BIOPH RES CO, V185, P264, DOI 10.1016/S0006-291X(05)80985-4; FISCHER KD, 1990, NUCLEIC ACIDS RES, V18, P5685, DOI 10.1093/nar/18.19.5685; GAI XX, 1992, NUCLEIC ACIDS RES, V20, P601, DOI 10.1093/nar/20.3.601; GOLDSTEIN J, 1990, P NATL ACAD SCI USA, V87, P283, DOI 10.1073/pnas.87.1.283; GRAY WJ, 1985, BLOOD, V66, pA71; GUMUCIO DL, 1991, BLOOD, V78, P1853; GUMUCIO DL, 1988, MOL CELL BIOL, V8, P5310, DOI 10.1128/MCB.8.12.5310; GUMUCIO DL, 1991, REGULATION HEMOGLOBI, P277; HASEGAWA SL, 1991, NUCLEIC ACIDS RES, V19, P4915, DOI 10.1093/nar/19.18.4915; Hill A.V., 1910, J PHYSIOL-LONDON, V40, piv; HTUN H, 1989, SCIENCE, V243, P1571, DOI 10.1126/science.2648571; JANE SM, 1993, MOL CELL BIOL, V13, P3272, DOI 10.1128/MCB.13.6.3272; KANG S, 1992, J BIOL CHEM, V267, P20887; KINNIBURGH AJ, 1989, NUCLEIC ACIDS RES, V17, P7771, DOI 10.1093/nar/17.19.7771; KOHWI Y, 1988, P NATL ACAD SCI USA, V85, P3781, DOI 10.1073/pnas.85.11.3781; KOLLIAS G, 1986, CELL, V46, P89, DOI 10.1016/0092-8674(86)90862-7; KOLLURI R, 1992, NUCLEIC ACIDS RES, V20, P111, DOI 10.1093/nar/20.1.111; KOLLURI R, 1991, NUCLEIC ACIDS RES, V19, P4771, DOI 10.1093/nar/19.17.4771; KOWALCZYKOWSKI SC, 1981, J MOL BIOL, V145, P75, DOI 10.1016/0022-2836(81)90335-1; LANDSMAN D, 1992, NUCLEIC ACIDS RES, V20, P2861, DOI 10.1093/nar/20.11.2861; LEY TJ, 1991, BLOOD, V77, P1146; LLOYD JA, 1992, MOL CELL BIOL, V12, P1561, DOI 10.1128/MCB.12.4.1561; LLOYD JA, 1989, NUCLEIC ACIDS RES, V17, P4339, DOI 10.1093/nar/17.11.4339; Lohman TM., 1990, BIOL NONSPECIFIC DNA, P131; LYAMICHEV VI, 1985, J BIOMOL STRUCT DYN, V3, P327, DOI 10.1080/07391102.1985.10508420; MCDONAGH KT, 1991, J BIOL CHEM, V266, P11965; NEWPORT JW, 1981, J MOL BIOL, V145, P105, DOI 10.1016/0022-2836(81)90336-3; ONEILL D, 1990, NUCLEIC ACIDS RES, V18, P1977, DOI 10.1093/nar/18.8.1977; OZER J, 1990, J BIOL CHEM, V265, P22143; PEREZSTABLE C, 1990, MOL CELL BIOL, V10, P1116, DOI 10.1128/MCB.10.3.1116; RANJAN M, 1993, GENE DEV, V7, P1725, DOI 10.1101/gad.7.9.1725; SAKURA H, 1988, GENE, V73, P499; SCHINDELIN H, 1993, NATURE, V364, P164, DOI 10.1038/364164a0; SCHINDELIN H, 1992, PROTEINS, V14, P120, DOI 10.1002/prot.340140113; SCHNUCHEL A, 1993, NATURE, V364, P169, DOI 10.1038/364169a0; SHAUGHNESSY M, 1992, CURR EYE RES, V11, P1992; SHIMIZU M, 1989, J BIOL CHEM, V264, P5944; SINGLETON CK, 1982, ANAL BIOCHEM, V122, P253, DOI 10.1016/0003-2697(82)90277-9; SPITKOVSKY DD, 1992, NUCLEIC ACIDS RES, V20, P797, DOI 10.1093/nar/20.4.797; SRIVASTAVA M, 1990, J BIOL CHEM, V265, P14922; STAMATOYANNOPOULOS G, 1991, SCIENCE, V252, P383, DOI 10.1126/science.2017679; STAMATOYANNOPOULOS G, 1993, MOL CELL BIOL, V13, P7636, DOI 10.1128/MCB.13.12.7636; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SYKES K, 1990, MOL CELL BIOL, V10, P95, DOI 10.1128/MCB.10.1.95; TAFURI SR, 1993, J BIOL CHEM, V268, P12213; TAFURI SR, 1992, NEW BIOL, V4, P349; TAFURI SR, 1990, P NATL ACAD SCI USA, V87, P9028, DOI 10.1073/pnas.87.22.9028; TRUDEL M, 1987, MOL CELL BIOL, V7, P4024, DOI 10.1128/MCB.7.11.4024; ULRICH MJ, 1990, BLOOD, V75, P990; ULRICH MJ, 1992, J BIOL CHEM, V267, P18649; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; WABER PG, 1986, BLOOD, V67, P551; WOLFFE AP, 1992, NEW BIOL, V4, P290	59	61	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					14130	14139						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188694				2022-12-25	WOS:A1994NL60600062
J	LEBRUN, JJ; ALI, S; SOFER, L; ULLRICH, A; KELLY, PA				LEBRUN, JJ; ALI, S; SOFER, L; ULLRICH, A; KELLY, PA			PROLACTIN-INDUCED PROLIFERATION OF NB2 CELLS INVOLVES TYROSINE PHOSPHORYLATION OF THE PROLACTIN RECEPTOR AND ITS ASSOCIATED TYROSINE KINASE JAK2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-HORMONE RECEPTORS; RAT LYMPHOMA-CELLS; ERYTHROPOIETIN RECEPTOR; EXPRESSION; PROTEIN; STIMULATION; ACTIVATION; FAMILY; FORMS	The interaction of prolactin with its receptor in the Nb2 cell line has been shown to induce the phosphorylation of cell associated proteins and mitogenesis. It has been reported previously that one of these proteins, phosphorylated upon prolactin stimulation, was a tyrosine kinase. We have identified this kinase as JAK2, and demonstrate its association with the prolactin receptor. In addition, we show that the prolactin receptor itself becomes tyrosine phosphorylated upon ligand stimulation in Nb2 cells. These actions are time-dependent and occur rapidly after prolactin stimulation, with first the kinase being activated within 5 min and then the receptor being phosphorylated maximally at 20 min. Moreover, phosphorylation of both JAK2 and the receptor as well as Nb2 cell proliferation are dependent on the concentration of lactogenic hormone, resulting in a bell-shaped response curve similar to that observed in the two site model of hGH action. This indicates that early events in signal transduction as well as later events like mitogenesis and proliferation involve prolactin receptor dimerization. Together these data indicate that the prolactin receptor in Nb2 cells is associated to JAK2 and that upon ligand stimulation, and receptor dimerization, the kinase and the receptor are tyrosine-phosphorylated, which represents the first event in the process of prolactin receptor signal transduction in Nb2 cells.	FAC MED NECKER ENFANTS MALAD, INSERM, U344, UNITE ENDOCRINOL MOLEC, F-75730 PARIS, FRANCE; MAX PLANCK INST BIOCHEM, DEPT MOLEC BIOL, W-8033 MARTINSRIED, GERMANY	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Max Planck Society			Kelly, Paul/A-7951-2008; Lebrun, Jean-Jacques/GNP-5222-2022	sofer, luc/0000-0001-9999-9667				ALI S, 1991, J BIOL CHEM, V266, P20110; ALI S, 1992, MOL ENDOCRINOL, V6, P1242, DOI 10.1210/me.6.8.1242; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BOUTIN JM, 1988, CELL, V53, P69, DOI 10.1016/0092-8674(88)90488-6; CARTERSU C, 1989, J BIOL CHEM, V264, P18654; COMSA J, 1981, REV PHYSIOL BIOCH P, V92, P115; COSMAN D, 1993, CYTOKINE, V5, P95, DOI 10.1016/1043-4666(93)90047-9; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; ELBERG G, 1990, J BIOL CHEM, V265, P14770; FOSTER CM, 1988, BIOCHEMISTRY-US, V27, P326, DOI 10.1021/bi00401a049; FUH G, 1993, J BIOL CHEM, V268, P5376; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; GOUT PW, 1980, CANCER RES, V40, P2433; KELLY PA, 1993, RECENT PROG HORM RES, V48; LESUEUR L, 1991, P NATL ACAD SCI USA, V88, P824, DOI 10.1073/pnas.88.3.824; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; NOBLE RL, 1975, CANCER RES, V35, P766; PELLEGRINI I, 1992, MOL ENDOCRINOL, V6, P1023, DOI 10.1210/me.6.7.1023; RICHARDS JF, 1982, MOL CELL ENDOCRINOL, V26, P41, DOI 10.1016/0303-7207(82)90005-3; RILLEMA JA, 1992, ENDOCRINOLOGY, V131, P973, DOI 10.1210/en.131.2.973; RUI H, 1992, J BIOL CHEM, V267, P24076; RUSSELL DH, 1984, BIOCHEM BIOPH RES CO, V121, P899, DOI 10.1016/0006-291X(84)90762-9; SABHARWAL P, 1992, P NATL ACAD SCI USA, V89, P7713, DOI 10.1073/pnas.89.16.7713; SHACKELFORD DA, 1991, CELL REGUL, V2, P73, DOI 10.1091/mbc.2.1.73; SHIROTA M, 1990, MOL ENDOCRINOL, V4, P1136, DOI 10.1210/mend-4-8-1136; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; UEHARA Y, 1989, BIOCHEM BIOPH RES CO, V163, P803, DOI 10.1016/0006-291X(89)92293-6; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WANG XY, 1993, J BIOL CHEM, V268, P3573; WATOWICH SS, 1992, P NATL ACAD SCI USA, V89, P2140, DOI 10.1073/pnas.89.6.2140; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; YOSHIMURA A, 1992, MOL CELL BIOL, V12, P706, DOI 10.1128/MCB.12.2.706	34	191	191	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					14021	14026						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188682				2022-12-25	WOS:A1994NL60600047
J	LILIE, H; MCLAUGHLIN, S; FREEDMAN, R; BUCHNER, J				LILIE, H; MCLAUGHLIN, S; FREEDMAN, R; BUCHNER, J			INFLUENCE OF PROTEIN DISULFIDE-ISOMERASE (PDI) ON ANTIBODY FOLDING IN-VITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNOGLOBULIN LIGHT CHAIN; ENDOPLASMIC-RETICULUM; CONSTANT FRAGMENT; PEPTIDE-BINDING; HEAVY-CHAIN; BIP; BIOSYNTHESIS; RENATURATION; COMPONENT; REDUCTION	The role of eucaryotic protein disulfide isomerase (PDI) in the folding and reoxidation of proteins in vitro was investigated using an antibody Fab fragment as a model substrate, since PDI is known to participate in the disulfide bond formation of immunoglobulins in vivo. PDI has no effect on the folding of the Fab fragment with intact disulfide bonds, suggesting that, at least in this system, PDI is not able to influence the folding process in a chaperone-like manner. Instead, the role of PDI is limited to disulfide bond formation as demonstrated for the folding of the denatured and reduced Fab fragment. Here, PDI influences the yield of reactivation enormously with a maximum effect at about stoichiometric amounts of PDI and Fab. Furthermore, PDI changes the redox dependence of the reaction. In the presence of PDI, formation of the correct disulfide bonds is possible at higher oxidizing conditions compared to the spontaneous reaction. The requirements both for stoichiometric amounts of PDI and for the presence of PDI during the first seconds of refolding suggest that there is a kinetic competition between rapid structure formation of the antibody domains and interaction of PDI with cysteine residues in the folding protein.	UNIV REGENSBURG, INST BIOPHYS & PHYS BIOCHEM, D-93053 REGENSBURG, GERMANY; UNIV KENT, BIOL LAB, CANTERBURY CT2 7NJ, KENT, ENGLAND	University of Regensburg; University of Kent			Buchner, Johannes/A-2651-2010	McLaughlin, Stephen/0000-0001-9135-6253				ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; BERGMAN LW, 1979, J BIOL CHEM, V254, P5690; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROCKWAY BE, 1980, BIOCHEM J, V191, P873, DOI 10.1042/bj1910873; BUCHNER J, 1991, CURR OPIN BIOTECH, V2, P532, DOI 10.1016/0958-1669(91)90077-I; BUCHNER J, 1992, ANAL BIOCHEM, V205, P263, DOI 10.1016/0003-2697(92)90433-8; BUCHNER J, 1991, BIO-TECHNOL, V9, P157, DOI 10.1038/nbt0291-157; BUCHNER J, 1990, DECHEMA BIOTECHNOLOG, V3, P1035; BUCKEL P, 1987, GENE, V51, P13, DOI 10.1016/0378-1119(87)90469-0; BULLEID NJ, 1988, NATURE, V335, P649, DOI 10.1038/335649a0; DELAMETTE F, 1975, CELL IMMUNOL, V19, P262, DOI 10.1016/0008-8749(75)90208-7; DELLACOR.E, 1973, BIOCHEM J, V136, P597; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; FREEDMAN RB, 1991, CONFORMATIONS FORCES, P204; Freedman Robert B., 1992, P455; GEETHAHABIB M, 1988, CELL, V54, P1053, DOI 10.1016/0092-8674(88)90120-1; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOTO Y, 1981, J MOL BIOL, V146, P321, DOI 10.1016/0022-2836(81)90391-0; HAAS IG, 1983, NATURE, V306, P387, DOI 10.1038/306387a0; HAWKINS HC, 1991, BIOCHEM J, V275, P335, DOI 10.1042/bj2750335; HOLMGREN A, 1979, J BIOL CHEM, V254, P9627; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; JAENICKE R, 1987, PROG BIOPHYS MOL BIO, V49, P117, DOI 10.1016/0079-6107(87)90011-3; JAENICKE R, 1993, CHEMTRACTS BIOCH MOL, V4, P1; JOHN DCA, 1993, EMBO J, V12, P1587, DOI 10.1002/j.1460-2075.1993.tb05803.x; JOHNSTONE A, 1987, IMMUNOCHEMISTRY PRAC, P55; KAWATA Y, 1991, BIOCHEMISTRY-US, V30, P4367, DOI 10.1021/bi00232a001; KHYSEANDERSON J, 1984, J BIOCHEM BIOPH METH, V10, P203; KIEFHABER T, 1990, BIOCHEMISTRY-US, V29, P3061, DOI 10.1021/bi00464a024; KIEFHABER T, 1991, BIO-TECHNOL, V9, P825, DOI 10.1038/nbt0991-825; KIKUCHI H, 1986, BIOCHEMISTRY-US, V25, P2009, DOI 10.1021/bi00356a026; KNITTLER MR, 1992, EMBO J, V11, P1573, DOI 10.1002/j.1460-2075.1992.tb05202.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBERT N, 1983, BIOCHEM J, V213, P225, DOI 10.1042/bj2130225; LILIE H, 1993, PROTEIN SCI, V2, P1490, DOI 10.1002/pro.5560020913; MELNICK J, 1992, J BIOL CHEM, V267, P21303; MILLS ENC, 1983, BIOCHEM J, V213, P245, DOI 10.1042/bj2130245; MYLLYLA R, 1983, EUR J BIOCHEM, V134, P7, DOI 10.1111/j.1432-1033.1983.tb07523.x; NOIVA R, 1992, J BIOL CHEM, V267, P3553; NOIVA R, 1991, J BIOL CHEM, V266, P19645; PAVER JL, 1989, FEBS LETT, V242, P352; PIHLAJANIEMI T, 1987, EMBO J, V6, P643, DOI 10.1002/j.1460-2075.1987.tb04803.x; ROTH RA, 1981, BIOCHEMISTRY-US, V20, P6594, DOI 10.1021/bi00526a012; ROTH RA, 1987, BIOCHEMISTRY-US, V26, P4179, DOI 10.1021/bi00388a001; RUDOLPH R, 1990, MODERN METHOD IN PROTEIN- AND NUCLEIC ACID RESEARCH, P149; SCHMIDT M, 1992, J BIOL CHEM, V267, P16829; WETTERAU JR, 1990, J BIOL CHEM, V265, P9800; WIECH H, 1992, NATURE, V358, P169, DOI 10.1038/358169a0; WILDE CE, 1978, BIOCHEMISTRY-US, V17, P3209, DOI 10.1021/bi00609a006	52	85	90	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					14290	14296						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188714				2022-12-25	WOS:A1994NL60600085
J	ROESLER, WJ; SIMARD, J; GRAHAM, JG; MCFIE, PJ				ROESLER, WJ; SIMARD, J; GRAHAM, JG; MCFIE, PJ			CHARACTERIZATION OF THE LIVER-SPECIFIC COMPONENT OF THE CAMP RESPONSE UNIT IN THE PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP) GENE PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCER-BINDING-PROTEIN; C/EBP-RELATED PROTEINS; CYCLIC-AMP; TRANSCRIPTION FACTOR; GLUCOCORTICOID RECEPTOR; REGULATORY ELEMENTS; HEPATOMA-CELLS; ALBUMIN GENE; EXPRESSION; INDUCTION	The cAMP response unit of the phosphoenolpyruvate carboxykinase (GTP) (EC 4.1.1.32) gene promoter consists of two independently weak components; the typical cAMP response element and a region of the promoter that contains three binding sites for CCAAT/enhancer-binding proteins. Previous work from our laboratory indicated that all three binding sites were required for the full response to cAMP. However, in the present study, we demonstrate that the activity of this latter component cannot be mimicked by multiple copies of other well characterized CCAAT/enhancer-binding protein binding sites. Re examination of the promoter region containing the three C/EBP binding sites revealed the presence of an additional cis-element, which is required to mediate the activation by cAMP. This DNA sequence binds a protein in HepG2 nuclear extracts that is distinct from CCAAT/enhancer-binding protein and cAMP response element-binding protein, and evidence is presented which suggests that its identity is activator protein-1. Thus, the robust response of the phosphoenolpyruvate carboxykinase gene promoter to cAMP in liver requires the involvement of three different transcription factors. Utilization of multiple transcription factors to mediate the activation by cAMP likely allows for a tissue-specific response to this signal, a mechanism whereby to fine-tune the extent of the response, and a mechanism whereby to integrate signals from separate signaling pathways into a coordinated response.			ROESLER, WJ (corresponding author), UNIV SASKATCHEWAN,COLL MED,DEPT BIOCHEM,SASKATOON S7N 0W0,SK,CANADA.							AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; BOKAR JA, 1988, J BIOL CHEM, V263, P19740; BURK O, 1993, EMBO J, V12, P2027, DOI 10.1002/j.1460-2075.1993.tb05852.x; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; FISCH TM, 1989, GENE DEV, V3, P198, DOI 10.1101/gad.3.2.198; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; GIRALT M, 1991, J BIOL CHEM, V266, P21991; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GURNEY AL, 1992, J BIOL CHEM, V267, P18133; HERRERA R, 1989, MOL CELL BIOL, V9, P5331, DOI 10.1128/MCB.9.12.5331; HYMAN SE, 1989, MOL CELL BIOL, V9, P321, DOI 10.1128/MCB.9.1.321; KATZ S, 1993, EMBO J, V12, P1321, DOI 10.1002/j.1460-2075.1993.tb05777.x; LAMERS WH, 1982, P NATL ACAD SCI-BIOL, V79, P5137, DOI 10.1073/pnas.79.17.5137; LECLAIR KP, 1992, P NATL ACAD SCI USA, V89, P8145, DOI 10.1073/pnas.89.17.8145; LICHTSTEINER S, 1987, CELL, V51, P963, DOI 10.1016/0092-8674(87)90583-6; LIU JS, 1991, J BIOL CHEM, V266, P19095; MEISNER H, 1985, BIOCHEMISTRY-US, V24, P421, DOI 10.1021/bi00323a027; MELLON PL, 1989, P NATL ACAD SCI USA, V86, P4887, DOI 10.1073/pnas.86.13.4887; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; MILOS PM, 1992, GENE DEV, V6, P991, DOI 10.1101/gad.6.6.991; NIELSEN DA, 1989, ANAL BIOCHEM, V179, P19, DOI 10.1016/0003-2697(89)90193-0; NISHIO Y, 1993, MOL CELL BIOL, V13, P1854, DOI 10.1128/MCB.13.3.1854; PARK EA, 1990, MOL CELL BIOL, V10, P6264, DOI 10.1128/MCB.10.12.6264; PARK EA, 1993, J BIOL CHEM, V268, P613; PEERS B, 1991, J BIOL CHEM, V266, P18127; QUINN PG, 1988, MOL CELL BIOL, V8, P3467, DOI 10.1128/MCB.8.8.3467; REHFUSS RP, 1991, J BIOL CHEM, V266, P18431; ROESLER WJ, 1990, TRENDS ENDOCRIN MET, V1, P347, DOI 10.1016/1043-2760(90)90082-E; ROESLER WJ, 1989, J BIOL CHEM, V264, P9657; ROESLER WJ, 1993, J BIOL CHEM, V268, P3791; ROESLER WJ, 1992, J BIOL CHEM, V267, P21235; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; Sambrook J, 1989, MOL CLONING LABORATO; SCHULE R, 1988, NATURE, V332, P87, DOI 10.1038/332087a0; SCHULE R, 1988, SCIENCE, V242, P1418, DOI 10.1126/science.3201230; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; STRAHLE U, 1988, EMBO J, V7, P3389, DOI 10.1002/j.1460-2075.1988.tb03212.x; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; YAMAMOTO KK, 1990, CELL, V60, P611, DOI 10.1016/0092-8674(90)90664-Z	42	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					14276	14283						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188712				2022-12-25	WOS:A1994NL60600083
J	RAYMOND, JR; ARTHUR, JM; CASANAS, SJ; OLSEN, CL; GETTYS, TW; MORTENSEN, RM				RAYMOND, JR; ARTHUR, JM; CASANAS, SJ; OLSEN, CL; GETTYS, TW; MORTENSEN, RM			ALPHA(2A) ADRENERGIC-RECEPTORS INHIBIT CAMP ACCUMULATION IN EMBRYONIC STEM-CELLS WHICH LACK G(I-ALPHA-2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CYCLIC-AMP ACCUMULATION; DISTINCT G-PROTEINS; ADENYLATE-CYCLASE; SUBTYPES; GI2; ACTIVATION; MUTANT; PHOSPHOLIPASE-A2; DIFFERENTIATION; IDENTIFICATION	alpha(2A) adrenergic receptors are thought to inhibit adenylyl cyclase primarily through G(i alpha 2). We tested the requirement for G(i alpha 2) to inhibit cAMP accumulation by stable expression of alpha(2A) adrenergic receptors in mouse embryonic stem cells. Host lines consisted of wild-type CCE cells, and CCE cells with targeted disruption of the G(i alpha 2) gene by two-stage homologous recombination (Mortensen, R. M., Zubiuar, M., Neer, E. J., and Seidman, J. G. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 7036-7040; Mortensen, R. M., Conner, D. A., Chao, S., Geisterfer-Lowrance, A. A., and Seidman, J. G. (1992) Mol. Cell. Biol. 12, 2391-2395). Knockouts were confirmed by Northern blot and immunoblot. We studied three clones derived from wild-type CCE cells (2, 6, and 8) expressing 450 +/- 50, 3000 +/- 120, and 150 +/- 20 fmol of receptor/mg of protein, respectively, and two G(i alpha 2)-null clones (7 and 18) expressing 2100 +/- 250 and 300 +/- 40 fmol of receptor/mg of protein. The specific agonist UK14304 caused an inhibition of cAMP accumulation in clones 2,6 and 8 (58 +/- 16%, 62 +/- 7%, and 52 +/- 12%) and in clones 7 (47 +/- 3%) and 18 (40 +/- 5%), but not in nontransfected CCE cells. IC50 values were similar for all clones (approximate to 200 nM). The effect was attenuated by pertussis toxin and the antagonist rauwolscine. These studies show that expression of G(i alpha 2) is not required for alpha(2A) adrenergic receptors to inhibit cAMP accumulation.	VET AFFAIRS MED CTR, DEPT MED, DURHAM, NC 27710 USA; MED UNIV S CAROLINA, CHARLESTON, SC 29425 USA; BRIGHAM & WOMENS HOSP, DIV ENDOCRINOL & HYPERTENS, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DEPT MED, BOSTON, MA 02115 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Medical University of South Carolina; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	RAYMOND, JR (corresponding author), DUKE UNIV, MED CTR, DEPT MED, BOX 3459, DURHAM, NC 27710 USA.		Gettys, Thomas W/N-1964-2017	Gettys, Thomas W/0000-0001-7125-7995; Arthur, John/0000-0003-4342-4762	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK042486] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049122] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030927] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK42486] Funding Source: Medline; NIGMS NIH HHS [GM49122] Funding Source: Medline; NINDS NIH HHS [NS30927] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BIRNBAUMER L, 1992, CELL, V71, P1069, DOI 10.1016/S0092-8674(05)80056-X; CARTER BD, 1993, P NATL ACAD SCI USA, V90, P4062, DOI 10.1073/pnas.90.9.4062; CHABRE O, 1994, J BIOL CHEM, V269, P5730; CONKLIN BR, 1992, J BIOL CHEM, V267, P31; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; DUZIC E, 1992, J BIOL CHEM, V267, P9844; FARGIN A, 1991, CELL SIGNAL, V3, P547, DOI 10.1016/0898-6568(91)90031-O; GERHARDT MA, 1991, MOL PHARMACOL, V40, P707; GOETZL EJ, 1994, J BIOL CHEM, V269, P809; GUPTA SK, 1990, SCIENCE, V249, P662, DOI 10.1126/science.2166341; INANOBE A, 1990, FEBS LETT, V263, P369, DOI 10.1016/0014-5793(90)81416-L; KLEUSS C, 1991, NATURE, V353, P43, DOI 10.1038/353043a0; KUROSE H, 1991, BIOCHEMISTRY-US, V30, P3335, DOI 10.1021/bi00227a024; LAMORTE VJ, 1992, J BIOL CHEM, V267, P691; LAW SF, 1993, J BIOL CHEM, V268, P10721; LLEDO PM, 1992, NEURON, V8, P455, DOI 10.1016/0896-6273(92)90273-G; LOWNDES JM, 1991, J BIOL CHEM, V266, P14193; MCCLUE SJ, 1992, BIOCHEM J, V284, P565, DOI 10.1042/bj2840565; MCKENZIE FR, 1990, BIOCHEM J, V267, P391, DOI 10.1042/bj2670391; MILLIGAN G, 1991, J BIOL CHEM, V266, P6447; MONTMAYEUR JP, 1993, MOL ENDOCRINOL, V7, P161, DOI 10.1210/me.7.2.161; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; MORTENSEN RM, 1991, P NATL ACAD SCI USA, V88, P7036, DOI 10.1073/pnas.88.16.7036; MULHERON JG, 1994, J BIOL CHEM, V269, P12954; OFFERMANNS S, 1991, METHOD ENZYMOL, V195, P286; POBINER BF, 1991, MOL PHARMACOL, V40, P157; RAYMOND JR, 1993, BIOCHEMISTRY-US, V32, P11064, DOI 10.1021/bi00092a016; REMAURY A, 1993, BIOCHEM J, V292, P283, DOI 10.1042/bj2920283; SENOGLES SE, 1990, J BIOL CHEM, V265, P4507; SIMONDS WF, 1989, P NATL ACAD SCI USA, V86, P7809, DOI 10.1073/pnas.86.20.7809; SUKI WN, 1987, FEBS LETT, V220, P187, DOI 10.1016/0014-5793(87)80900-6; TAUSSIG R, 1992, NEURON, V8, P799, DOI 10.1016/0896-6273(92)90100-R; TAUSSIG R, 1994, J BIOL CHEM, V269, P6093; THOMAS R, 1991, METHOD ENZYMOL, V195, P280; WANG HY, 1992, NATURE, V358, P334, DOI 10.1038/358334a0; WANG Z, 1993, MOL ENDOCRINOL, V7, P85, DOI 10.1210/me.7.1.85; WATKINS DC, 1992, SCIENCE, V258, P1373, DOI 10.1126/science.1455234; WILKBLASZCZAK MA, 1994, NEURON, V12, P109, DOI 10.1016/0896-6273(94)90156-2; WONG YH, 1992, SCIENCE, V255, P339, DOI 10.1126/science.1347957; WONG YH, 1991, NATURE, V351, P63, DOI 10.1038/351063a0	40	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13073	13075						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175730				2022-12-25	WOS:A1994NK18400005
J	MARTEN, NW; BURKE, EJ; HAYDEN, JM; STRAUS, DS				MARTEN, NW; BURKE, EJ; HAYDEN, JM; STRAUS, DS			EFFECT OF AMINO-ACID LIMITATION ON THE EXPRESSION OF 19 GENES IN RAT HEPATOMA-CELLS	FASEB JOURNAL			English	Article						AMINO ACIDS; SERUM ALBUMIN; HEPATOMA CELLS	TRANSCRIPTIONAL ACTIVATOR PROTEIN; ALBUMIN MESSENGER-RNA; ALPHA-1-ACID GLYCOPROTEIN; REGULATED EXPRESSION; C-FOS; LIVER; C/EBP; PROMOTER; LAP; DEPRIVATION	We showed previously that the abundance of serum albumin mRNA is decreased in H4-II-E rat hepatoma cells limited for a single essential amino acid (phenylalanine, methionine, leucine, or tryptophan). To define the specificity of this phenomenon, we examined the effect of amino acid limitation on the abundance of mRNAs for 19 genes in the H4-II-E cells. These genes included six genes whose expression is either completely liver-specific or highly enriched in the liver compared with other tissues [albumin, transthyretin (TTR), transferrin, carbamyl phosphate synthetase-I, urate oxidase, class I alcohol dehydrogenase], as well as a number of ubiquitously expressed ''housekeeping'' genes. The results indicated that the 19 genes could be divided into three classes based on their response to amino acid limitation. Class I genes (the six liver-specific genes and alpha-tubulin) exhibit decreased expression in response to amino acid limitation. The expression of class II genes [beta(2)- microglobulin, hypoxanthine-guanine phosphoribosyl transferase (HPRT), H-ferritin, ubiquitin (UbB), insulin-like growth factor binding protein-4, HNF-1 alpha] is not significantly affected by amino acid limitation. Class III genes [gadd153, beta-actin, ubiquitin (UbC), phosphoglycerate kinase-1, C/EBP alpha, C/EBP beta] exhibit increased expression in response to amino acid limitation. Thus, specific inductive as well as repressive effects on gene expression are quite common in amino acid-limited cells. The observation that all six genes whose expression is liver-specific exhibited decreased expression in amino acid-limited cells suggests a common mode of regulation of these genes by amino acid availability. The strong induction by amino acid limitation of the C/EBP inhibitor gadd153 is of interest in this regard, as increased levels of gadd153 could interfere with C/EBP, which is required for high expression of most liver-specific genes. To investigate further the molecular mechanism for the decrease in albumin mRNA abundance, albumin nuclear transcript levels were quantified in control and tryptophan-limited cells. Tryptophan limitation caused a decrease in albumin nuclear transcript abundance, and this decrease preceded the decrease in albumin mRNA, suggesting that the decrease in albumin mRNA was caused at least partly by a decrease in albumin gene transcription. Additional experiments with actinomycin D indicated that albumin mRNA was also destabilized in the tryptophan-limited cells. Thus, the overall results indicate that the decrease in albumin mRNA in the tryptophan-limited cells is caused by a specific decrease in albumin nuclear transcript abundance and destabilization of albumin mRNA.	UNIV CALIF RIVERSIDE,DIV BIOMED SCI,RIVERSIDE,CA 92521; UNIV CALIF RIVERSIDE,DEPT BIOL,RIVERSIDE,CA 92521	University of California System; University of California Riverside; University of California System; University of California Riverside					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039739] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01-DK39739] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CARLSON SG, 1993, MOL CELL BIOL, V13, P4736, DOI 10.1128/MCB.13.8.4736; CHENCYA, 1992, MOL CELL BIOL, V12, P5748; COWARD WA, 1981, BRIT MED BULL, V37, P19, DOI 10.1093/oxfordjournals.bmb.a071670; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; FORNACE AJ, 1989, NUCLEIC ACIDS RES, V17, P1215, DOI 10.1093/nar/17.3.1215; GAY DA, 1989, P NATL ACAD SCI USA, V86, P5763, DOI 10.1073/pnas.86.15.5763; GUERRINI L, 1993, MOL CELL BIOL, V13, P3202, DOI 10.1128/MCB.13.6.3202; HAYDEN JM, 1994, ENDOCRINOLOGY, V134, P760, DOI 10.1210/en.134.2.760; KLEIN ES, 1987, J BIOL CHEM, V262, P520; KLEIN ES, 1988, THESIS STANFORD U ST; KOELLER DM, 1991, P NATL ACAD SCI USA, V88, P7778, DOI 10.1073/pnas.88.17.7778; LAGACE M, 1992, GENE, V118, P231, DOI 10.1016/0378-1119(92)90193-S; LAI E, 1991, TRENDS BIOCHEM SCI, V16, P427, DOI 10.1016/0968-0004(91)90169-V; LAINE RO, 1991, J BIOL CHEM, V266, P16969; MENDELZON D, 1990, NUCLEIC ACIDS RES, V18, P5717, DOI 10.1093/nar/18.19.5717; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; PACHTER JS, 1987, CELL, V51, P283, DOI 10.1016/0092-8674(87)90155-3; POHJANPELTO P, 1990, MOL CELL BIOL, V10, P5814, DOI 10.1128/MCB.10.11.5814; POTTER JJ, 1992, ARCH BIOCHEM BIOPHYS, V295, P360, DOI 10.1016/0003-9861(92)90529-6; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; ROTHSCHILD MA, 1969, J NUTR, V98, P395, DOI 10.1093/jn/98.4.395; SAKUMA K, 1987, J NUTR, V117, P1141, DOI 10.1093/jn/117.6.1141; SIDRANSKY H, 1968, J BIOL CHEM, V243, P1123; STRAUS DS, 1991, J NUTR, V121, P1279, DOI 10.1093/jn/121.8.1279; STRAUS DS, 1988, BIOCHIM BIOPHYS ACTA, V972, P33; STRAUS DS, 1993, ENDOCRINOLOGY, V132, P1090, DOI 10.1210/en.132.3.1090; STRAUS DS, 1990, ENDOCRINOLOGY, V127, P1849, DOI 10.1210/endo-127-4-1849; VANNICE JL, 1984, P NATL ACAD SCI-BIOL, V81, P4241, DOI 10.1073/pnas.81.14.4241	31	118	120	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAY	1994	8	8					538	544		10.1096/fasebj.8.8.8181673	http://dx.doi.org/10.1096/fasebj.8.8.8181673			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	NM364	8181673				2022-12-25	WOS:A1994NM36400012
J	GAO, WY; AGBARIA, R; DRISCOLL, JS; MITSUYA, H				GAO, WY; AGBARIA, R; DRISCOLL, JS; MITSUYA, H			DIVERGENT ANTI-HUMAN-IMMUNODEFICIENCY-VIRUS ACTIVITY AND ANABOLIC PHOSPHORYLATION OF 2',3'-DIDEOXYNUCLEOSIDE ANALOGS IN RESTING AND ACTIVATED HUMAN-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN THYMIDINE KINASE-1; REVERSE-TRANSCRIPTASE; REPLICATION; TYPE-1; DNA; (-)-2'-DEOXY-3'-THIACYTIDINE; 3'-AZIDO-3'-DEOXYTHYMIDINE; 2',3'-DIDEOXYADENOSINE; 2',3'-DIDEOXYINOSINE; DIDEOXYNUCLEOSIDES	The mechanism of divergent anti-human immunodeficiency virus type I (HIV-I) activity of various 2',3'-dideoxynucleoside analogs (ddNs) in peripheral blood mononuclear cells (PBM) was studied. We demonstrate that the in vitro anti-EW-l activity of various ddNs varies profoundly and that the divergent antiviral activity is related to the extent of anabolic phosphorylation of each ddN and its counterpart 2' deoxynucleoside (dN). We also show that certain ddNs cause a reduction of their counterpart dNTP formation in PBM in the following order: 2',3'-dideoxycytidine (ddC) >> 2',3'-didehydro-2',3'-dideoxythymidine (d4T), 3'-thia-2',3'-dideoxycytidine (3TC), 2'3'-dideoxyinosine (ddI), 2',3'-dideoxyguanosine (ddG) > 3'-azido-2',3'-dideoxythymidine (AZT) > 2'-beta-fluoro-2',3'-dideoxyadenosine (F-ara-ddA). Based on the phosphorylation profiles, anti-HIV-1 ddNs can be classified into two groups: (i) cell-activation-dependent ddNs such as AZT and d4T that are preferentially phosphorylated, yield higher ratios of ddNTP/dNTP, and exert more potent anti-HIV-1 activity in activated cells than in resting cells; and (ii) cell-activation-independent ddNs including ddI (and 2',3'-dideoxyadenosine), F-ara-ddA, ddG, ddC, and 3TC that produce higher ratios of ddNTP/dNTP and exert more potent anti-HIV-1 activity in resting cells. These data should provide a basis for the elucidation of the mechanism of the divergent antiretroviral activity of ddNs.	NCI,MED BRANCH,EXPTL RETROVIROL SECT,BETHESDA,MD 20892; NCI,MED CHEM LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								ARNER ESJ, 1992, J BIOL CHEM, V267, P10968; BAGASRA O, 1992, NEW ENGL J MED, V326, P1385, DOI 10.1056/NEJM199205213262103; BUKRINSKY MI, 1991, SCIENCE, V254, P423, DOI 10.1126/science.1925601; CHANG CN, 1992, J BIOL CHEM, V267, P22414; COATES JAV, 1992, ANTIMICROB AGENTS CH, V36, P733, DOI 10.1128/AAC.36.4.733; ERIKSSON S, 1991, BIOCHEM BIOPH RES CO, V176, P586, DOI 10.1016/S0006-291X(05)80224-4; FURMAN PA, 1986, P NATL ACAD SCI USA, V83, P8333, DOI 10.1073/pnas.83.21.8333; GAO WY, 1993, J CLIN INVEST, V91, P2326, DOI 10.1172/JCI116463; GAO WY, 1993, P NATL ACAD SCI USA, V90, P8925, DOI 10.1073/pnas.90.19.8925; HAREL J, 1981, VIROLOGY, V110, P202, DOI 10.1016/0042-6822(81)90022-2; HART GJ, 1992, ANTIMICROB AGENTS CH, V36, P1688, DOI 10.1128/AAC.36.8.1688; HARTMAN NR, 1991, MOL PHARMACOL, V40, P118; JACKSON RC, 1989, INHIBITORS RIBONUCLE, P127; JOHNSON MA, 1989, MOL PHARMACOL, V36, P291; JOHNSTON MI, 1993, SCIENCE, V260, P1286, DOI 10.1126/science.7684163; MARQUEZ VE, 1987, BIOCHEM PHARMACOL, V36, P2719, DOI 10.1016/0006-2952(87)90254-1; MARQUEZ VE, 1990, J MED CHEM, V33, P978, DOI 10.1021/jm00165a015; MASOOD R, 1990, MOL PHARMACOL, V37, P590; MITSUYA H, 1990, SCIENCE, V249, P1533, DOI 10.1126/science.1699273; MUNCHPETERSEN B, 1991, J BIOL CHEM, V266, P9032; PERNO CF, 1989, J EXP MED, V169, P933, DOI 10.1084/jem.169.3.933; RUXRUNGTHAM K, 1993, 9 INT AIDS C BERL; SHERMAN PA, 1989, ANAL BIOCHEM, V180, P222, DOI 10.1016/0003-2697(89)90420-X; SHIRASAKA T, 1993, P NATL ACAD SCI USA, V90, P562, DOI 10.1073/pnas.90.2.562; STARNES MC, 1987, J BIOL CHEM, V262, P988; STEVENSON M, 1990, EMBO J, V9, P1551, DOI 10.1002/j.1460-2075.1990.tb08274.x; VARMUS HE, 1977, CELL, V11, P307, DOI 10.1016/0092-8674(77)90047-2; YARCHOAN R, 1991, BLOOD, V78, P859; YARCHOAN R, 1993, J INFECT DIS, V168, P810; ZACK JA, 1992, J VIROL, V66, P1717, DOI 10.1128/JVI.66.3.1717-1725.1992; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L	31	217	219	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12633	12638						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175673				2022-12-25	WOS:A1994NH71600043
J	JIMENEZ, SA; VARGA, J; OLSEN, A; LI, LY; DIAZ, A; HERHAL, J; KOCH, J				JIMENEZ, SA; VARGA, J; OLSEN, A; LI, LY; DIAZ, A; HERHAL, J; KOCH, J			FUNCTIONAL-ANALYSIS OF HUMAN ALPHA-1(I) PROCOLLAGEN GENE PROMOTER - DIFFERENTIAL ACTIVITY IN COLLAGEN-PRODUCING AND COLLAGEN-NONPRODUCING CELLS AND RESPONSE TO TRANSFORMING GROWTH-FACTOR BETA(1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA LEVELS; NUCLEAR FACTOR-I; CHICK-EMBRYO FIBROBLASTS; PROGRESSIVE SYSTEMIC-SCLEROSIS; 1ST INTRON CONTRIBUTE; ROUS-SARCOMA VIRUS; DNA-BINDING FACTOR; TRANSCRIPTION FACTOR; REGULATORY ELEMENTS; EXTRACELLULAR-MATRIX	To gain a further understanding of the regulation of human type I collagen gene expression under physiologic and pathologic conditions, we characterized 5.3 kilobase pairs (kb) of the human alpha 1(I) procollagen gene promoter. A series of deletion constructs containing portions of the alpha 1(I) procollagen 5'-flanking region (with end points from -5.3 kb to -84 base pairs (bp)) ligated to the chloramphenicol acetyltransferase (CAT) reporter gene were transiently transfected into NIH/3T3 cells. Maximal CAT activity was observed with constructs having 5' end points from -804 to -174 bp. A further 5' deletion to -84 bp caused a marked reduction in CAT activity. Cells transfected with plasmids containing longer 5'-flanking fragments of the al(I) procollagen gene (-2.3 or -5.3 kb) showed reduced CAT activity compared with the -804 bp construct. The activity of the al(I) procollagen promoter was much lower in cells that do not normally express type I collagen (HeLa cells) compared with collagen-producing NIH/3T3 cells. The CAT activity of deletion constructs containing longer 5' regions than -84 bp was increased by approximate to 2-fold in NIH/3T3 cells treated with transforming growth factor beta 1 (TGF beta 1). Electrophoretic mobility shift assays indicated that protein-DNA complex formation with a probe corresponding to the -170 to -80 bp fragment of the alpha 1(I) procollagen promoter was markedly enhanced in nuclear extracts prepared from TGF beta 1 treated fibroblasts as compared with untreated fibroblasts. The DNA binding activity stimulated by TGF beta 1 was specific for an Spl-like sequence at positions -164 to -142 bp in the promoter. These results demonstrate that 1) there are both positive and negative cis-acting regulatory elements in the human al(I) procollagen promoter, 2) these regulatory regions function differently in collagen-producing and -nonproducing cells, 3) the alpha 1(I) procollagen promoter contains TGF beta 1-responsive sequences located between -174 and -84 bp from the transcription start site, and 4) TGF beta 1 caused marked stimulation of the DNA binding activity of a nuclear factor interacting with an Sp1-like binding site located within a region encompassing -164 to -142 bp of the alpha 1(I) procollagen promoter.	THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT BIOCHEM & MOLEC BIOL,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,INST MOLEC MED,PHILADELPHIA,PA 19107	Jefferson University; Jefferson University	JIMENEZ, SA (corresponding author), THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT MED,RM 509,BLUEMLE LIFE SCI BLDG,233 S 10TH ST,PHILADELPHIA,PA 19107, USA.			Jimenez, Sergio/0000-0001-5213-1203	NIADDK NIH HHS [AM 19106] Funding Source: Medline; NIAMS NIH HHS [AR 42309] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042309] Funding Source: NIH RePORTER	NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ADAMS SL, 1977, P NATL ACAD SCI USA, V74, P3399, DOI 10.1073/pnas.74.8.3399; BOAST S, 1990, J BIOL CHEM, V265, P13351; BORNSTEIN P, 1988, J BIOL CHEM, V263, P1603; BORNSTEIN P, 1987, P NATL ACAD SCI USA, V84, P8869, DOI 10.1073/pnas.84.24.8869; BORUNDAARMENDAR.J, 1990, FASEB J, V4, P215; BRAWERMAN G, 1987, CELL, V48, P5, DOI 10.1016/0092-8674(87)90346-1; BROEKELMANN TJ, 1991, P NATL ACAD SCI USA, V88, P6642, DOI 10.1073/pnas.88.15.6642; CACERES J, 1990, ONCOGENE, V5, P59; CHOJKIER M, 1988, HEPATOLOGY, V8, P808, DOI 10.1002/hep.1840080419; CHU ML, 1985, J BIOL CHEM, V260, P2315; CONNOR TB, 1989, J CLIN INVEST, V83, P1661, DOI 10.1172/JCI114065; CZAJA MJ, 1989, J CELL BIOL, V108, P2477, DOI 10.1083/jcb.108.6.2477; DEWET W, 1987, J BIOL CHEM, V262, P16032; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; GIDONI D, 1984, NATURE, V312, P409, DOI 10.1038/312409a0; GOLDRING MB, 1986, J BIOL CHEM, V261, P9049; GOLDRING MB, 1987, J BIOL CHEM, V262, P16724; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRUSCHWITZ M, 1990, J INVEST DERMATOL, V94, P197, DOI 10.1111/1523-1747.ep12874503; HATA RI, 1977, P NATL ACAD SCI USA, V74, P2933, DOI 10.1073/pnas.74.7.2933; HATAMOCHI A, 1986, J BIOL CHEM, V261, P1310; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; IGNOTZ RA, 1986, J BIOL CHEM, V261, P4337; JIMENEZ SA, 1986, J BIOL CHEM, V261, P657; JIMENEZ SA, 1986, BIOCHEM J, V237, P837, DOI 10.1042/bj2370837; JIMENEZ SA, 1984, J CLIN INVEST, V74, P1112, DOI 10.1172/JCI111480; KARSENTY G, 1990, J BIOL CHEM, V265, P9934; LICHTLER A, 1989, J BIOL CHEM, V264, P3072; Liska Deann J., 1992, Gene Expression, V2, P379; MAITY SN, 1988, SCIENCE, V241, P582, DOI 10.1126/science.3399893; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MERLINO GT, 1983, J BIOL CHEM, V258, P41; MOEN RC, 1979, J BIOL CHEM, V254, P3526; NEHLS MC, 1991, MOL CELL BIOL, V11, P4065, DOI 10.1128/MCB.11.8.4065; NEHLS MC, 1992, DNA CELL BIOL, V11, P443, DOI 10.1089/dna.1992.11.443; NEHLS MC, 1991, BIOCHEM BIOPH RES CO, V177, P538; NEWMANN JR, 1987, BIOTECHNIQUES, V5, P444; OHTA A, 1987, ARTHRITIS RHEUM, V30, P404, DOI 10.1002/art.1780300407; OIKARINEN J, 1987, J BIOL CHEM, V262, P11064; PELTONEN J, 1990, J INVEST DERMATOL, V94, P365, DOI 10.1111/1523-1747.ep12874491; PETERKOFSKY B, 1986, J BIOL CHEM, V261, P6818; PIERCE RA, 1987, J BIOL CHEM, V262, P1652; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; RAGHOW R, 1989, J CLIN INVEST, V84, P1836, DOI 10.1172/JCI114369; RICCIO A, 1992, MOL CELL BIOL, V12, P1846, DOI 10.1128/MCB.12.4.1846; RIPPE RA, 1989, MOL CELL BIOL, V9, P2224, DOI 10.1128/MCB.9.5.2224; RITZENTHALER JD, 1993, J BIOL CHEM, V268, P13625; RITZENTHALER JD, 1991, BIOCHEM J, V280, P157, DOI 10.1042/bj2800157; ROBERTS AB, 1986, P NATL ACAD SCI USA, V83, P4167, DOI 10.1073/pnas.83.12.4167; ROBIDOUX S, 1992, MOL CELL BIOL, V12, P3796, DOI 10.1128/MCB.12.9.3796; ROSSI P, 1988, CELL, V52, P405, DOI 10.1016/S0092-8674(88)80033-3; ROWE DW, 1978, BIOCHEMISTRY-US, V17, P1581, DOI 10.1021/bi00602a001; SAFFER JD, 1990, GENE DEV, V4, P659, DOI 10.1101/gad.4.4.659; Sambrook J, 1989, MOL CLONING LABORATO; SANDMEYER S, 1979, J BIOL CHEM, V254, P4950; SANDMEYER S, 1981, CANCER RES, V41, P830; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMIDT A, 1984, J BIOL CHEM, V259, P7411; SIMKEVICH CP, 1992, BIOCHEM J, V286, P179, DOI 10.1042/bj2860179; SLACK JL, 1993, AM J MED GENET, V45, P140, DOI 10.1002/ajmg.1320450203; SPORN MB, 1992, J CELL BIOL, V119, P1017, DOI 10.1083/jcb.119.5.1017; TOLSTOSHEV P, 1981, J BIOL CHEM, V256, P9672; VARGA J, 1990, EUR J CLIN INVEST, V20, P487, DOI 10.1111/j.1365-2362.1990.tb01915.x; VARGA J, 1987, BIOCHEM J, V247, P597, DOI 10.1042/bj2470597; VUORIO E, 1990, ANNU REV BIOCHEM, V59, P837, DOI 10.1146/annurev.bi.59.070190.004201; YOON K, 1988, GENE, V66, P11, DOI 10.1016/0378-1119(88)90220-X	67	151	165	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12684	12691						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175678				2022-12-25	WOS:A1994NH71600050
J	SU, XL; CHEN, FL; HOKIN, LE				SU, XL; CHEN, FL; HOKIN, LE			CLONING AND EXPRESSION OF A NOVEL, HIGHLY TRUNCATED PHOSPHOINOSITIDE-SPECIFIC PHOSPHOLIPASE-C CDNA FROM EMBRYOS OF THE BRINE SHRIMP, ARTEMIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; SEQUENCE; ISOZYMES; BRAIN	A novel, highly truncated form of a cDNA encoding Artemia phosphoinositide-specific phospholipase C (PLC), designated PLC-beta(x), was isolated from a brine shrimp cDNA library. The full-length cDNA is of the beta-type, it is 2855 base pairs long, and it contains an open reading frame encoding 489 amino acids. The deduced amino acid sequence of PLC-beta(x) cDNA shows novel features. It lacks several hundred amino acids at the 5' end, as compared to PLC-beta s in the higher species. It contains conserved domains X and Y, but domain X is highly truncated at the 5' end (only 14-25 conserved amino acids as compared to about 150 amino acids in the higher eukaryotic organisms). Northern blot hybridization showed that the PLC-beta(x) cDNA corresponds to a 4.4-kilobase mRNA. Northern blot hybridization with a cDNA probe from the 5' end and PCR performed upstream from domain Y showed that PLC-beta(x) is not a cloning artifact due to fusion of an unrelated clone into the coding region of the PLC-beta homologue. A functional PLC and new protein bands on SDS-PAGE were observed after subcloning full-length PLC-beta(x) cDNA, as well as a fragment containing the conserved regions, into expression plasmid vectors and transfecting into Escherichia coli. 1 mM lithium markedly stimulated expression in E. coli.	UNIV WISCONSIN,SCH MED,DEPT PHARMACOL,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison					NHLBI NIH HHS [HL16318] Funding Source: Medline; NIGMS NIH HHS [GM33850] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016318] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033850] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUSUBEL FM, 1987, CURRENT PROTOCOLS MO, P491; BAXTERLOWE LA, 1989, FEBS LETT, V257, P181, DOI 10.1016/0014-5793(89)81816-2; BENNETT CF, 1988, NATURE, V334, P268, DOI 10.1038/334268a0; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BLOOMQUIST BT, 1988, CELL, V54, P723, DOI 10.1016/S0092-8674(88)80017-5; COCKCROFT S, 1992, BIOCHEM J, V288, P1; CORMACK BP, 1991, CELL, V65, P341, DOI 10.1016/0092-8674(91)90167-W; DENNIS EA, 1991, FASEB J, V5, P2068, DOI 10.1096/fasebj.5.7.1901288; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FERREIRA PA, 1993, P NATL ACAD SCI USA, V90, P6042, DOI 10.1073/pnas.90.13.6042; FIELD KG, 1988, SCIENCE, V239, P748, DOI 10.1126/science.3277277; GERFEN CR, 1988, P NATL ACAD SCI USA, V85, P3208, DOI 10.1073/pnas.85.9.3208; HENNER DJ, 1988, NUCLEIC ACIDS RES, V16, P1083; KATAN M, 1988, CELL, V54, P171, DOI 10.1016/0092-8674(88)90549-1; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KUPPE A, 1989, J BACTERIOL, V171, P6077, DOI 10.1128/jb.171.11.6077-6083.1989; MAJERUS PW, 1990, CELL, V63, P459, DOI 10.1016/0092-8674(90)90442-H; MICHELL RH, 1982, CELL CALCIUM, V3, P429, DOI 10.1016/0143-4160(82)90028-8; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; RANA RS, 1990, PHYSIOL REV, V70, P115, DOI 10.1152/physrev.1990.70.1.115; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; RHEE SG, 1991, TRENDS BIOCHEM SCI, V16, P297, DOI 10.1016/0968-0004(91)90122-C; ROSS CA, 1989, P NATL ACAD SCI USA, V86, P2923, DOI 10.1073/pnas.86.8.2923; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SUH PG, 1988, CELL, V54, P161, DOI 10.1016/0092-8674(88)90548-X	26	12	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12925	12931						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175710				2022-12-25	WOS:A1994NH71600084
J	TOGEL, M; MOSSIER, B; FUCHS, K; SIEGHART, W				TOGEL, M; MOSSIER, B; FUCHS, K; SIEGHART, W			GAMMA-AMINOBUTYRIC ACID(A) RECEPTORS DISPLAYING ASSOCIATION OF GAMMA(3)-SUBUNITS WITH BETA(2/3) AND DIFFERENT ALPHA-SUBUNITS EXHIBIT UNIQUE PHARMACOLOGICAL PROPERTIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A-BENZODIAZEPINE RECEPTOR; RAT-BRAIN; GABA(A) RECEPTORS; MESSENGER-RNAS; ALPHA-1-SUBUNIT; ANTAGONIST; AGONIST	Two polyclonal antibodies were raised against the gamma(3)-subunit of gamma-aminobutyric acid(A) (GABA(A)) receptors. These antibodies were able to precipitate GABA(A) receptors from brain membrane extracts, and the precipitated receptors exhibited benzodiazepine binding properties that were dramatically different from those of receptors precipitated by anti-gamma(2) antibodies. The anti-gamma(3) antibodies were used for immunopurification of GABA(A) receptors containing gamma(3)-subunits. Western blot analysis of the immunopurified GABA(A) receptors indicated that the gamma(3)-subunit exhibits an apparent molecular mass of 43-46 kDa. Furthermore, in addition to gamma(3)-subunits, beta(2/3)-, alpha(1)-, alpha(2)-, alpha(3)-, alpha(4)-, and alpha(6)-subunits could be detected in immunoaffinity column eluates from total brain and cerebellum, respectively. These data indicate that gamma(3)-subunits can combine with most alpha-subunits to form a multiplicity of GABA(A) receptors with distinct pharmacology.	UNIV VIENNA,PSYCHIAT CLIN,DEPT BIOCHEM PSYCHIAT,A-1090 VIENNA,AUSTRIA	University of Vienna			Sieghart, Werner/A-4877-2013	Sieghart, Werner/0000-0002-0443-0302				BENKE D, 1991, J BIOL CHEM, V266, P4478; BUCHSTALLER A, 1991, NEUROSCI LETT, V129, P237, DOI 10.1016/0304-3940(91)90470-E; BURT DR, 1991, FASEB J, V5, P2916, DOI 10.1096/fasebj.5.14.1661244; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; DREXLER G, 1986, J IMMUNOL METHODS, V95, P117, DOI 10.1016/0022-1759(86)90325-X; DUGGAN MJ, 1991, J BIOL CHEM, V266, P24778; EWERT M, 1990, J CELL BIOL, V110, P2043, DOI 10.1083/jcb.110.6.2043; FUCHS K, 1989, NEUROSCI LETT, V97, P329, DOI 10.1016/0304-3940(89)90619-8; HERB A, 1992, P NATL ACAD SCI USA, V89, P1433, DOI 10.1073/pnas.89.4.1433; HUCHO F, 1986, EUR J BIOCHEM, V158, P211, DOI 10.1111/j.1432-1033.1986.tb09740.x; Johnson D. A., 1984, Gene Analysis Techniques, V1, P3, DOI 10.1016/0735-0651(84)90049-9; KERN W, 1994, J NEUROCHEM, V62, P764; KHAN ZU, 1993, J NEUROCHEM, V60, P961, DOI 10.1111/j.1471-4159.1993.tb03243.x; LAURIE DJ, 1992, J NEUROSCI, V12, P1063; LUDDENS H, 1990, NATURE, V346, P648, DOI 10.1038/346648a0; MERTENS S, 1993, J BIOL CHEM, V268, P5965; MOHLER H, 1981, NATURE, V294, P763, DOI 10.1038/294763a0; POLLARD S, 1993, J BIOL CHEM, V268, P3753; PRITCHETT DB, 1989, NATURE, V338, P582, DOI 10.1038/338582a0; SIEGHART W, 1992, TRENDS PHARMACOL SCI, V13, P446, DOI 10.1016/0165-6147(92)90142-S; SIEGHART W, 1993, J NEUROCHEM, V60, P93, DOI 10.1111/j.1471-4159.1993.tb05826.x; SIEGHART W, 1987, J NEUROCHEM, V48, P46, DOI 10.1111/j.1471-4159.1987.tb13125.x; SIEGHART W, 1992, CELL SIGNAL, V4, P231, DOI 10.1016/0898-6568(92)90062-D; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; WISDEN W, 1992, J NEUROSCI, V12, P1040; ZEZULA J, 1991, FEBS LETT, V284, P15, DOI 10.1016/0014-5793(91)80750-W	26	48	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12993	12998						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175718				2022-12-25	WOS:A1994NH71600094
J	ABDELLATIF, M; MACLELLAN, WR; SCHNEIDER, MD				ABDELLATIF, M; MACLELLAN, WR; SCHNEIDER, MD			P21 RAS AS A GOVERNOR OF GLOBAL GENE-EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CARDIAC-MUSCLE; GROWTH-FACTORS; SIGNAL TRANSDUCTION; BETA-GALACTOSIDASE; BINDING PROTEIN; MAMMALIAN-CELLS; TRANSCRIPTION; P53; INDUCTION; RECEPTOR	The molecular mechanisms for signaling by receptor serine/threonine kinases are incompletely understood. To test the potential involvement of p21 H-Ras proteins in signal transduction for type beta transforming growth factors (TGF beta), TGF beta-responsive and constitutive reporter genes were cotransfected into cardiac myocytes and mink lung epithelial cells, with dominant inhibitory (Asn-17) or activated (Arg-12) Ras expression vectors. Asn-17 Ras inhibited both TGF beta-dependent and basal expression of inducible promoters (skeletal alpha-actin and plasminogen activator inhibitor-1), with equivalent dose-response relations. All seven reporter constructs were comparably sensitive to down-regulation by Asn-17 Ras, including those driven by nominally constitutive viral control regions or a TATA-less initiator element. Ah constructs were up-regulated by Arg-12 Ras more variably. Wild-type Ras had intermediate effects and could rescue a minimal thymidine kinase promoter from inhibition by dominant negative Ras. Thus, a Ras-dependent event is required for efficient expression of an unexpectedly global or inclusive set of genes.	BAYLOR COLL MED,DEPT MED,MOLEC CARDIOL UNIT,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT MOLEC PHYSIOL & BIOPHYS,HOUSTON,TX 77030	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007706, R01HL039141, R01HL047567] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL39141, T32 HL07706, R01 HL47567] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOGUSKI MS, 1993, NATURE, V366, P943; BRAND T, 1993, J BIOL CHEM, V268, P11500; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; EUSTICE DC, 1991, BIOTECHNIQUES, V11, P739; FEIG LA, 1986, P NATL ACAD SCI USA, V83, P4607, DOI 10.1073/pnas.83.13.4607; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FREDERICKSON RM, 1992, MOL CELL BIOL, V12, P1239, DOI 10.1128/MCB.12.3.1239; FRENCH BA, 1991, MOL CELL BIOL, V11, P2439, DOI 10.1128/MCB.11.5.2439; HAN M, 1991, GENE DEV, V5, P2188, DOI 10.1101/gad.5.12a.2188; HICKS GG, 1991, MOL CELL BIOL, V11, P1344, DOI 10.1128/MCB.11.3.1344; KEETON MR, 1991, J BIOL CHEM, V266, P23048; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; MACGREGOR GR, 1989, NUCLEIC ACIDS RES, V17, P2365, DOI 10.1093/nar/17.6.2365; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MCKNIGHT SL, 1982, SCIENCE, V217, P316, DOI 10.1126/science.6283634; MEDEMA RH, 1993, CRIT REV ONCOGENESIS, V4, P615; MEDEMA RH, 1991, MOL CELL BIOL, V11, P5963, DOI 10.1128/MCB.11.12.5963; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; PARKER TG, 1990, P NATL ACAD SCI USA, V87, P7066, DOI 10.1073/pnas.87.18.7066; PARKER TG, 1990, J CLIN INVEST, V85, P507, DOI 10.1172/JCI114466; PAYNE PA, 1987, P NATL ACAD SCI USA, V84, P8956, DOI 10.1073/pnas.84.24.8956; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; SADOSHIMA J, 1993, EMBO J, V12, P1681, DOI 10.1002/j.1460-2075.1993.tb05813.x; SETO E, 1991, NATURE, V354, P241, DOI 10.1038/354241a0; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SPANDIDOS DA, 1985, BIOSCIENCE REP, V5, P1035, DOI 10.1007/BF01119624; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; THOMPSON JF, 1991, GENE, V103, P171, DOI 10.1016/0378-1119(91)90270-L; THOMPSON WR, 1991, J BIOL CHEM, V266, P22678; THORBURN A, 1993, J BIOL CHEM, V268, P2244; WHITMAN M, 1992, NATURE, V357, P252, DOI 10.1038/357252a0; WOOD KV, 1991, BIOLUMINESCENCE AND CHEMILUMINESCENCE, P11; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; YATANI A, 1990, CELL, V61, P769, DOI 10.1016/0092-8674(90)90187-J	36	79	80	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15423	15426						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	8195182				2022-12-25	WOS:A1994NP51300007
J	KRISHNAN, V; WANG, XH; SAFE, S				KRISHNAN, V; WANG, XH; SAFE, S			ESTROGEN RECEPTOR-SP1 COMPLEXES MEDIATE ESTROGEN-INDUCED CATHEPSIN-D GENE-EXPRESSION IN MCF-7 HUMAN BREAST-CANCER CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL ACTIVATION; EXTRACELLULAR-MATRIX; RESPONSIVE ELEMENT; FLANKING REGION; REGULATED RNAS; GROWTH-FACTORS; MESSENGER-RNA; TAMOXIFEN; MECHANISM; 52-KILODALTON	Cathepsin D is an estrogen (17 beta-estradiol, E(2))-inducible lysosomal protease. A putative estrogen receptor (ER)-Sp1-like sequence (GGGCGG(n)(23)ACGGG) has been identified in the non-coding strand of the cathepsin D promoter (-199 to -165), and electromobility shift assays of nuclear extracts from MCF-7 and HeLa cells confirm that both the ER and Sp1 protein bind to P-32-labeled ER/Sp1 oligo. For example, nuclear extracts from MCF-7 cells bind to the P-32-labeled ER/Sp1 oligo; however, ER/ Sp1 binding can be decreased by selective competition with excess unlabeled estrogen responsive element and Sp1 oligos, immunodepletion with ER or Sp1 antibodies, and by treating cells with ICI 164,384, an antiestrogen which inhibits formation of ER homodimer. Moreover, E(2)-induced chloramphenicol acetyltransferase (CAT) activity in MCF-7 cells cotransfected with a human estrogen receptor expression plasmid and a plasmid containing an ER/Sp1 sequence cloned upstream to a thymidine kinase promoter and a CAT reporter. In cotreatment studies, ICI 164,384 inhibited E(2)-induced CAT activity. In contrast, E(2) did not induce CAT activity in MCF-7 cells transfected with plasmids containing mutations in the ER or Sp1 segments of the ER/Sp1 oligo, thus confirming that both cognate binding sites are required for estrogen responsiveness.	TEXAS A&M UNIV, DEPT VET PHYSIOL & PHARMACOL, COLLEGE STN, TX 77843 USA	Texas A&M University System; Texas A&M University College Station					NIEHS NIH HHS [ES04176] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES004176] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRIOZZO P, 1988, CANCER RES, V48, P3688; CAVAILLES V, 1988, NUCLEIC ACIDS RES, V16, P1903, DOI 10.1093/nar/16.5.1903; CAVAILLES V, 1989, MOL ENDOCRINOL, V3, P552, DOI 10.1210/mend-3-3-552; CAVAILLES V, 1991, BIOCHEM BIOPH RES CO, V174, P816, DOI 10.1016/0006-291X(91)91491-T; CAVAILLES V, 1993, P NATL ACAD SCI USA, V90, P203, DOI 10.1073/pnas.90.1.203; DAUVOIS S, 1992, P NATL ACAD SCI USA, V89, P4037, DOI 10.1073/pnas.89.9.4037; DENISON MS, 1990, MOL CELL ENDOCRINOL, V69, P51, DOI 10.1016/0303-7207(90)90088-P; DICKSON RB, 1987, ENDOCR REV, V8, P29, DOI 10.1210/edrv-8-1-29; DICKSON RB, 1986, CANCER SURV, V5, P617; DUBIK D, 1992, ONCOGENE, V7, P1587; JOHNSON MD, 1993, CANCER RES, V53, P873; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KLEINHITPASS L, 1986, CELL, V46, P1053, DOI 10.1016/0092-8674(86)90705-1; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; KUTE TE, 1992, CANCER RES, V52, P5198; LIPPMAN ME, 1989, RECENT PROG HORM RES, V45, P383; LYKKESFELDT AE, 1992, ACTA ONCOL, V31, P131, DOI 10.3109/02841869209088892; MANIATIS T, 1982, MOL CLONING LABORATO, P187; MAY FEB, 1987, J BIOL CHEM, V262, P15894; MONTCOURRIER P, 1990, CANCER RES, V50, P6045; MORISSET M, 1986, ENDOCRINOLOGY, V119, P2773, DOI 10.1210/endo-119-6-2773; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; REDECKER B, 1991, DNA CELL BIOL, V10, P423, DOI 10.1089/dna.1991.10.423; ROCHEFORT H, 1990, BREAST CANCER RES TR, V16, P3, DOI 10.1007/BF01806570; ROCHEFORT H, 1992, EUR J CANCER, V28A, P1780, DOI 10.1016/0959-8049(92)90003-K; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; SPYRATOS F, 1989, LANCET, V2, P1115; TANDON AK, 1990, NEW ENGL J MED, V322, P297, DOI 10.1056/NEJM199002013220504; THORPE SM, 1989, CANCER RES, V49, P6008; WAKELING AE, 1991, REGULATORY MECHANISM, P239; WANG X, 1993, MOL CELL ENDOCRINOL, V96, P159, DOI 10.1016/0303-7207(93)90106-T; WESTLEY B, 1980, CELL, V20, P353, DOI 10.1016/0092-8674(80)90621-2; WESTLEY B, 1984, J BIOL CHEM, V259, P30; WESTLEY BR, 1989, J STEROID BIOCHEM, V32, P365, DOI 10.1016/0022-4731(89)90208-2; WESTLEY BR, 1987, NUCLEIC ACIDS RES, V15, P3773, DOI 10.1093/nar/15.9.3773; WUPENG XS, 1992, MOL ENDOCRINOL, V6, P231, DOI 10.1210/me.6.2.231	37	204	211	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15912	15917						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	8195246				2022-12-25	WOS:A1994NP51300079
J	MARTENS, JA; BRANDL, CJ				MARTENS, JA; BRANDL, CJ			GCN4P ACTIVATION OF THE YEAST TRP3 GENE IS ENHANCED BY ABF1P AND USES A SUBOPTIMAL TATA ELEMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOMAL-PROTEIN GENES; DNA-BINDING PROTEIN; SACCHAROMYCES-CEREVISIAE; CONSTITUTIVE TRANSCRIPTION; SATURATION MUTAGENESIS; RESPONSIVE ELEMENTS; NUCLEOTIDE-SEQUENCE; HIS4 TRANSCRIPTION; UPSTREAM; SITE	Transcription of the TRP3 gene of Saccharomyces cerevisiae is regulated by GCN4p from a position proximal to the transcriptional initiation sites. The promoter's apparent lack of a conventional TATA element sequence has led it to be used as a model for TATA-less promoters. Through mutational analysis of the TRP3 promoter, we have identified two additional regulatory elements required for expression. The first, located 57 base pairs (bp) upstream of the GCN4p binding site, binds ABF1p in vitro. The ABF1p binding site was required for maximal levels of GCN4p-activated transcription in vivo; however, the -fold activation by GCN4p was not altered by ABF1p. The second element, positioned 23 bp downstream of the GCN4p binding site, contained the TATAlike sequence, TATTAA. This element was required for both basal and activated expression and almost certainly functions as a TATA-binding protein interaction site. Mutations that improved its TATA character for native or an altered specificity mutant of TATA-binding protein correspondingly improved its function. Interestingly, basal expression induced by ABF1p was virtually unchanged in the presence of point mutations in the TATTAA element. Furthermore, unlike the case for HIS3 where only a limited subset of TATA-like sequences can activate transcription in conjunction with GCN4p, many divergent TATA-like sequences allowed GCN4p activation of TRP3. We suggest that the apparent promoter specific use of these TATA elements by GCN4p results from ABF1p amplifying the GCN4p-induced expression to a detectable level.	UNIV WESTERN ONTARIO,DEPT BIOCHEM,LONDON N6A 5C1,ON,CANADA	Western University (University of Western Ontario)								AEBI M, 1984, CURR GENET, V8, P165, DOI 10.1007/BF00417812; ARNDT K, 1986, P NATL ACAD SCI USA, V83, P8516, DOI 10.1073/pnas.83.22.8516; ARNDT KT, 1987, SCIENCE, V237, P874, DOI 10.1126/science.3303332; BRAM RJ, 1987, MOL CELL BIOL, V7, P403, DOI 10.1128/MCB.7.1.403; BRANDL CJ, 1990, MOL CELL BIOL, V10, P4256, DOI 10.1128/MCB.10.8.4256; BRANDL CJ, 1992, J BIOL CHEM, V267, P20943; BRAUS GH, 1991, MICROBIOL REV, V55, P349, DOI 10.1128/MMBR.55.3.349-370.1991; BRINDLE PK, 1990, MOL CELL BIOL, V10, P4872, DOI 10.1128/MCB.10.9.4872; BUCHMAN AR, 1988, MOL CELL BIOL, V8, P210, DOI 10.1128/MCB.8.1.210; BUCHMAN AR, 1990, MOL CELL BIOL, V10, P887, DOI 10.1128/MCB.10.3.887; CAREY M, 1989, J MOL BIOL, V209, P423, DOI 10.1016/0022-2836(89)90007-7; CHAMBERS A, 1990, NUCLEIC ACIDS RES, V18, P5393, DOI 10.1093/nar/18.18.5393; CHASMAN DI, 1989, MOL CELL BIOL, V9, P4746, DOI 10.1128/MCB.9.11.4746; CHASMAN DI, 1990, GENE DEV, V4, P503, DOI 10.1101/gad.4.4.503; CHEN W, 1989, EMBO J, V8, P261, DOI 10.1002/j.1460-2075.1989.tb03372.x; CHEN W, 1988, P NATL ACAD SCI USA, V85, P2691, DOI 10.1073/pnas.85.8.2691; CHEN W, 1985, EMBO J, V4, P3273, DOI 10.1002/j.1460-2075.1985.tb04077.x; CORMACK BP, 1992, CELL, V69, P685, DOI 10.1016/0092-8674(92)90232-2; DELLASETA F, 1990, MOL CELL BIOL, V10, P2437, DOI 10.1128/MCB.10.5.2437; DEVLIN C, 1991, MOL CELL BIOL, V11, P3642, DOI 10.1128/MCB.11.7.3642; DIFFLEY JFX, 1988, P NATL ACAD SCI USA, V85, P2120, DOI 10.1073/pnas.85.7.2120; DORSMAN JC, 1989, NUCLEIC ACIDS RES, V17, P4917, DOI 10.1093/nar/17.13.4917; FEDOR MJ, 1988, J MOL BIOL, V204, P109, DOI 10.1016/0022-2836(88)90603-1; FURTERGRAVES EM, 1990, MOL GEN GENET, V223, P407, DOI 10.1007/BF00264447; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; HALFTER H, 1989, EMBO J, V8, P4265, DOI 10.1002/j.1460-2075.1989.tb08612.x; HAMIL KG, 1988, MOL CELL BIOL, V8, P4328, DOI 10.1128/MCB.8.10.4328; HARBURY PAB, 1989, MOL CELL BIOL, V9, P5298, DOI 10.1128/MCB.9.12.5298; HILL DE, 1986, SCIENCE, V234, P451, DOI 10.1126/science.3532321; KIM S, 1986, MOL CELL BIOL, V6, P4251, DOI 10.1128/MCB.6.12.4251; KLOPOTOW.T, 1965, ARCH BIOCHEM BIOPHYS, V112, P562, DOI 10.1016/0003-9861(65)90096-2; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MAHADEVAN S, 1990, MOL CELL BIOL, V10, P4447, DOI 10.1128/MCB.10.9.4447; MIOZZARI G, 1978, J BACTERIOL, V134, P48, DOI 10.1128/JB.134.1.48-59.1978; MORROW BE, 1989, J BIOL CHEM, V264, P9061; MOSCH HU, 1990, EMBO J, V9, P2951, DOI 10.1002/j.1460-2075.1990.tb07487.x; MOYEROWLEY WS, 1989, GENE DEV, V3, P283, DOI 10.1101/gad.3.3.283; NISHIZAWA M, 1989, MOL CELL BIOL, V9, P442, DOI 10.1128/MCB.9.2.442; OLIPHANT AR, 1986, GENE, V44, P177, DOI 10.1016/0378-1119(86)90180-0; REMACLE JE, 1992, MOL CELL BIOL, V12, P5516, DOI 10.1128/MCB.12.12.5516; Sambrook J, 1989, MOL CLONING LABORATO; SCHERER S, 1979, P NATL ACAD SCI USA, V76, P4951, DOI 10.1073/pnas.76.10.4951; SCOTT EW, 1990, NUCLEIC ACIDS RES, V18, P7099, DOI 10.1093/nar/18.23.7099; SCOTT EW, 1993, MOL CELL BIOL, V13, P543, DOI 10.1128/MCB.13.1.543; SHORE D, 1987, EMBO J, V6, P461, DOI 10.1002/j.1460-2075.1987.tb04776.x; SHORE D, 1987, CELL, V51, P721, DOI 10.1016/0092-8674(87)90095-X; SILVE S, 1992, MOL CELL BIOL, V12, P4197, DOI 10.1128/MCB.12.9.4197; STRUBIN M, 1992, CELL, V68, P721, DOI 10.1016/0092-8674(92)90147-5; STRUHL K, 1985, NUCLEIC ACIDS RES, V13, P8587, DOI 10.1093/nar/13.23.8587; STRUHL K, 1982, NATURE, V300, P284, DOI 10.1038/300284a0; STRUHL K, 1986, MOL CELL BIOL, V6, P3847, DOI 10.1128/MCB.6.11.3847; STRUHL K, 1985, P NATL ACAD SCI USA, V82, P8419, DOI 10.1073/pnas.82.24.8419; TICEBALDWIN K, 1989, SCIENCE, V246, P931, DOI 10.1126/science.2683089; TRAWICK JD, 1992, MOL CELL BIOL, V12, P2302, DOI 10.1128/MCB.12.5.2302; TSCHUMPER G, 1980, GENE, V10, P157, DOI 10.1016/0378-1119(80)90133-X; VIGNAIS ML, 1987, EMBO J, V6, P1451, DOI 10.1002/j.1460-2075.1987.tb02386.x; WALKER SS, 1989, MOL CELL BIOL, V9, P2914, DOI 10.1128/MCB.9.7.2914; WANG HM, 1990, MOL CELL BIOL, V10, P1743, DOI 10.1128/MCB.10.4.1743; WILLETT CE, 1993, MOL CELL BIOL, V13, P2623, DOI 10.1128/MCB.13.4.2623; WORKMAN JL, 1993, TRENDS BIOCHEM SCI, V18, P90, DOI 10.1016/0968-0004(93)90160-O; WU AL, 1993, J BIOL CHEM, V268, P18850; ZALKIN H, 1984, J BIOL CHEM, V259, P3985	62	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15661	15667						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	8195216				2022-12-25	WOS:A1994NP51300044
J	BORRELLO, MG; PELICCI, G; ARIGHI, E; DEFILIPPIS, L; GRECO, A; BONGARZONE, I; RIZZETTI, MG; PELICCI, PG; PIEROTTI, MA				BORRELLO, MG; PELICCI, G; ARIGHI, E; DEFILIPPIS, L; GRECO, A; BONGARZONE, I; RIZZETTI, MG; PELICCI, PG; PIEROTTI, MA			THE ONCOGENIC VERSIONS OF THE RET AND TRK TYROSINE KINASES BIND SHC AND GRB2 ADAPTER PROTEINS	ONCOGENE			English	Article							PAPILLARY THYROID CARCINOMAS; NERVE GROWTH-FACTOR; PROTO-ONCOGENE; NUCLEOTIDE EXCHANGE; SIGNAL TRANSDUCTION; PROTOONCOGENE; RECEPTOR; RAS; PRODUCT; ACTIVATION	Proto-TRK and proto-RET genes encode receptor type tyrosine kinases. Oncogenic rearrangements of both proto-oncogenes have been detected with a significant frequency in human papillary thyroid carcinomas. Chimeric Ret and Trk oncoproteins, encoded by different rearrangements of proto-TRK and proto-RET genes, display a constitutive phosphorylation on tyrosine. Moreover, it has been shown that phosphorylated tyrosine receptors, activated by their ligands, form multiprotein complexes responsible for transducing mitogenic or differentiation signals. We have therefore begun to analyse in this study the signal transduction pathways triggered by different Ret and Trk oncoproteins. We have shown that the SH2 domain of the adaptor protein She coimmunoprecipitates with all the Ret and Trk oncoproteins as well as with NGF-activated proto-Trk receptor. Tyrosine phosphorylation of Trk proteins both normal and oncogenic is necessary for their binding to She. In addition, in cells containing either Ret or TrK oncoproteins, She proteins are constitutively phosphorylated on tyrosine and bound to Grb2. Only in in vitro experiments were Ret and Trk oncoproteins shown to bind the SH2 region of Grb2. Finally, when proto-Trk product is stimulated by NGF, She phosphorylation and association with Grb2 are induced. In conclusion, we have shown that Ret and Trk oncoproteins can form multiprotein complexes, however, the functional meaning of the described interactions has to be elucidated.	UNIV PERUGIA,IST CLIN MED 1,MONTELUCE POLICLIN,I-06100 PERUGIA,ITALY	University of Perugia	BORRELLO, MG (corresponding author), IST NAZL TUMORI,DIV EXPTL ONCOL E,VIA VENEZIAN 1,I-20133 MILAN,ITALY.		Borrello, Maria Grazia/C-3161-2017; Bongarzone, Italia/B-9544-2017; Pelicci, Giuliana/AAA-8921-2022; Greco, Angela/C-1953-2017; Pelicci, Pier Giuseppe/AAL-6572-2020; De Filippis, Lidia/H-3098-2017	Borrello, Maria Grazia/0000-0002-6854-2848; Bongarzone, Italia/0000-0003-2530-9170; Pelicci, Giuliana/0000-0003-0986-8255; Greco, Angela/0000-0003-2994-0349; De Filippis, Lidia/0000-0002-2196-9430; Pierotti, Marco Alessandro/0000-0002-7431-8332				BARBACID M, 1991, BIOCHIM BIOPHYS ACTA, V1072, P115, DOI 10.1016/0304-419X(91)90010-I; BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GRECO A, 1992, ONCOGENE, V7, P237; GRECO A, 1993, CELL GROWTH DIFFER, V4, P539; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; HASHIMOTO S, 1988, J CELL BIOL, V107, P1531, DOI 10.1083/jcb.107.4.1531; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; ISHIZAKA Y, 1992, ONCOGENE, V7, P1441; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANZI C, 1992, ONCOGENE, V7, P2189; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MATUOKA K, 1993, EMBO J, V12, P3467, DOI 10.1002/j.1460-2075.1993.tb06021.x; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MITRA G, 1987, P NATL ACAD SCI USA, V84, P6707, DOI 10.1073/pnas.84.19.6707; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PIEROTTI MA, 1993, NATO ASI SER, P87; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SANTORO M, 1993, BRIT J CANCER, V68, P460, DOI 10.1038/bjc.1993.370; SANTORO M, 1990, ONCOGENE, V5, P1595; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SEGATTO O, 1993, ONCOGENE, V8, P2105; SOZZI G, 1992, GENE CHROMOSOME CANC, V5, P212, DOI 10.1002/gcc.2870050307; SUEN KL, 1993, MOL CELL BIOL, V13, P5500, DOI 10.1128/MCB.13.9.5500; SZENTIRMAY Z, 1990, ONCOGENE, V5, P701; TAHIRA T, 1990, ONCOGENE, V5, P97; TAKAHASHI M, 1988, ONCOGENE, V3, P571; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350	36	109	111	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1994	9	6					1661	1668						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NL815	8183561				2022-12-25	WOS:A1994NL81500018
J	LEE, YY; WILCZYNSKI, SP; CHUMAKOV, A; CHIH, D; KOEFFLER, HP				LEE, YY; WILCZYNSKI, SP; CHUMAKOV, A; CHIH, D; KOEFFLER, HP			CARCINOMA OF THE VULVA - HPV AND P53 MUTATIONS	ONCOGENE			English	Article							HUMAN PAPILLOMAVIRUS TYPE-16; POLYMERASE CHAIN-REACTION; SQUAMOUS-CELL CARCINOMA; CHRONIC MYELOCYTIC-LEUKEMIA; CERVICAL-CARCINOMA; INSITU HYBRIDIZATION; POINT MUTATIONS; BLAST CRISIS; N-RAS; GENE	Recent evidence suggests that squamous cell carcinoma of the vulva may have more than one etiology, with only some tumors associated with human papillomavirus (HPV). Cells infected with HPV produce a viral protein (E6) which binds to and causes rapid degradation of p53, possibly contributing to cellular transformation. In several human malignancies, point mutations of p53 alter activity of the p53 protein contributing to cellular transformation. We tested, for the first time, the possibility that HPV-negative tumors of the vulva may have a high incidence of inactivating mutations of p53; while HPV-containing vulvar tumors rarely would have p53 mutations. Twenty-one tumors of the vulva were evaluated for the presence of HPV sequences by amplication with the polymerase chain reaction (PCR) and Southern blotting. These were evaluated for p53 mutations by single strand conformation polymorphism and sequencing of PCR products. HPV DNA sequences were found in 12 of 21 (57%) cancers of the vulva; only one of these 12 (8%) HPV-positive samples had a missense mutation of p53. In contrast, four of nine (44%) HPV-negative vulvar tumors had point mutations of p53. The p53 mutations were found in only metastatic lesion and the only recurrent tumor samples suggesting that the acquisition of p53 mutations may be associated with neoplastic progression. In conclusion, alterations in p53 activity appear to be important in the development of carcinoma of the vulva.	UNIV CALIF LOS ANGELES,CEDARS SINAI MED CTR,SCH MED,DEPT MED,DIV HEMATOL ONCOL,LOS ANGELES,CA 90048; CITY HOPE NATL MED CTR,DEPT PATHOL,DUARTE,CA 91010	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; City of Hope			Chumakov, Alexey/N-1541-2014	Chumakov, Alexey/0000-0003-2733-3166	NATIONAL CANCER INSTITUTE [R29CA053005, P01CA042710, P30CA042710] Funding Source: NIH RePORTER; NCI NIH HHS [CA53005, CA42710] Funding Source: Medline; NIDDK NIH HHS [DK42702] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHUJA H, 1989, P NATL ACAD SCI USA, V86, P6783, DOI 10.1073/pnas.86.17.6783; ANDERSEN WA, 1991, AM J OBSTET GYNECOL, V165, P329, DOI 10.1016/0002-9378(91)90086-7; BISHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766; BLOSS JD, 1991, HUM PATHOL, V22, P711, DOI 10.1016/0046-8177(91)90294-Y; BORRESEN AL, 1992, LANCET, V339, P1350; BOSHART M, 1986, J VIROL, V58, P963, DOI 10.1128/JVI.58.3.963-966.1986; BUSBYEARLE RMC, 1992, LANCET, V339, P1350, DOI 10.1016/0140-6736(92)91993-I; BUSCEMA J, 1988, OBSTET GYNECOL, V71, P601; CARSON LF, 1988, OBSTET GYNECOL, V72, P63; CROOK T, 1992, LANCET, V339, P1070, DOI 10.1016/0140-6736(92)90662-M; CROOK T, 1992, EMBO J, V11, P3935, DOI 10.1002/j.1460-2075.1992.tb05487.x; CROOK T, 1991, ONCOGENE, V6, P873; CRUM CP, 1992, OBSTET GYNECOL, V79, P448, DOI 10.1097/00006250-199203000-00025; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FOTI A, 1991, BLOOD, V77, P2441; FUJITA M, 1992, CANCER RES, V52, P5323; FULTS D, 1992, CANCER RES, V52, P674; GUPTA J, 1987, AM J PATHOL, V127, P206; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LUBBERT M, 1990, BLOOD, V75, P1163; MANOS MM, 1989, CANCER CEL, V7, P209; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; NUOVO GJ, 1988, OBSTET GYNECOL, V72, P770; NUOVO GJ, 1991, GYNECOL ONCOL, V43, P275, DOI 10.1016/0090-8258(91)90035-4; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PAQUETTE RL, 1990, ONCOGENE, V5, P1659; PAQUETTE RL, 1993, CANCER-AM CANCER SOC, V72, P1272, DOI 10.1002/1097-0142(19930815)72:4<1272::AID-CNCR2820720420>3.0.CO;2-Q; PARK DJ, 1993, IN PRESS ONCOGENE; PFISTER H, 1987, ADV CANCER RES, V48, P113, DOI 10.1016/S0065-230X(08)60691-0; PILOTTI S, 1990, MODERN PATHOL, V3, P442; SAKASHITA A, 1992, BLOOD, V79, P477; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SOUSSI T, 1990, ONCOGENE, V5, P945; STRETCH JR, 1991, CANCER RES, V51, P5976; TAMURA G, 1991, CANCER RES, V51, P3056; TOKI T, 1991, INT J GYNECOL PATHOL, V10, P107, DOI 10.1097/00004347-199104000-00001; TWIGGS LB, 1988, INT J GYNECOL PATHOL, V7, P48, DOI 10.1097/00004347-198803000-00005; VENUTI A, 1989, J GEN VIROL, V70, P1587, DOI 10.1099/0022-1317-70-6-1587; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286	42	100	103	1	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1994	9	6					1655	1659						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NL815	8183560				2022-12-25	WOS:A1994NL81500017
J	MARCHAND, P; TANG, J; BOND, JS				MARCHAND, P; TANG, J; BOND, JS			MEMBRANE ASSOCIATION AND OLIGOMERIC ORGANIZATION OF THE ALPHA-SUBUNIT AND BETA-SUBUNIT OF MOUSE MEPRIN-A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMOSOMAL LOCALIZATION; COS-1 CELLS; EXPRESSION; KIDNEY; HYDROLASE; PROTEINS; CLONING; RECEPTORS; RELEASE; ENZYME	Meprins are oligomeric cell surface metalloproteinases of the ''astacin family.'' They consist of two types of subunits (alpha and beta), which are evolutionarily related and whose cDNA sequences predict a similar domain structure. The present work shows that reducing agents solubilized meprin alpha subunits (approximately 90%), but not beta subunits, from mouse kidney brush border membranes. In addition, immunoblotting of membranes or purified meprins with an antibody raised to the alpha subunit epidermal growth factor like domain, predicted to be near the COOH terminus from the cDNA-deduced amino acid sequence, indicated that this domain is not present in the mature alpha subunit. By contrast, an epitope predicted to be near the COOH terminus of the beta subunit was present in the mature form of beta. When meprins were solubilized from brush border membranes by papain, the size of the alpha subunit (approximately 90 kDa) did not change, while the beta subunit decreased from 110 to 90 kDa with concomitant loss of the COOH-terminal epitope. These data indicate that beta is a type I transmembrane protein, while alpha does not transverse the membrane and its association is dependent on disulfide bonds. The oligomeric organization of purified meprin A (EC 3.4.24.18), examined by sedimentation equilibrium analysis and native gradient gel electrophoresis, is that of disulfide-bridged dimers which aggregate noncovalently to form higher molecular weight complexes, predominantly tetramers. Western blotting of ICR kidney brush border membrane proteins identified alpha(2) homodimers and alpha beta heterodimers. Treatment of mouse or rat kidney brush border membranes with 7 M urea solubilized alpha(2), but not alpha beta dimers. Thus, the mature alpha subunit exists in alpha(2) and alpha beta disulfide linked dimers which form tetramers, and the alpha(2) homodimers associate with the membrane through noncovalent interactions with alpha beta.	PENN STATE UNIV,COLL MED,DEPT BIOCHEM & MOLEC BIOL,HERSHEY,PA 17033	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health					NIDDK NIH HHS [DK 19691] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019691, R37DK019691, R56DK019691] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AITHAL HN, 1988, J IMMUNOL METHODS, V112, P62; BECKMANN G, 1993, TRENDS BIOCHEM SCI, V18, P40, DOI 10.1016/0968-0004(93)90049-S; BELDENT V, 1993, J BIOL CHEM, V268, P26428; BUTLER PE, 1988, J BIOL CHEM, V263, P13419; BUTLER PE, 1989, PROTEOLYTIC ENZYMES, P193; CORBEIL D, 1993, FEBS LETT, V335, P361, DOI 10.1016/0014-5793(93)80420-Y; COTTON RGH, 1978, EUR J BIOCHEM, V83, P319, DOI 10.1111/j.1432-1033.1978.tb12097.x; DUMERMUTH E, 1993, FEBS LETT, V335, P367, DOI 10.1016/0014-5793(93)80421-P; EHLERS MRW, 1991, BIOCHEMISTRY-US, V30, P10065, DOI 10.1021/bi00106a001; GORBEA CM, 1993, J BIOL CHEM, V268, P21035; GORBEA CM, 1991, ARCH BIOCHEM BIOPHYS, V290, P549, DOI 10.1016/0003-9861(91)90580-C; GORBEA CM, IN PRESS MAMMALIAN B; GRUNBERG J, 1993, FEBS LETT, V335, P376, DOI 10.1016/0014-5793(93)80422-Q; HALL JL, 1993, ARCH BIOCHEM BIOPHYS, V307, P73, DOI 10.1006/abbi.1993.1562; Hirs C. H. W, 1967, METHODS ENZYMOL, V11, P197; JIANG WP, 1993, J BIOL CHEM, V268, P10380; JIANG WP, 1992, J BIOL CHEM, V267, P9185; JOHNSON GD, 1994, J BIOL CHEM, V269, P7682; JOHNSON GD, 1992, J BIOL CHEM, V267, P13505; KENNY AJ, 1987, BIOCHEM J, V245, P515, DOI 10.1042/bj2450515; KOUNNAS MZ, 1991, J BIOL CHEM, V266, P17350; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; NYKJAER A, 1994, J IMMUNOL, V152, P505; SIM RB, 1993, METHOD ENZYMOL, V223, P13; SINGER SJ, 1987, P NATL ACAD SCI USA, V84, P1960, DOI 10.1073/pnas.84.7.1960; SOJAR HT, 1987, METHOD ENZYMOL, V138, P341; STERCHI EE, 1988, ARCH BIOCHEM BIOPHYS, V265, P105, DOI 10.1016/0003-9861(88)90376-1; SUZUKI S, 1986, P NATL ACAD SCI USA, V83, P8614, DOI 10.1073/pnas.83.22.8614; VANDEVEN WJM, 1993, CRIT REV ONCOGENESIS, V4, P115	29	70	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					15388	15393						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195177				2022-12-25	WOS:A1994NP73800079
J	BOHNI, R; HEMMI, S; AGUET, M				BOHNI, R; HEMMI, S; AGUET, M			SIGNALING STEPS INVOLVING THE CYTOPLASMIC DOMAIN OF THE INTERFERON-GAMMA RECEPTOR ALPHA-SUBUNIT ARE NOT SPECIES-SPECIFIC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR DOMAIN; MOLECULAR-CLONING; ACCESSORY FACTOR; EXPRESSION; ANTIGEN; CDNA; DNA; PHOSPHORYLATION; PURIFICATION; SENSITIVITY	The ligand binding chain of the interferon-gamma receptor (IFN-gamma R) is a unique cell surface protein which has no similarities to other cytokine receptors. Expression of this receptor chain (alpha-subunit) is not sufficient to mediate responsiveness to IFN-gamma. We and others have shown that IFN-gamma-mediated signal transduction requires a species-specific interaction of the extracellular portion of the known IFN-gamma receptor alpha-chain with an additional receptor subunit that was cloned recently and designated IFN-gamma R beta-chain or accessory factor 1. Here, we investigated whether this tight species barrier also ap plies to signaling events mediated by the cytoplasmic receptor domain. A cell line derived from embryos that lack the IFN-gamma R alpha-subunit was reconstituted with a hybrid mouse-human alpha-subunit that consisted of an extracellular murine and transmembrane and cytoplasmic human domains. The experiments reported herein showed that in mouse cells, the human intracellular domain of the hybrid IFN-gamma R alpha-subunit was fully functional and that, therefore, signaling steps involving this domain are not species-specific.	UNIV ZURICH,INST MOLEC BIOL 1,CH-8093 ZURICH,SWITZERLAND	University of Zurich								AGUET M, 1987, J EXP MED, V165, P988, DOI 10.1084/jem.165.4.988; AGUET M, 1988, CELL, V55, P273, DOI 10.1016/0092-8674(88)90050-5; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BASU M, 1989, J INTERFERON RES, V9, P551, DOI 10.1089/jir.1989.9.551; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COFANO F, 1990, J BIOL CHEM, V265, P4064; COOK JR, 1992, P NATL ACAD SCI USA, V89, P11317, DOI 10.1073/pnas.89.23.11317; DALTON DK, 1993, SCIENCE, V259, P1739, DOI 10.1126/science.8456300; FARRAR MA, 1991, J BIOL CHEM, V266, P19626; FARRAR MA, 1993, ANNU REV IMMUNOL, V11, P571, DOI 10.1146/annurev.iy.11.040193.003035; FARRAR MA, 1992, P NATL ACAD SCI USA, V89, P11176; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; GIBBS VC, 1991, MOL CELL BIOL, V11, P5860, DOI 10.1128/MCB.11.12.5860; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRAY PW, 1989, P NATL ACAD SCI USA, V86, P8497, DOI 10.1073/pnas.86.21.8497; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; HAMMERLING GJ, 1982, P NATL ACAD SCI-BIOL, V79, P4737, DOI 10.1073/pnas.79.15.4737; HEMMI S, 1989, P NATL ACAD SCI USA, V86, P9901, DOI 10.1073/pnas.86.24.9901; HEMMI S, 1994, CELL, V76, P803, DOI 10.1016/0092-8674(94)90355-7; HEMMI S, 1992, P NATL ACAD SCI USA, V89, P2737, DOI 10.1073/pnas.89.7.2737; HERSHEY GKK, 1990, J BIOL CHEM, V265, P17868; HIBINO Y, 1992, J BIOL CHEM, V267, P3741; HIBINO Y, 1991, J BIOL CHEM, V266, P6948; HUANG S, 1993, SCIENCE, V259, P1742, DOI 10.1126/science.8456301; ISRAEL A, 1986, NATURE, V322, P743, DOI 10.1038/322743a0; JAT PS, 1986, MOL CELL BIOL, V6, P1204, DOI 10.1128/MCB.6.4.1204; JUNG V, 1987, P NATL ACAD SCI USA, V84, P4151, DOI 10.1073/pnas.84.12.4151; KALINA U, 1993, J VIROL, V67, P1702, DOI 10.1128/JVI.67.3.1702-1706.1993; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MAO C, 1990, J IMMUNOL, V145, P4257; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; PELLEGRINI S, 1993, TRENDS BIOCHEM SCI, V18, P338, DOI 10.1016/0968-0004(93)90070-4; REID LE, 1989, P NATL ACAD SCI USA, V86, P840, DOI 10.1073/pnas.86.3.840; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; SADOWSKI HB, 1993, SCIENCE, V261, P139; Sambrook J, 1989, MOL CLONING LABORATO; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SILVENNOINEN O, 1993, NATURE, V366, P583, DOI 10.1038/366583a0; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; SOH J, 1993, P NATL ACAD SCI USA, V90, P8737, DOI 10.1073/pnas.90.18.8737; SOH J, 1994, CELL, V76, P793, DOI 10.1016/0092-8674(94)90354-9; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STARK GR, 1992, J INTERFERON RES, V12, P147, DOI 10.1089/jir.1992.12.147; TRINCHIERI G, 1985, IMMUNOL TODAY, V6, P131, DOI 10.1016/0167-5699(85)90080-5; VALENTE G, 1992, EUR J IMMUNOL, V22, P2403, DOI 10.1002/eji.1830220933; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L	53	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14541	14545						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	8182061				2022-12-25	WOS:A1994NM06500038
J	HALL, ET; YAN, JP; MELANCON, P; KUCHTA, RD				HALL, ET; YAN, JP; MELANCON, P; KUCHTA, RD			3'-AZIDO-3'-DEOXYTHYMIDINE POTENTLY INHIBITS PROTEIN GLYCOSYLATION - A NOVEL MECHANISM FOR AZT CYTOTOXICITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ROUGH ENDOPLASMIC-RETICULUM; HAMSTER OVARY CELLS; N-LINKED GLYCANS; GOLGI-APPARATUS; RAT-LIVER; INFECTED CELLS; TRANSPORT; MEMBRANE; INVITRO; ACETYLGLUCOSAMINE	3'-Azido-3'-deoxythymidine (AZT) is one of the primary chemotherapeutic agents used in the treatment of human immunodeficiency virus (HIV) infection. Unfortunately, AZT therapy is accompanied by severe side effects. Using Golgi-enriched membrane fractions, we have determined that 3'-azido-3'-deoxythymidine monophosphate, the primary AZT metabolite in treated cells, potently inhibits protein glycosylation. This inhibition results from direct competition with several pyrimidine-sugars for transport into Golgi membranes. This potential mechanism of cytotoxicity does not involve 3'-azido-3'-deoxythymidine triphosphate, the AZT metabolite most likely responsible for its antiviral effects; thus, it may be possible to develop novel therapeutic strategies that prevent inhibition of glycosylation without affecting the anti-HIV properties of AZT.	UNIV COLORADO, DEPT CHEM & BIOCHEM, BOULDER, CO 80309 USA	University of Colorado System; University of Colorado Boulder			Melancon, Paul/P-1304-2018	Melancon, Paul/0000-0002-8085-3032	NIGMS NIH HHS [GM43378] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Albein A. D., 1987, ANNU REV BIOCHEM, V56, P497; BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; BALZARINI J, 1988, BIOCHEM PHARMACOL, V37, P897, DOI 10.1016/0006-2952(88)90178-5; BREMER EG, 1984, J BIOL CHEM, V259, P6818; BRILES EB, 1977, J BIOL CHEM, V252, P1107; CALVARUSO G, 1986, LIFE SCI, V39, P2221, DOI 10.1016/0024-3205(86)90400-5; CAPASSO JM, 1984, P NATL ACAD SCI-BIOL, V81, P7051, DOI 10.1073/pnas.81.22.7051; CAPASSO JM, 1984, BIOCHIM BIOPHYS ACTA, V777, P133, DOI 10.1016/0005-2736(84)90505-4; DUNPHY WG, 1981, P NATL ACAD SCI-BIOL, V78, P7453, DOI 10.1073/pnas.78.12.7453; FARAJ A, 1993, P ANN M AM ASS CANCE, V34, pA2111; FURMAN PA, 1986, P NATL ACAD SCI USA, V83, P8333, DOI 10.1073/pnas.83.21.8333; HAMMOND C, 1993, CURR BIOL, V3, P884, DOI 10.1016/0960-9822(93)90226-E; Hauschka P V, 1973, Methods Cell Biol, V7, P361; HAYES BK, 1993, J BIOL CHEM, V268, P16155; HIEBSCH RR, 1992, BIOCHEMISTRY-US, V31, P6111, DOI 10.1021/bi00141a022; HIRSCHBERG CB, 1987, ANNU REV BIOCHEM, V56, P63, DOI 10.1146/annurev.bi.56.070187.000431; IOFFE E, 1994, P NATL ACAD SCI USA, V91, P728, DOI 10.1073/pnas.91.2.728; KEPPLER DOR, 1977, CANCER RES, V37, P911; KORNFELD S, 1966, EXP CELL RES, V41, P592, DOI 10.1016/S0014-4827(66)80109-X; KREUTTER D, 1987, J BIOL CHEM, V262, P1633; KUCHTA RD, 1988, BIOCHEMISTRY-US, V27, P6716, DOI 10.1021/bi00418a012; LEELAVATHI DE, 1970, BIOCHIM BIOPHYS ACTA, V211, P124, DOI 10.1016/0005-2736(70)90087-8; OATES JA, 1989, NEW ENGL J MED, V321, P726; OLOFSSON S, 1988, VIROLOGY, V166, P440, DOI 10.1016/0042-6822(88)90515-6; OLOFSSON S, 1993, ARCH VIROL, V128, P241, DOI 10.1007/BF01309437; PEREZ M, 1985, J BIOL CHEM, V260, P4671; READING CL, 1978, J BIOL CHEM, V253, P5600; SOMMADOSSI JP, 1988, ANTIMICROB AGENTS CH, V32, P997, DOI 10.1128/AAC.32.7.997; STANLEY P, 1975, CELL, V6, P121, DOI 10.1016/0092-8674(75)90002-1; WALDMAN BC, 1990, BIOCHEMISTRY-US, V29, P44, DOI 10.1021/bi00453a006	30	46	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14355	14358						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	8182037				2022-12-25	WOS:A1994NM06500008
J	BRANCACCIO, A; CUTRUZZOLA, F; ALLOCATELLI, CT; BRUNORI, M; SMERDON, SJ; WILKINSON, AJ; DOU, Y; KEENAN, D; IKEDASAITO, M; BRANTLEY, RE; OLSON, JS				BRANCACCIO, A; CUTRUZZOLA, F; ALLOCATELLI, CT; BRUNORI, M; SMERDON, SJ; WILKINSON, AJ; DOU, Y; KEENAN, D; IKEDASAITO, M; BRANTLEY, RE; OLSON, JS			STRUCTURAL FACTORS GOVERNING AZIDE AND CYANIDE BINDING TO MAMMALIAN METMYOGLOBINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPERM WHALE MYOGLOBIN; SITE-DIRECTED MUTAGENESIS; FERRIC APLYSIA MYOGLOBIN; DISTAL HISTIDINE; LIGAND-BINDING; X-RAY; MOLECULAR-DYNAMICS; CRYSTAL-STRUCTURE; ANIONIC LIGANDS; CARBON-MONOXIDE	The structural factors governing azide and cyanide binding have been examined by measuring the effects of 46 mutations at key topological positions in the distal pocket in sperm whale, pig, and human myoglobin. Replacement of His(64)(E7) with smaller amino acids results in dramatic increases in the association rate constant for azide binding primarily due to relief of steric hindrance imposed by the imidazole side chain. Gln(64) and His(64) (native) metmyoglobins have abnormally low rate constants for azide dissociation (0.1-0.3 s(-1)) due to direct hydrogen bonding between the N-epsilon atoms of these residues and the bound ligand. Mutations at positions 67(E10) and 68(E11) produce large but complex changes in the azide binding parameters as a result of both steric and electrostatic effects, which alter water coordination, influence the rate of anion movement into the distal pocket, and affect the stability of the Fe-N-3 bond. Replacement of Phe(46) with Leu or Val and substitution of Arg(Lys)45 with Glu and Ser cause disorder in the position of the distal histidine side chain and result in 4-700-fold increases in both k'(N3) and k(N3) but produce little ohange in overall azide affinity. All of these results suggest strongly that azide enters the distal pocket of native myoglobin through a polar channel that is regulated by a His(64) ''gate.'' In contrast to azide binding, the rate constant for cyanide association decreases 4-300-fold when the distal histidine is replaced with apolar residues. His(64), Gln(64), and distal pocket water molecules appear to facilitate deprotonation of HCN, which is the major kinetic barrier to cyanide binding at neutral pH.	UNIV ROMA LA SAPIENZA,CNR,CTR BIOL MOLEC,I-00185 ROME,ITALY; UNIV YORK,DEPT CHEM,YORK YO1 5DD,N YORKSHIRE,ENGLAND; CASE WESTERN RESERVE UNIV,SCH MED,DEPT PHYSIOL & BIOPHYS,CLEVELAND,OH 44106; RICE UNIV,DEPT BIOCHEM & CELL BIOL,HOUSTON,TX 77251; RICE UNIV,WM KECK CTR COMPUTAT BIOL,HOUSTON,TX 77251	Consiglio Nazionale delle Ricerche (CNR); Sapienza University Rome; University of York - UK; Case Western Reserve University; Rice University; Rice University	BRANCACCIO, A (corresponding author), UNIV ROMA LA SAPIENZA,DEPT BIOCHEM SCI A ROSSI FANELLI,I-00185 ROME,ITALY.		Brancaccio, Andrea/C-5876-2009; Cutruzzola', Francesca/G-4052-2011	Brancaccio, Andrea/0000-0003-4690-8826; Cutruzzola', Francesca/0000-0002-4621-2135; Smerdon, Stephen/0000-0001-5688-8465; Brunori, Maurizio/0000-0002-7795-1635; Olson, John/0000-0002-0760-5403; Wilkinson, Anthony/0000-0003-4577-9479	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039492, T32GM008280, R01GM035649] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-35649, GM-08280, GM-39492] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLOCATELLI CT, 1993, BIOCHEMISTRY-US, V32, P6041; Antonini E., 1971, HEMOGLOBIN MYOGLOBIN; BOLOGNESI M, 1989, J MOL BIOL, V205, P529, DOI 10.1016/0022-2836(89)90224-6; BOLOGNESI M, 1990, J MOL BIOL, V213, P621, DOI 10.1016/S0022-2836(05)80249-9; BOLOGNESI M, 1982, J MOL BIOL, V158, P305, DOI 10.1016/0022-2836(82)90435-1; BRANTLEY RE, 1993, J BIOL CHEM, V268, P6995; CARVER TE, 1992, J BIOL CHEM, V267, P14443; CARVER TE, 1991, BIOCHEMISTRY-US, V30, P4697, DOI 10.1021/bi00233a009; CARVER TE, 1990, J BIOL CHEM, V265, P20007; CASE DA, 1979, J MOL BIOL, V132, P343, DOI 10.1016/0022-2836(79)90265-1; CUTRUZZOLA F, 1991, FEBS LETT, V282, P281, DOI 10.1016/0014-5793(91)80495-O; CZERMINSKI R, 1991, PROTEINS, V10, P70, DOI 10.1002/prot.340100107; DODSON G, 1988, PROTEIN ENG, V2, P233, DOI 10.1093/protein/2.3.233; EGEBERG KD, 1990, BIOCHEMISTRY-US, V29, P9783, DOI 10.1021/bi00494a004; Eigen M., 1974, TECHNIQUES CHEMIST 2, VVI, P63; ELBER R, 1990, J AM CHEM SOC, V112, P9161, DOI 10.1021/ja00181a020; GIACOMETTI GM, 1981, J MOL BIOL, V151, P315, DOI 10.1016/0022-2836(81)90518-0; GIACOMETTI GM, 1975, BIOCHEMISTRY-US, V14, P1584, DOI 10.1021/bi00679a006; GIACOMETTI GM, 1981, J MOL BIOL, V146, P363, DOI 10.1016/0022-2836(81)90393-4; GIBSON QH, 1992, J BIOL CHEM, V267, P22022; HARGROVE MS, 1994, J BIOL CHEM, V269, P4207; IKEDASAITO M, 1992, J BIOL CHEM, V267, P22843; IKEDASAITO M, 1993, J BIOL CHEM, V268, P6855; JOHNSON KA, 1989, J MOL BIOL, V207, P459, DOI 10.1016/0022-2836(89)90269-6; KOTTALAM J, 1988, J AM CHEM SOC, V110, P7690, DOI 10.1021/ja00231a018; LESTER HA, 1992, ANNU REV BIOPH BIOM, V21, P267, DOI 10.1146/annurev.bb.21.060192.001411; LI TS, 1994, BIOCHEMISTRY-US, V33, P1433, DOI 10.1021/bi00172a021; Mattevi A, 1991, J Mol Recognit, V4, P1, DOI 10.1002/jmr.300040102; MINTOROVITCH J, 1989, BIOCHEMISTRY-US, V28, P6099, DOI 10.1021/bi00440a055; MINTOROVITCH J, 1988, BIOCHEMISTRY-US, V27, P8045, DOI 10.1021/bi00421a011; MORIKIS D, 1989, BIOCHEMISTRY-US, V28, P4791, DOI 10.1021/bi00437a041; OLDFIELD TJ, 1992, BIOCHEMISTRY-US, V31, P8732, DOI 10.1021/bi00152a008; Olson J S, 1981, Methods Enzymol, V76, P631; OLSON JS, 1988, NATURE, V336, P265, DOI 10.1038/336265a0; PERUTZ MF, 1966, J MOL BIOL, V21, P199, DOI 10.1016/0022-2836(66)90088-X; PHILLIPS GN, 1990, PROTEINS, V7, P358, DOI 10.1002/prot.340070407; Pifat G, 1973, Biophys Chem, V1, P112, DOI 10.1016/0301-4622(73)80007-9; QUILLIN ML, 1993, J MOL BIOL, V234, P140, DOI 10.1006/jmbi.1993.1569; RINGE D, 1984, BIOCHEMISTRY-US, V23, P2, DOI 10.1021/bi00296a001; RIZZI M, 1991, STRUCTURE SPERM WHAL; ROHLFS RJ, 1990, J BIOL CHEM, V265, P3168; SMERDON SJ, 1991, BIOCHEMISTRY-US, V30, P6252, DOI 10.1021/bi00239a025; SPRINGER BA, 1987, P NATL ACAD SCI USA, V84, P8961, DOI 10.1073/pnas.84.24.8961; SPRINGER BA, 1989, J BIOL CHEM, V264, P3057; STFYER L, 1964, J MOL BIOL, V8, P309; Stitt F, 1939, J AM CHEM SOC, V61, P1263, DOI 10.1021/ja01874a075; TENTORI L, 1973, INT J PEPT PROT RES, V5, P187; UNWIN N, 1989, NEURON, V3, P665, DOI 10.1016/0896-6273(89)90235-3; VARADARAJAN R, 1985, P NATL ACAD SCI USA, V82, P6504; VERPLOEG DA, 1971, J BIOL CHEM, V246, P2725; VILLARROEL A, 1991, P ROY SOC B-BIOL SCI, V243, P69, DOI 10.1098/rspb.1991.0012	51	109	109	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					13843	13853						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188662				2022-12-25	WOS:A1994NL60600022
J	SEVERINOV, K; KASHLEV, M; SEVERINOVA, E; BASS, I; MCWILLIAM, K; KUTTER, E; NIKIFOROV, V; SNYDER, L; GOLDFARB, A				SEVERINOV, K; KASHLEV, M; SEVERINOVA, E; BASS, I; MCWILLIAM, K; KUTTER, E; NIKIFOROV, V; SNYDER, L; GOLDFARB, A			A NONESSENTIAL DOMAIN OF ESCHERICHIA-COLI RNA-POLYMERASE REQUIRED FOR THE ACTION OF THE TERMINATION FACTOR ALC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-SUBUNIT; RIFAMPICIN RESISTANCE; RPOB GENE; MUTATION; SEQUENCE; PURIFICATION; POLYPEPTIDE; EXPRESSION; SITES	An evolutionarily nonconserved region of similar to 250 amino acids can be deleted from the amino-terminal part of the beta subunit of Escherichia coli RNA polymerase without effect on the enzyme's basic function. The non-essential segment is located between two highly conserved motifs and is flanked by sequences participating in the rifampicin binding site. The results define the second non-essential domain in the beta subunit, in addition to the more distal dispensable segment identified previously. The Alc protein of bacteriophage T4 participates in the host transcription shutoff after infection by causing premature termination of transcription on E. coli DNA. Point mutations which prevent Ale action in vivo change amino acids in the non essential NH2-terminal domain of the beta subunit. These point mutations as well as deletions which remove the non-essential region also prevent Alc action. Thus, in the RNA polymerase molecule, the proximal non-essential domain of beta may function as an acceptor of Alc or other regulatory factors.	RUSSIAN ACAD SCI, INST MOLEC GENET, MOSCOW, RUSSIA; PUBL HLTH RES INST CITY NEW YORK INC, NEW YORK, NY 10016 USA; MICHIGAN STATE UNIV, DEPT MICROBIOL, E LANSING, MI 48824 USA; EVERGREEN STATE COLL, OLYMPIA, WA 98505 USA	Russian Academy of Sciences; Michigan State University			Severinov, Konstantin/C-8545-2016		NIGMS NIH HHS [GM-30717] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030717] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARRY G, 1979, P NATL ACAD SCI USA, V76, P4922, DOI 10.1073/pnas.76.10.4922; BAUTZ EKF, 1976, RNA POLYMERASE, P273; BORODIN AM, 1988, DOKL AKAD NAUK SSSR+, V302, P1261; BORUKHOV S, 1991, J BIOL CHEM, V266, P23921; BURGESS RR, 1975, BIOCHEMISTRY-US, V14, P4634, DOI 10.1021/bi00692a011; CLARK MA, 1992, CURR MICROBIOL, V25, P283, DOI 10.1007/BF01575863; GRACHEV MA, 1989, EUR J BIOCHEM, V180, P577, DOI 10.1111/j.1432-1033.1989.tb14684.x; IGARASHI K, 1991, CELL, V65, P1015, DOI 10.1016/0092-8674(91)90553-B; JAMES P, 1991, J BIOL CHEM, V266, P5616; JIN DJ, 1988, J MOL BIOL, V202, P45, DOI 10.1016/0022-2836(88)90517-7; KAO C, 1987, J BACTERIOL, V169, P1232, DOI 10.1128/jb.169.3.1232-1238.1987; KASHLEV M, 1990, SCIENCE, V248, P1006, DOI 10.1126/science.1693014; KASHLEV M, 1993, CELL, V75, P147, DOI 10.1016/S0092-8674(05)80091-1; LANDICK R, 1990, GENE DEV, V4, P1623, DOI 10.1101/gad.4.9.1623; LEE JY, 1991, P NATL ACAD SCI USA, V88, P6018, DOI 10.1073/pnas.88.14.6018; LIAO DQ, 1992, J BIOL CHEM, V267, P22787; LISITSYN N, 1988, EUR J BIOCHEM, V117, P363; LISITSYN NA, 1984, MOL GEN GENET, V196, P173, DOI 10.1007/BF00334112; MALIK S, 1984, J BIOL CHEM, V259, P3292; MUSTAEV A, 1991, J BIOL CHEM, V266, P23927; OHME M, 1986, FEBS LETT, V200, P87, DOI 10.1016/0014-5793(86)80516-6; OVCHINNIKOV YA, 1981, EUR J BIOCHEM, V116, P621, DOI 10.1111/j.1432-1033.1981.tb05381.x; SAGITOV V, 1992, J BIOL CHEM, V268, P2195; SEVERINOV K, 1993, J BIOL CHEM, V268, P14820; SNYDER L, 1988, GENETICS, V118, P173; SNYDER L, 1976, P NATL ACAD SCI USA, V69, P603; SWEETSER D, 1987, P NATL ACAD SCI USA, V84, P1192, DOI 10.1073/pnas.84.5.1192; ZALENSKAYA K, 1990, GENE, V89, P7, DOI 10.1016/0378-1119(90)90199-2	28	53	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					14254	14259						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188709				2022-12-25	WOS:A1994NL60600080
J	YAMANO, A; TEETER, MM				YAMANO, A; TEETER, MM			CORRELATED DISORDER OF THE PURE PRO(22)/LEU(25) FORM OF CRAMBIN AT 150-K REFINED TO 1.05-ANGSTROM RESOLUTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN CRAMBIN; CRYSTALS; MOVEMENTS	The high resolution crystal structure of crambin has been based on the crystals containing two sequence forms (the mixed form). Here, we report the crystal structure of the sequence isomer having Pro and Leu at residues 22 and 25 (the PL form), This elimination of the sequence heterogeneity resulted in a simpler structure which permits a more accurate modeling of protein disorder. In the observed disorder, the PL form structure and the mixed form structure have significant differences: 1) the disorder caused by the sequence heterogeneity (pro(2)/Ser(22), Leu/Ile(25), Tyr(29)) is absent in the PL form; 2) Phe(13) and Glu(23) disordered in the mixed form have only one conformation in the PL form; and 3) Asn(12) has multiple conformations in the PL form. During the study of disorder in the PL form structure, we found that conformational correlation can be inferred from a structure determined with Bragg's reflections by introducing fundamental stereochemical information, van der Waals contact (Gursky, O., Badger, J., Li, Y., and Caspar, D. L. D. (1992) Biophys. J. 63, 1210-1220), although an x-ray structure is an image averaged over a large number of copies and the period of data collection and does not carry direct evidence about correlations. The correlations among Thr(2), Arg(10), and Ile(34) present the dearest example. The dimension of this correlation is comparable with the short-range (4-8 Angstrom) correlations in the atomic displacements concluded from the x-ray diffuse scattering experiments (Caspar, D. L. D., Clarage, J. B., Salunke, D. M., and Clarage, M. S. (1988) Nature 322, 659-662; Clarage, J. B., Clarage, M. S., Phillips, W. C., Sweet, R. M., and Caspar, D. L. D. (1992) Proteins 12, 145-157).	BOSTON COLL,MERKERT CHEM CTR,DEPT CHEM,CHESTNUT HILL,MA 02167	Boston College								BAKER EN, 1984, PROG BIOPHYS MOL BIO, V44, P79; CANTOR CR, 1980, BIOPHYSICAL CHEM 1, P259; CASPAR DLD, 1988, NATURE, V332, P659, DOI 10.1038/332659a0; CLARAGE JB, 1992, PROTEINS, V12, P145, DOI 10.1002/prot.340120208; HENDRICKSON WA, 1980, COMPUTING CRYSTALLOG; HENDRICKSON WA, 1981, NATURE, V290, P109; HOPE H, 1988, ACTA CRYSTALLOGR B, V44, P22, DOI 10.1107/S0108768187008632; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KURIYAN J, 1991, PROTEINS, V10, P340, DOI 10.1002/prot.340100407; MCPHERSON A, 1989, PREPARATION ANAL PRO, P94; PETERS D, 1981, J MOL STRUCT, V85, P107; PONDER JW, 1987, J MOL BIOL, V193, P775, DOI 10.1016/0022-2836(87)90358-5; SMITH JL, 1986, BIOCHEMISTRY-US, V25, P5018, DOI 10.1021/bi00366a008; TEETER MM, 1993, J MOL BIOL, V230, P292, DOI 10.1006/jmbi.1993.1143; TEETER MM, 1981, BIOCHEMISTRY-US, V20, P5437, DOI 10.1021/bi00522a013; TEETER MM, 1979, J MOL BIOL, V127, P219, DOI 10.1016/0022-2836(79)90242-0; TEETER MM, 1986, ANN NY ACAD SCI, V482, P163; Van ETTEN C. H., 1965, PHYTOCHEMETRY, V4, P467, DOI 10.1016/S0031-9422(00)86198-1; VERMEULEN JAWH, 1987, FEBS LETT, V219, P426, DOI 10.1016/0014-5793(87)80265-X	19	28	29	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					13956	13965						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188676				2022-12-25	WOS:A1994NL60600039
J	YOUNG, CL; FEIERSTEIN, A; SOUTHWICK, FS				YOUNG, CL; FEIERSTEIN, A; SOUTHWICK, FS			CALCIUM REGULATION OF ACTIN FILAMENT CAPPING AND MONOMER BINDING BY MACROPHAGE CAPPING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC FREE CALCIUM; PLASMA GELSOLIN; VILLIN; SITES; PHAGOCYTOSIS; NUCLEATION; DOMAIN; POLYMERIZATION; CYTOSKELETON; PURIFICATION	Macrophage capping protein (MCP) is a unique member of the gelsolin-villin family of calcium-activated barbed end capping proteins which in micromolar Ca2+ also binds actin monomers and nucleates actin assembly. Unlike gelsolin, MCP cannot sever actin filaments, and its Ca2+ dependent interaction with actin is completely reversible. The Ca2+ binding properties of MCP and its Ca2+-dependent functions were studied quantitatively. MCP undergoes a Ca2+-induced conformational change as evidenced by different chymotryptic digest patterns in 0.2 mM CaCl2 compared with 2 mM EGTA. MCP has a single low affinity Ca2+ binding site (K-D = 37 mu M). Binding of MCP to actin monomers requires a similar Ca2+ concentration ([Ca2+](0.5) = 62 mu M) suggesting that MCP.Ca2+ complex formation promotes monomer binding. In contrast, filament capping by MCP requires 1/60th of the Ca2+ concentration required for monomer binding, half-maximal capping occurring at 1 mu M Ca2+. The marked difference in the Ca2+ sensitivity of these two functions indicate the MCP's primary actin regulatory role in the macrophage is likely to be capping of the barbed ends of actin filaments.	UNIV FLORIDA, COLL MED, DEPT BIOCHEM & MOLEC BIOL, GAINESVILLE, FL 32610 USA	State University System of Florida; University of Florida	YOUNG, CL (corresponding author), UNIV FLORIDA, COLL MED, DEPT MED, DIV INFECT DIS, GAINESVILLE, FL 32610 USA.				NIAID NIH HHS [R01 AI023262, AI 23262] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023262] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLISON AC, 1971, NATURE-NEW BIOL, V232, P153; BAZARI WL, 1988, P NATL ACAD SCI USA, V85, P4986, DOI 10.1073/pnas.85.14.4986; BRENNER SL, 1980, J BIOL CHEM, V255, P1670; BRYAN J, 1984, J BIOL CHEM, V259, P7480; BRYAN J, 1986, J CELL BIOL, V102, P1439, DOI 10.1083/jcb.102.4.1439; CANO ML, 1991, J CELL BIOL, V115, P677, DOI 10.1083/jcb.115.3.677; CASELLA JF, 1986, J BIOL CHEM, V261, P915; CHAPONNIER C, 1986, J CELL BIOL, V103, P1473, DOI 10.1083/jcb.103.4.1473; DABIRI GA, 1992, J BIOL CHEM, V267, P16545; ESTES JE, 1987, J BIOL CHEM, V262, P4952; FRIEDEN C, 1988, BIOCHEMISTRY-US, V27, P3812, DOI 10.1021/bi00410a044; GREENBERG S, 1991, J CELL BIOL, V113, P757, DOI 10.1083/jcb.113.4.757; HARTWIG JH, 1986, J CELL BIOL, V103, P1007, DOI 10.1083/jcb.103.3.1007; HESTERBERG LK, 1983, J BIOL CHEM, V258, P365; JANMEY PA, 1985, BIOCHEMISTRY-US, V24, P3714, DOI 10.1021/bi00335a046; KIM E, 1992, INFECT IMMUN, V60, P1244, DOI 10.1128/IAI.60.3.1244-1248.1992; KORN ED, 1987, SCIENCE, V238, P638, DOI 10.1126/science.3672117; KRUSKAL BA, 1987, J CELL BIOL, V105, P2685, DOI 10.1083/jcb.105.6.2685; KWIATKOWSKI DJ, 1986, NATURE, V323, P455, DOI 10.1038/323455a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAYNE E, 1957, METHOD ENZYMOL, V3, P447, DOI 10.1016/S0076-6879(57)03413-8; LIN DC, 1978, J BIOL CHEM, V253, P1415; MARTELL AE, 1980, CRITICAL STABILITY C, V5, P144; MATSUDAIRA P, 1990, METHOD ENZYMOL, V182, P602; NORTHROP J, 1986, J BIOL CHEM, V261, P9274; PERRIN DD, 1967, TALANTA, V14, P833, DOI 10.1016/0039-9140(67)80105-X; PINDER JC, 1986, J MOL BIOL, V191, P461, DOI 10.1016/0022-2836(86)90141-5; POTTER JD, 1983, METHOD ENZYMOL, V102, P135; PRENDERGAST GC, 1991, EMBO J, V10, P757, DOI 10.1002/j.1460-2075.1991.tb08007.x; RUPLEY JA, 1967, METHOD ENZYMOL, V11, P905; SOUTHWICK FS, 1986, J BIOL CHEM, V261, P14191; STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552; TROTTER JA, 1981, EXP CELL RES, V132, P235, DOI 10.1016/0014-4827(81)90099-9; WAY M, 1989, J CELL BIOL, V109, P593, DOI 10.1083/jcb.109.2.593; WAY M, 1990, EMBO J, V9, P4103, DOI 10.1002/j.1460-2075.1990.tb07632.x; WEEDS AG, 1986, EUR J BIOCHEM, V161, P69, DOI 10.1111/j.1432-1033.1986.tb10125.x; WERNESS P, 1985, J UROLOGY, V104, P1; YIN HL, 1980, J BIOL CHEM, V255, P9494; YIN HL, 1980, J BIOL CHEM, V255, P9490; YOUNG CL, 1990, BIOCHEMISTRY-US, V29, P2232, DOI 10.1021/bi00461a005; YU FX, 1990, SCIENCE, V250, P1413, DOI 10.1126/science.2255912; ZIMMERLE CT, 1987, BIOCHEMISTRY-US, V26, P6545, DOI 10.1021/bi00394a039	42	30	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					13997	14002						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188679				2022-12-25	WOS:A1994NL60600043
J	HARTONG, R; WANG, NS; KUROKAWA, R; LAZAR, MA; GLASS, CK; APRILETTI, JW; DILLMANN, WH				HARTONG, R; WANG, NS; KUROKAWA, R; LAZAR, MA; GLASS, CK; APRILETTI, JW; DILLMANN, WH			DELINEATION OF 3 DIFFERENT THYROID HORMONE-RESPONSE ELEMENTS IN PROMOTER OF RAT SARCOPLASMIC-RETICULUM CA2+-ATPASE GENE - DEMONSTRATION THAT RETINOID-X RECEPTOR BINDS 5' TO THYROID-HORMONE RECEPTOR IN RESPONSE ELEMENT-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								Thyroid hormone (3,5,3'-triiodothyronine) positively regulates transcription of the sarcoplasmic reticulum Ca(2+)ATPase gene in rat heart, and sequences within 559 nucleotides upstream from the transcription start site confer thyroid hormone responsiveness upon a reporter gene. In the present study, three thyroid hormone-response elements (TREs) are identified between nucleotides -485 and -190. Each TRE is active in transient transfection assays and specifically binds 3,5,3'-triiodothyronine receptors (TRs) alpha 1 and beta 1 alone and in combination with retinoid X receptors (RXRs) alpha and beta. TRE 1 is a direct repeat of two half-sites separated by four nucleotides; TREs 2 and 3 are inverted palindromes of two half-sites separated by four and six nucleotides, respectively. Methylation interference analysis of TRE 1 showed binding of a TR alpha 1 monomer to the 3' half-site, whereas the heterodimer contacts both half-sites. Subsequent studies employed TR beta and RXR alpha mutants in which their P-boxes were replaced with the P-box of the glucocorticoid receptor. Bandshifts of wild type and mutant proteins with either wild type TRE 1 or a mutant version, in which the 5' half-site was converted to a glucocorticoid response element half-site, demonstrated preferential binding of RXR to the 5' half-site and of TR to the 3' half-site of TRE 1.	UNIV PENN, SCH MED, DEPT MED, DIV ENDOCRINE, PHILADELPHIA, PA 19104 USA; UNIV PENN, SCH MED, DEPT GENET, PHILADELPHIA, PA 19104 USA; UNIV CALIF SAN FRANCISCO, METAB RES UNIT, SAN FRANCISCO, CA 94143 USA	University of Pennsylvania; University of Pennsylvania; University of California System; University of California San Francisco	HARTONG, R (corresponding author), UNIV CALIF SAN DIEGO, MED CTR, DEPT MED, DIV ENDOCRINOL & METAB, 200 W ARBOR DR 8412, SAN DIEGO, CA 92103 USA.		Glass, Christopher/AAI-3933-2021; Lazar, Mitchell A/AAF-3738-2019	Glass, Christopher/0000-0003-4344-3592; 	NATIONAL CANCER INSTITUTE [R01CA052599] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL025022] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043806, R37DK043806] Funding Source: NIH RePORTER; NCI NIH HHS [NCI RO1 CA52599] Funding Source: Medline; NHLBI NIH HHS [HL 25022] Funding Source: Medline; NIDDK NIH HHS [DK 43806] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BEEBE JS, 1991, MOL ENDOCRINOL, V5, P85, DOI 10.1210/mend-5-1-85; BRANDL CJ, 1987, J BIOL CHEM, V262, P3768; BRENT GA, 1989, MOL ENDOCRINOL, V3, P1996, DOI 10.1210/mend-3-12-1996; BURK SE, 1989, J BIOL CHEM, V264, P18561; BURNSIDE J, 1990, J BIOL CHEM, V265, P2500; CASADABAN MJ, 1983, METHOD ENZYMOL, V100, P293; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DARLING DS, 1991, MOL ENDOCRINOL, V5, P73, DOI 10.1210/mend-5-1-73; DARLING DS, 1993, J BIOL CHEM, V268, P10221; DELABASTIE D, 1990, CIRC RES, V66, P554, DOI 10.1161/01.RES.66.2.554; DESVERGNE B, 1991, J BIOL CHEM, V266, P1008; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FALCONE M, 1992, ENDOCRINOLOGY, V131, P2419, DOI 10.1210/en.131.5.2419; FARSETTI A, 1992, J BIOL CHEM, V267, P15784; GEBALLE AP, 1986, CELL, V46, P865, DOI 10.1016/0092-8674(86)90068-1; GIRALT M, 1991, J BIOL CHEM, V266, P21991; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; GLASS CK, 1990, BIOCHIM BIOPHYS ACTA, V1032, P157, DOI 10.1016/0304-419X(90)90002-I; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HALLENBECK PL, 1992, P NATL ACAD SCI USA, V89, P5572, DOI 10.1073/pnas.89.12.5572; HERMANN T, 1992, MOL ENDOCRINOL, V6, P1153, DOI 10.1210/me.6.7.1153; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HODIN RA, 1989, SCIENCE, V244, P76, DOI 10.1126/science.2539642; IZUMO S, 1988, NATURE, V334, P539, DOI 10.1038/334539a0; KATZ RW, 1993, J BIOL CHEM, V268, P19392; KIM HS, 1992, MOL ENDOCRINOL, V6, P1489, DOI 10.1210/me.6.9.1489; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KOENIG RJ, 1989, NATURE, V337, P659, DOI 10.1038/337659a0; KUROKAWA R, 1993, GENE DEV, V7, P1423, DOI 10.1101/gad.7.7b.1423; LANGER GA, 1992, FASEB J, V6, P893, DOI 10.1096/fasebj.6.3.1310947; LAZAR MA, 1988, MOL ENDOCRINOL, V2, P893, DOI 10.1210/mend-2-10-893; LAZAR MA, 1990, MOL ENDOCRINOL, V4, P1627, DOI 10.1210/mend-4-11-1627; LAZAR MA, 1991, MOL CELL BIOL, V11, P5005, DOI 10.1128/MCB.11.10.5005; LAZAR MA, 1989, P NATL ACAD SCI USA, V86, P7771, DOI 10.1073/pnas.86.20.7771; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEIDIG F, 1992, J BIOL CHEM, V267, P913; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; MARKS MS, 1992, MOL ENDOCRINOL, V6, P219, DOI 10.1210/me.6.2.219; MITSUHASHI T, 1988, P NATL ACAD SCI USA, V85, P5804, DOI 10.1073/pnas.85.16.5804; MORGAN JP, 1991, AM HEART J, V121, P961, DOI 10.1016/0002-8703(91)90227-9; MURRAY MB, 1989, MOL ENDOCRINOL, V3, P1434, DOI 10.1210/mend-3-9-1434; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; NAGAI R, 1989, P NATL ACAD SCI USA, V86, P2966, DOI 10.1073/pnas.86.8.2966; OJAMAA K, 1992, AM J PHYSIOL, V263, pE534, DOI 10.1152/ajpendo.1992.263.3.E534; PARK HY, 1993, MOL ENDOCRINOL, V7, P319, DOI 10.1210/me.7.3.319; PERLMANN T, 1993, GENE DEV, V7, P1411, DOI 10.1101/gad.7.7b.1411; RIBEIRO RC, 1992, MOL ENDOCRINOL, V6, P1142, DOI 10.1210/me.6.7.1142; ROHRER D, 1988, J BIOL CHEM, V263, P6941; ROHRER DK, 1991, J BIOL CHEM, V266, P8638; SAMUELS HH, 1979, ENDOCRINOLOGY, V105, P80, DOI 10.1210/endo-105-1-80; SAP J, 1990, EMBO J, V9, P887, DOI 10.1002/j.1460-2075.1990.tb08186.x; SCHWARTZ HL, 1992, J BIOL CHEM, V267, P11794; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; VOZ ML, 1992, MOL CELL BIOL, V12, P3991, DOI 10.1128/MCB.12.9.3991; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	67	103	103	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					13021	13029						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175722				2022-12-25	WOS:A1994NH71600098
J	MOSS, JB; MCQUINN, TC; SCHWARTZ, RJ				MOSS, JB; MCQUINN, TC; SCHWARTZ, RJ			THE AVIAN CARDIAC ALPHA-ACTIN PROMOTER IS REGULATED THROUGH A PAIR OF COMPLEX ELEMENTS COMPOSED OF E-BOXES AND SERUM RESPONSE ELEMENTS THAT BIND BOTH POSITIVE-ACTING AND NEGATIVE-ACTING FACTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HELIX-LOOP-HELIX; MUSCLE-SPECIFIC TRANSCRIPTION; DNA-BINDING; GENE-EXPRESSION; ACTIVATION; MYOD1; SITES; SEQUENCE; ENHANCER; CELLS	The chicken alpha-cardiac actin is one of the earliest contractile protein genes selectively expressed during embryonic skeletal and cardiac muscle differentiation. Cardiac actin promoter elements were examined in these two sarcomeric cell types. A portion of the alpha-cardiac actin promoter responsible for striated muscle specificity has been delineated (1, 2) and shown to contain four serum response elements (SRE). Previously, SRE3 was shown to be part of a complex element in cojunction with a functional E box (2), and we now show that SRE4 is also part of an upstream SRE E box cis-element complex. The SREs function similarly, but the E boxes have dissimilar properties within and between striated muscle types. The SRES-E1 box binds myogenic basic helix-loop-helix factors and is required for cardiac actin trans-activation in primary muscle cell cultures but functions as a negative regulatory element in cardiac muscle cells. The SRE4-E2 box, on the other hand, fails to bind basic helix-loop-helix (bHLH) factors, is negative acting in skeletal muscle cells, and is positive acting in cardiac myocytes. A DNA binding factor similar to HF1a (3) was identified that interacts specifically with the SRE4-E2 box. This study shows that the avian cardiac actin promoter elements are differentially used between skeletal and cardiac striated muscle cell lineages.	BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT PEDIAT,HOUSTON,TX 77030	Baylor College of Medicine; Baylor College of Medicine					NHLBI NIH HHS [R01 HL38401, P01 HL49953] Funding Source: Medline; NICHD NIH HHS [5P30-HD27823] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P30HD027823] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038401, P01HL049953] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ausubel F. M., 1993, CURRENT PROTOCOLS MO, V1; BERGSMA DJ, 1986, MOL CELL BIOL, V6, P2462, DOI 10.1128/MCB.6.7.2462; BLANK RS, 1992, J BIOL CHEM, V267, P984; BRAUN T, 1990, EMBO J, V9, P821, DOI 10.1002/j.1460-2075.1990.tb08179.x; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; CARROLL SL, 1986, J BIOL CHEM, V261, P8965; CHAKRABORTY T, 1991, MOL CELL BIOL, V11, P6103, DOI 10.1128/MCB.11.12.6103; CHAKRABORTY T, 1991, J BIOL CHEM, V266, P2878; CHANG KS, 1985, NUCLEIC ACIDS RES, V13, P1223, DOI 10.1093/nar/13.4.1223; CHIEN K, 1993, J CELL BIOCH D S, V17; CHOW KL, 1990, MOL CELL BIOL, V10, P528, DOI 10.1128/MCB.10.2.528; CSERJESI P, 1992, DEVELOPMENT, V115, P1087; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; ELDRIDGE J, 1985, GENE, V36, P55, DOI 10.1016/0378-1119(85)90069-1; FRENCH BA, 1991, MOL CELL BIOL, V11, P2439, DOI 10.1128/MCB.11.5.2439; FUNK WD, 1992, P NATL ACAD SCI USA, V89, P9484, DOI 10.1073/pnas.89.20.9484; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRUENEBERG DA, 1992, SCIENCE, V257, P1089, DOI 10.1126/science.257.5073.1089; HARLAND R, 1985, J CELL BIOL, V101, P1094, DOI 10.1083/jcb.101.3.1094; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; HAYWARD LJ, 1986, J CELL BIOL, V102, P1485, DOI 10.1083/jcb.102.4.1485; HINTERBERGER TJ, 1991, DEV BIOL, V147, P144, DOI 10.1016/S0012-1606(05)80014-4; HOPWOOD ND, 1990, NATURE, V347, P197, DOI 10.1038/347197a0; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEE TC, 1992, P NATL ACAD SCI USA, V89, P9814, DOI 10.1073/pnas.89.20.9814; LIN H, 1991, MOL CELL BIOL, V11, P267, DOI 10.1128/MCB.11.1.267; LIN ZY, 1989, GENE DEV, V3, P986, DOI 10.1101/gad.3.7.986; LITVIN J, 1993, DEV BIOL, V156, P409, DOI 10.1006/dbio.1993.1088; MAK KL, 1992, MOL CELL BIOL, V12, P4334, DOI 10.1128/MCB.12.10.4334; MAR JH, 1988, P NATL ACAD SCI USA, V85, P6404, DOI 10.1073/pnas.85.17.6404; MAR JH, 1990, MOL CELL BIOL, V10, P4271, DOI 10.1128/MCB.10.8.4271; MINTY A, 1986, MOL CELL BIOL, V6, P2125, DOI 10.1128/MCB.6.6.2125; MIWA T, 1987, P NATL ACAD SCI USA, V84, P6702, DOI 10.1073/pnas.84.19.6702; MOHUN TJ, 1986, EMBO J, V5, P3185, DOI 10.1002/j.1460-2075.1986.tb04628.x; MOHUN TJ, 1989, EMBO J, V8, P1153, DOI 10.1002/j.1460-2075.1989.tb03486.x; MOLENTKIN JD, 1993, J BIOL CHEM, V268, P2602; MURRE C, 1991, MOL CELL BIOL, V11, P1156, DOI 10.1128/MCB.11.2.1156; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NAVANKASATTUSAS S, 1992, MOL CELL BIOL, V12, P1469, DOI 10.1128/MCB.12.4.1469; PIETTE J, 1990, NATURE, V345, P353, DOI 10.1038/345353a0; QUITSCHKE WW, 1989, MOL CELL BIOL, V9, P3218, DOI 10.1128/MCB.9.8.3218; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; SARTORELLI V, 1990, GENE DEV, V4, P1811, DOI 10.1101/gad.4.10.1811; SARTORELLI V, 1992, P NATL ACAD SCI USA, V89, P4047, DOI 10.1073/pnas.89.9.4047; SASSOON D, 1989, NATURE, V341, P303, DOI 10.1038/341303a0; SHAW PE, 1989, EMBO J, V8, P2567, DOI 10.1002/j.1460-2075.1989.tb08395.x; SINGH H, 1988, CELL, V52, P415, DOI 10.1016/S0092-8674(88)80034-5; STRUB K, 1991, MOL CELL BIOL, V11, P3949, DOI 10.1128/MCB.11.8.3949; TAPSCOTT SJ, 1988, SCIENCE, V242, P405, DOI 10.1126/science.3175662; TUIL D, 1990, J MOL BIOL, V213, P677, DOI 10.1016/S0022-2836(05)80255-4; WEINTRAUB H, 1990, P NATL ACAD SCI USA, V87, P5623, DOI 10.1073/pnas.87.15.5623; WENTWORTH BM, 1991, P NATL ACAD SCI USA, V88, P1242, DOI 10.1073/pnas.88.4.1242; WEYDERT A, 1987, CELL, V49, P121, DOI 10.1016/0092-8674(87)90762-8; YUTZEY KE, 1990, MOL CELL BIOL, V10, P3934, DOI 10.1128/MCB.10.8.3934; ZHU H, 1991, MOL CELL BIOL, V11, P2273, DOI 10.1128/MCB.11.4.2273	58	46	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12731	12740						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175685				2022-12-25	WOS:A1994NH71600057
J	QIAN, YM; BLASKOVICH, MA; SALEEM, M; SEONG, CM; WATHEN, SP; HAMILTON, AD; SEBTI, SM				QIAN, YM; BLASKOVICH, MA; SALEEM, M; SEONG, CM; WATHEN, SP; HAMILTON, AD; SEBTI, SM			DESIGN AND STRUCTURAL REQUIREMENTS OF POTENT PEPTIDOMIMETIC INHIBITORS OF P21(RAS) FARNESYLTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PROTEIN FARNESYLTRANSFERASE; TETRAPEPTIDE INHIBITORS; RAS; P21RAS; FARNESYL; TRANSFORMATION; TRANSFERASE; TERMINUS; MEMBRANE	Cysteine farnesylation of the ras oncogene product, p21(ras), on its carboxyl terminal CA(1)A(2)X box (C = cysteine, A = aliphatic, and X = methionine or serine) is required for its transforming activity. p21(ras) farnesyltransferase (FTase), the enzyme responsible for this important posttranslational modification can be inhibited by simple CA(1)A(2)X peptides. We have synthesized a family of CA(1)A(2)X peptidomimetics where the central 2 aliphatic amino acids are replaced by a variety of spacer groups with different shapes and conformational characteristics to investigate the structural requirements of these inhibitors. The biological activities of CA(1)A(2)X peptidomimetics, where the dipeptide ''A(1)A(2)'' is replaced by 3- or 4-ami nomethylbenzoic acid (AMBA) and 3- or 4-aminobenzoic acid (ABA), are evaluated in a p21(ras) FTase inhibitory assay. Peptidomimetics Cys-4-ABA-Met and Cys-3-AMBA-Met contain spacers that provide good distance correspondence of the carboxylate and ammonium separation with that of the parent K-B p21(ras) tetrapeptide, Cys-Val-Ile-Met, and are as potent FTase inhibitors (IC50 values of 50 and 100 nM, respectively). In contrast, replacing the central dipeptide with 4-AMBA reduced FTase inhibitory activity by 17-fold whereas replacement by 3-ABA reduces inhibitory activity of the pep- tidomimetics by 43-fold. Cys-4-ABA-Met (IC50 = 50 nM) is 128 times more potent as a p21(ras) FTase inhibitor than Cys-3-ABA-Met (IC50 = 6400 nM), yet these two peptidomimetics differ only in the substitution pattern around the phenyl ring. These results coupled with computer modeling studies demonstrate that the interaction between FTase and the peptidomimetics requires precise structural and conformational characteristics; in particular, correct positioning of the Cys and Met must be respected. Furthermore, Cys-3-AMBA-Met and Cys-4-ABA-Met are true inhibitors of p21(ras) FTase since they are not farnesylated by this enzyme, in contrast to Cys-Val-Ile-Met, which inhibits the enzyme by acting as alternative substrate. Computer modeling studies of the potent FTase inhibitor Cys-4-ABA-Met show that a folded conformation, where the thiol and carboxylate groups are close, is not possible. Therefore a beta-turn conformation that would result in the simultaneous coordination of the Cys-thiol and Met-carboxylate to zinc ion is not important for inhibition of p21(ras) FTase, as previously suggested.	UNIV PITTSBURGH,FAC ARTS & SCI,DEPT CHEM,PITTSBURGH,PA 15261; UNIV PITTSBURGH,SCH MED,DEPT PHARMACOL,PITTSBURGH,PA 15261	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh								Barbacid M, 1986, Important Adv Oncol, P3; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BROWN MS, 1992, P NATL ACAD SCI USA, V89, P8313, DOI 10.1073/pnas.89.17.8313; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CHEN WJ, 1993, J BIOL CHEM, V268, P9675; GARCIA AM, 1993, J BIOL CHEM, V268, P18415; GIBBS JB, 1991, CELL, V65, P1, DOI 10.1016/0092-8674(91)90352-Y; GOLDSTEIN JL, 1991, J BIOL CHEM, V266, P15575; GRAND RJA, 1991, BIOCHEM J, V279, P609, DOI 10.1042/bj2790609; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; JACKSON JH, 1990, P NATL ACAD SCI USA, V87, P3042, DOI 10.1073/pnas.87.8.3042; JAMES GL, 1993, SCIENCE, V260, P1937, DOI 10.1126/science.8316834; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; LACAL JC, 1984, P NATL ACAD SCI-BIOL, V81, P5305, DOI 10.1073/pnas.81.17.5305; MOORES SL, 1991, J BIOL CHEM, V266, P14603; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NIGAM M, 1993, J BIOL CHEM, V268, P20695; POMPLIANO DL, 1992, BIOCHEMISTRY-US, V31, P3800, DOI 10.1021/bi00130a010; REISS Y, 1991, P NATL ACAD SCI USA, V88, P732, DOI 10.1073/pnas.88.3.732; REISS Y, 1991, J BIOL CHEM, V266, P10672; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; STRADLEY SJ, 1993, BIOCHEMISTRY-US, V32, P12586, DOI 10.1021/bi00210a006; WILLUMSEN BM, 1984, EMBO J, V3, P2581, DOI 10.1002/j.1460-2075.1984.tb02177.x; WILLUMSEN BM, 1984, NATURE, V310, P583, DOI 10.1038/310583a0	27	109	133	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12410	12413						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175645				2022-12-25	WOS:A1994NH71600008
J	SRINIVASAN, M; BEGUM, N				SRINIVASAN, M; BEGUM, N			REGULATION OF PROTEIN PHOSPHATASE-1 AND PHOSPHATASE-2A ACTIVITIES BY INSULIN DURING MYOGENESIS IN RAT SKELETAL-MUSCLE CELLS IN CULTURE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								In this study, we examined protein phosphatase 1 (PP-1) and protein phosphatase 2A (PP-2A) activities during various stages of myogenesis and their regulation by insulin in rat skeletal muscle cells. Protein phosphatase activities were measured using P-32-labeled phosphorylase alpha, glycogen synthase, and phosphorylase kinase as substrates. Spontaneous PP-1 activity increased progressively in cultures from 2 to 5 days, PP-2A activities remained constant in days 2-4 cultures and increased sharply on day 5. Most of the times in culture, a significant proportion (approximate to 65%) of PP-1 was in a form that could be activated by trypsin. Insulin stimulated PP-1 activity (40-80% increase over basal) in a time (t(1/2) approximate to 5 min)- and dose (EC(50) approximate to 0.1 nM)-dependent manner. Insulin activation of PP-1 was accompanied by a corresponding inhibition in PP-2A activity. The effects of insulin on PP-1 and PP-2A were differentiation dependent and were observed only in cells at fusion (day 5) and post-fusion. The insulin's effect on PP-1 correlated with the gradual appearance of PP-1 G subunit in cells at fusion. Immunoprecipitation of PP-1 from P-32-labeled cells with an antibody directed against the site 1 sequence of rabbit skeletal muscle PP-1G detected a 160-kDa protein, phosphorylation of which was significantly increased by insulin. This correlated well with the increase observed in immunoprecipitated PP-1G activity. Treatment of cells with a cAMP agonist (SpcAMP) completely blocked activation of PP-1 by insulin and diminished insulin-stimulated phosphorylation of the 160-kDa protein. The likely identity of the 160-kDa band as the regulatory subunit of PP-1 was confirmed by assay of PP-1 activity in the immunoprecipitates and by competition studies with the site 1 peptide against which the antibody was made. From these studies, we conclude that insulin activates PP-1 in L6 cells by increasing the phosphorylation of its regulatory subunit.	WINTHROP UNIV HOSP, DIABET RES LAB, MINEOLA, NY 11501 USA; SUNY STONY BROOK, SCH MED, STONY BROOK, NY 11794 USA	Winthrop University Hospital; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook								AVRUCH J, 1976, J BIOL CHEM, V251, P1511; BEGUINOT F, 1986, ENDOCRINOLOGY, V118, P446, DOI 10.1210/endo-118-1-446; BEGUINOT F, 1985, J BIOL CHEM, V260, P5892; BEGUM N, 1993, J BIOL CHEM, V268, P7917; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; CHAN CP, 1988, P NATL ACAD SCI USA, V85, P6257, DOI 10.1073/pnas.85.17.6257; CHEN J, 1992, SCIENCE, V257, P1261, DOI 10.1126/science.1325671; CHOU CK, 1987, J BIOL CHEM, V262, P1842; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN P, 1988, PROC R SOC SER B-BIO, V234, P115, DOI 10.1098/rspb.1988.0040; COHEN P, 1991, METHOD ENZYMOL, V201, P389; COHEN P, 1989, FEBS LETT, V250, P596, DOI 10.1016/0014-5793(89)80803-8; COHEN P, 1983, METHOD ENZYMOL, V99, P243; COHEN P, 1988, METHOD ENZYMOL, V159, P390; COHEN P, 1985, CURR TOP CELL REGUL, V27, P23; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; EBINA Y, 1987, P NATL ACAD SCI USA, V84, P704, DOI 10.1073/pnas.84.3.704; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; GIBBS EM, 1986, J BIOL CHEM, V261, P6597; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; GRUPPUSO PA, 1987, BIOCHEM BIOPH RES CO, V148, P1174, DOI 10.1016/S0006-291X(87)80256-5; HUBBARD MJ, 1989, EUR J BIOCHEM, V186, P701, DOI 10.1111/j.1432-1033.1989.tb15263.x; INGEBRITSEN TS, 1983, SCIENCE, V221, P331, DOI 10.1126/science.6306765; INOUE G, 1993, J BIOL CHEM, V268, P5272; KASUGA M, 1982, SCIENCE, V215, P185, DOI 10.1126/science.7031900; KIM SJ, 1992, J BIOL CHEM, V267, P15140; KLIP A, 1984, AM J PHYSIOL, V247, pE291, DOI 10.1152/ajpendo.1984.247.3.E291; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARNER J, 1990, ADV ENZYMOL RAMB, V63, P173; LAVOINNE A, 1991, EUR J BIOCHEM, V199, P723, DOI 10.1111/j.1432-1033.1991.tb16176.x; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MORGAN DO, 1987, P NATL ACAD SCI USA, V84, P41, DOI 10.1073/pnas.84.1.41; OLIVIER AR, 1990, J BIOL CHEM, V265, P22460; PERISIC O, 1983, J BIOL CHEM, V258, P9589; ROSEN OM, 1983, P NATL ACAD SCI-BIOL, V80, P3237, DOI 10.1073/pnas.80.11.3237; SEALS JR, 1979, J BIOL CHEM, V254, P6991; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STEVENSON BR, 1993, P NATL ACAD SCI USA, V90, P10305; TANG PM, 1991, J BIOL CHEM, V266, P15782; VILLAMORUZZI E, 1989, FEBS LETT, V258, P208, DOI 10.1016/0014-5793(89)81654-0; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; WHITE MF, 1985, J BIOL CHEM, V260, P9470; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; YAFFE D, 1968, P NATL ACAD SCI USA, V61, P477, DOI 10.1073/pnas.61.2.477; YU KT, 1984, J BIOL CHEM, V259, P5277; ZHANG JN, 1989, J BIOL CHEM, V264, P17513	47	73	75	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12514	12520						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175660				2022-12-25	WOS:A1994NH71600025
J	WAX, SD; ROSENFIELD, CL; TAUBMAN, MB				WAX, SD; ROSENFIELD, CL; TAUBMAN, MB			IDENTIFICATION OF A NOVEL GROWTH FACTOR-RESPONSIVE GENE IN VASCULAR SMOOTH-MUSCLE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPONTANEOUSLY HYPERTENSIVE RAT; CULTURED MOUSE CELLS; MYC MESSENGER-RNA; ANGIOTENSIN-II; PROTEIN-SYNTHESIS; ARTERIAL INJURY; C-FOS; EXPRESSION; INDUCTION; SEQUENCE	We have employed differential screening of a rat aortic smooth muscle cell cDNA library to isolate a cDNA clone, SM-20, whose nucleotide and deduced amino acid sequences are distinct from those reported previously. SM-20 encodes an mRNA of approximate to 2.5-3.0 kilobase pairs which is present at low levels in quiescent vascular smooth muscle cells. SM-20 levels increase within 1 h of treatment with growth agonists (serum, platelet-derived growth factor, angiotensin II), isoproterenol, and forskolin. Cycloheximide induces high levels of SM-20 mRNA and superinduces it in the presence of serum, suggesting that the increase in SM-20 mRNA levels is not dependent on protein synthesis and is part of the primary response to growth agonists. SM-20 is expressed at high levels in tissues and cells derived from muscle (smooth, skeletal, and cardiac) and nerve (brain, PC12 cells) and is not expressed in 3T3 fibroblasts or rat 6 fibroblasts. SM-20 encodes a new member of the immediate early gene family and is unusual in that it is expressed in vascular smooth muscle, but not in fibroblasts.	CUNY MT SINAI SCH MED,DEPT MED,DIV MOLEC MED,NEW YORK,NY 10029; CUNY MT SINAI SCH MED,DEPT MED,DIV CARDIOL,NEW YORK,NY 10029; CUNY MT SINAI SCH MED,BROOKDALE CTR MOLEC BIOL,NEW YORK,NY 10029	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai					NHLBI NIH HHS [HL43302] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043302] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BERK BC, 1989, HYPERTENSION, V13, P305, DOI 10.1161/01.HYP.13.4.305; BERK BC, 1986, SCIENCE, V232, P87, DOI 10.1126/science.3485309; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BRAVO R, 1990, CELL GROWTH DIFFER, V1, P305; BROWN KE, 1992, J BIOL CHEM, V267, P4625; CAMPBELL GR, 1987, VASCULAR SMOOTH MUSC, V1, P39; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLEVELAND D W, 1989, New Biologist, V1, P121; CLOWES AW, 1983, LAB INVEST, V49, P327; COCHRAN BH, 1983, CELL, V33, P939, DOI 10.1016/0092-8674(83)90037-5; FENG P, 1993, J BIOL CHEM, V268, P9387; GADEAU AP, 1991, J CELL PHYSIOL, V146, P356, DOI 10.1002/jcp.1041460304; GEISTERFER AAT, 1988, CIRC RES, V62, P749, DOI 10.1161/01.RES.62.4.749; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Guyton AC, 1986, TXB MED PHYSL; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HERSCHMAN HR, 1989, TRENDS BIOCHEM SCI, V14, P455, DOI 10.1016/0968-0004(89)90105-9; HSIAO WLW, 1986, MOL CELL BIOL, V6, P1943, DOI 10.1128/MCB.6.6.1943; KENYON K, 1991, SCIENCE, V253, P802, DOI 10.1126/science.1678898; KINDY MS, 1986, J BIOL CHEM, V261, P2865; KOMURO I, 1988, FEBS LETT, V238, P249, DOI 10.1016/0014-5793(88)80489-7; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAHERTY CD, 1992, J BIOL CHEM, V267, P3274; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; LEE RMKW, 1983, BLOOD VESSELS, V20, P72; LINZER DIH, 1983, P NATL ACAD SCI-BIOL, V80, P4271, DOI 10.1073/pnas.80.14.4271; MAJESKY MW, 1990, J CELL BIOL, V111, P2149, DOI 10.1083/jcb.111.5.2149; MARMUR JD, 1992, CIRCULATION, V86, P53; MATRISIAN LM, 1985, NUCLEIC ACIDS RES, V13, P711, DOI 10.1093/nar/13.3.711; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; NAFTILAN AJ, 1990, MOL CELL BIOL, V10, P5536, DOI 10.1128/MCB.10.10.5536; OLDBERG A, 1986, P NATL ACAD SCI USA, V83, P8819, DOI 10.1073/pnas.83.23.8819; OWENS GK, 1985, CIRC RES, V56, P525, DOI 10.1161/01.RES.56.4.525; OWENS GK, 1982, CIRC RES, V51, P280, DOI 10.1161/01.RES.51.3.280; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Sambrook J, 1989, MOL CLONING LABORATO; Schneider C, 1991, CURR OPIN CELL BIOL, V3, P276, DOI 10.1016/0955-0674(91)90152-O; SEIFERT RA, 1989, J BIOL CHEM, V264, P8771; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHEETS MD, 1990, NUCLEIC ACIDS RES, V18, P5799, DOI 10.1093/nar/18.19.5799; SIMONS M, 1992, CIRC RES, V70, P835, DOI 10.1161/01.RES.70.4.835; SJOLUND M, 1988, J CELL BIOL, V106, P403, DOI 10.1083/jcb.106.2.403; TAUBMAN MB, 1993, J CLIN INVEST, V91, P547, DOI 10.1172/JCI116234; TAUBMAN MB, 1992, CIRC RES, V70, P314, DOI 10.1161/01.RES.70.2.314; TAUBMAN MB, 1989, J BIOL CHEM, V264, P526; WATERSTON R, 1992, NAT GENET, V1, P114, DOI 10.1038/ng0592-114; WISDOM R, 1991, GENE DEV, V5, P232, DOI 10.1101/gad.5.2.232	50	80	83	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					13041	13047						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175725				2022-12-25	WOS:A1994NH71600101
J	MURATALIEV, MB; BOYER, PD				MURATALIEV, MB; BOYER, PD			INTERACTION OF MITOCHONDRIAL F-1-ATPASE WITH TRINITROPHENYL DERIVATIVES OF ATP AND ADP - PARTICIPATION OF 3RD CATALYTIC SITE AND ROLE OF MG2+ IN ENZYME INACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING-SITES; ESCHERICHIA-COLI F(1)-ATPASE; STEADY-STATE KINETICS; ISOLATED BETA-SUBUNIT; ADENOSINE-TRIPHOSPHATASE; CHLOROPLAST ATPASE; SINGLE SITE; F1-ATPASE; MECHANISM; HYDROLYSIS	Relatively high ATP concentrations show an unexpected lack of inhibition of the hydrolysis of low concentrations of trinitrophenyl ATP (TNP-ATP) by mitochondrial F-1-ATPase. In striking contrast low TNP-ATP concentrations markedly inhibit the hydrolysis of much higher ATP concentrations. The three catalytic sites undergoing sequential conformational changes have different conformations at any instant of catalysis, and only two need to be filled for rapid, steady-state ATP hydrolysis. The remaining site has low affinity for ATP (K-d 2 mM) but about 10(4) greater affinity for TNP-ATP (K-m and K-d about 0.2 mu M). Thus 500 mu M ATP does not prevent binding of less than 1 mu M TNP-ATP. As the site binding the TNP-ATP undergoes sequential conformational changes the TNP-ATP is hydrolyzed and products are released. The results give strong support to the view that all three catalytic sites proceed equivalently in ATP as well as TNP-ATP hydrolysis. The conformation that has the lowest affinity for ATP has over a 10-fold greater affinity for ADP (K-d 150 mu M) and may be akin to the conformation to which ADP binds during net ATP synthesis by the ATP synthase. The recognition of these features was made possible by new information obtained from detailed studies of the interactions of Mg2+, TNP-ADP, TNP-ATP, ATP, and noncatalytic sites on initial and steady-state hydrolysis rates.	SCRIPPS RES INST, LA JOLLA, CA 92037 USA; UNIV CALIF LOS ANGELES, INST MOLEC BIOL, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, DEPT CHEM & BIOCHEM, LOS ANGELES, CA 90024 USA	Scripps Research Institute; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles					NIDDK NIH HHS [DK08126] Funding Source: Medline; NIGMS NIH HHS [GM11094] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK008126, R01DK008126] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM011094] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIDWAI AP, 1989, J BIOL CHEM, V264, P11790; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; BULYGIN VV, 1991, BIOCHEM J, V276, P149, DOI 10.1042/bj2760149; CROSS RL, 1982, J BIOL CHEM, V257, P2101; CUNNINGHAM D, 1988, J BIOL CHEM, V263, P18850; DROBINSKAYA IY, 1985, FEBS LETT, V182, P419, DOI 10.1016/0014-5793(85)80346-X; EBEL RE, 1975, J BIOL CHEM, V250, P191; FALLER LD, 1990, BIOCHEMISTRY-US, V29, P3179, DOI 10.1021/bi00465a004; FELDMAN RI, 1985, J BIOL CHEM, V260, P3088; GARRETT NE, 1975, J BIOL CHEM, V250, P6640; GLYNN IM, 1964, BIOCHEM J, V90, P147, DOI 10.1042/bj0900147; GRUBMEYER C, 1981, J BIOL CHEM, V256, P3728; GRUBMEYER C, 1982, J BIOL CHEM, V257, P2092; GRUBMEYER C, 1981, J BIOL CHEM, V256, P3718; HIRATSUKA T, 1973, BIOCHIM BIOPHYS ACTA, V320, P635, DOI 10.1016/0304-4165(73)90143-8; HIRATSUKA T, 1975, J BIOCHEM-TOKYO, V78, P1135, DOI 10.1093/oxfordjournals.jbchem.a131009; HISABORI T, 1992, J BIOL CHEM, V267, P4551; HUTTON RL, 1979, J BIOL CHEM, V254, P9990; JAULT JM, 1993, J BIOL CHEM, V268, P1558; KALASHNIKOVA TY, 1988, EUR J BIOCHEM, V177, P213, DOI 10.1111/j.1432-1033.1988.tb14364.x; KIRONDE FAS, 1986, J BIOL CHEM, V261, P2544; KNOWLES AF, 1972, J BIOL CHEM, V247, P6624; KORMER ZS, 1982, EUR J BIOCHEM, V121, P451, DOI 10.1111/j.1432-1033.1982.tb05808.x; KOZLOV IA, 1985, FEBS LETT, V182, P425, DOI 10.1016/0014-5793(85)80347-1; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MILGROM YM, 1993, J BIOL CHEM, V268, P23179; MILLS DA, 1991, J BIOL CHEM, V266, P7440; MURATALIEV MB, 1991, BIOCHEMISTRY-US, V30, P8305, DOI 10.1021/bi00098a004; MURATALIEV MB, 1992, BIOCHEMISTRY-US, V31, P12885, DOI 10.1021/bi00166a025; MURATALIEV MB, 1992, EUR J BIOCHEM, V209, P681, DOI 10.1111/j.1432-1033.1992.tb17336.x; MUSIER KM, 1988, BIOCHEMISTRY-US, V27, P7015, DOI 10.1021/bi00418a052; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; RAO R, 1988, J BIOL CHEM, V263, P5569; SHAPIRO AB, 1991, J BIOL CHEM, V266, P17276; SINES JJ, 1986, BIOCHEMISTRY-US, V25, P6144, DOI 10.1021/bi00368a047; TIEDGE H, 1986, BIOL CHEM H-S, V367, P689, DOI 10.1515/bchm3.1986.367.2.689; TURINA P, 1993, J BIOL CHEM, V268, P6978; VASILYEVA EA, 1982, BIOCHEM J, V202, P15, DOI 10.1042/bj2020015; VASILYEVA EA, 1982, BIOCHEM J, V202, P9, DOI 10.1042/bj2020009; VULFSON EN, 1986, BIOL MEMBRANY, V3, P339; WAGNER R, 1986, EUR J BIOCHEM, V161, P205, DOI 10.1111/j.1432-1033.1986.tb10143.x; WALKER JE, 1985, J MOL BIOL, V184, P677, DOI 10.1016/0022-2836(85)90313-4; WATANABE T, 1982, J BIOL CHEM, V257, P1510; WEBER J, 1993, J BIOL CHEM, V268, P20126; ZOU JM, 1993, J BIOL CHEM, V268, P1531	45	31	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15431	15439						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	8195184				2022-12-25	WOS:A1994NP51300009
J	OHTA, Y; SAKAKI, T; YABUSAKI, Y; OHKAWA, H; KAWATO, S				OHTA, Y; SAKAKI, T; YABUSAKI, Y; OHKAWA, H; KAWATO, S			ROTATION AND MEMBRANE TOPOLOGY OF GENETICALLY EXPRESSED METHYLCHOLANTHRENE-INDUCIBLE CYTOCHROME P-450IA1 LACKING THE N-TERMINAL HYDROPHOBIC SEGMENT IN YEAST MICROSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER CYTOCHROME-P-450; PROTEIN ROTATION; NADPH-CYTOCHROME-P450 REDUCTASE; SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; ADRENOCORTICAL MITOCHONDRIA; PHOSPHOLIPID-VESICLES; INNER MEMBRANE; FUSED ENZYME; PROTEOLIPOSOMES	A modified rat liver cytochrome P-450IA1, lacking amino acids 2-30, a proposed membrane anchor for cytochrome P-450, was expressed genetically in yeast microsomal membranes. This truncated cytochrome is practically active in the deethylation of 7-ethoxycoumarin. A full-length cytochrome P-450IA1 was also expressed in yeast microsomes. Rotational diffusion of P-450IA1 was examined by observing the flash-induced absorption anisotropy r(t) of the P-450.CO complex. The anisotropy decayed to a time-independent value within a 2-ms time range. Since the decay curve has the characteristics of a slow rotation of membrane-embedded cytochrome, the theoretical analysis of r(t) was performed based on a ''rotation-about-membrane normal'' model. 41% of the shortened P-450IA1 was rotating with the rotational relaxation time phi of 1020 mu s, whereas 27% of the full length P-450IA1 was mobile with phi = 1101 mu s. The high salt treatment did not remove the shortened cytochrome from the membrane and also did not drastically weaken the interactions of the cytochrome with the membrane, as judged from the slow rotation characteristics (phi = 830 mu s). These results demonstrate that the N-terminal shortened P-450IA1 is incorporated properly into the yeast microsomal membrane and that the N-terminal hydrophobic segment is not solely responsible for attachment to the membrane, providing evidence that additional segments of P-450IA1 are involved in the membrane binding	UNIV TOKYO,COLL ARTS & SCI,INST PHYS,MEGURO KU,TOKYO 153,JAPAN; SUMITOMO CHEM CO LTD,TAKARAZUKA RES CTR,BIOTECHNOL LAB,TAKARAZUKA,HYOGO 665,JAPAN	University of Tokyo; Sumitomo Chem Co Ltd			Ohta, Yoshihiro/C-8741-2013	Ohta, Yoshihiro/0000-0001-7416-0507				BROWN CA, 1989, J BIOL CHEM, V264, P4442; Cherry R J, 1978, Methods Enzymol, V54, P47; DELEMOSCHIARANDINI C, 1987, J CELL BIOL, V104, P209, DOI 10.1083/jcb.104.2.209; EDWARDS RJ, 1991, BIOCHEMISTRY-US, V30, P71, DOI 10.1021/bi00215a011; ESTABROOK RW, 1979, ACS SYM SER, V97, P149; ETTER HU, 1991, J BIOL CHEM, V266, P18600; Gotoh O., 1989, FRONTIERS BIOTRANSFO, V1, P195; GUENGERICH FP, 1987, MAMMALIAN CYTOCHROME, V2; GUT J, 1982, J BIOL CHEM, V257, P7030; GUT J, 1985, BIOCHIM BIOPHYS ACTA, V817, P217, DOI 10.1016/0005-2736(85)90023-9; GUT J, 1983, J BIOL CHEM, V258, P8588; HARADA N, 1981, J BIOCHEM-TOKYO, V89, P237, DOI 10.1093/oxfordjournals.jbchem.a133187; IWASE T, 1991, BIOCHEMISTRY-US, V30, P8347, DOI 10.1021/bi00098a010; KAWATO S, 1982, J BIOL CHEM, V257, P7023; KAWATO S, 1991, J BIOCHEM-TOKYO, V109, P587, DOI 10.1093/oxfordjournals.jbchem.a123424; KAWATO S, 1981, BIOPHYS J, V36, P277, DOI 10.1016/S0006-3495(81)84728-5; KAWATO S, 1988, J BIOCHEM-TOKYO, V104, P188, DOI 10.1093/oxfordjournals.jbchem.a122439; KAWATO S, 1981, J BIOL CHEM, V256, P7518; LARSON JR, 1991, J BIOL CHEM, V266, P7321; MONIER S, 1988, J CELL BIOL, V107, P457, DOI 10.1083/jcb.107.2.457; MURAKAMI H, 1987, DNA-J MOLEC CELL BIO, V6, P189, DOI 10.1089/dna.1987.6.189; MURAKAMI H, 1990, J BIOCHEM, V108, P859, DOI 10.1093/oxfordjournals.jbchem.a123293; NELSON DR, 1988, J BIOL CHEM, V263, P6038; OEDA K, 1985, DNA CELL BIOL, V4, P204; OHTA Y, 1992, BIOCHEMISTRY-US, V31, P12680, DOI 10.1021/bi00165a019; OHTA Y, 1991, J BIOCHEM-TOKYO, V109, P594, DOI 10.1093/oxfordjournals.jbchem.a123425; OHTA Y, 1990, J BIOCHEM-TOKYO, V107, P97, DOI 10.1093/oxfordjournals.jbchem.a123020; OMURA T, 1964, J BIOL CHEM, V239, P2370; SAKAKI T, 1987, DNA-J MOLEC CELL BIO, V6, P31, DOI 10.1089/dna.1987.6.31; SAKAKI T, 1985, J BIOCHEM-TOKYO, V98, P167, DOI 10.1093/oxfordjournals.jbchem.a135255; SHIMIZU T, 1991, J BIOL CHEM, V266, P3372; VERGERES G, 1989, BIOCHEMISTRY-US, V28, P3650, DOI 10.1021/bi00435a005; WHITE RE, 1980, ANNU REV BIOCHEM, V49, P315, DOI 10.1146/annurev.bi.49.070180.001531; YABUSAKI Y, 1988, DNA-J MOLEC CELL BIO, V7, P701, DOI 10.1089/dna.1988.7.701	34	20	20	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15597	15600						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	8195206				2022-12-25	WOS:A1994NP51300034
J	CARBONE, M; PASS, HI; RIZZO, P; MARINETTI, MR; DIMUZIO, M; MEW, DJY; LEVINE, AS; PROCOPIO, A				CARBONE, M; PASS, HI; RIZZO, P; MARINETTI, MR; DIMUZIO, M; MEW, DJY; LEVINE, AS; PROCOPIO, A			SIMIAN-VIRUS 40-LIKE DNA-SEQUENCES IN HUMAN PLEURAL MESOTHELIOMA	ONCOGENE			English	Article							T-DELETION MUTANTS; GROWTH FACTOR-I; MALIGNANT MESOTHELIOMA; PROTEIN PHOSPHATASE-2A; ASBESTOS EXPOSURE; MINERAL FIBERS; TUMOR-ANTIGEN; SV40; CELLS; MECHANISMS	Mesotheliomas are pleural, pericardial, or peritoneal neoplasms frequently associated with asbestos exposure, and it is estimated that over the next twenty years up to 80,000 new cases are expected in the USA alone. We found simian virus 40-like DNA sequences in 29 of 48 mesotheliomas studied (60%) and demonstrated simian virus large-T antigen expression in 13 of 16 specimens. The matching lung samples did not contain simian virus 40-like sequences; however, they contained asbestos. These findings are to our knowledge the first demonstration of a physical link between DNA viruslike sequences and human mesothelioma. We suggest that a simian virus 40-like virus may act independently or as a co-carcinogen with asbestos. Moreover, the selective large T antigen expression by mesothelioma and not by the surrounding pulmonary parenchyma may have both diagnostic and therapeutic implications.	NCI, SURG BRANCH, THORAC ONCOL SECT, BETHESDA, MD 20892 USA; UNIV G DANNUNZIO, FAC MED, IST PATOL UMANA & MED SOCIALE, FISIOPATOL MOLEC LAB, I-66013 CHIETI, ITALY	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); G d'Annunzio University of Chieti-Pescara	CARBONE, M (corresponding author), NICHHD, DNA REPLICAT REPAIR & MUTAGENESIS SECT, BLDG 6, ROOM 1A11, BETHESDA, MD 20892 USA.		Procopio, Antonio Domenico/AAB-2451-2021	Procopio, Antonio Domenico/0000-0001-6897-8724; Pass, Harvey/0000-0003-3222-3471; rizzo, paola/0000-0001-7174-9674				ANTMAN KH, 1993, CANC PRINCIPLES PRAC, P1489; APPEL JD, 1988, P NATL ACAD SCI USA, V85, P7670, DOI 10.1073/pnas.85.20.7670; BERGSAGEL DJ, 1992, NEW ENGL J MED, V326, P988, DOI 10.1056/NEJM199204093261504; BROWN P, 1975, AM J EPIDEMIOL, V93, P291; BROWN RC, 1990, MOL ASPECTS MED, V11, P325, DOI 10.1016/0098-2997(90)90002-J; BUCHMAN AR, 1981, DNA TUMOR VIRUSES 2, P799; CARBONE M, 1992, J VIROL, V66, P1804, DOI 10.1128/JVI.66.3.1804-1808.1992; CARBONE M, 1989, CANCER RES, V49, P1565; CHURG A, 1993, MODERN PATHOL, V6, P509; CICALA C, 1993, AM J PATHOL, V142, P1524; CICALA C, 1992, VIROLOGY, V190, P475, DOI 10.1016/0042-6822(92)91237-O; CICALA C, 1994, IN PRESS J VIROL; DIAMANDOPOULOS GT, 1972, SCIENCE, V176, P173, DOI 10.1126/science.176.4031.173; DOUGHERTY RM, 1976, J GEN VIROL, V33, P61, DOI 10.1099/0022-1317-33-1-61; Dubes G. R., 1993, Proceedings of the American Association for Cancer Research Annual Meeting, V34, P185; EDDY BE, 1961, P SOC EXP BIOL MED, V107, P191; EDDY BE, 1962, VIROLOGY, V17, P65, DOI 10.1016/0042-6822(62)90082-X; FANNING E, 1992, ANNU REV BIOCHEM, V61, P55; FISHER W, 1931, HDB SPEZIELLEN PATHO, V3, P509; FRAUMENI JF, 1963, JAMA-J AM MED ASSOC, V185, P713, DOI 10.1001/jama.1963.03060090045016; GERBER P, 1962, VIROLOGY, V18, P582, DOI 10.1016/0042-6822(62)90061-2; GERBER P, 1967, P SOC EXP BIOL MED, V125, P1284, DOI 10.3181/00379727-125-32336; HENDERSON DW, 1992, CANCER SERIES, P183; Henderson DW, 1992, MALIGNANT MESOTHELIO, P69; JAURAND MC, 1987, J NATL CANCER I, V79, P797; KE Y, 1989, AM J PATHOL, V134, P979; KOPROWSKI H, 1962, J CELL COMPAR PHYSL, V59, P281, DOI 10.1002/jcp.1030590308; LANPHEAR BP, 1992, J OCCUP ENVIRON MED, V34, P718; LEE TC, 1993, CANCER RES, V53, P2858; LEWIS AM, 1985, SCIENCE, V227, P15, DOI 10.1126/science.3843807; LEWIS AM, 1979, P NATL ACAD SCI USA, V76, P4299, DOI 10.1073/pnas.76.9.4299; LEWIS AM, 1973, BIOHAZARDS BIOL RES, P96; Mallory TB, 1947, NEW ENGL J MED, V236, P407; MARK EJ, 1991, ANN NY ACAD SCI, V643, P196, DOI 10.1111/j.1749-6632.1991.tb24463.x; MAYOL X, 1993, ONCOGENE, V8, P2561; MELNICK JL, 1962, P SOC EXP BIOL MED, V109, P965, DOI 10.3181/00379727-109-27392; MEW D, 1993, CONT ONCOLOGY, V3, P50; MORRIS JA, 1961, P SOC EXP BIOL MED, V108, P56, DOI 10.3181/00379727-108-26843; MORTIMER EA, 1981, NEW ENGL J MED, V305, P1517, DOI 10.1056/NEJM198112173052507; MOSSMAN BT, 1990, SCIENCE, V247, P294, DOI 10.1126/science.2153315; MUSCAT JE, 1991, CANCER RES, V51, P2263; PASS HI, 1993, CURR PROB SURG, V30, P925; PETERSON JT, 1984, CANCER, V54, P951, DOI 10.1002/1097-0142(19840901)54:5<951::AID-CNCR2820540536>3.0.CO;2-A; PORCU P, 1992, MOL CELL BIOL, V12, P5069, DOI 10.1128/MCB.12.11.5069; RABSON AS, 1962, J NATL CANCER I, V29, P1123; REDDEL RR, 1989, J NATL CANCER I, V81, P945, DOI 10.1093/jnci/81.12.945; RESNICOFF M, IN PRESS J CANCER RE; ROGGLI VL, 1992, PATHOLOGY ASBESTOS A, P383; ROGGLI VL, 1992, PATHOLOGY ASBESTOS A, P109; ROGGLI VL, 1992, CANC SERIES, P201; SCHEIDTMANN KH, 1991, MOL CELL BIOL, V11, P1996, DOI 10.1128/MCB.11.4.1996; SELIKOFF IJ, 1980, CANCER, V46, P2736, DOI 10.1002/1097-0142(19801215)46:12<2736::AID-CNCR2820461233>3.0.CO;2-L; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; SHAH K, 1976, AM J EPIDEMIOL, V103, P1; SHAH KV, 1972, J NATL CANCER I, V48, P557; SHAH KV, 1971, AM J EPIDEMIOL, V93, P291, DOI 10.1093/oxfordjournals.aje.a121260; SHEIN HM, 1962, P NATL ACAD SCI USA, V48, P1164, DOI 10.1073/pnas.48.7.1164; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; SORIANO F, 1974, NATURE, V249, P421, DOI 10.1038/249421a0; SWEET BH, 1960, P SOC EXP BIOL MED, V105, P420, DOI 10.3181/00379727-105-26128; Topp WC, 1981, DNA TUMOR VIRUSES 2, P205; WAGNER J C, 1960, Br J Ind Med, V17, P260; WALSH JW, 1982, NEUROSURGERY, V10, P643, DOI 10.1227/00006123-198205000-00018; Weissmann L B, 1989, Oncology (Williston Park), V3, P67; WEITZMAN SA, 1984, ARCH BIOCHEM BIOPHYS, V228, P373, DOI 10.1016/0003-9861(84)90078-X; Willis RA, 1938, J PATHOL BACTERIOL, V47, P35, DOI 10.1002/path.1700470105; YANG SI, 1991, MOL CELL BIOL, V11, P1988, DOI 10.1128/MCB.11.4.1988; YEUNG RS, 1993, ONCOGENE, V8, P3465	68	382	384	0	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1994	9	6					1781	1790						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NL815	8183577				2022-12-25	WOS:A1994NL81500034
J	DELGADO, MD; HALLIER, M; MENECEUR, P; TAVITIAN, A; MOREAUGACHELIN, F				DELGADO, MD; HALLIER, M; MENECEUR, P; TAVITIAN, A; MOREAUGACHELIN, F			INHIBITION OF FRIEND-CELLS PROLIFERATION BY SPI-1 ANTISENSE OLIGODEOXYNUCLEOTIDES	ONCOGENE			English	Note							ETS GENE FAMILY; VIRUS-INDUCED ERYTHROLEUKEMIA; PUTATIVE ONCOGENE SPI-1; WILD-TYPE P53; TRANSCRIPTION FACTOR; C-MYB; ERYTHROPOIETIN RECEPTOR; OLIGOMER COMPLEMENTARY; TUMORIGENIC CELLS; LEUKEMIA-VIRUS	The spi-1 proto-oncogene encodes the transcription factor PU.1 which is normally expressed in all hematopoietic cell lineages except in T cell lines. During the murine acute erythroleukemia induced by the Friend retrovirus, SFFV, spi-1 deregulation by insertional mutagenesis results in the overexpression of Spi-1/PU.1 in the malignant proerythroblastic cell. To assess the Spi-1 role in the proliferation and the differentiation arrest of the Friend tumor cells we inhibited spi-1 gene expression in two Friend cell lines by using antisense oligodeoxyribonucleotides. Proliferation and cloning efficiency of both cell lines were significantly inhibited by spi1 antisense. This antiproliferative effect was not related to an apparent maturation of erythroleukemic cells demonstrating that repression of spi-1 expression is not sufficient per se to restore the ability of the proerythroblastic cells to spontaneously differentiate in mature erythroblasts. These data suggest that the spi-1 gene would be involved in the Friend leukemic process by promoting the proerythroblast to proliferate.	FAC MED PARIS,INSERM,U248,F-75010 PARIS,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm)			Delgado, M. Dolores/K-9056-2014	Delgado, M. Dolores/0000-0003-4682-4040				ANFOSSI G, 1989, P NATL ACAD SCI USA, V86, P3379, DOI 10.1073/pnas.86.9.3379; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; CHU G, 1987, NUCLEIC ACIDS RES, V15, P1311, DOI 10.1093/nar/15.3.1311; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; FEINSTEIN E, 1992, ONCOGENE, V7, P1853; FRIEND C, 1971, P NATL ACAD SCI USA, V68, P378; GAUTHIER JM, 1993, EMBO J, V12, P5089, DOI 10.1002/j.1460-2075.1993.tb06203.x; GEWIRTZ AM, 1989, SCIENCE, V245, P180, DOI 10.1126/science.2665077; GEWIRTZ AM, 1988, SCIENCE, V242, P1303, DOI 10.1126/science.2461588; GOEBL MG, 1990, CELL, V61, P1165, DOI 10.1016/0092-8674(90)90676-6; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; HOWARD JC, 1993, ONCOGENE, V8, P2721; JAEGER JA, 1989, P NATL ACAD SCI USA, V86, P7706, DOI 10.1073/pnas.86.20.7706; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; LACHMAN HM, 1984, NATURE, V310, P592, DOI 10.1038/310592a0; LAUDET V, 1993, BIOCHEM BIOPH RES CO, V190, P8, DOI 10.1006/bbrc.1993.1002; LAUTENBERGER JA, 1992, ONCOGENE, V7, P1713; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LI JP, 1990, NATURE, V343, P762, DOI 10.1038/343762a0; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MAGER DL, 1981, P NATL ACAD SCI-BIOL, V78, P1703, DOI 10.1073/pnas.78.3.1703; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; MOREAUGACHELIN F, 1990, LEUKEMIA, V4, P20; MUNROE DG, 1990, MOL CELL BIOL, V10, P3307, DOI 10.1128/MCB.10.7.3307; NGUYEN HQ, 1993, CELL, V72, P197, DOI 10.1016/0092-8674(93)90660-I; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; PAUL R, 1991, J VIROL, V65, P464, DOI 10.1128/JVI.65.1.464-467.1991; PAUL R, 1989, J VIROL, V63, P4958, DOI 10.1128/JVI.63.11.4958-4961.1989; RAMSAY RG, 1986, P NATL ACAD SCI USA, V83, P6849, DOI 10.1073/pnas.83.18.6849; RAY D, 1992, MOL CELL BIOL, V12, P4297, DOI 10.1128/MCB.12.10.4297; SCHUETZE S, 1993, MOL CELL BIOL, V13, P5670, DOI 10.1128/MCB.13.9.5670; SETH A, 1992, CELL GROWTH DIFFER, V3, P327; SHEN DW, 1983, P NATL ACAD SCI-BIOL, V80, P5919, DOI 10.1073/pnas.80.19.5919; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TAKESHITA K, 1993, P NATL ACAD SCI USA, V90, P3535, DOI 10.1073/pnas.90.8.3535; WANG YL, 1993, J VIROL, V67, P1322, DOI 10.1128/JVI.67.3.1322-1327.1993; WENDLING F, 1981, P NATL ACAD SCI-BIOL, V78, P3614, DOI 10.1073/pnas.78.6.3614; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	43	45	45	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1994	9	6					1723	1727						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NL815	8183568				2022-12-25	WOS:A1994NL81500025
J	FENG, GS; SHEN, R; HENG, HHQ; TSUI, LC; KAZLAUSKAS, A; PAWSON, T				FENG, GS; SHEN, R; HENG, HHQ; TSUI, LC; KAZLAUSKAS, A; PAWSON, T			RECEPTOR-BINDING, TYROSINE PHOSPHORYLATION AND CHROMOSOME LOCALIZATION OF THE MOUSE SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE SYP	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; HEMATOPOIETIC-CELL PHOSPHATASE; SRC HOMOLOGY-2 DOMAINS; PHOSPHOLIPASE-C-GAMMA; PDGF BETA-RECEPTOR; MOTH-EATEN MICE; SH2 DOMAIN; AUTOPHOSPHORYLATION SITES; SEQUENCE SIMILARITY; SIGNAL TRANSDUCTION	The murine phosphotyrosine phosphatase, Syp, is a widely-expressed cytoplasmic enzyme that contains two SH2 domains. Syp is physically associated with activated receptors for epidermal growth factor (EGF) and platelet-derived growth factor (PDGF), apparently through its SH2 domains. This phosphatase is rapidly phosphorylated in cells treated with PDGF or EGF, and is constitutively phosphorylated in v-src transformed cells. Here we report that either the N-terminal or C-terminal Syp SH2 domain alone bound to the activated beta PDGF receptor or EGF-receptor in vitro, and that the two SH2 domains linked together exhibited synergistic binding. Substitution of the Tyr1009 autophosphorylation site in the C-terminal tail of activated beta PDGFR with Phe abolished the in vitro binding of either SH2 domain to the activated receptor. A 9 amino acid phosphopeptide corresponding to the Tyr1009 autophosphorylation site of the beta PDGFR inhibited association of the Syp SH2 domains with the receptor. These results indicate that the Syp SH2 domains have an intrinsic specificity for the Tyr1009 autophosphorylation site of the beta PDGFR that dictates binding of the intact Syp phosphatase, and suggest that both SH2 domains have a related binding specificity. Phosphoamino acid analysis of Syp from PDGF-stimulated cells indicated that PDGF primarily induces Syp phosphorylation on tyrosine residues. The mouse Syp gene has been mapped to chromosome 5F region by the fluorescence in situ hybridization. These findings suggest specific functions for Syp in signal transduction downstream of receptor tyrosine kinases.	MT SINAI HOSP, SAMUEL LUNENFELD RES INST, DIV MOLEC & DEV BIOL, TORONTO M5G 1X5, ON, CANADA; UNIV TORONTO, DEPT MOLEC & MED GENET, TORONTO, ON, CANADA; HOSP SICK CHILDREN, DEPT GENET, TORONTO M5G 1X8, ON, CANADA; NATL JEWISH CTR IMMUNOL & RESP MED, DENVER, CO 80206 USA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); National Jewish Health			Pawson, Tony J/E-4578-2013; Tsui, Lap-chee/A-1081-2010					ADACHI M, 1992, FEBS LETT, V314, P335, DOI 10.1016/0014-5793(92)81500-L; AHMAD S, 1993, P NATL ACAD SCI USA, V90, P2197, DOI 10.1073/pnas.90.6.2197; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; GREEN MC, 1975, J HERED, V66, P250, DOI 10.1093/oxfordjournals.jhered.a108625; HENG HHQ, 1993, CHROMOSOMA, V102, P325, DOI 10.1007/BF00661275; HENG HHQ, 1992, P NATL ACAD SCI USA, V89, P9509, DOI 10.1073/pnas.89.20.9509; HENG HHQ, 1994, IN PRESS METHODS MOL; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOZLOWSKI M, 1993, J EXP MED, V178, P2157, DOI 10.1084/jem.178.6.2157; LAROSE L, 1993, ONCOGENE, V8, P2493; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P13434; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; RONNSTRAND L, 1992, EMBO J, V11, P3911, DOI 10.1002/j.1460-2075.1992.tb05484.x; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; Sambrook J, 1989, MOL CLONING LABORATO; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; Shultz L D, 1991, Semin Immunol, V3, P397; SHULTZ LD, 1984, AM J PATHOL, V116, P179; SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092-8674(93)90369-2; TSUI HW, 1993, NAT GENET, V4, P124, DOI 10.1038/ng0693-124; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VALIUS M, 1993, MOL CELL BIOL, V13, P133, DOI 10.1128/MCB.13.1.133; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; YEUNG YG, 1992, J BIOL CHEM, V267, P23447; YI TL, 1992, MOL CELL BIOL, V12, P836, DOI 10.1128/MCB.12.2.836; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; YI TL, 1993, MOL CELL BIOL, V13, P3350, DOI 10.1128/MCB.13.6.3350; ZHAO ZH, 1993, P NATL ACAD SCI USA, V90, P4251, DOI 10.1073/pnas.90.9.4251; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	43	71	71	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1994	9	6					1545	1550						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NL815	8183548				2022-12-25	WOS:A1994NL81500004
J	WONG, WT; KRAUS, MH; CARLOMAGNO, F; ZELANO, A; DRUCK, T; CROCE, CM; HUEBNER, K; DIFIORE, PP				WONG, WT; KRAUS, MH; CARLOMAGNO, F; ZELANO, A; DRUCK, T; CROCE, CM; HUEBNER, K; DIFIORE, PP			THE HUMAN EPS15 GENE, ENCODING A TYROSINE KINASE SUBSTRATE, IS CONSERVED IN EVOLUTION AND MAPS TO 1P31-P-32	ONCOGENE			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; FACTOR RECEPTOR KINASE; GROWTH-FACTOR; SIGNAL-TRANSDUCTION; ADAPTER PROTEIN; SH3 DOMAINS; RAS; GRB2; CLONING; SOS	Employing an expression cloning approach for tyrosine kinase substrates, we have previously isolated the coding sequence for a novel putative EGFR substrate, eps15, from NIH3T3 fibroblasts. Eps15 displayed a receptor-specific pattern of tyrosine phosphorylation in vivo and was able to transform NIH3T3 cells upon overexpression. To gain understanding of eps15 function as well as its role in normal and neoplastic proliferation, we cloned the human eps15 coding sequence and studied expression of the human RNA and protein, evolutionary conservation, and chromosomal location. The close structural similarity of human eps15 with the murine homologue is indicated by 89% and 90% identity of nucleotide and predicted amino acid sequences, respectively. Using the human eps15 coding sequence as probe, we demonstrate that eps15 is member of a gene family that is highly conserved during evolution. An essential function of eps15 in cell growth regulation is underscored by our observation of ubiquitous expression at the transcript and the protein level in normal and malignant human cells. The human EPS15 locus maps to chromosome 1p31-p32, a region involved in deletion in neuroblastoma, translocations in acute lymphoblastic leukemia, and exhibiting a fragile site.	NCI, CELLULAR & MOLEC BIOL LAB, BETHESDA, MD 20892 USA; THOMAS JEFFERSON UNIV, JEFFERSON MED COLL, JEFFERSON INST MOLEC MED, PHILADELPHIA, PA 19107 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Jefferson University			Di Fiore, Pier Paolo/K-2130-2012; Young, Richard A/F-6495-2012	Di Fiore, Pier Paolo/0000-0002-2252-0950; Young, Richard A/0000-0001-8855-8647	NCI NIH HHS [CA51083] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA051083] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; BRUNS GA, 1993, CHROMOSOME COORDINAT, V1, P143; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CIMINO G, 1991, CANCER RES, V51, P6712; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FAZIOLI F, 1993, EMBO J, V12, P3799, DOI 10.1002/j.1460-2075.1993.tb06058.x; FAZIOLI F, 1993, MOL CELL BIOL, V13, P5814, DOI 10.1128/MCB.13.9.5814; FAZIOLI F, 1993, ONCOGENE, V8, P1335; FAZIOLI F, 1992, J BIOL CHEM, V267, P5155; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; GLENNEY JR, 1991, METHOD ENZYMOL, V196, P65; HALUSKA FG, 1988, P NATL ACAD SCI USA, V85, P2215, DOI 10.1073/pnas.85.7.2215; HAN M, 1993, NATURE, V363, P133, DOI 10.1038/363133a0; HORVITZ HR, 1991, NATURE, V351, P535, DOI 10.1038/351535a0; HUEBNER K, 1991, AM J HUM GENET, V48, P726; KANNER SB, 1989, J IMMUNOL METHODS, V120, P115, DOI 10.1016/0022-1759(89)90296-2; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; Katz Wendy S., 1992, Current Opinion in Cell Biology, V4, P939, DOI 10.1016/0955-0674(92)90122-S; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KRAUS MH, 1991, METHOD ENZYMOL, V200, P546; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; LI N, 1993, NATURE, V363, P86; LINNENBACH AJ, 1993, MOL CELL BIOL, V13, P1507, DOI 10.1128/MCB.13.3.1507; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MAKELA TP, 1991, MOL CELL BIOL, V11, P4015; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; MITELMAN F, 1993, CHROMOSOME COORDINAT, V1, P700; MONTMINY M, 1993, SCIENCE, V261, P1694, DOI 10.1126/science.8397444; MORRIS SW, 1993, GENOMICS, V15, P677, DOI 10.1006/geno.1993.1124; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PARTANEN J, 1992, MOL CELL BIOL, V12, P1698, DOI 10.1128/MCB.12.4.1698; ROBERTS TM, 1992, NATURE, V360, P534, DOI 10.1038/360534a0; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; RUFF JS, 1993, SCIENCE, V261, P1733; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SHILO BZ, 1992, FASEB J, V6, P2915, DOI 10.1096/fasebj.6.11.1322852; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; TWEARDY DJ, 1992, BLOOD, V79, P1148, DOI 10.1182/blood.V79.5.1148.bloodjournal7951148; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6	49	45	47	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1994	9	6					1591	1597						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NL815	8183552				2022-12-25	WOS:A1994NL81500009
J	NAKANISHI, H; KAIBUCHI, K; ORITA, S; UENO, N; TAKAI, Y				NAKANISHI, H; KAIBUCHI, K; ORITA, S; UENO, N; TAKAI, Y			DIFFERENT FUNCTIONS OF SMG GDP DISSOCIATION STIMULATOR AND MAMMALIAN COUNTERPART OF YEAST CDC25	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-RELEASING FACTOR; GTP-BINDING PROTEINS; GDP/GTP EXCHANGE PROTEIN; RAS P21; SACCHAROMYCES-CEREVISIAE; MOLECULAR-CLONING; CYCLASE PATHWAY; TYROSINE KINASE; TERMINAL REGION; GRB2	We have previously shown that both Smg GDP dissociation stimulator (GDS) and mammalian Cdc25 (mCdc25) stimulate the GDP/GTP exchange reaction of Ki-Ras and that Smg GDS is active only on the posttranslationally lipid-modified form of Ki-Ras, whereas mCdc25 is active on both the lipid modified and unmodified forms but is more active on the lipid-modified form. In the present study, we compared more detailed kinetic properties of Smg GDS and mCdc25 by use of the lipid-modified form of Ki-Ras as a common substrate. Both Smg GDS and mCdc25 stimulated the dissociation of GDP from Ki-Ras and formed the stable binary complex with Ki-Ras. In the presence of guanosine 5'-(3-O-thio) triphosphate (GTP gamma S), the stable ternary complex of Smg GDS GTP gamma S-Ki-Ras was produced, whereas GTP gamma S induced the dissociation of mCdc25 from mCdc25-Ki-Ras complex, yielding GTP gamma S-Ki-Ras. mCdc25 stimulated the dissociation of GDP from both the membrane bound and soluble forms of Ki-Ras, whereas Sng GDS was far less active on the membrane-bound form than on the soluble form. Moreover, Smg GDS translocated the GTP gamma S-bound form of membrane bound Ki-Ras to the soluble fraction as the stable ternary complex of Smg GDS-GTP gamma S-Ki-Ras, whereas mCdc25 did not show this activity. These results suggest that Smg GDS and mCdc25 play different roles in the regulation of Ki-Ras.	OSAKA UNIV,SCH MED,DEPT MOLEC BIOL & BIOCHEM,SUITA,OSAKA 565,JAPAN; KOBE UNIV,SCH MED,DEPT BIOCHEM,KOBE 650,JAPAN; NATL INST PHYSIOL SCI,DEPT CELL PHYSIOL,OKAZAKI 444,AICHI,JAPAN; SHIONOGI INST MED SCI,SETTSU 566,JAPAN	Osaka University; Kobe University; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS); Shionogi & Company Limited				Nakanishi, Hiroyuki/0000-0002-9765-0266				BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROEK D, 1987, CELL, V48, P789, DOI 10.1016/0092-8674(87)90076-6; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HIROYOSHI M, 1991, J BIOL CHEM, V266, P2962; ITOH T, 1993, P NATL ACAD SCI USA, V90, P975, DOI 10.1073/pnas.90.3.975; ITOH T, 1993, J BIOL CHEM, V268, P3025; JACKSON JH, 1990, P NATL ACAD SCI USA, V87, P3042, DOI 10.1073/pnas.87.8.3042; KAIBUCHI K, 1991, MOL CELL BIOL, V11, P2873, DOI 10.1128/MCB.11.5.2873; KAWAMURA M, 1993, BIOCHEM BIOPH RES CO, V190, P832, DOI 10.1006/bbrc.1993.1124; KAWAMURA S, 1991, BIOCHEM BIOPH RES CO, V174, P1095, DOI 10.1016/0006-291X(91)91533-I; KAWATA M, 1990, P NATL ACAD SCI USA, V87, P8960, DOI 10.1073/pnas.87.22.8960; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; MARTEGANI E, 1992, EMBO J, V11, P2151, DOI 10.1002/j.1460-2075.1992.tb05274.x; MIZUNO T, 1991, P NATL ACAD SCI USA, V88, P6442, DOI 10.1073/pnas.88.15.6442; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; ORITA S, 1993, J BIOL CHEM, V268, P25542; ROBINSON LC, 1987, SCIENCE, V235, P1218, DOI 10.1126/science.3547648; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; Steck T L, 1974, Methods Enzymol, V31, P172; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9; YAMAMOTO T, 1990, J BIOL CHEM, V265, P16626; YOSHIDA K, 1988, CANCER RES, V48, P5503; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	36	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					15085	15091						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195145				2022-12-25	WOS:A1994NP73800038
J	PERREGAUX, D; GABEL, CA				PERREGAUX, D; GABEL, CA			INTERLEUKIN-1-BETA MATURATION AND RELEASE IN RESPONSE TO ATP AND NIGERICIN - EVIDENCE THAT POTASSIUM-DEPLETION MEDIATED BY THESE AGENTS IS A NECESSARY AND COMMON FEATURE OF THEIR ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR ATP; MOUSE MACROPHAGES; PRECURSOR INTERLEUKIN-1-BETA; SACCHAROMYCES-CEREVISIAE; BIOLOGICAL-ACTIVITY; PLASMA-MEMBRANES; LEADER PEPTIDE; IL-1-BETA; SECRETION; MONOCYTES	Lipopolysaccharide (LPS)-stimulated mouse peritoneal macrophages produce large quantities of interleukin (IL)-1 beta but in the absence of a secondary stimulus little of this cytokine is proteolytically processed to its mature biologically active state and externalized. The potassium-proton ionophore nigericin and ATP are known to promote the maturation and release of IL-1 beta from LPS-stimulated cells. We investigated the mechanisms by which these agents act in an attempt to understand requirements of the post-translational processing. Like nigericin, the ionophores A204 and lasalocid induced the release and maturation of IL-1 beta. The electrogenic potassium ionophore valinomycin, however, did not stimulate these post-translational events. Addition of nigericin or lasalocid to LPS-stimulated cells produced a rapid intracellular acidification; A204, however, did not alter pH, indicating that an acidification was not necessary for activation of IL-1 beta maturation. Macrophages treated with ATP became rounded and swollen, and after 30 min of treatment their appearance was comparable with cells treated with nigericin. Post-translational maturation and release of IL-1 beta began immediately after ATP addition. The majority of the 17-kDa mature IL-1 beta produced within the first 30 min of treatment was recovered extracellularly; in contrast, during this same time period the 35-kDa IL-1 beta precursor and the cytoplasmic marker enzyme lactate dehydrogenase and the lysosomal enzyme beta-N-acetylglucosaminidase remained cell-associated. ATP, therefore, promoted both the proteolytic maturation of IL-1 beta and the release of the biologically active species in the absence of cell lysis. Longer incubations with ATP caused cytolysis as judged by the release of the cytoplasmic enzymes. ADP was less active than ATP at initiating the post-translational maturation and release of IL-1 beta and AMP, GTP, and UTP were totally inactive. ATP, nigericin, A204, and lasalocid promoted a rapid and complete loss of the potassium analog Rb-86(+) from cells,that were preloaded with this cation; valinomycin-treated cells released only a portion of the radiolabeled cation. Agents that promoted the maturation and release of IL-1 beta from LPS-stimulated macrophages, therefore, shared an ability to mobilize intracellular potassium. Macrophages treated with ATP or nigericin in medium that contained KCl rather than NaCl failed to proteolytically activate and to release IL-1 beta. These data suggest that ATP and nigericin induce a net decrease in intracellular levels of K+ which is necessary for activation of the post-translational maturation of IL-1 beta.	PFIZER INC, DIV CENT RES, DEPT IMMUNOL & INFECT DIS, GROTON, CT 06340 USA	Pfizer								AURON PE, 1984, P NATL ACAD SCI-BIOL, V81, P7907, DOI 10.1073/pnas.81.24.7907; BALDARI C, 1987, EMBO J, V6, P229, DOI 10.1002/j.1460-2075.1987.tb04743.x; BALDARI CT, 1989, J IMMUNOL, V142, P785; BEUSCHER HU, 1990, J IMMUNOL, V144, P2179; BEYER EC, 1991, J BIOL CHEM, V266, P7971; BLACK RA, 1989, FEBS LETT, V247, P386, DOI 10.1016/0014-5793(89)81376-6; BUISMAN HP, 1988, P NATL ACAD SCI USA, V85, P7988, DOI 10.1073/pnas.85.21.7988; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; CHIN J, 1993, J IMMUNOL, V151, P5574; DINARELLO CA, 1991, BLOOD, V77, P1627; DINARELLO CA, 1984, REV INFECT DIS, V6, P51, DOI 10.1016/S1359-6101(97)00023-3; DUBYAK GR, 1993, AM J PHYSIOL, V265, pC577, DOI 10.1152/ajpcell.1993.265.3.C577; ELMOATASSIM C, 1992, BIOCHIM BIOPHYS ACTA, V1134, P31, DOI 10.1016/0167-4889(92)90025-7; GIRI JG, 1985, J IMMUNOL, V134, P343; GORDON JL, 1986, BIOCHEM J, V233, P309, DOI 10.1042/bj2330309; GRAY PW, 1986, J IMMUNOL, V137, P3644; GRINSTEIN S, 1989, METHOD ENZYMOL, V173, P777; Hall C W, 1978, Methods Enzymol, V50, P439; HARA N, 1990, COMP BIOCHEM PHYS A, V97, P417, DOI 10.1016/0300-9629(90)90633-4; HARA N, 1990, FEBS LETT, V267, P281, DOI 10.1016/0014-5793(90)80945-F; HAZUDA DJ, 1991, J BIOL CHEM, V266, P7081; HAZUDA DJ, 1990, J BIOL CHEM, V265, P6318; HOGQUIST KA, 1991, J IMMUNOL, V147, P2181; HOGQUIST KA, 1991, P NATL ACAD SCI USA, V88, P8485, DOI 10.1073/pnas.88.19.8485; HOWARD AD, 1991, J IMMUNOL, V147, P2964; JOBLING SA, 1988, J BIOL CHEM, V263, P16372; KOSTURA MJ, 1989, P NATL ACAD SCI USA, V86, P5227, DOI 10.1073/pnas.86.14.5227; LIVI GP, 1991, J BIOL CHEM, V266, P15348; LOMEDICO PT, 1984, NATURE, V312, P458, DOI 10.1038/312458a0; MARCH CJ, 1985, NATURE, V315, P641, DOI 10.1038/315641a0; MATSUSHIMA K, 1986, J IMMUNOL, V136, P2883; MIZUTANI H, 1991, J EXP MED, V174, P821, DOI 10.1084/jem.174.4.821; MOSLEY B, 1987, J BIOL CHEM, V262, P2941; PERREGAUX D, 1992, J IMMUNOL, V149, P1294; PRESSMAN BC, 1976, ANNU REV BIOCHEM, V45, P501, DOI 10.1146/annurev.bi.45.070176.002441; Reed P W, 1979, Methods Enzymol, V55, P435; RUBARTELLI A, 1990, EMBO J, V9, P1503, DOI 10.1002/j.1460-2075.1990.tb08268.x; SIDERS WM, 1993, J BIOL CHEM, V268, P22170; SINGER II, 1988, J EXP MED, V167, P389, DOI 10.1084/jem.167.2.389; SOUTHWICK FS, 1982, BIOCHEMISTRY-US, V21, P6321, DOI 10.1021/bi00267a043; STEINBERG TH, 1987, J BIOL CHEM, V262, P3118; STEINBERG TH, 1987, J BIOL CHEM, V262, P8884; SUNG SSJ, 1985, J BIOL CHEM, V260, P3442; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; YOUNG PR, 1988, J CELL BIOL, V107, P447, DOI 10.1083/jcb.107.2.447	45	583	592	0	35	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					15195	15203						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195155				2022-12-25	WOS:A1994NP73800052
J	SHIROTANI, K; TAYLORPAPADIMITRIOU, J; GENDLER, SJ; IRIMURA, T				SHIROTANI, K; TAYLORPAPADIMITRIOU, J; GENDLER, SJ; IRIMURA, T			TRANSCRIPTIONAL REGULATION OF THE MUC1 MUCIN GENE IN COLON-CARCINOMA CELLS BY A SOLUBLE FACTOR - IDENTIFICATION OF A REGULATORY ELEMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODY; BREAST-CANCER; CORE PROTEIN; EXPRESSION; GLYCOPROTEINS; TISSUES; ANTIGEN	We have investigated a mechanism of the regulation of mucin core polypeptide (MUC1) gene expression, which is induced by a soluble stimulatory factor, in KM12C human colon carcinoma cells. Conditioned media from normal human colon tissues elevated the level of expression of MUC1 mRNA. Transcriptional activation of the MUC1 gene was analyzed by transient expression of MUC1-CAT reporter plasmids containing the 5'-flanking sequence of the MUC1 gene fused to the bacterial chloramphenicol acetyltransferase (CAT) gene. A region between base pairs -531 and -520 of the 5'-flanking sequence of the MUC1 gene was sufficient for the induction of CAT activity by normal colon conditioned medium (NCCM). Mutagenesis of 3 base pairs within the region corresponding to sequence -531 to -517 from ACAGGGAGCGGTTAG to ACAGGGAGATTTTAG substantially decreased the induction of CAT activity by NCCM. Nuclear extracts from untreated or NCCM-treated KM12C cells were tested for their interaction with P-32-labeled oligonucleotides corresponding to this sequence. A specifically retarded band was identified after electrophoretic analysis. The quantity or mobility of this band was not changed by NCCM treatment. When an oligonucleotide with the three point mutations was used as a competitor, the retarded band remained at the same position. This element (positions -531 to -520), which we call the responsive mucin element, does not contain any sequence that corresponds to previously described cis-acting elements. A protein component complexed with this sequence was identified with a molecular mass of similar to 70 kDa by SDS-polyacrylamide gel electrophoresis.	UNIV TOKYO, FAC PHARMACEUT SCI, DIV CHEM TOXICOL & IMMUNOCHEM, BUNKYO KU, TOKYO 113, JAPAN; IMPERIAL CANC RES FUND, LONDON WC2A 3PX, ENGLAND; MAYO CLIN SCOTTSDALE, SCOTTSDALE, AZ 85259 USA	University of Tokyo; Cancer Research UK; Mayo Clinic; Mayo Clinic Phoenix								ABE M, 1993, P NATL ACAD SCI USA, V90, P282, DOI 10.1073/pnas.90.1.282; ABE M, 1990, J CELL PHYSIOL, V143, P226, DOI 10.1002/jcp.1041430205; BAECKSTROM D, 1993, CANCER RES, V53, P755; BURCHELL J, 1983, J IMMUNOL, V131, P508; BURCHELL J, 1987, CANCER RES, V47, P5476; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOHI DF, 1993, J BIOL CHEM, V268, P10133; GIRLING A, 1989, INT J CANCER, V43, P1072, DOI 10.1002/ijc.2910430620; HO SB, 1993, CANCER RES, V53, P641; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; IRIMURA T, 1990, CANCER RES, V50, P3331; KOVARIK A, 1993, J BIOL CHEM, V268, P9917; LANDCASTER CA, 1990, BIOCHEM BIOPH RES CO, V173, P1019; LIGTENBERG MJL, 1992, CANCER RES, V52, P2318; NAKAMORI S, 1994, GASTROENTEROLOGY, V106, P353, DOI 10.1016/0016-5085(94)90592-4; PEAT N, 1992, CANCER RES, V52, P1954; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOJAR HT, 1987, METHOD ENZYMOL, V138, P341; ZARETSKY JZ, 1990, FEBS LETT, V265, P46, DOI 10.1016/0014-5793(90)80880-R; ZOTTER S, 1987, LAB INVEST, V57, P193	22	28	28	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					15030	15035						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195140				2022-12-25	WOS:A1994NP73800031
J	ZWOLLO, P; DESIDERIO, S				ZWOLLO, P; DESIDERIO, S			SPECIFIC RECOGNITION OF THE BLK PROMOTER BY THE B-LYMPHOID TRANSCRIPTION FACTOR B-CELL-SPECIFIC ACTIVATOR PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIGEN RECEPTOR COMPLEX; TYROSINE KINASE GENE; IG-BETA COMPONENTS; LYMPHOCYTES-B; MEMBRANE IMMUNOGLOBULIN; MOLECULAR-COMPONENTS; WAARDENBURG SYNDROME; PAIRED DOMAIN; FACTOR BSAP; ASSOCIATION	Several genes of the src family encode protein-tyrosine kinases that associate with the B-cell antigen receptor complex and are activated upon receptor cross-linking, including blk, lyn, and fyn. The blk gene is the only member of this family whose expression is restricted to B-lymphhoid cells. In the B lineage, blk is developmentally regulated: blk transcripts are first detected in pro-B-cells and persist until the differentiation of mature B-cells to plasma cells. We have found that the blk promoter is a target for a specific DNA-binding protein whose activity in B-lymphoid cell lines is positively correlated with blk expression. By three criteria, we have identified this DNA-binding protein as the transcription factor B-cell-specific activator protein (BSAP): 1) oligonucleotides containing known BSAP recognition sites were found to compete specifically with blk for binding to the protein detected in B-lymphoid extracts; 2) authentic BSAP was shown to bind the same site within the blk promoter as the protein identified in B-lymphoid extracts; and 3) the specific DNA-protein complex formed in B-lymphoid extracts was shown to react with an anti-BSAP antiserum. BSAP has been implicated previously in the transcriptional regulation of CD19, whose pattern of expression in B-cell development coincides with that of blk. These observations, and the correlation between expression of BSAP and expression of blk, suggest that BSAP is a positive regulator of blk transcription.	JOHNS HOPKINS UNIV,SCH MED,DEPT MOLEC BIOL & GENET,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,BALTIMORE,MD 21205	Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University					NATIONAL CANCER INSTITUTE [P01CA016519] Funding Source: NIH RePORTER; NCI NIH HHS [CA16519] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS B, 1992, GENE DEV, V6, P1589, DOI 10.1101/gad.6.9.1589; ALESSANDRINI A, 1991, MOL CELL BIOL, V11, P2096, DOI 10.1128/MCB.11.4.2096; BALDWIN CT, 1992, NATURE, V355, P637, DOI 10.1038/355637a0; BARBERIS A, 1990, GENE DEV, V4, P849, DOI 10.1101/gad.4.5.849; BENOIST C, 1990, ANNU REV IMMUNOL, V8, P681, DOI 10.1146/annurev.immunol.8.1.681; BRUNSWICK M, 1991, P NATL ACAD SCI USA, V88, P1311, DOI 10.1073/pnas.88.4.1311; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; CAMPBELL KS, 1990, EMBO J, V9, P441, DOI 10.1002/j.1460-2075.1990.tb08129.x; CAMPBELL MA, 1992, MOL CELL BIOL, V12, P2315, DOI 10.1128/MCB.12.5.2315; CARTER RH, 1992, SCIENCE, V256, P105, DOI 10.1126/science.1373518; CARTER RH, 1991, P NATL ACAD SCI USA, V88, P2745, DOI 10.1073/pnas.88.7.2745; CLARK MR, 1992, SCIENCE, V258, P123, DOI 10.1126/science.1439759; CZERNY T, 1993, GENE DEV, V7, P2048, DOI 10.1101/gad.7.10.2048; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DYMECKI SM, 1992, J BIOL CHEM, V267, P4815; DYMECKI SM, 1990, SCIENCE, V247, P332, DOI 10.1126/science.2404338; FELDHAUS AL, 1992, MOL CELL BIOL, V12, P1126, DOI 10.1128/MCB.12.3.1126; GOLD MR, 1990, NATURE, V345, P810, DOI 10.1038/345810a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GROSSCHEDL R, 1985, CELL, V41, P885, DOI 10.1016/S0092-8674(85)80069-6; HAGMAN J, 1991, EMBO J, V10, P3409, DOI 10.1002/j.1460-2075.1991.tb04905.x; HAGMAN J, 1993, GENE DEV, V7, P760, DOI 10.1101/gad.7.5.760; Hill Robert E., 1992, Current Opinion in Cell Biology, V4, P967, DOI 10.1016/0955-0674(92)90126-W; HOMBACH J, 1990, NATURE, V343, P760, DOI 10.1038/343760a0; HOMBACH J, 1990, EUR J IMMUNOL, V20, P2795, DOI 10.1002/eji.1830201239; HUTCHCROFT JE, 1992, J BIOL CHEM, V267, P8613; HUTCHCROFT JE, 1991, J BIOL CHEM, V266, P14846; JORDAN T, 1992, NAT GENET, V1, P328, DOI 10.1038/ng0892-328; KASHIWAMURA SI, 1990, J IMMUNOL, V145, P337; KIM KM, 1993, EUR J IMMUNOL, V23, P911, DOI 10.1002/eji.1830230422; KOZMIK Z, 1992, MOL CELL BIOL, V12, P2662, DOI 10.1128/MCB.12.6.2662; LIAO F, 1992, J IMMUNOL, V148, P2909; NEL AE, 1984, BIOCHEM BIOPH RES CO, V125, P859, DOI 10.1016/0006-291X(84)91362-7; SAKAGUCHI N, 1988, EMBO J, V7, P3457, DOI 10.1002/j.1460-2075.1988.tb03220.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STAMENKOVIC I, 1988, J EXP MED, V168, P1205, DOI 10.1084/jem.168.3.1205; STAUDT LM, 1991, ANNU REV IMMUNOL, V9, P373; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; TASSABEHJI M, 1992, NATURE, V355, P635, DOI 10.1038/355635a0; TEDDER TF, 1989, J IMMUNOL, V143, P712; TON CCT, 1991, CELL, V67, P1059, DOI 10.1016/0092-8674(91)90284-6; TRAVIS A, 1991, MOL CELL BIOL, V11, P5756, DOI 10.1128/MCB.11.11.5756; WANG MM, 1993, NATURE, V364, P121, DOI 10.1038/364121a0; WIENANDS J, 1990, EMBO J, V9, P449, DOI 10.1002/j.1460-2075.1990.tb08130.x; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; YAMANASHI Y, 1992, P NATL ACAD SCI USA, V89, P1118, DOI 10.1073/pnas.89.3.1118	46	64	66	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					15310	15317						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195169				2022-12-25	WOS:A1994NP73800068
J	BUTT, E; ABEL, K; KRIEGER, M; PALM, D; HOPPE, V; HOPPE, J; WALTER, U				BUTT, E; ABEL, K; KRIEGER, M; PALM, D; HOPPE, V; HOPPE, J; WALTER, U			CAMP-DEPENDENT AND CGMP-DEPENDENT PROTEIN-KINASE PHOSPHORYLATION SITES OF THE FOCAL ADHESION VASODILATOR-STIMULATED PHOSPHOPROTEIN (VASP) IN-VITRO AND IN INTACT HUMAN PLATELETS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-AMP; REGULATED PHOSPHOPROTEIN; SUBSTRATE-SPECIFICITY; RABBIT CEREBELLUM; CELL-EXTRACTS; INHIBITION; SEQUENCES; ACTIVATOR; DARPP-32	The vasodilator-stimulated phosphoprotein (VASP) is a major substrate for cAMP-dependent- (cAK) and cGMP-dependent protein kinase (cGK) in human platelets and other cardiovascular cells. To identify the VASP phosphorylation sites, purified VASP was phosphorylated by either protein kinase and subjected to trypsin, V8 and Lys-C proteolysis, The phosphorylated proteolytic fragments obtained were separated by reversed phase high performance liquid chromatography. Sequence analysis of the phosphorylated peptides and P-32 measurement of the released P-32-labeled amino acids revealed three phosphorylation sites: a serine 1-containing site (LRKVSXQEEA), a serine 2-containing site (HIERRVSNAG), and a threonine-containing site (MNAVLARRRKATQVGE). Additional experiments with purified VASP demonstrated that both cAK and cGK phosphorylated serine 2 rapidly and the threonine residue slowly, whereas cGK phosphorylated the serine 1 residue more rapidly than the cAK. These differences in the phosphorylation rates of VASP by the two protein kinases were also observed with synthetic peptides corresponding to the sequences of the three identified phosphorylation sites. These experiments also established the synthetic peptide serine 1 as one of the best in vitro cGK substrates and the serine 2-containing site as the site responsible for the phosphorylation-induced mobility shift of VASP in sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Experiments with P-32-labeled platelets provided evidence that VASP is phosphorylated at the same three identified sites also in intact cells and that selective activation of cAK or cGK primarily increased the phosphorylation of both serine 2 and serine 1 but not threonine. Our results demonstrated overlapping substrate specificities of cAK and cGK in vitro and in intact cells. However, important quantitative and qualitative differences between cAK- and cGK-mediated phosphorylation of the focal adhesion protein VASP in human platelets were also observed, suggesting distinct functions of the two types of cyclic nucleotide-mediated VASP phosphorylation.	BIOZENTRUM WURZBURG, D-97074 WURZBURG, GERMANY	University of Wurzburg	BUTT, E (corresponding author), UNIV WURZBURG, MED KLIN, BIOCHEM & PATHOBIOCHEM KLIN, JOSEF SCHNEIDER STR 2, D-97080 WURZBURG, GERMANY.		Krieger, Marco/AAE-8611-2020; Walter, ulrich/W-2478-2017	Walter, ulrich/0000-0001-6784-2307				AITKEN A, 1981, J BIOL CHEM, V256, P3501; ASWAD DW, 1981, J BIOL CHEM, V256, P3494; BOWEN R, 1991, J CARDIOVASC PHARM, V17, P424, DOI 10.1097/00005344-199103000-00011; BUTT E, 1992, BIOCHEM PHARMACOL, V43, P2591, DOI 10.1016/0006-2952(92)90148-C; BUTT K, 1992, 8TH INT C 2ND MESS P; COLBRAN JL, 1992, J BIOL CHEM, V267, P9589; EIGENTHALER M, 1993, J BIOL CHEM, V268, P13526; EIGENTHALER M, 1992, EUR J BIOCHEM, V205, P471, DOI 10.1111/j.1432-1033.1992.tb16803.x; GEIGER J, 1992, P NATL ACAD SCI USA, V89, P1031, DOI 10.1073/pnas.89.3.1031; GLASS DB, 1990, PEPT PROT PHOSPH, P209; GUMBINER BM, 1992, CURR OPIN CELL BIOL, V4, P757; HALBRUGGE M, 1989, EUR J BIOCHEM, V185, P41, DOI 10.1111/j.1432-1033.1989.tb15079.x; HALBRUGGE M, 1990, J BIOL CHEM, V265, P3088; HALBRUGGE M, 1992, CELL SIGNAL, V4, P189, DOI 10.1016/0898-6568(92)90082-J; HASHIMOTO E, 1976, J BIOL CHEM, V251, P6287; HEMMINGS HC, 1984, J BIOL CHEM, V259, P4491; HOFMANN F, 1992, BIOCHIM BIOPHYS ACTA, V1135, P51, DOI 10.1016/0167-4889(92)90165-8; HOPPE J, 1981, EUR J BIOCHEM, V117, P585; KACZMAREK LK, 1980, P NATL ACAD SCI-BIOL, V77, P7487, DOI 10.1073/pnas.77.12.7487; KEMP BE, 1975, P NATL ACAD SCI USA, V72, P3448, DOI 10.1073/pnas.72.9.3448; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; MENDELSOHN ME, 1990, J BIOL CHEM, V265, P19028; MEYER HE, 1991, METHOD ENZYMOL, V201, P206; NOLTE C, 1991, J BIOL CHEM, V266, P14808; NOLTE C, 1991, BIOCHEM PHARMACOL, V42, P253, DOI 10.1016/0006-2952(91)90711-D; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; REINHARD M, 1992, EMBO J, V11, P2063, DOI 10.1002/j.1460-2075.1992.tb05264.x; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; SANDBERG M, 1991, BIOCHEM J, V279, P521, DOI 10.1042/bj2790521; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; THOMAS MK, 1990, J BIOL CHEM, V265, P14971; TSOU K, 1993, P NATL ACAD SCI USA, V90, P3462, DOI 10.1073/pnas.90.8.3462; WALAAS SI, 1983, NATURE, V301, P69; WALDMANN R, 1986, EUR J BIOCHEM, V158, P203, DOI 10.1111/j.1432-1033.1986.tb09739.x; WALDMANN R, 1987, EUR J BIOCHEM, V167, P441, DOI 10.1111/j.1432-1033.1987.tb13357.x; WALTER U, 1980, J BIOL CHEM, V255, P3757; WILLIGEN GV, 1991, BIOCHEM J, V273, P115; ZEILIG CE, 1981, J BIOL CHEM, V256, P994; Zetterqvist O.Z., 1990, PEPTIDES PROTEIN PHO, P171	39	388	400	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14509	14517						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	8182057				2022-12-25	WOS:A1994NM06500033
J	PAK, CC; KRUMBIEGEL, M; BLUMENTHAL, R; RAVIV, Y				PAK, CC; KRUMBIEGEL, M; BLUMENTHAL, R; RAVIV, Y			DETECTION OF INFLUENZA HEMAGGLUTININ INTERACTION WITH BIOLOGICAL-MEMBRANES BY PHOTOSENSITIZED ACTIVATION OF [I-125] IODONAPHTHYLAZIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED CONFORMATIONAL CHANGE; HUMAN-ERYTHROCYTE-MEMBRANE; RED-BLOOD-CELL; FUSION ACTIVITY; VIRUS HEMAGGLUTININ; 5-IODONAPHTHYL 1-AZIDE; AMPHIPHILIC COMPOUNDS; ANION PERMEABILITY; DISULFIDE BONDS; PROTEINS	Fusion of influenza virus with cells is triggered by a pH-dependent conformational change in the viral envelope protein, hemagglutinin, which results in exposure of the fusion peptide and its insertion into the target membrane. We have investigated the association of hemagglutinin with erythrocyte membranes by photosensitized labeling with [I-125]iodonaphthylazide. This technique relies on the collisional energy transfer from a photosensitizing chromophore to [I-125]iodonaphthylazide, which selectively labels proteins in the vicinity of the chromophore. Incubation of influenza virus with erythrocyte membranes containing chromophore and [I-125]iodonaphthylazide results in labeling of hemagglutinin under fusogenic conditions (pH 5 and 37 degrees C). We also examined photosensitized labeling of hemagglutinin upon incubation of the X31 strain of influenza virus with labeled erythrocyte membranes in a pre-fusion state (pH 5 and 4 degrees C). There was little hemagglutinin labeling under these conditions, although incubation of bromelain-cleaved hemagglutinin, which lacks the transmembrane region, resulted in rapid labeling. Hemagglutinin was also labeled by [I-125]iodonaphthylazide photosensitized by a fluorescent substrate transported through the erythrocyte band 3 sialoglycoprotein. Hemagglutinin labeling decreased after an initial rapid rise, suggesting that the fusion site is close to the sialoglycoprotein and that [I-125]iodonaphthylazide photosensitized labeling may be used to assay protein movement during fusion.	NCI, MEMBRANE STRUCT & FUNCT SECT, BETHESDA, MD 20892 USA; NIDDK, CELL BIOL & GENET LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								AROETI B, 1991, J BIOL CHEM, V266, P15845; BAYLEY H, 1980, BIOCHEMISTRY-US, V19, P3883, DOI 10.1021/bi00558a001; BERCOVICI T, 1978, BIOCHEMISTRY-US, V17, P1484, DOI 10.1021/bi00601a020; BOSSART W, 1973, VIROLOGY, V55, P295, DOI 10.1016/S0042-6822(73)81034-7; BRAND CM, 1972, NATURE-NEW BIOL, V238, P145, DOI 10.1038/newbio238145a0; BRUNNER J, 1991, BIOCHEMISTRY-US, V30, P2432, DOI 10.1021/bi00223a019; CABANTCHIK ZI, 1974, J MEMBRANE BIOL, V15, P207, DOI 10.1007/BF01870088; CORBETT JD, 1993, J CLIN INVEST, V91, P208, DOI 10.1172/JCI116172; COUSIN JL, 1979, J MEMBRANE BIOL, V46, P125, DOI 10.1007/BF01961377; COUSIN JL, 1982, BIOCHIM BIOPHYS ACTA, V687, P147, DOI 10.1016/0005-2736(82)90540-5; DOMS RW, 1985, J BIOL CHEM, V260, P2973; EIDELMAN O, 1983, J MEMBRANE BIOL, V71, P141, DOI 10.1007/BF01870682; EIDELMAN O, 1980, ANAL BIOCHEM, V106, P335, DOI 10.1016/0003-2697(80)90529-1; FIDGEN KJ, 1981, J VIROL METHODS, V3, P271, DOI 10.1016/0166-0934(81)90064-1; FRANK A, 1983, BIOCHEMISTRY-US, V22, P5647, DOI 10.1021/bi00293a029; GANONG BR, 1984, BIOCHEMISTRY-US, V23, P4977, DOI 10.1021/bi00316a023; Gitler C, 1980, Ann N Y Acad Sci, V346, P199, DOI 10.1111/j.1749-6632.1980.tb22100.x; GODLEY L, 1992, CELL, V68, P635, DOI 10.1016/0092-8674(92)90140-8; GOTTESMAN MM, 1992, DRUG RESISTANCE BIOC, P46; HARTER C, 1989, J BIOL CHEM, V264, P6459; HOEKSTRA D, 1990, J BIOENERG BIOMEMBR, V22, P121, DOI 10.1007/BF00762943; KAHANE I, 1978, SCIENCE, V201, P351, DOI 10.1126/science.663661; KAPLAN D, 1991, EXP CELL RES, V195, P137, DOI 10.1016/0014-4827(91)90509-S; KARLISH SJD, 1977, NATURE, V269, P716; KEMBLE GW, 1992, J VIROL, V66, P4940, DOI 10.1128/JVI.66.8.4940-4950.1992; LOWY RJ, 1993, J CELL BIOCHEM, V16, P131; LOYTER A, 1988, METHOD BIOCHEM ANAL, V33, P129; MATAYOSHI ED, 1991, BIOCHEMISTRY-US, V30, P3527, DOI 10.1021/bi00228a025; MCLEAN LR, 1981, BIOCHEMISTRY-US, V20, P2893, DOI 10.1021/bi00513a028; NICHOLS JW, 1981, BIOCHEMISTRY-US, V20, P2783, DOI 10.1021/bi00513a012; PAK CC, 1994, J GEN VIROL, V75, P395, DOI 10.1099/0022-1317-75-2-395; PURI A, 1990, J VIROL, V64, P3824, DOI 10.1128/JVI.64.8.3824-3832.1990; RAVIV Y, 1984, BIOCHEMISTRY-US, V23, P503, DOI 10.1021/bi00298a016; RAVIV Y, 1989, BIOCHEMISTRY-US, V28, P1313, DOI 10.1021/bi00429a055; RAVIV Y, 1990, J BIOL CHEM, V265, P3975; RAVIV Y, 1987, P NATL ACAD SCI USA, V84, P6103, DOI 10.1073/pnas.84.17.6103; ROSENWALD AG, 1991, J BIOL CHEM, V266, P9814; SIDMAN CL, 1980, MOL IMMUNOL, V17, P1575, DOI 10.1016/0161-5890(80)90183-2; STEGMANN T, 1991, J BIOL CHEM, V266, P18404; STEGMANN T, 1990, EMBO J, V9, P4231, DOI 10.1002/j.1460-2075.1990.tb07871.x; STEGMANN T, 1993, VIRAL FUSION MECHANI, P89; TSURUDOME M, 1992, J BIOL CHEM, V267, P20225; WHITE JM, 1987, J CELL BIOL, V105, P2887, DOI 10.1083/jcb.105.6.2887; WHITE JM, 1992, SCIENCE, V258, P917, DOI 10.1126/science.1439803; WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0; WYATT K, 1992, BIOCHIM BIOPHYS ACTA, V1103, P327, DOI 10.1016/0005-2736(92)90104-T; YOSHIMURA A, 1985, EXP CELL RES, V160, P126, DOI 10.1016/0014-4827(85)90242-3	47	35	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14614	14619						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	8182068				2022-12-25	WOS:A1994NM06500049
J	ROSALES, R; HARRIS, N; AHN, BY; MOSS, B				ROSALES, R; HARRIS, N; AHN, BY; MOSS, B			PURIFICATION AND IDENTIFICATION OF A VACCINIA VIRUS-ENCODED INTERMEDIATE STAGE PROMOTER-SPECIFIC TRANSCRIPTION FACTOR THAT HAS HOMOLOGY TO EUKARYOTIC TRANSCRIPTION FACTOR SII (TFIIS) AND AN ADDITIONAL ROLE AS A VIRAL-RNA POLYMERASE SUBUNIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; MUTATIONAL ANALYSIS; POLY(A) POLYMERASE; ELONGATION-FACTOR; DNA-REPLICATION; EARLY GENES; VIRIONS; GUANYLYLTRANSFERASE; EXPRESSION; TEMPLATE	Enzymes and factors, required for in vitro transcription of templates regulated by vaccinia virus intermediate stage promoters, are present in HeLa cells infected with vaccinia virus in the presence of an inhibitor of DNA replication. Previous studies indicated that in vitro transcription could be reconstituted by adding a partially purified transcription factor to the viral RNA polymerase and capping enzyme. By using an independent purification procedure, we isolated two vaccinia virus intermediate transcription factors VITF-1 and VITF-2 that were necessary for transcription of several different intermediate stage promoter templates but not for early or late stage promoter templates. VITF-1 was purified to homogeneity, and the sequences of two tryptic peptides were mapped to the fourth open reading frame within the HindIII E fragment (E4L) of the vaccinia virus genome, which had previously been shown to encode an RNA polymerase subunit of 30 kDa (RPO30) with homology to eukaryotic transcription elongation factor SII. Co-chromatography of VITF-1 with the E4L-derived protein was demonstrated using specific antiserum. In addition, transcriptionally active recombinant VITF-1 was made by expressing the E4L open reading frame in Escherichia coli. Thus, E4L encodes a multifunctional protein, serving as a RNA polymerase subunit and a stage-specific transcription factor. The stepwise binding of capping enzyme, VITF-1, and VITF-2 to a DNA/viral RNA polymerase complex was demonstrated.	NIAID,VIRAL DIS LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)				Moss, Bernard/0000-0002-2154-8564				AHN BY, 1992, P NATL ACAD SCI USA, V89, P3536, DOI 10.1073/pnas.89.8.3536; AHN BY, 1990, MOL CELL BIOL, V10, P5433, DOI 10.1128/MCB.10.10.5433; AHN BY, 1994, J BIOL CHEM, V269, P7552; BALDICK CJ, 1993, J VIROL, V67, P3515, DOI 10.1128/JVI.67.6.3515-3527.1993; BALDICK CJ, 1992, J VIROL, V66, P4710, DOI 10.1128/JVI.66.8.4710-4719.1992; BAROUDY BM, 1980, J BIOL CHEM, V255, P4372; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROYLES SS, 1988, J BIOL CHEM, V263, P10754; BROYLES SS, 1990, J VIROL, V64, P5376, DOI 10.1128/JVI.64.11.5376-5382.1990; BROYLES SS, 1990, J VIROL, V64, P1523, DOI 10.1128/JVI.64.4.1523-1529.1990; DAVISON AJ, 1989, J MOL BIOL, V210, P749, DOI 10.1016/0022-2836(89)90107-1; DAVISON AJ, 1989, J MOL BIOL, V210, P771, DOI 10.1016/0022-2836(89)90108-3; GERSHON PD, 1991, CELL, V66, P1269, DOI 10.1016/0092-8674(91)90048-4; GERSHON PD, 1990, P NATL ACAD SCI USA, V87, P4401, DOI 10.1073/pnas.87.11.4401; HAGLER J, 1993, J BIOL CHEM, V268, P2166; HARRIS N, 1993, P NATL ACAD SCI USA, V90, P2860, DOI 10.1073/pnas.90.7.2860; HIRSCHMANN P, 1990, J VIROL, V64, P6063, DOI 10.1128/JVI.64.12.6063-6069.1990; IZBAN MG, 1992, GENE DEV, V6, P1342, DOI 10.1101/gad.6.7.1342; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KATES J, 1970, J MOL BIOL, V50, P19, DOI 10.1016/0022-2836(70)90101-4; KATES JR, 1967, P NATL ACAD SCI USA, V58, P134, DOI 10.1073/pnas.58.1.134; KECK JG, 1990, CELL, V61, P801, DOI 10.1016/0092-8674(90)90190-P; KECK JG, 1993, J VIROL, V67, P5740, DOI 10.1128/JVI.67.10.5740-5748.1993; MANLEY JL, 1987, TRANSCRIPTION TRANSL, P72; MARTIN SA, 1975, J BIOL CHEM, V250, P9330; MOSS B, 1990, ANNU REV BIOCHEM, V59, P661, DOI 10.1146/annurev.biochem.59.1.661; MUNYON W, 1967, P NATL ACAD SCI USA, V58, P2280, DOI 10.1073/pnas.58.6.2280; ROHRMANN G, 1985, J VIROL, V56, P349, DOI 10.1128/JVI.56.2.349-355.1985; ROSALES R, 1994, P NATL ACAD SCI US, V91; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; SCHNIERLE BS, 1992, P NATL ACAD SCI USA, V89, P2897, DOI 10.1073/pnas.89.7.2897; SHUMAN S, 1987, J BIOL CHEM, V262, P12372; SHUMAN S, 1990, METHOD ENZYMOL, V181, P170; VENKATESAN S, 1980, J BIOL CHEM, V255, P903; VOS JC, 1991, CELL, V65, P105, DOI 10.1016/0092-8674(91)90412-R; VOS JC, 1991, EMBO J, V10, P2553, DOI 10.1002/j.1460-2075.1991.tb07795.x; VOS JC, 1988, EMBO J, V7, P3487, DOI 10.1002/j.1460-2075.1988.tb03224.x; WEI CM, 1975, P NATL ACAD SCI USA, V72, P318, DOI 10.1073/pnas.72.1.318; WRIGHT CF, 1991, J VIROL, V65, P3715, DOI 10.1128/JVI.65.7.3715-3720.1991; ZHANG YF, 1994, J VIROL, V68, P1360, DOI 10.1128/JVI.68.3.1360-1370.1994; [No title captured]	41	46	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					14260	14267						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188710				2022-12-25	WOS:A1994NL60600081
J	AZZI, L; MEIJER, L; OSTVOLD, AC; LEW, J; WANG, JH				AZZI, L; MEIJER, L; OSTVOLD, AC; LEW, J; WANG, JH			PURIFICATION OF A 15-KDA CDK4-BINDING AND CDK5-BINDING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATURATION-PROMOTING FACTOR; MOBILITY-GROUP PROTEINS; CELL-CYCLE REGULATION; XENOPUS CDC2 PROTEIN; CASEIN KINASE-II; FISSION YEAST; SCHIZOSACCHAROMYCES-POMBE; SACCHAROMYCES-CEREVISIAE; HMG-I; HISTONE-H1 KINASE	Yeasts p13(suc1)/p18(CKS) and their human homologues, p9(CKShs1)/p9(CKShs2), strongly interact with p34(cdc2) and p34(cdk2). While attempting to purify the starfish oocyte p13(suc1) homologue, we discovered a 15-kDa protein crossreactive with anti-p9(CRShs2)/anti-p13(suc1) antibodies. p15(cdk-BP)-Sepharose binds an anti-PSTAIRE cross-reactive protein of 33 kDa when loaded with starfish oocyte extracts. The p15(cdk-BP)-bound ''PSTAIRE signal'' is part of a 250-kDa complex distinct from p34(cdc2)/cyclin B. p15(cdk-BP)-Sepharose beads retain a kinase phosphorylating HMG I/Y, P1, and myelin basic protein (among 24 substrates tested). Major cdc2 kinase substrates are not phosphorylated by the p15(cdk-BP)-bound kinase. Phosphopeptide maps of P1 phosphorylated by the p15(cdk-BP)-bound kinase, p34(cdc2)/cyclin B, p33(cdk5)/p25, and casein kinase 2 showed that these kinases phosphorylate P1 on different sites. Phosphopeptide maps of P1 phosphorylated by the p15(cdk-BP)-bound starfish kinase and p15(cdk-BP)-bound human p34(cdh4)/cyclin D are largely coincident. To investigate the nature of the p15(cdk-BP)-bound kinase, extracts of mammalian tissues and cells were loaded on p9(CKShs1)- and p15(cdk-BP)-Sepharose and the bound proteins were analyzed using specific anti-cdk antibodies. cdc2 and cdk2 bind to p9(CKShs1)-Sepharose, but not to p15(cdk-BP). cdk4 and cdk5 bind to p15(cdk-BP)-Sepharose, but not to p9(CKShs1)-Sepharose. We conclude that p15(cdk-BP) specifically binds the cdk4/cyclin D and cdk5 kinases and, along with p13(suc1) and p9(CKShs), may be part of a larger family of cdk-binding proteins.	CNRS,BIOL STN,F-29682 ROSCOFF,FRANCE; UNIV OSLO,NEUROCHEM LAB,N-0317 OSLO 3,NORWAY; UNIV CALGARY,FAC MED,DEPT MED BIOCHEM,MRC,SIGNAL TRANSDUCT GRP,CALGARY T2N 4N1,AB,CANADA	Centre National de la Recherche Scientifique (CNRS); University of Oslo; University of Calgary								AKIYAMA T, 1992, P NATL ACAD SCI USA, V89, P7900, DOI 10.1073/pnas.89.17.7900; ARION D, 1988, CELL, V55, P371, DOI 10.1016/0092-8674(88)90060-8; AZZI L, 1992, EUR J BIOCHEM, V203, P353, DOI 10.1111/j.1432-1033.1992.tb16557.x; BARATTE B, 1992, ANTICANCER RES, V12, P873; BRIZUELA L, 1987, EMBO J, V6, P3507, DOI 10.1002/j.1460-2075.1987.tb02676.x; BUNNELL BA, 1990, P NATL ACAD SCI USA, V87, P7467, DOI 10.1073/pnas.87.19.7467; DRAETTA G, 1987, CELL, V50, P319, DOI 10.1016/0092-8674(87)90227-3; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; DUCOMMUN B, 1991, MOL CELL BIOL, V11, P6177, DOI 10.1128/MCB.11.12.6177; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; DUNPHY WG, 1989, CELL, V58, P181, DOI 10.1016/0092-8674(89)90414-5; ELLEDGE SJ, 1991, EMBO J, V10, P2653, DOI 10.1002/j.1460-2075.1991.tb07808.x; FASHENA SJ, 1992, MOL CELL BIOL, V12, P894, DOI 10.1128/MCB.12.2.894; FERRANTI P, 1992, J BIOL CHEM, V267, P22486; FORSBURG SL, 1991, ANNU REV CELL BIOL, V7, P227, DOI 10.1146/annurev.cb.07.110191.001303; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; GAVIN AC, 1992, MOL REPROD DEV, V33, P287, DOI 10.1002/mrd.1080330309; GIANCOTTI V, 1987, EMBO J, V6, P1981, DOI 10.1002/j.1460-2075.1987.tb02461.x; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HADWIGER JA, 1989, MOL CELL BIOL, V9, P2034, DOI 10.1128/MCB.9.5.2034; HANKS SK, 1987, P NATL ACAD SCI USA, V84, P388, DOI 10.1073/pnas.84.2.388; HAYLES J, 1986, MOL GEN GENET, V202, P291, DOI 10.1007/BF00331653; HAYLES J, 1986, EMBO J, V5, P3373, DOI 10.1002/j.1460-2075.1986.tb04653.x; HELLMICH MR, 1992, P NATL ACAD SCI USA, V89, P10867, DOI 10.1073/pnas.89.22.10867; HINDLEY J, 1987, MOL CELL BIOL, V7, P504, DOI 10.1128/MCB.7.1.504; HISANAGA S, 1991, J BIOL CHEM, V266, P21798; JOHNSON KR, 1989, MOL CELL BIOL, V9, P2114, DOI 10.1128/MCB.9.5.2114; JOHNSON KW, 1991, J BIOL CHEM, V266, P3402; KIDD VJ, 1992, MOL CARCINOGEN, V5, P95, DOI 10.1002/mc.2940050203; KUSUBATA M, 1992, J BIOL CHEM, V267, P20937; LABBE JC, 1989, EMBO J, V8, P3053, DOI 10.1002/j.1460-2075.1989.tb08456.x; LAPIDOTLIESON Y, 1992, P NATL ACAD SCI USA, V89, P579, DOI 10.1073/pnas.89.2.579; LEDESMA MD, 1992, FEBS LETT, V308, P218, DOI 10.1016/0014-5793(92)81278-T; Lee G, 1993, CURR OPIN CELL BIOL, V5, P88, DOI 10.1016/S0955-0674(05)80013-4; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEE VMY, 1991, SCIENCE, V251, P675, DOI 10.1126/science.1899488; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LEW J, 1992, J BIOL CHEM, V267, P25922; LEW J, 1992, J BIOL CHEM, V267, P13384; Liem RKH, 1993, CURR OPIN CELL BIOL, V5, P12, DOI 10.1016/S0955-0674(05)80003-1; LUND T, 1990, BIOCHEM BIOPH RES CO, V171, P342, DOI 10.1016/0006-291X(90)91399-D; LUND T, 1987, EUR J BIOCHEM, V166, P21, DOI 10.1111/j.1432-1033.1987.tb13477.x; MAELANDSMO GM, 1989, EUR J BIOCHEM, V184, P529, DOI 10.1111/j.1432-1033.1989.tb15046.x; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MAWALDEWAN M, 1992, J BIOL CHEM, V267, P19705; MEIJER L, 1988, EXP CELL RES, V174, P116, DOI 10.1016/0014-4827(88)90147-4; MEIJER L, 1989, EMBO J, V8, P2275, DOI 10.1002/j.1460-2075.1989.tb08353.x; MEIJER L, 1991, EMBO J, V10, P1545, DOI 10.1002/j.1460-2075.1991.tb07674.x; MEIJER L, 1991, EUR J BIOCHEM, V196, P557, DOI 10.1111/j.1432-1033.1991.tb15850.x; MEIJER L, 1986, CAH BIOL MAR, V25, P457; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; MOTOKURA T, 1993, GENE CHROMOSOME CANC, V7, P89, DOI 10.1002/gcc.2870070205; NINOMIYATSUJI J, 1991, P NATL ACAD SCI USA, V88, P9006, DOI 10.1073/pnas.88.20.9006; NISSEN MS, 1991, J BIOL CHEM, V266, P19945; OKUDA T, 1992, ONCOGENE, V7, P2249; OSTVOLD AC, 1985, EUR J BIOCHEM, V153, P469, DOI 10.1111/j.1432-1033.1985.tb09325.x; PALVIMO J, 1989, FEBS LETT, V257, P101, DOI 10.1016/0014-5793(89)81796-X; PARIS J, 1991, P NATL ACAD SCI USA, V88, P1039, DOI 10.1073/pnas.88.3.1039; PELECH SL, 1987, BIOCHEMISTRY-US, V26, P7960, DOI 10.1021/bi00398a062; PELECH SL, 1988, DEV BIOL, V130, P28, DOI 10.1016/0012-1606(88)90410-1; PONDAVEN P, 1990, GENE DEV, V4, P9, DOI 10.1101/gad.4.1.9; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; REEVES R, 1991, P NATL ACAD SCI USA, V88, P1671, DOI 10.1073/pnas.88.5.1671; RICHARDSON HE, 1990, GENE DEV, V4, P1332, DOI 10.1101/gad.4.8.1332; SAMIEI M, 1991, J BIOL CHEM, V266, P14889; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SERANO M, 1993, NATURE, V366, P704; SHIBUYA EK, 1992, EMBO J, V11, P3963, DOI 10.1002/j.1460-2075.1992.tb05490.x; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; TANG Y, 1993, GENE DEV, V7, P822, DOI 10.1101/gad.7.5.822; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; VARTIAINEN E, 1988, FEBS LETT, V228, P45, DOI 10.1016/0014-5793(88)80581-7; VULLIET PR, 1989, J BIOL CHEM, V264, P16292; WALAAS SI, 1989, FEBS LETT, V258, P106, DOI 10.1016/0014-5793(89)81626-6; Xiong Y, 1991, Curr Biol, V1, P362, DOI 10.1016/0960-9822(91)90193-Z; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; YAMASHITA M, 1991, DEV GROWTH DIFFER, V33, P617; YAMASHITA M, 1992, DEV BIOL, V149, P8, DOI 10.1016/0012-1606(92)90259-J; YANGYEN HF, 1988, MOL CELL BIOL, V8, P3406, DOI 10.1128/MCB.8.8.3406	84	63	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13279	13288						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175758				2022-12-25	WOS:A1994NK18400037
J	BENHAR, I; WANG, QC; FITZGERALD, D; PASTAN, I				BENHAR, I; WANG, QC; FITZGERALD, D; PASTAN, I			PSEUDOMONAS EXOTOXIN-A MUTANTS - REPLACEMENT OF SURFACE-EXPOSED RESIDUES IN DOMAIN-III WITH CYSTEINE RESIDUES THAT CAN BE MODIFIED WITH POLYETHYLENE-GLYCOL IN A SITE-SPECIFIC MANNER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT INTERLEUKIN-2; DIPHTHERIA-TOXIN; ACTIVE-SITE; ESCHERICHIA-COLI; ANIMAL TOXICITY; AERUGINOSA; PROTEIN; MUTAGENESIS; NAD; EXPRESSION	Pseudomonas exotoxin A (PE) is composed of three structural and functional domains. Domain Ia is responsible for cell recognition, domain II for translocation of PE across the cell membrane, and domain III for ADP-ribosylation of elongation factor 2. To investigate the role of the amino acids exposed on the surface of domain III, we replaced 15 of these, generating 29 different mutants at positions 412, 416, 418, 490, 513, 516, 522, 551, 576, 590, 599, 604, 606, 607 and 608. Ah but one mutant retained substantial ADP-ribosylation and cytotoxic activities. Modification of proteins with monomethoxypolyethylene glycol (mPEG) prolongs their circulation in the blood stream and reduces their immunogenicity. Unlike PEGylated enzymes acting on small molecule substrates, PEGylated toxins may lose those functions that are based on macromolecular interactions. Therefore, we selectively PEGylated mutant PEs at positions 490, 513, 516, 522, 604, and 606. Most PEs modified by a 5-kDa mPEG via a disulfide or a thioether bond retained high cytotoxic activity. However, when a 20-kDa mPEG was used there was a decrease in cytotoxic activity with the disulfide-bonded molecules being more active. Positions 522 and 604 are good sites for PEGylation, but 490 is not. We also found that PEGylation of PE 522C prolonged its in vivo circulation time in mice.	NCI,DIV CANC BIOL DIAG & CTR,MOLEC BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			pastan, ira/P-9319-2019	pastan, ira/0000-0002-9223-0270; Benhar, Itai/0000-0002-0824-7177				ABUCHOWSKI A, 1977, J BIOL CHEM, V252, P3578; ALLURED VS, 1986, P NATL ACAD SCI USA, V83, P1320, DOI 10.1073/pnas.83.5.1320; BRANDHUBER BJ, 1988, PROTEINS, V3, P146, DOI 10.1002/prot.340030303; BRINKMANN U, 1992, P NATL ACAD SCI USA, V89, P3065, DOI 10.1073/pnas.89.7.3065; CARROL SF, 1988, MOL MICROBIOL, V262, P293; CARROLL SF, 1987, J BIOL CHEM, V262, P8707; CHAUDHARY VK, 1988, P NATL ACAD SCI USA, V85, P2939, DOI 10.1073/pnas.85.9.2939; CHAUDHARY VK, 1990, P NATL ACAD SCI USA, V87, P308, DOI 10.1073/pnas.87.1.308; CHAUDHARY VK, 1990, J BIOL CHEM, V265, P16306; CHAUDHARY VK, 1987, P NATL ACAD SCI USA, V84, P4538, DOI 10.1073/pnas.84.13.4538; CHILDS CE, 1975, MICROCHEM J, V20, P190, DOI 10.1016/0026-265X(75)90038-7; COLLIER RJ, 1971, J BIOL CHEM, V246, P1496; DOMENIGHINI M, 1991, MOL MICROBIOL, V5, P23, DOI 10.1111/j.1365-2958.1991.tb01822.x; DREBORG S, 1990, CRIT REV THER DRUG, V6, P315; GOODSON RJ, 1990, BIO-TECHNOL, V8, P343, DOI 10.1038/nbt0490-343; GREENFIELD L, 1983, P NATL ACAD SCI-BIOL, V80, P6853, DOI 10.1073/pnas.80.22.6853; Habeeb A F, 1972, Methods Enzymol, V25, P457, DOI 10.1016/S0076-6879(72)25041-8; HERSHFIELD MS, 1991, P NATL ACAD SCI USA, V88, P7185, DOI 10.1073/pnas.88.16.7185; HWANG J, 1987, CELL, V48, P129, DOI 10.1016/0092-8674(87)90363-1; IGLEWSKI BH, 1975, P NATL ACAD SCI USA, V72, P2284, DOI 10.1073/pnas.72.6.2284; JINNO Y, 1989, J BIOL CHEM, V264, P15953; JINNO Y, 1988, J BIOL CHEM, V263, P13203; KASTURI S, 1992, J BIOL CHEM, V267, P23427; KATRE NV, 1987, P NATL ACAD SCI USA, V84, P1487, DOI 10.1073/pnas.84.6.1487; KITAMURA K, 1990, BIOCHEM BIOPH RES CO, V171, P1387, DOI 10.1016/0006-291X(90)90839-F; KNAUF MJ, 1988, J BIOL CHEM, V263, P15064; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P12420; KUAN CT, 1994, J BIOL CHEM, V269, P7610; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LISI PJ, 1982, J APPL BIOCHEM, V4, P19; LORY S, 1980, INFECT IMMUN, V28, P494; LUCAK M, 1988, BIOCHEMISTRY-US, V27, P7629; PASTAN I, 1992, ANNU REV BIOCHEM, V61, P331, DOI 10.1146/annurev.bi.61.070192.001555; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEETHARAM S, 1991, J BIOL CHEM, V266, P17376; SIEGALL CB, 1989, J BIOL CHEM, V264, P14256; SIMS GEC, 1980, ANAL BIOCHEM, V107, P60, DOI 10.1016/0003-2697(80)90492-3; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; THEUER CP, 1993, J UROLOGY, V149, P1626, DOI 10.1016/S0022-5347(17)36464-9; WANG QC, 1993, CANCER RES, V53, P4588; WOZNIAK DJ, 1988, P NATL ACAD SCI USA, V85, P8880, DOI 10.1073/pnas.85.23.8880; ZIMMERMAN RJ, 1989, CANCER RES, V49, P6521	44	41	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13398	13404						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175770				2022-12-25	WOS:A1994NK18400053
J	KIMATA, Y; KOHNO, K				KIMATA, Y; KOHNO, K			ELONGATION-FACTOR-2 MUTANTS DEFICIENT IN DIPHTHAMIDE FORMATION SHOW TEMPERATURE-SENSITIVE CELL-GROWTH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOXIN-RESISTANT MUTANTS; MR 100,000 SUBSTRATE; PROTEIN KINASE-III; DIPHTHERIA-TOXIN; SACCHAROMYCES-CEREVISIAE; BIOSYNTHESIS; METHYLTRANSFERASE; IDENTIFICATION; EXPRESSION; RECEPTOR	Protein synthesis elongation factor 2 (EF-2) from eukaryotes contains an unusual modified histidine residue, termed diphthamide. Diphthamide has been shown to be a site of ADP-ribosylation by bacterial toxins, but its function remains obscure. We expressed mutant genes of EF-2 with substitutions of 19 other amino acids for His-699, which is modified to diphthamide, in yeast cells and found that they can be classified into three groups. In the first group (Group 1), replacement of His-699 by the basic amino acid Arg or Lys showed not only loss of EF 2 activity but also inhibitory effects on the growth of cells co-expressing wild-type EF-2. In the second group (Group 2), replacement with Gly, Pro, Ser, or Asp resulted in nonfunctional EF-2, but it did not affect the growth of cells co-expressing wild-type EF-2. In the third group (Group 3), replacement by one of the other 13 amino acids resulted in a functional EF-2. In the Group 3 mutants, EF-2 was not ribosylated by diphtheria toxin, indicating that the mutant EF-2s did not form diphthamide. However, the viable cells grew more slowly than cells expressing wild-type EF-2 and showed temperature sensitivities. This result suggests that diphthamide may confer heat resistance on EF-2, although it still may be active without diphthamide at a normal temperature.	NARA INST SCI & TECHNOL, MARA 63001, JAPAN; OSAKA UNIV, INST MOLEC & CELLULAR BIOL, SUITA, OSAKA 565, JAPAN	Nara Institute of Science & Technology; Osaka University			Kohno, Kenji/AAZ-6573-2020	Kohno, Kenji/0000-0002-3503-6551				CHEN JYC, 1988, J BIOL CHEM, V263, P11692; FOLEY BT, 1992, SOMAT CELL MOLEC GEN, V18, P227, DOI 10.1007/BF01233859; GILL DM, 1969, J EXP MED, V129, P1, DOI 10.1084/jem.129.1.1; HONJO T, 1968, J BIOL CHEM, V243, P3553; IGLEWSKI BH, 1975, P NATL ACAD SCI USA, V72, P2284, DOI 10.1073/pnas.72.6.2284; JAZWINSKI SM, 1990, METHOD ENZYMOL, V182, P154; KESSEL M, 1980, NATURE, V287, P250, DOI 10.1038/287250a0; KIMATA Y, 1993, BIOCHEM BIOPH RES CO, V191, P1145, DOI 10.1006/bbrc.1993.1336; KIMATA Y, 1991, Cell Structure and Function, V16, P566; KOHNO K, 1987, EXP CELL RES, V172, P54, DOI 10.1016/0014-4827(87)90092-9; KOHNO K, 1985, SOMAT CELL MOLEC GEN, V11, P421, DOI 10.1007/BF01534836; KOHNO K, 1987, J BIOL CHEM, V262, P12298; KOHNO K, 1986, P NATL ACAD SCI USA, V83, P4978, DOI 10.1073/pnas.83.14.4978; MATTHEAKIS LC, 1992, MOL CELL BIOL, V12, P4026, DOI 10.1128/MCB.12.9.4026; MOEHRING JM, 1979, SOMAT CELL GENET, V5, P453, DOI 10.1007/BF01538880; MOEHRING JM, 1988, J BIOL CHEM, V263, P3840; MOEHRING JM, 1980, P NATL ACAD SCI-BIOL, V77, P1010, DOI 10.1073/pnas.77.2.1010; NAIRN AC, 1985, P NATL ACAD SCI USA, V82, P7939, DOI 10.1073/pnas.82.23.7939; NAIRN AC, 1987, J BIOL CHEM, V262, P17299; OMURA F, 1989, EUR J BIOCHEM, V180, P1, DOI 10.1111/j.1432-1033.1989.tb14607.x; PAPPENHEIMER AM, 1983, J BACTERIOL, V153, P1342, DOI 10.1128/JB.153.3.1342-1347.1983; PAPPENHEIMER AM, 1977, ANNU REV BIOCHEM, V46, P69, DOI 10.1146/annurev.bi.46.070177.000441; PERENTESIS JP, 1992, J BIOL CHEM, V267, P1190; PHAN LD, 1993, J BIOL CHEM, V268, P8665; Rose MD., 1990, METHODS YEAST GENETI; Sambrook J, 1989, MOL CLONING LABORATO; SIKORSKI RS, 1989, GENETICS, V122, P19; VANNESS BG, 1980, J BIOL CHEM, V255, P710	28	57	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13497	13501						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175783				2022-12-25	WOS:A1994NK18400066
J	KONG, GH; PENN, R; BENOVIC, JL				KONG, GH; PENN, R; BENOVIC, JL			A BETA-ADRENERGIC-RECEPTOR KINASE DOMINANT-NEGATIVE MUTANT ATTENUATES DESENSITIZATION OF THE BETA(2)-ADRENERGIC RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PROTEIN-KINASE; BETA-2-ADRENERGIC RECEPTOR; HOMOLOGOUS DESENSITIZATION; PHOSPHORYLATION SITES; S49-LYMPHOMA CELLS; ADENYLATE-CYCLASE; AGONIST; TRANSLOCATION; EXPRESSION; MECHANISM	The beta-adrenergic receptor kinase (beta ARK) specifically phosphorylates the activated form of the beta(2)-adrenergic receptor (beta(2)AR) and related G protein-coupled receptors. To further elucidate the role of beta ARK in receptor desensitization, we generated a beta ARK dominant negative mutant by converting an invariant lysine residue in the protein kinase catalytic domain to an arginine. Expressed and purified beta ARK-K220R was able to inhibit wild type beta ARK phosphorylation of the beta(2)AR in vitro. When stably transfected into human bronchial epithelial BEAS-2B cells, beta ARK-K220R promoted a >2-fold increase in p-agonist-stimulated cAMP production without affecting beta(2)AR sequestration. In contrast, beta ARK-K220R had no effect on the desensitization of the prostaglandin E, receptor response in BEAS-2B cells. These findings directly demonstrate a role for beta ARK in desensitization of the beta(2)AR in intact cells and establish the potential utility of using dominant negative mutants to elucidate the substrate specificity of G protein-coupled receptor kinases.	THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,DEPT PHARMACOL,PHILADELPHIA,PA 19107	Jefferson University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045964] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044944] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL45964] Funding Source: Medline; NIGMS NIH HHS [GM44944] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BENOVIC JL, 1987, J BIOL CHEM, V262, P9026; BENOVIC JL, 1988, ANNU REV CELL BIOL, V4, P405, DOI 10.1146/annurev.cb.04.110188.002201; BENOVIC JL, 1987, J BIOL CHEM, V262, P17251; BENOVIC JL, 1989, SCIENCE, V246, P235, DOI 10.1126/science.2552582; BENOVIC JL, 1993, J BIOL CHEM, V268, P19521; BENOVIC JL, 1987, P NATL ACAD SCI USA, V84, P8879, DOI 10.1073/pnas.84.24.8879; BENOVIC JL, 1986, P NATL ACAD SCI USA, V83, P2797, DOI 10.1073/pnas.83.9.2797; BOUVIER M, 1988, NATURE, V333, P370, DOI 10.1038/333370a0; CARRERA AC, 1993, P NATL ACAD SCI USA, V90, P442, DOI 10.1073/pnas.90.2.442; CHUANG TT, 1992, J BIOL CHEM, V267, P6886; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; GIBBS CS, 1991, J BIOL CHEM, V266, P8923; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HAUSDORFF WP, 1989, J BIOL CHEM, V264, P12657; KE Y, 1988, DIFFERENTIATION, V38, P60, DOI 10.1111/j.1432-0436.1988.tb00592.x; KIM CM, 1993, J BIOL CHEM, V268, P15412; KIM CM, 1993, RECEPTOR, V3, P39; KUNAPULI P, 1993, P NATL ACAD SCI USA, V90, P5588, DOI 10.1073/pnas.90.12.5588; KUNAPULI P, 1994, J BIOL CHEM, V269, P1099; KWATRA MM, 1993, J BIOL CHEM, V268, P9161; KWATRA MM, 1989, BIOCHEMISTRY-US, V28, P4543, DOI 10.1021/bi00437a005; LEFKOWITZ RJ, 1993, CELL, V74, P409, DOI 10.1016/0092-8674(93)80042-D; LOHSE MJ, 1990, J BIOL CHEM, V265, P3202; LOHSE MJ, 1989, P NATL ACAD SCI USA, V86, P3011, DOI 10.1073/pnas.86.9.3011; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; MAYOR F, 1987, J BIOL CHEM, V262, P6468; OHNO S, 1990, J BIOL CHEM, V265, P6296; PALCZEWSKI K, 1991, TRENDS BIOCHEM SCI, V16, P397; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; ROTH NS, 1991, P NATL ACAD SCI USA, V88, P6201, DOI 10.1073/pnas.88.14.6201; STRASSER RH, 1986, P NATL ACAD SCI USA, V83, P6362, DOI 10.1073/pnas.83.17.6362; STRASSER RH, 1986, BIOCHEMISTRY-US, V25, P1371, DOI 10.1021/bi00354a027; THOMIS DC, 1992, P NATL ACAD SCI USA, V89, P10837, DOI 10.1073/pnas.89.22.10837; VIALARD J, 1990, J VIROL, V64, P37, DOI 10.1128/JVI.64.1.37-50.1990	37	181	182	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13084	13087						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175732				2022-12-25	WOS:A1994NK18400008
J	LAMORTE, VJ; THORBURN, J; ABSHER, D; SPIEGEL, A; BROWN, JH; CHIEN, KR; FERAMISCO, JR; KNOWLTON, KU				LAMORTE, VJ; THORBURN, J; ABSHER, D; SPIEGEL, A; BROWN, JH; CHIEN, KR; FERAMISCO, JR; KNOWLTON, KU			G(G)-DEPENDENT AND RES-DEPENDENT PATHWAYS MEDIATE HYPERTROPHY OF NEONATAL RAT VENTRICULAR MYOCYTES FOLLOWING ALPHA(1)-ADRENERGIC STIMULATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATRIAL-NATRIURETIC-FACTOR; MYOSIN LIGHT CHAIN-2; PROTEIN-KINASE-C; ALPHA-ADRENERGIC STIMULATION; CARDIAC GENE-TRANSCRIPTION; MYOCARDIAL-CELLS; PHOSPHOLIPASE-C; TRISPHOSPHATE FORMATION; ADENYLYL CYCLASE; GQ FAMILY	alpha(1),-Adrenergic agonists activate a hypertrophic response in cultured neonatal ventricular myocytes, which include an increase in cell size, organization of contractile proteins into sarcomeric units, and the induction of the atrial natriuretic factor (ANF) gene. Previous findings have supported a role for ras in this signaling pathway. Utilizing microinjection techniques to deliver affinity-purified neutralizing antibodies to G alpha(q,11) into cultured ventricular myocytes, the current studies demonstrate a functional requirement for the heterotrimeric G protein, G(q), in the alpha(1)-adrenergic induction of the ANF gene, changes in cell size, organization of myofilaments, and phosphoinositide hydrolysis. Expression of a constitutively active mutant of G alpha(q) leads to the expression of ANF protein in these cells. Taken together, these data suggest that G(q)-dependent pathways are necessary and sufficient to activate defined features of the hypertrophic response. In attempts to further delineate the relative roles of ras and G(q) in this pathway, we found that G alpha(q) is required for alpha(1)-adrenergic phosphoinositide hydrolysis, though ras does not appear to be necessary for this response. In addition, we coexpressed an inhibitory ras mutant, along with the constitutively active G alpha(q). Expression of ANF protein stimulated by the G alpha(q) mutant was not inhibited. Thus, both ras- and G(q)-dependent pathways are necessary to fully transduce defined features of alpha(1)-adrenergic-stimulated hypertrophy of neonatal cardiac ventricular myocytes, but activated G(q) may be able to induce ANF expression independent of inhibitory ras.	UNIV CALIF SAN DIEGO, DEPT MED, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT PHARMACOL, LA JOLLA, CA 92093 USA; THEODORE GILDRED CANC CTR, LA JOLLA, CA 92093 USA; AMER HEART ASSOC, BUGHER FDN CTR MOLEC BIOL, LA JOLLA, CA 92093 USA; NIDDK, MOLEC PATHOPHYSIOL BRANCH, BETHESDA, MD 20892 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL046345] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036927] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-02618, HL46345] Funding Source: Medline; NIGMS NIH HHS [GM36927] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN LF, 1991, P NATL ACAD SCI USA, V88, P11354, DOI 10.1073/pnas.88.24.11354; ARGENTIN S, 1985, J BIOL CHEM, V260, P4568; BROWN JH, 1985, CIRC RES, V57, P532, DOI 10.1161/01.RES.57.4.532; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHERRINGTON JM, 1989, J VIROL, V63, P1435, DOI 10.1128/JVI.63.3.1435-1440.1989; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; CHIEN KR, 1993, SCIENCE, V260, P916, DOI 10.1126/science.8493528; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; CONKLIN BR, 1992, J BIOL CHEM, V267, P31; DEVIVO M, 1992, J BIOL CHEM, V267, P18263; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DUNNMON PM, 1990, J MOL CELL CARDIOL, V22, P901, DOI 10.1016/0022-2828(90)90121-H; HENDERSON SA, 1989, J BIOL CHEM, V264, P18142; IWAKI K, 1990, J BIOL CHEM, V265, P13809; KALINEC G, 1992, MOL CELL BIOL, V12, P4687, DOI 10.1128/MCB.12.10.4687; KARIYA K, 1991, J BIOL CHEM, V266, P10023; KNOWLTON KU, 1991, J BIOL CHEM, V266, P7759; KNOWLTON KU, 1993, J BIOL CHEM, V268, P15374; KUPPERMAN E, 1993, MOL CELL BIOL, V13, P4477, DOI 10.1128/MCB.13.8.4477; LAMORTE VJ, 1993, J BIOL CHEM, V268, P19411; LAMORTE VJ, 1993, J CELL BIOL, V121, P91, DOI 10.1083/jcb.121.1.91; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEE HR, 1988, J BIOL CHEM, V263, P7352; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MORGAN HE, 1991, CIRCULATION, V83, P13, DOI 10.1161/01.CIR.83.1.13; ORELLANA S, 1987, J BIOL CHEM, V262, P1638; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; SEI CA, 1991, J BIOL CHEM, V266, P15910; SHENKER A, 1991, J BIOL CHEM, V266, P9309; SHUBEITA HE, 1992, P NATL ACAD SCI USA, V89, P1305, DOI 10.1073/pnas.89.4.1305; SHUBEITA HE, 1990, J BIOL CHEM, V265, P20555; SHUBEITA HE, 1992, CIRCULATION, V85, P2236, DOI 10.1161/01.CIR.85.6.2236; SIMONDS WF, 1989, P NATL ACAD SCI USA, V86, P7809, DOI 10.1073/pnas.86.20.7809; SIMPSON P, 1983, J CLIN INVEST, V72, P732, DOI 10.1172/JCI111023; STEINBERG SF, 1989, J PHARMACOL EXP THER, V250, P1141; THORBURN A, 1993, J BIOL CHEM, V268, P2244; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; VENTURA C, 1991, BIOCHEM BIOPH RES CO, V179, P972, DOI 10.1016/0006-291X(91)91913-W; WU DQ, 1992, J BIOL CHEM, V267, P25798; XU HP, 1994, MOL CELL BIOL, V14, P50, DOI 10.1128/MCB.14.1.50	41	170	176	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13490	13496						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175782				2022-12-25	WOS:A1994NK18400065
J	MORGAN, JW; REDDY, GS; USKOKOVIC, MR; MAY, BK; OMDAHL, JL; MAIZEL, AL; SHARMA, S				MORGAN, JW; REDDY, GS; USKOKOVIC, MR; MAY, BK; OMDAHL, JL; MAIZEL, AL; SHARMA, S			FUNCTIONAL BLOCK FOR 1-ALPHA,25-DIHYDROXYVITAMIN D-3-MEDIATED GENE-REGULATION IN HUMAN B-LYMPHOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPSTEIN-BARR VIRUS; CELL GROWTH-FACTOR; MYELOID-LEUKEMIA CELLS; NORMAL HUMAN-MONOCYTES; 1,25-DIHYDROXYVITAMIN D3; VITAMIN-D; RECEPTOR EXPRESSION; RENAL METABOLISM; LINE U-937; DIFFERENTIATION	Elements necessary for the steroid hormone 1 alpha,25-dihydroxyvitamin D-3 (1 alpha,25-(OH)(2)D-3) to induce a biological response include the presence of specific intracellular receptors (vitamin D-3 receptors (VDR)) and modulation of gene expression via hormone-activated receptor binding to regulatory regions of target genes. These parameters were examined in normal and Epstein-Barr virus-immortalized human B cells and compared with 1 alpha,25-(OH)(2)D-3-responsive cells of the T and monocytic lineages. Although resting tonsillar B cells did not express VDR mRNA, activation of these cells with interleukin-4 induced VDR in the absence of exogenously supplemented 1 alpha,25-(OH)(2)D-3. As indicators of hormone-mediated gene regulation we analyzed modulation of CD23, a common B cell/monocyte surface antigen, and 28-hydroxylase. 1 alpha,25-(OH)(2)D-3 inhibited CD23 expression in U937 cells, yet failed to modulate CD23 expression in B cells. Furthermore, 1 alpha,25-(OH)(2)D-3 induced 24-hydroxylase mRNA expression and metabolic activity in both U937 cells and lectin-activated T cells, yet failed to induce 24-hydroxylase mRNA or its metabolic activity in B cells. These findings suggest that although human B lymphocytes can express VDR mRNA and protein, they exhibit a functional block for vitamin D dependent gene regulation.	BROWN UNIV,ROGER WILLIAMS CANC MED CTR,DEPT PATHOL,EXPTL PATHOL SECT,PROVIDENCE,RI 02908; BROWN UNIV,WOMEN & INFANTS HOSP,DEPT PEDIAT,PROVIDENCE,RI 02905; HOFFMANN LA ROCHE INC,DEPT CHEM,NUTLEY,NJ 07110; UNIV NEW MEXICO,SCH MED,DEPT BIOCHEM,ALBUQUERQUE,NM 87102	Brown University; Roger Williams Medical Center; Brown University; Women & Infants Hospital Rhode Island; Roche Holding; University of New Mexico			Morgan, James/N-8104-2018; Morgan, James/GRO-2905-2022	Morgan, James/0000-0002-8920-1065	NCI NIH HHS [CA54763, CA45418, CA55910] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA054763, U10CA045418, R01CA055910] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABE E, 1981, P NATL ACAD SCI-BIOL, V78, P4990, DOI 10.1073/pnas.78.8.4990; AMENTO E P, 1987, Steroids, V49, P55, DOI 10.1016/0039-128X(87)90079-1; ARNAOUT MA, 1990, BLOOD, V75, P1037; AUBRY JP, 1992, NATURE, V358, P505, DOI 10.1038/358505a0; BHALLA AK, 1983, J CLIN ENDOCR METAB, V57, P1308, DOI 10.1210/jcem-57-6-1308; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BROWN TA, 1990, J BIOL CHEM, V265, P10025; CARLBERG C, 1993, NATURE, V361, P657, DOI 10.1038/361657a0; CHEN KS, 1993, P NATL ACAD SCI USA, V90, P4543, DOI 10.1073/pnas.90.10.4543; CHEN WC, 1987, CLIN EXP IMMUNOL, V69, P639; CLARK JW, 1993, BIOORG MED CHEM LETT, V3, P1873, DOI 10.1016/S0960-894X(00)80123-7; DEFRANCE T, 1987, J EXP MED, V165, P1459, DOI 10.1084/jem.165.6.1459; FARGEAS C, 1990, J IMMUNOL, V145, P4053; FLORESROMO L, 1993, SCIENCE, V261, P1038, DOI 10.1126/science.8351517; GENDELMAN HE, 1990, J EXP MED, V172, P1433, DOI 10.1084/jem.172.5.1433; HAHN CN, 1993, CYTOGENET CELL GENET, V62, P192, DOI 10.1159/000133473; HEWISON M, 1989, IMMUNOLOGY, V68, P247; IHO S, 1986, J IMMUNOL, V136, P4427; JONES G, 1984, BIOCHEMISTRY-US, V23, P3749, DOI 10.1021/bi00311a028; KASONO K, 1993, BONE MINER, V21, P179, DOI 10.1016/S0169-6009(08)80229-2; KIKUTANI H, 1986, CELL, V47, P657, DOI 10.1016/0092-8674(86)90508-8; KIZAKI M, 1991, BLOOD, V77, P1238; LACEY DL, 1993, J CELL BIOCHEM, V53, P122, DOI 10.1002/jcb.240530205; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMIRE JM, 1985, J IMMUNOL, V134, P3032; MAIZEL AL, 1983, P NATL ACAD SCI-BIOL, V80, P5047, DOI 10.1073/pnas.80.16.5047; MANGELSDORF DJ, 1987, P NATL ACAD SCI USA, V84, P354, DOI 10.1073/pnas.84.2.354; MANOLAGAS SC, 1990, KIDNEY INT, V38, pS9; MARZLUFF WF, 1990, METHOD ENZYMOL, V181, P30; MAYUMI M, 1988, CLIN EXP IMMUNOL, V71, P202; MCCAFFREY PG, 1993, J BIOL CHEM, V268, P3747; MEZZETTI G, 1984, LIFE SCI, V34, P2185, DOI 10.1016/0024-3205(84)90319-9; MIYAURA C, 1981, BIOCHEM BIOPH RES CO, V102, P937, DOI 10.1016/0006-291X(81)91628-4; MORGAN J, 1989, J VIROL, V63, P3190, DOI 10.1128/JVI.63.7.3190-3194.1989; MULLER K, 1991, IMMUNOPHARMACOLOGY, V21, P121, DOI 10.1016/0162-3109(91)90015-Q; NEMERE I, 1991, MOL CELL ENDOCRINOL, V80, pC165, DOI 10.1016/0303-7207(91)90132-C; NOELLE R, 1984, P NATL ACAD SCI-BIOL, V81, P6149, DOI 10.1073/pnas.81.19.6149; NORMAN AW, 1993, J BIOL CHEM, V268, P20022; NUNN JD, 1986, IMMUNOLOGY, V59, P479; OHARA J, 1987, NATURE, V325, P537, DOI 10.1038/325537a0; PEACOCK M, 1982, VITAMIN D CHEM BIOCH, P83; PIKE JW, 1984, J BIOL CHEM, V259, P1167; PIKE JW, 1985, BIOCHEM BIOPH RES CO, V131, P378, DOI 10.1016/0006-291X(85)91813-3; PIKE JW, 1991, ANNU REV NUTR, V11, P189, DOI 10.1146/annurev.nu.11.070191.001201; PIKE JW, 1985, VITAMIN D CHEM BIOCH, P97; POLS HAP, 1990, J STEROID BIOCHEM, V37, P873, DOI 10.1016/0960-0760(90)90435-N; PROVVEDINI DM, 1986, J IMMUNOL, V136, P2734; PROVVEDINI DM, 1983, SCIENCE, V221, P1181, DOI 10.1126/science.6310748; PROVVEDINI DM, 1986, BONE, V7, P23; RABIN EM, 1985, P NATL ACAD SCI USA, V82, P2935, DOI 10.1073/pnas.82.9.2935; REDDY GS, 1989, BIOCHEMISTRY-US, V28, P1763, DOI 10.1021/bi00430a051; REICHEL H, 1989, NEW ENGL J MED, V320, P980, DOI 10.1056/NEJM198904133201506; REINHARDT TA, 1989, J BIOL CHEM, V264, P15917; RIGBY WFC, 1984, J CLIN INVEST, V74, P1451, DOI 10.1172/JCI111557; RIGBY WFC, 1988, IMMUNOL TODAY, V9, P54; RIGBY WFC, 1987, J CLIN INVEST, V79, P1659, DOI 10.1172/JCI113004; ROSMARIN AG, 1989, BLOOD, V73, P131; Sambrook J, 1989, MOL CLONING LABORATO; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; SCHRADER M, 1993, J BIOL CHEM, V268, P17830; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; SHIOZAWA S, 1987, INT J IMMUNOPHARMACO, V9, P719, DOI 10.1016/0192-0561(87)90043-9; SUGDEN B, 1983, J VIROL, V46, P800, DOI 10.1128/JVI.46.3.800-807.1983; SUNDSTROM C, 1976, INT J CANCER, V17, P565, DOI 10.1002/ijc.2910170504; THORLEYLAWSON DA, 1985, J IMMUNOL, V134, P3007; UENO K, 1992, BIOCHEM BIOPH RES CO, V189, P1521, DOI 10.1016/0006-291X(92)90248-J; VERCELLI D, 1988, J EXP MED, V167, P1406, DOI 10.1084/jem.167.4.1406; YOKOTA A, 1988, CELL, V55, P611, DOI 10.1016/0092-8674(88)90219-X; YU XP, 1991, J BIOL CHEM, V266, P7588	69	25	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13437	13443						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175775				2022-12-25	WOS:A1994NK18400058
J	MUKHOPADHYAY, CK; CHATTERJEE, IB				MUKHOPADHYAY, CK; CHATTERJEE, IB			NADPH-INITIATED CYTOCHROME P450-MEDIATED FREE METAL ION-INDEPENDENT OXIDATIVE DAMAGE OF MICROSOMAL PROTEINS - EXCLUSIVE PREVENTION BY ASCORBIC-ACID	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTAMINE-SYNTHETASE; OXYGEN RADICALS; COVALENT MODIFICATION; CATALYZED OXIDATION; LIPID-PEROXIDATION; LIVER-MICROSOMES; DEGRADATION; TURNOVER; INACTIVATION; CONSEQUENCES	In this paper we demonstrate that NADPH-initiated oxidative damage of microsomal proteins occurs in the absence of free metal ions and that this protein oxidation is mediated by cytochrome P450 (cyt P450). Oxidized proteins are rapidly degraded by proteases. Ascorbate (AH(2)) specifically inhibits free metal ion-independent cyt P450-mediated protein oxidation and thereby prevents subsequent proteolytic degradation. Other scavengers of reactive oxygen species including superoxide dismutase, catalase, and glutathione are ineffective. This is in variance with free metal ion-catalyzed protein oxidation, which is accelerated by AH(2), and inhibited by catalase. Oxidative damage of proteins has been assessed by the production of carbonyl groups, bi-tyrosine formation, and tryptophan loss. The mechanism of protein oxidation has been studied using a reconstituted system comprised of purified NADPH-cyt P450 reductase, cyt P450, and isolated microsomal proteins as well as model polypeptides, e.g. poly L-proline and poly-L-lysine. Cyt P450 Fe3+ is reduced by NADPH-cyt P450 reductase to cyt P450 Fe2+, which consumes oxygen in a stoichiometric proportion to produce cyt P450 Fe2+ O-2, the resonance form of which is a perferryl moiety, cyt P450 Fe3+.O-2(radical-anion). It is proposed that cyt P450 Fe3+.O-2(radical-anion) abstracts hydrogen from amino acid side chains leading to the production of carbonyl derivatives. Tentatively, AH(2) prevents protein oxidation by interacting with cyt P450 Fe3+.O-2(radical-anion).	UNIV COLL SCI CALCUTTA, DEPT BIOCHEM, CALCUTTA 700019, INDIA	University of Calcutta								AMICI A, 1989, J BIOL CHEM, V264, P3341; BIELSKI BHJ, 1975, ANN NY ACAD SCI, V258, P231, DOI 10.1111/j.1749-6632.1975.tb29283.x; CHAKRABARTY S, 1992, MOL CELL BIOCHEM, V111, P41; CHAKRABARTY S, 1993, IN PRESS FREE RADICA; CHAPMAN ML, 1989, J RHEUMATOL, V16, P15; CLEMETSON CAB, 1989, VITAMIN C, V2, P213; DAVIES KJA, 1987, J BIOL CHEM, V262, P9895; DAVIES KJA, 1987, J BIOL CHEM, V262, P8220; DAVIES KJA, 1987, J BIOL CHEM, V262, P9908; DAVIES KJA, 1987, J BIOL CHEM, V262, P9902; DAVIES KJA, 1987, J BIOL CHEM, V262, P9914; DAVIES KJA, 1987, J BIOL CHEM, V262, P8227; FARBER JM, 1982, FED PROC, V41, P865; FUCCI L, 1983, P NATL ACAD SCI-BIOL, V80, P1521, DOI 10.1073/pnas.80.6.1521; GARLAND D, 1986, ARCH BIOCHEM BIOPHYS, V251, P771, DOI 10.1016/0003-9861(86)90389-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVINE RL, 1990, METHOD ENZYMOL, V186, P464; LEVINE RL, 1981, P NATL ACAD SCI-BIOL, V78, P2120, DOI 10.1073/pnas.78.4.2120; LEVINE RL, 1983, J BIOL CHEM, V258, P1823; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Masters B, 1967, METHOD ENZYMOL, V10, P565; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; MINOTTI G, 1992, ARCH BIOCHEM BIOPHYS, V297, P189, DOI 10.1016/0003-9861(92)90661-F; MURPHY ME, 1989, BIOCHEM J, V260, P359, DOI 10.1042/bj2600359; OLIVER CN, 1987, J BIOL CHEM, V262, P5488; OLIVER CN, 1984, MOL BASIS AGING, P235; OMURA T, 1964, J BIOL CHEM, V239, P2370; PACIFICI RE, 1990, METHOD ENZYMOL, V186, P485; PALAMANDA JR, 1992, ARCH BIOCHEM BIOPHYS, V293, P103, DOI 10.1016/0003-9861(92)90371-3; PORTER TD, 1991, J BIOL CHEM, V266, P13469; RIVETT AJ, 1985, J BIOL CHEM, V260, P2600; RIVETT AJ, 1986, CURR TOP CELL REGUL, V28, P291; RIVETT AJ, 1985, J BIOL CHEM, V260, P300; ROSEMAN JE, 1987, J BIOL CHEM, V260, P12600; STADTMAN ER, 1986, TRENDS BIOCHEM SCI, V11, P11, DOI 10.1016/0968-0004(86)90221-5; STADTMAN ER, 1985, ARCH BIOCHEM BIOPHYS, V239, P379, DOI 10.1016/0003-9861(85)90703-9; STADTMAN ER, 1991, J BIOL CHEM, V266, P2005; STADTMAN ER, 1990, BIOCHEMISTRY-US, V29, P6323, DOI 10.1021/bi00479a001; STADTMAN ER, 1990, FREE RADICAL BIO MED, V9, P315, DOI 10.1016/0891-5849(90)90006-5; STARKEREED PE, 1989, ARCH BIOCHEM BIOPHYS, V275, P559, DOI 10.1016/0003-9861(89)90402-5; VANDERHO.TA, 1974, J BIOL CHEM, V249, P6302; ZANNONI VG, 1982, ADV CHEM SER, P349	42	38	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13390	13397						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175769				2022-12-25	WOS:A1994NK18400052
J	NISHIZAWA, M; YASUHARA, T; NAKAI, T; FUJIKI, Y; OHASHI, A				NISHIZAWA, M; YASUHARA, T; NAKAI, T; FUJIKI, Y; OHASHI, A			MOLECULAR-CLONING OF THE AMINOPEPTIDASE-Y GENE OF SACCHAROMYCES-CEREVISIAE - SEQUENCE-ANALYSIS AND GENE DISRUPTION OF A NEW AMINOPEPTIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEINASE YSCB; AMINO-ACIDS; YEAST; PROPEPTIDE; ACTIVATION; LOCALIZATION; MATURATION; CATALYSTS; PRECURSOR; CLEAVAGE	A yeast genomic DNA encoding a new vacuolar aminopeptidase, aminopeptidase Y, was isolated by using a cDNA fragment obtained by screening the lambda gt11 yeast cDNA library with anti-aminopeptidase Y antibody. The DNA sequence encodes 537 amino acids. The ''mature'' protein, whose NH2-terminal sequence was determined previously by analysis of the purified enzyme, consists of 481 amino acids, and the calculated molecular weight (52,900) coincides with the value obtained by SDS-polyacrylamide gel electrophoresis of the enzyme after removal of sugar chains, 53 kDa. The 56-residue preprosequence was divided into two parts by putative processing sites for signal peptidase and conversion to the mature form; the 21-residue presequence has a hydrophobic stretch which may function as the signal sequence for transit through the endoplasmic reticulum, and the 35-residue prosequence (4013 Da) accounts for the 4-kDa difference between proaminopeptidase Y in the vacuolar proteases-deleted ABYS1 mutant and wild-type mature enzyme. The aminopeptidase Y gene was localized on chromosome II by genetic mapping. A deletion mutant was constructed by disrupting the aminopeptidase Y gene. Vacuolar aminopeptidase activities toward Ala-4-methylcoumaryl-7-amide (MCA) and Lys-MCA were 13 and 20% of wild-type, and those in the presence of Co2+ were 2.2 and 2.8%, respectively. Mutant cells showed no ability to hydrolyze Lys-Ala-MCA to Lys and Ala-MCA although vacuolar carboxypeptidase Y activity was similar to that in wild-type cells.	MEIJI INST HLTH SCI,ODAWARA 250,JAPAN									AMMERER G, 1986, MOL CELL BIOL, V6, P2490, DOI 10.1128/MCB.6.7.2490; BURLEY SK, 1990, P NATL ACAD SCI USA, V87, P6878, DOI 10.1073/pnas.87.17.6878; CHANG YH, 1989, J BIOL CHEM, V264, P6979; FREY J, 1978, BIOCHIM BIOPHYS ACTA, V527, P31, DOI 10.1016/0005-2744(78)90253-X; GARCIAALVAREZ N, 1991, EUR J BIOCHEM, V202, P993, DOI 10.1111/j.1432-1033.1991.tb16461.x; HAMILTON R, 1987, NUCLEIC ACIDS RES, V15, P3581, DOI 10.1093/nar/15.8.3581; HIRSCH HH, 1992, EUR J BIOCHEM, V203, P641, DOI 10.1111/j.1432-1033.1992.tb16594.x; JOHNSON LM, 1987, CELL, V48, P875, DOI 10.1016/0092-8674(87)90084-5; JONES EW, 1991, J BIOL CHEM, V266, P7963; JONES EW, 1984, ANNU REV GENET, V18, P233, DOI 10.1146/annurev.ge.18.120184.001313; KLIONSKY DJ, 1988, MOL CELL BIOL, V8, P2105, DOI 10.1128/MCB.8.5.2105; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MECHLER B, 1987, EMBO J, V6, P2157, DOI 10.1002/j.1460-2075.1987.tb02483.x; METZ G, 1976, BIOCHIM BIOPHYS ACTA, V429, P933, DOI 10.1016/0005-2744(76)90338-7; NEBES VL, 1991, J BIOL CHEM, V266, P22851; OHSUMI Y, 1981, J BIOL CHEM, V256, P2079; PARODI AJ, 1979, BIOCHIM BIOPHYS ACTA, V559, P1, DOI 10.1016/0304-4157(79)90006-6; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; RIORDAN JF, 1984, METHOD ENZYMAT AN, V5, P44; Rothstein R., 1985, DNA CLONING, VII, P45; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TEICHERT U, 1989, J BIOL CHEM, V264, P16037; TRUMBLY RJ, 1983, J BACTERIOL, V156, P36, DOI 10.1128/JB.156.1.36-48.1983; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; VALLS LA, 1990, J CELL BIOL, V111, P361, DOI 10.1083/jcb.111.2.361; VALLS LA, 1987, CELL, V48, P887, DOI 10.1016/0092-8674(87)90085-7; VANDENHAZEL HB, 1992, EUR J BIOCHEM, V207, P277; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; YASUHARA T, 1994, J BIOL CHEM, V269, P13644	30	27	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13651	13655						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175800				2022-12-25	WOS:A1994NK18400086
J	SMITH, AG; SANTANA, MA; WALLACECOOK, ADM; ROPER, JM; LABBEBOIS, R				SMITH, AG; SANTANA, MA; WALLACECOOK, ADM; ROPER, JM; LABBEBOIS, R			ISOLATION OF A CDNA-ENCODING CHLOROPLAST FERROCHELATASE FROM ARABIDOPSIS-THALIANA BY FUNCTIONAL COMPLEMENTATION OF A YEAST MUTANT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; SUPEROXIDE-DISMUTASE; PRECURSOR PROTEINS; MOLECULAR-CLONING; SEQUENCE-ANALYSIS; GENE DISRUPTION; MITOCHONDRIA; EXPRESSION; PURIFICATION	Ferrochelatase catalyzes the insertion of ferrous iron into protoporphyrin IX to form protoheme. It is located in the mitochondria in all eukaryotes and is also found in plastids in plants. Although it has been purified from animals and microorganisms, and genes for it isolated and characterized, very little is known about plant ferrochelatases. We have isolated a cDNA for ferrochelatase from the higher plant Arabidopsis thaliana by functional complementation of a mutant of Saccharomyces cerevisiae defective in this enzyme. The cDNA encodes a protein of 52 kDa, which has 25-35% sequence similarity to ferrochelatases from other organisms. There is an N-terminal extension of about 65 residues, which is almost certainly the chloroplast transit peptide, since the precursor protein, transcribed and translated in vitro, is efficiently imported and processed to the mature size by isolated pea chloroplasts. In contrast, the precursor was not processed by mitochondrial processing peptidase activity, nor could import into isolated yeast mitochondria be demonstrated conclusively, although, presumably, in the rescued yeast mutant, at least some of the Arabidopsis ferrochelatase must be present in the mitochondria. A single transcript the same size as the cDNA was detected in both Arabidopsis leaves and roots, although the amount of message was greater in the photosynthetic tissue. Southern analysis suggests that there is a single gene for chloroplast ferrochelatase in Arabidopsis.	UNIV PARIS 07,INST JACQUES MONOD,F-75251 PARIS 05,FRANCE	UDICE-French Research Universities; Universite Paris Cite	SMITH, AG (corresponding author), UNIV CAMBRIDGE,DEPT PLANT SCI,DOWNING ST,CAMBRIDGE CB2 3EA,ENGLAND.			Smith, Alison Gail/0000-0001-6511-5704	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; Beale S. I., 1990, BIOSYNTHESIS HEME CH, P287; BEAUMONT C, 1984, EXP CELL RES, V154, P474, DOI 10.1016/0014-4827(84)90171-X; BOUTRY M, 1987, NATURE, V328, P340, DOI 10.1038/328340a0; BOWLER C, 1989, P NATL ACAD SCI USA, V86, P3237, DOI 10.1073/pnas.86.9.3237; BRENNER DA, 1991, P NATL ACAD SCI USA, V88, P849, DOI 10.1073/pnas.88.3.849; CAMADRO JM, 1988, J BIOL CHEM, V263, P11675; CAVENER DR, 1991, NUCLEIC ACIDS RES, V19, P3185, DOI 10.1093/nar/19.12.3185; CHAUMONT F, 1990, J BIOL CHEM, V265, P16856; CLINE K, 1985, J BIOL CHEM, V260, P3691; CLINE K, 1984, PLANT PHYSIOL, V75, P675, DOI 10.1104/pp.75.3.675; COLICELLI J, 1989, P NATL ACAD SCI USA, V86, P3599, DOI 10.1073/pnas.86.10.3599; Dailey H. A., 1990, BIOSYNTHESIS HEME CH, P123; DELAUNEY AJ, 1990, MOL GEN GENET, V221, P299, DOI 10.1007/BF00259392; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ELDRIDGE MG, 1992, PROTEIN SCI, V1, P271; FRUSTACI JM, 1992, J BACTERIOL, V174, P4223, DOI 10.1128/JB.174.13.4223-4229.1992; GASSER SM, 1982, J BIOL CHEM, V257, P3034; GIETL C, 1992, BIOCHIM BIOPHYS ACTA, V1100, P217, DOI 10.1016/0167-4838(92)90476-T; GOLDIN BR, 1969, BIOCHIM BIOPHYS ACTA, V171, P321, DOI 10.1016/0005-2744(69)90165-X; HANSSON M, 1992, J BACTERIOL, V174, P8081, DOI 10.1128/JB.174.24.8081-8093.1992; HENIKOFF S, 1981, NATURE, V289, P33, DOI 10.1038/289033a0; HIRT H, 1991, P NATL ACAD SCI USA, V88, P1636, DOI 10.1073/pnas.88.5.1636; HUANG JT, 1990, PLANT CELL, V2, P1249, DOI 10.1105/tpc.2.12.1249; HURT EC, 1986, EMBO J, V5, P1343, DOI 10.1002/j.1460-2075.1986.tb04365.x; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JONES OTG, 1968, BIOCHEM J, V107, P113, DOI 10.1042/bj1070113; KARR SR, 1988, BIOCHEM J, V254, P799, DOI 10.1042/bj2540799; KRONSTAD JW, 1989, GENE, V79, P97, DOI 10.1016/0378-1119(89)90095-4; LABBEBOIS R, 1990, J BIOL CHEM, V265, P7278; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LITTLE HN, 1976, BIOCHEM J, V156, P309, DOI 10.1042/bj1560309; MAARSE AC, 1984, EMBO J, V3, P2831, DOI 10.1002/j.1460-2075.1984.tb02216.x; MINET M, 1992, PLANT J, V2, P417; MIYAMOTO K, 1991, J MOL BIOL, V219, P393, DOI 10.1016/0022-2836(91)90180-E; MORGENTHALER JJ, 1975, ARCH BIOCHEM BIOPHYS, V168, P289, DOI 10.1016/0003-9861(75)90253-2; NAKAHASHI Y, 1990, BIOCHEM BIOPH RES CO, V173, P748, DOI 10.1016/S0006-291X(05)80099-3; NAKAHIGASHI K, 1991, P NATL ACAD SCI USA, V88, P10520, DOI 10.1073/pnas.88.23.10520; PFALLER R, 1989, J BIOL CHEM, V264, P34; PORRA RJ, 1968, BIOCHEM J, V108, P343, DOI 10.1042/bj1080343; PRUITT RE, 1986, J MOL BIOL, V187, P169, DOI 10.1016/0022-2836(86)90226-3; Sambrook J, 1989, MOL CLONING LABORATO; SENTENAC H, 1992, SCIENCE, V256, P663, DOI 10.1126/science.1585180; SMEEKENS S, 1987, PLANT MOL BIOL, V9, P377, DOI 10.1007/BF00014912; SOGAARD M, 1990, GENE, V94, P173, DOI 10.1016/0378-1119(90)90384-4; TAKETANI S, 1990, J BIOL CHEM, V265, P19377; THOMPSON WF, 1983, PLANTA, V158, P487, DOI 10.1007/BF00397240; VANCAMP W, 1990, P NATL ACAD SCI USA, V87, P9903, DOI 10.1073/pnas.87.24.9903; VOLLAND C, 1988, J BIOL CHEM, V263, P8294; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; WARD AC, 1990, NUCLEIC ACIDS RES, V18, P5319, DOI 10.1093/nar/18.17.5319; WHELAN J, 1990, PLANT MOL BIOL, V14, P977, DOI 10.1007/BF00019394; WHELAN J, 1991, PLANT MOL BIOL, V16, P283, DOI 10.1007/BF00020559; WITTY M, 1993, PLANT PHYSIOL, V103, P139, DOI 10.1104/pp.103.1.139; ZHU D, 1992, GENETICS, V131, P803	55	59	63	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13405	13413						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175771				2022-12-25	WOS:A1994NK18400054
J	TURINA, P; CAPALDI, RA				TURINA, P; CAPALDI, RA			ATP HYDROLYSIS-DRIVEN STRUCTURAL-CHANGES IN THE GAMMA-SUBUNIT OF ESCHERICHIA-COLI ATPASE MONITORED BY FLUORESCENCE FROM PROBES BOUND AT INTRODUCED CYSTEINE RESIDUES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL ADENOSINE-TRIPHOSPHATASE; EPSILON-SUBUNIT; CATALYTIC SITES; CRYOELECTRON MICROSCOPY; ELEMENTARY STEPS; RATE CONSTANTS; F1 ATPASE; F1-ATPASE; SYNTHASE; NUCLEOTIDE	Four mutants of the Escherichia coli F(1)ATPase, gamma S8-C, gamma T106-C, gamma S179-C, and gamma V286-C, which have a cysteine introduced at different sites in the gamma-subunit by site-directed mutagenesis, were reacted with the fluorescent reagent N-(4-7-(diethylamino)4-methylcoumarin-3-yl)-maleimide (CM) under conditions that selectively label the introduced Cys residue. With each mutant the effect of nucleotide binding on the fluorescence of the probe has been monitored. The results obtained with the mutants gamma S8-C and gamma T106-C are similar. In both cases, there was a spectral shift and change in fluorescence intensity on adding AMP.PNP or ATP to enzyme emptied of nucleotide from catalytic sites, while no change in the fluorescence spectrum was observed upon adding ADP. The fluorescence spectral changes obtained with ATP were transient and involved an initial rapid fluorescence enhancement followed by a subsequent fluorescence quenching. The kinetics of these ATP-induced fluorescence changes and the kinetics of ATP hydrolysis as monitored by the rates of ATP binding and of Pi formation were the same under conditions of unisite catalysis, indicating that the conformational changes in the gamma-subunit being measured by the fluorescent probe are driven by ATP hydrolysis in catalytic sites. No nucleotide-dependent fluorescence changes were observed with CM bound at a Cys at position 179. Nucleotide-dependent changes in fluorescence were seen with CM bound at position 286, but these appear to reflect structural changes due to binding of ADP or ATP in noncatalytic sites. The fluorescence changes observed in mutants gamma S8-C and gamma T106-C were not seen in subunit epsilon free E. coli F(1)ATPase, although such enzyme preparations are highly active ATPases. We conclude that the structural changes monitored by the fluorescent probe are a part of the conformational coupling, whereby catalytic site events are linked to proton channeling.	UNIV OREGON, INST MOLEC BIOL, EUGENE, OR 97403 USA	University of Oregon			Turina, Paola/P-9342-2015; Turina, Paola/GYJ-0656-2022	Turina, Paola/0000-0001-9174-511X; 	PHS HHS [LH 24236] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ABRAHAMS JP, 1993, EMBO J, V12, P1775, DOI 10.1002/j.1460-2075.1993.tb05825.x; AGGELER R, 1993, J BIOL CHEM, V268, P14576; AGGELER R, 1992, J BIOL CHEM, V267, P21355; AGGELER R, 1992, BIOCHEMISTRY-US, V31, P2956, DOI 10.1021/bi00126a016; ALSHAWI MK, 1988, J BIOL CHEM, V263, P19640; ALSHAWI MK, 1992, BIOCHEMISTRY-US, V31, P878, DOI 10.1021/bi00118a033; AVRON M, 1960, BIOCHIM BIOPHYS ACTA, V40, P257, DOI 10.1016/0006-3002(60)91350-0; BARSHOP BA, 1983, ANAL BIOCHEM, V130, P134, DOI 10.1016/0003-2697(83)90660-7; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; CAPALDI RA, 1994, IN PRESS TRENDS BIOC; CROSS RL, 1988, J BIOENERG BIOMEMBR, V20, P395, DOI 10.1007/BF00762200; CUNNINGHAMD, 1988, J BIOL CHEM, V263, P18850; DUNN SD, 1987, BIOCHEMISTRY-US, V26, P4488, DOI 10.1021/bi00388a047; DUNN SD, 1982, J BIOL CHEM, V257, P7354; DUNN SD, 1986, ANAL BIOCHEM, V159, P35, DOI 10.1016/0003-2697(86)90304-0; FUTAI M, 1989, ANNU REV BIOCHEM, V58, P111; GOGOL EP, 1989, BIOCHEMISTRY-US, V28, P4717, DOI 10.1021/bi00437a031; GOGOL EP, 1987, FEBS LETT, V219, P274, DOI 10.1016/0014-5793(87)80234-X; GOGOL EP, 1989, BIOCHEMISTRY-US, V28, P4709, DOI 10.1021/bi00437a030; GRUBMEYER C, 1982, J BIOL CHEM, V257, P2092; ISHII N, 1993, J BIOCHEM-TOKYO, V113, P245, DOI 10.1093/oxfordjournals.jbchem.a124034; LABAHN A, 1990, FEBS LETT, V271, P116, DOI 10.1016/0014-5793(90)80385-V; LAEMMLI UK, 1970, BIOCHEMISTRY-US, V9, P4620; LOTSCHER HR, 1984, BIOCHEMISTRY-US, V23, P4140, DOI 10.1021/bi00313a020; LUCKEN U, 1990, BIOCHEMISTRY-US, V29, P5339; MASUNOYAGI A, 1985, P NATL ACAD SCI USA, V82, P7550; MENDELHARTVIG J, 1991, BIOCHEMISTRY-US, V30, P1278, DOI 10.1021/bi00219a017; MENDELHARTVIG J, 1991, BIOCHEMISTRY-US, V30, P10987, DOI 10.1021/bi00109a025; MENDELHARTVIG J, 1991, BIOCHIM BIOPHYS ACTA, V1060, P115, DOI 10.1016/S0005-2728(05)80126-4; PATEL AM, 1990, MOL MICROBIOL, V4, P1941, DOI 10.1111/j.1365-2958.1990.tb02043.x; PENEFSKY HS, 1985, P NATL ACAD SCI USA, V82, P1589, DOI 10.1073/pnas.82.6.1589; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; PENEFSKY HS, 1986, METHOD ENZYMOL, V126, P608; RICHTER ML, 1987, J BIOL CHEM, V262, P15037; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; SIPPEL TO, 1981, J HISTOCHEM CYTOCHEM, V29, P1377, DOI 10.1177/29.12.7320496; STERNWEIS PC, 1980, BIOCHEMISTRY-US, V19, P526, DOI 10.1021/bi00544a021; TANG CL, 1994, J BIOL CHEM, V269, P4467; TURINA P, 1993, J BIOL CHEM, V268, P6978; WILKENS S, 1992, ARCH BIOCHEM BIOPHYS, V299, P105, DOI 10.1016/0003-9861(92)90250-Z; WILKENS S, 1994, HOPPESYELERS Z BIOL, V375, P43; WISE JG, 1981, J BIOL CHEM, V256, P383; WOOD JM, 1987, J BIOL CHEM, V262, P2180; [No title captured]	44	42	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13465	13471						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175779				2022-12-25	WOS:A1994NK18400062
J	WAKABAYASHI, S; BERTRAND, B; IKEDA, T; POUYSSEGUR, J; SHIGEKAWA, M				WAKABAYASHI, S; BERTRAND, B; IKEDA, T; POUYSSEGUR, J; SHIGEKAWA, M			MUTATION OF CALMODULIN-BINDING SITE RENDERS THE NA+/H+ EXCHANGER (NHE1) HIGHLY H+-SENSITIVE AND CA2+ REGULATION-DEFECTIVE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR PH REGULATION; GROWTH-FACTOR; MOLECULAR-CLONING; HUMAN-FIBROBLASTS; ALPHA-THROMBIN; OKADAIC ACID; KINASE-C; ANTIPORTER; ACTIVATION; EXPRESSION	The ubiquitous plasma membrane Na+/H+ exchanger (NHE1) is rapidly activated in response to various extracellular signals. To understand how the intracellular Ca2+ is involved in this activation process, we investigated the effect of Ca2+ ionophore ionomycin on activity of the wild-type or mutant NHE1 expressed in the exchanger deficient fibroblasts (PS120). In wild-type transfectants, a short (up to 1 min) incubation with ionomycin induced a significant alkaline shift (similar to 0.2 pH unit) in the intracellular pH (pH(i)) dependence of the rate of 5-(N-ethyl-N-isopropyl) amiloride-sensitive Na-22(+) uptake, without changes in the cell volume and phosphorylation state of NHE1. Mutations that prevented calmodulin (CaM) binding to a high affinity binding region (region A, amino acids 636-656) rendered NHE1 constitutively active by inducing a similar alkaline shift in pH(i) dependence of Na+/H+ exchange. These same mutations abolished the ionomycin-induced NHE1 activation. These data suggest that CaM-binding region A functions as an ''autoinhibitory domain'' and that Ca2+/CaM activates NHE1 by binding to region A and thus abolishing its inhibitory effect. Furthermore, we found that a short stimulation with thrombin and ionomycin had apparently no additive effects on the alkaline shift in the pH(i) dependence of Na+/H+ exchange and that deletion of region A also abolished such an alkaline shift induced by a short thrombin stimulation, The results strongly suggest that the early thrombin response and the ionomycin response share the same activation mechanism. Based on these data and the results shown in the accompanying paper (Bertrand, B., Wakabayashi, S., Ikeda, T, Pouyssegur, J., and Shigekawa, M. (1994) J. Biol. Chem. 269, 13703-13709), we propose that CaM is one of the major ''signal transducers'' that mediate distinct extracellular signals to the ''pH(i) sensor'' of NHE1.	UNIV NICE,CNRS,CTR BIOCHIM,F-06108 NICE 2,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	WAKABAYASHI, S (corresponding author), NATL CARDIOVASC CTR,RES INST,DEPT MOLEC PHYSIOL,SUITA,OSAKA 565,JAPAN.							ARONSON PS, 1982, NATURE, V299, P161, DOI 10.1038/299161a0; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERTRAND B, 1994, J BIOL CHEM, V269, P13703; BIANCHINI L, 1991, J BIOL CHEM, V266, P15406; BORGESE F, 1992, P NATL ACAD SCI USA, V89, P6765, DOI 10.1073/pnas.89.15.6765; FAFOURNOUX P, 1991, BIOCHEMISTRY-US, V30, P9510, DOI 10.1021/bi00103a018; FALCHETTO R, 1991, J BIOL CHEM, V266, P2930; GANZ MB, 1989, NATURE, V337, P648, DOI 10.1038/337648a0; GRINSTEIN S, 1987, J GEN PHYSIOL, V89, P185, DOI 10.1085/jgp.89.2.185; GRINSTEIN S, 1989, BIOCHIM BIOPHYS ACTA, V988, P73, DOI 10.1016/0304-4157(89)90004-X; HENDEY B, 1989, J BIOL CHEM, V264, P19540; HUANG CL, 1987, J BIOL CHEM, V262, P14134; IVES HE, 1987, P NATL ACAD SCI USA, V84, P1950, DOI 10.1073/pnas.84.7.1950; KIMURA M, 1990, J BIOL CHEM, V265, P21068; LALLEMAIN G, 1984, J BIOL CHEM, V259, P5809; MOOLENAAR WH, 1983, NATURE, V304, P645, DOI 10.1038/304645a0; MOOLENAAR WH, 1986, ANNU REV PHYSIOL, V48, P363; ORLOWSKI J, 1992, J BIOL CHEM, V267, P9331; ORLOWSKI J, 1993, J BIOL CHEM, V268, P16369; PARIS S, 1984, J BIOL CHEM, V259, P989; POUYSSEGUR J, 1984, P NATL ACAD SCI-BIOL, V81, P4833, DOI 10.1073/pnas.81.15.4833; SARDET C, 1990, SCIENCE, V247, P723, DOI 10.1126/science.2154036; SARDET C, 1989, CELL, V56, P271, DOI 10.1016/0092-8674(89)90901-X; SARDET C, 1991, J BIOL CHEM, V266, P19166; SODERLING TR, 1990, J BIOL CHEM, V265, P1823; TSE CM, 1992, J BIOL CHEM, V267, P9340; TSE CM, 1993, J BIOL CHEM, V268, P11917; VANOBBERGHENSCHILLING E, 1985, EMBO J, V4, P2927, DOI 10.1002/j.1460-2075.1985.tb04025.x; VICENTINI LM, 1985, P NATL ACAD SCI USA, V82, P8053, DOI 10.1073/pnas.82.23.8053; WAKABAYASHI S, 1992, REV PHYSIOL BIOCH P, V119, P157; WAKABAYASHI S, 1992, P NATL ACAD SCI USA, V89, P2424, DOI 10.1073/pnas.89.6.2424; WAKABAYASHI S, 1994, J BIOL CHEM, V269, P5583; WANG Z, 1993, J BIOL CHEM, V268, P11925; WOLL E, 1993, FEBS LETT, V322, P261, DOI 10.1016/0014-5793(93)81583-L	34	228	231	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13710	13715						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175807				2022-12-25	WOS:A1994NK18400095
J	BROWN, MP; SHAIKH, N; BRENOWITZ, M; BRAND, L				BROWN, MP; SHAIKH, N; BRENOWITZ, M; BRAND, L			THE ALLOSTERIC INTERACTION BETWEEN D-GALACTOSE AND THE ESCHERICHIA-COLI GALACTOSE REPRESSOR PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAL REPRESSOR; TRYPTOPHYL FLUORESCENCE; CONFORMATIONAL CHANGE; OPERON PROMOTERS; BINDING PROTEIN; LAC REPRESSOR; 2 PROMOTERS; L-ARABINOSE; OPERATOR; DNA	The Escherichia cell galactose repressor protein (GalR) inhibits transcription of the gal operon upon binding to two operator sites (1-7).This DNA binding activity is inhibited when D-galactose or D-fucose binds to GalR (8-14). Fluorescence spectroscopy was used to characterize the single tryptophan of GalR and to investigate the interaction between galactose and GalR. Fluorescence quenching experiments place both tryptophan residues of the GalR dimer in similar, solvent-exposed locations. Galactose is shown to enhance the intrinsic tryptophan fluorescence of GalR, the source of which is not explained by a change in decay times, but is due to an increase in the pre exponential factor of the longest of the three fluorescence decay times. It is shown that the beta-anomer of D-galactose is the likely form that binds to GalR. An increase in pH from 6.3 to 9.5 causes the equilibrium association constant (K-a) describing the galactose-GalR interaction to decrease 10-fold. The interaction is cooperative below pH 9.5, Over the pH range of 6.3 to 9.5, the tryptophan solvent exposure of GalR increases. Galactose binding also induces an increase in exposure. These results, and others presented in this paper, show that both pH and galactose cause global alterations in the structure of GalR.	JOHNS HOPKINS UNIV,DEPT BIOL,BALTIMORE,MD 21218; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT BIOCHEM,BRONX,NY 10461	Johns Hopkins University; Yeshiva University; Albert Einstein College of Medicine			FACS, Nina S. Naidu MD/W-8049-2019		NIGMS NIH HHS [GM07231, GM11632, GM39929] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039929, R29GM039929, R01GM011632] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADHYA S, 1966, J BACTERIOL, V92, P601, DOI 10.1128/JB.92.3.601-608.1966; ADHYA S, 1979, NATURE, V279, P492, DOI 10.1038/279492a0; ADHYA S, 1989, ANNU REV GENET, V23, P207; BOOS W, 1972, J BIOL CHEM, V247, P917; BRENOWITZ M, 1990, BIOCHEMISTRY-US, V29, P3374, DOI 10.1021/bi00465a033; BROCHON JC, 1977, BIOCHEM BIOPH RES CO, V79, P1261, DOI 10.1016/0006-291X(77)91142-1; BUTTIN G, 1963, J MOL BIOL, V7, P164, DOI 10.1016/S0022-2836(63)80044-3; CHAKERIAN AE, 1991, J BIOL CHEM, V266, P22206; CHANG WI, 1993, J BIOL CHEM, V268, P17613; Contino P B, 1991, J Fluoresc, V1, P5, DOI 10.1007/BF00865253; DALY TJ, 1986, BIOCHEMISTRY-US, V25, P5474, DOI 10.1021/bi00367a019; DILAURO R, 1979, NATURE, V279, P494, DOI 10.1038/279494a0; EFTINK MR, 1976, BIOCHEMISTRY-US, V15, P672, DOI 10.1021/bi00648a035; EFTINK MR, 1981, ANAL BIOCHEM, V114, P199, DOI 10.1016/0003-2697(81)90474-7; GARDNER JA, 1990, J BIOL CHEM, V265, P21061; GASTON K, 1988, BIOCHEM J, V253, P809, DOI 10.1042/bj2530809; GOODRICH JA, 1992, J MOL BIOL, V224, P15, DOI 10.1016/0022-2836(92)90573-3; HSIEH M, 1994, IN PRESS J BIOL CHEM, V269; IRANI M, 1989, J BACTERIOL, V171, P1623, DOI 10.1128/jb.171.3.1623-1630.1989; IRANI MH, 1983, CELL, V32, P783, DOI 10.1016/0092-8674(83)90064-8; JOHNSON ML, 1992, METHOD ENZYMOL, V210, P1; KALCKAR HM, 1959, P NATL ACAD SCI USA, V45, P1776, DOI 10.1073/pnas.45.12.1776; LEHRER SS, 1971, BIOCHEMISTRY-US, V10, P3254, DOI 10.1021/bi00793a015; MAJUMDAR A, 1989, J MOL BIOL, V208, P217, DOI 10.1016/0022-2836(89)90383-5; MAJUMDAR A, 1984, P NATL ACAD SCI-BIOL, V81, P6100, DOI 10.1073/pnas.81.19.6100; MAJUMDAR A, 1987, J BIOL CHEM, V262, P13258; MCGOWAN, 1974, BIOCHEMISTRY-US, V13, P993; MILLER DM, 1983, J BIOL CHEM, V258, P3665; NAKANISHI S, 1973, P NATL ACAD SCI USA, V70, P334, DOI 10.1073/pnas.70.2.334; PARKS JS, 1971, P NATL ACAD SCI USA, V68, P1891, DOI 10.1073/pnas.68.8.1891; PARSONS RG, 1974, J BIOL CHEM, V249, P3602; Pigman W., 1972, CARBOHYDRATES CHEM A, V1, P165; PONNAMBALAM S, 1986, J BIOL CHEM, V261, P6043; ROSS JBA, 1981, BIOCHEMISTRY-US, V20, P4369, DOI 10.1021/bi00518a021; SAEDLER H, 1968, MOL GEN GENET, V102, P79, DOI 10.1007/BF00341872; VYAS NK, 1991, J BIOL CHEM, V266, P5226; WARTELL RM, 1988, NUCLEIC ACIDS RES, V16, P11531, DOI 10.1093/nar/16.24.11531; WU PG, 1991, P NATL ACAD SCI USA, V88, P9355, DOI 10.1073/pnas.88.20.9355	38	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12600	12605						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175668				2022-12-25	WOS:A1994NH71600038
J	DASILVA, CP; EMMRICH, F; GUSE, AH				DASILVA, CP; EMMRICH, F; GUSE, AH			ADRIAMYCIN INHIBITS INOSITOL 1,4,5-TRISPHOSPHATE 3-KINASE ACTIVITY IN-VITRO AND BLOCKS FORMATION OF INOSITOL 1,3,4,5-TETRAKISPHOSPHATE IN STIMULATED JURKAT T-LYMPHOCYTES - DOES INOSITOL 1,3,4,5-TETRAKISPHOSPHATE PLAY A ROLE IN CA2+-ENTRY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; LIPID-PEROXIDATION; CA-2+ INFLUX; HL-60 CELLS; TETRAKISPHOSPHATE; POLYPHOSPHATES; ACTIVATION; TRISPHOSPHATE; MEMBRANE	Effects of the cytostatic drug adriamycin on inositol polyphosphate metabolism were analyzed in a human T-cell line (Jurkat) using a recently developed anion-exchange high performance liquid chromatography/ post-column complexometric dye system. Treatment of intact T-cells with adriamycin prior to stimulation with an anti-CD3 monoclonal antibody induced a dose- and time-dependent decrease in the intracellular level of inositol 1,3,4,5-tetrakisphosphate (complete inhibition after 2 h at 10 mu M adriamycin) and an increase in the level of inositol 1,3,4-trisphosphate without significantly changing the levels of other inositol phosphates. A marked inhibition of the inositol 1,4,5-trisphosphate 3-kinase activity and a slight activation of the inositol 1,3,4,5-tetrakisphosphate 5-phosphatase activity were observed in cytosolic extracts in the presence of adriamycin, providing an explanation for the drug-induced metabolic effect. Adriamycin thus seems to be an extremely valuable tool for further dissecting inositol polyphosphate metabolism, as well as signaling pathways. Along these lines, we observed that adriamycin did not change the free cytosolic Ca2+ concentration of Jurkat T-lymphocytes and, in particular, did not modulate Ca2+ influx upon T-cell receptor stimulation. We conclude that (i) inositol phosphate signaling pathways constitute an as yet undescribed target for the action of adriamycin and that (ii) an increase of inositol 1,3,4,5-tetrakisphosphate is not necessary for sustained Ca2+-entry in stimulated T-cells.	UNIV ERLANGEN NURNBERG,MAX PLANCK SOC,INST CLIN IMMUNOL,CLIN RES UNIT RHEUMATOL IMMUNOL,D-91054 ERLANGEN,GERMANY; UNIV COIMBRA,DEPT CHEM,P-3049 COIMBRA,PORTUGAL; UNIV COIMBRA,CTR CELL BIOL,P-3049 COIMBRA,PORTUGAL	Max Planck Society; University of Erlangen Nuremberg; Universidade de Coimbra; Universidade de Coimbra								BALLA T, 1991, J BIOL CHEM, V266, P24719; BANSAL VS, 1990, ANNU REV CELL BIOL, V6, P41, DOI 10.1146/annurev.cellbio.6.1.41; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BONADONNA G, 1988, HDB MED ONCOLOGY, P335; CAPRANICO G, 1990, BIOCHEMISTRY-US, V29, P562, DOI 10.1021/bi00454a033; CONNOLLY TM, 1986, CELL, V46, P951, DOI 10.1016/0092-8674(86)90077-2; ELY JA, 1990, BIOCHEM J, V268, P333, DOI 10.1042/bj2680333; GAMBETTA RA, 1989, TUMORI, V75, P358, DOI 10.1177/030089168907500411; GREENE RF, 1983, CANCER RES, V43, P3417; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUSE AH, 1993, BIOCHEM J, V291, P447, DOI 10.1042/bj2910447; GUSE AH, 1992, J CHROMATOGR, V593, P157, DOI 10.1016/0021-9673(92)80281-X; GUSE AH, 1992, BIOCHEM J, V288, P489, DOI 10.1042/bj2880489; GUSE AH, 1991, J BIOL CHEM, V266, P24498; HILL TD, 1989, J CELL PHYSIOL, V140, P403, DOI 10.1002/jcp.1041400227; IMBODEN JB, 1987, BIOCHEM J, V247, P695, DOI 10.1042/bj2470695; IRVINE RF, 1986, BIOCHEM J, V240, P917, DOI 10.1042/bj2400917; JOHNSON RM, 1989, SCIENCE, V246, P121, DOI 10.1126/science.2506643; KING WG, 1989, J BIOL CHEM, V264, P6070; LANZI C, 1988, BIOCHEM PHARMACOL, V37, P3497, DOI 10.1016/0006-2952(88)90702-2; LANZI C, 1991, INT J CANCER, V47, P136, DOI 10.1002/ijc.2910470124; LEAR L, 1992, BIOCHEM PHARMACOL, V44, P747, DOI 10.1016/0006-2952(92)90412-C; LUCKHOFF A, 1992, NATURE, V355, P356, DOI 10.1038/355356a0; MAYR GW, 1988, BIOCHEM J, V254, P585, DOI 10.1042/bj2540585; MAYR GW, 1990, METHODS INOSITIDE RE, P83; MCDONALD TV, 1993, J BIOL CHEM, V268, P3889; MURPHREE SA, 1981, BIOCHIM BIOPHYS ACTA, V649, P317, DOI 10.1016/0005-2736(81)90421-1; Neidle S., 1983, MOL ASPECTS ANTICANC, P35; PITTET D, 1989, J BIOL CHEM, V264, P18489; PITTET D, 1989, J BIOL CHEM, V264, P7251; POSADA J, 1989, CANCER RES, V49, P6634; SCHOBITZ B, 1991, EUR J BIOCHEM, V199, P257, DOI 10.1111/j.1432-1033.1991.tb16118.x; SIM SS, 1990, J BIOL CHEM, V265, P10367; TRITTON TR, 1982, SCIENCE, V217, P248, DOI 10.1126/science.7089561; WEISS A, 1986, ANNU REV IMMUNOL, V4, P593, DOI 10.1146/annurev.iy.04.040186.003113	36	24	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12521	12526						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175661				2022-12-25	WOS:A1994NH71600026
J	NARAYAN, S; WIDEN, SG; BEARD, WA; WILSON, SH				NARAYAN, S; WIDEN, SG; BEARD, WA; WILSON, SH			RNA-POLYMERASE-II TRANSCRIPTION .2. RATE OF PROMOTER CLEARANCE IS ENHANCED BY A PURIFIED ACTIVATING TRANSCRIPTION FACTOR CAMP RESPONSE ELEMENT-BINDING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL PREINITIATION COMPLEX; GENE-TRANSCRIPTION; DNA-BINDING; FACTOR CREB; PHOSPHORYLATION; INITIATION; MECHANISM; PURIFICATION; REPRESSOR; TARGETS	The core promoter of the human DNA beta-polymerase (beta-pol) gene is regulated by proteins binding at 3 GC boxes and the single activating transcription factor/ cAMP response element (ATF/CRE) centered at -45; the central 8 residues of this ATF/CRE match the ATF/CRE consensus sequence, TGACGTCA. Previously, we purified a beta-pol promoter ATF/CRE-binding protein (named palindrome-binding protein or PBP) from bovine testes and found that this protein is a beta-pol promoter transcriptional activator in vitro using a HeLa nuclear extract transcription system (Widen, S. G., and Wilson, S. H. (1991) Biochemistry 30, 6296-6305). In this study, we determined the mechanism of in vitro transcriptional activation by this purified PBP. We used a PBP-depleted HeLa nuclear extract transcription system with an artificial promoter containing a solitary activator element corresponding to the entire 22-nucleotide beta-pol promoter ATF/CRE-binding site. Kinetic analyses of the 180-nucleotide run-off product formation indicated that stimulation of transcriptional activity by PBP was due entirely to an increase in the rate constant for promoter clearance. Thus, under our conditions, the purified PBP had no effect on the rate of closed preinitiation complex formation or for the closed complex to open complex transition. Instead, the rate of productive initiation leading to the 180-nucleotide transcript was stimulated by PBP. We found that the rate of closed preinitiation complex formation was not in rapid equilibrium with promoter and RNA polymerase II, in contrast to the model with prokaryotic RNA polymerase transcription. The results also indicated that PBP binding to the ATF/ CRE is required for the stimulation of promoter clearance. These studies define the kinetic mechanism of a purified ATF/CRE-binding protein in stimulation of the in vitro transcription of a designed mammalian promoter.	UNIV TEXAS,MED BRANCH,SEALY CTR MOLEC SCI,GALVESTON,TX 77555	University of Texas System; University of Texas Medical Branch Galveston			Wilson, Samuel H/E-6644-2019	Wilson, Samuel H/0000-0002-1702-5293				BARSHOP BA, 1983, ANAL BIOCHEM, V130, P134, DOI 10.1016/0003-2697(83)90660-7; Carey M, 1991, CURR OPIN CELL BIOL, V3, P452, DOI 10.1016/0955-0674(91)90073-8; CONAWAY RC, 1990, J BIOL CHEM, V265, P7559; ENGLANDER EW, 1992, NUCLEIC ACIDS RES, V20, P5527, DOI 10.1093/nar/20.21.5527; ENGLANDER EW, 1991, NUCLEIC ACIDS RES, V19, P3369, DOI 10.1093/nar/19.12.3369; ENGLANDER EW, 1992, DNA CELL BIOL, V11, P61, DOI 10.1089/dna.1992.11.61; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GOODRICH JA, 1992, J MOL BIOL, V224, P15, DOI 10.1016/0022-2836(92)90573-3; HAI T, 1988, CELL, V54, P1043, DOI 10.1016/0092-8674(88)90119-5; HERSHBERGER PA, 1991, J MOL BIOL, V222, P479, DOI 10.1016/0022-2836(91)90491-N; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; IZBAN MG, 1992, J BIOL CHEM, V267, P13647; KEDAR PS, 1991, P NATL ACAD SCI USA, V88, P3729, DOI 10.1073/pnas.88.9.3729; LAMPH WW, 1990, P NATL ACAD SCI USA, V87, P4320, DOI 10.1073/pnas.87.11.4320; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEE CQ, 1990, EMBO J, V9, P4455, DOI 10.1002/j.1460-2075.1990.tb07896.x; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; MARTIN KJ, 1990, NATURE, V346, P147, DOI 10.1038/346147a0; MCCLURE WR, 1980, P NATL ACAD SCI-BIOL, V77, P5634, DOI 10.1073/pnas.77.10.5634; MCCLURE WR, 1985, ANNU REV BIOCHEM, V54, P171, DOI 10.1146/annurev.bi.54.070185.001131; NICHOLS M, 1992, EMBO J, V11, P3337, DOI 10.1002/j.1460-2075.1992.tb05412.x; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; REINBERG D, 1987, J BIOL CHEM, V262, P3310; SALTZMAN AG, 1989, FASEB J, V3, P1723, DOI 10.1096/fasebj.3.6.2649403; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; SUGDEN B, 1973, J BIOL CHEM, V218, P3777; WANG WD, 1992, SCIENCE, V255, P450, DOI 10.1126/science.1310361; WANG WD, 1992, GENE DEV, V6, P1716, DOI 10.1101/gad.6.9.1716; WEIBAUER K, 1990, P NATL ACAD SCI USA, V87, P5842; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; WIDEN SG, 1988, J BIOL CHEM, V263, P16992; WIDEN SG, 1991, BIOCHEMISTRY-US, V30, P6296, DOI 10.1021/bi00239a031; Wilson SH, 1990, EUKARYOTIC NUCLEUS, V1, P199; YAMAMOTO KK, 1990, CELL, V60, P611, DOI 10.1016/0092-8674(90)90664-Z	36	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12755	12763						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175688				2022-12-25	WOS:A1994NH71600060
J	CANCELA, ML; WILLIAMSON, MK; PRICE, PA				CANCELA, ML; WILLIAMSON, MK; PRICE, PA			THE PUTATIVE RGD-DEPENDENT CELL-ADHESION ACTIVITY OF MATRIX GLA PROTEIN IS DUE TO HIGHER MOLECULAR-WEIGHT CONTAMINANTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-CARBOXYGLUTAMIC ACID; MESSENGER-RNA; BONE; CARBOXYLASE; GENE; CDNA; RAT	This study was carried out to further characterize the RGD-dependent cell adhesion activity which was previously observed in the vitamin K-dependent matrix Gla protein (MGP) (Loeser, R. F., and Wallin, R. (1992) J. Biol. Chem. 267, 9459-9462). We have found that this cell adhesion activity can be completely removed from the 10-kDa MGP by gel filtration over Sephacryl S-800-HR. The higher molecular weight contaminants removed by the gel filtration step display potent cell adhesion activity. The additional evidence previously adduced in support of the putative cell adhesion activity of MGP is that heat decarboxylation of the vitamin K-dependent gamma-carboxyglutamate residues in MGP abolished the adhesion activity. The heat decarboxylation conditions used, however, appear to cause other chemical changes in proteins in addition to decarboxylation, as evidenced by the fact that the cell adhesion activity of fibronectin, which is not a vitamin K-dependent protein, is also destroyed by this procedure. The present evidence that the putative cell adhesion activity of MGP is caused by contaminating higher molecular weight cell adhesion proteins accounts for two apparent anomalies in the previously reported cell adhesion activity of MGP, the failure of antibodies raised against a synthetic peptide corresponding to the C-terminal 19 residues of bovine MGP to inhibit the cell adhesion activity of the intact, 79-residue bovine protein, and the potent inhibition of the cell adhesion activity of MGP by a synthetic peptide containing an RGD sequence, even though MGP does not contain this sequence.	UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093	University of California System; University of California San Diego			Cancela, M. Leonor/F-4665-2012	Cancela, M. Leonor/0000-0003-3114-6662	NIAMS NIH HHS [AR 25921] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR025921] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BRIEHL MM, 1991, MOL ENDOCRINOL, V5, P1381, DOI 10.1210/mend-5-10-1381; CANCELA L, 1990, J BIOL CHEM, V265, P15040; CANCELA ML, 1992, ENDOCRINOLOGY, V130, P102, DOI 10.1210/en.130.1.102; CHEN L, 1990, ONCOGENE, V5, P1391; ENGELKE JA, 1991, BIOCHIM BIOPHYS ACTA, V1078, P31, DOI 10.1016/0167-4838(91)90088-H; FRASER JD, 1988, J BIOL CHEM, V263, P11033; HALE JE, 1991, J BIOL CHEM, V266, P21145; HALE JE, 1988, J BIOL CHEM, V263, P5820; IKEDA T, 1991, J BONE MINER RES, V6, P1013; LANDEGREN U, 1984, J IMMUNOL METHODS, V67, P379, DOI 10.1016/0022-1759(84)90477-0; LOESER RF, 1993, ARTHRITIS RHEUM, V36, P1103, DOI 10.1002/art.1780360811; LOESER RF, 1992, J BIOL CHEM, V267, P9459; OTAWARA Y, 1986, J BIOL CHEM, V261, P828; POSER JW, 1979, J BIOL CHEM, V254, P431; PRICE PA, 1987, P NATL ACAD SCI USA, V84, P8335, DOI 10.1073/pnas.84.23.8335; PRICE PA, 1985, J BIOL CHEM, V260, P4971; PRICE PA, 1983, BIOCHEM BIOPH RES CO, V117, P765, DOI 10.1016/0006-291X(83)91663-7; RANNELS SR, 1993, AM J PHYSIOL, V265, pL270, DOI 10.1152/ajplung.1993.265.3.L270; RICE JS, 1994, IN PRESS J BONE MINE; SHANAHAN CM, 1993, CIRC RES, V73, P193, DOI 10.1161/01.RES.73.1.193	20	6	6	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					12185	12189						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163523				2022-12-25	WOS:A1994NG37700078
J	MATTHEWS, JB; SMITH, JA; TALLY, KJ; AWTREY, CS; NGUYEN, HV; RICH, J; MADARA, JL				MATTHEWS, JB; SMITH, JA; TALLY, KJ; AWTREY, CS; NGUYEN, HV; RICH, J; MADARA, JL			NA-K-2CL COTRANSPORT IN INTESTINAL EPITHELIAL-CELLS - INFLUENCE OF CHLORIDE EFFLUX AND F-ACTIN ON REGULATION OF COTRANSPORTER ACTIVITY AND BUMETANIDE BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K-CL COTRANSPORT; SHARK RECTAL GLAND; SMOOTH-MUSCLE CELLS; NA+/K+/CL COTRANSPORT; ADENOCARCINOMA CELLS; ACTIVATION; CAMP; CYTOSKELETON; PROTEIN; CHANNEL	Although cAMP-dependent epithelial chloride secretion is largely regulated via apical membrane chloride channels, cAMP also remodels basolateral F-actin and activates basolateral Na-K-2Cl cotransport. Whether activation of cotransport is a primary event or secondary to activation of chloride efflux is not established, and the basis for the cytoskeletal dependence is unknown. We studied cotransport in the intestinal line HT29 (which lacks cAMP-regulated chloride efflux) and in its subclone Cl.19A (in which this pathway is present). Cotransporter activity was enhanced by forskolin in both lines but to a considerably greater extent in subclone Cl.19A, in which the number of bumetanide binding sites was also observed to increase. The F-actin stabilizer phalloidin markedly attenuated cAMP-stimulated cotransport in Cl.19A monolayers, but the increase in bumetanide binding was preserved. These studies identify two mechanisms for activation of Na-K-2Cl cotransport by cAMP: components independent and dependent of cAMP elicited chloride efflux. Additional Na-K-2Cl cotransporters become accessible to the cell surface coincident with the salt efflux-dependent activation of cotransport. While F-actin rearrangements influence salt efflux-dependent up-regulation of the cotransporter, this influence occurs independently of increases in bumetanide-accessible cotransporters.	BRIGHAM & WOMENS HOSP, DEPT PATHOL, DIV GASTROINTESTINAL PATHOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; HARVARD UNIV, CTR DIGEST DIS, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University	MATTHEWS, JB (corresponding author), BETH ISRAEL HOSP, DEPT SURG, 330 BROOKLINE AVE, BOSTON, MA 02215 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK048010, R37DK035932, R01DK035932, P01DK033506] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-33506, DK-35932, R29 DK48010-01] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AUGERON C, 1984, CANCER RES, V44, P3961; BREITWIESER GE, 1990, AM J PHYSIOL, V258, pC749, DOI 10.1152/ajpcell.1990.258.4.C749; CANTIELLO H F, 1991, Journal of Cell Biology, V115, p353A; CANTIELLO HF, 1991, AM J PHYSIOL, V261, pC882, DOI 10.1152/ajpcell.1991.261.5.C882; CANTIELLO HF, 1993, J BIOL CHEM, V268, P4596; DING G, 1991, AM J PHYSIOL, V260, pC9, DOI 10.1152/ajpcell.1991.260.1.C9; FORBUSH B, 1992, AM J PHYSIOL, V262, pC1000, DOI 10.1152/ajpcell.1992.262.4.C1000; FRANKI N, 1992, AM J PHYSIOL, V263, pC995, DOI 10.1152/ajpcell.1992.263.5.C995; FRANKLIN CC, 1989, J BIOL CHEM, V264, P6667; FULLER CM, 1992, AM J PHYSIOL, V263, pC267, DOI 10.1152/ajpcell.1992.263.2.C267; GAO Y, 1992, AM J PHYSIOL, V263, pC908, DOI 10.1152/ajpcell.1992.263.4.C908; HAAS M, 1986, J BIOL CHEM, V261, P8434; HAAS M, 1993, AM J PHYSIOL, V264, pC189, DOI 10.1152/ajpcell.1993.264.1.C189; HAAS M, 1990, AM J PHYSIOL, V259, pC557, DOI 10.1152/ajpcell.1990.259.4.C557; HAAS M, 1989, ANNU REV PHYSIOL, V51, P443, DOI 10.1146/annurev.physiol.51.1.443; HALM DR, 1990, TXB SECRETORY DIARRH, P47; HECHT G, 1988, J CLIN INVEST, V82, P1516, DOI 10.1172/JCI113760; HOFFMANN EK, 1989, PHYSIOL REV, V69, P315, DOI 10.1152/physrev.1989.69.2.315; JESSEN F, 1992, BIOCHIM BIOPHYS ACTA, V1110, P199, DOI 10.1016/0005-2736(92)90359-T; KIM HD, 1988, BIOCHIM BIOPHYS ACTA, V946, P397, DOI 10.1016/0005-2736(88)90415-4; KLEIN JD, 1993, J GEN PHYSIOL, V102, pA18; LYTLE C, 1992, AM J PHYSIOL, V262, pC1009, DOI 10.1152/ajpcell.1992.262.4.C1009; LYTLE C, 1992, J BIOL CHEM, V267, P25438; MATTHEWS JB, 1992, J CLIN INVEST, V90, P1608, DOI 10.1172/JCI116030; MATTHEWS JB, 1993, AM J PHYSIOL, V265, pG371, DOI 10.1152/ajpgi.1993.265.2.G370; MOLITORIS BA, 1991, AM J PHYSIOL, V260, pF769; MORRIS AP, 1992, J BIOL CHEM, V267, P5575; NELSON WJ, 1989, J CELL BIOL, V108, P893, DOI 10.1083/jcb.108.3.893; ODONNELL ME, 1986, P NATL ACAD SCI USA, V83, P6132, DOI 10.1073/pnas.83.16.6132; ODONNELL ME, 1989, J BIOL CHEM, V264, P20326; OGRADY SM, 1987, AM J PHYSIOL, V253, pC177, DOI 10.1152/ajpcell.1987.253.2.C177; OWEN NE, 1985, J CELL BIOL, V101, P454, DOI 10.1083/jcb.101.2.454; PEWITT EB, 1990, J BIOL CHEM, V265, P20747; SHAPIRO M, 1991, J CLIN INVEST, V87, P1903, DOI 10.1172/JCI115215; SINGH AK, 1991, AM J PHYSIOL, V261, pC51, DOI 10.1152/ajpcell.1991.261.1.C51; SLOTKI IN, 1993, AM J PHYSIOL, V264, pC857, DOI 10.1152/ajpcell.1993.264.4.C857; SMITH PR, 1991, P NATL ACAD SCI USA, V88, P6971, DOI 10.1073/pnas.88.16.6971; TURNER JT, 1990, AM J PHYSIOL, V258, pC266, DOI 10.1152/ajpcell.1990.258.2.C266; VENGLARIK CJ, 1990, AM J PHYSIOL, V259, pC358; WADE JB, 1988, AM J PHYSIOL, V255, pC526, DOI 10.1152/ajpcell.1988.255.4.C526; ZIYADEH FN, 1992, AM J PHYSIOL, V262, pF468, DOI 10.1152/ajprenal.1992.262.3.F468; Zweibaum A., 1991, HDB PHYSL GASTROINTE, P223	42	70	70	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15703	15709						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	8195222				2022-12-25	WOS:A1994NP51300050
J	DEQUARDCHABLAT, M; SELLEM, CH				DEQUARDCHABLAT, M; SELLEM, CH			THE S12 RIBOSOMAL-PROTEIN OF PODOSPORA-ANSERINA BELONGS TO THE S19 BACTERIAL FAMILY AND CONTROLS THE MITOCHONDRIAL GENOME INTEGRITY THROUGH CYTOPLASMIC TRANSLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; GENE-EXPRESSION; TRANSFER-RNA; YEAST; DNA; TRANSFORMATION; SEQUENCES; RIG; IDENTIFICATION	In the filamentous fungus Podospora anserina, two nuclear genes are involved in the premature death syndrome associated with a site-specific deletion of the mitochondrial DNA: a mutant allele of the AS1 gene, encoding the cytoplasmic ribosomal protein S12, and an uncharacterized gene closely linked to the mating-type locus. We describe here the cloning and the sequencing of the wild-type and two mutant alleles of the AS1 gene. The P. anserina S12 protein belongs to the bacterial S19 ribosomal protein family and shows 72% identity with the S15 human ribosomal protein. Transformation experiments have shown that the AS1-4 mutation itself is responsible for the premature death phenotype and that it corresponds to a Gly to Asp change in the highly conserved COOH-terminal part of the protein. Use of antibodies directed against S12 did not permit detection of the mutant ribosomal protein inside the mitochondria. However, cross-reactions were observed with at least one mitochondrial ribosomal protein displaying a higher molecular weight than S12. The mitochondrial protein does not seem to be a by-product of the AS1 gene but is more likely the mitochondrial homologue of S12. These results strongly suggest that the mutant S12 protein acts indirectly to promote the mitochondrial deletion, via the cytoplasmic translation.	CNRS,CTR GENET MOLEC,F-91198 GIF SUR YVETTE,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	DEQUARDCHABLAT, M (corresponding author), UNIV PARIS 11,INST MICROBIOL & GENET,CNRS,URA 1354,BAT 400,F-91405 ORSAY,FRANCE.							BALLANCE DJ, 1986, YEAST, V2, P229, DOI 10.1002/yea.320020404; BELCOUR L, 1991, P NATL ACAD SCI USA, V88, P3579, DOI 10.1073/pnas.88.9.3579; BERGES T, 1989, J GEN MICROBIOL, V135, P601; BONEN L, 1993, FASEB J, V7, P40, DOI 10.1096/fasebj.7.1.8422973; BRYGOO Y, 1985, MOL GEN GENET, V200, P128, DOI 10.1007/BF00383325; CAMONIS JH, 1990, GENE, V86, P263, DOI 10.1016/0378-1119(90)90288-3; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONKLIN PL, 1991, NUCLEIC ACIDS RES, V19, P2701, DOI 10.1093/nar/19.10.2701; COPPINRAYNAL E, 1989, MOL GEN GENET, V219, P270, DOI 10.1007/BF00261187; DEBUCHY R, 1993, MOL GEN GENET, V241, P667, DOI 10.1007/BF00279909; DEQUARDCHABLAT M, 1986, J MOL BIOL, V190, P167, DOI 10.1016/0022-2836(86)90290-1; DEQUARDCHABLAT M, 1991, TRENDS GENET, V7, P240; DEQUARDCHABLAT M, 1987, THESIS U PARIS ORSAY; DIJK J, 1977, FEBS LETT, V77, P295, DOI 10.1016/0014-5793(77)80255-X; Dujon B., 1989, MOBILE DNA, P861; Esser K, 1974, HDB GENETICS, V1, P531; GOYON C, 1988, GENE, V63, P297, DOI 10.1016/0378-1119(88)90533-1; JONES BA, 1992, GENE DEV, V6, P380, DOI 10.1101/gad.6.3.380; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KITAGAWA M, 1991, FEBS LETT, V283, P210, DOI 10.1016/0014-5793(91)80590-Y; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LECELLIER G, 1994, CURR GENET, V25, P122, DOI 10.1007/BF00309536; LEFEBVRE O, 1992, P NATL ACAD SCI USA, V89, P10512, DOI 10.1073/pnas.89.21.10512; LIN FL, 1984, J MOL BIOL, V172, P77, DOI 10.1016/0022-2836(84)90415-7; MARCK C, 1988, NUCLEIC ACIDS RES, V16, P1829, DOI 10.1093/nar/16.5.1829; Marcou D., 1961, ANN SCI NAT BOT BIOL, V12, P653; MATHESON AT, 1990, RIBOSOME, P617; MORAES CT, 1991, AM J HUM GENET, V48, P492; NATSOULIS G, 1986, CELL, V46, P235, DOI 10.1016/0092-8674(86)90740-3; NEUPERT W, 1979, METHOD ENZYMOL, V61, P79; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PICARD M, 1991, GENETICS, V128, P539; PICARDBENNOUN M, 1985, FEBS LETT, V184, P1, DOI 10.1016/0014-5793(85)80640-2; PICARDBENNOUN M, 1976, MOL GEN GENET, V147, P299, DOI 10.1007/BF00582881; POHL T, 1988, J BIOL CHEM, V263, P4293; PON CL, 1982, FEBS LETT, V137, P163, DOI 10.1016/0014-5793(82)80339-6; RIZET G, 1953, CR HEBD ACAD SCI, V237, P838; RIZET G, 1953, CR HEBD ACAD SCI, V237, P1106; Rogers SO, 1988, PLANT MOL BIOL MAN A, VA6, P1, DOI DOI 10.1007/978-94-017-5294-7_; SELLEM CH, 1990, MOL GEN GENET, V224, P232, DOI 10.1007/BF00271556; SHIGA K, 1990, P NATL ACAD SCI USA, V87, P3594, DOI 10.1073/pnas.87.9.3594; STAPPERT J, 1992, NUCLEIC ACIDS RES, V20, P624, DOI 10.1093/nar/20.3.624; SUDARICKOV AB, 1986, MOL GEN GENET, V203, P316, DOI 10.1007/BF00333973; TAKASAWA S, 1992, FEBS LETT, V307, P318, DOI 10.1016/0014-5793(92)80704-K; TAKEMURA M, 1992, NUCLEIC ACIDS RES, V20, P3199, DOI 10.1093/nar/20.12.3199; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TZAGOLOFF A, 1990, MICROBIOL REV, V54, P211, DOI 10.1128/MMBR.54.3.211-225.1990; VIGNAIS ML, 1990, J BIOL CHEM, V265, P14669; WADA KN, 1990, NUCLEIC ACIDS RES, V18, P2367, DOI 10.1093/nar/18.suppl.2367; WITTMANNLIEBOLD B, 1990, RIBOSOME, P598; WOOL IG, 1990, RIBOSOME, P203; WOOLFORD JL, 1991, ADV GENET, V29, P63, DOI 10.1016/S0065-2660(08)60107-8; WU M, 1987, J BIOL CHEM, V262, P12275; YAGUCHI M, 1978, FEBS LETT, V88, P227, DOI 10.1016/0014-5793(78)80180-X; ZEVIANI M, 1990, AM J HUM GENET, V47, P904	55	31	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					14951	14956						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195128				2022-12-25	WOS:A1994NP73800019
J	KADOWAKI, H; GRANT, MA				KADOWAKI, H; GRANT, MA			MECHANISM OF G(M3) GANGLIOSIDE SYNTHESIS - KINETIC-STUDY OF RAT-LIVER CMP-N-NEURAMINATE-LACTOSYLCERAMIDE ALPHA-2,3-SIALYLTRANSFERASE EMPLOYING 19 MOLECULAR-SPECIES OF LACTOSYLCERAMIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; ACETYLNEURAMINIC ACID; GOLGI-APPARATUS; NEUTRAL GLYCOSPHINGOLIPIDS; ENZYMATIC CHARACTERIZATION; CERAMIDE COMPOSITION; MOUSE-LIVER; SIALIC-ACID; SIALYLTRANSFERASE; MEMBRANE	The apparent K-m and V-max of CMP-N-acetylneuraminate:lactosylceramide alpha 2,3-sialyltransferase (LacCer alpha 2,3-ST) for lactosylceramide and CMP-N-acetylneuraminic acid were determined using 19 molecular species of lactosylceramide. The K-m for lactosylceramide varied 6-fold among these molecular species of lactosylceramide, but there was a poor correlation between the K-m for a particular molecular species and the activity of LacCer alpha 2,3-ST for that molecular species. The K-m for CMP-N-acetylneuraminic acid also varied depending on the molecular species of lactosylceramide used as substrate, and there was a good correlation between the K-m of LacCer alpha 2,3-ST for CMP-N-acetylneuraminic acid and the activity of the enzyme. Kinetic studies indicate that the reaction mechanism of LacCer alpha 2,3-ST is a sequential, Ordered Bi Bi system. From considerations of the effects of the structure of the lactosylceramide molecular species on the V-max and K-m for CMP-N-acetylneuraminic acid, it is likely that LacCer alpha 2,3-ST first binds lactosylceramide and then CMP-N-acetylneuraminic acid and that the rate-limiting step in the reaction is the release of the product G(M3).	BOSTON UNIV,SCH MED,DEPT MED,BOSTON,MA 02118	Boston University	KADOWAKI, H (corresponding author), VET ADM MED CTR JAMAICA PLAIN,DIV LIPID METAB,RES BLDG,RM B-8,150 S HUNTINGTON AVE,BOSTON,MA 02130, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS023354] Funding Source: NIH RePORTER; NINDS NIH HHS [NS-23354] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BENDIAK B, 1982, EUR J BIOCHEM, V128, P355; BLOJ B, 1981, J BIOL CHEM, V256, P5988; BOSMANN HB, 1972, BIOCHIM BIOPHYS ACTA, V279, P456, DOI 10.1016/0304-4165(72)90167-5; BOUHOURS JF, 1993, ADV LIPID RES, V26, P353; BREIMER ME, 1974, BIOCHIM BIOPHYS ACTA, V348, P232, DOI 10.1016/0005-2760(74)90234-3; BURCZAK JD, 1984, BIOCHIM BIOPHYS ACTA, V804, P442, DOI 10.1016/0167-4889(84)90072-7; BUSAM K, 1986, EUR J BIOCHEM, V160, P23, DOI 10.1111/j.1432-1033.1986.tb09934.x; CAPASSO JM, 1984, P NATL ACAD SCI-BIOL, V81, P7051, DOI 10.1073/pnas.81.22.7051; CAREY DJ, 1980, CELL, V19, P597, DOI 10.1016/S0092-8674(80)80036-5; COATES SW, 1980, J BIOL CHEM, V255, P9225; CRAIN RC, 1980, BIOCHEMISTRY-US, V19, P1433, DOI 10.1021/bi00548a026; CREEK KE, 1981, BIOCHIM BIOPHYS ACTA, V643, P292, DOI 10.1016/0005-2736(81)90075-4; FELGNER PL, 1983, BIOCHEMISTRY-US, V22, P1670, DOI 10.1021/bi00276a023; FOLCH J, 1957, J BIOL CHEM, V226, P497; HAKOMORI SI, 1993, ADV LIPID RES, V25, P147; IBER H, 1991, EUR J BIOCHEM, V195, P115, DOI 10.1111/j.1432-1033.1991.tb15683.x; IWAMORI M, 1978, J BIOCHEM-TOKYO, V84, P1609, DOI 10.1093/oxfordjournals.jbchem.a132287; IWAMORI M, 1984, J BIOCHEM-TOKYO, V95, P761, DOI 10.1093/oxfordjournals.jbchem.a134667; KADOWAKI H, 1988, J LIPID RES, V29, P52; KADOWAKI H, 1989, J LIPID RES, V30, P1789; KADOWAKI H, 1989, J LIPID RES, V30, P616; KADOWAKI H, 1984, J LIPID RES, V25, P1132; KADOWAKI H, 1993, J LIPID RES, V34, P905; KANNAGI R, 1982, P NATL ACAD SCI-BIOL, V79, P3470, DOI 10.1073/pnas.79.11.3470; KANNAGI R, 1983, CANCER RES, V43, P4997; KARLSSON KA, 1989, ANNU REV BIOCHEM, V58, P309, DOI 10.1146/annurev.bi.58.070189.001521; KELETI T, 1984, BIOCHEM J, V223, P299, DOI 10.1042/bj2230299; LADISCH S, 1992, BIOCHIM BIOPHYS ACTA, V1125, P180, DOI 10.1016/0005-2760(92)90043-U; Lineweaver H, 1934, J AM CHEM SOC, V56, P658, DOI 10.1021/ja01318a036; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANSSON JE, 1978, J NEUROCHEM, V30, P273, DOI 10.1111/j.1471-4159.1978.tb07064.x; MANTEL CR, 1993, BIOCHEM J, V289, P815, DOI 10.1042/bj2890815; MASSEY JB, 1982, BIOCHEMISTRY-US, V21, P3630, DOI 10.1021/bi00258a016; MCLEAN LR, 1981, BIOCHEMISTRY-US, V20, P2893, DOI 10.1021/bi00513a028; MELKERSONWATSON LJ, 1991, J BIOL CHEM, V266, P19865; MELKERSONWATSON LJ, 1991, J BIOL CHEM, V266, P4448; NEUENHOFER S, 1985, BIOCHEMISTRY-US, V24, P525, DOI 10.1021/bi00323a042; PAULSON JC, 1977, J BIOL CHEM, V252, P2363; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; RADIN NS, 1974, LIPIDS, V9, P358, DOI 10.1007/BF02533114; REARICK JI, 1979, J BIOL CHEM, V254, P4444; RICHARDSON CL, 1977, BIOCHIM BIOPHYS ACTA, V488, P88, DOI 10.1016/0005-2760(77)90125-4; ROSEMAN MA, 1980, BIOCHEMISTRY-US, V19, P439, DOI 10.1021/bi00544a006; ROSENBERG A, 1966, J LIPID RES, V7, P122; SADLER JE, 1979, J BIOL CHEM, V254, P5934; SCHACHTE.H, 1970, J BIOL CHEM, V245, P1090; Segel I. H., 1975, ENZYME KINETICS, P560; STEWART RJ, 1993, BIOCHEMISTRY-US, V32, P10666, DOI 10.1021/bi00091a017; ULLMAN MD, 1977, J LIPID RES, V18, P371; WELCH GR, 1988, J THEOR BIOL, V130, P407, DOI 10.1016/S0022-5193(88)80206-6	52	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					14931	14938						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195125				2022-12-25	WOS:A1994NP73800016
J	MURAKAMI, S; CHEONG, J; KANEKO, S				MURAKAMI, S; CHEONG, J; KANEKO, S			HUMAN HEPATITIS-VIRUS X-GENE ENCODES A REGULATORY DOMAIN THAT REPRESSES TRANSACTIVATION OF X-PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; LONG TERMINAL REPEAT; B VIRUS; TRANS-ACTIVATION; STRUCTURAL PROTEINS; BINDING PROTEIN; VIRAL ENHANCERS; EXPRESSION; SEQUENCES; ELEMENTS	The human hepatitis B virus (HBV) X gene seems to be essential for establishment of viral infection, and the X gene product, HBx, transactivates virus and host genes through a wide variety of cis elements, whereas regulation of HBx has not been fully understood. We found that transactivation-negative HBx mutants truncated at the C-terminal portion specifically repressed the HBx transactivation in trans. The ability to trans repress the HBx transactivation is confined to the N-terminal third of HBx. Transactivation-positive constructs of HBx were divided into two groups by their sensitivity to transrepression due to the presence of the N-terminal third. Thus the regulatory domain, the N-terminal third, is separated from the transacting domain and responsible for the negative regulations, the trans-repression and sensitivity to X trans-repression. A possible direct association between the HBx regulatory domains was tested by far-Western blotting using purified fused forms of HBx proteins. The regulatory domain was found to associate preferentially with the full HBx or the regulatory domain, but not with the transacting domain. Taken together, it is possible that HBx has a self-regulatory mechanism that avoids excessive HBx transactivation and is important for regulation of X gene expression.	KANAZAWA UNIV, SCH MED, INST MED 1, KANAZAWA 920, ISHIKAWA, JAPAN	Kanazawa University	MURAKAMI, S (corresponding author), KANAZAWA UNIV, CANC RES INST, DEPT BIOPHYS, KANAZAWA 920, JAPAN.							AVANTAGGIATI ML, 1992, ARCH VIROL, P57; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN HS, 1993, J VIROL, V67, P1218, DOI 10.1128/JVI.67.3.1218-1226.1993; COLGROVE R, 1989, J VIROL, V63, P4019, DOI 10.1128/JVI.63.9.4019-4026.1989; DIAMANTIS ID, 1992, J HEPATOL, V15, P400, DOI 10.1016/0168-8278(92)90077-3; DIKSTEIN R, 1990, MOL CELL BIOL, V10, P3683, DOI 10.1128/MCB.10.7.3683; FAKTOR O, 1990, J VIROL, V64, P1861, DOI 10.1128/JVI.64.4.1861-1863.1990; FAKTOR O, 1990, ONCOGENE, V5, P867; GREENE WC, 1991, NEW ENGL J MED, V324, P308, DOI 10.1056/NEJM199101313240506; GUO WT, 1991, J VIROL, V65, P6686, DOI 10.1128/JVI.65.12.6686-6692.1991; GUTMAN A, 1991, MOL CELL BIOL, V11, P5381, DOI 10.1128/MCB.11.10.5381; HIDAKA M, 1988, EMBO J, V7, P519, DOI 10.1002/j.1460-2075.1988.tb02840.x; HOHNE M, 1990, EMBO J, V9, P1137, DOI 10.1002/j.1460-2075.1990.tb08220.x; HUAN BF, 1992, P NATL ACAD SCI USA, V89, P9059, DOI 10.1073/pnas.89.19.9059; HUGH FM, 1991, SCIENCE, V252, P842; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KANEKO S, 1988, J VIROL, V62, P3979, DOI 10.1128/JVI.62.11.3979-3984.1988; KEKULE AS, 1993, NATURE, V361, P742, DOI 10.1038/361742a0; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; KODAMA K, 1985, J VIROL, V56, P978, DOI 10.1128/JVI.56.3.978-986.1985; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUBER B, 1991, VIROLOGY, V184, P808, DOI 10.1016/0042-6822(91)90458-N; LUCITO R, 1992, J VIROL, V66, P983, DOI 10.1128/JVI.66.2.983-991.1992; MAHE Y, 1991, J BIOL CHEM, V266, P13759; MURAKAMI S, 1994, VIROLOGY, V199, P243, DOI 10.1006/viro.1994.1119; MURAKAMI S, 1990, GASTROENTEROL JPN, V2, P11; SETO E, 1988, P NATL ACAD SCI USA, V85, P8286, DOI 10.1073/pnas.85.21.8286; SETO E, 1990, NATURE, V344, P72, DOI 10.1038/344072a0; SIDDIQUI A, 1989, VIROLOGY, V169, P479, DOI 10.1016/0042-6822(89)90177-3; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SPANDAU DF, 1988, J VIROL, V62, P427, DOI 10.1128/JVI.62.2.427-434.1988; TAKADA S, 1990, JPN J CANCER RES, V81, P1191, DOI 10.1111/j.1349-7006.1990.tb02675.x; TIOLLAIS P, 1985, NATURE, V317, P489, DOI 10.1038/317489a0; TWU JS, 1989, P NATL ACAD SCI USA, V86, P2046, DOI 10.1073/pnas.86.6.2046; TWU JS, 1987, J VIROL, V61, P3448, DOI 10.1128/JVI.61.11.3448-3453.1987; TWU JS, 1989, P NATL ACAD SCI USA, V86, P5168, DOI 10.1073/pnas.86.13.5168; TWU JS, 1993, VIROLOGY, V192, P346, DOI 10.1006/viro.1993.1041; WU HL, 1991, VIROLOGY, V185, P644, DOI 10.1016/0042-6822(91)90535-J; WU JY, 1990, CELL, V63, P687, DOI 10.1016/0092-8674(90)90135-2; ZHANG P, 1992, VIROLOGY, V191, P31, DOI 10.1016/0042-6822(92)90163-J	40	106	117	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					15118	15123						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195148				2022-12-25	WOS:A1994NP73800042
J	OCONNELL, JP; WILLENBROCK, F; DOCHERTY, AJP; EATON, D; MURPHY, G				OCONNELL, JP; WILLENBROCK, F; DOCHERTY, AJP; EATON, D; MURPHY, G			ANALYSIS OF THE ROLE OF THE COOH-TERMINAL DOMAIN IN THE ACTIVATION, PROTEOLYTIC ACTIVITY, AND TISSUE INHIBITOR OF METALLOPROTEINASE INTERACTIONS OF GELATINASE-B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							72 KDA PROGELATINASE; IV COLLAGENASE; MATRIX METALLOPROTEINASE-9; MEDIATED INDUCTION; FIBROSARCOMA CELLS; COMPLEX-FORMATION; PURIFICATION; STROMELYSIN; PHENOTYPE; PLASMINOGEN	Recombinant human progelatinase B and a COOH terminally truncated version, pro-Delta(426-688) gelatinase B have been prepared from a myeloma cell expression system. Both proenzymes could be processed to active forms by stromelysin-1 to give an NH2 terminus of Phe(88), or by treatment with 4-aminophenylmercuric acetate resulting in an NH2-terminal Met(75). The kinetics of activation using either treatment was not affected by removal of the enzyme COOH-terminal domain. The specific activities of both gelatinase B and Delta(426-688) gelatinase B, activated using either method, were found to be similar using either a quenched fluorescent peptide or gelatin as the substrate. Fibroblast monolayers were shown to mediate processing of both progelatinases at similar rates in the presence of either plasminogen or prostromelysin-1. Active wild-ty pe gelatinase B was inhibited by tissue inhibitor of metalloproteinase (TIMP)-1 at a much faster rate than TIMP-2. COOH-terminal truncation of either enzyme or inhibitor gave a marked reduction in the rate constant for TIMP-1 inhibition but had no effect on the rate of TIMP-2 binding. It can be concluded that the COOH-terminal domain of progelatinase B is not involved in autolytic or cellular activation and does not affect the catalytic activity of the enzyme. However, COOH terminal domain interactions between active gelatinase B and TIMP-1 significantly enhance the rate of complex formation.	STRANGEWAYS RES LAB,CAMBRIDGE CB1 4RN,ENGLAND; CELLTECH LTD,DEPT BIOCHEM,SLOUGH SL1 4EN,BERKS,ENGLAND	Celltech Group Ltd								BALLIN M, 1988, BIOCHEM BIOPH RES CO, V154, P832, DOI 10.1016/0006-291X(88)90215-X; BERNHARD EJ, 1990, CANCER RES, V50, P3872; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; CRABBE T, 1992, BIOCHEMISTRY-US, V31, P8500, DOI 10.1021/bi00151a017; FRIDMAN R, 1992, J BIOL CHEM, V267, P15398; GAVRILOVIC J, 1989, CELL BIOL INT REP, V13, P367, DOI 10.1016/0309-1651(89)90163-X; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GOLDBERG GI, 1992, J BIOL CHEM, V267, P4583; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hunt L T, 1987, Protein Seq Data Anal, V1, P21; KNIGHT CG, 1992, FEBS LETT, V296, P263, DOI 10.1016/0014-5793(92)80300-6; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; KUBOTA S, 1991, BIOCHEM BIOPH RES CO, V181, P1539, DOI 10.1016/0006-291X(91)92114-Y; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; LIBRACH CL, 1991, J CELL BIOL, V113, P437, DOI 10.1083/jcb.113.2.437; MARCY AI, 1991, BIOCHEMISTRY-US, V30, P6476, DOI 10.1021/bi00240a018; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MORODOMI T, 1992, BIOCHEM J, V285, P603, DOI 10.1042/bj2850603; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; MURPHY G, 1989, BIOCHEM J, V258, P463, DOI 10.1042/bj2580463; MURPHY G, 1992, BIOCHEM J, V283, P637, DOI 10.1042/bj2830637; Murphy G, 1992, Matrix Suppl, V1, P224; MURPHY G, 1992, J BIOL CHEM, V267, P9612; MURPHY G, 1981, BIOCHEM J, V199, P807, DOI 10.1042/bj1990807; MURPHY G, 1991, BIOCHEMISTRY-US, V30, P8097, DOI 10.1021/bi00247a001; MURPHY G, 1992, ANN NY ACAD SCI, V667, P1, DOI 10.1111/j.1749-6632.1992.tb51590.x; NGUYEN Q, 1994, BIOCHEMISTRY-US, V33, P2089, DOI 10.1021/bi00174a015; OGATA Y, 1992, J BIOL CHEM, V267, P3581; OKADA Y, 1992, J BIOL CHEM, V267, P21712; OKADA Y, 1986, J BIOL CHEM, V261, P14245; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STACK MS, 1989, J BIOL CHEM, V264, P4277; STRONGIN AY, 1993, J BIOL CHEM, V268, P14033; TRIEBEL S, 1992, FEBS LETT, V298, P280, DOI 10.1016/0014-5793(92)80077-T; WARD RV, 1991, BIOCHEM J, V278, P179, DOI 10.1042/bj2780179; WARD RV, 1991, BIOCHIM BIOPHYS ACTA, V1079, P242, DOI 10.1016/0167-4838(91)90132-J; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; WILLENBROCK F, 1993, BIOCHEMISTRY-US, V32, P4330, DOI 10.1021/bi00067a023; YAMAGATA S, 1989, BIOCHEM BIOPH RES CO, V158, P228, DOI 10.1016/S0006-291X(89)80202-5	39	134	136	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					14967	14973						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195131				2022-12-25	WOS:A1994NP73800022
J	TAKAHAGI, M; IWASAKI, H; SHINAGAWA, H				TAKAHAGI, M; IWASAKI, H; SHINAGAWA, H			STRUCTURAL REQUIREMENTS OF SUBSTRATE DNA FOR BINDING TO AND CLEAVAGE BY RUVC, A HOLLIDAY JUNCTION RESOLVASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI RUVA; T4 ENDONUCLEASE-VII; SACCHAROMYCES-CEREVISIAE; CRUCIFORM DNA; CONJUGATIONAL RECOMBINATION; GENE-3 ENDONUCLEASE; BRANCH MIGRATION; SUPERCOILED DNA; 4-WAY JUNCTION; RESOLUTION	To elucidate the molecular mechanism of the resolution of Holliday junctions by Escherichia coli RuvC protein, we studied biochemical properties of the protein using various synthetic DNA junctions as model substrates. RuvC cleaves not only a four-way junction but also three-way junctions efficiently. The central core of homology in the junction is essential for the substrates to be cleavable by RuvC. Although the divalent cations are essential for the endonuclease activity, RuvC efficiently forms specific complexes with four-way junctions in the absence of the cations, irrespective of the presence of homologous core sequences. By using T7 endonuclease I as a probe, we studied the topology of the substrate junctions used in our study. The results suggest that RuvC cleaves the three-way junctions with homology core when they become four-way conformers. From the present studies, we propose that RuvC initially binds mostly nonproductively to four-way junctions, which does not require divalent metals, and subsequently cleaves the junctions by a mechanism dependent on a divalent cation and a particular topological conformer that is induced by the sequences at the mobile junctions.	OSAKA UNIV,MICROBIAL DIS RES INST,DEPT EXPTL CHEMOTHERAPY,SUITA,OSAKA 565,JAPAN	Osaka University			Iwasaki, Hiroshi/Y-7946-2018	Iwasaki, Hiroshi/0000-0002-0153-6873				BENNETT RJ, 1993, CELL, V74, P1021, DOI 10.1016/0092-8674(93)90724-5; BENSON F, 1991, MOL GEN GENET, V225, P266, DOI 10.1007/BF00269858; BHATTACHARYYA A, 1991, J MOL BIOL, V221, P1191, DOI 10.1016/0022-2836(91)90928-Y; BHATTACHARYYA A, 1989, NUCLEIC ACIDS RES, V17, P6821, DOI 10.1093/nar/17.17.6821; CHEN JH, 1988, BIOCHEMISTRY-US, V27, P6032, DOI 10.1021/bi00416a031; CHURCHILL MEA, 1988, P NATL ACAD SCI USA, V85, P4653, DOI 10.1073/pnas.85.13.4653; COOPER JP, 1987, J MOL BIOL, V198, P711, DOI 10.1016/0022-2836(87)90212-9; COOPER JP, 1989, P NATL ACAD SCI USA, V86, P7336, DOI 10.1073/pnas.86.19.7336; DEMASSY B, 1987, J MOL BIOL, V193, P359, DOI 10.1016/0022-2836(87)90224-5; DEMASSY B, 1984, COLD SPRING HARB SYM, V49, P715, DOI 10.1101/SQB.1984.049.01.081; DICKIE P, 1987, J BIOL CHEM, V262, P14826; DUCKETT DR, 1990, EMBO J, V9, P583, DOI 10.1002/j.1460-2075.1990.tb08146.x; DUCKETT DR, 1988, CELL, V55, P79, DOI 10.1016/0092-8674(88)90011-6; DUNDERDALE HJ, 1991, NATURE, V354, P506, DOI 10.1038/354506a0; ELBOROUGH KM, 1990, EMBO J, V9, P2931, DOI 10.1002/j.1460-2075.1990.tb07484.x; HOLLIDAY R, 1964, GENET RES, V5, P282, DOI 10.1017/S0016672300001233; HSIEH CH, 1989, P NATL ACAD SCI USA, V86, P4833, DOI 10.1073/pnas.86.13.4833; IWASAKI H, 1989, J BACTERIOL, V171, P5276, DOI 10.1128/jb.171.10.5276-5280.1989; IWASAKI H, 1989, MOL GEN GENET, V219, P328, DOI 10.1007/BF00261196; IWASAKI H, 1991, EMBO J, V10, P4381, DOI 10.1002/j.1460-2075.1991.tb05016.x; IWASAKI H, 1992, GENE DEV, V6, P2214, DOI 10.1101/gad.6.11.2214; JENSCH F, 1989, EMBO J, V8, P4325, DOI 10.1002/j.1460-2075.1989.tb08619.x; KEMPER B, 1984, COLD SPRING HARB SYM, V49, P815, DOI 10.1101/SQB.1984.049.01.092; LILLEY DMJ, 1984, CELL, V36, P413, DOI 10.1016/0092-8674(84)90234-4; LLOYD RG, 1991, J BACTERIOL, V173, P5414, DOI 10.1128/jb.173.17.5414-5418.1991; LLOYD RG, 1984, MOL GEN GENET, V194, P303, DOI 10.1007/BF00383532; LLOYD RG, 1987, J GEN MICROBIOL, V133, P2531; LU M, 1991, J BIOL CHEM, V266, P2531; LU M, 1990, J BIOL CHEM, V265, P16778; MIZUUCHI K, 1982, CELL, V29, P357, DOI 10.1016/0092-8674(82)90152-0; MUELLER JE, 1988, P NATL ACAD SCI USA, V85, P9441, DOI 10.1073/pnas.85.24.9441; MUELLER JE, 1990, J BIOL CHEM, V265, P13918; MURCHIE AIH, 1991, EMBO J, V10, P713, DOI 10.1002/j.1460-2075.1991.tb08001.x; MURCHIE AIH, 1989, NATURE, V341, P763, DOI 10.1038/341763a0; OTSUJI N, 1974, J BACTERIOL, V117, P337, DOI 10.1128/JB.117.2.337-344.1974; PARSONS CA, 1990, NUCLEIC ACIDS RES, V18, P4377, DOI 10.1093/nar/18.15.4377; PARSONS CA, 1990, J BIOL CHEM, V265, P9285; PARSONS CA, 1992, P NATL ACAD SCI USA, V89, P5452, DOI 10.1073/pnas.89.12.5452; PICKSLEY SM, 1990, J MOL BIOL, V212, P723, DOI 10.1016/0022-2836(90)90233-C; POTTMEYER S, 1992, J MOL BIOL, V223, P607, DOI 10.1016/0022-2836(92)90977-R; SHARPLES GJ, 1990, MOL GEN GENET, V221, P219, DOI 10.1007/BF00261724; SHIBA T, 1993, MOL GEN GENET, V237, P395, DOI 10.1007/BF00279443; SHIBA T, 1991, P NATL ACAD SCI USA, V88, P8445, DOI 10.1073/pnas.88.19.8445; SHINAGAWA H, 1991, BIOCHIMIE, V73, P505, DOI 10.1016/0300-9084(91)90120-P; SYMINGTON LS, 1985, P NATL ACAD SCI USA, V82, P7247, DOI 10.1073/pnas.82.21.7247; TAKAHAGI M, 1991, J BACTERIOL, V173, P5747, DOI 10.1128/jb.173.18.5747-5753.1991; TSANEVA IR, 1992, CELL, V69, P1171, DOI 10.1016/0092-8674(92)90638-S; VONKITZING E, 1990, NUCLEIC ACIDS RES, V18, P2671, DOI 10.1093/nar/18.9.2671; WEST SC, 1985, P NATL ACAD SCI USA, V82, P6445, DOI 10.1073/pnas.82.19.6445; WILLIAMSON JR, 1990, NUCLEIC ACIDS RES, V18, P379, DOI 10.1093/nar/18.2.379	50	51	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					15132	15139						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195150				2022-12-25	WOS:A1994NP73800044
J	TURK, E; MARTIN, MG; WRIGHT, EM				TURK, E; MARTIN, MG; WRIGHT, EM			STRUCTURE OF THE HUMAN NA+/GLUCOSE COTRANSPORTER GENE SGLT1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN INTESTINAL NA+/GLUCOSE; GLUCOSE TRANSPORTERS; EXPRESSION CLONING; FUNCTIONAL EXPRESSION; HUMAN-CHROMOSOMES; ORGANIZATION; CDNA; ASSIGNMENT; SEQUENCE; PROTEIN	Intestinal uptake of dietary glucose and galactose is mediated by the SGLT1 Na+/glucose cotransporter of the brush border. An SGLT1 missense mutation underlies hereditary glucose/galactose malabsorption, characterized by potentially fatal diarrhea; conversely, oral rehydration therapy exploits normal transport to alleviate life-threatening diarrhea of infectious origin. We have mapped the entire human SGLT1 Na+/glucose cotransporter gene from cosmid and lambda phage clones representing a genomic region of 112 kilobases. Transcription initiation occurred from a site 27 base pairs 3' of a TATAA sequence. All exon-flanking regions were sequenced, and the entire 112-kilobase region mapped with four restriction enzymes. SGLT1 is comprised of 15 exons (spanning 72 kilobases); a possible evolutionary origin from a six-membrane-span ancestral precursor via a gene duplication event is suggested from comparison of exons against protein secondary structure and from sequence considerations. A new missense mutation in exon 1 causing glucose/galactose malabsorption is also described. This is the first Na+-dependent cotransporter gene structure reported. These data facilitate the search for new glucose/galactose malabsorption-related mutations in this important gene and provide a basis for future evolutionary comparisons with other Na+-dependent cotransporters.	UNIV CALIF LOS ANGELES, SCH MED, DEPT PEDIAT, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA			Martín, María/HDL-9512-2022		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK041301, R01DK019567, R01DK044582] Funding Source: NIH RePORTER; NIDDK NIH HHS [NIDDK CURE-UCLA DK-41301, NIDDK DK-44582, NIDDK DK-19567] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BALDINI A, 1991, GENOMICS, V9, P770, DOI 10.1016/0888-7543(91)90374-N; BALDWIN SA, 1993, BIOCHIM BIOPHYS ACTA, V1154, P17, DOI 10.1016/0304-4157(93)90015-G; BELL GI, 1990, DIABETES CARE, V13, P198, DOI 10.2337/diacare.13.3.198; BIRD AP, 1987, TRENDS GENET, V3, P342, DOI 10.1016/0168-9525(87)90294-0; BIRREN BW, 1989, ANAL BIOCHEM, V177, P282, DOI 10.1016/0003-2697(89)90052-3; CARLE GF, 1986, SCIENCE, V232, P65, DOI 10.1126/science.3952500; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EVANS GA, 1987, METHOD ENZYMOL, V152, P604; GRAHAM MY, NUCLEIC ACIDS RES, V15, p443P7; GREGORY RJ, 1990, NATURE, V347, P382, DOI 10.1038/347382a0; HAGENBUCH B, 1991, P NATL ACAD SCI USA, V88, P10629, DOI 10.1073/pnas.88.23.10629; HEDIGER MA, 1989, P NATL ACAD SCI USA, V86, P5748, DOI 10.1073/pnas.86.15.5748; HEDIGER MA, 1987, NATURE, V330, P379, DOI 10.1038/330379a0; HEDIGER MA, 1989, GENOMICS, V4, P297, DOI 10.1016/0888-7543(89)90333-9; Hirayama Bruce A., 1992, Journal of General Physiology, V100, p19A; HIRSCHHORN N, 1991, SCI AM, V264, P50, DOI 10.1038/scientificamerican0591-50; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; KIMMICH GA, 1981, PHYSL GASTROINTESTIN, P1035; KONG CT, 1993, J BIOL CHEM, V268, P1509; KOPITO RR, 1987, J BIOL CHEM, V262, P8035; KORENBERG JR, 1978, HUM GENET, V43, P13, DOI 10.1007/BF00396473; KORENBERG JR, 1988, CELL, V53, P391, DOI 10.1016/0092-8674(88)90159-6; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; Krainer AR, 1988, TRANSCRIPTION SPLICI, P131; KWON HM, 1992, J BIOL CHEM, V267, P6297; LESCALEMATYS L, 1993, BIOCHEM J, V291, P435, DOI 10.1042/bj2910435; MAGAGNIN S, 1993, P NATL ACAD SCI USA, V90, P5979, DOI 10.1073/pnas.90.13.5979; MARGER MD, 1993, TRENDS BIOCHEM SCI, V18, P13, DOI 10.1016/0968-0004(93)90081-W; MCCLATCHEY AI, 1992, HUM MOL GENET, V1, P521; NEF P, 1984, P NATL ACAD SCI-BIOL, V81, P7975, DOI 10.1073/pnas.81.24.7975; OHTA T, 1990, MOL CELL BIOL, V10, P6491, DOI 10.1128/MCB.10.12.6491; PAJOR AM, 1992, J BIOL CHEM, V267, P3557; SHIRAZIBEECHEY SP, 1991, J PHYSIOL-LONDON, V437, P699, DOI 10.1113/jphysiol.1991.sp018620; TURK E, 1993, GENOMICS, V17, P752, DOI 10.1006/geno.1993.1399; TURK E, 1991, NATURE, V350, P354, DOI 10.1038/350354a0; WELLS RG, 1992, AM J PHYSIOL, V263, P459; WERNER A, 1991, P NATL ACAD SCI USA, V88, P9608, DOI 10.1073/pnas.88.21.9608; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P277, DOI 10.1016/0968-0004(90)90054-F; WRIGHT E M, 1992, Current Opinion in Cell Biology, V4, P696, DOI 10.1016/0955-0674(92)90091-P; WRIGHT EM, 1993, SOC GEN PHY, V48, P229; WRIGHT EM, 1994, IN PRESS PHYSL GASTR	42	91	94	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					15204	15209						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195156				2022-12-25	WOS:A1994NP73800053
J	JAYANTHI, LD; RAMAMOORTHY, S; MAHESH, VB; LEIBACH, FH; GANAPATHY, V				JAYANTHI, LD; RAMAMOORTHY, S; MAHESH, VB; LEIBACH, FH; GANAPATHY, V			CALMODULIN-DEPENDENT REGULATION OF THE CATALYTIC FUNCTION OF THE HUMAN SEROTONIN TRANSPORTER IN PLACENTAL CHORIOCARCINOMA CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BORDER MEMBRANE-VESICLES; PROTEIN-KINASE-C; 5-HYDROXYTRYPTAMINE TRANSPORTER; PARTIAL-PURIFICATION; RAT-BRAIN; LINE; ANTAGONISTS; EXPRESSION; INHIBITION; MODULATION	We investigated the involvement of calmodulin-dependent cellular processes in the regulation of the human serotonin transporter in placental choriocarcinoma cells. Treatment of JAR and BeWo cells with the selective calmodulin antagonist 1,3-dihydro-1-[1-((4-methyl-4H,6H-pyrrolo[1,2-alpha] [4,1]-benzoxapin-4-yl)-methyl)-4-piperindinyl]-2H-benzimidazol-2-one (CGS93-43B (CGS)) for 1 h decreased the imipramine-sensitive serotonin transport activity markedly. The inhibitory effect was specific and was reproducible with other calmodulin antagonists. The basal serotonin transport activity as well as the activity that was stimulated by cholera toxin were inhibited to a similar extent. The CGS-induced inhibition was accompanied by a decrease in the maximal velocity and in the affinities of the transporter for Na+ and Cl- and an increase in the affinity for serotonin. There was, however, no change in the Na+/Cl-/serotonin stoichiometry. The inhibition of the transport activity induced by the treatment of intact cells with CGS was observable in plasma membrane vesicles isolated hom these cells. Treatment with CGS had no effect on steady state levels of the serotonin transporter mRNAs nor on the transporter density in the plasma membrane. We conclude that the serotonin transporter is regulated by calmodulin-dependent processes in human placental choriocarcinoma cells involving posttranslational modification, most likely phosphorylation/dephosphorylation, of the transporter protein.	MED COLL GEORGIA,DEPT BIOCHEM & MOLEC BIOL,AUGUSTA,GA 30912	University System of Georgia; Augusta University					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD027487] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 27487] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANDERSON GM, 1992, BIOCHIM BIOPHYS ACTA, V1137, P331, DOI 10.1016/0167-4889(92)90154-4; BALKOVETZ DF, 1989, J BIOL CHEM, V264, P2195; BIESSEN EAL, 1990, BIOCHEMISTRY-US, V29, P3349, DOI 10.1021/bi00465a029; BLAKELY RD, 1991, NATURE, V354, P66, DOI 10.1038/354066a0; BOJA JW, 1992, SYNAPSE, V12, P27, DOI 10.1002/syn.890120104; BRANDSCH M, 1994, IN PRESS BIOCH BIOPH; COOL DR, 1991, J BIOL CHEM, V266, P15750; COOL DR, 1990, BIOCHEMISTRY-US, V29, P1818, DOI 10.1021/bi00459a022; FOGUET M, 1993, EMBO J, V12, P903, DOI 10.1002/j.1460-2075.1993.tb05731.x; FORSTNER GG, 1968, BIOCHEM J, V106, P381, DOI 10.1042/bj1060381; GANAPATHY V, 1989, J PHARMACOL EXP THER, V251, P9; GONZALEZHEYDRICH J, 1990, J CLIN PSYCHIAT, V51, P5; GRAHAM D, 1992, BIOCHEM J, V286, P801, DOI 10.1042/bj2860801; HOFFMAN BJ, 1991, SCIENCE, V254, P579, DOI 10.1126/science.1948036; LAUNAY JM, 1992, J BIOL CHEM, V267, P11344; LESCH KP, 1993, J NEUROCHEM, V60, P2319, DOI 10.1111/j.1471-4159.1993.tb03522.x; LESCH KP, 1993, J NEURAL TRANSM-GEN, V91, P67, DOI 10.1007/BF01244919; MYERS CL, 1989, AM J PHYSIOL, V257, pL253, DOI 10.1152/ajplung.1989.257.4.L253; NORMAN JA, 1987, MOL PHARMACOL, V31, P535; PRASAD PD, 1994, IN PRESS PLACENTA; RAMAMOORTHY S, 1992, PEDIATR RES, V32, P125, DOI 10.1203/00006450-199207000-00024; RAMAMOORTHY S, 1993, P NATL ACAD SCI USA, V90, P2542, DOI 10.1073/pnas.90.6.2542; RAMAMOORTHY S, 1993, J BIOL CHEM, V268, P21626; RAMAMOORTHY S, 1992, BIOCHEM J, V286, P89, DOI 10.1042/bj2860089; RAMAMOORTHY S, 1992, BIOCHIM BIOPHYS ACTA, V1136, P181, DOI 10.1016/0167-4889(92)90255-A; RAMAMOORTHY S, 1992, AM J PHYSIOL, V262, pC1189, DOI 10.1152/ajpcell.1992.262.5.C1189; RAMAMOORTHY S, 1993, BIOCHEMISTRY-US, V32, P1346, DOI 10.1021/bi00056a021; RAMAMOORTHY S, 1993, PLACENTA, V14, P449, DOI 10.1016/S0143-4004(05)80465-5; RUDNICK G, 1993, BIOCHIM BIOPHYS ACTA, V1144, P249, DOI 10.1016/0005-2728(93)90109-S; SCHATZMAN RC, 1981, BIOCHEM BIOPH RES CO, V98, P669, DOI 10.1016/0006-291X(81)91166-9; TANAKA T, 1982, MOL PHARMACOL, V22, P408; TURNER RJ, 1983, J MEMBRANE BIOL, V76, P1, DOI 10.1007/BF01871450; WALL SC, 1993, MOL PHARMACOL, V43, P264	33	99	101	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14424	14429						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	8182048				2022-12-25	WOS:A1994NM06500021
J	JUNTTIBERGGREN, L; CIVELEK, VN; BERGGREN, PO; SCHULTZ, V; CORKEY, BE; TORNHEIM, K				JUNTTIBERGGREN, L; CIVELEK, VN; BERGGREN, PO; SCHULTZ, V; CORKEY, BE; TORNHEIM, K			GLUCOSE-STIMULATED INCREASE IN CYTOPLASMIC PH PRECEDES INCREASE IN FREE CA2+ IN PANCREATIC BETA-CELLS - A POSSIBLE ROLE FOR PYRUVATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PURINE NUCLEOTIDE CYCLE; INDUCED INSULIN RELEASE; ACYL-COA ESTERS; INTRACELLULAR PH; AMMONIA PRODUCTION; EUKARYOTIC CELLS; ISLET CELLS; MALONYL-COA; B-CELLS; SECRETION	The temporal relationship of glucose-induced increases in cytoplasmic pH (pH(i)) and cytoplasmic free Ca2+ was studied in single mouse pancreatic beta cells and suspensions of clonal beta-cells (HIT). In both preparations of cells the increase in pH(i) preceded the cytoplasmic free Ca2+ increase. Therefore the alkalinization cannot be a consequence of the Ca2+ influx. A potential metabolic mechanism for the increase in pH(i), involving stimulation of pyruvate transport and oxidation, was demonstrated in a model system of liver mitochondria incubated with pyruvate, ATP, and hexokinase to which glucose was then added to initiate ATP use. The involvement of this mechanism in beta-cells is suggested by the observation that the alkalinization was prevented in most cells by incubation with 3-hydroxycyanocinnamate, a mitochondrial pyruvate transport inhibitor. On the other hand, the inhibited cells exhibited normal Ca2+ responses to glucose stimulation. This indicates that neither pyruvate metabolism nor the alkalinization is of critical importance for the Ca2+ signal, though pyruvate oxidation or its metabolites may be important in downstream regulation of secretion.	BOSTON UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02118; KAROLINSKA INST,KAROLINSKA HOSP,ROLF LUFT CTR DIABET RES,DEPT ENDOCRINOL,S-10401 STOCKHOLM,SWEDEN; BOSTON UNIV,SCH MED,EVANS DEPT MED,DIABET & METAB UNIT,BOSTON,MA 02118	Boston University; Karolinska Institutet; Karolinska University Hospital; Boston University			Civelek, Vildan Nur/D-7097-2014; Corkey, Barbara/E-7712-2015	Civelek, Vildan Nur/0000-0002-2942-6609; Berggren, Per-Olof/0000-0001-8991-413X; Tornheim, Keith/0000-0002-6235-5128; Corkey, Barbara/0000-0002-5467-1630	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK035914, R01DK031559, P30DK046200, R01DK035914] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-46200, DK-35914, DK-31559] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARAGON JJ, 1980, FEBS LETT, V117, pK56, DOI 10.1016/0014-5793(80)80570-9; ARKHAMMAR P, 1987, J BIOL CHEM, V262, P5448; ARKHAMMAR P, 1986, BIOSCIENCE REP, V6, P355, DOI 10.1007/BF01116422; ASHCROFT SJH, 1981, ISLETS LANGERHANS BI, P117; BEST L, 1988, J MOL ENDOCRINOL, V1, P33, DOI 10.1677/jme.0.0010033; BUKOWIECKI L, 1979, BIOCHIM BIOPHYS ACTA, V583, P370, DOI 10.1016/0304-4165(79)90461-6; CORKEY BE, 1982, J BIOL CHEM, V257, P9668; CORKEY BE, 1989, J BIOL CHEM, V264, P21608; DEENEY JT, 1992, J BIOL CHEM, V267, P19840; DELEERS M, 1985, HORM METAB RES, V17, P391, DOI 10.1055/s-2007-1013555; DELEERS M, 1983, FEBS LETT, V154, P97, DOI 10.1016/0014-5793(83)80882-5; FREINKEL N, 1974, J CLIN INVEST, V54, P1179, DOI 10.1172/JCI107861; GRAPENGIESSER E, 1989, BIOCHIM BIOPHYS ACTA, V1014, P219, DOI 10.1016/0167-4889(89)90215-2; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3340; HALESTRAP AP, 1975, BIOCHEM J, V148, P85, DOI 10.1042/bj1480085; HESKETH TR, 1985, NATURE, V313, P481, DOI 10.1038/313481a0; HUTTON JC, 1979, BIOCHEM J, V184, P291, DOI 10.1042/bj1840291; JUNTTIBERGGREN L, 1992, BIOCHEM J, V287, P59, DOI 10.1042/bj2870059; JUNTTIBERGGREN L, 1991, J BIOL CHEM, V266, P23537; KAIBARA M, 1988, J PHYSIOL-LONDON, V403, P621, DOI 10.1113/jphysiol.1988.sp017268; KAMP F, 1993, BIOCHEMISTRY-US, V32, P11074, DOI 10.1021/bi00092a017; KRZANOWSKI JJ, 1971, DIABETES, V20, P598, DOI 10.2337/diab.20.9.598; KUSHMERICK MJ, 1983, BIOCH EXERCISE, P50; LANOUE KF, 1979, ANNU REV BIOCHEM, V48, P871, DOI 10.1146/annurev.bi.48.070179.004255; LINDSTROM P, 1984, BIOCHEM J, V218, P887, DOI 10.1042/bj2180887; LINDSTROM P, 1986, BIOCHEM J, V239, P199, DOI 10.1042/bj2390199; LONGO EA, 1991, J BIOL CHEM, V266, P9314; LOWENSTE.J, 1971, SCIENCE, V171, P397, DOI 10.1126/science.171.3969.397; MADSHUS IH, 1988, BIOCHEM J, V250, P1, DOI 10.1042/bj2500001; MAHOWALD TA, 1962, J BIOL CHEM, V237, P1535; MALAISSE WJ, 1980, LIFE SCI, V26, P1367, DOI 10.1016/0024-3205(80)90038-7; MALAISSE WJ, 1979, DIABETOLOGIA, V16, P331, DOI 10.1007/BF01223623; MALAISSE WJ, 1981, METABOLISM, V30, P527, DOI 10.1016/0026-0495(81)90191-8; MALAISSE WJ, 1981, ISLETS LANGERHANS BI, P149; MARYNISSEN G, 1992, BIOCHEM MED METAB B, V48, P127, DOI 10.1016/0885-4505(92)90057-6; MCCORMACK JG, 1990, BIOCHEM J, V267, P527, DOI 10.1042/bj2670527; MEGLASSON M D, 1986, Diabetes Metabolism Reviews, V2, P163; MISLER S, 1989, J MEMBRANE BIOL, V109, P135, DOI 10.1007/BF01870852; PACE CS, 1986, METABOLISM, V35, P176, DOI 10.1016/0026-0495(86)90120-4; PACE CS, 1983, AM J PHYSIOL, V244, pE3, DOI 10.1152/ajpendo.1983.244.1.E3; PRENTKI M, 1992, J BIOL CHEM, V267, P5802; PRENTKI M, 1987, PHYSIOL REV, V67, P1185, DOI 10.1152/physrev.1987.67.4.1185; SCHNEIDER WC, 1950, J BIOL CHEM, V183, P123; SCHULTZ V, 1978, J BIOL CHEM, V253, P1938; SCHULTZ V, 1976, J BIOL CHEM, V251, P485; TAKAHASHI KI, 1993, J GEN PHYSIOL, V101, P695, DOI 10.1085/jgp.101.5.695; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; TORNHEIM K, 1973, J BIOL CHEM, V248, P2670; TRIVEDI B, 1966, J BIOL CHEM, V241, P4110; UI M, 1966, BIOCHIM BIOPHYS ACTA, V124, P310, DOI 10.1016/0304-4165(66)90194-2	50	26	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14391	14395						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	8182044				2022-12-25	WOS:A1994NM06500016
J	UMAR, A; BOYER, JC; THOMAS, DC; NGUYEN, DC; RISINGER, JI; BOYD, J; IONOV, Y; PERUCHO, M; KUNKEL, TA				UMAR, A; BOYER, JC; THOMAS, DC; NGUYEN, DC; RISINGER, JI; BOYD, J; IONOV, Y; PERUCHO, M; KUNKEL, TA			DEFECTIVE MISMATCH REPAIR IN EXTRACTS OF COLORECTAL AND ENDOMETRIAL CANCER CELL-LINES EXHIBITING MICROSATELLITE INSTABILITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CARCINOMA; ESTABLISHMENT; MUTATIONS	A replication error (RER(+)) phenotype, characterized by somatic instability in simple repeated sequences, is associated with several types of cancer. To determine if a defect in DNA replication fidelity or repair of replication errors might explain this instability, we compared both processes in cell-free extracts from RER(+) endometrial and colorectal cancer cell lines to RER(-) cell lines. SV40 origin-dependent replication of a microsatellite sequence is highly accurate in cell extracts regardless of their RER phenotype. However, extracts from RER(+) cell lines are defective in mismatch repair, while extracts of RER(-) cell lines are not. Lack of repair was observed when the signal (a nick) for strand specific repair was either 3' or 5' to the mispair. One colorectal cancer cell line contained deletions in both alleles of the putative mismatch repair gene hMSH2, and one endometrial cancer cell line contained a 4-base pair duplication in one hMSH2 allele. No hMSH2 mutation was detected in the other allele or in the other five RER(+) cell lines. Repair was readily detected when each of the defective extracts was mixed with a repair-proficient extract, demonstrating that no trans-acting inhibitor is present. Attempts to complement the repair deficiencies by mixing two different defective extracts identified three combinations that restored repair. The data suggest that: (i) defective repair is associated with colorectal and endometrial cancer and, by extrapolation, with other types of cancer; (ii) mutations in the hMSH2 gene, and possibly other genes, result in defective mismatch repair; (iii) the defect(s) in these lines likely involves pre-incision events or the excision step, but not the incision, polymerization, or ligation steps; and (iv) at least four functional complementation groups for mismatch repair may be involved in human cancer.	NIEHS,MOLEC GENET LAB,RES TRIANGLE PK,NC 27709; NIEHS,MOLEC CARCINOGENESIS LAB,GYNECOL PATHOBIOL SECT,RES TRIANGLE PK,NC 27709; CALIF INST BIOL RES,LA JOLLA,CA 92037	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)			Kunkel, Thomas A./D-5088-2019	Kunkel, Thomas A./0000-0002-9900-1788; Perucho, Manuel/0000-0002-2169-2662				AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; BOYD J, 1991, MOL CARCINOGEN, V4, P189, DOI 10.1002/mc.2940040305; BRATTAIN MG, 1981, CANCER RES, V41, P1751; COOPER DL, 1993, J BIOL CHEM, V268, P11823; DAWE CJ, 1964, JNCI-J NATL CANCER I, V33, P441; DEXTER DL, 1979, CANCER RES, V39, P1020; DREWINKO B, 1976, CANCER RES, V36, P467; FANG WH, 1993, J BIOL CHEM, V268, P11838; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; GOLDMACHER VS, 1986, J BIOL CHEM, V261, P2462; HAN HJ, 1993, CANCER RES, V53, P5087; HOLMES J, 1990, P NATL ACAD SCI USA, V87, P5837, DOI 10.1073/pnas.87.15.5837; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; KAT A, 1993, P NATL ACAD SCI USA, V90, P6424, DOI 10.1073/pnas.90.14.6424; KUNKEL TA, 1985, J BIOL CHEM, V260, P5787; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LEIBOVITZ A, 1976, CANCER RES, V36, P4562; LINDBLOM A, 1993, NAT GENET, V5, P279, DOI 10.1038/ng1193-279; LOTHE RA, 1993, CANCER RES, V53, P5849; MIRONOV NM, 1994, CANCER RES, V54, P41; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; Morisawa T, 1987, J JPN SOC CLIN CYTOL, V26, P433; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; PELTOMAKI P, 1993, SCIENCE, V260, P810, DOI 10.1126/science.8484120; PELTOMAKI P, 1993, CANCER RES, V53, P5853; PUCK TT, 1956, J EXP MED, V103, P273, DOI 10.1084/jem.103.2.273; RISINGER JI, 1993, CANCER RES, V53, P5100; RISINGER JI, 1994, IN PRESS NAT GENET, V6; ROBERTS JD, 1993, BIOCHEMISTRY-US, V32, P4083, DOI 10.1021/bi00066a033; ROBERTS JD, 1993, METHODS MOL GENET, V2, P295; SHIBATA D, 1994, NAT GENET, V6, P278; SKOPEK TR, 1978, BIOCHEM BIOPH RES CO, V84, P411, DOI 10.1016/0006-291X(78)90185-7; STRAND M, 1993, NATURE, V365, P273; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; THOMAS DC, 1991, J BIOL CHEM, V266, P3744; TOM BH, 1976, IN VITRO CELL DEV B, V12, P180; WOOSTER R, 1994, NAT GENET, V6, P152, DOI 10.1038/ng0294-152	38	326	332	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14367	14370						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	8182040				2022-12-25	WOS:A1994NM06500011
J	YANG, EY; HUESTIS, WH				YANG, EY; HUESTIS, WH			OXIDATIVE INTERACTIONS BETWEEN THE ERYTHROCYTE-MEMBRANE AND PHOSPHATIDYLCHOLINE VESICLES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RED BLOOD-CELLS; LOW-PH ASSOCIATION; VITAMIN-E; LIPID-PEROXIDATION; CROSS-LINKING; HEMOGLOBIN; PROTEINS; SUPEROXIDE; MECHANISM; TRANSGLUTAMINASES	Sonicated unilamellar phosphatidylcholine vesicles induce hemoglobin oxidation in erythrocytes and resealed membrane fragments (buds) at pH 5.5. No such oxidation was observed in vesicle-bud mixtures at pH 7.4, in cells or buds suspended in pH 5.5 buffer, or in cells incubated with multilamellar lipid vesicles at pH 5.5. In buds, vesicle-induced hemoglobin oxidation was accompanied by lipid peroxidation and formation of covalent high molecular weight protein aggregates. The causative relationships among the oxidative events were examined using selective antioxidants and membrane fragments in which the cytoplasmic domain of band 3 was cleaved. Protein cross-linking and lipid peroxidation were found to be independent events, but both were found only in concert with heme oxidation. Further, vesicle-induced hemoglobin oxidation was found to be correlated with quasi-stable adsorption of intact vesicles to cells; intercalation of foreign lipid into the cell bilayer was not required. The inability of multilamellar vesicles to induce these low pH oxidative effects suggests a steric Limitation on this cell-vesicle association. The results suggest that membrane component reorganization and patching induced by low pH may enhance vesicle adsorption, which in turn initiates oxidative damage.	STANFORD UNIV,DEPT CHEM,STANFORD,CA 94305	Stanford University					NHLBI NIH HHS [HL 23787] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL023787] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMES GFL, 1974, J BIOL CHEM, V249, P634; ARVINTE T, 1989, BIOCHIM BIOPHYS ACTA, V981, P51, DOI 10.1016/0005-2736(89)90081-3; ARVINTE T, 1989, BIOCHIM BIOPHYS ACTA, V981, P61, DOI 10.1016/0005-2736(89)90082-5; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BEPPU M, 1990, J BIOL CHEM, V265, P3226; BIABER B, 1977, J LAB CLIN MED, V85, P235; BOSSI L, 1975, BIOCHIM BIOPHYS ACTA, V375, P477, DOI 10.1016/0005-2736(75)90364-8; BURTON GW, 1983, ARCH BIOCHEM BIOPHYS, V221, P281, DOI 10.1016/0003-9861(83)90145-5; BUTIKOFER P, 1989, BLOOD, V74, P1481; CALVEZ JY, 1988, BIOCHEMISTRY-US, V27, P5666, DOI 10.1021/bi00415a041; CLASTER S, 1984, BLOOD, V64, P1079; CLASTER S, 1987, J LAB CLIN MED, V109, P201; COAKLEY WT, 1978, BIOCHIM BIOPHYS ACTA, V512, P318, DOI 10.1016/0005-2736(78)90256-0; CRICHTON RR, 1979, CIBA F S, V65, P57; Davies P J, 1988, Adv Exp Med Biol, V250, P391; DILLARD CJ, 1982, ARCH BIOCHEM BIOPHYS, V216, P204, DOI 10.1016/0003-9861(82)90205-3; DORMANDY TL, 1971, BRIT J HAEMATOL, V20, P457, DOI 10.1111/j.1365-2141.1971.tb07060.x; FLYNN TP, 1983, J CLIN INVEST, V71, P1215, DOI 10.1172/JCI110870; FLYNN TP, 1981, PROG CLIN BIOL RES, V91, P231; FOLK JE, 1980, ANNU REV BIOCHEM, V49, P517, DOI 10.1146/annurev.bi.49.070180.002505; FREI B, 1989, P NATL ACAD SCI USA, V86, P6377, DOI 10.1073/pnas.86.16.6377; FRIDOVICH I, 1975, ANNU REV BIOCHEM, V44, P147, DOI 10.1146/annurev.bi.44.070175.001051; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; HEBBEL RP, 1984, BLOOD, V64, P733; HERSCHBERGER LA, 1982, LIPIDS, V17, P686, DOI 10.1007/BF02534652; HUISMAN THJ, 1986, METHODS HEMATOLOGY, V15; ITABE H, 1988, BIOCHIM BIOPHYS ACTA, V961, P13; JAIN MK, 1980, INTRO BIOL MEMBRANES, P72; JOHNSON GJ, 1979, NEW ENGL J MED, V301, P522, DOI 10.1056/NEJM197909063011004; KIMELBERG HK, 1976, MOL CELL BIOCHEM, V10, P171, DOI 10.1007/BF01731688; KORNBRUST DJ, 1980, LIPIDS, V15, P315, DOI 10.1007/BF02533546; KWEI GY, 1985, NUTR REP INT, V32, P179; LABRAKE CC, 1992, J BIOL CHEM, V267, P16703; LITOV RE, 1981, TOXICOL APPL PHARM, V59, P96, DOI 10.1016/0041-008X(81)90456-7; LORAND L, 1984, MOL CELL BIOCHEM, V58, P9, DOI 10.1007/BF00240602; LORAND L, 1976, P NATL ACAD SCI USA, V73, P4479, DOI 10.1073/pnas.73.12.4479; LOW PS, 1985, SCIENCE, V227, P531, DOI 10.1126/science.2578228; LUBIN B, 1982, PEDIATR RES, V16, P928, DOI 10.1203/00006450-198211000-00005; MACDONALD VW, 1983, J LAB CLIN MED, V102, P762; MACHLIN LJ, 1980, VITAMIN E; MANNOJI M, 1985, SCAND J HAEMATOL, V35, P257; MCCAY PB, 1971, LIPIDS, V6, P297, DOI 10.1007/BF02531819; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; MISRA HP, 1972, J BIOL CHEM, V247, P6960; PALEK J, 1979, SEMIN HEMATOL, V14, P75; PAPAHADJOPOULOS D, 1973, Biochimica et Biophysica Acta, V330, P8, DOI 10.1016/0005-2736(73)90280-0; PAPAHADJOPOULOS D, 1975, BIOCHIM BIOPHYS ACTA, V401, P317, DOI 10.1016/0005-2736(75)90233-3; PRYOR W A, 1976, FREE RADICALS BIOLOG, P1; Riggs A., 1981, Methods in Enzymology, V76, P5; SALIN ML, 1975, J CLIN INVEST, V56, P1319, DOI 10.1172/JCI108208; SEVANIAN A, 1982, LIPIDS, V17, P269, DOI 10.1007/BF02534941; SHAKLAI N, 1978, ISRAEL J MED SCI, V14, P1152; SHVIRO Y, 1982, BIOCHIM BIOPHYS ACTA, V687, P63, DOI 10.1016/0005-2736(82)90170-5; SIEFRING GE, 1978, BIOCHEMISTRY-US, V17, P2598, DOI 10.1021/bi00606a022; SNYDER LM, 1983, BRIT J HAEMATOL, V53, P379, DOI 10.1111/j.1365-2141.1983.tb02038.x; Steck T L, 1974, Methods Enzymol, V31, P172; Steck T. L., 1974, METHODS MEMBRANE BIO, V2, P245; Stokes J, 1971, BRIT J HAEMATOL, V20, P95; SZEBENI J, 1988, BIOCHEMISTRY-US, V27, P6425, DOI 10.1021/bi00417a034; SZEBENI J, 1985, BIOCHEMISTRY-US, V24, P2827, DOI 10.1021/bi00333a003; SZEBENI J, 1984, BIOCHEM J, V220, P685, DOI 10.1042/bj2200685; TAPPEL AL, 1972, ANN NY ACAD SCI, V203, P12, DOI 10.1111/j.1749-6632.1972.tb27851.x; Tappel AL, 1980, FREE RADICALS BIOL, P1; VANHEMMEN JJ, 1977, ARCH BIOCHEM BIOPHYS, V182, P743, DOI 10.1016/0003-9861(77)90556-2; WALLACE WJ, 1974, BIOCHEM BIOPH RES CO, V57, P1104, DOI 10.1016/0006-291X(74)90810-9; WAUGH SM, 1985, BIOCHEMISTRY-US, V24, P34, DOI 10.1021/bi00322a006; WAUGH SM, 1987, BIOCHEMISTRY-US, V26, P1777, DOI 10.1021/bi00380a041; WEISS SJ, 1981, J CLIN INVEST, V68, P714, DOI 10.1172/JCI110307; WEISS SJ, 1980, J BIOL CHEM, V255, P9912; WINTERBOURN CC, 1976, BIOCHEM J, V155, P493, DOI 10.1042/bj1550493; ZLATKIS A, 1953, J LAB CLIN MED, V41, P486; [No title captured]	72	3	3	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14518	14524						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	8182058				2022-12-25	WOS:A1994NM06500034
J	DENG, L; SHUMAN, S				DENG, L; SHUMAN, S			A ROLE FOR THE H4 SUBUNIT OF VACCINIA RNA-POLYMERASE IN TRANSCRIPTION INITIATION AT A VIRAL EARLY PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS EARLY TRANSCRIPTION; MESSENGER-RNA; CAPPING ENZYME; ESCHERICHIA-COLI; EUKARYOTIC TRANSCRIPTION; GENE; IDENTIFICATION; PURIFICATION; TERMINATION; ELONGATION	The vaccinia virus H4 gene encodes an essential subunit of the DNA-dependent RNA polymerase holoenzyme encapsidated within virus particles (Ahn, B., and Moss, B. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 3536-3540; Kane, E. M., and Shuman, S. (1992) J. Virol. 66, 5752-5762). The role of this protein in transcription of viral early genes was revealed by the effects of affinity-purified anti-H4 antibody on discrete phases of the early transcription reaction in vitro. Anti-H4 specifically prevented the synthesis of a 21-nucleotide nascent RNA chain but had no impact on elongation of the 21-mer RNA by preassembled ternary complexes. Inhibition of initiation but not elongation was also observed with affinity-purified anti-D6 antibody directed against the 70-kDa subunit of the vaccinia early transcription initiation factor (ETF). Native gel mobility-shift assays showed that anti-H4 prevented the NTP-dependent recruitment of RNA polymerase to the preinitiation complex of ETF bound at the early promoter. Two species of ternary complexes could be resolved by native gel electrophoresis. Addition of anti-H4 to preformed complexes elicited a supershift of both ternary species but not of the preinitiation complex. Supershift by anti-D6 revealed that the more rapidly migrating species of ternary complex did not contain immunoreactive ETF. Loss of ETF from the ternary complex was time-dependent. Thus, whereas the H4 protein was a stable constituent of the elongation complex, ETF was dissociable. We suggest that H4 functions as a molecular bridge to ETF and thereby allows specific recognition of early promoters by the core RNA polymerase. H4 is unlike bacterial sigma factor in that it remains bound to polymerase after the elongation complex is established.			DENG, L (corresponding author), SLOAN KETTERING INST,PROGRAM MOLEC BIOL,NEW YORK,NY 10021, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042498] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM42498] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHN BY, 1992, P NATL ACAD SCI USA, V89, P3536, DOI 10.1073/pnas.89.8.3536; AHN BY, 1990, J VIROL, V64, P3019, DOI 10.1128/JVI.64.6.3019-3024.1990; AHN BY, 1990, MOL CELL BIOL, V10, P5433, DOI 10.1128/MCB.10.10.5433; AHN BY, 1992, J VIROL, V66, P971, DOI 10.1128/JVI.66.2.971-982.1992; AMEGADZIE BY, 1991, J BIOL CHEM, V266, P13712; AMEGADZIE BY, 1992, J VIROL, V66, P3003, DOI 10.1128/JVI.66.5.3003-3010.1992; BROYLES SS, 1988, J BIOL CHEM, V263, P10754; BROYLES SS, 1991, J BIOL CHEM, V266, P15539; BROYLES SS, 1990, J VIROL, V64, P5376, DOI 10.1128/JVI.64.11.5376-5382.1990; BROYLES SS, 1986, P NATL ACAD SCI USA, V83, P3141, DOI 10.1073/pnas.83.10.3141; CONG PJ, 1992, J BIOL CHEM, V267, P16424; EDWARDS AM, 1991, J BIOL CHEM, V266, P71; FLORES O, 1991, P NATL ACAD SCI USA, V88, P9999, DOI 10.1073/pnas.88.22.9999; HAGLER J, 1992, SCIENCE, V255, P983, DOI 10.1126/science.1546295; HAGLER J, 1994, J BIOL CHEM, V269, P10050; HAGLER J, 1993, J BIOL CHEM, V268, P2166; HAGLER J, 1992, J VIROL, V66, P2982, DOI 10.1128/JVI.66.5.2982-2989.1992; HAGLER J, 1992, J BIOL CHEM, V267, P7644; HAGLER J, 1992, P NATL ACAD SCI USA, V89, P10009; HARRIS N, 1993, P NATL ACAD SCI USA, V90, P2860, DOI 10.1073/pnas.90.7.2860; HIGMAN MA, 1992, J BIOL CHEM, V267, P16430; KANE EM, 1992, J VIROL, V66, P5752, DOI 10.1128/JVI.66.10.5752-5762.1992; KRUMMEL B, 1989, BIOCHEMISTRY-US, V28, P7829, DOI 10.1021/bi00445a045; LI J, 1993, J BIOL CHEM, V268, P20016; LI J, 1993, J BIOL CHEM, V268, P2773; LUO Y, 1991, J BIOL CHEM, V266, P13303; MOSS B, 1991, J BIOL CHEM, V266, P1355; PATEL DD, 1989, J VIROL, V63, P1076, DOI 10.1128/JVI.63.3.1076-1086.1989; QUICK SD, 1990, VIROLOGY, V178, P603, DOI 10.1016/0042-6822(90)90362-U; SHUMAN S, 1987, J BIOL CHEM, V262, P12372; SHUMAN S, 1989, J BIOL CHEM, V264, P21356; SHUMAN S, 1990, J BIOL CHEM, V265, P11967; STRANEY DC, 1985, CELL, V43, P449, DOI 10.1016/0092-8674(85)90175-8; VOS JC, 1991, EMBO J, V10, P2553, DOI 10.1002/j.1460-2075.1991.tb07795.x	34	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					14323	14328						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188718				2022-12-25	WOS:A1994NL60600090
J	BERANGER, F; CADWALLADER, K; PORFIRI, E; POWERS, S; EVANS, T; DEGUNZBURG, J; HANCOCK, JF				BERANGER, F; CADWALLADER, K; PORFIRI, E; POWERS, S; EVANS, T; DEGUNZBURG, J; HANCOCK, JF			DETERMINATION OF STRUCTURAL REQUIREMENTS FOR THE INTERACTION OF RAB6 WITH RABGDI AND RAB GERANYLGERANYLTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; GENE-PRODUCT; PROTEIN; GTPASE; METHYLATION; BINDING; PROTEOLYSIS; GAP	The importance of geranylgeranylation to the interaction of Rab proteins with RabGDI was investigated with a set of Rab6 mutants post-translationally modified by all known C-terminal lipid combinations. Rab6 proteins geranylgeranylated on CXC or CC motifs were found to be significantly better substrates for membrane extraction by RabGDI than either Rab6 proteins geranylgeranylated on CAAL motifs or Rab6 proteins that were farnesylated and palmitoylated. The methylation status of the CXC motif did not significantly affect interaction of wild type Rab6 with RabGDI. Rab6 protein sequences required for RabGDI interaction were then identified. Consistent with the significant homology between RabGDI and the Rab escort protein, a subunit of Rab geranylgeranyltransferase (RabGGTase), we show that there is an overlap between RabG motifs required for RabGDI binding and RabGGTase processing. The effector domain, loop3/beta 3 and the hypervariable region of RabG are all required for RabGDI binding, whereas loop3/beta 3 and the hypervariable region but not the effector domain are required for efficient processing of RabG by RabGGTase. Interestingly, however, loop3/beta 3 of RabG when introduced into H-Ras is sufficient to allow some in vivo processing of a C-terminal CSC motif.	ONYX PHARMACEUT,RICHMOND,CA 94806; INSERM,U248,F-75010 PARIS,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm)			Beranger, Florence/R-7581-2019	Hancock, John/0000-0003-0542-4710; Powers, Scott/0000-0003-2769-1932				ANDRES DA, 1993, CELL, V73, P1091, DOI 10.1016/0092-8674(93)90639-8; ARAKI S, 1990, J BIOL CHEM, V265, P13007; BERANGER F, 1994, MOL CELL BIOL, V14, P744, DOI 10.1128/MCB.14.1.744; BRENNWALD P, 1993, NATURE, V362, P560, DOI 10.1038/362560a0; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; BURSTEIN ES, 1991, J BIOL CHEM, V266, P2689; BURTON J, 1993, NATURE, V361, P464, DOI 10.1038/361464a0; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; Cremers Frans P. M., 1992, Human Molecular Genetics, V1, P71, DOI 10.1093/hmg/1.2.71; DUNN B, 1993, NATURE, V362, P563, DOI 10.1038/362563a0; GIANNAKOUROS T, 1993, LIPID MODIFICATIONS; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; HANCOCK JF, 1993, EMBO J, V12, P1915, DOI 10.1002/j.1460-2075.1993.tb05840.x; HANCOCK JF, 1991, EMBO J, V10, P641, DOI 10.1002/j.1460-2075.1991.tb07992.x; HRYCYNA CA, 1991, EMBO J, V10, P1699, DOI 10.1002/j.1460-2075.1991.tb07694.x; HUANG DCS, 1993, MOL CELL BIOL, V13, P2420, DOI 10.1128/MCB.13.4.2420; KATO K, 1992, P NATL ACAD SCI USA, V89, P6403, DOI 10.1073/pnas.89.14.6403; KHOSRAVIFAR R, 1992, J BIOL CHEM, V267, P24363; LOMBARDI D, 1993, EMBO J, V12, P677, DOI 10.1002/j.1460-2075.1993.tb05701.x; MOYA M, 1993, NATURE, V361, P460, DOI 10.1038/361460a0; NEWMAN CMH, 1992, J BIOL CHEM, V267, P11329; PHILIPS MR, 1993, SCIENCE, V259, P977, DOI 10.1126/science.8438158; PLUTNER H, 1991, J CELL BIOL, V115, P31, DOI 10.1083/jcb.115.1.31; RUBINFELD B, 1991, CELL, V65, P1033, DOI 10.1016/0092-8674(91)90555-D; SANFORD JC, 1993, J BIOL CHEM, V268, P23773; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; SEABRA MC, 1993, SCIENCE, V259, P377, DOI 10.1126/science.8380507; SEABRA MC, 1992, J BIOL CHEM, V267, P14497; SEABRA MC, 1992, J BIOL CHEM, V70, P1049; SEGAL M, 1993, P NATL ACAD SCI USA, V90, P5564, DOI 10.1073/pnas.90.12.5564; SOLDATI T, 1993, MOL BIOL CELL, V4, P425, DOI 10.1091/mbc.4.4.425; STROM M, 1993, NATURE, V361, P736, DOI 10.1038/361736a0; ULLRICH O, 1993, J BIOL CHEM, V268, P18143; WEI C, 1992, ONCOGENE, V7, P467; WILSON AL, 1993, J BIOL CHEM, V268, P14561; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; Zerial M, 1993, CURR OPIN CELL BIOL, V5, P613, DOI 10.1016/0955-0674(93)90130-I; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	38	62	64	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13637	13643						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175798				2022-12-25	WOS:A1994NK18400084
J	KINDMAN, LA; KIM, S; MCDONALD, TV; GARDNER, P				KINDMAN, LA; KIM, S; MCDONALD, TV; GARDNER, P			CHARACTERIZATION OF A NOVEL INTRACELLULAR SPHINGOLIPID-GATED CA2+-PERMEABLE CHANNEL FROM RAT BASOPHILIC LEUKEMIA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SARCOPLASMIC-RETICULUM; CALCIUM CHANNELS; SPHINGOSINE; RELEASE; DERIVATIVES; BINDING	Sphingolipids stimulate the release of Ca2+ from intracellular stores. However, the mechanism by which this process occurs has not been characterized. Through single-channel recording from microsomes incorporated into planar lipid bilayers, we describe a novel channel that gates Ba2+ in response to sphingosyl-phosphorylcholine. The channel is both ligand-gated and voltage-modulated. Maximal open probability is observed between -10 and -20 mV and has a relatively high conductance (160 picosiemens with 53 mM Ba2+). We also observe that Ca2+ efflux from permeabilized rat basephilic leukemia cells is not antagonized by heparin, La3+, Ni2+, nifedipine, or Omega-conotoxin GVIa. The sphingolipid-gated Ca2+-permeable channel is therefore a new member of the Ca2+-permeable, ligand-gated channel family.	STANFORD UNIV,MED CTR,DEPT MED,STANFORD,CA 94305; STANFORD UNIV,MED CTR,DEPT PHARMACOL,STANFORD,CA 94305	Stanford University; Stanford University	KINDMAN, LA (corresponding author), DUKE UNIV,MED CTR,DIV CARDIOVASC MED,BOX 3547,DURHAM,NC 27710, USA.				NHLBI NIH HHS [NHLBI K11-HL02361, NHLBI K11-HL02397] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K11HL002361, K11HL002397] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON K, 1989, J BIOL CHEM, V264, P1329; BERTL A, 1992, SCIENCE, V258, P873, DOI 10.1126/science.1439795; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COLQUHOUN D, 1981, NATURE, V294, P752, DOI 10.1038/294752a0; DESAI NN, 1993, J CELL BIOL, V121, P1385, DOI 10.1083/jcb.121.6.1385; DIXON DA, 1989, J BIOL CHEM, V264, P13612; DURIEUX ME, 1993, AM J PHYSIOL, V264, pC1360, DOI 10.1152/ajpcell.1993.264.5.C1360; EHRLICH BE, 1988, NATURE, V336, P583, DOI 10.1038/336583a0; FIELDS R, 1971, BIOCHEM J, V124, P581, DOI 10.1042/bj1240581; FUJINO Y, 1968, BIOCHEM J, V109, P310, DOI 10.1042/bj1090310; GHOSH TK, 1990, SCIENCE, V248, P1653, DOI 10.1126/science.2163543; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; KINDMAN LA, 1993, BIOCHEMISTRY-US, V32, P1270, DOI 10.1021/bi00056a011; KOLESNICK RN, 1991, PROG LIPID RES, V30, P1, DOI 10.1016/0163-7827(91)90005-P; MATHIAS S, 1993, SCIENCE, V259, P519, DOI 10.1126/science.8424175; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; SMITH JS, 1985, NATURE, V316, P446, DOI 10.1038/316446a0; TSIEN RW, 1988, TRENDS NEUROSCI, V11, P431, DOI 10.1016/0166-2236(88)90194-4; VANVELDHOVEN PP, 1989, ANAL BIOCHEM, V183, P177, DOI 10.1016/0003-2697(89)90186-3; WATRAS J, 1987, BIOCHIM BIOPHYS ACTA, V931, P354, DOI 10.1016/0167-4889(87)90227-8; ZHANG H, 1991, J CELL BIOL, V114, P155, DOI 10.1083/jcb.114.1.155	23	61	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13088	13091						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175733				2022-12-25	WOS:A1994NK18400009
J	BOUSSAC, A; RUTHERFORD, AW				BOUSSAC, A; RUTHERFORD, AW			ELECTRON-TRANSFER EVENTS IN CHLORIDE-DEPLETED PHOTOSYSTEM-II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXYGEN-EVOLVING COMPLEX; PHOTOSYNTHETIC WATER OXIDATION; S3 EPR SIGNAL; D1 POLYPEPTIDE; ENZYME; STATE; TYROSINE; EVOLUTION; CALCIUM; SYSTEM	Cl- and Ca2+ are obligatory cofactors in photosystem II (PS-II), the oxygen-evolving enzyme of plants. The electron transfer events in Cl--depleted PS-II were investigated by using continuous wave (cw) and pulsed EPR, and the results were compared with those obtained in untreated and Ca2+-depleted PS-II. In Cl--depleted PS II, the S-1 to S-2 transition is not accompanied by the appearance of the S-2 manganese signal in both cw and field-swept echo experiments. In the S-3 state, the cw experiment reveals the presence of a radical signal, and the field-swept echo experiment reveals the presence of a manganese signal similar to that observed in the S-2 state in Cl--reconstituted PS-II. A relaxation enhancement study of the oxidized tyrosine D indicates that a relaxation enhancement occurs only in the S-2 to S-3 transition and not in the S-1 to S-2 transition. The results are interpreted by the following preferred model. In Cl--depleted PS-II, the S-1 to S-2 transition corresponds to the oxidation of a component other than the manganese cluster, possibly an amino acid, and the S-2 to S-3 transition corresponds to the oxidation of the manganese complex. This oxidation sequence is the opposite of that observed in Ca2+-depleted PS-II. and may be due to a modulation by chloride of the relative redox potentials of the mangenese cluster and a nearby oxidizable amino acid. An alternative model involving manganese oxidation that is invisible in the S-1 to S-2 transition but that becomes visible on S-3 formation cannot be ruled out, although it is considered less likely.			BOUSSAC, A (corresponding author), CTR ETUD SACLAY,DEPT BIOL CELLULAIRE & MOLEC,SERV BIOENERGET,CNRS,UNITE RECH ASSOCIEE 1290,F-91191 GIF SUR YVETTE,FRANCE.		Rutherford, Alfred W/A-7831-2019	Rutherford, Alfred W/0000-0002-3124-154X				BARRY BA, 1987, P NATL ACAD SCI USA, V84, P7099, DOI 10.1073/pnas.84.20.7099; BAUMGARTEN M, 1990, BIOCHEMISTRY-US, V29, P10814, DOI 10.1021/bi00500a014; BOUSSAC A, 1990, FEBS LETT, V277, P69, DOI 10.1016/0014-5793(90)80811-V; BOUSSAC A, 1992, BIOCHEMISTRY-US, V31, P1224, DOI 10.1021/bi00119a036; BOUSSAC A, 1989, BIOCHEMISTRY-US, V28, P8984, DOI 10.1021/bi00449a005; BOUSSAC A, 1988, BIOCHEMISTRY-US, V27, P3476, DOI 10.1021/bi00409a052; BOUSSAC A, 1990, NATURE, V347, P303, DOI 10.1038/347303a0; BOUSSAC A, 1985, BIOCHIM BIOPHYS ACTA, V808, P231, DOI 10.1016/0005-2728(85)90004-0; BOUSSAC A, 1992, BIOCHEMISTRY-US, V31, P7441, DOI 10.1021/bi00148a003; BOUSSAC A, 1993, RES PHOTOSYNTHESIS, V1, P235; COLEMAN WJ, 1990, PHOTOSYNTH RES, V23, P1, DOI 10.1007/BF00030059; DEBUS RJ, 1988, BIOCHEMISTRY-US, V27, P9071, DOI 10.1021/bi00426a001; DEBUS RJ, 1988, P NATL ACAD SCI USA, V85, P427, DOI 10.1073/pnas.85.2.427; DEBUS RJ, 1992, BIOCHIM BIOPHYS ACTA, V1102, P269, DOI 10.1016/0005-2728(92)90133-M; DEGROOT A, 1986, BIOCHIM BIOPHYS ACTA, V848, P8, DOI 10.1016/0005-2728(86)90154-4; DISMUKES GC, 1981, P NATL ACAD SCI-BIOL, V78, P274, DOI 10.1073/pnas.78.1.274; HOMANN PH, 1986, BIOCHIM BIOPHYS ACTA, V850, P10, DOI 10.1016/0005-2728(86)90003-4; HOMANN PH, 1987, J BIOENERG BIOMEMBR, V19, P105, DOI 10.1007/BF00762720; KOK B, 1970, PHOTOCHEM PHOTOBIOL, V11, P457, DOI 10.1111/j.1751-1097.1970.tb06017.x; METZ JG, 1989, BIOCHEMISTRY-US, V28, P6960, DOI 10.1021/bi00443a028; MICHEL H, 1988, BIOCHEMISTRY-US, V27, P1, DOI 10.1021/bi00401a001; ONO T, 1986, BIOCHIM BIOPHYS ACTA, V851, P193, DOI 10.1016/0005-2728(86)90125-8; RUTHERFORD AW, 1991, NEW J CHEM, V15, P491; RUTHERFORD AW, 1989, TRENDS BIOCHEM SCI, V14, P227, DOI 10.1016/0968-0004(89)90032-7; RUTHERFORD AW, 1992, RES PHOTOSYNTHESIS, V2, P21; RUTHERFORD AW, 1992, TOPICS PHOTOSYNTHESI, V11, P179; STYRING S, 1988, BIOCHIM BIOPHYS ACTA, V933, P378, DOI 10.1016/0005-2728(88)90046-1; STYRING S, 1987, BIOCHEMISTRY-US, V26, P2401, DOI 10.1021/bi00383a001; VERMAAS WFJ, 1988, P NATL ACAD SCI USA, V85, P8477, DOI 10.1073/pnas.85.22.8477; YOCUM CF, 1991, BIOCHIM BIOPHYS ACTA, V1059, P1, DOI 10.1016/S0005-2728(05)80182-3; ZIMMERMANN JL, 1993, BIOCHEMISTRY-US, V32, P4831, DOI 10.1021/bi00069a019	31	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12462	12467						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175652				2022-12-25	WOS:A1994NH71600017
J	IMMENSCHUH, S; NAGAE, Y; SATOH, H; BAUMANN, H; MULLEREBERHARD, U				IMMENSCHUH, S; NAGAE, Y; SATOH, H; BAUMANN, H; MULLEREBERHARD, U			THE RAT AND HUMAN HEMOPEXIN GENES CONTAIN AN IDENTICAL INTERLEUKIN-6 RESPONSE ELEMENT THAT IS NOT A TARGET OF CAAT ENHANCER-BINDING PROTEIN ISOFORMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								Hemopexin (Hx) is an abundant acute-phase protein (APP) that binds heme with high affinity. In rat hepatic cells, the transcription rate of the Hx gene is increased by interleukin (IL)-1 and IL-6. To investigate the cis-acting regulatory elements (REs) responsive to these hormones, chloramphenicol acetyltransferase constructs of rat and human Hx gene sequences were tested in transiently transfected hepatoma cells. An IL-6-RE was identified in the promoter of both rat and human Hx genes, the function of which was dependent on the core sequence (CCGGGAA) common in other APP genes. The previously characterized Hx A element mediated a relatively minor cytokine response as compared with the Hx IL-6-RE. The human Hx A element, in contrast to the rat and human Hx IL-6-REs, was strongly trans activated by cotransfected CAAT enhancer-binding proteins (C/EBP)-beta and -delta. The rat gene homolog of the human Hx A element was inactive as a cytokine RE and was minimally trans-activated by C/EBP isoforms. Results of electrophoretic mobility shift assays indicated that the Hx IL-6-RE is a binding site for the IL-6-inducible nuclear protein IL-6 RE-BP, which also binds to the conserved IL-6-REs of other APP genes and is distinct from C/EBP beta.	CORNELL UNIV, COLL MED, DEPT PEDIAT, NEW YORK, NY 10021 USA; CORNELL UNIV, COLL MED, DEPT BIOCHEM, NEW YORK, NY 10021 USA; CORNELL UNIV, COLL MED, DEPT PHARMACOL, NEW YORK, NY 10021 USA; ROSWELL PK CANC INST, DEPT MOLEC & CELLULAR BIOL, BUFFALO, NY 14263 USA	Cornell University; Cornell University; Cornell University; Roswell Park Cancer Institute			Immenschuh, Stephan/AAM-9181-2020	Immenschuh, Stephan/0000-0003-3722-5791	NCI NIH HHS [CA 26122] Funding Source: Medline; NIDDK NIH HHS [DK 30664] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA026122] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030664] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; ALAM T, 1992, J BIOL CHEM, V267, P5021; Aldred A.R., 1993, ACUTE PHASE PROTEINS, V1st ed., P21; ANDERSON GM, 1993, J BIOL CHEM, V268, P22650; BALLA G, 1991, LAB INVEST, V64, P648; BARNARD ML, 1993, BIOCHEM BIOPH RES CO, V192, P82, DOI 10.1006/bbrc.1993.1384; BAUMANN H, 1989, IN VITRO CELL DEV B, V25, P115; BAUMANN H, 1992, J BIOL CHEM, V267, P19744; BAUMANN H, 1990, MOL CELL BIOL, V10, P5967, DOI 10.1128/MCB.10.11.5967; BAUMANN H, 1989, ANN NY ACAD SCI, V557, P280; BRASIER AR, 1990, EMBO J, V9, P3933, DOI 10.1002/j.1460-2075.1990.tb07614.x; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHANG CJ, 1990, MOL CELL BIOL, V10, P6642, DOI 10.1128/MCB.10.12.6642; CHEN HM, 1993, J BIOL CHEM, V268, P25311; DALMON J, 1993, MOL CELL BIOL, V13, P1183, DOI 10.1128/MCB.13.2.1183; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Fey G H, 1990, Prog Liver Dis, V9, P89; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HATTORI M, 1990, P NATL ACAD SCI USA, V87, P2364, DOI 10.1073/pnas.87.6.2364; HEINRICH PC, 1990, BIOCHEM J, V265, P621, DOI 10.1042/bj2650621; HOCKE GM, 1992, MOL CELL BIOL, V12, P2282, DOI 10.1128/MCB.12.5.2282; KINOSHITA S, 1992, P NATL ACAD SCI USA, V89, P1473, DOI 10.1073/pnas.89.4.1473; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; KOJ A, 1985, ACUTE PHASE RESPONSE, P00145; KUSHNER I, 1972, J LAB CLIN MED, V80, P18; KUSHNER I, 1982, ANN NY ACAD SCI, V389, P39, DOI 10.1111/j.1749-6632.1982.tb22124.x; LAMERS WH, 1982, P NATL ACAD SCI-BIOL, V79, P5137, DOI 10.1073/pnas.79.17.5137; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LI XX, 1991, J BIOL CHEM, V266, P15192; LICHTSTEINER S, 1987, CELL, V51, P963, DOI 10.1016/0092-8674(87)90583-6; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; MAJELLO B, 1990, EMBO J, V9, P457, DOI 10.1002/j.1460-2075.1990.tb08131.x; MARINKOVIC S, 1990, MOL CELL BIOL, V10, P1573, DOI 10.1128/MCB.10.4.1573; MORRONE G, 1988, J BIOL CHEM, V263, P12554; Muller- Eberhard U, 1974, STRUCTURE FUNCTION P, V1, ppp; MULLEREBERHARD U, 1988, METHOD ENZYMOL, V163, P536; NAGAE Y, 1992, BIOCHEM BIOPH RES CO, V185, P420, DOI 10.1016/S0006-291X(05)81002-2; OLIVIERO S, 1989, EMBO J, V8, P1145, DOI 10.1002/j.1460-2075.1989.tb03485.x; PINA B, 1990, MOL CELL BIOL, V10, P625, DOI 10.1128/MCB.10.2.625; POLI V, 1989, NUCLEIC ACIDS RES, V17, P9351; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; POLI V, 1989, P NATL ACAD SCI USA, V86, P8202, DOI 10.1073/pnas.86.21.8202; PROWSE KR, 1988, MOL CELL BIOL, V8, P42, DOI 10.1128/MCB.8.1.42; RAMJI DP, 1993, NUCLEIC ACIDS RES, V21, P289, DOI 10.1093/nar/21.2.289; RON D, 1990, MOL CELL BIOL, V10, P1023, DOI 10.1128/MCB.10.3.1023; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; Sambrook J, 1989, MOL CLONING LABORATO; SATOH H, 1994, IN PRESS J BIOL CHEM; TRAUTWEIN C, 1993, NATURE, V364, P544, DOI 10.1038/364544a0; VINCENT SH, 1988, ARCH BIOCHEM BIOPHYS, V265, P539, DOI 10.1016/0003-9861(88)90159-2; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; WILSON DR, 1990, MOL CELL BIOL, V10, P6181, DOI 10.1128/MCB.10.12.6181; WON KA, 1990, MOL CELL BIOL, V10, P3965, DOI 10.1128/MCB.10.8.3965	58	42	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12654	12661						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175675				2022-12-25	WOS:A1994NH71600046
J	SWIFT, GH; ROSE, SD; MACDONALD, RJ				SWIFT, GH; ROSE, SD; MACDONALD, RJ			AN ELEMENT OF THE ELASTASE-I ENHANCER IS AN OVERLAPPING BIPARTITE BINDING-SITE ACTIVATED BY A HETEROMERIC FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN GROWTH-HORMONE; PANCREATIC ACINAR-CELLS; GENE-EXPRESSION; TRANSGENIC MICE; REGULATORY ELEMENT; ENDOTHELIAL-CELLS; TRANSFECTED CELLS; 2 DOMAINS; TRANSCRIPTION; PROMOTER	The B element of the elastase I transcriptional enhancer is active in both exocrine and endocrine cells of the pancreas. Cell transfection experiments revealed that in an acinar cell line the active sequence of the element is more extensive than in an endocrine cell line. Electrophoretic mobility shift assays identified three major complexes (designated C, M, and L) from acinar cell. nuclear extracts bound to the element. The C complex appears to be responsible for the activity of the element in acinar cells because its binding site, determined by methylation interference and mobility shift competition experiments, matches the critical sequence identified by cell transfection analysis of mutated B elements. The DNA sequence requirements for formation of the C complex is the sum of those for the M and L complexes. Methylation interference experiments indicated that the sensitivity of the C complex to guanine methylation also was the sum of that of the M and L complexes. Diagonal electrophoretic mobility shift assays confirmed that L is a component of complex C. However, the M complex which we identified as GATA-4, is not part of the C complex, because the C complex was neither competed by GATA-binding sites nor supershifted by anti-GATA-4 antiserum. Both the C and L complexes are specific to the pancreatic acinar cell line.			SWIFT, GH (corresponding author), UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235, USA.		MacDonald, Ray/AAA-1290-2022		NIADDK NIH HHS [AM27430] Funding Source: Medline; NIGMS NIH HHS [GM31689] Funding Source: Medline; NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [R01AM027430] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM031689] Funding Source: NIH RePORTER	NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARCECI RJ, 1993, MOL CELL BIOL, V13, P2235, DOI 10.1128/MCB.13.4.2235; BASSELDUBY R, 1992, MOL CELL BIOL, V12, P5024, DOI 10.1128/MCB.12.11.5024; COCKELL M, 1989, MOL CELL BIOL, V9, P2464, DOI 10.1128/MCB.9.6.2464; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DORFMAN DM, 1992, J BIOL CHEM, V267, P1279; DUBASP, 1988, NUCLEIC ACIDS RES, V16, P1251; EVANS T, 1988, P NATL ACAD SCI USA, V85, P5976, DOI 10.1073/pnas.85.16.5976; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRONOWICZ ES, 1980, J IMMUNOL, V125, P976; HAMMER RE, 1987, MOL CELL BIOL, V7, P2956, DOI 10.1128/MCB.7.8.2956; HENNEY CS, 1971, J IMMUNOL, V107, P1558; KNEPEL W, 1990, J BIOL CHEM, V265, P8725; KO LJ, 1991, MOL CELL BIOL, V11, P2778, DOI 10.1128/MCB.11.5.2778; KRUSE F, 1993, GENE DEV, V7, P774, DOI 10.1101/gad.7.5.774; KRUSE F, 1988, MOL CELL BIOL, V8, P893, DOI 10.1128/MCB.8.2.893; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUZIEL WA, 1987, NATURE, V328, P263, DOI 10.1038/328263a0; LEDOUARIN NM, 1988, CELL, V53, P169, DOI 10.1016/0092-8674(88)90375-3; LEE ME, 1991, J BIOL CHEM, V266, P16188; NIELSEN DA, 1989, ANAL BIOCHEM, V179, P19, DOI 10.1016/0003-2697(89)90193-0; ORKIN SH, 1992, BLOOD, V80, P575; ORNITZ DM, 1985, COLD SPRING HARB SYM, V50, P399, DOI 10.1101/SQB.1985.050.01.050; ORNITZ DM, 1985, NATURE, V313, P600, DOI 10.1038/313600a0; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; Pictet R., 1972, HDB PHYSIOLOGY     7, V1, P25; PLUMB M, 1989, NUCLEIC ACIDS RES, V17, P73, DOI 10.1093/nar/17.1.73; ROSE SD, 1994, MOL CELL BIOL, V14, P2048, DOI 10.1128/MCB.14.3.2048; RUTTER WJ, 1968, J CELL PHYSIOL, V72, P1, DOI 10.1002/jcp.1040720403; SCHAUFELE F, 1990, J BIOL CHEM, V265, P14592; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; SWIFT GH, 1989, GENE DEV, V3, P687, DOI 10.1101/gad.3.5.687; YAMAMOTO M, 1990, GENE DEV, V4, P1650, DOI 10.1101/gad.4.10.1650	32	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12809	12815						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175694				2022-12-25	WOS:A1994NH71600068
J	WILCOX, MD; SCHEY, KL; DINGUS, J; MEHTA, ND; TATUM, BS; HALUSHKA, M; FINCH, JW; HILDEBRANDT, JD				WILCOX, MD; SCHEY, KL; DINGUS, J; MEHTA, ND; TATUM, BS; HALUSHKA, M; FINCH, JW; HILDEBRANDT, JD			ANALYSIS OF G-PROTEIN GAMMA-SUBUNIT HETEROGENEITY USING MASS-SPECTROMETRY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING-PROTEIN; C-TERMINAL CYSTEINE; ADENYLYL CYCLASE; BETA-SUBUNIT; BRAIN; DIVERSITY; NS; NI; TRANSDUCTION; PURIFICATION	The diversity of the gamma subunits in bovine brain G protein preparations was investigated using matrix-assisted laser desorption ionization (MALDI) mass spectrometry. Analysis of these G protein mixtures revealed art least four gamma subunit masses by the following four criteria. 1) The measured masses were in the same mass range as the predicted molecular weights of gamma isoforms. 2) The masses were reproducible between the same or different preparations of G proteins. 3) The masses were independent of the matrix used for MALDI analysis. 4) The masses comigrated with the gamma subunit, as part of the heterotrimer, the beta gamma dimer, or the separated gamma subunit. These measured masses were compared with those calculated from cDNA sequences of known bovine brain gamma isoforms with the addition of plausible post-translationmodifications. The mass of each spectral peak was consistent with the calculated mass for only one of four known bovine brain gamma subunit isoforms, but the data suggest modifications of the gamma subunits in addition to those already known or suspected at their carboxyl termini. Besides these four major masses, several additional, less resolved spectral peaks were observed whose measured masses did not correlate with any known gamma subunit or plausible modification. MALDI mass spectrometry promises to be a powerful technique for the analysis of the diversity of the gamma subunit in G proteins and for the characterization of their post-translational modifications.	MED UNIV S CAROLINA,DEPT CELL & MOLEC PHARMACOL & EXPTL THERAPEUT,CHARLESTON,SC 29425	Medical University of South Carolina				Halushka, Marc/0000-0002-7112-7389	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037219] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK37219] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BACKLUND PS, 1990, J BIOL CHEM, V265, P15572; Beavis R C, 1989, Rapid Commun Mass Spectrom, V3, P432, DOI 10.1002/rcm.1290031207; BIRNBAUMER L, 1990, FASEB J, V4, P3178, DOI 10.1096/fasebj.4.14.2172060; BIRNBAUMER L, 1992, CELL, V71, P1069, DOI 10.1016/S0092-8674(05)80056-X; BIRNBAUMER L, 1990, ANNU REV PHARMACOL, V30, P675; BOKOCH GM, 1984, J BIOL CHEM, V259, P3560; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CALI JJ, 1992, J BIOL CHEM, V267, P24023; CAROZZI A, 1993, FEBS LETT, V315, P340, DOI 10.1016/0014-5793(93)81190-B; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; DINGUS J, 1994, METHOD ENZYMOL, V237, P457; FISHER KJ, 1992, MOL CELL BIOL, V12, P1585, DOI 10.1128/MCB.12.4.1585; FUNG BKK, 1990, FEBS LETT, V260, P313, DOI 10.1016/0014-5793(90)80132-3; GAUTAM N, 1990, P NATL ACAD SCI USA, V87, P7973, DOI 10.1073/pnas.87.20.7973; GAUTAM N, 1989, SCIENCE, V244, P971, DOI 10.1126/science.2499046; GIERSCHIK P, 1985, P NATL ACAD SCI USA, V82, P727, DOI 10.1073/pnas.82.3.727; GILMAN AG, 1989, JAMA-J AM MED ASSOC, V262, P1819, DOI 10.1001/jama.262.13.1819; HILDEBRANDT JD, 1985, J BIOL CHEM, V260, P4867; HILDEBRANDT JD, 1984, J BIOL CHEM, V259, P2039; HURLEY JB, 1980, BIOCHEM BIOPH RES CO, V92, P505, DOI 10.1016/0006-291X(80)90362-9; KARAS M, 1988, ANAL CHEM, V60, P2299, DOI 10.1021/ac00171a028; KATADA T, 1987, J BIOL CHEM, V262, P11897; KOHNKEN RE, 1989, J BIOL CHEM, V264, P20688; KUHN H, 1980, NATURE, V283, P587, DOI 10.1038/283587a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MALTESE WA, 1990, J BIOL CHEM, V265, P18071; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P5873, DOI 10.1073/pnas.87.15.5873; MUNTZ KH, 1992, MOL BIOL CELL, V3, P49, DOI 10.1091/mbc.3.1.49; PARK DG, 1993, J BIOL CHEM, V268, P4573; ROBISHAW JD, 1989, J BIOL CHEM, V264, P15758; ROBISHAW JD, 1992, BIOCHEM J, V286, P677, DOI 10.1042/bj2860677; SANFORD J, 1991, J BIOL CHEM, V266, P9570; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SMRCKA AV, 1993, J BIOL CHEM, V268, P9667; SPIEGEL AM, 1991, TRENDS BIOCHEM SCI, V16, P338, DOI 10.1016/0968-0004(91)90139-M; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; TAMIR H, 1991, BIOCHEMISTRY-US, V30, P3929, DOI 10.1021/bi00230a018; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; WU DQ, 1993, P NATL ACAD SCI USA, V90, P5297, DOI 10.1073/pnas.90.11.5297; XIE H, 1990, Methods (Orlando), V1, P276, DOI 10.1016/S1046-2023(05)80328-7; YAMANE HK, 1990, P NATL ACAD SCI USA, V87, P5868, DOI 10.1073/pnas.87.15.5868	42	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12508	12513						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175659				2022-12-25	WOS:A1994NH71600024
J	UEKI, K; MATSUDA, S; TOBE, K; GOTOH, Y; TAMEMOTO, H; YACHI, M; AKANUMA, Y; YAZAKI, Y; NISHIDA, E; KADOWAKI, T				UEKI, K; MATSUDA, S; TOBE, K; GOTOH, Y; TAMEMOTO, H; YACHI, M; AKANUMA, Y; YAZAKI, Y; NISHIDA, E; KADOWAKI, T			FEEDBACK-REGULATION OF MITOGEN-ACTIVATED PROTEIN-KINASE KINASE KINASE-ACTIVITY OF C-RAF-1 BY INSULIN AND PHORBOL ESTER STIMULATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE; THREONINE PHOSPHORYLATION; TYROSINE PHOSPHORYLATION; SIGNAL TRANSDUCTION; NUCLEOTIDE EXCHANGE; RAF-1 KINASE; RAS; RECEPTOR; SERINE; GRB2	Recently, it has been reported that Raf-1 kinase (Raf-1) has mitogen-activated protein kinase kinase kinase (MAPKKK) activity in various cells, although Raf-1 and MAP kinase kinase (MAPKK) can be phosphorylated by MAP kinase (MAPK) in vitro. Here we show that the maximal hyperphosphorylation of Raf-1 and MAPKK (10 min) was substantially achieved after the maximal activation of MAPKKK of Raf-1, MAPKK (2-5 min), and MAPK in Chinese hamster ovary cells overexpressing human insulin receptor (CHO-HIR cells) treated with insulin or 12-O-tetradecanoylphorbol-13-acetate (TPA). Moreover, we show that overexpression of MAPK in CHO-HIR cells resulted in enhanced hyperphosphorylation of Raf-1, MAPKK, and mammalian homolog of son of sevenless (mSos) after insulin or TPA stimulation as compared with parental cells. Furthermore, the maximal hyperphosphorylation of Raf-1 appears to be accompanied by a significant decrease in MAPKKK activity. These results suggest that 1) signals initiated by insulin and TPA converge on Raf-1 and activate its MAPKKK activity and 2) Raf-1, MAPKK, and mSos not only lie upstream of MAPK but also are phosphorylated by MAPK, directly or indirectly, and at least Raf-1 kinase activity might be down-regulated by this feedback mechanism.	UNIV TOKYO,FAC MED,DEPT INTERNAL MED 3,BUNKYO KU,TOKYO 113,JAPAN; UNIV TOKYO,FAC SCI,DEPT BIOPHYS & BIOCHEM,BUNKYO KU,TOKYO 113,JAPAN; ASAHI LIFE FDN,INST DIABET CARE & RES,CHIYODA KU,TOKYO 100,JAPAN	University of Tokyo; University of Tokyo; Asahi Life Foundation								AHN NG, 1991, J BIOL CHEM, V266, P4220; ANDERSON NG, 1991, BIOCHEM J, V277, P573, DOI 10.1042/bj2770573; BOTWELL D, 1992, P NATL ACAD SCI USA, V89, P6511; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GARDNER AM, 1993, J BIOL CHEM, V268, P17896; GARTNER A, 1992, GENE DEV, V6, P1280, DOI 10.1101/gad.6.7.1280; GAUSE KC, 1993, J BIOL CHEM, V268, P16124; HOSHI M, 1988, J BIOL CHEM, V263, P5396; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; IRIE K, 1993, MOL CELL BIOL, V13, P3076, DOI 10.1128/MCB.13.5.3076; IZUMI T, 1991, J BIOL CHEM, V266, P7933; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KOSAKO H, 1993, EMBO J, V12, P787, DOI 10.1002/j.1460-2075.1993.tb05713.x; KOSAKO H, 1992, EMBO J, V11, P2903, DOI 10.1002/j.1460-2075.1992.tb05359.x; KYRIAKIS JM, 1993, J BIOL CHEM, V268, P16009; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEE KS, 1993, MOL CELL BIOL, V13, P3067, DOI 10.1128/MCB.13.5.3067; LEE RM, 1992, J BIOL CHEM, V267, P1088; LEVERE E, 1992, EMBO J, V11, P4815; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; MATSUDA S, 1993, J BIOL CHEM, V268, P3277; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; RAY LB, 1988, P NATL ACAD SCI USA, V85, P3753, DOI 10.1073/pnas.85.11.3753; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; STURGILL TW, 1988, NATURE, V344, P7150; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TOBE K, 1992, J BIOL CHEM, V267, P21089; TOBE K, 1991, J BIOL CHEM, V266, P24793; TOBE K, 1993, J BIOL CHEM, V268, P11167; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WILLIAMS NG, 1993, P NATL ACAD SCI USA, V90, P5772, DOI 10.1073/pnas.90.12.5772; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	45	81	83	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15756	15761						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	8195229				2022-12-25	WOS:A1994NP51300057
J	ISOBE, M; HINODA, Y; IMAI, K; ADACHI, M				ISOBE, M; HINODA, Y; IMAI, K; ADACHI, M			CHROMOSOMAL LOCALIZATION OF AN SH2 CONTAINING TYROSINE PHOSPHATASE (SH-PTP3) GENE TO CHROMOSOME 12Q24.1	ONCOGENE			English	Note							SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; SEQUENCE SIMILARITY; MOLECULAR-CLONING; EXPRESSION; ACTIVATION; DOMAINS; TRISOMY-12; CORKSCREW; KINASES; CELLS	A genomic DNA fragment, isolated from a human phage library using a human BPTP3 cDNA probe, was shown to be derived from the human SH-PTP3 (also called SH-PTP2, PTP-1D, PTP-2C, or Syp) locus. We have used fluorescent in situ hybridization (FISH) to map SH-PTP3 in chromosome band 12q24.1, a region vicinity to the second locus for autosomal dominant cerebellar ataxia (SCA2).	SAPPORO MED UNIV,SCH MED,DEPT INTERNAL MED,SECT 1,CHUO KU,SAPPORO 060,JAPAN		ISOBE, M (corresponding author), TOYAMA MED & PHARMACEUT UNIV,ORIENTAL MED RES INST,DEPT PATHOBIOCHEM,2630 SUGITANI,TOYAMA 93001,JAPAN.							ADACHI M, 1992, BIOCHEM BIOPH RES CO, V186, P1607, DOI 10.1016/S0006-291X(05)81592-X; ADACHI M, 1992, CANCER RES, V52, P737; ADACHI M, 1992, FEBS LETT, V314, P335, DOI 10.1016/0014-5793(92)81500-L; AHMAD S, 1993, P NATL ACAD SCI USA, V90, P2197, DOI 10.1073/pnas.90.6.2197; BARKER HM, 1993, BIOCHIM BIOPHYS ACTA, V1178, P228, DOI 10.1016/0167-4889(93)90014-G; BASTIEN L, 1993, BIOCHEM BIOPH RES CO, V196, P124, DOI 10.1006/bbrc.1993.2224; EINHORN S, 1990, CANCER GENET CYTOGEN, V48, P183, DOI 10.1016/0165-4608(90)90118-T; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; GISPERT S, 1993, NAT GENET, V4, P295, DOI 10.1038/ng0793-295; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LU XY, 1993, GENE DEV, V7, P621, DOI 10.1101/gad.7.4.621; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; QUE TH, 1993, BLOOD, V82, P571; SAMANIEGO F, 1990, GENE CHROMOSOME CANC, V1, P289, DOI 10.1002/gcc.2870010406; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092-8674(93)90369-2; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; YI TL, 1992, MOL CELL BIOL, V12, P836, DOI 10.1128/MCB.12.2.836; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0	23	11	11	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1994	9	6					1751	1753						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NL815	8183573				2022-12-25	WOS:A1994NL81500030
J	FONG, TM; YU, H; CASCIERI, MA; UNDERWOOD, D; SWAIN, CJ; STRADER, CD				FONG, TM; YU, H; CASCIERI, MA; UNDERWOOD, D; SWAIN, CJ; STRADER, CD			INTERACTION OF GLUTAMINE-165 IN THE 4TH TRANSMEMBRANE SEGMENT OF THE HUMAN NEUROKININ-1 RECEPTOR WITH QUINUCLIDINE ANTAGONISTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTANCE-P ANTAGONIST; NONPEPTIDE ANTAGONIST; NK1 RECEPTOR; POTENT; BINDING; RHODOPSIN; PEPTIDES	Substance P binds to and activates the neurokinin-1 receptor with high affinity, thereby modulating several neuronal pathways including pain transmission and neurogenic inflammation. Several high affinity non-peptide antagonists have recently been described. To elucidate the molecular interactions specific for binding to the neurokinin-1 receptor, site-directed mutagenesis has been utilized to identify amino acid residues that interact directly with antagonists. Glutamine 165 in the fourth transmembrane segment was shown to be critical for the binding of CP-96,345 but not SR140333. Analysis of quinuclidine analogs suggests that glutamine 165 interacts with the C-3 heteroatom in this class of antagonists, probably through a hydrogen bond. Glutamine 165 also plays a minor role in the binding of peptides and RP67580. In contrast, serine 169 was determined to be critical for the binding of RP67580. These data indicate that residues 165 and 169 in the fourth transmembrane segment, along with residues in the fifth, sixth, and seventh transmembrane segments as demonstrated previously, form the non-peptide antagonist binding site in the neurokinin-l receptor. Furthermore, the antagonist binding site overlaps with the binding site for peptide agonists in the fourth and seventh transmembrane segments.	MERCK & CO INC,MERCK SHARP & DOHME RES LABS,DEPT MOLEC SYST,RAHWAY,NJ 07065; MERCK SHARP & DOHME LTD,RES LABS,HARLOW CM20 2PT,ESSEX,ENGLAND	Merck & Company; Merck & Company	FONG, TM (corresponding author), MERCK & CO INC,MERCK SHARP & DOHME RES LABS,DEPT MOLEC PHARMACOL & BIOCHEM,BLDG 80M-213,RAHWAY,NJ 07065, USA.							ANDREWS PR, 1986, TRENDS PHARMACOL SCI, P148; ATTWOOD TK, 1991, GENE, V98, P153, DOI 10.1016/0378-1119(91)90168-B; CASCIERI MA, 1992, MOL PHARMACOL, V42, P458; FONG TM, 1994, J BIOL CHEM, V269, P2728; FONG TM, 1992, BIOCHEMISTRY-US, V31, P11806, DOI 10.1021/bi00162a019; FONG TM, 1993, NATURE, V362, P350; GARRET C, 1991, P NATL ACAD SCI USA, V88, P10208, DOI 10.1073/pnas.88.22.10208; GETHER U, 1993, NATURE, V362, P345, DOI 10.1038/362345a0; HELKE CJ, 1990, FASEB J, V4, P1606, DOI 10.1096/fasebj.4.6.1969374; HENRY JL, 1993, REGUL PEPTIDES, V46, P138, DOI 10.1016/0167-0115(93)90024-3; HERSHEY AD, 1990, SCIENCE, V247, P958, DOI 10.1126/science.2154852; HUANG RRC, 1994, BIOCHEMISTRY-US, V33, P3007, DOI 10.1021/bi00176a033; IVERSEN LL, 1987, TOP MED CHEM, V65, P1; Lefevre I. A., 1993, Society for Neuroscience Abstracts, V19, P722; LOWE JA, 1992, J MED CHEM, V35, P2591, DOI 10.1021/jm00092a009; NAKANISHI S, 1991, ANNU REV NEUROSCI, V14, P123, DOI 10.1146/annurev.ne.14.030191.001011; PEYRONEL JF, 1992, BIOORG MED CHEM LETT, V2, P37, DOI 10.1016/S0960-894X(00)80650-2; REES DC, 1989, SCIENCE, V245, P510, DOI 10.1126/science.2667138; REGOLI D, 1989, PHARMACOLOGY, V38, P1, DOI 10.1159/000138512; SACHAIS BS, 1993, J BIOL CHEM, V268, P2319; SCHERTLER GFX, 1993, NATURE, V362, P770, DOI 10.1038/362770a0; SCHMIDT AW, 1992, EUR J PHARMACOL, V215, P351, DOI 10.1016/0014-2999(92)90057-B; SNIDER RM, 1991, SCIENCE, V251, P435, DOI 10.1126/science.1703323; STRADER CD, 1989, FASEB J, V3, P1825, DOI 10.1096/fasebj.3.7.2541037; SWAIN CJ, 1993, BIOORG MED CHEM LETT, V3, P1703, DOI 10.1016/S0960-894X(00)80046-3; THOMAS DD, 1982, J MOL BIOL, V154, P145, DOI 10.1016/0022-2836(82)90422-3; WILLIAMS KA, 1991, BIOCHEMISTRY-US, V30, P8919, DOI 10.1021/bi00101a001; YOKOTA Y, 1992, EMBO J, V11, P3585, DOI 10.1002/j.1460-2075.1992.tb05442.x	28	60	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					14957	14961						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195129				2022-12-25	WOS:A1994NP73800020
J	JUANG, SH; HUANG, JQ; LI, YQ; SALAS, PJI; FREGIEN, N; CARRAWAY, CAC; CARRAWAY, KL				JUANG, SH; HUANG, JQ; LI, YQ; SALAS, PJI; FREGIEN, N; CARRAWAY, CAC; CARRAWAY, KL			MOLECULAR-CLONING AND SEQUENCING OF A 58-KDA MEMBRANE-ASSOCIATED AND MICROFILAMENT-ASSOCIATED PROTEIN FROM ASCITES TUMOR-CELL MICROVILLI WITH SEQUENCE SIMILARITIES TO RETROVIRAL GAG PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT MAMMARY ADENOCARCINOMA; MURINE LEUKEMIA-VIRUS; SIGNAL TRANSDUCTION; GLYCOPROTEIN COMPLEX; SARCOMA-VIRUS; CYTOSKELETON; ACTIN; IDENTIFICATION; SUBLINES; ACID	The MAT-C1 subline of the 13762 rat mammary adenocarcinoma has highly stable, branched microvilli and immobile cell surface receptors. A membrane- and microfilament-associated 58-kDa protein (p58) in the MAT-C1 microvilli has been implicated in the stabilization of the microvilli and microfilament-membrane interactions. This protein is associated with a high M(r) glycoprotein complex containing the (proto)oncogene p185(neu) and other signal transduction components in a putative microfilament-associated signal transduction particle. Amino acid sequences were obtained from two trypsin peptides of p58. Screening a MAT-C1 cDNA library with a degenerate oligonucleotide derived from the larger peptide and polymerase chain reaction amplification of cDNA ends permitted the isolation of overlapping cDNAs encoding the 427-amino acid open reading frame of p58. In vitro transcription and translation using a full-length cDNA gave a protein of approximately 55 kDa, which reacts with anti-p58 antiserum and reconstitutes into a complex with actin and glycoproteins from the membrane-microfilament interaction site. When COS-7 cells were transfected with the full-length cDNA, p58 was localized in a punctate distribution. In addition, the transfected cells exhibited fewer microfilament cables than untransfected neighboring cells. The amino acid sequence showed a surprising similarity to mammalian retroviral Gag proteins and included regions corresponding to p15, p12 and the N-terminal 80% of p30. Comparisons of p58 and the corresponding regions of the Gag proteins for Moloney murine leukemia virus indicated that about 60% of their amino acid residues were identical. These studies suggest that p58 is the product of an endogenous retroviral gene whose expression as a cellular protein alters the properties of the tumor cell to provide a selective advantage for tumor growth in the animal.	UNIV MIAMI,SCH MED,DEPT CELL BIOL & ANAT R124,MIAMI,FL 33101; UNIV MIAMI,SCH MED,DEPT BIOCHEM & MOLEC BIOL,MIAMI,FL 33101	University of Miami; University of Miami			Salas, Pedro J./AAS-9455-2021	Salas, Pedro/0000-0002-7411-1366	NATIONAL CANCER INSTITUTE [P30CA014395] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033795] Funding Source: NIH RePORTER; NCI NIH HHS [CA 14395] Funding Source: Medline; NIGMS NIH HHS [GM 33795] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; BENNETT V, 1991, J CLIN INVEST, V87, P1483, DOI 10.1172/JCI115157; BENNETT V, 1989, BIOCHIM BIOPHYS ACTA, V988, P107, DOI 10.1016/0304-4157(89)90006-3; BOLOGNESI DP, 1978, SCIENCE, V199, P183, DOI 10.1126/science.202022; BURRIDGE K, 1986, Cancer Reviews, V4, P18; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CARRAWAY CAC, 1983, P NATL ACAD SCI-BIOL, V80, P430, DOI 10.1073/pnas.80.2.430; CARRAWAY CAC, 1985, EXP CELL RES, V161, P150, DOI 10.1016/0014-4827(85)90499-9; CARRAWAY CAC, 1982, BIOCHIM BIOPHYS ACTA, V719, P126; CARRAWAY CAC, 1991, J BIOL CHEM, V266, P16238; CARRAWAY CAC, 1985, EXP CELL RES, V157, P71, DOI 10.1016/0014-4827(85)90153-3; CARRAWAY CAC, 1993, J BIOL CHEM, V268, P5582; CARRAWAY CAC, 1983, CELL MOTIL CYTOSKEL, V3, P491, DOI 10.1002/cm.970030516; CARRAWAY KL, 1980, NATURE, V285, P508, DOI 10.1038/285508a0; CARRAWAY KL, 1982, J CELL BIOL, V94, P624, DOI 10.1083/jcb.94.3.624; CARRAWAY KL, 1989, BIOCHIM BIOPHYS ACTA, V988, P147, DOI 10.1016/0304-4157(89)90017-8; CARRAWAY KL, 1979, J CELL BIOL, V83, P529, DOI 10.1083/jcb.83.3.529; COUDRIER E, 1983, EMBO J, V2, P469, DOI 10.1002/j.1460-2075.1983.tb01446.x; DAMSKY CH, 1977, J CELL BIOL, V75, P593, DOI 10.1083/jcb.75.2.593; EDBAUER CA, 1983, VIROLOGY, V130, P415, DOI 10.1016/0042-6822(83)90096-X; EDBAUER CA, 1984, VIROLOGY, V134, P389, DOI 10.1016/0042-6822(84)90306-4; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; Geiger B, 1989, CURR OPIN CELL BIOL, V1, P103, DOI 10.1016/S0955-0674(89)80045-6; GIUFFRE RM, 1982, J VIROL, V42, P963, DOI 10.1128/JVI.42.3.963-968.1982; GLENNEY JR, 1992, BIOCHIM BIOPHYS ACTA, V1134, P113, DOI 10.1016/0167-4889(92)90034-9; HALL A, 1992, MOL BIOL CELL, V3, P475, DOI 10.1091/mbc.3.5.475; HENDERSON LE, 1981, J BIOL CHEM, V256, P8400; HOWARD SC, 1982, JNCI-J NATL CANCER I, V69, P33; HUGGINS JW, 1980, EXP CELL RES, V127, P27; KELLIE S, 1988, BIOESSAYS, V8, P25, DOI 10.1002/bies.950080107; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LIU YC, 1989, J BIOL CHEM, V264, P1208; LUNA EJ, 1992, SCIENCE, V258, P955, DOI 10.1126/science.1439807; MOOSEKER MS, 1985, ANNU REV CELL BIOL, V1, P209, DOI 10.1146/annurev.cellbio.1.1.209; PALMITER RD, 1978, VIROLOGY, V91, P423, DOI 10.1016/0042-6822(78)90388-4; PRYWES R, 1985, J VIROL, V54, P123, DOI 10.1128/JVI.54.1.123-132.1985; RASHEED S, 1983, SCIENCE, V221, P155, DOI 10.1126/science.6344220; ROHRSCHNEIDER LR, 1984, J VIROL, V51, P547, DOI 10.1128/JVI.51.2.547-552.1984; SCHULTZ AM, 1983, J VIROL, V46, P355, DOI 10.1128/JVI.46.2.355-361.1983; SCHWARTZ M A, 1992, Trends in Cell Biology, V2, P304, DOI 10.1016/0962-8924(92)90120-C; SHENG ZQ, 1992, J BIOL CHEM, V267, P16341; SHERBLOM AP, 1980, EXP CELL RES, V126, P417, DOI 10.1016/0014-4827(80)90281-5; STONE JC, 1984, CELL, V37, P549, DOI 10.1016/0092-8674(84)90385-4; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WANG Y-L, 1992, P1; WEISS R, 1985, RNA TUMOR VIRUSES MO, P999; YARON A, 1993, CRIT REV BIOCHEM MOL, V28, P31, DOI 10.3109/10409239309082572	47	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					15067	15075						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195143				2022-12-25	WOS:A1994NP73800036
J	MOTEJLEK, K; HAUSELMANN, R; LEITGEB, S; LUSCHER, B				MOTEJLEK, K; HAUSELMANN, R; LEITGEB, S; LUSCHER, B			BSF1, A NOVEL BRAIN-SPECIFIC DNA-BINDING PROTEIN RECOGNIZING A TANDEMLY REPEATED PURINE DNA ELEMENT IN THE GABA(A) RECEPTOR DELTA-SUBUNIT GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR FACTORS INTERACT; MESSENGER-RNAS; RAT-BRAIN; TRANSCRIPTION FACTOR; A-RECEPTORS; MOLECULAR-BIOLOGY; ALPHA-SUBUNIT; NGFI-C; EXPRESSION; PROMOTER	The rat GABA(A) receptor delta subunit gene has been isolated and its promoter mapped to facilitate studies of neuron-specific gene transcription. The gene is transcribed from a single promoter with several clustered transcriptional initiation sites. The major start site maps to a prototype initiator sequence located in the center of a TATA-less CpG-rich island, Analysis of the 5'-flanking region of the GABA(A) receptor delta subunit gene revealed a novel tandemly repeated purine sequence element. Furthermore, gel retardation assays identified several tissue-specific and ubiquitous proteins that bind to this sequence. One of these factors, brain specific factor (BSF) 1, was only observed in extracts from brain and was distinct from BETA and PAL, two DNA-binding proteins with similar purine rich recognition sequences. The distribution of BSF1 in brain closely matched the expression pattern previously determined for the delta subunit mRNA, and its binding activity appeared simultaneously with GABA(A) receptor delta subunit mRNA during differentiation of cerebellar granule cells in vitro. Our data therefore suggest that BSF1 is a novel brain-specific and neuronal cell type-enriched factor possibly involved in differential transcription of the GABA(A) receptor delta subunit gene.	UNIV ZURICH,INST PHARMACOL,ZURICH,SWITZERLAND	University of Zurich			Luscher, Bernhard/C-3528-2009	Luscher, Bernhard/0000-0003-1375-1906				BENKE D, 1991, J BIOL CHEM, V266, P4478; BIANCHI A, 1990, J BIOL CHEM, V265, P21789; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BOVOLIN P, 1992, J NEUROCHEM, V59, P62, DOI 10.1111/j.1471-4159.1992.tb08876.x; BOVOLIN P, 1992, P NATL ACAD SCI USA, V89, P9344, DOI 10.1073/pnas.89.19.9344; BURT DR, 1991, FASEB J, V5, P2916, DOI 10.1096/fasebj.5.14.1661244; CORDEN J, 1980, SCIENCE, V209, P1406, DOI 10.1126/science.6251548; CROSBY SD, 1992, P NATL ACAD SCI USA, V89, P4739, DOI 10.1073/pnas.89.10.4739; CROSBY SD, 1991, MOL CELL BIOL, V11, P3835, DOI 10.1128/MCB.11.8.3835; CUTTING GR, 1992, GENOMICS, V12, P801, DOI 10.1016/0888-7543(92)90312-G; ELDER GA, 1992, MOL BRAIN RES, V15, P99, DOI 10.1016/0169-328X(92)90156-6; ELDER GA, 1992, MOL BRAIN RES, V15, P85, DOI 10.1016/0169-328X(92)90155-5; FISCHER G, 1982, EXP CELL RES, V139, P285, DOI 10.1016/0014-4827(82)90253-1; FRAIN M, 1989, CELL, V59, P145, DOI 10.1016/0092-8674(89)90877-5; FRITSCHY JM, 1992, P NATL ACAD SCI USA, V89, P6726, DOI 10.1073/pnas.89.15.6726; GAMBARANA C, 1991, NEUROSCIENCE, V45, P423, DOI 10.1016/0306-4522(91)90238-J; HAAS S, 1993, MOL CELL BIOL, V13, P3103, DOI 10.1128/MCB.13.5.3103; HE X, 1991, NEURON, V7, P183, DOI 10.1016/0896-6273(91)90257-Z; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JACKSON SP, 1989, P NATL ACAD SCI USA, V86, P1781, DOI 10.1073/pnas.86.6.1781; JOHNSON JE, 1990, NATURE, V346, P858, DOI 10.1038/346858a0; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KIRKNESS EF, 1993, J BIOL CHEM, V268, P4420; KORNER M, 1989, NEURON, V3, P563, DOI 10.1016/0896-6273(89)90266-3; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; LAURIE DJ, 1992, J NEUROSCI, V12, P4151; LAURIE DJ, 1992, J NEUROSCI, V12, P1063; LEONARD JP, 1991, MOL NEUROBIOLOGY PRA, P161; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; MALHERBE P, 1990, MOL BRAIN RES, V8, P199, DOI 10.1016/0169-328X(90)90017-8; MATHIS JM, 1992, EMBO J, V11, P2551, DOI 10.1002/j.1460-2075.1992.tb05320.x; Maxam A M, 1980, Methods Enzymol, V65, P499; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MIURA M, 1990, J NEUROCHEM, V55, P1180, DOI 10.1111/j.1471-4159.1990.tb03123.x; MOHLER H, 1990, NEUROCHEM RES, V15, P199, DOI 10.1007/BF00972210; MULLER T, 1994, IN PRESS J NEUROSCI; NEDIVI E, 1992, J NEUROSCI, V12, P691; OLSEN RW, 1990, FASEB J, V4, P1469, DOI 10.1096/fasebj.4.5.2155149; PECORINO LT, 1991, MOL CELL BIOL, V11, P3139, DOI 10.1128/MCB.11.6.3139; PIANI D, 1992, EUR J IMMUNOL, V22, P2429, DOI 10.1002/eji.1830220936; POULTER MO, 1992, J NEUROSCI, V12, P2888, DOI 10.1523/JNEUROSCI.12-08-02888.1992; RIPPE K, 1992, METHOD ENZYMOL, V211, P199; RIPPE K, 1992, EMBO J, V11, P3777, DOI 10.1002/j.1460-2075.1992.tb05463.x; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; ROSENFELD MG, 1991, GENE DEV, V5, P897, DOI 10.1101/gad.5.6.897; SAUERWALD A, 1990, J BIOL CHEM, V265, P14932; SCHNITZER J, 1981, J NEUROIMMUNOL, V1, P429, DOI 10.1016/0165-5728(81)90022-9; SCHOFIELD PR, 1990, TRENDS NEUROSCI, V13, P8, DOI 10.1016/0166-2236(90)90052-C; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SERFLING E, 1985, TRENDS GENET, V1, P224, DOI 10.1016/0168-9525(85)90088-5; SHIVERS BD, 1989, NEURON, V3, P327, DOI 10.1016/0896-6273(89)90257-2; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SOMMER B, 1990, DNA CELL BIOL, V9, P561, DOI 10.1089/dna.1990.9.561; STOYKOVA AS, 1992, NEURON, V8, P541, DOI 10.1016/0896-6273(92)90282-I; VANDAELE S, 1991, GENE DEV, V5, P1136, DOI 10.1101/gad.5.7.1136; WELLS RD, 1988, FASEB J, V2, P2939, DOI 10.1096/fasebj.2.14.3053307; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; Wisden W, 1992, Curr Opin Neurobiol, V2, P263, DOI 10.1016/0959-4388(92)90113-Y; WISDEN W, 1992, J NEUROSCI, V12, P1040	61	34	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					15265	15273						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195163				2022-12-25	WOS:A1994NP73800062
J	LI, GP; BARBIERI, MA; COLOMBO, MI; STAHL, PD				LI, GP; BARBIERI, MA; COLOMBO, MI; STAHL, PD			STRUCTURAL FEATURES OF THE GTP-BINDING DEFECTIVE RAB5 MUTANTS REQUIRED FOR THEIR INHIBITORY ACTIVITY ON ENDOCYTOSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PUTATIVE TARGET PROTEIN; NUCLEOTIDE EXCHANGE; ACTIVATING PROTEIN; EFFECTOR DOMAIN; MEMBRANE ASSOCIATION; MUTATIONAL ANALYSIS; H-RAS; MUTAGENESIS; ENDOSOMES; INTERACTS	Rab5 is a Ras-like small GTPase that regulates early events of endocytosis. Previous work indicates that two GTP-binding defective Rab5 mutants (Rab5:S34N and Rab5:N133I) are dominant inhibitors of endocytosis. In this report, we have initiated experiments to address the structural features necessary for the inhibitory activity of these two Rab5 mutants. Second-site mutations were introduced into Rab5:S34N and Rab5:N133I, respectively, and the resulting double mutants were expressed in cultured BHK-21 cells via a Sindbis virus expression vector. Endocytic activity of the cells was monitored by following the uptake of a fluid-phase endocytic marker (horseradish peroxidase). The effects of the Rab5 mutants on endosome fusion in vitro were also examined. Truncation of the C-terminal isoprenylation motif CCSN abolished the inhibitory activity of both Rab5:S34N and Rab5:N133I. The same held true when the secondary mutation was a substitution mutation (F57S) in the effector domain. Another substitution mutation in this region (I53A) had no effect on the inhibitory activity of either Rab5:S34N or Rab5:N133I. The final mutation (R81A) was created immediately downstream of the second GTP binding motif (WDTAGQER), i.e. in the loop 4 region based on the structural model of Pas. This mutation greatly decreased the isoprenylation of Rab5:N133I and its inhibitory activity on endocytosis. It is believed that Rab5 function requires protein-protein interactions with Rab5-specific regulators and effecters. Some of these interactions are disrupted by Rab5:S34N and Rab5:N133I. By analogy to Ras, both Rab5:S34N and Rab5:N133I are likely to sequester a Rab5-specific guanine nucleotide exchange factor. This interaction requires the effector domain Phe(57) residue and C-terminal isoprenylation of Rab5.	WASHINGTON UNIV,SCH MED,DEPT CELL BIOL & PHYSIOL,ST LOUIS,MO 63110	Washington University (WUSTL)			Stahl, Philip/D-6315-2012; Li, Guangpu/GRS-5397-2022		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042259] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM42259-19] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; ANDERSON DJ, 1983, METHOD ENZYMOL, V96, P111; AUSUBEL FM, 1981, CURRENT PROTOCOLS MO; BALDINI G, 1992, P NATL ACAD SCI USA, V89, P5049, DOI 10.1073/pnas.89.11.5049; BECKER J, 1991, EMBO J, V10, P785, DOI 10.1002/j.1460-2075.1991.tb08010.x; BISCHOFF FR, 1991, P NATL ACAD SCI USA, V88, P10830, DOI 10.1073/pnas.88.23.10830; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURSTEIN ES, 1993, J BIOL CHEM, V268, P22247; BURSTEIN ES, 1992, P NATL ACAD SCI USA, V89, P1154, DOI 10.1073/pnas.89.4.1154; BURSTEIN ES, 1992, J BIOL CHEM, V267, P22715; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; CHUNG HH, 1993, P NATL ACAD SCI USA, V90, P10145, DOI 10.1073/pnas.90.21.10145; DIAZ R, 1988, J BIOL CHEM, V263, P6093; ELFERINK LA, 1992, J BIOL CHEM, V267, P5768; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOLDENRING JR, 1993, J BIOL CHEM, V268, P18419; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; GOUD B, 1990, NATURE, V345, P553, DOI 10.1038/345553a0; HANN CS, 1992, P NATL ACAD SCI USA, V89, P2679; HWANG YW, 1993, J BIOL CHEM, V268, P24692; KAHN RA, 1992, FASEB J, V6, P2512, DOI 10.1096/fasebj.6.8.1592203; KRENGEL U, 1990, CELL, V62, P539, DOI 10.1016/0092-8674(90)90018-A; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LI GP, 1993, J BIOL CHEM, V268, P24475; LI GP, 1993, ARCH BIOCHEM BIOPHYS, V304, P471, DOI 10.1006/abbi.1993.1377; LOMBARDI D, 1993, EMBO J, V12, P677, DOI 10.1002/j.1460-2075.1993.tb05701.x; LUTCKE A, 1993, J CELL BIOL, V121, P553, DOI 10.1083/jcb.121.3.553; MCKIERNAN CJ, 1993, J BIOL CHEM, V268, P24449; MOYA M, 1993, NATURE, V361, P460, DOI 10.1038/361460a0; MYERS RM, 1985, SCIENCE, V229, P242, DOI 10.1126/science.2990046; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; SANFORD JC, 1993, J BIOL CHEM, V268, P23773; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASAKI T, 1990, J BIOL CHEM, V265, P2333; SCHWEIGHOFFER F, 1993, MOL CELL BIOL, V13, P39, DOI 10.1128/MCB.13.1.39; SHIRATAKI H, 1993, MOL CELL BIOL, V13, P2061, DOI 10.1128/MCB.13.4.2061; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P4725, DOI 10.1073/pnas.83.13.4725; STONE JC, 1988, MOL CELL BIOL, V8, P3565, DOI 10.1128/MCB.8.8.3565; STROM M, 1993, NATURE, V361, P736, DOI 10.1038/361736a0; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; TISDALE EJ, 1992, J CELL BIOL, V119, P749, DOI 10.1083/jcb.119.4.749; ULLRICH O, 1993, J BIOL CHEM, V268, P18143; VANDERSLUIJS P, 1991, P NATL ACAD SCI USA, V88, P6313, DOI 10.1073/pnas.88.14.6313; VONMOLLARD GF, 1990, P NATL ACAD SCI USA, V87, P1988, DOI 10.1073/pnas.87.5.1988; Zerial M, 1993, CURR OPIN CELL BIOL, V5, P613, DOI 10.1016/0955-0674(93)90130-I	49	98	99	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14631	14635						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	8182071				2022-12-25	WOS:A1994NM06500052
J	MCCLOSKEY, MA; QIAN, YX				MCCLOSKEY, MA; QIAN, YX			SELECTIVE EXPRESSION OF POTASSIUM CHANNELS DURING CELL-DIFFERENTIATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASOPHILIC LEUKEMIA-CELLS; MUCOSAL MAST-CELLS; INDUCED HISTAMINE-RELEASE; ANTI-ALLERGIC COMPOUNDS; CALCIUM INFLUX; INTRACELLULAR CALCIUM; PATCH-CLAMP; IGE BINDING; RAT; RECEPTORS	In rodents, mast cell progenitors differentiate into distinct mucosal and serosal phenotypes which differ markedly in their functional responses to antigenic and peptidergic stimulation. Although the molecular basis of mast cell differentiation or functional specialization is unknown, it is possible that regulation of calcium entry contributes to one or both processes. The prolonged secretory response of mucosal mast cells (MMC) and the antigen-elicited synthesis of interleukin-3 by immature MMC both require a rise of cytoplasmic calcium sustained by Ca2+ influx across the plasma membrane. This Ca2+ entry is highly sensitive to membrane potential, affording a possible site for regulation of mast cell function by receptor-linked ion channels. We found that rat interleukin-3-dependent bone marrow-derived mast cells of the mucosal phenotype expressed two K+ conductances, neither of which is present in the prototype serosal mast cell from rat peritoneum. An inwardly rectifying K+ conductance was constitutively active and a latent outwardly rectifying K+ conductance was elicited rapidly upon ligation of cell surface adenosine or P-2 purinergic receptors linked to G proteins of the G(i) family. Stimulation of P2( )receptors dramatically potentiated antigen-triggered secretion in a pertussis toxin-sensitive manner, suggesting that activation of the outwardly rectifying K+ channel may regulate antigen-dependent functions of MMC.			MCCLOSKEY, MA (corresponding author), IOWA STATE UNIV SCI & TECHNOL,DEPT ZOOL & GENET,AMES,IA 50011, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048144] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM48144] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALI H, 1990, J BIOL CHEM, V265, P745; BARSUMIAN EL, 1981, EUR J IMMUNOL, V11, P317, DOI 10.1002/eji.1830110410; BASCIANO LK, 1986, J BIOL CHEM, V261, P1823; BEFUS AD, 1982, J IMMUNOL, V128, P2475; COCKCROFT S, 1979, NATURE, V279, P541, DOI 10.1038/279541a0; COHEN DR, 1986, NUCLEIC ACIDS RES, V14, P3641, DOI 10.1093/nar/14.9.3641; ECKSTEIN F, 1979, J BIOL CHEM, V254, P9829; FERNANDEZ JM, 1984, NATURE, V312, P453, DOI 10.1038/312453a0; FEWTRELL C, 1987, BIOCHEMISTRY-US, V26, P6995, DOI 10.1021/bi00396a021; FROESE A, 1982, IMMUNOLOGY, V46, P117; GHILDYAL N, 1993, J IMMUNOL, V151, P3206; HAIG DM, 1988, IMMUNOLOGY, V65, P205; HAIG DM, 1982, NATURE, V300, P188, DOI 10.1038/300188a0; HAIG DM, 1988, LYMPHOKINES, V15, P65; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HIDE M, 1991, J BIOL CHEM, V266, P15221; KANNER BI, 1983, P NATL ACAD SCI-BIOL, V80, P5744, DOI 10.1073/pnas.80.18.5744; KITAMURA Y, 1989, ANNU REV IMMUNOL, V7, P59, DOI 10.1146/annurev.iy.07.040189.000423; LEE TDG, 1985, IMMUNOLOGY, V55, P721; LINDAU M, 1986, J GEN PHYSIOL, V88, P349, DOI 10.1085/jgp.88.3.349; LIU FT, 1980, J IMMUNOL, V124, P2728; MACDONALD AJ, 1989, IMMUNOLOGY, V67, P414; MATTHEWS G, 1989, J PHYSIOL-LONDON, V418, P105, DOI 10.1113/jphysiol.1989.sp017830; MCCLOSKEY MA, 1984, J CELL BIOL, V99, P778, DOI 10.1083/jcb.99.3.778; MCCLOSKEY MA, 1990, J GEN PHYSIOL, V95, P205, DOI 10.1085/jgp.95.2.205; MEYER C, 1983, J IMMUNOL, V131, P911; Miller H. R. P., 1992, Allergy and immunity to helminths: common mechanisms or divergent pathways., P228; MOHR FC, 1987, J CELL BIOL, V104, P783, DOI 10.1083/jcb.104.3.783; MOHR FC, 1987, J BIOL CHEM, V262, P10638; MOHR FC, 1987, J IMMUNOL, V138, P1564; MUKAI M, 1992, AM J PHYSIOL, V262, pC84, DOI 10.1152/ajpcell.1992.262.1.C84; NEHER E, 1988, J PHYSIOL-LONDON, V395, P193, DOI 10.1113/jphysiol.1988.sp016914; OSIPCHUK Y, 1992, NATURE, V359, P241, DOI 10.1038/359241a0; PEARCE FL, 1982, J IMMUNOL, V128, P2481; PENNER R, 1988, NATURE, V334, P499, DOI 10.1038/334499a0; PLAUT M, 1989, NATURE, V339, P64, DOI 10.1038/339064a0; QIAN YX, 1993, P NATL ACAD SCI USA, V90, P7844, DOI 10.1073/pnas.90.16.7844; QIAN YX, 1993, J IMMUNOL, V150, pA145; RAMKUMAR V, 1993, J BIOL CHEM, V268, P16887; RANDRIAMAMPITA C, 1991, CELL CALCIUM, V12, P313, DOI 10.1016/0143-4160(91)90005-Y; SAGIEISENBERG R, 1983, J MEMBRANE BIOL, V75, P97, DOI 10.1007/BF01995629; SELDIN DC, 1985, P NATL ACAD SCI USA, V82, P3871, DOI 10.1073/pnas.82.11.3871; SHANAHAN F, 1985, J IMMUNOL, V135, P1331; SHANAHAN F, 1986, INT ARCH ALLER A IMM, V80, P424, DOI 10.1159/000234092; VLODAVSKY I, 1980, CELL, V19, P607, DOI 10.1016/S0092-8674(80)80037-7; WILGENBUS KK, 1992, INT J CANCER, V51, P522, DOI 10.1002/ijc.2910510404; WODNARFILIPOWICZ A, 1989, NATURE, V339, P150, DOI 10.1038/339150a0; WODNARFILIPOWICZ A, 1990, P NATL ACAD SCI USA, V87, P777, DOI 10.1073/pnas.87.2.777; WOODBURY RG, 1984, NATURE, V312, P450, DOI 10.1038/312450a0	49	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14813	14819						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	8182088				2022-12-25	WOS:A1994NM06500078
J	SANDIG, M; RAO, Y; SIU, CH				SANDIG, M; RAO, Y; SIU, CH			THE HOMOPHILIC BINDING-SITE OF THE NEURAL CELL-ADHESION MOLECULE NCAM IS DIRECTLY INVOLVED IN PROMOTING NEURITE OUTGROWTH FROM CULTURED NEURAL RETINAL CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-CAM; INTERCELLULAR-ADHESION; MEMBRANE ATTACHMENT; HOMOPHILIC BINDING; CHICK-EMBRYO; NEURONS; ANTIBODIES; CADHERIN; DOMAINS; GROWTH	The neural cell adhesion molecule NCAM mediates intercellular adhesion by hemophilic binding and its homophilic binding site has been mapped to a decapeptide sequence 243-KYSFNYDGSE-252 located within the third immunoglobulin-like domain of chick NCAM. To investigate the relationship between homophilic binding and NCAM-dependent neurite outgrowth, mutations were created in the binding site of NCAM-140 cDNA. Mutant NCAMs were expressed in L cells, and their ability to promote neurite outgrowth from chick retinal ganglion cells was assayed in coculture systems. Mutations that resulted in the loss of NCAM homophilic binding failed to promote neurite outgrowth from retinal cells. Alternatively, synthetic peptides containing the decapeptide sequence of the homophilic binding site were used to block NCAM homophilic interaction. Peptides that inhibited NCAM-NCAM binding also blocked neurite elongation. However, the peptide P5 (243-KYSFNY-DGSELIIKKVDKSDE-263), despite being an inhibitor of NCAM-NCAM binding, induced the sprouting of multiple neurites. Moreover, peptide P5 stimulated a 2-fold increase in neurite-bearing cells, suggesting that P5 is a potent inducer of neurite outgrowth. Only E4-E6 retinal cells could be induced by P5, corresponding closely to their NCAM-responsive embryonic stages. The P5 effects were inhibited by pertussis toxin, indicating the involvement of a G-protein-dependent pathway. Taken together, these results provide evidence for a direct role of the NCAM homophilic binding site in the regulation of neurite outgrowth.	UNIV TORONTO, CHARLES H BEST INST, BANTING & BEST DEPT MED RES, TORONTO M5G 1L6, ON, CANADA; UNIV TORONTO, DEPT BIOCHEM, TORONTO M5G 1L6, ON, CANADA	University of Toronto; University of Toronto								ATASHI JR, 1992, NEURON, V8, P831, DOI 10.1016/0896-6273(92)90197-L; BHAT TN, 1990, NATURE, V344, P371; BIXBY JL, 1987, DEV BIOL, V119, P363, DOI 10.1016/0012-1606(87)90041-8; BIXBY JL, 1987, P NATL ACAD SCI USA, V84, P2555, DOI 10.1073/pnas.84.8.2555; BLOCH RJ, 1992, J CELL BIOL, V116, P449, DOI 10.1083/jcb.116.2.449; COLE GJ, 1987, NEUROSCI LETT, V78, P227, DOI 10.1016/0304-3940(87)90638-0; COLE GJ, 1989, NEURON, V2, P1157, DOI 10.1016/0896-6273(89)90182-7; COLE GJ, 1986, J CELL BIOL, V102, P403, DOI 10.1083/jcb.102.2.403; CROSSIN KL, 1985, P NATL ACAD SCI USA, V82, P6942, DOI 10.1073/pnas.82.20.6942; CUNNINGHAM BA, 1987, SCIENCE, V236, P799, DOI 10.1126/science.3576199; Doherty P, 1992, Curr Opin Neurobiol, V2, P595, DOI 10.1016/0959-4388(92)90024-F; DOHERTY P, 1990, NATURE, V343, P464, DOI 10.1038/343464a0; DOHERTY P, 1991, CELL, V67, P21, DOI 10.1016/0092-8674(91)90569-K; DOHERTY P, 1992, NATURE, V356, P791, DOI 10.1038/356791a0; DOHERTY P, 1990, NEURON, V5, P209, DOI 10.1016/0896-6273(90)90310-C; DOHERTY P, 1989, J CELL BIOL, V109, P789, DOI 10.1083/jcb.109.2.789; DOHERTY P, 1993, J CELL BIOL, V122, P181, DOI 10.1083/jcb.122.1.181; DRAZBA J, 1990, DEV BIOL, V138, P82, DOI 10.1016/0012-1606(90)90178-L; EDELMAN GM, 1991, ANNU REV BIOCHEM, V60, P155, DOI 10.1146/annurev.bi.60.070191.001103; EDELMAN GM, 1987, P NATL ACAD SCI USA, V84, P8502, DOI 10.1073/pnas.84.23.8502; FREI T, 1992, J CELL BIOL, V118, P177, DOI 10.1083/jcb.118.1.177; GENNARINI G, 1991, NEURON, V6, P595, DOI 10.1016/0896-6273(91)90062-5; GRUMET M, 1993, J CELL BIOL, V120, P815, DOI 10.1083/jcb.120.3.815; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HE HT, 1986, EMBO J, V5, P2489, DOI 10.1002/j.1460-2075.1986.tb04526.x; HEMPERLY JJ, 1986, P NATL ACAD SCI USA, V83, P9822, DOI 10.1073/pnas.83.24.9822; HOFFMAN S, 1983, P NATL ACAD SCI-BIOL, V80, P5762, DOI 10.1073/pnas.80.18.5762; HOFFMAN S, 1986, J CELL BIOL, V103, P145, DOI 10.1083/jcb.103.1.145; HOFFMAN S, 1982, J BIOL CHEM, V257, P7720; HORSTKORTE R, 1993, J CELL BIOL, V121, P1409, DOI 10.1083/jcb.121.6.1409; JOHNSON PW, 1989, NEURON, V3, P377, DOI 10.1016/0896-6273(89)90262-6; KADMON G, 1990, J CELL BIOL, V110, P193, DOI 10.1083/jcb.110.1.193; KEILHAUER G, 1985, NATURE, V316, P728, DOI 10.1038/316728a0; KUHN TB, 1991, J CELL BIOL, V115, P1113, DOI 10.1083/jcb.115.4.1113; MAHANTHAPPA NK, 1992, DEV BIOL, V150, P47, DOI 10.1016/0012-1606(92)90006-3; MATSUNAGA M, 1988, NATURE, V334, P62, DOI 10.1038/334062a0; MURRAY BA, 1992, J CELL BIOL, V117, P1311, DOI 10.1083/jcb.117.6.1311; NEUGEBAUER KM, 1988, J CELL BIOL, V107, P1177, DOI 10.1083/jcb.107.3.1177; PIZZEY JA, 1989, J CELL BIOL, V109, P3465, DOI 10.1083/jcb.109.6.3465; POLLERBERG GE, 1993, DEV BIOL, V156, P324, DOI 10.1006/dbio.1993.1081; RAO Y, 1993, J BIOL CHEM, V268, P20630; RAO Y, 1992, J CELL BIOL, V118, P937, DOI 10.1083/jcb.118.4.937; REICHARDT LF, 1991, ANNU REV NEUROSCI, V14, P531, DOI 10.1146/annurev.neuro.14.1.531; RUTISHAUSER U, 1982, P NATL ACAD SCI-BIOL, V79, P685, DOI 10.1073/pnas.79.2.685; RUTISHAUSER U, 1976, P NATL ACAD SCI USA, V73, P577, DOI 10.1073/pnas.73.2.577; RUTISHAUSER U, 1980, J CELL BIOL, V87, P370, DOI 10.1083/jcb.87.2.370; RUTISHAUSER U, 1988, PHYSIOL REV, V68, P819, DOI 10.1152/physrev.1988.68.3.819; RUTISHAUSER U, 1983, J CELL BIOL, V97, P145, DOI 10.1083/jcb.97.1.145; RUTISHAUSER U, 1986, NEURON, V1, P3; Sambrook J, 1989, MOL CLONING LABORATO; SCHUCH U, 1989, NEURON, V3, P13, DOI 10.1016/0896-6273(89)90111-6; STANFIELD RL, 1990, SCIENCE, V248, P712, DOI 10.1126/science.2333521; Stewart JM, 1984, SOLID PHASE PEPTIDE; TAKEICHI M, 1990, ANNU REV BIOCHEM, V59, P237, DOI 10.1146/annurev.biochem.59.1.237; THANOS S, 1984, P NATL ACAD SCI-BIOL, V81, P1906, DOI 10.1073/pnas.81.6.1906; THIERY JP, 1977, J BIOL CHEM, V252, P6841; Walsh F. S., 1991, SEMIN NEUROSCI, V3, P271; WATANABE M, 1986, J CELL BIOL, V103, P1721, DOI 10.1083/jcb.103.5.1721; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; WILLIAMS EJ, 1992, J CELL BIOL, V119, P883, DOI 10.1083/jcb.119.4.883; WYSOCKI LJ, 1978, P NATL ACAD SCI USA, V75, P2844, DOI 10.1073/pnas.75.6.2844; YAZAKI T, 1991, BIOMED RES-TOKYO, V12, P223, DOI 10.2220/biomedres.12.223	62	37	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14841	14848						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	8182092				2022-12-25	WOS:A1994NM06500082
J	SARDANA, VV; WOLFGANG, JA; VELOSKI, CA; LONG, WJ; LEGROW, K; WOLANSKI, B; EMINI, EA; LAFEMINA, RL				SARDANA, VV; WOLFGANG, JA; VELOSKI, CA; LONG, WJ; LEGROW, K; WOLANSKI, B; EMINI, EA; LAFEMINA, RL			PEPTIDE SUBSTRATE CLEAVAGE SPECIFICITY OF THE HUMAN CYTOMEGALOVIRUS PROTEASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							IDENTIFICATION; GENE; PROTEINASE; EXPRESSION; SEQUENCE; PRODUCT; FRAME; SITES; DNA	The human cytomegalovirus UL80 gene encodes an 80-kDa precursor polyprotein whose N-terminal 256-amino acid domain is a protease. This enzyme cleaves a specific peptide bond that results in its own release from the precursor, as well as a peptide bond near the C terminus of the viral assembly protein. The latter cleavage is apparently required for encapsidation of the viral genomic DNA and maturation of the viral capsid. A series of peptide substrates, representing the assembly protein cleavage site, was used to study the enzyme's substrate requirements and specificity. It was found that efficient cleavage minimally required the amino acid residues spanning the P4 to P4' positions. Substitution at any of these residues adversely affected the reaction. Conservation of the hydrophobic residues at P3 and P4 was essential. In addition, cleavage of a peptide representing the protease domain release site was reduced almost 100-fold relative to cleavage of the assembly protein maturation site peptide substrate.			SARDANA, VV (corresponding author), MERCK SHARP & DOHME LTD, RES LABS, DEPT ANTIVIRAL RES, WP16-206, West Point, PA 19486 USA.							AHMED AK, 1975, J BIOL CHEM, V250, P8477; BAUM EZ, 1993, J VIROL, V67, P497, DOI 10.1128/JVI.67.1.497-506.1993; CHEE MS, 1990, CURR TOP MICROBIOL, V154, P125; LAFEMINA RL, 1983, J GEN VIROL, V64, P373, DOI 10.1099/0022-1317-64-2-373; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; PRESTON VG, 1992, VIROLOGY, V186, P87, DOI 10.1016/0042-6822(92)90063-U; PRESTON VG, 1983, J VIROL, V45, P1056, DOI 10.1128/JVI.45.3.1056-1064.1983; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; WELCH AR, 1991, P NATL ACAD SCI USA, V88, P10792, DOI 10.1073/pnas.88.23.10792; WELCH AR, 1991, J VIROL, V65, P4091, DOI 10.1128/JVI.65.8.4091-4100.1991; WELCH AR, 1993, J VIROL, V67, P7360, DOI 10.1128/JVI.67.12.7360-7372.1993	11	54	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14337	14340						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	8182034				2022-12-25	WOS:A1994NM06500003
J	WORLEY, JF; MCINTYRE, MS; SPENCER, B; MERTZ, RJ; ROE, MW; DUKES, ID				WORLEY, JF; MCINTYRE, MS; SPENCER, B; MERTZ, RJ; ROE, MW; DUKES, ID			ENDOPLASMIC-RETICULUM CALCIUM STORE REGULATES MEMBRANE-POTENTIAL IN MOUSE ISLET BETA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PANCREATIC B-CELLS; THAPSIGARGIN; INFLUX; INHIBITION	Glucose stimulation of islet beta-cell insulin secretion is initiated by membrane depolarization and an elevation in intracellular free calcium concentration ([Ca2+](i)) from a combination of influx through depolarization-activated Ca2+ channels and intracellular Ca2+ store release. Prevention of Ca2+ store refilling with thapsigargin produced a sustained depolarization, leading to enhanced Ca2+ influx and an elevation in [Ca2+](i) in 12 mM glucose. Depletion of intracellular Ca2+ stores by external EGTA reduced [Ca2+](i) and also caused a long lasting depolarization. In single beta-cells, external EGTA activated an inward current, the voltage range and kinetic properties of which differed from those of voltage-dependent Ca2+ channels. A novel pathway thus exists in beta-cells by which depletion of endoplasmic reticulum Ca2+ stores results in the activation of an inward current that, by inducing depolarization, facilitates Ca2+ influx through voltage-gated Ca2+ channels. The physiological relevance of this pathway in the control of beta cell function is indicated by the stimulation of insulin secretion by thapsigargin.	GLAXO INC,RES INST,DEPT CELL PHYSIOL,RES TRIANGLE PK,NC 27709	GlaxoSmithKline								ASHCROFT FM, 1989, PROG BIOPHYS MOL BIO, V54, P87, DOI 10.1016/0079-6107(89)90013-8; Atwater I, 1980, Horm Metab Res Suppl, VSuppl 10, P100; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; COOK DL, 1984, NATURE, V311, P271, DOI 10.1038/311271a0; DUKES ID, 1994, J BIOL CHEM, V269, P10979; DUKES ID, 1993, AM J PHYSIOL, V264, pE348, DOI 10.1152/ajpendo.1993.264.3.E348; GERICKE M, 1993, PFLUG ARCH EUR J PHY, V422, P552, DOI 10.1007/BF00374001; GILON P, 1992, J BIOL CHEM, V267, P20713; HENQUIN JC, 1988, ENDOCRINOLOGY, V122, P2134, DOI 10.1210/endo-122-5-2134; HENQUIN JC, 1984, EXPERIENTIA, V40, P1043, DOI 10.1007/BF01971450; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; KIRBY MS, 1992, J BIOL CHEM, V267, P12545; LYTTON J, 1991, J BIOL CHEM, V266, P17067; MELDOLESI J, 1991, TRENDS PHARMACOL SCI, V12, P289, DOI 10.1016/0165-6147(91)90577-F; PAREKH AB, 1993, NATURE, V364, P814, DOI 10.1038/364814a0; PUTNEY JW, 1993, SCIENCE, V262, P676, DOI 10.1126/science.8235587; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; ROBINSON IM, 1992, BIOCHEM J, V288, P457, DOI 10.1042/bj2880457; ROE MW, 1993, J BIOL CHEM, V268, P9953; ROE MW, 1994, AM J PHYSL, V266; ROE MW, 1993, BIOPHYS J, V64, P126; ROE MW, 1993, DIABETES, V42, P77; ROSSI JP, 1989, BIOCHIM BIOPHYS ACTA, V943, P175; SAGARA Y, 1992, J BIOL CHEM, V267, P12606; SANTOS RM, 1991, PFLUG ARCH EUR J PHY, V418, P417, DOI 10.1007/BF00550880; SMOLEN P, 1992, J MEMBRANE BIOL, V127, P9; WOLLHEIM CB, 1981, PHYSIOL REV, V61, P914, DOI 10.1152/physrev.1981.61.4.914; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6295, DOI 10.1073/pnas.90.13.6295	28	133	135	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14359	14362						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	8182038				2022-12-25	WOS:A1994NM06500009
J	ALLGEIER, A; OFFERMANNS, S; VANSANDE, J; SPICHER, K; SCHULTZ, G; DUMONT, JE				ALLGEIER, A; OFFERMANNS, S; VANSANDE, J; SPICHER, K; SCHULTZ, G; DUMONT, JE			THE HUMAN THYROTROPIN RECEPTOR ACTIVATES G-PROTEINS G(S) AND G(Q/11)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							BETA-GAMMA-SUBUNITS; CYCLIC-AMP CASCADES; 2 G-PROTEINS; PHOSPHOLIPASE-C; ADENYLYL CYCLASE; ALPHA-SUBUNITS; PHOSPHATIDYLINOSITOL HYDROLYSIS; MUSCARINIC RECEPTOR; CELLS; HORMONE	The human thyrotropin receptor leads upon activation to the stimulation of phospholipase C and adenylyl cyclase. It is presently not known whether this bifurcating signaling occurs via two different G-proteins (G(q/11) and G(s)) or via one G-protein (G(s)). Receptor-activated G(s) releases beta gamma subunits and alpha(s), which then could regulate phospholipase C and adenylyl cyclase, respectively. In order to elucidate the signaling pathways induced by the activated thyroid-stimulating hormone (TSH) receptor, we studied the coupling of the TSH receptor to G(s) and G(q/11) in human thyroid membranes. TSH concentration dependently led to the activation of two forms of G(s) (G(s short) and G(s long) ) as well as of G(q) and G(11), demonstrating that signaling pathways induced by TSH already bifurcate in the course of the receptor-G-protein interaction. These data strongly suggest the concept that phospholipase C and adenylyl cyclase activation through the TSH receptor are mediated by G(q/11) and G(s), respectively.	FREE UNIV BERLIN, INST PHARMAKOL, D-14195 BERLIN, GERMANY	Free University of Berlin	ALLGEIER, A (corresponding author), FREE UNIV BRUSSELS, INST INTERDISCIPLINARY RES, 808 ROUTE LENNIK, B-1070 BRUSSELS, BELGIUM.		Offermanns, Stefan/L-3313-2017	Offermanns, Stefan/0000-0001-8676-6805				ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732; ASHKENAZI A, 1987, SCIENCE, V238, P672, DOI 10.1126/science.2823384; BERSTEIN G, 1992, J BIOL CHEM, V267, P8081; BIRNBAUMER L, 1992, CELL, V71, P1069, DOI 10.1016/S0092-8674(05)80056-X; BLANK JL, 1991, J BIOL CHEM, V266, P18206; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; COCHAUX P, 1987, EUR J BIOCHEM, V170, P435, DOI 10.1111/j.1432-1033.1987.tb13718.x; EASON MG, 1992, J BIOL CHEM, V267, P15795; FARGIN A, 1989, J BIOL CHEM, V264, P14848; GRAZIANO MP, 1987, J BIOL CHEM, V262, P11375; GUDERMANN T, 1992, J BIOL CHEM, V267, P4479; HEPLER JR, 1993, J BIOL CHEM, V268, P14367; HIDAKA A, 1993, BIOCHEM BIOPH RES CO, V196, P187, DOI 10.1006/bbrc.1993.2233; HUNG DT, 1992, J BIOL CHEM, V267, P20831; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; LARSON E, 1986, ANAL BIOCHEM, V155, P243, DOI 10.1016/0003-2697(86)90432-X; LAUGWITZ KL, 1994, METHOD ENZYMOL, V237, P283; LAURENT E, 1991, J CLIN INVEST, V87, P1634, DOI 10.1172/JCI115178; LAURENT E, 1987, MOL CELL ENDOCRINOL, V52, P273, DOI 10.1016/0303-7207(87)90055-4; NAKAJIMA Y, 1992, J BIOL CHEM, V267, P2437; ODA K, 1992, FEBS LETT, V299, P187, DOI 10.1016/0014-5793(92)80244-B; OFFERMANNS S, 1994, P NATL ACAD SCI USA, V91, P504, DOI 10.1073/pnas.91.2.504; OFFERMANNS S, 1992, BIOCHEM J, V282, P551, DOI 10.1042/bj2820551; OFFERMANNS S, 1991, METHOD ENZYMOL, V195, P286; PARMENTIER M, 1989, SCIENCE, V246, P1620, DOI 10.1126/science.2556796; PAULSSEN RH, 1992, EUR J BIOCHEM, V204, P413, DOI 10.1111/j.1432-1033.1992.tb16651.x; SMRCKA AV, 1993, J BIOL CHEM, V268, P9667; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TAYLOR SJ, 1991, FEBS LETT, V286, P214, DOI 10.1016/0014-5793(91)80976-A; VANSANDE J, 1990, MOL CELL ENDOCRINOL, V74, pR1, DOI 10.1016/0303-7207(90)90209-Q; VANSANDE J, 1993, EUR J PHARM-MOLEC PH, V247, P177, DOI 10.1016/0922-4106(93)90075-K; WU DQ, 1992, J BIOL CHEM, V267, P1811	32	168	169	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					13733	13735						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188646				2022-12-25	WOS:A1994NL60600003
J	FARIA, TN; BLAKESLEY, VA; KATO, H; STANNARD, B; LEROITH, D; ROBERTS, CT				FARIA, TN; BLAKESLEY, VA; KATO, H; STANNARD, B; LEROITH, D; ROBERTS, CT			ROLE OF THE CARBOXYL-TERMINAL DOMAINS OF THE INSULIN AND INSULIN-LIKE GROWTH-FACTOR-I RECEPTORS IN RECEPTOR FUNCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE AUTOPHOSPHORYLATION SITES; PROTEIN KINASE-C; FAMILY; PHOSPHORYLATION; SPECIFICITY; BINDING; MITOGENESIS; REGIONS; LIGAND; GENE	The insulin and insulin-like growth factor I receptors (IR and IGF-IR, respectively) are heterotetrameric tyrosine kinases consisting of two extracellular ligand-binding alpha subunits and two transmembrane catalytic beta subunits. A number of lines of evidence have suggested that the IR and IGF-IR differ with respect to their ability to elicit mitogenic versus metabolic events upon activation by cognate ligands. To ascertain the contribution of the poorly conserved carboxyl-terminal domains to the differential functioning of the IR and IGF-IR, we have constructed receptor chimeras in which the carboxyl-terminal domain of one receptor was fused to the remainder of the heterologous receptor. The responses of a number of parameters after ligand stimulation were examined in stably transfected NIH-3T3 cells expressing the chimeric receptors or the analogous wild-type receptor sequence. Replacement of the IR carboxyl terminus with that of the IGF-IR severely affected insulin stimulated responses, whereas substitution of the carboxyl terminus of the IGF-IR with that of the IR had a minimal effect. These data suggest that the carboxyl-terminal domains of the IR and IGF-IR are not interchangeable and that the mitogenic activity of the IR can be influenced by sequences present in the carboxyl-terminal domain. The analogous functions of the IGF-IR, on the other hand, do not appear to be greatly affected by the presence of the IR carboxyl-terminal domain.	NIDDK,DIABET BRANCH,MOLEC & CELLULAR PHYSIOL SECT,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)			Roberts, Charles/K-6953-2017	Roberts, Charles/0000-0003-1756-5772				ABBOTT AM, 1992, J BIOL CHEM, V267, P10759; ADAMO M, 1992, BIOFACTORS, V3, P151; ANDO A, 1992, J BIOL CHEM, V267, P12788; BACKER JM, 1992, J BIOL CHEM, V267, P1367; BAKER J, 1993, CELL, V75, P73, DOI 10.1016/0092-8674(93)90680-O; BARON V, 1991, BIOCHEMISTRY-US, V30, P9365, DOI 10.1021/bi00102a033; BARON V, 1990, BIOCHEMISTRY-US, V29, P4634, DOI 10.1021/bi00471a019; CAMA A, 1993, J BIOL CHEM, V268, P8060; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; DICKENS M, 1992, BIOCHEM J, V287, P201, DOI 10.1042/bj2870201; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FUJITAYAMAGUCHI Y, 1989, BIOCHEM J, V263, P813, DOI 10.1042/bj2630813; GOTTSCHALK WK, 1992, BIOCHEM BIOPH RES CO, V189, P906; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HOVIS JG, 1986, J BIOL CHEM, V261, P380; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; KALIMAN P, 1992, J BIOL CHEM, V267, P10645; KATO H, 1994, MOL ENDOCRINOL, V8, P40, DOI 10.1210/me.8.1.40; KATO H, 1993, J BIOL CHEM, V268, P2655; KURACHI H, 1992, BIOCHEM BIOPH RES CO, V187, P934, DOI 10.1016/0006-291X(92)91287-Z; LAMMERS R, 1989, EMBO J, V8, P1369, DOI 10.1002/j.1460-2075.1989.tb03517.x; LEVYTOLEDANO R, 1993, BIOCHIM BIOPHYS ACTA, V1220, P1, DOI 10.1016/0167-4889(93)90090-C; LEWIS RE, 1990, BIOCHEMISTRY-US, V29, P1807, DOI 10.1021/bi00459a020; LEWIS RE, 1990, J BIOL CHEM, V265, P947; LIU DL, 1993, J VIROL, V67, P6835, DOI 10.1128/JVI.67.11.6835-6840.1993; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/S0092-8674(05)80084-4; MCCLAIN DA, 1988, J BIOL CHEM, V263, P8904; MEYERS MG, 1991, J BIOL CHEM, V266, P10616; MORRISON BD, 1989, J BIOL CHEM, V264, P9994; MURAKAMI MS, 1991, J BIOL CHEM, V266, P22653; SAHAL D, 1988, ARCH BIOCHEM BIOPHYS, V260, P416, DOI 10.1016/0003-9861(88)90465-1; SCHUMACHER R, 1991, J BIOL CHEM, V266, P19288; SEINO S, 1989, P NATL ACAD SCI USA, V86, P114, DOI 10.1073/pnas.86.1.114; SHIER P, 1989, J BIOL CHEM, V264, P14605; TAKATA Y, 1992, J BIOL CHEM, V267, P9065; TAKATA Y, 1991, J BIOL CHEM, V266, P9135; TAVARE JM, 1993, BIOCHIM BIOPHYS ACTA, V1178, P21, DOI 10.1016/0167-4889(93)90106-Y; THIES RS, 1989, J BIOL CHEM, V264, P12820; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; YAMAMOTOHONDA R, 1993, J BIOL CHEM, V268, P16859	42	52	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					13922	13928						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188672				2022-12-25	WOS:A1994NL60600034
J	HSIEH, M; HENSLEY, P; BRENOWITZ, M; FETROW, JS				HSIEH, M; HENSLEY, P; BRENOWITZ, M; FETROW, JS			A MOLECULAR-MODEL OF THE INDUCER BINDING DOMAIN OF THE GALACTOSE REPRESSOR OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LACTOSE REPRESSOR; GAL REPRESSOR; LAC REPRESSOR; L-ARABINOSE; ACTIVE-TRANSPORT; 3-DIMENSIONAL STRUCTURE; CONFORMATIONAL CHANGE; TERTIARY TEMPLATES; PROTEIN STRUCTURES; GLOBULAR-PROTEINS	The C-terminal inducer binding domain of the Escherichia coli galactose repressor (GalR) is homologous to several periplasmic chemoreceptor proteins whose three-dimensional structures have been determined at high resolution (Vyas, N. K., Vyas, M. N., and Quiocho, F. A. (1991) J. Biol. Chem. 266, 5226-5237; Mowbray, S. L. and Cole, L. B. (1992) J. Mol. Biol. 225, 155-175). The protein backbone was constructed from the coordinates of glucose/galactose-binding protein using the Homology program (Biosym Technologies, San Diego). Loops were built by searching for substructures in the structure data base, and the side chains were built using a rotamer-based program. A small amount of energy minimization relieved steric strain within the model. The GalR model that has been constructed is consistent with the principles of protein structure; values obtained for the compactness and buried surface area of the model compare favorably with those determined for the chemoreceptor protein structures. The model is consistent with, and provides structural interpretations for, experimental results obtained from physical and biochemical studies. Predictions are made concerning the residues conferring the specificity of galactose induction of GalR and for self association to dimers. The model provides a first step toward correlating the structure and regulation of GalR and in determining the chemistry of its homologous and heterologous interactions that are critical to its role as a regulator of transcription initiation.	YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT BIOCHEM, BRONX, NY 10461 USA; SUNY ALBANY, DEPT BIOL SCI, ALBANY, NY 12222 USA; SMITH KLINE & BEECHAM LABS, RES & DEV, DEPT MACROMOLEC SCI, KING OF PRUSSIA, PA 19406 USA	Yeshiva University; Albert Einstein College of Medicine; State University of New York (SUNY) System; State University of New York (SUNY) Albany; GlaxoSmithKline				Fetrow, Jacquelyn/0000-0002-0528-2049	NCI NIH HHS [2P30CA13330-22] Funding Source: Medline; NIGMS NIH HHS [GM39929, 5-F31-GM13850] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA013330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039929, F31GM013850, R29GM039929] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADHYA S, 1989, ANNU REV GENET, V23, P227, DOI 10.1146/annurev.genet.23.1.227; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ANDERSON BF, 1990, NATURE, V344, P784, DOI 10.1038/344784a0; AULD DS, 1991, BIOCHEMISTRY-US, V30, P8684, DOI 10.1021/bi00099a028; BLUNDELL TL, 1987, NATURE, V326, P347, DOI 10.1038/326347a0; BOWIE JU, 1991, SCIENCE, V253, P164, DOI 10.1126/science.1853201; BRENOWITZ M, 1990, BIOCHEMISTRY-US, V29, P3374, DOI 10.1021/bi00465a033; BROWN MP, 1994, J BIOL CHEM, V269, P12600; BRYANT SH, 1993, PROTEINS, V16, P92, DOI 10.1002/prot.340160110; BUTTIN G, 1963, J MOL BIOL, V7, P183, DOI 10.1016/S0022-2836(63)80045-5; CHAKERIAN AE, 1991, J BIOL CHEM, V266, P22206; CHANG WI, 1993, J BIOL CHEM, V268, P17613; CHEN J, 1992, J BIOL CHEM, V267, P13843; CHOY HE, 1992, P NATL ACAD SCI USA, V89, P11264, DOI 10.1073/pnas.89.23.11264; COHEN FE, 1991, BIOCHEMISTRY-US, V30, P11221, DOI 10.1021/bi00111a005; Cohn E. J., 1943, PROTEINS AMINO ACIDS, P370; DALMAWEISZHAUSZ DD, 1992, BIOCHEMISTRY-US, V31, P6980, DOI 10.1021/bi00145a016; DALY TJ, 1986, BIOCHEMISTRY-US, V25, P5479, DOI 10.1021/bi00367a020; DALY TJ, 1986, BIOCHEMISTRY-US, V25, P5468, DOI 10.1021/bi00367a018; DALY TJ, 1986, BIOCHEMISTRY-US, V25, P5474, DOI 10.1021/bi00367a019; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FETROW JS, 1993, BIO-TECHNOL, V11, P479, DOI 10.1038/nbt0493-479; GODZIK A, 1992, P NATL ACAD SCI USA, V89, P12098, DOI 10.1073/pnas.89.24.12098; GOODRICH JA, 1992, J MOL BIOL, V224, P15, DOI 10.1016/0022-2836(92)90573-3; GRAHAM HC, 1991, EUR J BIOCHEM, V196, P261, DOI 10.1111/j.1432-1033.1991.tb15813.x; GREER J, 1991, METHOD ENZYMOL, V202, P239; GREER J, 1980, P NATL ACAD SCI-BIOL, V77, P3393, DOI 10.1073/pnas.77.6.3393; HABER R, 1988, P NATL ACAD SCI USA, V85, P9683, DOI 10.1073/pnas.85.24.9683; HENSLEY P, 1975, J BIOL CHEM, V250, P952; HOGG RW, 1977, J BIOL CHEM, V252, P5135; JOHNSON ML, 1992, METHOD ENZYMOL, V210, P1; JONES DT, 1992, NATURE, V358, P86, DOI 10.1038/358086a0; JONES TA, 1986, EMBO J, V5, P819, DOI 10.1002/j.1460-2075.1986.tb04287.x; KLEINA LG, 1990, J MOL BIOL, V212, P295, DOI 10.1016/0022-2836(90)90126-7; LAMERICHS RMJN, 1989, BIOCHEMISTRY-US, V28, P2985, DOI 10.1021/bi00433a037; LAMERICHS RMJN, 1990, EUR J BIOCHEM, V194, P629, DOI 10.1111/j.1432-1033.1990.tb15662.x; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; MAJUMDAR A, 1987, J BIOL CHEM, V262, P2326; MALONEYHUSS K, 1992, J MOL BIOL, V225, P859, DOI 10.1016/0022-2836(92)90406-A; MATTHEW JB, 1985, ANNU REV BIOPHYS BIO, V14, P387; MATTHEWS KS, 1979, J BIOL CHEM, V254, P3348; MENG MH, 1991, P NATL ACAD SCI USA, V88, P4015, DOI 10.1073/pnas.88.9.4015; MOWBRAY SL, 1992, J MOL BIOL, V225, P155, DOI 10.1016/0022-2836(92)91033-L; MOWBRAY SL, 1992, J MOL BIOL, V227, P418, DOI 10.1016/0022-2836(92)90898-T; MULLERHILL B, 1983, NATURE, V302, P163, DOI 10.1038/302163a0; NEWCOMER ME, 1981, J BIOL CHEM, V256, P3218; NICHOLS JC, 1993, J BIOL CHEM, V268, P17602; OVERINGTON J, 1992, PROTEIN SCI, V1, P216; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PACE HC, 1990, P NATL ACAD SCI USA, V87, P1870, DOI 10.1073/pnas.87.5.1870; PLATT T, 1973, J BIOL CHEM, V248, P110; PONDER JW, 1987, J MOL BIOL, V193, P775, DOI 10.1016/0022-2836(87)90358-5; QUIOCHO FA, 1990, PHILOS T R SOC B, V326, P341, DOI 10.1098/rstb.1990.0016; QUIOCHO FA, 1984, NATURE, V310, P381, DOI 10.1038/310381a0; RASHIN AA, 1984, J MOL BIOL, V173, P515, DOI 10.1016/0022-2836(84)90394-2; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; SCHUMACHER MA, 1993, J BIOL CHEM, V268, P12282; SCRIPTURE JB, 1987, J MOL BIOL, V197, P37, DOI 10.1016/0022-2836(87)90607-3; SENEAR DF, 1993, ELECTROPHORESIS, V14, P704, DOI 10.1002/elps.11501401112; SHARFF AJ, 1992, BIOCHEMISTRY-US, V31, P10657, DOI 10.1021/bi00159a003; SPURLINO JC, 1991, J BIOL CHEM, V266, P5202; STEITZ TA, 1976, J MOL BIOL, V104, P197, DOI 10.1016/0022-2836(76)90009-7; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; VONWILCKENBERGMANN B, 1982, P NATL ACAD SCI-BIOL, V79, P2427; VYAS MN, 1989, J BIOL CHEM, V264, P20817; VYAS NK, 1991, J BIOL CHEM, V266, P5226; WARTELL RM, 1988, NUCLEIC ACIDS RES, V16, P11531, DOI 10.1093/nar/16.24.11531; WEICKERT MJ, 1992, J MOL BIOL, V226, P69, DOI 10.1016/0022-2836(92)90125-4; WEICKERT MJ, 1992, J BIOL CHEM, V267, P15869; YANG JT, 1986, METHOD ENZYMOL, V130, P208; ZEHFUS MH, 1986, BIOCHEMISTRY-US, V25, P5759, DOI 10.1021/bi00367a062	72	20	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					13825	13835						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188660				2022-12-25	WOS:A1994NL60600020
J	MATHUR, M; GOODWIN, L; COWIN, P				MATHUR, M; GOODWIN, L; COWIN, P			INTERACTIONS OF THE CYTOPLASMIC DOMAIN OF THE DESMOSOMAL CADHERIN DSG1 WITH PLAKOGLOBIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULES; JUNCTIONAL PLAQUE PROTEIN; BETA-CATENIN; PEMPHIGUS-VULGARIS; ALPHA-ACTININ; FAMILY; UVOMORULIN; VINCULIN; HOMOLOG; IDENTIFICATION	Dsg1 is a 165-kDa glycoprotein component of suprabasal epidermal desmosomes and the prototype of a subset of the cadherin superfamily of cell-cell adhesion proteins known as desmogleins. The adhesive function of classical cadherins is known to be dependent upon their association with cytoplasmic components called catenins. In the case of desmogleins, a single interaction has been described with a protein called plakoglobin that is found in desmosomal plaques, adherens junctions, and the cytosol. Several proteins with homology to plakoglobin have been described that regulate junction assembly and implement morphoregulatory signals. To address the functional significance of plakoglobin-desmoglein interaction, we have mapped the sequences of Dsg1 that are crucial for this association by using blot overlay techniques. By examining the binding of plakoglobin to a deletion series of the Dsg1 cytoplasmic domain expressed as fusion proteins, we have defined a 19-amino acid sequence that is important for association. This region of Dsg1 sequence shows significant similarity to the catenin-binding domain of classical cadherins, suggesting a common mechanism for the association of plakoglobin with desmosomes and adherens junctions.	NYU, MED CTR, RONALD O PERELMAN DEPT DERMATOL, NEW YORK, NY 10016 USA; NYU, MED CTR, DEPT CELL BIOL, NEW YORK, NY 10016 USA; NYU, MED CTR, KAPLAN CANC CTR, NEW YORK, NY 10016 USA	New York University; New York University; New York University				Cowin, Pamela/0000-0002-1827-1154	NIGMS NIH HHS [R01-GM47429] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047429] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMAGAI M, 1991, CELL, V67, P869, DOI 10.1016/0092-8674(91)90360-B; BRADLEY RS, 1993, J CELL BIOL, V123, P1857, DOI 10.1083/jcb.123.6.1857; BURRIDGE K, 1984, NATURE, V308, P744, DOI 10.1038/308744a0; BUTZ S, 1992, SCIENCE, V257, P1142, DOI 10.1126/science.257.5073.1142-a; Buxton R S, 1992, Semin Cell Biol, V3, P157; COLLINS JE, 1991, J CELL BIOL, V113, P381, DOI 10.1083/jcb.113.2.381; COWIN P, 1985, J CELL BIOL, V101, P1442, DOI 10.1083/jcb.101.4.1442; COWIN P, 1986, CELL, V46, P1063, DOI 10.1016/0092-8674(86)90706-3; COWIN P, 1993, MOL BASIS MORPHOGENE, P49; CRAWFORD AW, 1992, J CELL BIOL, V116, P1381, DOI 10.1083/jcb.116.6.1381; FARQUHAR MG, 1963, J CELL BIOL, V17, P375, DOI 10.1083/jcb.17.2.375; FRANKE WW, 1987, BIOL CELL, V59, P205, DOI 10.1111/j.1768-322X.1987.tb00532.x; FRANKE WW, 1989, P NATL ACAD SCI USA, V86, P4027, DOI 10.1073/pnas.86.11.4027; GEIGER B, 1983, DIFFERENTIATION, V23, P189; GOODWIN L, 1990, BIOCHEM BIOPH RES CO, V173, P1224, DOI 10.1016/S0006-291X(05)80917-9; GORBSKY G, 1981, J CELL BIOL, V90, P243, DOI 10.1083/jcb.90.1.243; HERRENKNECHT K, 1991, P NATL ACAD SCI USA, V88, P9156, DOI 10.1073/pnas.88.20.9156; HIGGINS RC, 1979, ANAL BIOCHEM, V93, P257, DOI 10.1016/S0003-2697(79)80077-9; KAPPRELL HP, 1987, EUR J BIOCHEM, V166, P505, DOI 10.1111/j.1432-1033.1987.tb13543.x; KAPPRELL HP, 1988, J CELL BIOL, V106, P1679, DOI 10.1083/jcb.106.5.1679; KINTNER C, 1992, CELL, V69, P225, DOI 10.1016/0092-8674(92)90404-Z; KNUDSEN KA, 1992, J CELL BIOL, V118, P671, DOI 10.1083/jcb.118.3.671; KOCH PJ, 1990, EUR J CELL BIOL, V53, P1; KOCH PJ, 1992, P NATL ACAD SCI USA, V89, P353, DOI 10.1073/pnas.89.1.353; KORMAN NJ, 1989, NEW ENGL J MED, V321, P631, DOI 10.1056/NEJM198909073211002; MARRS JA, 1993, J CELL BIOL, V123, P149, DOI 10.1083/jcb.123.1.149; MCCREA PD, 1991, SCIENCE, V254, P1359, DOI 10.1126/science.1962194; MCNEILL H, 1990, CELL, V62, P309, DOI 10.1016/0092-8674(90)90368-O; MECHANIC S, 1991, P NATL ACAD SCI USA, V88, P4476, DOI 10.1073/pnas.88.10.4476; NAGAFUCHI A, 1991, CELL, V65, P849, DOI 10.1016/0092-8674(91)90392-C; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; NAGAFUCHI A, 1989, CELL REGUL, V1, P37, DOI 10.1091/mbc.1.1.37; NATHKE IS, 1993, MOL BIOL CELL, V4, pA473; NILLES LA, 1991, J CELL SCI, V99, P809; NOSE A, 1988, CELL, V54, P993, DOI 10.1016/0092-8674(88)90114-6; OTEY CA, 1990, J CELL BIOL, V111, P721, DOI 10.1083/jcb.111.2.721; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; OZAWA M, 1990, P NATL ACAD SCI USA, V87, P4246, DOI 10.1073/pnas.87.11.4246; PARKER AE, 1991, J BIOL CHEM, V266, P10438; PEIFER M, 1992, J CELL BIOL, V118, P681, DOI 10.1083/jcb.118.3.681; PEIFER M, 1990, CELL, V63, P1167, DOI 10.1016/0092-8674(90)90413-9; PEIFER M, 1994, CELL, V76, P789, DOI 10.1016/0092-8674(94)90353-0; PIEPENHAGEN PA, 1993, J CELL SCI, V104, P751; PUTTAGUNTA S, 1994, J BIOL CHEM, V269, P1949; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TROYANOVSKY SM, 1993, CELL, V72, P561, DOI 10.1016/0092-8674(93)90075-2; TSUKITA S, 1989, J CELL BIOL, V108, P2369, DOI 10.1083/jcb.108.6.2369; TSUKITA S, 1985, J CELL BIOL, V101, P2070, DOI 10.1083/jcb.101.6.2070; TSUKITA S, 1991, J CELL BIOL, V113, P867, DOI 10.1083/jcb.113.4.867; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; WHEELER GN, 1991, P NATL ACAD SCI USA, V88, P4796, DOI 10.1073/pnas.88.11.4796	54	120	120	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					14075	14080						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188687				2022-12-25	WOS:A1994NL60600054
J	TORNKVIST, A; PARPAL, S; GUSTAVSSON, J; STRALFORS, P				TORNKVIST, A; PARPAL, S; GUSTAVSSON, J; STRALFORS, P			INHIBITION OF RAF-1 KINASE EXPRESSION ABOLISHES INSULIN STIMULATION OF DNA-SYNTHESIS IN H4IIE HEPATOMA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE THREONINE KINASES; GROWTH-FACTOR; MITOGENIC SIGNAL; PROTEIN-KINASE; PHOSPHORYLATION; RECEPTORS; CHO-K1	The involvement of Raf-1 kinase in the insulin signal transduction chain leading to control of cell proliferation was studied in the H4IIE rat hepatoma cell line by inhibiting expression of the kinase with antisense oligodeoxyribonucleotide directed against Raf-1 mRNA, Antisense oligonucleotide was found to reduce (at 2 mu M) or completely block (at 15 mu M) the stimulation by insulin of DNA synthesis, measured as thymidine incorporation. The residual DNA synthesis seen in the absence of insulin stimulation was also inhibited by the Raf-1 kinase antisense oligonucleotide.	LINKOPING UNIV,FAC HLTH SCI,DEPT CELL BIOL,S-58185 LINKOPING,SWEDEN	Linkoping University				Stralfors, Peter/0000-0002-1196-1806				BELFRAGE P, 1986, MECHANISMS INSULIN A; BLACKSHEAR PJ, 1990, J BIOL CHEM, V265, P12131; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CARROLL MP, 1991, J BIOL CHEM, V266, P14964; DENT P, 1993, MOL BIOL CELL, V4, P483, DOI 10.1091/mbc.4.5.483; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DICKENS M, 1992, BIOCHEM J, V287, P201, DOI 10.1042/bj2870201; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; HOFMANN C, 1989, J BIOL CHEM, V264, P8606; IZUMI T, 1991, J BIOL CHEM, V266, P7933; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KOONTZ JW, 1981, SCIENCE, V211, P947, DOI 10.1126/science.7008195; KOVACINA KS, 1990, J BIOL CHEM, V265, P12115; LEE RM, 1992, J BIOL CHEM, V267, P1088; MAMOUNAS M, 1991, P NATL ACAD SCI USA, V88, P3530, DOI 10.1073/pnas.88.9.3530; MAMOUNAS M, 1989, P NATL ACAD SCI USA, V86, P9294, DOI 10.1073/pnas.86.23.9294; MESSINA JL, 1990, BIOCHEM BIOPH RES CO, V172, P759, DOI 10.1016/0006-291X(90)90739-A; OBRIEN RM, 1991, BIOCHEM J, V278, P609, DOI 10.1042/bj2780609; OSTEROP APRM, 1992, J BIOL CHEM, V267, P14647; SHIMIZU Y, 1986, J BIOL CHEM, V261, P7342	20	13	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					13919	13921						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188671				2022-12-25	WOS:A1994NL60600033
J	BERTRAND, B; WAKABAYASHI, S; IKEDA, T; POUYSSEGUR, J; SHIGEKAWA, M				BERTRAND, B; WAKABAYASHI, S; IKEDA, T; POUYSSEGUR, J; SHIGEKAWA, M			THE NA+/H+ EXCHANGER ISOFORM-1 (NHE1) IS A NOVEL MEMBER OF THE CALMODULIN-BINDING PROTEINS - IDENTIFICATION AND CHARACTERIZATION OF CALMODULIN-BINDING SITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR PH REGULATION; LIGHT CHAIN KINASE; GROWTH-FACTORS; HUMAN-FIBROBLASTS; CA-2+ PUMP; MOLECULAR-CLONING; ALPHA-THROMBIN; CYTOPLASMIC PH; OKADAIC ACID; ACTIVATION	The Na+/H+ exchange activity (NHE1 human isoform) is rapidly activated in response to growth factors and hyperosmotic stress. To get insight into the mechanism of NHE1 activation, we studied the direct interaction of a ubiquitous Ca2+-dependent regulatory factor, calmodulin (CaM) with NHE1. Binding experiments with CaM-Sepharose, as well as fluorescence measurements with dansylated CaM, revealed that the NHE1 cytoplasmic domain strongly binds CaM in a Ca2+-dependent manner. Fusion protein analysis with deletion mutants provided evidence for high (K-d similar to 20 nM) and intermediate (K-d similar to 350 nM) affinity CaM-binding sites located in neighboring regions of NHE1 (amino acids 636-656 and 657-700). To assess a regulatory role of CaM-binding sites, several cDNAs having deletion and point mutations in the high affinity site were generated and expressed in the exchanger-deficient fibroblast cell line PS120. Deletion and point mutations of positively charged residues of the high affinity CaM-binding site resulted in up to 50 and 80% reductions of cytoplasmic alkalinization caused by growth factors (alpha-thrombin, etc.) and 100 mM sucrose, respectively. In these mutants, the reduction in alkalinization was apparently in proportion to that of the CaM-binding ability. These results suggest that binding of Ca2+/CaM to the high affinity site is involved at least partly in the activation of NHE1 in response to different extracellular signals.	UNIV NICE,CNRS,CTR BIOCHIM,F-06108 NICE 2,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	BERTRAND, B (corresponding author), NATL CARDIOVASC CTR,RES INST,DEPT MOLEC PHYSIOL,SUITA,OSAKA 565,JAPAN.							ARONSON PS, 1982, NATURE, V299, P161, DOI 10.1038/299161a0; ARONSON PS, 1986, NAPLUS HPLUS EXCHANG; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BIANCHINI L, 1991, J BIOL CHEM, V266, P15406; BLUMENTHAL DK, 1985, P NATL ACAD SCI USA, V82, P3187, DOI 10.1073/pnas.82.10.3187; BUSCHMEIER B, 1987, J BIOL CHEM, V262, P9454; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P211, DOI 10.1021/bi00699a001; COX JA, 1985, J BIOL CHEM, V260, P2527; DASGUPTA M, 1989, J BIOL CHEM, V264, P17156; ERICKSONVIITANEN S, 1987, METHOD ENZYMOL, V139, P455; FAFOURNOUX P, 1994, J BIOL CHEM, V269, P2598; GNEGY ME, 1993, ANN REV PHARM TOXICO, V32, P45; GRINSTEIN S, 1985, J GEN PHYSIOL, V85, P765, DOI 10.1085/jgp.85.5.765; GRINSTEIN S, 1993, EMBO J, V12, P5209, DOI 10.1002/j.1460-2075.1993.tb06216.x; GRINSTEIN S, 1992, J BIOL CHEM, V267, P23823; GRINSTEIN S, 1989, BIOCHIM BIOPHYS ACTA, V988, P73, DOI 10.1016/0304-4157(89)90004-X; GRINSTEIN S, 1988, NAPLUS HPLUS EXCHANG; HANLEY RM, 1987, SCIENCE, V237, P293, DOI 10.1126/science.3037704; HENDEY B, 1989, J BIOL CHEM, V264, P19540; JAMES P, 1988, J BIOL CHEM, V263, P2905; KIMURA M, 1990, J BIOL CHEM, V265, P21068; LADANT D, 1988, J BIOL CHEM, V263, P2612; LALLEMAIN G, 1984, J BIOL CHEM, V259, P5809; LUKAS TJ, 1986, BIOCHEMISTRY-US, V25, P1458, DOI 10.1021/bi00354a041; MEECH RW, 1977, J PHYSIOL-LONDON, V265, P867, DOI 10.1113/jphysiol.1977.sp011749; MITSUHASHI T, 1988, J BIOL CHEM, V263, P8790; MOOLENAAR WH, 1983, NATURE, V304, P645, DOI 10.1038/304645a0; MOOLENAAR WH, 1986, ANNU REV PHYSIOL, V48, P363; MULDOON LL, 1985, AM J PHYSIOL, V249, pC140, DOI 10.1152/ajpcell.1985.249.1.C140; NIGGLI V, 1982, J BIOL CHEM, V257, P2350; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; PARIS S, 1984, J BIOL CHEM, V259, P989; POUYSSEGUR J, 1984, P NATL ACAD SCI-BIOL, V81, P4833, DOI 10.1073/pnas.81.15.4833; SARDET C, 1990, SCIENCE, V247, P723, DOI 10.1126/science.2154036; SARDET C, 1989, CELL, V56, P271, DOI 10.1016/0092-8674(89)90901-X; SARDET C, 1991, J BIOL CHEM, V266, P19166; SCHWARTZ MA, 1989, P NATL ACAD SCI USA, V86, P4525, DOI 10.1073/pnas.86.12.4525; SCHWARTZ MA, 1991, P NATL ACAD SCI USA, V88, P7849, DOI 10.1073/pnas.88.17.7849; STINSON RA, 1973, BIOCHEM J, V131, P719, DOI 10.1042/bj1310719; TSE CM, 1991, EMBO J, V10, P1957, DOI 10.1002/j.1460-2075.1991.tb07725.x; VANOBBERGHENSCHILLING E, 1985, EMBO J, V4, P2927, DOI 10.1002/j.1460-2075.1985.tb04025.x; VICENTINI LM, 1985, P NATL ACAD SCI USA, V82, P8053, DOI 10.1073/pnas.82.23.8053; VORHERR T, 1990, BIOCHEMISTRY-US, V29, P355, DOI 10.1021/bi00454a008; WAKABAYASHI S, 1992, P NATL ACAD SCI USA, V89, P2424, DOI 10.1073/pnas.89.6.2424; WAKABAYASHI S, 1994, J BIOL CHEM, V269, P13710; WAKABAYASHI S, 1994, J BIOL CHEM, V269, P5583; ZIEGELSTEIN RC, 1992, SCIENCE, V258, P656, DOI 10.1126/science.1329207	47	298	302	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13703	13709						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175806				2022-12-25	WOS:A1994NK18400094
J	KOZARSKY, KF; MCKINLEY, DR; AUSTIN, LL; RAPER, SE; STRATFORDPERRICAUDET, LD; WILSON, JM				KOZARSKY, KF; MCKINLEY, DR; AUSTIN, LL; RAPER, SE; STRATFORDPERRICAUDET, LD; WILSON, JM			IN-VIVO CORRECTION OF LOW-DENSITY-LIPOPROTEIN RECEPTOR DEFICIENCY IN THE WATANABE HERITABLE HYPERLIPIDEMIC RABBIT WITH RECOMBINANT ADENOVIRUSES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA; MEDIATED GENE-TRANSFER; LIVER-TRANSPLANTATION; WHHL-RABBIT; INVIVO; EXPRESSION; ATHEROSCLEROSIS; IMPROVEMENT; HEPATOCYTES; THERAPY	A rabbit animal model of the human disease familial hypercholesterolemia (FH), which is the result of low density lipoprotein (LDL) receptor deficiency, was used to develop an in vivo approach to gene therapy based on recombinant adenoviruses. Recombinant, replication-defective adenoviruses expressing the lacZ gene under the control of different promoters were infused into the portal circulation of New Zealand White (NZW) rabbits. Expression of lacZ could be obtained in virtually all hepatocytes within 3 days post infusion, but was undetectable by 3 weeks. This was not associated with liver pathology, An LDL receptor expressing adenovirus was constructed using the most active promoter and was infused into the portal vein of rabbits deficient in LDL receptor. Analysis of liver tissues harvested 3 days after virus infusion demonstrated human LDL receptor protein in the majority of hepatocytes that exceeded the levels found in human liver by at least 10-fold. Transgene expression was stable for 7-10 days and diminished to undetectable levels within 3 weeks. Infusion of LDL receptor expressing virus led to substantial reductions in serum cholesterol that returned to base line within 3 weeks; this acute reduction in serum cholesterol was associated with accumulations of lipid in hepatocytes. The development of neutralizing antibodies to the recombinant adenovirus markedly diminished the effectiveness of a second dose. These studies illustrate the advantages of recombinant adenoviruses for the treatment of liver metabolic diseases and define issues, such as viral genome instability and blocking immune response, that need to be overcome before the promise of this technology can be fully realized.	UNIV PENN,WISTAR INST,INST HUMAN GENE THERAPY,PHILADELPHIA,PA 19104; UNIV PENN,DEPT MOLEC & CELLULAR ENGN,PHILADELPHIA,PA 19104; UNIV PENN,DEPT MED,PHILADELPHIA,PA 19104; UNIV PENN,DEPT SURG,PHILADELPHIA,PA 19104; UNIV MICHIGAN,SCH MED,DEPT INTERNAL MED,ANN ARBOR,MI 48109; INST GUSTAVE ROUSSY,CNRS,UA 1301,F-94805 VILLEJUIF,FRANCE	The Wistar Institute; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Michigan System; University of Michigan; Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy			Wilson, James M/F-9220-2011	Wilson, James M/0000-0002-9630-3131				BARR E, 1994, GENE THER, V1, P51; BILHEIMER DW, 1984, NEW ENGL J MED, V311, P1658, DOI 10.1056/NEJM198412273112603; CHOWDHURY JR, 1991, SCIENCE, V254, P1802, DOI 10.1126/science.1722351; ENGELHARDT JF, 1993, NAT GENET, V4, P27, DOI 10.1038/ng0593-27; ENGELHARDT JF, 1994, IN PRESS P NATL ACAD; FERRY N, 1991, P NATL ACAD SCI USA, V88, P8377, DOI 10.1073/pnas.88.19.8377; Goldstein J.L., 1989, METABOLIC BASIS INHE, P1215; GOLDSTEIN JL, 1983, NEW ENGL J MED, V309, P288, DOI 10.1056/NEJM198308043090507; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; GROSSMAN M, 1992, HUM GENE THER, V3, P501, DOI 10.1089/hum.1992.3.5-501; GROSSMAN M, 1993, J LAB CLIN MED, V121, P472; HERZ J, 1993, P NATL ACAD SCI USA, V90, P2812, DOI 10.1073/pnas.90.7.2812; HIERHOLZER JC, 1978, J CLIN MICROBIOL, V7, P499; HOEG JM, 1987, AM J CARDIOL, V59, P705, DOI 10.1016/0002-9149(87)91199-4; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; JAFFE HA, 1992, NAT GENET, V1, P372, DOI 10.1038/ng0892-372; KOZARSKY K, 1993, SOMAT CELL MOLEC GEN, V19, P449, DOI 10.1007/BF01233250; LOGAN J, 1984, P NATL ACAD SCI-BIOL, V81, P3655, DOI 10.1073/pnas.81.12.3655; NICOLAU C, 1987, METHOD ENZYMOL, V149, P157; PRICE J, 1987, P NATL ACAD SCI USA, V84, P156, DOI 10.1073/pnas.84.1.156; ROESSLER BJ, 1993, J CLIN INVEST, V92, P1085, DOI 10.1172/JCI116614; SMITH TAG, 1993, NAT GENET, V5, P397, DOI 10.1038/ng1293-397; STARZL TE, 1984, LANCET, V1, P1382; STRATFORDPERRICAUDET LD, 1990, HUM GENE THER, V1, P241, DOI 10.1089/hum.1990.1.3-241; STRATFORDPERRICAUDET LD, 1992, J CLIN INVEST, V90, P626, DOI 10.1172/JCI115902; Strauss SE, 1984, ADENOVIRUSES, P451; WATANABE Y, 1980, ATHEROSCLEROSIS, V36, P261, DOI 10.1016/0021-9150(80)90234-8; WILSON JM, 1992, HUM GENE THER, V3, P179, DOI 10.1089/hum.1992.3.2-179; WILSON JM, 1992, J BIOL CHEM, V267, P963; WU GY, 1991, J BIOL CHEM, V266, P14338; YAMAMOTO T, 1986, SCIENCE, V232, P1230, DOI 10.1126/science.3010466; YANG Y, 1994, IN PRESS P NATL ACAD; YANG YP, 1993, P NATL ACAD SCI USA, V90, P4601, DOI 10.1073/pnas.90.10.4601; ZABNER J, 1994, NAT GENET, V6, P75, DOI 10.1038/ng0194-75	34	275	294	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13695	13702						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175805				2022-12-25	WOS:A1994NK18400093
J	LUJAN, HD; MOWATT, MR; HELMAN, LJ; NASH, TE				LUJAN, HD; MOWATT, MR; HELMAN, LJ; NASH, TE			INSULIN-LIKE GROWTH-FACTORS STIMULATE GROWTH AND L-CYSTEINE UPTAKE BY THE INTESTINAL PARASITE GIARDIA-LAMBLIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MANNOSE 6-PHOSPHATE RECEPTOR; COHN FRACTION-IV; II IGF-II; HUMAN-PLASMA; GASTROINTESTINAL-TRACT; PROTEIN; IDENTIFICATION; PURIFICATION; ANTIBODIES; PEPTIDES	Giardia lamblia, a parasitic protozoan responsible for diarrhea and malabsorption in humans, grows axeni- cally only in media that contain serum and a high concentration of L-cysteine. During our attempts to grow Giardia in the absence of serum, we found that: (a) human insulin-like growth factors (especially IGF-II), but not insulin, promote the growth and L-cysteine uptake by G. lamblia trophozoites; (b) the growth stimulation was inhibited by alpha IR3, an anti-type 1 IGF receptor monoclonal antibody, but an anti-type 2 IGF receptor antibody had no effect; and (c) IGFs act on Giardia through a type 1 IGF receptor-like protein, which can bind IGF-II with higher affinity than IGF-I, and most likely possesses intrinsic phosphotyrosine kinase activity.	NCI,PEDIAT BRANCH,MOLEC GENET SECT,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	LUJAN, HD (corresponding author), NIAID,PARASIT DIS LAB,9000 ROCKVILLE PIKE,BLDG 4,RM B1-31,BETHESDA,MD 20892, USA.							ADAM RD, 1991, MICROBIOL REV, V55, P706, DOI 10.1128/MMBR.55.4.706-732.1991; [Anonymous], 1991, INSULIN LIKE GROWTH; Baxter R C, 1989, Prog Growth Factor Res, V1, P49, DOI 10.1016/0955-2235(89)90041-0; BLUM WF, 1986, ACTA ENDOCRINOL-COP, V111, P271, DOI 10.1530/acta.0.1110271; CZECH MP, 1989, CELL, V59, P235, DOI 10.1016/0092-8674(89)90281-X; DUNCAN M D, 1991, Gastroenterology, V100, pA638; DURONIO V, 1988, RECEPTOR BIOCH MET B, V12, P3; GILLIN FD, 1982, MOL CELL BIOL, V2, P369, DOI 10.1128/MCB.2.4.369; HARI J, 1987, EMBO J, V6, P3367, DOI 10.1002/j.1460-2075.1987.tb02658.x; HEIDE K, 1960, PLASMA PROTEINS, P545; HEINZERIAN P, 1991, ENDOCRINOLOGY, V129, P1769, DOI 10.1210/endo-129-4-1769; HIDE G, 1989, MOL BIOCHEM PARASIT, V36, P65; JAFFE D L, 1990, Gastroenterology, V98, pA659; KATO H, 1993, J BIOL CHEM, V268, P2655; KEISTER DB, 1983, T ROY SOC TROP MED H, V77, P487, DOI 10.1016/0035-9203(83)90120-7; KENNER KA, 1993, J BIOL CHEM, V268, P25455; KULL FC, 1983, J BIOL CHEM, V258, P6561; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAUTERIO TJ, 1987, PHYSIOL BEHAV, V40, P755, DOI 10.1016/0031-9384(87)90279-4; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUJAN HD, 1994, IN PRESS J EUK MICRO; MARTIN JL, 1986, J BIOL CHEM, V261, P8754; MASSAGUE J, 1982, J BIOL CHEM, V257, P5038; MINNITI CP, 1992, J BIOL CHEM, V267, P9000; NOLAN CM, 1987, J CELL BIOCHEM, V35, P137, DOI 10.1002/jcb.240350207; OH Y, 1993, GROWTH REGULAT, V3, P113; OKAMOTO T, 1990, CELL, V62, P709, DOI 10.1016/0092-8674(90)90116-V; PARKES JL, 1986, BIOCHEM BIOPH RES CO, V134, P427, DOI 10.1016/0006-291X(86)90581-4; PORAT R, 1991, SCIENCE, V254, P430, DOI 10.1126/science.1833820; READ LC, 1991, MODERN CONCEPTS INSU, P225; ROSENZWEIG SA, 1990, J BIOL CHEM, V265, P18030; ROTH RA, 1988, SCIENCE, V239, P1269, DOI 10.1126/science.2964085; SOGIN ML, 1989, SCIENCE, V243, P75, DOI 10.1126/science.2911720; STRACZEK J, 1990, J CHROMATOGR-BIOMED, V532, P237, DOI 10.1016/S0378-4347(00)83775-5; THOMPSON RCA, 1993, ADV PARASIT, V32, P71, DOI 10.1016/S0065-308X(08)60207-9; TONG PY, 1988, J BIOL CHEM, V263, P2585; VANDENBRANDE JL, 1990, ACTA ENDOCRINOL-COP, V122, P683, DOI 10.1530/acta.0.1220683; WIEDER SC, 1983, J PARASITOL, V69, P1181, DOI 10.2307/3280897; ZUMKELLER W, 1992, J PEDIATR GASTR NUTR, V15, P357, DOI 10.1097/00005176-199211000-00001	39	18	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13069	13072						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175729				2022-12-25	WOS:A1994NK18400004
J	MIDURA, RJ; EVANKO, SP; HASCALL, VC				MIDURA, RJ; EVANKO, SP; HASCALL, VC			PARATHYROID-HORMONE STIMULATES HYALURONAN SYNTHESIS IN AN OSTEOBLAST-LIKE CELL-LINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSTEOGENIC-SARCOMA CELLS; ISOLATED BONE-CELLS; CYCLIC-AMP; UMR 106-01; BIOCHEMICAL-CHARACTERIZATION; COLLAGEN-SYNTHESIS; EMBRYONIC CHICKEN; CULTURE SYSTEM; CALCIUM; PROTEOGLYCANS	An osteoblast-like cell line (UMR 106-01 BSP), cloned from a transplantable osteosarcoma, was cultured in the presence of parathyroid hormone (PTH1-34) and metabolically labeled with [S-35]sulfate, [H-3]glucosamine, and [H-3]tyrosine to determine proteoglycan, glycoconjugate, and protein synthesis, respectively. The synthesis of secreted proteins was substantially increased by PTH treatment. However, the synthesis of bone sialoprotein and proteoglycans was, at best, only moderately stimulated by PTH. Hyaluronan (HA) synthesis was dramatically stimulated by PTH in this cell line. A 5-6-fold increase in HA production was observed using 10(-8) M PTH, and even a 50% increase was detected using 10(-10) M PTH. The PTH-induced stimulation of HA synthesis was rapid and transient, reaching a maximum level (similar to 560 pmol of HA disaccharide equivalents/h/10(6) cells at 10(-8) M PTH) by 4-7 h after hormone exposure and returning to control levels by 12-15 h after the initial treatment. Lastly, the majority of this HA synthesis stimulated by PTH required only a short exposure (<90 min) to the hormone. These data suggest (i) that normal osteoblasts (or a sub-population of preosteoblasts) probably synthesize HA in response to PTH treatment, and (ii) that this PTH-induced synthesis of HA most likely involves some signal transduction mechanism(s).	NIDR, BONE RES BRANCH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)								BERESFORD JM, 1984, METAB BONE DIS RELAT, V5, P335; BIANCO P, 1991, CALCIFIED TISSUE INT, V49, P421, DOI 10.1007/BF02555854; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; BRECHT M, 1986, BIOCHEM J, V239, P445, DOI 10.1042/bj2390445; CHAMBERS TJ, 1985, ENDOCRINOLOGY, V116, P234, DOI 10.1210/endo-116-1-234; COCHRAN DL, 1987, CALCIFIED TISSUE INT, V41, P79, DOI 10.1007/BF02555249; CONOVER CA, 1993, ENDOCRINOLOGY, V132, P2525, DOI 10.1210/en.132.6.2525; DICKSON IR, 1993, BIOCHIM BIOPHYS ACTA, V1181, P15, DOI 10.1016/0925-4439(93)90084-E; DONAHUE HJ, 1988, J BIOL CHEM, V263, P13522; DUNLAY R, 1990, CALCIUM REGUL BONE M, V10, P24; DZIAK R, 1975, ENDOCRINOLOGY, V97, P1281, DOI 10.1210/endo-97-5-1281; EANES ED, 1992, GLYCOBIOLOGY, V2, P571, DOI 10.1093/glycob/2.6.571; FARNDALE RW, 1988, BIOCHEM J, V252, P263, DOI 10.1042/bj2520263; FELDMAN RS, 1980, ENDOCRINOLOGY, V107, P1137, DOI 10.1210/endo-107-4-1137; FISHER LW, 1983, J BIOL CHEM, V258, P6588; FORREST SM, 1985, CALCIFIED TISSUE INT, V37, P51, DOI 10.1007/BF02557679; HAMILTON JA, 1985, ENDOCRINOLOGY, V116, P2186, DOI 10.1210/endo-116-6-2186; JONES SJ, 1976, CELL TISSUE RES, V169, P449; JONGEN JWJM, 1993, J CELL PHYSIOL, V155, P36, DOI 10.1002/jcp.1041550106; KARPF DB, 1990, CALCIUM REGUL BONE M, V10, P15; KREAM BE, 1980, P NATL ACAD SCI-BIOL, V77, P5654, DOI 10.1073/pnas.77.10.5654; KUJAWA MJ, 1986, DEV BIOL, V113, P10, DOI 10.1016/0012-1606(86)90103-X; KUJAWA MJ, 1986, DEV BIOL, V114, P519, DOI 10.1016/0012-1606(86)90215-0; Laurent T.C, 1970, CHEM MOL BIOL INTERC, P703; LAURENT TC, 1986, FUNCTIONS PROTEOGLYC, P9; LORENZO JA, 1983, J CLIN INVEST, V72, P1924, DOI 10.1172/JCI111156; LUBEN RA, 1974, ENDOCRINOLOGY, V94, P737, DOI 10.1210/endo-94-3-737; LUBEN RA, 1976, ENDOCRINOLOGY, V98, P413, DOI 10.1210/endo-98-2-413; LUBEN RA, 1976, ENDOCRINOLOGY, V99, P526, DOI 10.1210/endo-99-2-526; MAJESKA RJ, 1982, CALCIFIED TISSUE INT, V34, P59, DOI 10.1007/BF02411210; MARTIN TJ, 1979, CLIN ORTHOP RELAT R, P247; MARTIN TJ, 1985, CHEM BIOL MINERALIZE, P311; MARTIN TJ, 1987, CLIN ENDOCRINOLOGY C, P1; MCQUILLAN DJ, 1991, BIOCHEM J, V277, P199, DOI 10.1042/bj2770199; MCQUILLAN DJ, 1992, BIOCHEM J, V285, P25, DOI 10.1042/bj2850025; MERRITT BS, 1992, J CELL PHYSIOL, V152, P520, DOI 10.1002/jcp.1041520311; MIDURA RJ, 1989, J BIOL CHEM, V264, P1414; MIDURA RJ, 1990, J BIOL CHEM, V265, P5285; MILLER SS, 1976, SCIENCE, V192, P1340, DOI 10.1126/science.1273593; OIKE Y, 1980, BIOCHEM J, V191, P193, DOI 10.1042/bj1910193; PARTRIDGE NC, 1980, FEBS LETT, V115, P139, DOI 10.1016/0014-5793(80)80744-7; PARTRIDGE NC, 1987, ENDOCRINOLOGY, V120, P1956, DOI 10.1210/endo-120-5-1956; PARTRIDGE NC, 1981, ENDOCRINOLOGY, V108, P220, DOI 10.1210/endo-108-1-220; PARTRIDGE NC, 1983, CANCER RES, V43, P4308; PARTRIDGE NC, 1989, MOL ENDOCRINOL, V3, P232, DOI 10.1210/mend-3-2-232; PARTRIDGE NC, 1981, ENDOCRINOLOGY, V108, P213, DOI 10.1210/endo-108-1-213; PASCHALAKIS P, 1993, BIOCHIM BIOPHYS ACTA, V1158, P129, DOI 10.1016/0304-4165(93)90006-T; PECK WA, 1977, ENDOCRINOLOGY, V100, P1357, DOI 10.1210/endo-100-5-1357; REID IR, 1987, AM J PHYSIOL, V253, pE45, DOI 10.1152/ajpendo.1987.253.1.E45; RIZZOLI RE, 1983, ENDOCRINOLOGY, V113, P1832, DOI 10.1210/endo-113-5-1832; SALUSTRI A, 1989, J BIOL CHEM, V264, P13840; SEVERSON AR, 1983, EXP CELL BIOL, V51, P70; SEVERSON AR, 1973, ENDOCRINOLOGY, V92, P1282, DOI 10.1210/endo-92-4-1282; SILVE CM, 1982, J CELL BIOL, V94, P379, DOI 10.1083/jcb.94.2.379; TURLEY EA, 1989, CIBA F SYMP, V143, P121; UNDERWOOD JCE, 1979, EUR J CANCER, V15, P1151, DOI 10.1016/0014-2964(79)90131-2; WONG GL, 1977, SCIENCE, V197, P663, DOI 10.1126/science.195343; WONG GL, 1984, J BIOL CHEM, V259, P4019; YANAGISHITA M, 1989, METHOD ENZYMOL, V179, P435; YANAGISHITA M, 1987, METHOD ENZYMOL, V138, P279; ZEBROWER ME, 1986, ANAL BIOCHEM, V157, P93, DOI 10.1016/0003-2697(86)90201-0	61	22	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13200	13206						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175749				2022-12-25	WOS:A1994NK18400026
J	ONDA, M; KUDO, S; FUKUDA, M				ONDA, M; KUDO, S; FUKUDA, M			GENOMIC ORGANIZATION OF GLYCOPHORIN-A GENE FAMILY REVEALED BY YEAST ARTIFICIAL CHROMOSOMES CONTAINING HUMAN GENOMIC DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; HOMINOID PRIMATES; B-GENES; IDENTIFICATION; SEQUENCE; POLYMORPHISMS; POLYMERASE; CLONES; CDNA; STA	Human glycophorins A, B, and E are members of the glycophorin gene family located at chromosome 4, band q31. These genes were apparently generated by two successive gene duplications, and the following evolutionary pathway was proposed based on the genomic sequences. First, the ancestral gene was duplicated, and one of the duplicated genes evolved directly into the GPA gene. Another duplicated gene acquired a 3' sequence from the precursor genomic segment and was then duplicated to yield glycophorin B and E genes (Onda, M., Kudo, S., Rearden, A., Mattei, M.-G. and Fukuda, M. (1993) Proc. Natl. Acad. Sci. USA 90, 7220-7224). Although the above hypothesis was proposed, it has been difficult to provide solid evidence for this, because no genomic clones studied encompass two members of the gene family. In this study we isolated several yeast artificial chromosome (YAC) clones encoding the entire region or a portion of this gene locus. The physical gene mapping was carried out by testing the presence of specific sequences using a polymerase chain reaction. Moreover, the YAC clones were digested by rare cutting restriction enzymes, and the resultant large DNA fragments were separated by pulse-field electrophoresis. Southern blot analyses of those DNA fragments were carried out using various probes encoding specific portions of glycophorin genes, The results obtained revealed that the distance between glycophorin A and B genes is almost the same as that between glycophorin B and E genes. Moreover, it was shown that no precursor genomic sequence was present in the sequences downstream from the GPB or GPE gene, suggesting that the duplication of glycophorin B/E progenitor gene was made through unequal crossing over homologous recombination. These combined results suggest that two duplication events took place tandemly to produce these three members of the glycophorin gene family.	LA JOLLA CANC RES FDN,CANC RES CTR,GLYCOBIOL PROGRAM,LA JOLLA,CA 92037	Sanford Burnham Prebys Medical Discovery Institute					NATIONAL CANCER INSTITUTE [R37CA033000, R01CA033000] Funding Source: NIH RePORTER; NCI NIH HHS [CA33000] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BURKE DT, 1987, SCIENCE, V236, P806, DOI 10.1126/science.3033825; CARTRON JP, 1992, PROTEIN BLOOD GROUP, P101; CARTRON JP, 1990, BLOOD CELL BIOCH, V1, P299; COOK PJL, 1981, ANN HUM GENET, V45, P39, DOI 10.1111/j.1469-1809.1981.tb00304.x; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FUKUDA M, 1993, SEMIN HEMATOL, V30, P138; FURTHMAYR H, 1978, NATURE, V271, P519, DOI 10.1038/271519a0; HUANG CH, 1991, J BIOL CHEM, V266, P23306; HUANG CH, 1993, J BIOL CHEM, V268, P4945; KUDO S, 1990, J BIOL CHEM, V265, P13825; KUDO S, 1990, J BIOL CHEM, V265, P1102; KUDO S, 1989, P NATL ACAD SCI USA, V86, P4619, DOI 10.1073/pnas.86.12.4619; LU WM, 1990, BIOCHEM GENET, V28, P399, DOI 10.1007/BF02401428; MAEDA N, 1986, P NATL ACAD SCI USA, V83, P7395, DOI 10.1073/pnas.83.19.7395; MANIATITIS T, 1982, MOL CLONING LABORATO; ONDA M, 1993, P NATL ACAD SCI USA, V90, P7220, DOI 10.1073/pnas.90.15.7220; PETERSON KR, 1993, P NATL ACAD SCI USA, V90, P7593, DOI 10.1073/pnas.90.16.7593; RAHUEL C, 1988, EUR J BIOCHEM, V172, P147, DOI 10.1111/j.1432-1033.1988.tb13866.x; REARDEN A, 1990, BIOCHEM GENET, V28, P209, DOI 10.1007/BF00561338; REARDEN A, 1993, J BIOL CHEM, V268, P2260; REARDEN A, 1990, J BIOL CHEM, V265, P9259; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCHWARTZ DC, 1984, CELL, V37, P67, DOI 10.1016/0092-8674(84)90301-5; SIBLEY CG, 1984, J MOL EVOL, V20, P2, DOI 10.1007/BF02101980; SIEBERT PD, 1987, P NATL ACAD SCI USA, V84, P6735, DOI 10.1073/pnas.84.19.6735; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TATE CG, 1989, BIOCHEM J, V263, P993, DOI 10.1042/bj2630993; TOMITA M, 1978, BIOCHEMISTRY-US, V17, P4756, DOI 10.1021/bi00615a025; VIGNAL A, 1990, GENE, V95, P289, DOI 10.1016/0378-1119(90)90374-Z; VIGNAL A, 1990, EUR J BIOCHEM, V191, P619, DOI 10.1111/j.1432-1033.1990.tb19166.x; WASNIOWSKA K, 1977, BIOCHEM BIOPH RES CO, V76, P385	31	15	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					13013	13020						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175721				2022-12-25	WOS:A1994NH71600097
J	RAMPERSAUD, A; HARLOCKER, SL; INOUYE, M				RAMPERSAUD, A; HARLOCKER, SL; INOUYE, M			THE OMPR PROTEIN OF ESCHERICHIA-COLI BINDS TO SITES IN THE OMPF PROMOTER REGION IN A HIERARCHICAL MANNER DETERMINED BY ITS DEGREE OF PHOSPHORYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE SIGNAL TRANSDUCTION; 2 REGULATORY COMPONENTS; DNA-BINDING; ACTIVATOR PROTEIN; TRANSCRIPTIONAL ACTIVATION; POSITIVE REGULATOR; GENETIC-ANALYSIS; ENVZ; OSMOREGULATION; EXPRESSION	In Escherichia coli the ompF gene encodes a major outer membrane porin protein that is differentially regulated by the OmpR protein. OmpR acts as a positive as well as a negative regulator of ompF expression by binding to DNA sequences in the ompF promoter region. The DNA binding activity of OmpR is itself regulated by phosphorylation through the kinase protein EnvZ. Phosphorylation is believed to change the function of OmpR from an activator to a repressor molecule. By using purified OmpR and various regions of the ompF promoter we show that phosphorylation causes binding of OmpR to a DNA region between the -40 to -100 region of the ompF promoter previously shown to be important for ompF expression. As the amount of OmpR phosphate increases, a binding site located at a further upstream -360 to -380 region was occupied. This latter site has been reported to be important for ompF repression. Fur ther experiments indicate that the -70 to -100 region is a high affinity site, while the -45 to -60 and -360 to -380 regions are low affinity sites. We also provide evidence that OmpR binding at the -360 to -380 region requires previous binding at downstream sequences, which is indicative of long range interactions between OmpR molecules. We intrepret our results in terms of a model for ompF regulation involving hierarchical binding by phosphorylated OmpR and potential DNA looping.	UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT BIOCHEM,PISCATAWAY,NJ 08854; OHIO STATE UNIV,DEPT PATHOL,COLUMBUS,OH 43210	Rutgers State University New Brunswick; Rutgers State University Medical Center; University System of Ohio; Ohio State University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM019043, R37GM019043] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM19043] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIBA H, 1989, J BIOL CHEM, V264, P14090; AIBA H, 1989, J BIOCHEM-TOKYO, V106, P5, DOI 10.1093/oxfordjournals.jbchem.a122817; CSONKA LN, 1989, MICROBIOL REV, V53, P121, DOI 10.1128/MMBR.53.1.121-147.1989; FORST S, 1988, J BACTERIOL, V170, P5080, DOI 10.1128/jb.170.11.5080-5085.1988; FORST S, 1990, J BACTERIOL, V172, P3473, DOI 10.1128/jb.172.6.3473-3477.1990; FORST S, 1987, J BIOL CHEM, V262, P16433; FORST S, 1989, P NATL ACAD SCI USA, V86, P6052, DOI 10.1073/pnas.86.16.6052; FORST SA, 1989, J BACTERIOL, V171, P2949, DOI 10.1128/jb.171.6.2949-2955.1989; HALL MN, 1979, J BACTERIOL, V140, P342, DOI 10.1128/JB.140.2.342-350.1979; HALL MN, 1981, J MOL BIOL, V151, P1, DOI 10.1016/0022-2836(81)90218-7; HALL MN, 1981, J MOL BIOL, V146, P23, DOI 10.1016/0022-2836(81)90364-8; HARLOCKER SL, 1993, J BACTERIOL, V175, P1956, DOI 10.1128/JB.175.7.1956-1960.1993; IGO MM, 1989, GENE DEV, V3, P598, DOI 10.1101/gad.3.5.598; IKENAKA K, 1988, MOL GEN GENET, V211, P538, DOI 10.1007/BF00425713; JO YL, 1986, J BIOL CHEM, V261, P5252; KANAMARU K, 1990, J BIOCHEM-TOKYO, V108, P483, DOI 10.1093/oxfordjournals.jbchem.a123225; LOPILATO J, 1986, MOL GEN GENET, V205, P285, DOI 10.1007/BF00430440; MATTHEWS KS, 1992, MICROBIOL REV, V56, P123, DOI 10.1128/MMBR.56.1.123-136.1992; MIZUNO T, 1988, J BIOL CHEM, V263, P1008; MIZUNO T, 1987, J BIOCHEM-TOKYO, V101, P387, DOI 10.1093/oxfordjournals.jbchem.a121923; MIZUNO T, 1987, GENE, V54, P57, DOI 10.1016/0378-1119(87)90347-7; NAKASHIMA K, 1991, J BIOL CHEM, V266, P10775; NINFA AJ, 1988, P NATL ACAD SCI USA, V85, P5492, DOI 10.1073/pnas.85.15.5492; NORIOKA S, 1986, J BIOL CHEM, V261, P7113; OSTROW KA, 1986, J BACTERIOL, V168, P736; RAMAKRISHNAN G, 1985, J BACTERIOL, V163, P82, DOI 10.1128/JB.163.1.82-87.1985; RAMPERSAUD A, 1989, J BIOL CHEM, V264, P18693; RAMPERSAUD A, 1991, J BACTERIOL, V173, P6882, DOI 10.1128/jb.173.21.6882-6888.1991; RUSSO FD, 1991, J MOL BIOL, V222, P567, DOI 10.1016/0022-2836(91)90497-T; SCHLEIF R, 1992, ANNU REV BIOCHEM, V61, P199, DOI 10.1146/annurev.bi.61.070192.001215; SIMONS RW, 1987, GENE, V53, P85, DOI 10.1016/0378-1119(87)90095-3; SLAUCH JM, 1991, J BACTERIOL, V173, P4039, DOI 10.1128/jb.173.13.4039-4048.1991; SLAUCH JM, 1989, J MOL BIOL, V210, P281, DOI 10.1016/0022-2836(89)90330-6; TOKISHITA S, 1990, J BIOCHEM-TOKYO, V108, P488, DOI 10.1093/oxfordjournals.jbchem.a123226; TSUI P, 1988, J BACTERIOL, V170, P4950, DOI 10.1128/jb.170.10.4950-4953.1988; TSUNG K, 1989, J BIOL CHEM, V264, P10104; VANALPHEN W, 1977, J BACTERIOL, V131, P623	37	79	79	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12559	12566						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175665				2022-12-25	WOS:A1994NH71600032
J	BASSING, CH; HOWE, DJ; SEGARINI, PR; DONAHOE, PK; WANG, XF				BASSING, CH; HOWE, DJ; SEGARINI, PR; DONAHOE, PK; WANG, XF			A SINGLE HETEROMERIC RECEPTOR COMPLEX IS SUFFICIENT TO MEDIATE BIOLOGICAL EFFECTS OF TRANSFORMING GROWTH-FACTOR-BETA LIGANDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SERINE THREONINE KINASE; II RECEPTOR; CELL-PROLIFERATION; ACTIVIN; CLONING; EXPRESSION; FAMILY	Transforming growth factor beta (TGF-beta), a multifunctional cytokine that regulates a variety of biological functions, signals through a heteromeric receptor complex of the type I and type II TGF-beta receptors. The type II receptor, a transmembrane serine-threonine kinase, was cloned based on its ability to directly bind TGF-beta. Recently, a number of candidate type I TGF-beta receptors have been isolated. Although only one of these transmembrane kinases (R4) has been shown to mediate TGF-beta-dependent gene activation, others bind TGF-beta when overexpressed in COS cells. Consequently, it has been postulated that the diversity of TGF-beta responses is generated through the association of distinct type I receptors with the type II TGF-beta receptor, thus creating receptor complexes of differential signaling capacities. In contrast to this model, we demonstrate that stable expression of only the R4 type I TGF-beta receptor in a mutant cell line lacking endogenous type I TGF-beta receptor was able to complex with the endogenous type II TGF-beta receptor and restore the effects of TGF-beta on inhibition of cell proliferation and activation of specific genes, regardless of which of the three mammalian isoforms of TGF-beta was used as the ligand. Therefore, R4 acts as a fully functional type I TGF-beta receptor and the differential effects of TGF-beta are likely mediated by a single receptor complex consisting of R4 and the type II receptor.	DUKE UNIV, MED CTR, DEPT PHARMACOL, DURHAM, NC 27710 USA; CELTRIX PHARMACEUT, SANTA CLARA, CA 95054 USA; MASSACHUSETTS GEN HOSP, PEDIAT SURG RES LAB, BOSTON, MA 02114 USA; MASSACHUSETTS GEN HOSP, DEPT SURG, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02114 USA	Duke University; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045746] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK45746] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; BASSING CH, 1994, SCIENCE, V263, P87, DOI 10.1126/science.8272871; BOURNE HR, 1989, ONCOGENES MOL ORIGIN, P97; BOYD FT, 1989, J BIOL CHEM, V264, P2272; EBNER R, 1993, SCIENCE, V260, P1344, DOI 10.1126/science.8388127; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; HE WW, 1993, DEV DYNAM, V196, P133, DOI 10.1002/aja.1001960207; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; Lin Herbert Y., 1993, Trends in Cell Biology, V3, P14, DOI 10.1016/0962-8924(93)90195-7; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LYONS RM, 1990, EUR J BIOCHEM, V187, P467, DOI 10.1111/j.1432-1033.1990.tb15327.x; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MATSUZAKI K, 1993, J BIOL CHEM, V268, P12719; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P421; TENDIJKE P, 1994, SCIENCE, V264, P101, DOI 10.1126/science.8140412; TENDIJKE P, 1993, ONCOGENE, V8, P2879; TSUCHIDA K, 1993, P NATL ACAD SCI USA, V90, P11242, DOI 10.1073/pnas.90.23.11242; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; YAMAZAKI Y, 1993, DNA SEQUENCE, V3, P297	20	52	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					14861	14864						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195115				2022-12-25	WOS:A1994NP73800004
J	ITABE, H; TAKESHIMA, E; IWASAKI, H; KIMURA, J; YOSHIDA, Y; IMANAKA, T; TAKANO, T				ITABE, H; TAKESHIMA, E; IWASAKI, H; KIMURA, J; YOSHIDA, Y; IMANAKA, T; TAKANO, T			A MONOCLONAL-ANTIBODY AGAINST OXIDIZED LIPOPROTEIN RECOGNIZES FOAM CELLS IN ATHEROSCLEROTIC LESIONS - COMPLEX-FORMATION OF OXIDIZED PHOSPHATIDYLCHOLINES AND POLYPEPTIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; ACTIVATING FACTOR ACETYLHYDROLASE; CHOLESTERYL ESTER ACCUMULATION; MACROPHAGE SCAVENGER RECEPTOR; ENDOTHELIAL-CELLS; LIPID-PEROXIDATION; APOLIPOPROTEIN-B; ARACHIDONIC-ACID; LINOLEIC-ACID; OXIDATION	In this study we have used homogenates of human atheromatous plaque as immunogen to establish a murine monoclonal antibody which recognizes oxidized low density lipoprotein (LDL). This monoclonal antibody, FOH1a/DLH3, reacted with oxidized LDL, but enzyme-linked immunosorbent assay showed that it had no reaction with native, acetylated, or malonaldehydetreated LDL. The antibody cross reacted with oxidized high density lipoprotein, suggesting that specific sequences of the apolipoprotein B are not essential for antigen recognition by the antibody. Immunohistochemical analysis of thin paraffin sections from human coronary arteries showed that foam cells derived from macrophages in atherosclerotic lesions were heavily stained by this antibody. Several other structures in the lesions, including swollen collagen fibers, cellular debris in necrotic cores, and endothelial cells, were moderately stained. The epitope of this antibody was characterized by a model antigen generating system using ferrous ion-induced peroxidation of lipids. When the total lipid fraction extracted from LDL was treated with the ferrous ion-induced peroxidation system, the reaction mixture was recognized by the antibody. Antigenic product(s) was produced only when phosphatidylcholine (PC) was treated with the ferrous ion-induced peroxidation, other lipids failed to react to the antibody. To investigate the possible formation of a complex of antigenic product with a polypeptide, a synthetic peptide and a rabbit antiserum against the peptide were used. Reaction mixture of ferrous ion-induced peroxidation of PC in the presence of the peptide was added to a microtiter well precoated with the monoclonal antibody FOH1a/DLH3. After washing, the peptide remaining in the well was detected with rabbit antiserum against the peptide, whereas no reactivity was observed when peptide alone was added to the well. Binding of the antigenic complex to the precoated monoclonal antibody was competed by oxidized PC produced in the absence of any polypeptide. We conclude that oxidized phospholipid product(s) is the epitope of the monoclonal antibody and that the oxidized phospholipid forms complexes with polypeptides. The antigenic materials are detected in foam cells in atherosclerotic lesions.	VESSEL RES LAB INC,KANAGAWA 25901,JAPAN; YAMANASHI MED UNIV,DEPT PATHOL,YAMANASHI 40938,JAPAN	University of Yamanashi	ITABE, H (corresponding author), TEIKYO UNIV,FAC PHARMACEUT SCI,DEPT MICROBIOL & MOLEC PATHOL,SAGAMIKO,KANAGAWA 19901,JAPAN.		板部板部, 洋之/ABC-7746-2020	Imanaka, Tsuneo/0000-0003-4677-1356				BASU SK, 1976, P NATL ACAD SCI USA, V73, P3178, DOI 10.1073/pnas.73.9.3178; BHADRA S, 1991, BIOCHEM BIOPH RES CO, V176, P431, DOI 10.1016/0006-291X(91)90942-Z; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOYD HC, 1989, AM J PATHOL, V135, P815; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; Buege J A, 1978, Methods Enzymol, V52, P302; CARPENTER KLH, 1993, BIOCHIM BIOPHYS ACTA, V1167, P121, DOI 10.1016/0005-2760(93)90151-X; ENDEMANN G, 1993, J BIOL CHEM, V268, P11811; FOGELMAN AM, 1980, P NATL ACAD SCI-BIOL, V77, P2214, DOI 10.1073/pnas.77.4.2214; GALIS ZS, 1992, LAB INVEST, V66, P624; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; GONEN B, 1987, ATHEROSCLEROSIS, V65, P265, DOI 10.1016/0021-9150(87)90042-6; GRAHAM A, 1993, FEBS LETT, V330, P181, DOI 10.1016/0014-5793(93)80269-Z; HARBERLAND ME, 1988, SCIENCE, V241, P215; HOFF HF, 1991, ARTERIOSCLER THROMB, V11, P1209, DOI 10.1161/01.ATV.11.5.1209; HOFF HF, 1992, J BIOL CHEM, V267, P602; ITABE H, 1988, BIOCHIM BIOPHYS ACTA, V962, P8; JESSUP W, 1992, BIOCHIM BIOPHYS ACTA, V1126, P167, DOI 10.1016/0005-2760(92)90287-6; KAMIDO H, 1992, FEBS LETT, V304, P269, DOI 10.1016/0014-5793(92)80635-T; KIMURA J, 1986, VIRCHOWS ARCH A, V410, P159; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; KODAMA T, 1988, P NATL ACAD SCI USA, V85, P9238, DOI 10.1073/pnas.85.23.9238; LOUGHEED M, 1991, J BIOL CHEM, V266, P14519; MAHLEY RW, 1979, J CLIN INVEST, V64, P743, DOI 10.1172/JCI109518; MANGIN EL, 1993, CIRC RES, V72, P161, DOI 10.1161/01.RES.72.1.161; MATSUMOTO A, 1990, P NATL ACAD SCI USA, V87, P9133, DOI 10.1073/pnas.87.23.9133; MOWRI H, 1988, BIOCHIM BIOPHYS ACTA, V963, P208, DOI 10.1016/0005-2760(88)90282-2; OBRIEN PJ, 1969, CAN J BIOCHEM CELL B, V47, P485, DOI 10.1139/o69-076; PLAINSKI W, 1990, ARTERIOSCLEROSIS, V10, P325; REDGRAVE TG, 1975, ANAL BIOCHEM, V65, P42, DOI 10.1016/0003-2697(75)90488-1; ROMA P, 1992, J LIPID RES, V33, P819; ROSENFELD ME, 1990, ARTERIOSCLEROSIS, V10, P336, DOI 10.1161/01.ATV.10.3.336; SATTLER W, 1991, BIOCHIM BIOPHYS ACTA, V1081, P65, DOI 10.1016/0005-2760(91)90251-C; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STANTON LW, 1992, J BIOL CHEM, V267, P22446; STEINBRECHER UP, 1989, J LIPID RES, V30, P305; STEINBRECHER UP, 1984, P NATL ACAD SCI-BIOL, V81, P3883, DOI 10.1073/pnas.81.12.3883; STREMLER KE, 1989, J BIOL CHEM, V264, P5331; TANAKA T, 1993, BIOCHIM BIOPHYS ACTA, V1166, P264, DOI 10.1016/0005-2760(93)90107-K; TOKUMURA A, 1988, BIOCHEM BIOPH RES CO, V155, P863, DOI 10.1016/S0006-291X(88)80575-8; TRAKHT IN, 1986, ATHEROSCLER REV, V17, P51; VIJAYAGOPAL P, 1985, BIOCHIM BIOPHYS ACTA, V837, P251, DOI 10.1016/0005-2760(85)90048-7; WANG T, 1991, BIOCHIM BIOPHYS ACTA, V1084, P129, DOI 10.1016/0005-2760(91)90211-Y; WANG T, 1992, J LIPID RES, V33, P525; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499; YLAHERTTUALA S, 1989, J CLIN INVEST, V84, P1086, DOI 10.1172/JCI114271; ZHOU X, 1992, J LIPID RES, V33, P1233	47	265	273	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					15274	15279						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195164				2022-12-25	WOS:A1994NP73800063
J	MATRINGE, M; CAMADRO, JM; JOYARD, J; DOUCE, R				MATRINGE, M; CAMADRO, JM; JOYARD, J; DOUCE, R			LOCALIZATION OF FERROCHELATASE ACTIVITY WITHIN MATURE PEA-CHLOROPLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEVELOPING CUCUMBER CHLOROPLASTS; HORDEUM-VULGARE-L; PROTOPORPHYRINOGEN OXIDASE; PROTOCHLOROPHYLLIDE OXIDOREDUCTASE; SPINACH-CHLOROPLASTS; MOLECULAR-CLONING; ETIOLATED BARLEY; HERBICIDES; GENE; ETIOPLASTS	Precise localization within the chloroplast of the membrane-bound enzymes involved in heme and chlorophyll biosynthetic pathways is of central importance for better understanding the regulation of the carbon flow into these two pathways. In this study we examine the localization of ferrochelatase activity within mature pea chloroplasts. Our results provide evidence that chloroplast ferrochelatase is associated only with thylakoid membranes. The presence of ferrochelatase in chloroplast thylakoids emphasizes the role of this membrane system in chloroplast protoheme biosynthesis. Furthermore, these results raise the possibility that heme and chlorophyll biosynthesis are compartmentalized in two distinct membrane systems within mature chloroplasts.	CEN,DEPT BIOL MOLEC & STRUCT,PHYSIOL CELLULAIRE VEGETALE LAB,CNRS,URA 576,F-38041 GRENOBLE,FRANCE; UNIV GRENOBLE 1,F-38041 GRENOBLE,FRANCE; UNIV PARIS 07,INST JACQUES MONOD,BIOCHIM PORRPHYRINES LAB,CNRS,F-75251 PARIS,FRANCE	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite				Camadro, Jean-Michel/0000-0002-8549-2707				[Anonymous], METHODS CHLOROPLAST; ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; Beale S. I., 1990, BIOSYNTHESIS HEME CH, P287; BLOCK MA, 1980, BIOCHIM BIOPHYS ACTA, V631, P210, DOI 10.1016/0304-4165(80)90069-0; BROWN SB, 1984, BIOCHEM J, V220, P861, DOI 10.1042/bj2200861; CAMADRO JM, 1984, J BIOL CHEM, V259, P5678; CAMADRO JM, 1981, BIOCHIMIE, V63, P463, DOI 10.1016/S0300-9084(81)80022-3; Dailey H. A., 1990, BIOSYNTHESIS HEME CH, P123; DEHESH K, 1986, PLANTA, V169, P172, DOI 10.1007/BF00392311; DEMATTEIS F, 1980, BIOCHEM J, V187, P285, DOI 10.1042/bj1870285; DORNE AJ, 1990, P NATL ACAD SCI USA, V87, P71, DOI 10.1073/pnas.87.1.71; Douce R., 1979, Advances in Botanical Research, V7, P1, DOI 10.1016/S0065-2296(08)60087-7; FRUSTACI JM, 1992, J BACTERIOL, V174, P4223, DOI 10.1128/JB.174.13.4223-4229.1992; FUESLER TP, 1984, PLANT PHYSIOL, V75, P662, DOI 10.1104/pp.75.3.662; FUHRHOP JH, 1975, PORPHYRINS METALLOPO, P806; HANSSON M, 1992, J BACTERIOL, V174, P8081, DOI 10.1128/JB.174.24.8081-8093.1992; JACOBS JM, 1991, PLANT PHYSIOL, V97, P197, DOI 10.1104/pp.97.1.197; JONES MS, 1970, BIOCHEM J, V119, P453, DOI 10.1042/bj1190453; JONES OTG, 1968, BIOCHEM J, V107, P113, DOI 10.1042/bj1070113; JONES OTG, 1967, BIOCHEM BIOPH RES CO, V28, P671, DOI 10.1016/0006-291X(67)90367-1; JOYARD J, 1990, J BIOL CHEM, V265, P21820; LABBEBOIS R, 1990, J BIOL CHEM, V265, P7278; LABBEBOIS R, 1993, METAL IONS FUNGI; LEE HJ, 1993, PLANT PHYSIOL, V102, P881, DOI 10.1104/pp.102.3.881; LITTLE HN, 1976, BIOCHEM J, V156, P309, DOI 10.1042/bj1560309; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATRINGE M, 1992, J BIOL CHEM, V267, P4646; MATRINGE M, 1992, EUR J BIOCHEM, V209, P861, DOI 10.1111/j.1432-1033.1992.tb17358.x; MIYAMOTO K, 1991, J MOL BIOL, V219, P393, DOI 10.1016/0022-2836(91)90180-E; NAKAHASHI Y, 1990, BIOCHEM BIOPH RES CO, V173, P748, DOI 10.1016/S0006-291X(05)80099-3; PORRA RJ, 1968, BIOCHEM J, V108, P343, DOI 10.1042/bj1080343; PORRA RJ, 1963, BIOCHEM J, V87, P181, DOI 10.1042/bj0870181; SATO N, 1993, EMBO J, V12, P555, DOI 10.1002/j.1460-2075.1993.tb05687.x; SCALLA R, 1993, REV WEED SCI, V6, P103; SHAW P, 1985, EUR J CELL BIOL, V39, P50; TAKETANI S, 1990, J BIOL CHEM, V265, P19377; WALKER CJ, 1991, PLANT PHYSIOL, V95, P1189, DOI 10.1104/pp.95.4.1189	37	29	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					15010	15015						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195137				2022-12-25	WOS:A1994NP73800028
J	PENN, RB; BENOVIC, JL				PENN, RB; BENOVIC, JL			STRUCTURE OF THE HUMAN GENE ENCODING THE BETA-ADRENERGIC-RECEPTOR KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-2-ADRENERGIC RECEPTOR; CHROMOSOMAL LOCALIZATION; MOLECULAR-CLONING; RHODOPSIN KINASE; PROTEIN; FAMILY; EXPRESSION; TRANSCRIPTION; TRANSLOCATION; MEMBER	The beta-adrenergic receptor kinase (beta ARK) specifically phosphorylates the agonist-occupied forms of the beta(2)-adrenergic receptor and related G protein-coupled receptors. beta ARK is one of the best characterized members of a growing family of G protein-coupled receptor kinases. In this article we report the isolation and structural organization of the human beta ARK gene. The gene spans approximately 23 kilobases and is composed of 21 exons interrupted by 20 introns. Exon sizes range from 52 bases (exon 7) to over 1200 bases (exon 21), intron sizes from 68 bases (intron L) to 10.8 kilobases (intron A). The splice sites for donor and acceptor were in agreement with the canonical GT/AG rule. Functional regions of beta ARK are described with respect to their location within the exon-intron organization of the gene. Primer extension and RNase protection assays suggest a major transcription start site approximately 246 bases upstream of the start ATG. Sequence analysis of the 5'-flanking/promoter region reveals many features characteristic of mammalian housekeeping genes, i.e. the lack of a TATA box, an absent or nonstandard positioned CAAT box, high GC content, and the presence of Sp1-binding sites. The extraordinarily high GC content of the 5'-flanking region (>80%) helps define this region as a CpG island that may be a principal regulator of beta ARK expression.	THOMAS JEFFERSON UNIV, JEFFERSON CANC INST, DEPT PHARMACOL, PHILADELPHIA, PA 19107 USA	Jefferson University								Ambrose Christine, 1992, Human Molecular Genetics, V1, P697, DOI 10.1093/hmg/1.9.697; ARRIZA JL, 1992, J NEUROSCI, V12, P4045; BENOVIC JL, 1991, J BIOL CHEM, V266, P14939; BENOVIC JL, 1987, J BIOL CHEM, V262, P9026; BENOVIC JL, 1991, FEBS LETT, V283, P122, DOI 10.1016/0014-5793(91)80568-N; BENOVIC JL, 1987, J BIOL CHEM, V262, P17251; BENOVIC JL, 1989, SCIENCE, V246, P235, DOI 10.1126/science.2552582; BENOVIC JL, 1993, J BIOL CHEM, V268, P19521; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BLAKE MC, 1990, MOL CELL BIOL, V10, P6632, DOI 10.1128/MCB.10.12.6632; CASSILL JA, 1991, P NATL ACAD SCI USA, V88, P11067, DOI 10.1073/pnas.88.24.11067; CAWLEY KC, 1993, J BIOL CHEM, V268, P1194; CHUANG TT, 1992, J BIOL CHEM, V267, P6886; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; FRASER CM, 1989, J BIOL CHEM, V264, P11754; GUREVICH VV, 1993, J BIOL CHEM, V268, P11628; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; INGLESE J, 1993, J BIOL CHEM, V268, P23735; KAGEYAMA R, 1989, CELL, V59, P815, DOI 10.1016/0092-8674(89)90605-3; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; KUNAPULI P, 1994, J BIOL CHEM, V269, P10209; KUNAPULI P, 1993, P NATL ACAD SCI USA, V90, P5588, DOI 10.1073/pnas.90.12.5588; KWATRA MM, 1993, J BIOL CHEM, V268, P9161; KWATRA MM, 1989, BIOCHEMISTRY-US, V28, P4543, DOI 10.1021/bi00437a005; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; LORENZ W, 1991, P NATL ACAD SCI USA, V88, P8715, DOI 10.1073/pnas.88.19.8715; MAYOR F, 1987, J BIOL CHEM, V262, P6468; MCKNIGHT S, 1986, CELL, V46, P795, DOI 10.1016/0092-8674(86)90061-9; MCKNIGHT SL, 1982, SCIENCE, V217, P316, DOI 10.1126/science.6283634; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; NUDEL U, 1983, NUCLEIC ACIDS RES, V11, P1759, DOI 10.1093/nar/11.6.1759; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; PALCZEWSKI K, 1993, J BIOL CHEM, V268, P6004; PALCZEWSKI K, 1991, TRENDS BIOCHEM SCI, V16, P387, DOI 10.1016/0968-0004(91)90157-Q; PALCZEWSKI K, 1992, J BIOL CHEM, V267, P18991; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; PIECHACZYK M, 1984, NUCLEIC ACIDS RES, V12, P6951, DOI 10.1093/nar/12.18.6951; PRESTRIDGE DS, 1991, COMPUT APPL BIOSCI, V7, P203; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHEETS MD, 1990, NUCLEIC ACIDS RES, V18, P5799, DOI 10.1093/nar/18.19.5799; STRASSER RH, 1986, P NATL ACAD SCI USA, V83, P6362, DOI 10.1073/pnas.83.17.6362; TAYLOR SS, 1993, TRENDS BIOCHEM SCI, V18, P84, DOI 10.1016/0968-0004(93)80001-R; Vega Laso Maria R., 1993, Journal of Biological Chemistry, V268, P6453	47	37	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					14924	14930						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195124				2022-12-25	WOS:A1994NP73800015
J	CUOZZO, JW; SAHAGIAN, GG				CUOZZO, JW; SAHAGIAN, GG			LYSINE IS A COMMON DETERMINANT FOR MANNOSE PHOSPHORYLATION OF LYSOSOMAL PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							6-PHOSPHATE RECEPTOR; ENZYME N-ACETYLGLUCOSAMINE-1-PHOSPHOTRANSFERASE; CATHEPSIN-L; RECOGNITION; SECRETION; OLIGOSACCHARIDES; FIBROBLASTS; PROTEASE	The phosphorylation of lysosomal enzymes on high mannose residues is the first step in the targeting of these enzymes to lysosomes in a wide range of mammalian cells. Phosphorylated lysosomal enzymes bind to mannose 6-phosphate receptors, which divert them from the secretory pathway and direct them toward the lysosome. We have been investigating the basis for the specific recognition of lysosomal enzymes by UDP-Glc-NAc:lysosomal enzyme GlcNAc-1-phosphotransferase by using the precursor form of the lysosomal cysteine protease, cathepsin L, as a model lysosomal enzyme in an in vitro assay for mannose phosphorylation. Cathepsin L was found to be phosphorylated in vitro with the same efficiency as other lysosomal enzymes and to contain a conformationally sensitive protein signal that is recognized by phosphotransferase. Biochemical modification of lysine residues on cathepsin L with sulfo-N-hydroxysuccinimide acetate prevented the enzyme from being phosphorylated, indicating that lysine is an important component of the signal. The modification itself did not cause any major conformational changes in cathepsin L. When the same modification was performed on a number of other lysosomal enzymes, phosphorylation was also inhibited. Thus, we conclude that lysine residues are important features of lysosomal enzyme phosphotransferase recognition sites in general, and we discuss the implications of this finding in the ongoing efforts to define the phosphotransferase recognition site.	TUFTS UNIV,SCH MED,DEPT PHYSIOL,BOSTON,MA 02111; TUFTS UNIV,SCH VET MED,BOSTON,MA 02111	Tufts University; Tufts University				Cuozzo, John/0000-0002-6229-0395	NIDDK NIH HHS [DK36632] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036632] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARANSKI TJ, 1991, J BIOL CHEM, V266, P23365; BARANSKI TJ, 1992, J BIOL CHEM, V267, P23342; BARANSKI TJ, 1990, CELL, V63, P281, DOI 10.1016/0092-8674(90)90161-7; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; BAUMBACH GA, 1984, P NATL ACAD SCI-BIOL, V81, P2985, DOI 10.1073/pnas.81.10.2985; CHAO HHJ, 1990, EMBO J, V9, P3507, DOI 10.1002/j.1460-2075.1990.tb07559.x; CUATRECASAS P, 1972, BIOCHEMISTRY-US, V11, P2291, DOI 10.1021/bi00762a013; DISTLER J, 1979, P NATL ACAD SCI USA, V76, P4235, DOI 10.1073/pnas.76.9.4235; DONG JM, 1989, J BIOL CHEM, V264, P7377; DONG JM, 1990, J BIOL CHEM, V265, P4210; GAL S, 1985, J CELL BIOL, V100, P535, DOI 10.1083/jcb.100.2.535; GAL S, 1986, J BIOL CHEM, V261, P1760; GONZALEZNORIEGA A, 1980, J CELL BIOL, V85, P839, DOI 10.1083/jcb.85.3.839; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LANG L, 1984, J BIOL CHEM, V259, P4663; LAZZARINO D, 1990, J BIOL CHEM, V265, P11864; REITMAN ML, 1981, J BIOL CHEM, V256, P1977; REITMAN ML, 1984, METHOD ENZYMOL, V107, P163; RIDDLES PW, 1979, ANAL BIOCHEM, V94, P75, DOI 10.1016/0003-2697(79)90792-9; Schmid FX., 1989, SPECTRAL METHODS CHA, P251; STEARNS NA, 1990, ARCH BIOCHEM BIOPHYS, V283, P447, DOI 10.1016/0003-9861(90)90666-M; TAO K, 1994, IN PRESS ARCH BIOCH	22	20	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14490	14496						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	8182054				2022-12-25	WOS:A1994NM06500030
J	BENNETT, BD; WANG, ZY; KUANG, WJ; WANG, AL; GROOPMAN, JE; GOEDDEL, DV; SCADDEN, DT				BENNETT, BD; WANG, ZY; KUANG, WJ; WANG, AL; GROOPMAN, JE; GOEDDEL, DV; SCADDEN, DT			CLONING AND CHARACTERIZATION OF HTK, A NOVEL TRANSMEMBRANE TYROSINE KINASE OF THE EPH SUBFAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; CONSERVED FEATURES; RECEPTOR; GENE; FAMILY; IDENTIFICATION; SEQUENCE; MOUSE; PHOSPHORYLATION; CLASSIFICATION	Using a polymerase chain reaction based strategy, we identified a novel transmembrane tyrosine kinase in CD34+ human bone marrow cells and a human hepatocellular carcinoma cell line, Hep3B. This protein, hepatoma transmembrane kinase or Htk, shares amino acid similarity with the EPH subfamily of tyrosine kinases. The HTK gene is located on human chromosome 7. The predicted 987-amino acid sequence of Htk includes a transmembrane region and signal sequence. In the predicted extracellular domain, a cysteine-rich region and tandem fibronectin type III repeats are present while a single uninterrupted catalytic domain is present in the intracellular domain. These features are consistent with other members of the Eph subfamily. Antibodies raised against Htk extracellular domain immunoprecipitated a 120-kDa protein from either in vitro translated HTK or Hep3B cells which localized primarily to the Hep3B membrane subcellular fraction. Purified in vitro translated Htk was enzymatically active and autophosphorylated on tyrosine in kinase assays. Furthermore, antibodies against Htk ECD were agonistic, inducing Htk tyrosine phosphorylation in transfected NIH3T3 cells. Northern blot analysis demonstrated a single HTK transcript abundantly present in placenta and in a range of primary tissues and malignant cell lines. HTK appears to be expressed in fetal but not adult brain and in primitive and myeloid but not lymphoid hematopoietic cells. The novel transmembrane protein, Htk, may function as a receptor with an expression pattern suggesting a role in events mediating differentiation and development.	HARVARD UNIV, NEW ENGLAND DEACONESS HOSP, SCH MED, DIV HEMATOL ONCOL, BOSTON, MA 02215 USA; GENENTECH INC, San Francisco, CA 94080 USA	Harvard University; Harvard Medical School; Roche Holding; Genentech								BAER M R, 1992, Current Opinion in Oncology, V4, P24, DOI 10.1097/00001622-199202000-00005; BENNETT BD, 1991, J BIOL CHEM, V266, P23060; BOHME B, 1993, ONCOGENE, V8, P2857; COOPER JA, 1984, J BIOL CHEM, V259, P7835; GILARDIHEBENSTREIT P, 1992, ONCOGENE, V7, P2499; GORMAN CM, 1990, DNA PROTEIN ENG TECH, V2, P3; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Hanks SK, 1991, CURR OPIN STRUC BIOL, V1, P369, DOI 10.1016/0959-440X(91)90035-R; HAWKINS JD, 1988, NUCLEIC ACIDS RES, V16, P9893, DOI 10.1093/nar/16.21.9893; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; HUNTER T, 1991, METHOD ENZYMOL, V200, P3; HUNTER T, 1982, J BIOL CHEM, V257, P4843; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LETWIN K, 1988, ONCOGENE, V3, P621; LHOTAK V, 1991, MOL CELL BIOL, V11, P2496, DOI 10.1128/MCB.11.5.2496; LHOTAK V, 1993, MOL CELL BIOL, V13, P7071, DOI 10.1128/MCB.13.11.7071; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; MAISONPIERRE PC, 1993, ONCOGENE, V8, P3277; MARU Y, 1990, MOL CELL BIOL, V10, P435; MATTHEWS W, 1991, CELL, V65, P1143, DOI 10.1016/0092-8674(91)90010-V; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; NIETO MA, 1992, DEVELOPMENT, V116, P1137; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; PASQUALE EB, 1991, CELL REGUL, V2, P523, DOI 10.1091/mbc.2.7.523; PASQUALE EB, 1992, J NEUROSCI, V12, P3956; PATSCHINSKY T, 1982, P NATL ACAD SCI-BIOL, V79, P973, DOI 10.1073/pnas.79.4.973; PAWSON T, 1990, TRENDS GENET, V6, P350, DOI 10.1016/0168-9525(90)90276-C; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; SAJJADI FG, 1993, ONCOGENE, V8, P1807; SAJJADI FG, 1991, NEW BIOL, V3, P769; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SKORSTENGAARD K, 1986, EUR J BIOCHEM, V161, P441, DOI 10.1111/j.1432-1033.1986.tb10464.x; SMITH MW, 1988, J MOL EVOL, V27, P45, DOI 10.1007/BF02099729; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WICKS IP, 1992, P NATL ACAD SCI USA, V89, P1611, DOI 10.1073/pnas.89.5.1611; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	41	75	100	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					14211	14218						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188704				2022-12-25	WOS:A1994NL60600074
J	REMMERS, AE; POSNER, R; NEUBIG, RR				REMMERS, AE; POSNER, R; NEUBIG, RR			FLUORESCENT GUANINE-NUCLEOTIDE ANALOGS AND G-PROTEIN ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING REGULATORY PROTEINS; INTRINSIC FLUORESCENCE; ALPHA-SUBUNIT; CONFORMATIONAL CHANGE; CRYSTAL-STRUCTURE; MOLECULAR SWITCH; HIGH-AFFINITY; RAS PROTEIN; GTP; RECEPTOR	The N-methyl-3'-O-anthranoyl (MANT) guanine nucleotide analogs are useful environmentally sensitive fluorescent probes for studying G protein mechanisms. Both MANT-GTF gamma S (mGTP gamma S) and MANT-GTP (mGTP) displayed a magnesium-dependent increase in fluorescence upon binding to bovine brain G(o). A much greater increase in MANT-guanine nucleotide fluorescence was observed with excitation at 280 nm compared with 350 nm, due to energy transfer from tryptophan in G(o). G(o)- bound mGTP gamma S displays a blue-shift in its emission spectrum indicating a nonpolar environment for the G(o)- bound MANT For the hydrolyzable analog, mGTP, the increase in fluorescence is followed by a decrease as it is hydrolyzed to mGDP. Unexpectedly, dissociation of mGDP was fast (t(1/2) 1.7 s) by comparison with GDP itself (t(1/2) 120 s). Binding of mGTP gamma S to G(o) was slow, but mastoparan increased the rate approximately 4-fold. For mGTP, mastoparan increased both the rate of binding and the peak fluorescence, even at saturating mGTP concentrations. Modeling the mGTP fluorescence kinetics in the presence and absence of mastoparan results in two novel conclusions. First, mGTP does not fully activate the G protein, even when bound. Second, mastoparan appears to increase the rate of the G protein conformational activation step, in addition to its known effect on GDP release.	UNIV MICHIGAN, SCH MED, DEPT PHARMACOL, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, SCH MED, DEPT INTERNAL MED, ANN ARBOR, MI 48109 USA; NO ARIZONA UNIV, DEPT CHEM, FLAGSTAFF, AZ 86011 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Northern Arizona University				Neubig, Richard/0000-0003-0501-0008; Remmers, Ann/0000-0002-2465-7651	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000042] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM014654] Funding Source: NIH RePORTER; NCRR NIH HHS [MO1 RR00042] Funding Source: Medline; NIGMS NIH HHS [GM 39561, GM 14654] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENNETT N, 1985, J BIOL CHEM, V260, P4156; BERLOT CH, 1992, CELL, V68, P911, DOI 10.1016/0092-8674(92)90034-A; BRANDT DR, 1986, J BIOL CHEM, V261, P1656; BRUNGER AT, 1990, P NATL ACAD SCI USA, V87, P4849, DOI 10.1073/pnas.87.12.4849; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; ECCLESTON JF, 1991, BIOCHEM SOC T, V19, P432, DOI 10.1042/bst0190432; FAUROBERT E, 1993, EMBO J, V12, P4191, DOI 10.1002/j.1460-2075.1993.tb06103.x; FERGUSON KM, 1986, J BIOL CHEM, V261, P7393; FLORIO VA, 1989, J BIOL CHEM, V264, P3909; FREISSMUTH M, 1989, FASEB J, V3, P2125, DOI 10.1096/fasebj.3.10.2546847; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GUY PM, 1990, BIOCHEMISTRY-US, V29, P6954, DOI 10.1021/bi00482a003; HAZLETT TL, 1990, BIOPHYS J, V57, P289; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P762; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P757; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P752; HIGASHIJIMA T, 1988, J BIOL CHEM, V263, P6491; HIGASHIJIMA T, 1990, J BIOL CHEM, V265, P14176; HIGASHIJIMA T, 1991, METHOD ENZYMOL, V195, P321; HIRATSUKA T, 1983, BIOCHIM BIOPHYS ACTA, V742, P496, DOI 10.1016/0167-4838(83)90267-4; HOLBROOK SR, 1989, P NATL ACAD SCI USA, V86, P1751, DOI 10.1073/pnas.86.6.1751; KATADA T, 1987, FEBS LETT, V213, P353, DOI 10.1016/0014-5793(87)81521-1; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KIM MH, 1987, BIOCHEMISTRY-US, V26, P3664, DOI 10.1021/bi00386a061; Lakowicz J.R., 2010, PRINCIPLE FLUORESCEN, DOI 10.1007/978-0-387-46312-4/COVER; MASTERS SB, 1986, PROTEIN ENG, V1, P47, DOI 10.1093/protein/1.1.47; MAZZONI MR, 1993, J PROTEIN CHEM, V12, P215, DOI 10.1007/BF01026043; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; MILLS JS, 1991, BIOPHYS J, V59, P348; NEAL SE, 1990, P NATL ACAD SCI USA, V87, P3562, DOI 10.1073/pnas.87.9.3562; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; NORTHUP JK, 1982, J BIOL CHEM, V257, P1416; PHILLIPS WJ, 1988, J BIOL CHEM, V263, P15498; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SCHLICHTING I, 1990, NATURE, V345, P309, DOI 10.1038/345309a0; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; VANMEURS KP, 1987, P NATL ACAD SCI USA, V84, P3107, DOI 10.1073/pnas.84.10.3107; WITTINGHOFER A, 1991, TRENDS BIOCHEM SCI, V16, P382, DOI 10.1016/0968-0004(91)90156-P	38	61	63	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					13771	13778						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188654				2022-12-25	WOS:A1994NL60600012
J	KONDA, Y; GANTZ, I; DELVALLE, J; SHIMOTO, Y; MIWA, H; YAMADA, T				KONDA, Y; GANTZ, I; DELVALLE, J; SHIMOTO, Y; MIWA, H; YAMADA, T			INTERACTION OF DUAL INTRACELLULAR SIGNALING PATHWAYS ACTIVATED BY THE MELANOCORTIN-3 RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; CYCLIC-AMP; INOSITOL PHOSPHATES; ADENYLYL CYCLASE; ALPHA-MSH; L-CELLS; CALCIUM; STIMULATION; HYDROLYSIS; CAMP	We undertook these studies to explore the intracellular signaling mechanisms activated by a newly described human brain melanocortin receptor (hMC3R). Hepa cells transfected with the hMC3R gene responded to stimulation with alpha-melanocyte stimulation hormone (alpha-MSH) and adrenocorticotropic hormone (ACTH) with dose-dependent increases in cellular content of cyclic 3',5'-adenosine monophosphate (cAMP) reaching a maximum of over 1500% of control cells at the 10(-8) M dose (EC(50) = 10(-11) M). In contrast, the production of [H-3]inositol phosphates in cells prelabeled with myo [2-H-3]inositol exhibited a biphasic dose-response curve with increases as high as 155% of basal at 10-(11) M alpha-MSH or ACTH, but beyond that a dose dependent decrease was observed. The inhibitory component of the dose-re sponse curve could be abolished by pretreatment of transfected cells with the cAMP antagonist (Rp)-adenosine 3',5'-monophosphorothioate (Rp-cAMP) or the pro tein kinase A inhibitor H-89. Increases in intracellular calcium induced in transfected cells by alpha-MSH in doses ranging from 10(-11) to 10(-7) M could not be observed unless the cells were pretreated with H-89. By replacing the third intracytoplasmic loop of the canine H2-histamine receptor with that of hMC3R the biphasic characteristic of agonist-induced production of [H-3]inositol phosphates was conferred to the chimeric receptor. These data indicate that the hMC3R is coupled to both cAMP and inositol phospholipid/Ca2+-mediated post-receptor signaling systems and that the latter response is regulated by protein kinase A activity.	UNIV MICHIGAN,MED CTR,DEPT INTERNAL MED,ANN ARBOR,MI 48109; UNIV MICHIGAN,MED CTR,DEPT SURG,ANN ARBOR,MI 48109; UNIV MICHIGAN,MED CTR,DEPT PHYSIOL,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034306, P30DK034933, R01DK033500] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01DK33500, R01DK34306, P30DK34933] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; BROWN NA, 1990, J BIOL CHEM, V265, P13181; BUFFEY J, 1992, J ENDOCRINOL, V133, P333, DOI 10.1677/joe.0.1330333; CANNON JG, 1986, J IMMUNOL, V137, P2232; CHABRE O, 1992, MOL ENDOCRINOL, V6, P551, DOI 10.1210/me.6.4.551; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; CLARK D, 1978, NATURE, V273, P163, DOI 10.1038/273163a0; COTECCHIA S, 1990, J BIOL CHEM, V265, P63; DEGANI H, 1991, P NATL ACAD SCI USA, V88, P1506, DOI 10.1073/pnas.88.4.1506; DELVALLE J, 1992, AM J PHYSIOL, V263, pG967; DELVALLE J, 1992, AM J PHYSIOL, V262, pG420, DOI 10.1152/ajpgi.1992.262.3.G420; ENYEART JJ, 1993, MOL ENDOCRINOL, V7, P1031, DOI 10.1210/me.7.8.1031; FARESE RV, 1986, BIOCHEM BIOPH RES CO, V135, P742, DOI 10.1016/0006-291X(86)90991-5; GANTZ I, 1991, P NATL ACAD SCI USA, V88, P429, DOI 10.1073/pnas.88.2.429; GANTZ I, 1993, J BIOL CHEM, V268, P8246; GUDERMANN T, 1992, J BIOL CHEM, V267, P4479; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; ILAN AB, 1992, PROSTAGLANDINS, V43, P31, DOI 10.1016/0090-6980(92)90062-X; JELINEK LJ, 1993, SCIENCE, V259, P1614, DOI 10.1126/science.8384375; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KOJIMA I, 1985, J BIOL CHEM, V260, P4248; LEFKOWITZ RJ, 1988, J BIOL CHEM, V263, P4993; NAKAJIMA Y, 1992, J BIOL CHEM, V267, P2437; PERALTA EG, 1988, NATURE, V334, P434, DOI 10.1038/334434a0; RHEE SG, 1993, ADV SEC MESS PHOSPH, V28, P57; SUPATTAPONE S, 1988, P NATL ACAD SCI USA, V85, P8747, DOI 10.1073/pnas.85.22.8747; TATRO JB, 1993, METHODS NEUROSCIENCE, V11, P87; VANSANDE J, 1990, MOL CELL ENDOCRINOL, V74, pR1, DOI 10.1016/0303-7207(90)90209-Q; WALKER JM, 1980, SCIENCE, V210, P1247, DOI 10.1126/science.6254152; WOODCOCK EA, 1989, MOL CELL ENDOCRINOL, V63, P247, DOI 10.1016/0303-7207(89)90101-9; WREGGETT KA, 1987, BIOCHEM J, V245, P655, DOI 10.1042/bj2450655	32	125	138	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13162	13166						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175743				2022-12-25	WOS:A1994NK18400020
J	LEE, HB; XU, L; MEISSNER, G				LEE, HB; XU, L; MEISSNER, G			RECONSTITUTION OF THE SKELETAL-MUSCLE RYANODINE RECEPTOR-CA2+ RELEASE CHANNEL PROTEIN COMPLEX INTO PROTEOLIPOSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM; CA-2+ RELEASE; EXPRESSION; ACTIVATION; DIGESTION; JUNCTION; TRIAD; FORMS; CDNA	The 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonic acid-solubilized 30 S ryanodine receptor (RyR)/Ca2+ release channel complex from rabbit skeletal muscle, purified by density gradient centrifugation, was reconstituted with an excess of phospholipid into proteoliposomes by removal of the detergent by dialysis. Reconstituted proteoliposomes were concentrated by centrifugation, frozen and thawed, and sonicated. [H-3]Ryanodine binding measurements indicated close to 50% recovery of calculated binding activity following reconstitution of the purified RyR and dynamic light scattering measurements a mean vesicle diameter of similar to 150 nm. Using these values, a functional RyR was estimated to be present in only a small fraction (<15%) of the reconstituted vesicles. SDS-polyacrylamide gel electrophoresis of trypsin-treated proteoliposomes revealed that about four-fifths of the reconstituted 30 S complex was readily accessible to proteolytic attack. Vesicle(45)Ca(2+) flux and fusion of proteoliposomes with planar lipid bilayers showed that the reconstituted channel complex could be activated by Ca2+ and ATP, inhibited by Mg2+ and ruthenium red, and modified by ryanodine, similarly as observed for native sarcoplasmic reticulum vesicles. These results suggest that the method described here results in the reconstitution of a functional channel and thus provides the opportunity to study the structure and function of the sarcoplasmic reticulum Ca2+ release channel under well defined conditions.	UNIV N CAROLINA, DEPT BIOCHEM & BIOPHYS, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, DEPT PHYSIOL, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill					NIAMS NIH HHS [AR 18687] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR018687, R01AR018687] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		CHEN SRW, 1993, BIOCHEMISTRY-US, V32, P2743; CHU A, 1988, BIOCHEMISTRY-US, V27, P2827, DOI 10.1021/bi00408a025; CORBETT AM, 1985, J MEMBRANE BIOL, V86, P267, DOI 10.1007/BF01870606; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; FLEISCHER S, 1985, P NATL ACAD SCI USA, V82, P7256, DOI 10.1073/pnas.82.21.7256; FRANZINI.C, 1970, J CELL BIOL, V47, P488, DOI 10.1083/jcb.47.2.488; HILKERT R, 1992, ARCH BIOCHEM BIOPHYS, V292, P1, DOI 10.1016/0003-9861(92)90043-V; Hoult J.R.S., METHODS ENZYMOLOGY, P443, DOI [10.1016/0076-6879(94)34115-X, DOI 10.1016/0076-6879(94)34115-X, DOI 10.1016/0076-6879(67)10072-4]; HYMEL L, 1988, P NATL ACAD SCI USA, V85, P441, DOI 10.1073/pnas.85.2.441; IMAGAWA T, 1987, J BIOL CHEM, V262, P16636; INUI M, 1987, J BIOL CHEM, V262, P15637; KAPLAN RS, 1985, ANAL BIOCHEM, V150, P97, DOI 10.1016/0003-2697(85)90445-2; LAI FA, 1989, J BIOL CHEM, V264, P16776; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; LATTANZIO FA, 1987, J BIOL CHEM, V262, P2711; LINDSAY ARG, 1991, BIOCHIM BIOPHYS ACTA, V1064, P89, DOI 10.1016/0005-2736(91)90415-5; LIU QY, 1989, BIOPHYS J, V55, P415, DOI 10.1016/S0006-3495(89)82835-8; MEISSNER G, 1989, J BIOL CHEM, V264, P1715; MEISSNER G, 1984, J BIOL CHEM, V259, P2365; MEISSNER G, 1986, J BIOL CHEM, V261, P6300; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4; PENNER R, 1989, FEBS LETT, V259, P217, DOI 10.1016/0014-5793(89)81532-7; PICK U, 1981, ARCH BIOCHEM BIOPHYS, V212, P186, DOI 10.1016/0003-9861(81)90358-1; SHOMER NH, 1993, AM J PHYSIOL, V264, pC125, DOI 10.1152/ajpcell.1993.264.1.C125; SHOSHANBARMATZ V, 1987, J BIOL CHEM, V262, P11559; SMITH JS, 1986, J GEN PHYSIOL, V88, P573, DOI 10.1085/jgp.88.5.573; SMITH JS, 1988, J GEN PHYSIOL, V92, P1, DOI 10.1085/jgp.92.1.1; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; TIMERMAN AP, 1993, J BIOL CHEM, V268, P22992; TRIMM JL, 1988, J BIOL CHEM, V263, P17443; XU L, 1993, J GEN PHYSIOL, V101, P207, DOI 10.1085/jgp.101.2.207; ZORZATO F, 1990, J BIOL CHEM, V265, P2244	33	51	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13305	13312						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175760				2022-12-25	WOS:A1994NK18400040
J	ZHOU, ZX; SAR, M; SIMENTAL, JA; LANE, MV; WILSON, EM				ZHOU, ZX; SAR, M; SIMENTAL, JA; LANE, MV; WILSON, EM			LIGAND-DEPENDENT BIPARTITE NUCLEAR TARGETING SIGNAL IN THE HUMAN ANDROGEN RECEPTOR - REQUIREMENT FOR THE DNA-BINDING DOMAIN AND MODULATION BY NH2-TERMINAL AND CARBOXYL-TERMINAL SEQUENCES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; HUMAN C-MYC; PROGESTERONE-RECEPTOR; GLUCOCORTICOID RECEPTORS; TRANSCRIPTIONAL ACTIVATION; MONOCLONAL-ANTIBODIES; LOCATION SIGNAL; IMMUNOCYTOCHEMICAL LOCALIZATION; T-ANTIGEN; TRANSPORT	The amino acid sequence requirements for androgen-dependent androgen receptor nuclear import were determined by immunostaining transiently expressed full-length wild type and mutant human androgen receptors (AR) in monkey kidney COS cells and measuring transcriptional activity by cotransfection with a luciferase reporter vector in monkey kidney CV1 cells. Mutagenesis studies revealed a bipartite nuclear targeting sequence in the DNA binding and hinge regions at amino acids 617-633, consisting of two clusters of basic amino acids separated by 10 amino acids, RKCYEAGMTLGAR-KLKK. In a series of deletion mutants, AR NH2-terminal fragments (residues 1-639 through 1-723) displayed constitutive nuclear import, and transcriptional activity was similar to that of the ligand-activated full-length wild type AR. In contrast, nuclear import and transcriptional activation were inhibited by sequence extensions into the steroid-binding domain (1-771). Constitutive nuclear import was regained in part by NH2-terminal deletions of full-length AR. Expression of AR/pyruvate kinase chimeras defined a sequence required for pre dominant nuclear localization as residues 580-661, comprised of the second zinc finger region of the DNA-binding domain, the 17-amino-acid putative targeting sequence, and 28 residues of flanking carboxyl-terminal sequence. These studies suggest that the bipartite nuclear targeting sequence of AR includes flanking sequence and is modulated by interactions between the NH2- and carboxyl-terminal regions.	UNIV N CAROLINA,REPROD BIOL LAB,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT PEDIAT,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT CELL BIOL & ANAT,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT BIOCHEM & BIOPHYS,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD016910, P30HD018968, R37HD016910] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS017479] Funding Source: NIH RePORTER; NICHD NIH HHS [HD16910, P30-HD18968] Funding Source: Medline; NINDS NIH HHS [NS17479] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADAM SA, 1991, CELL, V66, P837, DOI 10.1016/0092-8674(91)90431-W; AKEY CW, 1989, J CELL BIOL, V109, P971, DOI 10.1083/jcb.109.3.971; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BENDITT JO, 1989, P NATL ACAD SCI USA, V86, P9327, DOI 10.1073/pnas.86.23.9327; BREEUWER M, 1990, CELL, V60, P999, DOI 10.1016/0092-8674(90)90348-I; CADEPOND F, 1991, J BIOL CHEM, V266, P5834; CATELLI MG, 1985, EMBO J, V4, P3131, DOI 10.1002/j.1460-2075.1985.tb04055.x; CHANDRAN UR, 1992, MOL ENDOCRINOL, V6, P837, DOI 10.1210/me.6.5.837; DANG CV, 1988, MOL CELL BIOL, V8, P4048, DOI 10.1128/MCB.8.10.4048; DANG CV, 1989, J BIOL CHEM, V264, P18019; DEFRANCO DB, 1991, MOL ENDOCRINOL, V5, P1215, DOI 10.1210/mend-5-9-1215; DINGWALL C, 1992, SCIENCE, V258, P942, DOI 10.1126/science.1439805; DINGWALL C, 1986, ANNU REV CELL BIOL, V2, P367, DOI 10.1146/annurev.cellbio.2.1.367; ELASHRYSTOWERS D, 1988, CANCER RES, V48, P6462; FELDHERR CM, 1990, J CELL BIOL, V111, P1, DOI 10.1083/jcb.111.1.1; FINLAY DR, 1991, J CELL BIOL, V114, P169, DOI 10.1083/jcb.114.1.169; FREEDMAN LP, 1992, ENDOCR REV, V13, P129, DOI 10.1210/er.13.2.129; Gorski J, 1968, Recent Prog Horm Res, V24, P45; GUIOCHONMANTEL A, 1989, CELL, V57, P1147, DOI 10.1016/0092-8674(89)90052-4; GUIOCHONMANTEL A, 1991, EMBO J, V10, P3851, DOI 10.1002/j.1460-2075.1991.tb04954.x; HUNT T, 1989, CELL, V59, P949, DOI 10.1016/0092-8674(89)90747-2; HUSMANN DA, 1990, ENDOCRINOLOGY, V126, P2359, DOI 10.1210/endo-126-5-2359; JENSEN EV, 1968, P NATL ACAD SCI USA, V59, P632, DOI 10.1073/pnas.59.2.632; JENSTER G, 1991, MOL ENDOCRINOL, V5, P1396, DOI 10.1210/mend-5-10-1396; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; KEMPPAINEN JA, 1992, J BIOL CHEM, V267, P968; KING WJ, 1984, NATURE, V307, P745, DOI 10.1038/307745a0; KOST SL, 1989, MOL CELL BIOL, V9, P3829, DOI 10.1128/MCB.9.9.3829; LUBAHN DB, 1989, P NATL ACAD SCI USA, V86, P9534, DOI 10.1073/pnas.86.23.9534; LUBAHN DB, 1988, MOL ENDOCRINOL, V2, P1265, DOI 10.1210/mend-2-12-1265; MARTINS VR, 1991, MOL ENDOCRINOL, V5, P217, DOI 10.1210/mend-5-2-217; MOLL T, 1991, CELL, V66, P743, DOI 10.1016/0092-8674(91)90118-I; NEWMEYER DD, 1988, CELL, V52, P641, DOI 10.1016/0092-8674(88)90402-3; ONATE SA, 1991, MOL ENDOCRINOL, V5, P1993, DOI 10.1210/mend-5-12-1993; PERROTAPPLANAT M, 1985, ENDOCRINOLOGY, V116, P1473, DOI 10.1210/endo-116-4-1473; PICARD D, 1990, CELL REGUL, V1, P291, DOI 10.1091/mbc.1.3.291; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; QUARMBY VE, 1990, MOL ENDOCRINOL, V4, P1399, DOI 10.1210/mend-4-9-1399; RICHARDSON WD, 1988, CELL, V52, P655, DOI 10.1016/0092-8674(88)90403-5; RIHS HP, 1989, EMBO J, V8, P1479, DOI 10.1002/j.1460-2075.1989.tb03531.x; RIHS HP, 1991, EMBO J, V10, P633, DOI 10.1002/j.1460-2075.1991.tb07991.x; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; ROBERTS B, 1989, BIOCHIM BIOPHYS ACTA, V1008, P263, DOI 10.1016/0167-4781(89)90016-X; ROBERTS BL, 1987, CELL, V50, P465, DOI 10.1016/0092-8674(87)90500-9; ROUX P, 1990, CELL, V63, P341, DOI 10.1016/0092-8674(90)90167-D; SANCHEZ ER, 1985, J BIOL CHEM, V260, P2398; SANCHEZ ER, 1990, J BIOL CHEM, V265, P20123; SAR M, 1990, ENDOCRINOLOGY, V127, P3180, DOI 10.1210/endo-127-6-3180; SCHOWALTER DB, 1991, J BIOL CHEM, V266, P21165; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; SIMENTAL JA, 1991, J BIOL CHEM, V266, P510; STOCHAJ U, 1991, J CELL BIOL, V113, P1243, DOI 10.1083/jcb.113.6.1243; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; TAN JA, 1988, MOL ENDOCRINOL, V2, P1276, DOI 10.1210/mend-2-12-1276; WELSHONS WV, 1984, NATURE, V307, P747, DOI 10.1038/307747a0; WIKSTROM AC, 1987, ENDOCRINOLOGY, V120, P1232, DOI 10.1210/endo-120-4-1232; WONG CI, 1993, J BIOL CHEM, V268, P19004; YARBROUGH WG, 1990, J BIOL CHEM, V265, P8893; YLIKOMI T, 1992, EMBO J, V11, P3681, DOI 10.1002/j.1460-2075.1992.tb05453.x; ZHOU ZX, 1994, RECENT PROG HORM RES, V49, P249	61	252	276	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13115	13123						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175737				2022-12-25	WOS:A1994NK18400013
J	BOCCACCIO, C; GAUDINO, G; GAMBAROTTA, G; GALIMI, F; COMOGLIO, PM				BOCCACCIO, C; GAUDINO, G; GAMBAROTTA, G; GALIMI, F; COMOGLIO, PM			HEPATOCYTE GROWTH-FACTOR (HGF) RECEPTOR EXPRESSION IS INDUCIBLE AND IS PART OF THE DELAYED-EARLY RESPONSE TO HGF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR SCATTER FACTOR; PROTEIN-KINASE-C; TYROSINE KINASE; MET PROTOONCOGENE; MOLECULAR-CLONING; EPITHELIAL-CELLS; OWN RECEPTOR; ONCOGENE; GENE; ACTIVATION	The c-MET proto oncogene encodes the tyrosine kinase receptor for hepatocyte growth factor (HGF), also known as scatter factor, a potent mitogen and motogen for epithelial cells. The level of the HGF receptor expressed by epithelial cells varies in different growth conditions, being lower in growth arrested confluent monolayers and higher in growing sparse cells. The amount of HGF receptor mRNA increases from 3- to 5-fold after stimulation of confluent monolayers by serum and up to 10-fold after stimulation of protein kinase C by 12-O-tetradecanoylphorbol-13-acetate (TPA). An increased level of the receptor mRNA was also observed after cell stimulation with nanomolar concentration of HGF itself. The effect was transient, dose, and time dependent. Transcription of a reporter gene under control of the cloned 297 base pair c-MET promoter was also stimulated by serum, TPA, or HGF. The accumulation of specific mRNA is followed by appearance of the HGF receptor precursor protein, which is further processed to the receptor mature form. After HGF stimulation, HGF receptor expression follows c-FOS and c-JUN induction with a peak similar to 4 h. Pretreatment with the protein synthesis inhibitor puromycin strongly reduced the response to HGF, while cycloheximide alone increased the level of the receptor mRNA These data show that c-MET behaves as a delayed early-response gene and suggest that the HGF response is autoamplified by inducing the specific receptor.	UNIV TURIN,SCH MED,DEPT BIOMED SCI & ONCOL,I-10126 TURIN,ITALY	University of Turin			Boccaccio, Carla/AHE-7875-2022; Gambarotta, Giovanna/I-8473-2012; Galimi, Francesco/J-4238-2012	Boccaccio, Carla/0000-0003-2620-9083; Gambarotta, Giovanna/0000-0002-8380-5925; Comoglio, Paolo/0000-0002-7056-5328				BARDELLI A, 1992, ONCOGENE, V7, P1973; BJORGE JD, 1987, J BIOL CHEM, V262, P6615; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK AJL, 1985, P NATL ACAD SCI USA, V82, P8374, DOI 10.1073/pnas.82.24.8374; COMOGLIO PM, 1993, HEPATOCYTE GROWTH FA, P131; DIRENZO MF, 1993, ONCOGENE, V8, P219; DIRENZO MF, 1991, ONCOGENE, V6, P1997; DIRENZO MF, 1992, ONCOGENE, V7, P2549; EARP HS, 1986, J BIOL CHEM, V261, P4777; EDWARDS DR, 1992, EMBO J, V11, P2415, DOI 10.1002/j.1460-2075.1992.tb05306.x; GAMBAROTTA G, 1993, J BIOL CHEM, V269, P12852; GANDINO L, 1991, J BIOL CHEM, V266, P16098; GANDINO L, 1990, ONCOGENE, V5, P721; GHERARDI E, 1991, CANCER CELL-MON REV, V3, P227; GIORDANO S, 1989, ONCOGENE, V4, P1383; GIORDANO S, 1993, P NATL ACAD SCI USA, V90, P649, DOI 10.1073/pnas.90.2.649; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; GRANT DS, 1993, P NATL ACAD SCI USA, V90, P1937, DOI 10.1073/pnas.90.5.1937; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; GRAZIANI A, 1993, J BIOL CHEM, V268, P9165; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARTMANN G, 1992, P NATL ACAD SCI USA, V89, P11574, DOI 10.1073/pnas.89.23.11574; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; ITO T, 1993, BIOCHEM BIOPH RES CO, V190, P870, DOI 10.1006/bbrc.1993.1129; KIKKAWA U, 1986, ANNU REV CELL BIOL, V2, P149, DOI 10.1146/annurev.cb.02.110186.001053; KUDLOW JE, 1986, J BIOL CHEM, V261, P4134; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANAHAN A, 1992, MOL CELL BIOL, V12, P3919, DOI 10.1128/MCB.12.9.3919; LAU LF, 1991, MOL ASPECTS CELLULAR, V6, P257; LEVY JR, 1992, J BIOL CHEM, V267, P25289; LINDROOS PM, 1991, HEPATOLOGY, V13, P743, DOI 10.1002/hep.1840130422; LOKKER NA, 1992, EMBO J, V11, P2503, DOI 10.1002/j.1460-2075.1992.tb05315.x; LUND LR, 1991, J BIOL CHEM, V266, P5177; MICHALOPOULOS G, 1984, CANCER RES, V44, P4414; MIYAZAWA K, 1993, J BIOL CHEM, V268, P10024; MIYAZAWA K, 1989, BIOCHEM BIOPH RES CO, V163, P967, DOI 10.1016/0006-291X(89)92316-4; MONDINO A, 1991, MOL CELL BIOL, V11, P6084, DOI 10.1128/MCB.11.12.6084; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; NAKA D, 1992, J BIOL CHEM, V267, P20114; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NAKAMURA T, 1984, BIOCHEM BIOPH RES CO, V122, P1450, DOI 10.1016/0006-291X(84)91253-1; NALDINI L, 1992, EMBO J, V11, P4825, DOI 10.1002/j.1460-2075.1992.tb05588.x; NALDINI L, 1991, ONCOGENE, V6, P501; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; NATALI PG, 1993, BRIT J CANCER, V68, P746, DOI 10.1038/bjc.1993.422; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PEPPER MS, 1992, J BIOL CHEM, V267, P20493; PONZETTO C, 1993, MOL CELL BIOL, V13, P4600, DOI 10.1128/MCB.13.8.4600; PONZETTO C, 1991, ONCOGENE, V6, P553; PRAT M, 1991, INT J CANCER, V49, P323, DOI 10.1002/ijc.2910490302; PRAT M, 1991, MOL CELL BIOL, V11, P5954, DOI 10.1128/MCB.11.12.5954; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; ROSEN OM, 1987, SCIENCE, V237, P1452, DOI 10.1126/science.2442814; SEKI T, 1991, GENE, V102, P213; SHOYAB M, 1980, NATURE, V288, P451, DOI 10.1038/288451a0; STERN CD, 1990, DEVELOPMENT, V110, P1271; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; VILLAMORUZZI E, 1993, J BIOL CHEM, V268, P18176; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; WEIDNER KM, 1991, P NATL ACAD SCI USA, V88, P7001, DOI 10.1073/pnas.88.16.7001; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481	63	148	150	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12846	12851						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175699				2022-12-25	WOS:A1994NH71600073
J	LIAO, JK				LIAO, JK			INHIBITION OF G(I) PROTEINS BY LOW-DENSITY-LIPOPROTEIN ATTENUATES BRADYKININ-STIMULATED RELEASE OF ENDOTHELIAL-DERIVED NITRIC-OXIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORCINE CORONARY-ARTERIES; PHOSPHOLIPASE-C ACTIVITY; VASCULAR SMOOTH-MUSCLE; DEPENDENT RELAXATION; RELAXING FACTOR; ALPHA-SUBUNITS; ERYTHROCYTE-MEMBRANE; ESCHERICHIA-COLI; RABBIT AORTA; CELLS	The mechanism(s) by which low density lipoprotein (LDL) attenuates the release of endothelial-derived nitric oxide (EDNO) is not known but may involve inhibition of membrane signal transduction. To test this hypothesis, we treated bovine aortic endothelial cells with LDL (0-500 mu g/ml, 72 h) to determine its effect on G proteins (G(i) and G(q)) which are known to couple the bradykinin receptor to EDNO release. Bradykinin-stimulated EDNO release was measured by perfusion bioassay and showed a maximal 56% decrease which was unaffected by cotreatment with pertussis toxin (PTX, 100 ng/ml, 16 h). Although radioligand binding studies and Western blotting did not detect any significant changes in the amount of bradykinin receptor, alpha(i2), alpha(i3), and alpha(q), both agonist-stimulated GTPase activity and phosphatidylinositol 4,5-bisphosphate (PIP2) hydrolysis were reduced by LDL treatment (77 and 70%, respectively). When G(i) and G(q) function in LDL-treated membranes were assessed by PTX and COOH-terminal antisera to alpha(i2) (P4), alpha(i3) (JL14), and alpha(q) (Q17), only the Q17 antisera caused a further reduction in GTPase activity and PIP2 hydrolysis while treatment with PTX alone or in combination with the P4 and JL14 antisera had no further inhibitory effect. These results suggest that LDL attenuates EDNO release by preferentially inhibiting the function of G(i).	HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Harvard Medical School	LIAO, JK (corresponding author), BRIGHAM & WOMENS HOSP,DIV CARDIOVASC,221 LONGWOOD AVE,LMRC-307,BOSTON,MA 02115, USA.				NHLBI NIH HHS [HL02508] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K11HL002508] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLAIN CC, 1974, CLIN CHEM, V20, P470; ANDREWS HE, 1987, NATURE, V327, P237, DOI 10.1038/327237a0; BARNETT JV, 1989, J BIOL CHEM, V264, P10779; BERTIN B, 1992, J BIOL CHEM, V267, P8200; BOROCHOV H, 1979, BIOCHEMISTRY-US, V18, P251, DOI 10.1021/bi00569a002; BOSSALER C, 1987, J CLIN INVEST, V79, P179; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; COHEN RA, 1988, CIRC RES, V63, P903, DOI 10.1161/01.RES.63.5.903; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; CROUCH MF, 1988, J BIOL CHEM, V263, P3363; CUSHING DJ, 1990, J PHARMACOL EXP THER, V254, P28; DRATZ EA, 1993, NATURE, V363, P276, DOI 10.1038/363276a0; FOSSATI P, 1982, CLIN CHEM, V28, P2077; FURCHGOTT RF, 1984, ANNU REV PHARMACOL, V24, P175, DOI 10.1146/annurev.pa.24.040184.001135; GARG UC, 1989, J CLIN INVEST, V83, P1774, DOI 10.1172/JCI114081; GRAZIANO MP, 1989, J BIOL CHEM, V264, P15475; HOFMANN SL, 1982, J BIOL CHEM, V257, P4359; INOUE N, 1992, CIRC RES, V71, P1410, DOI 10.1161/01.RES.71.6.1410; JACOBS M, 1990, BRIT J PHARMACOL, V100, P21, DOI 10.1111/j.1476-5381.1990.tb12045.x; JANSSENS SP, 1992, J BIOL CHEM, V267, P14519; KUGIYAMA K, 1990, NATURE, V344, P160, DOI 10.1038/344160a0; LAMBERT TL, 1986, J BIOL CHEM, V261, P5288; LIAO JK, 1992, CIRC RES, V70, P1018, DOI 10.1161/01.RES.70.5.1018; LIAO JK, 1991, CIRC RES, V68, P1027, DOI 10.1161/01.RES.68.4.1027; LIAO JK, 1993, J CLIN INVEST, V92, P2168, DOI 10.1172/JCI116818; LIAO JK, 1993, J BIOL CHEM, V268, P19528; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCCALEB ML, 1981, J BIOL CHEM, V256, P1051; MELCHIOR DL, 1979, J BIOL CHEM, V254, P8744; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NIGG EA, 1979, BIOCHEMISTRY-US, V18, P3457, DOI 10.1021/bi00583a004; RUBALCAV.B, 1973, J BIOL CHEM, V248, P3831; SHIMOKAWA H, 1989, CIRC RES, V64, P900, DOI 10.1161/01.RES.64.5.900; SHIMOKAWA H, 1989, CIRC RES, V65, P740, DOI 10.1161/01.RES.65.3.740; SHIMOKAWA H, 1991, CIRCULATION, V83, P652, DOI 10.1161/01.CIR.83.2.652; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; SNEDDON JM, 1988, P NATL ACAD SCI USA, V85, P2800, DOI 10.1073/pnas.85.8.2800; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; TANNER FC, 1991, CIRCULATION, V83, P2012, DOI 10.1161/01.CIR.83.6.2012; TOMITA T, 1990, CIRC RES, V66, P18, DOI 10.1161/01.RES.66.1.18; WU DQ, 1992, J BIOL CHEM, V267, P1811; YAGI K, 1976, BIOCHEM MED METAB B, V15, P212, DOI 10.1016/0006-2944(76)90049-1	42	63	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12987	12992						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175717				2022-12-25	WOS:A1994NH71600093
J	PLANK, C; OBERHAUSER, B; MECHTLER, K; KOCH, C; WAGNER, E				PLANK, C; OBERHAUSER, B; MECHTLER, K; KOCH, C; WAGNER, E			THE INFLUENCE OF ENDOSOME-DISRUPTIVE PEPTIDES ON GENE-TRANSFER USING SYNTHETIC VIRUS-LIKE GENE-TRANSFER SYSTEMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEMAGGLUTININ MEMBRANE GLYCOPROTEIN; POLYLYSINE DNA COMPLEXES; UNILAMELLAR VESICLES; AMPHIPATHIC PEPTIDE; ANIMAL-CELLS; FUSION; PH; DELIVERY; BINDING; ADENOVIRUS	The process by which viruses destabilize endosomal membranes in an acidification dependent manner has been mimicked with synthetic peptides that are able to disrupt liposomes, erythrocytes, or endosomes of cultured cells. Peptides containing the 20 amino-terminal amino acid sequence of influenza virus hemagglutinin as well as acidic derivatives showed erythrocyte lysis activity only when peptides were elongated by an amphipathic helix or by carboxyl-terminal dimerization. Interestingly, peptides consisting of the 23 amino-terminal amino acids of influenza virus hemagglutinin were also active in erythrocyte lysis. When peptides were in corporated into DNA complexes that utilize a receptor-mediated endocytosis pathway for uptake into cultured cells, either by ionic interaction with positively charged polylysine-DNA complexes or by a streptavidin-biotin bridge, a strong correlation between pH-specific erythrocyte disruption activity and gene transfer was observed. A high-level expression of luciferase or interleukin-2 was obtained with optimized gene transfer complexes in human melanoma cells and several cell lines.	RES INST MOLEC PATHOL,A-1030 VIENNA,AUSTRIA	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)			Wagner, Ernst/A-7435-2012; Mechtler, Karl/AAF-2717-2019; Plank, Christian/F-9628-2011; Wagner, Ernst/ABB-5976-2020	Wagner, Ernst/0000-0001-8413-0934; Mechtler, Karl/0000-0002-3392-9946; Wagner, Ernst/0000-0001-8413-0934; Plank, Christian/0000-0002-6072-4903				ALOUF JE, 1989, EUR J BIOCHEM, V183, P381, DOI 10.1111/j.1432-1033.1989.tb14939.x; ANDREWS NW, 1990, CELL, V61, P1277, DOI 10.1016/0092-8674(90)90692-8; ARGIOLAS A, 1985, J BIOL CHEM, V260, P1437; ATHERTON E, 1979, BIOORG CHEM, V8, P351, DOI 10.1016/0045-2068(79)90062-2; BLOBEL CP, 1992, NATURE, V356, P248, DOI 10.1038/356248a0; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; CARR CM, 1993, CELL, V73, P823, DOI 10.1016/0092-8674(93)90260-W; CHRISTENSEN B, 1988, P NATL ACAD SCI USA, V85, P5072, DOI 10.1073/pnas.85.14.5072; COTTEN M, 1992, P NATL ACAD SCI USA, V89, P6094, DOI 10.1073/pnas.89.13.6094; COTTEN M, 1993, METHOD ENZYMOL, V217, P618; CURIEL DT, 1991, P NATL ACAD SCI USA, V88, P8850, DOI 10.1073/pnas.88.19.8850; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; ESSER AF, 1991, IMMUNOL TODAY, V12, P316, DOI 10.1016/0167-5699(91)90006-F; FRANCHINI G, 1989, SCIENCE, V244, P694; FRICKS CE, 1990, J VIROL, V64, P1934, DOI 10.1128/JVI.64.5.1934-1945.1990; GAILLARD JL, 1987, INFECT IMMUN, V55, P2822, DOI 10.1128/IAI.55.11.2822-2829.1987; GETHING MJ, 1978, P NATL ACAD SCI USA, V75, P2737, DOI 10.1073/pnas.75.6.2737; HABERMAN.E, 1972, SCIENCE, V177, P314, DOI 10.1126/science.177.4046.314; HAENSLER J, 1993, BIOCONJUGATE CHEM, V4, P372, DOI 10.1021/bc00023a012; HOEKSTRA D, 1990, J BIOENERG BIOMEMBR, V22, P121, DOI 10.1007/BF00762943; KNORR R, 1989, TETRAHEDRON LETT, V30, P1927, DOI 10.1016/S0040-4039(00)99616-3; LEAR JD, 1987, J BIOL CHEM, V262, P6500; LEHRER RI, 1991, CELL, V64, P229, DOI 10.1016/0092-8674(91)90632-9; LEIPPE M, 1991, P NATL ACAD SCI USA, V88, P7659, DOI 10.1073/pnas.88.17.7659; MACDONALD RC, 1991, BIOCHIM BIOPHYS ACTA, V1061, P297, DOI 10.1016/0005-2736(91)90295-J; MACFARLANE RD, 1980, J AM CHEM SOC, V102, P875, DOI 10.1021/ja00522a088; MIDOUX P, 1993, NUCLEIC ACIDS RES, V21, P871, DOI 10.1093/nar/21.4.871; MURATA M, 1992, BIOCHEMISTRY-US, V31, P1986, DOI 10.1021/bi00122a013; MURATA M, 1987, J BIOCHEM-TOKYO, V102, P957, DOI 10.1093/oxfordjournals.jbchem.a122137; OJCIUS DM, 1991, TRENDS BIOCHEM SCI, V16, P225, DOI 10.1016/0968-0004(91)90090-I; OSHANNESSY DJ, 1992, ANAL BIOCHEM, V205, P132, DOI 10.1016/0003-2697(92)90589-Y; PARENTE RA, 1988, J BIOL CHEM, V263, P4724; PARENTE RA, 1990, BIOCHEMISTRY-US, V29, P8720, DOI 10.1021/bi00489a031; PLANK C, 1992, BIOCONJUGATE CHEM, V3, P533, DOI 10.1021/bc00018a012; Prchla E., 1993, Molecular Biology of the Cell, V4, p435A; SHAI Y, 1990, J BIOL CHEM, V265, P20202; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SUBBARAO NK, 1987, BIOCHEMISTRY-US, V26, P2964, DOI 10.1021/bi00385a002; SZOKA F, 1978, P NATL ACAD SCI USA, V75, P4194, DOI 10.1073/pnas.75.9.4194; TAKAHASHI S, 1990, BIOCHEMISTRY-US, V29, P6257, DOI 10.1021/bi00478a021; WAGNER E, 1992, P NATL ACAD SCI USA, V89, P7934, DOI 10.1073/pnas.89.17.7934; WAGNER E, 1991, BIOCONJUGATE CHEM, V2, P226, DOI 10.1021/bc00010a006; WAGNER E, 1992, P NATL ACAD SCI USA, V89, P6099, DOI 10.1073/pnas.89.13.6099; WAGNER E, 1990, P NATL ACAD SCI USA, V87, P3410, DOI 10.1073/pnas.87.9.3410; WAKELAM MJO, 1988, CURRENT TOPICS MEMBR, V32, P87; WHARTON SA, 1988, J GEN VIROL, V69, P1847, DOI 10.1099/0022-1317-69-8-1847; WHITE JM, 1992, SCIENCE, V258, P917, DOI 10.1126/science.1439803; WHITE JM, 1990, ANNU REV PHYSIOL, V52, P675, DOI 10.1146/annurev.ph.52.030190.003331; WILEY DC, 1987, ANNU REV BIOCHEM, V56, P365, DOI 10.1146/annurev.bi.56.070187.002053; WILEY DC, 1981, NATURE, V289, P373, DOI 10.1038/289373a0; WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0; WU GY, 1987, J BIOL CHEM, V262, P4429; ZASLOFF M, 1987, P NATL ACAD SCI USA, V84, P5449, DOI 10.1073/pnas.84.15.5449	53	592	670	1	48	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12918	12924						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175709				2022-12-25	WOS:A1994NH71600083
J	TESSLER, S; ROCKWELL, P; HICKLIN, D; COHEN, T; LEVI, BZ; WITTE, L; LEMISCHKA, IR; NEUFELD, G				TESSLER, S; ROCKWELL, P; HICKLIN, D; COHEN, T; LEVI, BZ; WITTE, L; LEMISCHKA, IR; NEUFELD, G			HEPARIN MODULATES THE INTERACTION OF VEGF(165) WITH SOLUBLE AND CELL-ASSOCIATED FLK-1 RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; VASCULAR-PERMEABILITY FACTOR; TYROSINE KINASE; HEMATOPOIETIC STEM; BINDING; MITOGEN; FAMILY; IDENTIFICATION; ANGIOGENESIS; EXPRESSION	The 165-amino acid form of vascular endothelial growth factor (VEGF(165)) is a mitogen for vascular endothelial cells and a potent angiogenic factor. Expression of a chimeric receptor containing the extracellular domain of the flk-1 receptor fused to the transmembrane and intracellular domains of the human c-fms receptor in NIH-3T3 cells, resulted in the appearance of high affinity binding sites for I-125-VEGF(165) on transfected cells. The binding of I-125-VEGF(165) to the flk-1/fms chimeric receptor of the transfected cells as well as the VEGF(165)-induced autophosphorylation of the chimeric receptors were inhibited in the presence of low concentrations of heparin (1-10 mu g/ml). In contrast, similar concentrations of heparin potentiated the binding of I-125-VEGF(165) to the endogenous VEGF receptors of the transfected cells, indicating that to some extent, the effect of heparin on I-125-VEGF(165) binding is receptor type-dependent. A soluble fusion protein containing the extracellular domain of flk-1 fused to alkaline phosphatase (flk-1/SEAP) was used to study the effects of heparin on the binding of I-125-VEGF(165) to flk-1 in a cell-free environment. The fusion protein specifically inhibited VEGF(165)-induced proliferation of vascular endothelial cells, but bound I-125-VEGF(165) inefficiently in the absence of heparin. Addition of low concentrations of heparin or heparan sulfate (0.1-1 mu g/ml) resulted in a strong potentiation of I-125-VEGF(165) binding, whereas higher heparin or heparan sulfate concentrations inhibited the binding. The effect of heparin on the binding of I-125-VEGF(165) to flk-1/SEAP could not be mimicked by desulfated heparin or by chondroitin sulfate. Both bFGF and aFGF inhibited the binding when low concentrations of heparin were added to the binding reaction. However, higher concentrations of heparin abolished the inhibition, indicating that the inhibition is probably caused by competition for available heparin. Taken as a whole, these results indicate that heparin like molecules regulate the binding of VEGF(165) to its receptors in complex ways which depend on the heparin binding properties of VEGF(165) on the specific VEGF receptor type involved, and on the amount and composition of heparin-like molecules that are present on the cell surface of VEGF receptor containing cells.	TECHNION ISRAEL INST TECHNOL,DEPT BIOL,IL-32000 HAIFA,ISRAEL; TECHNION ISRAEL INST TECHNOL,DEPT FOOD ENGN & BIOTECHNOL,IL-32000 HAIFA,ISRAEL; PRINCETON UNIV,DEPT MOLEC BIOL,PRINCETON,NJ 08544; IMCLONE SYST INC,NEW YORK,NY 10014	Technion Israel Institute of Technology; Technion Israel Institute of Technology; Princeton University; Eli Lilly			Neufeld, Gera/F-1524-2019					BARZU T, 1985, BIOCHIM BIOPHYS ACTA, V845, P196, DOI 10.1016/0167-4889(85)90177-6; CHARNOCKJONES SD, 1993, BIOL REPROD, V48, P1120; Cohen T, 1992, GROWTH FACTORS, V7, P131, DOI 10.3109/08977199209046402; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; FERRARA N, 1993, J CLIN INVEST, V91, P160, DOI 10.1172/JCI116166; FERRARA N, 1992, ENDOCR REV, V13, P18, DOI 10.1210/er.13.1.18; GITAYGOREN H, 1993, BIOCHEM BIOPH RES CO, V190, P702, DOI 10.1006/bbrc.1993.1106; GITAYGOREN H, 1992, J BIOL CHEM, V267, P6093; GOSPODAROWICZ D, 1989, P NATL ACAD SCI USA, V86, P7311, DOI 10.1073/pnas.86.19.7311; GOSPODAROWICZ D, 1987, ENDOCR REV, V8, P95, DOI 10.1210/edrv-8-2-95; ISHAIMICHAELI R, 1992, BIOCHEMISTRY-US, V31, P2080, DOI 10.1021/bi00122a027; JORDAN CT, 1990, CELL, V61, P953, DOI 10.1016/0092-8674(90)90061-I; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; MATTHEWS W, 1991, CELL, V65, P1143, DOI 10.1016/0092-8674(91)90010-V; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NEUFELD G, 1988, J CELL PHYSIOL, V136, P537, DOI 10.1002/jcp.1041360321; NEUFELD G, 1988, J CELL BIOL, V106, P1385, DOI 10.1083/jcb.106.4.1385; OLANDER JV, 1991, BIOCHEM BIOPH RES CO, V175, P68, DOI 10.1016/S0006-291X(05)81201-X; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; PERETZ D, 1992, BIOCHEM BIOPH RES CO, V182, P1340, DOI 10.1016/0006-291X(92)91880-Y; PLOUET J, 1990, J BIOL CHEM, V265, P22071; PLOUET J, 1989, EMBO J, V8, P3801, DOI 10.1002/j.1460-2075.1989.tb08557.x; ROUSSEL MF, 1990, MOL CELL BIOL, V10, P2407, DOI 10.1128/MCB.10.5.2407; SHIBUYA M, 1990, ONCOGENE, V5, P519; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; TISCHER E, 1989, BIOCHEM BIOPH RES CO, V165, P1198, DOI 10.1016/0006-291X(89)92729-0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VAISMAN N, 1990, J BIOL CHEM, V265, P19461; WILKS JW, 1991, INT J RADIAT BIOL, V60, P73, DOI 10.1080/09553009114551581; YANAGISHITA M, 1992, J BIOL CHEM, V267, P9451	36	171	187	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12456	12461						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175651				2022-12-25	WOS:A1994NH71600016
J	RAJU, RVS; KALRA, J; SHARMA, RK				RAJU, RVS; KALRA, J; SHARMA, RK			PURIFICATION AND PROPERTIES OF BOVINE SPLEEN N-MYRISTOYL-COA PROTEIN-N-MYRISTOYLTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID; TRANSFERASE; PEPTIDE; IDENTIFICATION; MYRISTYLATION; ACYLATION; TISSUES; BINDING; VIRUS; FORMS	Myristoyl-CoA:protein N-myristoyltransferase (NMT) catalyzes the addition of myristate to the amino-terminal glycine residue of a number of eukaryotic proteins. In this report, a simple and rapid purification as well as the properties of this enzyme from bovine spleen is described. Using combination of ammonium sulfate precipitation, chromatography on SP-Sepharose fast flow, phenyl-Sepharose CL BB, DEAE-Sepharose CL-6B, and Superose 12 (HR/30) gel filtration fast protein liquid chromatography, the enzyme was purified 1475-fold with a high yield. Under native conditions, the enzyme exhibited an apparent molecular mass of 58 kDa, whereas under denaturing conditions the enzyme represented an apparent molecular mass of 50 kDa, suggesting that spleen NMT is a monomeric protein. The NMT activity could be greatly activated to severalfold with the use of Tris-HC1 buffer. Kinetic properties indicated that spleen NMT had an apparent low K-m for pp60(src) and myristoylated alanine-rich C kinase substrate as compared with cAMP-dependent protein kinase and the M2 gene segment of reovirus type 3-derived peptides, Bovine spleen NMT was potently inhibited in a concentration-dependent manner by NIP71 (a bovine brain NMT inhibitory protein) with a half-maximal inhibition of 0.816 mu g/ml. Results of this study along with the existing knowledge on NMT indicate that the activity of enzyme resides in a single polypeptide chain of molecular mass between 50 and 68 M)a.	UNIV SASKATCHEWAN,ROYAL UNIV HOSP,COLL MED,DEPT PATHOL,SASKATOON S7N 0W0,SK,CANADA; UNIV SASKATCHEWAN,ROYAL UNIV HOSP,COLL MED,SASKATOON CANC CTR,SASKATOON S7N 0W0,SK,CANADA	University of Saskatchewan; University of Saskatchewan								AITKEN A, 1982, FEBS LETT, V150, P314, DOI 10.1016/0014-5793(82)80759-X; BOUTIN JA, 1993, EUR J BIOCHEM, V214, P853, DOI 10.1111/j.1432-1033.1993.tb17989.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSS JE, 1984, MOL CELL BIOL, V4, P2697, DOI 10.1128/MCB.4.12.2697; CAMMACK R, 1971, BIOCHEM BIOPH RES CO, V44, P8, DOI 10.1016/S0006-291X(71)80151-1; CARR SA, 1982, P NATL ACAD SCI-BIOL, V79, P6128, DOI 10.1073/pnas.79.20.6128; DAVIS KA, 1969, BIOCHEMISTRY-US, V8, P3355, DOI 10.1021/bi00836a033; DEICHAITE I, 1988, MOL CELL BIOL, V8, P4295, DOI 10.1128/MCB.8.10.4295; GLOVER CJ, 1988, BIOCHEM J, V250, P485, DOI 10.1042/bj2500485; GORDON JA, 1972, BIOCHEMISTRY-US, V11, P1862, DOI 10.1021/bi00760a021; Hatefi Y, 1974, Methods Enzymol, V31, P770; HEUCKEROTH RO, 1988, J BIOL CHEM, V263, P2127; HEUCKEROTH RO, 1988, P NATL ACAD SCI USA, V85, P8795, DOI 10.1073/pnas.85.23.8795; HOLTZER A, 1960, BIOCHIM BIOPHYS ACTA, V42, P453, DOI 10.1016/0006-3002(60)90823-4; KING MJ, 1991, ANAL BIOCHEM, V199, P149, DOI 10.1016/0003-2697(91)90082-5; KING MJ, 1993, BIOCHEM BIOPH RES CO, V196, P665, DOI 10.1006/bbrc.1993.2301; KING MJ, 1993, BIOCHIM BIOPHYS ACTA, V1165, P259, DOI 10.1016/0005-2760(93)90134-U; KING MJ, 1992, MOL CELL BIOCHEM, V113, P77; KING MJ, 1993, BIOCHEM J, V291, P635, DOI 10.1042/bj2910635; LEAMMLI UK, 1970, NATURE, V227, P680, DOI DOI 10.1038/227680A0; MCILHINNEY RAJ, 1989, BIOCHEM J, V263, P387, DOI 10.1042/bj2630387; MCILHINNEY RAJ, 1990, J NEUROCHEM, V54, P110, DOI 10.1111/j.1471-4159.1990.tb13289.x; MCILHINNEY RAJ, 1993, BIOCHEM J, V290, P405, DOI 10.1042/bj2900405; Merrifield RB, 1976, SCIENCE, V232, P341, DOI DOI 10.1126/SCIENCE.3961484; PAIGE LA, 1989, ANAL BIOCHEM, V181, P254, DOI 10.1016/0003-2697(89)90239-X; REIN A, 1986, P NATL ACAD SCI USA, V83, P7246, DOI 10.1073/pnas.83.19.7246; RUDNICK DA, 1990, J BIOL CHEM, V265, P13370; RUDNICK DA, 1991, J BIOL CHEM, V266, P9732; SHULTZ AM, 1987, BIOCHEM BIOPH RES CO, V146, P1234; SWARUP G, 1983, J BIOL CHEM, V258, P341; TOWLER D, 1986, P NATL ACAD SCI USA, V83, P2812, DOI 10.1073/pnas.83.9.2812; TOWLER DA, 1987, P NATL ACAD SCI USA, V84, P2708, DOI 10.1073/pnas.84.9.2708; TOWLER DA, 1988, J BIOL CHEM, V263, P1784; TOWLER DA, 1987, J BIOL CHEM, V262, P1030; WOLFF J, 1962, J BIOL CHEM, V237, P230	35	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					12080	12083						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163512				2022-12-25	WOS:A1994NG37700062
J	WANG, W; HENDRIKS, DF; SCHARPE, SS				WANG, W; HENDRIKS, DF; SCHARPE, SS			CARBOXYPEPTIDASE-U, A PLASMA CARBOXYPEPTIDASE WITH HIGH-AFFINITY FOR PLASMINOGEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-SERUM; CATALYZED HYDROLYSIS; TERMINAL LYSINE; CREATINE-KINASE; BINDING-SITES; FIBRIN; ACTIVATOR; ANAPHYLATOXIN; PURIFICATION; MECHANISM	A novel basic carboxypeptidase clearly different from carboxypeptidase N has been isolated from human plasma. It circulates as an enzymatically inactive precursor enzyme bound to plasminogen. During fibrinolysis, it can be converted to its active form, carboxypeptidase U, through the action of plasmin. The active enzyme has an apparent molecular weight of 53,000 as determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. It hydrolyzes the synthetic peptides hippuryl-L-arsnine and hippuryl-L-lysine but, in contrast to other human basic carboxypeptidases, has only a limited esterase activity. After its activation, carboxypeptidase U tends to be very unstable.	UNIV INSTELLING ANTWERP,DEPT MED BIOCHEM,B-2610 WILRIJK,BELGIUM	University of Antwerp			Hendriks, Dirk/E-3797-2017					AVILES FX, 1993, EUR J BIOCHEM, V211, P381, DOI 10.1111/j.1432-1033.1993.tb17561.x; BELEW M, 1980, BIOCHIM BIOPHYS ACTA, V621, P169, DOI 10.1016/0005-2795(80)90169-5; BOKISCH VA, 1970, J CLIN INVEST, V49, P2427, DOI 10.1172/JCI106462; CAMPBELL W, 1989, BIOCHEM BIOPH RES CO, V162, P933, DOI 10.1016/0006-291X(89)90762-6; CAMPBELL W, 1991, J LAB CLIN MED, V115, P610; CHRISTENSEN U, 1979, BIOCHIM BIOPHYS ACTA, V569, P177, DOI 10.1016/0005-2744(79)90052-4; CORNISHB.A, 1974, BIOCHEM J, V137, P143, DOI 10.1042/bj1370143; DEUTSCH DG, 1970, SCIENCE, V170, P1095, DOI 10.1126/science.170.3962.1095; DIXON M, 1953, BIOCHEM J, V55, P170, DOI 10.1042/bj0550170; EATON DL, 1991, J BIOL CHEM, V266, P21833; EISENTHAL R, 1974, BIOCHEM J, V139, P715, DOI 10.1042/bj1390715; Erdos E., 1979, HDB EXPT PHARM S, VXXV, P427; ERDOS EG, 1967, BIOCHEM PHARMACOL, V16, P1287, DOI 10.1016/0006-2952(67)90159-1; GORSKI JP, 1979, P NATL ACAD SCI USA, V76, P5299, DOI 10.1073/pnas.76.10.5299; GUREWICH V, 1992, ANN NY ACAD SCI, V667, P224, DOI 10.1111/j.1749-6632.1992.tb51619.x; HARPEL PC, 1989, P NATL ACAD SCI USA, V86, P3847, DOI 10.1073/pnas.86.10.3847; HARPEL PC, 1985, J BIOL CHEM, V260, P4432; HENDRIKS D, 1985, CLIN CHEM, V31, P1936; HENDRIKS D, 1988, CLIN CHIM ACTA, V172, P253, DOI 10.1016/0009-8981(88)90331-2; HENDRIKS D, 1990, BIOCHIM BIOPHYS ACTA, V1034, P86, DOI 10.1016/0304-4165(90)90157-R; HENDRIKS D, 1989, J CLIN CHEM CLIN BIO, V27, P277; HENDRIKS D, 1989, CLIN CHEM, V35, P177; HENDRIKS D, 1987, BIOCHEM SOC T, V16, P359; HORTIN GL, 1988, BIOCHEM BIOPH RES CO, V155, P591, DOI 10.1016/S0006-291X(88)80535-7; HOYLAERTS M, 1982, J BIOL CHEM, V257, P2912; LEVIN Y, 1982, P NATL ACAD SCI-BIOL, V79, P4618, DOI 10.1073/pnas.79.15.4618; PANNELL R, 1988, J CLIN INVEST, V81, P853, DOI 10.1172/JCI113394; PERRYMAN MB, 1984, CLIN CHEM, V30, P662; PLUMMER TH, 1978, J BIOL CHEM, V253, P3907; SKIDGEL RA, 1988, TRENDS PHARMACOL SCI, V9, P299, DOI 10.1016/0165-6147(88)90015-6; SKIDGEL RA, 1984, BIOCHEM PHARMACOL, V33, P3471, DOI 10.1016/0006-2952(84)90122-9; TULINSKY A, 1988, PROTEINS, V3, P85, DOI 10.1002/prot.340030203; VOGEL AJ, 1970, PRACTICAL ORGANIC CH, P584	33	177	182	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15937	15944						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	8195249				2022-12-25	WOS:A1994NP51300083
J	HAO, H; TYSHENKO, MG; WALKER, VK				HAO, H; TYSHENKO, MG; WALKER, VK			DIHYDROFOLATE-REDUCTASE OF DROSOPHILA - CLONING AND EXPRESSION OF A GENE WITH A RARE TRANSCRIPT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; MESSENGER-RNA; SACCHAROMYCES-CEREVISIAE; NUCLEOTIDE-SEQUENCE; INTRON SIZE; MELANOGASTER; CELLS; HETEROGENEITY; ORGANIZATION; REGION	Traditionally, dihydrofolate reductase (DHFR) has been isolated and the corresponding gene cloned from drug-resistant cell lines which have amplified DHFR genes after selection. A Dhfr sequence has now been obtained by nested polymerase chain reaction (PCR) from Drosophila bearing a single gene copy. Using the PCR amplified partial cDNA as a probe, Dhfr was cloned by screening a Drosophila genomic library. It consists of regulatory regions as well as a 599-nucleotide coding region with a single 50-base pair (bp) intron and encodes a protein of 182 amino acids. Previously we have shown that the enzyme has kinetic properties characteristic of both ''prokaryotic'' and ''eukaryotic'' DHFRs. Here we show that the organization of Drosophila Dhfr is strikingly different from its mammalian counterparts and most similar to that of mosquito. A 790-bp transcript was detected by Northern blot analysis, with a single transcription start site located 27 bp upstream of ATG codon. The Drosophila genome contains a single Dhfr copy at 89E and a selected cell line has not amplified the gene. Confirmation of the identity of this gene has been obtained by kinetic studies of recombinant DHFR overexpressed in Escherichia coli cells.	QUEENS UNIV,DEPT BIOL,KINGSTON K7L 3N6,ON,CANADA	Queens University - Canada								AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; ALT FW, 1978, J BIOL CHEM, V253, P1357; ANDREWS J, 1985, GENE, V35, P217, DOI 10.1016/0378-1119(85)90174-X; BARCLAY BJ, 1988, GENE, V63, P175, DOI 10.1016/0378-1119(88)90523-9; BEVERLEY SM, 1986, P NATL ACAD SCI USA, V83, P2584, DOI 10.1073/pnas.83.8.2584; BREATHNACH R, 1978, P NATL ACAD SCI USA, V75, P4853, DOI 10.1073/pnas.75.10.4853; CAROTHERS AM, 1983, NUCLEIC ACIDS RES, V11, P1997, DOI 10.1093/nar/11.7.1997; CHEN MJ, 1984, J BIOL CHEM, V259, P3933; CHIA W, 1985, J MOL BIOL, V186, P689, DOI 10.1016/0022-2836(85)90389-4; CROUSE GF, 1982, J BIOL CHEM, V257, P7887; ENGELS WR, 1986, FOCUS, V8, P6; HAMLIN JL, 1990, BIOCHIM BIOPHYS ACTA, V1087, P107, DOI 10.1016/0167-4781(90)90195-8; HARLOW E, 1988, ANTIBODIES LABORATOR, P497; KUMAR AA, 1980, BIOCHEMISTRY-US, V19, P667, DOI 10.1021/bi00545a010; LAGOSKY PA, 1987, NUCLEIC ACIDS RES, V15, P10355, DOI 10.1093/nar/15.24.10355; LINTON JP, 1989, MOL CELL BIOL, V9, P3058, DOI 10.1128/MCB.9.7.3058; MASTERS JN, 1985, MOL CELL BIOL, V5, P493, DOI 10.1128/MCB.5.3.493; MCGROGAN M, 1985, J BIOL CHEM, V260, P2307; MCPHERSON MJ, 1991, PCR PRACTICAL APPROA, P42; MITCHELL PJ, 1986, MOL CELL BIOL, V6, P425, DOI 10.1128/MCB.6.2.425; MOUNT SM, 1992, NUCLEIC ACIDS RES, V20, P4255, DOI 10.1093/nar/20.16.4255; NUNBERG JH, 1980, CELL, V19, P355, DOI 10.1016/0092-8674(80)90510-3; PALAZZOLO MJ, 1990, GENE, V88, P25, DOI 10.1016/0378-1119(90)90056-W; PARDUE ML, 1986, DROSOPHILA PRACTICAL, V5, P120; PARK YJ, 1993, INSECT BIOCHEM MOLEC, V23, P255, DOI 10.1016/0965-1748(93)90006-E; RANCOURT SL, 1990, BIOCHEM CELL BIOL, V68, P1075, DOI 10.1139/o90-161; RANCOURT SL, 1990, BIOCHIM BIOPHYS ACTA, V1039, P261, DOI 10.1016/0167-4838(90)90258-H; Sambrook J, 1989, MOL CLONING LABORATO; SHOTKOSKI FA, 1991, EUR J BIOCHEM, V201, P157, DOI 10.1111/j.1432-1033.1991.tb16268.x; SMITH DR, 1980, NUCLEIC ACIDS RES, V8, P2255, DOI 10.1093/nar/8.10.2255; STONE D, 1979, J BIOL CHEM, V254, P480; YANG JK, 1984, J MOL BIOL, V176, P169, DOI 10.1016/0022-2836(84)90419-4	32	17	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					15179	15185						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195153				2022-12-25	WOS:A1994NP73800050
J	KATO, K; GOTO, S; INAGUMA, Y; HASEGAWA, K; MORISHITA, R; ASANO, T				KATO, K; GOTO, S; INAGUMA, Y; HASEGAWA, K; MORISHITA, R; ASANO, T			PURIFICATION AND CHARACTERIZATION OF A 20-KDA PROTEIN THAT IS HIGHLY HOMOLOGOUS TO ALPHA-B-CRYSTALLIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; NON-LENTICULAR TISSUES; HUMAN GLIOMA-CELLS; SENSITIVE IMMUNOASSAY; STRESS PROTEINS; BRAIN; TRANSLOCATION; LOCALIZATION; KIDNEY; HSP28	A 20-kDa protein (p20) that had internal amino acid sequences highly similar to those of alpha B crystallin was purified from rat and human skeletal muscle. p20 coeluted with alpha B crystallin and HSP27/28 during column chromatography on DEAE-Sepharose and on Bio-Gel A-5m. p20 was separated from alpha B crystallin and HSP27/28 and was resolved into two fractions, a minor first peak and a major second peak, by column chromatography on S-Sepharose in the presence of 7 M urea. During chromatography on a column of Superdex 75pg, even in the presence of 7 M urea, p20 in the second peak was eluted as aggregates near the exclusion volume of the column, whereas p20 in the first peak was eluted in fractions that corresponded to a lower molecular mass. Further chromatography on a TSK-SP-5PW column yielded pure preparations of each of the two forms of rat and human p20. The fragmentation patterns of the two forms of the respective p20 proteins generated by digestion with endoproteinase Asp-N were identical. The primary structures of rat and human p20, determined with an NH2-terminal sequenator, were highly homologous to those of alpha B crystallin and HSP27/28. p20 was present in all rat tissues examined and at high levels (>1 mu g/mg protein) in the soleus muscle, heart, and diaphragm, as are alpha B crystallin and HSP27. Centrifugation on sucrose density gradients allowed detection of the aggregated form and the small form of p20, as well as of HSP27, in extracts of rat muscle tissues. During heating at 45 degrees C of tissue in vitro, p20 in rat diaphragm was redistributed from the cytoplasm to the insoluble fraction, and dissociation of the aggregated p20 to the small form was enhanced. These results suggest that p20 is related to stress proteins.			KATO, K (corresponding author), AICHI PREFECTURAL COLONY,INST DEV RES,DEPT BIOCHEM,KASUGAI,AICHI 48003,JAPAN.							BHAT SP, 1989, BIOCHEM BIOPH RES CO, V158, P319, DOI 10.1016/S0006-291X(89)80215-3; CORCES V, 1980, P NATL ACAD SCI-BIOL, V77, P5390, DOI 10.1073/pnas.77.9.5390; DUBIN RA, 1989, MOL CELL BIOL, V9, P1083, DOI 10.1128/MCB.9.3.1083; ENGEL WK, 1962, NEUROLOGY, V12, P778, DOI 10.1212/WNL.12.11.778; Gros E., 1967, METHOD ENZYMOL, V11, P238; INAGUMA Y, 1992, BIOCHEM BIOPH RES CO, V182, P844, DOI 10.1016/0006-291X(92)91809-5; INAGUMA Y, 1993, J BIOCHEM-TOKYO, V114, P378, DOI 10.1093/oxfordjournals.jbchem.a124184; IWAKI A, 1990, J BIOL CHEM, V265, P22197; IWAKI T, 1990, J HISTOCHEM CYTOCHEM, V38, P31, DOI 10.1177/38.1.2294148; IWAKI T, 1989, CELL, V57, P71, DOI 10.1016/0092-8674(89)90173-6; KATO K, 1983, METHOD ENZYMOL, V92, P345; KATO K, 1993, BIOCHIM BIOPHYS ACTA, V1175, P257, DOI 10.1016/0167-4889(93)90214-A; KATO K, 1993, J BIOCHEM-TOKYO, V114, P640, DOI 10.1093/oxfordjournals.jbchem.a124230; KATO K, 1976, J IMMUNOL, V116, P1554; KATO K, 1994, J BIOL CHEM, V269, P11274; KATO K, 1991, BIOCHIM BIOPHYS ACTA, V1074, P201, DOI 10.1016/0304-4165(91)90062-L; KATO K, 1992, J BIOL CHEM, V267, P7718; KLEMENZ R, 1991, P NATL ACAD SCI USA, V88, P3652, DOI 10.1073/pnas.88.9.3652; KUROBE N, 1990, BIOMED RES-TOKYO, V11, P187, DOI 10.2220/biomedres.11.187; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; LONGONI S, 1990, MOL CELL BIOCHEM, V97, P113, DOI 10.1007/BF00221052; NAGINENI CN, 1989, FEBS LETT, V249, P89, DOI 10.1016/0014-5793(89)80022-5; TAKEISHI K, 1982, J BIOCHEM-TOKYO, V92, P1173, DOI 10.1093/oxfordjournals.jbchem.a134033; TISSIERES A, 1974, J MOL BIOL, V84, P389, DOI 10.1016/0022-2836(74)90447-1; VINCENT M, 1982, J MOL BIOL, V162, P365, DOI 10.1016/0022-2836(82)90532-0; WELCH WJ, 1984, J BIOL CHEM, V259, P4501; ZANTEMA A, 1992, J BIOL CHEM, V267, P12936	28	198	207	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					15302	15309						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195168				2022-12-25	WOS:A1994NP73800067
J	YAMAZOE, M; SHIRAHIGE, K; RASHID, MB; KANEKO, Y; NAKAYAMA, T; OGASAWARA, N; YOSHIKAWA, H				YAMAZOE, M; SHIRAHIGE, K; RASHID, MB; KANEKO, Y; NAKAYAMA, T; OGASAWARA, N; YOSHIKAWA, H			A PROTEIN WHICH BINDS PREFERENTIALLY TO SINGLE-STRANDED CORE SEQUENCE OF AUTONOMOUSLY REPLICATING SEQUENCE IS ESSENTIAL FOR RESPIRATORY-FUNCTION IN MITOCHONDRIA OF SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-RICH STRAND; MULTIPROTEIN COMPLEX; ESCHERICHIA-COLI; SHUTTLE VECTORS; YEAST; DNA; GENE; IDENTIFICATION; PURIFICATION; ACTIVATION	From yeast nuclear extract, we have identified several DNA-protein complexes using the T-rich strand of core consensus sequence of autonomously replicating sequence by gel shift assay. One of them showed preferential binding to the T-rich sequence of the DNA. We have partially purified a protein constituent of this complex and cloned its gene. The gene has an open reading frame encoding a protein of 380 amino acids (M(r) = 42,100) which is processed to a mature protein of 371 amino acids (M(r) = 40,900). The protein has neither significant amino acid homology with any previously reported proteins nor characteristic motifs. A putative HAP2/HAP3/HAP4 binding sequence was found at about 1 kilobase upstream of the gene. Disruption of the chromosomal gene revealed that the gene was neither essential for cell viability nor involved in DNA replication, but was essential for mitochondrial respiratory function. We therefore named the gene MRF1 for mitochondrial respiratory function 1. In a mrf1 null mutant the absorption spectra of cytochromes b, a, and a(3) were undetectable, although mitochondrial DNA and protein synthesis in mitochondria were intact. Antibodies against MRF1 detected the antigen localized predominantly in the nucleus in vivo. These results suggest that MRF1 is a transcriptional regulatory protein of some genes whose products are necessary for the functional assembly of mitochondrial respiratory proteins.	NARA ADV INST SCI & TECHNOL, GRAD SCH BIOL SCI, DEPT MOLEC BIOL, IKOMA, OSAKA 63001, JAPAN; OSAKA UNIV, SCH MED, DEPT GENET, SUITA, OSAKA 565, JAPAN; OSAKA UNIV, FAC ENGN, DEPT BIOTECHNOL, SUITA, OSAKA 565, JAPAN; MIYAZAKI MED COLL, DEPT BIOCHEM, MIYAZAKI 88916, JAPAN	Nara Institute of Science & Technology; Osaka University; Osaka University; University of Miyazaki			Ogasawara, Naotake/B-7971-2011	Shirahige, Katsuhiko/0000-0002-7862-1144				ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; DIFFLEY JFX, 1991, P NATL ACAD SCI USA, V88, P7864, DOI 10.1073/pnas.88.17.7864; DIFFLEY JFX, 1988, CANCER CELL, V6, P235; DONNINI C, 1986, J BACTERIOL, V168, P1250, DOI 10.1128/jb.168.3.1250-1253.1986; ESTES HG, 1992, P NATL ACAD SCI USA, V89, P11156, DOI 10.1073/pnas.89.23.11156; FANGMAN WL, 1991, ANNU REV CELL BIOL, V7, P375, DOI 10.1146/annurev.cb.07.110191.002111; FORSBURG SL, 1989, ANNU REV CELL BIOL, V5, P153, DOI 10.1146/annurev.cb.05.110189.001101; FOX TD, 1991, METHOD ENZYMOL, V194, P149; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GRAYHACK EJ, 1992, MOL CELL BIOL, V12, P3573, DOI 10.1128/MCB.12.8.3573; GUARENTE L, 1984, CELL, V36, P503, DOI 10.1016/0092-8674(84)90243-5; HOFMANN JFX, 1991, CELL, V64, P951, DOI 10.1016/0092-8674(91)90319-T; KENG T, 1992, MOL GEN GENET, V234, P233, DOI 10.1007/BF00283844; KUNO K, 1991, MOL GEN GENET, V230, P45, DOI 10.1007/BF00290649; KUNO K, 1990, GENE, V95, P73, DOI 10.1016/0378-1119(90)90415-N; LANNIGAN DA, 1989, P NATL ACAD SCI USA, V86, P863, DOI 10.1073/pnas.86.3.863; MARMIROLI N, 1984, MOL GEN GENET, V198, P69, DOI 10.1007/BF00328703; PARISI MA, 1993, MOL CELL BIOL, V13, P1951, DOI 10.1128/MCB.13.3.1951; PARISI MA, 1991, SCIENCE, V252, P965, DOI 10.1126/science.2035027; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P565; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; Sambrook J, 1989, MOL CLONING LABORATO; SANTORO IM, 1991, MOL CELL BIOL, V11, P1944, DOI 10.1128/MCB.11.4.1944; SCHMIDT AMA, 1991, EMBO J, V10, P981, DOI 10.1002/j.1460-2075.1991.tb08032.x; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SHIRAHIGE K, 1993, MOL CELL BIOL, V13, P5043, DOI 10.1128/MCB.13.8.5043; SIKORSKI RS, 1989, GENETICS, V122, P19; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TRAWICK JD, 1989, MOL CELL BIOL, V9, P5350, DOI 10.1128/MCB.9.12.5350; VERDIER JM, 1990, YEAST, V6, P271, DOI 10.1002/yea.320060402; VERMA R, 1992, J BIOL CHEM, V267, P1648; ZEIDLER R, 1993, J BIOL CHEM, V268, P20191	33	26	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					15244	15252						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195160				2022-12-25	WOS:A1994NP73800059
J	NARANDA, T; STRONG, WB; MENAYA, J; FABBRI, BJ; HERSHEY, JWB				NARANDA, T; STRONG, WB; MENAYA, J; FABBRI, BJ; HERSHEY, JWB			2 STRUCTURAL DOMAINS OF INITIATION-FACTOR EIF-4B ARE INVOLVED IN BINDING TO RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL NUCLEAR RIBONUCLEOPROTEIN; MAMMALIAN PROTEIN-SYNTHESIS; MESSENGER-RNA; TRANSLATION; RECOGNITION; EXPRESSION; MECHANISM; CONSENSUS; MUTATIONS; SEQUENCE	Translation initiation factor eIF-4B promotes the binding of mRNA to 40 S preinitiation complexes and together with eIF-4A possesses RNA helicase activity. To elucidate structural features involved in its function, a series of internal and C-terminal deletions, as well as point mutations, were constructed in the eIF-4B cDNA The mutated cDNAs were expressed in transiently transfected COS-1 cells, and mutant forms of the factor were overproduced up to about 25-fold over endogenous eIF-4B levels. Inhibition of dihydrofolate reductase (DHFR) synthesis by high levels of eIF-4B variants was determined in vivo, and the binding of the eIF-4B forms to biotinylated RNA was measured in vitro. The results indicate that the N-terminal region containing the RNA binding motif with its RNP1 and RNP2 consensus elements is sufficient for inhibition of DHFR synthesis. Deletion of the RNP1 sequence abrogates RNA binding, but amino acid substitutions at conserved residues do not always inhibit RNA binding. Deletion of the DRYG domain near the middle of eIF-4B results in inhibition of RNA binding, but not of DHFR synthesis. Up to 164 residues of the C terminus are not required for RNA binding, but removal of 226 or more residues completely inhibits RNA binding, perhaps by the loss of two arginine-rich regions. The results suggest that both the RNA recognition motif and the arginine-rich region are required for stable RNA binding but that both are not necessary for in vivo inhibition of protein synthesis.	UNIV CALIF DAVIS,SCH MED,DEPT BIOL CHEM,DAVIS,CA 95616	University of California System; University of California Davis					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022135, T32GM007377, F32GM014311] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM07377, GM14311, GM22135] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTMANN M, 1993, EMBO J, V12, P3997, DOI 10.1002/j.1460-2075.1993.tb06077.x; BANDZIULIS RJ, 1989, GENE DEV, V3, P431, DOI 10.1101/gad.3.4.431; BENNE R, 1978, J BIOL CHEM, V253, P3078; BRENNAN CA, 1991, J BIOL CHEM, V266, P17296; COPPOLECCHIA R, 1993, EMBO J, V12, P4005, DOI 10.1002/j.1460-2075.1993.tb06078.x; DATAR KV, 1993, NUCLEIC ACIDS RES, V21, P439, DOI 10.1093/nar/21.3.439; DUNCAN R, 1984, J BIOL CHEM, V259, P1882; GRIFO JA, 1984, J BIOL CHEM, V259, P8648; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HOFFMAN DW, 1991, P NATL ACAD SCI USA, V88, P2495, DOI 10.1073/pnas.88.6.2495; JESSEN TH, 1991, EMBO J, V10, P3447, DOI 10.1002/j.1460-2075.1991.tb04909.x; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATTAJ IW, 1989, CELL, V57, P1, DOI 10.1016/0092-8674(89)90164-5; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; METHOT N, 1994, MOL CELL BIOL, V14, P2307, DOI 10.1128/MCB.14.4.2307; MEYER LJ, 1982, BIOCHEMISTRY-US, V21, P4206, DOI 10.1021/bi00261a003; MILBURN SC, 1990, EMBO J, V9, P2783, DOI 10.1002/j.1460-2075.1990.tb07466.x; NAGAI K, 1990, NATURE, V348, P515, DOI 10.1038/348515a0; PAUSE A, 1993, MOL CELL BIOL, V13, P6789, DOI 10.1128/MCB.13.11.6789; PAUSE A, 1992, EMBO J, V11, P2643, DOI 10.1002/j.1460-2075.1992.tb05330.x; RAY BK, 1985, J BIOL CHEM, V260, P7651; RHOADS RE, 1988, TRENDS BIOCHEM SCI, V13, P52, DOI 10.1016/0968-0004(88)90028-X; ROZEN F, 1990, MOL CELL BIOL, V10, P1134, DOI 10.1128/MCB.10.3.1134; Sambrook J, 1989, MOL CLONING LABORATO; SONENBERG N, 1988, PROG NUCLEIC ACID RE, V35, P173, DOI 10.1016/S0079-6603(08)60614-5; STANSSENS P, 1989, NUCLEIC ACIDS RES, V17, P4441, DOI 10.1093/nar/17.12.4441; TAKAGAKI Y, 1992, P NATL ACAD SCI USA, V89, P1403, DOI 10.1073/pnas.89.4.1403; TRACHSEL H, 1977, J MOL BIOL, V116, P755, DOI 10.1016/0022-2836(77)90269-8	31	61	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14465	14472						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	8182051				2022-12-25	WOS:A1994NM06500027
J	QUINN, PG				QUINN, PG			INHIBITION BY INSULIN OF PROTEIN-KINASE A-INDUCED TRANSCRIPTION OF THE PHOSPHOENOLPYRUVATE CARBOXYKINASE GENE - MEDIATION BY THE ACTIVATION DOMAIN OF CAMP RESPONSE ELEMENT-BINDING PROTEIN (CREB) AND FACTORS BOUND TO THE TATA BOX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MULTIHORMONAL REGULATION; MESSENGER-RNA; GTP GENE; EXPRESSION; IDENTIFICATION; INDUCTION; PROMOTER; ISOFORMS; SEQUENCE; UNIT	The minimal promoter/transcription factor requirements for induction of phosphoenolpyruvate carboxykinase (PEPCK) transcription by cAMP-activated protein kinase A (PKA) and inhibition of this induction by insulin were investigated. H4 hepatoma cells were treated with or without insulin following cotransfection with chloramphenicol acetyltransferase reporter genes and expression vectors coding for the cAMP response element-binding protein (CREB) activation domain fused to the GAL4 DNA binding domain (CRG) and the catalytic subunit of PRA. Mutation of the PEPCK CRE to a GAL4 binding site (G4-PEPCK) within the fully responsive PEPCK promoter (-600/+69) made induction by PKA dependent upon cotransfection of CRG and this induction by CRG + PKA was inhibited by insulin. Mutation of the insulin regulatory sequence (Delta IRS-G4-PEPCK) did not prevent induction by cAMP or inhibition by insulin. Fusion of GAL4 binding sites to the PEPCK TATA region (-40/+1, G4-PT) allowed induction by CRG + PKA and inhibition by insulin. However, inhibition by insulin was not observed when the CREB activation domain in CRG was replaced with the activation domain of VP16 (G4-VP16) or when the PEPCK TATA region was replaced with TATA regions from other genes. Our results indicate that the minimal requirements for induction of PEPCK by PKA and inhibition by insulin include: 1) the CREB activation domain, 2) the PEPCK TATA sequence, and 3) insulin-responsive hepatoma cells. These data suggest that specific factors interacting with both the PEPCB TATA region and the CREB activation domain are required for insulin inhibition of PKA-induced transcription.			QUINN, PG (corresponding author), PENN STATE UNIV, COLL MED, DEPT CELLULAR & MOLEC PHYSIOL, HERSHEY, PA 17033 USA.				NIDDK NIH HHS [DK43871] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043871] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEALE EG, 1985, J BIOL CHEM, V260, P748; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; CHU DTW, 1986, J BIOL CHEM, V261, P6848; CHU DTW, 1988, J BIOL CHEM, V263, P13007; FOREST CD, 1990, MOL ENDOCRINOL, V4, P1302, DOI 10.1210/mend-4-9-1302; FRIEDMAN AD, 1988, NATURE, V335, P452, DOI 10.1038/335452a0; GRANNER D, 1991, RECENT PROG HORM RES, V47, P319; HAGIWARA M, 1992, CELL, V70, P105, DOI 10.1016/0092-8674(92)90537-M; IMAI E, 1990, MOL CELL BIOL, V10, P4712, DOI 10.1128/MCB.10.9.4712; LAMERS WH, 1982, P NATL ACAD SCI-BIOL, V79, P5137, DOI 10.1073/pnas.79.17.5137; LIU JS, 1991, J BIOL CHEM, V266, P19095; MAGNUSON MA, 1987, J BIOL CHEM, V262, P14917; MAURER RA, 1989, J BIOL CHEM, V264, P6870; OBRIEN RM, 1991, BIOCHEM J, V278, P609, DOI 10.1042/bj2780609; OBRIEN RM, 1990, SCIENCE, V249, P533, DOI 10.1126/science.2166335; PILKIS SJ, 1992, ANNU REV PHYSIOL, V54, P885, DOI 10.1146/annurev.ph.54.030192.004321; QUINN PG, 1988, MOL CELL BIOL, V8, P3467, DOI 10.1128/MCB.8.8.3467; QUINN PG, 1993, J BIOL CHEM, V268, P16999; RENKAWITZ R, 1990, TRENDS GENET, V6, P192, DOI 10.1016/0168-9525(90)90176-7; ROESLER WJ, 1993, J BIOL CHEM, V268, P3791; RUPPERT S, 1992, EMBO J, V11, P1503, DOI 10.1002/j.1460-2075.1992.tb05195.x; SASAKI K, 1984, J BIOL CHEM, V259, P5242; WADZINSKI BE, 1993, MOL CELL BIOL, V13, P2822, DOI 10.1128/MCB.13.5.2822; XING LP, 1993, MOL ENDOCRINOL, V7, P1484, DOI 10.1210/me.7.11.1484	24	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14375	14378						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	8182041				2022-12-25	WOS:A1994NM06500013
J	DWIVEDI, UN; SHIRAISHI, N; CAMPBELL, WH				DWIVEDI, UN; SHIRAISHI, N; CAMPBELL, WH			IDENTIFICATION OF AN ESSENTIAL CYSTEINE OF NITRATE REDUCTASE VIA MUTAGENESIS OF ITS RECOMBINANT CYTOCHROME-B REDUCTASE DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NADH-CYTOCHROME-B5 REDUCTASE; ESCHERICHIA-COLI; SQUASH NADH; BINDING; EXPRESSION; SEQUENCE; CORN; CHLORELLA; FAMILY; SITE	Five cysteine residues in the recombinant cytochrome b reductase domain of corn leaf NADH:nitrate reductase (EC 1.6.6.1) were modified by site-directed mutagenesis. At least two amino acid replacement mutants were generated for each of the 5 cysteines of this domain. Characteristics of the amino acid replacement mutants correlated well with the structural location of the cysteine residues in the preliminary three-dimensional model of the cytochrome b reductase domain: somewhat exposed cysteines could be replaced by hydrophilic amino acid residues, while more buried cysteines by hydrophobic residues. An exception was found for the invariant cysteine near the C terminus, which is found in all nitrate reductases and also in the closely related NADH: cytochrome b(5) reductase, as well as, most other members of this flavoenzyme family. No substitution for the invariant cysteine yielded highly active enzyme, although these mutants had normal visible spectra. When the in variant cysteine was mutated to serine, the cytochrome b reductase domain was resistant to inhibition by pchloromercuribenzoate, an inhibitor of nitrate reductases. Kinetic analysis suggested that the catalytic efficiency of the mutant was markedly reduced. We concluded, the invariant cysteine plays an important role in catalysis and may be essential for high catalytic efficiency of nitrate reductases.	MICHIGAN TECHNOL UNIV,PHYTOTECHNOL RES CTR,HOUGHTON,MI 49931; MICHIGAN TECHNOL UNIV,DEPT BIOL SCI,HOUGHTON,MI 49931	Michigan Technological University; Michigan Technological University			Dwivedi, Upendra/AAM-7657-2021	Dwivedi, Upendra/0000-0002-4053-2795; Campbell, Wilbur/0000-0001-6432-7537				ALIVERTI A, 1993, BIOCHEMISTRY-US, V32, P6374, DOI 10.1021/bi00076a010; ANDREWS SC, 1992, FEBS LETT, V302, P247, DOI 10.1016/0014-5793(92)80452-M; BARBER MJ, 1986, J BIOL CHEM, V261, P4562; CAMPBELL WH, 1990, TRENDS BIOCHEM SCI, V15, P315, DOI 10.1016/0968-0004(90)90021-3; CAMPBELL WH, 1992, PLANT PHYSIOL, V99, P693, DOI 10.1104/pp.99.2.693; CANNONS AC, 1993, J BIOL CHEM, V268, P3268; CANNONS AC, 1991, BIOCHEM J, V278, P203, DOI 10.1042/bj2780203; CORRELL CC, 1992, SCIENCE, V258, P1604, DOI 10.1126/science.1280857; CORRELL CC, 1993, PROTEIN SCI, V2, P2112, DOI 10.1002/pro.5560021212; DEV IK, 1988, P NATL ACAD SCI USA, V85, P1472, DOI 10.1073/pnas.85.5.1472; EVANS HJ, 1953, PLANT PHYSIOL, V28, P233, DOI 10.1104/pp.28.2.233; GARRETT RH, 1969, J BIOL CHEM, V244, P2870; HANIU M, 1989, BIOCHEMISTRY-US, V28, P8639, DOI 10.1021/bi00447a054; HYDE GE, 1990, BIOCHEM BIOPH RES CO, V168, P1285, DOI 10.1016/0006-291X(90)91168-R; HYDE GE, 1991, J BIOL CHEM, V266, P23542; HYDE GE, 1989, PLANT MOL BIOL, V13, P233, DOI 10.1007/BF00016141; KARPLUS PA, 1991, SCIENCE, V251, P60, DOI 10.1126/science.1986412; KUBO Y, 1988, J BIOL CHEM, V263, P19684; LU GG, 1992, J MOL BIOL, V224, P277, DOI 10.1016/0022-2836(92)90592-8; NASON A, 1953, J BIOL CHEM, V202, P655; NEAME PJ, 1989, J BIOL CHEM, V264, P20894; ORIHUELIRANZO B, 1981, PHOTOSYNTHESIS, V4, P715; RAY FA, 1992, BIOTECHNIQUES, V13, P342; REDINBAUGH MG, 1985, J BIOL CHEM, V260, P3380; RELIMPIO AM, 1971, FEBS LETT, V17, P226, DOI 10.1016/0014-5793(71)80152-7; ROUZE P, 1992, SOC EXP BIOL SEMIN S, V49, P45, DOI 10.1017/CBO9780511600395.004; SHEN AL, 1991, J BIOL CHEM, V266, P19976; SHIRABE K, 1991, J BIOL CHEM, V266, P7531; SOLOMONSON LP, 1990, ANNU REV PLANT PHYS, V41, P225, DOI 10.1146/annurev.pp.41.060190.001301	29	37	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					13785	13791						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188655				2022-12-25	WOS:A1994NL60600014
J	BRAUNHUT, SJ; MOSES, MA				BRAUNHUT, SJ; MOSES, MA			RETINOIDS MODULATE ENDOTHELIAL-CELL PRODUCTION OF MATRIX-DEGRADING PROTEASES AND TISSUE INHIBITORS OF METALLOPROTEINASES (TIMP)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST COLLAGENASE INHIBITOR; EXTRACELLULAR-MATRIX; GROWTH-FACTOR; IV COLLAGENASE; CDNA CLONING; EXPRESSION; SECRETION; PROTEINS; ACID; NEOVASCULARIZATION	We have previously reported that vitamin A inhibits the growth of capillary endothelial cells (EC) (Braunhut, S. J., and Palomares, M. (1991) Microvasc. Res. 41, 47-62). In this study, we have analyzed the effect of retinoids on the production and activity of enzymes involved in the proteolytic degradation of extracellular matrix (ECM) by EC. Substrate gel electrophoresis (zymography) revealed several major matrix metalloproteinases (MMP), of similar to 98-96, 72-68, and 46-45 kDa, whose activities were altered in their amounts in the conditioned media (CM) of EC following retinol or retinoic acid treatment when compared to amounts detected in CM of control cells. All of these gelatinases were inactivated by 1,10-phenanthroline, indicating that they were MMPs. MMP inhibitors (MMPI) were also present in these CM and were separated by gel filtration. Four distinct peaks of MMPIs were detected in the CM of EC. Chromatographic profiles indicated that an similar to 27-kDa MMPI was specifically increased in the CM of retinol-treated cells, whereas a 22-18.5-kDa MMPI was increased in CM derived from retinoic acid treated cells. The MMPI synthesized by retinol-treated EC was immunologically related to tis sue inhibitor of metalloproteinases, type 1 (TIMP-1), and the MMPI produced by retinoic acid-treated cells was related to TIMP-2, as indicated by biosynthetic labeling and immunoprecipitation studies as well as Western blot analysis. Therefore, retinol and retinoic acid treatment of EC differentially affects the types and activity of MMPs and MMPIs produced by the cells, distinct changes which are both correlated with growth inhibition.	HARVARD UNIV,SCH MED,DEPT SURG,BOSTON,MA 02115; CHILDRENS HOSP,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital	BRAUNHUT, SJ (corresponding author), HARVARD UNIV,SCH MED,DEPT OPHTHALMOL,BOSTON,MA 02115, USA.				NCI NIH HHS [CA46776] Funding Source: Medline; NEI NIH HHS [EY06047, EY06726] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA046776] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R29EY006726] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		APODACA G, 1990, CANCER RES, V50, P2322; AUDETTE M, 1983, CANCER DETECT PREV, V6, P497; BOONE TC, 1990, P NATL ACAD SCI USA, V87, P2800, DOI 10.1073/pnas.87.7.2800; BRAUNHUT SJ, 1989, J CELL BIOL, V108, P2467, DOI 10.1083/jcb.108.6.2467; BRAUNHUT SJ, 1991, MICROVASC RES, V41, P47, DOI 10.1016/0026-2862(91)90007-X; BRAUNHUT SJ, 1991, J CELL BIOCHH, V15, pA247; BRENNER CA, 1989, GENE DEV, V3, P848, DOI 10.1101/gad.3.6.848; BUCK J, 1990, J EXP MED, V171, P1613, DOI 10.1084/jem.171.5.1613; BUCK J, 1991, J CELL BIOL, V115, P851, DOI 10.1083/jcb.115.3.851; CARMICHAEL DF, 1986, P NATL ACAD SCI USA, V83, P2407, DOI 10.1073/pnas.83.8.2407; CHEN JM, 1987, CELL, V48, P193, DOI 10.1016/0092-8674(87)90423-5; CHUA CC, 1985, J BIOL CHEM, V260, P5213; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; COTTAM DW, 1992, INVEST OPHTH VIS SCI, V33, P1923; DAMORE PA, 1988, ENDOTHELIAL CELLS, V2, P13; DOCHERTY AJP, 1985, NATURE, V318, P66, DOI 10.1038/318066a0; ENGERMAN RL, 1967, LAB INVEST, V17, P738; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; GOLDBERG GI, 1986, J BIOL CHEM, V261, P6600; GOLDBERG GI, 1989, P NATL ACAD SCI USA, V86, P8207, DOI 10.1073/pnas.86.21.8207; Goodman DS, 1984, RETINOIDS, V2, P2; GROSS JL, 1982, J CELL BIOL, V95, P974, DOI 10.1083/jcb.95.3.974; HERRON GS, 1986, J BIOL CHEM, V261, P2814; HERRON GS, 1986, J BIOL CHEM, V261, P2810; HOWARD EW, 1991, J BIOL CHEM, V266, P13064; JOHNSONWINT B, 1980, ANAL BIOCHEM, V104, P175, DOI 10.1016/0003-2697(80)90295-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MASTERS DB, 1992, BIOTECHNIQUES, V12, P902; Matrisian L.M., 1990, Current Topics in Developmental Biology, V24, P219, DOI 10.1016/S0070-2153(08)60089-7; MIYAZAKI K, 1993, J BIOL CHEM, V268, P14387; MOSCATELLI D, 1980, CELL, V20, P343, DOI 10.1016/0092-8674(80)90620-0; MOSES MA, 1992, J CELL BIOL, V119, P475, DOI 10.1083/jcb.119.2.475; MOSES MA, 1990, SCIENCE, V248, P1408, DOI 10.1126/science.1694043; MOSES MA, 1991, BIO-TECHNOL, V9, P630, DOI 10.1038/nbt0791-630; MURRAY JB, 1986, J BIOL CHEM, V261, P4154; PAIGE K, 1991, IN VITRO CELL DEV B, V27, P151; RUNDHAUG J, 1987, CANCER RES, V47, P5637; SHERMAN MI, 1986, RETINOIDS CELL DIFFE, P161; SPORN MB, 1991, MOL ENDOCRINOL, V5, P3, DOI 10.1210/mend-5-1-3; STETLERSTEVENSON WG, 1989, J BIOL CHEM, V264, P17374; TALHOUK RS, 1992, J CELL BIOL, V118, P1271, DOI 10.1083/jcb.118.5.1271; TSUBOI R, 1990, J CELL BIOL, V110, P511, DOI 10.1083/jcb.110.2.511; UNEMORI EN, 1990, J BIOL CHEM, V265, P445; WAHRENDORF J, 1986, AM J EPIDEMIOL, V123, P544, DOI 10.1093/oxfordjournals.aje.a114269; WELGUS HG, 1990, J CLIN INVEST, V86, P1496, DOI 10.1172/JCI114867; WELGUS HG, 1983, J BIOL CHEM, V258, P2259; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	50	90	90	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13472	13479						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175780				2022-12-25	WOS:A1994NK18400063
J	KULKARNI, MS; SHERMAN, F				KULKARNI, MS; SHERMAN, F			NAT2, AN ESSENTIAL GENE ENCODING METHIONINE N-ALPHA-ACETYLTRANSFERASE IN THE YEAST SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL ACETYLTRANSFERASE; MESSENGER-RNA; MUTANTS; IDENTIFICATION; ACETYLATION; PROTEINS; SEQUENCE; INVIVO; ACTIN; AMINOPEPTIDASE	N-alpha-Acetylation is catalyzed by N-alpha-acetyltransferases, which transfer acetyl groups from acetyl coenzyme A to the N termini of most eukaryotic proteins co-translationally. NAT1 and ARD1 from the yeast Saccharomyces cerevisiae (Mullen, J. R., Kayne, P. S., Moerschell, R. P, Tsunasawa, S., Gribskov, M., Colavito-Shepanski, M., Grunstein, M., Sherman, F., and Sternglanz, R. (1989) EMBO J. 8, 2067-2075) were previously shown to encode the major N-alpha-acetyltransferase, which act on certain proteins having serine, glycine, and alanine but not methionine termini (Sherman, F., Moerschell, R. P., Tsuna sawa, S., and Sternglanz, R. (1993) in Methods in Protein Sequence Analysis (Imahori, K., and Sakiyama, F., eds) pp. 173-181, Plenum Publishing Corp., New York). We have identified a second gene, NAT2, that may correspend to the N-alpha-acetyltransferase acting on a subset of proteins having methionine termini. Crude extracts of a series of heat-sensitive mutants (Ts(-)) were screened for acetylation of a 24-amino acid synthetic peptide Met-Asn-Asn- in vitro. One mutant, nat2-1, out of 115 strains examined, lacked acetyltransferase activity, and the mutation co segregated as a single gene with the heat-sensitive phenotype. The nat2-1 mutants were deficient in the ability to acetylate Met-Asn-Asn- and Met-Glu-Arg-peptides but were able to N-alpha-acetylate Ser-Glu-Phe- and Ser-Tyr-Ser- peptides in vitro. The NAT2 wild-type gene was cloned by complementation of the nat2-1 mutant, and the DNA sequence revealed an open reading frame of 288 amino acids. Gene disruption demonstrated that NAT2 is an essential gene, and hybridization analysis indicated that it is located on chromosome VII. Furthermore, there was limited, but significant identities between the yeast N-alpha-acetyltransferases Nat1, Ard1, Nat2, and Mak3, although no common motifs could be identified. We propose that NAT2 encodes the major N-alpha-acetyl-transferase acting on certain proteins with only methionine termini, and that N-alpha-acetylation of some of these proteins is essential for viability.	UNIV ROCHESTER, SCH MED & DENT, DEPT BIOCHEM, ROCHESTER, NY 14642 USA; UNIV ROCHESTER, SCH MED & DENT, DEPT BIOPHYS, ROCHESTER, NY 14642 USA	University of Rochester; University of Rochester					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM012702] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM 12702] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ANDREW C, 1976, MOL GEN GENET, V144, P29, DOI 10.1007/BF00277300; BERGER EM, 1981, BIOCHEM GENET, V19, P321, DOI 10.1007/BF00504277; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COOK RK, 1992, J BIOL CHEM, V267, P9430; COOK RK, 1991, J BIOL CHEM, V266, P16825; CUMBERLIDGE AG, 1979, J MOL BIOL, V131, P169, DOI 10.1016/0022-2836(79)90072-X; DINARDO S, 1984, P NATL ACAD SCI-BIOL, V81, P2616, DOI 10.1073/pnas.81.9.2616; DRIESSEN HPC, 1985, CRIT REV BIOCHEM MOL, V18, P281, DOI 10.3109/10409238509086784; FABIAN GR, 1987, J BACTERIOL, V169, P1571, DOI 10.1128/jb.169.4.1571-1578.1987; FENG DF, 1987, J MOL EVOL, V25, P351, DOI 10.1007/BF02603120; HARTWELL LH, 1967, J BACTERIOL, V93, P1662, DOI 10.1128/JB.93.5.1662-1670.1967; HERSHKO A, 1984, P NATL ACAD SCI USA, V81, P7051; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JOHANNES FJ, 1991, EMBO J, V10, P3951, DOI 10.1002/j.1460-2075.1991.tb04965.x; JOHNSON GG, 1988, J BIOL CHEM, V263, P9079; KLEFF S, 1992, EMBO J, V11, P699, DOI 10.1002/j.1460-2075.1992.tb05102.x; LEE FJS, 1990, J BIOL CHEM, V265, P3603; LEE FJS, 1989, FEBS LETT, V256, P139, DOI 10.1016/0014-5793(89)81734-X; LEE FJS, 1988, J BIOL CHEM, V263, P14948; LINK AJ, 1991, GENETICS, V127, P681; LUSTIG AJ, 1986, P NATL ACAD SCI USA, V83, P1398, DOI 10.1073/pnas.83.5.1398; MATSUURA S, 1981, P NATL ACAD SCI-BIOL, V78, P4368, DOI 10.1073/pnas.78.7.4368; MOERSCHELL RP, 1990, J BIOL CHEM, V265, P19638; MOOPENN WF, 1977, BIOCHEMISTRY-US, V16, P4872, DOI 10.1021/bi00641a019; MULLEN JR, 1989, EMBO J, V8, P2067, DOI 10.1002/j.1460-2075.1989.tb03615.x; MYERS AM, 1986, GENE, V45, P299, DOI 10.1016/0378-1119(86)90028-4; NICHOLS BP, 1979, P NATL ACAD SCI USA, V76, P5244, DOI 10.1073/pnas.76.10.5244; PARK EC, 1992, EMBO J, V11, P2087, DOI 10.1002/j.1460-2075.1992.tb05267.x; PATEL D, 1992, MOL CELL BIOL, V12, P3297, DOI 10.1128/MCB.12.7.3297; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RAMACHANDRAN J, 1967, ADV ENZYMOL RAMB, V29, P391; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; RUSSO P, 1991, EMBO J, V10, P563, DOI 10.1002/j.1460-2075.1991.tb07983.x; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHERMAN F, 1985, BIOESSAYS, V3, P27, DOI 10.1002/bies.950030108; SHERMAN F, 1993, METHODS IN PROTEIN SEQUENCE ANALYSIS, P173; SHERMAN F, 1991, METHOD ENZYMOL, V194, P21; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SHERMAN F, 1992, J PROTEIN CHEM, V11, P380; SIDDIG MAM, 1980, J MOL BIOL, V137, P125, DOI 10.1016/0022-2836(80)90320-4; Smith T.F., 1981, ADV APPL MATH, V2, P482, DOI DOI 10.1016/0196-8858(81)90046-4; SOKOLIK CW, 1992, J BIOL CHEM, V267, P1067; STONE EM, 1991, MOL CELL BIOL, V11, P2253, DOI 10.1128/MCB.11.4.2253; SYMTH DG, 1979, NATURE, V279, P252; SYMTH DG, 1980, NATURE, V288, P613; TAKAKURA H, 1992, J BIOL CHEM, V267, P5442; TERCERO JC, 1992, J BIOL CHEM, V267, P20270; TERCERO JC, 1992, J BIOL CHEM, V267, P20277; TERCERO JC, 1993, J BACTERIOL, V175, P3192, DOI 10.1128/JB.175.10.3192-3194.1993; THRASH C, 1984, J BIOL CHEM, V259, P1375; TSUNASAWA S, 1985, J BIOL CHEM, V260, P5382; WERTMAN KF, 1992, GENETICS, V132, P337; WINEY M, 1988, GENETICS, V118, P609; YAMADA R, 1991, BIOCHEMISTRY-US, V30, P1010, DOI 10.1021/bi00218a018; YAMADA R, 1991, BIOCHEMISTRY-US, V30, P1017, DOI 10.1021/bi00218a019	59	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13141	13147						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175741				2022-12-25	WOS:A1994NK18400017
J	HOFFSCHUTE, HK; DREES, B; MULLER, M				HOFFSCHUTE, HK; DREES, B; MULLER, M			IDENTIFICATION OF A SOLUBLE SECA/SECB COMPLEX BY MEANS OF A SUBFRACTIONATED CELL-FREE EXPORT SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								We have reconstituted the cell-free synthesis of the Escherichia coli precursor protein LamB from partially purified subfractions of an E. coli cell extract. PreLamB synthesized in this manner is translocated into salt-extracted plasma membrane vesicles only in the presence of SecA/SecB- or SecB-containing preparations of the E. coli cytosol. The most active preparations obtained upon purification were those containing a soluble SecA/ SecB complex. Complex formation between SecA and SecB was verified by co-sedimentation and co-immunoprecipitation. When preLamB was synthesized in the presence of this material, a considerable amount of precursor was recovered from a soluble ternary complex consisting of preLamB, SecA, and SecB. Our results suggest that a soluble SecA/SecB complex participates in the export of preLamB and that this complex is functionally equivalent to a previously described 12 S (7 S) export factor (Muller, M., and Blobel, G. (1984) Proc. Natl. Acad. Sci. U. S. A. 81, 7737-7741; Watanabe, M., and Blobel, G. (1989) Proc. Natl. Acad. Sci. U. S. A. 86, 2728-2732).	UNIV MUNICH, INST PHYS BIOCHEM, D-80336 MUNICH, GERMANY	University of Munich								AKITA M, 1990, J BIOL CHEM, V265, P8164; ALTMAN E, 1990, J BIOL CHEM, V265, P18154; BIEKER KL, 1990, J BIOENERG BIOMEMBR, V22, P291, DOI 10.1007/BF00763169; BIEKER KL, 1990, CELL, V61, P833, DOI 10.1016/0092-8674(90)90193-I; BRUNDAGE L, 1990, CELL, V62, P649, DOI 10.1016/0092-8674(90)90111-Q; CABELLI RJ, 1991, J BIOL CHEM, V266, P24420; CABELLI RJ, 1988, CELL, V55, P683, DOI 10.1016/0092-8674(88)90227-9; COLLIER DN, 1988, CELL, V53, P273, DOI 10.1016/0092-8674(88)90389-3; CROOKE E, 1988, EMBO J, V7, P1831, DOI 10.1002/j.1460-2075.1988.tb03015.x; CROOKE E, 1987, P NATL ACAD SCI USA, V84, P5216, DOI 10.1073/pnas.84.15.5216; CUNNINGHAM K, 1989, EMBO J, V8, P955, DOI 10.1002/j.1460-2075.1989.tb03457.x; DECOCK H, 1992, MOL MICROBIOL, V6, P599; DRIESSEN AJM, 1992, TRENDS BIOCHEM SCI, V17, P219, DOI 10.1016/0968-0004(92)90381-I; ERNST F, 1994, J BIOL CHEM, V269, P12840; FIKES JD, 1989, J BACTERIOL, V171, P402, DOI 10.1128/jb.171.1.402-409.1989; FREUDL R, 1985, EMBO J, V4, P3593, DOI 10.1002/j.1460-2075.1985.tb04122.x; GELLER BL, 1991, MOL MICROBIOL, V5, P2093, DOI 10.1111/j.1365-2958.1991.tb02138.x; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; ITO K, 1992, MOL MICROBIOL, V6, P2423; JOLY JC, 1993, EMBO J, V12, P255, DOI 10.1002/j.1460-2075.1993.tb05651.x; KAWASAKI S, 1993, J BIOL CHEM, V268, P8193; KUMAMOTO CA, 1990, J BIOENERG BIOMEMBR, V22, P337, DOI 10.1007/BF00763171; KUMAMOTO CA, 1989, P NATL ACAD SCI USA, V86, P5320, DOI 10.1073/pnas.86.14.5320; KUMAMOTO CA, 1985, J BACTERIOL, V163, P267, DOI 10.1128/JB.163.1.267-274.1985; KUMAMOTO CA, 1993, J BACTERIOL, V175, P2184, DOI 10.1128/JB.175.8.2184-2188.1993; KUSUKAWA N, 1989, EMBO J, V8, P3517, DOI 10.1002/j.1460-2075.1989.tb08517.x; LECKER S, 1989, EMBO J, V8, P2703, DOI 10.1002/j.1460-2075.1989.tb08411.x; LIEBKE HH, 1987, J BACTERIOL, V169, P1174, DOI 10.1128/jb.169.3.1174-1181.1987; LILL R, 1989, EMBO J, V8, P961, DOI 10.1002/j.1460-2075.1989.tb03458.x; LIU GP, 1989, P NATL ACAD SCI USA, V86, P9213, DOI 10.1073/pnas.86.23.9213; MCFARLAND L, 1993, J BACTERIOL, V175, P2255, DOI 10.1128/JB.175.8.2255-2262.1993; MULLER M, 1984, P NATL ACAD SCI-BIOL, V81, P7421, DOI 10.1073/pnas.81.23.7421; MULLER M, 1984, P NATL ACAD SCI-BIOL, V81, P7737, DOI 10.1073/pnas.81.24.7737; OLIVER DB, 1982, CELL, V30, P311, DOI 10.1016/0092-8674(82)90037-X; OLIVER DB, 1990, J BIOENERG BIOMEMBR, V22, P311, DOI 10.1007/BF00763170; PORITZ MA, 1988, CELL, V55, P4, DOI 10.1016/0092-8674(88)90003-7; SCHATZ PJ, 1990, ANNU REV GENET, V24, P215, DOI 10.1146/annurev.ge.24.120190.001243; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; SWIDERSKY UE, 1990, EMBO J, V9, P1777, DOI 10.1002/j.1460-2075.1990.tb08302.x; TROSCHEL D, 1990, J CELL BIOL, V111, P87, DOI 10.1083/jcb.111.1.87; WATANABE M, 1989, P NATL ACAD SCI USA, V86, P2728, DOI 10.1073/pnas.86.8.2728; WATANABE M, 1989, CELL, V58, P695, DOI 10.1016/0092-8674(89)90104-9; WATANABE T, 1988, J BACTERIOL, V170, P4001, DOI 10.1128/jb.170.9.4001-4007.1988; WEISS JB, 1988, P NATL ACAD SCI USA, V85, P8978, DOI 10.1073/pnas.85.23.8978; WICKNER W, 1991, ANNU REV BIOCHEM, V60, P101, DOI 10.1146/annurev.bi.60.070191.000533	45	44	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12833	12839						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175697				2022-12-25	WOS:A1994NH71600071
J	TANS, G; NICOLAES, GAF; CHRISTELLA, M; THOMASSEN, LGD; HEMKER, HC; VANZONNEVELD, AJ; PANNEKOEK, H; ROSING, J				TANS, G; NICOLAES, GAF; CHRISTELLA, M; THOMASSEN, LGD; HEMKER, HC; VANZONNEVELD, AJ; PANNEKOEK, H; ROSING, J			ACTIVATION OF HUMAN FACTOR-V BY MEIZOTHROMBIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							THROMBIN-CATALYZED ACTIVATION; COAGULATION FACTOR-V; BOVINE FACTOR-V; FACTOR-XA; PROTHROMBIN ACTIVATION; PROTEIN-C; INTERMEDIATE; PHOSPHOLIPIDS; PURIFICATION; CONVERSION	A recombinant human prothrombin was prepared in which Arg(155) was replaced by Ala. The recombinant prothrombin was converted into a meizothrombin derivative (R155A meizothrombin) that was resistant to autocatalytic removal of the fragment 1 domain. R155A meizothrombin appeared to be a potent factor V activator in reaction mixtures that contained negatively charged phospholipid vesicles. Factor V activation by R155A meizothrombin was characterized by second-order rate constants of 0.06 x 10(6) M(-1) S-1 in the absence of phospholipid and 18 x 10(6) M(-1) S-1 in the presence of 60 mu M phospholipid vesicles composed of a 10:90 mol/mol mixture of phosphatidylserine (PS) and phosphatidylcholine (PC). The rate constant for thrombin-catalyzed activation of factor V was hardly affected by the presence of phospholipid vesicles and was 4.0 x 10(6) M(-1) S-1. The initial rate of activation of 3 nM factor V by R155A meizothrombin was a function of the concentration of PS/PC vesicles present in the reaction mixture, and the calculated rate constant reached a plateau value at greater than or equal to 50 mu M PS/PC. Gel electrophoretic analysis of factor V activation showed that R155A meizothrombin and thrombin cleaved the susceptible peptide bonds in factor V at different rates. However, both activators finally generated a factor Va molecule composed of a heavy chain with an M(r) of 104,000 and a light chain doublet with M(r) values of 74,000 and 71,000. Since meizothrombin is one of the major reaction products formed during the initial phase of prothrombin activation, these findings are indicative of a significant contribution of meizothrombin to in vivo factor V activation.	UNIV LIMBURG,CARDIOVASC RES INST,DEPT BIOCHEM,6200 MD MAASTRICHT,NETHERLANDS; UNIV AMSTERDAM,ACAD MED CTR,DEPT BIOCHEM,1105 AZ AMSTERDAM,NETHERLANDS	Hasselt University; Maastricht University; University of Amsterdam; Academic Medical Center Amsterdam			van Zonneveld, Anton Jan/D-8060-2018; Nicolaes, Gerry A.F./A-8421-2016	van Zonneveld, Anton Jan/0000-0002-1676-7738; Nicolaes, Gerry A.F./0000-0002-2482-0412; Thomassen, Stella/0000-0002-9686-6364; Hemker, Coen/0000-0003-1669-2358				BOVILL EG, 1993, THROMB HAEMOSTASIS, V69, P779; DAHLBACK B, 1980, J CLIN INVEST, V66, P583, DOI 10.1172/JCI109890; DOYLE MF, 1990, J BIOL CHEM, V265, P10693; ESMON CT, 1979, J BIOL CHEM, V254, P964; ESMON CT, 1989, J BIOL CHEM, V264, P4743; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HORREVOETS AJG, 1993, J BIOL CHEM, V268, P779; KANE WH, 1981, J BIOL CHEM, V256, P1002; KRISHNASWAMY S, 1986, J BIOL CHEM, V261, P8977; KUWADA M, 1983, ANAL BIOCHEM, V131, P173, DOI 10.1016/0003-2697(83)90150-1; MANN KG, 1990, BLOOD, V76, P1; MONKOVIC DD, 1990, BIOCHEMISTRY-US, V29, P1118, DOI 10.1021/bi00457a004; NESHEIM ME, 1979, J BIOL CHEM, V254, P1326; NESHEIM ME, 1979, J BIOL CHEM, V254, P952; PIETERS J, 1988, BLOOD, V72, P2048; RHEE MJ, 1982, BIOCHEMISTRY-US, V21, P3437, DOI 10.1021/bi00257a029; ROSING J, 1993, J BIOL CHEM, V268, P21130; ROSING J, 1986, J BIOL CHEM, V261, P4224; ROSING J, 1980, J BIOL CHEM, V255, P274; SUZUKI K, 1982, J BIOL CHEM, V257, P6556; TANS G, 1991, J BIOL CHEM, V266, P21864; VANRIJN JLML, 1984, BIOCHEMISTRY-US, V23, P4557, DOI 10.1021/bi00315a008; WALLS JD, 1989, GENE, V81, P139, DOI 10.1016/0378-1119(89)90344-2	23	45	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					15969	15972						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206891				2022-12-25	WOS:A1994NQ72900004
J	GAO, B; KUNOS, G				GAO, B; KUNOS, G			TRANSCRIPTION OF THE RAT ALPHA(1B) ADRENERGIC-RECEPTOR GENE IN LIVER IS CONTROLLED BY 3 PROMOTERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-PROTEIN; MESSENGER-RNAS; ALPHA-1B-ADRENERGIC RECEPTOR; DNA-SYNTHESIS; EXPRESSION; TISSUE; CELLS; DIFFERENTIATION; PURIFICATION; STIMULATION	The proximal 5'-flanking region of the rat alpha(1B) adrenergic receptor (alpha(1B)AR) gene contains discrete transcription start points (tsp) utilized in liver, located at -54, -57 (tsp1), and -443 base pairs (tsp2) upstream from the translation start codon (Gao, B., and Kunos, G. (1993) Gene (Amst.) 131, 243-247). Primer extension analyses using 5' upstream primers now identify an additional cluster of tsp between -1035 and -1340 base pairs (tsp3). Northern blots of rat liver mRNA reveal three alpha(1B)AR mRNAs of 2.3, 2.7, and 3.3 kilobases in length. Transient transfections of putative promoter/pCAT constructs document the existence of three promoters, P1 (-127, -49), P2 (-813, -432), and P3 (-1363, -1107), which direct transcription from tsp1, tsp2, and tsp3, respectively. P1 contains no recognition sequences for known transcription factors. P2 is (G + C)-rich, lacks a TATA box, and contains a cAMP response element, GC, CACC, and GCAAT boxes, and binding sites for nuclear factor I. P3 contains a putative TATATA and CCAAT box and is flanked by recognition sites for the liver-specific CCAAT/enhancer binding protein and hepatocyte nuclear factor 5. These findings indicate that heterogeneity of alpha(1B)AR mRNA in liver is related to transcription of the gene by three distinct promoters. Differential control of these promoters may underlie the well documented developmental and tissue-specific regulation of the alpha(1B)AR.	VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DEPT PHARMACOL & TOXICOL, RICHMOND, VA 23298 USA; VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DEPT MED, RICHMOND, VA 23298 USA	Virginia Commonwealth University; Virginia Commonwealth University								ALLEN LF, 1991, P NATL ACAD SCI USA, V88, P11354, DOI 10.1073/pnas.88.24.11354; AYER DE, 1988, MOL CELL BIOL, V8, P2021, DOI 10.1128/MCB.8.5.2021; BLAKE MC, 1990, MOL CELL BIOL, V10, P6632, DOI 10.1128/MCB.10.12.6632; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; BURCH RM, 1986, J BIOL CHEM, V261, P1236; CARLSON M, 1982, CELL, V28, P145, DOI 10.1016/0092-8674(82)90384-1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; COHEN JB, 1989, CELL, V58, P461, DOI 10.1016/0092-8674(89)90427-3; CRUISE JL, 1985, SCIENCE, V227, P749, DOI 10.1126/science.2982212; DENG CL, 1994, J RECEPTOR RES, V14, P119, DOI 10.3109/10799899409067000; DYNAN WS, 1985, NATURE, V262, P864; GAO B, 1993, GENE, V131, P243, DOI 10.1016/0378-1119(93)90300-R; GARLATTI M, 1993, J BIOL CHEM, V268, P6567; GRANGE T, 1991, NUCLEIC ACIDS RES, V19, P131, DOI 10.1093/nar/19.1.131; HEIKKILA P, 1993, J BIOL CHEM, V268, P24677; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HU ZW, 1993, J BIOL CHEM, V268, P3610; ISHAC EJN, 1992, J CELL PHYSIOL, V152, P79, DOI 10.1002/jcp.1041520111; JOHNSON AC, 1988, MOL CELL BIOL, V8, P4174, DOI 10.1128/MCB.8.10.4174; KOST DP, 1992, PATHOBIOLOGY, V60, P303, DOI 10.1159/000163740; KUNOS G, 1987, BIOCHEM PHARMACOL, V36, P1185, DOI 10.1016/0006-2952(87)90068-2; KUNOS G, 1984, TRENDS PHARMACOL SCI, V5, P380, DOI 10.1016/0165-6147(84)90476-0; LAZARWESLEY E, 1991, ENDOCRINOLOGY, V129, P1116, DOI 10.1210/endo-129-2-1116; LOMASNEY JW, 1991, J BIOL CHEM, V266, P6365; MARTINEZ R, 1987, SCIENCE, V237, P411, DOI 10.1126/science.2440106; MCGEHEE RE, 1990, MOL CELL ENDOCRINOL, V74, P1, DOI 10.1016/0303-7207(90)90200-R; MCGEHEE RE, 1991, J RECEPTOR RES, V11, P773, DOI 10.3109/10799899109064679; MCGROGAN M, 1985, J BIOL CHEM, V260, P2307; MEANS AL, 1990, MOL CELL BIOL, V10, P653, DOI 10.1128/MCB.10.2.653; MISCHOULON D, 1992, MOL CELL BIOL, V12, P2553, DOI 10.1128/MCB.12.6.2553; PAONESSA G, 1988, EMBO J, V7, P3115, DOI 10.1002/j.1460-2075.1988.tb03178.x; QUINN PG, 1993, J BIOL CHEM, V268, P16999; RAMARAO CS, 1992, J BIOL CHEM, V267, P21936; REFSNES M, 1992, J CELL PHYSIOL, V151, P164, DOI 10.1002/jcp.1041510121; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; Sambrook J, 1989, MOL CLONING LABORATO; SCHIBLER U, 1987, ANNU REV GENET, V21, P237, DOI 10.1146/annurev.ge.21.120187.001321; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SPANOPOULOU E, 1991, MOL CELL BIOL, V11, P2216, DOI 10.1128/MCB.11.4.2216; WEBER BL, 1990, SCIENCE, V249, P1291, DOI 10.1126/science.2205003	41	45	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15762	15767						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	8195230				2022-12-25	WOS:A1994NP51300058
J	BANERJEE, AC; RECUPERO, AJ; MAL, A; PIOTRKOWSKI, AM; WANG, DM; HARTER, ML				BANERJEE, AC; RECUPERO, AJ; MAL, A; PIOTRKOWSKI, AM; WANG, DM; HARTER, ML			THE ADENOVIRUS E1A 289R AND 243R PROTEINS INHIBIT THE PHOSPHORYLATION OF P300	ONCOGENE			English	Note							REGION 1A PROTEINS; RETINOBLASTOMA PROTEIN; ESCHERICHIA-COLI; ASSOCIATION; KINASE; TRANSCRIPTION; POLYPEPTIDES; COMPLEXES; PRODUCTS; CYCLINS	A protein of 300 kDa (p300) associates with the adenovirus E1A proteins and has been implicated in the control of cell cycle progression. In mammalian cells, p300 is actively phosphorylated in both quiescent and proliferating cells and its level of phosphorylation increases as it travels from late G1 into M phase. E1A requires p300 for the induction of cellular DNA synthesis and the repression of enhancer mediated transcription, suggesting that p300 may be involved in pathways that are important to cell proliferation and gene expression. Since the activities of most cell cycle regulatory proteins depend on their phosphorylation state, the possibility exists that certain activities of p300 might also be controlled by phosphorylation and that E1A might in fact be affecting these events. We show here by in vitro analysis that E1A inhibits the phosphorylation of p300 by decreasing the rate of incorporation of phosphate into p300. We also show that p300 can be used as a substrate for the cyclin-dependent p33(cdk2) and p34(cdc2) kinases, and propose that E1A might be antagonistic to these enzymes in phosphorylating p300. Thus, these results indicate a possible novel function by which E1A can interfere with cellular pathways.	CLEVELAND CLIN FDN,DEPT MOLEC BIOL,CLEVELAND,OH 44195	Cleveland Clinic Foundation								ABRAHAM SE, 1993, ONCOGENE, V8, P1639; BRUNER M, 1988, J BIOL CHEM, V263, P3984; DATTA S, 1991, J VIROL, V65, P5297, DOI 10.1128/JVI.65.10.5297-5304.1991; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DYSON N, 1992, CANCER SURV, V12, P161; ENGSTROM L, 1984, METHOD ENZYMOL, V107, P130; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FAHA B, 1993, J VIROL, V67, P2456, DOI 10.1128/JVI.67.5.2456-2465.1993; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HU Q, 1991, MOL CELL BIOL, V11, P5729; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; RIKITAKE Y, 1992, MOL CELL BIOL, V12, P2826, DOI 10.1128/MCB.12.6.2826; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; WANG DM, 1992, PROTEIN EXPRES PURIF, V3, P8, DOI 10.1016/1046-5928(92)90050-7; WANG HGH, 1991, MOL CELL BIOL, V11, P4253, DOI 10.1128/MCB.11.8.4253; YACIUK P, 1991, MOL CELL BIOL, V11, P5389, DOI 10.1128/MCB.11.11.5389; YEE SP, 1985, VIROLOGY, V147, P142, DOI 10.1016/0042-6822(85)90234-X; YU IJ, 1991, J CELL BIOL, V114, P1217, DOI 10.1083/jcb.114.6.1217	22	36	37	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1994	9	6					1733	1737						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NL815	8183570				2022-12-25	WOS:A1994NL81500027
J	BRISTOW, RG; JANG, A; PEACOCK, J; CHUNG, S; BENCHIMOL, S; HILL, RP				BRISTOW, RG; JANG, A; PEACOCK, J; CHUNG, S; BENCHIMOL, S; HILL, RP			MUTANT P53 INCREASES RADIORESISTANCE IN RAT EMBRYO FIBROBLASTS SIMULTANEOUSLY TRANSFECTED WITH HPV16-E7 AND/OR ACTIVATED H-RAS	ONCOGENE			English	Article							WILD-TYPE P53; SQUAMOUS-CELL CARCINOMAS; IONIZING-RADIATION; INVITRO RADIOSENSITIVITY; SKIN FIBROBLASTS; CYCLE CHECKPOINT; NIH-3T3 CELLS; EXPRESSION; ONCOGENE; CANCER	Recently, it has been suggested that abrogation of the wild type p53 protein function may alter the cellular response to DNA damaging agents, including ionizing radiation. This study was designed to compare the relative radiosensitivity and tumorigenicity of rat embryo fibroblast (REF) cell lines transfected with a mutant form of the p53 gene (plasmid MTp53pro193), alone, or in combination, with the H-ras (plasmid pEJ6.6) and HPV16-E7 (plasmid pJ4 Omega 16.E7) oncogenes. Transfection of the mutant p53pro193 gene alone resulted in selected clones having increased radioresistance in culture which correlated with increased mutant p53 expression in these clones. However, the co-transfection of mutant p53 and H-vas genes or triple transfection of mutant p53, H-uas and E7 genes resulted in clones with high mutant p53 expression, significantly increased radioresistance and uniform tumorigenicity. There was no correlation between intrinsic radioresistance and spontaneous metastasis in the tumorigenic REF transfectant clones. Stepwise acquisition of radioresistance and an aggressive tumor cell phenotype is observed when the mutant p53 gene and HPV E7 co-operate with the ras oncogene in transfection assays, and can be correlated to increases in mutant p53 expression.	PRINCESS MARGARET HOSP, ONTARIO CANC INST, DEPT RES, DIV CELL & MOLEC BIOL, TORONTO M4X 1K9, ON, CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre	BRISTOW, RG (corresponding author), PRINCESS MARGARET HOSP, ONTARIO CANC INST, DEPT RADIAT ONCOL, DIV EXPTL THERAPEUT, 500 SHERBOURNE ST, TORONTO M4X 1K9, ON, CANADA.			Hill, Richard Peter/0000-0001-5331-8045; Benchimol, Samuel/0000-0003-3433-890X; Bristow, Robert/0000-0002-8553-9544				ALAPETITE C, 1991, INT J RADIAT BIOL, V59, P385, DOI 10.1080/09553009114550351; ALLAM A, 1993, J NATL CANCER I, V85, P1954, DOI 10.1093/jnci/85.23.1954; BARBOSA MS, 1990, EMBO J, V9, P153, DOI 10.1002/j.1460-2075.1990.tb08091.x; BRACHMAN DG, 1993, CANCER RES, V53, P3667; BRISTOW RG, 1990, INT J RADIAT ONCOL, V18, P331, DOI 10.1016/0360-3016(90)90098-5; BROCK WA, 1989, INT J RADIAT BIOL, V56, P751, DOI 10.1080/09553008914552001; CHANG EH, 1987, SCIENCE, V237, P1036, DOI 10.1126/science.3616624; CROOK T, 1992, LANCET, V339, P1070, DOI 10.1016/0140-6736(92)90662-M; CROOK T, 1991, J VIROL, V65, P505, DOI 10.1128/JVI.65.1.505-510.1991; CROOK T, 1992, EMBO J, V11, P3935, DOI 10.1002/j.1460-2075.1992.tb05487.x; DATTA R, 1992, CELL GROWTH DIFFER, V3, P637; DAVIDOFF AM, 1991, SURGERY, V110, P259; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; FUJIWARA T, 1993, CANCER RES, V53, P4129; GIRINSKY T, 1992, INT J RADIAT ONCOL, V25, P3; GRANT ML, 1990, ONCOGENE, V5, P1159; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; Hill R. P., 1992, BASIC SCI ONCOLOGY, P259; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; JUNG M, 1992, CANCER RES, V52, P6390; KASID U, 1989, SCIENCE, V243, P1354, DOI 10.1126/science.2466340; KASID U, 1993, CANCER RES, V61, P195; KASID UN, 1989, CANCER RES, V49, P3396; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MCKENNA WG, 1990, CANCER RES, V50, P97; MENDONCA MS, 1991, INT J RADIAT BIOL, V59, P1195, DOI 10.1080/09553009114551071; MUSCHEL RJ, 1991, CANCER RES, V51, P5113; ONG A, 1993, RADIAT RES, V134, P251, DOI 10.2307/3578467; PARDO FS, 1991, P NATL ACAD SCI USA, V88, P10652, DOI 10.1073/pnas.88.23.10652; PEACOCK J, 1990, ONCOGENE, V2, P1769; PIROLLO KF, 1993, RADIAT RES, V135, P234, DOI 10.2307/3578300; ROVINSKI B, 1988, ONCOGENE, V2, P445; SAMID D, 1991, RADIAT RES, V126, P244, DOI 10.2307/3577825; SASAKI K, 1986, CYTOMETRY, V7, P391, DOI 10.1002/cyto.990070415; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SIDERANSKY D, 1992, NATURE, V355, P846; SKLAR MD, 1988, SCIENCE, V239, P645, DOI 10.1126/science.3277276; SLICHENMYER WJ, 1993, CANCER RES, V53, P4164; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; STEEG PS, 1988, CANCER RES, V48, P6550; STEPHENS LC, 1993, RADIAT RES, V135, P75, DOI 10.2307/3578399; SU LN, 1992, INT J RADIAT BIOL, V62, P461, DOI 10.1080/09553009214552341; SUIT HD, 1992, INT J RADIAT ONCOL, V23, P653, DOI 10.1016/0360-3016(92)90025-D; SUN XF, 1992, LANCET, V340, P1369, DOI 10.1016/0140-6736(92)92558-W; TAYLOR WR, 1992, ONCOGENE, V7, P1383; TISHLER RB, 1993, CANCER RES, V53, P2212; TOMMASINO M, 1993, ONCOGENE, V8, P195; VISAKORPI T, 1992, J NATL CANCER I, V84, P883, DOI 10.1093/jnci/84.11.883; VOUSDEN K, 1993, FASEB J, V7, P872, DOI 10.1096/fasebj.7.10.8393818; WEISCHELBAUM RR, 1991, JNCI-J NATL CANCER I, V83, P480; WEST CML, 1993, BRIT J CANCER, V68, P819, DOI 10.1038/bjc.1993.434; YIN XY, 1993, INT J CANCER, V54, P322, DOI 10.1002/ijc.2910540226; YOUNG SD, 1990, JNCI-J NATL CANCER I, V82, P371, DOI 10.1093/jnci/82.5.371; ZAMBETTI GP, 1992, P NATL ACAD SCI USA, V89, P3952, DOI 10.1073/pnas.89.9.3952; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485	59	91	92	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1994	9	6					1527	1536						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NL815	8183546				2022-12-25	WOS:A1994NL81500002
J	MIYASHITA, T; KRAJEWSKI, S; KRAJEWSKA, M; WANG, HG; LIN, HK; LIEBERMANN, DA; HOFFMAN, B; REED, JC				MIYASHITA, T; KRAJEWSKI, S; KRAJEWSKA, M; WANG, HG; LIN, HK; LIEBERMANN, DA; HOFFMAN, B; REED, JC			TUMOR-SUPPRESSOR P53 IS A REGULATOR OF BCL-2 AND BAX GENE-EXPRESSION IN-VITRO AND IN-VIVO	ONCOGENE			English	Article							HUMAN FOLLICULAR LYMPHOMA; PROGRAMMED CELL-DEATH; WILD-TYPE P53; ANTICANCER AGENTS; INDUCED APOPTOSIS; PROTOONCOGENE; PROTEIN; LINE; ONCOPROTEIN; CARCINOMA	The p53 tumor suppressor gene product can induce apoptotic cell death through an unknown mechanism. Here we demonstrate that a temperature-sensitive p53 induces temperature-dependent decreases in the expression of the apoptosis-suppressing gene bcl-2 in the murine leukemia cell M1, while simultaneously stimulating increases in the expression of bax, a gene which encodes a dominant-inhibitor of the Bcl-2 protein. Mice deficient in p53 exhibit increases in Bcl-2 and decreases in Bax protein levels in several tissues as determined by immunohistochemical and immunoblot methods. The findings suggest a potential mechanism by which p53 regulates apoptosis, as well as responses to radiation and chemotherapeutic drugs in cancer.	LA JOLLA CANC RES FDN,CANC RES CTR,LA JOLLA,CA 92037; TEMPLE UNIV,SCH MED,FELS INST CANC RES & MOLEC BIOL,PHILADELPHIA,PA 19140; UNIV PENN,DEPT PHARMACOL,PHILADELPHIA,PA 19104	Sanford Burnham Prebys Medical Discovery Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Pennsylvania			Wang, Hong-Gang/A-3018-2015	Wang, Hong-Gang/0000-0003-0551-0571	NCI NIH HHS [CA43618, CA-60181, CA51162] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA060181, R01CA043618] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CAMPOS L, 1993, BLOOD, V81, P3091; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DEJONG D, 1994, CANCER RES, V54, P256; EASTMAN A, 1990, CANCER CELL-MON REV, V2, P275; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; HARPER JW, 1993, CELL, V75, P805; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JACOBSON MD, 1993, NATURE, V361, P365, DOI 10.1038/361365a0; KITADA S, IN PRESS ANTISENSE R; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LU QL, 1993, INT J CANCER, V53, P29, DOI 10.1002/ijc.2910530107; MCDONNELL TJ, 1992, CANCER RES, V52, P6940; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MIYASHITA T, 1993, BLOOD, V81, P151; MONAGHAN P, 1992, J HISTOCHEM CYTOCHEM, V40, P1819, DOI 10.1177/40.12.1453000; MUNAKATA S, 1993, J HISTOCHEM CYTOCHEM, V41, P1241, DOI 10.1177/41.8.8331288; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PARNES JR, 1981, P NATL ACAD SCI-BIOL, V78, P2253, DOI 10.1073/pnas.78.4.2253; PEZZELLA F, 1993, NEW ENGL J MED, V329, P690, DOI 10.1056/NEJM199309023291003; REED JC, 1989, ONCOGENE RES, V4, P271; REED JC, 1991, CANCER RES, V51, P6529; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; TSUJIMOTO Y, 1987, P NATL ACAD SCI USA, V84, P1329, DOI 10.1073/pnas.84.5.1329; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WANG YS, 1993, ONCOGENE, V8, P3427; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YUNIS JJ, 1989, NEW ENGL J MED, V320, P1047, DOI 10.1056/NEJM198904203201605	33	2161	2223	1	126	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1994	9	6					1799	1805						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NL815	8183579				2022-12-25	WOS:A1994NL81500036
J	OETKEN, C; COUTURE, C; BERGMAN, M; BONNEFOYBERARD, N; WILLIAMS, S; ALITALO, K; BURN, P; MUSTELIN, T				OETKEN, C; COUTURE, C; BERGMAN, M; BONNEFOYBERARD, N; WILLIAMS, S; ALITALO, K; BURN, P; MUSTELIN, T			TCR/CD3-TRIGGERING CAUSES INCREASED ACTIVITY OF THE P50(CSK) TYROSINE KINASE AND ENGAGEMENT OF ITS SH2 DOMAIN	ONCOGENE			English	Article							CELL ANTIGEN RECEPTOR; CD45 PHOSPHOTYROSINE PHOSPHATASE; TERMINAL SRC KINASE; PROTEIN-KINASE; PHOSPHOLIPASE C-GAMMA-1; SIGNAL TRANSDUCTION; C-SRC; T-CELLS; AUTOPHOSPHORYLATION SITE; CROSS-LINKING	The majority of known protein tyrosine kinases are integral membrane proteins or bound to cellular membranes via a covalently attached myristic acid. An exception is the newly described p50(csk) tyrosine kinase, which is believed to control the activity of the sue-family of protein tyrosine kinases. This small kinase does not contain a myristylation signal or other known membrane attachment motifs, and indeed appears to be cytosolic. Recently, we found that p50(csk) specifically phosphorylates the negative regulatory Tyr-505 of the T cell-specific sue-family kinase p56(lck), and thereby suppresses its catalytic activity. Here we show that p50(csk) is activated in Jurkat T cells within one minute after stimulation of the cells with anti-CD3 MAbs. In parallel with this activation, p50(csk) formed a stable complex with one major 72 kDa tyrosine phosphorylated protein and minor polypeptides at 90 and 110 kDa. The isolated SH2 domain of p50(csk) specifically bound the 72 kDa protein in lysates from activated, but not resting, T or B cells, By several criteria, the 72 kDa protein was not a tyrosine kinase itself and it did not react with antibodies to a panel of known proteins of this molecular size. Our results suggest that p50(csk) is rapidly engaged via its SH2 domain and participates in the earliest events of T cell activation.	LA JOLLA INST ALLERGY & IMMUNOL, DIV CELL BIOL, LA JOLLA, CA 92037 USA; UNIV HELSINKI, DEPT PATHOL, CANC BIOL LAB, SF-00014 HELSINKI, FINLAND; F HOFFMANN LA ROCHE & CO LTD, PHARMACEUT RES NEW TECHNOL, DEPT BIOL, BASEL, SWITZERLAND	La Jolla Institute for Immunology; University of Helsinki; Roche Holding			Alitalo, Kari K/J-5013-2014; Bonnefoy, Nathalie/J-2536-2012	Alitalo, Kari K/0000-0002-7331-0902; Bonnefoy, Nathalie/0000-0003-4814-6722; Mustelin, Tomas/0000-0001-5912-8840	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM048960] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-48960] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAM N, 1991, NATURE, V350, P62, DOI 10.1038/350062a0; AMREIN KE, 1988, P NATL ACAD SCI USA, V85, P4247, DOI 10.1073/pnas.85.12.4247; APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; AUTERO M, 1994, MOL CELL BIOL, V14, P1308, DOI 10.1128/MCB.14.2.1308; BENNETT BD, 1994, IN PRESS J BIOL CHEM; BERGMAN M, 1992, EMBO J, V11, P2919, DOI 10.1002/j.1460-2075.1992.tb05361.x; BOUGERET C, 1993, ONCOGENE, V8, P1241; CHALUPNY NJ, 1991, EMBO J, V10, P1201, DOI 10.1002/j.1460-2075.1991.tb08061.x; CHAN AC, 1991, P NATL ACAD SCI USA, V88, P9166, DOI 10.1073/pnas.88.20.9166; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CHOW LML, 1993, NATURE, V365, P156, DOI 10.1038/365156a0; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; COUTURE C, 1994, IN PRESS P NAT ACAD; DANIELIAN S, 1992, EUR J IMMUNOL, V22, P2915, DOI 10.1002/eji.1830221124; DASILVA AJ, 1992, MOL IMMUNOL, V29, P1417, DOI 10.1016/0161-5890(92)90215-J; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; HSI ED, 1989, J BIOL CHEM, V264, P10836; HURLEY TR, 1993, MOL CELL BIOL, V13, P1651, DOI 10.1128/MCB.13.3.1651; JUNE CH, 1990, J IMMUNOL, V144, P1591; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KLAGES S, 1994, IN PRESS P NATL ACAD; LIU XQ, 1993, ONCOGENE, V8, P1119; LUO KX, 1990, MOL CELL BIOL, V10, P5305, DOI 10.1128/MCB.10.10.5305; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; MCFARLAND EDC, 1993, P NATL ACAD SCI USA, V90, P1402, DOI 10.1073/pnas.90.4.1402; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; MORGAN DO, 1991, METHOD ENZYMOL, V200, P645; MURPHY SM, 1993, MOL CELL BIOL, V13, P5290, DOI 10.1128/MCB.13.9.5290; MUSTELIN T, 1989, P NATL ACAD SCI USA, V86, P6302, DOI 10.1073/pnas.86.16.6302; MUSTELIN T, 1992, EUR J IMMUNOL, V22, P1173, DOI 10.1002/eji.1830220510; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; MUSTELIN T, 1989, IMMUNOL TODAY, V10, P189, DOI 10.1016/0167-5699(89)90322-8; MUSTELIN T, 1990, ONCOGENE, V5, P809; MUSTELIN T, 1991, SCAND J IMMUNOL, V34, P259, DOI 10.1111/j.1365-3083.1991.tb01545.x; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; OETKEN C, 1992, EUR J HAEMATOL, V49, P208; OKADA M, 1991, J BIOL CHEM, V266, P24249; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; PARK DJ, 1991, P NATL ACAD SCI USA, V88, P5453, DOI 10.1073/pnas.88.12.5453; PARTANEN J, 1991, ONCOGENE, V6, P2013; ROUSSEL RR, 1991, P NATL ACAD SCI USA, V88, P10696, DOI 10.1073/pnas.88.23.10696; SABE H, 1992, P NATL ACAD SCI USA, V89, P2190, DOI 10.1073/pnas.89.6.2190; SABE H, 1992, MOL CELL BIOL, V12, P4706, DOI 10.1128/MCB.12.10.4706; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SAMELSON LE, 1986, NATURE, V324, P674, DOI 10.1038/324674a0; SECRIST JP, 1991, J BIOL CHEM, V266, P12135; SHOELSON SE, 1993, EMBO J, V12, P795, DOI 10.1002/j.1460-2075.1993.tb05714.x; SIEH M, 1993, EMBO J, V12, P315, DOI 10.1002/j.1460-2075.1993.tb05659.x; SILICIANO JD, 1992, P NATL ACAD SCI USA, V89, P11194, DOI 10.1073/pnas.89.23.11194; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; STOVER DR, 1991, P NATL ACAD SCI USA, V88, P7704, DOI 10.1073/pnas.88.17.7704; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TSYGANKOV AY, 1992, J BIOL CHEM, V267, P18259; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; VONWILLEBRAND M, 1994, EUR J IMMUNOL, V24, P234, DOI 10.1002/eji.1830240137; WEBER JR, 1992, J EXP MED, V176, P373, DOI 10.1084/jem.176.2.373; WEISS A, 1991, P NATL ACAD SCI USA, V88, P5484, DOI 10.1073/pnas.88.13.5484	58	34	34	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1994	9	6					1625	1631						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NL815	8183556				2022-12-25	WOS:A1994NL81500013
J	CANTLEY, LG; CUNHA, MJ; ZHOU, XM				CANTLEY, LG; CUNHA, MJ; ZHOU, XM			OUABAIN-RESISTANT OR6 CELLS EXPRESS THE MURINE ALPHA(1)-SUBUNIT OF THE NA,K-ATPASE WITH A T-797-I-797 SUBSTITUTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; ALPHA-SUBUNIT; GENE; IDENTIFICATION; SENSITIVITY; REGION; CHAIN; CDNA	Introduction of the murine ''ouabain resistance gene'' (Levenson, R., Racaniello, V., Albritton, L., and Housman, D. (1984) Proc. Natl. Acad. Sci. U. S. A. 81, 1489-1493) into African Green monkey CV1 cells reportedly resulted in one cell line, OR6 cells, which was found to be resistant to >1 mM ouabain (English, L., Epstein, J., Cantley, L., Housman, D., and Levenson, R. (1985) J. Biol. Chem. 260, 1114-1119). The present analysis of the genomic sequence of the alpha(1)-subunit of the Na,K-ATPase from OR6 cells reveals copies of the gene for the murine and human alpha(1)-subunit of the Na,K-ATPase and not the monkey gene, indicating that the cells have been misidentified. The sequence of the murine alpha(1)-subunit from OR6 cells reveals a single point mutation encoding a T-797-I-797 amino acid substitution at the H-6 membrane border. Transfection of CV1 cells with a murine alpha(1) cDNA containing this point mutation resulted in cells with an IC50 for ouabain of approximately 5 mM. These data show that the super ouabain-resistant phenotype of OR6 cells is due to expression of a mutant form of the murine alpha(1)-subunit of the sodium pump (rather than the ouabain resistance gene) and further support the recent data suggesting involvement of the H-5-H-6 domain in ouabain inhibition of the sodium pump.	ARIAD PHARMACEUT, BOSTON, MA 02139 USA	Takeda Pharmaceutical Company Ltd; Takeda Oncology	CANTLEY, LG (corresponding author), HARVARD UNIV, BETH ISRAEL HOSP, SCH MED, DIV NEPHROL, 330 BROOKLINE AVE, BOSTON, MA 02215 USA.				NIDDK NIH HHS [DK18078] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK018078] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BURNS EL, 1993, J BIOL CHEM, V268, P25632; CANTLEY LG, 1992, J BIOL CHEM, V267, P17271; EMANUEL JR, 1988, J BIOL CHEM, V263, P7726; EMANUEL JR, 1989, MOL CELL BIOL, V9, P3744, DOI 10.1128/MCB.9.9.3744; ENGLISH LH, 1985, J BIOL CHEM, V260, P1114; EPSTEIN JA, 1988, AM J PHYSIOL, V254, pC847, DOI 10.1152/ajpcell.1988.254.6.C847; KARLISH SJD, 1993, J BIOL CHEM, V268, P3471; KENT RB, 1987, SCIENCE, V237, P901, DOI 10.1126/science.3039660; LEVENSON R, 1984, P NATL ACAD SCI-BIOL, V81, P1489, DOI 10.1073/pnas.81.5.1489; LINGREL JB, 1990, PROG NUCLEIC ACID RE, V38, P37; LUGO TG, 1985, BIOCHEM GENET, V23, P1, DOI 10.1007/BF00499108; PRICE EM, 1989, J BIOL CHEM, V264, P21902; PRICE EM, 1990, J BIOL CHEM, V265, P6638; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULTHEIS PJ, 1993, J BIOL CHEM, V268, P22686; SCHULZ JT, 1988, J BIOL CHEM, V263, P624; SWEADNER KJ, 1991, SOC GEN PHY, V46, P63; ZHOU XM, 1993, J BIOL CHEM, V268, P4126	18	6	6	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					15358	15361						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195174				2022-12-25	WOS:A1994NP73800075
J	SUN, XM; COHEN, GM				SUN, XM; COHEN, GM			MG2+-DEPENDENT CLEAVAGE OF DNA INTO KILOBASE PAIR FRAGMENTS IS RESPONSIBLE FOR THE INITIAL DEGRADATION OF DNA IN APOPTOSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CALCIUM-DEPENDENT ENDONUCLEASE; PROGRAMMED CELL-DEATH; INTERNUCLEOSOMAL FRAGMENTATION; ACTIVATION; THYMOCYTES; CHROMATIN; ABSENCE; IDENTIFICATION; PURIFICATION	Cleavage of DNA into oligonucleosomal fragments, recognizable as a DNA ladder on agarose gel electrophoresis, is usually considered as the biochemical hallmark of apoptosis. Recently, it has been shown that this internucleosomal cleavage is preceded by the formation of large fragments of DNA of greater than or equal to 700, 200-250, and 30-50 kilobase pairs (kbp) in length. Using isolated thymocyte nuclei, we now demonstrate that the formation of these large fragments is Mg2+- but not Ca2+-dependent. Further degradation of greater than or equal to 460- and 200-250-kbp fragments to 30-5O-kbp fragments but not oligonucleosomal cleavage is also Mg2+-dependent but is facilitated by Ca2+. In contrast, formation of oligonucleosomal fragments does not occur in the presence of either Ca2+ or Mg2+ alone but requires the presence of both cations. These results sup port the hypothesis that the formation of these large fragments and the subsequent internucleosomal cleavage are distinct steps in the degradation of DNA in apoptosis in thymocytes.	UNIV LEICESTER, MRC, TOXICOL UNIT, LEICESTER LE1 9HN, ENGLAND	University of Leicester			Cohen, Gerald M/A-1687-2008					ARENDS MJ, 1990, AM J PATHOL, V136, P593; ARENDS MJ, 1991, INT REV EXP PATHOL, V32, P223; BARRES BA, 1992, CELL, V70, P31, DOI 10.1016/0092-8674(92)90531-G; BARRY MA, 1993, ARCH BIOCHEM BIOPHYS, V300, P440, DOI 10.1006/abbi.1993.1060; BELLARD M, 1989, METHOD ENZYMOL, V170, P317; BROWN DG, 1993, J BIOL CHEM, V268, P3037; COHEN GM, 1992, BIOCHEM J, V286, P331, DOI 10.1042/bj2860331; COHEN JJ, 1984, J IMMUNOL, V132, P38; COHEN JJ, 1992, ANNU REV IMMUNOL, V10, P267, DOI 10.1146/annurev.immunol.10.1.267; COMPTON MM, 1992, CANCER METAST REV, V11, P105, DOI 10.1007/BF00048058; FILIPSKI J, 1990, EMBO J, V9, P1319, DOI 10.1002/j.1460-2075.1990.tb08241.x; GAIDO ML, 1991, J BIOL CHEM, V266, P18580; GOTTLIEB J, 1990, J BIOL CHEM, V265, P10836; HEWISH DR, 1973, BIOCHEM BIOPH RES CO, V52, P475, DOI 10.1016/0006-291X(73)90736-5; KAWABATA H, 1993, BIOCHEM BIOPH RES CO, V191, P247, DOI 10.1006/bbrc.1993.1209; KOKILEVA L, 1981, INT J BIOCHEM, V13, P483, DOI 10.1016/0020-711X(81)90121-X; MCCONKEY DJ, 1990, ARCH BIOCHEM BIOPHYS, V278, P284, DOI 10.1016/0003-9861(90)90261-V; NELIPOVICH PA, 1988, INT J RADIAT BIOL, V53, P749, DOI 10.1080/09553008814551111; NIKONOVA LV, 1982, BIOCHIM BIOPHYS ACTA, V699, P281, DOI 10.1016/0167-4781(82)90118-X; OBERHAMMER F, 1993, J CELL SCI, V104, P317; OBERHAMMER F, 1993, EMBO J, V12, P3679, DOI 10.1002/j.1460-2075.1993.tb06042.x; ORRENIUS S, 1992, TOXICOL LETT, V64-5, P357, DOI 10.1016/0378-4274(92)90208-2; PEITSCH MC, 1993, EMBO J, V12, P371, DOI 10.1002/j.1460-2075.1993.tb05666.x; PRESTON RR, 1990, SCIENCE, V250, P285, DOI 10.1126/science.2218533; SOOKITOTH A, 1989, EXP CELL RES, V184, P44, DOI 10.1016/0014-4827(89)90362-5; SORENSON CM, 1990, JNCI-J NATL CANCER I, V82, P749, DOI 10.1093/jnci/82.9.749; TOMEI LD, 1993, P NATL ACAD SCI USA, V90, P853, DOI 10.1073/pnas.90.3.853; WALKER PR, 1986, J BIOL CHEM, V261, P7044; WALKER PR, 1991, CANCER RES, V51, P1078; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WILLIAMS G T, 1992, Trends in Cell Biology, V2, P263, DOI 10.1016/0962-8924(92)90198-V; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0	33	130	136	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					14857	14860						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195114				2022-12-25	WOS:A1994NP73800003
J	BURNETT, VL; LAWTON, MP; PHILPOT, RM				BURNETT, VL; LAWTON, MP; PHILPOT, RM			CLONING AND SEQUENCING OF FLAVIN-CONTAINING MONOOXYGENASES FMO3 AND FMO4 FROM RABBIT AND CHARACTERIZATION OF FMO3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PIG-LIVER-MICROSOMES; FUNCTION AMINE OXIDASE; MULTIPLE FORMS; GEL-ELECTROPHORESIS; COVALENT STRUCTURE; RIBONUCLEIC-ACID; MOUSE; PURIFICATION; LUNG; GENE	The flavin-containing monooxygenases (FMO) are a family of enzymes that contain putative FAD- and NADPH-binding domains within the first 200 residues of their N termini. The cDNAs encoding these enzymes contain an area of relatively high identity over the 5' half of the coding region. Rabbit genomic DNA was probed under low stringency conditions, with a mixture of 5' cDNA fragments encoding rabbit FMO1, FMO2, or FMO5. Bands associated specifically with FMO1, FMO2, or FMO5 were resolved by analysis at high stringency with individual probes. Several bands were detected that could not be assigned to FMO1, FMO2, or FMO5. The behavior of the 5' probes at low versus high stringency was used to facilitate the isolation of cDNAs corresponding to the unknown DNA bands. A cDNA library was constructed from rabbit liver mRNA and screened under low stringency hybridization conditions (30 degrees C, 50% formamide, 1 x SSC, 0.1% SDS) with the mixture of 5' FMO1, FMO2, and FMO5 cDNA probes. A total of 157 clones was detected. Of these, 117 clones remained under high stringency hybridization conditions (65 degrees C, 50% formamide, 0.1 x SSC, 0.1% SDS) and were identified as FMO1 (95 clones) or FMO5 (22 clones). Of the 40 remaining clones, 36 were characterized by sequence analysis as encoding FMO3, previously identified at the protein level by Ozols (Ozols, J. (1991) Arch. Biochem. Biophys. 290, 103-115) as a second rabbit liver FMO. Four clones were shown to encode an FMO not previously described for the rabbit, FMO4. No clones encoding FMO2 were isolated from the liver library. Sequence analysis revealed that FMO3 and FMO4 are 56% identical, and analysis of genomic DNA indicated that each is encoded by a single gene. Message distribution was tissue-, species-, and form-specific. The properties of FMO3 cDNA expressed in Escherichia coli were found to be more similar to those of FMO1 than FMO2, but to differ significantly from both. Rabbit genomic DNA was probed under conditions of low stringency with a mixture of 5' cDNA fragments encoding all five FMO forms and produced results consistent with the possibility of one additional FMO.	NIEHS,CELLULAR & MOLEC PHARMACOL LAB,RES TRIANGLE PK,NC 27709; N CAROLINA STATE UNIV,DEPT TOXICOL,RALEIGH,NC 27695	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of North Carolina; North Carolina State University								ARMSTRONG KA, 1989, YEAST GENETIC ENG, P165; ATTAASAFOADJEI E, 1993, J BIOL CHEM, V268, P9681; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; AYESH R, 1990, PHARMACOL THERAPEUT, V45, P387, DOI 10.1016/0163-7258(90)90074-C; BAILEY JM, 1976, ANAL BIOCHEM, V70, P75, DOI 10.1016/S0003-2697(76)80049-8; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DANNAN GA, 1982, MOL PHARMACOL, V22, P787; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DEVEREUX TR, 1977, CHEM-BIOL INTERACT, V18, P277, DOI 10.1016/0009-2797(77)90014-X; DIXIT A, 1984, ARCH BIOCHEM BIOPHYS, V233, P50, DOI 10.1016/0003-9861(84)90600-3; DOLPHIN C, 1991, J BIOL CHEM, V266, P12379; DOLPHIN CT, 1992, BIOCHEM J, V287, P261, DOI 10.1042/bj2870261; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GASSER R, 1990, BIOCHEMISTRY-US, V29, P119, DOI 10.1021/bi00453a014; GASSER R, 1988, MOL PHARMACOL, V32, P22; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; GUAN SH, 1991, BIOCHEMISTRY-US, V30, P9892, DOI 10.1021/bi00105a012; HAJJAR NP, 1982, BIOCHEM PHARMACOL, V31, P745, DOI 10.1016/0006-2952(82)90458-0; HOVLAND P, 1989, GENE, V83, P57, DOI 10.1016/0378-1119(89)90403-4; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; ITOH K, 1993, BIOCHIM BIOPHYS ACTA, V1173, P165, DOI 10.1016/0167-4781(93)90177-F; KIMURA T, 1983, BIOCHEM BIOPH RES CO, V110, P640, DOI 10.1016/0006-291X(83)91197-X; LAWTON MP, 1994, ARCH BIOCHEM BIOPHYS, V308, P254, DOI 10.1006/abbi.1994.1035; LAWTON MP, 1993, J BIOL CHEM, V268, P5728; LAWTON MP, 1991, MOL PHARMACOL, V40, P692; LAWTON MP, 1990, J BIOL CHEM, V265, P5855; LI SSL, 1985, EUR J BIOCHEM, V149, P215, DOI 10.1111/j.1432-1033.1985.tb08914.x; LOMRI N, 1992, P NATL ACAD SCI USA, V89, P1685, DOI 10.1073/pnas.89.5.1685; MCCLELLAND M, 1982, NUCLEIC ACIDS RES, V10, P7865, DOI 10.1093/nar/10.23.7865; NIKBAKHT KN, 1992, PHARMACOGENETICS, V2, P207, DOI 10.1097/00008571-199210000-00003; OZOLS J, 1990, J BIOL CHEM, V265, P10289; OZOLS J, 1991, ARCH BIOCHEM BIOPHYS, V290, P103, DOI 10.1016/0003-9861(91)90596-B; PERNECKY SJ, 1993, P NATL ACAD SCI USA, V90, P2651, DOI 10.1073/pnas.90.7.2651; POULSEN LL, 1977, ARCH BIOCHEM BIOPHYS, V183, P563, DOI 10.1016/0003-9861(77)90391-5; SABOURIN PJ, 1984, INT J BIOCHEM, V16, P713, DOI 10.1016/0020-711X(84)90180-0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAUSEN PJ, 1990, J BIOL CHEM, V265, P6139; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; SMYSER BP, 1985, BIOCHEM PHARMACOL, V34, P1145, DOI 10.1016/0006-2952(85)90487-3; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TYNES RE, 1985, BIOCHEM BIOPH RES CO, V126, P1069, DOI 10.1016/0006-291X(85)90294-3; TYNES RE, 1987, MOL PHARMACOL, V31, P569; VENKATESH K, 1991, BIOCHEM PHARMACOL, V42, P1411, DOI 10.1016/0006-2952(91)90453-C; WELLS D, 1985, P NATL ACAD SCI USA, V82, P2834, DOI 10.1073/pnas.82.9.2834; WILLIAMS DE, 1984, BIOCHEM BIOPH RES CO, V125, P116, DOI 10.1016/S0006-291X(84)80342-3; YAMADA H, 1990, ARCH BIOCHEM BIOPHYS, V280, P305, DOI 10.1016/0003-9861(90)90334-U; Ziegler D. M., 1988, DRUG METAB REV, V6, P1; ZIEGLER DM, 1977, TRENDS BIOCHEM SCI, V2, P79, DOI 10.1016/0968-0004(77)90042-1; ZIEGLER DM, 1972, ARCH BIOCHEM BIOPHYS, V150, P116, DOI 10.1016/0003-9861(72)90017-3; Ziegler DM., 1980, ENZYMATIC BASIS DETO, VI, P201	50	48	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					14314	14322						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188717				2022-12-25	WOS:A1994NL60600089
J	AIYAR, SE; HELMANN, JD; DEHASETH, PL				AIYAR, SE; HELMANN, JD; DEHASETH, PL			A MISMATCH BUBBLE IN DOUBLE-STRANDED DNA SUFFICES TO DIRECT PRECISE TRANSCRIPTION INITIATION BY ESCHERICHIA-COLI RNA-POLYMERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGMA-70 SUBUNIT; PROMOTER DNA; T7 DNA; HOLOENZYME; MECHANISM; BINDING; COMPLEXES; SPECIFICITY; RECOGNITION; TERMINATION	Formation of a transcription-competent ''open'' complex: between Escherichia coli RNA polymerase and a promoter, where base pairing is disrupted over a region of 12 base pairs including the start site of transcription, is a complex process involving at least three steps: recognition of specific DNA sequences, a conformational change in RNA polymerase, and DNA melting. By using synthetic constructs devoid of promoter-specific sequences, we show here that a mismatch bubble of 12 base pairs suffices to direct transcription initiation in divergent directions from its edges, reflecting the absence of polarity determinants for RNA polymerase binding. Bubble transcription is obtained with both core polymerase and holoenzyme, but efficient formation of heparin-resistant initiation complexes requires the a (specificity) factor. Based on these results it is likely that the a factor blocks access of the heparin to a site on the holoenzyme.	CASE WESTERN RESERVE UNIV, SCH MED, DEPT BIOCHEM, CLEVELAND, OH 44106 USA; CORNELL UNIV, MICROBIOL SECT, ITHACA, NY 14853 USA	Case Western Reserve University; Cornell University				Helmann, John/0000-0002-3832-3249	NATIONAL CANCER INSTITUTE [P30CA043703] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031808, R01GM047446] Funding Source: NIH RePORTER; NCI NIH HHS [P30CA43703] Funding Source: Medline; NIGMS NIH HHS [GM 47446, GM 31808] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNDT KM, 1988, J MOL BIOL, V202, P271, DOI 10.1016/0022-2836(88)90457-3; BORUKHOV S, 1993, CELL, V72, P459, DOI 10.1016/0092-8674(93)90121-6; BURGESS RR, 1975, BIOCHEMISTRY-US, V14, P4634, DOI 10.1021/bi00692a011; CAMPBELL FE, 1992, MOL CELL BIOL, V12, P2260, DOI 10.1128/MCB.12.5.2260; CAREY J, 1991, METHOD ENZYMOL, V208, P103; CHAMBERLIN MJ, 1976, COLD SPRING HARBOR M; CHAMBERLIN MJ, 1993, IN PRESS HARVEY LECT; DAUBE SS, 1992, SCIENCE, V258, P1320, DOI 10.1126/science.1280856; DOMBROSKI AJ, 1992, CELL, V70, P501, DOI 10.1016/0092-8674(92)90174-B; GARDELLA T, 1989, J MOL BIOL, V206, P579, DOI 10.1016/0022-2836(89)90567-6; GONZALEZ N, 1977, ARCH BIOCHEM BIOPHYS, V182, P404, DOI 10.1016/0003-9861(77)90521-5; GRAY CP, 1978, P NATL ACAD SCI USA, V75, P50, DOI 10.1073/pnas.75.1.50; HELMANN JD, 1988, ANNU REV BIOCHEM, V57, P839, DOI 10.1146/annurev.bi.57.070188.004203; HERSHBERGER PA, 1991, J MOL BIOL, V222, P479, DOI 10.1016/0022-2836(91)90491-N; HINKLE DC, 1972, J MOL BIOL, V70, P197, DOI 10.1016/0022-2836(72)90533-5; JUANG YL, 1994, J MOL BIOL, V235, P1470, DOI 10.1006/jmbi.1994.1102; KADESCH TR, 1982, J BIOL CHEM, V257, P5286; LEIRMO S, 1990, NUCLEIC ACIDS MOL BI, V4, P123; LONETTO M, 1992, J BACTERIOL, V174, P3843, DOI 10.1128/jb.174.12.3843-3849.1992; MCCLURE WR, 1985, ANNU REV BIOCHEM, V54, P171, DOI 10.1146/annurev.bi.54.070185.001131; MELANCON P, 1983, BIOCHEMISTRY-US, V22, P5169, DOI 10.1021/bi00291a017; METZGER W, 1993, J MOL BIOL, V232, P35, DOI 10.1006/jmbi.1993.1368; MULLIGAN ME, 1984, NUCLEIC ACIDS RES, V12, P789, DOI 10.1093/nar/12.1Part2.789; PFEFFER SR, 1977, J BIOL CHEM, V252, P5403; Sambrook J, 1989, MOL CLONING LABORATO; SASSEDWIGHT S, 1989, J BIOL CHEM, V264, P8074; SIEBENLIST U, 1980, CELL, V20, P269, DOI 10.1016/0092-8674(80)90613-3; SIEGELE DA, 1989, J MOL BIOL, V206, P591, DOI 10.1016/0022-2836(89)90568-8; STRICKLAND MS, 1988, BIOCHEMISTRY-US, V27, P5755, DOI 10.1021/bi00415a054; SURRATT CK, 1991, P NATL ACAD SCI USA, V88, P7983, DOI 10.1073/pnas.88.18.7983; TRIPATARA A, 1993, J MOL BIOL, V233, P349, DOI 10.1006/jmbi.1993.1516; VOGT V, 1969, NATURE, V223, P854, DOI 10.1038/223854a0; VONHIPPEL PH, 1984, ANNU REV BIOCHEM, V53, P389, DOI 10.1146/annurev.bi.53.070184.002133; WALTER G, 1967, EUR J BIOCHEM, V3, P194, DOI 10.1111/j.1432-1033.1967.tb19515.x; WARNE SE, 1993, BIOCHEMISTRY-US, V32, P6134, DOI 10.1021/bi00075a003	35	32	40	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13179	13184						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175746				2022-12-25	WOS:A1994NK18400023
J	NGUYEN, T; RUSHMORE, TH; PICKETT, CB				NGUYEN, T; RUSHMORE, TH; PICKETT, CB			TRANSCRIPTIONAL REGULATION OF A RAT-LIVER GLUTATHIONE-S-TRANSFERASE YA SUBUNIT GENE - ANALYSIS OF THE ANTIOXIDANT RESPONSE ELEMENT AND ITS ACTIVATION BY THE PHORBOL ESTER 12-O-TETRADECANOYLPHORBOL-13-ACETATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONTROLLING INDUCIBLE EXPRESSION; PLANAR AROMATIC-COMPOUNDS; AH RECEPTOR COMPLEX; PHENOLIC ANTIOXIDANTS; OXIDATIVE STRESS; BASAL LEVEL; JUN GENE; IDENTIFICATION; PROTEIN; DIOXIN	Using transfection and gel retardation assays, we have characterized further the antioxidant response element (ARE) found in the 5'-flanking region of the rat glutathione S-transferase Ya subunit gene. The ARE core sequence (5-GTGACAAAGC-3') is sufficient for transcriptional activation of the Ya subunit gene by metabolizable planar aromatic compounds, phenolic antioxidants, and hydrogen peroxide. When the ARE sequence is ligated to a chloramphenicol acetyltransferase reporter gene and transfected into HepG2 cells, chloramphenicol acetyltransferase activity is modestly inducible by the phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA). Since the ARE is responsive to TPA and shows some sequence similarity to an AP-1-binding site (Jun/Fos recognition motif), we have explored whether members of the Jun/Fos family of transcription factors might bind to the ARE. Using in vitro synthesized Jun and Fos, binding to the ARE could not be detected, whereas Jun/Fos binding to a classical AP-1-binding site, a TPA response element (TRE) from the human collagenase gene, could be demonstrated by gel retardation assays. If the 2 A nucleotides underlined in the ARE core sequence (5'-GTGACAAAGC-3') are changed to TC, the ARE sequence (ARE-TRE) becomes a high-affinity AP-1-binding site and retains xenobiotic inducibility. Removal of the -GC- dinucleotide at the 3'-end of the ARE or the ARE-TRE eliminates xenobiotic inducibility. However, the ARE-TRE construct without the -GC- dinucleotide is still a high-affinity AP-1 site and responsive to TPA. Taken together, our data suggest that the ARE is not a high-affinity binding site for the Jun/Fos heterodimer. Functionally, however, an AP-1-binding site can resemble an ARE in its response to various xenobiotics if a 3'-GC- dinucleotide is present.	MERCK FROSST CANADA INC, MERCK FROSST CTR THERAPEUT RES, DEPT MOLEC BIOL, POINTE CLAIRE H9R 4P8, PQ, CANADA	Merck & Company								ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; Chasseaud L F, 1979, Adv Cancer Res, V29, P175, DOI 10.1016/S0065-230X(08)60848-9; CLEWELL DB, 1972, J BACTERIOL, V110, P667, DOI 10.1128/JB.110.2.667-676.1972; CLEWELL DB, 1969, P NATL ACAD SCI USA, V62, P1159, DOI 10.1073/pnas.62.4.1159; DANIEL V, 1988, NUCLEIC ACIDS RES, V16, P351, DOI 10.1093/nar/16.1.351; DANIEL V, 1989, DNA-J MOLEC CELL BIO, V8, P399, DOI 10.1089/dna.1.1989.8.399; DENISON MS, 1989, J BIOL CHEM, V264, P16478; DENISON MS, 1988, J BIOL CHEM, V263, P17221; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; FAVREAU LV, 1991, J BIOL CHEM, V266, P4556; FRILING RS, 1990, P NATL ACAD SCI USA, V87, P6258, DOI 10.1073/pnas.87.16.6258; FRILING RS, 1992, P NATL ACAD SCI USA, V89, P668, DOI 10.1073/pnas.89.2.668; FUJISAWASEHARA A, 1988, P NATL ACAD SCI USA, V85, P5859, DOI 10.1073/pnas.85.16.5859; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; JAISWAL AK, 1991, BIOCHEMISTRY-US, V30, P10647, DOI 10.1021/bi00108a007; LI Y, 1992, J BIOL CHEM, V267, P15097; LITWACK G, 1971, NATURE, V234, P466, DOI 10.1038/234466a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANNERVIK B, 1988, CRC CR REV BIOCH MOL, V23, P283, DOI 10.3109/10409238809088226; Mannervik B, 1985, Adv Enzymol Relat Areas Mol Biol, V57, P357; NEUBOLD LA, 1989, MOL CELL BIOL, V9, P2378; NGUYEN T, 1992, J BIOL CHEM, V267, P13535; PAULSON KE, 1990, MOL CELL BIOL, V10, P1841, DOI 10.1128/MCB.10.5.1841; PICKETT CB, 1989, ANNU REV BIOCHEM, V58, P743, DOI 10.1146/annurev.bi.58.070189.003523; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; RILEY RJ, 1992, BIOCHEM PHARMACOL, V43, P1657, DOI 10.1016/0006-2952(92)90694-E; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; RUSHMORE TH, 1991, METHOD ENZYMOL, V206, P409; RUSHMORE TH, 1990, J BIOL CHEM, V265, P14648; RUSHMORE TH, 1990, P NATL ACAD SCI USA, V87, P3826, DOI 10.1073/pnas.87.10.3826; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; STORZ G, 1990, SCIENCE, V248, P189, DOI 10.1126/science.2183352; TELAKOWSKIHOPKINS CA, 1988, P NATL ACAD SCI USA, V85, P1000, DOI 10.1073/pnas.85.4.1000; TSUCHIDA S, 1992, CRIT REV BIOCHEM MOL, V27, P337, DOI 10.3109/10409239209082566; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; WHITLOCK JP, 1987, PHARMACOL REV, V39, P147	39	144	145	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13656	13662						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175801				2022-12-25	WOS:A1994NK18400087
J	PALLEROS, DR; SHI, L; REID, KL; FINK, AL				PALLEROS, DR; SHI, L; REID, KL; FINK, AL			HSP70-PROTEIN COMPLEXES - COMPLEX STABILITY AND CONFORMATION OF BOUND SUBSTRATE PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAIN BINDING-PROTEIN; HEAT-SHOCK PROTEIN; STAPHYLOCOCCAL NUCLEASE; UNFOLDED PROTEINS; PEPTIDE-BINDING; ATPASE ACTIVITY; DNAK; CHAPERONE; CELLS; MUTANT	The presence of bound substrate protein increases the thermostability of hsp70 molecular chaperones (heat shock proteins of molecular mass 70 kDa). Complexes between hsp70 and unfolded substrate proteins were isolated by size-exclusion high performance liquid chromatography. The isolated complexes were observed to dissociate at a significant rate even in the absence of ATP. The presence of ADP caused a substantial increase in the stability of the complex. Both ADP and inorganic phosphate were found to inhibit the ATP-induced dissociation of complex. ADP was also observed to increase both the rate of complex formation and its stability as a function of temperature, suggesting an important regu latory role for nucleotides during heat shock. Circular dichroism and fluorescence studies of the complex between DnaK and a thermally unstable mutant of staphylococcal nuclease indicate that the bound substrate protein is significantly unfolded. A model for the hsp70 cycle of complex formation and dissociation, which accounts for the regulatory role of nucleotides, is proposed.	UNIV CALIF SANTA CRUZ,DEPT CHEM & BIOCHEM,SANTA CRUZ,CA 95064	University of California System; University of California Santa Cruz					NIGMS NIH HHS [GM45316] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANTONINO LC, 1991, P NATL ACAD SCI USA, V88, P7715, DOI 10.1073/pnas.88.17.7715; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BECKTEL WJ, 1987, BIOPOLYMERS, V26, P1859, DOI 10.1002/bip.360261104; BLONDELGUINDI S, 1993, J BIOL CHEM, V268, P12730; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BROWN CR, 1993, J CELL BIOL, V120, P1101, DOI 10.1083/jcb.120.5.1101; CARLSON N, 1987, J CELL BIOL, V104, P547, DOI 10.1083/jcb.104.3.547; CHAPPELL TG, 1987, J BIOL CHEM, V262, P746; CORBETT RJT, 1984, BIOCHEMISTRY-US, V23, P1888, DOI 10.1021/bi00303a047; DORNER AJ, 1987, J CELL BIOL, V105, P2665, DOI 10.1083/jcb.105.6.2665; DUBOIS MF, 1991, J BIOL CHEM, V266, P9707; EFTINK MR, 1991, BIOCHEMISTRY-US, V30, P8945, DOI 10.1021/bi00101a005; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; FINDLY RC, 1983, SCIENCE, V219, P1223, DOI 10.1126/science.6828852; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; GAO BC, 1993, J BIOL CHEM, V268, P8507; GETHING MJ, 1986, CELL, V46, P939, DOI 10.1016/0092-8674(86)90076-0; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HIGHTOWER LE, 1981, J CELL PHYSIOL, V108, P261, DOI 10.1002/jcp.1041080216; HYNES TR, 1989, NATURE, V339, P73, DOI 10.1038/339073a0; IKEGUCHI M, 1989, INT J PEPT PROT RES, V33, P289; JANIN J, 1990, J BIOL CHEM, V265, P16027; LAM KT, 1992, BIOCHEM BIOPH RES CO, V184, P167, DOI 10.1016/0006-291X(92)91174-O; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LEWIS MJ, 1985, EMBO J, V4, P3137, DOI 10.1002/j.1460-2075.1985.tb04056.x; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; LIBEREK K, 1991, J BIOL CHEM, V266, P14491; LITTLEWOOD TD, 1987, J CELL SCI, V88, P65; MCCARTY JS, 1991, P NATL ACAD SCI USA, V88, P9513, DOI 10.1073/pnas.88.21.9513; MCKAY DB, 1993, ADV PROTEIN CHEM, V44, P67, DOI 10.1016/S0065-3233(08)60564-1; MONTGOMERY D, 1993, J MOL BIOL, V232, P680, DOI 10.1006/jmbi.1993.1418; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; PALLEROS DR, 1991, P NATL ACAD SCI USA, V88, P5719, DOI 10.1073/pnas.88.13.5719; PALLEROS DR, 1993, BIOCHEMISTRY-US, V32, P4314, DOI 10.1021/bi00067a021; PALLEROS DR, 1993, FEBS LETT, V336, P124, DOI 10.1016/0014-5793(93)81624-9; PALLEROS DR, 1993, NATURE, V365, P664, DOI 10.1038/365664a0; PALLEROS DR, 1992, J BIOL CHEM, V267, P5279; PARK K, 1993, PROTEIN SCI, V2, P325; PELHAM HRB, 1984, EMBO J, V3, P3095, DOI 10.1002/j.1460-2075.1984.tb02264.x; SADIS S, 1992, BIOCHEMISTRY-US, V31, P9406, DOI 10.1021/bi00154a012; SCHMID SL, 1985, J BIOL CHEM, V260, P57; WELCH WJ, 1985, MOL CELL BIOL, V5, P1229, DOI 10.1128/MCB.5.6.1229; WELCH WJ, 1984, J BIOL CHEM, V259, P4501; ZYLICZ M, 1983, P NATL ACAD SCI-BIOL, V80, P6431, DOI 10.1073/pnas.80.21.6431	49	95	98	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13107	13114						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175736				2022-12-25	WOS:A1994NK18400012
J	WOLFE, CL; LOU, YC; HOPPER, AK; MARTIN, NC				WOLFE, CL; LOU, YC; HOPPER, AK; MARTIN, NC			INTERPLAY OF HETEROGENEOUS TRANSCRIPTIONAL START SITES AND TRANSLATIONAL SELECTION OF AUGS DICTATE THE PRODUCTION OF MITOCHONDRIAL AND CYTOSOLIC NUCLEAR TRANSFER-RNA NUCLEOTIDYLTRANSFERASE FROM THE SAME GENE IN YEAST	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA NUCLEOTIDYLTRANSFERASE; CYTOPLASMIC TRANSFER-RNA; SACCHAROMYCES-CEREVISIAE; MESSENGER-RNA; SECONDARY-STRUCTURE; INITIATOR REGION; SEQUENCE; PROTEINS; ENCODES; EXTENSION	ATP (CTP):tRNA nucleotidyltransferase catalyzes the addition of the CCA end to tRNAs. In yeast, nucleotidyltransferase is encoded by the CCA1 gene and is localized to three cellular compartments: mitochondria, nucleus, and cytosol. There are three in-frame ATGs near the 5' end of the CCA1 open reading frame. Primer extension experiments show multiple transcription initiation sites upstream of ATG1 and between ATG1 and ATG2. Fractionation of cells carrying a CCA1-COXIV fusion gene demonstrates that all three in frame AUGs are used as sites of initiation of translation. Therefore, both transcription of CCA1 mRNA with heterogeneous 5' ends and translation from downstream AUGs in CCA1 mRNAs play a role in the synthesis of three nucleotidyltransferase isozymes. Protein initiating from AUG1 is required for mitochondrial protein synthesis and, like many other proteins targeted to mitochondria, it is processed at the amino terminus upon import into the organelle. The shorter proteins arising from AUG2 and AUG3 provide nuclear/cytosol activity.	UNIV LOUISVILLE,SCH MED,DEPT BIOCHEM,LOUISVILLE,KY 40292; PENN STATE UNIV,MILTON S HERSHEY MED CTR,DEPT BIOL CHEM,HERSHEY,PA 17033	University of Louisville; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health					NIGMS NIH HHS [GM42454] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042454] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AEBI M, 1990, J BIOL CHEM, V265, P16216; BACH ML, 1979, P NATL ACAD SCI USA, V76, P386, DOI 10.1073/pnas.76.1.386; BAIM SB, 1988, MOL CELL BIOL, V8, P1591, DOI 10.1128/MCB.8.4.1591; BELTZER JP, 1988, J BIOL CHEM, V263, P368; BOGUTA M, 1994, MOL CELL BIOL, V14, P2298, DOI 10.1128/MCB.14.4.2298; CHATTON B, 1988, J BIOL CHEM, V263, P52; CHEN JY, 1990, J BIOL CHEM, V265, P16221; CHIU MI, 1992, GENETICS, V132, P987; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CIGAN AM, 1987, GENE, V59, P1; CIGAN AM, 1988, MOL CELL BIOL, V8, P2964, DOI 10.1128/MCB.8.7.2964; DEUTSCHER MP, 1972, J BIOL CHEM, V247, P450; DONAHUE TF, 1988, MOL CELL BIOL, V8, P2955, DOI 10.1128/MCB.8.7.2955; ELLIS SR, 1987, P NATL ACAD SCI USA, V84, P5172, DOI 10.1073/pnas.84.15.5172; ELLIS SR, 1986, J BIOL CHEM, V261, P9703; ELLIS SR, 1989, MOL CELL BIOL, V9, P1611, DOI 10.1128/MCB.9.4.1611; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GILLMAN EC, 1991, MOL CELL BIOL, V11, P2382, DOI 10.1128/MCB.11.5.2382; HENDRICK JP, 1989, P NATL ACAD SCI USA, V86, P4056, DOI 10.1073/pnas.86.11.4056; HOPPER AK, 1992, MOL CELLULAR BIOL YE, V2, P110; KNAPP G, 1978, CELL, V14, P221, DOI 10.1016/0092-8674(78)90109-5; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUO CL, 1983, MOL CELL BIOL, V3, P1730, DOI 10.1128/MCB.3.10.1730; LI JM, 1989, J CELL BIOL, V109, P1411, DOI 10.1083/jcb.109.4.1411; MORALES MJ, 1989, NUCLEIC ACIDS RES, V17, P6865, DOI 10.1093/nar/17.17.6865; MORALES MJ, 1992, P NATL ACAD SCI USA, V89, P9875, DOI 10.1073/pnas.89.20.9875; NAJARIAN D, 1987, MOL CELL BIOL, V7, P185, DOI 10.1128/MCB.7.1.185; NATSOULIS G, 1986, CELL, V46, P235, DOI 10.1016/0092-8674(86)90740-3; ODA T, 1990, J BIOL CHEM, V265, P7513; PEEBLES CL, 1979, CELL, V18, P27, DOI 10.1016/0092-8674(79)90350-7; PFANNER N, 1990, ANNU REV BIOCHEM, V59, P331, DOI 10.1146/annurev.biochem.59.1.331; ROISE D, 1986, EMBO J, V5, P1327, DOI 10.1002/j.1460-2075.1986.tb04363.x; ROISE D, 1988, EMBO J, V7, P649, DOI 10.1002/j.1460-2075.1988.tb02859.x; ROSE AM, 1992, MOL CELL BIOL, V12, P5652, DOI 10.1128/MCB.12.12.5652; ROSSET R, 1965, BIOCHIM BIOPHYS ACTA, V108, P376, DOI 10.1016/0005-2787(65)90030-4; Sambrook J, 1989, MOL CLONING LABORATO; SCHLEIF RB, 1981, PRACTICAL METHODS ME, P81; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; SHERMAN F, 1974, METHODS YEAST GENETI, P62; SHERMAN F, 1982, MOL BIOL YEAST SACCH, P301; SIKORSKI RS, 1989, GENETICS, V122, P19; SLUPPHAUG G, 1993, NUCLEIC ACIDS RES, V21, P2579, DOI 10.1093/nar/21.11.2579; SLUSHER LB, 1991, P NATL ACAD SCI USA, V88, P9789, DOI 10.1073/pnas.88.21.9789; SOLARI A, 1982, NUCLEIC ACIDS RES, V10, P4397, DOI 10.1093/nar/10.14.4397; TRIEZENBERG SJ, 1993, CURRENT PROTOCOLS MO, V2; VANLOON APGM, 1987, EMBO J, V6, P2433, DOI 10.1002/j.1460-2075.1987.tb02522.x; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; VONHEIJNE G, 1986, EMBO J, V5, P1335, DOI 10.1002/j.1460-2075.1986.tb04364.x; WESOLOWSKI M, 1979, MOL GEN GENET, V170, P261, DOI 10.1007/BF00267059; WU M, 1987, J BIOL CHEM, V262, P12275	53	51	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13361	13366						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175766				2022-12-25	WOS:A1994NK18400048
J	DECOTTIGNIES, A; KOLACZKOWSKI, M; BALZI, E; GOFFEAU, A				DECOTTIGNIES, A; KOLACZKOWSKI, M; BALZI, E; GOFFEAU, A			SOLUBILIZATION AND CHARACTERIZATION OF THE OVEREXPRESSED PDR5 MULTIDRUG-RESISTANCE NUCLEOTIDE TRIPHOSPHATASE OF YEAST	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								A 160-kDa plasma membrane protein of the yeast Saccharomyces cerevisiae was overexpressed by mutating the PDR1 or the PDR3 transcription factor gene. The protein is the membrane-bound ATP binding cassette transporter PDR5 (Balzi, E., Wang, M., Leterme, S., Van Dyck, L., and Goffeau, A. (1994) J. Biol. Chem. 269, 2206-2214). PDR5 was solubilized with n-dodecyl-beta-D-maltoside and separated from the PMA1 plasma membrane H+-ATPase by glycerol gradient centrifugation. The PDR5 protein hydrolyzes nucleoside diphosphates and triphosphates. This activity is sensitive to low concentrations of vanadate, of oligomycin, and of a variety of hydrophobic compounds. Many of these properties liken PDR5 to the purified mammalian P-glycoprotein responsible for multidrug resistance.	UNIV CATHOLIQUE LOUVAIN, UNITE BIOCHIM PHYSIOL, B-1348 LOUVAIN, BELGIUM	Universite Catholique Louvain								ALSHAWI MK, 1993, J BIOL CHEM, V268, P4197; AMBUDKAR SV, 1986, METHOD ENZYMOL, V125, P558; AMBUDKAR SV, 1992, P NATL ACAD SCI USA, V89, P8472, DOI 10.1073/pnas.89.18.8472; AMES GFL, 1986, ANNU REV BIOCHEM, V55, P397, DOI 10.1146/annurev.biochem.55.1.397; ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; BALZI E, 1987, J BIOL CHEM, V262, P16871; BALZI E, 1994, J BIOL CHEM, V269, P2206; BALZI E, 1991, BIOCHIM BIOPHYS ACTA, V1073, P241, DOI 10.1016/0304-4165(91)90128-4; BISHOP L, 1989, P NATL ACAD SCI USA, V86, P6953, DOI 10.1073/pnas.86.18.6953; BISSINGER PH, 1994, J BIOL CHEM, V269, P4180; BORSTPAUWELS GWFH, 1977, BIOCHIM BIOPHYS ACTA, V466, P488, DOI 10.1016/0005-2736(77)90341-8; COLSON AM, 1974, MOL GEN GENET, V135, P309, DOI 10.1007/BF00271146; DELAVEAU T, 1992, YEAST, V8, P761, DOI 10.1002/yea.320080909; DEXTER D, 1994, GENETICS, V136, P505; DOIGE CA, 1993, BIOCHIM BIOPHYS ACTA, V1146, P65, DOI 10.1016/0005-2736(93)90339-2; DOIGE CA, 1992, BIOCHIM BIOPHYS ACTA, V1109, P149, DOI 10.1016/0005-2736(92)90078-Z; DUFOUR JP, 1980, EUR J BIOCHEM, V105, P145, DOI 10.1111/j.1432-1033.1980.tb04484.x; DUFOUR JP, 1980, J BIOL CHEM, V255, P5735; DULLEY JR, 1975, ANAL BIOCHEM, V67, P91, DOI 10.1016/0003-2697(75)90275-4; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; Fiske CH, 1925, J BIOL CHEM, V66, P375; FOOTE SJ, 1989, CELL, V57, P921, DOI 10.1016/0092-8674(89)90330-9; GOFFEAU A, 1988, METHOD ENZYMOL, V157, P528; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GUERINEAU M, 1974, BIOCHEM BIOPH RES CO, V61, P462, DOI 10.1016/0006-291X(74)90979-6; HAMADA H, 1988, CANCER RES, V48, P4926; HAMADA H, 1988, J BIOL CHEM, V263, P1454; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HORIO M, 1988, P NATL ACAD SCI USA, V85, P3580, DOI 10.1073/pnas.85.10.3580; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KUCHLER K, 1989, EMBO J, V8, P3973, DOI 10.1002/j.1460-2075.1989.tb08580.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEPPERT G, 1990, GENETICS, V125, P13; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCGRATH JP, 1989, NATURE, V340, P400, DOI 10.1038/340400a0; MEYERS S, 1992, CURR GENET, V21, P431, DOI 10.1007/BF00351651; NUOFFER C, 1991, MOL CELL BIOL, V11, P27, DOI 10.1128/MCB.11.1.27; PURNELLE B, 1991, YEAST, V7, P867, DOI 10.1002/yea.320070813; RIORDAN JR, 1985, NATURE, V316, P817, DOI 10.1038/316817a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; SARKADI B, 1992, J BIOL CHEM, V267, P4854; SERRANO R, 1978, MOL CELL BIOCHEM, V22, P51; SERVOS J, 1993, MOL GEN GENET, V236, P214, DOI 10.1007/BF00277115; SHARMA RC, 1992, J BIOL CHEM, V267, P5731; SHIMABUKU AM, 1992, J BIOL CHEM, V267, P4308; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SMITH RL, 1980, J BIOL CHEM, V255, P9852; SUBIK J, 1986, CURR GENET, V10, P665, DOI 10.1007/BF00410914; VAI M, 1991, J BIOL CHEM, V266, P12242; VANBREUSEGHEM NP, 1962, BIOCHEM PHARMACOL, V11, P813; Vanden Bossche H, 1985, Curr Top Med Mycol, V1, P313; WACH A, 1991, EUR J BIOCHEM, V201, P91, DOI 10.1111/j.1432-1033.1991.tb16260.x; WILLSKY GR, 1979, J BIOL CHEM, V254, P3326; WILSON CM, 1989, SCIENCE, V244, P1184, DOI 10.1126/science.2658061	55	103	105	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12797	12803						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175692				2022-12-25	WOS:A1994NH71600066
J	HANNON, GE; HANNON, GJ; MARONEY, PA; NILSEN, TW				HANNON, GE; HANNON, GJ; MARONEY, PA; NILSEN, TW			TRANSCRIPTION OF A NEMATODE U1 SMALL NUCLEAR-RNA IN-VITRO - 3'-END FORMATION REQUIRES CIS-ACTING ELEMENTS WITHIN THE CODING SEQUENCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							3' END-FORMATION; SPLICED LEADER RNA; INITIATION; EXPRESSION; PROMOTER	We have used block-substitution mutagenesis and in vitro transcription assays to identify cis-acting DNA sequence elements important for initiation and 3'-end formation of a U1 small nuclear RNA (snRNA) in the parasitic nematode Ascaris lumbricoides. Efficient initiation of synthesis by RNA polymerase II requires a compact element centered similar to 50 base pairs upstream of the transcriptional start site. Surprisingly, 3'-end formation of U1 snRNAs synthesized in vitro is solely dependent upon elements within the U1 coding sequence. In all other systems studied thus far, 3'-end formation of U snRNAs requires signals present in the 3'-flanking region. We also show that sequence elements that direct 3'-end formation of the A. lumbricoides trans-spliced leader RNA function when RNA synthesis is initiated from the U1 promoter. These results indicate that 3'-end formation of U snRNAs in nematodes is mechanistically distinct from the analogous process in higher eukaryotes.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT MOLEC BIOL & MICROBIOL,CLEVELAND,OH 44106	Case Western Reserve University			Hannon, Gregory/AAB-3568-2019		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028799] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-28799] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGABIAN N, 1990, CELL, V61, P1157, DOI 10.1016/0092-8674(90)90674-4; CILIBERTO G, 1986, EMBO J, V11, P2931; DAHLBERG JE, 1988, NUCLEIC ACIDS RES, V16, P5827, DOI 10.1093/nar/16.13.5827; Dahlberg JE, 1988, STRUCTURE FUNCTION M, P38, DOI [10.1007/978-3-642- 73020-7_2, DOI 10.1007/978-3-642-73020-7_2]; DEVEGVAR HEN, 1986, CELL, V47, P259; HANNON GJ, 1990, EMBO J, V9, P1915, DOI 10.1002/j.1460-2075.1990.tb08318.x; HERNANDEZ N, 1988, EMBO J, V7, P3125, DOI 10.1002/j.1460-2075.1988.tb03179.x; JACOBSON MR, 1993, MOL CELL BIOL, V13, P1119, DOI 10.1128/MCB.13.2.1119; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MARONEY PA, 1990, P NATL ACAD SCI USA, V87, P709, DOI 10.1073/pnas.87.2.709; NILSEN TW, 1993, ANNU REV MICROBIOL, V47, P413, DOI 10.1146/annurev.mi.47.100193.002213; NILSEN TW, 1989, MOL CELL BIOL, V9, P3543, DOI 10.1128/MCB.9.8.3543; PARRY HD, 1989, NUCLEIC ACIDS RES, V17, P3633, DOI 10.1093/nar/17.10.3633; PARRY HD, 1989, TRENDS BIOCHEM SCI, V14, P15, DOI 10.1016/0968-0004(89)90083-2; SHAMBAUGH JD, IN PRESS MOL BIOCH P; SOUTHGATE C, 1989, EMBO J, V8, P539, DOI 10.1002/j.1460-2075.1989.tb03408.x; STEINBERG TH, 1990, J BIOL CHEM, V265, P499; TAKACS AM, 1988, P NATL ACAD SCI USA, V85, P7932, DOI 10.1073/pnas.85.21.7932; VIERA J, 1987, METHOD ENZYMOL, V153, P3; WENDELBURG BJ, 1992, MOL CELL BIOL, V12, P4132, DOI 10.1128/MCB.12.9.4132	20	6	6	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12387	12390						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175641				2022-12-25	WOS:A1994NH71600002
J	HORREVOETS, AJG; SMILDE, A; DEVRIES, C; PANNEKOEK, H				HORREVOETS, AJG; SMILDE, A; DEVRIES, C; PANNEKOEK, H			THE SPECIFIC ROLES OF FINGER AND KRINGLE-2 DOMAINS OF TISSUE-TYPE PLASMINOGEN-ACTIVATOR DURING IN-VITRO FIBRINOLYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLOROMETHYL KETONE; ONE-CHAIN; BINDING; FRAGMENTS; PURIFICATION; DEGRADATION; EXPRESSION; DELETION; CLONING; LYSINE	The specific roles of the finger (F) and kringle 2 (K2) domains of tissue-type plasminogen activator (t-PA) were quantified with regard to fibrin binding and kinetic parameters for plasminogen activation by employing domain-deletion variants. On an intact fibrin clot, active site-blocked I-125-t-pA has a dissociation constant (K-d) of 0.36 +/- 0.08 mu M and a single binding site per fibrin monomer (n = 1.1 +/- 0.1). Deletion of the K2 domain results in a 3-fold increase of the K-d (1.1 +/- 0.2 mu M) and a 2-fold increase of the binding sites per fibrin monomer (n = 2.0 +/- 0.3). Deletion of the F domain results in nonsaturable binding with high K-d (3.2 +/- 0.6 mu M). These results indicate that the high affinity binding of t-PA to intact fibrin is the resultant of the cooperation of two low affinity binding sites assembled on intact t-PA. Furthermore, fibrin clot lysis experiments were performed, using polymerized fibrin and plasminogen. Enzymatic activity of t-PA (variants) was assessed by following the decrease in turbidity of the polymerized fibrin. Intact recombinant t-PA exhibited a Michaelis constant for plasminogen activation (K-m) of 37 +/- 2 nM. Deletion of either the K2 or F domain results in an increase of the K-m for plasminogen of 4- and 16-fold, respectively. We interpret these kinetic parameters in terms of the ternary complex model: binding of t-PA to fibrin, mediated simultaneously by both the F and K2 domain, is essential for a correct orientation of the enzyme on the fibrin polymer to yield the optimal. ''K-m-driven'' stimulation of fibrin on the activation of plasminogen. The different potencies of various deletion mutants in a plasma clot are explained by decreased affinity of the enzymes both for fibrin and for the substrate plasminogen.	UNIV AMSTERDAM,ACAD MED CTR,DEPT BIOCHEM K1159,1105 AZ AMSTERDAM,NETHERLANDS	University of Amsterdam; Academic Medical Center Amsterdam								BECKMANN R, 1988, J BIOL CHEM, V263, P7176; BENNETT WF, 1991, J BIOL CHEM, V266, P5191; BURCK PJ, 1990, J BIOL CHEM, V265, P5170; CHRISTENSEN U, 1984, BIOCHEM J, V223, P413, DOI 10.1042/bj2230413; COLLEN D, 1980, THROMB HAEMOSTASIS, V43, P77; DEMUNK GAW, 1989, BIOCHEMISTRY-US, V28, P7318, DOI 10.1021/bi00444a026; DEUTSCH DG, 1970, SCIENCE, V170, P1095, DOI 10.1126/science.170.3962.1095; DEVRIES C, 1989, J BIOL CHEM, V264, P12604; DEVRIES C, 1991, THROMB HAEMOSTASIS, V65, P280; EHRLICH HJ, 1990, J BIOL CHEM, V265, P1021; FLEURY V, 1991, BIOCHEMISTRY-US, V30, P7630, DOI 10.1021/bi00244a035; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HEUSSEN C, 1984, J BIOL CHEM, V259, P1635; HIGGINS DL, 1987, BIOCHEMISTRY-US, V26, P7786, DOI 10.1021/bi00398a038; HOYLAERTS M, 1982, J BIOL CHEM, V257, P2912; KEYT BA, 1992, ANAL BIOCHEM, V206, P73, DOI 10.1016/S0003-2697(05)80013-2; KRAUSE J, 1989, FIBRINOLYSIS, V3, P85, DOI 10.1016/0268-9499(89)90036-2; LAU HK, 1979, J BIOL CHEM, V254, P8751; LEWIS ML, 1991, THROMB RES, V64, P223, DOI 10.1016/0049-3848(91)90121-C; LIJNEN HR, 1990, J BIOL CHEM, V265, P5677; NESHEIM M, 1990, J BIOL CHEM, V265, P21541; NORRMAN B, 1985, EUR J BIOCHEM, V149, P193, DOI 10.1111/j.1432-1033.1985.tb08911.x; PANNEKOEK H, 1988, Fibrinolysis, V2, P123, DOI 10.1016/0268-9499(88)90025-2; PAONI NF, 1993, PROTEIN ENG, V6, P529, DOI 10.1093/protein/6.5.529; PENNICA D, 1983, NATURE, V301, P214, DOI 10.1038/301214a0; PETERSEN LC, 1988, BIOCHIM BIOPHYS ACTA, V952, P245, DOI 10.1016/0167-4838(88)90123-9; ROLDAN AL, 1990, EMBO J, V9, P467, DOI 10.1002/j.1460-2075.1990.tb08132.x; STRAUGHN W, 1966, THROMB DIATH HAEMOST, V16, P198, DOI 10.1055/s-0038-1655637; SUENSON E, 1986, BIOCHIM BIOPHYS ACTA, V870, P510, DOI 10.1016/0167-4838(86)90260-8; SUENSON E, 1984, EUR J BIOCHEM, V140, P513, DOI 10.1111/j.1432-1033.1984.tb08132.x; SUENSON E, 1990, J BIOL CHEM, V265, P22228; THORSEN S, 1975, BIOCHIM BIOPHYS ACTA, V393, P55, DOI 10.1016/0005-2795(75)90216-0; URANO S, 1989, P NATL ACAD SCI USA, V86, P2568, DOI 10.1073/pnas.86.8.2568; VANZONNEVELD AJ, 1986, P NATL ACAD SCI USA, V83, P4670; VANZONNEVELD AJ, 1986, J BIOL CHEM, V261, P14214; WEENINGVERHOEFF EJD, 1990, PROTEIN ENG, V4, P191, DOI 10.1093/protein/4.2.191	36	51	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12639	12644						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175674				2022-12-25	WOS:A1994NH71600044
J	SHIMBA, S; REDDY, R				SHIMBA, S; REDDY, R			PURIFICATION OF HUMAN U6 SMALL NUCLEAR-RNA CAPPING ENZYME - EVIDENCE FOR A COMMON CAPPING ENZYME FOR GAMMA-MONOMETHYL-CAPPED SMALL RNAS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL NUCLEOLAR RNA; POLYMERASE-III; SEQUENCE; RIBONUCLEOPROTEIN; IDENTIFICATION; TRANSCRIPTION; CELLS; N6-METHYLADENOSINE; ANTIBODIES; PHOSPHATE	To understand the mechanism of gamma-monomethyl (meppp) cap formation, we attempted to identify and purify the U6 small nuclear RNA capping enzyme. Although more than one protein was cross-linked to U6, 7SK, B2, or plant U3 RNA, only one protein of approximately 130 kDa was common to all four meppp-capped RNAs; 5 S RNA, which is an uncapped RNA, was not cross-linked to this protein. In addition to specific cross-linking with meppp-capped RNAs, an similar to 130-kDa protein was also cross-linked to H-3-labeled AdoMet. We purified the capping enzyme from a HeLa cell S-100 extract by several successive chromatographic steps, and an similar to 130-kDa protein was purified along with the capping activity. The capping activity and the similar to 130-kDa protein also cosedimented on a glycerol gradient. The purified enzyme catalyzed meppp cap formation of U6, 7SK, B2, and plant U3 RNA, and this enzyme is probably responsible for the capping of multiple RNAs in vivo. The capping activity is distinct from U6 snRNA N-6-adenosine methyltransferase, and this is the first methyltransferase to be purified that methylates gamma-phosphate residues in RNAs.			SHIMBA, S (corresponding author), BAYLOR COLL MED,DEPT PHARMACOL,HOUSTON,TX 77030, USA.				NIGMS NIH HHS [GM 38320] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038320] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CANAANI D, 1979, NUCLEIC ACIDS RES, V6, P2879, DOI 10.1093/nar/6.8.2879; DIMOCK K, 1977, BIOCHEMISTRY-US, V16, P471, DOI 10.1021/bi00622a021; ELICEIRI GL, 1980, J CELL PHYSIOL, V102, P199, DOI 10.1002/jcp.1041020211; EPSTEIN P, 1980, J BIOL CHEM, V255, P8901; FISCHER U, 1990, SCIENCE, V249, P786, DOI 10.1126/science.2143847; GRONING K, 1991, MOL CELL BIOL, V11, P2026; GUPTA S, 1990, J BIOL CHEM, V265, P9491; GUPTA S, 1990, J BIOL CHEM, V265, P19137; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; HAMM J, 1990, CELL, V62, P569, DOI 10.1016/0092-8674(90)90021-6; KLEINSCHMIDT AM, 1990, P NATL ACAD SCI USA, V87, P1283, DOI 10.1073/pnas.87.4.1283; LIU MH, 1992, NUCLEIC ACIDS RES, V20, P4299, DOI 10.1093/nar/20.16.4299; MATTAJ IW, 1986, CELL, V46, P905, DOI 10.1016/0092-8674(86)90072-3; NICHOLS JL, 1981, PLANT SCI LETT, V21, P75, DOI 10.1016/0304-4211(81)90071-7; REDDY R, 1974, J BIOL CHEM, V249, P6486; REDDY R, 1992, PHARMACOL THERAPEUT, V54, P249, DOI 10.1016/0163-7258(92)90002-H; Reddy R., 1988, STRUCTURE FUNCTION M, P1, DOI 10.1007/978-3-642-73020-7_1; SHIMBA S, 1992, J BIOL CHEM, V267, P13772; SHUMYATSKY G, 1993, NUCLEIC ACIDS RES, V21, P4756, DOI 10.1093/nar/21.20.4756; SHUMYATSKY GP, 1990, NUCLEIC ACIDS RES, V18, P6347, DOI 10.1093/nar/18.21.6347; Silberklang M, 1979, Methods Enzymol, V59, P58; SINGH R, 1990, MOL CELL BIOL, V10, P939, DOI 10.1128/MCB.10.3.939; SINGH R, 1989, P NATL ACAD SCI USA, V86, P8280, DOI 10.1073/pnas.86.21.8280; SKUZESKI JM, 1984, J BIOL CHEM, V259, P8345; Steitz J. A., 1988, STRUCTURE FUNCTION M, P115; WEIL PA, 1979, J BIOL CHEM, V254, P6163	26	25	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12419	12423						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175647				2022-12-25	WOS:A1994NH71600010
J	UNSON, CG; WU, CR; FITZPATRICK, KJ; MERRIFIELD, RB				UNSON, CG; WU, CR; FITZPATRICK, KJ; MERRIFIELD, RB			MULTIPLE-SITE REPLACEMENT ANALOGS OF GLUCAGON - A MOLECULAR-BASIS FOR ANTAGONIST DESIGN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENYLATE-CYCLASE; CONFORMATIONAL CONSIDERATIONS; RECEPTOR-BINDING	Extensive structure activity analysis has allowed us to identify specific residues in the glucagon sequence that are responsible for either receptor recognition or signal transduction. For instance, we have demonstrated that aspartic acid 9 and histidine 1 are essential for activation, and that an ionic interaction between the negative carboxylate and the protonated imidazole may contribute to the activation reaction at the molecular level. In the absence of the carboxylic group at position 9, aspartic 21 or aspartic 15 might furnish distal electrostatic effects to maintain partial agonism. Further investigation established that each of the 4 serine residues in the hormone play distinct roles. Serine 8 provides an important determinant of binding. Whereas neither serines 2, 11, nor 16 are required for receptor recognition. We have shown that serine 16 is essential for signal transduction and thus have identified it to be the third residue in glucagon to participate in a putative catalytic triad to gether with aspartic 9 and histidine 1, in the transduction of the glucagon response. In this work, we utilized insights into the functional significance of particular residues in the peptide appropriated from our structure-function assignments, as the basis of a molecular approach for the design of active-site directed antagonists of glucagon. The importance as well as the accuracy of our findings are confirmed by the synthesis of a series of improved glucagon antagonists based on replacements at positions 1, 9, 11, 16, and 21. The inhibition index, (I/A)(50) of our best antagonist des-His(1)[Nle(9)-Ala(11)-Ala(16)]glucagon amide, has been improved 10 fold over the previous best glucagon inhibitor.			UNSON, CG (corresponding author), ROCKEFELLER UNIV,1230 YORK AVE,NEW YORK,NY 10021, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK024039] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 24039] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDREU D, 1987, EUR J BIOCHEM, V64, P585; ARUNLAKSHANA O, 1959, BRIT J PHARM CHEMOTH, V14, P48, DOI 10.1111/j.1476-5381.1959.tb00928.x; Barany G, 1979, PEPTIDES           A, V2, P1; HRUBY VJ, 1986, BIOPOLYMERS, V25, pS135; JELINEK LJ, 1993, SCIENCE, V259, P1614, DOI 10.1126/science.8384375; KRSTENANSKY JL, 1986, J AM CHEM SOC, V108, P1696, DOI 10.1021/ja00267a053; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MERRIFIELD RB, 1987, PEPTIDES 1986, P517; MERRIFIELD RB, 1993, 1992 PEPT P CHIN PEP, P251; POHL SL, 1976, METHODS RECEPTOR R 1, P160; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; UNGER RH, 1976, DIABETES, V25, P136, DOI 10.2337/diab.25.2.136; UNSON CG, 1987, P NATL ACAD SCI USA, V84, P4083, DOI 10.1073/pnas.84.12.4083; UNSON CG, 1993, ARCH BIOCHEM BIOPHYS, V300, P747, DOI 10.1006/abbi.1993.1103; UNSON CG, 1991, J BIOL CHEM, V266, P2763; UNSON CG, 1994, P NATL ACAD SCI USA, V91, P454, DOI 10.1073/pnas.91.2.454; UNSON CG, 1989, J BIOL CHEM, V264, P789; UNSON CG, 1990, PEPTIDES CHEM STRUCT, P203; UNSON CG, 1994, IN PRESS 13TH P AM P; UNSON CG, 1991, 21ST PEPT 1990 P EUR, P729; WRIGHT DE, 1979, J BIOL CHEM, V254, P268	21	39	42	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12548	12551						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175663				2022-12-25	WOS:A1994NH71600030
J	YAMASAKI, S; BAUMEISTER, A; BLASI, J; LINK, E; CORNILLE, F; ROQUES, B; FYKSE, EM; SUDHOF, TC; JAHN, R; NIEMANN, H; BINZ, T				YAMASAKI, S; BAUMEISTER, A; BLASI, J; LINK, E; CORNILLE, F; ROQUES, B; FYKSE, EM; SUDHOF, TC; JAHN, R; NIEMANN, H; BINZ, T			CLEAVAGE OF MEMBERS OF THE SYNAPTOBREVIN/VAMP FAMILY BY TYPE-D AND TYPE-F BOTULINAL NEUROTOXINS AND TETANUS TOXIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRAL MEMBRANE-PROTEIN; SYNAPTIC VESICLES; SECRETORY PATHWAY; RAT-BRAIN; EXOCYTOSIS; BINDING; SYNAPTOTAGMIN; GLYCOPROTEIN; SYNAPTOSOMES; PURIFICATION	Tetanus toxin (TeTx) and the various forms of botulinal neurotoxins (BoNT/A to BoNT/G) potently inhibit neurotransmission by means of their L chains which selectively proteolyze synaptic proteins such as synaptobrevin (TeTx, BoNT/B, BoNT/F), SNAP-25 (BoNT/A), and syntaxin (BoNT/C1). Here we show that BoNT/D cleaves rat synaptobrevin 1 and 2 in toxified synaptosomes and in isolated vesicles. In contrast, synaptobrevin 1, as generated by in vitro translation, is only a poor substrate for BoNT/D, whereas this species is cleaved by BoNT/F with similar potency. Cleavage by BoNT/D occurs at the peptide bond Lys(59)-Leu(60) which is adjacent to the BoNT/F cleavage site (Gln(58)-Lys(59)) and again differs from the site hydrolyzed by TeTx and BoNT/B (Gln(76)Phe(77)). Cellubrevin, a recently discovered isoform expressed outside the nervous system, is efficiently cleaved by ah three toxins examined. For further characterization of the substrate requirements of BoNT/D, we tested amino- and carboxyl-terminal deletion mutants of synaptobrevin 2 as well as synthetic peptides. Shorter peptides containing up to 15 amino acids on either side of the cleavage site were not cleaved, and a peptide extending from Arg(47) to Thr(116) was a poor substrate for all three toxins tested. However, cleavability was restored when the peptide is further extended at the NH2 terminus (Thr(27)-Thr(116)) demonstrating that NH2 terminally located sequences of synaptobrevin which are distal from the respective cleavage sites are required for proteolysis. To further examine the isoform specificity, several mutants of rat synaptobrevin 2 were generated in which individual amino acids were replaced with those found in rat synaptobrevin 1. We show that a Met(46) to Ile(46) substitution drastically diminishes cleavability by BoNT/D and that the presence of Val(76) instead of Gln(76) dictates the reduced cleavability of synaptobrevin isoforms by TeTx.	FED RES CTR VIRUS DIS ANIM,DEPT MICROBIOL,D-72001 TUBINGEN,GERMANY; YALE UNIV,SCH MED,DEPT PHARMACOL,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT CELL BIOL,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510; UNIV PARIS 05,UNITE PHARMACOCHIM MOLEC,F-75270 PARIS 06,FRANCE; UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235	Yale University; Yale University; Howard Hughes Medical Institute; Yale University; UDICE-French Research Universities; Universite Paris Cite; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Blasi, Juan/K-7943-2014	Blasi, Juan/0000-0002-0482-9444; Jahn, Reinhard/0000-0003-1542-3498				ARCHER BT, 1990, J BIOL CHEM, V265, P17267; BARNSTABLE CJ, 1985, DEV BRAIN RES, V20, P286, DOI 10.1016/0165-3806(85)90116-6; BAUMERT M, 1989, EMBO J, V8, P379, DOI 10.1002/j.1460-2075.1989.tb03388.x; BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BINZ T, 1994, J BIOL CHEM, V269, P1617; BLASI J, 1993, NATURE, V365, P160, DOI 10.1038/365160a0; BLASI J, 1993, EMBO J, V12, P4821, DOI 10.1002/j.1460-2075.1993.tb06171.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; BUCKLEY K, 1985, J CELL BIOL, V100, P1284, DOI 10.1083/jcb.100.4.1284; EISEL U, 1993, EMBO J, V12, P3365, DOI 10.1002/j.1460-2075.1993.tb06010.x; ELFERINK LA, 1989, J BIOL CHEM, V264, P11061; HATA Y, 1993, NATURE, V366, P347, DOI 10.1038/366347a0; HELL JW, 1988, EMBO J, V7, P3023, DOI 10.1002/j.1460-2075.1988.tb03166.x; JAHN R, 1985, P NATL ACAD SCI USA, V82, P4137, DOI 10.1073/pnas.82.12.4137; JAHN R, 1994, IN PRESS ANN REV NEU; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINK E, 1992, BIOCHEM BIOPH RES CO, V189, P1017, DOI 10.1016/0006-291X(92)92305-H; MATTEOLI M, 1991, J CELL BIOL, V115, P625, DOI 10.1083/jcb.115.3.625; MAYER T, 1988, J BIOL CHEM, V263, P14956; MCMAHON HT, 1992, J BIOL CHEM, V267, P21338; MCMAHON HT, 1993, NATURE, V364, P346, DOI 10.1038/364346a0; MIYAZAKI S, 1977, INFECT IMMUN, V17, P395, DOI 10.1128/IAI.17.2.395-401.1977; NICHOLLS DG, 1986, NATURE, V321, P772, DOI 10.1038/321772a0; OHISHI I, 1974, APPL MICROBIOL, V28, P923, DOI 10.1128/AEM.28.6.923-928.1974; PETRENKO AG, 1991, NATURE, V353, P65, DOI 10.1038/353065a0; ROQUES BR, 1993, IN PRESS PHARM REV, V45; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SATHYAMOORTHY V, 1985, J BIOL CHEM, V260, P461; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; SCHIAVO G, 1993, J BIOL CHEM, V268, P11516; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SUDHOF TC, 1991, NEURON, V6, P665, DOI 10.1016/0896-6273(91)90165-V; SUDHOF TC, 1993, CELL, V75, P1; SUDHOF TC, 1989, NEURON, V2, P1475, DOI 10.1016/0896-6273(89)90193-1; SUGII S, 1975, INFECT IMMUN, V12, P1262, DOI 10.1128/IAI.12.6.1262-1270.1975; TRIMBLE WS, 1988, P NATL ACAD SCI USA, V85, P4538, DOI 10.1073/pnas.85.12.4538; VONMOLLARD GF, 1991, NATURE, V349, P79, DOI 10.1038/349079a0; [No title captured]	41	226	245	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12764	12772						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175689				2022-12-25	WOS:A1994NH71600061
J	FERREIRAPEREIRA, A; ALVESFERREIRA, M; DECARVALHOALVES, PC				FERREIRAPEREIRA, A; ALVESFERREIRA, M; DECARVALHOALVES, PC			P-NITROPHENYLPHOSPHATASE ACTIVITY OF PLASMA-MEMBRANE H+-ATPASE FROM YEAST - IMPLICATIONS FOR THE REGULATION OF THE CATALYTIC CYCLE BY H+	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCHIZOSACCHAROMYCES-POMBE; ENERGY TRANSDUCTION; ION-TRANSPORT; HYDROLYSIS; PHOSPHATE; SITES; IDENTIFICATION; MECHANISM; EXCHANGE; CLEAVAGE	The H+-ATPase from Schizosaccharomyces pombe belongs to the group of transport ATPases which displays two main conformational states, E(1) and E(2) (P-type ATPase). In this report, we show that, as in the case of other P-type ATPases, the purified enzyme exhibits a p-nitrophenylphosphatase activity which can be completely inhibited by vanadate. In aqueous medium, p-nitrophenylphosphate hydrolysis proceeds at only 0.5% of the rate of ATP hydrolysis, and both activities can be stimulated 3- to 4-fold by decreasing the pH from 7.5 to 6.5. Addition of the organic solvent dimethyl sulfoxide (10-40%), which has been shown to favor the E(2) conformation, stimulates the p-nitrophenylphosphatase activity but inhibits the ATPase activity. At pH 7.5, the K-m for p-nitrophenyl phosphate decreases when dimethyl sulfoxide is present. In the presence of 30% (v/v) dimethyl sulfoxide, the phosphatase activity can be inhibited by ATP (K-i 300 mu M) or by P-i (K-i 1 mM). The H+-ATPase incorporated into lipo somes retains pNPPase activity, but it does not support H+ transport. Gel electrophoresis reveals that the pattern of H+-ATPase cleavage by trypsin changes when vanadate, Me(2)SO, or both compounds are present in the medium, regardless of the pH used during trypsinization. We propose that p-nitrophenyl phosphate is hydrolyzed by a H+-ATPase conformation distinct from that which hydrolyzes ATP, most probably an E(2)-like form. We also suggest that, in addition to the E(1)-E(2) transition, the enzyme activity can be regulated by protons at another step of the catalytic cycle.			FERREIRAPEREIRA, A (corresponding author), FED UNIV RIO DE JANEIRO,ICB CCS,DEPT BIOQUIM MED,CIDADE UNIV,BR-21941590 RIO JANEIRO,BRAZIL.		Ferreira, Marcelo/C-2770-2014; Ferreira-Pereira, Antonio/A-2910-2011	Ferreira-Pereira, Antonio/0000-0002-0474-8388				ADDISON R, 1982, J BIOL CHEM, V257, P421; AMORY A, 1982, J BIOL CHEM, V257, P2509; ANSORGE W, 1985, J BIOCHEM BIOPH METH, V11, P13, DOI 10.1016/0165-022X(85)90037-5; ASANO S, 1992, J BIOL CHEM, V267, P6590; BLANPAIN JP, 1992, J BIOL CHEM, V267, P3735; BLANPAIN JP, 1986, THESIS U CATHOLIQUE; BOWMAN BJ, 1986, J MEMBRANE BIOL, V94, P83, DOI 10.1007/BF01871190; CARIDE AJ, 1982, BIOCHIM BIOPHYS ACTA, V689, P421, DOI 10.1016/0005-2736(82)90298-X; DEMEIS L, 1989, BIOCHIM BIOPHYS ACTA, V973, P333, DOI 10.1016/S0005-2728(89)80440-2; DEMEIS L, 1987, FEBS LETT, V212, P323, DOI 10.1016/0014-5793(87)81369-8; DUFOUR JP, 1978, J BIOL CHEM, V253, P7026; DUFOUR JP, 1982, J BIOL CHEM, V257, P9365; ERLANGER BF, 1961, ARCH BIOCHEM BIOPHYS, V95, P271, DOI 10.1016/0003-9861(61)90145-X; GOFFEAU A, 1981, BIOCHIM BIOPHYS ACTA, V639, P197, DOI 10.1016/0304-4173(81)90010-0; GRUBMEYER C, 1981, J BIOL CHEM, V256, P3728; HENNESSEY JP, 1990, J BIOL CHEM, V265, P532; INESI G, 1971, SCIENCE, V171, P901, DOI 10.1126/science.171.3974.901; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANDALA SM, 1988, J BIOL CHEM, V263, P15122; MORJANA NA, 1989, BIOCHIM BIOPHYS ACTA, V985, P19, DOI 10.1016/0005-2736(89)90097-7; Penefsky H S, 1979, Methods Enzymol, V56, P527; PERLIN DS, 1987, J BIOL CHEM, V262, P6788; RAO R, 1992, ANN NY ACAD SCI, V671, P195, DOI 10.1111/j.1749-6632.1992.tb43796.x; ROBINSON JD, 1983, BIOCHIM BIOPHYS ACTA, V731, P406, DOI 10.1016/0005-2736(83)90035-4; SCARPA A, 1992, ANN NY ACAD SCI, V671; WACH A, 1991, EUR J BIOCHEM, V201, P91, DOI 10.1111/j.1432-1033.1991.tb16260.x; WALSETH TF, 1979, BIOCHIM BIOPHYS ACTA, V562, P11, DOI 10.1016/0005-2787(79)90122-9	27	8	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					12074	12079						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163511				2022-12-25	WOS:A1994NG37700061
J	CROUCH, E; CHANG, D; RUST, K; PERSSON, A; HEUSER, J				CROUCH, E; CHANG, D; RUST, K; PERSSON, A; HEUSER, J			RECOMBINANT PULMONARY SURFACTANT PROTEIN-D - POSTTRANSLATIONAL MODIFICATION AND MOLECULAR ASSEMBLY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; CARBOHYDRATE-RECOGNITION DOMAIN; MANNOSE-BINDING PROTEIN; SP-A; STRUCTURAL SIMILARITY; EXPRESSION; COLLAGEN; CDNA; ACCUMULATION; ORGANIZATION	Pulmonary surfactant protein D (SP-D) is a member of a family of collagenous C-type lectins that includes the serum mannose binding proteins and surfactant protein A. Recent studies have shown that rat SP-D (rSP-D) molecules are assembled as tetramers of trimeric subunits (12 mers) and that dodecamers can participate in higher orders of molecular assembly involving interactions of the amino-terminal peptide domains. In order to further study the assembly of SP-D in vitro, Chinese hamster ovary K1 cells were transfected with a full-length rat SP-D cDNA, and stable transfectants with high levels of SP-D production (approximately 6 x 10(6) dodecamers/ cell/24 h) were obtained using a glutamine synthetase selection system. The secreted molecules (RrSP-D), which were purified by affinity chromatography on maltosyl-agarose, comigrated with rSP-D on SDS-polyacrylamide gel electrophoresis in the presence and absence of reduction, and coeluted with rSP-D dodecamers from 4% agarose. The major bacterial collagenase-resistant peptide showed a decreased mobility on reduction consistent with the formation of intrachain disulfide bonds. A 17-kDa pepsin-resistant fragment was isolated following overnight digestion with pepsin at 27 degrees C, confirming the formation of a triple helical domain comparable in size and thermal stability to that of natural SP-D. The expressed protein contained sialylated endoglycosidase F-sensitive carbohydrate; amino acid analysis of acid and alkaline hydrolysates demonstrated essentially normal levels of hydroxyproline, hydroxylysine, and hydroxylysine-glycosides. Electron microscopic studies showed a molecular structure indistinguishable from lung SP-D, with a similar small subpopulation of molecules showing higher orders of multimerization. Solid-phase neoglycoprotein binding assays gave the same saccharide inhibition profile as natural rat SP-D, and both proteins showed efficient saccharide-dependent agglutination of Escherichia coli. These studies demonstrate that a single genetically distinct chain type can account for the various and complex molecular assemblies of SP-D, and further verify the potential physiologic significance of the disulfide-bonded multimers and higher aggregates isolated from rat, bovine, and human lung lavage.	WASHINGTON UNIV, SCH MED, DEPT PATHOL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT MED, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT CELL BIOL & PHYSIOL, ST LOUIS, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)					NHLBI NIH HHS [HL-44015] Funding Source: Medline; NIGMS NIH HHS [GM-29647] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044015] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029647] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALAKOKKO L, 1991, J BIOL CHEM, V266, P14175; ALCORN JL, 1992, AM J PHYSIOL, V262, pL437, DOI 10.1152/ajplung.1992.262.4.L437; AUSUBEL FM, 1992, CURRENT PROTOCOLS MO, pCH16; BONALDO P, 1990, MATRIX, V10, P139, DOI 10.1016/S0934-8832(11)80162-9; COCKETT MI, 1990, BIO-TECHNOL, V8, P662, DOI 10.1038/nbt0790-662; CROUCH E, 1991, AM J PATHOL, V139, P765; CROUCH E, 1993, AM J PATHOL, V142, P241; CROUCH E, 1991, AM J RESP CELL MOL, V5, P13, DOI 10.1165/ajrcmb/5.1.13; CROUCH E, 1993, J BIOL CHEM, V268, P2976; CROUCH E, 1991, AM J PHYSIOL, V260, pL247, DOI 10.1152/ajplung.1991.260.4.L247; CROUCH E, 1992, FASEB J, V6, pA1160; GREENSPAN DS, 1989, J BIOL CHEM, V264, P20683; HAAGSMAN HP, 1989, AM J PHYSIOL, V257, pL421, DOI 10.1152/ajplung.1989.257.6.L421; HEUSER JE, 1983, J MOL BIOL, V169, P155, DOI 10.1016/S0022-2836(83)80179-X; KALINA M, 1993, J HISTOCHEM CYTOCHEM, V41, P57, DOI 10.1177/41.1.8417113; KUAN SF, 1992, J CLIN INVEST, V90, P97, DOI 10.1172/JCI115861; LEE ST, 1988, J BIOL CHEM, V263, P13414; LIM BL, 1993, IMMUNOLOGY, V78, P159; LU JH, 1992, BIOCHEM J, V284, P795, DOI 10.1042/bj2840795; LU JH, 1993, EUR J BIOCHEM, V215, P793, DOI 10.1111/j.1432-1033.1993.tb18094.x; MANZKEINKE H, 1992, EUR J CELL BIOL, V57, P95; MAZZORANA M, 1993, J BIOL CHEM, V268, P3029; MCCORMACK FX, 1990, BIOCHIM BIOPHYS ACTA, V1087, P190, DOI 10.1016/0167-4781(90)90204-F; PENMAN M, 1991, J BIOL CHEM, V266, P23985; PERSSON A, 1989, BIOCHEMISTRY-US, V28, P6361, DOI 10.1021/bi00441a031; PERSSON A, 1990, J BIOL CHEM, V265, P5755; PERSSON A, 1988, BIOCHEMISTRY-US, V27, P8576, DOI 10.1021/bi00423a011; PERSSON AV, 1992, BIOCHEMISTRY-US, V31, P12183, DOI 10.1021/bi00163a030; QUESENBERRY MS, 1992, J BIOL CHEM, V267, P10831; RUST K, 1991, ARCH BIOCHEM BIOPHYS, V290, P116, DOI 10.1016/0003-9861(91)90597-C; SASTRY K, 1993, CURR OPIN IMMUNOL, V5, P59, DOI 10.1016/0952-7915(93)90082-4; SCHWEINLE JE, 1993, J BIOL CHEM, V268, P364; SHIMIZU H, 1992, J BIOL CHEM, V267, P1853; VOSS T, 1991, AM J RESP CELL MOL, V4, P88, DOI 10.1165/ajrcmb/4.1.88; VOSS T, 1988, J MOL BIOL, V201, P219, DOI 10.1016/0022-2836(88)90448-2	35	109	110	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15808	15813						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	8195236				2022-12-25	WOS:A1994NP51300064
J	ZHANG, YJ; RUTLEDGE, BJ; ROLLINS, BJ				ZHANG, YJ; RUTLEDGE, BJ; ROLLINS, BJ			STRUCTURE/ACTIVITY ANALYSIS OF HUMAN MONOCYTE CHEMOATTRACTANT PROTEIN-1 (MCP-1) BY MUTAGENESIS - IDENTIFICATION OF A MUTATED PROTEIN THAT INHIBITS MCP-1-MEDIATED MONOCYTE CHEMOTAXIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-DIMENSIONAL STRUCTURE; RECOMBINANT PROTEINS; RECEPTOR-BINDING; CYTOKINE FAMILY; JE GENE; INTERLEUKIN-8; CELLS; PURIFICATION; RESIDUES	Monocyte chemoattractant protein-1 (MCP-1) is a monocyte-specific chemoattractant and activator and is a member of the chemokine-beta family of cytokines. To identify regions of MCP-1 which are required for its biological activity, me constructed human MCP-1 mutants that were expressed in eukaryotic cells and tested for their ability to attract monocytes in vitro. Deletion of amino acids 2-8 destroyed activity, suggesting that the amino-terminal region is necessary for activity. Within the deleted region, mutation of aspartate 3 to alanine produced a protein with 9% of wild-type activity, whereas mutation of asparagine 6 to alanine produced a protein with 52.9% of wild-type activity. Mutation of amino acids within the first intercysteine loop yielded variable results. Changing tyrosine 28 to aspartate or arginine 30 to leucine each produced proteins with essentially no monocyte chemoattractant activity. The side chains of these amino acids are predicted to point into a putative receptor binding cleft, and these loss-of-function mutations are consistent with this model. Also consistent is the retention of 60% of wad-type activity after mutation of serine 27 to glutamine, since the side chain of serine 27 is predicted to point away from the binding cleft. However, mutation of arginine 24, which lies outside of this area, to phenylalanine produced a protein with only 5% of wild-type activity, suggesting more complex interactions. Truncations of the carboxyl terminus, as well as mutation of aspartate 68 to leucine, generated proteins with 10-20% of wild-type activity. (Another carboxyl-terminal insertional mutation demonstrated that O-linked carbohydrate in MCP-l alpha may be added to a threonine in the carboxyl-terminal region.) These findings are consistent with a structural model of dimeric MCP-1 which is similar to interleukin-8 in which amino acids that point into a cleft between the two carboxyl-terminal alpha-helices of the subunits are important for receptor binding. In addition, however, amino acids at the amino terminus and others outside of the interhelical cleft are also essential for activity. The carboxyl terminal alpha-helix is not required for signaling per se but is required for maximal specific activity. Finally, four mutant proteins partially inhibited the ability of wild-type MCP-1 to attract monocytes in vitro. In particular, mutant 7ND (deletion of amino acids 2-8) in hibited MCP-1 activity by 50% at a molar ratio of 75:1, displaced MCP-1 from its receptor on monocytes at a similar ratio, and bound to a single class of receptors on human monocytes with a K-d of 2.6 nM. However, 7ND bound only to 10% of the number of receptors to which MCP-1 bound, suggesting that part of its inhibitory activity may be due to binding to MCP-1 itself.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DEPT MED,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School					NATIONAL CANCER INSTITUTE [R01CA053091] Funding Source: NIH RePORTER; NCI NIH HHS [CA53091] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALDWIN ET, 1991, P NATL ACAD SCI USA, V88, P502, DOI 10.1073/pnas.88.2.502; BEALL CJ, 1992, J BIOL CHEM, V267, P3455; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P23128; CLARKLEWIS I, 1993, P NATL ACAD SCI USA, V90, P3574, DOI 10.1073/pnas.90.8.3574; Clore G M, 1992, Cytokines, V4, P18; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P1689, DOI 10.1021/bi00459a004; ERNST CA, 1994, J IMMUNOL, V152, P3541; FALK W, 1980, J IMMUNOL METHODS, V33, P239, DOI 10.1016/S0022-1759(80)80014-7; GRONENBORN AM, 1991, PROTEIN ENG, V4, P263, DOI 10.1093/protein/4.3.263; HEBERT CA, 1991, J BIOL CHEM, V266, P18989; JIANG YL, 1990, J BIOL CHEM, V265, P18318; KAUFMAN RJ, 1987, EMBO J, V6, P187, DOI 10.1002/j.1460-2075.1987.tb04737.x; LEONARD EJ, 1990, IMMUNOL TODAY, V11, P97, DOI 10.1016/0167-5699(90)90035-8; MUNSON PJ, 1992, MACLIGAND VERSION 4; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; PRICKETT KS, 1989, BIOTECHNIQUES, V7, P580; ROLLINS BJ, 1991, CANCER CELL-MON REV, V3, P517; ROLLINS BJ, 1990, AM J PATHOL, V136, P1229; ROLLINS BJ, 1989, MOL CELL BIOL, V9, P4687, DOI 10.1128/MCB.9.11.4687; ROLLINS BJ, 1991, BLOOD, V78, P1112; ROLLINS BJ, 1991, MOL CELL BIOL, V11, P3125, DOI 10.1128/MCB.11.6.3125; SCHALL TJ, 1991, CYTOKINE, V3, P165, DOI 10.1016/1043-4666(91)90013-4; SCHRAUFSTATTER IU, 1993, J IMMUNOL, V151, P6418; SICILIANO SJ, 1994, P NATL ACAD SCI USA, V91, P1214, DOI 10.1073/pnas.91.4.1214; TANAKA S, 1988, FEBS LETT, V236, P467, DOI 10.1016/0014-5793(88)80078-4; VALENTE AJ, 1991, BIOCHEM BIOPH RES CO, V176, P309, DOI 10.1016/0006-291X(91)90925-W; WEBB LMC, 1993, P NATL ACAD SCI USA, V90, P7158, DOI 10.1073/pnas.90.15.7158; WONG GG, 1985, SCIENCE, V228, P810, DOI 10.1126/science.3923623; YOSHIMURA T, 1989, J IMMUNOL, V142, P1956	30	151	175	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15918	15924						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	8195247				2022-12-25	WOS:A1994NP51300080
J	SEKIDO, Y; BADER, S; LATIF, F; GNARRA, JR; GAZDAR, AF; LINEHAN, WM; ZBAR, B; LERMAN, MI; MINNA, LD				SEKIDO, Y; BADER, S; LATIF, F; GNARRA, JR; GAZDAR, AF; LINEHAN, WM; ZBAR, B; LERMAN, MI; MINNA, LD			MOLECULAR ANALYSIS OF THE VON HIPPEL-LINDAU DISEASE TUMOR-SUPPRESSOR GENE IN HUMAN LUNG-CANCER CELL-LINES	ONCOGENE			English	Article							CLONAL CHROMOSOME-ABNORMALITIES; HUMAN BREAST CARCINOMAS; FREE DEFINED MEDIUM; SHORT ARM; HOMOZYGOUS DELETION; CLINICAL SPECIMENS; SMALL REGION; P53 GENE; HETEROZYGOSITY; 3P	The deletion of the short arm of chromosome 3 is frequently observed in lung cancer. To determine whether the von Hippel-Lindau (VHL) disease tumor suppressor gene located at 3p25 is responsible for oncogenesis in lung cancer, we searched the known open reading frame using the single-strand conformation polymorphism (SSCP) technique for mutations in the VHL gene in 72 cancer cell lines including small cell (SCLC) and nonsmall cell (NSCLC) lung cancers, carcinoids, and mesotheliomas. SSCP analysis showed that four cell lines have altered SSCP patterns within the coding region and one in an intron of the VHL gene. SCLC line NCI-H1672 had a somatic mutation, G to A at nucleotide (nt) 530, leading to amino acid substitution (glycine to aspartic acid) compared to normal DNA from the same patient. Mesothelioma line NCI-H28 had T to A mutation at nt 479 leading to leucine to histidine amino acid change. We found one frequent polymorphism A (0.72) or G (0.28) at nt 19 resulting in either serine or glycine at this position, changes also found in normal peripheral blood cell DNA, often in a heterozygous state. In addition, we found single rare polymorphisms which did not alter the coding region including: C to G at mt 396, G to T at nt 843, and C to T change in an intron. These results suggest that the VHL gene is only rarely mutated in thoracic malignancies.	UNIV TEXAS,SOUTHWESTERN MED CTR,SIMMONS CANC CTR,DALLAS,TX 75235; NCI,FREDERICK CANC RES & DEV CTR,IMMUNOBIOL LAB,FREDERICK,MD 21702; NCI,SURG BRANCH,UROL ONCOL SECT,BETHESDA,MD 20892	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Sekido, Yoshitaka/P-9756-2015	Gnarra, James/0000-0002-6369-3110; Sekido, Yoshitaka/0000-0002-2428-3848	NATIONAL CANCER INSTITUTE [P20CA058220] Funding Source: NIH RePORTER; NCI NIH HHS [NCI CA58220-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERGERHEIM U, 1989, CANCER RES, V49, P1390; BRAUCH H, 1987, NEW ENGL J MED, V317, P1109, DOI 10.1056/NEJM198710293171803; BRAUCH H, 1990, GENE CHROMOSOME CANC, V1, P240, DOI 10.1002/gcc.2870010309; BROWER M, 1986, CANCER RES, V46, P798; CARNEY DN, 1985, CANCER RES, V45, P2913; CHIBA I, 1990, ONCOGENE, V5, P1603; COHEN AJ, 1979, NEW ENGL J MED, V301, P592, DOI 10.1056/NEJM197909133011107; DALY MC, 1991, GENOMICS, V9, P113, DOI 10.1016/0888-7543(91)90227-6; DALY MC, 1993, ONCOGENE, V8, P1721; DEVILEE P, 1989, GENOMICS, V5, P554, DOI 10.1016/0888-7543(89)90023-2; EHLEN T, 1990, ONCOGENE, V5, P219; GAZDAR AF, 1986, CANCER RES, V46, P6011; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HIBI K, 1992, ONCOGENE, V7, P445; HORTON WA, 1976, ARCH INTERN MED, V136, P769, DOI 10.1001/archinte.136.7.769; HOSOE S, 1990, GENOMICS, V8, P634, DOI 10.1016/0888-7543(90)90249-T; KOK K, 1987, NATURE, V330, P578, DOI 10.1038/330578a0; KOVACS G, 1988, P NATL ACAD SCI USA, V85, P1571, DOI 10.1073/pnas.85.5.1571; LAMIELL JM, 1989, MEDICINE, V68, P1; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; LEDUC F, 1989, AM J HUM GENET, V44, P282; LOTHE RA, 1989, GENOMICS, V5, P134, DOI 10.1016/0888-7543(89)90097-9; MAHER ER, 1991, GENOMICS, V10, P957, DOI 10.1016/0888-7543(91)90185-H; MELMON KL, 1964, AM J MED, V36, P595, DOI 10.1016/0002-9343(64)90107-X; MITSUDOMI T, 1992, ONCOGENE, V7, P171; NAYLOR SL, 1987, NATURE, V329, P451, DOI 10.1038/329451a0; PANDIS N, 1993, GENE CHROMOSOME CANC, V6, P151, DOI 10.1002/gcc.2870060304; PATHAK S, 1982, SCIENCE, V217, P939, DOI 10.1126/science.7112106; RABBITTS P, 1990, GENE CHROMOSOME CANC, V2, P231, DOI 10.1002/gcc.2870020312; Sambrook J, 1989, MOL CLONING LABORATO; SATO T, 1991, CANCER RES, V51, P5794; SEIZINGER BR, 1991, P NATL ACAD SCI USA, V88, P2864, DOI 10.1073/pnas.88.7.2864; SEIZINGER BR, 1988, NATURE, V332, P268, DOI 10.1038/332268a0; SHEFFIELD VC, 1993, GENOMICS, V16, P325, DOI 10.1006/geno.1993.1193; SITHANANDAM G, 1989, ONCOGENE, V4, P451; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; THOMPSON F, 1993, GENE CHROMOSOME CANC, V7, P185, DOI 10.1002/gcc.2870070402; TORY K, 1989, J NATL CANCER I, V81, P1097, DOI 10.1093/jnci/81.14.1097; TRENT J, 1993, GENE CHROMOSOME CANC, V7, P194, DOI 10.1002/gcc.2870070403; WANG N, 1984, CANCER GENET CYTOGEN, V11, P479, DOI 10.1016/0165-4608(84)90028-1; WHANGPENG J, 1984, CANCER GENET CYTOGEN, V11, P91, DOI 10.1016/0165-4608(84)90102-X; WHANGPENG J, 1991, GENE CHROMOSOME CANC, V3, P168, DOI 10.1002/gcc.2870030303; WHANGPENG J, 1982, SCIENCE, V215, P181, DOI 10.1126/science.6274023; YAMAKAWA K, 1993, ONCOGENE, V8, P327; YAMAKAWA K, 1991, CANCER RES, V51, P4707; YOKOTA J, 1989, CANCER RES, V49, P3598; ZBAR B, 1987, NATURE, V327, P721, DOI 10.1038/327721a0	47	90	94	0	8	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1994	9	6					1599	1604						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NL815	8183553				2022-12-25	WOS:A1994NL81500010
J	PAVELAVRANCIC, M; PFEIFER, E; SCHRODER, W; VONDOHREN, H; KLEINKAUF, H				PAVELAVRANCIC, M; PFEIFER, E; SCHRODER, W; VONDOHREN, H; KLEINKAUF, H			IDENTIFICATION OF THE ATP BINDING-SITE IN TYROCIDINE SYNTHETASE-1 BY SELECTIVE MODIFICATION WITH FLUORESCEIN 5'-ISOTHIOCYANATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER RNA-SYNTHETASES; METHIONYL-TRANSFER RNA; AMINO-ACID-SEQUENCE; SARCOPLASMIC-RETICULUM; ESCHERICHIA-COLI; ASPERGILLUS-NIDULANS; SIGNATURE SEQUENCE; NEUROSPORA-CRASSA; ADENYLATE KINASE; LABELED PEPTIDE	Identification of the nucleotide binding site in peptide synthetases has been approached by affinity labeling of tyrocidine synthetase 1 with fluorescein 5'-isothiocyanate. Binding was accompanied by irreversible inhibition of the ATP-dependent phenylalanine activation reaction and was prevented in the presence of MgATP(2-). The reaction obeyed pseudo first-order rate kinetics and was accelerated by Mg2+. Complete inhibition corresponded to incorporation of 2.3 mol of fluorescein 5'-isothiocyanate (FITC)/mol of protein. Upon protection by MgATP(2-), about 1 mol of FITC is still incorporated; however, this does not affect activity. The modified synthetase was extensively fragmented by tryptic digestion and the labeled fragments isolated by reverse-phase high performance liquid chromatography. Two peptides, DHQVKIR and LDKMPLTPNDKIDR, have been identified by sequencing, and the FITC conjugate of the former peptide has been detected by laser desorption mass spectrometry. The labeled residues, Lys-422 and Lys-505, are located within highly conserved segments of this new class of synthetases.	TECH UNIV BERLIN,INST BIOCHEM & MOLEK BIOL,D-10587 BERLIN,GERMANY; FREE UNIV BERLIN,INST BIOCHEM,SEQUENZIERUNGS LAB,D-14195 BERLIN,GERMANY	Technical University of Berlin; Free University of Berlin			Pavela-Vrancic, Maja/E-5424-2017	Pavela-Vrancic, Maja/0000-0002-2036-5547				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; BURBAUM JJ, 1991, J BIOL CHEM, V266, P16965; CONNERTON IF, 1990, MOL MICROBIOL, V4, P451, DOI 10.1111/j.1365-2958.1990.tb00611.x; CREMO CR, 1989, J BIOL CHEM, V264, P6608; DEVOS AM, 1988, SCIENCE, V239, P888, DOI 10.1126/science.2448879; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DREUSICKE D, 1988, J MOL BIOL, V199, P649; FARLEY RA, 1984, J BIOL CHEM, V259, P9532; FILOTEO AG, 1987, J BIOL CHEM, V262, P6526; FRY DC, 1986, P NATL ACAD SCI USA, V83, P907, DOI 10.1073/pnas.83.4.907; FRY DC, 1985, BIOCHEMISTRY-US, V24, P4680, DOI 10.1021/bi00338a030; GABROCZI DN, 1988, J BIOL CHEM, V263, P812; HOUNTONDJI C, 1990, BIOCHEMISTRY-US, V29, P11266, DOI 10.1021/bi00503a016; KLEINKAUF H, 1990, EUR J BIOCHEM, V192, P1, DOI 10.1111/j.1432-1033.1990.tb19188.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOYOZA E, 1988, EUR J BIOCHEM, V176, P661; MACCABE AP, 1991, J BIOL CHEM, V266, P12646; MARAHIEL MA, 1992, FEBS LETT, V307, P40, DOI 10.1016/0014-5793(92)80898-Q; MARAHIEL MA, 1985, MOL GEN GENET, V201, P231, DOI 10.1007/BF00425664; MECHULAM Y, 1991, J MOL BIOL, V217, P465, DOI 10.1016/0022-2836(91)90750-Z; MITCHINSON C, 1982, FEBS LETT, V146, P87, DOI 10.1016/0014-5793(82)80710-2; MOLLER W, 1985, FEBS LETT, V186, P1, DOI 10.1016/0014-5793(85)81326-0; ORR I, 1993, J BIOL CHEM, V268, P1376; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PARDO JP, 1988, J BIOL CHEM, V263, P18664; PAVELAVRANCIC M, 1994, EUR J BIOCHEM, V220, P535, DOI 10.1111/j.1432-1033.1994.tb18653.x; PHILLIPS NFB, 1988, BIOCHEMISTRY-US, V27, P3314, DOI 10.1021/bi00409a029; SCHLUMBOHM W, 1991, J BIOL CHEM, V266, P23135; SERRANO R, 1988, BIOCHIM BIOPHYS ACTA, V974, P1; TATE CA, 1991, J BIOL CHEM, V266, P16165; TAYLOR WR, 1989, EUR J BIOCHEM, V179, P241, DOI 10.1111/j.1432-1033.1989.tb14547.x; TURGAY K, 1992, MOL MICROBIOL, V6, P529, DOI 10.1111/j.1365-2958.1992.tb01498.x; VANLIEMPT H, 1993, 50 YEARS PENICILLIN, P136; VANLIEMPT H, 1991, BIOMED BIOCHIM ACTA, V50, P256; VONDOHREN H, 1993, INDUSTRIAL MICROORGANISMS: BASIC AND APPLIED MOLECULAR GENETICS, P159; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WANG K, 1992, J BIOL CHEM, V267, P3577; WECKERMANN R, 1988, NUCLEIC ACIDS RES, V16, P11841, DOI 10.1093/nar/16.24.11841; ZHENG JH, 1993, BIOCHEMISTRY-US, V32, P2154, DOI 10.1021/bi00060a005	40	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					14962	14966						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195130				2022-12-25	WOS:A1994NP73800021
J	FINAN, P; SHIMIZU, Y; GOUT, I; HSUAN, J; TRUONG, O; BUTCHER, C; BENNETT, P; WATERFIELD, MD; KELLIE, S				FINAN, P; SHIMIZU, Y; GOUT, I; HSUAN, J; TRUONG, O; BUTCHER, C; BENNETT, P; WATERFIELD, MD; KELLIE, S			AN SH3 DOMAIN AND PROLINE-RICH SEQUENCE MEDIATE AN INTERACTION BETWEEN 2 COMPONENTS OF THE PHAGOCYTE NADPH OXIDASE COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CYTOSOLIC COMPONENTS; ACTIVATION; MEMBRANE; PROTEIN	Neutrophils possess a multicomponent NADPH oxidase system capable of producing large quantities of superoxide in a process known as the respiratory burst (1). Upon stimulation of a phagocytic cell, two cytosolic components of the oxidase, p67(phox) and p47(phax), associate with a membrane-bound flavocytochrome b and a small GTP-binding protein to form a functional enzyme complex. Each of the Phox proteins contains two src homology 3 (SH3) domains, which are of unknown function but are potential mediators of protein-protein interactions between components of the activated oxidase. We have isolated a 47-kDa protein from lysates of differentiated HL60 cells that specifically bound to the carboxyl-terminal SH3 domain of p67(phox) and not to any other SH3 domain tested. This protein was identified as p47(phox), and the putative SH3 domain binding site was located to a carboxyl terminal proline-rich region. Proline-rich synthetic peptides based on this carboxyl-terminal region specifically inhibited the binding of p47(phox) to the carboxyl-terminal SH3 domain of p67(phox), and sequential truncation defined a unique minimal sequence, which, although similar, does not match the consensus sequence defined for other SH3-binding proteins.	LUDWIG INST CANC RES,LONDON W1P 8BT,ENGLAND; UNIV LONDON UNIV COLL,DEPT BIOCHEM & MOLEC BIOL,LONDON WC1E 6BT,ENGLAND	Ludwig Institute for Cancer Research; University of London; University College London	FINAN, P (corresponding author), LITTLEMORE HOSP,YAMANOUCHI RES INST,OXFORD OX4 4XN,ENGLAND.		Hsuan, Justin/C-8825-2009; Kellie, Stuart/A-6036-2010	Hsuan, Justin/0000-0001-6083-7564; Kellie, Stuart/0000-0002-8163-1474				ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; CLARK RA, 1990, J CLIN INVEST, V85, P714, DOI 10.1172/JCI114496; DUSI S, 1993, BIOCHEM J, V296, P367, DOI 10.1042/bj2960367; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LUI X, 1993, MOL CELL BIOL, V13, P5225; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PARK JW, 1992, J BIOL CHEM, V267, P17327; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PRASAD KVS, 1993, P NATL ACAD SCI USA, V90, P7366, DOI 10.1073/pnas.90.15.7366; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; ROTROSEN D, 1990, J BIOL CHEM, V265, P19910; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SEGAL AW, 1993, TRENDS BIOCHEM SCI, V18, P43, DOI 10.1016/0968-0004(93)90051-N; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TOTTY NF, 1992, PROTEIN SCI, V1, P1215, DOI 10.1002/pro.5560010914; WENG ZG, 1993, J BIOL CHEM, V268, P14956; WIENTJES FB, 1993, BIOCHEM J, V296, P557, DOI 10.1042/bj2960557	23	141	142	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					13752	13755						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188650				2022-12-25	WOS:A1994NL60600008
J	HANLON, DW; ORDAL, GW				HANLON, DW; ORDAL, GW			CLONING AND CHARACTERIZATION OF GENES ENCODING METHYL-ACCEPTING CHEMOTAXIS PROTEINS IN BACILLUS-SUBTILIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; BACTERIAL CHEMOTAXIS; SENSORY TRANSDUCTION; SIGNAL TRANSDUCTION; FUNCTIONAL HOMOLOGY; RNA-POLYMERASE; GROUP TURNOVER; PHOSPHORYLATION; ADAPTATION; METHYLESTERASE	Several genes homologous to the methyl-accepting chemotaxis proteins (MCPs) of Escherichia coli have been cloned and characterized from the Gram-positive bacterium, Bacillus subtilis. Sequence analysis reveals four large open reading frames, designated mcpA, mcpB, tlpA, and tlpB, each encoding a predicted 72-kDa protein. These proteins exhibit strong homology to chemoreceptors from several organisms, although similarity is limited to the C-terminal domain. These transducer genes were mapped to a chromosomal position of 279 degrees, which is distant from previously identified fla, mot, or che loci, Each gene was inactivated by insertion of a nonpolar chloramphenicol acetyltransferase cassette in the N-terminal region. In vivo methylation of the bacterial strain deficient in mcpA revealed the loss of several methylated bands in the range of the MCP previously designated as H1, and greatly reduced methylation of the MCP designated as H2. Furthermore, this bacterial strain exhibited a chemotaxis deficiency toward glucose and alpha-methylglucoside. Inactivation of mcpB caused a reduction in methylation of the MCP designated as H3, while chemotaxis toward asparagine, aspartate, glutamine, and histidine was significantly impaired in this strain. Despite strong homology, inactivation of tlpA and tlpB did not result in an observed deficiency in chemotaxis. Most unusually, these mutant strains exhibited a striking tendency to adhere together and resisted disaggregation.	UNIV ILLINOIS,COLL MED,DEPT BIOCHEM,URBANA,IL 61801; UNIV ILLINOIS,COLL LIBERAL ARTS & SCI,DEPT BIOCHEM,URBANA,IL 61801	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020336] Funding Source: NIH RePORTER; NIAID NIH HHS [AI20336] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AHLGREN JA, 1983, BIOCHEM J, V213, P759, DOI 10.1042/bj2130759; ALLEY MRK, 1992, GENE DEV, V6, P825, DOI 10.1101/gad.6.5.825; AZEVEDO V, 1993, P NATL ACAD SCI USA, V90, P6047, DOI 10.1073/pnas.90.13.6047; BEDALE WA, 1988, J BACTERIOL, V170, P223, DOI 10.1128/jb.170.1.223-227.1988; BERG HC, 1972, NATURE, V239, P500, DOI 10.1038/239500a0; BISCHOFF DS, 1992, MOL MICROBIOL, V6, P23, DOI 10.1111/j.1365-2958.1992.tb00833.x; BOLLINGER J, 1984, P NATL ACAD SCI-BIOL, V81, P3287, DOI 10.1073/pnas.81.11.3287; BORKOVICH KA, 1989, P NATL ACAD SCI USA, V86, P1208, DOI 10.1073/pnas.86.4.1208; BOYD A, 1980, J BACTERIOL, V143, P809, DOI 10.1128/JB.143.2.809-815.1980; BOYD A, 1983, NATURE, V301, P623, DOI 10.1038/301623a0; BURGESSCASSLER A, 1982, J BIOL CHEM, V257, P2835; GOLDMAN DJ, 1982, BIOCHEMISTRY-US, V21, P915, DOI 10.1021/bi00534a016; GOLDMAN DJ, 1984, BIOCHEMISTRY-US, V23, P2600, DOI 10.1021/bi00307a010; GOY MF, 1977, P NATL ACAD SCI USA, V74, P4964, DOI 10.1073/pnas.74.11.4964; Hanahan D., 1985, DNA CLONING PRACTICA, V1, P109; HANLON DW, 1993, BIOCHIM BIOPHYS ACTA, V1158, P345, DOI 10.1016/0304-4165(93)90034-6; HANLON DW, 1992, J BACTERIOL, V174, P4218, DOI 10.1128/JB.174.13.4218-4222.1992; HANLON DW, 1994, IN PRESS MICROBIOLOG; HAZELBAUER GL, 1988, CAN J MICROBIOL, V34, P466, DOI 10.1139/m88-080; HAZELBAUER GL, 1983, INT REV CYTOL, V81, P33, DOI 10.1016/S0074-7696(08)62334-7; Hazelbauer GL, 1992, CURR OPIN STRUC BIOL, V2, P505; HELMANN JD, 1988, ANNU REV BIOCHEM, V57, P839, DOI 10.1146/annurev.bi.57.070188.004203; HESS JF, 1988, CELL, V53, P79, DOI 10.1016/0092-8674(88)90489-8; KEHRY MR, 1983, P NATL ACAD SCI USA, V81, P3287; KIRSCH ML, 1993, J BIOL CHEM, V268, P18610; KLEENE SJ, 1977, J BIOL CHEM, V252, P3214; KRIKOS A, 1983, CELL, V33, P615, DOI 10.1016/0092-8674(83)90442-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKEY RA, 1975, EUR J BIOCHEM, V56, P335, DOI 10.1111/j.1432-1033.1975.tb02238.x; LIU JD, 1991, J BACTERIOL, V173, P4941, DOI 10.1128/jb.173.16.4941-4951.1991; LUPAS A, 1989, J BIOL CHEM, V264, P17337; MACNAB RM, 1972, P NATL ACAD SCI USA, V69, P2509, DOI 10.1073/pnas.69.9.2509; Maniatis T., 1982, MOL CLONING; MARQUEZ LM, 1990, J BACTERIOL, V172, P3435, DOI 10.1128/jb.172.6.3435-3443.1990; MCCLEARY WR, 1990, J BACTERIOL, V172, P4877, DOI 10.1128/jb.172.9.4877-4887.1990; MIREL DB, 1989, J BACTERIOL, V171, P3095, DOI 10.1128/jb.171.6.3095-3101.1989; MIREL DB, 1992, J BACTERIOL, V174, P4197, DOI 10.1128/JB.174.13.4197-4204.1992; NETTLETON DO, 1989, J BACTERIOL, V171, P120, DOI 10.1128/jb.171.1.120-123.1989; NOWLIN DM, 1987, J BIOL CHEM, V262, P6039; ORDAL GW, 1976, J MOL BIOL, V100, P103, DOI 10.1016/S0022-2836(76)80037-X; ORDAL GW, 1983, J BACTERIOL, V154, P1088, DOI 10.1128/JB.154.3.1088-1097.1983; ORDAL GW, 1977, J BACTERIOL, V129, P151, DOI 10.1128/JB.129.1.151-155.1977; ORDAL GW, 1977, J BACTERIOL, V129, P156, DOI 10.1128/JB.129.1.156-165.1977; ORDAL GW, 1975, SCIENCE, V189, P802, DOI 10.1126/science.808854; ORDAL GW, 1979, J GEN MICROBIOL, V118, P471; RUSSO AF, 1983, SCIENCE, V220, P1016, DOI 10.1126/science.6302843; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SPRINGER WR, 1977, P NATL ACAD SCI USA, V74, P533, DOI 10.1073/pnas.74.2.533; STEWART RC, 1990, J BACTERIOL, V172, P3388, DOI 10.1128/jb.172.6.3388-3399.1990; STOCK JB, 1978, P NATL ACAD SCI USA, V75, P3659, DOI 10.1073/pnas.75.8.3659; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; TAYLOR BL, 1990, MEMBRANE TRANSPORT I, P69; TERWILLIGER TC, 1986, J BIOL CHEM, V261, P814; THOELKE MS, 1990, J BIOL CHEM, V265, P1928; THOELKE MS, 1988, BIOCHEMISTRY-US, V27, P8453, DOI 10.1021/bi00422a024; THOELKE MS, 1989, BIOCHEMISTRY-US, V27, P8453; ULLAH AHJ, 1981, J BACTERIOL, V145, P958, DOI 10.1128/JB.145.2.958-965.1981; VANDERWERF P, 1977, J BIOL CHEM, V252, P2793; YAO VJ, 1992, P NATL ACAD SCI USA, V89, P11915, DOI 10.1073/pnas.89.24.11915; ZUBERI AR, 1990, J BACTERIOL, V172, P1870, DOI 10.1128/jb.172.4.1870-1876.1990	60	88	96	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					14038	14046						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188684				2022-12-25	WOS:A1994NL60600050
J	VASSBOTN, FS; HAVNEN, OK; HELDIN, CH; HOLMSEN, H				VASSBOTN, FS; HAVNEN, OK; HELDIN, CH; HOLMSEN, H			NEGATIVE FEEDBACK-REGULATION OF HUMAN PLATELETS VIA AUTOCRINE ACTIVATION OF THE PLATELET-DERIVED GROWTH-FACTOR ALPHA-RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR SMOOTH-MUSCLE; TYROSINE PHOSPHORYLATION; PDGF RECEPTOR; PROTEIN-PHOSPHORYLATION; SIGNAL TRANSDUCTION; C3H FIBROBLASTS; B-CHAIN; CELLS; BINDING; IDENTIFICATION	Human platelets contain platelet-derived growth factor (PDGF) in their alpha-granules which is released during platelet exocytosis. We show by immunoprecipitation and I-125-PDGF binding experiments that human platelets have functionally active PDGF alpha-receptors, but not beta-receptors. The PDGF alpha-receptor (PDGFR-alpha) was identified as a 170-kDa glycosylated protein-tyrosine kinase as found in other cell types. Stimulation of platelets with 0.1 unit/ml thrombin resulted in a significant increase (2-5-fold) of the tyrosine phosphorylation of the PDGFR-alpha, as determined by immunoprecipitation with phosphotyrosine antiserum as well as with PDGFR-alpha antiserum. The observed thrombin-induced autophosphorylation of the PDGFR-alpha was inhibited by the addition of a neutralizing monoclonal PDGF antibody. Thus, our results suggest that the platelet PDGFR-alpha is stimulated in an autocrine manner by PDGF secreted during platelet activation. Preincubation of platelets with PDGF inhibited thrombin-induced platelet aggregation and secretion of ATP + ADP and beta-hexosaminidase. Thrombin-induced platelet aggregation was also reversed when PDGF was added 30 s after thrombin stimulation. Inhi bition of the autocrine PDGF pathway during platelet activation by the PDGF antibody led to a potentiation of thrombin-induced beta-hexosaminidase secretion. Thus, the PDGFR-alpha takes part in a negative feedback regulation during platelet activation. Our demonstration of PDGF alpha-receptors on human platelets and its inhibitory function during platelet activation identifies a new possible role of PDGF in the regulation of thrombosis.	BIOMED CTR,LUDWIG INST CANC RES,S-75123 UPPSALA,SWEDEN	Ludwig Institute for Cancer Research	VASSBOTN, FS (corresponding author), UNIV BERGEN,DEPT BIOCHEM & MOLEC BIOL,N-5009 BERGEN,NORWAY.							AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BAR RS, 1989, ENDOCRINOLOGY, V124, P1841, DOI 10.1210/endo-124-4-1841; BISHAYEE S, 1989, J BIOL CHEM, V264, P11699; Botting R, 1989, Arch Mal Coeur Vaiss, V82 Spec No 4, P11; BRYCKAERT MC, 1989, J BIOL CHEM, V264, P4336; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; CLAESSONWELSH L, 1989, J BIOL CHEM, V264, P1742; COUGHLIN SR, 1989, SCIENCE, V243, P1191; DANGELMAIER CA, 1980, ANAL BIOCHEM, V104, P182, DOI 10.1016/0003-2697(80)90296-1; DICORLETO PE, 1983, P NATL ACAD SCI-BIOL, V80, P1919, DOI 10.1073/pnas.80.7.1919; EK B, 1984, J BIOL CHEM, V259, P1145; ERIKSSON A, 1992, EMBO J, V11, P543, DOI 10.1002/j.1460-2075.1992.tb05085.x; FERRELL JE, 1988, MOL CELL BIOL, V8, P3603, DOI 10.1128/MCB.8.9.3603; FURCHGOTT RF, 1983, CIRC RES, V53, P557, DOI 10.1161/01.RES.53.5.557; GERRARD JM, 1985, NOUV REV FR HEMATOL, V27, P267; GOLDEN A, 1989, P NATL ACAD SCI USA, V86, P901, DOI 10.1073/pnas.86.3.901; GOLDEN A, 1986, P NATL ACAD SCI USA, V83, P852, DOI 10.1073/pnas.83.4.852; HAMMACHER A, 1988, J BIOL CHEM, V263, P16493; HART CE, 1990, BIOCHEMISTRY-US, V29, P166, DOI 10.1021/bi00453a022; HELDIN CH, 1990, CELL REGUL, V1, P555, DOI 10.1091/mbc.1.8.555; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; HOLMSEN H, 1989, BIOCHEM J, V260, P589, DOI 10.1042/bj2600589; Holmsen H., 1990, HEMATOLOGY, P1200; HORAK ID, 1990, ONCOGENE, V5, P597; KAPLAN DR, 1979, BLOOD, V53, P1043; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KOYAMA N, 1992, J BIOL CHEM, V267, P22806; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MEISENHELDER J, 1992, MOL CELL BIOL, V12, P5834; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; NAKURAMA SI, 1989, J BIOL CHEM, V264, P7089; Ostman A, 1989, GROWTH FACTORS, V1, P271, DOI 10.3109/08977198908998003; RAINES EW, 1993, BIOL PLATELET DERIVE, P74; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SEIFERT RA, 1989, J BIOL CHEM, V264, P8771; Shattil SJ, 1991, CURR OPIN CELL BIOL, V3, P869, DOI 10.1016/0955-0674(91)90062-4; SIEGBAHN A, 1990, J CLIN INVEST, V85, P916, DOI 10.1172/JCI114519; SMITS A, 1991, P NATL ACAD SCI USA, V88, P8159, DOI 10.1073/pnas.88.18.8159; Smits A, 1989, GROWTH FACTORS, V2, P1, DOI 10.3109/08977198909069076; STEEN VM, 1985, THROMB HAEMOSTASIS, V54, P680; TYSNES OB, 1985, THROMB RES, V40, P329, DOI 10.1016/0049-3848(85)90268-3; VASSBOTN FS, 1992, J BIOL CHEM, V267, P15635; VASSBOTN FS, 1994, J CELL PHYSIOL, V158, P381, DOI 10.1002/jcp.1041580221; VASSBOTN FS, 1990, BIOCHIM BIOPHYS ACTA, V1054, P246, DOI 10.1016/0167-4889(90)90248-C; WAHL MI, 1989, MOL CELL BIOL, V9, P2934, DOI 10.1128/MCB.9.7.2934; WITTE LD, 1978, CIRC RES, V42, P402, DOI 10.1161/01.RES.42.3.402; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; ZHAO YH, 1990, ONCOGENE, V5, P1629	50	73	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					13874	13879						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188664				2022-12-25	WOS:A1994NL60600026
J	WANG, MH; GONIAS, SL; SKEEL, A; WOLF, BB; YOSHIMURA, T; LEONARD, EJ				WANG, MH; GONIAS, SL; SKEEL, A; WOLF, BB; YOSHIMURA, T; LEONARD, EJ			PROTEOLYTIC ACTIVATION OF SINGLE-CHAIN PRECURSOR MACROPHAGE-STIMULATING PROTEIN BY NERVE GROWTH FACTOR-GAMMA AND EPIDERMAL GROWTH FACTOR-BINDING PROTEIN, MEMBERS OF THE KALLIKREIN FAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCATTER FACTOR; BIOSYNTHESIS; SEQUENCE; MICE	Promacrophage-stimulating protein (MSP) is an 80 kDa protein that acquires biological activity after cleavage at an Arg-Val bond to a disulfide-linked alpha beta heterodimer by serine proteases of the intrinsic coagulation cascade. These proteases, which include serum kallikrein, factor XIIa and factor XIa, are members of the trypsin family of serine proteases. We now report that two other members of the family, nerve growth factor -gamma (NGF-gamma) and epidermal growth factor-binding protein (EGF-BP), cleave and activate pro-MSP to the disulfide-linked alpha beta heterodimer. Cleavage of 1.5 nM pro-MSP by 1 nM NGF-gamma or EGF-BP at 37 degrees C was almost complete within 30 min. These concentrations of enzyme are about 2 orders of magnitude less than is required for cleavage by serum kalllikrein or factor XIIa. Cleavage of pro-MSP to MSP was associated with a conformational change in the protein, because the cleaved product, but not pro-MSP, was detected by a sandwich enzyme linked immunoassay. Cleavage caused the appearance of biological activity, as measured by chemotactic activity of MSP for resident peritoneal macrophages, by MSP induced macrophage shape change, and by stimulation of macrophage ingestion of C3bi-coated erythrocytes. These findings suggest the possibility of cooperative interactions between NGF-gamma or EGF-BP and pro-MSP in inflammation and wound healing.	UNIV VIRGINIA, HLTH SCI CTR, DEPT PATHOL, CHARLOTTESVILLE, VA 22908 USA; UNIV VIRGINIA, HLTH SCI CTR, DEPT BIOCHEM, CHARLOTTESVILLE, VA 22908 USA	University of Virginia; University of Virginia	WANG, MH (corresponding author), NCI, FREDERICK CANC RES & DEV CTR,IMMUNOBIOL LAB, IMMUNOPATHOL SECT,BLDG 560, RM 12-71, FREDERICK, MD 21702 USA.							BOWCOCK AM, 1988, MOL BRAIN RES, V3, P165, DOI 10.1016/0169-328X(88)90062-9; BOYLE MDP, 1985, J IMMUNOL, V134, P564; BOYLE MDP, 1982, P NATL ACAD SCI-BIOL, V79, P2519, DOI 10.1073/pnas.79.8.2519; BRACCI-LAUDIERO L, 1992, NEUROSCI LETT, V147, P9; BRACCILAUDIERO L, 1993, NEUROREPORT, V4, P563, DOI 10.1097/00001756-199305000-00025; BRENNER S, 1988, NATURE, V334, P528, DOI 10.1038/334528a0; BRODIE C, 1992, J IMMUNOL, V148, P3492; CHASE T, 1967, BIOCHEM BIOPH RES CO, V29, P508, DOI 10.1016/0006-291X(67)90513-X; DARLING TL, 1984, CELL CULTURE METHODS, V4, P79; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DRINKWATER CC, 1988, TRENDS BIOCHEM SCI, V13, P169, DOI 10.1016/0968-0004(88)90144-2; FAHNESTOCK M, 1991, CURR TOP MICROBIOL, V165, P1; HUTSON JM, 1979, NATURE, V279, P793, DOI 10.1038/279793a0; LEONARD EJ, 1976, EXP CELL RES, V102, P434, DOI 10.1016/0014-4827(76)90065-3; LEONARD EJ, 1978, EXP CELL RES, V114, P117, DOI 10.1016/0014-4827(78)90043-5; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; LI AKC, 1980, P NATL ACAD SCI-BIOL, V77, P4379, DOI 10.1073/pnas.77.7.4379; MAGNUSSON S, 1975, PROTEASES BIOL CONTR, P123; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NALDINI L, 1992, EMBO J, V11, P4825, DOI 10.1002/j.1460-2075.1992.tb05588.x; SHIMAMOTO A, 1993, FEBS LETT, V333, P61, DOI 10.1016/0014-5793(93)80375-5; SKEEL A, 1991, J EXP MED, V173, P1227, DOI 10.1084/jem.173.5.1227; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; WANG MH, 1993, J LEUKOCYTE BIOL, V54, P289, DOI 10.1002/jlb.54.4.289; WANG MH, 1994, IN PRESS J BIOL CHEM; WOLF BB, 1993, J BIOL CHEM, V268, P16327; YOSHIMURA T, 1993, J BIOL CHEM, V268, P15461; YOUNG M, 1979, BIOCHEMISTRY-US, V18, P3050, DOI 10.1021/bi00581a022	28	51	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					13806	13810						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188657				2022-12-25	WOS:A1994NL60600017
J	CHEN, Q; OSTERYOUNG, K; VIERLING, E				CHEN, Q; OSTERYOUNG, K; VIERLING, E			A 21-KDA CHLOROPLAST HEAT-SHOCK PROTEIN ASSEMBLES INTO HIGH-MOLECULAR-WEIGHT COMPLEXES IN-VIVO AND IN ORGANELLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-CRYSTALLIN; SACCHAROMYCES-CEREVISIAE; DROSOPHILA DEVELOPMENT; RODENT CELLS; EXPRESSION; LOCALIZATION; SUPERFAMILY; RESISTANCE; CHAPERONE; SEQUENCE	The conservation of the carboxyl terminal ''heat shock'' domain among small (sm) cytoplasmic and chloroplast heat shock proteins (HSPs) suggests that these smHSPs perform similar functions. Previous studies have established that cytoplasmic smHSPs are found in higher order structures in vivo (approximately 500 kDa). To determine if the chloroplast smHSP is found in similar complexes, we examined the size of the 21-kDa chloroplast smHSP from Pisum sativum, PsHSP21, under non-denaturing conditions. Following sedimentation of chloroplast stromal extracts on sucrose gradients PsHSP21 is detected in fractions corresponding to 10-11 S. Upon non-denaturing gel electrophoresis, PsHSP21 was detected in two high molecular mass complexes of approximately 230 and 200 kDa, in good agreement with the sucrose gradient data. These PsHSP21 containing particles were stable under different salt and Mg2+ conditions, and their integrity was not affected by 1.0% Triton X-100 or 10 mM ATP. To study assembly of the high molecular weight complexes containing PsHSP21, in vitro translated PsHSP21 was imported into chloroplasts and its size was examined. Following import into chloroplasts isolated from heat-stressed plants, greater than 50% of PsHSP21 was recovered in the higher molecular weight forms. In contrast, following import into chloroplasts isolated from control plants the protein was recovered exclusively in a 5 S (approximately 42-kDa) form. These data suggest that preexisting PsHSP21 or other heat-induced factors may be required for assembly of the higher molecular weight particles. We propose that the 10-11 S particles are the functional form of PsHSP21.	UNIV ARIZONA,DEPT BIOCHEM,TUCSON,AZ 85721	University of Arizona				chen, qiang/0000-0003-1498-7013; Vierling, Elizabeth/0000-0002-0066-4881	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM013953, R01GM042762] Funding Source: NIH RePORTER; NIGMS NIH HHS [F32 GM13953-10A1, R01 GM42762] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSSON LO, 1972, FEBS LETT, V20, P199, DOI 10.1016/0014-5793(72)80793-2; ARRIGO AP, 1988, EXP CELL RES, V175, P169, DOI 10.1016/0014-4827(88)90264-9; ARRIGO AP, 1987, J BIOL CHEM, V262, P15359; ARRIGO AP, 1987, DEV BIOL, V122, P39, DOI 10.1016/0012-1606(87)90330-7; BEHLKE J, 1991, FEBS LETT, V288, P119, DOI 10.1016/0014-5793(91)81016-2; BENTLEY NJ, 1992, YEAST, V8, P95, DOI 10.1002/yea.320080204; CHEN Q, 1990, J CELL BIOL, V110, P1873, DOI 10.1083/jcb.110.6.1873; CHEN Q, 1991, MOL GEN GENET, V226, P425, DOI 10.1007/BF00260655; COLLIER NC, 1988, J CELL BIOL, V106, P1131, DOI 10.1083/jcb.106.4.1131; DEJONG WW, 1993, MOL BIOL EVOL, V10, P103; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HELM KW, 1993, MOL CELL BIOL, V13, P238, DOI 10.1128/MCB.13.1.238; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; HUOT J, 1991, CANCER RES, V51, P5245; INGOLIA TD, 1982, P NATL ACAD SCI-BIOL, V79, P2360, DOI 10.1073/pnas.79.7.2360; JAENICKE R, 1993, CURR BIOL, V3, P234, DOI 10.1016/0960-9822(93)90342-L; JAKOB U, 1993, J BIOL CHEM, V268, P1517; KLOPPSTECH K, 1985, EMBO J, V4, P1901, DOI 10.1002/j.1460-2075.1985.tb03869.x; KRAUSE GH, 1975, PLANTA, V127, P285, DOI 10.1007/BF00380726; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDRY J, 1989, J CELL BIOL, V109, P7, DOI 10.1083/jcb.109.1.7; LI HM, 1990, P NATL ACAD SCI USA, V87, P6748, DOI 10.1073/pnas.87.17.6748; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; LORIMER GH, 1993, PHILOS T R SOC B, V339, P297, DOI 10.1098/rstb.1993.0028; LUBBEN TH, 1989, PLANT CELL, V1, P1223, DOI 10.1105/tpc.1.12.1223; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; MERCK KB, 1993, J BIOL CHEM, V268, P1046; NIETOSOTELO J, 1990, PLANT PHYSIOL, V93, P1321, DOI 10.1104/pp.93.4.1321; NOVER L, 1989, MOL CELL BIOL, V9, P1298, DOI 10.1128/MCB.9.3.1298; OSTERYOUNG KW, 1994, IN PRESS NATO ASI H; PETKO L, 1986, CELL, V45, P885, DOI 10.1016/0092-8674(86)90563-5; PLESOFSKYVIG N, 1992, J MOL EVOL, V35, P537, DOI 10.1007/BF00160214; ROLLET E, 1992, BIOCHEM BIOPH RES CO, V185, P116, DOI 10.1016/S0006-291X(05)80963-5; ROY H, 1982, J CELL BIOL, V94, P20, DOI 10.1083/jcb.94.1.20; SHAVIT N, 1967, BIOCHEM BIOPH RES CO, V28, P277, DOI 10.1016/0006-291X(67)90441-X; SUSEK RE, 1989, MOL CELL BIOL, V9, P5265, DOI 10.1128/MCB.9.11.5265; SUSS KH, 1986, PLANT PHYSIOL, V81, P192, DOI 10.1104/pp.81.1.192; VIERLING E, 1991, ANNU REV PLANT PHYS, V42, P579, DOI 10.1146/annurev.pp.42.060191.003051; VIERLING E, 1989, MOL CELL BIOL, V9, P461, DOI 10.1128/MCB.9.2.461; VIERLING E, 1986, P NATL ACAD SCI USA, V83, P361, DOI 10.1073/pnas.83.2.361; VIERLING E, 1988, EMBO J, V7, P575, DOI 10.1002/j.1460-2075.1988.tb02849.x; WALSH MT, 1991, J BIOL CHEM, V266, P20079; WENG J, 1991, PLANT MOL BIOL, V17, P255, DOI 10.1007/BF00039500; WESTWOOD JT, 1993, MOL CELL BIOL, V13, P3481, DOI 10.1128/MCB.13.6.3481; WISTOW GJ, 1988, ANNU REV BIOCHEM, V57, P479, DOI 10.1146/annurev.bi.57.070188.002403; ZANTEMA A, 1992, J BIOL CHEM, V267, P12936	46	52	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13216	13223						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175751				2022-12-25	WOS:A1994NK18400028
J	JI, ZS; FAZIO, S; MAHLEY, RW				JI, ZS; FAZIO, S; MAHLEY, RW			VARIABLE HEPARAN-SULFATE PROTEOGLYCAN BINDING OF APOLIPOPROTEIN-E VARIANTS MAY MODULATE THE EXPRESSION OF TYPE-III HYPERLIPOPROTEINEMIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; RECEPTOR-RELATED PROTEIN; HERITABLE HYPERLIPIDEMIC RABBITS; CULTURED-CELLS; CLEARANCE; LIVER; MICE; HYPERCHOLESTEROLEMIA; CHOLESTEROL; HEPATOCYTES	The initial step in the clearance of apolipoprotein (apo) E-enriched remnant lipoproteins from the plasma appears to be sequestration within the liver mediated by their binding to heparan sulfate proteoglycans (HSPG). The surface-bound remnants are believed to be internalized by their interaction with the low density lipoprotein (LDL) receptor-related protein or by the LDL receptor. Cholesterol-induced rabbit beta-very low density lipoproteins (beta-VLDL) enriched in human apoE3 display 4-5-fold enhanced binding to cultured cells. The present study attempts to determine whether recessive versus dominant type III hyperlipoproteinemia might be explained, at least in part, by a variable interaction of the mutant forms of apoE with the HSPG and impaired uptake. The beta-VLDL + apoE2(Arg(158) --> Cys), which is associated with recessive type III hyperlipoproteinemia, bound more poorly than beta-VLDL + apoE3 but still possessed significant enhanced binding (similar to 2-2.5-fold compared with beta-VLDL without added apoE) to HepG2 and McA-RH7777 cells. In comparison, beta-VLDL + apoE(Arg(142) --> Cys), beta-VLDL + apoE(Arg(145) --> Cys), and beta-VLDL + apoE-Leiden, which are associated with dominant type III hyperlipoproteinemia, bound more poorly. This same hierarchy of binding and uptake was determined by [C-14]oleate incorporation into cholesteryl esters in LDL receptor-negative cells and by secretion of apoE3 and the variant apoE forms from McA-RH7777 cells. Furthermore, the enhanced binding of the apoE-enriched beta-VLDL was almost totally inhibited by heparinase treatment of the cells, and the basal binding activity was inhibited by 80-90% following addition of an LDL receptor antibody capable of blocking receptor-ligand interaction. The beta-VLDL enriched in apoE or apoE dimyristoylphosphatidylcholine complexes bound to isolated HSPG from McA-RH7777 cells or the rat liver to a very similar degree. Likewise, the binding of beta-VLDL plus the various forms of apoE to the LDL receptor-related protein on ligand blots paralleled the results of other studies. In conclusion, all of the type III hyperlipoproteinemic apoE variants are defective in displaying enhanced binding to HSPG and in the cellular uptake initiated by HSPG. However, apoE2(Arg(158) --> Cys) displayed more activity than the variants associated with the dominant forms of type III hyperlipoproteinemia. The hierarchy of binding and uptake was as follows: apoE3 > apoE2(Arg(158) --> Cys) > apoE(Arg(145) --> Cys) > apoE(Arg(142) --> Cys) approximate to apoE-Leiden (the latter two usually displaying very little, if any, enhanced binding and uptake). Thus, a correlation exists between the mode of expression of type III hyperlipoproteinemia and the binding and uptake of the specific apoE mutation.	UNIV CALIF SAN FRANCISCO,DEPT PATHOL,SAN FRANCISCO,CA 94141; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94141; UNIV CALIF SAN FRANCISCO,GLADSTONE INST CARDIOVASC DIS,CARDIOVASC RES INST,SAN FRANCISCO,CA 94141	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; The J David Gladstone Institutes					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041633] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL41633] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; BROWN MS, 1991, CURR OPIN LIPIDOL, V2, P65; Brunzell JD, 1989, METABOLIC BASIS INHE, P1165; CHOI SSY, 1991, J CLIN INVEST, V88, P1173, DOI 10.1172/JCI115419; EHNHOLM C, 1984, P NATL ACAD SCI-BIOL, V81, P5566, DOI 10.1073/pnas.81.17.5566; FAZIO S, 1993, J LIPID RES, V34, P447; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; HAMILTON RL, 1990, J LIPID RES, V31, P1589; HERZ J, 1990, J BIOL CHEM, V265, P21355; Herz Joachim, 1993, Current Opinion in Lipidology, V4, P107, DOI 10.1097/00041433-199304000-00006; HIXSON JE, 1990, J LIPID RES, V31, P545; HORIE Y, 1992, J BIOL CHEM, V267, P1962; HUSSAIN MM, 1989, J BIOL CHEM, V264, P9571; HUSSAIN MM, 1991, J BIOL CHEM, V266, P13926; JI ZS, 1994, J BIOL CHEM, V269, P2764; JI ZS, 1994, J BIOL CHEM, V269, P13429; JI ZS, 1993, J BIOL CHEM, V268, P10160; KHAN MY, 1991, ANAL BIOCHEM, V196, P373; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; KOWAL RC, 1990, J BIOL CHEM, V265, P10771; LOHSE P, 1991, J BIOL CHEM, V266, P10479; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mahley Jr RWRS, 1989, METABOLIC BASIS INHE, P1195; Mahley R. W., 1991, CURR OPIN LIPIDOL, V2, P170; MAHLEY RW, 1989, J CLIN INVEST, V83, P2125, DOI 10.1172/JCI114126; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MANN WA, 1989, BIOCHIM BIOPHYS ACTA, V1005, P239, DOI 10.1016/0005-2760(89)90043-X; PITAS RE, 1980, J BIOL CHEM, V255, P5454; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; RALL SC, 1986, METHOD ENZYMOL, V128, P273; RALLSC, 1992, J INTERN MED, V231, P653; SIMONET WS, 1991, J BIOL CHEM, V266, P8651; SMIT M, 1990, J LIPID RES, V31, P45; SOROKA CJ, 1991, J CELL BIOL, V113, P1231, DOI 10.1083/jcb.113.5.1231; STOW JL, 1985, J CELL BIOL, V100, P975, DOI 10.1083/jcb.100.3.975; STOW JL, 1987, J CELL BIOL, V105, P529, DOI 10.1083/jcb.105.1.529; THUREN T, 1992, BIOCHEMISTRY-US, V31, P2332, DOI 10.1021/bi00123a018; WERNETTEHAMMOND ME, 1989, J BIOL CHEM, V264, P9094; WERNETTEHAMMOND ME, 1989, ARTERIOSCLEROSIS, V9, P501, DOI 10.1161/01.ATV.9.4.501; YAMADA N, 1989, P NATL ACAD SCI USA, V86, P665, DOI 10.1073/pnas.86.2.665; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543	42	122	124	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13421	13428						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175773				2022-12-25	WOS:A1994NK18400056
J	MROCZKOWSKI, BS; HUVAR, A; LERNHARDT, W; MISONO, K; NIELSON, K; SCOTT, B				MROCZKOWSKI, BS; HUVAR, A; LERNHARDT, W; MISONO, K; NIELSON, K; SCOTT, B			SECRETION OF THERMOSTABLE DNA-POLYMERASE USING A NOVEL BACULOVIRUS VECTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFECTED INSECT CELLS; RECOMBINANT BACULOVIRUS; HONEYBEE PREPROMELITTIN; ALKALINE-PHOSPHATASE; PYROCOCCUS-FURIOSUS; EXPRESSION VECTORS; INFLUENZA-VIRUS; SIGNAL PEPTIDE; SEQUENCE; PROTEINS	Baculovirus-mediated expression has become a powerful tool for the high yield production of functionally active recombinant proteins. In order to further enhance the utility of this expression system, we constructed versatile transfer vectors that facilitate the secretion of recombinant proteins from host insect cells by inserting functional secretory leader sequences down-stream of the polyhedrin promoter. In-frame insertion of cDNA sequences results in the synthesis of fusion proteins containing a heterologous signal sequence which directs the recombinant protein to the secretory pathway. Human and insect leader sequences were successfully tested with a number of proteins including the thermostable Pyrococcus furiosus (Pfu) DNA polymerase in an effort to maximize secretion of heterologous proteins from insect cells. The human placental alkaline phosphatase signal sequence (MLGPCMLLLLLLLGLR-LQLSLG) proved to be optimal for the secretion of not only this thermostable bacterial enzyme but also for the secretion of other biologically active polypeptides.	STRATAGENE INC,DIV RES & DEV,LA JOLLA,CA 92037; CLEVELAND CLIN FDN,CLEVELAND,OH 44195	Cleveland Clinic Foundation	MROCZKOWSKI, BS (corresponding author), AGOURON INST,LA JOLLA,CA 92037, USA.							AYOLA B, 1993, VIROLOGY, V194, P370, DOI 10.1006/viro.1993.1270; BESMAN M, 1985, J BIOL CHEM, V260, P1190; BHASIN R, 1991, P NATL ACAD SCI USA, V88, P10307, DOI 10.1073/pnas.88.22.10307; BLISSARD GW, 1990, ANNU REV ENTOMOL, V35, P127, DOI 10.1146/annurev.en.35.010190.001015; BUSTOS MM, 1988, PLANT MOL BIOL, V10, P475, DOI 10.1007/BF00033603; CAVENER DR, 1991, NUCLEIC ACIDS RES, V19, P3185, DOI 10.1093/nar/19.12.3185; COBB RR, 1992, BIOCHEM BIOPH RES CO, V185, P1022, DOI 10.1016/0006-291X(92)91729-A; COPELAND WC, 1991, J BIOL CHEM, V266, P22739; ERTL PF, 1991, J GEN VIROL, V72, P1729, DOI 10.1099/0022-1317-72-7-1729; FIALA G, 1986, ARCH MICROBIOL, V145, P56, DOI 10.1007/BF00413027; FOLZ RJ, 1987, BIOCHEM BIOPH RES CO, V146, P870, DOI 10.1016/0006-291X(87)90611-5; FURLONG AM, 1988, BIOTECHNOL APPL BIOC, V10, P454; GILLESPIE LS, 1991, J BIOL CHEM, V266, P3995; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; GRIPPO P, 1971, J BIOL CHEM, V246, P6867; KLOC M, 1991, J BIOL CHEM, V266, P8206; KOBAYASHI M, 1992, VIRUS RES, V22, P235, DOI 10.1016/0168-1702(92)90055-E; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KURODA K, 1990, VIROLOGY, V174, P418, DOI 10.1016/0042-6822(90)90095-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBACQVERHEYDEN AM, 1988, MOL CELL BIOL, V8, P3129, DOI 10.1128/MCB.8.8.3129; LERNHARDT W, 1993, STRATEGIES, V5, P21; LUCKOW VA, 1988, BIO-TECHNOL, V6, P47, DOI 10.1038/nbt0188-47; LUNDBERG KS, 1991, GENE, V108, P1, DOI 10.1016/0378-1119(91)90480-Y; MAEDA S, 1989, ANNU REV ENTOMOL, V34, P351, DOI 10.1146/annurev.en.34.010189.002031; MILLAN JL, 1986, J BIOL CHEM, V261, P3112; MILLER LK, 1988, ANNU REV MICROBIOL, V42, P177, DOI 10.1146/annurev.micro.42.1.177; MOLLAY C, 1982, P NATL ACAD SCI-BIOL, V79, P2260, DOI 10.1073/pnas.79.7.2260; MONKOVIC DD, 1992, BIOCHEM BIOPH RES CO, V189, P233, DOI 10.1016/0006-291X(92)91549-6; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; RAMACHANDRA M, 1993, J BIOL CHEM, V268, P442; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SMITH GE, 1983, MOL CELL BIOL, V3, P2156, DOI 10.1128/MCB.3.12.2156; SMITH GE, 1985, P NATL ACAD SCI USA, V82, P8404, DOI 10.1073/pnas.82.24.8404; SUCHANEK G, 1978, P NATL ACAD SCI USA, V75, P701, DOI 10.1073/pnas.75.2.701; SUMMERS MD, 1988, TEXAS AGR EXPT STATI, V1555, P10; TESSIER DC, 1991, GENE, V98, P177, DOI 10.1016/0378-1119(91)90171-7; TINDALL KR, 1988, BIOCHEMISTRY-US, V27, P6008, DOI 10.1021/bi00416a027; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VIALARD J, 1990, J VIROL, V64, P37, DOI 10.1128/JVI.64.1.37-50.1990; VLASAK R, 1983, EUR J BIOCHEM, V135, P123, DOI 10.1111/j.1432-1033.1983.tb07626.x; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17	43	20	25	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13522	13528						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175786				2022-12-25	WOS:A1994NK18400069
J	DIIANNI, CL; STEVENS, JT; BOLGAR, M; OBOYLE, DR; WEINHEIMER, SP; COLONNO, RJ				DIIANNI, CL; STEVENS, JT; BOLGAR, M; OBOYLE, DR; WEINHEIMER, SP; COLONNO, RJ			IDENTIFICATION OF THE SERINE RESIDUE AT THE ACTIVE-SITE OF THE HERPES-SIMPLEX VIRUS TYPE-1 PROTEASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE DNA-SEQUENCE; ASSEMBLY PROTEIN; GENE; BACTERIOPHAGE-T4; CLEAVAGE; BINDING; VIRION; DOMAIN; HEAD	Herpes simplex virus type 1 (HSV-1) encodes a protease that is essential for proteolytic processing of itself and of the nucleocapsid-associated protein, ICP35 (infected cell protein 35) (Liu, F., and Roizman, B. (1991) J. Virol. 65, 5149-5156). Inhibitor studies indicated that the HSV-1 protease is sensitive to the serine protease inactivator diisopropyl fluorophosphate (DFP). Inactivation is irreversible and dependent on time and concentration of DFP. Loss of activity correlates linearly with the incorporation of [H-3]DFP. Analysis of completely inactivated protease by mass spectrometry indicated a stoichiometry of 1 DFP/protease. In order to identify the specific residue modified by DFP, the protease was labeled with [H-3]DFP and subsequently digested with trypsin or chymotrypsin. The peptides resulting from each digestion were separated by reverse phase HPLC, and the radioactivity was recovered in a single peak. Mass spectrometric studies and sequencing analysis by Edman degradation identified Ser-129 as the residue modified by DFP. This residue and the region in which it is found is highly conserved among the herpes viral proteases. These data demonstrate that HSV-1 protease is a serine protease and that Ser-129 is the active site nucleophile.	BRISTOL MYERS SQUIBB,PHARMACEUT RES INST,DEPT ANALYT RES & DEV,PRINCETON,NJ 08543	Bristol-Myers Squibb	DIIANNI, CL (corresponding author), BRISTOL MYERS SQUIBB,PHARMACEUT RES INST,DEPT VIROL,POB 4000,PRINCETON,NJ 08543, USA.							ALBRECHT JC, 1992, J VIROL, V66, P5047, DOI 10.1128/JVI.66.8.5047-5058.1992; BAUM EZ, 1993, J VIROL, V67, P497, DOI 10.1128/JVI.67.1.497-506.1993; BRAUN DK, 1984, J VIROL, V49, P142, DOI 10.1128/JVI.49.1.142-153.1984; DAVISON AJ, 1986, J GEN VIROL, V67, P1759, DOI 10.1099/0022-1317-67-9-1759; DAVISON MD, 1992, J GEN VIROL, V73, P2709, DOI 10.1099/0022-1317-73-10-2709; DECKMAN IC, 1992, J VIROL, V66, P7362, DOI 10.1128/JVI.66.12.7362-7367.1992; DIIANNI CL, 1993, J BIOL CHEM, V268, P25449; DILANNI CL, 1993, J BIOL CHEM, V268, P2028; GIBSON W, 1972, J VIROL, V10, P1044, DOI 10.1128/JVI.10.5.1044-1052.1972; GIBSON W, 1974, J VIROL, V13, P155, DOI 10.1128/JVI.13.1.155-165.1974; GRIFFIN AM, 1990, NUCLEIC ACIDS RES, V18, P3664, DOI 10.1093/nar/18.12.3664; KELLER B, 1986, GENE, V49, P245, DOI 10.1016/0378-1119(86)90285-4; KING J, 1974, NATURE, V251, P112, DOI 10.1038/251112a0; LAEMMLI UK, 1974, VIROLOGY, V62, P483, DOI 10.1016/0042-6822(74)90409-7; LIU FY, 1991, J VIROL, V65, P5149, DOI 10.1128/JVI.65.10.5149-5156.1991; LIU FY, 1991, J VIROL, V65, P206, DOI 10.1128/JVI.65.1.206-212.1991; LIU FY, 1993, J VIROL, V67, P1300, DOI 10.1128/JVI.67.3.1300-1309.1993; LIU FY, 1992, P NATL ACAD SCI USA, V89, P2076, DOI 10.1073/pnas.89.6.2076; LUFTIG RB, 1973, P NATL ACAD SCI USA, V70, P1636, DOI 10.1073/pnas.70.6.1636; MCGEOCH DJ, 1988, J GEN VIROL, V69, P1531, DOI 10.1099/0022-1317-69-7-1531; NEWCOMB WW, 1989, J VIROL, V63, P4697, DOI 10.1128/JVI.63.11.4697-4702.1989; ONORATO L, 1978, J VIROL, V27, P409, DOI 10.1128/JVI.27.2.409-426.1978; PERDUE ML, 1974, VIROLOGY, V59, P201, DOI 10.1016/0042-6822(74)90216-5; PRESTON VG, 1983, J VIROL, V45, P1056, DOI 10.1128/JVI.45.3.1056-1064.1983; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; SHOWE MK, 1976, J MOL BIOL, V107, P55, DOI 10.1016/S0022-2836(76)80017-4; SHOWE MK, 1976, J MOL BIOL, V107, P35, DOI 10.1016/S0022-2836(76)80016-2; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; TELFORD EAR, 1992, VIROLOGY, V189, P304, DOI 10.1016/0042-6822(92)90706-U; WEINHEIMER SP, 1993, J VIROL, V67, P5813, DOI 10.1128/JVI.67.10.5813-5822.1993; WELCH AR, 1991, P NATL ACAD SCI USA, V88, P10792, DOI 10.1073/pnas.88.23.10792; WELCH AR, 1991, J VIROL, V65, P4091, DOI 10.1128/JVI.65.8.4091-4100.1991; WELCH AR, 1993, J VIROL, V67, P7360, DOI 10.1128/JVI.67.12.7360-7372.1993	33	23	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12672	12676						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175677				2022-12-25	WOS:A1994NH71600048
J	LEW, RA; TETAZ, TJ; GLUCKSMAN, MJ; ROBERTS, JL; SMITH, AI				LEW, RA; TETAZ, TJ; GLUCKSMAN, MJ; ROBERTS, JL; SMITH, AI			EVIDENCE FOR A 2-STEP MECHANISM OF GONADOTROPIN-RELEASING-HORMONE METABOLISM BY PROLYL ENDOPEPTIDASE AND METALLOENDOPEPTIDASE EC-3.4.24.15 IN OVINE HYPOTHALAMIC EXTRACTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; ENKEPHALIN-CONTAINING PEPTIDES; RABBIT BRAIN; SOLUBLE METALLOENDOPEPTIDASE; NEUTRAL ENDOPEPTIDASE; CONVERTING ENZYME; NATURAL PEPTIDES; RAT TESTES; DEGRADATION; SPECIFICITY	The metalloendopeptidase EC 3.4.24.15 is believed to degrade gonadotropin releasing hormone (GnRH) (pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2) by cleavage at the Tyr(5)Gly(6) bond. We compared the ability of crude and partially purified endopeptidase 24.15 from ovine hypothalamus with recombinant rat testicular endopeptidase 24.15 to degrade synthetic GnRH. Both soluble and membrane hypothalamic fractions degraded GnRH to GnRH(1-5) with some production of GnRH(1-9) and GnRH(1-3). Generation of the smaller fragments was blocked by a specific endopeptidase 24.15 inhibitor (CFP-AAY-pAB), but production of GnRH(1-9) was reciprocally enhanced, suggesting this peptide may be an intermediate generated by prolyl endopeptidase. In deed, both bacitracin and Z-Pro-prolinal, inhibitors of this enzyme, markedly reduced GnRH degradation to any product. Degradation of synthetic GnRH(1-9) was more rapid than that of GnRH and was inhibited by CFP-AAY-pAB but not bacitracin. Activity against either substrate was greater in the soluble fraction. Repeated washing of the membrane fraction followed by extraction with Triton X-114 suggested that both endopeptidase 24.15 and prolyl endopeptidase, although predomi nantly soluble, can be peripherally associated with membranes, When fractionated by hydrophobic interaction chromatography, soluble endopeptidase 24.15 degraded GnRH only in fractions that also exhibited prolyl endopeptidase activity. In contrast, maximal degradation of GnRH(1-9) was observed in adjacent fractions, which also contained the highest levels of immunoreactive endopeptidase 24.15. The affinity of recombinant endopeptidase 24.15 for GnRH was low (K-m = 1.35 mM), was improved 10-15-fold by removal of the COOH-terminal amide or glycinamide (K-m = 90 and 119 mu M, respectively), and could be inhibited by CFP-AAY-pAB but not bacitracin. Taken together, these results suggest that GnRH metabolism in the hypothalamus may occur via a two step process involving first removal of Gly(10)-NH2, by prolyl endopeptidase, followed by cleavage by endopeptidase 24.15 at the Tyr(5)-Gly(6) bond.	BAKER MED RES INST,PEPTIDE BIOL LAB,PRAHRAN,VIC 3181,AUSTRALIA; CUNY MT SINAI SCH MED,DR AUTHOR M FISHBERG RES CTR NEUROBIOL,NEW YORK,NY 10029	Baker Heart and Diabetes Institute; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai			Lew, Rebecca A/C-5454-2008	Smith, Ian/0000-0002-4143-2892				ACKER GR, 1987, J NEUROCHEM, V48, P284, DOI 10.1111/j.1471-4159.1987.tb13160.x; ADVIS JP, 1982, ANAL BIOCHEM, V125, P41, DOI 10.1016/0003-2697(82)90380-3; BORDIER C, 1981, J BIOL CHEM, V256, P1604; CAMARGO ACM, 1973, BIOCHEMISTRY-US, V12, P1838, DOI 10.1021/bi00733a028; CARVALHO KM, 1981, BIOCHEMISTRY-US, V20, P7082, DOI 10.1021/bi00528a005; CHAPPELL MC, 1992, PEPTIDES, V13, P943, DOI 10.1016/0196-9781(92)90053-6; CHU TG, 1985, ENDOCRINOLOGY, V116, P1418, DOI 10.1210/endo-116-4-1418; DECAMARGO ACM, 1982, J BIOL CHEM, V257, P9265; DRESDNER K, 1982, J NEUROCHEM, V38, P1151, DOI 10.1111/j.1471-4159.1982.tb05362.x; HORSTHEMKE B, 1982, BIOCHEMISTRY-US, V21, P1033, DOI 10.1021/bi00534a032; LABRIE F, 1984, LHRH ITS ANALOGUES B, P3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPP CA, 1986, NEUROENDOCRINOLOGY, V43, P230, DOI 10.1159/000124531; LASDUN A, 1989, J PHARMACOL EXP THER, V251, P439; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCDERMOTT JR, 1982, REGUL PEPTIDES, V3, P257, DOI 10.1016/0167-0115(82)90131-8; MCDERMOTT JR, 1983, PEPTIDES, V4, P25, DOI 10.1016/0196-9781(83)90160-2; MCDERMOTT JR, 1992, BIOCHEM BIOPH RES CO, V185, P746, DOI 10.1016/0006-291X(92)91689-N; MCKELVY JF, 1976, BIOCHEM BIOPH RES CO, V73, P507, DOI 10.1016/0006-291X(76)90736-1; MCKIE N, 1993, BIOCHEM J, V295, P57, DOI 10.1042/bj2950057; MOLINEAUX CJ, 1988, J NEUROCHEM, V51, P624, DOI 10.1111/j.1471-4159.1988.tb01084.x; ORLOWSKI M, 1983, EUR J BIOCHEM, V135, P81, DOI 10.1111/j.1432-1033.1983.tb07620.x; ORLOWSKI M, 1988, BIOCHEMISTRY-US, V27, P597, DOI 10.1021/bi00402a015; ORLOWSKI M, 1989, BIOCHEM J, V261, P951, DOI 10.1042/bj2610951; PIEROTTI A, 1990, BIOCHEMISTRY-US, V29, P10323, DOI 10.1021/bi00497a006; PIEROTTI A, 1994, IN PRESS BIOCHEMISTR; SKIDGEL RA, 1985, P NATL ACAD SCI USA, V82, P1025, DOI 10.1073/pnas.82.4.1025; SKIDGEL RA, 1987, NEUROPEPTIDES THEIR, P165; SMITH AI, 1992, SERONO SYM, V86, P207; SOUBRIER F, 1993, J HYPERTENS, V11, P471, DOI 10.1097/00004872-199305000-00001; TISLJAR U, 1989, ARCH BIOCHEM BIOPHYS, V274, P138, DOI 10.1016/0003-9861(89)90424-4; WILK S, 1983, J NEUROCHEM, V41, P69, DOI 10.1111/j.1471-4159.1983.tb11815.x; YOSHIMOTO T, 1979, BIOCHIM BIOPHYS ACTA, V569, P184, DOI 10.1016/0005-2744(79)90053-6	33	63	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12626	12632						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175672				2022-12-25	WOS:A1994NH71600042
J	BUSH, AI; PETTINGELL, WH; PARADIS, MD; TANZI, RE				BUSH, AI; PETTINGELL, WH; PARADIS, MD; TANZI, RE			MODULATION OF A-BETA ADHESIVENESS AND SECRETASE SITE CLEAVAGE BY ZINC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; TANGLE-BEARING NEURONS; ALZHEIMERS-DISEASE; PARKINSONISM-DEMENTIA; DOWNS-SYNDROME; NEUROFIBRILLARY TANGLES; ALUMINUM ACCUMULATION; CEREBRAL-HEMORRHAGE; BRAIN; RAT	Abnormalities of zinc homeostasis occur in Alzheimer's disease (AD), a dementia characterized by the aggregation of A beta in the brain, and in Down syndrome, a condition characterized by premature AD, We studied the binding of Zn2+ to a synthetic peptide representing residues 1-40 (A beta(1-40)), as well as other domains of A beta. Two classes of Zn2+ binding were identified by Zn-65(2+) labeling: highly specific pH-dependent high affinity (K-alpha = 107 nM) binding, and lower affinity (K-alpha = 5.2 mu M) binding. Gel filtration chromatography identified monomeric, dimeric, and polymeric A beta species. Zinc induced a marked loss of A beta solubility upon chromatographic analysis. This was attributed to precipitation onto the column glass, which contains aluminosilicate, and was confirmed by the observation of zinc-accelerated precipitation of A beta by kaolin, a hydrated aluminum silicate suspension. Zinc binding also increased A beta resistance to tryptic cleavage at the secretase site, indicating that a small (<3 mu M) increase in brain Zn2+ concentration could significantly alter A beta metabolism, We propose that elevated brain interstitial zinc levels may increase A beta adhesiveness and interfere with A beta catabolism. Consequently, abnormalities of regional zinc concentrations in the brains of patients with AD or Down syndrome may contribute to A beta amyloidosis in these disorders.	HARVARD UNIV, MASSACHUSETTS GEN HOSP, SCH MED, GENET & AGING LAB, BOSTON, MA 02129 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital			Bush, Ashley I/A-1186-2007; Tanzi, Rudolph/AAE-9622-2019; Bush, Ashley/Y-2457-2019	Bush, Ashley I/0000-0001-8259-9069; Tanzi, Rudolph/0000-0002-7032-1454; Bush, Ashley/0000-0001-8259-9069; Paradis, Marc d./0000-0003-2387-3157				ASSAF SY, 1984, NATURE, V308, P734, DOI 10.1038/308734a0; BACKSTROM JR, 1992, J NEUROCHEM, V58, P983, DOI 10.1111/j.1471-4159.1992.tb09352.x; BAKER RJ, 1978, THROMB HAEMOSTASIS, V39, P360; BJORKSTEN B, 1980, ACTA PAEDIATR SCAND, V69, P183, DOI 10.1111/j.1651-2227.1980.tb07057.x; BUSH AI, 1992, ANN NEUROL, V32, P57, DOI 10.1002/ana.410320110; BUSH AI, 1990, J BIOL CHEM, V265, P15977; BUSH AI, 1993, J BIOL CHEM, V268, P16109; CANDY JM, 1986, LANCET, V1, P354; CANDY JM, 1992, BIOCHEM SOC T, V21, pS53; CONSTANTINIDIS J, 1990, Encephale, V16, P231; CORRIGAN FM, 1993, BIOMETALS, V6, P149; Dawson R. M. C., 1986, DATA BIOCH RES, V3rd; DUNCAN MW, 1992, J NEUROSCI, V12, P1523, DOI 10.1523/jneurosci.12-04-01523.1992; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; FRANCESCHI C, 1988, J MENT DEFIC RES, V32, P169; FREDERICKSON CJ, 1983, BRAIN RES, V273, P335, DOI 10.1016/0006-8993(83)90858-2; FREDERICKSON CJ, 1989, INT REV NEUROBIOL, V31, P145; FREDERICKSON CJ, 1987, J HISTOCHEM CYTOCHEM, V35, P579, DOI 10.1177/35.5.2435783; FREDERICQ E, 1956, ARCH BIOCHEM BIOPHYS, V65, P218, DOI 10.1016/0003-9861(56)90189-8; GARRUTO RM, 1984, P NATL ACAD SCI-BIOL, V81, P1875, DOI 10.1073/pnas.81.6.1875; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; GOLDGABER D, 1987, SCIENCE, V235, P877, DOI 10.1126/science.3810169; GOLDMAN J, 1974, BIOCHEMISTRY-US, V13, P4566, DOI 10.1021/bi00719a015; GUIROY DC, 1987, P NATL ACAD SCI USA, V84, P2073, DOI 10.1073/pnas.84.7.2073; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HENDRIKS L, 1992, NAT GENET, V1, P218, DOI 10.1038/ng0692-218; HERSHEY CO, 1983, NEUROLOGY, V33, P1350, DOI 10.1212/WNL.33.10.1350; HOWELL GA, 1984, NATURE, V308, P736, DOI 10.1038/308736a0; HYMAN BT, 1986, ANN NEUROL, V20, P472, DOI 10.1002/ana.410200406; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KOH JY, 1990, BRAIN RES, V533, P315, DOI 10.1016/0006-8993(90)91355-K; KOO EH, 1993, P NATL ACAD SCI USA, V90, P4748, DOI 10.1073/pnas.90.10.4748; LEVY E, 1990, SCIENCE, V248, P1124, DOI 10.1126/science.2111584; LUI E, 1990, J AM GERIATR SOC, V38, P633, DOI 10.1111/j.1532-5415.1990.tb01421.x; MANTYH PW, 1993, J NEUROCHEM, V61, P1171, DOI 10.1111/j.1471-4159.1993.tb03639.x; MASTERS CL, 1985, EMBO J, V4, P2757, DOI 10.1002/j.1460-2075.1985.tb04000.x; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MCLACHLAN DRC, 1991, LANCET, V337, P1304, DOI 10.1016/0140-6736(91)92978-B; MILWARD EA, 1992, NEURON, V9, P129, DOI 10.1016/0896-6273(92)90228-6; MURRELL J, 1991, SCIENCE, V254, P97, DOI 10.1126/science.1925564; PEREZCLAUSELL J, 1985, BRAIN RES, V337, P91, DOI 10.1016/0006-8993(85)91612-9; PERL DP, 1982, SCIENCE, V217, P1053, DOI 10.1126/science.7112111; PERL DP, 1980, SCIENCE, V208, P297, DOI 10.1126/science.7367858; ROBAKIS NK, 1987, P NATL ACAD SCI USA, V84, P4190, DOI 10.1073/pnas.84.12.4190; RUMBLE B, 1989, NEW ENGL J MED, V320, P1446, DOI 10.1056/NEJM198906013202203; SCHUBERT W, 1991, BRAIN RES, V563, P184, DOI 10.1016/0006-8993(91)91532-6; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHIVERS BD, 1988, EMBO J, V7, P1365, DOI 10.1002/j.1460-2075.1988.tb02952.x; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; STEWART GR, 1984, BRAIN RES, V290, P43, DOI 10.1016/0006-8993(84)90734-0; TANZI RE, 1987, SCIENCE, V235, P880, DOI 10.1126/science.2949367; TOMSKI SJ, 1992, ARCH BIOCHEM BIOPHYS, V294, P630, DOI 10.1016/0003-9861(92)90735-F; UCHIDA Y, 1991, NEURON, V7, P337, DOI 10.1016/0896-6273(91)90272-2; WEISS JH, 1989, NATURE, V338, P212, DOI 10.1038/338212b0; WENSTRUP D, 1990, BRAIN RES, V533, P125, DOI 10.1016/0006-8993(90)91804-P; WOLF G, 1984, NEUROSCI LETT, V51, P277, DOI 10.1016/0304-3940(84)90564-0; XIE XM, 1991, NATURE, V349, P521, DOI 10.1038/349521a0; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531	60	303	321	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					12152	12158						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163520				2022-12-25	WOS:A1994NG37700073
J	MELIKIAN, HE; MCDONALD, JK; GU, H; RUDNICK, G; MOORE, KR; BLAKELY, RD				MELIKIAN, HE; MCDONALD, JK; GU, H; RUDNICK, G; MOORE, KR; BLAKELY, RD			HUMAN NOREPINEPHRINE TRANSPORTER - BIOSYNTHETIC-STUDIES USING A SITE-DIRECTED POLYCLONAL ANTIBODY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINOBUTYRIC-ACID TRANSPORTER; PLASMA-MEMBRANE; NEUROTRANSMITTER TRANSPORTERS; DOPAMINE TRANSPORTER; EXPRESSION CLONING; COCAINE; PROTEINS; PURIFICATION; TOPOGRAPHY; RECEPTORS	Antibodies have been raised against synthetic peptides derived from the predicted primary sequence of the human cocaine and antidepressant-sensitive norepinephrine (NE) transporter (NET). One antibody (N430), raised and purified against a putative intracellular human norepinephrine transporter (hNET) epitope, detects hNET expression in a stably transfected cell line (LLC-NET) by indirect immunofluorescence only in the presence of detergent, while no immunoreactivity is observed in either the parental cells (LLC-PK1) or in LLC-NET cells incubated with preimmune sera or peptide absorbed antibody. N430 immunoblots of LLC-NET cell extracts reveal two major immunoreactive hNET species in these cells, migrating at 80 and 54 kDa, respectively. Pulse-chase N430 immunoprecipitation studies confirm that the 54-kDa species is a transient, glycosylated intermediate of a longer lived, more highly glycosylated protein with an apparant M(r) of 80,000. In contrast, a 54-kDa species is the primary hNET product in vaccinia virus T7-infected HeLa cells, transiently transfected with hNET cDNA PNGase F digestion of extracts prepared from LLC-NET- and hNET-transfected HeLa cells convert all immunoreactive species to a 46-kDa form, equivalent to that observed following incubation of whole cells with the glycosylation inhibitor tunicamycin. As transiently transfected HeLa and stable LLC-NET cells exhibit a pharmacologically similar NE transport activity, it appears likely that the additional glycosylation evident in the stable line does not contribute significantly to antagonist sensitivity. On the other hand, NE transport and antagonist ([I-125]RTI-55) binding assays on whole LLC-NET cells treated with tunicamycin reveal a pronounced reduction in NE transport activity and hNET membrane density paralleled by an inability of NET proteins to replenish the higher M(r) hNET pool. These findings suggest an obligate role for N-linked glycosylation in hNET biosynthetic maturation, stability, and functional expression. In summary, N430 antibody is a useful tool for the visualization and characterization of hNET gene products and has permitted the first direct evaluation of biosynthetic steps leading to functional catecholamine transporter expression.	EMORY UNIV, SCH MED, DEPT ANAT & CELL BIOL, ATLANTA, GA 30322 USA; EMORY UNIV, DIV BIOL & BIOMED SCI, GRAD PROGRAM NEUROSCI, ATLANTA, GA 30322 USA; YALE UNIV, SCH MED, DEPT PHARMACOL, NEW HAVEN, CT 06510 USA	Emory University; Emory University; Yale University			Melikian, Haley/S-8301-2016	Melikian, Haley/0000-0002-9694-5556	NIDA NIH HHS [DA07390, DA8213, DA7259] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA007390, R01DA008213, R01DA007259] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		AMARA SG, 1992, NATURE, V360, P420, DOI 10.1038/360420d0; AMARA SG, 1993, ANNU REV NEUROSCI, V16, P73, DOI 10.1146/annurev.ne.16.030193.000445; ASHTON H, 1987, BRAIN SYSTEMS DISORD, P331; AXELROD J, 1961, SCIENCE, V133, P383, DOI 10.1126/science.133.3450.383; BENDAHAN A, 1993, FEBS LETT, V318, P41, DOI 10.1016/0014-5793(93)81323-R; BERGER SP, 1991, MOL PHARMACOL, V39, P429; BLAKELY RD, 1993, SOC GEN PHY, V48, P283; BLAKELY RD, 1991, ANAL BIOCHEM, V194, P302, DOI 10.1016/0003-2697(91)90233-J; BLAKELY RD, 1992, CURR OPIN PSYCHIATR, V5, P69; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FISCHMAN MW, 1987, PSYCHOPHARMACOLOGY 3, P1543; GOLDSTEIN DS, 1988, CIRCULATION, V78, P41, DOI 10.1161/01.CIR.78.1.41; GRAHAM D, 1992, BIOCHEM J, V286, P801, DOI 10.1042/bj2860801; GRIGORIADIS DE, 1989, J NEUROSCI, V9, P2664; GU H, 1993, IN PRESS J BIOL CHEM; HARLOW E, 1988, ANTIBODIES LABORATOR; HOWARD BD, 1990, J NEUROSCI RES, V26, P149, DOI 10.1002/jnr.490260204; Iversen L., 1967, UPTAKE STORAGE NORAD; IVERSEN LL, 1965, J PHARM PHARMACOL, V17, P62, DOI 10.1111/j.2042-7158.1965.tb07572.x; JENNINGS ML, 1989, ANNU REV BIOCHEM, V58, P999; KANNER BI, 1987, CRIT REV BIOCHEM MOL, V22, P1, DOI 10.3109/10409238709082546; KANNER BI, 1989, BIOCHEMISTRY-US, V28, P3722, DOI 10.1021/bi00435a015; KEYNAN S, 1992, BIOCHEMISTRY-US, V31, P1974, DOI 10.1021/bi00122a011; KILTY JE, 1991, SCIENCE, V254, P578, DOI 10.1126/science.1948035; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAUNAY JM, 1992, J BIOL CHEM, V267, P11344; LECONTE I, 1992, J BIOL CHEM, V267, P17415; LEW R, 1992, BRAIN RES, V584, P266, DOI 10.1016/0006-8993(92)90905-O; Melikian H. E., 1993, Society for Neuroscience Abstracts, V19, P494; MOSS B, 1987, ANNU REV IMMUNOL, V5, P305, DOI 10.1146/annurev.iy.05.040187.001513; PACHOLCZYK T, 1991, NATURE, V350, P350, DOI 10.1038/350350a0; PANTANOWITZ S, 1993, J BIOL CHEM, V268, P3222; PATEL A, 1993, J NEUROCHEM, V61, P496; RAMAMOORTHY S, 1993, J BIOL CHEM, V268, P21626; RITZ MC, 1987, SCIENCE, V237, P1219, DOI 10.1126/science.2820058; RONNETT GV, 1984, J BIOL CHEM, V259, P4566; SALLEE FR, 1989, FEBS LETT, V256, P219, DOI 10.1016/0014-5793(89)81752-1; SCHLOSS P, 1992, FEBS LETT, V307, P76, DOI 10.1016/0014-5793(92)80905-V; SHIMADA S, 1991, SCIENCE, V254, P576, DOI 10.1126/science.1948034; TAKAGI T, 1991, ADV ELECTROPHORESIS, V4, P391; UHL GR, 1992, TRENDS NEUROSCI, V15, P265, DOI 10.1016/0166-2236(92)90068-J; VAUGHAN RA, 1993, MOL CELL NEUROSCI, V4, P209, DOI 10.1006/mcne.1993.1025; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530; WANG HY, 1989, J BIOL CHEM, V264, P14424; ZALESKA MM, 1987, NEUROSCI LETT, V82, P107, DOI 10.1016/0304-3940(87)90179-0; ZHU JH, 1992, NEUROCHEM INT, V21, P521, DOI 10.1016/0197-0186(92)90083-4; [No title captured]	47	104	105	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					12290	12297						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163533				2022-12-25	WOS:A1994NG37700093
J	APERIA, A; HOLTBACK, U; SYREN, ML; SVENSSON, LB; FRYCKSTEDT, J; GREENGARD, P				APERIA, A; HOLTBACK, U; SYREN, ML; SVENSSON, LB; FRYCKSTEDT, J; GREENGARD, P			ACTIVATION/DEACTIVATION OF RENAL NA+,K+-ATPASE - A FINAL COMMON PATHWAY FOR REGULATION OF NATRIURESIS	FASEB JOURNAL			English	Article						SODIUM TRANSPORT SYSTEM; KIDNEY PERFUSION; ANGIOTENSIN; NATRIURETIC HORMONE	NA+-K+-ATPASE; TUBULAR SODIUM-REABSORPTION; ANGIOTENSIN-II; PROXIMAL TUBULE; CELLS; DOPAMINE; STIMULATION; INHIBITION; TRANSPORT; PHOSPHOPROTEIN	Renal sodium metabolism, a major determinant of blood pressure, is regulated with great precision by a variety of endocrine, autocrine, and neuronal factors. Although these factors are known to regulate sodium metabolism by affecting the rate of tubular sodium reabsorption, the molecular mechanisms by which they act are poorly understood. Na+,K+-ATPase plays a pivotal role for sodium reabsorption in all tubular segments. The activity of this enzyme can be dynamically regulated by phosphorylation and dephosphorylation. Here we summarize both old and new evidence that several major substances believed to be involved in the regulation of sodium metabolism and blood pressure, i.e., the antidiuretic agents angiotensin II and norepinephrine, and the diuretic agents dopamine and atrial natriuretic peptide (ANP), may achieve their effects through a common pathway that involves reversible activation/deactivation of renal tubular Na+,K+-ATPase. Regulation of Na+,K+-ATPase activity was studied using a preparation of single proximal tubule (PT) segments, dissected from rat kidneys. Na+,K+-ATPase activity was stimulated by angiotensin II and the alpha-adrenergic agonist, oxymetazoline, at physiological, nonsaturating Nai concentrations. These stimulatory effects were blocked by dopamine and ANP as well as by their respective second messengers, cAMP and cGMP. They were also blocked by the specific protein phosphatase 2B inhibitor FK506. These results indicate that regulation of sodium excretion by norepinephrine, angiotensin II, dopamine, and ANP can be accounted for by a bidirectionally regulated intracellular protein phosphorylation cascade that modulates the activity of renal tubular Na+,K+-ATPase.	ROCKEFELLER UNIV,MOLEC & CELLULAR NEUROSCI LAB,NEW YORK,NY 10021; KAROLINSKA INST,ST GORANS CHILDRENS HOSP,DEPT WOMEN & CHILD HLTH,PEDIAT UNIT,S-11281 STOCKHOLM,SWEDEN	Rockefeller University; Karolinska Institutet				Syren, Marie-Louise/0000-0003-0857-8432	NIMH NIH HHS [MH-40899] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [P01MH040899] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		APERIA A, 1991, P NATL ACAD SCI USA, V88, P2798, DOI 10.1073/pnas.88.7.2798; APERIA A, 1992, P NATL ACAD SCI USA, V89, P7394, DOI 10.1073/pnas.89.16.7394; APERIA A, 1987, AM J PHYSIOL, V252, pF39, DOI 10.1152/ajprenal.1987.252.1.F39; BERTORELLO AM, 1991, P NATL ACAD SCI USA, V88, P11359, DOI 10.1073/pnas.88.24.11359; CHINKERS M, 1989, NATURE, V338, P78, DOI 10.1038/338078a0; CLAUSEN T, 1991, PHYSIOL REV, V71, P733, DOI 10.1152/physrev.1991.71.3.733; DAHL LK, 1972, AM J CLIN NUTR, V25, P231; DIBONA GF, 1985, FED PROC, V44, P2816; DOUCET A, 1979, AM J PHYSIOL, V237, pF105, DOI 10.1152/ajprenal.1979.237.2.F105; GARVIN JL, 1989, AM J PHYSIOL, V257, pF907, DOI 10.1152/ajprenal.1989.257.5.F907; GOLIGORSKY MS, 1986, J CELL PHYSIOL, V128, P466, DOI 10.1002/jcp.1041280316; GUYTON AC, 1991, SCIENCE, V252, P1813, DOI 10.1126/science.2063193; HALPAIN S, 1990, NATURE, V343, P369, DOI 10.1038/343369a0; HARRIS PJ, 1987, NATURE, V326, P697, DOI 10.1038/326697a0; HARRIS PJ, 1977, PFLUG ARCH EUR J PHY, V367, P295, DOI 10.1007/BF00581370; HEMMINGS HC, 1984, NATURE, V310, P503, DOI 10.1038/310503a0; IBARRA F, 1993, P NATL ACAD SCI USA, V90, P21, DOI 10.1073/pnas.90.1.21; JABS K, 1989, AM J PHYSIOL, V257, pF424, DOI 10.1152/ajprenal.1989.257.3.F424; KUCHEL OG, 1991, HYPERTENSION, V18, P709, DOI 10.1161/01.HYP.18.6.709; LANG CC, 1992, KIDNEY INT, V42, P433, DOI 10.1038/ki.1992.306; LARSSON S, 1986, AM J PHYSIOL, V251, pC455, DOI 10.1152/ajpcell.1986.251.3.C455; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LYTTON J, 1985, J BIOL CHEM, V260, P75; NISHI A, 1993, HYPERTENSION, V21, P767, DOI 10.1161/01.HYP.21.6.767; POGGIOLI J, 1992, AM J PHYSIOL, V263, pC750, DOI 10.1152/ajpcell.1992.263.4.C750; RIBEIRO CP, 1992, AM J PHYSIOL, V262, pF209, DOI 10.1152/ajprenal.1992.262.2.F209; SCHUSTER VL, 1984, J CLIN INVEST, V73, P507, DOI 10.1172/JCI111237; SOWERS JR, 1988, HYPERTENSION, V12, P485, DOI 10.1161/01.HYP.12.5.485; WANG T, 1990, J PHARMACOL EXP THER, V252, P689; ZEIDEL ML, 1989, AM J PHYSIOL, V257, pC1101, DOI 10.1152/ajpcell.1989.257.6.C1101	30	225	227	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	APR 1	1994	8	6					436	439		10.1096/fasebj.8.6.8168694	http://dx.doi.org/10.1096/fasebj.8.6.8168694			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	NH250	8168694				2022-12-25	WOS:A1994NH25000011
J	GIROS, B; WANG, YM; SUTER, S; MCLESKEY, SB; PIFL, C; CARON, MG				GIROS, B; WANG, YM; SUTER, S; MCLESKEY, SB; PIFL, C; CARON, MG			DELINEATION OF DISCRETE DOMAINS FOR SUBSTRATE, COCAINE, AND TRICYCLIC ANTIDEPRESSANT INTERACTIONS USING CHIMERIC DOPAMINE-NOREPINEPHRINE TRANSPORTERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CLONING; EXPRESSION	Neurotransmitter transporters determine the intensity and duration of signal transduction by controlling the rapid removal of transmitter molecules from the synaptic cleft. The importance of their function is further reflected by the medical and social implications of compounds that inhibit their activity such as the antidepressants and cocaine. Molecular characterization of these transporters has revealed that they are members of a large family of membrane proteins with 12 putative transmembrane domains. However, little information exists as to whether discrete domains of these proteins mediate the various defined functions of these transporters. In this study, we constructed a series of chimeras between two structurally related but pharmacologically distinct transporters, the dopamine and norepinephrine transporters. The properties of these chimeric transporters suggest that distinct regions of these molecules determine these individual functions. Regions from the amino-terminal through the first five transmembrane domains are likely to be involved in the uptake mechanisms and ionic dependence. Regions within transmembrane domains 6-8 determine tricyclic antidepressant binding and cocaine interactions, whereas the carboxyl-terminal region encompassing transmembrane domain 9 through the COOH-terminal tail appears to be responsible for the stereoselectivity and high affinity for substrates. The dissociation of the substrate uptake and cocaine binding properties of these transporters further raises the possibility that antagonists of cocaine action devoid of uptake blockade activity might be developed for the clinical management of cocaine addiction.	DUKE UNIV,MED CTR,DEPT MED,DURHAM,NC 27710	Duke University	GIROS, B (corresponding author), DUKE UNIV,MED CTR,DEPT CELL BIOL,HOWARD HUGHES MED INST LABS,BOX 3287,DURHAM,NC 27710, USA.		GIROS, Bruno/ABD-5790-2021	GIROS, Bruno/0000-0001-5876-9822; Pifl, Christian/0000-0003-1456-4264	NATIONAL INSTITUTE OF MENTAL HEALTH [P30MH040159, P50MH040159] Funding Source: NIH RePORTER; NIMH NIH HHS [MH-44221, MH-40159] Funding Source: Medline; NINDS NIH HHS [NS-15976] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AMARA SG, 1993, ANNU REV NEUROSCI, V16, P73, DOI 10.1146/annurev.ne.16.030193.000445; CARON MG, 1993, NATURE, V366, P409, DOI 10.1038/366409a0; GIROS B, 1989, NATURE, V342, P923, DOI 10.1038/342923a0; GIROS B, 1991, FEBS LETT, V295, P149, DOI 10.1016/0014-5793(91)81406-X; GIROS B, 1993, TRENDS PHARMACOL SCI, V14, P43, DOI 10.1016/0165-6147(93)90029-J; GIROS B, 1992, MOL PHARMACOL, V42, P383; KANNER BI, 1983, BIOCHIM BIOPHYS ACTA, V726, P293, DOI 10.1016/0304-4173(83)90013-7; KILTY JE, 1991, SCIENCE, V254, P578, DOI 10.1126/science.1948035; KITAYAMA S, 1993, SYNAPSE, V15, P58, DOI 10.1002/syn.890150107; MCELVAIN JS, 1992, BIOCHEM PHARMACOL, V43, P2189, DOI 10.1016/0006-2952(92)90178-L; PACHOLCZYK T, 1991, NATURE, V350, P350, DOI 10.1038/350350a0; PIFL C, 1993, J NEUROSCI, V13, P4246, DOI 10.1523/jneurosci.13-10-04246.1993; RITZ MC, 1987, SCIENCE, V237, P1219, DOI 10.1126/science.2820058; RUDNICK G, 1993, BIOCHIM BIOPHYS ACTA, V1144, P249, DOI 10.1016/0005-2728(93)90109-S; SHIMADA S, 1991, SCIENCE, V254, P576, DOI 10.1126/science.1948034; UHL GR, 1992, TRENDS PHARMACOL SCI, V13, P421, DOI 10.1016/0165-6147(92)90133-Q; USDIN TB, 1991, P NATL ACAD SCI USA, V88, P11168, DOI 10.1073/pnas.88.24.11168; VANDENBERG OJ, 1992, MOL BRAIN RES, V15, P161	18	255	258	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					15985	15988						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206893				2022-12-25	WOS:A1994NQ72900008
J	CARILLO, S; PARIAT, M; STEFF, AM; ROUX, P; ETIENNEJULAN, M; LORCA, T; PIECHACZYK, M				CARILLO, S; PARIAT, M; STEFF, AM; ROUX, P; ETIENNEJULAN, M; LORCA, T; PIECHACZYK, M			DIFFERENTIAL SENSITIVITY OF FOS AND JUN FAMILY MEMBERS TO CALPAINS	ONCOGENE			English	Article							NEUTRAL PROTEASE CALPAIN; C-FOS; V-FOS; DEPENDENT PROTEASES; MESSENGER-RNAS; PROTEINS; DEGRADATION; PROTEOLYSIS; INVITRO; SYSTEM	Degradation of c-fos protein (c-FOS) in the cytoplasm is very rapid in vivo and constitutes a crucial regulation of the nuclear steady-state level through the control of the amount of full-length molecules available for nuclear transport. Using cytoplasmic extracts from various origins, we report herein that c-FOS degradation can be initiated in a calcium-dependent manner which involves cysteine proteases called milli- and micro-calpain. Interestingly, FOS-B, a member of the fos multigene family, as well as all members of the jun family (JUN-B, c-JUN and JUN-D) are also sensitive to calpains albeit to different extents. FRA-2, which is a c-FOS-related protein, is resistant to micro- but not to milli-calpain whereas FRA-1, another member of the fos family, is resistant to both proteases. Given the fact that a work by others (Hirai et al., 1991b) suggests that calpains can be involved in c-FOS and c-JUN degradation in vivo, our observations raises the possibility of a novel contribution to the regulation of AP-1 transcription complex activity through a differential control of the steady-state level of some of its components that involves calpains.	INST GENET MOLEC MONTPELLIER,UMR 9942,F-34033 MONTPELLIER 01,FRANCE; CTR RECH BIOCHIM MACROMOLEC,CNRS,F-34033 MONTPELLIER 01,FRANCE	Centre National de la Recherche Scientifique (CNRS)			PIECHACZYK, Marc/E-7896-2013; Roux, Pierre/D-8833-2017	PIECHACZYK, Marc/0000-0003-1367-2597; ETIENNE-JULAN, Maryse/0000-0003-1339-6545; Lorca, Thierry/0000-0003-2007-8924; Steff, Ann-Muriel/0000-0002-9817-6164				ABATE C, 1990, CELL GROWTH DIFFER, V1, P455; Abate C, 1990, Semin Cancer Biol, V1, P19; BARBER JR, 1987, MOL CELL BIOL, V7, P2201, DOI 10.1128/MCB.7.6.2201; BLANCHARD JM, 1992, MED SCI, V5, P455; CIECHANOVER A, 1991, P NATL ACAD SCI USA, V88, P139, DOI 10.1073/pnas.88.1.139; CROALL DE, 1991, PHYSIOL REV, V71, P813, DOI 10.1152/physrev.1991.71.3.813; Curran T, 1988, ONCOGENE HDB, P307; DOBRZANSKI P, 1991, MOL CELL BIOL, V11, P5470, DOI 10.1128/MCB.11.11.5470; DOHERTY FJ, 1992, INTRACELLULAR DEGRAD; GOTTESMAN S, 1992, MICROBIOL REV, V56, P592, DOI 10.1128/MMBR.56.4.592-621.1992; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HIRAI S, 1991, FEBS LETT, V287, P57, DOI 10.1016/0014-5793(91)80015-U; HIRAI SI, 1990, ONCOGENE, V5, P39; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; KISHIMOTO A, 1989, J BIOL CHEM, V264, P4088; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAKI M, 1989, J BIOL CHEM, V264, P18866; MATSUI M, 1990, ONCOGENE, V5, P249; MELLGREN RL, 1987, FASEB J, V1, P110, DOI 10.1096/fasebj.1.2.2886390; MELLGREN RL, 1991, J BIOL CHEM, V266, P13920; MELLONI E, 1989, TRENDS NEUROSCI, V12, P438, DOI 10.1016/0166-2236(89)90093-3; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; MUMBERG D, 1991, GENE DEV, V5, P1212, DOI 10.1101/gad.5.7.1212; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; PAPAVASSILIOU AG, 1992, SCIENCE, V258, P1941, DOI 10.1126/science.1470918; PARNAIK VK, 1990, MOL CELL BIOL, V10, P1287, DOI 10.1128/MCB.10.3.1287; PIECHACZYK M, 1994, IN PRESS CRIT REV ON; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; Rechsteiner M, 1990, Semin Cell Biol, V1, P433; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; ROUX P, 1991, ONCOGENE, V6, P2155; ROUX P, 1990, CELL, V63, P341, DOI 10.1016/0092-8674(90)90167-D; ROUX P, 1994, IN PRESS FOS ONCOGEN; RYSECK RP, 1991, ONCOGENE, V6, P533; Sambrook J., 1989, MOL CLONING; SCHOLLMEYER JE, 1988, SCIENCE, V240, P911, DOI 10.1126/science.2834825; SCHUERMANN M, 1991, ONCOGENE, V6, P567; SETLOW P, 1988, ANNU REV MICROBIOL, V42, P319, DOI 10.1146/annurev.mi.42.100188.001535; TOKES ZA, 1989, J BIOL CHEM, V264, P15059; VARSHAVSKY A, 1992, CELL, V69, P725, DOI 10.1016/0092-8674(92)90285-K; VINCENT S, 1990, NUCLEIC ACIDS RES, V18, P3054, DOI 10.1093/nar/18.10.3054; WANG KKW, 1990, TRENDS PHARMACOL SCI, V11, P139, DOI 10.1016/0165-6147(90)90060-L; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0	45	75	77	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1994	9	6					1679	1689						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NL815	8183563				2022-12-25	WOS:A1994NL81500020
J	LITHGOW, T; JUNNE, T; WACHTER, C; SCHATZ, G				LITHGOW, T; JUNNE, T; WACHTER, C; SCHATZ, G			YEAST MITOCHONDRIA LACKING THE 2 IMPORT RECEPTORS MAS20P AND MAS70P CAN EFFICIENTLY AND SPECIFICALLY IMPORT PRECURSOR PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER-MEMBRANE PROTEIN; INTERMEMBRANE SPACE; CYTOCHROME-B2; COMPLEX; CARRIER; STEPS; MOM19; ATP	Mas20p and Mas70p are integral proteins of the yeast mitochondrial outer membrane that appear to function as receptors for precursor proteins imported from the cytosol. Loss of either receptor alone does not block import or kill the cells, but deletion of Mas20p causes loss of respiration (Ramage, L., Junne, T., Hahne, K., Lithgow, T, and Schatz, G. (1993) EMBO J. 12, 4115-4123). Here we show that this respiratory deficiency is only temporary; given time to adapt, virtually all cells lacking Mas20p regain respiration without regaining Mas20p. The respiratory defect can also be suppressed (at a frequency of about 10(-6)) by a dominant mutation of a single nuclear gene. The suppressed cells, unlike the unsuppressed ones, tolerate disruption of the MAS70 gene. The resulting double disruptants lack both Mas20p and Mas70p, yet are viable and able to respire. Protein import into mitochondria isolated from these cells is efficient, specific, and highly sensitive to protease treatment. We propose that at least one additional mitochondrial surface protein can function as a protein import receptor and that the activity of this component is up-regulated by a stress response or by an extragenic suppressor.			LITHGOW, T (corresponding author), UNIV BASEL,BIOCTR,KLINGELBERGSTR 70,CH-4056 BASEL,SWITZERLAND.		Lithgow, Trevor J/H-5925-2017	Lithgow, Trevor J/0000-0002-0102-7884				DAUM G, 1982, J BIOL CHEM, V257, P3075; DAUM G, 1982, J BIOL CHEM, V257, P3028; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GLICK BS, 1992, CELL, V69, P809, DOI 10.1016/0092-8674(92)90292-K; HAID A, 1983, METHOD ENZYMOL, V96, P192; Hannavy K, 1993, CURR OPIN CELL BIOL, V5, P694, DOI 10.1016/0955-0674(93)90142-D; HINES V, 1990, EMBO J, V9, P3191, DOI 10.1002/j.1460-2075.1990.tb07517.x; HURT EC, 1986, EMBO J, V5, P1343, DOI 10.1002/j.1460-2075.1986.tb04365.x; HURT EC, 1984, EMBO J, V3, P3149, DOI 10.1002/j.1460-2075.1984.tb02272.x; KASSENBROCK CK, 1993, EMBO J, V12, P3023, DOI 10.1002/j.1460-2075.1993.tb05971.x; KIEBLER M, 1993, CELL, V74, P483, DOI 10.1016/0092-8674(93)80050-O; MOCZKO M, 1993, FEBS LETT, V326, P251, DOI 10.1016/0014-5793(93)81801-6; NAKAI M, 1993, J BIOL CHEM, V268, P24262; OHASHI A, 1982, J BIOL CHEM, V257, P3042; OLSEN LJ, 1992, J BIOL CHEM, V267, P433; PFALLER R, 1989, J BIOL CHEM, V264, P34; PFANNER N, 1987, J BIOL CHEM, V262, P7528; RAMAGE L, 1993, EMBO J, V12, P4115, DOI 10.1002/j.1460-2075.1993.tb06095.x; RIEZMAN H, 1983, EMBO J, V2, P1113, DOI 10.1002/j.1460-2075.1983.tb01554.x; SCHNEIDER H, 1991, SCIENCE, V254, P1659, DOI 10.1126/science.1661031; SOLLNER T, 1989, CELL, V59, P1061, DOI 10.1016/0092-8674(89)90762-9; SOLLNER T, 1992, NATURE, V355, P84, DOI 10.1038/355084a0; SOLLNER T, 1990, CELL, V62, P107, DOI 10.1016/0092-8674(90)90244-9; VESTWEBER D, 1989, NATURE, V341, P205, DOI 10.1038/341205a0; WACHTER C, 1992, EMBO J, V11, P4787, DOI 10.1002/j.1460-2075.1992.tb05584.x; YAFFE MP, 1984, P NATL ACAD SCI-BIOL, V81, P4819, DOI 10.1073/pnas.81.15.4819; ZWIZINSKI C, 1984, J BIOL CHEM, V259, P7850	27	75	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					15325	15330						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195170				2022-12-25	WOS:A1994NP73800070
J	THIEL, G; SCHOCH, S; PETERSOHN, D				THIEL, G; SCHOCH, S; PETERSOHN, D			REGULATION OF SYNAPSIN-I GENE-EXPRESSION BY THE ZINC-FINGER TRANSCRIPTION FACTOR ZIF268/EGR-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONAL CARCINOMA-CELLS; IMMEDIATE EARLY GENES; SERUM GROWTH-FACTORS; C-FOS; SILENCER ELEMENT; BINDING; PROTEIN; ACTIVATION; MOUSE; DIFFERENTIATION	zif268/egr-1 is an immediate early response gene that is involved in regulation of growth and differentiation. Its mRNA encodes a sequence-specific transcriptional activator containing three zinc fingers that act as the DNA-binding domain. Although zif268/egr-1 is expressed in the nervous system during neuronal excitation, no target gene has yet been identified. Here we report that the zif268/egr-1 protein bound in vitro to two sites in the proximal regulatory region of the human synapsin I gene. The zif268/egr-1 protein was also shown to stimulate transcription from this control region in transactivation assays. Additionally, the presence of a putative neural-restrictive silencer element next to one of the zif268/egr-1-binding sites interfered with transactivation in a tissue-independent manner. An analysis of the temporal expression pattern of zif268/egr-1 and synapsin I during neuronal differentiation of P19 embryonal carcinoma cells revealed that zif268/egr-1 mRNA was induced on day 5 and synapsin I mRNA on day 8 after retinoic acid treatment. From this data we conclude that the synapsin I gene is a target of the zif268 transcription factor; however, intermediate factors may also be involved in the activation.			THIEL, G (corresponding author), UNIV COLOGNE, INST GENET, ZULPICHERESTR 47, D-50674 COLOGNE, GERMANY.		Schoch, Susanne/F-7741-2012					ACKERMAN SL, 1991, P NATL ACAD SCI USA, V88, P7523, DOI 10.1073/pnas.88.17.7523; ARCHER BT, 1990, J BIOL CHEM, V265, P17267; BLAU HM, 1992, ANNU REV BIOCHEM, V61, P1213, DOI 10.1146/annurev.bi.61.070192.010025; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; CAO XM, 1993, J BIOL CHEM, V268, P16949; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; COLE AJ, 1989, NATURE, V340, P474, DOI 10.1038/340474a0; DARLAND T, 1991, ONCOGENE, V6, P1367; DUMAN RS, 1992, J NEUROCHEM, V59, P1753, DOI 10.1111/j.1471-4159.1992.tb11007.x; GERSTER T, 1990, EMBO J, V9, P1635, DOI 10.1002/j.1460-2075.1990.tb08283.x; GREENGARD P, 1993, SCIENCE, V259, P780, DOI 10.1126/science.8430330; HERSCHMAN HR, 1989, TRENDS BIOCHEM SCI, V14, P455, DOI 10.1016/0968-0004(89)90105-9; IGUCHIARIGA SMM, 1989, GENE DEV, V3, P612, DOI 10.1101/gad.3.5.612; KRANER SD, 1992, NEURON, V9, P37, DOI 10.1016/0896-6273(92)90218-3; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; LANOIX J, 1991, CELL GROWTH DIFFER, V2, P391; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; LI LA, 1993, P NATL ACAD SCI USA, V90, P1460, DOI 10.1073/pnas.90.4.1460; LIM RW, 1987, ONCOGENE, V1, P263; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MORI N, 1992, NEURON, V9, P45, DOI 10.1016/0896-6273(92)90219-4; MORRIS CHT, 1988, NUCLEIC ACIDS RES, V16, P8835, DOI 10.1093/nar/16.18.8835; NARANJO JR, 1991, NEURON, V6, P607, DOI 10.1016/0896-6273(91)90063-6; NEDIVI E, 1993, NATURE, V363, P718, DOI 10.1038/363718a0; OZCELIK T, 1990, AM J HUM GENET, V47, P551; PAPAVASSILIOU AG, 1992, NUCLEIC ACIDS RES, V20, P4365, DOI 10.1093/nar/20.16.4365; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; Runnicki M.A., 1987, TERATOCARCINOMAS EMB, P19; SAFFEN DW, 1988, P NATL ACAD SCI USA, V85, P7795, DOI 10.1073/pnas.85.20.7795; SAUERWALD A, 1990, J BIOL CHEM, V265, P14932; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SEKULOVICH RE, 1988, J VIROL, V62, P4510, DOI 10.1128/JVI.62.12.4510-4522.1988; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; SIERRA F, 1990, LABORATORY GUIDE IN; SONNENBERG JL, 1989, SCIENCE, V246, P1622, DOI 10.1126/science.2512642; SUDHOF TC, 1990, J BIOL CHEM, V265, P7849; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; THIEL G, 1991, P NATL ACAD SCI USA, V88, P3431, DOI 10.1073/pnas.88.8.3431; THIEL G, 1993, BRAIN PATHOL, V3, P87, DOI 10.1111/j.1750-3639.1993.tb00729.x; THOMAS M, 1993, EUR J BIOCHEM, V218, P143, DOI 10.1111/j.1432-1033.1993.tb18360.x; WESTIN G, 1987, NUCLEIC ACIDS RES, V15, P6787, DOI 10.1093/nar/15.17.6787; WILLIAMS GT, 1993, MOL CELL BIOL, V13, P6124, DOI 10.1128/MCB.13.10.6124; WISDEN W, 1990, NEURON, V4, P603, DOI 10.1016/0896-6273(90)90118-Y; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481	49	171	176	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					15294	15301						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195167				2022-12-25	WOS:A1994NP73800066
J	UCHIJIMA, M; SATO, H; FUJII, M; SEIKI, M				UCHIJIMA, M; SATO, H; FUJII, M; SEIKI, M			TAX PROTEINS OF HUMAN T-CELL LEUKEMIA-VIRUS TYPE-1 AND TYPE-2 INDUCE EXPRESSION OF THE GENE ENCODING ERYTHROID-POTENTIATING ACTIVITY (TISSUE INHIBITOR OF METALLOPROTEINASES-1, TIMP-1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL ACTIVATOR TAX; CAMP-RESPONSIVE ELEMENT; HTLV-I; TRANSACTIVATOR TAX; TUMOR-CELLS; DNA-BINDING; ENHANCER; SEQUENCE; SERUM; LEUKEMOGENESIS	A growth factor-like activity for erythroid cells (erythroid-potentiating activity) is produced by the T cells infected with human T cell leukemia virus type 2 (HTLV-2) (Gasson, J. C., Golde, D, W, Kaufman, S. E., Westbrook, C. A, Hewick, R. M., Kaufmann, R. J., Wong, G. G., Temple, P.A., Leary, A. C., Brown, E. L., Orr, E. C., and Clark, S. C. (1985) Nature 315, 768-771) and is reportedly identical with tissue inhibitors of matrix metalloproteinases-l (TIMP-1) (Docherty, A. J. P., Lyons, A., Smith, B. J., Wright, E. M., Stephens, P. E., Harris, T J. R., Murphy, G., and Reynolds, J. J. (1985) Nature 318, 66-69). We found that adult T-cell leukemia cell lines infected with HTLV-1 also express high levels of a TMIP-1 transcript. A viral transactivator of HTLV-1, Taxi, in a human T-cell line (Jurkat), was sufficient to stimulate transcription of the TIMP-1 gene. Deletion and mutation analysis of the TIMP-1 gene promoter showed that the AP-1 binding site in the 38-base pair sequence conserved between the human and mouse genes was essential for activation by Taxi. The transactivator of HTLV-2 also stimulated the promoter through the same cis-element. The reported growth promoting activity of TIMP-1 against erythroid cells and potentially against HTLV-1-infected T-cells may modulate the clinical course of adult T-cell leukemia.	KANAZAWA UNIV, CANC RES INST, DEPT MOLEC ONCOL & VIROL, KANAZAWA, ISHIKAWA 920, JAPAN	Kanazawa University			Seiki, Motoharu/K-9443-2015; SATO, Hiroshi/D-8454-2015					ALEXANDRE C, 1991, ONCOGENE, V6, P1851; ARMSTRONG AP, 1993, P NATL ACAD SCI USA, V90, P7303, DOI 10.1073/pnas.90.15.7303; AVALOS BR, 1988, BLOOD, V71, P1720; CAMPBELL CE, 1991, J BIOL CHEM, V266, P7199; CANN AJ, 1989, J VIROL, V63, P1474, DOI 10.1128/JVI.63.3.1474-1479.1989; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOCHERTY AJP, 1985, NATURE, V318, P66, DOI 10.1038/318066a0; EDWARDS DR, 1992, BIOCHIM BIOPHYS ACTA, V1171, P41, DOI 10.1016/0167-4781(92)90138-P; FEUER G, 1992, BIOCHIM BIOPHYS ACTA, V1114, P223, DOI 10.1016/0304-419X(92)90017-S; FUJII M, 1991, ONCOGENE, V6, P2349; FUJII M, 1991, ONCOGENE, V6, P1023; FUJII M, 1992, GENE DEV, V6, P2066, DOI 10.1101/gad.6.11.2066; FUJISAWA J, 1989, J VIROL, V63, P3234, DOI 10.1128/JVI.63.8.3234-3239.1989; GASSON JC, 1985, NATURE, V315, P768, DOI 10.1038/315768a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAYAKAWA T, 1992, FEBS LETT, V298, P29, DOI 10.1016/0014-5793(92)80015-9; HIRAI H, 1992, ONCOGENE, V7, P1737; JEANG KT, 1991, VIROLOGY, V181, P218, DOI 10.1016/0042-6822(91)90487-V; KATOH I, 1989, EMBO J, V8, P497, DOI 10.1002/j.1460-2075.1989.tb03403.x; KELLY K, 1992, ONCOGENE, V7, P1463; KOSSAKOWSKA AE, 1991, BLOOD, V77, P2475; MURATE T, 1993, EXP HEMATOL, V21, P169; NAGATA K, 1989, J VIROL, V63, P3220, DOI 10.1128/JVI.63.8.3220-3226.1989; NEMETH JA, 1993, EXP CELL RES, V207, P376, DOI 10.1006/excr.1993.1204; SATO H, 1992, ONCOGENE, V7, P77; SATO H, 1993, ONCOGENE, V8, P395; SEIKI M, 1986, EMBO J, V5, P561, DOI 10.1002/j.1460-2075.1986.tb04247.x; SHIMOTOHNO K, 1986, P NATL ACAD SCI USA, V83, P8112, DOI 10.1073/pnas.83.21.8112; SODROSKI J, 1992, BIOCHIM BIOPHYS ACTA, V1114, P19, DOI 10.1016/0304-419X(92)90003-H; SODROSKI JG, 1984, SCIENCE, V225, P381, DOI 10.1126/science.6330891; STETLERSTEVENSON WG, 1992, FEBS LETT, V296, P231, DOI 10.1016/0014-5793(92)80386-U; SUZUKI T, 1993, P NATL ACAD SCI USA, V90, P610, DOI 10.1073/pnas.90.2.610; TSUCHIYA H, 1993, J VIROL, V67, P7001, DOI 10.1128/JVI.67.12.7001-7007.1993; TSUCHIYA Y, 1993, CANCER RES, V53, P1397; WAGNER S, 1993, SCIENCE, V262, P395, DOI 10.1126/science.8211160; Weiss R A, 1992, Semin Cancer Biol, V3, P321; WOESSNER JF, 1991, J RHEUMATOL, V18, P99; YAMAGUCHI K, 1990, PATHOGENESIS ADULT T; YOSHIDA M, 1987, ANNU REV IMMUNOL, V5, P541, DOI 10.1146/annurev.iy.05.040187.002545; YOSHIDA M, 1989, GENOME, V31, P662, DOI 10.1139/g89-121; ZHAO LJ, 1991, P NATL ACAD SCI USA, V88, P11445, DOI 10.1073/pnas.88.24.11445	41	53	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					14946	14950						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195127				2022-12-25	WOS:A1994NP73800018
J	YOKOTE, K; MORI, S; HANSEN, K; MCGLADE, J; PAWSON, T; HELDIN, CH; CLAESSONWELSH, L				YOKOTE, K; MORI, S; HANSEN, K; MCGLADE, J; PAWSON, T; HELDIN, CH; CLAESSONWELSH, L			DIRECT INTERACTION BETWEEN SHC AND THE PLATELET-DERIVED GROWTH-FACTOR BETA-RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTOR; PROTEIN-TYROSINE KINASES; PHOSPHOLIPASE-C-GAMMA; PDGF RECEPTOR; SIGNAL TRANSDUCTION; SRC-FAMILY; PHOSPHORYLATION SITES; AUTOPHOSPHORYLATION SITES; CDNA CLONING; IDENTIFICATION	The Src homology 2 (SH2) domain-containing Shc proteins p52(shc) and p46(shc) become phosphorylated upon activation of several tyrosine kinases and are implicated in mitogenic signal transduction. Ligand stimulation of the platelet-derived growth factor (PDGF) beta-receptor leads to autophosphorylation of tyrosine residues, which is known to mediate interactions with several SH2 domain containing signaling molecules. In this study, we have characterized the interaction between the PDGF beta-receptor and Shc. PDGF beta-receptor coprecipitation in Shc immunoprecipitates was dependent on stimulation with PDGF-BB. The Shc SH2 domain expressed as a bacterial fusion protein bound the autophosphorylated PDGF beta-receptor. Moreover, the Shc SH2 domain could bind the autophosphorylated purified baculovirus-expressed PDGF beta-receptor intracellular domain, which indicates a direct association of Shc with the PDGF beta-receptor. Activation of the PDGF beta-receptor induced the preferential phosphorylation of p52(shc). Tyrosine-phosphorylated Shc, in turn, formed a complex with the signaling molecule Grb2. Synthetic peptide analysis revealed that certain autophosphorylation sites in the PDGF beta-receptor (Tyr-579, Tyr-740, Tyr-751, and Tyr-771) were able to mediate the specific binding of the Shc SH2 domain as well as intact Shc proteins. A mutant PDGF beta-receptor in which Tyr-579 was replaced with phenylalanine showed 40% impaired association of Shc in vivo, but phosphorylation of Shc proteins was not affected. We conclude that multiple autophosphorylation sites in the PDGF beta-receptor are responsible for the binding of Shc. This is in contrast to previously characterized interactions between the PDGF beta-receptor and SH2 domain-containing proteins, which generally involve one high affinity binding site in the receptor.	MT SINAI HOSP, SAMUEL LUNENFELD RES INST, DIV MOLEC & DEV BIOL, TORONTO M5G 1X5, ON, CANADA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	YOKOTE, K (corresponding author), LUDWIG INST CANC RES, CTR BIOMED, BOX 595, S-75124 UPPSALA, SWEDEN.		Pawson, Tony J/E-4578-2013	Claesson-Welsh, Lena/0000-0003-4275-2000; Hansen, Klaus/0000-0001-9657-8816				BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURNS LA, 1993, J BIOL CHEM, V268, P17659; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; Claesson-Welsh Lena, 1994, Progress in Growth Factor Research, V5, P37, DOI 10.1016/0955-2235(94)90016-7; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; CLAESSONWELSH L, 1989, J BIOL CHEM, V264, P1742; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; GOTOH N, 1994, P NATL ACAD SCI USA, V91, P167, DOI 10.1073/pnas.91.1.167; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HELDIN CH, 1990, CELL REGUL, V1, P555, DOI 10.1091/mbc.1.8.555; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KASHISHIAN A, 1993, MOL BIOL CELL, V4, P49, DOI 10.1091/mbc.4.1.49; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KNORR R, 1989, TETRAHEDRON LETT, V30, P1927, DOI 10.1016/S0040-4039(00)99616-3; KOBAYASHI N, 1993, P NATL ACAD SCI USA, V90, P4201, DOI 10.1073/pnas.90.9.4201; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MIYAZONO K, 1987, J BIOL CHEM, V262, P4098; MORI S, 1991, J BIOL CHEM, V266, P21158; MORI S, 1992, J BIOL CHEM, V267, P6429; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; NISHIMURA R, 1993, MOL CELL BIOL, V13, P6889, DOI 10.1128/MCB.13.11.6889; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; RAINES EW, 1990, HDB EXPT PHARM 1, V95, P173; RONNSTRAND L, 1992, EMBO J, V11, P3911, DOI 10.1002/j.1460-2075.1992.tb05484.x; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SEGATTO O, 1993, ONCOGENE, V8, P2105; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SUMMERS MD, 1988, MANUAL METHODS BACUL; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VALIUS M, 1993, MOL CELL BIOL, V13, P133, DOI 10.1128/MCB.13.1.133; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	43	161	165	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					15337	15343						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195171				2022-12-25	WOS:A1994NP73800072
J	PEJLER, G; MACCARANA, M				PEJLER, G; MACCARANA, M			INTERACTION OF HEPARIN WITH RAT MAST-CELL PROTEASE-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHYMOTRYPSIN-LIKE PROTEINASE; SERINE PROTEASES; HUMAN-SKIN; BINDING; CHYMASE; GLYCOSAMINOGLYCANS; PROTEOGLYCAN; ANTITHROMBIN; SULFATE; OLIGOSACCHARIDES	Heparin is a sulfated glycosaminoglycan, synthesized by connective tissue-type mast cells. Rat mast cell protease 1 (RMCP-1), a chymotrypsin-like serine protease expressed specifically by connective tissue-type mast cells, is recovered in a macromolecular complex with heparin proteoglycan. The heparin.RMCP-1 complexes are stored in the secretory granules of the cells and are released following mast cell activation. We showed previously that dissociation of RMCP-1 from heparin resulted in loss of protease activity, as measured by its ability to inactivate thrombin. In the present report the binding of heparin to RMCP-1 was characterized. Affinity chromatography on heparin-Sepharose showed that RMCP-1 displayed high affinity for heparin, with similar to 1.2 M NaCl being required for elution of RMCP-1 from the affinity matrix, The structural requirements for the binding of heparin to RMCP-1 were investigated. Heparan sulfate, chondroitin sulfate, and dermatan sulfate, three glycosaminoglycans structurally related to heparin, were greater than or equal to 80-fold less effective in binding to RMCP-1 than heparin. The 2-O-sulfate, 6-O-sulfate, and N-sulfate groups in heparin were all shown to contribute in the binding. The minimal heparin sequence required for binding to RMCP-1 was found in a 14-saccharide fraction. 14-Saccharide species, obtained after separation by anion exchange chromatography, showed continuously increased binding with increasing anionic charge densities. The 16-18-saccharides were the smallest heparin oligosaccharides capable of accelerating the inactivation of thrombin by RMCP-1.	BIOMED CTR, DEPT MED & PHYSIOL CHEM, S-75123 UPPSALA, SWEDEN		PEJLER, G (corresponding author), BIOMED CTR, DEPT VET MED CHEM, POB 575, S-75123 UPPSALA, SWEDEN.		maccarana, marco/AAB-4764-2021	Maccarana, Marco/0000-0003-3549-8921				BOURIN MC, 1993, BIOCHEM J, V289, P313, DOI 10.1042/bj2890313; DANISHEF.V, 1965, BIOCHIM BIOPHYS ACTA, V101, P37; EKRE HPT, 1986, INT J IMMUNOPHARMACO, V8, P277, DOI 10.1016/0192-0561(86)90109-8; ENERBACK L, 1985, BIOCHEM J, V227, P661, DOI 10.1042/bj2270661; GERVASONI JE, 1986, J IMMUNOL, V136, P285; HOOK M, 1982, ANAL BIOCHEM, V119, P236, DOI 10.1016/0003-2697(82)90580-2; HUANG RY, 1991, EUR J IMMUNOL, V21, P1611, DOI 10.1002/eji.1830210706; KATUNUMA N, 1988, J CELL BIOCHEM, V38, P291, DOI 10.1002/jcb.240380408; KJELLEN L, 1989, BIOCHEM J, V263, P105, DOI 10.1042/bj2630105; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; Klagsbrun M, 1990, CURR OPIN CELL BIOL, V2, P857, DOI 10.1016/0955-0674(90)90084-R; LANE DA, 1984, BIOCHEM J, V218, P725, DOI 10.1042/bj2180725; LANE DA, 1987, J BIOL CHEM, V262, P16343; LINDAHL U, 1965, J BIOL CHEM, V240, P2817; LINDAHL U, 1989, ARCH BIOCHEM BIOPHYS, V273, P180, DOI 10.1016/0003-9861(89)90177-X; LLOYD AG, 1971, BIOCHEM PHARMACOL, V20, P637, DOI 10.1016/0006-2952(71)90150-X; LYCKE E, 1991, J GEN VIROL, V72, P1131, DOI 10.1099/0022-1317-72-5-1131; MACCARANA M, 1993, J BIOL CHEM, V268, P23898; MACCARANA M, 1993, GLYCOBIOLOGY, V3, P271, DOI 10.1093/glycob/3.3.271; MILLER JS, 1989, J CLIN INVEST, V84, P1188, DOI 10.1172/JCI114284; Nader H. B., 1989, HEPARIN CHEM BIOL PR, P81; NAGASAWA K, 1977, CARBOHYD RES, V58, P47, DOI 10.1016/S0008-6215(00)83402-3; NELSON DS, 1963, LANCET, V2, P175; OGAMO A, 1985, BIOCHIM BIOPHYS ACTA, V841, P30; OLIVECRONA T, 1989, HEPARIN, P335; OLSON ST, 1993, METHOD ENZYMOL, V222, P525; PEJLER G, 1993, J BIOL CHEM, V268, P11817; PEJLER G, 1987, J BIOL CHEM, V262, P11413; PEJLER G, 1988, J BIOL CHEM, V263, P5197; PEJLER G, 1987, J BIOL CHEM, V262, P5036; PEJLER G, 1994, BIOCHEM J, V299, P507, DOI 10.1042/bj2990507; REYNOLDS DS, 1990, P NATL ACAD SCI USA, V87, P3230, DOI 10.1073/pnas.87.8.3230; SAKASHITA S, 1980, FEBS LETT, V116, P243, DOI 10.1016/0014-5793(80)80654-5; SAYAMA S, 1987, J BIOL CHEM, V262, P6808; SCHECHTER NM, 1986, J IMMUNOL, V137, P962; SCHWARTZ LB, 1981, J IMMUNOL, V126, P2071; SERAFIN WE, 1986, J BIOL CHEM, V261, P5017; STEVENS RL, 1989, IMMUNOL TODAY, V10, P381, DOI 10.1016/0167-5699(89)90272-7; SUZUKI S, 1984, J BIOL CHEM, V259, P5307; SY MS, 1983, CELL IMMUNOL, V82, P23, DOI 10.1016/0008-8749(83)90137-5; THUNBERG L, 1982, CARBOHYD RES, V100, P393, DOI 10.1016/S0008-6215(00)81050-2; TOLLEFSEN DM, 1989, HEPARIN CHEM BIOL PR, P257; TRONG HL, 1987, BIOCHEMISTRY-US, V26, P6988; YURT R, 1977, J EXP MED, V146, P1405, DOI 10.1084/jem.146.5.1405	44	41	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14451	14456						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	8182050				2022-12-25	WOS:A1994NM06500025
J	HAO, LN; RIGAUD, JL; INESI, G				HAO, LN; RIGAUD, JL; INESI, G			CA2+/H+ COUNTERTRANSPORT AND ELECTROGENICITY IN PROTEOLIPOSOMES CONTAINING ERYTHROCYTE PLASMA-MEMBRANE CA-ATPASE AND EXOGENOUS LIPIDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM CA-2+-ATPASE; CALCIUM-PUMP; CA-2+ PUMP; PURIFICATION; CALMODULIN; ACTIVATOR; PHOSPHODIESTERASE; RECONSTITUTION; LIPOSOMES; TRANSPORT	A reconstituted proteoliposomal system was obtained with Ca-ATPase purified from human erythrocyte membrane (plasma membrane, PM ATPase), and liposomes prepared by reverse-phase evaporation. The reconstituted PM ATPase behaved as an electrogenic Ca2(+)/H+ exchanger and, under optimal conditions, utilization of 1 mol of ATP was accompanied by uptake of one Ca2+ by the vesicles, and ejection of one H+ from the lumen of the vesicles. Ca2+ uptake was greatly (5-fold) stimulated by the addition of calmodulin, and by collapsing the H+ gradient with the ionophore carbonyl cyanide p-trifluoromethoxyphenylhydrazone. In the presence of calmodulin and p-trifluoromethoxyphenylhydrazone, the reconstituted system sustained transport rates of 1.00 +/- 0.12 mu mol of Ca2+/mg of protein min(-1) (30 degrees C), reaching asymptotic levels of 8.05 +/- 0.41 mu mol of Ca2+/mg of protein (i.e. 20 mM lumenal Ca2+). The corresponding net charge transfer produced a maximal electrical gradient of 40.5 +/- 1.8 mV at steady state. Demonstration of the electrogenic behavior of the PM ATPase, obtained for the first time with these experiments, was critically dependent on the detergent used in the reconstitution procedure. The lumenal pH rise had a much greater rate-limiting effect on the pump, than the electrical potential developed by the pump.	CENS,DEPT BIOL CELLULAIRE & MOLEC,F-91191 GIF SUR YVETTE,FRANCE	CEA	HAO, LN (corresponding author), UNIV MARYLAND,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21201, USA.							APELL HJ, 1987, BIOCHIM BIOPHYS ACTA, V903, P480, DOI 10.1016/0005-2736(87)90055-1; CARAFOLI E, 1991, ANNU REV PHYSIOL, V53, P531, DOI 10.1146/annurev.physiol.53.1.531; CARAFOLI E, 1992, J BIOL CHEM, V267, P2115; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; GASSNER B, 1988, CELL CALCIUM, V9, P95, DOI 10.1016/0143-4160(88)90029-2; GOPINATH RM, 1977, BIOCHEM BIOPH RES CO, V77, P1203, DOI 10.1016/S0006-291X(77)80107-1; HORGAN DJ, 1972, ANAL BIOCHEM, V48, P147, DOI 10.1016/0003-2697(72)90178-9; INESI G, 1989, J BIOL CHEM, V264, P5929; JARRETT HW, 1978, J BIOL CHEM, V253, P4676; JARRETT HW, 1977, BIOCHEM BIOPH RES CO, V77, P1210, DOI 10.1016/S0006-291X(77)80108-3; KOSKKOSICKA D, 1988, J BIOL CHEM, V263, P18184; KOSKOSICKA D, 1986, J BIOL CHEM, V261, P3333; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVY D, 1990, J BIOL CHEM, V265, P19524; LEVY D, 1992, BIOCHIM BIOPHYS ACTA, V1107, P283, DOI 10.1016/0005-2736(92)90415-I; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; NIGGLI V, 1982, J BIOL CHEM, V257, P2350; NIGGLI V, 1981, J BIOL CHEM, V256, P395; NIGGLI V, 1979, J BIOL CHEM, V254, P9955; RIGAUD JL, 1983, BIOCHEM BIOPH RES CO, V111, P373, DOI 10.1016/0006-291X(83)90316-9; ROSSI JPFC, 1982, J PHYSIOL-LONDON, V327, P1; Scarpa A, 1979, Methods Enzymol, V56, P301; SCHATZMANN HJ, 1973, J PHYSIOL-LONDON, V235, P551, DOI 10.1113/jphysiol.1973.sp010403; SMALLWOOD JI, 1983, J BIOL CHEM, V258, P1092; VERMA AK, 1988, J BIOL CHEM, V263, P14152; WAISMAN DM, 1981, J BIOL CHEM, V256, P415; YU X, 1993, BIOPHYS J, V64, P1232, DOI 10.1016/S0006-3495(93)81489-9; YU X, 1993, FEBS LETT, V328, P301, DOI 10.1016/0014-5793(93)80948-T	28	70	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					14268	14275						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188711				2022-12-25	WOS:A1994NL60600082
J	LIU, YF; JAKOBS, KH; RASENICK, MM; ALBERT, PR				LIU, YF; JAKOBS, KH; RASENICK, MM; ALBERT, PR			G-PROTEIN SPECIFICITY IN RECEPTOR-EFFECTOR COUPLING - ANALYSIS OF THE ROLES OF G(O) AND G(I)2 IN GH4C1 PITUITARY-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING-PROTEIN; BETA-GAMMA-SUBUNITS; ADENYLYL CYCLASE; SOMATOSTATIN RECEPTORS; DOPAMINE-D2 RECEPTOR; SIGNAL TRANSDUCTION; KINASE-C; INHIBITION; ALPHA; HYDROLYSIS	In rat pituitary GH4C1 cells, activation of transfected dopamine D-2 receptors (long, D-2L, or short, D-2S, form) and endogenously expressed somatostatin and muscarinic M4 receptors induced inhibition of cAMP synthesis and of Bay K 8644-induced calcium entry via pertussis toxin-sensitive G proteins. To analyze the role of alpha(o) and alpha(i)2 in relaying of these signals, alpha(o) or alpha(i)2 antisense constructs were separately and stably transfected into GH4C1 cells. Reverse transcription-polymerase chain reaction and Western blot analyses indicated specific ablation of alpha(o) or alpha(i)2 in the antisense transfectant clones. Elimination of alpha(o) selectively abolished receptor-mediated inhibition of calcium entry. Notably, the action of dopamine D-2L receptor was partially (about 30%) retained. By contrast, depletion of alpha(i)2 selectively impaired receptor-mediated inhibition of cAMP accumulation. Inhibition of basal cAMP synthesis by any of the four receptors studied was blocked in alpha(i)2-depleted clones. Additionally, dopamine D-2L, somatostatin and muscarinic M4 receptor-mediated inhibition of vasoactive intestinal peptide-stimulated cAMP formation was also abolished. Remarkably, somatostatin even potentiated (by 30%) the action of vasoactive intestinal peptide in alpha(i)2-antisense clones. In contrast, the action of dopamine D-2S receptor on stimulated cAMP synthesis remained largely unaltered. The results demonstrate that alpha(o) specifically triggers receptor-induced closure of calcium channels, whereas alpha(i)2 specifically mediates inhibition of adenylyl cyclase in GH4C1 cells. Furthermore, the data suggest that G(i) protein specificity in receptor coupling to inhibition of adenylyl cyclase depends critically on the activity state of the enzyme. Moreover, the results indicate an essential difference in coupling of dopamine D-2L and D-2S receptors to G proteins.	MCGILL UNIV,DEPT PHARMACOL & THERAPEUT,MONTREAL H3G 1Y6,PQ,CANADA; UNIV ILLINOIS,DEPT PHYSIOL & BIOPHYS,CHICAGO,IL 60612	McGill University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	LIU, YF (corresponding author), UNIV ESSEN GESAMTHSCH,INST PHARMAKOL,D-45122 ESSEN,GERMANY.		Albert, Paul/E-4804-2010	Albert, Paul/0000-0002-1809-3554				ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732; ALBERT PR, 1990, J BIOL CHEM, V265, P2098; Ausubel FM., 1988, CURRENT PROTOCOLS MO; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; CARLSON KE, 1989, J BIOL CHEM, V264, P13298; COTECCHIA S, 1990, P NATL ACAD SCI USA, V87, P2896, DOI 10.1073/pnas.87.8.2896; COTECCHIA S, 1990, J BIOL CHEM, V265, P1633; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; GIERSCHIK P, 1989, J BIOL CHEM, V264, P21470; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GRANDY DK, 1989, P NATL ACAD SCI USA, V86, P9762, DOI 10.1073/pnas.86.24.9762; GUDERMANN T, 1992, J BIOL CHEM, V267, P4479; HAUSDORFF WP, 1990, J BIOL CHEM, V265, P1393; JELINEK LJ, 1993, SCIENCE, V259, P1614, DOI 10.1126/science.8384375; JONES DT, 1987, J BIOL CHEM, V262, P14211; KLEUSS C, 1992, NATURE, V358, P424, DOI 10.1038/358424a0; KLEUSS C, 1991, NATURE, V353, P43, DOI 10.1038/353043a0; KLEUSS C, 1993, SCIENCE, V259, P832, DOI 10.1126/science.8094261; LAW SF, 1992, MOL PHARMACOL, V42, P398; LAW SF, 1991, J BIOL CHEM, V266, P17885; LIGGETT SB, 1991, J BIOL CHEM, V266, P4816; LIU YF, 1992, J NEUROCHEM, V59, P2311; LIU YF, 1991, J BIOL CHEM, V266, P23689; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCFADZEAN I, 1989, NEURON, V3, P177, DOI 10.1016/0896-6273(89)90030-5; PINKASKRAMARSKI R, 1990, NEUROSCI LETT, V108, P335, DOI 10.1016/0304-3940(90)90663-T; ROSS EM, 1989, NEURON, V3, P141, DOI 10.1016/0896-6273(89)90027-5; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; SCHONBRUNN A, 1978, J BIOL CHEM, V253, P6437; SENOGLES SE, 1990, J BIOL CHEM, V265, P4507; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P6477, DOI 10.1073/pnas.87.17.6477; TANG WJ, 1992, CELL, V70, P869, DOI 10.1016/0092-8674(92)90236-6; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TSUKAMOTO T, 1991, P NATL ACAD SCI USA, V88, P2974, DOI 10.1073/pnas.88.8.2974; VALLAR L, 1990, J BIOL CHEM, V265, P10320; WANG N, 1990, J BIOL CHEM, V265, P1239; WU DQ, 1992, J BIOL CHEM, V267, P25798	40	124	124	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					13880	13886						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188665				2022-12-25	WOS:A1994NL60600027
J	MOSIOR, M; EPAND, RM				MOSIOR, M; EPAND, RM			CHARACTERIZATION OF THE CALCIUM-BINDING SITE THAT REGULATES ASSOCIATION OF PROTEIN-KINASE-C WITH PHOSPHOLIPID-BILAYERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIVALENT-CATIONS; LIPID VESICLES; MEMBRANES; PHOSPHATIDYLSERINE; COOPERATIVITY; ACTIVATION; DIACYLGLYCEROL; POTENTIALS; ADSORPTION; SUBSTRATE	Association of calcium-dependent isotypes of protein kinase C (PKC) with a phospholipid bilayer is regulated by a single Ca2+-binding site. The dependence of PKC association with phosphatidylserine containing mem branes on the concentration of Ca2+ is linear in the submicro- to submillimolar range. The Ca2+-regulated association of PKC with the membrane is sensitive to the factors that alter the diffuse double-layer potential produced by anionic lipids such as phosphatidylserine (PS). This indicates that the Ca2+-binding site on the membrane-bound enzyme senses a higher concentration of Ca2+ than is present in bulk solution. This is a consequence of the accumulation of Ca2+ in the layer adjacent to the plane of the membrane by the double-layer potential. Calculations based on the Gouy-Chapman-Stern theory of the diffuse double layer yielded a unique value of the Ca2+ dissociation constant for the Ca2+-PKC-bilayer complex equal to similar to 700 nM. The soluble form of the enzyme has a 3.5 order of magnitude lower affinity for Ca2+. The free energy of interaction between the Ca2+- and PS-binding sites is large (similar to 5 kcal/mol). In contrast, the interaction between the diacylglycerol-binding site and either the Ca2+- or PS-binding site appears to be weak.	MCMASTER UNIV, DEPT BIOCHEM, HAMILTON L8N 3Z5, ON, CANADA	McMaster University			, Richard/R-2316-2019	, Richard/0000-0002-9602-9558				BAZZI MD, 1991, BIOCHEMISTRY-US, V30, P7970, DOI 10.1021/bi00246a014; BAZZI MD, 1989, BIOCHEMISTRY-US, V28, P9317, DOI 10.1021/bi00450a011; BAZZI MD, 1987, BIOCHEMISTRY-US, V26, P115, DOI 10.1021/bi00375a017; BURNS DJ, 1990, J BIOL CHEM, V265, P12044; BURNS DJ, 1992, PROTEIN KINASE C CUR, P25; CHAKRAVARTHY BR, 1991, ANAL BIOCHEM, V196, P144, DOI 10.1016/0003-2697(91)90130-L; DWYER JD, 1981, BIOPOLYMERS, V20, P2323, DOI 10.1002/bip.1981.360201104; EPAND RM, 1992, EUR J BIOCHEM, V208, P327, DOI 10.1111/j.1432-1033.1992.tb17190.x; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; HANNUN YA, 1985, J BIOL CHEM, V260, P39; HUANG KP, 1986, J BIOL CHEM, V261, P2134; KAIBUCHI K, 1981, J BIOL CHEM, V256, P7146; KISHIMOTO A, 1983, J BIOL CHEM, V258, P1156; KROLL MH, 1993, J BIOL CHEM, V268, P3520; LESTER DS, 1990, INT J BIOL MACROMOL, V12, P251, DOI 10.1016/0141-8130(90)90005-U; LUO JH, 1993, J BIOL CHEM, V268, P23580; MAURER MC, 1992, BIOCHEMISTRY-US, V31, P7714, DOI 10.1021/bi00148a036; MCLAUGHLIN A, 1978, BIOCHIM BIOPHYS ACTA, V513, P338, DOI 10.1016/0005-2736(78)90203-1; MCLAUGHLIN S, 1988, J PHYSIOL-LONDON, V396, P189, DOI 10.1113/jphysiol.1988.sp016958; MCLAUGHLIN S, 1981, J GEN PHYSIOL, V77, P445, DOI 10.1085/jgp.77.4.445; MCLAUGHLIN S, 1989, ANNU REV BIOPHYS BIO, V18, P113, DOI 10.1146/annurev.biophys.18.1.113; MCLAUGHLIN S, 1977, CURR TOP MEMBR TRANS, V9, P71; MOSIOR M, 1993, BIOCHEMISTRY-US, V32, P65, DOI 10.1021/bi00052a010; MOSIOR M, 1992, BIOCHIM BIOPHYS ACTA, V1105, P185, DOI 10.1016/0005-2736(92)90178-O; NEWTON AC, 1989, J BIOL CHEM, V264, P14909; NISHIZUKA Y, 1989, CANCER, V63, P1892, DOI 10.1002/1097-0142(19890515)63:10<1892::AID-CNCR2820631005>3.0.CO;2-Z; ORR JW, 1992, J BIOL CHEM, V267, P15263; ORR JW, 1992, BIOCHEMISTRY-US, V31, P4661, DOI 10.1021/bi00134a018; REBECCHI M, 1992, BIOCHEMISTRY-US, V31, P12742, DOI 10.1021/bi00166a005; REYNOLDS JA, 1979, BIOCHEMISTRY-US, V18, P264, DOI 10.1021/bi00569a004; SHAH J, 1992, BIOCHIM BIOPHYS ACTA, V1119, P19, DOI 10.1016/0167-4838(92)90228-6; STABEL S, 1991, PHARMACOL THERAPEUT, V51, P71, DOI 10.1016/0163-7258(91)90042-K	33	53	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					13798	13805						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188656				2022-12-25	WOS:A1994NL60600016
J	MUKHERJI, S; SODERLING, TR				MUKHERJI, S; SODERLING, TR			REGULATION OF CA2+ CALMODULIN-DEPENDENT PROTEIN-KINASE-II BY INTERSUBUNIT-CATALYZED AND INTRASUBUNIT-CATALYZED AUTOPHOSPHORYLATIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							LONG-TERM POTENTIATION; DIRECTED MUTAGENESIS; PHOSPHORYLATION; SITE; PURIFICATION; INHIBITION; EXPRESSION; MECHANISM; SUBUNIT; BRAIN	Autophosphorylation of CaM kinase II on Thr(286) is known to occur by an intraholoenzyme mechanism, but it is not known whether this reaction is intra or intersubunit catalyzed in the native heteromeric enzyme containing 10-12 alpha/beta subunits. In this study inactive CaM kinase II beta subunit, generated by mutation of Lys(43) to Ala, and active kinase a subunit were expressed separately (homomeric kinases) or co expressed (heteromeric kinase) using the baculovirus/Sf9 cell expression system and purified on CaM-Sepharose. Ca2+/CaM-de- pendent autophosphorylation of heteromeric alpha/beta kinase, which activated the enzyme, produced rapid autophosphorylation on Thr(286) in both the active alpha and inactive beta subunits; the latter could only occur by intersubunit catalysis. Ca2+/CaM-independent autophosphorylation of nonactivated heteromeric kinase was slow, resulted in partial loss of total kinase activity, occurred only in the alpha subunit, and existed on Thr(306) but not Thr(286). This result demonstrates intrasubunit catalysis of Thr(306) autophosphorylation. These observations that regulatory autophosphorylations of Thr(286) and Thr(306) were inter- and intrasubunit-catalyzed, respectively, have important consequences for structure/function models of CaM kinase II and for involvement of CaM kinase II autophosphorylation and activation during synaptic plasticity in neural systems.			MUKHERJI, S (corresponding author), OREGON HLTH SCI UNIV, VOLLUM INST, PORTLAND, OR 97201 USA.				NIGMS NIH HHS [GM 41292] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041292] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENNETT MK, 1983, J BIOL CHEM, V258, P2735; BRICKEY DA, 1990, BIOCHEM BIOPH RES CO, V173, P578, DOI 10.1016/S0006-291X(05)80074-9; Colbran R J, 1990, Curr Top Cell Regul, V31, P181; COLBRAN RJ, 1989, J BIOL CHEM, V264, P4800; COLBRAN RJ, 1993, J BIOL CHEM, V268, P7163; COLBRAN RJ, 1990, J BIOL CHEM, V265, P11213; FLINT AJ, 1990, SCIENCE, V249, P408, DOI 10.1126/science.2377895; FUKUNAGA K, 1993, J BIOL CHEM, V268, P7863; GOPALAKRISHNA R, 1982, BIOCHEM BIOPH RES CO, V104, P830, DOI 10.1016/0006-291X(82)90712-4; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; HANSON PI, 1992, J BIOL CHEM, V267, P17216; HANSON PI, 1989, NEURON, V3, P59, DOI 10.1016/0896-6273(89)90115-3; HASHIMOTO Y, 1987, ARCH BIOCHEM BIOPHYS, V252, P418, DOI 10.1016/0003-9861(87)90048-8; HASHIMOTO Y, 1987, J BIOL CHEM, V262, P8051; KAPILOFF MS, 1991, P NATL ACAD SCI USA, V88, P3710, DOI 10.1073/pnas.88.9.3710; KREBS EG, 1979, ANNU REV BIOCHEM, V48, P923, DOI 10.1146/annurev.bi.48.070179.004423; KURET J, 1985, J BIOL CHEM, V260, P6427; LAI Y, 1986, P NATL ACAD SCI USA, V83, P4253, DOI 10.1073/pnas.83.12.4253; LISMAN J, 1989, P NATL ACAD SCI USA, V86, P9574, DOI 10.1073/pnas.86.23.9574; MEFFERT MK, 1991, ANN NY ACAD SCI, V627, P2; MILLER SG, 1986, CELL, V44, P861, DOI 10.1016/0092-8674(86)90008-5; NAKAMAYE KL, 1986, NUCLEIC ACIDS RES, V14, P9679, DOI 10.1093/nar/14.24.9679; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHWORER CM, 1988, J BIOL CHEM, V263, P13486; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; SODERLING TR, 1993, MOL CELL BIOCHEM, V128, P93, DOI 10.1007/BF01076760; SODERLING TR, 1990, J BIOL CHEM, V265, P1823; TODHUNTER JA, 1977, BIOCHIM BIOPHYS ACTA, V485, P87, DOI 10.1016/0005-2744(77)90195-4	29	102	103	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					13744	13747						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188649				2022-12-25	WOS:A1994NL60600006
J	SELVAN, RS; BUTTERFIELD, JH; KRANGEL, MS				SELVAN, RS; BUTTERFIELD, JH; KRANGEL, MS			EXPRESSION OF MULTIPLE CHEMOKINE GENES BY A HUMAN MAST-CELL LEUKEMIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; SMOOTH-MUSCLE CELLS; GROWTH-FACTOR; MONOCYTE CHEMOATTRACTANT; GLUCOCORTICOIDS INHIBIT; INFLAMMATORY CYTOKINES; INTERLEUKIN-1; FAMILY; IGE; DEXAMETHASONE	The chemokines are a large group of cytokines that are recognized to be important mediators of inflammation. In this study we show that the human mast cell leukemia line HMC-1 is a source of multiple chemokines, including I-309, monocyte chemoattractant protein 1, macrophage inflammatory protein-1 alpha, macrophage inflammatory protein-1 beta, RANTES, and interleukin-8. I-309 and MCP-1 transcripts are expressed at low levels in unstimulated HMC-1. However, phorbol ester treatment up-regulates these and other chemokine transcript levels and also up regulates chemokine protein synthesis and secretion. Induction of chemokine transcripts in HMC-1 requires de novo protein synthesis. We compared the effects of anti-inflammatory glucocorticoids on the expression of chemokine genes in HMC-1 to their effects in activated T cells. We find that methyl prednisolone reduces MCP-1 but not other chemokine transcripts in HMC-1, even though there are distinct and more general effects on chemokine transcripts in activated T-cells. These effects are attributed to inhibition of transcription rather than transcript stability. Our results suggest that human mast cells may be a source of multiple chemokines, that glucocorticoids may inhibit the expression of only a subset of these chemokines, and that mast cells and T-cell chemokine expression may occur via distinct regulatory pathways.	DUKE UNIV, MED CTR, DEPT IMMUNOL, DURHAM, NC 27710 USA; MAYO CLIN & MAYO FDN, DEPT INTERNAL MED, DIV ALLERG DIS, ROCHESTER, MN 55905 USA	Duke University; Mayo Clinic								ALIZADEH H, 1986, J IMMUNOL, V137, P2555; ARYA SK, 1984, J IMMUNOL, V133, P273; Ausubel F.M., 1992, SHORT PROTOCOLS MOL; BENYON RC, 1991, J IMMUNOL, V147, P2253; BEUTLER B, 1989, ANNU REV IMMUNOL, V7, P625, DOI 10.1146/annurev.immunol.7.1.625; BOCHNER BS, 1987, J IMMUNOL, V139, P2303; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; BRADDING P, 1992, J EXP MED, V176, P1381, DOI 10.1084/jem.176.5.1381; BURD PR, 1989, J EXP MED, V170, P245, DOI 10.1084/jem.170.1.245; BUTTERFIELD JH, 1988, LEUKEMIA RES, V12, P345, DOI 10.1016/0145-2126(88)90050-1; CHENSUE SW, 1991, AM J PATHOL, V138, P395; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COSER P, 1980, BRIT J HAEMATOL, V45, P5, DOI 10.1111/j.1365-2141.1980.tb03805.x; DINARELLO CA, 1987, NEW ENGL J MED, V317, P940, DOI 10.1056/NEJM198710083171506; DJALDETTI R, 1990, BIOMED PHARMACOTHER, V44, P515, DOI 10.1016/0753-3322(90)90172-6; GORDON JR, 1990, NATURE, V346, P274, DOI 10.1038/346274a0; IRANI AMA, 1992, BLOOD, V80, P3009; JIANG YL, 1991, BIOCHEM BIOPH RES CO, V178, P1400, DOI 10.1016/0006-291X(91)91049-I; JIANG YL, 1990, J BIOL CHEM, V265, P18318; KAWAHARA RS, 1991, J BIOL CHEM, V266, P13261; KIRNBAUER R, 1991, J INVEST DERMATOL, V96, P484, DOI 10.1111/1523-1747.ep12470181; KNUDSEN PJ, 1987, J IMMUNOL, V139, P4129; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; MILLER MD, 1990, J IMMUNOL, V145, P2737; MILLER MD, 1992, CRIT REV IMMUNOL, V12, P17; MILLER MD, 1992, P NATL ACAD SCI USA, V89, P2950, DOI 10.1073/pnas.89.7.2950; MILLER MD, 1989, J IMMUNOL, V143, P2907; MOLLER A, 1993, J IMMUNOL, V151, P3261; MUKAIDA N, 1991, J IMMUNOL, V146, P1212; NORTHROP JP, 1992, J EXP MED, V175, P1235, DOI 10.1084/jem.175.5.1235; PLAUT M, 1989, NATURE, V339, P64, DOI 10.1038/339064a0; POON M, 1991, J BIOL CHEM, V266, P22375; SCHALL TJ, 1991, CYTOKINE, V3, P165, DOI 10.1016/1043-4666(91)90013-4; SCHULMAN ES, 1993, CRIT REV IMMUNOL, V13, P35; STOECKLE M Y, 1990, New Biologist, V2, P313; VILLIGER PM, 1992, J IMMUNOL, V149, P722; WITTE LD, 1978, CIRC RES, V42, P402, DOI 10.1161/01.RES.42.3.402; WODNARFILIPOWICZ A, 1989, NATURE, V339, P150, DOI 10.1038/339150a0; ZIPFEL PF, 1989, J IMMUNOL, V142, P1582; ZUCKERMAN SH, 1989, EUR J IMMUNOL, V19, P301, DOI 10.1002/eji.1830190213	41	124	127	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					13893	13898						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188667				2022-12-25	WOS:A1994NL60600029
J	BARKOCYGALLAGHER, GA; CANNON, JG; BASSFORD, PJ				BARKOCYGALLAGHER, GA; CANNON, JG; BASSFORD, PJ			BETA-TURN FORMATION IN THE PROCESSING REGION IS IMPORTANT FOR EFFICIENT MATURATION OF ESCHERICHIA-COLI MALTOSE-BINDING PROTEIN BY SIGNAL PEPTIDASE-I IN-VIVO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEADER PEPTIDASE; CLEAVAGE SITE; DIRECTED MUTAGENESIS; SUPPRESSOR MUTATIONS; SEQUENCE; EXPORT; SECRETION; MEMBRANE; LACTAMASE; INVIVO	Signal peptidase I (also called leader peptidase) is the endopeptidase that removes the signal peptides of most secreted proteins during or after translocation in Escherichia coli. Precursor recognition is contingent in part on the presence of small, uncharged residues in the -3 and -1 positions relative to the cleavage site, and may also depend on the structure of the processing region. Most precursor processing regions include residues likely to form a beta-turn. Mutations were introduced into the processing region of maltose binding protein (MBP) that altered the prediction of beta-turn formation in this region. MBP species with a decreased probability of beta-turn formation were processed slowly or not at all, whereas MBP species with an increased probability of beta-turn formation were processed efficiently. Mutations altering the prediction of beta-turn formation in the MBP processing region were also made in cis to a proline in the +1 position. Cleavage at the normal processing site is blocked by proline in the +1 position; this MBP species, MBP27-P, inhibits processing of other proteins by signal peptidase I. Decreasing the probability of beta-turn formation in the processing region of MBP27-P eliminated the inhibition of signal peptidase I, and these MBP27-P derivatives remained unprocessed, suggesting that the formation of a beta-turn in the MBP processing region was necessary for recognition by signal peptidase I. Increasing the probability of beta-turn formation in cis to proline at +1 in MBP did not alter recognition of the protein by the processing enzyme. The results presented here are consistent with the hypothesis that the efficiency of recognition and processing by signal peptidase I is increased by the formation of a beta-turn in the processing region of the MBP signal peptide.	UNIV N CAROLINA,SCH MED,DEPT MICROBIOL & IMMUNOL,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI017292] Funding Source: NIH RePORTER; NIAID NIH HHS [NIAID AI17292] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAMS MD, 1991, J CELL BIOCHEM, V46, P321, DOI 10.1002/jcb.240460407; BANKAITIS VA, 1984, J BIOL CHEM, V259, P2193; BANKAITIS VA, 1984, CELL, V37, P243, DOI 10.1016/0092-8674(84)90320-9; BARKOCYGALLAGHER GA, 1992, J BIOL CHEM, V267, P1231; BASSFORD PJ, 1990, J BIOENERG BIOMEMBR, V22, P401, DOI 10.1007/BF00763175; BRIGGS MS, 1986, SCIENCE, V233, P206, DOI 10.1126/science.2941862; CASADABAN MJ, 1976, J MOL BIOL, V104, P541, DOI 10.1016/0022-2836(76)90119-4; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; COLLIER DN, 1990, J BACTERIOL, V172, P6875, DOI 10.1128/jb.172.12.6875-6884.1990; COLLIER DN, 1989, J BACTERIOL, V171, P4640, DOI 10.1128/jb.171.9.4640-4647.1989; COLLIER DN, 1988, CELL, V53, P273, DOI 10.1016/0092-8674(88)90389-3; DALBEY RE, 1985, J BIOL CHEM, V260, P5925; DEV IK, 1990, J BIOENERG BIOMEMBR, V22, P271, DOI 10.1007/BF00763168; DUFFAUD G, 1988, J BIOL CHEM, V263, P10224; DUFFAUD GD, 1985, CURR TOP MEMBR TRANS, V24, P65; EMR SD, 1982, J BIOL CHEM, V257, P5852; FIKES JD, 1990, J BIOL CHEM, V265, P3417; FIKES JD, 1987, J BACTERIOL, V169, P2352, DOI 10.1128/jb.169.6.2352-2359.1987; HUTCHISON CA, 1986, P NATL ACAD SCI USA, V83, P710, DOI 10.1073/pnas.83.3.710; IINO T, 1988, J BIOL CHEM, V263, P19077; INOUYE M, 1980, CRC CR REV BIOCH MOL, V7, P339, DOI 10.3109/10409238009105465; KADONAGA JT, 1985, J BIOL CHEM, V260, P6192; KENDALL DA, 1990, BIOPOLYMERS, V29, P139, DOI 10.1002/bip.360290119; KOSHLAND D, 1982, CELL, V30, P903, DOI 10.1016/0092-8674(82)90295-1; KUHN A, 1985, J BIOL CHEM, V260, P5914; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAFORET GA, 1991, J BIOL CHEM, V266, P1326; Miller J. H., 1972, EXPT MOL GENETICS, P431; NOTHWEHR SF, 1990, BIOESSAYS, V12, P479, DOI 10.1002/bies.950121005; NOTHWEHR SF, 1989, J BIOL CHEM, V264, P3979; PERLMAN D, 1983, J MOL BIOL, V167, P391, DOI 10.1016/S0022-2836(83)80341-6; PLUCKTHUN A, 1988, J BIOL CHEM, V263, P14315; RANDALL LL, 1989, SCIENCE, V243, P1156, DOI 10.1126/science.2646712; RASMUSSEN BA, 1985, J BACTERIOL, V164, P665, DOI 10.1128/JB.164.2.665-673.1985; SHEN LM, 1991, BIOCHEMISTRY-US, V30, P11775, DOI 10.1021/bi00115a006; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; YAMAMOTO Y, 1989, BIOCHEMISTRY-US, V28, P2728, DOI 10.1021/bi00432a054; ZOLLER MJ, 1984, DNA-J MOLEC CELL BIO, V3, P479, DOI 10.1089/dna.1.1984.3.479	40	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13609	13613						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175796				2022-12-25	WOS:A1994NK18400080
J	GABUZDA, D; BUSCIGLIO, J; CHEN, LB; MATSUDAIRA, P; YANKNER, BA				GABUZDA, D; BUSCIGLIO, J; CHEN, LB; MATSUDAIRA, P; YANKNER, BA			INHIBITION OF ENERGY-METABOLISM ALTERS THE PROCESSING OF AMYLOID PRECURSOR PROTEIN AND INDUCES A POTENTIALLY AMYLOIDOGENIC DERIVATIVE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; BETA-PROTEIN; ENDOPLASMIC-RETICULUM; BREFELDIN-A; NEXIN-II; DEGRADATION; IDENTIFICATION; CLEAVAGE; PEPTIDE; DOMAIN	The cellular mechanisms which lead to the generation and pathological deposition of beta amyloid in Alzheimer's disease are unknown. In this report we describe the proteolytic processing of the amyloid precursor protein (APP) to an 11.5-kDa COOH-terminal derivative which contains the full-length beta amyloid sequence. This processing step normally occurs at low levels in parallel with APP maturation in the secretory pathway. Inhibition of oxidative energy metabolism by sodium azide or the mitochondrial uncoupler carbonyl cyanide m-chlorophenylhydrazone increased the proteolysis of APP to the 11.5-kDa derivative by about 80-fold with accumulation of this APP derivative in the Golgi complex. Agents which inhibit protein transport in the secretory pathway, including monensin and brefeldin A, also increased the production of the 11.5-kDa derivative. Inhibition of APP maturation demonstrated that the 11.5-kDa derivative could be produced by proteolysis of immature APP. These results demonstrate that APP processing to potentially amyloidogenic COOH-terminal derivatives occurs in either the endoplasmic reticulum or Golgi complex and can be modulated by the state of cellular energy metabolism. Deficits in oxidative energy metabolism have recently been found in the cerebral cortex of patients with Alzheimer's disease. These findings raise the possibility that energy-related metabolic stress may lead to altered metabolism of APP and contribute to amyloidosis in Alzheimer's disease.	HARVARD UNIV, CHILDRENS HOSP, SCH MED, DEPT NEUROL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DANA FARBER CANC INST, BOSTON, MA 02115 USA; MIT, WHITEHEAD INST BIOMED RES, DEPT BIOL, CAMBRIDGE, MA 02142 USA; HARVARD UNIV, SCH MED, DEPT PATHOL, BOSTON, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Massachusetts Institute of Technology (MIT); Whitehead Institute; Harvard University; Harvard Medical School			Matsudaira, Paul/H-1475-2012	Matsudaira, Paul/0000-0002-8399-3276	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030352] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R29AG009229] Funding Source: NIH RePORTER; NIA NIH HHS [AG09229] Funding Source: Medline; NINDS NIH HHS [NS30352] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BOWLING AC, 1993, J NEUROCHEM, V60, P1964, DOI 10.1111/j.1471-4159.1993.tb13430.x; BUSCIGLIO J, 1993, P NATL ACAD SCI USA, V90, P2092, DOI 10.1073/pnas.90.5.2092; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; CAPORASO GL, 1992, P NATL ACAD SCI USA, V89, P2252, DOI 10.1073/pnas.89.6.2252; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; CORRALDEBRINSKI M, 1992, NAT GENET, V2, P324, DOI 10.1038/ng1292-324; DEDUVE C, 1974, BIOCHEM PHARMACOL, V23, P2495, DOI 10.1016/0006-2952(74)90174-9; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; ESTUS S, 1992, SCIENCE, V255, P726, DOI 10.1126/science.1738846; FRIES E, 1980, P NATL ACAD SCI-BIOL, V77, P3870, DOI 10.1073/pnas.77.7.3870; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; HAASS C, 1993, J BIOL CHEM, V268, P3021; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; HAASS C, 1992, NATURE, V359, P325; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KNOPS J, 1992, J BIOL CHEM, V267, P16022; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MECOCCI P, 1993, ANN NEUROL, V34, P609, DOI 10.1002/ana.410340416; MUTISYA EM, 1993, ABSTR NEUR, V19, P1474; OLTERSDORF T, 1990, J BIOL CHEM, V265, P4492; OLTERSDORF T, 1989, NATURE, V341, P144, DOI 10.1038/341144a0; PERSSON R, 1992, J BIOL CHEM, V267, P2760; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; ROHER AE, 1993, J BIOL CHEM, V268, P3072; SAMBAMURTI K, 1992, J NEUROSCI RES, V33, P319, DOI 10.1002/jnr.490330216; SELKOE DJ, 1991, NEURON, V6, P487, DOI 10.1016/0896-6273(91)90052-2; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SEUBERT P, 1993, NATURE, V361, P260, DOI 10.1038/361260a0; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; TARTAKOFF AM, 1983, CELL, V32, P1026, DOI 10.1016/0092-8674(83)90286-6; VANNOSTRAND WE, 1989, NATURE, V341, P546; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; WOODS CM, 1985, CELL, V40, P959, DOI 10.1016/0092-8674(85)90356-3; YANKNER BA, 1991, NEW ENGL J MED, V325, P1849; ZHONG ZY, 1994, J BIOL CHEM, V269, P12179	46	322	335	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13623	13628						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175797				2022-12-25	WOS:A1994NK18400082
J	RUBINCHIK, S; PARRIS, W; GOLD, M				RUBINCHIK, S; PARRIS, W; GOLD, M			THE IN-VITRO ENDONUCLEASE ACTIVITY OF GENE-PRODUCT-A, THE LARGE SUBUNIT OF THE BACTERIOPHAGE-LAMBDA TERMINASE, AND ITS RELATIONSHIP TO THE ENDONUCLEASE ACTIVITY OF THE HOLOENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRATION HOST FACTOR; COHESIVE END SITE; ESCHERICHIA-COLI; COS DNA; BINDING; PROTEIN; OVERPRODUCTION; MUTATIONS; MECHANISM; SEQUENCES	The reaction requirements and kinetic properties of the in vitro endonuclease activity of the bacteriophage lambda terminase and its large subunit, gene product (gp) A, have been analyzed. Optimal cleavage reaction activity for both proteins requires Mg2+, a pH between 8.5 and 9.0, and is enhanced by ATP or ATP analogs. Under these conditions both terminase and gpA generate aberrant nicks in and around cosN. Optimal nicking specificity of terminase is observed under conditions of 50-100 mM salt, 5 mM spermidine, 1.5 mM ATP, and a pH between 7.0 and 7.5. Specific activity of terminase is greatly reduced under these conditions, and gpA is completely inactive at all protein concentrations tested. Under optimal reaction conditions, gpA endonuclease activity differs from that of the holoenzyme in that it can only be detected at high concentrations, is strongly protein concentration-dependent, and can not be stimulated by the Escherichia coli protein integration host factor. Addition of purified gpNu1 partially, but not completely, minimized these differences, suggesting that the role of gpNu1 in the holoenzyme is to modulate the basal endonuclease of gpA.	UNIV TORONTO, DEPT MOLEC & MED GENET, TORONTO M5S 1A8, ON, CANADA	University of Toronto								BAEZA I, 1987, BIOCHEMISTRY-US, V26, P6380; BEAR SE, 1984, J VIROL, V52, P966, DOI 10.1128/JVI.52.3.966-972.1984; BECKER A, 1977, VIROLOGY, V78, P291, DOI 10.1016/0042-6822(77)90100-3; BECKER A, 1990, J BACTERIOL, V172, P2819, DOI 10.1128/jb.172.6.2819-2824.1990; BECKER A, 1978, P NATL ACAD SCI USA, V75, P4199, DOI 10.1073/pnas.75.9.4199; CHOW S, 1987, GENE, V60, P277, DOI 10.1016/0378-1119(87)90236-8; DAVIDSON A, 1991, J BACTERIOL, V173, P5086, DOI 10.1128/jb.173.16.5086-5096.1991; DAVIDSON AR, 1992, VIROLOGY, V189, P21, DOI 10.1016/0042-6822(92)90677-H; FEISS M, 1986, TRENDS GENET, V2, P100, DOI 10.1016/0168-9525(86)90193-9; FEISS M, 1983, GENE, V24, P207, DOI 10.1016/0378-1119(83)90081-1; GOLD M, 1983, J BIOL CHEM, V258, P4619; GOLD M, 1986, NUCLEIC ACIDS RES, V14, P9797, DOI 10.1093/nar/14.24.9797; HIGGINS RR, 1988, CELL, V54, P765, DOI 10.1016/S0092-8674(88)91021-5; HOHN B, 1983, P NATL ACAD SCI-BIOL, V80, P7456, DOI 10.1073/pnas.80.24.7456; HSU MT, 1978, BIOCHEMISTRY-US, V17, P131, DOI 10.1021/bi00594a019; JOHNSTON RF, 1990, ELECTROPHORESIS, V11, P355, DOI 10.1002/elps.1150110503; KEELER CL, 1987, THESIS U MARYLAND BA; KOSTURKO LD, 1989, NUCLEIC ACIDS RES, V17, P317, DOI 10.1093/nar/17.1.317; KRASNOW MA, 1982, J BIOL CHEM, V257, P2687; Maxam A M, 1980, Methods Enzymol, V65, P499; MIWA T, 1983, GENE, V24, P199; MIWA T, 1982, GENE, V20, P265; MURIALDO H, 1991, ANNU REV BIOCHEM, V60, P125; NASH HA, 1987, J BACTERIOL, V169, P4124, DOI 10.1128/jb.169.9.4124-4127.1987; PARRIS W, 1988, J BIOL CHEM, V263, P8413; PARRIS W, 1994, J BIOL CHEM, V269, P13564; RUBINCHIK S, 1994, J BIOL CHEM, V269, P13586; Sambrook J, 1989, MOL CLONING LABORATO; SHINDER G, 1988, J VIROL, V62, P387, DOI 10.1128/JVI.62.2.387-392.1988; SHINDER G, 1989, NUCLEIC ACIDS RES, V17, P2005, DOI 10.1093/nar/17.5.2005; SHINDER G, 1989, THESIS U TORONTO; TOMKA MA, 1993, J BIOL CHEM, V268, P3056; VONHIPPEL PH, 1989, J BIOL CHEM, V264, P675; WILLIS RC, 1992, THESIS U TORONTO; XIN W, 1993, J MOL BIOL, V230, P505, DOI 10.1006/jmbi.1993.1167; XIN W, 1993, J MOL BIOL, V230, P492, DOI 10.1006/jmbi.1993.1166; XU S, 1989, THESIS U IOWA; ZIMMERMAN SB, 1991, J MOL BIOL, V222, P599, DOI 10.1016/0022-2836(91)90499-V	38	36	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13575	13585						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175793				2022-12-25	WOS:A1994NK18400076
J	SCHWARTZ, ML; KATAGI, C; BRUCE, J; SCHLAEPFER, WW				SCHWARTZ, ML; KATAGI, C; BRUCE, J; SCHLAEPFER, WW			BRAIN-SPECIFIC ENHANCEMENT OF THE MOUSE NEUROFILAMENT HEAVY GENE PROMOTER IN-VITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-M; MESSENGER-RNA; EXPRESSION; PROTEINS; TRANSCRIPTION; PHOSPHORYLATION; SUBUNITS; INTERACT; REVEALS; BOX	We have investigated the DNA elements responsible for transcription from the proximal portion of the mouse neurofilament heavy gene (NF-H) promoter by in vitro transcription using extracts from expressing (brain) and non-expressing (liver) tissues. We have found that constructs containing 5' region from -1314 to -115 exhibit a 3-5-fold higher level of NF-H promoter activity, relative to the adenovirus major late promoter (pML), in brain versus liver extracts. Deletion to -85 lowers the level of brain transcription by 2-fold, while deletion from -65 through -31 reduces transcription by 5-fold to a relatively strong (10% of pML) basal level. Basal level expression is observed in all deletions transcribed with liver extract. Deletion to -24 (TATA-less) abolishes promoter activity with both extracts. Deletion of the -115 to -65 region from a larger construct reduces transcription in brain extracts to basal levels, suggesting that this region contains the elements necessary for the brain specific enhancement of promoter function. Mutation of a palindromic sequence within this region abolishes brain specific enhanced promoter activity. This loss of enhanced transcriptional activity is correlated with the loss of a shifted band in gel shift assays. Our studies suggest that the sequence (-106)GGGGAG-GAGG-(15 bp)-CCTCCTCCCC(-72) (where bp = base pairs) is important in brain-specific enhancement of transcription from the mouse NF-H promoter.			SCHWARTZ, ML (corresponding author), UNIV PENN,SCH MED,DIV NEUROPATHOL,435 JOHNSON PAVILION,PHILADELPHIA,PA 19104, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [T32NS007064, R01NS015722] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS15722, T32 NS07064] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALMOUZNI G, 1993, GENE DEV, V7, P2033, DOI 10.1101/gad.7.10.2033; BEAUDET L, 1992, GENE, V116, P205, DOI 10.1016/0378-1119(92)90517-S; CARDEN MJ, 1987, J NEUROSCI, V7, P3489; CHU HM, 1991, NUCLEIC ACIDS RES, V19, P2721, DOI 10.1093/nar/19.10.2721; COTE F, 1993, CELL, V73, P35, DOI 10.1016/0092-8674(93)90158-M; ELDER GA, 1992, MOL BRAIN RES, V15, P99, DOI 10.1016/0169-328X(92)90156-6; ELDER GA, 1992, MOL BRAIN RES, V15, P85, DOI 10.1016/0169-328X(92)90155-5; GOLDSTEIN ME, 1988, MOL BRAIN RES, V3, P287, DOI 10.1016/0169-328X(88)90051-4; GOODRICH JA, 1990, NUCLEIC ACIDS RES, V18, P4993, DOI 10.1093/nar/18.17.4993; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; HIGUCHI H, 1992, BIOCHEM BIOPH RES CO, V189, P1553, DOI 10.1016/0006-291X(92)90253-H; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOFFMAN PN, 1987, P NATL ACAD SCI USA, V84, P3472, DOI 10.1073/pnas.84.10.3472; ISHIGURO H, 1993, J BIOL CHEM, V268, P17987; JULIEN JP, 1987, BIOCHIM BIOPHYS ACTA, V909, P10, DOI 10.1016/0167-4781(87)90041-8; LEE VMY, 1992, MOL BRAIN RES, V15, P76, DOI 10.1016/0169-328X(92)90154-4; LEVY E, 1987, EUR J BIOCHEM, V166, P71, DOI 10.1111/j.1432-1033.1987.tb13485.x; MANDEL G, 1993, ANNU REV NEUROSCI, V16, P323, DOI 10.1146/annurev.ne.16.030193.001543; MONTEIRO MJ, 1989, J CELL BIOL, V108, P579, DOI 10.1083/jcb.108.2.579; MONTMINY MR, 1990, TRENDS NEUROSCI, V13, P184, DOI 10.1016/0166-2236(90)90045-C; NAKAHIRA K, 1990, J BIOL CHEM, V265, P19786; PALMITER RD, 1993, MOL CELL BIOL, V13, P5266, DOI 10.1128/MCB.13.9.5266; PECORINO LT, 1991, MOL CELL BIOL, V11, P3139, DOI 10.1128/MCB.11.6.3139; PLEASURE SJ, 1990, J NEUROSCI, V10, P2428; REEBEN M, 1993, BIOCHEM BIOPH RES CO, V192, P465, DOI 10.1006/bbrc.1993.1438; SCHLAEPFER WW, 1990, J NEUROSCI RES, V25, P39, DOI 10.1002/jnr.490250106; SCHWARTZ ML, 1992, J BIOL CHEM, V267, P24596; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; SHNEIDMAN PS, 1992, MOL BRAIN RES, V13, P127, DOI 10.1016/0169-328X(92)90052-D; SMITH CL, 1993, P NATL ACAD SCI USA, V90, P11202, DOI 10.1073/pnas.90.23.11202; THHOREY I, 1993, MOL CELL BIOL, V13, P6742; XU ZS, 1993, CELL, V73, P23, DOI 10.1016/0092-8674(93)90157-L; YAMASAKI H, 1992, LAB INVEST, V66, P734; YAZDANBAKHSH K, 1993, NUCLEIC ACIDS RES, V21, P4555; YOON SO, 1992, NEURON, V9, P55, DOI 10.1016/0896-6273(92)90220-8; ZOPF D, 1990, NUCLEIC ACIDS RES, V18, P521, DOI 10.1093/nar/18.3.521	36	29	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13444	13450						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175776				2022-12-25	WOS:A1994NK18400059
J	KWON, NS; LEE, SH; CHOI, CS; LEE, HS; KHO, T				KWON, NS; LEE, SH; CHOI, CS; LEE, HS; KHO, T			NITRIC-OXIDE GENERATION FROM STREPTOZOTOCIN	FASEB JOURNAL			English	Article						AORTIC STRIPS; HEMOGLOBIN; NITRITE; NITRATE; LIGHT; DIABETES MELLITUS	INDUCED PANCREATIC INSULITIS; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; RIBONUCLEOTIDE REDUCTASE; BIOLOGICAL-FLUIDS; ADP-RIBOSYLATION; RELAXING FACTOR; CELLS; INHIBITION; ISLETS; DNA	Streptozotocin (STZ), a diabetogenic agent, is thought to damage pancreatic beta-cells by activating immune mechanisms and by alkylating DNA. In the present study, we demonstrated that STZ can produce nitric oxide (NO), a bioregulatory and cytotoxic molecule. When STZ was dissolved in a sodium phosphate buffer (50 mM, pH 7.4) and irradiated with a 22 W circular fluorescent light, nitrite and nitrate, stable oxidation products of NO, were produced. The wavelengths of light most responsible for the photo-decomposition were 300-310 nm and 410-420 nm. When a mixture of reduced hemoglobin and STZ was irradiated with UV light (280-320 nm), hemoglobin underwent characteristic NO-dependent spectral changes. STZ relaxed deendothelialized aortic strips only in the presence of light. STZ/light-dependent relaxation was attenuated by reduced hemoglobin. These results indicated photoinduced NO production from STZ. NO generation depended on the concentration of STZ, the duration of irradiation, and the distance between sample and light source. In acidic conditions, NO production from STZ was spontaneous even in the dark. Light-independent NO generation was augmented by increasing acidity, and markedly diminished in a D2O-based buffer, indicating the involvement of protons in the mechanism of STZ decomposition in acid. These results imply the usefulness of STZ as an NO-generating reagent, and indicate that direct NO-generation may be a mechanism of STZ toxicity in diabetogenesis.			KWON, NS (corresponding author), CHUNG ANG UNIV,COLL MED,DEPT BIOCHEM,221 HEUCKSUK DONG,SEOUL 156756,SOUTH KOREA.							ANDRADE J, 1993, FEBS LETT, V327, P32, DOI 10.1016/0014-5793(93)81033-V; APPEL KE, 1982, CARCINOGENESIS, V3, P293, DOI 10.1093/carcin/3.3.293; ARMSTRONG D, 1991, FREE RADICAL BIO MED, V11, P433, DOI 10.1016/0891-5849(91)90161-U; ARNOLD WP, 1984, ANESTHESIOLOGY, V61, P254, DOI 10.1097/00000542-198409000-00004; BENNETT RA, 1981, CANCER RES, V41, P2786; BREDT DS, 1992, NEURON, V8, P3, DOI 10.1016/0896-6273(92)90104-L; BUGA GM, 1992, FASEB J, V6, pA1733; CHANG KC, 1993, BIOCHEM BIOPH RES CO, V191, P509, DOI 10.1006/bbrc.1993.1247; CORBETT JA, 1991, J BIOL CHEM, V266, P21351; CORBETT JA, 1992, J CLIN INVEST, V90, P2384, DOI 10.1172/JCI116129; DIMMELER S, 1993, J IMMUNOL, V150, P2964; DIMMELER S, 1992, J BIOL CHEM, V267, P16771; DRAPIER JC, 1986, J CLIN INVEST, V78, P790, DOI 10.1172/JCI112642; FEELISCH M, 1987, EUR J PHARMACOL, V139, P19, DOI 10.1016/0014-2999(87)90493-6; FURCHGOTT R, 1961, J GEN PHYSIOL, V44, P499, DOI 10.1085/jgp.44.3.499; FURCHGOTT RF, 1991, BLOOD VESSELS, V28, P52; GARTHWAITE G, 1991, TRENDS NEUROSCI, V2, P60; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; GROVER TA, 1987, FREE RADICAL BIO MED, V3, P27, DOI 10.1016/0891-5849(87)90036-0; HERR RR, 1967, J AM CHEM SOC, V89, P4808, DOI 10.1021/ja00994a053; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; IVANOVA K, 1993, EUR J PHARM-MOLEC PH, V244, P37, DOI 10.1016/0922-4106(93)90057-G; JOHANSSON EB, 1978, ACTA ENDOCRINOL-COP, V89, P339, DOI 10.1530/acta.0.0890339; JOHNSON DD, 1986, CURR EYE RES, V5, P1, DOI 10.3109/02713688608995159; Kolb H, 1993, DIABETES REV, V1, P116; KRONCKE KD, 1991, BIOCHEM BIOPH RES CO, V175, P752, DOI 10.1016/0006-291X(91)91630-U; KWON NS, 1991, J EXP MED, V174, P761, DOI 10.1084/jem.174.4.761; LEPOIVRE M, 1992, J BIOL CHEM, V267, P22994; LIKE AA, 1976, SCIENCE, V193, P415, DOI 10.1126/science.180605; LIKE AA, 1978, LAB INVEST, V38, P470; MARCH J, 1985, ADV ORG CHEM, P1106; MUSSON DG, 1979, J PHARM SCI, V68, P1159, DOI 10.1002/jps.2600680927; NGUYEN T, 1992, P NATL ACAD SCI USA, V89, P3030, DOI 10.1073/pnas.89.7.3030; ODELL TJ, 1991, P NATL ACAD SCI USA, V88, P11285, DOI 10.1073/pnas.88.24.11285; OHKUMA S, 1978, P NATL ACAD SCI USA, V75, P3327, DOI 10.1073/pnas.75.7.3327; ONEILL SK, 1993, J PHARMACOL TOXICOL, V29, P217, DOI 10.1016/1056-8719(93)90028-D; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; POTTER DW, 1982, ARCH BIOCHEM BIOPHYS, V216, P158, DOI 10.1016/0003-9861(82)90200-4; POTTER DW, 1983, J BIOL CHEM, V258, P6906; SHIBUKI K, 1991, NATURE, V349, P326, DOI 10.1038/349326a0; SHUKER DEG, 1983, ANAL CHEM, V55, P2152, DOI 10.1021/ac00263a034; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P7674, DOI 10.1073/pnas.89.16.7674; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; STUEHR DJ, 1989, J EXP MED, V169, P1543, DOI 10.1084/jem.169.5.1543; THOMAS G, 1989, EUR J PHARMACOL, V161, P279, DOI 10.1016/0014-2999(89)90860-1; VESELY DL, 1977, CANCER RES, V37, P28; WELSH N, 1992, BIOCHEM BIOPH RES CO, V182, P333, DOI 10.1016/S0006-291X(05)80149-4; WINK DA, 1991, SCIENCE, V254, P1001, DOI 10.1126/science.1948068; YAMAMOTO H, 1981, NATURE, V294, P284, DOI 10.1038/294284a0	49	115	118	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAY	1994	8	8					529	533		10.1096/fasebj.8.8.8181671	http://dx.doi.org/10.1096/fasebj.8.8.8181671			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	NM364	8181671				2022-12-25	WOS:A1994NM36400010
J	HERBST, JJ; OPRESKO, LK; WALSH, BJ; LAUFFENBURGER, DA; WILEY, HS				HERBST, JJ; OPRESKO, LK; WALSH, BJ; LAUFFENBURGER, DA; WILEY, HS			REGULATION OF POSTENDOCYTIC TRAFFICKING OF THE EPIDERMAL GROWTH-FACTOR RECEPTOR THROUGH ENDOSOMAL RETENTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								Little is known about the regulation of EGF receptor (EGF-R) trafficking following endocytosis. We investigated this by using a series of EGF-R with altered cytoplasmic tails and comparing their ability to undergo recycling and lysosomal targeting in both the occupied and empty state. We found that 2-3% of empty EGF-R are internalized each minute, but rapidly recycle (t(1/2) approximately 5 min). This constitutive internalization and recycling of empty receptors was independent of cytoplasmic receptor sequences. Occupied EGF-R, in contrast, displayed a much slower rate of recycling (t(1/2) between 10-23 min) due to retention within recycling endosomes. Endosomal retention of different EGF-R correlated with lysosomal targeting of EGF. Intrinsic receptor tyrosine kinase activity had no discernible effect on postendocytic trafficking of EGF. Although sequences within the cytoplasmic tail of the EGF-R appear to be required for occupancy-dependent endosomal retention, they are distinct from those required for ligand-induced endocytosis. Our studies indicate that intracellular trafficking of the EGF-R is regulated by endosomal components that preferentially recognize occupied receptors. Down-regulation of the EGF-R thus involves two distinct regulatory processes: one at the level of internalization and one at the level of recycling.	UNIV UTAH, MED CTR, DEPT PATHOL, DIV CELL BIOL & IMMUNOL, SALT LAKE CITY, UT 84132 USA; UNIV ILLINOIS, DEPT CHEM ENGN, URBANA, IL 61801 USA; UNIV ILLINOIS, DEPT CELL & STRUCT BIOL, URBANA, IL 61801 USA	Utah System of Higher Education; University of Utah; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign				Wiley, Steven/0000-0003-0232-6867				AJIOKA RS, 1986, P NATL ACAD SCI USA, V83, P6445, DOI 10.1073/pnas.83.17.6445; BACKER JM, 1992, J CELL BIOL, V118, P831, DOI 10.1083/jcb.118.4.831; BALCH WE, 1985, ARCH BIOCHEM BIOPHYS, V240, P413, DOI 10.1016/0003-9861(85)90046-3; BANSAL A, 1991, CELL, V67, P1195, DOI 10.1016/0092-8674(91)90295-A; BEGUINOT L, 1985, P NATL ACAD SCI USA, V82, P2774, DOI 10.1073/pnas.82.9.2774; BROWN MS, 1983, CELL, V32, P663, DOI 10.1016/0092-8674(83)90052-1; CHANG CP, 1991, J BIOL CHEM, V266, P23467; CHANG CP, 1993, J BIOL CHEM, V268, P19312; CHEN JW, 1986, BIOCHEM SOC SYMP, P97; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; COUNTAWAY JL, 1992, J BIOL CHEM, V267, P1129; DAVIS CG, 1987, J BIOL CHEM, V262, P4075; EBERLE W, 1991, CELL, V67, P1203, DOI 10.1016/0092-8674(91)90296-B; EBNER R, 1991, CELL REGUL, V2, P599, DOI 10.1091/mbc.2.8.599; FELDER S, 1990, CELL, V61, P623, DOI 10.1016/0092-8674(90)90474-S; FELDER S, 1992, J CELL BIOL, V117, P203, DOI 10.1083/jcb.117.1.203; FIRE E, 1991, J CELL BIOL, V115, P1585, DOI 10.1083/jcb.115.6.1585; GILL GN, 1984, J BIOL CHEM, V259, P7755; GLENNEY JR, 1988, CELL, V52, P675, DOI 10.1016/0092-8674(88)90405-9; HARLOW E, 1988, ABTIBODIES LABORATOR; HELIN K, 1991, J BIOL CHEM, V266, P8363; HONEGGER AM, 1987, MOL CELL BIOL, V7, P4568, DOI 10.1128/MCB.7.12.4568; HONEGGER AM, 1990, J CELL BIOL, V110, P1541, DOI 10.1083/jcb.110.5.1541; HOPKINS CR, 1990, NATURE, V346, P335, DOI 10.1038/346335a0; JING SQ, 1990, J CELL BIOL, V110, P283, DOI 10.1083/jcb.110.2.283; JOHNSON KF, 1992, J CELL BIOL, V119, P249, DOI 10.1083/jcb.119.2.249; KAMPS MP, 1988, ONCOGENE, V2, P305; KAPLAN J, 1981, SCIENCE, V212, P14, DOI 10.1126/science.6259730; KLAUSNER RD, 1983, P NATL ACAD SCI-BIOL, V80, P2263, DOI 10.1073/pnas.80.8.2263; KNUTSON VP, 1983, J BIOL CHEM, V258, P2139; KTISTAKIS NT, 1990, J CELL BIOL, V111, P1393, DOI 10.1083/jcb.111.4.1393; LINDERMAN JJ, 1988, J THEOR BIOL, V132, P203, DOI 10.1016/S0022-5193(88)80157-7; LLOYD CE, 1983, J CELL BIOL, V96, P521, DOI 10.1083/jcb.96.2.521; LOBEL P, 1989, CELL, V57, P787, DOI 10.1016/0092-8674(89)90793-9; LUND KA, 1990, J BIOL CHEM, V265, P15713; LUND KA, 1990, J BIOL CHEM, V265, P20517; MARSHALL S, 1985, J BIOL CHEM, V260, P3524; MARTIN P, 1989, CELL, V59, P21, DOI 10.1016/0092-8674(89)90866-0; MCGRAW TE, 1990, CELL REGUL, V1, P369, DOI 10.1091/mbc.1.4.369; MURTHY U, 1986, J CELL BIOL, V103, P333, DOI 10.1083/jcb.103.2.333; ONODA T, 1990, DRUG EXP CLIN RES, V16, P249; OPRESKO L, 1980, CELL, V22, P47, DOI 10.1016/0092-8674(80)90153-1; OPRESKO LK, 1987, J BIOL CHEM, V262, P4116; PEARSE BMF, 1988, EMBO J, V7, P3331, DOI 10.1002/j.1460-2075.1988.tb03204.x; PIDOUX AL, 1992, EMBO J, V11, P1583, DOI 10.1002/j.1460-2075.1992.tb05203.x; REID PA, 1990, NATURE, V346, P655, DOI 10.1038/346655a0; SAVAGE CR, 1972, J BIOL CHEM, V247, P7609; SIBLEY DR, 1987, CELL, V48, P913, DOI 10.1016/0092-8674(87)90700-8; SORKIN A, 1992, J BIOL CHEM, V267, P8672; SORKIN A, 1991, J BIOL CHEM, V266, P23453; SORKIN A, 1991, J BIOL CHEM, V266, P8355; SORKIN A, 1989, BIOCHIM BIOPHYS ACTA, V1011, P88, DOI 10.1016/0167-4889(89)90083-9; SORKIN A, 1991, J CELL BIOL, V112, P55, DOI 10.1083/jcb.112.1.55; THIES RS, 1990, J BIOL CHEM, V265, P10132; VERREY F, 1990, CELL REGUL, V1, P471, DOI 10.1091/mbc.1.6.471; WATTS C, 1985, J CELL BIOL, V100, P633, DOI 10.1083/jcb.100.2.633; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; WILEY HS, 1991, J BIOL CHEM, V266, P11083; WILEY HS, 1982, J BIOL CHEM, V257, P4222; WILEY HS, 1981, CELL, V25, P433, DOI 10.1016/0092-8674(81)90061-1; WILEY HS, 1985, CURR TOP MEMBR TRANS, V24, P369; WILEY HS, 1985, J BIOL CHEM, V260, P5290; WILSON PD, 1991, AM J PHYSIOL, V260, pF420, DOI 10.1152/ajprenal.1991.260.3.F420; WINKLER ME, 1989, BIOCHEMISTRY-US, V28, P6373, DOI 10.1021/bi00441a033	64	119	124	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12865	12873						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175702				2022-12-25	WOS:A1994NH71600076
J	YEN, PM; IKEDA, M; WILCOX, EC; BRUBAKER, JH; SPANJAARD, RA; SUGAWARA, A; CHIN, WW				YEN, PM; IKEDA, M; WILCOX, EC; BRUBAKER, JH; SPANJAARD, RA; SUGAWARA, A; CHIN, WW			HALF-SITE ARRANGEMENT OF HYBRID GLUCOCORTICOID AND THYROID-HORMONE RESPONSE ELEMENTS SPECIFIES THYROID-HORMONE RECEPTOR COMPLEX BINDING TO DNA AND TRANSCRIPTIONAL ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOID-X-RECEPTOR; AUXILIARY PROTEIN; NUCLEAR RECEPTORS; ENHANCES BINDING; ACID RECEPTORS; LIGAND-BINDING; AMINO-ACIDS; RXR-BETA; GENE; HETERODIMERIZATION	Thyroid hormone receptors bind to thyroid hormone response elements (TREs) as heterodimers with 3,5,3'-L-triiodothyronine (T-3) receptor auxiliary protein (TRAP) and retinoid X receptors (RXRs). Currently, it is not known whether TR/TRAP or TR/RXR heterodimers need to bind to both TRE half-sites and whether there is a preferred orientation for TR/RXR heterodimer binding to TREs or transcriptional activation. Accordingly, we created a mutant TR alpha (TR-P box) by changing 3 amino acids in the P box region of the first zinc finger of the DNA-binding domain to that of the glucocorticoid receptor (GR), and we examined wild-type TR alpha and TR-P box complex binding to hybrid response elements containing TRE and glucocorticoid receptor element (GRE) half sites arranged as a direct repeat with a four-nucleotide gap. TR-P box/RXR heterodimers selectively bound to the hybrid response element in which the GRE half-site was the downstream half-site, whereas TR alpha/ RXR bound to hybrid response elements in which GREs were in either position. Additionally, TR/TRAP or TR/ RXR heterodimer required two half-sites for binding to DNA, with strong binding to at least one of the half-sites. Last, co-transfection assays and methylation interference studies using the hybrid response elements suggest that the sequential arrangement of strong and weak half-sites in the TRE may be a critical determinant of TR/RXR heterodimer binding and transcriptional activation.	HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Harvard Medical School	YEN, PM (corresponding author), BRIGHAM & WOMENS HOSP,HOWARD HUGHES MED INST,DEPT MED,DIV GENET,GW THORN RES BLDG,RM 905,BOSTON,MA 02115, USA.		Yen, Paul M/V-9857-2019	Yen, Paul/0000-0002-3790-8114; Sugawara, Akira/0000-0003-4511-8101				ANDERSSON ML, 1992, NUCLEIC ACIDS RES, V20, P4803, DOI 10.1093/nar/20.18.4803; BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BERRODIN TJ, 1992, MOL ENDOCRINOL, V6, P1468, DOI 10.1210/me.6.9.1468; BLANCHARD KL, 1992, MOL CELL BIOL, V12, P5373, DOI 10.1128/MCB.12.12.5373; BRENT G A, 1989, New Biologist, V1, P329; BRENT GA, 1989, MOL ENDOCRINOL, V3, P1996, DOI 10.1210/mend-3-12-1996; BURNSIDE J, 1990, J BIOL CHEM, V265, P2500; DANIELSEN M, 1989, CELL, V57, P1131, DOI 10.1016/0092-8674(89)90050-0; DARLING DS, 1991, MOL ENDOCRINOL, V5, P73, DOI 10.1210/mend-5-1-73; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FORMAN BM, 1992, MOL ENDOCRINOL, V6, P429, DOI 10.1210/me.6.3.429; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; HOLLOWAY JM, 1990, P NATL ACAD SCI USA, V87, P8160, DOI 10.1073/pnas.87.20.8160; KIM HS, 1992, MOL ENDOCRINOL, V6, P1489, DOI 10.1210/me.6.9.1489; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KUROKAWA R, 1993, GENE DEV, V7, P1423, DOI 10.1101/gad.7.7b.1423; LAZAR MA, 1990, J CLIN INVEST, V86, P1777, DOI 10.1172/JCI114906; LAZAR MA, 1991, MOL CELL BIOL, V11, P5005, DOI 10.1128/MCB.11.10.5005; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; MADER S, 1989, NATURE, V338, P271, DOI 10.1038/338271a0; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; MIYAMOTO T, 1993, MOL ENDOCRINOL, V7, P224, DOI 10.1210/me.7.2.224; MURRAY MB, 1989, MOL ENDOCRINOL, V3, P1434, DOI 10.1210/mend-3-9-1434; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; NELSON CC, 1993, MOL ENDOCRINOL, V7, P1185, DOI 10.1210/me.7.9.1185; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; PERLMANN T, 1993, GENE DEV, V7, P1411, DOI 10.1101/gad.7.7b.1411; RIBIERO RCJ, 1992, MOL ENDOCRINOL, V6, P1142; Sambrook J, 1989, MOL CLONING LABORATO; SPANJAARD RA, 1991, P NATL ACAD SCI USA, V88, P8587, DOI 10.1073/pnas.88.19.8587; SUGAWARA A, 1993, ENDOCRINOLOGY, V133, P965, DOI 10.1210/en.133.3.965; THOMPSON CC, 1989, P NATL ACAD SCI USA, V86, P3494, DOI 10.1073/pnas.86.10.3494; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WIDOM RL, 1992, MOL CELL BIOL, V12, P3380, DOI 10.1128/MCB.12.8.3380; YEN PM, 1992, J BIOL CHEM, V267, P3565; YEN PM, 1992, J BIOL CHEM, V267, P23248; YEN PM, 1993, ENDOCR J, V1, P461; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG XK, 1991, NEW BIOL, V3, P169; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0; ZHOU YH, 1993, CELL, V73, P375, DOI 10.1016/0092-8674(93)90236-J	45	29	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12704	12709						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175681				2022-12-25	WOS:A1994NH71600053
J	HARRIS, HW; ZEIDEL, ML; JO, IH; HAMMOND, TG				HARRIS, HW; ZEIDEL, ML; JO, IH; HAMMOND, TG			CHARACTERIZATION OF PURIFIED ENDOSOMES CONTAINING THE ANTIDIURETIC HORMONE-SENSITIVE WATER CHANNEL FROM RAT RENAL PAPILLA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRAL MEMBRANE-PROTEIN; STIMULATED TOAD BLADDER; DUCT PRINCIPAL CELLS; COLLECTING DUCT; PERMEABILITY RESPONSE; ENDOCYTIC VESICLES; CHIP28 PROTEIN; COATED PITS; PROTON; CONTAIN	Antidiuretic hormone (ADH) stimulation of renal epithelial cells elicits a large increase in apical membrane osmotic water permeability (P-f) produced by the fusion of water channel containing vesicles with the apical membrane. Removal of ADH stimulation results in retrieval of apical water channels into a specialized nonacidic endosomal compartment. Previous studies (Sabolic, I., Wuarin, E., and Shi, L, B. (1992) J. Cell Biol. 119, 111-122) have shown that water channel containing papillary endosomes labeled with fluorescein-dextran can be isolated from rat renal papilla. We have utilized small particle flow sorting methodology to both monitor and improve upon the purification of these water channel containing endosomes (WCV). Flow cytometry analysis on a vesicle-by-vesicle basis demonstrates that WCV are homogenous with respect to entrapped fluorescein-dextran, the apical membrane enzyme marker leucine amino peptidase and ultrastructural morphology. WCV do not acidify their luminal contents after addition of Mg-ATP but contain abundant functional water channels (P-f 0.28 cm/s at 23 degrees C) as determined by stopped flow fluorimetry. SDS-polyacrylamide gel electrophoresis analysis shows that purified WCV are composed of 20 major protein bands. To determine the identity of WCV water channels, WCV proteins were probed with affinity purified antisera recognizing two renal water channel proteins. These include Aquaporin-CHIP found in the proximal tubule and thin descending limb of Henle and the candidate ADH water channel protein WCH-1 or Aquaporin- (AQP) CD present in the ADH-responsive epithelial cells of the collecting duct. These data reveal that WCV contained little or no AQP-CHIP protein. In contrast, WCV are highly enriched for AQP-CD protein. Together, these data define the protein composition of the papillary WCV and link directly the presence of functional apical membrane water channels with the presence of the AQP-CD protein.	BROCKTON W ROXBURY VET ADM MED CTR,DIV NEPHROL,BOSTON,MA 02115; UNIV PITTSBURGH,SCH MED,DIV RENAL & ELECTROLYTE,PITTSBURGH,PA 15213; UNIV WISCONSIN HOSP & CLIN,WILLIAM S MIDDLETON MEM VET ADM HOSP,MADISON,WI 53792	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Wisconsin System; University of Wisconsin Madison; US Department of Veterans Affairs; Veterans Health Administration (VHA); William S Middleton Memorial Veterans Hospital	HARRIS, HW (corresponding author), CHILDRENS HOSP,DIV NEPHROL,HUNNEWELL 3,300 LONGWOOD AVE,BOSTON,MA 02115, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK046117, R01DK038874, R01DK043955] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 43955, DK 38874, DK 46117] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGRE P, 1993, AM J PHYSIOL, V265, pF463; BONDY C, 1993, P NATL ACAD SCI USA, V90, P4500, DOI 10.1073/pnas.90.10.4500; BROWN D, 1983, NATURE, V302, P253, DOI 10.1038/302253a0; BROWN D, 1988, EUR J CELL BIOL, V46, P336; COLEMAN RA, 1992, EUR J CELL BIOL, V58, P44; DENKER BM, 1988, J BIOL CHEM, V263, P15634; DING G, 1993, AM J PHYSIOL, V255, pC641; DOLBEARE FA, 1977, CLIN CHEM, V23, P1485; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; FUSHIMI K, 1993, NATURE, V361, P549, DOI 10.1038/361549a0; HAMMON DTG, 1993, CYTOMETRY, V14, P411; HAMMOND TG, 1993, BIOCHEM J, V295, P471, DOI 10.1042/bj2950471; HARRIS HW, 1990, AM J PHYSIOL, V259, pF366, DOI 10.1152/ajprenal.1990.259.2.F366; HARRIS HW, 1991, J CLIN INVEST, V88, P1, DOI 10.1172/JCI115263; HARRIS HW, 1990, AM J PHYSIOL, V258, pF237, DOI 10.1152/ajprenal.1990.258.2.F237; HARRIS HW, 1992, J BIOL CHEM, V267, P22115; HARRIS HW, 1987, J MEMBRANE BIOL, V96, P175, DOI 10.1007/BF01869243; HARRIS HW, 1988, J MEMBRANE BIOL, V103, P207, DOI 10.1007/BF01993980; HARRIS HW, 1991, AM J PHYSIOL, V261, pC143, DOI 10.1152/ajpcell.1991.261.1.C143; HARRIS HW, 1993, AM J PHYSIOL, V265, pC822; HASEGAWA H, 1993, AM J PHYSIOL, V264, pC237, DOI 10.1152/ajpcell.1993.264.1.C237; HUMBERT F, 1977, EXPERIENTIA, V33, P1364, DOI 10.1007/BF01920184; KNEPPER MA, 1993, AM J PHYSIOL, V265, pF214, DOI 10.1152/ajprenal.1993.265.2.F214; LANKFORD SP, 1991, AM J PHYSIOL, V261, pF554, DOI 10.1152/ajprenal.1991.261.3.F554; LENCER WI, 1990, J CELL BIOL, V111, P379, DOI 10.1083/jcb.111.2.379; LENCER WI, 1990, AM J PHYSIOL, V258, pC309, DOI 10.1152/ajpcell.1990.258.2.C309; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; MOON C, 1993, J BIOL CHEM, V268, P15772; MULLER J, 1984, AM J PHYSIOL, V247, pC90, DOI 10.1152/ajpcell.1984.247.1.C90; NADLER SP, 1990, AM J PHYSIOL, V258, pF266, DOI 10.1152/ajprenal.1990.258.2.F266; NEILSEN S, 1993, P NATL ACAD SCI USA, V90, P7275; NEILSEN S, 1993, J CELL BIOL, V120, P371; NEILSEN S, 1993, P NATL ACAD SCI USA, V90, P11663; NEILSEN S, 1993, AM J PHYSIOL, V265, pF225; PRESTON GM, 1992, SCIENCE, V256, P385, DOI 10.1126/science.256.5055.385; PRESTON GM, 1991, P NATL ACAD SCI USA, V88, P11110, DOI 10.1073/pnas.88.24.11110; SABOLIC I, 1992, J CELL BIOL, V119, P111, DOI 10.1083/jcb.119.1.111; SABOLIC I, 1992, AM JPHYSL, V263, pC1223; SHI LB, 1990, J GEN PHYSIOL, V95, P941, DOI 10.1085/jgp.95.5.941; SMITH BL, 1991, J BIOL CHEM, V266, P6407; STRANGE K, 1988, J MEMBRANE BIOL, V103, P17, DOI 10.1007/BF01871929; VERKMAN AS, 1988, NATURE, V333, P268, DOI 10.1038/333268a0; VERKMAN AS, 1989, J BIOL CHEM, V264, pC237; Wade J B, 1981, Ann N Y Acad Sci, V372, P106, DOI 10.1111/j.1749-6632.1981.tb15464.x; WANG YX, 1991, BIOCHEMISTRY-US, V30, P2888, DOI 10.1021/bi00225a023; ZEIDEL ML, 1992, AM J PHYSIOL, V263, pF62, DOI 10.1152/ajprenal.1992.263.1.F62; ZEIDEL ML, 1992, BIOCHEMISTRY-US, V31, P7436, DOI 10.1021/bi00148a002; ZHANG R, 1993, J CELL BIOL, V120, P13261	48	48	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					11993	12000						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163502				2022-12-25	WOS:A1994NG37700051
J	KOKENYESI, R; BERNFIELD, M				KOKENYESI, R; BERNFIELD, M			CORE PROTEIN-STRUCTURE AND SEQUENCE DETERMINE THE SITE AND PRESENCE OF HEPARAN-SULFATE AND CHONDROITIN SULFATE ON SYNDECAN-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY EPITHELIAL-CELLS; AMINO-ACID-SEQUENCES; SURFACE PROTEOGLYCAN; MEMBRANE PROTEOGLYCAN; GROWTH-FACTOR; RECEPTOR; CLONING; BETA; LOCALIZATION; EXPRESSION	Most proteoglycans bear either chondroitin sulfate or heparan sulfate chains linked to serine residues at Ser-Gly attachment sites on the core protein. However, only a fraction of proteins with Ser-Gly sites exhibit glycosaminoglycan chains. A variable proportion of these sites may be glycanated, and an unknown mechanism distinguishes whether these sites are for chondroitin sulfate or heparan sulfate. To evaluate the core protein features that determine whether and where chondroitin sulfate or heparan sulfate will be linked, we have studied mouse syndecan-1, a transmembrane proteoglycan that is invariably glycanated and can contain both chondroitin sulfate and heparan sulfate chains. The extracellular domain of the syndecan-1 core protein contains five Ser-Gly sites, three clustered near its N terminus and two adjacent to the transmembrane domain near its C terminus. We have established the distribution of glycosaminoglycans on these attachment clusters. In contrast to the C-terminal cluster, the N terminal cluster was always glycanated, suggesting that this domain of the core protein contains sequences responsible for the invariable attachment of glycosaminoglycan chains. Solely chondroitin sulfate was found on the C-terminal cluster. This cluster contains the sequences EGSGE and ETSGE, both estimated to be on the protein surface in a hydrophilic environment. Heparan sulfate was found solely on the N-terminal cluster, which also bears some chondroitin sulfate. This cluster contains the sequences FSGSGTG and DGSGD, the former estimated to be in a hydrophobic pocket and the latter, similar to the sequence on the C-terminal cluster, in an exposed hydrophilic region. This glycosaminoglycan distribution was identical on mouse syndecan-1 produced by either mouse epithelial (NMuMG) or hamster mesenchymal (CHO) cells, suggesting that site-specific attachment of glycosaminoglycans is independent of cell type. These results implicate a cellular mechanism that distinguishes among the potential sites and attaches the correct glycosaminoglycan type unambiguously. Thus, structural elements of the core protein other than the Ser-Gly attachment sites determine if a site will be glycanated and, if so, whether with chondroitin sulfate or heparan sulfate.	HARVARD UNIV, CHILDRENS HOSP, SCH MED, JOINT PROGRAM NEONATOL, BOSTON, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard Medical School					NCI NIH HHS [CA28735] Funding Source: Medline; NICHD NIH HHS [HD06763] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD006763, R37HD006763] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA028735] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ACHESON A, 1988, J CELL BIOL, V106, P479, DOI 10.1083/jcb.106.2.479; ANDRES JL, 1989, J CELL BIOL, V109, P3137, DOI 10.1083/jcb.109.6.3137; BERNFIELD M, 1991, ANN NY ACAD SCI, V638, P182, DOI 10.1111/j.1749-6632.1991.tb49029.x; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BROWN TA, 1991, J CELL BIOL, V113, P207, DOI 10.1083/jcb.113.1.207; CIZMECISMITH G, 1992, J BIOL CHEM, V267, P15729; COUCHMAN JR, 1985, J BIOL CHEM, V260, P3755; DAVID G, 1979, P NATL ACAD SCI USA, V76, P786, DOI 10.1073/pnas.76.2.786; ELENIUS K, 1992, J BIOL CHEM, V267, P6435; EMINI EA, 1985, J VIROL, V55, P836, DOI 10.1128/JVI.55.3.836-839.1985; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; Engvall E, 1980, Methods Enzymol, V70, P419; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HINKES MT, 1993, J BIOL CHEM, V268, P11440; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; HUGHES WL, 1957, ANN NY ACAD SCI, V70, P3, DOI 10.1111/j.1749-6632.1957.tb35373.x; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; INKI P, 1992, LAB INVEST, V67, P225; JALKANEN M, 1985, J CELL BIOL, V101, P976, DOI 10.1083/jcb.101.3.976; KIEFER MC, 1990, P NATL ACAD SCI USA, V87, P6985, DOI 10.1073/pnas.87.18.6985; KIRJAVAINEN J, 1993, MOL BIOL CELL, V4, P849, DOI 10.1091/mbc.4.8.849; KOBATA A, 1992, CELL SURFACE CARBOHY, P1; KODA JE, 1985, J BIOL CHEM, V260, P8157; KRUEGER RC, 1990, J BIOL CHEM, V265, P12075; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; LEPPA S, 1991, CELL REGUL, V2, P1; LUGEMWA FN, 1991, J BIOL CHEM, V266, P6674; NAUJOKAS MF, 1993, CELL, V74, P257, DOI 10.1016/0092-8674(93)90417-O; RAPRAEGER A, 1985, J BIOL CHEM, V260, P1046; RAPRAEGER A, 1985, J BIOL CHEM, V260, P4103; SALMIVIRTA M, 1991, J BIOL CHEM, V266, P7733; Sambrook J, 1989, MOL CLONING LABORATO; SANDERSON RD, 1992, J INVEST DERMATOL, V99, P390, DOI 10.1111/1523-1747.ep12616103; SANDERSON RD, 1988, P NATL ACAD SCI USA, V85, P9562, DOI 10.1073/pnas.85.24.9562; SANT AJ, 1985, J EXP MED, V162, P1916, DOI 10.1084/jem.162.6.1916; SAUNDERS S, 1988, J CELL BIOL, V106, P423, DOI 10.1083/jcb.106.2.423; SAUNDERS S, 1989, J CELL BIOL, V108, P1547, DOI 10.1083/jcb.108.4.1547; SPRING J, 1994, P NATL ACAD SCI USA, V91, P3334, DOI 10.1073/pnas.91.8.3334; STALLCUP WB, 1983, COLD SPRING HARB SYM, V48, P761, DOI 10.1101/SQB.1983.048.01.078; STAMENKOVIC I, 1989, CELL, V56, P1057, DOI 10.1016/0092-8674(89)90638-7; SUN XJ, 1989, J BIOL CHEM, V264, P11288; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TZARTOS SJ, 1988, P NATL ACAD SCI USA, V85, P2899, DOI 10.1073/pnas.85.9.2899; WEITZHANDLER M, 1988, J BIOL CHEM, V263, P6949; WOODS A, 1992, ADV EXP MED BIOL, V313, P87	46	127	131	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					12304	12309						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163535				2022-12-25	WOS:A1994NG37700095
J	HIGMAN, MA; NILES, EG				HIGMAN, MA; NILES, EG			LOCATION OF THE S-ADENOSYL-L-METHIONINE BINDING REGION OF THE VACCINIA VIRUS MESSENGER-RNA (GUANINE-7-)METHYLTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA CAPPING ENZYME; MESSENGER-RNA; O-METHYLTRANSFERASE; ESCHERICHIA-COLI; DNA; PROTEIN; GUANYLYLTRANSFERASE; IDENTIFICATION; METHYLATION; VIRIONS	The mRNA (guanine-7-)methyltransferase activity of the heterodimeric vaccinia virus mRNA capping enzyme was previously mapped to the carboxyl terminal 396 amino acids of the large subunit, D1R. This activity is enhanced 30- to 50-fold by the association of the the small subunit, D12L (Higman, M. A., Christen, L. A., and Niles, E. G. (1994) J. Biol. Chem. 269, 14974-14981). Irradiation with ultraviolet light specifically photolinks S-[methyl-H-3]S-adenosyl-L-methionine to the large subunit of both the intact capping enzyme and a methyltransferase subdomain, which consists of the D12L subunit associated with the carboxyl-terminal 346 amino acids of the D1R subunit. The extent of linkage was shown to be dependent on the length of incubation, intensity of ultraviolet light, and the concentration of both active enzyme and substrate. The covalent modification was inhibited by S-adenosyl-L-homocysteine, a known competitive inhibitor of the mRNA (guanine-7-)methyltransferase activity, demonstrating specific photolabeling of the active site. Sequence-specific chemical cleavage of the photolinked methyltransferase domain with mild acid or cyanogen bromide revealed linkage of S-adenosyl-L-methionine to two regions of the large subunit. Analysis of the products of cyanogen bromide and hydroxylamine cleavage mapped the photolinked fragments to amino acids 499 to 579 and 806 to 844 of the D1R subunit. Photolinkage of AdoMet to D1R(498-844) was shown to be unaffected by the association of the small subunit.	SUNY BUFFALO, SCH MED & BIOMED SCI, DEPT BIOCHEM, BUFFALO, NY 14214 USA; SUNY BUFFALO, SCH MED & BIOMED SCI, CTR ADV MOLEC BIOL & IMMUNOL, BUFFALO, NY 14214 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028824] Funding Source: NIH RePORTER; NIAID NIH HHS [AI28824] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARBOSA E, 1978, J BIOL CHEM, V253, P7692; BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I; BJORK GR, 1987, ANNU REV BIOCHEM, V56, P263, DOI 10.1146/annurev.bi.56.070187.001403; Bornstein P, 1977, Methods Enzymol, V47, P132; CHENG XD, 1993, CELL, V74, P299, DOI 10.1016/0092-8674(93)90421-L; CONG PJ, 1993, J BIOL CHEM, V268, P7256; CONG PJ, 1992, J BIOL CHEM, V267, P16424; GREENLEN D, 1993, MOL MICROBIOL, V9, P145; Gros E., 1967, METHOD ENZYMOL, V11, P238; HALEY BE, 1991, METHOD ENZYMOL, V200, P477; HIGMAN MA, 1994, J BIOL CHEM, V269, P14974; HIGMAN MA, 1992, J BIOL CHEM, V267, P16430; HIGMAN MA, 1992, J BIOL CHEM, V269, P14930; INGROSSO D, 1989, J BIOL CHEM, V264, P20131; KOONIN EV, 1993, J GEN VIROL, V74, P733, DOI 10.1099/0022-1317-74-4-733; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Landon, 1977, Methods Enzymol, V47, P145; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; MARKHAM GD, 1980, J BIOL CHEM, V255, P9082; MARTIN SA, 1975, J BIOL CHEM, V250, P9330; MARTIN SA, 1976, J BIOL CHEM, V251, P7313; MARTIN SA, 1975, J BIOL CHEM, V250, P9322; MORGAN JR, 1984, J VIROL, V52, P283; NILES EG, 1993, J BIOL CHEM, V268, P24986; NILES EG, 1989, VIROLOGY, V172, P513, DOI 10.1016/0042-6822(89)90194-3; PAIK WK, 1989, BIOCHEM CELL BIOL, V67, P602; REICH NO, 1990, J BIOL CHEM, V265, P8929; ROTH JA, 1992, REV PHYSIOL BIOCH P, V120, P1, DOI 10.1007/BFb0036121; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHUMAN S, 1990, J BIOL CHEM, V265, P11967; SOM S, 1990, J BIOL CHEM, V265, P4278; SUBBARAMAIAH K, 1992, J BIOL CHEM, V267, P8636; SUMNER J, 1986, J BIOL CHEM, V261, P7697; SYED SK, 1993, BIOCHEMISTRY-US, V32, P2242, DOI 10.1021/bi00060a016; VENKATESAN S, 1980, J BIOL CHEM, V255, P903; WARD LD, 1990, CURRENT RES PROTEIN, P179; WRIGHT LS, 1993, J NEUROCHEM, V60, P1475, DOI 10.1111/j.1471-4159.1993.tb03310.x; YUAN R, 1981, ANNU REV BIOCHEM, V50, P285, DOI 10.1146/annurev.bi.50.070181.001441	38	23	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					14982	14987						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195133				2022-12-25	WOS:A1994NP73800024
J	SAVAS, U; BHATTACHARYYA, KK; CHRISTOU, M; ALEXANDER, DL; JEFCOATE, CR				SAVAS, U; BHATTACHARYYA, KK; CHRISTOU, M; ALEXANDER, DL; JEFCOATE, CR			MOUSE CYTOCHROME P-450EF, REPRESENTATIVE OF A NEW 1B SUBFAMILY OF CYTOCHROME P-450S - CLONING, SEQUENCE DETERMINATION AND TISSUE EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYCYCLIC AROMATIC-HYDROCARBONS; INDUCIBLE CYTOCHROME-P450; METABOLISM; P450; ENZYMES; CELLS; GENE; 2,3,7,8-TETRACHLORODIBENZO-PARA-DIOXIN; 7,12-DIMETHYLBENZ<A>ANTHRACENE; CARCINOGENESIS	A novel benz[a]anthracene and 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)-inducible cytochrome P-450 (P450EF), which is very active in polycyclic aromatic hydrocarbon metabolism, has been purified from C3H10T1/2 mouse embryo fibroblasts (Pottenger, L. H., Christou, M., and Jefcoate, C. R. (1991) Arch. Biochem. Biophys. 286, 488-497). P450EF was shown to be immunologically unrelated to the major known P-450 families. A 4.9-kilobase (kb) cDNA encoding P450EF has been isolated from a lambda ZAP cDNA expression library generated from mRNA of TCDD-induced C3H10T1/2 cells. This cDNA comprises 175-base pair (bp) 5'-noncoding, 1629-bp open reading, and about 3100-bp 3'-noncoding sequence. A SmaI fragment of the 4.9-kb cDNA hybridized to a 5.2-kb mRNA species equally induced by benz[a]anthracene (10 mu M) and TCDD (10 nM) in C3H10T1/2 cells, consistent with the involvement of the Ah receptor in this induction process. The deduced amino acid sequence (543 amino acids), the longest of any known cytochrome P-450, exhibits 41 and 38% identity to mouse CYP1A1 and CYP1A2, respectively, and less but substantial similarity (30-33% identity) to many members of the CYP2 family. There are five extended regions of greater than or equal to 50% identity to CYP1A1 as follows: (a) 51-118; (b) 199-222; (c) 326-343 (I-helix, O-2-binding threonine); (d) 357-430; and (e) 460-487 (heme-binding cysteine). These sequence relationships suggest that P450EF is a member of a new CYP1B subfamily (mouse CYP1B1). Hybridization of mRNA and immunoblot analyses of microsomes both demonstrated beta-naphthoflavone (beta-NF) inducibility of Cyp1b-1 expression in C3H mouse lung, liver, and uterus although at lower levels relative to Cyp1a-1. The mobility of the beta-NF-inducible immunoreactive liver protein was significantly higher than that of the CYP1B1 protein detected in mouse lung, uterus, and C3H10T1/2 cells, Compared with the beta-NF-induced uterus, polycyclic aromatic hydrocarbon-induced uterine fibroblasts exhibited 10-20-fold higher levels of CYP1B1, suggesting that stromal fibroblasts are a major source of the protein.	UNIV WISCONSIN,SCH MED,DEPT PHARMACOL,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison					NCI NIH HHS [CA16265] Funding Source: Medline; NIEHS NIH HHS [T32 ES07015] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA016265] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007015] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BERNHARDT R, 1983, BIOCHIM BIOPHYS ACTA, V745, P140, DOI 10.1016/0167-4838(83)90042-0; BIRNBOIM HC, 1983, METHOD ENZYMOL, V100, P243; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHRISTOU M, 1990, CARCINOGENESIS, V11, P1691, DOI 10.1093/carcin/11.10.1691; CHRISTOU M, 1993, CANCER RES, V53, P968; CHRISTOU M, 1989, ARCH BIOCHEM BIOPHYS, V270, P162, DOI 10.1016/0003-9861(89)90018-0; CHRISTOU M, IN PRESS CARCINOGENE; CONNEY AH, 1982, CANCER RES, V42, P4875; EDWARDS RJ, 1989, BIOCHEMISTRY-US, V28, P3762, DOI 10.1021/bi00435a021; FEINBERG AP, 1983, ANAL BIOCHEM, V12, P6; GUENGERICH FP, 1992, FASEB J, V6, P745, DOI 10.1096/fasebj.6.2.1537465; HENIKOFF S, 1987, METHOD ENZYMOL, V28, P357; JAISWAL AK, 1985, SCIENCE, V228, P80, DOI 10.1126/science.3838385; JEFCOATE CR, 1992, FRONTIERS BIOTRANSFO, V6, P33; KOZAK M, 1983, MICROBIOL REV, V47, P1; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; NEBERT DW, 1987, ANNU REV BIOCHEM, V56, P945, DOI 10.1146/annurev.biochem.56.1.945; NELSON DR, 1993, DNA CELL BIOL, V12, P1, DOI 10.1089/dna.1993.12.1; NELSON DR, 1988, J BIOL CHEM, V263, P6038; OTTO S, 1992, ENDOCRINOLOGY, V131, P3067, DOI 10.1210/en.131.6.3067; OTTO S, 1991, ENDOCRINOLOGY, V129, P970, DOI 10.1210/endo-129-2-970; PELKONEN O, 1982, PHARMACOL REV, V34, P189; PORTER TD, 1991, J BIOL CHEM, V266, P13469; POTTENGER LH, 1990, CARCINOGENESIS, V11, P321, DOI 10.1093/carcin/11.2.321; POTTENGER LH, 1991, ARCH BIOCHEM BIOPHYS, V286, P488, DOI 10.1016/0003-9861(91)90070-Y; POULOS TL, 1992, FASEB J, V6, P674, DOI 10.1096/fasebj.6.2.1537455; POULOS TL, 1985, J BIOL CHEM, V260, P6122; PYERIN W, 1986, BIOCHEM BIOPH RES CO, V134, P461, DOI 10.1016/S0006-291X(86)80443-0; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAVAS U, 1993, CARCINOGENESIS, V14, P2013, DOI 10.1093/carcin/14.10.2013; SHEN ZY, 1993, P NATL ACAD SCI USA, V90, P11483, DOI 10.1073/pnas.90.24.11483; SHIMIZU T, 1991, J BIOL CHEM, V266, P3372; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; SUTTER TR, 1991, SCIENCE, V254, P415, DOI 10.1126/science.1925598; WAXMAN DJ, 1988, BIOCHEM PHARMACOL, V37, P71, DOI 10.1016/0006-2952(88)90756-3; WHITLOCK JP, 1987, PHARMACOL REV, V39, P147; WILSON NM, 1984, CARCINOGENESIS, V5, P1475, DOI 10.1093/carcin/5.11.1475	40	208	216	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					14905	14911						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195121				2022-12-25	WOS:A1994NP73800012
J	TIAN, WN; PIGNATARE, JN; STANTON, RC				TIAN, WN; PIGNATARE, JN; STANTON, RC			SIGNAL-TRANSDUCTION PROTEINS THAT ASSOCIATE WITH THE PLATELET-DERIVED GROWTH-FACTOR (PDGF) RECEPTOR MEDIATE THE (PDGF)-INDUCED RELEASE OF GLUCOSE-6-PHOSPHATE-DEHYDROGENASE FROM PERMEABILIZED CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEA-URCHIN EGGS; RAT HEPATOCYTES; TYROSINE PHOSPHORYLATION; ENZYME; BINDING; INVIVO; ADULT; GAP	Permeabilized rat kidney cells rapidly released glucose 6-phosphate dehydrogenase (G6PD) following stimulation with peptide growth factors (Stanton, R. C., Seifter, J. L., Boxer, D. C., Zimmerman, E., and Cantley, L. C. (1991) J. Biol. Chem. 266, 12442-12448). To evaluate the signal transduction pathways mediating release of G6PD, two cell Lines transfected with wild type or mutant platelet-derived growth factor (PDGF) receptors (PDGFR) were studied using two permeabilization protocols. G6PD release was evaluated by enzyme activity and Western blot analysis. PDGF caused a significant increase in G6PD release in 1 min in cells transfected with wild type PDGFR. PDGF did not stimulate G6PD release in cells transfected with tyrosine kinase-deficient PDGFR. PDGF did not stimulate G6PD release in cells transfected with partially autophosphorylation-deficient PDGFR in which four known signaling proteins do not associate with the PDGFR The PDGF-stimulated release of G6PD was partially restored in PDGFR mutants in which either phosphatidylinositol-3-kinase or phospholipase C gamma 1 could associate with the PDGFR Lastly, there was no basal or PDGF-stimulated phosphorylation of G6PD. We conclude that release of G6PD: 1) requires intrinsic PDGFR tyrosine kinase activity; 2) requires PDGFR autophosphorylation; 3) is mediated by signaling proteins that associate with the PDGFR; 4) is not mediated by direct phosphorylation of G6PD.	NEW ENGLAND DEACONESS HOSP,JOSLIN DIABET CTR,DIV RENAL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School								ARORA KK, 1993, J BIOL CHEM, V268, P18259; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CONRICODE KM, 1990, J BIOL CHEM, V265, P20931; FARQUHAR JK, 1968, P SOC EXP BIOL MED, V129, P809; HARRISON ML, 1991, J BIOL CHEM, V266, P4106; HORECKER BL, 1965, J CHEM EDUC, V42, P244, DOI 10.1021/ed042p244; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LOW PS, 1987, J BIOL CHEM, V262, P4592; NAPIER MA, 1987, ARCH BIOCHEM BIOPHYS, V259, P296, DOI 10.1016/0003-9861(87)90496-6; REED BY, 1987, J BIOL CHEM, V262, P8712; SCHAFFER WT, 1985, AM J PHYSIOL, V248, pE719, DOI 10.1152/ajpendo.1985.248.6.E719; SOCHOR M, 1986, BIOCHEM J, V234, P573, DOI 10.1042/bj2340573; STANTON RC, 1988, AM J PHYSIOL, V254, pC267, DOI 10.1152/ajpcell.1988.254.2.C267; STANTON RC, 1991, J BIOL CHEM, V266, P12442; SWEZEY RR, 1986, J CELL BIOL, V103, P1509, DOI 10.1083/jcb.103.4.1509; SWEZEY RR, 1988, P NATL ACAD SCI USA, V85, P812, DOI 10.1073/pnas.85.3.812; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; WEBER G, 1987, MOD LIVER CELL EXP, V43, P303; Wilson J E, 1980, Curr Top Cell Regul, V16, P1; WOOD T, 1985, PENTOSE PHOSPHATE PA, P1; YOSHIMOTO K, 1983, J BIOL CHEM, V258, P2355	25	77	80	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14798	14805						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	8182086				2022-12-25	WOS:A1994NM06500076
J	CHEN, XS; KURRE, U; JENKINS, NA; COPELAND, NG; FUNK, CD				CHEN, XS; KURRE, U; JENKINS, NA; COPELAND, NG; FUNK, CD			CDNA CLONING, EXPRESSION, MUTAGENESIS OF C-TERMINAL ISOLEUCINE, GENOMIC STRUCTURE, AND CHROMOSOMAL LOCALIZATIONS OF MURINE 12-LIPOXYGENASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SPECIFIC 15-LIPOXYGENASE; AMINO-ACID SEQUENCE; ARACHIDONATE 12-LIPOXYGENASE; MOLECULAR-CLONING; POLYMORPHONUCLEAR LEUKOCYTES; HUMAN 5-LIPOXYGENASE; PORCINE LEUKOCYTES; MESSENGER-RNA; LIPOXYGENASE; PLATELETS	Two types of 12-lipoxygenase that catalyze the transformation of arachidonic acid to 12(S)-hydroperoxyeicosatetraenoic acid (12-HPETE) have been previously classified into platelet-type and leukocyte-type categories. Here, we document, for the first time, a molecular characterization of both forms within the same species. The amino acid sequence of the murine platelet 12-lipoxygenase deduced from its cDNA is 58% identical to the murine spleen/leukocyte 12-lipoxygenase. Expression constructs carrying the cDNAs for the two 12-lipoxygenase forms were introduced into human embryonic kidney 293 cells. The platelet-type enzyme metabolized arachidonic acid exclusively to 12-HPETE, whereas the leukocyte-type enzyme formed both 12-HPETE and 15-hydro(pero)xyeicosatetraenoic acid in a ratio of approximate to 3:1. Linoleic acid was metabolized to a similar extent by the latter enzyme to 13-hydro(pero)xyoctadecadienoic acid but not by the platelet enzyme. Mutagenesis and deletion of the highly conserved lipoxygenase C-terminal isoleucine (Ile(663)), a residue believed to be involved in the non-heme iron atom coordination of all lipoxygenases, was performed. Deletion of Ile(663) and substitution with most amino acids abolished enzyme activity. Only a valine substitution retained significant activity. These findings would tend to indicate a stringent requirement for the proper spatial alignment and folding of the C-terminal chain back into the core of the enzyme to interact with the iron atom by analogy with the recently determined crystal structure of a soybean lipoxygenase (Boyington, J. C., Gaffney, B. J., and Amzel, L. M. (1993) Science 260, 1482-1486). The platelet-type and leukocyte-type 12-lipoxygenase genes were cloned from a murine 129 Sv genomic library. Both genes are divided into a similar 14-exon/13-intron format, with the platelet-type gene being approximately twice the size of the leukocyte-type gene (13 versus 7.5 kilobases). A segment of a third gene was also isolated and probably represents a pseudogene derivative of either of these 12-lipoxygenase genes. All three genes were mapped to the central region of mouse chromosome 11 in a region of homology with human chromosome 17. Antibodies prepared against the two forms of 12-lipoxygenase revealed the differential distribution of the two enzymes throughout the mouse.	VANDERBILT UNIV,DEPT PHARMACOL,NASHVILLE,TN 37232; NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,MAMMALIAN GENET LAB,FREDERICK,MD 21702	Vanderbilt University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick			Funk, Colin D/A-9518-2010	Funk, Colin/0000-0001-7029-4233	NCI NIH HHS [NCI N01-CO-74101] Funding Source: Medline; NHLBI NIH HHS [HL02710, HL46017] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046017] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ARAKAWA T, 1992, J BIOL CHEM, V267, P12188; BALCAREK JM, 1988, J BIOL CHEM, V263, P13937; BELLQUILLEY CP, 1993, J PHARMACOL EXP THER, V267, P676; BOYINGTON JC, 1993, SCIENCE, V260, P1482, DOI 10.1126/science.8502991; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCHBERG AM, 1989, GENETICS, V122, P153; CHANG WC, 1993, J BIOL CHEM, V268, P18734; CHEN XS, 1993, FASEB J, V7, P694, DOI 10.1096/fasebj.7.8.8500694; CHEN XS, 1993, EUR J BIOCHEM, V214, P845, DOI 10.1111/j.1432-1033.1993.tb17988.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOPRA H, 1991, INT J CANCER, V49, P774, DOI 10.1002/ijc.2910490524; COPELAND NG, 1991, TRENDS GENET, V7, P113, DOI 10.1016/0168-9525(91)90455-Y; DEMARZO N, 1992, AM J PHYSIOL, V262, pL198; FLEMING J, 1989, GENE, V79, P181, DOI 10.1016/0378-1119(89)90103-0; FUNK CD, 1992, P NATL ACAD SCI USA, V89, P3962, DOI 10.1073/pnas.89.9.3962; FUNK CD, 1989, P NATL ACAD SCI USA, V86, P2587, DOI 10.1073/pnas.86.8.2587; FUNK CD, 1991, J BIOL CHEM, V266, P12508; FUNK CD, 1990, P NATL ACAD SCI USA, V87, P5638, DOI 10.1073/pnas.87.15.5638; FUNK CD, 1993, PROG NUCLEIC ACID RE, V45, P67, DOI 10.1016/S0079-6603(08)60867-3; FUNK CD, 1991, PROSTAGLANDINS LEUKO, P97; GORMAN CM, 1990, DNA PROTEIN ENG TECH, V2, P3; Green EL, 1981, GENETICS PROBABILITY, P77; HAMBERG M, 1974, P NATL ACAD SCI USA, V71, P3400, DOI 10.1073/pnas.71.9.3400; HILL RJ, 1988, J LAB CLIN MED, V111, P73; HONN KV, 1989, FASEB J, V3, P2285, DOI 10.1096/fasebj.3.11.2673900; HUSSAIN H, 1994, AM J PHYSIOL, V266, pC243, DOI 10.1152/ajpcell.1994.266.1.C243; IZUMI T, 1991, EUR J BIOCHEM, V202, P1231, DOI 10.1111/j.1432-1033.1991.tb16495.x; JENKINS NA, 1982, J VIROL, V43, P26, DOI 10.1128/JVI.43.1.26-36.1982; MARGALIT A, 1993, P NATL ACAD SCI USA, V90, P2589, DOI 10.1073/pnas.90.7.2589; MATSUDA S, 1993, BIOCHIM BIOPHYS ACTA, V1180, P243, DOI 10.1016/0925-4439(93)90045-3; MATSUMOTO T, 1988, P NATL ACAD SCI USA, V85, P26, DOI 10.1073/pnas.85.1.26; MINOR W, 1993, BIOCHEMISTRY-US, V32, P6320, DOI 10.1021/bi00076a003; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NADEL JA, 1991, J CLIN INVEST, V87, P1139, DOI 10.1172/JCI115110; NISHIYAMA M, 1993, J HISTOCHEM CYTOCHEM, V41, P111, DOI 10.1177/41.1.8417106; NISHIYAMA M, 1992, J NEUROCHEM, V58, P1395, DOI 10.1111/j.1471-4159.1992.tb11355.x; NUGTEREN DH, 1975, BIOCHIM BIOPHYS ACTA, V380, P299, DOI 10.1016/0005-2760(75)90016-8; OKUMA M, 1977, NEW ENGL J MED, V297, P1351; OPREY J, 1989, GENE, V84, P493, DOI 10.1016/0378-1119(89)90526-X; PEMBER SO, 1983, BLOOD, V61, P1105; Sambrook J, 1989, MOL CLONING LABORATO; SHANNON VR, 1993, AM J PHYSIOL, V264, pG104, DOI 10.1152/ajpgi.1993.264.1.G104; SHEPPARD KA, 1992, BIOCHIM BIOPHYS ACTA, V1133, P223, DOI 10.1016/0167-4889(92)90073-K; SHIBATA D, 1987, J BIOL CHEM, V262, P10080; SIGAL E, 1988, BIOCHEM BIOPH RES CO, V157, P457, DOI 10.1016/S0006-291X(88)80271-7; SINZINGER H, 1991, AM J HEMATOL, V36, P202, DOI 10.1002/ajh.2830360308; SLOANE DL, 1991, NATURE, V354, P149, DOI 10.1038/354149a0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TAKAHASHI Y, 1993, J BIOL CHEM, V268, P16443; TAKAHASHI Y, 1988, ARCH BIOCHEM BIOPHYS, V266, P613, DOI 10.1016/0003-9861(88)90294-9; UEDA N, 1990, J BIOL CHEM, V265, P2311; WALL NA, 1992, MECH DEVELOP, V37, P111, DOI 10.1016/0925-4773(92)90073-S; WALSTRA P, 1987, BIOCHIM BIOPHYS ACTA, V921, P312, DOI 10.1016/0005-2760(87)90032-4; WATANABE T, 1993, EUR J BIOCHEM, V212, P605, DOI 10.1111/j.1432-1033.1993.tb17699.x; WATANABE T, 1993, BIOCHEM BIOPH RES CO, V192, P1023, DOI 10.1006/bbrc.1993.1519; YAMAMOTO S, 1992, BIOCHIM BIOPHYS ACTA, V1128, P117, DOI 10.1016/0005-2760(92)90297-9; YOKOYAMA C, 1986, J BIOL CHEM, V261, P6714; YOSHIMOTO T, 1990, P NATL ACAD SCI USA, V87, P2142, DOI 10.1073/pnas.87.6.2142; YOSHIMOTO T, 1992, J BIOL CHEM, V267, P24805	60	188	192	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					13979	13987						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188678				2022-12-25	WOS:A1994NL60600041
J	KASLIN, E; HEYER, WD				KASLIN, E; HEYER, WD			SCHIZOSACCHAROMYCES-POMBE FATTY-ACID SYNTHASE MEDIATES DNA STRAND EXCHANGE IN-VITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; RECA PROTEIN; HOMOLOGOUS RECOMBINATION; STIMULATORY FACTOR; SEQUENCE-ANALYSIS; RENATURATION; GENE; PURIFICATION; MECHANISM; BINDING	During purification of a strand exchange activity from Schizosaccharomyces pombe using the three-strand reaction of double-stranded linear and circular single-stranded DNA, we identified p190/210 as an activity that stimulated the strand exchange activity of p140(exo2) by about 10-fold. The accompanying report (Kaslin, E., and Heyer, W.-D. (1994) J. Biol. Chem. 269, 0000-0000) described the purification and characterization of p140(exo2), likely to be the S. pombe homolog of the Saccharomyces cerevisiae strand exchange protein p175(SEP1). Here, we report the purification of p190/210 from S. pombe cells and its identification as fatty acid synthase (FAS). S. pombe FAS (p190/210) binds to single-stranded and double-stranded DNA, leading to condensation of DNA into large aggregates. In addition, it is capable of renaturing complementary single-stranded DNA. Besides stimulating the strand exchange activity of p140(exo2), FAS (p190/210) itself exhibits strand exchange activity provided the double-stranded substrate has single-stranded tails. We propose a probable mechanism for the action of FAS (p190/210) during DNA strand exchange in vitro. Since FAS (p190/210) is highly unlikely to have a role in homologous recombination in vivo, we discuss the implications of our data on the interpretation of other homologous pairing and strand exchange proteins purified from eukaryotes using this or similar assays.	UNIV BERN, INST GEN MICROBIOL, CH-3012 BERN, SWITZERLAND	University of Bern								ALBERTS BM, 1970, NATURE, V227, P1313, DOI 10.1038/2271313a0; BAHLER J, 1993, IN PRESS CHROMOSOMA; BEDALE WA, 1993, J BIOL CHEM, V268, P15004; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLARK AB, 1991, MOL CELL BIOL, V11, P2576, DOI 10.1128/MCB.11.5.2576; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DYKSTRA CC, 1991, MOL CELL BIOL, V11, P2583, DOI 10.1128/MCB.11.5.2583; EGGLESTON AK, 1991, BIOCHIMIE, V73, P163, DOI 10.1016/0300-9084(91)90199-B; GRIFFITH JD, 1988, CRC CR REV BIOCH MOL, V23, pS43, DOI 10.3109/10409238809083375; HALBROOK J, 1989, J BIOL CHEM, V264, P21403; HAMATAKE RK, 1989, J BIOL CHEM, V264, P13336; HEYER WD, 1988, J BIOL CHEM, V263, P15189; HEYER WD, 1989, BIOCHEMISTRY-US, V28, P2856, DOI 10.1021/bi00433a017; JOHNSON AW, 1991, J BIOL CHEM, V266, P14046; KASLIN E, 1994, J BIOL CHEM, V269, P14094; KAWASAKI I, 1990, P NATL ACAD SCI USA, V87, P1628, DOI 10.1073/pnas.87.4.1628; KAWASAKI I, 1989, P NATL ACAD SCI USA, V86, P5281, DOI 10.1073/pnas.86.14.5281; KIM JM, 1990, GENETICS, V126, P799; KOHNE DE, 1977, BIOCHEMISTRY-US, V16, P5329, DOI 10.1021/bi00643a026; KOLODNER R, 1987, P NATL ACAD SCI USA, V84, P5560, DOI 10.1073/pnas.84.16.5560; KONFORTI BB, 1992, J MOL BIOL, V227, P38, DOI 10.1016/0022-2836(92)90680-I; KOTTIG H, 1991, MOL GEN GENET, V226, P310, DOI 10.1007/BF00273618; KOWALCZYKOWSKI SC, 1991, ANNU REV BIOPHYS BIO, V20, P539, DOI 10.1146/annurev.bb.20.060191.002543; KRASNOW MA, 1982, J BIOL CHEM, V257, P2687; KUHN L, 1972, EUR J BIOCHEM, V24, P492, DOI 10.1111/j.1432-1033.1972.tb19711.x; KUMAR A, 1990, BIOCHEMISTRY-US, V29, P10717, DOI 10.1021/bi00500a001; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVERY PE, 1992, J BIOL CHEM, V267, P9315; LYNEN F, 1969, METHOD ENZYMOL, V14, P17; MANNING GS, 1978, Q REV BIOPHYS, V11, P179, DOI 10.1017/S0033583500002031; MOORE SP, 1990, J BIOL CHEM, V265, P11108; MUNIYAPPA K, 1984, P NATL ACAD SCI-BIOL, V81, P2757, DOI 10.1073/pnas.81.9.2757; NORRIS D, 1990, BIOCHEMISTRY-US, V29, P7911, DOI 10.1021/bi00486a019; NORRIS D, 1990, BIOCHEMISTRY-US, V29, P7903, DOI 10.1021/bi00486a018; PANYUTIN IG, 1993, J MOL BIOL, V230, P413, DOI 10.1006/jmbi.1993.1159; Petes T. D., 1991, MOL CELLULAR BIOL YE, P407; PONTIUS BW, 1992, J BIOL CHEM, V267, P13815; PONTIUS BW, 1990, P NATL ACAD SCI USA, V87, P8403, DOI 10.1073/pnas.87.21.8403; PONTIUS BW, 1991, P NATL ACAD SCI USA, V88, P8237, DOI 10.1073/pnas.88.18.8237; SANDER M, 1991, P NATL ACAD SCI USA, V88, P6780, DOI 10.1073/pnas.88.15.6780; SCHIEDNER G, 1990, EMBO J, V9, P2937, DOI 10.1002/j.1460-2075.1990.tb07485.x; SCHWEIZER E, 1978, MOL CELL BIOCHEM, V21, P95; SCHWEIZER M, 1986, MOL GEN GENET, V203, P479, DOI 10.1007/BF00422073; SIKORAV JL, 1991, J MOL BIOL, V222, P1085, DOI 10.1016/0022-2836(91)90595-W; SMITH GR, 1988, MICROBIOL REV, V52, P1; STOOPS JK, 1978, J BIOL CHEM, V253, P4464; SZANKASI P, 1992, BIOCHEMISTRY-US, V31, P6769, DOI 10.1021/bi00144a017; TISHKOFF DX, 1991, MOL CELL BIOL, V11, P2593, DOI 10.1128/MCB.11.5.2593; TSANG SS, 1985, BIOCHEMISTRY-US, V24, P3226, DOI 10.1021/bi00334a023; WEINSTOCK GM, 1979, P NATL ACAD SCI USA, V76, P126, DOI 10.1073/pnas.76.1.126; WEST SC, 1992, ANNU REV BIOCHEM, V61, P603, DOI 10.1146/annurev.bi.61.070192.003131; WIEDER R, 1981, BIOPOLYMERS, V20, P1537, DOI 10.1002/bip.1981.360200711; WIESNER P, 1988, EUR J BIOCHEM, V177, P69, DOI 10.1111/j.1432-1033.1988.tb14346.x	53	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					14103	14110						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188691				2022-12-25	WOS:A1994NL60600058
J	SHEN, GZ; VERMAAS, WFJ				SHEN, GZ; VERMAAS, WFJ			CHLOROPHYLL IN A SYNECHOCYSTIS SP PCC-6803 MUTANT WITHOUT PHOTOSYSTEM-I AND PHOTOSYSTEM-II CORE COMPLEXES - EVIDENCE FOR PERIPHERAL ANTENNA CHLOROPHYLLS IN CYANOBACTERIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-HARVESTING COMPLEX; ANACYSTIS-NIDULANS R2; A/B PROTEIN COMPLEX; SPECTROSCOPIC PROPERTIES; SP PCC-6803; POLYPEPTIDE; ORGANIZATION; PURIFICATION; MEMBRANES; SUBUNIT	The chlorophyll protein organization has been investigated in thylakoid membranes from mutants of the cyanobacterium Synechocystis sp. PCC 6803, in which the photosystem II (PS II) genes psbB and/or psbC (coding for CP47 and CP43, respectively) were inactivated together with the psaAB operon (coding for the photosystem I (PS I) core complex) and the apcE gene (coding for the phycobilisome anchor protein). Lack of the CP43 protein led to a significant decrease of the D1, D2, and CP47 proteins and a decrease in the 77 K fluorescence emission peak at 685 nm. In the absence of the CP47 protein, no PS II reaction center assembly was detected and the 77 K fluorescence emission peak at 695 nm was lost. The psbB(-)/psbC(-)/PS I-less/apcE(-) mutant had no assembly of the D1, D2, CP47, and CP43 proteins, had lost the 77 K fluorescence emission peaks at 685 and 695 nm, but retained about 15% of the chlorophyll present in the PS I-less/apcE(-) background strain. A broad 77 K fluorescence emission band with a maximum at 678 nm was displayed in the PS II-less, PS I-less mutant upon excitation of the remaining chlorophyll. A 678 nm shoulder was observed in the 77 K fluorescence emission spectrum of thylakoids from the psbB(-)/PS I-less/apcE(-) mutant, which still contains CP43 but no PS LI reaction center. This shoulder was absent in thylakoids from the psbC(-)/PS I-less/apcE(-) mutant, which contain some PS II reaction center complexes. These results are consistent with the chlorophyll associated with the 678 nm emission to serve as peripheral antenna to PS II. The fluorescence emission characteristics of this chlorophyll are different from those of an accessory chlorophyll-binding protein expressed under iron-stress conditions in cyanobacteria. The chlorophyll remaining in the absence of PS II and PS I is indicative of a new chlorophyll binding protein in cyanobacterial thylakoids.	ARIZONA STATE UNIV,DEPT BOT,TEMPE,AZ 85287; ARIZONA STATE UNIV,CTR STUDY EARLY EVENTS PHOTOSYNTHESIS,TEMPE,AZ 85287	Arizona State University; Arizona State University-Tempe; Arizona State University; Arizona State University-Tempe								AKABORI K, 1988, BIOCHIM BIOPHYS ACTA, V932, P345, DOI 10.1016/0005-2728(88)90170-3; ANDERSON JM, 1986, ENCY PLANT PHYSL, V19, P269; BARBATO R, 1991, FEBS LETT, V286, P86, DOI 10.1016/0014-5793(91)80947-2; BASSI R, 1987, J BIOL CHEM, V262, P13333; BASSI R, 1987, EUR J BIOCHEM, V163, P221, DOI 10.1111/j.1432-1033.1987.tb10791.x; BERTHOLD DA, 1981, FEBS LETT, V134, P231, DOI 10.1016/0014-5793(81)80608-4; BOERNER RJ, 1993, J BIOL CHEM, V268, P1817; BRYANT DA, 1992, PHOTOSYSTEMS STRUCTU, P501; Bryant DA, 1991, PHOTOSYNTHETIC APP B, V7, P257; BULLERJAHN GS, 1985, BIOCHIM BIOPHYS ACTA, V810, P148, DOI 10.1016/0005-2728(85)90130-6; BURNAP RL, 1993, PLANT PHYSIOL, V103, P893, DOI 10.1104/pp.103.3.893; DEVITRY C, 1984, BIOCHIM BIOPHYS ACTA, V767, P415, DOI 10.1016/0005-2728(84)90039-2; EATONRYE JJ, 1991, PLANT MOL BIOL, V17, P1165, DOI 10.1007/BF00028733; FUJITA Y, 1988, PLANT CELL PHYSL, V29, P305; GOLBECK JH, 1988, FEBS LETT, V228, P268, DOI 10.1016/0014-5793(88)80013-9; HAWORTH P, 1983, BIOCHIM BIOPHYS ACTA, V724, P151, DOI 10.1016/0005-2728(83)90036-1; HEMELRIJK PW, 1992, BIOCHIM BIOPHYS ACTA, V1098, P159, DOI 10.1016/S0005-2728(05)80331-7; HERRIN DL, 1987, ARCH BIOCHEM BIOPHYS, V254, P397, DOI 10.1016/0003-9861(87)90117-2; HUNDAL T, 1990, BIOCHIM BIOPHYS ACTA, V1017, P235, DOI 10.1016/0005-2728(90)90190-F; IKEUCHI M, 1992, BOT MAG TOKYO, V105, P327, DOI 10.1007/BF02489425; IKEUCHI M, 1992, RES PHOTOSYNTHESIS, V2, P175; KIM S, 1992, FEBS LETT, V314, P67, DOI 10.1016/0014-5793(92)81463-V; KUANG TY, 1984, ARCH BIOCHEM BIOPHYS, V235, P618, DOI 10.1016/0003-9861(84)90236-4; KWA SLS, 1992, BIOCHIM BIOPHYS ACTA, V1101, P143, DOI 10.1016/0005-2728(92)90198-B; LAM E, 1984, PLANT PHYSIOL, V74, P650, DOI 10.1104/pp.74.3.650; LAUDENBACH DE, 1988, J BACTERIOL, V170, P5018, DOI 10.1128/jb.170.11.5018-5026.1988; LICHTENTHALER HK, 1987, METHOD ENZYMOL, V148, P350; LJUNGBERG U, 1986, EUR J BIOCHEM, V158, P477, DOI 10.1111/j.1432-1033.1986.tb09779.x; LUNDELL DJ, 1985, J BIOL CHEM, V260, P646; MacKinney G, 1941, J BIOL CHEM, V140, P315; MONTOYA G, 1991, FEBS LETT, V283, P255, DOI 10.1016/0014-5793(91)80601-X; NAKATANI HY, 1984, BIOCHIM BIOPHYS ACTA, V765, P347, DOI 10.1016/0005-2728(84)90175-0; NAKAYAMA K, 1990, PLANT CELL PHYSIOL, V31, P253; NILSSON F, 1990, PLANT MOL BIOL, V14, P1051, DOI 10.1007/BF00019402; PAKRASI HB, 1985, P NATL ACAD SCI USA, V82, P6903, DOI 10.1073/pnas.82.20.6903; PAKRASI HB, 1992, PHOTOSYSTEMS STRUCTU, P231; RIETHMAN HC, 1988, BIOCHIM BIOPHYS ACTA, V935, P141, DOI 10.1016/0005-2728(88)90211-3; RIETHMAN HC, 1988, PLANT PHYSIOL, V88, P497, DOI 10.1104/pp.88.2.497; RIPPKA R, 1979, J GEN MICROBIOL, V111, P1, DOI 10.1099/00221287-111-1-1; ROGNER M, 1990, J BIOL CHEM, V265, P6189; SATOH K, 1979, PLANT CELL PHYSIOL, V20, P499; SATOH K, 1983, OXYGEN EVOLVING SYST, P27; SHEN GZ, 1993, PLANT CELL, V5, P1853, DOI 10.1105/tpc.5.12.1853; SHEN GZ, 1993, BIOCHEMISTRY-US, V32, P5109, DOI 10.1021/bi00070a019; TANG XS, 1984, PLANT CELL PHYSIOL, V25, P935; THORNBER JP, 1986, ENCY PLANT PHYSL, V19, P98; VANDORSSEN RJ, 1987, BIOCHIM BIOPHYS ACTA, V890, P134, DOI 10.1016/0005-2728(87)90014-4; VERMAAS W, 1990, BIOCHEMISTRY-US, V29, P5325, DOI 10.1021/bi00474a017; VERMAAS WFJ, 1988, PHOTOSYNTH RES, V17, P97, DOI 10.1007/BF00047683; VERMAAS WFJ, 1986, P NATL ACAD SCI USA, V83, P9474, DOI 10.1073/pnas.83.24.9474; VERMAAS WFJ, 1991, PHOTOSYNTHETIC APP B, V7, P25; WEDEL N, 1992, FEBS LETT, V314, P61, DOI 10.1016/0014-5793(92)81462-U; WITT HT, 1990, CURRENT RES PHOTOSYN, V2, P547; WOLLMAN FA, 1982, BIOCHIM BIOPHYS ACTA, V680, P352, DOI 10.1016/0005-2728(82)90149-9; YAMAGUCHI N, 1988, PLANT CELL PHYSIOL, V29, P123; YU JJ, 1990, PLANT CELL, V2, P315	56	53	59	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					13904	13910						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188669				2022-12-25	WOS:A1994NL60600031
J	CHENG, Q; CANT, CA; MOLL, T; HOFERWARBINEK, R; WAGNER, E; BIRNSTIEL, ML; BACH, FH; DEMARTIN, R				CHENG, Q; CANT, CA; MOLL, T; HOFERWARBINEK, R; WAGNER, E; BIRNSTIEL, ML; BACH, FH; DEMARTIN, R			NF-KAPPA-B SUBUNIT-SPECIFIC REGULATION OF THE I-KAPPA-B-ALPHA PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING SUBUNIT; ELAM-1 GENE-TRANSCRIPTION; REL ONCOGENE; PROTEIN; ACTIVATION; CLONING; INDUCTION; ENCODES; CELLS; P50	Stimulation of endothelial cells by cytokines and bacterial lipopolysaccharide leads to activation of the transcription factor NF-kappa B. NF-kappa B in turn regulates the expression of several genes involved in the inflammatory reaction, including cell adhesion molecules, interleukins, and transcription factors. One of these induced genes encodes an inhibitor of NF-kappa B, ECI-6/I kappa B alpha, that contains in its 5' regulatory region six consensus binding sites for NF-kappa B. We demonstrate here that these sites display striking differences in their ability in vitro to bind to various NF-kappa B subunits. In vivo, all six sites contribute, though to varying degrees, to transcription from the ECI-6/I kappa B alpha promoter, as demonstrated by deletion and mutation analysis. Among the NF-kappa B subunits tested p65, the p65/p50 heterodimer and, to a lesser extent, c-Rel, are able to activate transcription, whereas p50 or p50/RelB were inactive. Since many genes regulated by NF-kappa B contain only one or two DNA-binding sites for this transcription factor, the presence of six functional NF-kappa B-binding sites in the ECI-6/I kappa B alpha promoter represents a unique feature of this gene.	VIENNA INT RES COOP CTR,A-1235 VIENNA,AUSTRIA; INST MOLEC PATHOL,A-1030 VIENNA,AUSTRIA; HARVARD UNIV,NEW ENGLAND DEACONESS HOSP,SCH MED,SANDOZ CTR IMMUNOBIOL,BOSTON,MA 02215	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); Harvard University; Harvard Medical School; Novartis; Sandoz			Wagner, Ernst/ABB-5976-2020; Wagner, Ernst/A-7435-2012	Wagner, Ernst/0000-0001-8413-0934; Wagner, Ernst/0000-0001-8413-0934				AUSUBEL FM, 1990, CURRENT PROTOCOLS MO; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BALLARD DW, 1992, P NATL ACAD SCI USA, V89, P1875, DOI 10.1073/pnas.89.5.1875; BLANK V, 1992, TIBS TRENDS BIOCH SC, V17, P136; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; COGSWELL PC, 1993, J IMMUNOL, V150, P2794; CORDLE SR, 1993, J BIOL CHEM, V268, P11803; CROSS SL, 1989, SCIENCE, V244, P466, DOI 10.1126/science.2497520; CURIEL DT, 1991, P NATL ACAD SCI USA, V88, P8850, DOI 10.1073/pnas.88.19.8850; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; DEMARTIN R, 1993, GENE, V124, P137, DOI 10.1016/0378-1119(93)90776-Y; DEMARTIN R, 1993, EMBO J, V12, P2773, DOI 10.1002/j.1460-2075.1993.tb05938.x; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DIGNAM J, 1983, NUCLEIC ACIDS RES, V11, P1445; DIRICK L, 1992, NATURE, V357, P508, DOI 10.1038/357508a0; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GRIMM S, 1993, BIOCHEM J, V290, P297, DOI 10.1042/bj2900297; HANNINK M, 1990, ONCOGENE, V5, P1843; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; IADEMARCO MF, 1992, J BIOL CHEM, V267, P16323; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KUNSCH C, 1993, MOL CELL BIOL, V13, P6137, DOI 10.1128/MCB.13.10.6137; KUUNSCH C, 1993, MOL CELL BIOL, V12, P4412; LAYBOURN PJ, 1992, SCIENCE, V257, P1682, DOI 10.1126/science.1388287; LERNBECHER T, 1993, NATURE, V365, P767, DOI 10.1038/365767a0; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; MACKMAN N, 1991, J EXP MED, V174, P1517, DOI 10.1084/jem.174.6.1517; MERCURIO F, 1992, DNA CELL BIOL, V11, P523, DOI 10.1089/dna.1992.11.523; MEYER R, 1991, P NATL ACAD SCI USA, V88, P966, DOI 10.1073/pnas.88.3.966; MONTGOMERY KF, 1991, P NATL ACAD SCI USA, V88, P6523, DOI 10.1073/pnas.88.15.6523; MUKAIDA N, 1990, J BIOL CHEM, V265, P21128; MULLER JM, 1993, IMMUNOBIOLOGY, V187, P233; NEISH AS, 1992, J EXP MED, V176, P1583, DOI 10.1084/jem.176.6.1583; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; RUBEN SM, 1992, GENE DEV, V6, P745, DOI 10.1101/gad.6.5.745; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; SCOTT ML, 1993, GENE DEV, V7, P1266, DOI 10.1101/gad.7.7a.1266; SHU HB, 1993, MOL CELL BIOL, V13, P6283, DOI 10.1128/MCB.13.10.6283; SPARACIO SM, 1992, NEUROIMMUNOLOGY, V39, P231; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; TEN RM, 1992, EMBO J, V11, P195, DOI 10.1002/j.1460-2075.1992.tb05042.x; TEWARI M, 1992, MOL CELL BIOL, V12, P2898, DOI 10.1128/MCB.12.6.2898; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; WAGNER E, 1992, P NATL ACAD SCI USA, V89, P6099, DOI 10.1073/pnas.89.13.6099; WARREN JB, 1990, ENDOTHELIUM, P253; WHELAN J, 1991, NUCLEIC ACIDS RES, V19, P2645, DOI 10.1093/nar/19.10.2645; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P	57	110	111	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13551	13557						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175790				2022-12-25	WOS:A1994NK18400073
J	RUBINCHIK, S; PARRIS, W; GOLD, M				RUBINCHIK, S; PARRIS, W; GOLD, M			THE IN-VITRO ATPASES OF BACTERIOPHAGE-LAMBDA TERMINASE AND ITS LARGE SUBUNIT, GENE-PRODUCT-A - THE RELATIONSHIP WITH THEIR DNA HELICASE AND PACKAGING ACTIVITIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COHESIVE END SITE; ESCHERICHIA-COLI; INVITRO; PURIFICATION; SYSTEM; ATP; MECHANISM; LOCATION; ENZYME; GP16	The bacteriophage lambda terminase is composed of two subunits, gpNu1 and gpA. In vitro, the holoenzyme is a site specific endonuclease, helicase, ATPase, and can package lambda DNA into proheads. gpApossesses ATPase and helicase activities which are similar to those of the holoenzyme. Both terminase and gpA can hydrolyze a wide range of deoxyribo- and ribonucleoside triphosphates to inorganic phosphate and the corresponding diphosphate. Nucleoside diphosphates are not substrates for either protein. ATPase of both proteins is stimulated by double stranded DNA. The ATPase of gpA is protein concentration dependent, while that of terminase is not. Helicase activity of both proteins is not concentration-dependent, and requires a hydrolyzable triphosphate. ATP, dATP, and GTP supported helicase activity, while adenosine 5'-(beta,gamma>-methylene)triphosphate, adenosine 5'3- O-(thio)triphosphate, ADP, CTP, and UTP did not. The kinetic parameters of ATPase and helicase activities were similar for both proteins, but packaging with terminase was optimal only at a significantly higher level of ATP. Packaging was detectable at significant levels with CTP and UTP, but not with GTP. Packaging also differed from ATPase and helicase in the utilization of divalent metal cations and susceptibility to various inhibitors.	DEPT MOLEC & MED GENET,TORONTO M5S 1A8,ON,CANADA									BECKER A, 1977, VIROLOGY, V78, P291, DOI 10.1016/0042-6822(77)90100-3; BECKER A, 1988, J MOL BIOL, V199, P219, DOI 10.1016/0022-2836(88)90391-9; BECKER A, 1978, P NATL ACAD SCI USA, V75, P4199, DOI 10.1073/pnas.75.9.4199; BLACK LW, 1988, BACTERIOPHAGES, V2, P321; CASJENS S, 1985, VIRUS STRUCTURE ASSE, P76; EARNSHAW WC, 1980, CELL, V21, P319, DOI 10.1016/0092-8674(80)90468-7; FEISS M, 1983, GENE, V24, P207, DOI 10.1016/0378-1119(83)90081-1; FUJISAWA H, 1987, VIROLOGY, V161, P228, DOI 10.1016/0042-6822(87)90189-9; GOLD M, 1983, J BIOL CHEM, V258, P4619; GOODNO CC, 1979, P NATL ACAD SCI USA, V76, P2620, DOI 10.1073/pnas.76.6.2620; GUO PX, 1987, J MOL BIOL, V197, P229, DOI 10.1016/0022-2836(87)90121-5; GUO PX, 1986, P NATL ACAD SCI USA, V83, P3505, DOI 10.1073/pnas.83.10.3505; HAMADA K, 1986, VIROLOGY, V151, P110, DOI 10.1016/0042-6822(86)90108-X; HAMADA K, 1987, VIROLOGY, V159, P244, DOI 10.1016/0042-6822(87)90461-2; HIGGINS RR, 1988, CELL, V54, P765, DOI 10.1016/S0092-8674(88)91021-5; KORANGY F, 1993, BIOCHEMISTRY-US, V32, P4873, DOI 10.1021/bi00069a024; MATSON SW, 1990, ANNU REV BIOCHEM, V59, P289, DOI 10.1146/annurev.bi.59.070190.001445; MORITA M, 1993, VIROLOGY, V193, P748, DOI 10.1006/viro.1993.1183; MURIALDO H, 1987, NUCLEIC ACIDS RES, V15, P119, DOI 10.1093/nar/15.1.119; NOUMI T, 1987, FEBS LETT, V213, P381, DOI 10.1016/0014-5793(87)81526-0; PARRIS W, 1988, J BIOL CHEM, V263, P8413; PARRIS W, 1994, J BIOL CHEM, V269, P13564; PERUCCHETTI R, 1988, VIROLOGY, V165, P103, DOI 10.1016/0042-6822(88)90663-0; RAO VB, 1988, J MOL BIOL, V200, P475, DOI 10.1016/0022-2836(88)90537-2; ROMAN LJ, 1989, BIOCHEMISTRY-US, V28, P2873, DOI 10.1021/bi00433a019; RUBINCHIK S, 1994, J BIOL CHEM, V269, P13575; Sambrook J, 1989, MOL CLONING LABORATO; SEIFRIED SE, 1992, P NATL ACAD SCI USA, V89, P10454, DOI 10.1073/pnas.89.21.10454; SHPETNER HS, 1988, J CELL BIOL, V107, P1001, DOI 10.1083/jcb.107.3.1001; TURNQUIST S, 1992, P NATL ACAD SCI USA, V89, P10479, DOI 10.1073/pnas.89.21.10479; VONHIPPEL PH, 1989, J BIOL CHEM, V264, P675; YANG YC, 1993, THESIS U TORONTO	32	40	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13586	13593						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175794				2022-12-25	WOS:A1994NK18400077
J	ENDO, H; MATSUDA, C; KAGAWA, Y				ENDO, H; MATSUDA, C; KAGAWA, Y			EXCLUSION OF AN ALTERNATIVELY SPLICED EXON IN HUMAN ATP SYNTHASE GAMMA-SUBUNIT PRE-MESSENGER-RNA REQUIRES DE-NOVO PROTEIN-SYNTHESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRACT-BINDING-PROTEIN; EARLY MESSENGER-RNAS; SEXUAL-DIFFERENTIATION; GENE-EXPRESSION; SINGLE GENE; KINASE-C; CELLS; FACTOR-SF2; TRANSCRIPTION; DEHYDROGENASE	Tissue-specific isoforms of the mitochondrial ATP synthase gamma-subunit are generated by alternative splicing, and the heart/skeletal muscle specific transcript lacks exon 9 in a cassette fashion (Matsuda, C., Endo, H., Hirata, H., Morosawa, H., Nakanishi, M., and Kagawa, Y. (1993) FEBS Lett. 325, 281-284; and Matsuda, C., Endo, H., Ohta, S., and Kagawa, Y. (1993) J. Biol. Chem. 268, 24950-24958). Here, we show that the endogenous heart-type mRNA is cell-specifically induced by the extracellular pH value in the HT1080 (human fibrosarcoma) and KYM-1 (human rhabdomyosarcoma) cell lines. In these cells, a low extracellular pH value induced exclusion of exon 9, and this induction was inhibited by cycloheximide treatment. In contrast, a high extracellular pH value resulted in mRNA transcription of the liver type, including exon 9, and did not require de novo protein synthesis. These results suggest that alternative splicing in the gamma-subunit pre-mRNA is regulated by on-off switching of protein synthesis of a trans-acting factor involved in this exon-excluding step. The signal of low pH value was blocked by the protein kinase inhibitor H-7 or Calphostin C (protein kinase C inhibitor), indicating the involvement of protein kinase C in the alternative splicing. This is a good model system for studies on the induction mechanism of alternative splicing in cultured mammalian cells, in which intracellular factors play a pivotal role for the exon-excluding step in the tissue-specific alternative splicing mechanism.			ENDO, H (corresponding author), JICHI MED SCH,DEPT BIOCHEM,MINAMI KAWACHI,TOCHIGI 32904,JAPAN.							ALPERN RJ, 1985, J GEN PHYSIOL, V86, P613, DOI 10.1085/jgp.86.5.613; AMARA SG, 1982, NATURE, V298, P240, DOI 10.1038/298240a0; ARCARI P, 1984, NUCLEIC ACIDS RES, V12, P9179, DOI 10.1093/nar/12.23.9179; BENJAMIN IJ, 1992, J CLIN INVEST, V89, P1685, DOI 10.1172/JCI115768; BERK AJ, 1978, P NATL ACAD SCI USA, V75, P1274, DOI 10.1073/pnas.75.3.1274; BERK AJ, 1978, CELL, V14, P695, DOI 10.1016/0092-8674(78)90252-0; BOGGS RT, 1987, CELL, V50, P739, DOI 10.1016/0092-8674(87)90332-1; BREITBART RE, 1987, CELL, V49, P793, DOI 10.1016/0092-8674(87)90617-9; BURTIS KC, 1989, CELL, V56, P997, DOI 10.1016/0092-8674(89)90633-8; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; ENDO H, 1989, AM J HUM GENET, V44, P358; FU XD, 1993, NATURE, V365, P82, DOI 10.1038/365082a0; GE H, 1990, CELL, V62, P25, DOI 10.1016/0092-8674(90)90236-8; GUO W, 1991, GENE DEV, V5, P2096, DOI 10.1101/gad.5.11.2096; HELFMAN DM, 1986, MOL CELL BIOL, V6, P3582, DOI 10.1128/MCB.6.11.3582; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; KAISER S, 1991, J BIOL CHEM, V266, P9397; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; KRAINER AR, 1990, GENE DEV, V4, P1158, DOI 10.1101/gad.4.7.1158; KRAINER AR, 1990, CELL, V62, P35, DOI 10.1016/0092-8674(90)90237-9; MANIATIS T, 1991, SCIENCE, V251, P33, DOI 10.1126/science.1824726; Maniatis T., 1982, MOL CLONING; MATSUDA C, 1993, J BIOL CHEM, V268, P24950; MATSUDA C, 1993, FEBS LETT, V325, P281, DOI 10.1016/0014-5793(93)81089-I; MAYEDA A, 1992, CELL, V68, P365, DOI 10.1016/0092-8674(92)90477-T; MULLIGAN GJ, 1992, J BIOL CHEM, V267, P25480; PATTON JG, 1993, GENE DEV, V7, P393, DOI 10.1101/gad.7.3.393; PATTON JG, 1991, GENE DEV, V5, P1237, DOI 10.1101/gad.5.7.1237; PERIASAMY M, 1984, J BIOL CHEM, V259, P3595; ROESSER JR, 1993, J BIOL CHEM, V268, P8366; RUIZOPAZO N, 1987, J BIOL CHEM, V262, P4755; SANTONI MJ, 1989, EMBO J, V8, P385, DOI 10.1002/j.1460-2075.1989.tb03389.x; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; TAZI J, 1993, NATURE, V363, P283, DOI 10.1038/363283a0; VALCARCEL J, 1993, NATURE, V362, P171, DOI 10.1038/362171a0; WOPPMANN A, 1993, NUCLEIC ACIDS RES, V21, P2815, DOI 10.1093/nar/21.12.2815; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837; ZAHLER AM, 1993, SCIENCE, V260, P219, DOI 10.1126/science.8385799; ZAMORE PD, 1992, NATURE, V355, P609, DOI 10.1038/355609a0	39	20	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12488	12493						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175656				2022-12-25	WOS:A1994NH71600021
J	HART, SL; KNIGHT, AM; HARBOTTLE, RP; MISTRY, A; HUNGER, HD; CUTLER, DF; WILLIAMSON, R; COUTELLE, C				HART, SL; KNIGHT, AM; HARBOTTLE, RP; MISTRY, A; HUNGER, HD; CUTLER, DF; WILLIAMSON, R; COUTELLE, C			CELL-BINDING AND INTERNALIZATION BY FILAMENTOUS PHAGE DISPLAYING A CYCLIC ARG-GLY-ASP-CONTAINING PEPTIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								Ligands that bind mammalian cell surface integrins with high affinity can mediate cellular internalization. We show that particles of the bacteriophage fd that display the cyclic integrin-binding peptide sequence GGCRGDMFGC in a proportion of their major coat protein subunits bind to cells and are efficiently internalized. In the displayed peptide the conformation of the RGD motif is restricted within a hairpin loop formed by a disulfide bridge between the 2 cysteine residues. Cellular internalization of phage was demonstrated by confocal and non confocal immunofluorescence microscopy of tissue-cultured cells incubated with phage particles. The phage were contained in juxtanuclear vesicles in the same serial sections as transferrin receptor but were not colocalized with the cell surface marker alkaline phosphatase. Cell binding and internalization was in- hibited by preincubation of cells with the integrin-binding peptide GRGDSP, whereas the control peptide GRGESP had no inhibitory effect. These results indicate that cyclic integrin-binding peptides can be used to target and enter cells and that it should be possible to exploit such peptides for the introduction of DNA, drugs, or other macromolecules.	MAX DELBRUCK CTR MOLEC MED, D-13122 BERLIN, GERMANY; UNIV LONDON UNIV COLL, MRC, MOLEC CELL BIOL LAB, LONDON WC1E 6BT, ENGLAND	Helmholtz Association; Max Delbruck Center for Molecular Medicine; University of London; University College London	HART, SL (corresponding author), ST MARYS HOSP, SCH MED, DEPT BIOCHEM & MOLEC GENET, NORFOLK PL, LONDON W2 1PG, ENGLAND.		Hart, Stephen L/C-1615-2008	Hart, Stephen L/0000-0001-8254-376X; Harbottle, Richard/0000-0002-3332-8024; Cutler, Daniel/0000-0002-4288-7530				BERGELSON JM, 1992, SCIENCE, V255, P1718, DOI 10.1126/science.1553561; BLOBEL CP, 1992, NATURE, V356, P248, DOI 10.1038/356248a0; BRASAEMLE DL, 1988, BIOTECHNIQUES, V6, P418; CHOWDHURY NR, 1993, J BIOL CHEM, V268, P11265; CHUNG CT, 1988, NUCLEIC ACIDS RES, V16, P3580, DOI 10.1093/nar/16.8.3580; CLACKSON T, 1991, NATURE, V352, P624, DOI 10.1038/352624a0; CURIEL DT, 1992, AM J RESP CELL MOL, V6, P247, DOI 10.1165/ajrcmb/6.3.247; DEFER C, 1990, J VIROL, V64, P3661, DOI 10.1128/JVI.64.8.3661-3673.1990; GAO L, 1993, HUM GENE THER, V4, P17, DOI 10.1089/hum.1993.4.1-17; GOULD RJ, 1990, P SOC EXP BIOL MED, V195, P168, DOI 10.3181/00379727-195-43129B; GREBER UF, 1993, CELL, V75, P477, DOI 10.1016/0092-8674(93)90382-Z; GREENWOOD J, 1991, J MOL BIOL, V220, P821, DOI 10.1016/0022-2836(91)90354-9; HUMPHRIES MJ, 1990, J CELL SCI, V97, P585; HUNGER HD, 1990, ANAL BIOCHEM, V186, P159, DOI 10.1016/0003-2697(90)90590-6; ISBERG RR, 1991, SCIENCE, V252, P934, DOI 10.1126/science.1674624; ISBERG RR, 1990, CELL, V60, P861, DOI 10.1016/0092-8674(90)90099-Z; ISHHOROWICZ D, 1981, NUCLEIC ACIDS RES, V9, P2989, DOI 10.1093/nar/9.13.2989; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEONG JM, 1990, EMBO J, V9, P1979, DOI 10.1002/j.1460-2075.1990.tb08326.x; LOGAN D, 1993, NATURE, V362, P566, DOI 10.1038/362566a0; MCCAFFERTY J, 1990, NATURE, V348, P552, DOI 10.1038/348552a0; NHIEU GTV, 1991, J BIOL CHEM, V266, P24367; ONEIL KT, 1992, PROTEINS, V14, P509, DOI 10.1002/prot.340140411; PIERSCHBACHER MD, 1987, J BIOL CHEM, V262, P17294; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; RELMAN D, 1990, CELL, V61, P1375, DOI 10.1016/0092-8674(90)90701-F; ROWITCH DH, 1988, J MOL BIOL, V204, P663, DOI 10.1016/0022-2836(88)90363-4; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCARBOROUGH RM, 1993, J BIOL CHEM, V268, P1066; SCARBOROUGH RM, 1993, J BIOL CHEM, V268, P1058; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SMYTHE E, 1991, EUR J BIOCHEM, V202, P689, DOI 10.1111/j.1432-1033.1991.tb16424.x; VANNHIEU GT, 1993, EMBO J, V12, P1887, DOI 10.1002/j.1460-2075.1993.tb05837.x; WAGNER E, 1991, P NATL ACAD SCI USA, V88, P4255, DOI 10.1073/pnas.88.10.4255; WAGNER E, 1992, P NATL ACAD SCI USA, V89, P7934, DOI 10.1073/pnas.89.17.7934; WICKHAM TJ, 1993, CELL, V73, P309, DOI 10.1016/0092-8674(93)90231-E; WU GY, 1987, J BIOL CHEM, V262, P4429; WU GY, 1988, J BIOL CHEM, V263, P14621	39	145	180	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12468	12474						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175653				2022-12-25	WOS:A1994NH71600018
J	MAURUS, R; BOGUMIL, R; LUO, YG; TANG, HL; SMITH, M; MAUK, AG; BRAYER, GD				MAURUS, R; BOGUMIL, R; LUO, YG; TANG, HL; SMITH, M; MAUK, AG; BRAYER, GD			STRUCTURAL CHARACTERIZATION OF HEME LIGATION IN THE HIS(64)-]TYR VARIANT OF MYOGLOBIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; SPERM WHALE MYOGLOBIN; HORSE HEART METMYOGLOBIN; FERRIC HEME; 3-DIMENSIONAL STRUCTURE; DISTAL HISTIDINE; RESONANCE RAMAN; LIGAND-BINDING; HEMOGLOBINS-M; M BOSTON	A site specific mutant of horse heart myoglobin has been prepared in which the distal heme pocket residue, His(64), is replaced by tyrosine. The structure pf this myoglobin variant has been determined to 2.0-Angstrom resolution using x-ray diffraction techniques and refined to a final crystallographic R-factor of 16.9%. The polypeptide backbone conformation of the His(64) --> Tyr variant of myoglobin is very similar to that of the wild-type protein. However, in the variant the water normally found coordinated to the heme iron atom and hydrogen-bonded to His(64) has been displaced by the hydroxyl oxygen of the Tyr(64) Side chain. The tyrosine oxygen atom is directly coordinated to the heme iron atom with a bond length of 2.18 Angstrom. Distortion of heme planarity and changes in the packing of the Leu(29) and Leu(104) side chains are related to this mutation. The ligand environment of the ferric iron has been studied by electron paramagnetic resonance (EPR) spectroscopy using crystalline material and protein in solution. The protein in solution exhibits a rhombically split ferric high spin EPR spectrum with g values of 6.64, 5.34, and 1.98. The EPR spectrum of the crystalline sample consists of two different ferric high spin signals. The main signal is similar to the signal observed in solution and is assigned to His(93)-Fe(III)-Tyr(64) coordination. The relatively high rhombicity of this signal can be explained as arising from distortions of the heme plane seen in the crystal structure. The second, more axial high spin signal found in the crystalline state can be tentatively assigned to another form of iron ligation with a different iron-tyro-sine bond length and a less distorted heme plane.	UNIV BRITISH COLUMBIA,DEPT BIOCHEM & MOLEC BIOL,VANCOUVER V6T 1Z3,BC,CANADA; UNIV BRITISH COLUMBIA,PROT ENGN NETWORK CTR EXCELLENCE,VANCOUVER V6T 1Z3,BC,CANADA	University of British Columbia; University of British Columbia								Antonini E., 1971, HEMOGLOBIN MYOGLOBIN; BERGHUIS AM, 1992, J MOL BIOL, V223, P959, DOI 10.1016/0022-2836(92)90255-I; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; CARVER TE, 1992, J BIOL CHEM, V267, P14443; CARVER TE, 1990, J BIOL CHEM, V265, P20007; CRUICKSHANK DWJ, 1985, INT TABLES XRAY CRYS, V2, P317; CUTRUZZOLA F, 1991, FEBS LETT, V282, P281, DOI 10.1016/0014-5793(91)80495-O; EGEBERG KD, 1990, BIOCHEMISTRY-US, V29, P9783, DOI 10.1021/bi00494a004; EVANS SV, 1990, J MOL BIOL, V213, P885, DOI 10.1016/S0022-2836(05)80270-0; EVANS SV, 1988, J BIOL CHEM, V263, P4263; FITA I, 1986, ACTA CRYSTALLOGR B, V42, P497, DOI 10.1107/S0108768186097835; HAYASHI A, 1969, BIOCHIM BIOPHYS ACTA, V194, P6, DOI 10.1016/0005-2795(69)90173-1; Hendrickson W. A., 1981, BIOMOLECULAR STRUCTU, V1, P43; IKEDASAITO M, 1992, J BIOL CHEM, V267, P22843; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; NAGAI K, 1983, BIOCHEMISTRY-US, V22, P1305, DOI 10.1021/bi00274a048; NAGAI M, 1989, BIOCHEMISTRY-US, V28, P2418, DOI 10.1021/bi00432a012; PEISACH J, 1971, J BIOL CHEM, V246, P3342; PULSINELLI PD, 1973, P NATL ACAD SCI USA, V70, P3870, DOI 10.1073/pnas.70.12.3870; ROHLFS RJ, 1990, J BIOL CHEM, V265, P3168; SATO F, 1990, J BIOL CHEM, V265, P18823; SPRINGER BA, 1989, J BIOL CHEM, V264, P3057; TANG HL, 1994, IN PRESS BIOCH BIOPH; TONG H, 1994, IN PRESS J APPL CRYS	24	29	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12606	12610						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175669				2022-12-25	WOS:A1994NH71600039
J	MEZGUELDI, M; DERANCOURT, J; CALAS, B; KASSAB, R; FATTOUM, A				MEZGUELDI, M; DERANCOURT, J; CALAS, B; KASSAB, R; FATTOUM, A			PRECISE IDENTIFICATION OF THE REGULATORY F-ACTIN-BINDING AND CALMODULIN-BINDING SEQUENCES IN THE 10-KDA CARBOXYL-TERMINAL DOMAIN OF CALDESMON	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT CHAIN KINASE; SMOOTH-MUSCLE; PROTEIN; PEPTIDE; REGION; MYOSIN; PHOSPHORYLATION; LOCALIZATION; PURIFICATION; FRAGMENT	The precise location of the regulatory F-actin- and calmodulin-binding sites in the COOH-terminal sequence Trp(659)-Pro(756) of gizzard caldesmon was investigated by subjecting the corresponding 10-kDa CNBr fragment, characterized earlier (Bartegi, A., Fattoum, A., Derancourt, J., and Kassab, R. (1990) J. Biol. Chem. 265, 15231-15238), to limited chymotryptic reactions conducted in the absence and presence of F-actin-tropomyosin. As a result, the F-actin-binding and actomyosin ATPase inhibitory activity was separated from the regulatory Ca2+-calmodulin-binding site. Seven chymotryptic peptides accounting for the entire primary structure of the CB10 fragment were isolated, and their complete amino acid sequences were established by combining NH2-terminal sequencing, mass spectrometry, and gel electrophoresis. Reversed-phase high performance liquid chromatography analyses of the binding of F-actin to these peptides revealed the 30-residue sequence Leu(693)-Trp(722) as the unique crucial stretch for actin interaction and ATPase inhibition. This segment was also specifically protected by F-actin against proteolytic degradation. We further determined the functional properties of three synthetic peptides which successively cover the sequences Asn(675)-Lys(695), Leu(693)-Trp(722), and Arg(711)-Lys(729). The first peptide segment specifically bound Ca2+-calmodulin as assessed by affinity chromatography and spectrofluorometry and should contain a potent novel calmodulin-binding subsite. The second immediately adjacent peptide inhibited the actomyosin ATPase in a tropomyosin-sensitive manner, as expected. In contrast, the third peptide displayed no detectable function, The results indicate that the overall sequence Asn(675)-Trp(722) represents the essential regulatory unit of the COOH terminal 10-kDa domain of caldesmon.	UNIV MONTPELLIER 1,CNRS,CTR RECH BIOCHIM MACROMOLEC,INSERM,U249,F-34033 MONTPELLIER,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier								ADAM LP, 1993, FEBS LETT, V322, P56, DOI 10.1016/0014-5793(93)81110-L; BARTEGI A, 1990, J BIOL CHEM, V265, P15231; BARTEGI A, 1991, BIOPHYS J, V59, pA65; BRYAN J, 1989, J BIOL CHEM, V264, P13873; CHALOVICH JM, 1992, J BIOL CHEM, V267, P16644; CZURYLO EA, 1991, BIOPHYS CHEM, V40, P181, DOI 10.1016/0301-4622(91)87007-R; DEDMAN JR, 1983, METHOD ENZYMOL, V102, P1; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GOPALAKRISHNA R, 1982, BIOCHEM BIOPH RES CO, V104, P830, DOI 10.1016/0006-291X(82)90712-4; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; KANOH S, 1993, BIOCHEMISTRY-US, V32, P8902, DOI 10.1021/bi00085a023; KOBAYASHI H, 1992, J BIOCHEM-TOKYO, V112, P786, DOI 10.1093/oxfordjournals.jbchem.a123976; KOHAMA K, 1992, BIOCHEM BIOPH RES CO, V184, P1204, DOI 10.1016/S0006-291X(05)80010-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMAIRE M, 1993, ANAL BIOCHEM, V214, P50, DOI 10.1006/abio.1993.1455; MABUCHI K, 1993, J MUSCLE RES CELL M, V14, P54, DOI 10.1007/BF00132180; MAK AS, 1991, J BIOL CHEM, V266, P6678; MARSTON SB, 1992, J BIOL CHEM, V267, P16796; MARSTON SB, 1994, J BIOL CHEM, V269, P8134; MARSTON SB, 1991, BIOCHEM J, V279, P1; Matsumura F, 1993, CURR OPIN CELL BIOL, V5, P70, DOI 10.1016/S0955-0674(05)80010-9; MEZGUELDI M, 1992, J BIOL CHEM, V267, P15943; REDWOOD CS, 1993, J BIOL CHEM, V268, P10969; REDWOOD CS, 1993, FEBS LETT, V327, P85, DOI 10.1016/0014-5793(93)81045-2; REDWOOD CS, 1993, BIOPHYS J, V64, pA30; SHIRINSKY VP, 1988, BIOCHEM J, V255, P203; SOBUE K, 1991, J BIOL CHEM, V266, P12115; VALEMBOIS C, 1992, TETRAHEDRON LETT, V33, P4005, DOI 10.1016/0040-4039(92)88085-J; VOROTNIKOV AV, 1992, BIOCHEM J, V284, P911, DOI 10.1042/bj2840911; WANG CLA, 1991, J BIOL CHEM, V266, P9166; ZHAN Q, 1991, J BIOL CHEM, V266, P21810	32	46	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12824	12832						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175696				2022-12-25	WOS:A1994NH71600070
J	DEMORAIS, SMF; GIANNONE, JV; OKEY, AB				DEMORAIS, SMF; GIANNONE, JV; OKEY, AB			PHOTOAFFINITY-LABELING OF THE AH RECEPTOR WITH 3-[H-3]METHYLCHOLANTHRENE AND FORMATION OF A 165-KDA COMPLEX BETWEEN THE LIGAND-BINDING SUBUNIT AND A NOVEL CYTOSOLIC PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARYL-HYDROCARBON HYDROXYLASE; RAT HEPATIC CYTOSOLS; HEAT-SHOCK PROTEIN; CELL-LINE; GLUCOCORTICOID RECEPTOR; DIOXIN RECEPTOR; NUCLEAR FORMS; 2,3,7,8-TETRACHLORODIBENZO-PARA-DIOXIN; MOUSE; INDUCTION	The aromatic hydrocarbon (Ah) receptor is a cytosolic protein that binds halogenated ligands such as 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and nonhalogenated ligands such as 3-methylcholanthrene (MC) and benzo[alpha]pyrene. The best characterized biological response mediated by the Ah receptor is induction of cytochrome P4501A1 (CYP1A1). Photoaffinity labeling of the Ah receptor has been reported only with halogenated ligands such as TCDD and some of its iodinated derivatives. In this study, photolabeling of the Ah receptor was achieved with the nonhalogenated aromatic hydrocarbon [H-3]MC. Sources of Ah receptor were the mouse hepatoma cell line Hepa-1c1c9 and the human colon adenocarcinoma line LS180. Cytosolic fractions either were used in a crude form or were enriched by glycerol density gradient centrifugation. These then were incubated with [H-3]MC, irradiated with UV light (>300 nm), precipitated with acetone, and analyzed by SDS-polyacrylamide gel electrophoresis. The yield of photoadduct formation was lower with [H-3]MC (similar to 1%) compared with [H-3]TCDD (3.5%) in Hepa-1c1c9 cells. The same was true in LS180 cells, i.e. the yield was 0.2% for [H-3]MC versus 5.48 +/- 0.26% for [H-3]TCDD. The relative molecular mass of the [H-3]MC-labeled receptor estimated by SDS-polyacrylamide gel electrophoresis was 94,600 +/- 2,400 (mean +/- S.E.) for Hepa-1c1c9 cells and 113,600 +/- 3,200 for LS180 cells; these are the same molecular masses as determined by photolabeling with [H-3]TCDD. In velocity sedimentation assays of mouse cytosol, [H-3]MC binds specifically to two cytosolic proteins: the 4 S carcinogen-binding protein and the Ah receptor (9 S). However, no photolabeling of the 4 S protein was detected in our experiments. [H-3]MC photolabeling of the human Ah receptor from LS180 cells was detected only in experiments using enriched cytosolic preparations. In addition to the 95-kDa ligand-binding subunit, a specifically radiolabeled protein of 164,900 +/- 5,800 kDa was also detected in Hepa-1c1c9 cytosol photolabeled with [H-3]MC, suggesting cross-linking, by MC, of another subunit of the multimeric Ah receptor complex to the ligand-binding subunit. Immunochemical analysis showed that the ligand-binding subunit of the Ah receptor is one component of the 165-kDa complex. The other protein in the complex could not be identified with antibodies to the heat shock proteins hsp90 or hsp70 or with antibodies to the p59 protein or Ah receptor nuclear translocator protein. The identity and function of the protein that becomes cross-linked to the ligand-binding subunit require further investigation.	UNIV TORONTO,DEPT PHARMACOL,TORONTO M5S 1A8,ON,CANADA	University of Toronto								ARNOLD PS, 1987, BIOCHEM J, V242, P375, DOI 10.1042/bj2420375; Bayley H, 1977, Methods Enzymol, V46, P69; BRADFIELD CA, 1991, MOL PHARMACOL, V39, P13; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; COLLINS S, 1986, BIOCHEMISTRY-US, V25, P4322, DOI 10.1021/bi00363a022; DENIS M, 1988, BIOCHEM BIOPH RES CO, V155, P801, DOI 10.1016/S0006-291X(88)80566-7; DENISON MS, 1986, CHEMOSPHERE, V15, P1665, DOI 10.1016/0045-6535(86)90452-2; EMA M, 1992, BIOCHEM BIOPH RES CO, V184, P246, DOI 10.1016/0006-291X(92)91185-S; HANKINSON O, 1993, ARCH BIOCHEM BIOPHYS, V300, P1, DOI 10.1006/abbi.1993.1001; HARPER PA, 1988, CANCER RES, V48, P2388; HARPER PA, 1991, ARCH BIOCHEM BIOPHYS, V290, P27, DOI 10.1016/0003-9861(91)90587-9; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; HOROWITZ KB, 1988, AFFINITY LABELLING C, P186; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDERS JP, 1989, J BIOL CHEM, V264, P18463; LANDERS JP, 1991, BIOCHEM J, V276, P273, DOI 10.1042/bj2760273; LESCA P, 1987, J BIOL CHEM, V262, P4827; LORENZEN A, 1991, TOXICOL APPL PHARM, V107, P203, DOI 10.1016/0041-008X(91)90203-Q; MANCHESTER DK, 1987, CANCER RES, V47, P4861; NEBERT DW, 1987, ANNU REV BIOCHEM, V56, P945, DOI 10.1146/annurev.biochem.56.1.945; OKEY AB, 1982, EUR J BIOCHEM, V127, P39, DOI 10.1111/j.1432-1033.1982.tb06834.x; OKEY AB, 1984, CANCER RES, V44, P1426; OKEY AB, 1990, PHARMACOL THERAPEUT, V45, P241, DOI 10.1016/0163-7258(90)90030-6; OKEY AB, 1988, MICROSOMES DRUG OXID, P31; PERDEW GH, 1992, BIOCHEM BIOPH RES CO, V182, P55, DOI 10.1016/S0006-291X(05)80111-1; PERDEW GH, 1988, J BIOL CHEM, V263, P13802; POLAND A, 1975, MOL PHARMACOL, V11, P389; POLAND A, 1990, MOL PHARMACOL, V38, P306; POLAND A, 1986, J BIOL CHEM, V261, P6352; POLAND A, 1974, MOL PHARMACOL, V10, P349; POLAND A, 1976, J BIOL CHEM, V251, P4936; POLAND A, 1991, MOL PHARMACOL, V39, P20; POLAND A, 1988, ARCH BIOCHEM BIOPHYS, V261, P103, DOI 10.1016/0003-9861(88)90109-9; POLLAND A, 1987, BIOCHEM BIOPH RES CO, V146, P1439; PROBST MR, 1993, MOL PHARMACOL, V44, P511; PROKIPCAK RD, 1989, ARCH BIOCHEM BIOPHYS, V274, P648, DOI 10.1016/0003-9861(89)90480-3; PROKIPCAK RD, 1990, BIOCHEM BIOPH RES CO, V172, P698, DOI 10.1016/0006-291X(90)90730-B; REYES H, 1992, SCIENCE, V256, P1193, DOI 10.1126/science.256.5060.1193; RIDDICK DS, 1994, J BIOL CHEM, V269, P12118; ROBERTS EA, 1986, CANCER RES, V46, P3739; RUOHO AE, 1973, P NATL ACAD SCI USA, V70, P2567, DOI 10.1073/pnas.70.9.2567; TAI PKK, 1986, BIOCHEMISTRY-US, V25, P5269, DOI 10.1021/bi00366a043; TAI PKK, 1992, SCIENCE, V256, P1315, DOI 10.1126/science.1376003; WAITHE WI, 1991, BIOCHEM PHARMACOL, V41, P85, DOI 10.1016/0006-2952(91)90014-V; WANG X, 1991, ARCH BIOCHEM BIOPHYS, V287, P186, DOI 10.1016/0003-9861(91)90405-8; WHITELAW M, 1993, MOL CELL BIOL, V13, P2504, DOI 10.1128/MCB.13.4.2504; WHITLOCK JP, 1990, ANNU REV PHARMACOL, V30, P251	48	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					12129	12136						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163517				2022-12-25	WOS:A1994NG37700069
J	ENSLEN, H; SUN, PQ; BRICKEY, D; SODERLING, SH; KLAMO, E; SODERLING, TR				ENSLEN, H; SUN, PQ; BRICKEY, D; SODERLING, SH; KLAMO, E; SODERLING, TR			CHARACTERIZATION OF CA2+/CALMODULIN-DEPENDENT PROTEIN-KINASE-IV - ROLE IN TRANSCRIPTIONAL REGULATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALMODULIN-BINDING PROTEIN; MEMBRANE DEPOLARIZATION; GENE-TRANSCRIPTION; BRAIN CALMODULIN; EXPRESSION; PHOSPHORYLATION; GR; AUTOPHOSPHORYLATION; CELLS; CREB	We have characterized Ca2+/calmodulin-dependent protein kinase IV (CaM kinase IV), expressed using the baculovirus/Sf9 cell system, to assess its potential role in Ca2+-dependent transcriptional regulation. CaM kinase IV was strongly inhibited in vitro by KN-62, a specific CaM kinase inhibitor which suppresses Ca2+-dependent transcription of several genes, so we tested whether CaM kinase IV could stimulate transcription. Co-transfection of COS-1 cells by cDNA for CaM kinase IV gave no 3-fold stimulation of a reporter gene expression, whereas co-transfection with CaM kinase II gave no transcriptional stimulation, Since this transcriptional response was mediated by phosphorylation of cAMP responsive element-binding protein (CREB), we determined the kinetics and site specificities of CaM kinases IV and II for phosphorylating CREB in vitro. CaM kinases IV and II and cAMP kinase (protein kinase A) all had similar K-m values for CREB (1-5 mu M), but the V-max of CaM kinase IV was 40-fold lower than those of CaM kinase II and protein kinase A. Although all three kinases phosphorylated Ser(133) in CREB, CaM kinase II also gave equal phosphorylation of a second site which was not Ser(98). The two CREB phosphorylation sites were separately P-32-labeled, and the abilities of protein phosphatases 1, 2A, and 2B (calcineurin) to dephosphorylate them were tested. Our results show that all three phosphatases could dephosphorylate both sites, and calcineurin was a stronger catalyst for dephosphorylating site 1 (Ser(133)) than for site 2. These results indicate that CaM kinase TV may be important in Ca2+-dependent transcriptional regulation through phosphorylation of Ser(133) in CREB. The fact that CaM kinase II phosphorylates another site in addition to Ser(333) in CREB raises the possibility that this second phosphorylation site may account for the suppressed ability of CaM kinase II to enhance transcription through the CRE/CREB system. In addition multiple protein phosphatases, including calcineurin, may exert a modulatory effect on transcription depending on which site they dephosphorylate.	OREGON HLTH SCI UNIV, VOLLUM INST, PORTLAND, OR 97201 USA; OREGON HLTH SCI UNIV, DEPT CELL BIOL & ANAT, PORTLAND, OR 97201 USA	Oregon Health & Science University; Oregon Health & Science University			Enslen, Hervé/M-3400-2017	Enslen, Hervé/0000-0001-9741-5293	NIDDK NIH HHS [DK44239] Funding Source: Medline; NIGMS NIH HHS [GM41292] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK044239] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041292] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BRICKEY DA, 1990, BIOCHEM BIOPH RES CO, V173, P578, DOI 10.1016/S0006-291X(05)80074-9; Choi EJ, 1993, CURR OPIN CELL BIOL, V5, P269, DOI 10.1016/0955-0674(93)90115-7; Colbran R J, 1990, Curr Top Cell Regul, V31, P181; COLBRAN RJ, 1988, J BIOL CHEM, V263, P18145; CRUZALEGUI FH, 1993, J BIOL CHEM, V268, P26171; DASH PK, 1991, P NATL ACAD SCI USA, V88, P5061, DOI 10.1073/pnas.88.11.5061; DEGROOT RP, 1993, MOL ENDOCRINOL, V7, P1495, DOI 10.1210/me.7.11.1495; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; FRANGAKIS MV, 1991, J BIOL CHEM, V266, P17592; FRANGAKIS MV, 1991, J BIOL CHEM, V266, P11309; GINTY DD, 1991, J BIOL CHEM, V266, P17454; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GORMAN C, 1983, SCIENCE, V221, P551, DOI 10.1126/science.6306768; HAGIWARA M, 1992, CELL, V70, P105, DOI 10.1016/0092-8674(92)90537-M; HANISSIAN SH, 1993, J BIOL CHEM, V268, P20055; JENSEN KF, 1991, P NATL ACAD SCI USA, V88, P2850, DOI 10.1073/pnas.88.7.2850; JONES DA, 1991, FEBS LETT, V289, P105, DOI 10.1016/0014-5793(91)80919-T; KAMESHITA I, 1993, J BIOCHEM-TOKYO, V113, P583, DOI 10.1093/oxfordjournals.jbchem.a124087; KAPILOFF MS, 1991, P NATL ACAD SCI USA, V88, P3710, DOI 10.1073/pnas.88.9.3710; MAURER RA, 1989, J BIOL CHEM, V264, P6870; MCDONALD OB, 1993, J BIOL CHEM, V268, P10054; MEANS AR, 1991, MOL CELL BIOL, V11, P3960, DOI 10.1128/MCB.11.8.3960; MIYANO O, 1992, J BIOL CHEM, V267, P1198; OFIR R, 1990, NATURE, V348, P80, DOI 10.1038/348080a0; OHMSTEDE CA, 1991, P NATL ACAD SCI USA, V88, P5784, DOI 10.1073/pnas.88.13.5784; OHMSTEDE CA, 1989, J BIOL CHEM, V264, P5866; OKUNO S, 1993, J BIOCHEM-TOKYO, V114, P167, DOI 10.1093/oxfordjournals.jbchem.a124149; PICCIOTTO MR, 1993, J BIOL CHEM, V268, P26512; SCHWANINGER M, 1993, J BIOL CHEM, V268, P5168; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; SIKELA JM, 1987, P NATL ACAD SCI USA, V84, P3038, DOI 10.1073/pnas.84.9.3038; SUN PQ, 1992, MOL ENDOCRINOL, V6, P1858, DOI 10.1210/me.6.11.1858; TOKUMITSU H, 1990, J BIOL CHEM, V265, P4315; TRATNER I, 1992, MOL CELL BIOL, V12, P998, DOI 10.1128/MCB.12.3.998; WADZINSKI BE, 1993, MOL CELL BIOL, V13, P2822, DOI 10.1128/MCB.13.5.2822; WEGNER M, 1992, SCIENCE, V256, P370, DOI 10.1126/science.256.5055.370	40	343	351	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15520	15527						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	8195196				2022-12-25	WOS:A1994NP51300022
J	CLARKE, AR; GLEDHILL, S; HOOPER, ML; BIRD, CC; WYLLIE, AH				CLARKE, AR; GLEDHILL, S; HOOPER, ML; BIRD, CC; WYLLIE, AH			P53 DEPENDENCE OR EARLY APOPTOTIC AND PROLIFERATIVE RESPONSES WITHIN THE MOUSE INTESTINAL EPITHELIUM FOLLOWING GAMMA-IRRADIATION	ONCOGENE			English	Article							CELL-CYCLE CHECKPOINT; WILD-TYPE P53; P53-DEFICIENT MICE; IONIZING-RADIATION; COLORECTAL-CANCER; DNA-SYNTHESIS; MUTATIONS; TUMORS; GENE; IDENTIFICATION	p53 is now well characterised as a tumour suppressor gene, with loss of normal p53 function being recorded as the commonest genetic event associated with human malignancy. In particular, its involvement with tumorigenesis within the intestine is well established. Normal p53 function has been shown to be crucial for the induction of apoptosis in tumour cell lines, murine thymocytes and murine haematopoietic cells following DNA damage. To elucidate further the role of p53 in the cellular response to DNA damage we have investigated the response to gamma-irradiation of crypt cells in vivo from the small and large intestine of mice bearing a constitutive p53 deletion. Four hours after gamma-irradiation, a time point at which wild type crypt cells show abundant apoptosis, crypt cells from p53-deficient mice differed in that they were completely resistant to the induction of apoptosis. The p53 dose dependence of this phenomenon was clearly shown by the intermediate level of apoptosis observed in p53 heterozygotes. Analysis of the mitotic index and the bromodeoxyuridine labelling index showed that two other responses of wild type crypts to gamma-irradiation, namely the G2 block and the reduction in bromodeoxyuridine incorporation, were both largely intact in p53 deficient animals. These observations demonstrate that p53 function is essential for a major component of the normal response to gamma-irradiation induced DNA damage in intestinal mucosal cells, and suggest that p53 deficiency permits a population of cells bearing DNA damage to escape the normal process of deletion.			CLARKE, AR (corresponding author), UNIV EDINBURGH,SCH MED,DEPT PATHOL,CRC LABS,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND.		Clarke, Alan R/A-6256-2008; clarke, alan r/P-2820-2014	Clarke, Alan/0000-0002-4281-426X				ARMITAGE P, 1987, STATISTICAL METHODS, P372; BRUGAL G, 1992, CYTOMETRY, V13, P109, DOI 10.1002/cyto.990130202; CHAWLINSKI S, 1988, CELL TISSUE KINET, V21, P317; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DIETRICH WF, 1993, CELL, V75, P631, DOI 10.1016/0092-8674(93)90484-8; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; HARVEY M, 1993, ONCOGENE, V8, P2457; HARVEY M, 1993, FASEB J, V7, P938, DOI 10.1096/fasebj.7.10.8344491; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LALLEV A, 1993, EUR J BIOCHEM, V216, P177, DOI 10.1111/j.1432-1033.1993.tb18130.x; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LAVIGUEUR A, 1989, MOL CELL BIOL, V9, P3982, DOI 10.1128/MCB.9.9.3982; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LOTEM J, 1993, BLOOD, V82, P1092, DOI 10.1182/blood.V82.4.1092.bloodjournal8241092; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MERRITT AJ, 1994, IN PRESS CANCER RES; Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229; MOSER AR, 1992, J CELL BIOL, V116, P1517, DOI 10.1083/jcb.116.6.1517; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; PAINTER RB, 1986, INT J RADIAT BIOL, V49, P771; PERRY ME, 1993, CURR OPIN GENET DEV, V3, P50, DOI 10.1016/S0959-437X(05)80340-5; POTTEN CS, 1990, INT J RADIAT BIOL, V58, P925, DOI 10.1080/09553009014552281; PURDIE CA, 1994, ONCOGENE, V9, P603; SLICHENMYER WJ, 1993, CANCER RES, V53, P4164; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; SU LK, 1992, SCIENCE, V256, P688; TSUKADA T, 1993, ONCOGENE, V8, P3313; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570	41	272	272	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1994	9	6					1767	1773						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NL815	8183575				2022-12-25	WOS:A1994NL81500032
J	FUNABIKI, T; KREIDER, BL; IHLE, JN				FUNABIKI, T; KREIDER, BL; IHLE, JN			THE CARBOXYL DOMAIN OF ZINC FINGERS OF THE EVI-1 MYELOID TRANSFORMING GENE BINDS A CONSENSUS SEQUENCE OF GAAGATGAG	ONCOGENE			English	Article							DNA-BINDING; RETROVIRAL INSERTIONS; RNA GENE; EXPRESSION; PROTEIN; TRANSCRIPTION; SPECIFICITY; TRANSLOCATIONS; RECOGNITION; ACTIVATION	Inappropriate expression of the Evi-1 zinc finger gene is associated with myeloid leukemia and myelodysplastic syndromes in mice and humans and has been hypothesized to contribute to pathology by blocking myeloid differentiation. Evi-1 contains two domains of zinc fingers, an amino-terminal domain of seven fingers and a carboxyl domain of three fingers. The first domain binds a consensus sequence of GA(C/T)AAGATAAGATAA in binding and amplication reactions or GATA repeat containing regions of genomic DNA. The experiments described here, establish a consensus sequence for the carboxyl domain of zinc fingers consisting of GAAGATGAG. Unlike the first domain, the consensus sequence established for the carboxyl domain is identical to that which would be predicted by the current rules relating to C2H2 zinc fingers and DNA recognition. Substitution of sequences in finger 8 with those in finger 9, demonstrate that the individual fingers bind the predicted region of the consensus sequence. In an attempt to engineer binding of constructs containing the carboxyl domain, a variety of mutations were made in the middle finger that would be predicted to change the consensus sequence in specific ways. Remarkably, most of the mutations were deleterious and destroyed specific DNA binding. Although Evi-1 contains potential transcriptional activation domains, it was not able to activate gene transcription from CAT constructs containing the consensus sequence.	UNIV TENNESSEE, DEPT BIOCHEM, MEMPHIS, TN 38163 USA; ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38105 USA	University of Tennessee System; University of Tennessee Health Science Center; St Jude Children's Research Hospital					NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA21765, CA51020] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARTHOLOMEW C, 1991, MOL CELL BIOL, V11, P1820, DOI 10.1128/MCB.11.4.1820; BARTHOLOMEW C, 1989, ONCOGENE, V4, P529; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; CLEMENS KR, 1992, P NATL ACAD SCI USA, V89, P10822, DOI 10.1073/pnas.89.22.10822; DELWEL R, 1993, MOL CELL BIOL, V13, P4291, DOI 10.1128/MCB.13.7.4291; DESJARLAIS JR, 1992, PROTEINS, V12, P101, DOI 10.1002/prot.340120202; DESJARLAIS JR, 1993, P NATL ACAD SCI USA, V90, P2256, DOI 10.1073/pnas.90.6.2256; DESJARLAIS JR, 1992, P NATL ACAD SCI USA, V89, P7344; FUNABIKI T, 1993, UNPUB; HAYES JJ, 1992, BIOCHEMISTRY-US, V31, P11600, DOI 10.1021/bi00161a045; HUPPI K, 1990, P NATL ACAD SCI USA, V87, P6964, DOI 10.1073/pnas.87.18.6964; KLEIN R, 1990, CELL, V61, P647, DOI 10.1016/0092-8674(90)90476-U; KLEVIT RE, 1991, SCIENCE, V253, P1367, DOI 10.1126/science.1896847; KREIDER BL, 1993, P NATL ACAD SCI USA, V90, P6454, DOI 10.1073/pnas.90.14.6454; LEVY ER, 1994, BLOOD, V83, P1348; MATSUGI T, 1990, MOL CELL BIOL, V10, P1259, DOI 10.1128/MCB.10.3.1259; MATSUGI T, 1993, UNPUB; MORISHITA K, 1992, MOL CELL BIOL, V12, P183, DOI 10.1128/MCB.12.1.183; MORISHITA K, 1992, P NATL ACAD SCI USA, V89, P3937, DOI 10.1073/pnas.89.9.3937; MORISHITA K, 1988, CELL, V54, P831, DOI 10.1016/S0092-8674(88)91175-0; MORISHITA K, 1990, ONCOGENE, V5, P1419; OTSUKA S, 1993, UNPUB; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PERKINS AS, 1991, MOL CELL BIOL, V11, P2665, DOI 10.1128/MCB.11.5.2665; PERKINS AS, 1991, DEVELOPMENT, V111, P479; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; THUKRAL SK, 1991, P NATL ACAD SCI USA, V88, P9188, DOI 10.1073/pnas.88.20.9188; THUKRAL SK, 1992, MOL CELL BIOL, V12, P2784, DOI 10.1128/MCB.12.6.2784	28	87	87	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	1994	9	6					1575	1581						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NL815	8183551				2022-12-25	WOS:A1994NL81500007
J	ING, YL; LEUNG, IWL; HENG, HHQ; TSUI, LC; LASSAM, NJ				ING, YL; LEUNG, IWL; HENG, HHQ; TSUI, LC; LASSAM, NJ			MLK-3 - IDENTIFICATION OF A WIDELY-EXPRESSED PROTEIN-KINASE BEARING AN SH3 DOMAIN AND A LEUCINE ZIPPER-BASIC REGION DOMAIN	ONCOGENE			English	Note							RECEPTOR TYROSINE KINASES; ENDOCRINE NEOPLASIA TYPE-1; LIGAND-BINDING SITE; CRYSTAL-STRUCTURE; MESSENGER-RNAS; DNA-BINDING; FAMILY; CHROMOSOME-11; SPECIFICITY; FEATURES	We have identified a novel protein kinase, designated MLK-3, from human thymus using RT-PCR and cDNA library screening. The deduced open reading frame, derived from sequencing a 3.5 kb MLK-3 cDNA, encodes a protein of 847 amino acids with several interesting structural features. These include an SH3 domain in the absence of an SH2 domain, a region containing two leucine zippers with an adjacent carboxy-terminal basic region, and a proline rich region. This kinase shows homology with the mixed-lineage family of protein kinases (MLK) and shares the unusual leucine zipper-basic motif found in previously identified MLK kinases. By northern analysis, MLK-3 mRNA was detected in a wide variety of normal and transformed human cell lines and tissue specimens. The gene encoding MLK-3 has been mapped using fluorescence in situ hybridization to human chromosome 11 q13.1-13.3, a region frequently altered in human malignancies.	UNIV TORONTO,DEPT CLIN BIOCHEM,TORONTO M5G 1X8,ON,CANADA; UNIV TORONTO,DEPT MED,TORONTO M5G 1X8,ON,CANADA; UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO M5G 1X8,ON,CANADA; HOSP SICK CHILDREN,DEPT GENET,TORONTO M5S 1A8,ON,CANADA	University of Toronto; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)			Tsui, Lap-chee/A-1081-2010					BALE SJ, 1989, GENOMICS, V4, P320, DOI 10.1016/0888-7543(89)90336-4; BOOKER GW, 1993, CELL, V73, P813, DOI 10.1016/0092-8674(93)90259-S; Borson N D, 1992, PCR Methods Appl, V2, P144; CLARK SG, 1992, NATURE, V356, P87; DOROW DS, 1993, EUR J BIOCHEM, V213, P701, DOI 10.1111/j.1432-1033.1993.tb17810.x; FROHMAN MA, 1989, TECHNIQUE, V1, P165; GARCIABUSTOS J, 1991, BIOCHIM BIOPHYS ACTA, V1071, P83, DOI 10.1016/0304-4157(91)90013-M; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HENG HHQ, 1993, IN PRESS METHODS MOL; KOHDA D, 1993, CELL, V72, P953, DOI 10.1016/0092-8674(93)90583-C; KOYAMA S, 1993, CELL, V72, P945, DOI 10.1016/0092-8674(93)90582-B; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LAMMIE GA, 1991, CANCER CELL-MON REV, V3, P413; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LARSSON C, 1988, NATURE, V332, P85, DOI 10.1038/332085a0; LEE ST, 1993, ONCOGENE, V8, P3403; LINDBERG RA, 1992, TRENDS BIOCHEM SCI, V17, P114, DOI 10.1016/0968-0004(92)90248-8; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; MUSACCHIO A, 1992, NATURE, V359, P851, DOI 10.1038/359851a0; MUSACCHIO A, 1992, FEBS LETT, V307, P55, DOI 10.1016/0014-5793(92)80901-R; MUSACCHIO A, 1992, FEBS LETT, V359, P851; NOBLE MEM, 1993, EMBO J, V12, P2617, DOI 10.1002/j.1460-2075.1993.tb05922.x; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PAWSON T, 1993, PHILOS T R SOC B, V340, P279, DOI 10.1098/rstb.1993.0069; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANHEECKEREN W, 1992, NUCLEIC ACIDS RES, V14, P3721; VINSON CR, 1993, GENE DEV, V7, P1047, DOI 10.1101/gad.7.6.1047; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; YU HT, 1992, SCIENCE, V258, P1665, DOI 10.1126/science.1280858	34	87	91	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1994	9	6					1745	1750						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NL815	8183572				2022-12-25	WOS:A1994NL81500029
J	SHA, M; BALASTA, ML; GOSS, DJ				SHA, M; BALASTA, ML; GOSS, DJ			AN INTERACTION OF WHEAT-GERM INITIATION-FACTOR 4B WITH OLIGORIBONUCLEOTIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-SYNTHESIS INITIATION; SINGLE-STRANDED-DNA; MESSENGER-RNA; CAP ANALOGS; BINDING; FLUORESCENCE; TRANSLATION; COMPLEXES	The binding of oligoribonucleotides to wheat germ protein synthesis initiation factor eIF-4B was measured by direct fluorescence techniques. An analysis of the equilibrium association constants (K-eq) indicates that eIF-4B binding is not affected by the m(7)GTP cap structure or the AUG. eIF-4B is insensitive to hairpin structures within the oligoribonucleotide. The binding site size is approximately 18 bases. The binding of oligoribonucleotide to eIF-4B as a function of pH, temperature, and ionic strength is also described. The pH dependent binding showed an increase in binding with increasing pH in contrast to the sharp pH optimum observed for cap binding protein eIF-4E (Carberry, S. E., Darzynkiewicz, E., and Goss, D. J. (1991) Biochemistry 30, 1624-1627). Assuming all tryptophan residues contribute to the observed fluorescence, iodide quenching showed that 8(+/- 1) out 9 of eIF-4B's tryptophan residues are on the surface of the eIF-4B protein. A specific anion effect of Cl- on eIF-4B binding to oligoribonucleotide was found when comparing the ionic strength effect of KC2H3O2 and KCl.	CUNY HUNTER COLL, DEPT CHEM, NEW YORK, NY 10021 USA	City University of New York (CUNY) System; Hunter College (CUNY)								BALASTA ML, 1993, J BIOL CHEM, V268, P18599; BROWNING KS, 1989, J BIOL CHEM, V264, P8491; BROWNING KS, 1987, J BIOL CHEM, V262, P538; BUJALOWSKI W, 1988, J BIOL CHEM, V263, P4629; BUJALOWSKI W, 1986, BIOCHEMISTRY-US, V25, P7799, DOI 10.1021/bi00372a003; CARBERRY SE, 1989, BIOCHEMISTRY-US, V28, P8078, DOI 10.1021/bi00446a017; CARBERRY SE, 1991, BIOCHEMISTRY-US, V30, P1624, DOI 10.1021/bi00220a026; CARBERRY SE, 1990, BIOCHEMISTRY-US, V29, P3337, DOI 10.1021/bi00465a027; CARBERRY SE, 1992, BIOCHEMISTRY-US, V31, P1427, DOI 10.1021/bi00120a020; DRAPER DE, 1988, METHOD ENZYMOL, V164, P221; Eadie GS, 1942, J BIOL CHEM, V146, P85; EDERY I, 1983, J BIOL CHEM, V258, P1398; GILL SJ, 1976, J CHEM THERMODYN, V8, P445, DOI 10.1016/0021-9614(76)90065-3; GILL SJ, 1967, BIOCHEMISTRY-US, V6, P272, DOI 10.1021/bi00853a042; GOSS DJ, 1984, J BIOL CHEM, V259, P7374; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; LAKOWICZ JR, 1973, BIOCHEMISTRY-US, V12, P4171, DOI 10.1021/bi00745a021; LAKOWICZ JR, 1983, PRINCIPLES FLUORESCE, P279; LAWSON TG, 1989, BIOCHEMISTRY-US, V28, P4729, DOI 10.1021/bi00437a033; LAX SR, 1986, METHOD ENZYMOL, V118, P109; LAX SR, 1986, J BIOL CHEM, V261, P5632; LEHRER SS, 1971, BIOCHEMISTRY-US, V10, P3254, DOI 10.1021/bi00793a015; LIN TI, 1977, ANAL BIOCHEM, V77, P10, DOI 10.1016/0003-2697(77)90284-6; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; MILBURN SC, 1990, EMBO J, V9, P2783, DOI 10.1002/j.1460-2075.1990.tb07466.x; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; PIMENTEL GC, 1971, ANNU REV PHYS CHEM, V22, P347, DOI 10.1146/annurev.pc.22.100171.002023; ROSS PD, 1981, BIOCHEMISTRY-US, V20, P3096, DOI 10.1021/bi00514a017; ROZEN F, 1990, MOL CELL BIOL, V10, P1134, DOI 10.1128/MCB.10.3.1134; SHATKIN AJ, 1985, CELL, V40, P223, DOI 10.1016/0092-8674(85)90132-1; WEBER G, 1975, ADV PROTEIN CHEM, V29, P2	31	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					14872	14877						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195117				2022-12-25	WOS:A1994NP73800007
J	YANG, ZT; BERGSTROM, J; KARLSSON, KA				YANG, ZT; BERGSTROM, J; KARLSSON, KA			GLYCOPROTEINS WITH GAL-ALPHA-4GAL ARE ABSENT FROM HUMAN ERYTHROCYTE-MEMBRANES, INDICATING THAT GLYCOLIPIDS ARE THE SOLE CARRIERS OF BLOOD-GROUP-P ACTIVITIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UROPATHOGENIC ESCHERICHIA-COLI; ANTIGENS; BINDING; GLYCOSPHINGOLIPIDS; SPECIFICITY; ANTIBODIES; INTESTINE; CERAMIDE; BACTERIA; STRAIN	The antigenic determinants of the blood group P family (P-1, P, P-k and LKE antigens) are chemically based on Gal alpha 4Gal. For human erythrocytes it has been claimed that the majority of P-1 determinants are expressed in glycoproteins, mainly band 4.5 (Haselberger, C. G., and Schenkel-Brunner, H. (1982) PEBS Lett. 149, 126-128). In the present work, the existence of Gal alpha 4Gal in glycoproteins of erythrocyte membranes (ghosts) of P-1 positive and negative human individuals was carefully analyzed on replicas of sodium dodecyl sulfate-polyacrylamide electrophoresis gels using specific reagents (Escherichia coli HB101/pDC1 expressing the Pop gene and monoclonal antibodies with specificities for P-1 and P-k antigens). No binding to glycoproteins was detected with any of these ligands when the ghosts had been pretreated with butanol to remove glycolipids. Therefore, all antigenic determinants of the P blood group family on human red cells are exclusively expressed in glycolipids and are absent from glycoproteins.	UNIV GOTHENBURG, DEPT BIOCHEM MED, S-41390 GOTHENBURG, SWEDEN	University of Gothenburg				Bergstrom, Jorgen/0000-0003-3255-5150				ANSTEE DJ, 1990, J IMMUNOGENET, V17, P219; BOCK K, 1985, J BIOL CHEM, V260, P8545; BRUCE M, 1988, VOX SANG, V55, P237, DOI 10.1111/j.1423-0410.1988.tb04704.x; CLAUSEN H, 1989, VOX SANG, V56, P1, DOI 10.1111/j.1423-0410.1989.tb03040.x; CLEGG S, 1982, INFECT IMMUN, V38, P739, DOI 10.1128/IAI.38.2.739-744.1982; HAKOMORI SI, 1981, SEMIN HEMATOL, V18, P39; HANSSON GC, 1983, BIOCHIM BIOPHYS ACTA, V750, P214, DOI 10.1016/0005-2760(83)90224-2; HASELBERGER CG, 1982, FEBS LETT, V149, P126, DOI 10.1016/0014-5793(82)81086-7; KARLSSON KA, 1987, METHOD ENZYMOL, V138, P212; KARLSSON KA, 1989, ANNU REV BIOCHEM, V58, P309, DOI 10.1146/annurev.bi.58.070189.001521; KARLSSON KA, 1992, FEMS SYMP, V61, P115; LEWIS M, 1990, VOX SANG, V58, P152; LI SC, 1986, BIOCHEM BIOPH RES CO, V141, P346, DOI 10.1016/S0006-291X(86)80375-8; MARCUS DM, 1981, SEMIN HEMATOL, V18, P63; MARKLUND BI, 1991, THESIS U UMEA SWEDEN; MCKIBBIN JM, 1982, J BIOL CHEM, V257, P755; NAIKI M, 1975, BIOCHEMISTRY-US, V14, P4837, DOI 10.1021/bi00693a010; NAIKI M, 1975, BIOCHEMISTRY-US, V14, P4831, DOI 10.1021/bi00693a009; Steck T L, 1974, Methods Enzymol, V31, P172; STROMBERG N, 1990, EMBO J, V9, P2001, DOI 10.1002/j.1460-2075.1990.tb08328.x; THURIN J, 1988, CURR TOP MICROBIOL, V139, P59; TIPPETT P, 1986, VOX SANG, V51, P53, DOI 10.1111/j.1423-0410.1986.tb00209.x	22	49	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14620	14624						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	8182069				2022-12-25	WOS:A1994NM06500050
J	BENOS, DJ; MCPHERSON, S; HAHN, BH; CHAIKIN, MA; BENVENISTE, EN				BENOS, DJ; MCPHERSON, S; HAHN, BH; CHAIKIN, MA; BENVENISTE, EN			CYTOKINES AND HIV ENVELOPE GLYCOPROTEIN GP120 STIMULATE NA+/H+ EXCHANGE IN ASTROCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; HUMAN-IMMUNODEFICIENCY-VIRUS; CENTRAL-NERVOUS-SYSTEM; TRANSFORMING GROWTH FACTOR-BETA-1; FACTOR-ALPHA; INTERFERON-GAMMA; GENE-EXPRESSION; FACTOR-BETA; BRAIN; INTERLEUKIN-1	The pathogenesis of the human immunodeficiency virus (HIV)-associated cognitive/motor complex, or acquired immunodeficiency syndrome (AIDS) dementia complex, is unknown, but it afflicts over 50% of all patients infected with HIV-1. Because neurons are not directly infected with HIV-1, the causes of neuronal dysfunction are undoubtedly indirect. We investigated the role of the astrocyte in the development of AIDS dementia complex, focusing on cytokine and HIV-1 gp120 stimulation of Na+/H+ exchange (NHE) activity of primary rat astrocytes, Our results show that the cytokines tumor necrosis factor-alpha, interferon (IFN)-gamma, and interleukin (IL)-1 beta (all found to be elevated in the central nervous system of AIDS patients), can stimulate Na+/H+ exchange, but that transforming growth factor-beta, IL-2, and IL-6 do not. IFN-gamma and gp120-induced activation of Na+/H+ exchange appears to be mediated through activation of tyrosine-kinase (TK), because TK inhibitors block the action of IFN-gamma and gp120. Additionally, gp120 induces tyrosine phosphorylation of two proteins (similar to 90 and 130 kDa), which is also inhibited by TK inhibitors. The predominant NHE isoform present in rat astrocytes is NHE-1; however, other isoforms are also present. We conclude that Na+/H+ exchange of rat astrocytes can be differentially stimulated by cytokines and HIV-1 gp120. We hypothesize that the resultant increase in intracellular pH with its concomitant changes in astrocyte membrane permeability properties produces an imbalance in the K+ and glutamate microenvironment of the neurons, leading to a rise in intraneuronal Ca2+ and eventual neuronal dysfunction and/or demise.	UNIV ALABAMA,DEPT MED,BIRMINGHAM,AL 35294; UNIV ALABAMA,DEPT CELL BIOL,BIRMINGHAM,AL 35294; UNIV ALABAMA,AIDS RES CTR,BIRMINGHAM,AL 35294; SMITHKLINE BEECHAM PHARMACEUT,KING OF PRUSSIA,PA 19406	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; GlaxoSmithKline	BENOS, DJ (corresponding author), UNIV ALABAMA,DEPT PHYSIOL & BIOPHYS,BHSB 706,BIRMINGHAM,AL 35294, USA.			Hahn, Beatrice/0000-0002-9400-9887	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH050421] Funding Source: NIH RePORTER; NIMH NIH HHS [MH 50421] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BENOS DJ, 1994, P NATL ACAD SCI USA, V91, P494, DOI 10.1073/pnas.91.2.494; BENVENISTE EN, 1991, J BIOL CHEM, V266, P18119; BENVENISTE EN, 1992, AM J PHYSIOL, V263, pC1, DOI 10.1152/ajpcell.1992.263.1.C1; BIGNAMI A, 1972, BRAIN RES, V43, P429, DOI 10.1016/0006-8993(72)90398-8; Boron WF, 1992, KIDNEY PHYSL PATHOPH, P219; EDDLESTON M, 1993, NEUROSCIENCE, V54, P15, DOI 10.1016/0306-4522(93)90380-X; EPSTEIN LG, 1993, ANN NEUROL, V33, P429, DOI 10.1002/ana.410330502; FAUCI AS, 1993, SCIENCE, V262, P1011, DOI 10.1126/science.8235617; FREI K, 1989, EUR J IMMUNOL, V19, P689, DOI 10.1002/eji.1830190418; GALLO P, 1989, J NEUROIMMUNOL, V23, P109, DOI 10.1016/0165-5728(89)90029-5; GIULIAN D, 1985, SCIENCE, V228, P497, DOI 10.1126/science.3872478; GRINSTEIN S, 1988, NA PLUS H PLUS EXCHA, P359; HENRARD DR, 1992, AIDS RES HUM RETROV, V8, P47, DOI 10.1089/aid.1992.8.47; IVEYHOYLE M, 1991, P NATL ACAD SCI USA, V88, P512, DOI 10.1073/pnas.88.2.512; LASKY LA, 1986, SCIENCE, V233, P209, DOI 10.1126/science.3014647; LINDHOLM D, 1992, J CELL BIOL, V117, P395, DOI 10.1083/jcb.117.2.395; MERRILL JE, 1992, J VIROL, V66, P2217, DOI 10.1128/JVI.66.4.2217-2225.1992; MERRILL JE, 1989, J VIROL, V63, P4404, DOI 10.1128/JVI.63.10.4404-4408.1989; MERRILL JE, 1991, FASEB J, V5, P2391, DOI 10.1096/fasebj.5.10.2065887; MORGANTIKOSSMANN MC, 1992, J NEUROIMMUNOL, V39, P163, DOI 10.1016/0165-5728(92)90185-N; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MUNIS JR, 1990, J CLIN INVEST, V85, P591, DOI 10.1172/JCI114478; NORRIS JG, 1994, J IMMUNOL, V152, P841; ORLOWSKI J, 1992, J BIOL CHEM, V267, P9331; PANEK RB, 1992, P NATL ACAD SCI USA, V89, P11518, DOI 10.1073/pnas.89.23.11518; SCHLUESENER HJ, 1990, J NEUROIMMUNOL, V27, P41, DOI 10.1016/0165-5728(90)90134-9; SCHNEIDERSCHAULIES J, 1992, VIROLOGY, V191, P765, DOI 10.1016/0042-6822(92)90252-K; SELMAJ KW, 1990, J IMMUNOL, V144, P129; SPENCER DC, 1992, ANNU REV MICROBIOL, V46, P655; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; TORUDELBAUFFE D, 1990, J NEUROCHEM, V54, P1056, DOI 10.1111/j.1471-4159.1990.tb02357.x; TYOR WR, 1992, ANN NEUROL, V31, P3499; WAHL LM, 1989, P NATL ACAD SCI USA, V86, P621, DOI 10.1073/pnas.86.2.621; WAHL SM, 1991, J EXP MED, V173, P981, DOI 10.1084/jem.173.4.981; WAKABAYASHI S, 1992, REV PHYSIOL BIOCH P, V119, P157; WANG Z, 1993, J BIOL CHEM, V268, P11925; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; YONG VW, 1991, P NATL ACAD SCI USA, V88, P7016, DOI 10.1073/pnas.88.16.7016	38	95	98	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					13811	13816						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188658				2022-12-25	WOS:A1994NL60600018
J	LANS, MS; LI, Q; LU, J; MODI, WS; NOTKINS, AL				LANS, MS; LI, Q; LU, J; MODI, WS; NOTKINS, AL			GENOMIC ORGANIZATION, 5'-UPSTREAM SEQUENCE, AND CHROMOSOMAL LOCALIZATION OF AN INSULINOMA-ASSOCIATED INTRONLESS GENE, IA-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; RECEPTOR; PROMOTER; EXPRESSION; PROTEIN; REGIONS; SV40; DNA	IA-1 is a novel cDNA originally isolated from a human insulinoma subtraction library (ISL-153). It encodes a protein containing both a zinc finger DNA-binding domain and a putative prohormone domain. IA-1 transcripts have been found thus far only in tumors of neuroendocrine origin. Clinical studies have shown that IA-1 is a sensitive marker for neuroendocrine differentiation of human lung tumors. In this study, we cloned and sequenced the entire IA-1 gene and its 5'-upstream region from a human liver genomic library. In situ hybridization localized the IA-1 gene to the short arm of human chromosome 20. Sequence analysis and restriction enzyme mapping showed that the IA-1 gene is uninterrupted and appears to be intronless. Evidence that IA-1 is an intronless gene that can translate into protein was obtained from in vitro translation studies that showed that both IA-1 cDNA and IA-1 genomic DNA yielded identical protein products of approximately 61,000 daltons. Examination of the 5'-upstream region (2090 base pairs) revealed several tissue-specific regulatory elements, including glucokinase upstream promoter elements and a Pit-1 factor binding site. The presence of several different upstream regulatory elements may account for IA-1 gene expression in different neuroendocrine tumors.	NCI,FREDERICK CANC RES & DEV CTR,PROGRAM RESOURCES INC DYNCORP,BIOL CARCINOGENESIS DEV PROGRAM,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	LANS, MS (corresponding author), NIDR,ORAL MED LAB,BLDG 30,RM 121,BETHESDA,MD 20892, USA.							ALLARD WJ, 1987, NUCLEIC ACIDS RES, V15, P10604, DOI 10.1093/nar/15.24.10604; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; DEMCHYSHYN L, 1992, P NATL ACAD SCI USA, V89, P5522, DOI 10.1073/pnas.89.12.5522; FANNING E, 1992, ANNU REV BIOCHEM, V61, P55; GOTO Y, 1992, J BIOL CHEM, V267, P15252; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; JONES KA, 1984, CELL, V36, P155, DOI 10.1016/0092-8674(84)90084-9; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KOBILKA BK, 1987, J BIOL CHEM, V262, P7321; KOBILKA BK, 1987, SCIENCE, V238, P650, DOI 10.1126/science.2823383; LAN MS, 1993, CANCER RES, V53, P4169; LAWN RM, 1981, NUCLEIC ACIDS RES, V9, P1045, DOI 10.1093/nar/9.5.1045; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; MCKNIGHT SL, 1982, SCIENCE, V217, P316, DOI 10.1126/science.6283634; MELTON DW, 1984, P NATL ACAD SCI-BIOL, V81, P2147, DOI 10.1073/pnas.81.7.2147; NAGATA S, 1980, NATURE, V287, P401, DOI 10.1038/287401a0; NAKAYAMA N, 1985, EMBO J, V4, P2643, DOI 10.1002/j.1460-2075.1985.tb03982.x; NINOMIYA Y, 1986, J BIOL CHEM, V261, P5041; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; REYNOLDS GA, 1984, CELL, V38, P275, DOI 10.1016/0092-8674(84)90549-X; Sambrook J, 1989, MOL CLONING LABORATO; SHELTON NE, 1992, J MED GENET, V12, P4578; STEIN GS, 1984, HISTONE GENES STRUCT, P397; SUNAHARA RK, 1990, NATURE, V347, P80, DOI 10.1038/347080a0; TEEBI AS, 1992, AM J MED GENET, V42, P35, DOI 10.1002/ajmg.1320420109; TORY K, 1992, GENOMICS, V13, P275, DOI 10.1016/0888-7543(92)90243-L; VALERIO D, 1985, EMBO J, V4, P437, DOI 10.1002/j.1460-2075.1985.tb03648.x; WHITTAKER PA, 1986, GENE, V41, P129, DOI 10.1016/0378-1119(86)90276-3; YOUNG D, 1986, CELL, V45, P711, DOI 10.1016/0092-8674(86)90785-3	30	152	156	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					14170	14174						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188699				2022-12-25	WOS:A1994NL60600068
J	BULLESBACH, EE; SCHWABE, C				BULLESBACH, EE; SCHWABE, C			FUNCTIONAL IMPORTANCE OF THE A-CHAIN LOOP IN RELAXIN AND INSULIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-BINDING SITE; SEQUENCE DETERMINATION; PORCINE RELAXIN; PURIFICATION; GENE	Relaxin and insulin are disulfide homologues with divergent functions and antigenicity. We have synthesized human relaxin II and porcine insulin and several A chain loop variants of each and measured the effect of substitutions in vivo and in vitro. Substitution of Ile(A10) in insulin with glycine reduced the receptor binding ability by 2 orders of magnitude. Conversely, exchange of the glycine A14 residue in relaxin, which corresponds to the insulin position A10 for isoleucine, reduced the bioactivity and the receptor binding capacity of relaxin about 100-fold. Substitution of L-Ala in insulin as well as relaxin represented a compromise that allowed both hormones to recover about 30% of the native potency. X-ray analysis and computer derived energy calculation confirm our receptor binding and biological potency studies, which suggest that the functional difference be tween derivatives and native hormones is based upon a structural change introduced into the A chain loop by substitution of the penultimate, intrachain loop residue. In order to achieve a conformation that favors dynamic or passive interaction with the receptor, insulin and relaxin require a different A chain loop structure in spite of the striking overall similarity.			BULLESBACH, EE (corresponding author), MED UNIV S CAROLINA,DEPT BIOCHEM & MOLEC BIOL,CHARLESTON,SC 29425, USA.				NIDDK NIH HHS [DK38348] Funding Source: Medline; NIGMS NIH HHS [GM48829] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK038348] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048829] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adler A J, 1973, Methods Enzymol, V27, P675; BERNATOWICZ MS, 1986, INT J PEPT PROT RES, V28, P107; BULLESBACH EE, 1992, J BIOL CHEM, V267, P22957; BULLESBACH EE, 1991, J BIOL CHEM, V266, P10754; BULLESBACH EE, 1980, H-S Z PHYSIOL CHEM, V361, P865, DOI 10.1515/bchm2.1980.361.1.865; BULLESBACH EE, 1987, BIOCHEM BIOPH RES CO, V143, P273; BULLESBACH EE, 1988, INT J PEPT PROT RES, V32, P361; BULLESBACH EE, 1986, EUR J BIOCHEM, V161, P335, DOI 10.1111/j.1432-1033.1986.tb10452.x; CRAWFORD RJ, 1989, J MOL ENDOCRINOL, V3, P169, DOI 10.1677/jme.0.0030169; EIGENBROT C, 1991, J MOL BIOL, V221, P15, DOI 10.1016/0022-2836(91)90796-9; GOWAN LK, 1981, FEBS LETT, V129, P80, DOI 10.1016/0014-5793(81)80760-0; HOCK RA, 1980, J BIOL CHEM, V255, P731; HUA QX, 1991, NATURE, V354, P238, DOI 10.1038/354238a0; HUDSON P, 1984, EMBO J, V3, P2333, DOI 10.1002/j.1460-2075.1984.tb02135.x; HUDSON P, 1983, NATURE, V301, P628, DOI 10.1038/301628a0; JAMES R, 1977, NATURE, V267, P544, DOI 10.1038/267544a0; LEE YA, 1992, ENDOCRINOLOGY, V130, P1165, DOI 10.1210/en.130.3.1165; LINDE S, 1986, J CHROMATOGR, V369, P327, DOI 10.1016/S0021-9673(00)90139-0; NAKAGAWA SH, 1991, J BIOL CHEM, V266, P11502; SCHWABE C, 1977, BIOCHEM BIOPH RES CO, V75, P503, DOI 10.1016/0006-291X(77)91070-1; SCHWABE C, 1976, BIOCHEM BIOPH RES CO, V70, P397, DOI 10.1016/0006-291X(76)91059-7; SCHWABE C, 1989, J BIOL CHEM, V264, P940; SCHWABE C, 1990, COMP BIOCHEM PHYS B, V96, P15, DOI 10.1016/0305-0491(90)90335-Q; SIEBER P, 1977, HELV CHIM ACTA, V60, P27, DOI 10.1002/hlca.19770600105; STEINETZ BG, 1960, ENDOCRINOLOGY, V67, P102, DOI 10.1210/endo-67-1-102; STEWART DR, 1991, ENDOCRINOLOGY, V129, P375, DOI 10.1210/endo-129-1-375; STEWART DR, 1992, J PROTEIN CHEM, V11, P247, DOI 10.1007/BF01024863; WOODS AS, 1991, INT J MASS SPECTROM, V111, P77, DOI 10.1016/0168-1176(91)85049-R; YANG S, 1992, ENDOCRINOLOGY, V130, P179, DOI 10.1210/en.130.1.179	29	25	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13124	13128						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175738				2022-12-25	WOS:A1994NK18400014
J	KUMAR, C; MWANGI, V; NUTHULAGANTI, P; WU, HL; PULLEN, M; BRUN, K; AIYAR, H; MORRIS, RA; NAUGHTON, R; NAMBI, P				KUMAR, C; MWANGI, V; NUTHULAGANTI, P; WU, HL; PULLEN, M; BRUN, K; AIYAR, H; MORRIS, RA; NAUGHTON, R; NAMBI, P			CLONING AND CHARACTERIZATION OF A NOVEL ENDOTHELIN RECEPTOR FROM XENOPUS HEART	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBTYPE-SELECTIVE LIGANDS; FUNCTIONAL EXPRESSION; IDENTIFICATION; CDNA; TISSUES; BINDING; FAMILY; CORTEX; GENE; ACID	Endothelin (ET) receptors display subtype heterogeneity and so far three subtypes of ET receptors, namely ET(A), ET(B), and ET(C), have been identified, cloned, sequenced, and characterized. Based on the binding profile of ET and related peptides, a novel ET receptor (ET(AX)) was identified in the follicular membranes of Xenopus laevis oocytes (Kumar, C. S., Nuthulaganti, P., Pullen, M., and Nambi, P. (1993). Mol. Pharmacol. 44, 153-157). Here we report the cloning and characterization of this ET(AX) subtype from X. Laevis heart. A cDNA was isolated that encodes a protein of 415 amino acids that shares 74, 60, and 51% identities with human ET(A), human ET(B), and Xenopus ET(C) receptors, respectively. Competition binding studies of the cloned receptor expressed in COS cells using ET-related peptides suggested that this receptor is pharmacologically identical to that expressed in Xenopus oocyte follicular, heart, and lung membranes. Phosphoinositide turnover and oocyte electrophysiological studies indicated that the cloned receptor is functionally coupled to a second messenger system.	SMITHKLINE BEECHAM PHARMACEUT,DEPT RENAL PHARMACOL,KING OF PRUSSIA,PA 19406	GlaxoSmithKline	KUMAR, C (corresponding author), SMITHKLINE BEECHAM PHARMACEUT,DEPT MOLEC GENET,UE0548,POB 1539,KING OF PRUSSIA,PA 19406, USA.							ADACHI M, 1992, FEBS LETT, V311, P179, DOI 10.1016/0014-5793(92)81393-Z; AIYAR N, 1986, LIFE SCI, V39, P37, DOI 10.1016/0024-3205(86)90435-2; ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BERGSMA DJ, 1992, BIOCHEM BIOPH RES CO, V183, P989, DOI 10.1016/S0006-291X(05)80288-8; BROOKS DP, 1994, IN PRESS J PHARM EXP; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOHLMAN HG, 1987, BIOCHEMISTRY-US, V26, P2657, DOI 10.1021/bi00384a001; EDWARDS RM, 1992, AM J PHYSIOL, V263, pF1020, DOI 10.1152/ajprenal.1992.263.6.F1020; ELSHOURBAGY NA, 1993, J BIOL CHEM, V268, P3873; ELSHOURBAGY NA, 1992, MOL PHARMACOL, V41, P465; HOSODAK, 1992, J BIOL CHEM, V267, P18797; HUBBARD SC, 1981, ANNU REV BIOCHEM, V50, P555, DOI 10.1146/annurev.bi.50.070181.003011; IHARA M, 1992, LIFE SCI, V50, P247, DOI 10.1016/0024-3205(92)90331-I; KARNE S, 1993, J BIOL CHEM, V268, P19126; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KLOOG Y, 1989, TRENDS PHARMACOL SCI, V10, P212, DOI 10.1016/0165-6147(89)90261-7; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; KUMAR CS, 1993, MOL PHARMACOL, V44, P153; KUMAR CS, 1988, J BIOL CHEM, V263, P13493; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LIN HY, 1991, P NATL ACAD SCI USA, V88, P3185, DOI 10.1073/pnas.88.8.3185; MIZUNO T, 1992, BIOCHEM J, V287, P305, DOI 10.1042/bj2870305; NAMBI P, 1992, MOL PHARMACOL, V42, P336; NAMBI P, 1994, NEUROPEPTIDES, V26, P181, DOI 10.1016/0143-4179(94)90128-7; NAMBI P, 1992, ENDOCRINOLOGY, V131, P1081, DOI 10.1210/en.131.3.1081; NAMBI P, 1990, NEUROPEPTIDES, V16, P195, DOI 10.1016/0143-4179(90)90062-4; RUBANYI GM, 1991, FASEB J, V5, P2713, DOI 10.1096/fasebj.5.12.1916094; SAKAMOTO A, 1991, BIOCHEM BIOPH RES CO, V178, P656, DOI 10.1016/0006-291X(91)90158-4; SAKAMOTO A, 1993, J BIOL CHEM, V268, P8547; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; SAMBROOK J, 1989, MOL CLONING LABORATO, V2; SIMONSON MS, 1990, FASEB J, V4, P2989, DOI 10.1096/fasebj.4.12.2168326; SOKOLOVSKY M, 1993, BIOCHEM BIOPH RES CO, V196, P32, DOI 10.1006/bbrc.1993.2212; TAKAYANAGI R, 1991, REGUL PEPTIDES, V32, P23, DOI 10.1016/0167-0115(91)90004-Z; WHITE MM, 1985, P NATL ACAD SCI USA, V82, P4852, DOI 10.1073/pnas.82.14.4852; WILLIAMS DL, 1991, BIOCHEM BIOPH RES CO, V175, P556, DOI 10.1016/0006-291X(91)91601-8; WILLIAMS DL, 1991, BIOCHEM BIOPH RES CO, V180, P475, DOI 10.1016/S0006-291X(05)81089-7; YANAGISAWA M, 1988, NATURE, V332, P1111	40	65	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13414	13420						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175772				2022-12-25	WOS:A1994NK18400055
J	SANDERSON, RD; TURNBULL, JE; GALLAGHER, JT; LANDER, AD				SANDERSON, RD; TURNBULL, JE; GALLAGHER, JT; LANDER, AD			FINE-STRUCTURE OF HEPARAN-SULFATE REGULATES SYNDECAN-1 FUNCTION AND CELL BEHAVIOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY EPITHELIAL-CELLS; FIBROBLAST GROWTH-FACTOR; SURFACE PROTEOGLYCAN; MOLECULAR POLYMORPHISM; BINDING SEQUENCE; MEMBRANE; GLYCOSAMINOGLYCANS; RECEPTOR; AFFINITY	Two myeloma cell lines, MPC-11 and P3X63Ag8.653 (P3), have almost identical amounts of syndecan-1 at their cell surface. The syndecan-1 molecules from both lines are similar in size, have indistinguishable core proteins, and have similarly sized heparan sulfate chains. Nevertheless, syndecan-1 on MPC-11 mediates cell adhesion to type I collagen, whereas P3 cells do not bind collagen. Affinity co-electrophoresis reveals that intact syndecan-1 isolated from P3 cells binds collagen poorly and that syndecan-1 heparan sulfate isolated from MPC-11 has a 20-fold higher affinity for collagen than syndecan-1 heparan sulfate from P3. Analysis of disaccharide composition and oligosaccharide mapping also reveals differences between MPC-11 and P3 heparan sul fate. Most notably, the level of N-sulfation and 2-O-sulfation is higher, and 6-O-sulfation lower, in syndecan-1 heparan sulfate from MPC-11 than from P3. Interestingly, levels of total sulfation of syndecan-1 heparan sulfate from MPC-11 and P3 are similar (75.6 and 72.6 sulfates/100 disaccharides, respectively), indicating that the difference in their affinity for collagen is not due to a difference in net charge. These data indicate that the fine structure of heparan sulfate can differ on identical proteoglycan core proteins, and these differences can control fundamental cellular properties such as cell matrix adhesion.	UNIV ARKANSAS MED SCI HOSP, DEPT ANAT, LITTLE ROCK, AR 72205 USA; UNIV ARKANSAS MED SCI HOSP, CTR MUSCULOSKELETAL RES, LITTLE ROCK, AR 72205 USA; UNIV MANCHESTER, CHRISTIE HOSP, CRC, DEPT MED ONCOL, MANCHESTER M20 9BX, LANCS, ENGLAND; MIT, DEPT BRAIN & COGNIT SCI, CAMBRIDGE, MA 02139 USA	University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences; Christie NHS Foundation Trust; Christie Hospital; University of Manchester; Massachusetts Institute of Technology (MIT)	SANDERSON, RD (corresponding author), UNIV ARKANSAS MED SCI HOSP, DEPT PATHOL, SLOT 517, 4301 W MARKHAM, LITTLE ROCK, AR 72205 USA.		Lander, Arthur/L-2827-2019; Lander, Arthur D/C-9008-2011	Lander, Arthur/0000-0002-4380-5525; Lander, Arthur D/0000-0002-4380-5525	NCI NIH HHS [CA55879] Funding Source: Medline; NINDS NIH HHS [NS26862] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA055879] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026862] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BERNFIELD M, 1991, ANN NY ACAD SCI, V638, P182, DOI 10.1111/j.1749-6632.1991.tb49029.x; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BRAUKER JH, 1991, DEV BIOL, V147, P285, DOI 10.1016/0012-1606(91)90286-C; GALLAGHER JT, 1992, GLYCOBIOLOGY, V2, P523, DOI 10.1093/glycob/2.6.523; GALLAGHER JT, 1985, BIOCHEM J, V230, P665, DOI 10.1042/bj2300665; GALLAGHER JT, 1986, BIOCHEM J, V236, P313, DOI 10.1042/bj2360313; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; HINKES MT, 1993, J BIOL CHEM, V268, P11440; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; JALKANEN M, 1985, J CELL BIOL, V101, P976, DOI 10.1083/jcb.101.3.976; KATO M, 1991, Journal of Cell Biology, V115, p125A; KIEFER MC, 1990, P NATL ACAD SCI USA, V87, P6985, DOI 10.1073/pnas.87.18.6985; KODA JE, 1985, J BIOL CHEM, V260, P8157; LEE MK, 1991, P NATL ACAD SCI USA, V88, P2768, DOI 10.1073/pnas.88.7.2768; LINDAHL U, 1984, J BIOL CHEM, V259, P2368; LINHARDT RJ, 1990, BIOCHEMISTRY-US, V29, P2611, DOI 10.1021/bi00462a026; MACCARANA M, 1993, J BIOL CHEM, V268, P23898; MARCUM JA, 1986, J BIOL CHEM, V261, P7507; NURCOMBE V, 1993, SCIENCE, V260, P103, DOI 10.1126/science.7682010; RAPRAEGER A, 1985, J BIOL CHEM, V260, P4103; RIDLEY RC, 1993, BLOOD, V81, P767; SALMIVIRTA M, 1991, J BIOL CHEM, V266, P7733; SANANTONIO JD, 1993, BIOCHEMISTRY-US, V32, P4746, DOI 10.1021/bi00069a008; SANDERSON RD, 1992, J IMMUNOL, V148, P3902; SANDERSON RD, 1988, P NATL ACAD SCI USA, V85, P9562, DOI 10.1073/pnas.85.24.9562; SANDERSON RD, 1989, CELL REGUL, V1, P27, DOI 10.1091/mbc.1.1.27; SAUNDERS S, 1988, J CELL BIOL, V106, P423, DOI 10.1083/jcb.106.2.423; SUN XJ, 1989, J BIOL CHEM, V264, P11288; TURNBULL JE, 1992, J BIOL CHEM, V267, P10337; TURNBULL JE, 1990, BIOCHEM J, V265, P715, DOI 10.1042/bj2650715; TURNBULL JE, 1993, BIOCHEM SOC T, V21, P477, DOI 10.1042/bst0210477; TURNBULL JE, 1991, BIOCHEM J, V273, P553, DOI 10.1042/bj2730553; TURNBULL JE, 1988, BIOCHEM J, V251, P597, DOI 10.1042/bj2510597; VIHINEN T, 1993, J BIOL CHEM, V268, P17261; WALKER A, 1994, J BIOL CHEM, V269, P931	35	158	164	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13100	13106						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175735				2022-12-25	WOS:A1994NK18400011
J	ZHOU, J; DING, M; ZHAO, ZH; REEDERS, ST				ZHOU, J; DING, M; ZHAO, ZH; REEDERS, ST			COMPLETE PRIMARY STRUCTURE OF THE 6TH CHAIN OF HUMAN BASEMENT-MEMBRANE COLLAGEN, ALPHA-6(IV) - ISOLATION OF THE CDNAS FOR ALPHA-6(IV) AND COMPARISON WITH 5 OTHER TYPE-IV COLLAGEN CHAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPORT SYNDROME; BIDIRECTIONAL PROMOTER; ALPHA-2(IV) COLLAGEN; GOODPASTURE ANTIGEN; EXTENSIVE HOMOLOGY; CELL-ADHESION; IDENTIFICATION; DOMAIN; ALPHA-1(IV); REGION	Basement membranes were previously believed to contain five distinct type IV collagen subunits. We have recently isolated part of the cDNA for a novel type IV collagen, alpha 6(IV), and shown that COL4A6, the gene encoding this new chain, is deleted in Alport syndrome-associated leiomyomatosis (Zhou, J., Mochizuki, T., Smeets, H., Antignac, C., Laurila, P., de Paepe, A., Tryg- gvason, K., and Reeders, S. T. (1993) Science 261, 1167-1169). Here, we describe the entire human (alpha 6(IV) cDNA and show that the gene encodes a classical type IV collagen with homology throughout its length to all the other five chains. There is a 21-residue signal peptide, a 1417-residue collagenous domain interrupted at 25 points, and a 228-residue carboxyl-terminal non-collagenous domain. When the complete primary structure of this new chain was compared with all the other known chains, it became clear that (alpha 6(IV) has the most resemblance to alpha 2(IV) and alpha 4(IV). The evolution of the six chains was deduced, allowing a new classification of the type IV collagen family. The alpha 6(IV) chain is a candidate gene for X-linked Alport syndrome; knowledge of the complete structure of the chain will permit us to screen systematically for mutations in patients and to generate recombinant proteins and synthetic peptides for further study of cell-matrix interactions involving the alpha 6(IV) chain.			ZHOU, J (corresponding author), HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT NEPHROL,BOSTON,MA 02115, USA.							BARKER DF, 1990, SCIENCE, V248, P1224, DOI 10.1126/science.2349482; BURBELO PD, 1988, P NATL ACAD SCI USA, V85, P9679, DOI 10.1073/pnas.85.24.9679; BUTKOWSKI RJ, 1987, J BIOL CHEM, V262, P7874; DOLZ R, 1988, EUR J BIOCHEM, V178, P357, DOI 10.1111/j.1432-1033.1988.tb14458.x; GUNWAR S, 1990, J BIOL CHEM, V265, P5466; GUNWAR S, 1991, J BIOL CHEM, V266, P15318; HOFMANN H, 1984, J MOL BIOL, V172, P325, DOI 10.1016/S0022-2836(84)80029-7; HOSTIKKA SL, 1988, J BIOL CHEM, V263, P19488; HOSTIKKA SL, 1987, FEBS LETT, V216, P281, DOI 10.1016/0014-5793(87)80706-8; HOSTIKKA SL, 1990, P NATL ACAD SCI USA, V87, P1606, DOI 10.1073/pnas.87.4.1606; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KUHN K, 1981, FEBS LETT, V125, P123, DOI 10.1016/0014-5793(81)81012-5; KURKINEN M, 1987, J BIOL CHEM, V262, P8496; MARIYAMA M, 1992, GENOMICS, V13, P809, DOI 10.1016/0888-7543(92)90157-N; MARIYAMA M, 1992, J BIOL CHEM, V267, P1253; MORRISON KE, 1991, AM J HUM GENET, V49, P545; MUTHUKUMARAN G, 1989, J BIOL CHEM, V264, P6310; NETZER KO, 1992, KIDNEY INT, V42, P1336, DOI 10.1038/ki.1992.425; PIHLAJANIEMI T, 1990, J BIOL CHEM, V265, P13758; POSCHL E, 1988, EMBO J, V7, P2687, DOI 10.1002/j.1460-2075.1988.tb03122.x; RISTELI J, 1980, EUR J BIOCHEM, V108, P239, DOI 10.1111/j.1432-1033.1980.tb04717.x; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SAUS J, 1988, J BIOL CHEM, V263, P13374; SCHUPPAN D, 1984, BIOCHEM J, V220, P227, DOI 10.1042/bj2200227; SIBLEY MH, 1993, J CELL BIOL, V123, P255, DOI 10.1083/jcb.123.1.255; SIEBOLD B, 1987, EUR J BIOCHEM, V168, P569, DOI 10.1111/j.1432-1033.1987.tb13455.x; SMEETS HJM, 1992, KIDNEY INT, V42, P83, DOI 10.1038/ki.1992.264; SOININEN R, 1988, J BIOL CHEM, V263, P17217; SOININEN R, 1987, FEBS LETT, V225, P188; SUGIMOTO M, 1993, FEBS LETT, V330, P122, DOI 10.1016/0014-5793(93)80256-T; TIMPL R, 1981, EUR J BIOCHEM, V120, P203, DOI 10.1111/j.1432-1033.1981.tb05690.x; TIMPL R, 1989, EUR J BIOCHEM, V180, P487, DOI 10.1111/j.1432-1033.1989.tb14673.x; TRYGGVASON K, 1993, KIDNEY INT, V43, P38, DOI 10.1038/ki.1993.8; TSILIBARY EC, 1986, J CELL BIOL, V103, P2467, DOI 10.1083/jcb.103.6.2467; YURCHENCO PD, 1987, J BIOL CHEM, V262, P17668; ZHOU J, 1993, SCIENCE, V261, P1167, DOI 10.1126/science.8356449; ZHOU J, 1991, GENOMICS, V9, P10, DOI 10.1016/0888-7543(91)90215-Z; ZHOU J, 1993, KIDNEY INT, V43, P722, DOI 10.1038/ki.1993.103; ZHOU J, 1992, J BIOL CHEM, V267, P12475	39	99	104	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13193	13199						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175748				2022-12-25	WOS:A1994NK18400025
J	LOFT, S; ASTRUP, A; BUEMANN, B; POULSEN, HE				LOFT, S; ASTRUP, A; BUEMANN, B; POULSEN, HE			OXIDATIVE DNA-DAMAGE CORRELATES WITH OXYGEN-CONSUMPTION IN HUMANS	FASEB JOURNAL			English	Article						MITOCHONDRIAL RESPIRATION; 8-OXODG EXCRETION; SMOKING	COLI FPG PROTEIN; ENERGY-EXPENDITURE; 8-HYDROXYGUANINE; REPAIR; 8-HYDROXY-2'-DEOXYGUANOSINE; MITOCHONDRIAL; METABOLISM; NUCLEOTIDE; MUTATIONS; CODON-12	Generation of reactive oxygen species from mitochondrial respiration has been proposed as an important determinant of longevity and cumulative cancer risk. Interspecies correlations and animal calorie restriction studies of metabolic rate and oxidative DNA damage support this notion. In the present study we have demonstrated a close association between oxidative DNA damage as assessed by the urinary excretion of 8-oxo-7,8-dihydro-2'-deoxyguanosine (8-oxodG) and oxygen consumption in 33 healthy premenopausal women (r = 0.64; p = 0.00007). In the 12 women who smoked, 8-oxodG excretion was increased by 35%, although oxygen consumption increased only 10% compared with the 21 nonsmoking women. Apparently, the rate of oxidative DNA damage relates to mitochondrial respiration in humans and is aggravated by smoking.	ROYAL VET & AGR UNIV, HUMAN NUTR RES DEPT, DK-1870 FREDERIKSBERG, DENMARK	University of Copenhagen	LOFT, S (corresponding author), UNIV COPENHAGEN, PANUM INST, DEPT PHARMACOL, ROOM 18-5-32, BLEGDAMSVEJ 3, DK-2200 COPENHAGEN N, DENMARK.		Astrup, Arne/B-1407-2015	Astrup, Arne/0000-0001-8968-8996; Poulsen, Henrik Enghusen/0000-0003-4242-9924; Buemann, Benjamin/0000-0002-8657-419X; Loft, Steffen/0000-0001-9552-8518				ADELMAN R, 1988, P NATL ACAD SCI USA, V85, P2706, DOI 10.1073/pnas.85.8.2706; ASTRUP A, 1992, J CLIN ENDOCR METAB, V74, P279, DOI 10.1210/jc.74.2.279; BOITEUX S, 1992, BIOCHEMISTRY-US, V31, P106, DOI 10.1021/bi00116a016; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; CHENG KC, 1992, J BIOL CHEM, V267, P166; CHUNG MH, 1992, FREE RADICAL BIO MED, V12, P523, DOI 10.1016/0891-5849(92)90105-P; CUTLER RG, 1991, ANN NY ACAD SCI, V621, P1; CZECZOT H, 1991, J BACTERIOL, V173, P3419, DOI 10.1128/jb.173.11.3419-3424.1991; DORGAN JF, 1991, HEMATOL ONCOL CLIN N, V5, P43, DOI 10.1016/S0889-8588(18)30453-2; ELSE PL, 1985, AM J PHYSIOL, V248, pR415, DOI 10.1152/ajpregu.1985.248.4.R415; FRAGA CG, 1990, P NATL ACAD SCI USA, V87, P4533, DOI 10.1073/pnas.87.12.4533; GVOZDJAKOVA A, 1992, CARDIOLOGY, V81, P81, DOI 10.1159/000175780; HAYAKAWA M, 1992, BIOCHEM BIOPH RES CO, V189, P979, DOI 10.1016/0006-291X(92)92300-M; HIGINBOTHAM KG, 1992, CANCER RES, V52, P4747; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KAMIYA H, 1992, CANCER RES, V52, P3483; KASAI H, 1986, CARCINOGENESIS, V7, P1849, DOI 10.1093/carcin/7.11.1849; KLEIN JC, 1992, NUCLEIC ACIDS RES, V20, P4437, DOI 10.1093/nar/20.17.4437; LEANDERSON P, 1992, CHEM-BIOL INTERACT, V81, P197, DOI 10.1016/0009-2797(92)90034-I; MALINS DC, 1991, CANCER RES, V51, P5430; MO JY, 1992, P NATL ACAD SCI USA, V89, P11021, DOI 10.1073/pnas.89.22.11021; OLINSKI R, 1992, FEBS LETT, V309, P193, DOI 10.1016/0014-5793(92)81093-2; PARK EM, 1992, P NATL ACAD SCI USA, V89, P3375, DOI 10.1073/pnas.89.8.3375; RICHTER C, 1988, P NATL ACAD SCI USA, V85, P6465, DOI 10.1073/pnas.85.17.6465; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; SHIGENAGA MK, 1989, P NATL ACAD SCI USA, V86, P9697, DOI 10.1073/pnas.86.24.9697; SIMIC MG, 1991, MUTAT RES, V250, P17, DOI 10.1016/0027-5107(91)90158-K; SOHAL RS, 1992, ANN NY ACAD SCI, V663, P74, DOI 10.1111/j.1749-6632.1992.tb38651.x; VAUGHAN L, 1991, AM J CLIN NUTR, V53, P821, DOI 10.1093/ajcn/53.4.821; VISTISEN K, 1992, CARCINOGENESIS, V13, P1561, DOI 10.1093/carcin/13.9.1561; YAMAMOTO F, 1992, JPN J CANCER RES, V83, P351, DOI 10.1111/j.1349-7006.1992.tb00114.x	31	156	156	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	1994	8	8					534	537		10.1096/fasebj.8.8.8181672	http://dx.doi.org/10.1096/fasebj.8.8.8181672			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	NM364	8181672				2022-12-25	WOS:A1994NM36400011
J	BUSCH, AE; WALDEGGER, S; HERZER, T; BIBER, J; MARKOVICH, D; MURER, H; LANG, F				BUSCH, AE; WALDEGGER, S; HERZER, T; BIBER, J; MARKOVICH, D; MURER, H; LANG, F			ELECTROGENIC COTRANSPORT OF NA+ AND SULFATE IN XENOPUS-OOCYTES EXPRESSING THE CLONED NA+/SO42- TRANSPORT PROTEIN NASI-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							BORDER MEMBRANE-VESICLES; GLUCOSE COTRANSPORTER	The Na+/sulfate cotransporter cloned from rat kidney cortex (NaSi-1) has been expressed in oocytes of Xenopus laevis and subjected to electrophysiological analysis by current and voltage clamp methods. In current-clamped oocytes, superfusion with 1 mM sulfate resulted in a 12-mV depolarization of the cell membrane. Accordingly, in voltage-clamped oocytes sulfate induced an inward current (I-S), which was dependent on both the concentration of Na+ and sulfate in the superfusate. Half-maximal I-S was observed at about 0.1 mM sulfate and 70 mM Na+. The Hill coefficients were 1 and 2.8 for sulfate and Na+, respectively. Thiosulfate and selenate created similar currents as sulfate with a similar K-m. At saturating concentrations of thiosulfate and selenate, addition of sulfate could not induce an additive current. Phosphate (1 mM) did not inhibit sulfate-induced currents. Finally, I-S was dependent on the holding potential being larger at more negative potentials. The results of this study strongly suggest an electrogenic cotransport of sulfate and Na+ with a stoichiometry of 1:3.	UNIV ZURICH,INST PHYSIOL,CH-8057 ZURICH,SWITZERLAND	University of Zurich	BUSCH, AE (corresponding author), UNIV TUBINGEN,INST PHYSIOL 1,GMELINSTR 5,D-72076 TUBINGEN,GERMANY.		Markovich, Daniel/F-7884-2012					AHEARN GA, 1984, J MEMBRANE BIOL, V78, P177, DOI 10.1007/BF01925966; BAESTLEIN C, 1986, AM J PHYSIOL, V250, pF226; BUSCH AE, 1992, J PHYSIOL-LONDON, V450, P491, DOI 10.1113/jphysiol.1992.sp019138; COHEN JJ, 1957, AM J PHYSIOL, V189, P331, DOI 10.1152/ajplegacy.1957.189.2.331; DENNIS VW, 1982, KIDNEY INT, V22, P498, DOI 10.1038/ki.1982.203; KAVANAUGH MP, 1993, BIOCHEMISTRY-US, V32, P5781, DOI 10.1021/bi00073a009; KLOCKNER U, 1993, J BIOL CHEM, V268, P14594; LOO DDF, 1993, P NATL ACAD SCI USA, V90, P5767, DOI 10.1073/pnas.90.12.5767; LUCKE H, 1979, BIOCHEM J, V182, P223; MAGAGNIN S, 1993, P NATL ACAD SCI USA, V90, P5979, DOI 10.1073/pnas.90.13.5979; MARKOVICH D, 1993, P NATL ACAD SCI USA, V90, P8073, DOI 10.1073/pnas.90.17.8073; MURER H, 1992, HDB PHYSL 8, V2, P2165; PARENT L, 1992, J MEMBRANE BIOL, V125, P63; PARENT L, 1992, J MEMBRANE BIOL, V125, P49; RENFRO JL, 1989, AM J PHYSIOL, V256, pR1176, DOI 10.1152/ajpregu.1989.256.6.R1176; SCHNEIDER EG, 1984, J BIOL CHEM, V259, P4591; TURNER RJ, 1984, AM J PHYSIOL, V247, pF793, DOI 10.1152/ajprenal.1984.247.5.F793	17	60	60	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12407	12409						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175644				2022-12-25	WOS:A1994NH71600007
J	DUNWOODIE, SL; JOYA, JE; ARKELL, RM; HARDEMAN, EC				DUNWOODIE, SL; JOYA, JE; ARKELL, RM; HARDEMAN, EC			MULTIPLE REGIONS OF THE HUMAN CARDIAC ACTIN GENE ARE NECESSARY FOR MATURATION-BASED EXPRESSION IN STRIATED-MUSCLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC EXPRESSION; TRANSGENIC MICE; SKELETAL-MUSCLE; MESSENGER-RNA; BETA-ACTIN; DEVELOPMENTAL REGULATION; ALPHA-SKELETAL; PROMOTER; MOUSE; TRANSCRIPTION	In order to elucidate mechanisms involved in striated muscle contractile protein isoform expression, we have defined regulatory elements in the cardiac actin gene necessary for postnatal expression at the level of transcript accumulation in the heart and hindlimb muscles of transgenic mice. During this developmental period in the rodent, cardiac actin expression essentially remains constant in the heart, but declines significantly in skeletal muscle. We determined that a 13-kilobase human cardiac actin gene fragment contains sufficient information to direct this maturation-based developmental ex- pression, as well as striated muscle-specific and high level expression. We localized an element responsible for maturation-based down-regulation in the 3' flank of the gene between approximately 950 and 2120 base pairs downstream of the polyadenylation site. Furthermore, we determined that -800 base pairs of 5'-flanking DNA, which contains multiple MyoD1 binding sites, as well as serum response element and AP1 binding sites, can account for striated muscle specific expression, but not high level expression. Findings indicate that sequence(s) responsible for high level expression of the gene must be located within the body of the gene. We conclude that the human cardiac actin gene contains distinct sequences which confer developmental, tissue-specific, and high level expression.	CHILDRENS MED RES INST,MUSCLE DEV UNIT,WENTWORTHVILLE,NSW 2145,AUSTRALIA	Children's Medical Research Institute - Australia			Dunwoodie, Sally L/M-4019-2018; Hardeman, Edna C/F-8872-2012; arkell, ruth m/D-1525-2009	Dunwoodie, Sally L/0000-0002-2069-7349; arkell, ruth m/0000-0002-6213-7323; Hardeman, Edna/0000-0003-1649-7712				ALONSO S, 1990, J MOL BIOL, V211, P727, DOI 10.1016/0022-2836(90)90073-U; BANDMAN E, 1992, DEV BIOL, V154, P273, DOI 10.1016/0012-1606(92)90067-Q; BLAU HM, 1981, P NATL ACAD SCI-BIOL, V78, P5623, DOI 10.1073/pnas.78.9.5623; BOHELER KR, 1991, J CLIN INVEST, V88, P323, DOI 10.1172/JCI115295; BRENNAN KJ, 1993, J BIOL CHEM, V268, P719; CHAUSSEPIED P, 1989, NATURE, V342, P950, DOI 10.1038/342950a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOW KL, 1990, MOL CELL BIOL, V10, P528, DOI 10.1128/MCB.10.2.528; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; COX RD, 1992, DEV BIOL, V149, P228, DOI 10.1016/0012-1606(92)90279-P; DENHARDT DT, 1966, BIOCHEM BIOPH RES CO, V23, P641, DOI 10.1016/0006-291X(66)90447-5; DEPONTIZILLI L, 1988, P NATL ACAD SCI USA, V85, P1389, DOI 10.1073/pnas.85.5.1389; EPPENBERGEREBERHARDT M, 1990, DEV BIOL, V139, P269, DOI 10.1016/0012-1606(90)90296-U; EPSTEIN HF, 1991, SCIENCE, V251, P1029; GARNER I, 1989, DEV BIOL, V134, P236, DOI 10.1016/0012-1606(89)90093-6; GREENBLATT J, 1993, NATURE, V364, P401, DOI 10.1038/364401a0; GUNNING P, 1987, MOL CELL BIOL, V7, P4100, DOI 10.1128/MCB.7.11.4100; GUNNING P, 1984, CELL, V36, P709, DOI 10.1016/0092-8674(84)90351-9; GUNNING P, 1983, MOL CELL BIOL, V3, P1985, DOI 10.1128/MCB.3.11.1985; HARDEMAN EC, 1986, CELL, V47, P123, DOI 10.1016/0092-8674(86)90373-9; HAYWARD LJ, 1986, J CELL BIOL, V102, P1485, DOI 10.1083/jcb.102.4.1485; HOGAN B, 1986, MANIPULATING MOUSE E; HUANG MTF, 1990, MOL CELL BIOL, V10, P1805, DOI 10.1128/MCB.10.4.1805; KHILLAN JS, 1986, P NATL ACAD SCI USA, V83, P725, DOI 10.1073/pnas.83.3.725; LACY E, 1983, CELL, V34, P343, DOI 10.1016/0092-8674(83)90369-0; LLOYD C, 1992, J CELL BIOL, V117, P787, DOI 10.1083/jcb.117.4.787; LOHSE P, 1988, NUCLEIC ACIDS RES, V167, P2787; Maniatis T., 1982, MOL CLONING; MAYER Y, 1984, NUCLEIC ACIDS RES, V12, P1087, DOI 10.1093/nar/12.2.1087; MCHUGH KM, 1991, DEV BIOL, V148, P442, DOI 10.1016/0012-1606(91)90263-3; MCKNIGHT GS, 1983, CELL, V34, P335; MINTY A, 1986, MOL CELL BIOL, V6, P2125, DOI 10.1128/MCB.6.6.2125; MOHUN TJ, 1986, EMBO J, V5, P3185, DOI 10.1002/j.1460-2075.1986.tb04628.x; PARI G, 1991, MOL CELL BIOL, V11, P4796, DOI 10.1128/MCB.11.9.4796; PROUDFOOT NJ, 1989, TRENDS BIOCHEM SCI, V14, P105, DOI 10.1016/0968-0004(89)90132-1; RENKAWITZ R, 1990, TRENDS GENET, V6, P192, DOI 10.1016/0168-9525(90)90176-7; ROSENTHAL N, 1989, P NATL ACAD SCI USA, V86, P7780, DOI 10.1073/pnas.86.20.7780; RUZICKA DL, 1988, J CELL BIOL, V107, P2575, DOI 10.1083/jcb.107.6.2575; SARTORELLI V, 1990, GENE DEV, V4, P1811, DOI 10.1101/gad.4.10.1811; SARTORELLI V, 1992, P NATL ACAD SCI USA, V89, P4047, DOI 10.1073/pnas.89.9.4047; SASSOON DA, 1988, DEVELOPMENT, V104, P155; SCHACHAT FH, 1985, J BIOL CHEM, V260, P1108; SHANI M, 1988, MOL CELL BIOL, V8, P1006, DOI 10.1128/MCB.8.2.1006; SOLDATI T, 1991, CELL, V66, P277, DOI 10.1016/0092-8674(91)90618-9; STROHMAN RC, 1977, CELL, V10, P265, DOI 10.1016/0092-8674(77)90220-3; SUBRAMANIAM A, 1991, J BIOL CHEM, V266, P24613; SUTHERLAND CJ, 1993, DEV DYNAM, V196, P25, DOI 10.1002/aja.1001960104; SUTHERLAND CJ, 1991, DEV BIOL, V146, P167, DOI 10.1016/0012-1606(91)90457-E; TAYLOR MV, 1991, GENE DEV, V5, P1149, DOI 10.1101/gad.5.7.1149; WADE R, 1989, ANNU REV PHYSIOL, V51, P179, DOI 10.1146/annurev.physiol.51.1.179; WRIGHT S, 1993, MOL BIOL CELL, V4, P661, DOI 10.1091/mbc.4.7.661	51	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					12212	12219						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163527				2022-12-25	WOS:A1994NG37700082
J	LEBRUN, DP; CLEARY, ML				LEBRUN, DP; CLEARY, ML			FUSION WITH E2A ALTERS THE TRANSCRIPTIONAL PROPERTIES OF THE HOMEODOMAIN PROTEIN PBX1 IN T(119) LEUKEMIAS	ONCOGENE			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; GLUTATHIONE-S-TRANSFERASE; HUMAN PROTOONCOGENE PBX1; LOOP-HELIX PROTEINS; DNA-BINDING; MAMMALIAN-CELLS; PRE-B; CHROMOSOMAL TRANSLOCATIONS; ENHANCER BINDING; GENE	The t(1;19) chromosomal translocation is observed in pre-B cell acute lymphoblastic leukemias and results in expression of chimeric E2A-PBX1 proteins that contain transcriptional activation domains from E2A and the homeodomain of PBX1. Since homeodomains mediate DNA-binding, a potential model for the action of E2A-PBX1 is that it disrupts the transcriptional regulation of genes normally controlled by PBX1 or its closely-related family members PBX2 or PBX3. Using a binding site selection assay, we identified a consensus nucleotide sequence ATCAATCA specifically bound by the PBX1 homeodomain and those of its closely-related family members PBX2 and PBX3. An endogenous protein with the properties of PBX3b specifically bound to this sequence in nuclear extracts of precursor B cells. Transfection of reporter genes containing PBX binding sites linked to a minimal promoter demonstrated transactivation by E2A-PBX1 fusion protein dependent upon presence of the homeodomain. In contrast, wild-type PBX proteins were incapable of activating transcription. The striking differences in transcriptional properties of fusion and wild-type PBX proteins,provides strong functional evidence for the importance of aberrant transcriptional regulation in the genesis of t(l;19)-bearing leukemias.			LEBRUN, DP (corresponding author), STANFORD UNIV,MED CTR,DEPT PATHOL,EXPTL ONCOL LAB,STANFORD,CA 94305, USA.				NCI NIH HHS [CA42971] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042971, R37CA042971] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARONHEIM A, 1993, P NATL ACAD SCI USA, V90, P8063, DOI 10.1073/pnas.90.17.8063; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; BURGLIN TR, 1992, NAT GENET, V1, P319, DOI 10.1038/ng0892-319; CLEARY ML, 1991, CELL, V66, P619, DOI 10.1016/0092-8674(91)90105-8; CORDLE SR, 1991, MOL CELL BIOL, V11, P1734, DOI 10.1128/MCB.11.3.1734; CRIST WM, 1990, BLOOD, V76, P117; DOLAN JW, 1991, BIOCHIM BIOPHYS ACTA, V1088, P155, DOI 10.1016/0167-4781(91)90051-M; FAINSOD A, 1991, NUCLEIC ACIDS RES, V19, P4005, DOI 10.1093/nar/19.14.4005; GAUSS GH, 1992, NUCLEIC ACIDS RES, V20, P6739, DOI 10.1093/nar/20.24.6739; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAN KH, 1989, CELL, V56, P573, DOI 10.1016/0092-8674(89)90580-1; HAN KY, 1993, GENE DEV, V7, P491, DOI 10.1101/gad.7.3.491; HENTHORN P, 1990, SCIENCE, V247, P467, DOI 10.1126/science.2105528; HUNGER SP, 1992, GENE DEV, V6, P1608, DOI 10.1101/gad.6.9.1608; KADESCH T, 1992, IMMUNOL TODAY, V13, P31, DOI 10.1016/0167-5699(92)90201-H; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KRASNOW MA, 1989, CELL, V57, P1031, DOI 10.1016/0092-8674(89)90341-3; LAUGHON A, 1991, BIOCHEMISTRY-US, V30, P11357, DOI 10.1021/bi00112a001; MELLENTIN JD, 1989, SCIENCE, V246, P379, DOI 10.1126/science.2799390; MONICA K, 1991, MOL CELL BIOL, V11, P6149, DOI 10.1128/MCB.11.12.6149; MURRE C, 1991, MOL CELL BIOL, V11, P1156, DOI 10.1128/MCB.11.2.1156; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; PEIFER M, 1990, GENE DEV, V4, P1209, DOI 10.1101/gad.4.7.1209; QUONG MW, 1993, MOL CELL BIOL, V13, P792, DOI 10.1128/MCB.13.2.792; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; RAUSKOLB C, 1993, CELL, V74, P1101, DOI 10.1016/0092-8674(93)90731-5; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; VANDIJK MA, 1993, P NATL ACAD SCI USA, V90, P6061, DOI 10.1073/pnas.90.13.6061; WEISS MJ, 1988, J BIOL CHEM, V263, P12002; WILLIAMS DL, 1984, CELL, V36, P101, DOI 10.1016/0092-8674(84)90078-3	31	82	84	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1994	9	6					1641	1647						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NL815	8183558				2022-12-25	WOS:A1994NL81500015
J	SELVAKUMARAN, M; LIN, HK; MIYASHITA, T; WANG, HG; KRAJEWSKI, S; REED, JC; HOFFMAN, B; LIEBERMANN, D				SELVAKUMARAN, M; LIN, HK; MIYASHITA, T; WANG, HG; KRAJEWSKI, S; REED, JC; HOFFMAN, B; LIEBERMANN, D			IMMEDIATE-EARLY UP-REGULATION OF BAX EXPRESSION BY P53 BUT NOT TGF-BETA-1 - A PARADIGM FOR DISTINCT APOPTOTIC PATHWAYS	ONCOGENE			English	Article							LEUKEMIA INHIBITORY FACTOR; WILD-TYPE P53; CELL-CYCLE CHECKPOINT; GROWTH-ARREST; TERMINAL DIFFERENTIATION; C-MYC; BCL-2 GENE; EARLY RESPONSE; MYELOID CELLS; DEATH	Recently, both Bcl-2, which promotes cell survival, and Bax, which promotes cell death, have been implicated as major players in the control of apoptotic pathways, and it has been suggested that the ratio of Bcl-2 and Bax protein controls the relative susceptibility of cells to death stimuli. We have used M1 myeloid leukemia cells and genetically engineered M1 variants as a model system to study apoptosis induced by two distinct apoptotic stimuli. This includes apoptosis induced by activation of wild type p53 function of a temperature sensitive p53 transgene expressed in M1 cells, which do not express endogenous p53, and apoptosis induced by TGF beta 1. It is shown that the kinetics of apoptosis induced by p53 is more rapid than apoptosis induced by TGF beta 1. It is also shown that ectopic expression of Bcl-2, at levels which blocked TGF beta 1-induced apoptosis of M1 cells, delayed, but did not block, p53-induced apoptosis. Both p53 and TGF beta 1 down-regulated endogenous Bcl-2 expression, but only p53 up-regulated Bax expression, where bax has been identified as a p53 immediate early response gene. Thus, the p53-mediated up-regulation of Bax may provide at least a partial explanation for the more rapid rate of apoptosis induced by p53 compared to by TGF beta 1, as well as for the ineffectiveness of ectopic Bcl-2 to abrogate p53-mediated apoptosis. These findings provide first insights to the molecular mechanisms which mediate p53-induced apoptosis, identifying bax and bcl-2 as p53 regulated genes, and serve as a paradigm of how the intracellular balance of Bcl-2 to Bax is differentially altered by distinct death stimuli.	TEMPLE UNIV, SCH MED, FELS INST CANC RES & MOLEC BIOL, PHILADELPHIA, PA 19140 USA; LA JOLLA CANC RES FDN, CANC RES CTR, ONCOGENE & TUMOR SUPPRESSOR GENE PROGRAM, LA JOLLA, CA 92037 USA; UNIV PENN, DEPT PHARMACOL, PHILADELPHIA, PA 19104 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Sanford Burnham Prebys Medical Discovery Institute; University of Pennsylvania			Wang, Hong-Gang/A-3018-2015	Wang, Hong-Gang/0000-0003-0551-0571	NATIONAL CANCER INSTITUTE [R01CA043618, R01CA060181, R01CA051162] Funding Source: NIH RePORTER; NCI NIH HHS [1RO1CA43618, CA-60181, 1RO1CA51162] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABDOLLAHI A, 1991, ONCOGENE, V6, P165; ABDOLLAHI A, 1991, CELL GROWTH DIFFER, V2, P401; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELIYAHU D, 1985, NATURE, V316, P158, DOI 10.1038/316158a0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; FORNACE AJ, 1992, ANN NY ACAD SCI, V663, P139, DOI 10.1111/j.1749-6632.1992.tb38657.x; FORNACE AJ, 1992, ANNU REV GENET, V26, P507; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HOFFMANLIEBERMANN B, 1991, MOL CELL BIOL, V11, P2375, DOI 10.1128/MCB.11.5.2375; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JUVEN T, 1993, ONCOGENE, V8, P3411; KARTASOVA T, 1988, MOL CELL BIOL, V8, P2195, DOI 10.1128/MCB.8.5.2195; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KITADA S, 1992, BLOOD, V80, P879; KORSMEYER SJ, 1992, CELL, V71, P587; LORD KA, 1990, ONCOGENE, V5, P387; LORD KA, 1990, CELL GROWTH DIFFER, V1, P637; LORD KA, 1990, NUCLEIC ACIDS RES, V18, P2823, DOI 10.1093/nar/18.9.2823; LOTEM J, 1990, BLOOD, V76, P1315; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MARX J, 1993, SCIENCE, V259, P760, DOI 10.1126/science.8430327; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MIYASHITA T, 1993, BLOOD, V81, P151; MIYASHITA T, 1992, CANCER RES, V52, P5407; MIYASHITA T, 1994, ONCOGENE, V9, P1799; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; QUESENBERRY PJ, 1990, HEMATOLOGY, P129; REED JC, 1991, CANCER RES, V51, P6529; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; REISS M, 1993, CANCER RES, V53, P899; SACHS L, 1987, SCIENCE, V238, P1374, DOI 10.1126/science.3317831; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; SCHNEIDER C, 1988, CELL, V54, P787, DOI 10.1016/S0092-8674(88)91065-3; SELVAKUMARAN M, 1993, BLOOD, V81, P2257; SELVAKUMARAN M, 1992, MOL CELL BIOL, V12, P2493, DOI 10.1128/MCB.12.6.2493; SELVAKUMARAN M, 1994, MOL CELL BIOL, V14, P2352, DOI 10.1128/MCB.14.4.2352; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; STANBRIDGE EJ, 1990, CELL, V63, P867, DOI 10.1016/0092-8674(90)90490-6; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WANG YS, 1993, ONCOGENE, V8, P3427; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; Wyllie A H, 1980, Int Rev Cytol, V68, P251; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361	58	537	552	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1994	9	6					1791	1798						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NL815	8183578				2022-12-25	WOS:A1994NL81500035
J	BUBB, MR; SENDEROWICZ, AMJ; SAUSVILLE, EA; DUNCAN, KLK; KORN, ED				BUBB, MR; SENDEROWICZ, AMJ; SAUSVILLE, EA; DUNCAN, KLK; KORN, ED			JASPLAKINOLIDE, A CYTOTOXIC NATURAL PRODUCT, INDUCES ACTIN POLYMERIZATION AND COMPETITIVELY INHIBITS THE BINDING OF PHALLOIDIN TO F-ACTIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SPONGE	Jasplakinolide, a naturally occurring cyclic peptide from the marine sponge, Jaspis johnstoni, has both fungicidal and antiproliferative activity. We now report that this peptide is a potent inducer of actin polymerization in vitro. The peptide has a much greater effect on Mg2+-actin than on Ca2+-actin. Competitive binding studies using rhodamine-phalloidin suggest that jasplakinolide binds to F-actin competitively with phalloidin with a dissociation constant of approximately 15 nM. This compares favorably to the previously reported IC50 of 35 nn for the antiproliferative effect of jasplakinolide on PC3 prostate carcinoma cells. The binding curve suggests that nearest neighbor positive cooperativity influences the binding of jasplakinolide (and perhaps also phalloidin) to F actin. These results imply that jasplakinolide may exert its cytotoxic effect in vivo by inducing actin polymerization and/or stabilizing pre-existing actin filaments.	NHLBI, CELL BIOL LAB, BETHESDA, MD 20892 USA; NCI, DIV CANC TREATMENT, DEV THERAPEUT PROGRAM, BIOL CHEM LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Duncan, Kimberly/C-3655-2013; Korn, Edward D/F-9929-2012	Korn, Edward/0000-0003-3867-6295				CARLIER MF, 1986, J BIOL CHEM, V261, P785; COLUCCIO LM, 1984, J CELL BIOL, V99, P529, DOI 10.1083/jcb.99.2.529; CREWS P, 1986, TETRAHEDRON LETT, V27, P2797, DOI 10.1016/S0040-4039(00)84645-6; DANCKER P, 1990, BIOCHIM BIOPHYS ACTA, V1035, P197, DOI 10.1016/0304-4165(90)90116-E; ESTES JE, 1981, BIOCHEMISTRY-US, V20, P708, DOI 10.1021/bi00507a006; ESTES JE, 1981, BIOCHEMISTRY-US, V261, P10785; FAULSTICH H, 1982, CHEM PEPTIDES PROTEI, V1, P279; HILL TL, 1985, COOPERATIVITY THEORY, P327; HUANG ZJ, 1992, ANAL BIOCHEM, V200, P199, DOI 10.1016/0003-2697(92)90299-M; JOOS L, 1987, BIOCHEM CELL BIOL, V65, P261, DOI 10.1139/o87-034; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lynen F, 1938, LIEBIGS ANN CHEM, V533, P93; MCGHEE JD, 1974, J MOL BIOL, V86, P469, DOI 10.1016/0022-2836(74)90031-X; MIYAMOTO Y, 1986, J BIOCHEM-TOKYO, V100, P1677, DOI 10.1093/oxfordjournals.jbchem.a121877; MUNEKATA E, 1978, LIEBIGS ANN CHEM, P776; Senderowicz A. M. J., 1994, Proceedings of the American Association for Cancer Research Annual Meeting, V35, P409; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; STINGL J, 1992, CANCER CHEMOTH PHARM, V30, P401, DOI 10.1007/BF00689969; WEHLAND J, 1980, EUR J CELL BIOL, V21, P188; WIELAND T, 1984, P NATL ACAD SCI-BIOL, V81, P5232, DOI 10.1073/pnas.81.16.5232; ZABRISKIE TM, 1986, J AM CHEM SOC, V108, P3123, DOI 10.1021/ja00271a062	22	679	690	0	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					14869	14871						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195116				2022-12-25	WOS:A1994NP73800006
J	BURBACH, JPH; DASILVA, SL; COX, JJ; ADAN, RAH; COONEY, AJ; TSAI, MJ; TSAI, SY				BURBACH, JPH; DASILVA, SL; COX, JJ; ADAN, RAH; COONEY, AJ; TSAI, MJ; TSAI, SY			REPRESSION OF ESTROGEN-DEPENDENT STIMULATION OF THE OXYTOCIN GENE BY CHICKEN OVALBUMIN UPSTREAM PROMOTER TRANSCRIPTION FACTOR-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOID-X-RECEPTOR; THYROID-HORMONE RECEPTOR; FACTOR COUP-TF; RESPONSE ELEMENTS; ACID RECEPTORS; LACTOFERRIN GENE; ORPHAN RECEPTORS; VITAMIN-D; RXR-BETA; EXPRESSION	The orphan receptor chicken ovalbumin upstream promoter transcription factor I (COUP-TF I) fully prevented not only the activation of the oxytocin gene by retinoic acid and thyroid hormone but also completely repressed the estrogen dependent stimulation in transfected P19 EC cells. DNase I footprinting showed that the COUP-TF I protein bound to the 5'-flanking region of the oxytocin gene at the site of the distal composite hormone response element, which mediates the responses to estrogen, retinoic acid, and thyroid hormone. Electrophoretic mobility shift assay using this composite hormone response element as probe showed that COUP-TF I and the estrogen receptor competed for binding but did not form a heterodimer. The binding by COUP-TF I was stronger than the binding of the estrogen receptor. Thus, the mechanism of repression involves occupancy of integrated binding sites. By mutagenesis of the composite hormone response element, the COUP-TF I binding site and the estrogen response element could be separated, resulting in functional dissociation of the repressive action of COUP-TF I and the induction by estrogen. The results show that repression of gene expression by COUP-TF I is not limited to receptors that act through heterodimerization but also extends to the homodimer-forming estrogen receptor in a context-dependent manner. This interaction between COUP-TF I and the estrogen receptor may provide a physiological mechanism of selective antagonism of gene regulation by estrogens.	UNIV UTRECHT, RUDOLF MAGNUS INST PHARMACOL, DEPT MED PHARMACOL, 3584 CG UTRECHT, NETHERLANDS; BAYLOR COLL MED, DEPT CELL BIOL, HOUSTON, TX 77030 USA	Utrecht University; Baylor College of Medicine					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK045641, R01DK045641] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-45641] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAN RAH, 1993, MOL ENDOCRINOL, V7, P47, DOI 10.1210/me.7.1.47; ADAN RAH, 1991, BIOCHEM BIOPH RES CO, V175, P117, DOI 10.1016/S0006-291X(05)81208-2; ADAN RAH, 1992, J BIOL CHEM, V267, P3771; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BEEKMAN JM, 1993, MOL ENDOCRINOL, V7, P1266, DOI 10.1210/me.7.10.1266; BERRODIN TJ, 1992, MOL ENDOCRINOL, V6, P1468, DOI 10.1210/me.6.9.1468; BRADLEY DJ, 1992, J NEUROSCI, V12, P2288; BROWN M, 1990, J BIOL CHEM, V265, P11238; BURBACH JPH, 1992, ANN NY ACAD SCI, V652, P1, DOI 10.1111/j.1749-6632.1992.tb34341.x; CHANG C, IN PRESS P NATL ACAD; COONEY AJ, 1991, J VIROL, V65, P2853, DOI 10.1128/JVI.65.6.2853-2860.1991; COONEY AJ, 1992, MOL CELL BIOL, V12, P4153, DOI 10.1128/MCB.12.9.4153; COONEY AJ, 1993, J BIOL CHEM, V268, P4152; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GEISER M, 1983, J BIOL CHEM, V258, P9024; IVELL R, 1984, P NATL ACAD SCI-BIOL, V81, P2006, DOI 10.1073/pnas.81.7.2006; JONK LJC, 1993, THESIS UTRECHT U; KADOWAKI Y, 1992, BIOCHEM BIOPH RES CO, V183, P492, DOI 10.1016/0006-291X(92)90509-J; KLIEWER SA, 1992, P NATL ACAD SCI USA, V89, P1448, DOI 10.1073/pnas.89.4.1448; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KUMAR V, 1986, EMBO J, V5, P2231, DOI 10.1002/j.1460-2075.1986.tb04489.x; KURAMOCHI S, 1990, J MOL BIOL, V216, P567, DOI 10.1016/0022-2836(90)90384-X; LAUDET V, 1992, EMBO J, V11, P1003, DOI 10.1002/j.1460-2075.1992.tb05139.x; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LIU YH, 1993, MOL CELL BIOL, V13, P1836, DOI 10.1128/MCB.13.3.1836; LUTZ B, 1994, DEVELOPMENT, V120, P25, DOI 10.1242/dev.120.1.25; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; MCBURNEY MW, 1982, NATURE, V299, P165, DOI 10.1038/299165a0; METZGER D, 1988, NATURE, V334, P31, DOI 10.1038/334031a0; MIYAJIMA N, 1988, NUCLEIC ACIDS RES, V16, P11057, DOI 10.1093/nar/16.23.11057; MOHR E, 1991, MOL BRAIN RES, V9, P293, DOI 10.1016/0169-328X(91)90075-9; OMALLEY BW, 1992, MOL ENDOCRINOL, V6, P1359, DOI 10.1210/me.6.9.1359; RICHARD S, 1991, J BIOL CHEM, V266, P21428; RICHARD S, 1990, J BIOL CHEM, V265, P6098; ROUET P, 1992, J BIOL CHEM, V267, P20765; SAGAMI I, 1986, MOL CELL BIOL, V6, P4259, DOI 10.1128/MCB.6.12.4259; Sambrook J, 1989, MOL CLONING LABORATO; SCHMITZ E, 1991, DNA CELL BIOL, V10, P81, DOI 10.1089/dna.1991.10.81; SWANSON LW, 1992, PROG BRAIN RES, V92, P97, DOI 10.1016/S0079-6123(08)61167-X; TENG CT, 1992, MOL ENDOCRINOL, V6, P1969, DOI 10.1210/me.6.11.1969; THOMPSON CC, 1989, P NATL ACAD SCI USA, V86, P3494, DOI 10.1073/pnas.86.10.3494; TRAN P, 1992, MOL CELL BIOL, V12, P4666, DOI 10.1128/MCB.12.10.4666; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; van der Eb A J, 1980, Methods Enzymol, V65, P826; VANZONNEVELD AJ, 1988, P NATL ACAD SCI USA, V85, P5525; WANG LH, 1987, J BIOL CHEM, V262, P16080; WANG LH, 1989, NATURE, V340, P163, DOI 10.1038/340163a0; WEHRENBERG U, 1992, BIOCHEM BIOPH RES CO, V189, P496, DOI 10.1016/0006-291X(92)91585-E; WEHRENBERG U, 1994, J NEUROENDOCRINOL, V6, P1, DOI 10.1111/j.1365-2826.1994.tb00546.x; WEHRENBERG U, 1994, IN PRESS P NATL ACAD; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	53	64	64	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					15046	15053						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195142				2022-12-25	WOS:A1994NP73800033
J	CHANDRA, S; FEWTRELL, C; MILLARD, PJ; SANDISON, DR; WEBB, WW; MORRISON, GH				CHANDRA, S; FEWTRELL, C; MILLARD, PJ; SANDISON, DR; WEBB, WW; MORRISON, GH			IMAGING OF TOTAL INTRACELLULAR CALCIUM AND CALCIUM INFLUX AND EFFLUX IN INDIVIDUAL RESTING AND STIMULATED TUMOR MAST-CELLS USING ION MICROSCOPY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASOPHILIC LEUKEMIA-CELLS; GOLGI-APPARATUS; CULTURED-CELLS; ENDOPLASMIC-RETICULUM; ELEMENTAL DISTRIBUTION; CONFOCAL MICROSCOPY; HISTAMINE-RELEASE; IMMUNOGLOBULIN-E; 2H3 CELLS; RAT-LIVER	Ion microscopy was employed to investigate intracellular total calcium concentrations and calcium influx, and efflux in resting and antigen-stimulated tumor mast cells (RBL-2H3 cells). The nucleus, a perinuclear region which included the Golgi apparatus (Golgi region), and the remaining cytoplasm were spatially resolved with the Cameca IMS-3f ion microscope in cryogenically prepared cells. In resting cells the nucleus contained about 0.60 mM, the Golgi region about 1.2 mM, and the remaining cytoplasm about 1.0 mM total calcium. Antigen stimulation of rat basophilic leukemia cells resulted in a significant loading of calcium in all three cellular compartments. Antigen stimulation in the absence of extracellular calcium resulted in a significant loss of total calcium from all three intracellular compartments. Influx and efflux of calcium were measured simultaneously in resting and stimulated cells by using stable Ca-44 in the extracellular solution, and by imaging mass 40 to determine the native intracellular calcium (Ca-40) and mass 44 to localize the Ca-44 that entered the cell from extracellular solution. After a 10-min incubation, 0.240 fmol of the total calcium per cell had been replaced with Ca-44, which amounts to about 33% of the total cell calcium. If antigen was present during this incubation there was an additional loss of 0.229 fmol of Ca-40 and an added gain of 0.476 fmol of Ca-44 per cell, which corresponds to a net increase in total intracellular calcium of 0.247 fmol.	CORNELL UNIV, DEPT PHARMACOL, ITHACA, NY 14853 USA; CORNELL UNIV, SCH APPL & ENGN PHYS, ITHACA, NY 14853 USA	Cornell University; Cornell University	CHANDRA, S (corresponding author), CORNELL UNIV, DEPT CHEM, BAKER LAB, ITHACA, NY 14853 USA.		Webb, Watt W./B-5905-2011		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024314] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 24314] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUSSERER WA, 1989, J MICROSC-OXFORD, V154, P39, DOI 10.1111/j.1365-2818.1989.tb00566.x; AUSSERER WA, 1989, ANAL CHEM, V61, P2690, DOI 10.1021/ac00199a002; BACHS O, 1987, J BIOL CHEM, V262, P10786; BAKER D, 1990, P NATL ACAD SCI USA, V87, P355, DOI 10.1073/pnas.87.1.355; BARSUMIAN EL, 1981, EUR J IMMUNOL, V11, P317, DOI 10.1002/eji.1830110410; BEAVEN MA, 1984, J BIOL CHEM, V259, P7129; BEAVEN MA, 1984, J BIOL CHEM, V259, P7137; BEAVEN MA, 1988, PROG ALLERGY, V42, P123; BECKERS CJM, 1989, J CELL BIOL, V108, P1245, DOI 10.1083/jcb.108.4.1245; BERLIN RD, 1993, CELL CALCIUM, V14, P379, DOI 10.1016/0143-4160(93)90042-5; BLACKMORE PF, 1978, J BIOL CHEM, V253, P4851; Castaing R., 1962, J MICROSC PARIS, V1, P395; CHANDRA S, 1991, J CELL SCI, V100, P747; CHANDRA S, 1987, J MICROSC-OXFORD, V148, P223, DOI 10.1111/j.1365-2818.1987.tb02869.x; CHANDRA S, 1985, SCIENCE, V228, P1543, DOI 10.1126/science.2990033; CHANDRA S, 1986, J MICROSC-OXFORD, V144, P15, DOI 10.1111/j.1365-2818.1986.tb04670.x; CHANDRA S, 1992, J CELL SCI, V102, P417; CHANDRA S, 1988, METHOD ENZYMOL, V158, P157, DOI 10.1016/0076-6879(88)58054-0; CHANDRA S, 1992, BIOL CELL, V74, P31, DOI 10.1016/0248-4900(92)90006-M; DOUGLAS WW, 1975, CALCIUM TRANSPORT CO, P167; EISEN HN, 1959, J EXP MED, V110, P187, DOI 10.1084/jem.110.2.187; FEWTRELL C, 1989, CIBA F SYMP, V147, P114; FEWTRELL C, 1987, BIOCHEMISTRY-US, V26, P6995, DOI 10.1021/bi00396a021; FEWTRELL C, 1981, BIOCH ACUTE ALLERGIC, P295; GOMPERTS BD, 1983, NATURE, V306, P64, DOI 10.1038/306064a0; HERNANDEZCRUZ A, 1990, SCIENCE, V247, P858, DOI 10.1126/science.2154851; HODSON S, 1978, J CELL SCI, V30, P117; HOLOWKA D, 1982, MOL IMMUNOL, V19, P219, DOI 10.1016/0161-5890(82)90334-0; KANNER BI, 1984, J BIOL CHEM, V26, P6995; LING YC, 1987, J CHEM INF COMP SCI, V27, P86, DOI 10.1021/ci00054a009; LIPSKY NG, 1985, SCIENCE, V228, P745, DOI 10.1126/science.2581316; LIPSKY NG, 1985, J CELL BIOL, V100, P27, DOI 10.1083/jcb.100.1.27; LIU FT, 1980, J IMMUNOL, V124, P2728; MANTUS DS, 1990, ANAL CHEM, V62, P1148, DOI 10.1021/ac00210a011; MCCLOSKEY MA, 1990, J GEN PHYSIOL, V95, P205, DOI 10.1085/jgp.95.2.205; MCCORMACK JG, 1992, BIOCHEM SOC T, V20, P153, DOI 10.1042/bst0200153; MILLARD PJ, 1989, J BIOL CHEM, V264, P19730; MILLARD PJ, 1988, P NATL ACAD SCI USA, V85, P1854, DOI 10.1073/pnas.85.6.1854; MOHR FC, 1987, J CELL BIOL, V104, P783, DOI 10.1083/jcb.104.3.783; MOHR FC, 1990, AM J PHYSIOL, V258, pC217, DOI 10.1152/ajpcell.1990.258.2.C217; NARASIMHAN V, 1988, J BIOL CHEM, V263, P19626; NICOTERA P, 1990, P NATL ACAD SCI USA, V87, P6858, DOI 10.1073/pnas.87.17.6858; ROSS CA, 1989, NATURE, V339, P468, DOI 10.1038/339468a0; SATOH T, 1990, J CELL BIOL, V111, P615, DOI 10.1083/jcb.111.2.615; SCHIBECI A, 1980, EUR J BIOCHEM, V113, P5; SELDIN DC, 1985, P NATL ACAD SCI USA, V82, P3871, DOI 10.1073/pnas.82.11.3871; SNEDECOR GW, 1989, STATISTICAL METHODS, P255; SOMLYO AP, 1985, NATURE, V314, P622, DOI 10.1038/314622a0; TAUROG JD, 1979, J IMMUNOL, V122, P2150; WEST DW, 1981, BIOCHIM BIOPHYS ACTA, V673, P374, DOI 10.1016/0304-4165(81)90469-4; [No title captured]	51	43	44	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					15186	15194						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195154				2022-12-25	WOS:A1994NP73800051
J	NGUYEN, HHT; SHIEMKE, AK; JACOBS, SJ; HALES, BJ; LIDSTROM, ME; CHAN, SI				NGUYEN, HHT; SHIEMKE, AK; JACOBS, SJ; HALES, BJ; LIDSTROM, ME; CHAN, SI			THE NATURE OF THE COPPER IONS IN THE MEMBRANES CONTAINING THE PARTICULATE METHANE MONOOXYGENASE FROM METHYLOCOCCUS-CAPSULATUS (BATH)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHYLOSINUS-TRICHOSPORIUM OB3B; HYDROXYLASE COMPONENT; MONO-OXYGENASE; METHANOTROPHS; PURIFICATION; OXIDATION	It is shown that the particulate methane monooxygenase (pMMO) has an obligate requirement for copper. The MMO activity in the particulate fractions obtained from Methylococcus capsulatus (Bath) cells is found to increase with increasing copper content of the membranes. The enzyme activity from membranes obtained from cells grown at low copper levels can be stimulated further by the addition of Cu(II) ions to the assay medium. The membrane-bound copper ions can exist in both Cu(II) and Cu(I) forms. EPR and magnetic susceptibility characterizations of the membranes indicate the presence of an exchange-coupled trinuclear Cu(II) cluster when the bulk of the copper ions is oxidized. However, the functional form of the enzyme is the reduced or partially reduced form. The copper ions in the membrane fractions as isolated often exhibit a high level of reduction. An EPR spectrum with one unpaired electron spin delocalized over three copper nuclei has been observed for the two-electron reduced trinuclear copper cluster. The high correlation between the copper level in the membranes and enzymatic activity as well as the high reactivity of the reduced copper clusters toward dioxygen strongly indicate that the membrane-bound copper ions constitute the active sites of the pMMO.	CALTECH, ARTHUR AMOS NOYES LAB CHEM PHYS, PASADENA, CA 91125 USA; CALTECH, WM KECK ENVIRONM ENGN SCI LAB, PASADENA, CA 91125 USA; LOUISIANA STATE UNIV, DEPT CHEM, BATON ROUGE, LA 70803 USA	California Institute of Technology; California Institute of Technology; Louisiana State University System; Louisiana State University					NIGMS NIH HHS [GM 22432, GM 40859] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM022432, R01GM022432, R01GM040859] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKENT'EVA N P, 1988, Biokhimiya, V53, P91; ALLENDORF MD, 1985, P NATL ACAD SCI USA, V82, P3063, DOI 10.1073/pnas.82.10.3063; ANTHONY C, 1982, BIOCH METHYLOTROPHS, P1; BEDARD C, 1989, MICROBIOL REV, V53, P68; BURROWS KJ, 1984, J GEN MICROBIOL, V130, P3327; Carlin R. L, 1986, MAGNETOCHEMISTRY, P1; Chan S.I., 1993, BIOINORGANIC CHEM CO, P184; CORNISH A, 1985, BIOTECHNOL LETT, V5, P319; Dalton H, 1984, MICROBIAL GROWTH C C, P1; DEWITT JG, 1991, J AM CHEM SOC, V113, P9219, DOI 10.1021/ja00024a031; DRUMMOND D, 1989, EUR J BIOCHEM, V182, P667; FOX BG, 1990, METHOD ENZYMOL, V188, P191; FROLAND WA, 1992, J BIOL CHEM, V267, P17588; GERLOCK M, 1983, MAGNETISM LIGAND FIE, P250; KOH SC, 1993, APPL ENVIRON MICROB, V59, P960, DOI 10.1128/AEM.59.4.960-967.1993; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEAK DJ, 1983, J GEN MICROBIOL, V129, P3487; LIDSTROM ME, 1988, A VAN LEEUW J MICROB, V54, P189, DOI 10.1007/BF00443577; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARATHE VR, 1974, CHEM PHYS LETT, V27, P103, DOI 10.1016/0009-2614(74)80454-9; MESSERSCHMIDT A, 1989, J MOL BIOL, V206, P13; MUHOBERAC BB, 1988, BIOCHEMISTRY-US, V27, P746, DOI 10.1021/bi00402a038; Murrell J. C., 1993, P109; NAKAJIMA T, 1992, BIOSCI BIOTECH BIOCH, V56, P736, DOI 10.1271/bbb.56.736; ORBACH R, 1961, PROC R SOC LON SER-A, V264, P458, DOI 10.1098/rspa.1961.0211; PRIOR SD, 1985, J GEN MICROBIOL, V131, P155; ROSENZWEIG AC, 1993, NATURE, V366, P537, DOI 10.1038/366537a0; STAINTHORPE AC, 1990, GENE, V91, P27, DOI 10.1016/0378-1119(90)90158-N; STAINTHORPE AC, 1991, FEMS MICROBIOL LETT, V70, P211; TONGE GM, 1977, BIOCHEM J, V161, P333, DOI 10.1042/bj1610333; Van Vleck J. H., 1932, THEORY ELECTRIC MAGN, P89; VERMAAS A, 1974, CHEM PHYS LETT, V27, P583, DOI 10.1016/0009-2614(74)80310-6; WHITTENBURY R, 1981, PROKARYOTES, V1, P894	33	173	173	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					14995	15005						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195135				2022-12-25	WOS:A1994NP73800026
J	GOVINDJEE, R; BALASHOV, S; EBREY, T; OESTERHELT, D; STEINBERG, G; SHEVES, M				GOVINDJEE, R; BALASHOV, S; EBREY, T; OESTERHELT, D; STEINBERG, G; SHEVES, M			LOWERING THE INTRINSIC PK(A) OF THE CHROMOPHORES SCHIFF-BASE CAN RESTORE ITS LIGHT-INDUCED DEPROTONATION IN THE INACTIVE TYR-57-]ASN MUTANT OF BACTERIORHODOPSIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							RETINAL PROTEINS; TRANSLOCATION; MECHANISM; ANALOGS; MODEL	Following light absorption, at neutral pH the bacterio rhodopsin mutant Y57N does not show Schiff base deprotonation (no M intermediate) or proton pumping activity. We reasoned that this might be due to improper Delta pK(a) between the proton-donating Schiff base and the proton-accepting Asp-85 after light absorption. To test this, we reduced the intrinsic pK(a) of the protonated Schiff base in the pigment (and thus in the photointermediates) by replacing the retinal chromophore with an analogue, 14-F retinal. This substitution restores light-induced M formation, strongly suggesting that light-induced Schiff base deprotonation is accomplished by lowering its pK(a) during the photochemical cycle. Thus, while it is generally accepted that the Schiff base deprotonation during the photocycle takes place because of the light-induced reduction in its pK(a), we provide here the first experimental evidence of this phenomenon.	UNIV ILLINOIS,DEPT CELL & STRUCT BIOL,URBANA,IL 61801; MAX PLANCK INST BIOCHEM,W-8033 MARTINSRIED,GERMANY; WEIZMANN INST SCI,DEPT ORGAN CHEM,IL-76100 REHOVOT,ISRAEL	University of Illinois System; University of Illinois Urbana-Champaign; Max Planck Society; Weizmann Institute of Science	GOVINDJEE, R (corresponding author), UNIV ILLINOIS,CTR BIOPHYS & COMP BIOL,URBANA,IL 61801, USA.							ASATO AE, 1978, J AM CHEM SOC, V100, P5957, DOI 10.1021/ja00486a066; DRUCKMANN S, 1982, BIOCHEMISTRY-US, V21, P4953, DOI 10.1021/bi00263a019; Ebrey T.G., 1993, THERMODYNAMICS MEMBR, P353; ELSAYED MA, 1992, ACCOUNTS CHEM RES, V25, P279, DOI 10.1021/ar00019a002; GAT Y, 1993, J AM CHEM SOC, V115, P3772, DOI 10.1021/ja00062a052; GOVINDJEE R, 1992, STRUCTURE FUNCTION R, V221, P115; LANYI JK, 1993, BIOCHIM BIOPHYS ACTA, V1183, P241, DOI 10.1016/0005-2728(93)90226-6; MATHIES RA, 1991, ANNU REV BIOPHYS BIO, V20, P491, DOI 10.1146/annurev.bb.20.060191.002423; MOGI T, 1987, P NATL ACAD SCI USA, V84, P5595, DOI 10.1073/pnas.84.16.5595; OESTERHELT D, 1971, NATURE-NEW BIOL, V233, P149, DOI 10.1038/newbio233149a0; OESTERHELT D, 1992, J BIOENERG BIOMEMBR, V24, P181, DOI 10.1007/BF00762676; SHEVES M, 1986, P NATL ACAD SCI USA, V83, P3262, DOI 10.1073/pnas.83.10.3262; SOPPA J, 1989, J BIOL CHEM, V264, P13049	14	24	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14353	14354						2	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	8182036				2022-12-25	WOS:A1994NM06500007
J	KRUSZKA, KK; GROSSI, RW				KRUSZKA, KK; GROSSI, RW			THE ATP-INDEPENDENT AND COA-INDEPENDENT SYNTHESIS OF ARACHIDONOYLETHANOLAMIDE - A NOVEL MECHANISM UNDERLYING THE SYNTHESIS OF THE ENDOGENOUS LIGAND OF THE CANNABINOID RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							BRAIN CONSTITUENT; RAT-LIVER; ANANDAMIDE; ACYLATION; AGONIST; ACIDS	Recently, arachidonoylethanolamide was identified as the endogenous ligand of the Delta(9) tetrahydrocannabinol receptor. Herein, we demonstrate that the synthesis of arachidonoylethanolamide is catalyzed by a novel CoA- and ATP-independent pathway, which is highly selective for arachidonic acid as the aliphatic constituent, is specific for ethanolamine as the polar moiety and occurs through a mechanism that utilizes a critical sulfhydryl residue. The production of arachidonoylethanolamide was calcium-independent and heat-labile and was selectively catalyzed by brain microsomal and cytosolic proteins among the tissues examined. Four independent lines of evidence demonstrate that the synthesis of arachidonoylethanolamide occurs through an ATP- and CoA-independent process. 1) The depletion of endogenous rabbit brain cytosolic or microsomal CoA and ATP by dialysis, or depletion of ATP by apyrase treatment, did not diminish the production of arachidonoylethanolamide; 2) the addition of exogenous ATP or CoA to cofactor depleted cytosol or microsomes did not stimulate arachidonoylethanolamide production; 3) the synthesis of arachidonoylethanolamide occurred in the absence of detectable arachidonoyl-CoA and did not correlate with either the amount of arachidonoyl-CoA in the incubation medium or the amount of arachidonoyl-CoA incorporated into polar and nonpolar lipids; 4) the addition of a 20-fold molar excess of unlabeled arachidonoyl-CoA to incubations containing [H-3]arachidonic acid and ethanolamine did not attenuate the production of [H-3]arachidonoylethanolamide by rabbit brain cytosolic or microsomal proteins. Collectively, these results demonstrate a novel chemical paradigm for the ATP- and CoA-independent conjugation of the carboxylate moiety of arachidonic acid to yield arachidonoylethanolamide, the first member of a new class of biologically active eicosanoid second messengers.	WASHINGTON UNIV,SCH MED,DEPT INTERNAL MED,DIV BIOORGAN CHEM & MOLEC PHARMACOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT CHEM,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MOLEC BIOL & PHARMACOL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)					PHS HHS [35864] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		DAAE LNW, 1970, BIOCHIM BIOPHYS ACTA, V210, P92; DEUTSCH DG, 1993, BIOCHEM PHARMACOL, V46, P791, DOI 10.1016/0006-2952(93)90486-G; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; FRIDE E, 1993, EUR J PHARMACOL, V231, P313, DOI 10.1016/0014-2999(93)90468-W; HERSH LB, 1967, J BIOL CHEM, V242, P3468; JACKIE K, 1993, MOL PHARMACOL, V44, P496; Jencks W. P., 1969, CATALYSIS CHEM ENZYM; JENCKS WP, 1960, J BIOL CHEM, V235, P3608; KORNBERG A, 1953, J BIOL CHEM, V204, P329; LOEB LA, 1986, J BIOL CHEM, V261, P467; MCKEAN ML, 1981, J BIOL CHEM, V256, P1522; MONROY G, 1972, J BIOL CHEM, V247, P6884; MOORE SA, 1982, J BIOL CHEM, V257, P882; MOURAD N, 1966, J BIOL CHEM, V241, P271; MUDERHWA JM, 1992, BIOCHEMISTRY-US, V31, P141, DOI 10.1021/bi00116a021; Numa S, 1974, Curr Top Cell Regul, V8, P197; ONTKO JA, 1972, J BIOL CHEM, V247, P1788; SILVERSTEIN R, 1967, J BIOL CHEM, V242, P1338; STERN W, 1978, J BIOL CHEM, V253, P8047; VOGEL Z, 1993, J NEUROCHEM, V61, P352, DOI 10.1111/j.1471-4159.1993.tb03576.x	20	122	123	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14345	14348						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	8182035				2022-12-25	WOS:A1994NM06500005
J	VANDEWATER, B; ZOETEWEIJ, JP; DEBONT, HJGM; MULDER, GJ; NAGELKERKE, JF				VANDEWATER, B; ZOETEWEIJ, JP; DEBONT, HJGM; MULDER, GJ; NAGELKERKE, JF			ROLE OF MITOCHONDRIAL CA2+ IN THE OXIDATIVE STRESS-INDUCED DISSIPATION OF THE MITOCHONDRIAL-MEMBRANE POTENTIAL - STUDIES IN ISOLATED PROXIMAL TUBULAR CELLS USING THE NEPHROTOXIN 1,2-DICHLOROVINYL-L-CYSTEINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONJUGATE BETA-LYASE; RAT-KIDNEY; LIPID-PEROXIDATION; MECHANISM; CALCIUM; TOXICITY; CA-2+; DEATH; HYDROPEROXIDES; PERMEABILITY	The relationship between mitochondrial Ca2+, oxidative stress, and a dissipation of the mitochondrial membrane potential (Delta psi) was investigated in proximal tubular kidney cells. Freshly isolated proximal tubular cells from rat kidney were exposed to the nephrotoxin 1,2-dichlorovinyl-L-cysteine (DCVC). DCVC stimulated the formation of hydroperoxides as determined by flow cytometry using the hydroperoxide-sensitive compound dichlorofluorescin. This was prevented by the antioxidant diphenylphenylenediamine (DPPD) and the iron chelator desferrioxamine. Studies in individual cells with video-intensified fluorescence microscopy showed that a DCVC-induced increase in the intracellular fi ee calcium concentration ([Ca2+](i)) was accompanied by an increase in the mitochondrial free calcium concentration ([Ca2+](m)). The latter increase was selectively prevented by an inhibitor of the mitochondrial calcium uniporter, ruthenium red (RR). Chelation of cellular Ca2+ with EGTA acetoxymethyl ester (EGTA/AM) completely prevented the formation of hydroperoxides, whereas inhibition of the uptake of Ca2+ by the mitochondria with RR reduced it. This indicates that the increase in [Ca2+](m) is important for the induction of oxidative stress by DCVC. DPPD and desferrioxamine did not protect against a DCVC-induced increase in [Ca2+](i) and [Ca2+](m), indicating that oxidative stress is the consequence rather than the cause of the cellular calcium perturbations. DCVC decreased Delta psi and caused cell death; both effects were clearly delayed by EGTA/AM and RR, although they could not prevent a decrease in Delta psi. The latter decrease was completely prevented by inhibition of the beta-lyase-mediated metabolism of DCVC with aminooxyacetic acid. Like EGTA/AM, inhibition of oxidative stress with DPPD and desferrioxamine delayed the decrease in Delta psi This strongly suggests that the decrease in Delta psi caused by metabolites of DCVC directly is potentiated by Ca2+-dependent DCVC-induced hydroperoxide formation. The importance of both hydroperoxide formation and mitochondrial damage in DCVC-induced cell billing is discussed.	LEIDEN UNIV,LEIDEN AMSTERDAM CTR DRUG RES,DIV TOXICOL,2300 RA LEIDEN,NETHERLANDS	Leiden University; Leiden University - Excl LUMC								BOOGAARD PJ, 1989, TOXICOL APPL PHARM, V101, P135, DOI 10.1016/0041-008X(89)90219-6; BUROW S, 1987, EUR J CELL BIOL, V43, P128; CADENAS E, 1980, BIOCHEM J, V188, P31, DOI 10.1042/bj1880031; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.biochem.56.1.395; CARBONERA D, 1988, BIOCHIM BIOPHYS ACTA, V943, P245, DOI 10.1016/0005-2736(88)90556-1; CATHCART R, 1983, ANAL BIOCHEM, V134, P111, DOI 10.1016/0003-2697(83)90270-1; CHACON E, 1991, TOXICOL APPL PHARM, V107, P117, DOI 10.1016/0041-008X(91)90336-D; CHACONE, 1992, BIOCHEM J, V281, P871; CHEN Q, 1990, J BIOL CHEM, V265, P21603; COMMANDEUR JNM, 1990, CHEM RES TOXICOL, V3, P212, DOI 10.1021/tx00015a005; DEKANT W, 1989, DRUG METAB REV, V20, P43, DOI 10.3109/03602538908994144; ELFARRA AA, 1986, MOL PHARMACOL, V31, P208; GROVES CE, 1991, TOXICOL APPL PHARM, V107, P54, DOI 10.1016/0041-008X(91)90330-H; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755; HARRIS EJ, 1982, FEBS LETT, V146, P267, DOI 10.1016/0014-5793(82)80932-0; HAYDEN PJ, 1990, MOL PHARMACOL, V37, P468; HEMMELFARB J, 1992, CYTOMETRY, V13, P83; LASH LH, 1987, MOL PHARMACOL, V32, P549; LOCK EA, 1988, CRIT REV TOXICOL, V19, P23, DOI 10.3109/10408448809040816; LOCK EA, 1989, TOXICOL LETT, V46, P93, DOI 10.1016/0378-4274(89)90120-3; MALIS CD, 1986, J BIOL CHEM, V261, P14201; NAGELKERKE JF, 1991, LIFE SCI, V49, P1769; NICHOLLS D, 1982, BIOCHIM BIOPHYS ACTA, V683, P57, DOI 10.1016/0304-4173(82)90013-1; NOVGORODOV SA, 1991, BIOCHIM BIOPHYS ACTA, V1058, P242, DOI 10.1016/S0005-2728(05)80243-9; NOVGORODOV SA, 1989, FEBS LETT, V247, P255, DOI 10.1016/0014-5793(89)81347-X; NOVGORODOV SA, 1989, FEBS LETT, V248, P179, DOI 10.1016/0014-5793(89)80456-9; RICHTER C, 1988, FREE RADICAL BIO MED, V4, P365, DOI 10.1016/0891-5849(88)90088-3; RICHTER C, 1991, CHEM-BIOL INTERACT, V77, P1, DOI 10.1016/0009-2797(91)90002-O; SCOTT JA, 1988, FREE RADICAL BIO MED, V4, P79, DOI 10.1016/0891-5849(88)90067-6; STEVENS JL, 1986, J BIOL CHEM, V261, P5529; STEVENS JL, 1988, J BIOL CHEM, V263, P3395; VANDEWATER B, 1993, BIOCHEM PHARMACOL, V45, P2259, DOI 10.1016/0006-2952(93)90197-5; VANDEWATER B, 1992, TOXICOL LETT S, P209; ZOETEWEIJ JP, 1992, BIOCHEM J, V288, P207, DOI 10.1042/bj2880207; ZOETEWEIJ JP, J BIOL CHEM, V2684, P93	35	90	91	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14546	14552						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	8182062				2022-12-25	WOS:A1994NM06500039
J	SHIMOMURA, Y; MURAKAMI, T; FUJITSUKA, N; NAKAI, N; SATO, Y; SUGIYAMA, S; SHIMOMURA, N; IRWIN, J; HAWES, JW; HARRIS, RA				SHIMOMURA, Y; MURAKAMI, T; FUJITSUKA, N; NAKAI, N; SATO, Y; SUGIYAMA, S; SHIMOMURA, N; IRWIN, J; HAWES, JW; HARRIS, RA			PURIFICATION AND PARTIAL CHARACTERIZATION OF 3-HYDROXYISOBUTYRYL-COENZYME-A HYDROLASE OF RAT-LIVER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHYLMALONATE-SEMIALDEHYDE DEHYDROGENASE; VALINE METABOLISM; ACID; HINDQUARTER	An unusual feature of valine catabolism is a reaction in which an intermediate of its catabolic pathway, (S)- 3-hydroxyisobutyryl-CoA, is hydrolyzed to give the free acid and CoA-SH. The enzyme responsible for this reaction, 3-hydroxyisobutyryl-CoA hydrolase (EC 3.1.2.4), was purified 7200-fold from rat liver in this study. The purified enzyme consists of a single polypeptide with an M(r) of 36,000 in the native and denatured forms. The hydrolase is highly specific for (S)-3-hydroxyisobutyryl-CoA and 3 hydroxypropionyl-CoA (K-m, 6 and 25 mu M, respectively) with optimal activity around pH 8. The turnover rate of the enzyme for (S)-3-hydroxyisobutyryl-CoA is 270 s(-1), which is high relative to other enzymes of the valine pathway. Likewise, activity of the enzyme expressed on a wet weight basis is also very high in the major tissues of the rat. These findings suggest that rapid destruction of (S)-3-hydroxyisobutyryl-CoA produced during valine catabolism is physiologically important. We propose that the need for a mechanism to protect cells against the toxic effects of methacrylyl-CoA which is maintained in equilibrium with (S)-3-hydroxyisobutyryl-CoA by crotonase, explains why valine catabolism involves this enzyme and why its tissue activity is so high.	INDIANA UNIV, SCH MED, DEPT BIOCHEM & MOLEC BIOL, INDIANAPOLIS, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis	SHIMOMURA, Y (corresponding author), NAGOYA INST TECHNOL, DEPT BIOSCI, SHOWA KU, GOKISO CHO, NAGOYA, AICHI 466, JAPAN.			Murakami, Taro/0000-0002-5367-2658	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040441] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 40441] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABELES RH, 1992, BIOCHEMISTRY-US, P52; BROWN GK, 1982, PEDIATRICS, V70, P532; CORKEY BE, 1982, J BIOL CHEM, V257, P9668; DEARFIELD KL, 1991, MUTAGENESIS, V6, P519, DOI 10.1093/mutage/6.6.519; DIXON M, 1979, ENZYMES, P350; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; GOODWIN GW, 1989, J BIOL CHEM, V264, P14965; Johnson  D., 1967, METHOD ENZYMOL, V10, P94, DOI DOI 10.1016/0076-6879(67)10018-9; KEDISHVILI NY, 1992, J BIOL CHEM, V267, P19724; KOVACHY RJ, 1983, J BIOL CHEM, V258, P1415; KOVACHY RJ, 1988, METHOD ENZYMOL, V166, P393; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDAAS S, 1975, CLIN CHIM ACTA, V64, P143, DOI 10.1016/0009-8981(75)90196-5; LAU EP, 1977, BIOCHEMISTRY-US, V16, P2581, DOI 10.1021/bi00631a001; LEE SHC, 1986, BIOCHEM J, V233, P621, DOI 10.1042/bj2330621; LETTO J, 1986, BIOCHEM J, V240, P909, DOI 10.1042/bj2400909; RENDINA G, 1957, J BIOL CHEM, V225, P523; ROUGRAFF PM, 1988, J BIOL CHEM, V263, P327; ROUGRAFF PM, 1990, ANAL BIOCHEM, V184, P317, DOI 10.1016/0003-2697(90)90687-5; SHIMOMURA Y, 1987, ANAL BIOCHEM, V163, P74, DOI 10.1016/0003-2697(87)90094-7; SINGH AR, 1972, J DENT RES, V51, P1632, DOI 10.1177/00220345720510062201; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SPEIR TW, 1971, BIOCHEM J, V125, P267, DOI 10.1042/bj1250267; SPYDEVOLD O, 1979, EUR J BIOCHEM, V97, P389, DOI 10.1111/j.1432-1033.1979.tb13125.x; STERN JR, 1956, J BIOL CHEM, V218, P971; STERN JR, 1956, J BIOL CHEM, V218, P985; WAGENMAKERS AJM, 1985, INT J BIOCHEM, V17, P957, DOI 10.1016/0020-711X(85)90240-X; WIELAND T, 1953, ANGEW CHEM-GER EDIT, V65, P186, DOI 10.1002/ange.19530650706; ZHANG B, 1987, BIOCHEM J, V246, P625, DOI 10.1042/bj2460625; 1986, NIH872570 US PHS PUB	30	50	92	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					14248	14253						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188708				2022-12-25	WOS:A1994NL60600079
J	OBUNIKE, JC; EDWARDS, IJ; RUMSEY, SC; CURTISS, LK; WAGNER, WD; DECKELBAUM, RJ; GOLDBERG, IJ				OBUNIKE, JC; EDWARDS, IJ; RUMSEY, SC; CURTISS, LK; WAGNER, WD; DECKELBAUM, RJ; GOLDBERG, IJ			CELLULAR DIFFERENCES IN LIPOPROTEIN LIPASE-MEDIATED UPTAKE OF LOW-DENSITY LIPOPROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-RELATED PROTEIN; HEPARAN-SULFATE PROTEOGLYCANS; SMOOTH-MUSCLE CELLS; BINDING; METABOLISM; ATHEROSCLEROSIS; CHYLOMICRONS; LOCALIZATION; DEGRADATION; FIBROBLASTS	Lipoprotein lipase (LPL) increases the cellular uptake and degradation of LDL by fibroblasts and macrophages via a heparin-sensitive process. The roles of the LDL receptor, LDL receptor related protein (LRP), and proteoglycans in this process were studied. In up regulated human fibroblasts, LPL increased degradation of I-125-low density lipoprotein (LDL) (5 mu g/ml) only 30% during a 6-h incubation at 37 degrees C. Monoclonal antibody 47 (which interacts with the receptor binding region of apoB) decreased LDL degradation 93% in the absence of LPL, but did not reduce the LPL mediated increase in degradation. In contrast, addition of the 39-kDa receptor-associated protein (RAP) caused a 43% decrease in the LPL-dependent LDL degradation in non-up-regulated fibroblasts. Monoclonal antibody 47 did not decrease LDL degradation by THP-1 macrophages and RAP caused a <13% decrease in LPL-mediated LDL degradation. LPL also increased the association of acetyl LDL with the surface of the macrophages but did not increase acetyl LDL degradation. The kinetics of LPL- mediated LDL metabolism in macrophages was then compared with that in fibroblasts. The half lives of cell surface LDL and LPL during a subsequent 37 degrees C incubation were approximately 1 h in THP-1 cells versus 6 h in fibroblasts. In addition, 50% of the I-125-LDL and 30% of the I-125-LPL were degraded within 3 h. After metabolic labeling of THP-1 proteoglycans with (SO4)-S-35, >30% of pericellular heparan sulfate was lost between 2-4 h of the chase period. Therefore, some of the LPL-mediated LDL degradation in the THP-1 cells could be accounted for by internalization of cell surface proteoglycans. We conclude that LRP, but not the LDL receptor, is involved in LPL mediated degradation of LDL in fibroblasts. This process is much more rapid in THP-1 cells and in addition to LRP may involve other receptors and internalization of proteoglycans.	COLUMBIA UNIV, COLL PHYS & SURG, DEPT MED, NEW YORK, NY 10032 USA; COLUMBIA UNIV, COLL PHYS & SURG, DEPT PEDIAT, NEW YORK, NY 10032 USA; BOWMAN GRAY SCH MED, DEPT COMPARAT MED, WINSTON SALEM, NC 27157 USA; SCRIPPS RES INST, LA JOLLA, CA 92037 USA	Columbia University; Columbia University; Wake Forest University; Wake Forest Baptist Medical Center; Scripps Research Institute					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL014197, R01HL040404, R01HL045095, R37HL045095] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-40404, HL-45095, HL-14197] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AUWERX JH, 1989, BIOCHEMISTRY-US, V28, P4563, DOI 10.1021/bi00437a009; AVIRAM M, 1988, J BIOL CHEM, V263, P15416; BABIRAK SP, 1989, ARTERIOSCLEROSIS, V9, P326, DOI 10.1161/01.ATV.9.3.326; BEISIEGEL U, 1989, NATURE, V341, P162, DOI 10.1038/341162a0; BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; CHAPPELL DA, 1992, J BIOL CHEM, V267, P25764; CHAPPELL DA, 1993, J BIOL CHEM, V268, P14168; CHATTERJEE S, 1976, P NATL ACAD SCI USA, V73, P4339, DOI 10.1073/pnas.73.12.4339; CHOI SY, 1993, J BIOL CHEM, V268, P15804; DESCAMPS O, 1993, J BIOL CHEM, V268, P974; EDWARDS IJ, 1988, J BIOL CHEM, V263, P9612; EDWARDS IJ, 1992, AM J PATHOL, V140, P193; EISENBERG S, 1992, J CLIN INVEST, V90, P2013, DOI 10.1172/JCI116081; FELTS JM, 1975, BIOCHEM BIOPH RES CO, V66, P1467, DOI 10.1016/0006-291X(75)90524-0; GOLDBERG IJ, 1989, J LIPID RES, V30, P1569; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HUSSAIN MM, 1991, J BIOL CHEM, V266, P13936; JACKLE S, 1993, J LIPID RES, V34, P309; LAMARRE J, 1993, J CLIN INVEST, V91, P1219, DOI 10.1172/JCI116283; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MULDER M, 1992, BIOCHEM BIOPH RES CO, V185, P582, DOI 10.1016/0006-291X(92)91664-C; MULDER M, 1993, J BIOL CHEM, V268, P9369; NYKJAER A, 1993, J BIOL CHEM, V268, P15048; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; OBRIEN KD, 1992, J CLIN INVEST, V89, P1544, DOI 10.1172/JCI115747; Olivecrona Thomas, 1993, Current Opinion in Lipidology, V4, P187, DOI 10.1097/00041433-199306000-00003; RUMSEY SC, 1992, J CLIN INVEST, V90, P1504, DOI 10.1172/JCI116018; SAXENA U, 1989, J BIOL CHEM, V264, P4349; SAXENA U, 1993, J BIOL CHEM, V268, P14812; SAXENA U, 1992, J CLIN INVEST, V89, P373, DOI 10.1172/JCI115595; SOCORRO L, 1985, PREP BIOCHEM, V15, P133, DOI 10.1080/10826068508062267; VILARO S, 1988, BIOCHEM J, V249, P549, DOI 10.1042/bj2490549; WILLIAMS KJ, 1992, J BIOL CHEM, V267, P13284; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172; YLAHERTTUALA S, 1991, P NATL ACAD SCI USA, V88, P10143, DOI 10.1073/pnas.88.22.10143; YOUNG SG, 1986, ARTERIOSCLEROSIS, V6, P178, DOI 10.1161/01.ATV.6.2.178; ZIERE GJ, 1992, J BIOL CHEM, V267, P11229	41	79	79	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13129	13135						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175739				2022-12-25	WOS:A1994NK18400015
J	PAWLOWSKI, JE; PENNING, TM				PAWLOWSKI, JE; PENNING, TM			OVEREXPRESSION AND MUTAGENESIS OF THE CDNA FOR RAT-LIVER 3-ALPHA-HYDROXYSTEROID DIHYDRODIOL DEHYDROGENASE - ROLE OF CYSTEINES AND TYROSINES IN CATALYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLACENTAL ESTRADIOL 17-BETA-DEHYDROGENASE; TRANS-DIHYDRODIOL OXIDATION; ANTI-INFLAMMATORY DRUGS; ALDOSE REDUCTASE; ALDEHYDE REDUCTASE; MULTIPLE FORMS; ACTIVE-SITE; IDENTIFICATION; INHIBITION; PURIFICATION	The overexpression and purification of recombinant rat liver 3 alpha-hydroxysteroid/dihydrodiol dehydrogenase (3 alpha-HSD; EC 1.1.1.50) in Escherichia coli are described. The properties of the homogeneous recombinant 3 alpha-HSD (r3 alpha-HSD) confirm that a single polypeptide can function as a HSD, as a dihydrodiol dehydrogenase, and as an aromatic aldehyde, ketone, and quinone reductase. Cys-170, Cys-242, and Cys-217, implicated by bromoacetoxysteroid affinity-labeling agents as points of contact for the C-3, C-11, and C-17 positions of steroid ligands, were mutated to alanines. Unexpectedly, the homogeneous C170A and C242A mutants were kinetically similar to wild-type r3 alpha-HSD. By contrast, the C217A mutant gave K-m values that were 4-fold higher for androstanedione and 2-fold higher for NADH. Inspection of the recently solved crystal structure of rat liver 3 alpha-HSD (Hoog, S. S., Pawlowski, J. E., Alzari, P. M., Penning, T. M., and Lewis, M. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 2517-2521) places Cys-170 and Cys-242 on the periphery of an alpha/beta-barrel so that they cannot be involved in catalysis or steroid recognition. This demonstrates that bromoacetoxysteroid affinity-labeling agents may provide misleading information regarding the topography of steroid hormone binding sites. When NADPH was modeled into the crystal structure of 3 alpha-HSD, Tyr-55 was implicated as the general acid, since it is in close proximity to the C-4 position of the nicotinamide ring and could polarize the substrate carbonyl. In support of this model, the purified Y55F mutant was found to be catalytically inactive, but still formed an E.NADPH complex (measured by fluorescence titration) and an E.NADH testosterone complex (measured by equilibrium dialysis). The ability of the Y55F mutant to form binary and ternary complexes, but not aid in hydride transfer, is consistent with Tyr-55 acting as the general acid. 3 alpha-HSD is a member of the aldo-keto reductase superfamily, and Tyr-55 is invariant in members of this family where it may perform a similar function. Tyr-205 is present in a pentapeptide sequence that is conserved in HSDs that belong to the short-chain alcohol dehydrogenase family and has been implicated as the general acid within these enzymes. The Y205F mutant was found to be kinetically similar to wild-type r3 alpha-HSD. Our data support the concept that the tyrosines used as general acids in catalysis are different for the HSDs that belong to the aldo-keto reductase and short chain alcohol dehydrogenase families.	UNIV PENN,SCH MED,DEPT PHARMACOL,PHILADELPHIA,PA 19104	University of Pennsylvania				Penning, Trevor/0000-0002-3937-1066	NATIONAL CANCER INSTITUTE [R01CA039504, R01CA055711] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047015] Funding Source: NIH RePORTER; NCI NIH HHS [CA39504, CA55711] Funding Source: Medline; NIDDK NIH HHS [DK47015] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBARRACIN CT, 1993, 75TH ANN M END SOC L; ASKONAS LJ, 1991, BIOCHEM J, V278, P835, DOI 10.1042/bj2780835; BHATNAGAR YM, 1978, J BIOL CHEM, V253, P811; CARPER D, 1987, FEBS LETT, V220, P209, DOI 10.1016/0014-5793(87)80905-5; CHEN Z, 1993, BIOCHEMISTRY-US, V32, P3342, DOI 10.1021/bi00064a017; CHENG KC, 1991, MOL ENDOCRINOL, V5, P823, DOI 10.1210/mend-5-6-823; CHIN CC, 1982, BIOCHEMISTRY-US, V21, P3322, DOI 10.1021/bi00257a012; CHUNG S, 1989, J BIOL CHEM, V264, P14775; Cleland W W, 1979, Methods Enzymol, V63, P103; Cory M, 1977, Methods Enzymol, V46, P115; DIXON M, 1953, BIOCHEM J, V55, P170, DOI 10.1042/bj0550170; ENSOR CM, 1991, BIOCHEM BIOPH RES CO, V176, P840, DOI 10.1016/S0006-291X(05)80262-1; HARA A, 1985, BIOCHEM J, V225, P177, DOI 10.1042/bj2250177; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HOFF HG, 1973, H-S Z PHYSIOL CHEM, V354, P507, DOI 10.1515/bchm2.1973.354.1.507; HOOG SS, 1994, P NATL ACAD SCI USA, V91, P2517, DOI 10.1073/pnas.91.7.2517; IKEDA M, 1981, H-S Z PHYSIOL CHEM, V362, P511, DOI 10.1515/bchm2.1981.362.1.511; IVINS JK, 1987, CANCER RES, V47, P680; KLEIN J, 1992, EUR J BIOCHEM, V205, P1155, DOI 10.1111/j.1432-1033.1992.tb16885.x; LACY WR, 1993, MOL ENDOCRINOL, V7, P58, DOI 10.1210/me.7.1.58; Leatherbarrow R.J, 1987, ENZFITTER NONLINEAR; LEVY MA, 1987, BIOCHEMISTRY-US, V26, P2270, DOI 10.1021/bi00382a030; LI YK, 1993, BIOCHEMISTRY-US, V32, P1816, DOI 10.1021/bi00058a016; LOWRY OH, 1961, J BIOL CHEM, V236, P2756; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATSUURA K, 1987, BIOCHIM BIOPHYS ACTA, V912, P270, DOI 10.1016/0167-4838(87)90097-5; MURDOCK GL, 1983, J BIOL CHEM, V258, P1460; MURDOCK GL, 1986, BIOCHEMISTRY-US, V25, P641, DOI 10.1021/bi00351a019; MURDOCK GL, 1986, BIOCHIM BIOPHYS ACTA, V1076, P197; NAKAGAWA M, 1989, CHEM PHARM BULL, V37, P2852; OBEID J, 1992, BIOCHEM BIOPH RES CO, V188, P222, DOI 10.1016/0006-291X(92)92373-6; PAWLOWSKI JE, 1991, J BIOL CHEM, V266, P8820; PENNING TM, 1987, BIOCHEM BIOPH RES CO, V148, P646, DOI 10.1016/0006-291X(87)90925-9; PENNING TM, 1986, STEROIDS, V47, P221; PENNING TM, 1984, BIOCHEM J, V222, P601, DOI 10.1042/bj2220601; PENNING TM, 1991, J BIOL CHEM, V266, P8826; PETRASH JM, 1989, CURR EYE RES, V8, P1021, DOI 10.3109/02713688908997394; RICIGLIANO JW, 1990, BIOCHEM J, V269, P749, DOI 10.1042/bj2690749; SAWADA H, 1988, BIOCHEM PHARMACOL, V37, P453, DOI 10.1016/0006-2952(88)90214-6; SMITHGALL TE, 1986, CARCINOGENESIS, V7, P583, DOI 10.1093/carcin/7.4.583; SMITHGALL TE, 1988, BIOCHEM J, V254, P715, DOI 10.1042/bj2540715; SMITHGALL TE, 1986, J BIOL CHEM, V261, P6184; SMITHGALL TE, 1988, J BIOL CHEM, V263, P1814; STOLZ A, 1991, J BIOL CHEM, V266, P15253; STOLZ A, 1987, J CLIN INVEST, V79, P427, DOI 10.1172/JCI112829; STOLZ A, 1993, J BIOL CHEM, V268, P10448; TOMKINS GM, 1956, J BIOL CHEM, V218, P437; WARREN JC, 1993, BIOCHEMISTRY-US, V32, P1401, DOI 10.1021/bi00057a003; WATANABE K, 1988, P NATL ACAD SCI USA, V85, P11, DOI 10.1073/pnas.85.1.11; WILKINSON G, 1961, BIOCHEM J, V80, P324, DOI 10.1042/bj0800324; WILSON DK, 1992, SCIENCE, V257, P81, DOI 10.1126/science.1621098; WINTERS CJ, 1990, BIOCHEMISTRY-US, V29, P1080, DOI 10.1021/bi00456a034	52	74	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13502	13510						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175784				2022-12-25	WOS:A1994NK18400067
J	CHEN, J; ALBERTI, S; MATTHEWS, KS				CHEN, J; ALBERTI, S; MATTHEWS, KS			WILD-TYPE OPERATOR BINDING AND ALTERED COOPERATIVITY FOR INDUCER BINDING OF LAC REPRESSOR DIMER MUTANT R3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LACTOSE REPRESSOR; LEUCINE ZIPPER; DNA COMPLEX; COILED COIL; PROTEIN; RECOGNITION; DISSOCIATION; MUTATIONS	Substitution of the C-terminal leucine heptad repeat region of the normally tetrameric lactose repressor by the leucine heptad repeat dimerization domain of GCN4 protein resulted in cell extracts containing protein, designated R3, which behaved as a dimer based on gel retardation analysis of DNA binding (Alberti, S., Oehler, S., von Wilcken-Bergmann, B., and Muller-Hill, B. (1993) EMBO J. 12, 3227-3236). We have purified this R3 protein and characterized its properties in comparison with the wild-type repressor. R3 protein elutes from a molecular sieve with a Stokes radius characteristic of a dimer and a deduced molecular mass of 66 kDa. Unlike other dimeric repressors, produced by deletion or mutation in the leucine heptad repeat region, which display reduced apparent operator affinity R3 binds to operator DNA sequences with wild-type equilibrium and kinetic properties. Although inducer affinity at neutral pH is similar for R3 and wild-type protein, at elevated pH the R3 protein undergoes a slightly smaller decrease in affinity and exhibits minimal cooperativity in sugar binding compared with the wild-type protein. Interestingly, in the presence of operator DNA, a state in which inducer binding to wild-type repressor is also of reduced affinity and slightly cooperative, R3 binding affinity is decreased to a greater extent, and the protein displays higher cooperativity than wild-type repressor. Consistent with inducer binding data in the presence of operator, the release of operator from R3 protein requires a higher sugar concentration than wild-type protein. These results are interpreted in the context of alterations involving the subunit interface which affect the allosteric behavior of the repressor protein.	RICE UNIV,DEPT BIOCHEM & CELL BIOL,HOUSTON,TX 77251; UNIV COLOGNE,INST GENET,D-50931 COLOGNE,GERMANY	Rice University; University of Cologne				Chen, Jie/0000-0002-7887-3747	NIGMS NIH HHS [GM22441] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022441] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADLER K, 1972, NATURE, V237, P322, DOI 10.1038/237322a0; ALBERTI S, 1993, EMBO J, V12, P3227, DOI 10.1002/j.1460-2075.1993.tb05992.x; ALBERTI S, 1991, NEW BIOL, V3, P57; BARKLEY MD, 1975, BIOCHEMISTRY-US, V14, P1700, DOI 10.1021/bi00679a024; BOURGEOIS S, 1971, METHODS ENZYMOLOGY D, V21, P491; BRENOWITZ M, 1991, J BIOL CHEM, V266, P1281; CHAKERIAN AE, 1991, J BIOL CHEM, V266, P1371; CHANG WI, 1993, J BIOL CHEM, V268, P17613; CHARLIER M, 1981, J MOL BIOL, V153, P177, DOI 10.1016/0022-2836(81)90533-7; CHARLIER M, 1980, NATURE, V286, P423, DOI 10.1038/286423a0; CHEN J, 1992, GENE, V111, P145, DOI 10.1016/0378-1119(92)90618-Y; CHEN J, 1992, J BIOL CHEM, V267, P13843; CHEN J, 1994, BIOCHEMISTRY-US, V33, P1234, DOI 10.1021/bi00171a025; CULARD F, 1982, FEBS LETT, V146, P153, DOI 10.1016/0014-5793(82)80724-2; CULARD F, 1981, NUCLEIC ACIDS RES, V9, P5175, DOI 10.1093/nar/9.19.5175; DALY TJ, 1986, BIOCHEMISTRY-US, V25, P5479, DOI 10.1021/bi00367a020; DALY TJ, 1986, BIOCHEMISTRY-US, V25, P5468, DOI 10.1021/bi00367a018; DALY TJ, 1986, BIOCHEMISTRY-US, V25, P5474, DOI 10.1021/bi00367a019; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; KISTERSWOIKE B, 1991, EUR J BIOCHEM, V198, P411, DOI 10.1111/j.1432-1033.1991.tb16030.x; KLEINA LG, 1990, J MOL BIOL, V212, P295, DOI 10.1016/0022-2836(90)90126-7; LAMERICHS RMJN, 1989, BIOCHEMISTRY-US, V28, P2985, DOI 10.1021/bi00433a037; LEHMING N, 1990, EMBO J, V9, P615, DOI 10.1002/j.1460-2075.1990.tb08153.x; LEHMING N, 1987, EMBO J, V6, P3145, DOI 10.1002/j.1460-2075.1987.tb02625.x; LEHMING N, 1988, P NATL ACAD SCI USA, V85, P7947, DOI 10.1073/pnas.85.21.7947; LIN SY, 1975, BIOCHEM BIOPH RES CO, V62, P704, DOI 10.1016/0006-291X(75)90456-8; MCKAY DB, 1982, J MOL BIOL, V156, P175, DOI 10.1016/0022-2836(82)90465-X; Miller J. H., 1980, OPERON; MILLER JH, 1979, J MOL BIOL, V131, P249, DOI 10.1016/0022-2836(79)90075-5; MILLER JH, 1979, J MOL BIOL, V131, P191, DOI 10.1016/0022-2836(79)90073-1; Muller-Hill B, 1975, Prog Biophys Mol Biol, V30, P227; OGATA RT, 1979, J MOL BIOL, V132, P709, DOI 10.1016/0022-2836(79)90384-X; OGORMAN RB, 1980, J BIOL CHEM, V255, P107; OGORMAN RB, 1980, J BIOL CHEM, V255, P100; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; OSHEA EK, 1989, SCIENCE, V245, P646, DOI 10.1126/science.2503872; PILZ I, 1980, BIOCHEMISTRY-US, V19, P4087, DOI 10.1021/bi00558a028; PLATT T, 1973, J BIOL CHEM, V248, P110; RIGGS AD, 1970, J MOL BIOL, V53, P401, DOI 10.1016/0022-2836(70)90074-4; RIGGS AD, 1968, J MOL BIOL, V34, P361, DOI 10.1016/0022-2836(68)90260-X; RIGGS AD, 1968, J MOL BIOL, V34, P365, DOI 10.1016/0022-2836(68)90261-1; ROYER CA, 1986, BIOCHEMISTRY-US, V25, P8308, DOI 10.1021/bi00373a027; SAMS CF, 1985, J BIOL CHEM, V260, P1185; SCHMITZ A, 1976, J BIOL CHEM, V251, P3359; STEITZ TA, 1974, P NATL ACAD SCI USA, V71, P593, DOI 10.1073/pnas.71.3.593; WHITSON PA, 1986, BIOCHEMISTRY-US, V25, P3845, DOI 10.1021/bi00361a016	47	26	27	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12482	12487						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175655				2022-12-25	WOS:A1994NH71600020
J	SKEIKY, YAW; DREVET, JR; SWEVERS, L; IATROU, K				SKEIKY, YAW; DREVET, JR; SWEVERS, L; IATROU, K			PROTEIN-PHOSPHORYLATION AND CONTROL OF CHORION GENE ACTIVATION THROUGH TEMPORAL MOBILIZATION OF A PROMOTER DNA-BINDING FACTOR FROM THE CYTOPLASM INTO THE NUCLEUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; BOMBYX-MORI; TRANSCRIPTIONAL REGULATION; DEVELOPMENTAL REGULATION; IFN-GAMMA; SEQUENCE; DROSOPHILA; EXPRESSION; CHROMATIN; CACTUS	The transcriptional activation of high cysteine chorion genes in the follicular cells of the silkworm Bombyx mori occurs at the end of oogenesis and coincides with the appearance of a chorion promoter DNA binding factor, BCFI, in follicular cell nuclei. Follicular cells of vitellogenic and choriogenic follicles that do not express high cysteine chorion genes contain high levels of a latent form of BCFI in their cytoplasm. The abundance of the cytoplasmic factor, termed cBCFI, is dramatically reduced during late choriogenesis, coincident with the appearance of factor BCFI in the nucleus and the transcriptional activation of high cysteine genes. Mobility shift assays performed with partially proteolyzed nuclear and cytoplasmic extracts of follicular cells, DNA binding assays carried out in the presence of anti- BCFI antibodies, and electrophoretic analyses of the proteins present in the nuclear and cytoplasmic fractions of follicular cells and recognized by the same antibodies suggest that factor cBCFI represents a covalently modified version of BCFI. The DNA-binding sites of BCFI and cBCFI include a core sequence, AGATAA, but, while this sequence is sufficient for specific binding of BCFI, it only constitutes part of the DNA-binding site of cBCFI. Dephosphorylation of cBCFI results in a change of its binding specificity to that of BCFI. The cytoplasmic sequestration of cBCFI appears to be mediated by a phosphorylation-dependent, reversible association of this factor with an ancillary cytoplasmic factor.	UNIV CALGARY,DEPT MED BIOCHEM,CALGARY T2N 4N1,AB,CANADA	University of Calgary			Drevet, Joël/W-2692-2019	Drevet, Joël/0000-0003-3077-6558				BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; CANNON PD, 1989, THESIS U CALGARY CAN; DECKER T, 1991, EMBO J, V10, P927, DOI 10.1002/j.1460-2075.1991.tb08026.x; DREVET JR, 1994, IN PRESS J BIOL CHEM, V269; EVANS T, 1988, P NATL ACAD SCI USA, V85, P5976, DOI 10.1073/pnas.85.16.5976; EVANS T, 1989, CELL, V58, P877, DOI 10.1016/0092-8674(89)90940-9; GEISLER R, 1992, CELL, V71, P613, DOI 10.1016/0092-8674(92)90595-4; HUNT T, 1989, CELL, V59, P949, DOI 10.1016/0092-8674(89)90747-2; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; IATROU K, 1980, CELL, V20, P659, DOI 10.1016/0092-8674(80)90312-8; IATROU K, 1983, EMBO J, V2, P1431, DOI 10.1002/j.1460-2075.1983.tb01604.x; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; Kafatos F.C, 1977, Results Probl Cell Differ, V8, P45; KARIN M, 1992, TRENDS BIOCHEM SCI, V17, P418, DOI 10.1016/0968-0004(92)90012-X; KIDD S, 1992, CELL, V71, P623, DOI 10.1016/0092-8674(92)90596-5; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MOUNIER N, 1986, BIOCHIMIE, V68, P1053, DOI 10.1016/S0300-9084(86)80179-1; ORKIN SH, 1990, CELL, V63, P665, DOI 10.1016/0092-8674(90)90133-Y; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SKEIKY YAW, 1991, J MOL BIOL, V218, P517, DOI 10.1016/0022-2836(91)90698-6; SKEIKY YAW, 1990, J MOL BIOL, V213, P53, DOI 10.1016/S0022-2836(05)80121-4; SKEIKY YAW, 1991, MOL CELL BIOL, V11, P1954, DOI 10.1128/MCB.11.4.1954; SWEVERS L, 1992, DEV BIOL, V150, P12, DOI 10.1016/0012-1606(92)90003-Y; WU C, 1984, NATURE, V311, P81, DOI 10.1038/311081a0; WU C, 1984, NATURE, V309, P229, DOI 10.1038/309229a0	31	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					12196	12203						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163525				2022-12-25	WOS:A1994NG37700080
J	WALDRON, RT; SHORT, AD; MEADOWS, JJ; GHOSH, TK; GILL, DL				WALDRON, RT; SHORT, AD; MEADOWS, JJ; GHOSH, TK; GILL, DL			ENDOPLASMIC-RETICULUM CALCIUM-PUMP EXPRESSION AND CONTROL OF CELL-GROWTH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM; THAPSIGARGIN; INHIBITION; PROTEINS; MUSCLE; CA-2+; GTP; CA-2+-ATPASE; INVOLVEMENT; MECHANISM	Intracellular Ca2+ pump expression and Ca2+ pool function are shown to be closely associated with growth and proliferation of DDT(1)MF-2 hamster smooth muscle cells. The Ca2+ pump blocker thapsigargin induces sustained Ca2+ pool emptying and entry of cells into a quiescent G(0)-like state (Short, A. D., Bian, J., Ghosh, T. K., Waldron, R. T., Rybak, S. L., and Gill, D. L. (1993) Proc. Natl. Acad. Sci. U.S.A. 90, 4986-4990). Using DDT(1)MF-2 cells growth-arrested by exposure to 3 mu M thapsigargin for 24 h, treatment with 20% serum for 6 h without thapsigargin induced expression of functional Ca2+ pump protein detected as a 110-kDa thapsigargin-sensitive phosphorylated intermediate; 2.5% serum treatment resulted in no functional pump expression. Western analysis revealed only a slight serum-induced increase in total Ca2+ pump protein, New functional Ca2+ pump protein could be detected within 1 h of high serum treatment of thapsigargin-arrested cells, increasing over a 6-h period and correlating with the appearance of new Ca2+ pools. Induction of Ca2+ pools required serum at 10% or higher; no pools appeared with 5% serum or less, Significantly, high serum was required for only a brief but precise period of time. Exposure of thapsigargin-arrested cells to a 45-min pulse of 20% serum followed by continued culture in 2.5% serum was sufficient for full induction of new functional Ca2+ pump protein and Ca2+ pools; in contrast, no primps or pools were detected after a 30-min serum pulse. A 40-min high serum pulse resulted in arrested cells reentering the cell cycle, synthesizing DNA, and resuming normal proliferation; in contrast, 35 min of serum treatment resulted in cells remaining totally quiescent. The results provide important evidence for the necessity of functional endoplasmic reticulum Ca2+ pumps in serum-induced cell growth and reflect a remarkably precise signaling period during which quiescent cells become committed to a progression of events including Ca2+ pump expression, Ca2+ pool function, reentry into the cell cycle, and cell division.	UNIV MARYLAND, SCH MED, DEPT BIOL CHEM, BALTIMORE, MD 21201 USA	University System of Maryland; University of Maryland Baltimore			Waldron, Richard Taliesin/ABF-2773-2020	Waldron, Richard Taliesin/0000-0003-3151-6002	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS019304] Funding Source: NIH RePORTER; NINDS NIH HHS [NS19304] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BIAN JH, 1991, J BIOL CHEM, V266, P8801; CANTILINA T, 1993, J BIOL CHEM, V268, P17018; CHUEH SH, 1987, J BIOL CHEM, V262, P13857; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; GHOSH TK, 1989, NATURE, V340, P236, DOI 10.1038/340236a0; GHOSH TK, 1990, SCIENCE, V248, P1653, DOI 10.1126/science.2163543; GHOSH TK, 1988, J BIOL CHEM, V263, P11075; GHOSH TK, 1991, J BIOL CHEM, V266, P24690; Gill Donald L., 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P265; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAN JK, 1992, J CELL BIOL, V116, P147, DOI 10.1083/jcb.116.1.147; INESI G, 1992, ANN NY ACAD SCI, V671, P32, DOI 10.1111/j.1749-6632.1992.tb43782.x; KAO JPY, 1990, J CELL BIOL, V111, P183, DOI 10.1083/jcb.111.1.183; KIJIMA Y, 1991, J BIOL CHEM, V266, P22912; KUZNETSOV G, 1992, J BIOL CHEM, V267, P3932; KUZNETSOV G, 1993, J BIOL CHEM, V268, P2001; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LODISH HF, 1992, J BIOL CHEM, V267, P12753; MACLENNAN DH, 1992, ANN NY ACAD SCI, V671, P1, DOI 10.1111/j.1749-6632.1992.tb43779.x; MAGNIER C, 1992, J BIOL CHEM, V267, P15808; MICHALAK M, 1992, BIOCHEM J, V285, P681, DOI 10.1042/bj2850681; MILNER RE, 1992, MOL CELL BIOCHEM, V112, P1; MOORE GA, 1987, FEBS LETT, V224, P331, DOI 10.1016/0014-5793(87)80479-9; MULLANEY JM, 1988, P NATL ACAD SCI USA, V85, P2499, DOI 10.1073/pnas.85.8.2499; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; RENARDROONEY DC, 1993, J BIOL CHEM, V268, P23601; ROSSIER MF, 1991, TRENDS NEUROSCI, V14, P310, DOI 10.1016/0166-2236(91)90143-I; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; SAGARA Y, 1991, J BIOL CHEM, V266, P13503; SAMBROOK JF, 1990, CELL, V61, P197, DOI 10.1016/0092-8674(90)90798-J; SHORT AD, 1993, J BIOL CHEM, V268, P25887; SHORT AD, 1993, P NATL ACAD SCI USA, V90, P4986, DOI 10.1073/pnas.90.11.4986; STEINHARDT RA, 1988, NATURE, V332, P364, DOI 10.1038/332364a0; SULLIVAN KMC, 1993, CELL, V73, P1411, DOI 10.1016/0092-8674(93)90366-X; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; WEBER K, 1969, J BIOL CHEM, V244, P4406; WHITAKER M, 1990, DEVELOPMENT, V108, P525; WICTOME M, 1992, BIOCHEM J, V283, P525, DOI 10.1042/bj2830525; WIKSTROM L, 1993, J BIOL CHEM, V268, P14412; WONG WL, 1993, BIOCHEM J, V289, P71, DOI 10.1042/bj2890071	42	95	99	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					11927	11933						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163492				2022-12-25	WOS:A1994NG37700040
J	RIENDEAU, D; GUAY, J; WEECH, PK; LALIBERTE, F; YERGEY, J; LI, C; DESMARAIS, S; PERRIER, H; LIU, S; NICOLLGRIFFITH, D; STREET, IP				RIENDEAU, D; GUAY, J; WEECH, PK; LALIBERTE, F; YERGEY, J; LI, C; DESMARAIS, S; PERRIER, H; LIU, S; NICOLLGRIFFITH, D; STREET, IP			ARACHIDONYL TRIFLUOROMETHYL KETONE, A POTENT INHIBITOR OF 85-KDA PHOSPHOLIPASE A(2), BLOCKS PRODUCTION OF ARACHIDONATE AND 12-HYDROXYEICOSATETRAENOIC ACID BY CALCIUM IONOPHORE-CHALLENGED PLATELETS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC PHOSPHOLIPASE-A2; INDEPENDENT PHOSPHOLIPASE-A2; PREFERENTIALLY HYDROLYZES; CONTAINING VESICLES; SUICIDE INHIBITION; U937 CELLS; RELEASE; PURIFICATION; RAT; ENZYME	Arachidonyl trifluoromethyl ketone (AACOCF(3)) is a potent and selective slow binding inhibitor of the 85-kDa cytosolic phospholipase A(2) (cPLA(2)) (Street, I. P., Lin, H.-K., Laliberte, F., Ghomashchi, F., Wang, Z., Perrier; H., Tremblay, N. M., Huang, Z., Weech, P.K., and Gelb, M. H. (1993) Biochemistry 32, 5935-5940). AACOCF(3) and a number of its structural analogues have been used to investigate the role of cPLA(2) in the cellular generation of free arachidonic acid (AA) and in eicosanoid biosynthesis. AACOCF(3) inhibited the release of AA from calcium ionophore-challenged U937 cells (IC50 = 8 mu M, 2 x 10(6) cells ml(-1)) and from platelets (IC50 = 2 mu M, 4 x 10(7) cells ml(-1)). Arachidonyl methyl ketone (AACOCH(3)) and AACH(OH)CF3, both of which are noninhibitory to the purified cPLA(2), did not inhibit the production of AA in the ionophore-challenged cells. In addition 60 the release of AA, AA-COCF3 also inhibited the production of 12-hydroxyeicosatetraenoic acid (12-HETE) and thromboxane B-2, two of the major metabolites of AA produced by platelets. The inhibition of 12-HETE biosynthesis showed a dose dependence similar to that of AA release in ionophore-challenged platelets; however, when platelet 12-HETE production was stimulated with 10 mu M AA to circumvent the PLA(2)-dependent step, AACOCF(3) no longer inhibited the production of 12-HETE. In contrast, AACOCF(3) blocked thromboxane B-2 formation by both calcium ionophore- and AA-challenged platelets, indicating that the compound affects the cyclooxygenase pathway in addition to AA release. The crude cytosol and membrane fractions from platelets were assayed for calcium-dependent and calcium-independent PLA(2) activities and for the susceptibility of each to inhibition by AACOCF(3). At AACOCF(3) concentrations as high as 10 mol %, only one of the observed PLA(2) activities was inhibited by more than 25%. The AACOCF(3)-susceptible PLA(2) (77% inhibition at 1.6 mol %) was found in the cytosolic platelet fraction and showed the functional characteristics of the cPLA(2). These results suggest that the cPLA(2) plays an important role in the generation of free AA for 12-HETE biosynthesis in platelets.	MERCK FROSST CTR THERAPEUT RES, DEPT MOLEC BIOL & BIOCHEM, POINTE CLAIRE H9R 4P8, PQ, CANADA; MERCK FROSST CTR THERAPEUT RES, DEPT MED CHEM, POINTE CLAIRE H9R 4P8, PQ, CANADA	Merck & Company; Merck & Company								APITZCASTRO RJ, 1979, BIOCHEM BIOPH RES CO, V91, P63, DOI 10.1016/0006-291X(79)90583-7; BARBOUR SE, 1993, J BIOL CHEM, V268, P21875; BELL RL, 1979, P NATL ACAD SCI USA, V76, P3238, DOI 10.1073/pnas.76.7.3238; CHAU LY, 1983, BIOCHEM BIOPH RES CO, V113, P241, DOI 10.1016/0006-291X(83)90457-6; CHEVY F, 1991, LIPIDS, V26, P1080, DOI 10.1007/BF02536506; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CLARK JD, 1990, P NATL ACAD SCI USA, V87, P7708, DOI 10.1073/pnas.87.19.7708; GHOMASHCHI F, 1992, BIOCHEMISTRY-US, V31, P3814, DOI 10.1021/bi00130a012; HANEL AM, 1993, BIOCHEMISTRY-US, V32, P5949, DOI 10.1021/bi00074a005; HAZEN SL, 1990, J BIOL CHEM, V265, P10622; HAZEN SL, 1991, J BIOL CHEM, V266, P7227; HAZEN SL, 1991, BIOCHEM J, V280, P581, DOI 10.1042/bj2800581; HORIGOME K, 1987, J BIOCHEM-TOKYO, V101, P625, DOI 10.1093/jb/101.3.625; IMAI A, 1982, JPN J EXP MED, V52, P99; KANNAGI R, 1979, ARCH BIOCHEM BIOPHYS, V196, P534, DOI 10.1016/0003-9861(79)90305-9; KIM DK, 1988, J BIOCHEM-TOKYO, V104, P492, DOI 10.1093/oxfordjournals.jbchem.a122496; Kramer R M, 1990, Adv Exp Med Biol, V275, P35; KRAMER RM, 1993, J LIPID MEDIATOR, V6, P209; KRAMER RM, 1993, J BIOL CHEM, V268, P26796; LEHMAN JJ, 1993, J BIOL CHEM, V268, P20713; LEHR M, 1992, PHARM PHARM LETT, V2, P176; LI C, 1991, 39TH P ASMS C MASS S; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; LU AYH, 1972, BIOCHEM BIOPH RES CO, V46, P1334, DOI 10.1016/S0006-291X(72)80121-9; MEADE CJ, 1986, BIOCHEM J, V238, P425, DOI 10.1042/bj2380425; MIZUSHIMA H, 1989, J BIOCHEM-TOKYO, V105, P520, DOI 10.1093/oxfordjournals.jbchem.a122699; MOUNIER C, 1993, EUR J BIOCHEM, V216, P169, DOI 10.1111/j.1432-1033.1993.tb18129.x; MURAKAMI M, 1993, J BIOL CHEM, V268, P839; MURAKAMI M, 1990, BIOCHIM BIOPHYS ACTA, V1043, P34, DOI 10.1016/0005-2760(90)90107-9; RAMANADHAM S, 1993, BIOCHEMISTRY-US, V32, P337, DOI 10.1021/bi00052a042; RAMANADHAM S, 1992, BIOCHEM BIOPH RES CO, V184, P647, DOI 10.1016/0006-291X(92)90638-2; SCHALKWIJK CG, 1992, EUR J BIOCHEM, V210, P169, DOI 10.1111/j.1432-1033.1992.tb17405.x; STREET IP, 1993, BIOCHEMISTRY-US, V32, P5935, DOI 10.1021/bi00074a003; TAKAYAMA K, 1991, FEBS LETT, V282, P326, DOI 10.1016/0014-5793(91)80506-X; TREMBLAY NM, 1993, PROTEIN EXPRES PURIF, V4, P490, DOI 10.1006/prep.1993.1064; TREMBLAY NM, 1992, BIOCHEM BIOPH RES CO, V183, P121, DOI 10.1016/0006-291X(92)91617-Y; WINKLER JD, 1991, BIOCHIM BIOPHYS ACTA, V1081, P339, DOI 10.1016/0005-2760(91)90291-O; ZUPAN LA, 1993, J MED CHEM, V36, P95, DOI 10.1021/jm00053a012	39	248	252	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15619	15624						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	8195210				2022-12-25	WOS:A1994NP51300038
J	LEE, SL; YU, ASL; LYTTON, J				LEE, SL; YU, ASL; LYTTON, J			TISSUE-SPECIFIC EXPRESSION OF NA+-CA2+ EXCHANGER ISOFORMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SODIUM-CALCIUM EXCHANGER; FUNCTIONAL EXPRESSION; NA+/CA2+ EXCHANGER; MOLECULAR-CLONING; RABBIT KIDNEY; HELA-CELLS; GENE; RAT; LOCALIZATION; TRANSCRIPTS	The sodium-calcium exchanger (NCE) plays a critical role in diverse processes in many different tissues including heart, nerve, and kidney. Surprisingly, the NCE is encoded by a single gene. We have isolated and sequenced a rat renal NCE clone, denoted F1, that was identical to previous rat NCEs, except for two unique sequences: one in the 5'-untranslated region and the other at a site of alternative splicing in the coding sequence. To explore these regions further, we examined NCE transcripts in several tissues using- ''rapid amplification of cDNA 5'-ends'' and polymerase chain reaction amplification. Three species were identified each with a different 5'-end exon spliced to a common NCE core at nucleotide -34 in the 5'-untranslated region. Based on Northern analysis, each of these species had a unique tissue distribution. Whereas the F1 5'-end variant was abundantly expressed only in kidney, a second variant was expressed mostly in heart, and the third variant was expressed ubiquitously elsewhere. Investigation of the region of alternative splicing in the coding sequence also revealed tissue-specific expression of five major species. These findings indicate that the NCE expression is controlled and regulated under the influence of different promoters in a tissue-specific fashion. Therefore, we propose that the structural complexity of the single NCE gene allows it to respond independently to the unique demands of different environments.	BRIGHAM & WOMENS HOSP,DEPT MED,DIV RENAL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School			Yu, Alan/AID-7467-2022	Yu, Alan/0000-0002-1776-2533; Lytton, Jonathan/0000-0003-4770-2512	NIDDK NIH HHS [T32 DK07527] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007527] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ACETO JF, 1992, ARCH BIOCHEM BIOPHYS, V298, P553, DOI 10.1016/0003-9861(92)90449-7; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BINDELS RJM, 1992, PFLUG ARCH EUR J PHY, V420, P566, DOI 10.1007/BF00374634; BLAUSTEIN MP, 1991, ANN NY ACAD SCI, V639, P254, DOI 10.1111/j.1749-6632.1991.tb17315.x; BLAUSTEIN MP, 1991, ANN NY ACAD SCI, V639; BOURDEAU JE, 1993, J AM SOC NEPHROL, V4, P105; DURKIN JT, 1991, ARCH BIOCHEM BIOPHYS, V290, P369, DOI 10.1016/0003-9861(91)90553-U; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FURMAN I, 1993, FEBS LETT, V319, P105, DOI 10.1016/0014-5793(93)80046-W; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HAHN SL, 1993, J NEUROCHEM, V60, P1058, DOI 10.1111/j.1471-4159.1993.tb03254.x; HRYSHKO LV, 1993, BIOCHIM BIOPHYS ACTA, V1151, P35, DOI 10.1016/0005-2736(93)90068-B; KILPATRICK DL, 1990, MOL CELL BIOL, V10, P3717, DOI 10.1128/MCB.10.7.3717; KOFUJI P, 1993, AM J PHYSIOL, V265, pF598, DOI 10.1152/ajprenal.1993.265.4.F598; KOFUJI P, 1994, J BIOL CHEM, V269, P5145; KOFUJI P, 1992, AM J PHYSIOL, V263, pC1241, DOI 10.1152/ajpcell.1992.263.6.C1241; KOMURO I, 1992, P NATL ACAD SCI USA, V89, P4769, DOI 10.1073/pnas.89.10.4769; LAUGHON A, 1986, MOL CELL BIOL, V6, P4676, DOI 10.1128/MCB.6.12.4676; LEE SL, 1994, BIOPHYS J, V66, pA330; LI ZP, 1993, J BIOL CHEM, V268, P11489; LI ZP, 1992, J BIOL CHEM, V267, P7828; LOW W, 1993, FEBS LETT, V316, P63, DOI 10.1016/0014-5793(93)81737-K; MATSUOKA S, 1993, P NATL ACAD SCI USA, V90, P3870, DOI 10.1073/pnas.90.9.3870; MCDANIEL LD, 1993, CYTOGENET CELL GENET, V63, P192, DOI 10.1159/000133532; NICOLL DA, 1990, SCIENCE, V250, P562, DOI 10.1126/science.1700476; PIJUAN V, 1993, AM J PHYSIOL, V264, pC1066, DOI 10.1152/ajpcell.1993.264.4.C1066; REILLY RF, 1993, AM J PHYSIOL, V265, pF327, DOI 10.1152/ajprenal.1993.265.2.F327; REILLY RF, 1992, AM J PHYSIOL, V262, pF1105, DOI 10.1152/ajprenal.1992.262.6.F1105; SAMBROOK J, 1989, MOL CLONIN LABORATOR; TAYLOR Z, 1985, J BIOL CHEM, V260, P15473; VORONOVA AF, 1987, MOL CELL BIOL, V7, P4407, DOI 10.1128/MCB.7.12.4407; WU KD, 1993, AM J PHYSIOL, V264, pC333, DOI 10.1152/ajpcell.1993.264.2.C333; YU ASL, 1992, AM J PHYSIOL, V263, pF680, DOI 10.1152/ajprenal.1992.263.4.F680; [No title captured]	34	220	223	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					14849	14852						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195112				2022-12-25	WOS:A1994NP73800001
J	LAND, M; ISLASTREJO, A; RUBIN, CS				LAND, M; ISLASTREJO, A; RUBIN, CS			ORIGIN, PROPERTIES, AND REGULATED EXPRESSION OF MULTIPLE MESSENGER-RNAS ENCODED BY THE PROTEIN-KINASE C1 GENE OF CAENORHABDITIS-ELEGANS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPLICED LEADER RNA; RAT-BRAIN; IMMUNOCYTOCHEMICAL LOCALIZATION; DEVELOPMENTAL REGULATION; CATALYTIC SUBUNIT; MESSENGER-RNA; SINGLE GENE; BETA-GENE; SEQUENCE; CLONING	Recently, we cloned and characterized cDNA encoding a novel, protein kinase C (designated PKC1B) from Caenorhabditis elegans. PKC1B (707 amino acid residues) is a developmentally regulated, calcium-independent kinase that is expressed exclusively in sensory neurons and related interneurons. We have now discovered a mechanism by which a second, distinct mRNA (PKC1A mRNA) with increased protein coding potential is generated from the C. elegans PKC1 gene. PKC1A mRNA is produced in a process that involves the utilization of an alternative, distal promoter, the incorporation of two unique exons into the mRNA, and alternative cis/trans splicing. Diversity among PKC1 gene transcripts is increased substantially by trans-splicing. The 5' end of PKC1A mRNA contains an acceptor site that is modified by the addition of either a classical spliced leader sequence 2 or one of four novel spliced leaders. PKC1A mRNA encodes a predicted kinase that contains the entire sequence of PKC1B as well as an N-terminal extension of 56 residues. The extension contains a preponderance of basic amino acids. The levels of transcripts arising from the distal (1A) and proximal (1B) promoters for the PKC1 gene are differentially regulated during C. elegans development. The ratio of 1B mRNA:1A mRNA varies from 40:1 to unity as the nematodes progress from early larval stages to mature adults. The novel exons in the PKC1A structural gene are not contiguous with the PKC1A promoter but are instead positioned downstream from a second gene, kinase upstream gene-1, in the context of a multicistronic operon. PKC1A and kinase upstream gene-1 mRNAs are coordinately expressed in a fixed ratio throughout C. elegans post-embryonic development, suggesting that a shared upstream promoter regulates transcription of both genes. Finally, PKC1A and PKC1B mRNA levels are differentially regulated by phorbol esters in a process that may involve the participation of another PKC isoform that is analogous to mammalian PKC delta.			LAND, M (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED,ATRAN LABS,DEPT MOLEC PHARMACOL,1300 MORRIS PK AVE,BRONX,NY 10461, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044957, T32DK007513] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK07513, DK44957] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ASAOKA Y, 1992, TRENDS BIOCHEM SCI, V17, P414, DOI 10.1016/0968-0004(92)90011-W; BAIER G, 1993, J BIOL CHEM, V268, P4997; BERRA E, 1993, CELL, V74, P555, DOI 10.1016/0092-8674(93)80056-K; BLOBE GC, 1993, J BIOL CHEM, V268, P10627; BLUMENTHAL T, 1988, TRENDS GENET, V4, P305, DOI 10.1016/0168-9525(88)90107-2; BURNS DJ, 1990, J BIOL CHEM, V265, P12044; CHEN KH, 1990, J BIOL CHEM, V265, P19961; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; CUMMINS C, 1988, MOL CELL BIOL, V8, P5339, DOI 10.1128/MCB.8.12.5339; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; FIRE A, 1991, DEVELOPMENT, V113, P503; FIRE A, 1990, GENE, V93, P189, DOI 10.1016/0378-1119(90)90224-F; FREEDMAN JH, 1993, J BIOL CHEM, V268, P2554; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GROSS RE, 1990, J BIOL CHEM, V265, P6896; HAN M, 1990, CELL, V63, P921, DOI 10.1016/0092-8674(90)90495-Z; HAN M, 1993, NATURE, V363, P133, DOI 10.1038/363133a0; HOSODA K, 1989, P NATL ACAD SCI USA, V86, P1393, DOI 10.1073/pnas.86.4.1393; HU E, 1991, J BIOL CHEM, V266, P19796; HU ED, 1990, J BIOL CHEM, V265, P5072; HUANG XY, 1989, P NATL ACAD SCI USA, V86, P8640, DOI 10.1073/pnas.86.22.8640; Jaken S, 1990, CURR OPIN CELL BIOL, V2, P192, DOI 10.1016/0955-0674(90)90006-Z; KENYON C, 1988, SCIENCE, V240, P1448, DOI 10.1126/science.3287621; KHAN WA, 1993, J BIOL CHEM, V268, P5063; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; KOIDE H, 1992, P NATL ACAD SCI USA, V89, P1149, DOI 10.1073/pnas.89.4.1149; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; KRUGER KE, 1991, J NEUROSCI, V11, P2303; KUWABARA PE, 1992, MOL BIOL CELL, V3, P461, DOI 10.1091/mbc.3.4.461; LAND M, 1994, J BIOL CHEM, V269, P9234; LU X, 1990, J BIOL CHEM, V265, P3292; MARAIS RM, 1990, FEBS LETT, V277, P151, DOI 10.1016/0014-5793(90)80831-3; MCSWINEKENNICK RL, 1991, J BIOL CHEM, V266, P15135; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; NIINO YS, 1992, J BIOL CHEM, V267, P6158; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OBEID LM, 1992, J BIOL CHEM, V267, P20804; OBEID LM, 1990, J BIOL CHEM, V265, P2370; OHNO S, 1988, CELL, V53, P731, DOI 10.1016/0092-8674(88)90091-8; ONO Y, 1987, SCIENCE, V236, P1116, DOI 10.1126/science.3576226; ONO Y, 1988, J BIOL CHEM, V263, P6927; OSADA S, 1990, J BIOL CHEM, V265, P22434; OZAWA K, 1993, J BIOL CHEM, V268, P2280; OZAWA K, 1993, J BIOL CHEM, V268, P1749; PEARS C, 1991, BIOCHEM J, V276, P257, DOI 10.1042/bj2760257; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; SAITO N, 1989, P NATL ACAD SCI USA, V86, P3409, DOI 10.1073/pnas.86.9.3409; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAAP D, 1990, J BIOL CHEM, V265, P7301; SPIETH J, 1993, CELL, V73, P521, DOI 10.1016/0092-8674(93)90139-H; STABEL S, 1991, PHARMACOL THERAPEUT, V51, P71, DOI 10.1016/0163-7258(91)90042-K; SULSTON J, 1988, NEMATODE CAENORHABDI, P123; TABUSE Y, 1983, CARCINOGENESIS, V4, P783, DOI 10.1093/carcin/4.6.783; TABUSE Y, 1989, SCIENCE, V243, P1713, DOI 10.1126/science.2538925; THOMAS JD, 1988, CELL, V54, P533, DOI 10.1016/0092-8674(88)90075-X; VANDOREN K, 1988, NATURE, V335, P556; WETSEL WC, 1992, J CELL BIOL, V117, P121, DOI 10.1083/jcb.117.1.121; WOOTEN MW, 1992, FEBS LETT, V298, P74, DOI 10.1016/0014-5793(92)80025-C; YOSHIDA Y, 1988, J BIOL CHEM, V263, P9868; ZWAAL RR, 1993, P NATL ACAD SCI USA, V90, P7431, DOI 10.1073/pnas.90.16.7431; [No title captured]	63	34	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14820	14827						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	8182089				2022-12-25	WOS:A1994NM06500079
J	CARRAWAY, KL; SLIWKOWSKI, MX; AKITA, R; PLATKO, JV; GUY, PM; NUIJENS, A; DIAMONTI, AJ; VANDLEN, RL; CANTLEY, LC; CERIONE, RA				CARRAWAY, KL; SLIWKOWSKI, MX; AKITA, R; PLATKO, JV; GUY, PM; NUIJENS, A; DIAMONTI, AJ; VANDLEN, RL; CANTLEY, LC; CERIONE, RA			THE ERBB3 GENE-PRODUCT IS A RECEPTOR FOR HEREGULIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-ACTIVITY; HUMAN-BREAST; EXPRESSION; ONCOGENE; CANCER; LIGAND; CELLS	ErbB3 is a member of the epidermal growth factor (EGF) receptor subfamily of receptor tyrosine kinases and is believed to be a receptor for an unknown ligand. We have tested the possibility that heregulin, a growth factor possessing an EGF-like domain, is a ligand for ErbB3. We have found that the iodinated recombinant EGF-like domain of heregulin-beta 1 (I-125-rHRG beta 1(177-244)) bound specifically to insect cell-expressed bovine ErbB3 with a dissociation constant of 0.85 nM. Moreover, I-125-rHRG beta 1(177-244) bound to NIH3T3 fibroblasts stably transfected with bovine erbB3 with a dissociation constant of 60 pM, but did not bind to parental cells. I-125-rHRG beta 1(177-244) could be chemically cross-linked to a 170-180 kDa protein in erbB3-transfected fibroblasts, and the cross-linked product could be immunoprecipitated with antibodies specific for ErbB3. Finally, rHRG beta 1 stimulated the tyrosine phosphorylation of both ErbB3 and endogenous p185(erbB2/neu) in, transfectants but not in parental cells. We conclude that ErbB3 is a receptor for HRG and is capable of mediating HRG-stimulated tyrosine phosphorylation of itself and pl85(erbB2/neu) in cells that express both receptors.	HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115; BETH ISRAEL HOSP,DIV SIGNAL TRANSDUCT,BOSTON,MA 02115; GENENTECH INC,S SAN FRANCISCO,CA 94080; CORNELL UNIV,DEPT PHARMACOL,ITHACA,NY 14853	Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Roche Holding; Genentech; Cornell University			Cantley, Lewis C/D-1800-2014	Cantley, Lewis C/0000-0002-1298-7653	NIGMS NIH HHS [R01 GM041890, GM40654, GM41890] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040654, R01GM041890, R37GM041890] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CULOUSCOU JM, 1993, J BIOL CHEM, V268, P18407; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; GREENFIELD C, 1988, EMBO J, V7, P139, DOI 10.1002/j.1460-2075.1988.tb02793.x; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; KRAUS MH, 1993, P NATL ACAD SCI USA, V90, P2900, DOI 10.1073/pnas.90.7.2900; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; PELES E, 1993, EMBO J, V12, P961, DOI 10.1002/j.1460-2075.1993.tb05737.x; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; PRIGENT S A, 1992, Progress in Growth Factor Research, V4, P1, DOI 10.1016/0955-2235(92)90002-Y; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	18	361	393	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					14303	14306						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188716				2022-12-25	WOS:A1994NL60600087
J	KASLIN, E; HEYER, WD				KASLIN, E; HEYER, WD			A MULTIFUNCTIONAL EXONUCLEASE FROM VEGETATIVE SCHIZOSACCHAROMYCES-POMBE CELLS EXHIBITING IN-VITRO STRAND EXCHANGE ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER PROTEIN-ALPHA; SACCHAROMYCES-CEREVISIAE; GENETIC-RECOMBINATION; ESCHERICHIA-COLI; HOMOLOGOUS RECOMBINATION; DNA EXONUCLEASE; MEIOTIC CELLS; RECA PROTEIN; PURIFICATION; BINDING	A 140-kDa polypeptide (p140) has been purified over 2000-fold from vegetative Schizosaccharomyces pombe cells using an assay of homologous pairing and strand exchange between linear double-stranded DNA (dsDNA) and circular single-stranded DNA (ssDNA) in vitro. Electron microscopic analysis of the reaction products showed displacement of one strand of the linear duplex DNA by the circular ssDNA molecule. In addition, the protein contained 5' to 3' exonuclease activity on ssDNA and dsDNA (with a 50-fold preference on the single-stranded substrate) as well as on single stranded RNA. Furthermore, p140 was capable of renaturing complementary ssDNA as shown by S1 nuclease assays. p140 behaved like a monomer in solution under reaction conditions. Direct comparison of the biochemical properties, sequence analysis, and cross-reactivity to a monoclonal antibody suggests that p140 is probably identical with ExoII, purified from S. pombe meiotic cells as a ssDNA exonuclease (Szankasi, P., and Smith, G. R. (1992) Biochemistry 31, 6769-6773). Given the diverse activities of p140, the protein might be involved in DNA and/or RNA metabolism in vivo.	UNIV BERN,INST GEN MICROBIOL,CH-3012 BERN,SWITZERLAND	University of Bern								ARAI N, 1992, J BIOL CHEM, V267, P3514; BAHLER J, 1994, IN PRESS CHROMOSOMA; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASSUTO E, 1971, NATURE-NEW BIOL, V229, P13, DOI 10.1038/newbio229013a0; CLARK AB, 1991, MOL CELL BIOL, V11, P2576, DOI 10.1128/MCB.11.5.2576; COX MM, 1981, P NATL ACAD SCI-BIOL, V78, P3433, DOI 10.1073/pnas.78.6.3433; Davis R.W., 1971, METHODS ENZYMOL, V21, P413; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DYKSTRA CC, 1991, MOL CELL BIOL, V11, P2583, DOI 10.1128/MCB.11.5.2583; DYKSTRA CC, 1990, J BIOL CHEM, V265, P10968; EGGLESTON AK, 1991, BIOCHIMIE, V73, P163, DOI 10.1016/0300-9084(91)90199-B; FISHEL RA, 1981, NATURE, V294, P184, DOI 10.1038/294184a0; HALBROOK J, 1989, J BIOL CHEM, V264, P21403; HALL SD, 1993, J BACTERIOL, V175, P277, DOI 10.1128/JB.175.1.277-287.1993; HEYER WD, 1988, J BIOL CHEM, V263, P15189; HEYER WD, 1993, PROG NUCLEIC ACID RE, V46, P221, DOI 10.1016/S0079-6603(08)61023-5; JOHNSON AW, 1991, J BIOL CHEM, V266, P14046; JOSEPH JW, 1983, J BIOL CHEM, V258, P418; KASLIN E, 1994, J BIOL CHEM, V269, P14103; KERR C, 1972, J BIOL CHEM, V247, P305; KIM JM, 1990, GENETICS, V126, P799; KOLODNER R, 1987, P NATL ACAD SCI USA, V84, P5560, DOI 10.1073/pnas.84.16.5560; KOWALCZYKOWSKI SC, 1991, ANNU REV BIOPHYS BIO, V20, P539, DOI 10.1146/annurev.bb.20.060191.002543; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVERY PE, 1992, J BIOL CHEM, V267, P9307; LLOYD RG, 1988, MOL GEN GENET, V212, P317, DOI 10.1007/BF00334702; LOVETT ST, 1988, GENETICS, V120, P37; LOVETT ST, 1989, P NATL ACAD SCI USA, V86, P2627, DOI 10.1073/pnas.86.8.2627; LOVETT ST, 1984, J BACTERIOL, V157, P190, DOI 10.1128/JB.157.1.190-196.1984; LOWENHAUPT K, 1989, J BIOL CHEM, V264, P20568; MELIN L, 1992, EMBO J, V11, P691, DOI 10.1002/j.1460-2075.1992.tb05101.x; MESELSON MS, 1975, P NATL ACAD SCI USA, V72, P358, DOI 10.1073/pnas.72.1.358; MOORE SP, 1990, J BIOL CHEM, V265, P11108; MUNIYAPPA K, 1986, J BIOL CHEM, V261, P7472; NORRIS D, 1990, BIOCHEMISTRY-US, V29, P7903, DOI 10.1021/bi00486a018; Petes T. D., 1991, MOL CELLULAR BIOL YE, P407; RICHARDSON CC, 1966, J MOL BIOL, V15, P49, DOI 10.1016/S0022-2836(66)80208-5; SADOWSKI PD, 1985, NUCLEASES, P23; SANDER M, 1991, P NATL ACAD SCI USA, V88, P6780, DOI 10.1073/pnas.88.15.6780; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; SIKORAV JL, 1991, J MOL BIOL, V222, P1085, DOI 10.1016/0022-2836(91)90595-W; Sipiczki M, 1989, MOL BIOL FISSION YEA, P431; SMITH GR, 1988, MICROBIOL REV, V52, P1; STEVENS A, 1978, BIOCHEM BIOPH RES CO, V81, P656, DOI 10.1016/0006-291X(78)91586-3; STEVENS A, 1991, J BACTERIOL, V173, P7024, DOI 10.1128/jb.173.21.7024-7028.1991; STEVENS A, 1980, J BIOL CHEM, V255, P3080; STEVENS A, 1987, ARCH BIOCHEM BIOPHYS, V252, P339, DOI 10.1016/0003-9861(87)90040-3; SUGINO A, 1988, P NATL ACAD SCI USA, V85, P3683, DOI 10.1073/pnas.85.11.3683; SZANKASI P, 1992, J BIOL CHEM, V267, P3014; SZANKASI P, 1992, BIOCHEMISTRY-US, V31, P6769, DOI 10.1021/bi00144a017; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; TISHKOFF DX, 1991, MOL CELL BIOL, V11, P2593, DOI 10.1128/MCB.11.5.2593; WEST SC, 1992, ANNU REV BIOCHEM, V61, P603, DOI 10.1146/annurev.bi.61.070192.003131; [No title captured]	54	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					14094	14102						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188690				2022-12-25	WOS:A1994NL60600057
J	RAO, GHR; FIELDS, CG; WHITE, JG; FIELDS, GB				RAO, GHR; FIELDS, CG; WHITE, JG; FIELDS, GB			PROMOTION OF HUMAN PLATELET-ADHESION AND AGGREGATION BY A SYNTHETIC, TRIPLE-HELICAL MINI-COLLAGEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM MOBILIZATION; BASEMENT-MEMBRANE; IV COLLAGEN; ACTIVATION; IDENTIFICATION; REQUIREMENT; SEQUENCES; ALPHA-2-BETA-1-INTEGRIN; SUBENDOTHELIUM; ALPHA-1(IV)	Platelet activation and aggregation by fibrillar collagens are based on substrate primary, secondary, tertiary, and quaternary structure. Although several peptides incorporating sequences from the triple-helical domains of types I and III collagen inhibit collagen-mediated platelet aggregation, none independently promote platelet activation and aggregation. It is believed that the absence of these platelet activities is due to the lack of proper substrate tertiary and quaternary structures. We have utilized a synthetic, triple-helical ''mini-collagen'' that incorporates a known cell adhesion site (alpha 1(IV)1263-1277) to better understand the relationship between substrate primary, secondary, tertiary, and quaternary structure and platelet activation and aggregation. The promotion of platelet adhesion, activation, and aggregation was compared for this triple helical polypeptide (THP), fibrillar and type TV collagens, and a single-stranded peptide (SSP) incorporating the alpha 1(TV)1263-1277 sequence. Glass coated fibrillar and type IV collagens and the THP supported platelet adhesion at substrate concentrations of 0.33 nM, 0.20 an, and 0.89 mu M, respectively. When platelets were stirred with 10 mu g/ml of fibrillar (0.33 nn) and type TV (0.20 nM) collagen, SSP (2.1 mu M), and THP (0.89 mu M), only the fibrillar collagen caused H-3-labeled arachidonic acid release, elevation of cytosolic calcium, irreversible aggregation, and secretion of granule contents. The THP (0.45-1.8 mu M) effectively inhibited fibrillar collagen-mediated platelet aggregation, while the SSP did not. At a substrate concentration of 40 mu g/ml, the THP (3.6 mu M) was as effective as fibrillar collagen (1.3 nM) at inducing H-3-labeled oleic acid-labeled platelet activation and microaggregate formation, while the SSP and type IV collagen were relatively ineffective. Rotary shadowing images indicated that aggregates of the THP could form distinct quaternary structures, while the type TV collagen used here could not. These results are the first demonstrations of a synthetic peptide promoting platelet adhesion, activation, and aggregation and suggest that the combination of THP primary, secondary, tertiary, and quaternary structural features are required for platelet aggregation.			RAO, GHR (corresponding author), UNIV MINNESOTA,SCH MED,DEPT LAB MED & PATHOL,BOX 198 UMHC,420 DELAWARE ST SE,MINNEAPOLIS,MN 55455, USA.			Rao, Gundu H.R./0000-0002-2692-7950	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL011880, R01HL049556, R37HL011880] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL11880, HL49556] Funding Source: Medline; PHS HHS [KD44494] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BABEL W, 1984, EUR J BIOCHEM, V143, P545, DOI 10.1111/j.1432-1033.1984.tb08404.x; BALLEISEN L, 1976, HAEMOSTASIS, V5, P155; BARNES MJ, 1980, THROMB RES, V18, P375, DOI 10.1016/0049-3848(80)90333-3; BAUMGARTNER HR, 1977, THROMB HAEMOSTASIS, V37, P1; BRASS LF, 1974, J CLIN INVEST, V54, P1480, DOI 10.1172/JCI107896; CHELBERG MK, 1990, J CELL BIOL, V111, P262; CHIANG TM, 1980, J LAB CLIN MED, V95, P99; CHIANG TM, 1990, THROMB RES, V59, P509, DOI 10.1016/0049-3848(90)90411-5; CHIANG TM, 1977, J CLIN INVEST, V59, P405, DOI 10.1172/JCI108653; CHIANG TM, 1975, J BIOL CHEM, V250, P6919; DIMILLA PA, 1993, J CELL BIOL, V122, P729, DOI 10.1083/jcb.122.3.729; ERICKSON PR, 1992, J BIOL CHEM, V267, P10018; FIELDS CG, 1993, J BIOL CHEM, V268, P14153; FIELDS CG, 1993, BIOPOLYMERS, V33, P1695, DOI 10.1002/bip.360331107; GRYKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HUGUES J, 1976, THROMB RES, V9, P223, DOI 10.1016/0049-3848(76)90211-5; JAFFE R, 1974, J CLIN INVEST, V53, P875, DOI 10.1172/JCI107628; KARNIGUIAN A, 1983, THROMB RES, V32, P593, DOI 10.1016/0049-3848(83)90061-0; KOLIAKOS GG, 1989, J BIOL CHEM, V264, P2313; LEGRAND YJ, 1980, BIOCHEM BIOPH RES CO, V96, P1579, DOI 10.1016/0006-291X(80)91354-6; MAZUROV AV, 1989, MATRIX, V9, P214, DOI 10.1016/S0934-8832(89)80053-8; MISELWITZ F, 1970, BIOCHIM BIOPHYS ACTA, V923, P436; MONBOISSE JC, 1990, BIOCHEM J, V270, P459, DOI 10.1042/bj2700459; MORIYAMA T, 1988, J BIOCHEM-TOKYO, V103, P901, DOI 10.1093/oxfordjournals.jbchem.a122383; MORTON L F, 1991, Biochemical Society Transactions, V19, p439S; MORTON LF, 1985, COLLAGEN REL RES, V5, P493; MORTON LF, 1993, THROMB RES, V72, P367, DOI 10.1016/0049-3848(93)90148-H; MUGGLI R, 1973, Thrombosis Research, V3, P715, DOI 10.1016/0049-3848(73)90018-2; PERRIS R, 1993, J CELL SCI, V106, P1357; RAO GHR, 1987, BIOCHEM BIOPH RES CO, V148, P768, DOI 10.1016/0006-291X(87)90942-9; SANTORO SA, 1991, CELL REGUL, V2, P905, DOI 10.1091/mbc.2.11.905; SANTORO SA, 1986, CELL, V46, P913, DOI 10.1016/0092-8674(86)90073-5; SANTORO SA, 1988, PLATELET MEMBRANE RE, P291; SCHARFFETTERKOCHANEK K, 1992, J INVEST DERMATOL, V98, P3, DOI 10.1111/1523-1747.ep12493266; SMITH CM, 1992, BLOOD, V80, P2774; SMITH JB, 1990, ANAL BIOCHEM, V187, P173, DOI 10.1016/0003-2697(90)90437-E; SMITH JB, 1992, BIOCHEM J, V288, P925, DOI 10.1042/bj2880925; STAATZ WD, 1991, J BIOL CHEM, V266, P7363; TRELSTAD RL, 1979, J LAB CLIN MED, V93, P499; WEISS HJ, 1978, J LAB CLIN MED, V92, P750; YURCHENCO PD, 1990, FASEB J, V4, P1577, DOI 10.1096/fasebj.4.6.2180767; ZIJENAH LS, 1990, THROMB RES, V59, P553, DOI 10.1016/0049-3848(90)90415-9	42	32	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					13899	13903						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188668				2022-12-25	WOS:A1994NL60600030
J	SAWA, H; SOBEL, BE; FUJII, S				SAWA, H; SOBEL, BE; FUJII, S			INHIBITION OF TYPE-1 PLASMINOGEN-ACTIVATOR INHIBITOR PRODUCTION BY ANTISENSE OLIGONUCLEOTIDES IN HUMAN VASCULAR ENDOTHELIAL AND SMOOTH-MUSCLE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPRESSION; CULTURE; SURFACE; GROWTH	We have hypothesized that type-1 plasminogen activator inhibitor (PAI-1) may exacerbate accumulation of extracellular matrix in atheroma by inhibiting local generation of plasmin and intramural proteolysis. Thus, suppression of PAI-1 expression would decrease atherogenesis. To inhibit expression of PAI-1 in cultured human umbilical vein endothelial and aortic smooth muscle cells, a 20-base antisense phosphorothioate oligonucleotide targeting specific sequences in the 3'-untranslated region of the PAI-1 gene was used. Studies with P-32-labeled oligomers verified stability in media. Secretion of PAI-1 protein assayed by enzyme-linked immunosorbent assay declined specifically and dose-dependently in cells exposed to the antisense oligonucleotide treated under basal conditions and after stimulation of PAI-1 expression with transforming growth factor beta (0.5 ng/ml for endothelial cell, 5 ng/ml for smooth muscle cell). Inhibition of expression was confirmed by immunoprecipitation of S-35-labeled PAI-1 and was paralleled by decreased steady-state levels of PAI-1 mRNA (Northern blots). Decreased PAI-1 synthesis was accompanied by augmentation of cell-associated plasmin activity. Thus, the antisense oligonucleotide down-regulated PAI-1 elaboration, an approach that may be useful in limiting obstructive vascular lesions.	WASHINGTON UNIV, SCH MED, DIV CARDIOVASC, ST LOUIS, MO 63110 USA	Washington University (WUSTL)			Sawa, Hirofumi/AAW-8816-2021; Sawa, Hirofumi/F-6954-2012	Sawa, Hirofumi/0000-0003-2569-2755	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P60HL017646, P50HL017646] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-17646] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOSMA PJ, 1988, J BIOL CHEM, V263, P9129; EPSTEIN SE, 1993, CIRCULATION, V88, P1351, DOI 10.1161/01.CIR.88.3.1351; FUJII S, 1991, CIRCULATION, V83, P645, DOI 10.1161/01.CIR.83.2.645; FUUJI S, CIRCULATION, V86, P2000; GE M, 1992, J CLIN INVEST, V90, P2508, DOI 10.1172/JCI116144; HAJJAR KA, 1989, NATURE, V339, P303, DOI 10.1038/339303a0; HAJJAR KA, 1986, J BIOL CHEM, V261, P1656; HAJJAR KA, 1988, J CLIN INVEST, V82, P1769, DOI 10.1172/JCI113790; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; KESSLER SW, 1975, J IMMUNOL, V115, P1617; LOSKUTOFF DJ, 1989, PROG HEMOSTASIS THRO, V9; LUCORE CL, 1988, J BIOL CHEM, V263, P15845; LUPU F, 1993, ARTERIOSCLER THROMB, V13, P1090, DOI 10.1161/01.ATV.13.7.1090; NECKERS L, 1992, Critical Reviews in Oncogenesis, V3, P175; NODAHEINY H, 1993, CIRC RES, V72, P36, DOI 10.1161/01.RES.72.1.36; ROSS R, 1971, J CELL BIOL, V50, P172, DOI 10.1083/jcb.50.1.172; Sambrook J, 1989, MOL CLONING LABORATO; SAWA H, 1992, ARTERIOSCLER THROMB, V12, P1507, DOI 10.1161/01.ATV.12.12.1507; SAWA H, 1993, CIRC RES, V73, P671, DOI 10.1161/01.RES.73.4.671; TIPPING PG, 1993, AM J PATHOL, V143, P875	20	27	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					14149	14152						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188696				2022-12-25	WOS:A1994NL60600064
J	HAGA, K; KAMEYAMA, K; HAGA, T				HAGA, K; KAMEYAMA, K; HAGA, T			SYNERGISTIC ACTIVATION OF A G-PROTEIN-COUPLED RECEPTOR KINASE BY G-PROTEIN BETA-GAMMA-SUBUNITS AND MASTOPARAN OR RELATED PEPTIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCARINIC ACETYLCHOLINE-RECEPTORS; AGONIST-DEPENDENT PHOSPHORYLATION; BINDING REGULATORY PROTEINS; ADRENERGIC-RECEPTOR; RHODOPSIN KINASE; AMINO-ACIDS; FAMILY; TRANSDUCIN; LOCALIZATION; INHIBITION	Muscarinic acetylcholine receptors (mAChR, m2 subtype) are phosphorylated in an agonist-dependent manner by a G protein-coupled receptor kinase (GR kinase) at sites located in the central part of mAChR. The GR kinase phosphorylated a glutathione S-transferase fusion protein containing the m2 phosphorylation sites (I3-GST). Phosphorylation of I3-GST was markedly stimulated by mastoparan: the K-m for I3-GST decreased from 7.3 to 0.17 mu M in the presence of 100 mu M mastoparan and the V-max increased 23-fold. beta gamma Subunits of G proteins synergistically stimulated the phosphorylation of I3-GST in the presence of 1-10 mu M mastoparan by increasing the affinity of mastoparan for the GR kinase. The phosphorylation of mAChR by the GR kinase was also synergistically stimulated by 1-10 mu M mastoparan in the presence of beta gamma subunits, but was inhibited by 100 mu M mastoparan. Similar stimulatory and inhibitory effects on the phosphorylation of I3-GST and mAChR were observed using synthetic peptides of 15-20 amino acid residues corresponding to sequences of intracellular segments adjacent to the transmembrane segments of mAChR. These results are consistent with and support the idea that the GR kinase is synergistically activated by both G protein beta gamma subunits and agonist-bound receptors.			HAGA, K (corresponding author), UNIV TOKYO,FAC MED,INST BRAIN RES,DEPT BIOCHEM,BUNKYO KU,7-3-1 HONGO,TOKYO 113,JAPAN.							BENOVIC JL, 1991, J BIOL CHEM, V266, P14939; BENOVIC JL, 1989, J BIOL CHEM, V264, P6707; BENOVIC JL, 1989, SCIENCE, V246, P235, DOI 10.1126/science.2552582; BENOVIC JL, 1993, J BIOL CHEM, V268, P19521; BENOVIC JL, 1990, BRIT J CLIN PHARMACO, V30, pS3, DOI 10.1111/j.1365-2125.1990.tb05462.x; BROWN NG, 1992, EUR J BIOCHEM, V208, P659, DOI 10.1111/j.1432-1033.1992.tb17232.x; CHEN CY, 1993, J BIOL CHEM, V268, P7825; CHEUNG AH, 1992, MOL PHARMACOL, V41, P1061; DALMAN HM, 1991, J BIOL CHEM, V266, P11025; DOHLMAN HG, 1987, J BIOL CHEM, V262, P14282; FOWLES C, 1988, FEBS LETT, V238, P56, DOI 10.1016/0014-5793(88)80224-2; FRANKE RR, 1992, J BIOL CHEM, V267, P14767; HAGA K, 1992, J BIOL CHEM, V267, P2222; HAGA K, 1989, BIOMED RES-TOKYO, V10, P293, DOI 10.2220/biomedres.10.293; HAGA K, 1990, FEBS LETT, V268, P43, DOI 10.1016/0014-5793(90)80968-O; HAGA T, 1994, IN PRESS J NEUROCHEM; HIGASHIJIMA T, 1988, J BIOL CHEM, V263, P6491; HOSEY MM, 1992, FASEB J, V6, P845, DOI 10.1096/fasebj.6.3.1740234; KAMEYAMA K, 1993, J BIOL CHEM, V268, P7753; KELLEHER DJ, 1990, J BIOL CHEM, V265, P2632; KELLEHER DJ, 1988, MOL PHARMACOL, V34, P452; KIM CM, 1993, J BIOL CHEM, V268, P15412; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; KONIG B, 1989, P NATL ACAD SCI USA, V86, P6878, DOI 10.1073/pnas.86.18.6878; Kuhn H, 1984, PROGR RETINAL RES, V3, P123; KUNAPULI P, 1993, P NATL ACAD SCI USA, V90, P5588, DOI 10.1073/pnas.90.12.5588; KWATRA MM, 1993, J BIOL CHEM, V268, P9161; LECHLEITER J, 1990, EMBO J, V9, P4381, DOI 10.1002/j.1460-2075.1990.tb07888.x; LEFKOWITZ RJ, 1993, CELL, V74, P409, DOI 10.1016/0092-8674(93)80042-D; LORENZ W, 1991, P NATL ACAD SCI USA, V88, P8715, DOI 10.1073/pnas.88.19.8715; MORO O, 1993, J BIOL CHEM, V268, P22273; NAKATA H, 1994, IN PRESS EUR J BIOCH; NAMBA T, 1993, NATURE, V365, P166, DOI 10.1038/365166a0; OKAMOTO T, 1992, J BIOL CHEM, V267, P8342; ONORATO JJ, 1991, BIOCHEMISTRY-US, V30, P5118, DOI 10.1021/bi00235a002; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P12949; PALCZEWSKI K, 1993, J BIOL CHEM, V268, P6004; PALCZEWSKI K, 1991, TRENDS BIOCHEM SCI, V16, P387, DOI 10.1016/0968-0004(91)90157-Q; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; REN Q, 1993, J BIOL CHEM, V268, P16483; RICHARDSON RM, 1993, J BIOL CHEM, V268, P13650; THOMPSON P, 1984, BIOCHEM J, V220, P773, DOI 10.1042/bj2200773	42	57	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12594	12599						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175667				2022-12-25	WOS:A1994NH71600037
J	MOORE, SEH; SPIRO, RG				MOORE, SEH; SPIRO, RG			INTRACELLULAR COMPARTMENTALIZATION AND DEGRADATION OF FREE POLYMANNOSE OLIGOSACCHARIDES RELEASED DURING GLYCOPROTEIN-BIOSYNTHESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								The intracellular site for the degradation of free polymannose oligosaccharides released during glycoprotein biosynthesis has been studied by permeabilizing the plasma membrane of metabolically radiolabeled HepG2 cells with streptolysin O. This pore-forming agent permitted us to examine the breakdown in both the cytosolic and vesicular compartments of the previously recognized (Anumula, K. R., and Spiro, R. G. (1983) J. Biol. Chem. 258, 15274-15282) polymannose components terminating in a di-N-acetylchitobiose sequence (OS-Glc-NAc2) or a single N-acetylglucosamine residue (OS-Glc-NAc1) residue. Pulse-chase studies indicated that although the OS-GlcNAc(2) saccharides were about equally distributed between vesicles and cytosol and rapidly disappeared after reaching the Man(8) stage, the OS-GlcNAc(1) species were found predominantly in the extravesicular compartment and there underwent a distinctive demannosylation sequence resulting in the formation of a Man(5)GlcNAc isomer (Man alpha 1-->2Man alpha 1--> 2Man alpha 1-->3(Man alpha 1-->6)Man beta 1-->4GlcNAc) which was different from the product of Golgi processing enzymes. Further trimming of this cytosolic limit product required its translocation into a vesicular compartment, believed to be lysosomes, in which Man(2-4)GlcNAc components appeared as the metabolic chase progressed. The accumulation of Glc(1)Man(5)GlcNAc in the cytosol during the chase suggested that glucose interferes with the cytosolic-vesicular transfer and this became even more evident by the pronounced pile-up of extravesicular Glc(3)Man(5)GlcNAc when the cells were incubated in the presence of castanospermine. Although the biological significance and mechanism of free polymannose oligosaccharide entry into the cytosol is not yet known, the possibility that it may reflect an endoplasmic reticulum-situated degradative process of glycoproteins merits consideration.	JOSLIN DIABET CTR, ELLIOTT P JOSLIN RES LAB, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, DEPT BIOL CHEM, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02215 USA	Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School			Moore, Stuart/AAF-3920-2021	Moore, Stuart/0000-0002-1020-2242	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK017477] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 17477] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHNERTHILGER G, 1989, METHOD CELL BIOL, V31, P63; ALDAHER S, 1992, BIOCHEM J, V286, P47, DOI 10.1042/bj2860047; ALEXANDER DR, 1989, BIOCHEM J, V260, P893, DOI 10.1042/bj2600893; ANUMULA KR, 1983, J BIOL CHEM, V258, P5274; BHAKDI S, 1987, REV PHYSIOL BIOCH P, V107, P147, DOI 10.1007/BFb0027646; CACAN R, 1987, EUR J BIOCHEM, V166, P469, DOI 10.1111/j.1432-1033.1987.tb13539.x; CACAN R, 1989, EUR J BIOCHEM, V185, P173, DOI 10.1111/j.1432-1033.1989.tb15099.x; DEGASPERI R, 1992, J BIOL CHEM, V267, P9706; ELBEIN AD, 1991, FASEB J, V5, P3055, DOI 10.1096/fasebj.5.15.1743438; GODELAINE D, 1981, J BIOL CHEM, V256, P161; GRINNA LS, 1979, J BIOL CHEM, V254, P8814; Gutmann I., 1974, METHODS ENZYMATIC AN, P1464; HASE S, 1984, J BIOCHEM-TOKYO, V95, P197, DOI 10.1093/oxfordjournals.jbchem.a134585; HUBBARD SC, 1979, J BIOL CHEM, V254, P4568; KLAUSNER R D, 1989, New Biologist, V1, P3; KORNFELD S, 1978, J BIOL CHEM, V253, P7771; LUBAS WA, 1987, J BIOL CHEM, V262, P3775; LUBAS WA, 1988, J BIOL CHEM, V263, P3990; LUCOCQ JM, 1986, J CELL BIOL, V102, P2137, DOI 10.1083/jcb.102.6.2137; MOORE SEH, 1992, J BIOL CHEM, V267, P8443; MOORE SEH, 1990, J BIOL CHEM, V265, P13104; PIERCE RJ, 1979, BIOCHEM J, V180, P673, DOI 10.1042/bj1800673; SPIRO MJ, 1980, ARCH BIOCHEM BIOPHYS, V202, P35, DOI 10.1016/0003-9861(80)90403-8; SPIRO MJ, 1985, J BIOL CHEM, V260, P5808; SPIRO MJ, 1976, J BIOL CHEM, V251, P6400; SPIRO MJ, 1991, J BIOL CHEM, V266, P5311; STAFFORD FJ, 1991, J CELL BIOL, V115, P1225, DOI 10.1083/jcb.115.5.1225; TAI T, 1977, BIOCHEM BIOPH RES CO, V78, P434, DOI 10.1016/0006-291X(77)91273-6; TULSIANI DRP, 1987, J BIOL CHEM, V262, P6506; VARKI A, 1983, J BIOL CHEM, V258, P2808; WENG SA, 1993, J BIOL CHEM, V268, P25656	31	85	85	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12715	12721						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175683				2022-12-25	WOS:A1994NH71600055
J	WILBANKS, SM; DELUCAFLAHERTY, C; MCKAY, DB				WILBANKS, SM; DELUCAFLAHERTY, C; MCKAY, DB			STRUCTURAL BASIS OF THE 70-KILODALTON HEAT-SHOCK COGNATE PROTEIN ATP HYDROLYTIC ACTIVITY .1. KINETIC ANALYSES OF ACTIVE-SITE MUTANTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSLOCATION; MUTAGENESIS; FRAGMENT	The 70-kDa heat shock cognate protein is a member of a highly conserved family of molecular chaperones in which the binding and release of target polypeptides are coupled to the chaperones' ATPase activity. The ATPase activity resides in the amino-terminal 44-kDa fragment of the protein. Four acidic residues of the ATPase fragment which might participate in catalysis (Asp-10 and Asp-199, which are Mg2+ ion ligands; Glu-175 and Asp-206, which are candidates for a role as catalytic base) have been individually mutated to both the cognate amide residue (aspartate to asparagine, glutamate to glutamine) and to serine, and the effects of the mutations on the kinetics (this manuscript) and structure (Flaherty, K. M., Wilbanks, S. M., DeLuca-Flaherty, C., and McKay, D. B. (1994) J. Biol. Chem. 269, 12899-12907) have been determined. Changes at Asp-10 and Asp-199 reduced k(cat) to similar to 1% of wild type; changes at Glu-175 and Asp-206 reduced k(cat) to similar to 10% of wild type. Changes to Asp-199 and Asp-206 had little effect on K-m; changes to Asp-10 and Glu-175 increased K-m 10-100-fold. These data suggest that the bound magnesium ion and its local environment are crucial to catalysis; they argue against a single residue acting as the sole essential general base catalyst in the hydrolytic reaction.	STANFORD UNIV,SCH MED,DEPT CELL BIOL,BECKMAN LABS STRUCT BIOL,STANFORD,CA 94305	Stanford University				Wilbanks, Sigurd/0000-0001-7565-8913	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039928] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-39928] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON CM, 1978, J MOL BIOL, V123, P207, DOI 10.1016/0022-2836(78)90321-2; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; CHAPPELL TG, 1987, J BIOL CHEM, V262, P746; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; DELUCAFLAHERTY C, 1988, J MOL BIOL, V200, P749, DOI 10.1016/0022-2836(88)90487-1; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; FERSHT A, 1985, ENZYME STRUCTURE MEC, P235; FLAHERTY KM, 1991, P NATL ACAD SCI USA, V88, P5041, DOI 10.1073/pnas.88.11.5041; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; FLAHERTY KM, 1994, J BIOL CHEM, V269, P12899; GAO BC, 1993, J BIOL CHEM, V268, P8507; GAUT JR, 1993, J BIOL CHEM, V268, P7248; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HUANG SP, 1993, J BIOL CHEM, V268, P2063; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MCKAY DB, 1993, ADV PROTEIN CHEM, V44, P67, DOI 10.1016/S0065-3233(08)60564-1; NORRANDER J, 1983, GENE, V26, P101, DOI 10.1016/0378-1119(83)90040-9; OBRIEN MC, 1993, J BIOL CHEM, V268, P24323; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; PLAUH JL, 1986, NUCLEIC ACIDS RES, V14, P7851; SCHLOSSMAN DM, 1984, J CELL BIOL, V99, P723, DOI 10.1083/jcb.99.2.723; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TABOR S, 1990, CURRENT PROTOCOLS MO	23	92	93	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12893	12898						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175706				2022-12-25	WOS:A1994NH71600080
J	VALERA, A; FILLAT, C; COSTA, C; SABATER, J; VISA, J; PUJOL, A; BOSCH, F				VALERA, A; FILLAT, C; COSTA, C; SABATER, J; VISA, J; PUJOL, A; BOSCH, F			REGULATED EXPRESSION OF HUMAN INSULIN IN THE LIVER OF TRANSGENIC MICE CORRECTS DIABETIC ALTERATIONS	FASEB JOURNAL			English	Article						DIABETES; INSULIN; P-ENOLPYRUVATE CARBOXYKINASE; TRANSGENIC MICE; GENE THERAPY	PHOSPHOENOLPYRUVATE CARBOXYKINASE GTP; HEPATIC GLUCOSE-PRODUCTION; GROWTH-HORMONE GENE; MESSENGER-RNA; RAT-LIVER; DIETARY-REGULATION; GLYCOGEN-SYNTHASE; GLUCOKINASE GENE; CYCLIC-AMP; CELLS	Transgenic mice expressing the P-enolpyruvate carboxykinase (PEPCK)/human insulin chimeric gene have been obtained as a model to study the feasibility of gene therapy for diabetes. These transgenic animals were healthy and normoglycemic and expressed human insulin in a physiologically regulated manner, mainly in the liver. Streptozotocin-treated transgenic mice had high levels of human insulin immunoreactivity in serum and showed a significant decrease (up to 40%) in glycemia compared with streptozotocin-treated control mice. The expression of genes involved in liver glucose metabolism, such as glucokinase, pyruvate kinase, and PEPCK, which is markedly altered by diabetes, was significantly recovered in transgenic mice treated with streptozotocin. In addition, the activity of both glucokinase and glycogen synthase, and the content of glucose 6-phosphate and glycogen, were normal in the liver, even when transgenic animals were treated with diabetogenic doses of streptozotocin. These results constitute an indication in vivo that diabetes gene therapy is possible, by means of the production of insulin in extrapancreatic tissues.	AUTONOMOUS UNIV BARCELONA, SCH VET MED, DEPT BIOCHEM & MOLEC BIOL, E-08193 BARCELONA, SPAIN	Autonomous University of Barcelona			Costa, Cristina/AAP-4005-2020; Pujol, Anna/J-7939-2017; costa, cristina/P-5924-2014; Fillat, Cristina/ABH-1674-2020	Costa, Cristina/0000-0002-1837-4268; Pujol, Anna/0000-0002-3484-598X; costa, cristina/0000-0002-6549-4553; Fillat, Cristina/0000-0002-0801-3338; BOSCH, FATIMA/0000-0002-7705-5515				ANDREONE TL, 1989, J BIOL CHEM, V264, P363; [Anonymous], 2012, BIOMETRY PRINCIPLES; BANCROFT JD, 1982, THEORY PRACTICE HIST, P122; BEALE EG, 1985, J BIOL CHEM, V260, P748; BELL GI, 1980, NATURE, V284, P26, DOI 10.1038/284026a0; BELL GI, 1979, NATURE, V282, P525, DOI 10.1038/282525a0; BOSCH F, 1990, J BIOL CHEM, V265, P13677; BUCCHINI D, 1986, P NATL ACAD SCI USA, V83, P2511, DOI 10.1073/pnas.83.8.2511; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CONSOLI A, 1989, DIABETES, V38, P550, DOI 10.2337/diabetes.38.5.550; DAVIDSON AL, 1987, ARCH BIOCHEM BIOPHYS, V253, P156, DOI 10.1016/0003-9861(87)90648-5; DEFRONZO RA, 1989, METABOLISM, V38, P387, DOI 10.1016/0026-0495(89)90129-7; EISENBERGER CL, 1992, MOL CELL BIOL, V12, P1396, DOI 10.1128/MCB.12.3.1396; GARCIARUIZ JP, 1978, P NATL ACAD SCI USA, V75, P4189; GIL J, 1988, J BIOL CHEM, V263, P1868; GRANNER D, 1983, NATURE, V305, P549, DOI 10.1038/305549a0; GRANNER D, 1990, J BIOL CHEM, V265, P10173; GUINOVART JJ, 1979, FEBS LETT, V106, P284, DOI 10.1016/0014-5793(79)80515-3; HATZOGLOU M, 1988, J BIOL CHEM, V263, P17798; HOGAN B, 1986, MANIPULATING MOUSE E; IMAI E, 1990, MOL CELL BIOL, V10, P4712, DOI 10.1128/MCB.10.9.4712; INAGAKI N, 1992, P NATL ACAD SCI USA, V89, P1045, DOI 10.1073/pnas.89.3.1045; IYNEDJIAN PB, 1988, J BIOL CHEM, V263, P740; IYNEDJIAN PB, 1987, J BIOL CHEM, V262, P6032; IYNEDJIAN PB, 1989, J BIOL CHEM, V264, P21824; Keppler D., 1984, METHOD ENZYMAT AN, V6, P11; KIOUSSIS D, 1978, J BIOL CHEM, V253, P4327; KORNER J, 1991, P NATL ACAD SCI USA, V88, P6834, DOI 10.1073/pnas.88.15.6834; LAMERS WH, 1982, P NATL ACAD SCI-BIOL, V79, P5137, DOI 10.1073/pnas.79.17.5137; LARNER J, 1990, ADV ENZYMOL RAMB, V63, P173; LIU JS, 1991, J BIOL CHEM, V266, P19095; MAGNUSON MA, 1989, P NATL ACAD SCI USA, V86, P4838, DOI 10.1073/pnas.86.13.4838; MAGNUSSON I, 1992, J CLIN INVEST, V90, P1323, DOI 10.1172/JCI115997; MCGARRY JD, 1992, SCIENCE, V258, P766, DOI 10.1126/science.1439783; MCGARRY JD, 1989, DIABETES METAB REV, V5, P271, DOI 10.1002/dmr.5610050305; MCGRANE MM, 1990, J BIOL CHEM, V265, P22371; MCGRANE MM, 1988, J BIOL CHEM, V263, P11443; MEGLASSON M D, 1986, Diabetes Metabolism Reviews, V2, P163; MICHAL G, 1981, METHOD ENZYMAT AN, V6, P185; MILLER TB, 1973, J BIOL CHEM, V248, P3483; OBRIEN RM, 1990, SCIENCE, V249, P533, DOI 10.1126/science.2166335; PILKIS SJ, 1988, ANNU REV BIOCHEM, V57, P755, DOI 10.1146/annurev.bi.57.070188.003543; PILKIS SJ, 1992, ANNU REV PHYSIOL, V54, P885, DOI 10.1146/annurev.ph.54.030192.004321; ROACH PJ, 1990, FASEB J, V4, P2961, DOI 10.1096/fasebj.4.12.2168324; SELDEN RF, 1987, NEW ENGL J MED, V317, P1067; SELDEN RF, 1986, NATURE, V321, P525, DOI 10.1038/321525a0; SHENNAN KIJ, 1991, FEBS LETT, V284, P277, DOI 10.1016/0014-5793(91)80703-6; SHORT JM, 1986, J BIOL CHEM, V261, P9721; SHORT MK, 1992, MOL CELL BIOL, V12, P1007, DOI 10.1128/MCB.12.3.1007; SIBROWSKI W, 1984, J BIOL CHEM, V259, P343; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; TAYLOR R, 1988, BIOCHEM J, V250, P625, DOI 10.1042/bj2500625; TILGHMAN S M, 1974, Proceedings of the National Academy of Sciences of the United States of America, V71, P1304, DOI 10.1073/pnas.71.4.1304; UNGER R H, 1985, P1018; UNGER RH, 1991, SCIENCE, V251, P1200, DOI 10.1126/science.2006409; UNGER RH, 1983, HDB EXPT PHARM, V2, P431; VALERA A, 1993, J CLIN INVEST, V92, P4, DOI 10.1172/JCI116580; VALERA A, 1993, FASEB J, V7, P791, DOI 10.1096/fasebj.7.9.8330686; VOLLENWEIDER F, 1992, J BIOL CHEM, V267, P14629; WEINHOUSE S, 1976, CURR TOP CELL REGUL, V11, P1; YOOWARREN H, 1983, P NATL ACAD SCI-BIOL, V80, P3656, DOI 10.1073/pnas.80.12.3656; ZIMMER DB, 1990, J HISTOCHEM CYTOCHEM, V38, P171, DOI 10.1177/38.2.1688895	63	68	81	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR 1	1994	8	6					440	447		10.1096/fasebj.8.6.8168695	http://dx.doi.org/10.1096/fasebj.8.6.8168695			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	NH250	8168695				2022-12-25	WOS:A1994NH25000012
J	BRAIN, R; JENKINS, JR				BRAIN, R; JENKINS, JR			HUMAN P53 DIRECTS DNA STRAND REASSOCIATION AND IS PHOTOLABELED BY 8-AZIDO ATP	ONCOGENE			English	Article							CELLULAR TUMOR-ANTIGEN; LARGE T-ANTIGEN; NUCLEOTIDE-SEQUENCE; HELICASE ACTIVITY; PROTEIN; TRANSFORMATION; GENE; REPLICATION; ONCOGENE; INVITRO	p53 is the most frequent known target for mutation in human cancer. Evidence suggests that p53 protein may be involved variously in transcription and cell cycle control, in DNA replication and in G1 checkpoint control following the cellular response to radiation induced DNA damage. p53 blocks DNA replication of the small DNA tumour virus, simian virus 40, by inhibiting unwinding of the viral origin of replication by the DNA helicase activity of the virally encoded large T antigen protein. Here we report the novel observation that human p53 protein can bind ATP and exhibits an intrinsic ATP stimulated DNA strand reassociation activity. Both activities map to the carboxyl terminal 128 amino acids of p53. Thus, in addition to any role in transcription, our results indicate that p53 is potentially capable of inhibiting mammalian replicative DNA synthesis by blocking the DNA strand separation step during replication origin recruitment. However, the ability of p53 to modulate the topological relationship between complementary nucleotide strands is also compatible with a direct role for p53 in other aspects of DNA synthesis, recombination or repair,	MARIE CURIE RES INST,CELL PROLIFERAT LAB,OXTED RH8 0TL,SURREY,ENGLAND									ABATE C, 1990, P NATL ACAD SCI USA, V87, P1032, DOI 10.1073/pnas.87.3.1032; BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; COLE ST, 1987, J MOL BIOL, V193, P599, DOI 10.1016/0022-2836(87)90343-3; COX MM, 1981, NUCLEIC ACIDS RES, V9, P389, DOI 10.1093/nar/9.2.389; CSERMELY P, 1991, J BIOL CHEM, V266, P4943; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GENTZ R, 1989, P NATL ACAD SCI USA, V86, P821, DOI 10.1073/pnas.86.3.821; GOETZ GS, 1988, J BIOL CHEM, V263, P383; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JENKINS JR, 1985, NATURE, V317, P816, DOI 10.1038/317816a0; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; JENKINS JR, 1988, J VIROL, V62, P3903, DOI 10.1128/JVI.62.10.3903-3906.1988; JENKINS JR, 1988, ONCOGENE HDB, P403; KANDA T, 1994, IN PRESS MOL CELL BI; KAO CC, 1990, VIROLOGY, V179, P806, DOI 10.1016/0042-6822(90)90148-K; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OBEROSLER P, 1993, EMBO J, V12, P2389, DOI 10.1002/j.1460-2075.1993.tb05893.x; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; POTTER RL, 1983, METHOD ENZYMOL, V91, P613; ROVINSKI B, 1988, ONCOGENE, V2, P445; SIMANIS V, 1985, VIROLOGY, V144, P88, DOI 10.1016/0042-6822(85)90308-3; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; STURZBECHER HW, 1988, ONCOGENE, V3, P405; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; SUTCLIFFE JG, 1978, P NATL ACAD SCI USA, V75, P3737, DOI 10.1073/pnas.75.8.3737; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	37	73	75	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1994	9	6					1775	1780						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NL815	8183576				2022-12-25	WOS:A1994NL81500033
J	GORUPPI, S; GUSTINCICH, S; BRANCOLINI, C; LEE, WMF; SCHNEIDER, C				GORUPPI, S; GUSTINCICH, S; BRANCOLINI, C; LEE, WMF; SCHNEIDER, C			DISSECTION OF C-MYC DOMAINS INVOLVED IN S-PHASE INDUCTION OF NIH3T3 FIBROBLASTS	ONCOGENE			English	Article							DNA-BINDING; CELL-CYCLE; NUCLEAR-LOCALIZATION; PROTEIN EXPRESSION; MURINE FIBROBLASTS; SURVIVAL FACTORS; MESSENGER-RNA; TRANSFORMATION; GENE; MAX	The product of the c-myc proto-oncogene is an important regulator of cell proliferation and apoptosis in murine fibroblasts. Addition of the tumor promoter, phorbol myristate acetate (PMA), prevents apoptotic cell death induced by low serum concentrations in NIH3T3 cells that constitutively express and are transformed by v-myc. The protective effect of PMA allowed us to analyse the ability of normal c-Myc and Myc deletion mutants to induce serum starved, untransformed NIH3T3 cells to enter S phase. By microinjecting these quiescent cells with wild type and mutant human c-myc plasmids, we showed that full length c-myc is able to induce S phase entry in presence of PMA, but that c-Myc mutants that delete amino acids Delta 7/91, Delta 41/53, Delta 56/103, Delta 106/143, Delta 265/317 and Delta 414/433 are totally inactive. c-Myc did not shorten the period before entry into S phase, since Myc overexpressing cells entered S phase with the same kinetics as control cells when both were stimulated with 20% fetal calf serum (FCS). However, c-Myc overexpression did increase the percentage of cells entering S phase when these cells were stimulated with 2% fetal calf serum. Interestingly, this ability to enhance stimulation by a suboptimal concentration of FCS was retained to a significant degree by Myc mutants that delete amino acids Delta 41/53, Delta 56/103 or Delta 265/317. Finally, Myc mutants that delete Delta 106/143 or Delta 414/433 exerted a dominant negative effect on S phase entry both in quiescent cells stimulated with 2% FCS and in unsynchronized, cycling cells.	LNCIB, I-34012 TRIESTE, ITALY; UNIV PENN, DEPT MED, HEMATOL ONCOL SECT, PHILADELPHIA, PA 19104 USA; UNIV UDINE, DIPARTIMENTO SCI & TECNOL BIOMED, SEZ BIOL, I-33100 UDINE, ITALY	University of Pennsylvania; Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); University of Udine				Gustincich, Stefano/0000-0002-2749-2514; BRANCOLINI, Claudio/0000-0002-6597-5373				AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; ASKEW DS, 1991, ONCOGENE, V6, P1915; BIGNAMI M, 1988, ONCOGENE, V2, P509; BIRO S, 1993, P NATL ACAD SCI USA, V90, P654, DOI 10.1073/pnas.90.2.654; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BRANCOLINI C, 1992, J CELL BIOL, V117, P1251, DOI 10.1083/jcb.117.6.1251; COLE MD, 1991, CELL, V65, P715, DOI 10.1016/0092-8674(91)90377-B; DANG CV, 1989, NATURE, V337, P664, DOI 10.1038/337664a0; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; DELSAL G, 1992, CELL, V70, P595, DOI 10.1016/0092-8674(92)90429-G; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; FREYTAG SO, 1990, CELL GROWTH DIFFER, V1, P339; HANN SR, 1985, NATURE, V314, P366, DOI 10.1038/314366a0; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; KACZMAREK L, 1985, SCIENCE, V228, P1313, DOI 10.1126/science.4001943; KARN J, 1989, ONCOGENE, V4, P773; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; OHMORI Y, 1993, ONCOGENE, V8, P379; PENN LJZ, 1990, MOL CELL BIOL, V10, P4961, DOI 10.1128/MCB.10.9.4961; PRENDERGAST GC, 1992, TRENDS GENET, V8, P91, DOI 10.1016/0168-9525(92)90196-B; RABBITTS PH, 1985, EMBO J, V4, P2009, DOI 10.1002/j.1460-2075.1985.tb03885.x; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RIHS HP, 1991, EMBO J, V10, P633, DOI 10.1002/j.1460-2075.1991.tb07991.x; Sambrook J, 1989, MOL CLONING LABORATO; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; SORRENTINO V, 1986, P NATL ACAD SCI USA, V83, P8167, DOI 10.1073/pnas.83.21.8167; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; TAMM I, 1991, P NATL ACAD SCI USA, V88, P3372, DOI 10.1073/pnas.88.8.3372; TAMM I, 1990, J CELL PHYSIOL, V143, P494, DOI 10.1002/jcp.1041430314; TAMM I, 1991, J CELL PHYSIOL, V148, P85, DOI 10.1002/jcp.1041480111; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; WATERS CM, 1991, ONCOGENE, V6, P797; WATERS CM, 1992, CELL, V69, P119	42	20	29	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1994	9	6					1537	1544						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NL815	8183547				2022-12-25	WOS:A1994NL81500003
J	ISSHIKI, K; SENG, BA; ELDER, DE; GUERRY, D; LINNENBACH, AJ				ISSHIKI, K; SENG, BA; ELDER, DE; GUERRY, D; LINNENBACH, AJ			CHROMOSOME-9 DELETION IN SPORADIC AND FAMILIAL MELANOMAS IN-VIVO	ONCOGENE			English	Article							HUMAN-MALIGNANT MELANOMA; HOMOZYGOUS DELETIONS; COLORECTAL-CANCER; TUMOR PROGRESSION; DYSPLASTIC NEVUS; CELL-LINES; SHORT ARM; LOCUS; GENE; LINKAGE	Twenty microsatellite loci on chromosome 9 were analysed for allelic losses in DNAs from 30 uncultured melanomas from 25 patients, relative to DNA from autologous peripheral blood lymphocytes. All patients were constitutionally heterozygous at several loci, and loss of heterozygosity (LOH) affecting 9p was observed in melanoma DNAs from 18 individuals (72%). Observations of losses of identical alleles in different metastatic lesions from the same patients, and of LOH in a vertical growth phase primary melanoma, were consistent with previous reports of chromosome 9 deletion early in melanoma development. LOH data suggested the loss of entire copies of chromosome 9 in 11 cases, and the terminal deletion of all or a portion of 9p in six cases. A somatic interstitial deletion of 9p between D9S162 and D9S169 was seen in a familial melanoma. This 21 cM deleted region corresponded with the previously reported positions of homozygous deletions in melanoma cell lines, and of the familial melanoma susceptibility locus (MLM). As 16 of the 18 cases of 9p LOH in the present study were observed in individuals with no family history of melanoma, it is likely that the MLM locus plays a role in the development of most sporadic melanomas.	WISTAR INST ANAT & BIOL, PHILADELPHIA, PA 19104 USA; UNIV PENN, DEPT PATHOL & LAB MED, PHILADELPHIA, PA 19104 USA; UNIV PENN, CTR CANC, PHILADELPHIA, PA 19104 USA; UNIV PENN, DEPT MED, DIV HEMATOL ONCOL, PHILADELPHIA, PA 19104 USA	The Wistar Institute; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania					NATIONAL CANCER INSTITUTE [P01CA025874, R01CA025298, P30CA010815] Funding Source: NIH RePORTER; NCI NIH HHS [CA25874, CA10815, CA25298] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; ANDERSEN LB, 1993, NAT GENET, V3, P118, DOI 10.1038/ng0293-118; BALE SJ, 1989, NEW ENGL J MED, V320, P1367, DOI 10.1056/NEJM198905253202102; CANNONALBRIGHT LA, 1992, SCIENCE, V258, P1148, DOI 10.1126/science.1439824; Cowan J M, 1991, Cancer Treat Res, V54, P3; COWAN JM, 1988, J NATL CANCER I, V80, P1159, DOI 10.1093/jnci/80.14.1159; DRACOPOLI NC, 1987, CANCER RES, V47, P3995; DRACOPOLI NC, 1989, P NATL ACAD SCI USA, V86, P4614, DOI 10.1073/pnas.86.12.4614; DRACOPOLI NC, 1985, P NATL ACAD SCI USA, V82, P1470, DOI 10.1073/pnas.82.5.1470; FOUNTAIN JW, 1992, P NATL ACAD SCI USA, V89, P10557, DOI 10.1073/pnas.89.21.10557; GOLDSTEIN AM, 1993, AM J HUM GENET, V52, P537; Greene MH, 1979, HUMAN MALIGNANT MELA, P139; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; ISSHIKI K, 1993, GENE CHROMOSOME CANC, V8, P178, DOI 10.1002/gcc.2870080307; JAMES CD, 1993, CANCER RES, V53, P3674; KWIATKOWSKI DJ, 1993, CYTOGENET CELL GENET, V64, P94; LINDBLOM A, 1993, NAT GENET, V5, P279, DOI 10.1038/ng1193-279; LINNENBACH AJ, 1993, HUM MOL GENET, V2, P1407; LINNENBACH AJ, 1994, NATURE, V367, P419, DOI 10.1038/367419b0; LITT M, 1989, AM J HUM GENET, V44, P397; MILLIKIN D, 1991, CANCER RES, V51, P5449; NANCARROW DJ, 1993, AM J HUM GENET, V53, P936; OLOPADE OI, 1992, GENOMICS, V14, P437, DOI 10.1016/S0888-7543(05)80238-1; OLOPADE OI, 1993, CANCER RES, V53, P2410; Parmiter A., 1988, MALIGNANT MELANOMA B, P47; PEDERSEN MI, 1989, CANCER GENET CYTOGEN, V41, P185, DOI 10.1016/0165-4608(89)90245-8; PELTOMAKI P, 1993, SCIENCE, V260, P810, DOI 10.1126/science.8484120; PETTY EM, 1993, AM J HUM GENET, V53, P96; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; VOLKENANDT M, 1991, PIGM CELL RES, V4, P35, DOI 10.1111/j.1600-0749.1991.tb00311.x; WEBER JL, 1989, AM J HUM GENET, V44, P388; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0	32	54	55	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1994	9	6					1649	1653						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NL815	8183559				2022-12-25	WOS:A1994NL81500016
J	BAENZIGER, NL; MACK, P; JONG, YJI; DALEMAR, LR; PEREZ, N; LINDBERG, C; WILHELM, B; HADDOCK, RC				BAENZIGER, NL; MACK, P; JONG, YJI; DALEMAR, LR; PEREZ, N; LINDBERG, C; WILHELM, B; HADDOCK, RC			AN ENVIRONMENTALLY REGULATED RECEPTOR FOR DIAMINE OXIDASE MODULATES HUMAN ENDOTHELIAL CELL/FIBROBLAST HISTAMINE DEGRADATIVE UPTAKE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; FIBROBLAST GROWTH-FACTOR; GAMMA-AMINOBUTYRIC ACID; LIPOPROTEIN-LIPASE; HEPARAN-SULFATE; PHORBOL ESTERS; PROSTACYCLIN SYNTHESIS; MEDIATED ENDOCYTOSIS; SKIN FIBROBLASTS; PHOSPHOLIPASE-C	Human vascular endothelial cells and fibroblasts express a cell-surface degradative pathway for the multifunctional mediator histamine, which employs a receptor for the metabolic enzyme diamine oxidase (DAO) and results in cellular accumulation of the final metabolite methylimidazoleacetic acid. We demonstrate recognition and regulatory properties of DAO receptors as a function of cellular environmental conditions. Fast and slow ligand binding receptor populations bind DAO at 4 degrees C maximally in 1 and 7 h, respectively; upon warming cells to 37 degrees C both populations participate in degradative uptake of histamine accumulated as methylimidazoleacetic acid. Bound DAO is displaced by heparin with 24-fold greater potency than dextran sulfate, implicating structural specificity of heparin-like glycosaminoglycan moieties as a critical factor in initial receptor/ enzyme interaction at fast and slow sites. Receptor-bound DAO is retained under mildly acidic conditions characteristic of early to mid endocytic intracellular compartments and thus could recycle to the plasma membrane intact after internalization. DAO initially bound to receptors in whole cells is retained through cell disruption/membrane fractionation procedures, but DAO binds poorly to isolated membrane fractions or presolubilized receptors, suggesting that the geometry of DAO binding components is not readily maintained upon cell disruption unless DAO is already bound. Cells down-regulate their complement of DAO receptors upon prolonged exposure to DAO. In cells plated at high density, half of the bound DAO becomes nondisplaceable by heparin within 15 min at 37 degrees C, a time consistent with receptor internalization, whereas cells plated at low density retain all bound DAO in a heparin-sensitive state. The protein kinase C activator phorbol 12-myristate 13-acetate modulates DAO receptor number by 35% and total histamine degradative uptake by >2 fold. Thus this pathway is subject to regulation at the levels of DAO receptor numbers, their state of cell-surface display, and additional cellular elements of the degradative pathway with which the DAO receptors interface.			BAENZIGER, NL (corresponding author), WASHINGTON UNIV,SCH MED,DEPT ANAT & NEUROBIOL,660 S EUCLID AVE,BOX 8108,ST LOUIS,MO 63110, USA.				NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [T32AM007296] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033699] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [T32NS007071] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 33699] Funding Source: Medline; NIADDK NIH HHS [2T32 AMO7296] Funding Source: Medline; NINDS NIH HHS [5T32 NS07071] Funding Source: Medline	NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAENZIGER N L, 1990, Journal of Cell Biology, V111, p184A; BAENZIGER NL, 1981, CELL, V24, P915, DOI 10.1016/0092-8674(81)90117-3; BAENZIGER NL, 1980, BIOCHEM BIOPH RES CO, V92, P1435, DOI 10.1016/0006-291X(80)90447-7; BASU SK, 1981, CELL, V24, P493, DOI 10.1016/0092-8674(81)90340-8; BAYLIN SB, 1973, J CLIN INVEST, V52, P1985, DOI 10.1172/JCI107383; BAYLIN SB, 1975, BIOCHIM BIOPHYS ACTA, V397, P294, DOI 10.1016/0005-2744(75)90119-9; BEAVEN MA, 1982, PHARM HISTAMINE RECE, P103; BERGERON JJM, 1985, ANNU REV PHYSIOL, V47, P383; BLACKSHEAR PJ, 1986, J BIOL CHEM, V261, P1459; BLASI F, 1987, J CELL BIOL, V104, P801, DOI 10.1083/jcb.104.4.801; BOSNER MS, 1988, P NATL ACAD SCI USA, V85, P7438, DOI 10.1073/pnas.85.20.7438; BROCK TA, 1988, J CELL PHYSIOL, V136, P54, DOI 10.1002/jcp.1041360107; CARTER TD, 1989, BIOCHEM J, V262, P431, DOI 10.1042/bj2620431; CASTELLOT JJ, 1986, J CELL BIOL, V102, P1979, DOI 10.1083/jcb.102.5.1979; CHENG CF, 1981, J BIOL CHEM, V256, P2893; CHERIFI Y, 1992, J BIOL CHEM, V267, P25315; DAGOSTINO L, 1989, BIOCHIM BIOPHYS ACTA, V993, P228, DOI 10.1016/0304-4165(89)90169-4; DANIELE B, 1990, GASTROENTEROLOGY, V99, P1675, DOI 10.1016/0016-5085(90)90474-F; DEAGOSTINI AI, 1990, J CELL BIOL, V111, P1293, DOI 10.1083/jcb.111.3.1293; ERDMAN SH, 1989, GASTROENTEROLOGY, V96, P1533, DOI 10.1016/0016-5085(89)90523-4; FERREIRA SH, 1973, BRIT J PHARMACOL, V49, P543, DOI 10.1111/j.1476-5381.1973.tb17265.x; GANTZ I, 1991, P NATL ACAD SCI USA, V88, P429, DOI 10.1073/pnas.88.2.429; GRANERUS G, 1982, AGENTS ACTIONS, V12, P29, DOI 10.1007/BF01965102; GREEN JP, 1987, AGENTS ACTIONS, V22, P1, DOI 10.1007/BF01968810; HACHIYA HL, 1987, J BIOL CHEM, V262, P6417; HADDOCK RC, 1987, J BIOL CHEM, V262, P10220; HADDOCK RC, 1990, J BIOL CHEM, V265, P14395; HARDING C, 1983, BIOCHEM BIOPH RES CO, V113, P650, DOI 10.1016/0006-291X(83)91776-X; HARDING C, 1983, J CELL BIOL, V97, P329, DOI 10.1083/jcb.97.2.329; HOPKINS CR, 1983, CELL, V35, P321, DOI 10.1016/0092-8674(83)90235-0; HOUGH LB, 1979, J PHARMACOL EXP THER, V208, P422; IACOPETTA B, 1986, J CELL BIOL, V103, P851, DOI 10.1083/jcb.103.3.851; JONG YJI, 1993, P NATL ACAD SCI USA, V90, P10994, DOI 10.1073/pnas.90.23.10994; KANNER BI, 1978, BIOCHEMISTRY-US, V17, P1207, DOI 10.1021/bi00600a011; KARLSSON K, 1988, BIOCHIM BIOPHYS ACTA, V967, P110, DOI 10.1016/0304-4165(88)90195-X; KEATING MT, 1988, J BIOL CHEM, V263, P12805; KHANDELWAL JK, 1989, J NEUROCHEM, V52, P1107, DOI 10.1111/j.1471-4159.1989.tb01854.x; KLAUSNER RD, 1983, J BIOL CHEM, V258, P4715; KOSHI S, 1991, BIOCHIM BIOPHYS ACTA, V1075, P231, DOI 10.1016/0304-4165(91)90271-H; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LESSOF MH, 1990, CLIN EXP ALLERGY, V20, P373, DOI 10.1111/j.1365-2222.1990.tb02796.x; LUK GD, 1980, J CLIN INVEST, V66, P66, DOI 10.1172/JCI109836; MILLER LP, 1986, J NEUROCHEM, V46, P1412, DOI 10.1111/j.1471-4159.1986.tb01756.x; MONDOVI B, 1981, ADV POLYAMINE RES, V3, P75; NUSSENZVEIG DR, 1990, J BIOL CHEM, V265, P20952; OHRUI T, 1992, J PHARMACOL EXP THER, V261, P1268; OOSTING E, 1987, AGENTS ACTIONS, V21, P54, DOI 10.1007/BF01974921; PEPPER MS, 1993, J CELL BIOL, V122, P673, DOI 10.1083/jcb.122.3.673; REILLY MA, 1971, BRIT J PHARMACOL, V43, P349; ROBINSONWHITE A, 1985, J CLIN INVEST, V76, P93, DOI 10.1172/JCI111983; ROGHANI M, 1992, J BIOL CHEM, V267, P22156; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P7244, DOI 10.1073/pnas.80.23.7244; SESSA A, 1982, BIOCHIM BIOPHYS ACTA, V698, P11, DOI 10.1016/0167-4781(82)90177-4; SHAKIR KMM, 1977, BIOCHEM PHARMACOL, V26, P2343, DOI 10.1016/0006-2952(77)90438-5; SHIMADA K, 1981, J CLIN INVEST, V68, P995, DOI 10.1172/JCI110354; SHIPP MA, 1993, BLOOD, V82, P1052, DOI 10.1182/blood.V82.4.1052.bloodjournal8241052; SICZKOWSKI M, 1992, BLOOD, V80, P912; SUNKARA PS, 1981, LIFE SCI, V28, P1497, DOI 10.1016/0024-3205(81)90382-9; SWANSON JA, 1985, J CELL BIOL, V100, P851, DOI 10.1083/jcb.100.3.851; TAKEDA T, 1992, J CELL SCI, V101, P745; TANIGUCHI T, 1993, CELL, V73, P5, DOI 10.1016/0092-8674(93)90152-G; VIHINEN T, 1993, J BIOL CHEM, V268, P17261; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	63	15	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					14892	14898						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195119				2022-12-25	WOS:A1994NP73800010
J	EKRYLANDER, B; FLORES, M; WENDEL, M; HEINEGARD, D; ANDERSSON, G				EKRYLANDER, B; FLORES, M; WENDEL, M; HEINEGARD, D; ANDERSSON, G			DEPHOSPHORYLATION OF OSTEOPONTIN AND BONE SIALOPROTEIN BY OSTEOCLASTIC TARTRATE-RESISTANT ACID-PHOSPHATASE - MODULATION OF OSTEOCLAST ADHESION IN-VITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							JB6 EPIDERMAL-CELLS; RAT-KIDNEY CELLS; SECRETED PHOSPHOPROTEIN-1; DEVELOPMENTAL EXPRESSION; PHYSIOLOGICAL-PROPERTIES; NONPHOSPHORYLATED FORMS; BINDING-PROPERTIES; PROTEINS; INTEGRIN; MATRIX	The tartrate-resistant acid phosphatase (TRAP) of skeletal osteoclasts was found to partially dephosphorylate the bone matrix phosphoproteins osteopontin (OPN) and bone sialoprotein (BSP). TRAP also partially dephosphorylated metabolically [P-32]PO4-labeled OPN as well as BSP, whereas comparable amounts of either alkaline phosphatase or prostatic acid phosphatase, at their respective pH optima, were ineffective, indicating a certain preference of TRAP for these phosphoprotein substrates. It has previously (Flores, M., Norgard, M., Heinegard, D., Reinholt, F. P., and Andersson, G. (1992) Exp. Cell Res. 201, 526-530) been shown that osteoclasts bind to OPN as well as to BSP coated onto glass. We can now show that the partially dephosphorylated proteins no longer support osteoclast binding. These results indicate that the secretion of TRAP from osteoclasts into the resorption area could exert a regulatory influence on the attachment of the cells to the bone surface. This could imply roles in the development of ruffled borders and/or in the regulation of osteoclast motility on the bone surface.	KAROLINSKA INST, HUDDINGE HOSP, DEPT IMMUNOL MICROBIOL PATHOL & INFECT DIS, DIV PATHOL, S-14186 HUDDINGE, SWEDEN; LUND UNIV, DEPT MED & PHYSIOL CHEM, S-22100 LUND, SWEDEN	Karolinska Institutet; Lund University								ANDERSON TR, 1986, ARCH BIOCHEM BIOPHYS, V247, P131, DOI 10.1016/0003-9861(86)90541-2; ANDERSSON G, 1984, ARCH BIOCHEM BIOPHYS, V228, P431, DOI 10.1016/0003-9861(84)90007-9; ANDERSSON G, 1991, BIOL PHYSL OSTEOCLAS, P55; BOSKEY AL, 1993, BONE MINER, V22, P147, DOI 10.1016/S0169-6009(08)80225-5; CHANG PL, 1991, CANCER RES, V51, P2144; CHANG PL, 1993, CANCER RES, V53, P2217; CHEN JK, 1992, J BONE MINER RES, V7, P987; CHEN Y, 1992, J BIOL CHEM, V267, P24871; DEBRUYNE I, 1983, ANAL BIOCHEM, V133, P110, DOI 10.1016/0003-2697(83)90229-4; EKRYLANDER B, 1991, J BIOL CHEM, V266, P24684; FLORES ME, 1992, EXP CELL RES, V201, P526, DOI 10.1016/0014-4827(92)90305-R; FRANZEN A, 1985, BIOCHEM J, V232, P715, DOI 10.1042/bj2320715; HEINEGARD D, 1989, CONNECT TISSUE RES, V21, P333; HELFRICH MH, 1992, J BONE MINER RES, V7, P335; HORTON MA, 1988, ISI ATLAS-IMMUNOL, V1, P35; HULTENBY K, 1991, MATRIX, V11, P206, DOI 10.1016/S0934-8832(11)80160-5; HULTENBY K, 1993, EUR J CELL BIOL, V62, P86; HULTENBY K, 1994, EUR J CELL BIOL, V63, P230; HUNTER GK, 1993, P NATL ACAD SCI USA, V90, P8562, DOI 10.1073/pnas.90.18.8562; KASUGAI S, 1991, BONE MINER, V13, P235, DOI 10.1016/0169-6009(91)90071-7; KASUGAI S, 1991, J CELL PHYSIOL, V147, P111, DOI 10.1002/jcp.1041470115; MIDURA RJ, 1990, J BIOL CHEM, V265, P5285; NEMIR M, 1989, J BIOL CHEM, V264, P18202; OLDBERG A, 1986, P NATL ACAD SCI USA, V83, P8819, DOI 10.1073/pnas.83.23.8819; OLDBERG A, 1988, J BIOL CHEM, V263, P19430; OLDBERG A, 1988, J BIOL CHEM, V263, P19433; PRINCE CW, 1987, J BIOL CHEM, V262, P2900; REINHOLT FP, 1990, P NATL ACAD SCI USA, V87, P4473, DOI 10.1073/pnas.87.12.4473; REINHOLT FP, 1990, J BONE MINER RES, V5, P1055; ROSS FP, 1993, J BIOL CHEM, V268, P9901; SINGH K, 1990, J BIOL CHEM, V265, P18696; SINGH K, 1993, J BIOCHEM-TOKYO, V114, P702, DOI 10.1093/oxfordjournals.jbchem.a124240; ZHANG R, 1990, J BIOL CHEM, V265, P15375	33	251	255	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					14853	14856						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195113				2022-12-25	WOS:A1994NP73800002
J	HULETT, MD; WITORT, E; BRINKWORTH, RI; MCKENZIE, IFC; HOGARTH, PM				HULETT, MD; WITORT, E; BRINKWORTH, RI; MCKENZIE, IFC; HOGARTH, PM			IDENTIFICATION OF THE IGG BINDING-SITE OF THE HUMAN LOW-AFFINITY RECEPTOR FOR IGG FC-GAMMA-RII - ENHANCEMENT AND ABLATION OF BINDING BY SITE-DIRECTED MUTAGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NATURAL-KILLER CELLS; MONOCLONAL-ANTIBODIES; EPSILON-RI; IMMUNOGLOBULIN SUPERFAMILY; MOLECULAR-CLONING; EXPRESSION; ANTIGEN; DOMAINS; DNA; POLYMORPHISM	Fc receptor-antibody interactions are key mechanisms through which antibody effector functions are mediated. The low affinity receptor for IgG, Fc gamma RII, is expressed on most hematopoietic cells, and through the binding of immune complexes mediates a large spectrum of biological responses vital for resistance to infection and the regulation of immunity. In this study the key residues of human Fc gamma RII involved in the interaction with IgG1 have been identified. Chimeric receptors composed of extracellular regions of Fc gamma RII and the Fc epsilon RI alpha chain have been used to localize the IgG1 binding site of Fc gamma RII to an 8-residue stretch in the second extracellular domain, Asn(154) to Ser(161). Site-directed mutagenesis of this region revealed that substitution of Ile(155) or Gly(156) With alanine ablated the binding of human and mouse IgG1, whereas replacement of Leu(159), Phe(160), or Ser(161) with alanine enhanced binding. Molecular modeling has been used to generate a putative 3-dimensional model structure of the second extracellular domain of Fc gamma RII, suggesting that the binding site lies in an exposed loop region at the interface of domains 1 and 2.	AUSTIN HOSP, AUSTIN RES INST, HEIDELBERG, VIC 3084, AUSTRALIA; UNIV QUEENSLAND, CTR DRUG DESIGN & DEV, BRISBANE, QLD 4072, AUSTRALIA	Austin Research Institute; Florey Institute of Neuroscience & Mental Health; University of Queensland			Hulett, Mark D/C-4160-2012	Hogarth, Mark/0000-0002-0360-7890; Hulett, Mark/0000-0003-2072-5968				ANDERSON CL, 1990, J EXP MED, V171, P1333, DOI 10.1084/jem.171.4.1333; BROOKS DG, 1989, J EXP MED, V170, P1369, DOI 10.1084/jem.170.4.1369; EY PL, 1978, IMMUNOCHEMISTRY, V15, P429, DOI 10.1016/0161-5890(78)90070-6; GRAZIANO RF, 1987, J IMMUNOL, V139, P3536; HARLOW E, 1988, ANTIBODIES LABORATOR; HIBBS ML, 1988, P NATL ACAD SCI USA, V85, P2240, DOI 10.1073/pnas.85.7.2240; HIBBS ML, 1985, IMMUNOGENETICS, V22, P335, DOI 10.1007/BF00430917; HIBBS ML, 1988, J IMMUNOL, V140, P544; HOGARTH PM, 1982, IMMUNOLOGY, V46, P135; HOGARTH PM, 1992, IMMUNOL REV, V125, P21, DOI 10.1111/j.1600-065X.1992.tb00623.x; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; HULETT MD, 1993, EUR J IMMUNOL, V23, P640, DOI 10.1002/eji.1830230310; IERINO FL, 1993, J IMMUNOL, V150, P1794; IERINO FL, 1993, J EXP MED, V178, P1617, DOI 10.1084/jem.178.5.1617; LAH M, 1990, IMMUNOGENETICS, V31, P202, DOI 10.1007/BF00211557; LOPEZ AF, 1983, IMMUNOLOGY, V48, P503; LUND J, 1991, J IMMUNOL, V147, P2657; PARISH CR, 1974, PROC R SOC SER B-BIO, V187, P47, DOI 10.1098/rspb.1974.0060; PIETERSZ GA, 1988, CANCER RES, V48, P4469; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; RAVETCH JV, 1989, J EXP MED, V170, P481, DOI 10.1084/jem.170.2.481; RIGLEY KP, 1989, EUR J IMMUNOL, V19, P481, DOI 10.1002/eji.1830190311; RISKE F, 1991, J BIOL CHEM, V266, P11245; RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SHIMIZU A, 1988, P NATL ACAD SCI USA, V85, P1907, DOI 10.1073/pnas.85.6.1907; SIMMONS D, 1988, NATURE, V333, P568, DOI 10.1038/333568a0; STENGELIN S, 1988, EMBO J, V7, P1053, DOI 10.1002/j.1460-2075.1988.tb02913.x; STUART SG, 1987, J EXP MED, V166, P1668, DOI 10.1084/jem.166.6.1668; STUART SG, 1989, EMBO J, V8, P3657, DOI 10.1002/j.1460-2075.1989.tb08540.x; TATE BJ, 1992, IMMUNOL CELL BIOL, V70, P79, DOI 10.1038/icb.1992.12; TAX WJM, 1983, NATURE, V304, P445, DOI 10.1038/304445a0; UNKELESS JC, 1988, ANNU REV IMMUNOL, V6, P251, DOI 10.1146/annurev.iy.06.040188.001343; VANDEWINKEL JGJ, 1991, J LEUKOCYTE BIOL, V49, P511, DOI 10.1002/jlb.49.5.511; VANDOREN K, 1984, J VIROL, V50, P606, DOI 10.1128/JVI.50.2.606-614.1984; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0; WARMERDAM PAM, 1991, J IMMUNOL, V147, P1338; WILLIAMS AF, 1989, COLD SPRING HARB SYM, V54, P637; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121	42	63	94	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					15287	15293						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195166				2022-12-25	WOS:A1994NP73800065
J	MALLARDO, M; GIORDANO, V; DRAGONETTI, E; SCALA, G; QUINTO, I				MALLARDO, M; GIORDANO, V; DRAGONETTI, E; SCALA, G; QUINTO, I			DNA-DAMAGING AGENTS INCREASE THE STABILITY OF INTERLEUKIN-1-ALPHA, INTERLEUKIN-1-BETA, AND INTERLEUKIN-6 TRANSCRIPTS AND THE PRODUCTION OF THE RELATIVE PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; IMMUNODEFICIENCY-VIRUS TYPE-1; HEPATOCYTE-STIMULATING FACTOR; MESSENGER-RNA DEGRADATION; AUTOCRINE GROWTH-FACTOR; 3' UNTRANSLATED REGION; ALKYLATING-AGENTS; KINASE-C; CARCINOGENIC POTENCY; GENOTOXIC POTENCY	In this study, we addressed the question of whether carcinogens affected the expression of interleukin-1 alpha (IL1 alpha), interleukin-1 beta (IL1 beta), and interleukin-6 (IL6) genes and the production of the relative proteins. Primary cultures of human monocytes were exposed to the alkylating agents mitomycin C (Mit C), methylmethane sulfonate (MMS), and ethylmethane sulfonate (EMS) and tested for the production of IL1 alpha, IL1 beta, and IL6 proteins, as well as for the expression of IL1 alpha, IL1 beta, and IL6 transcripts. The production of IL1 beta and IL6 was significantly augmented by all the three chemicals after 24-48 h of treatment. IL1 alpha was also increased by Mit C and MMS. By Northern blotting analysis, the increased expression of IL1 alpha, IL1 beta, and IL6 genes was shown to occur at 30 min of Mit C and MMS treatment and to decline after 8 h. Similarly, EMS up-regulated the expression of IL1 beta and IL6 genes. The mutagen-mediated increase in interleukin transcripts did not require de novo protein synthesis, and it was due to the enhanced half-life of IL1 alpha, IL1 beta, and IL6 mRNAs rather than to the increased rate of gene transcription. These results suggest that carcinogens, in addition to causing DNA mutations and rearrangements, may also affect cell growth and differentiation by enhancing the expression of cytokine genes.	UNIV NAPLES FEDERICO II, DIPARTIMENTO BIOCHIM & BIOTECNOL MED, I-80131 NAPLES, ITALY; UNIV REGGIO CALABRIA, DIPARTIMENTO MED SPERIMENTALE & CLIN, I-88100 CATANZARO, ITALY	University of Naples Federico II; Universita Mediterranea di Reggio Calabria			SCALA, GIUSEPPE/A-3280-2009	QUINTO, Ileana/0000-0001-8212-8515; MALLARDO, Massimo/0000-0002-4001-3856				[Anonymous], 1985, DNA REPAIR; BENDTZEN K, 1986, SCIENCE, V232, P1545, DOI 10.1126/science.3086977; BODEL P, 1980, J CLIN INVEST, V65, P514, DOI 10.1172/JCI109695; BOHJANEN PR, 1991, MOL CELL BIOL, V11, P3288, DOI 10.1128/MCB.11.6.3288; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COZZOLINO F, 1989, P NATL ACAD SCI USA, V86, P2369, DOI 10.1073/pnas.86.7.2369; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DINARELLO CA, 1993, IMMUNOL TODAY, V14, P260, DOI 10.1016/0167-5699(93)90042-J; DINARELLO CA, 1991, BLOOD, V77, P1627; DINARELLO CA, 1987, J IMMUNOL, V139, P1902; FENTON MJ, 1987, J IMMUNOL, V138, P3972; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GAULDIE J, 1987, P NATL ACAD SCI USA, V84, P7251, DOI 10.1073/pnas.84.20.7251; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GOROSPE M, 1993, J BIOL CHEM, V268, P6214; HALLAHAN DE, 1991, P NATL ACAD SCI USA, V88, P2156, DOI 10.1073/pnas.88.6.2156; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HIRANO T, 1986, NATURE, V324, P73, DOI 10.1038/324073a0; HOLBROOK NJ, 1991, NEW BIOL, V3, P825; ISSHIKI H, 1990, MOL CELL BIOL, V10, P2757, DOI 10.1128/MCB.10.6.2757; KAWANO M, 1988, NATURE, V332, P83, DOI 10.1038/332083a0; KISHIMOTO T, 1992, SCIENCE, V258, P593, DOI 10.1126/science.1411569; KODAKA T, 1989, JPN J CANCER RES, V80, P531, DOI 10.1111/j.1349-7006.1989.tb01672.x; KRAMER M, 1993, J BIOL CHEM, V268, P6734; KRIPKE ML, 1990, PHOTOCHEM PHOTOBIOL, V52, P919, DOI 10.1111/j.1751-1097.1990.tb08703.x; LINDSTEN T, 1989, SCIENCE, V244, P339, DOI 10.1126/science.2540528; MACCHIA G, 1990, MOL CELL BIOL, V10, P2731, DOI 10.1128/MCB.10.6.2731; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MALTER JS, 1991, J BIOL CHEM, V266, P3167; MIKI S, 1989, FEBS LETT, V250, P607, DOI 10.1016/0014-5793(89)80805-1; NOONAN FP, 1990, PHOTOCHEM PHOTOBIOL, V52, P801, DOI 10.1111/j.1751-1097.1990.tb08685.x; NORDAN RP, 1986, SCIENCE, V233, P566, DOI 10.1126/science.3726549; PISTOIA V, 1986, J IMMUNOL, V136, P1688; POLI V, 1989, P NATL ACAD SCI USA, V86, P8202, DOI 10.1073/pnas.86.21.8202; QUINTO I, 1993, J BIOL CHEM, V268, P26719; QUINTO I, 1990, MUTAT RES, V228, P177, DOI 10.1016/0027-5107(90)90074-E; QUINTO I, 1987, MUTAT RES, V181, P235, DOI 10.1016/0027-5107(87)90101-1; RAY A, 1988, P NATL ACAD SCI USA, V85, P6701, DOI 10.1073/pnas.85.18.6701; RAY A, 1990, MOL CELL BIOL, V10, P5736, DOI 10.1128/MCB.10.11.5736; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; ROSS HJ, 1991, BLOOD, V77, P1787; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; SCALA G, 1984, J EXP MED, V159, P1637, DOI 10.1084/jem.159.6.1637; SCALA G, 1990, J EXP MED, V172, P61, DOI 10.1084/jem.172.1.61; SCALA G, 1984, NATURE, V309, P56, DOI 10.1038/309056a0; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHIMIZU S, 1988, BLOOD, V72, P1826; SPORN MB, 1980, NEW ENGL J MED, V303, P878, DOI 10.1056/NEJM198010093031511; SUNG SSJ, 1988, J EXP MED, V167, P937, DOI 10.1084/jem.167.3.937; SUTTER TR, 1991, SCIENCE, V254, P415, DOI 10.1126/science.1925598; VAKALOPOULOU E, 1991, MOL CELL BIOL, V11, P3355, DOI 10.1128/MCB.11.6.3355; VALERIE K, 1988, NATURE, V333, P78, DOI 10.1038/333078a0; WAAGE A, 1989, CLIN IMMUNOL IMMUNOP, V50, P394, DOI 10.1016/0090-1229(89)90146-3	55	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					14899	14904						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195120				2022-12-25	WOS:A1994NP73800011
J	BETTENDORFF, L; WINS, P				BETTENDORFF, L; WINS, P			MECHANISM OF THIAMINE TRANSPORT IN NEUROBLASTOMA-CELLS - INHIBITION OF A HIGH-AFFINITY CARRIER BY SODIUM-CHANNEL ACTIVATORS AND DEPENDENCE OF THIAMINE UPTAKE ON MEMBRANE-POTENTIAL AND INTRACELLULAR ATP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOLATED RAT HEPATOCYTES; VOLTAGE-GATED SODIUM; BLOOD-BRAIN-BARRIER; NA+ IONOPHORE; PHOSPHATE-ESTERS; PYROPHOSPHOKINASE; NEUROTOXINS; ASTROCYTES; METABOLISM; SYSTEM	Nerve cells are particularly sensitive to thiamine deficiency. We studied thiamine transport in mouse neuroblastoma (Neuro 2a) cells. At low external concentration, [C-14]thiamine was taken up through a saturable high affinity mechanism (K-m = 35 nM). This was blocked by low concentrations of the Na+ channel activators veratridine (IC50 = 7 +/- 4 mu M) and batrachotoxin (IC50 = 0.9 mu M). These effects were not antagonized by tetrodotoxin and were also observed in cell lines devoid of Na+ channels, suggesting that these channels are not involved in the mechanism of inhibition. At high extracellular concentrations, thiamine uptake proceeds essentially via a low affinity carrier (K-m = 0.8 mM), insensitive to veratridine but blocked by divalent cations. In both cases, the uptake was independent on external sodium, partially inhibited (10-35%) by depolarization and sensitive to metabolic inhibitors. A linear relationship between the rate of thiamine transport and intracellular ATP concentration was found. When cells grown in a medium of low thiamine concentration (6 nM) were exposed to 100 nM extracellular thiamine, a 3-fold increase in intracellular thiamine diphosphate was observed after 2 h while the concomitant increase in intracellular free thiamine was barely significant. These data suggest a secondary active transport of thiamine, the main driving force being thiamine phosphorylation rather than the sodium gradient.			BETTENDORFF, L (corresponding author), UNIV LIEGE,GEN & COMPARAT BIOCHEM LAB,17 PL DELCOUR,B-4020 LIEGE,BELGIUM.							BENOS DJ, 1992, REV PHYSL BIOCH PHAR, V120, P21; BERS DM, 1982, AM J PHYSIOL, V242, pC404, DOI 10.1152/ajpcell.1982.242.5.C404; BETTENDORFF L, 1993, J MEMBRANE BIOL, V136, P281; BETTENDORFF L, 1991, ANAL BIOCHEM, V198, P52, DOI 10.1016/0003-2697(91)90505-N; BETTENDORFF L, 1986, J CHROMATOGR, V382, P297, DOI 10.1016/S0378-4347(00)83533-1; BETTENDORFF L, 1993, J NEUROCHEM, V60, P423, DOI 10.1111/j.1471-4159.1993.tb03168.x; BEVAN S, 1985, PROC R SOC SER B-BIO, V225, P299, DOI 10.1098/rspb.1985.0063; BLASS JP, 1982, J NEUROCHEM, V39, P729, DOI 10.1111/j.1471-4159.1982.tb07953.x; CASIROLA D, 1988, J PHYSIOL-LONDON, V398, P329, DOI 10.1113/jphysiol.1988.sp017045; CASIROLA D, 1990, J MEMBRANE BIOL, V118, P11, DOI 10.1007/BF01872201; CATTERALL WA, 1992, PHYSIOL REV, V72, pS15, DOI 10.1152/physrev.1992.72.suppl_4.S15; CATTERALL WA, 1977, J BIOL CHEM, V252, P8669; CATTERALL WA, 1975, P NATL ACAD SCI USA, V72, P1782, DOI 10.1073/pnas.72.5.1782; CATTERALL WA, 1973, P NATL ACAD SCI USA, V70, P3759, DOI 10.1073/pnas.70.12.3759; CATTERALL WA, 1976, P NATL ACAD SCI USA, V73, P2682, DOI 10.1073/pnas.73.8.2682; COOPER JR, 1979, NEUROCHEM RES, V4, P223, DOI 10.1007/BF00964146; GREENWOOD J, 1986, BRAIN RES, V399, P148, DOI 10.1016/0006-8993(86)90609-8; GREENWOOD J, 1982, J PHYSIOL-LONDON, V327, P95, DOI 10.1113/jphysiol.1982.sp014222; HILL M, 1988, FEBS LETT, V230, P47, DOI 10.1016/0014-5793(88)80639-2; JOHNSON LR, 1968, BIOCHIM BIOPHYS ACTA, V156, P85, DOI 10.1016/0304-4165(68)90107-4; KSIEZAKREDING H, 1982, J NEUROCHEM, V38, P1627, DOI 10.1111/j.1471-4159.1982.tb06643.x; LUMENG L, 1979, J BIOL CHEM, V254, P7265; MATSUDA T, 1985, EXPERIENTIA, V41, P924, DOI 10.1007/BF01970015; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PETERSON JW, 1975, BIOCHIM BIOPHYS ACTA, V397, P377, DOI 10.1016/0005-2744(75)90127-8; POUYSSEGUR J, 1980, NATURE, V286, P162, DOI 10.1038/286162a0; REED JK, 1986, BIOCHEM CELL BIOL, V64, P1153, DOI 10.1139/o86-152; SHARMA SK, 1965, BIOCHEM J, V94, P790, DOI 10.1042/bj0940790; SMITH TC, 1989, J MEMBRANE BIOL, V107, P169, DOI 10.1007/BF01871722; SPECTOR R, 1976, AM J PHYSIOL, V230, P1101, DOI 10.1152/ajplegacy.1976.230.4.1101; YAMAMOTO S, 1981, J BIOCHEM-TOKYO, V89, P809, DOI 10.1093/oxfordjournals.jbchem.a133263; YOSHIOKA K, 1984, BIOCHIM BIOPHYS ACTA, V778, P201, DOI 10.1016/0005-2736(84)90463-2; YOSHIOKA K, 1985, BIOCHIM BIOPHYS ACTA, V815, P499, DOI 10.1016/0005-2736(85)90378-5	33	60	61	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14379	14385						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	8182042				2022-12-25	WOS:A1994NM06500014
J	FLACK, MR; FROEHLICH, J; BENNET, AP; ANASTI, J; NISULA, BC				FLACK, MR; FROEHLICH, J; BENNET, AP; ANASTI, J; NISULA, BC			SITE-DIRECTED MUTAGENESIS DEFINES THE INDIVIDUAL ROLES OF THE GLYCOSYLATION SITES ON FOLLICLE-STIMULATING-HORMONE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CHORIO-GONADOTROPIN; ASPARAGINE-LINKED OLIGOSACCHARIDES; PITUITARY GLYCOPROTEIN HORMONES; CELL AROMATASE BIOASSAY; BETA-SUBUNIT; RECEPTOR-BINDING; SIALYLATED OLIGOSACCHARIDES; SIGNAL TRANSDUCTION; ALPHA-SUBUNIT; FOLLITROPIN	To determine the specific role of each follicle stimulating hormone (FSH) oligosaccharide, we mutated Asn to Gln at each glycosylation site (alpha Gln(52), alpha Gln(78), alpha Gln(52-78), beta Gln(7), beta Gln(24), and beta Gln(7-24)) to selectively inhibit oligosaccharide attachment. For wild-type and mutant FSH, we determined the binding affinity to homogenized rat Sertoli cells and the signal-transducing activity in cultured rat granulosa cells. The binding affinity of FSH lacking any one of the oligosaccharides was increased over wild-type FSH, while the signal-transducing activity of FSH lacking the oligosaccharide at alpha Asn(52) (alpha Gln(52) FSH) was markedly reduced, and that of FSH lacking either beta oligosaccharide (beta Gln(7) and beta Gln(24) FSH) was slightly reduced. At each FSH beta glycosylation site, we made a second amino acid substitution to inhibit glycosylation (beta Tyr(9) and beta Tyr(26)) and an amino acid substitution that preserved glycosylation (beta Ser(9) and beta Ser(26)). The amino acid sequence of the second p subunit glycosylation site was important for signal transduction, regardless of the presense or absence of the oligosaccharide. Thus, while each FSH oligosaccharide has a similar impact on binding affinity, the alpha(52) oligosaccharide has a disproportionate role in signal transduction, and the amino acid sequence at beta Asn(24) functions in both binding and signal transduction.			FLACK, MR (corresponding author), NICHHD, DEV ENDOCRINOL BRANCH, BLDG 10, RM 10N262, 9000 ROCKVILLE PK, BETHESDA, MD 20892 USA.							AMR S, 1984, ARCH BIOCHEM BIOPHYS, V229, P170, DOI 10.1016/0003-9861(84)90141-3; CALVO FO, 1986, BIOCHEMISTRY-US, V25, P3938, DOI 10.1021/bi00361a030; CAMPBELL RK, 1991, P NATL ACAD SCI USA, V88, P760, DOI 10.1073/pnas.88.3.760; DAHL KD, 1989, METHOD ENZYMOL, V168, P414; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; GOODMAN AL, 1977, P SOC EXP BIOL MED, V155, P479; GOVERMAN JM, 1982, J BIOL CHEM, V257, P5059; GREEN ED, 1988, J BIOL CHEM, V263, P25; GREEN ED, 1988, J BIOL CHEM, V263, P36; HAGEVANNOORT M, 1992, P NATL ACAD SCI USA, V89, P3922, DOI 10.1073/pnas.89.9.3922; HARTREE AS, 1992, BIOCHEM J, V287, P665, DOI 10.1042/bj2870665; HATTORI M, 1988, MOL CELL ENDOCRINOL, V57, P17; HAYASHIZAKI Y, 1989, EMBO J, V8, P2291, DOI 10.1002/j.1460-2075.1989.tb08355.x; JIA XC, 1986, ENDOCRINOLOGY, V119, P1570, DOI 10.1210/endo-119-4-1570; KALYAN NK, 1983, J BIOL CHEM, V258, P67; KEUTMANN HT, 1992, MOL CELL ENDOCRINOL, V86, pC1, DOI 10.1016/0303-7207(92)90168-6; LASH RW, 1992, J ENDOCRINOL INVEST, V15, P255, DOI 10.1007/BF03348723; LIU L, 1988, J ANDROL, V9, P62; LUSTBADER JW, 1993, ENDOCR REV, V14, P291, DOI 10.1210/er.14.3.291; MANJUNATH P, 1982, MOL CELL ENDOCRINOL, V28, P125, DOI 10.1016/0303-7207(82)90026-0; MATZUK MM, 1989, J BIOL CHEM, V264, P2409; PADMANABHAN V, 1991, MOL CELL ENDOCRINOL, V79, P119, DOI 10.1016/0303-7207(91)90102-X; PIERCE JG, 1981, ANNU REV BIOCHEM, V50, P465, DOI 10.1146/annurev.bi.50.070181.002341; RICHARDSON MC, 1984, J ENDOCRINOL, V101, P327, DOI 10.1677/joe.0.1010327; SAIRAM MR, 1982, MOL CELL ENDOCRINOL, V28, P139, DOI 10.1016/0303-7207(82)90027-2; SAIRAM MR, 1983, J BIOL CHEM, V258, P445; SAIRAM MR, 1985, SCIENCE, V229, P65, DOI 10.1126/science.2990039; SAIRAM MR, 1985, RECEPTORS, V2, P307; SANTACOLOMA TA, 1991, MOL CELL ENDOCRINOL, V78, P197, DOI 10.1016/0303-7207(91)90123-A; STRICKLAND TW, 1982, ENDOCRINOLOGY, V111, P95, DOI 10.1210/endo-111-1-95	30	90	97	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					14015	14020						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188681				2022-12-25	WOS:A1994NL60600046
J	LINGUEGLIA, E; RENARD, S; WALDMANN, R; VOILLEY, N; CHAMPIGNY, G; PLASS, H; LAZDUNSKI, M; BARBRY, P				LINGUEGLIA, E; RENARD, S; WALDMANN, R; VOILLEY, N; CHAMPIGNY, G; PLASS, H; LAZDUNSKI, M; BARBRY, P			DIFFERENT HOMOLOGOUS SUBUNITS OF THE AMILORIDE-SENSITIVE NA+ CHANNEL ARE DIFFERENTLY REGULATED BY ALDOSTERONE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ACETYLCHOLINE-RECEPTOR	Long term regulation of the amiloride-sensitive Na+ channel activity by steroid hormones occurs via de novo protein synthesis. The messenger level of RCNaCh1, previously shown by expression cloning to be a component of this channel, was measured in colons from rats fed with a low sodium diet. After 1 week of this diet, the channel activity was increased in an all-or-none fashion, whereas the level of RCNaCh1 messenger remained constant. A cDNA coding for another subunit of the Na+ channel was obtained by polymerase chain reaction. The 650-amino acid protein, entitled RCNaCh2, is 58% homologous to RCNaCh1 and displays a similar structure. It had no intrinsic activity when expressed alone in Xenopus oocytes, but its co-expression with RCNaCh1 increased the channel activity 18 +/- B-fold. The increase in messenger level for RCNaCh2 during the time course of the diet is likely to explain the positive regulation of the rat colon Na+ channel by steroids. Immunocytochemical localization of the RC-NaCh1 subunit revealed an apical labeling in colon from sodium-depleted rats. No labeling was observed in colon from control animals. These results suggest that oligomerization is needed for the proper expression of RCNaCh1 at the cell surface.	INST PHARMACOL MOLEC & CELLULAIRE,F-06560 VALBONNE,FRANCE				Barbry, Pascal/O-5021-2016; Waldmann, Rainer/Q-2108-2016; LINGUEGLIA, Eric/F-5509-2013	Barbry, Pascal/0000-0001-9632-6483; Waldmann, Rainer/0000-0002-4599-2926; LINGUEGLIA, Eric/0000-0003-3902-3405; Renard, Stephane/0000-0002-1374-4960				BETZ H, 1990, BIOCHEMISTRY-US, V29, P3591, DOI 10.1021/bi00467a001; BLOUNT P, 1988, J BIOL CHEM, V263, P1072; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; CHALFIE M, 1993, J NEUROBIOL, V24, P1433, DOI 10.1002/neu.480241013; CRABBE J, 1961, J CLIN INVEST, V40, P2103, DOI 10.1172/JCI104436; DRISCOLL M, 1991, NATURE, V349, P588, DOI 10.1038/349588a0; GALZI JL, 1991, ANNU REV PHARMACOL, V31, P37, DOI 10.1146/annurev.pa.31.040191.000345; GARTY H, 1988, PHYSIOL REV, V68, P309, DOI 10.1152/physrev.1988.68.2.309; GREEN WN, 1993, CELL, V74, P57, DOI 10.1016/0092-8674(93)90294-Z; JAN LY, 1992, CELL, V69, P715, DOI 10.1016/0092-8674(92)90280-P; Karlin A, 1993, Curr Opin Neurobiol, V3, P299, DOI 10.1016/0959-4388(93)90121-E; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LINGUEGLIA E, 1993, FEBS LETT, V318, P95, DOI 10.1016/0014-5793(93)81336-X; PONGS O, 1992, PHYSIOL REV, V72, pS69, DOI 10.1152/physrev.1992.72.suppl_4.S69; RENARD S, 1994, J BIOL CHEM, V269, P12981; Rossier BC, 1992, KIDNEY PHYSL PATHOPH, P1373; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; VOILLEY N, 1994, P NATL ACAD SCI USA, V91, P247, DOI 10.1073/pnas.91.1.247; WILL PC, 1980, AM J PHYSIOL, V238, pF261, DOI 10.1152/ajprenal.1980.238.4.F261; Wisden W, 1993, Curr Opin Neurobiol, V3, P291, DOI 10.1016/0959-4388(93)90120-N	21	174	176	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					13736	13739						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188647				2022-12-25	WOS:A1994NL60600004
J	EXPOSITO, JY; SUZUKI, H; GEOURJON, C; GARRONE, R; SOLURSH, M; RAMIREZ, F				EXPOSITO, JY; SUZUKI, H; GEOURJON, C; GARRONE, R; SOLURSH, M; RAMIREZ, F			IDENTIFICATION OF A CELL LINEAGE-SPECIFIC GENE CODING FOR A SEA-URCHIN ALPHA-2(IV)-LIKE COLLAGEN CHAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IV COLLAGEN; BASEMENT-MEMBRANE; GOODPASTURE ANTIGEN; PROCOLLAGEN; EXPRESSION; EMBRYO; ALPHA-1(IV); SEQUENCE	We report the isolation of several overlapping cDNAs from an embryonic library of Strongylocentrotus purpuratus coding for a novel sea urchin collagen chain. The conceptual amino acid translation of the cDNAs indicated that the protein displays the structural features of a vertebrate type IV-like collagen a chain. In addition to a putative 31-residue signal peptide, the sea urchin molecule contains a 14-residue amino terminal non collagenous segment, a discontinuous 1,477 amino acid triple helical domain, and a 225-residue carboxyl-terminal domain rich in cysteines. The amino- and carboxyl-terminal non collagenous regions of the echinoid molecule are remarkably similar to the 7 S and carboxyl-terminal non-collagenous (NC1) domains of the alpha 1 and alpha 2 chains of vertebrate type IV collagen. The sequence similarity and distinct structural features of the 7 S and NC1 domains strongly suggest that the sea urchin polypeptide is evolutionarily related to the alpha 2(TV) class of collagen chains. Finally, in situ hybridizations revealed that expression of this collagen gene is restricted to the mesenchyme cell lineage of the developing sea urchin embryo.	CUNY MT SINAI SCH MED,BROOKDALE CTR MOLEC BIOL,NEW YORK,NY 10029; INST BIOL & CHIM PROT,CNRS,UPR 412,F-69367 LYON 07,FRANCE; UNIV IOWA,DEPT BIOL,IOWA CITY,IA 52242	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Centre National de la Recherche Scientifique (CNRS); University of Iowa				Exposito, Jean-Yves/0000-0002-4926-4942	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041849] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-41849] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANGERER LM, 1987, IN SITU HYBRIDIZATIO, P42; BLUMBERG B, 1988, J BIOL CHEM, V263, P18328; DALESSIO M, 1989, P NATL ACAD SCI USA, V86, P9303, DOI 10.1073/pnas.86.23.9303; DALESSIO M, 1989, P NATL ACAD SCI USA, V265, P7050; DAVIDSON EH, 1989, DEVELOPMENT, V105, P421; EXPOSITO JY, 1993, J BIOL CHEM, V268, P5249; EXPOSITO JY, 1992, J BIOL CHEM, V267, P17404; EXPOSITO JY, 1992, J BIOL CHEM, V267, P15559; GEOURJON C, 1993, COMPUT APPL BIOSCI, V9, P87; GLANVILLE RW, 1987, STRUCTURE FUNCTION C, P47; GUNWAR S, 1990, J BIOL CHEM, V265, P5466; GUO XD, 1989, J BIOL CHEM, V264, P17574; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HOSTIKKA SL, 1988, J BIOL CHEM, V263, P19488; HOSTIKKA SL, 1990, P NATL ACAD SCI USA, V87, P1606, DOI 10.1073/pnas.87.4.1606; LEAHY PS, 1986, METHOD CELL BIOL, V27, P1, DOI 10.1016/S0091-679X(08)60339-8; MORRISON KE, 1991, J BIOL CHEM, V266, P34; NEMER M, 1988, BIOCHIM BIOPHYS ACTA, V950, P445, DOI 10.1016/0167-4781(88)90143-1; PETTITT J, 1991, J BIOL CHEM, V266, P16149; POSCHL E, 1988, EMBO J, V7, P2687, DOI 10.1002/j.1460-2075.1988.tb03122.x; QUINONES S, 1992, J BIOL CHEM, V267, P19780; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAUS J, 1988, J BIOL CHEM, V263, P13374; SIBLEY MH, 1993, J CELL BIOL, V123, P255, DOI 10.1083/jcb.123.1.255; SU MW, 1991, J CELL BIOL, V115, P565, DOI 10.1083/jcb.115.2.565; SUGIMOTO M, 1993, FEBS LETT, V330, P122, DOI 10.1016/0014-5793(93)80256-T; SWALLA BJ, 1988, DEV BIOL, V125, P51, DOI 10.1016/0012-1606(88)90057-7; VANDERREST M, 1991, FASEB J, V5, P2814, DOI 10.1096/fasebj.5.13.1916105; WESSEL GM, 1987, DEV BIOL, V121, P149, DOI 10.1016/0012-1606(87)90148-5; WESSEL GM, 1991, DEV BIOL, V148, P261, DOI 10.1016/0012-1606(91)90335-Z; ZHOU J, 1993, SCIENCE, V261, P1167, DOI 10.1126/science.8356449	32	27	27	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13167	13171						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175744				2022-12-25	WOS:A1994NK18400021
J	PANDEY, VN; KAUSHIK, N; MODAK, MJ				PANDEY, VN; KAUSHIK, N; MODAK, MJ			ROLE OF LYSINE-758 OF ESCHERICHIA-COLI DNA-POLYMERASE-I AS ASSESSED BY SITE-DIRECTED MUTAGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KLENOW FRAGMENT; PROTEOLYTIC FRAGMENT; TEMPLATE-PRIMER; BINDING DOMAIN; IDENTIFICATION; INHIBITION; SUBSTRATE; CATALYSIS	Lys-758 of Escherichia coli DNA polymerase I has been implicated in the process of substrate dNTP binding (Basu, A., and Modak, M. J. (1987) Biochemistry 26, 1704-1709). To confirm and define the role of Lys-758 in the catalytic mechanism, we carried out site-directed mutagenesis of this residue. Catalytic activity of the purified mutant enzymes, K758A and K758R, showed severe reduction in the polymerase activity but little difference in the 3' --> 5' exonuclease activity. Most interestingly, the catalytic ability of both mutant enzymes was maximally affected (300-1,000-fold decrease in k(cat)) with poly(dA).(dT)(15) as template primer (TP), whereas the ability to use poly(dC) templates decreased by only 20-fold in K758A and remained nearly unchanged with K758R. Kinetic characterization showed that K-m(dNTP) increased moderately only with K758A, whereas K-d(TP) remained unchanged for both the mutants, However, binary complex formation between K758A and dNTP, but not between K758A and TP, was severely reduced. Analysis of the processive mode of DNA synthesis by K758A indicated that the mutant enzyme pauses at dA bases but does not dissociate from TP, suggesting a defect in its translocation ability. Thus, Lys-758 in polymerase I appears to participate in two distinct functions: (a) it facilitates the dNTP binding, and (b) it is required for the translocation along the template polynucleotide,	UNIV MED & DENT NEW JERSEY,NEW JERSEY MED SCH,DEPT BIOCHEM & MOLEC BIOL,NEWARK,NJ 07103	Rutgers State University New Brunswick; Rutgers State University Medical Center				Pandey, Virendra N/0000-0001-6041-6786	NIGMS NIH HHS [GM-36307] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAM KI, 1984, BIOCHEMISTRY-US, V23, P1176, DOI 10.1021/bi00301a023; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BASU A, 1985, BIOCHEM BIOPH RES CO, V128, P1395, DOI 10.1016/0006-291X(85)91095-2; BASU A, 1987, BIOCHEMISTRY-US, V26, P1704, DOI 10.1021/bi00380a032; BASU A, 1989, J BIOL CHEM, V264, P8746; BASU S, 1988, BIOCHEMISTRY-US, V27, P6710, DOI 10.1021/bi00418a011; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRYANT FR, 1983, BIOCHEMISTRY-US, V22, P3537, DOI 10.1021/bi00284a001; DAHLBERG ME, 1991, BIOCHEMISTRY-US, V30, P4835, DOI 10.1021/bi00234a002; DERBYSHIRE V, 1989, J BIOL CHEM, V264, P10858; JOYCE CM, 1983, P NATL ACAD SCI-BIOL, V80, P1830, DOI 10.1073/pnas.80.7.1830; KAUSHIK NA, 1993, CURR SCI INDIA, V64, P102; Kornberg A., 1992, DNA REPLICATION, VSecond, P113; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARCUS SL, 1974, BIOCHEM BIOPH RES CO, V56, P516, DOI 10.1016/0006-291X(74)90873-0; MARTIN JL, 1993, J BIOL CHEM, V268, P2565; MODAK MJ, 1976, BIOCHEMISTRY-US, V15, P3620, DOI 10.1021/bi00661a033; MODAK MJ, 1980, BIOCHEM BIOPH RES CO, V96, P931, DOI 10.1016/0006-291X(80)91444-8; OLLIS DL, 1985, NATURE, V313, P762, DOI 10.1038/313762a0; PANDEY VN, 1990, J BIOL CHEM, V265, P3679; PANDEY VN, 1993, EUR J BIOCHEM, V214, P59, DOI 10.1111/j.1432-1033.1993.tb17896.x; PANDEY VN, 1987, BIOCHEMISTRY-US, V26, P7744, DOI 10.1021/bi00398a031; PANDEY VN, 1988, J BIOL CHEM, V263, P6068; POLESKY AH, 1992, J BIOL CHEM, V267, P8417; POLESKY AH, 1990, J BIOL CHEM, V265, P14579; RUSH J, 1990, J BIOL CHEM, V265, P4821; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SETLOW P, 1972, J BIOL CHEM, V247, P224; YADAV PNS, 1992, BIOCHEMISTRY-US, V31, P2879, DOI 10.1021/bi00126a006	30	28	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13259	13265						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175756				2022-12-25	WOS:A1994NK18400034
J	PARRIS, W; RUBINCHIK, S; YANG, YC; GOLD, M				PARRIS, W; RUBINCHIK, S; YANG, YC; GOLD, M			A NEW PROCEDURE FOR THE PURIFICATION OF THE BACTERIOPHAGE-LAMBDA TERMINASE ENZYME AND ITS SUBUNITS - PROPERTIES OF GENE-PRODUCT-A, THE LARGE SUBUNIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA TERMINASE; COS DNA; PROTEIN; BINDING; HEAD; MUTATIONS; CLEAVAGE; INVITRO; END; OVERPRODUCTION	New methods for the purification of highly active bacteriophage lambda terminase holoenzyme, and its individual subunits, gene products (gp) A and gpNu1, have been developed. These methods are rapid, simple, reproducible, and give high yields of unaggregated protein from small volumes of culture. The procedures involve fractionation of extracts of Esherichia coli strains harboring plasmids engineered to overproduce the respective proteins. Ah purified proteins exist as monomers or dimers at moderate concentrations. At concentrations where holoenzyme efficiently promotes in vitro cosN-cleavage and lambda DNA packaging, gpA displays neither of these activities unless supplemented with gpNu1 and the E. coli protein integration host factor. At high protein concentrations, however, gpA can promote cos-cleavage by itself. Although gpNu1 itself cannot promote either cosN-cleavage or DNA packaging, it does modulate these activities of gpA. GpA is a DNA-stimulated ATPase whose catalytic parameters closely resemble those of the holoenzyme. Like the holoenzyme, gpA displays a DNA helicase activity which is able to melt the annealed cosN overhangs. Certain preparations of gpA appear to undergo a time-dependent amino-terminal clipping at discrete sites even in the presence of as many as four protease inhibitors and at low temperature.	UNIV TORONTO, DEPT MOLEC & MED GENET, TORONTO M5S 1A8, ON, CANADA	University of Toronto								BECKER A, 1977, VIROLOGY, V78, P291, DOI 10.1016/0042-6822(77)90100-3; BECKER A, 1988, J MOL BIOL, V199, P219, DOI 10.1016/0022-2836(88)90391-9; BECKER A, 1990, J BACTERIOL, V172, P2819, DOI 10.1128/jb.172.6.2819-2824.1990; BERG JM, 1986, SCIENCE, V232, P485, DOI 10.1126/science.2421409; CHOW S, 1987, GENE, V60, P277, DOI 10.1016/0378-1119(87)90236-8; DAVIDSON A, 1991, J BACTERIOL, V173, P5086, DOI 10.1128/jb.173.16.5086-5096.1991; DAVIDSON AR, 1992, VIROLOGY, V189, P21, DOI 10.1016/0042-6822(92)90677-H; FEISS M, 1986, TRENDS GENET, V2, P100, DOI 10.1016/0168-9525(86)90193-9; FEISS M, 1982, P NATL ACAD SCI-BIOL, V79, P3498, DOI 10.1073/pnas.79.11.3498; FEISS M, 1983, LAMBDA, V2, P305; FRANKEL S, 1991, P NATL ACAD SCI USA, V88, P1192, DOI 10.1073/pnas.88.4.1192; GOLD L, 1981, ANNU REV MICROBIOL, V35, P365, DOI 10.1146/annurev.mi.35.100181.002053; GOLD M, 1983, J BIOL CHEM, V258, P4619; GUO PX, 1987, J MOL BIOL, V197, P229, DOI 10.1016/0022-2836(87)90121-5; HIGGINS RR, 1988, CELL, V54, P765, DOI 10.1016/S0092-8674(88)91021-5; HSIAO CL, 1977, P NATL ACAD SCI USA, V74, P3652, DOI 10.1073/pnas.74.9.3652; JENKINS WT, 1991, ANAL BIOCHEM, V194, P136, DOI 10.1016/0003-2697(91)90160-U; JOHNSON G, 1991, J BACTERIOL, V173, P2733, DOI 10.1128/JB.173.9.2733-2738.1991; JOHNSTON RF, 1990, ELECTROPHORESIS, V11, P355, DOI 10.1002/elps.1150110503; KALLWASS HKW, 1992, J AM CHEM SOC, V114, P4551, DOI 10.1021/ja00038a016; KEELER CL, 1987, THESIS U MARYLAND BA; KYPR J, 1986, J MOL BIOL, V191, P139, DOI 10.1016/0022-2836(86)90430-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAYNE E, 1957, METHOD ENZYMOL, V3, P447, DOI 10.1016/S0076-6879(57)03413-8; LEGENDRE N, 1989, PRACTICAL GUIDE PROT, P51; MILLER G, 1985, J MOL BIOL, V183, P246, DOI 10.1016/0022-2836(85)90217-7; MITRAKI A, 1991, SCIENCE, V253, P54, DOI 10.1126/science.1648264; MIWA T, 1983, GENE, V24, P199; MIWA T, 1982, GENE, V20, P265; MURIALDO H, 1991, ANNU REV BIOCHEM, V60, P125; MURIALDO H, 1987, NUCLEIC ACIDS RES, V15, P119, DOI 10.1093/nar/15.1.119; NASH HA, 1987, J BACTERIOL, V169, P4124, DOI 10.1128/jb.169.9.4124-4127.1987; PARRIS W, 1988, J BIOL CHEM, V263, P8413; PERUCCHETTI R, 1988, VIROLOGY, V165, P103, DOI 10.1016/0042-6822(88)90663-0; RAO VB, 1988, J MOL BIOL, V200, P475, DOI 10.1016/0022-2836(88)90537-2; REYES O, 1979, VIROLOGY, V94, P400, DOI 10.1016/0042-6822(79)90470-7; RUBINCHIK S, 1994, J BIOL CHEM, V269, P13586; RUBINCHIK S, 1994, J BIOL CHEM, V269, P13575; SHINDER G, 1988, J VIROL, V62, P387, DOI 10.1128/JVI.62.2.387-392.1988; SIPPY J, 1992, J BACTERIOL, V174, P850, DOI 10.1128/jb.174.3.850-856.1992; SMITH MP, 1993, J BACTERIOL, V175, P2393, DOI 10.1128/JB.175.8.2393-2399.1993; TOMKA MA, 1993, J BIOL CHEM, V268, P3056; TURNQUIST S, 1992, P NATL ACAD SCI USA, V89, P10479, DOI 10.1073/pnas.89.21.10479; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; WILLIS RC, 1992, THESIS U TORONTO; WU WF, 1988, GENETICS, V119, P477; XU S, 1989, THESIS U IOWA; YANG YC, 1993, THESIS U TORONTO; YANOFSKY C, 1966, J MOL BIOL, V21, P313, DOI 10.1016/0022-2836(66)90102-1	49	27	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13564	13574						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175792				2022-12-25	WOS:A1994NK18400075
J	QUINN, GB; TRIMBOLI, AJ; BARBER, MJ				QUINN, GB; TRIMBOLI, AJ; BARBER, MJ			CONSTRUCTION AND EXPRESSION OF A FLAVOCYTOCHROME B(5) CHIMERA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPINACH NITRATE REDUCTASE; NUCLEOTIDE-SEQUENCE; PROTEOLYSIS; DOMAINS; CDNA	A gene has been constructed coding for a chimeric flavocytochrome b(5) protein that comprises the soluble domain of rat hepatic cytochrome b(5) as the NH2-terminal portion of the chimera and the flavin-containing domain of spinach assimilatory NADH:nitrate reductase as the C terminus. The chimeric protein has been expressed in Escherichia coli and purified to homogeneity using a combination of ammonium sulfate precipitation, affinity chromatography on 5'-ADP-agarose, anion-exchange chromatography, and fast protein liquid chromatography gel filtration with an estimated molecular mass of 43 kDa from polyacrylamide gel electrophoresis. Visible and fluorescence spectroscopy indicated the purified protein contained both a b-type cytochrome and FAD prosthetic groups. The chimeric hemoflavoprotein immunologically cross-reacted with both anti-rat cytochrome b(5) and anti-spinach nitrate reductase polyclonal antibodies, indicating the conservation of antigenic determinants from both native domains. NH2 terminal and internal amino acid sequencing of the native and CNBr-digested protein confirmed the presence of peptides derived from both the heme- and flavin-binding portions of the sequence which were identical to the deduced amino acid sequence. The chimera exhibited both NADH:ferricyanide reductase and NADH:cytochrome c reductase activities with V-max values of 88 and 37 mu mol of NADH consumed per min/nmol of heme (mu = 0.05 and pH 7.0) and K-m values of 2.1, 32, and 1.4 mu M for NADH, ferricyanide, and cytochrome c, respectively. This work represents the first successful bacterial expression of a mammalian-plant chimeric metalloflavoprotein. The chimera exhibited properties extremely similar to those of the native cytochrome b(5) heme and spinach nitrate reductase FAD components.	UNIV S FLORIDA, COLL MED, DEPT BIOCHEM & MOLEC BIOL, TAMPA, FL 33612 USA; INST BIOMOLEC SCI, TAMPA, FL 33612 USA	State University System of Florida; University of South Florida					NIGMS NIH HHS [GM 32696] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032696] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARBER MJ, 1987, BIOCHEM J, V242, P89, DOI 10.1042/bj2420089; CAMPBELL WH, 1990, TRENDS BIOCHEM SCI, V15, P315, DOI 10.1016/0968-0004(90)90021-3; CANNONS AC, 1993, J BIOL CHEM, V268, P3268; KAY CJ, 1988, BIOCHEMISTRY-US, V27, P6142, DOI 10.1021/bi00416a047; KAY CJ, 1986, J BIOL CHEM, V261, P14125; KUBO Y, 1988, J BIOL CHEM, V263, P19684; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEDERER F, 1991, CHEM BIOCH FLAVOENZY, V2, P153; MATHEWS FS, 1971, COLD SPRING HARB SYM, V36, P387, DOI 10.1101/SQB.1972.036.01.050; NEAME PJ, 1989, J BIOL CHEM, V264, P20894; NOTTON BA, 1989, PHYTOCHEMISTRY, V28, P2261, DOI 10.1016/S0031-9422(00)97964-0; OZOLS J, 1982, BIOCHIM BIOPHYS ACTA, V704, P163, DOI 10.1016/0167-4838(82)90143-1; PROSSER IM, 1990, PLANT MOL BIOL, V15, P187, DOI 10.1007/BF00017743; SHIRAISHI N, 1991, PLANT CELL PHYSIOL, V32, P1031, DOI 10.1093/oxfordjournals.pcp.a078166; SOLOMONSON LP, 1990, ANNU REV PLANT PHYS, V41, P225, DOI 10.1146/annurev.pp.41.060190.001301; SOLOMONSON LP, 1986, J BIOL CHEM, V261, P1290; STRITTMATTER P, 1974, P NATL ACAD SCI USA, V71, P4565, DOI 10.1073/pnas.71.11.4565; STRITTMATTER P, 1992, J BIOL CHEM, V267, P2519; UNGER BP, 1986, J BIOL CHEM, V261, P1158; VONBODMAN SB, 1986, P NATL ACAD SCI USA, V83, P9443; WEBER G, 1950, BIOCHEM J, V47, P114, DOI 10.1042/bj0470114	21	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13375	13381						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175767				2022-12-25	WOS:A1994NK18400050
J	TELFER, A; BISHOP, SM; PHILLIPS, D; BARBER, J				TELFER, A; BISHOP, SM; PHILLIPS, D; BARBER, J			ISOLATED PHOTOSYNTHETIC REACTION-CENTER OF PHOTOSYSTEM-II AS A SENSITIZER FOR THE FORMATION OF SINGLET OXYGEN - DETECTION AND QUANTUM YIELD DETERMINATION USING A CHEMICAL TRAPPING TECHNIQUE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REACTION CENTER COMPLEX; CHLOROPHYLL-ALPHA; ELECTRON-ACCEPTOR; MOLECULAR-OXYGEN; PISUM-SATIVUM; BETA-CAROTENE; OXIDATION; LIGHT; PHOTOSENSITIZERS; CHLOROPLASTS	Singlet oxygen formation by photosystem II reaction centers isolated from Pisum sativum has been detected by two chemical trapping techniques: histidine dependent oxygen uptake and bleaching of p-nitrosodimethylaniline by the intermediary endoperoxide of histidine. The quantum yield of singlet oxygen formation determined by these methods was estimated to be 0.16 by comparison with the known quantum yields of standard singlet oxygen sensitizers. Singlet oxygen was formed on illumination of reaction centers under conditions that lead to formation of the triplet state of the primary electron donor, P680. Experiments with deuterated buffer and active oxygen scavengers indicated that singlet oxygen was the only active oxygen species produced by this reaction. Neither azide nor histidine, which are scavengers of singlet oxygen, protected against photobleaching of the chlorophyll of reaction centers that occurs concomitantly with singlet oxygen formation, suggesting that bleaching involves singlet oxygen generated within the protein matrix of the complex. Singlet oxygen sensitized exogenously by rose bengal (when excited specifically at 550 nm) was also found to bleach reaction center chlorophyll in a manner similar to the intrinsic mechanism. We conclude that singlet oxygen formed within the hydrophobic interior of the reaction center attacks the chlorophylls of P680, and presumably also amino acids in the vicinity, and that only the singlet oxygen that escapes to the medium is affected by added scavengers or deuterated medium. These experiments extend our earlier report of the detection of singlet oxygen by its luminescence at 1270 nm when isolated photosystem II reaction centers are illuminated (Macpherson, A. N., Telfer, A., Barber, J., and Truscott, T. G. (1993) Biochim. Biophys. Acta 1143, 301-309). Moreover, our results support the hypothesis that production of singlet oxygen underlies the vulnerability of photosystem II to photodamage and hence necessitates the rapid turnover of the D1 protein of the reaction center.	UNIV LONDON IMPERIAL COLL SCI & TECHNOL, DEPT CHEM, LONDON SW7 2AY, ENGLAND	Imperial College London	TELFER, A (corresponding author), UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, DEPT BIOCHEM, AGR & FOOD RES COUNCIL, LONDON SW7 2AY, ENGLAND.							AMBROZ M, 1991, J PHOTOCH PHOTOBIO B, V9, P87, DOI 10.1016/1011-1344(91)80006-4; ANDERSON IC, 1960, PLANT PHYSIOL, V35, P531, DOI 10.1104/pp.35.4.531; ASADA K, 1987, TOPICS PHOTOSYNTHESI, V9, P227; BARBER J, 1987, FEBS LETT, V220, P67, DOI 10.1016/0014-5793(87)80877-3; BARBER J, 1992, TRENDS BIOCHEM SCI, V17, P61, DOI 10.1016/0968-0004(92)90503-2; Barber J., 1992, P125; BARBER J, 1993, PHOTOSYNTHETICA PRAG, V27, P63; BEEBY A, 1992, INT CONGR SER, V1011, P732; BEEBY A, 1993, SCI ENG RES COUNCIL, P158; BIELSKI BHJ, 1971, J PHYS CHEM-US, V75, P2263, DOI 10.1021/j100684a006; BISHOP SM, 1993, THESIS U LONDON; BODANNES RS, 1979, FEBS LETT, V105, P195, DOI 10.1016/0014-5793(79)80609-2; BOOTH PJ, 1990, BIOCHIM BIOPHYS ACTA, V1016, P141, DOI 10.1016/0005-2728(90)90053-7; CHAPMAN DJ, 1988, BIOCHIM BIOPHYS ACTA, V933, P423, DOI 10.1016/0005-2728(88)90077-1; CHAPMAN DJ, 1989, PHOTOSYNTHETICA, V23, P411; CHAPMAN DJ, 1990, METHODS PLANT BIOCH, V5, P171; COGDELL RJ, 1987, BIOCHIM BIOPHYS ACTA, V895, P63, DOI 10.1016/S0304-4173(87)80008-3; DAVILA J, 1989, PHOTOCHEM PHOTOBIOL, V50, P29, DOI 10.1111/j.1751-1097.1989.tb04126.x; DEISENHOFER J, 1991, ANNU REV BIOPHYS BIO, V20, P247; DELASRIVAS J, 1993, BIOCHIM BIOPHYS ACTA, V1142, P155, DOI 10.1016/0005-2728(93)90097-Y; DURRANT JR, 1990, BIOCHIM BIOPHYS ACTA, V1017, P167, DOI 10.1016/0005-2728(90)90148-W; EGOROV SY, 1989, CHEM PHYS LETT, V163, P421, DOI 10.1016/0009-2614(89)85161-9; EGOROV SY, 1988, OPT SPEKTROSK+, V65, P899; ELSTNER EF, 1978, PLANT SCI LETT, V13, P15, DOI 10.1016/0304-4211(78)90059-7; FIREY PA, 1988, PHOTOCHEM PHOTOBIOL, V47, P615, DOI 10.1111/j.1751-1097.1988.tb02756.x; FOOTE CS, 1970, ANN NY ACAD SCI, V171, P139, DOI 10.1111/j.1749-6632.1970.tb39317.x; Foote CS., 1990, FUTURE DIRECTIONS AP, P115; Gollnick K., 1968, ADV PHOTOCHEM, V6, P1; GOUNARIS K, 1990, FEBS LETT, V265, P88, DOI 10.1016/0014-5793(90)80890-U; GRIFFITHS M, 1955, NATURE, V176, P1211, DOI 10.1038/1761211a0; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; HAWORTH P, 1988, PLANT PHYSIOL, V86, P672, DOI 10.1104/pp.86.3.672; JOSHI PC, 1984, J INVEST DERMATOL, V82, P67, DOI 10.1111/1523-1747.ep12259146; JUNG J, 1990, PHOTOCHEM PHOTOBIOL, V52, P1003, DOI 10.1111/j.1751-1097.1990.tb01817.x; KEIR WF, 1987, PHOTOCHEM PHOTOBIOL, V46, P587, DOI 10.1111/j.1751-1097.1987.tb04818.x; KIM CS, 1993, PHOTOCHEM PHOTOBIOL, V57, P1069, DOI 10.1111/j.1751-1097.1993.tb02973.x; KLIMOV VV, 1979, DOKL AKAD NAUK SSSR+, V249, P227; KNOX JP, 1985, PHYTOCHEMISTRY, V24, P889, DOI 10.1016/S0031-9422(00)83147-7; KOBAYASHI M, 1990, FEBS LETT, V260, P138, DOI 10.1016/0014-5793(90)80086-X; KOKA P, 1978, PHOTOCHEM PHOTOBIOL, V28, P509, DOI 10.1111/j.1751-1097.1978.tb06959.x; KRALJIC I, 1978, PHOTOCHEM PHOTOBIOL, V28, P577, DOI 10.1111/j.1751-1097.1978.tb06972.x; KYLE DJ, 1987, TOPICS PHOTOSYNTHESI, V9, P197; MACPHERSON AN, 1993, BIOCHIM BIOPHYS ACTA, V1143, P301, DOI 10.1016/0005-2728(93)90201-P; MATHEWS MM, 1964, NATURE, V203, P1092, DOI 10.1038/2031092a0; MAXWELL WA, 1964, PHOTOCHEM PHOTOBIOL, V5, P567; MCTAVISH H, 1989, PLANT PHYSIOL, V89, P452, DOI 10.1104/pp.89.2.452; MICHEL H, 1988, BIOCHEMISTRY-US, V27, P1, DOI 10.1021/bi00401a001; MISKOSKI S, 1993, PHOTOCHEM PHOTOBIOL, V57, P447, DOI 10.1111/j.1751-1097.1993.tb02317.x; NANBA O, 1987, P NATL ACAD SCI USA, V84, P109, DOI 10.1073/pnas.84.1.109; NILSSON R, 1972, PHOTOCHEM PHOTOBIOL, V16, P117, DOI 10.1111/j.1751-1097.1972.tb07343.x; NUGENT JHA, 1989, FEBS LETT, V255, P53, DOI 10.1016/0014-5793(89)81059-2; Okamura MY., 1987, PROGR PHOTOSYNTHESIS, V1, P379; PRASIL O, 1992, TOPICS PHOTOSYNTHESI, V11, P295; ROSENTHAL I, 1986, RADIAT RES, V107, P136, DOI 10.2307/3576857; SAGER R, 1958, NATURE, V182, P98, DOI 10.1038/182098a0; SATOH K, 1981, PHOTOBIOCH PHOTOBIOP, V2, P189; SCHENCK CC, 1982, BIOCHIM BIOPHYS ACTA, V680, P216, DOI 10.1016/0005-2728(82)90014-7; SINGH A, 1982, CAN J PHYSIOL PHARM, V60, P1330, DOI 10.1139/y82-200; TAKAHASHI Y, 1989, FEBS LETT, V255, P133, DOI 10.1016/0014-5793(89)81076-2; TAKAHASHI Y, 1987, BIOCHIM BIOPHYS ACTA, V893, P49, DOI 10.1016/0005-2728(87)90147-2; TELFER A, 1991, BIOCHIM BIOPHYS ACTA, V1060, P106, DOI 10.1016/S0005-2728(05)80125-2; TELFER A, 1989, FEBS LETT, V246, P223, DOI 10.1016/0014-5793(89)80287-X; VANMIEGHEM FJE, 1989, BIOCHIM BIOPHYS ACTA, V977, P207, DOI 10.1016/S0005-2728(89)80073-8; VASS I, 1992, P NATL ACAD SCI USA, V89, P1408, DOI 10.1073/pnas.89.4.1408; VELTHUYS BR, 1981, FEBS LETT, V126, P272, DOI 10.1016/0014-5793(81)80259-1; VERLHAC JB, 1984, NOUV J CHIM, V8, P401; WILKINSON F, 1981, J PHYS CHEM REF DATA, V10, P809, DOI 10.1063/1.555655	67	211	214	2	48	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13244	13253						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175754				2022-12-25	WOS:A1994NK18400032
J	TOUSSAINT, C; BOUSQUETLEMERCIER, B; GARLATTI, M; HANOUNE, J; BAROUKI, R				TOUSSAINT, C; BOUSQUETLEMERCIER, B; GARLATTI, M; HANOUNE, J; BAROUKI, R			TESTIS-SPECIFIC TRANSCRIPTION START SITE IN THE ASPARTATE-AMINOTRANSFERASE HOUSEKEEPING GENE PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANGIOTENSIN-CONVERTING ENZYME; MESSENGER-RNAS; TRANSGENIC MICE; MOUSE; EXPRESSION; RAT; ELEMENT; BINDING; ACID; SPERMATOGENESIS	We have studied the expression and regulation of the rat testis cytosolic aspartate aminotransferase gene. The cytosolic aspartate aminotransferase activity was 5-fold lower in the testis than in the liver and kidney. A 1.9 kilobase mRNA form was detected in the rat testis in contrast to the 2.1- and 1.8-kilobase forms present in other organs. Using Northern blot and S1 mapping analyses, we found that the proximal polyadenylation site was almost exclusively used in the testis as opposed to other organs where the distal site was preferentially used. RNase protection and primer extension analysis showed that transcription was initiated at multiple sites in all organs, but the pattern of those start sites was different in the testis; in particular, a novel transcription start site was specifically detected in this organ (at position -115 from the translation start site). This site was first observed in 29-day-old rats and was maximally utilized in the adult testis. DNase I footprinting using testis nuclear extracts revealed the presence of three sites of DNA-protein interaction in the 250-base pair proximal promoter, a pattern similar to the one found using liver nuclear extracts. However, the proteins bound had different properties as shown by gel retardation experiments. We conclude that the pattern of transcription initiation and the polyadenylation site selection of a housekeeping gene can be tissue-specific.	HOP HENRI MONDOR,INSERM,U99,F-94010 CRETEIL,FRANCE	Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)								AGGERBECK M, 1993, BIOCHEMISTRY-US, V32, P9065, DOI 10.1021/bi00086a011; ALSHAWI R, 1991, MOL CELL BIOL, V11, P4207, DOI 10.1128/MCB.11.8.4207; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BAROUKI R, 1989, EUR J BIOCHEM, V186, P79, DOI 10.1111/j.1432-1033.1989.tb15180.x; BOUSQUETLEMERCIER B, 1990, BIOCHEMISTRY-US, V29, P5293, DOI 10.1021/bi00474a011; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CHANG CJ, 1990, MOL CELL BIOL, V10, P6642, DOI 10.1128/MCB.10.12.6642; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTEN P, 1985, TRANSAMINASES, P173; COOPER AJL, 1985, TRANSAMINASES, P534; ERICKSON RP, 1990, TRENDS GENET, V6, P264, DOI 10.1016/0168-9525(90)90209-O; FABER PW, 1993, J BIOL CHEM, V268, P9296; GARLATTI M, 1993, J BIOL CHEM, V268, P6567; GENG YP, 1993, MOL CELL BIOL, V13, P4894, DOI 10.1128/MCB.13.8.4894; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; HAKE LE, 1993, J BIOL CHEM, V268, P4788; HECHT NB, 1989, PERSPECTIVES ANDROLO, P25; HOWARD TE, 1990, MOL CELL BIOL, V10, P4294, DOI 10.1128/MCB.10.8.4294; JOHNSON PF, 1987, GENE DEV, V1, P133, DOI 10.1101/gad.1.2.133; KILPATRICK DL, 1990, MOL CELL BIOL, V10, P3717, DOI 10.1128/MCB.10.7.3717; LANGFORD KG, 1991, J BIOL CHEM, V266, P15559; LEE DK, 1991, CELL, V67, P1241, DOI 10.1016/0092-8674(91)90300-N; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; MEANS AL, 1990, MOL CELL BIOL, V10, P653, DOI 10.1128/MCB.10.2.653; MEIJER D, 1987, EMBO J, V6, P4041, DOI 10.1002/j.1460-2075.1987.tb02749.x; OBARU K, 1988, J MOL BIOL, V200, P13, DOI 10.1016/0022-2836(88)90329-4; PARLI JA, 1987, BIOCHIM BIOPHYS ACTA, V925, P175, DOI 10.1016/0304-4165(87)90107-3; PAVEPREUX M, 1988, J BIOL CHEM, V263, P17459; PAVEPREUX M, 1990, J BIOL CHEM, V265, P4444; PROSPST F, 1988, TRENDS GENET, V4, P183; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; SETO E, 1991, NATURE, V354, P241, DOI 10.1038/354241a0; SHAPER NL, 1990, P NATL ACAD SCI USA, V87, P791, DOI 10.1073/pnas.87.2.791; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; STARBORG M, 1992, MOL REPROD DEV, V33, P243, DOI 10.1002/mrd.1080330303; TERUYA JH, 1990, MOL CELL BIOL, V10, P2315, DOI 10.1128/MCB.10.5.2315; VAULONT S, 1989, J MOL BIOL, V209, P205, DOI 10.1016/0022-2836(89)90273-8; VILLASANTE A, 1986, MOL CELL BIOL, V6, P2409, DOI 10.1128/MCB.6.7.2409; WEISINGER G, 1992, J BIOL CHEM, V267, P4508; WILLISON K, 1987, TRENDS GENET, V3, P351, DOI 10.1016/0168-9525(87)90296-4; WOLGEMUTH DJ, 1991, MAMM GENOME, V1, P283, DOI 10.1007/BF00352340; ZAMBROWICZ BP, 1993, P NATL ACAD SCI USA, V90, P5071, DOI 10.1073/pnas.90.11.5071	44	20	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13318	13324						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175762				2022-12-25	WOS:A1994NK18400042
J	MIESBAUER, LR; ZHOU, XJ; YANG, ZC; YANG, ZY; SUN, YP; SMITH, DL; SMITH, JB				MIESBAUER, LR; ZHOU, XJ; YANG, ZC; YANG, ZY; SUN, YP; SMITH, DL; SMITH, JB			POSTTRANSLATIONAL MODIFICATIONS OF WATER-SOLUBLE HUMAN LENS CRYSTALLINS FROM YOUNG-ADULTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								Post-translational modifications of the water-soluble human lens crystallins from young adult donors were identified and located using electrospray ionization mass spectrometric analysis of the intact proteins and fast atom bombardment mass spectrometry of enzymatic digests. Peptides corresponding to all of the sequences of alpha A, alpha B, and beta B2 crystallins were found, per- mitting the entire sequences to be searched for modifications. The major portions of these three crystallins were not modified. Modifications of alpha A-crystallin that were detected included 2 phosphorylated Ser residues (1 of which appears to be unique to human lenses), deamidation at some Gln and Asn residues, a disulfide bond between Cys-131 and Cys-142, and loss of the COOH-terminal Ser residue. Three phosphorylated Ser residues, but no deamidation, were found in alpha B crystallin. The molecular weights of neither the intact protein nor the peptides in the enzymatic digests indicated any post-translational modification of the principal beta-crystallin, beta B2. The molecular weights of the other beta- and gamma-crystallins for which sequences have been published suggested the presence of post-translational modifications or errors in the published sequences. Although enough peptides were found to establish the presence of specific proteins, peptides corresponding to all portions of these proteins were not found, and elucidation of these structures is not yet complete. This mass spectrometric characterization of the total water-soluble proteins from normal young adult lenses provides a reference data base for future investigations of the modifications present in aged and cataractous lenses.	PURDUE UNIV, DEPT MED CHEM & PHARMACOGNOSY, W LAFAYETTE, IN 47907 USA; PROCTER & GAMBLE CO, MIAMI VALLEY LABS, CINCINNATI, OH 45239 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Procter & Gamble					NEI NIH HHS [EY RO1 07609] Funding Source: Medline; NIGMS NIH HHS [GM 08298] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY007609] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008298] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AARTS HJM, 1989, J MOL EVOL, V28, P313, DOI 10.1007/BF02103427; AUGUSTEYN RC, 1989, BIOCHIM BIOPHYS ACTA, V999, P293, DOI 10.1016/0167-4838(89)90012-5; BANERJEE P, 1990, P NATL ACAD SCI USA, V87, P8550, DOI 10.1073/pnas.87.21.8550; BINDELS JG, 1981, EXP EYE RES, V33, P333, DOI 10.1016/S0014-4835(81)80056-5; BLOEMENDAL H, 1989, EXP EYE RES, V48, P465, DOI 10.1016/0014-4835(89)90029-8; BLOEMENDAL H, 1977, SCIENCE, V197, P127, DOI 10.1126/science.877544; BLOEMENDAL H, 1972, EXP EYE RES, V14, P80, DOI 10.1016/0014-4835(72)90147-9; CHIESA R, 1987, BIOCHEM BIOPH RES CO, V144, P1340, DOI 10.1016/0006-291X(87)91457-4; CHIESA R, 1987, J BIOL CHEM, V262, P1438; de Jong W.W., 1988, Advances in Experimental Medicine and Biology, V231, P95; DEJONG WW, 1977, BIOCHIM BIOPHYS ACTA, V491, P573, DOI 10.1016/0005-2795(77)90303-8; DEJONG WW, 1981, NATURE, V292, P538, DOI 10.1038/292538a0; DEJONG WW, 1975, FEBS LETT, V58, P310, DOI 10.1016/0014-5793(75)80286-9; DELAYE M, 1983, NATURE, V302, P415, DOI 10.1038/302415a0; DENDUNNEN JT, 1985, GENE, V38, P197, DOI 10.1016/0378-1119(85)90218-5; DUBIN RA, 1990, GENOMICS, V7, P594, DOI 10.1016/0888-7543(90)90204-8; EMMONS T, 1992, EXP EYE RES, V55, P551, DOI 10.1016/S0014-4835(05)80167-8; GLASS DB, 1980, ANNU REV PHARMACOL, V20, P363, DOI 10.1146/annurev.pa.20.040180.002051; HARDING JJ, 1985, ADV PROTEIN CHEM, V37, P247, DOI 10.1016/S0065-3233(08)60066-2; HOGG D, 1986, J BIOL CHEM, V261, P2420; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; KODAMA T, 1988, INVEST OPHTH VIS SCI, V29, P145; KRAMPS JA, 1977, FEBS LETT, V74, P82, DOI 10.1016/0014-5793(77)80757-6; KRAMPS JA, 1978, BIOCHIM BIOPHYS ACTA, V533, P487, DOI 10.1016/0005-2795(78)90394-X; LOO JA, 1989, ANAL BIOCHEM, V179, P404, DOI 10.1016/0003-2697(89)90153-X; Lorand L, 1988, Adv Exp Med Biol, V231, P79; LOU MF, 1989, CURR EYE RES, V8, P883; LOU MF, 1992, EXP EYE RES, V55, P889, DOI 10.1016/0014-4835(92)90015-K; MAITI M, 1988, FEBS LETT, V236, P109, DOI 10.1016/0014-5793(88)80295-3; MEAKIN SO, 1985, MOL CELL BIOL, V5, P1408, DOI 10.1128/MCB.5.6.1408; MEAKIN SO, 1987, MOL CELL BIOL, V7, P2671, DOI 10.1128/MCB.7.8.2671; MIESBAUER LR, 1993, PROTEIN SCI, V2, P290; MUKHOPADHYAY NK, 1992, J BIOL CHEM, V267, P3325; OZAKI Y, 1987, J BIOL CHEM, V262, P15445; PADGAONKAR V, 1989, EXP EYE RES, V49, P887, DOI 10.1016/S0014-4835(89)80047-8; PALMER WG, 1969, P NATL ACAD SCI USA, V64, P404, DOI 10.1073/pnas.64.1.404; PARVEEN R, 1993, J PROTEIN CHEM, V12, P93, DOI 10.1007/BF01024920; PERRY RE, 1986, J CHROMATOGR, V351, P103, DOI 10.1016/S0021-9673(01)83476-2; SANGHERA JS, 1992, BIOCHIM BIOPHYS ACTA, V1135, P335, DOI 10.1016/0167-4889(92)90240-C; SHERMAN MY, 1992, NATURE, V357, P167, DOI 10.1038/357167a0; SIEZEN RJ, 1987, P NATL ACAD SCI USA, V84, P6088, DOI 10.1073/pnas.84.17.6088; SMITH JB, 1991, INT J MASS SPECTROM, V111, P229, DOI 10.1016/0168-1176(91)85057-S; SMITH JB, 1991, ANAL BIOCHEM, V193, P118, DOI 10.1016/0003-2697(91)90050-4; SMITH JB, 1992, PROTEIN SCI, V1, P601, DOI 10.1002/pro.5560010506; SPECTOR A, 1985, P NATL ACAD SCI USA, V82, P4712, DOI 10.1073/pnas.82.14.4712; SPECTOR A, 1978, P NATL ACAD SCI USA, V75, P3244, DOI 10.1073/pnas.75.7.3244; STEADMAN BL, 1989, BIOCHEMISTRY-US, V28, P9653, DOI 10.1021/bi00451a017; SUN YP, 1988, ANAL BIOCHEM, V172, P130, DOI 10.1016/0003-2697(88)90421-6; TAKEMOTO L, 1991, EXP EYE RES, V53, P811, DOI 10.1016/0014-4835(91)90119-Y; TAKEMOTO L, 1992, INVEST OPHTH VIS SCI, V33, P2024; TAKEMOTO LJ, 1982, INVEST OPHTH VIS SCI, V22, P336; TAKEMOTO LJ, 1993, INVEST OPHTH VIS SCI, V34, P1340; VANKLEEF FSM, 1975, NATURE, V258, P264, DOI 10.1038/258264a0; VANKLEEF FSM, 1976, EUR J BIOCHEM, V66, P477; VANVENROOIJ WJ, 1974, EXP EYE RES, V19, P157, DOI 10.1016/0014-4835(74)90031-1; VOORTER CEM, 1989, FEBS LETT, V259, P50; VOORTER CEM, 1986, EUR J BIOCHEM, V160, P203; VULLIET PR, 1989, J BIOL CHEM, V264, P16292; WAGNER BJ, 1991, EXP EYE RES, V53, P609, DOI 10.1016/0014-4835(91)90220-9; WATSON E, 1992, J CHROMATOGR, V606, P165, DOI 10.1016/0021-9673(92)87021-Y; WEN Q, 1992, EXP EYE RES, V54, P23, DOI 10.1016/0014-4835(92)90065-Z; YAZDANPARAST R, 1987, J BIOL CHEM, V262, P2507; YU NT, 1985, P NATL ACAD SCI USA, V82, P7965, DOI 10.1073/pnas.82.23.7965; ZARINA S, 1992, BIOCHEM J, V287, P375, DOI 10.1042/bj2870375; ZHANG ZQ, 1993, PROTEIN SCI, V2, P522; ZIGLER JS, 1980, EXP EYE RES, V31, P41, DOI 10.1016/0014-4835(80)90089-5	66	173	180	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12494	12502						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175657				2022-12-25	WOS:A1994NH71600022
J	BHAUMIK, D; YANG, BL; TRANGAS, T; BARTLETT, JS; COLEMAN, MS; SORSCHER, DH				BHAUMIK, D; YANG, BL; TRANGAS, T; BARTLETT, JS; COLEMAN, MS; SORSCHER, DH			IDENTIFICATION OF A TRIPARTITE BASAL PROMOTER WHICH REGULATES HUMAN TERMINAL DEOXYNUCLEOTIDYL TRANSFERASE GENE-EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; N-REGIONS; TRANSCRIPTION; ELEMENT; CELLS; INITIATOR; LYMPHOCYTES; CONTAINS; COMPLEX; SITE	In order to locate the promoter region of the human terminal deoxynucleotidyl transferase gene, serially truncated segments of the 5'-flanking region of the gene were cloned into a chloramphenicol acetyltransferase reporter vector. Transient transfection analyses of the terminal transferase-reporter gene constructs identified the basal promoter region within -34 to +40 base pairs relative to the transcription start site. Three promoter elements were defined in this region. The primary element is within 34 base pairs upstream of the transcription start site. The CAP site is 62 base pairs upstream of the translation start site. The secondary element involves sequences around the transcription start site. The third is located 25 base pairs downstream from the initiation site (+25 to +40). This tripartite basal promoter was not tissue specific; similar patterns of promoter activity were observed in terminal transferase expressing and non-expressing cells. Transfection analyses also indicated the presence of negative regulatory elements upstream of the basal promoter region, and these elements were preferentially active in cells expressing terminal transferase.	UNIV N CAROLINA,DEPT BIOCHEM & BIOPHYS,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill					NATIONAL CANCER INSTITUTE [R01CA019492] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA19492] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAMS JM, 1989, MOL CELL BIOL, V9, P620, DOI 10.1128/MCB.9.2.620; AYER DE, 1988, MOL CELL BIOL, V8, P2021, DOI 10.1128/MCB.8.5.2021; BANIAHMAD A, 1987, EMBO J, V6, P2297, DOI 10.1002/j.1460-2075.1987.tb02504.x; Bollum F.J., 1974, ENZYMES, P145; CRABB DW, 1987, ANAL BIOCHEM, V163, P88, DOI 10.1016/0003-2697(87)90096-0; DEIBEL MR, 1983, J IMMUNOL, V131, P195; DESIDERIO SV, 1984, NATURE, V311, P752, DOI 10.1038/311752a0; DREXLER HG, 1985, LEUKEMIA RES, V9, P209, DOI 10.1016/0145-2126(85)90084-0; ERNST P, 1993, MOL CELL BIOL, V13, P2982, DOI 10.1128/MCB.13.5.2982; GILFILLAN S, 1993, SCIENCE, V261, P1175, DOI 10.1126/science.8356452; IKUTA K, 1992, ANNU REV IMMUNOL, V10, P759; KOIWAI O, 1988, BIOCHEM BIOPH RES CO, V154, P91, DOI 10.1016/0006-291X(88)90654-7; KOLLMAR R, 1993, P SOC EXP BIOL MED, V203, P127; KOMORI T, 1993, SCIENCE, V261, P1171, DOI 10.1126/science.8356451; LO K, 1991, MOL CELL BIOL, V11, P5229, DOI 10.1128/MCB.11.10.5229; MATSUSHIMA GK, 1992, MOL CELL BIOL, V12, P5610, DOI 10.1128/MCB.12.12.5610; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; PUGH BF, 1992, J BIOL CHEM, V267, P679; RILEY LK, 1988, P NATL ACAD SCI USA, V85, P2489, DOI 10.1073/pnas.85.8.2489; RINCONLIMAS DE, 1991, MOL CELL BIOL, V11, P4157, DOI 10.1128/MCB.11.8.4157; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; Sambrook J, 1989, MOL CLONING LABORATO; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SCHATZ DG, 1988, CELL, V53, P107, DOI 10.1016/0092-8674(88)90492-8; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; TRANGAS T, 1989, BIOCHEM BIOPH RES CO, V164, P750, DOI 10.1016/0006-291X(89)91523-4; WANG TC, 1990, J BIOL CHEM, V265, P8908; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; ZENZIEGREGORY B, 1993, J BIOL CHEM, V268, P15823; ZENZIEGREGORY B, 1992, J BIOL CHEM, V267, P2828	31	16	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15861	15867						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	8195241				2022-12-25	WOS:A1994NP51300072
J	SOLEIMANI, M; BOOKSTEIN, C; MCATEER, JA; HATTABAUGH, YJ; BIZAL, GL; MUSCH, MW; VILLEREAL, M; RAO, MC; HOWARD, RL; CHANG, EB				SOLEIMANI, M; BOOKSTEIN, C; MCATEER, JA; HATTABAUGH, YJ; BIZAL, GL; MUSCH, MW; VILLEREAL, M; RAO, MC; HOWARD, RL; CHANG, EB			EFFECT OF HIGH-OSMOLALITY ON NA+/H+ EXCHANGE IN RENAL PROXIMAL TUBULE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASOLATERAL MEMBRANE-VESICLES; SMOOTH-MUSCLE CELLS; RAT NA/H EXCHANGER; VOLUME REGULATION; H+ EXCHANGER; NA+-HCO3 COTRANSPORT; MOLECULAR-CLONING; EPITHELIAL-CELLS; PROTEIN-KINASE; RABBIT KIDNEY	Na+/H+ exchanger isoform and the effect of high osmolality on its function was studied in cultured renal epithelial cells (LLC-PK, and OK). Using NHE-3-specific antibody, immunoblots of luminal membranes from LLC-PK1 and OK cells specifically labeled proteins with molecular masses 90 and 95 kDa, indicating that NHE-3 is the isoform expressed on the luminal membranes of these epithelia. Proximal tubular suspensions from rabbit kidney cortex were incubated in control (310 mosm/ liter) or high osmolality (510 mosm/liter) medium for 45 min and utilized for brush border membrane vesicle preparation. Influx of amiloride-sensitive Na-22(+) at 10 s (pH(o) 7.5, pH(i) 6.0) into brush border membrane vesicles was 37% lower in the high osmolality group (p < 0.03). LLC-PK, or OK cells were grown to confluence and examined for Na+/H+ exchange activity. An increase in medium osmolality to 510 mosm following acid loading decreased the 5-min uptake of the amiloride-sensitive Na-22(+) in LLC-PK1 and OK cells (p < 0.04 and <0.03 for LLC-PK1 cell OK cells, respectively). An increase in medium osmolality to 510 mosm in vascular smooth muscle cells, which express NHE-1, produced 45 and 64% stimulation of the amiloride-sensitive Na-22(+) influx at base-line pH(i) and acid-loaded condition, respectively (p < 0.03 and < 0.01). Down-regulation of protein kinase C by preincubation with phorbol 12-myristate 13-acetate or inhibition of Ca2+-calmodulin-dependent protein kinase (calmodulin-kinase II) by N-6-aminohexyl-5-chloro-1-naphthalenesulfonamide (W-7) in LLC-PK1 cells did not block the inhibitory effect of high osmolality on Na+/H+ exchange activity. We conclude that renal proximal tubule epithelial cells express Na+/H+ exchange isoform NHE-3 on their luminal membranes and that hyperosmolality decreases transporter activity during cell acidification. This inhibitory effect might be unique to the NHE-3 isoform, since vascular smooth muscle cells which express NHE-1 exhibit an increase in Na+/H+ exchange activity in response to high osmolality.	INDIANA UNIV,DEPT ANAT,INDIANAPOLIS,IN 46202; VET AFFAIRS MED CTR,INDIANAPOLIS,IN 46202; UNIV CHICAGO,DEPT MED,CHICAGO,IL 60637; UNIV ILLINOIS,DEPT PHYSIOL & BIOPHYS,CHICAGO,IL 60612	Indiana University System; Indiana University-Purdue University Indianapolis; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Chicago; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	SOLEIMANI, M (corresponding author), INDIANA UNIV,SCH MED,DEPT MED,NEPHROL SECT,FESLER HALL 108,1120 S DR,INDIANAPOLIS,IN 46202, USA.			soleimani, m/0000-0002-3446-8870	NIDDK NIH HHS [DK 42086, DK 38510] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038510, P30DK042086] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BIEMESDERFER D, 1993, AM J PHYSIOL, V265, pF736, DOI 10.1152/ajprenal.1993.265.5.F736; BIEMESDERFER D, 1992, AM J PHYSIOL, V263, pF833, DOI 10.1152/ajprenal.1992.263.5.F833; BOOKSTEIN C, 1994, J CLIN INVEST, V93, P106, DOI 10.1172/JCI116933; BROWN CDA, 1984, BIOCHIM BIOPHYS ACTA, V769, P471, DOI 10.1016/0005-2736(84)90332-8; BURNS KD, 1991, AM J PHYSIOL, V261, pF607, DOI 10.1152/ajprenal.1991.261.4.F607; CHAMLEY JH, 1977, CELL TISSUE RES, V177, P503; COUNILLON L, 1993, P NATL ACAD SCI USA, V90, P4508, DOI 10.1073/pnas.90.10.4508; DASCALU A, 1992, J PHYSIOL-LONDON, V456, P503, DOI 10.1113/jphysiol.1992.sp019349; ESCOBALES N, 1990, AM J PHYSIOL, V259, pC640, DOI 10.1152/ajpcell.1990.259.4.C640; EVERS C, 1978, MEMBRANE BIOCHEM, V1, P202; GRASSL SM, 1986, J BIOL CHEM, V261, P8778; GRINSTEIN S, 1986, CURR TOP MEMBR TRANS, V26, P115; GRINSTEIN S, 1992, J BIOL CHEM, V267, P23823; HEBERT SC, 1986, AM J PHYSIOL, V250, pC920, DOI 10.1152/ajpcell.1986.250.6.C920; KRAPF R, 1993, J MEMBRANE BIOL, V131, P1, DOI 10.1007/BF02258529; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MONTROSE MH, 1988, AM J PHYSIOL, V255, pC76, DOI 10.1152/ajpcell.1988.255.1.C76; MONTROSERAFIZADEH C, 1990, ANNU REV PHYSIOL, V52, P761; MORAN A, 1987, AM J PHYSIOL, V252, pC63, DOI 10.1152/ajpcell.1987.252.1.C63; ORLOWSKI J, 1992, J BIOL CHEM, V267, P9331; POUYSSEGUR J, 1985, TRENDS BIOCHEM SCI, V10, P453, DOI 10.1016/0968-0004(85)90030-1; POUYSSEGUR J, 1984, P NATL ACAD SCI-BIOL, V81, P4833, DOI 10.1073/pnas.81.15.4833; RAO GN, 1990, J BIOL CHEM, V265, P19393; REILLY RF, 1991, AM J PHYSIOL, V261, pF1088, DOI 10.1152/ajprenal.1991.261.6.F1088; SARDET C, 1989, CELL, V56, P271, DOI 10.1016/0092-8674(89)90901-X; SERGEANT S, 1989, J MEMBRANE BIOL, V109, P209, DOI 10.1007/BF01870278; SOLEIMANI M, 1989, J BIOL CHEM, V264, P18302; SOLEIMANI M, 1994, CIRC RES, V74, P48, DOI 10.1161/01.RES.74.1.48; SOLEIMANI M, 1992, J CLIN INVEST, V90, P211, DOI 10.1172/JCI115838; SOLEIMANI M, 1990, J CLIN INVEST, V86, P1076, DOI 10.1172/JCI114810; SOLEIMANI M, 1993, J AM SOC NEPHROL, V4, pA847; TSE CM, 1992, J BIOL CHEM, V267, P9340; TSE CM, 1993, P NATL ACAD SCI USA, V90, P9110, DOI 10.1073/pnas.90.19.9110; TSE CM, 1993, J BIOL CHEM, V268, P11917; WANG Z, 1993, J BIOL CHEM, V268, P11925; WHALLEY DW, 1991, J PHYSIOL-LONDON, V444, P193, DOI 10.1113/jphysiol.1991.sp018873	36	80	81	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15613	15618						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	8195209				2022-12-25	WOS:A1994NP51300037
J	WELSH, CF; MOSS, J; VAUGHAN, M				WELSH, CF; MOSS, J; VAUGHAN, M			ISOLATION OF RECOMBINANT ADP-RIBOSYLATION FACTOR-6, A SIMILAR-TO-20-KDA GUANINE-NUCLEOTIDE-BINDING PROTEIN, IN AN ACTIVATED GTP-BOUND STATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHOLERA-TOXIN; ESCHERICHIA-COLI; GOLGI MEMBRANES; BREFELDIN-A; BOVINE BRAIN; HUMAN GENE; FACTOR-III; FACTOR-I; ARF; EXCHANGE	ADP-ribosylation factors (ARFs) are similar to 20-kDa guanine nucleotide-binding proteins, which, like other members of the ras superfamily, are activated by exchanging bound GDP for GTP and inactivated through hydrolysis of the gamma-phosphate of bound GTP to form GDP in a highly regulated cycle. ARF 6, a class III ARF, was expressed in Escherichia coli with its amino terminus fused to maltose-binding protein. Following release from maltose-binding protein, recombinant ARF 6 (rARF 6) exhibited maximal activity with or without GTP. Such constitutive activation was due to the predominance of ARF-GTP over ARF-GDP, as demonstrated by nucleotide analysis. rARF 6 expressed in E. coli without amino-terminal extension was bound primarily to GDP and exhibited typical GTP-dependent activity. After release from maltose-binding protein, rARF 6-GTP was stable; only a fraction of the nucleotide was removed using EDTA, whereas urea denaturation restored complete GTP dependence. [alpha-P-32]GTP bound to rARF 6 was in part protected from hydrolysis by alkaline phosphatase and resulted in the formation of [alpha-P-32]GTP, -GDP, and -GMP, whereas unbound nucleotide was completely hydrolyzed to guanosine. Thus, amino-terminal extension of rARF 6, by maltose-binding protein, promoted the formation of a constitutively activated GTP-bound species. By analysis of this species, we confirmed that rARF 6 lacks the intrinsic ability to hydrolyze bound GTP and speculate that maltose-binding protein may inhibit hydrolysis by extrinsic factors.	NHLBI,CELLULAR METAB LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)								BAGNARA AS, 1973, EUR J BIOCHEM, V36, P422, DOI 10.1111/j.1432-1033.1973.tb02927.x; BAGNARA AS, 1972, ANAL BIOCHEM, V45, P24, DOI 10.1016/0003-2697(72)90004-8; BOBAK DA, 1989, P NATL ACAD SCI USA, V86, P6101, DOI 10.1073/pnas.86.16.6101; BOBAK DA, 1990, BIOCHEMISTRY-US, V29, P855, DOI 10.1021/bi00456a600; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; FERGUSON KM, 1986, J BIOL CHEM, V261, P7393; FRECH M, 1990, J BIOL CHEM, V265, P6353; HALL A, 1986, J BIOL CHEM, V261, P963; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; KAHN RA, 1984, J BIOL CHEM, V259, P6228; KAHN RA, 1986, J BIOL CHEM, V261, P7906; LEE CM, 1992, J BIOL CHEM, V267, P9028; MONACO L, 1990, P NATL ACAD SCI USA, V87, P2206, DOI 10.1073/pnas.87.6.2206; NODA M, 1990, BIOCHIM BIOPHYS ACTA, V1034, P195, DOI 10.1016/0304-4165(90)90076-9; PRICE SR, 1988, P NATL ACAD SCI USA, V85, P5488, DOI 10.1073/pnas.85.15.5488; PRICE SR, 1992, J BIOL CHEM, V267, P17766; RANDAZZO PA, 1993, J BIOL CHEM, V268, P9555; REGAZZI R, 1991, BIOCHEM J, V275, P639, DOI 10.1042/bj2750639; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; SERVENTI IM, 1993, J BIOL CHEM, V268, P4863; SEWELL JL, 1988, P NATL ACAD SCI USA, V85, P4620, DOI 10.1073/pnas.85.13.4620; TSAI SC, 1987, P NATL ACAD SCI USA, V84, P5139, DOI 10.1073/pnas.84.15.5139; TSAI SC, 1988, J BIOL CHEM, V263, P1768; TSAI SC, 1991, J BIOL CHEM, V266, P23053; TSAI SC, 1992, P NATL ACAD SCI USA, V89, P9272, DOI 10.1073/pnas.89.19.9272; TSUCHIYA M, 1991, J BIOL CHEM, V266, P2772; WALKER MW, 1992, J BIOL CHEM, V267, P3230; WEISS O, 1989, J BIOL CHEM, V264, P21066	30	13	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15583	15587						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	8195204				2022-12-25	WOS:A1994NP51300032
J	BOURS, V; AZARENKO, V; DEJARDIN, E; SIEBENLIST, U				BOURS, V; AZARENKO, V; DEJARDIN, E; SIEBENLIST, U			HUMAN RELB (I-REL) FUNCTIONS AS A KAPPA-B SITE-DEPENDENT TRANSACTIVATING MEMBER OF THE FAMILY OF REL-RELATED PROTEINS	ONCOGENE			English	Article							DNA-BINDING SUBUNIT; V-REL; TRANSCRIPTION ACTIVATOR; ONCOPROTEIN BCL-3; PROTO-ONCOGENE; CLONING; P50; GENE; EXPRESSION; HOMOLOGY	RelB belongs to the family of Rel-related proteins, dimers of which determine NF-kappa B activity. The murine RelB protein has been reported to be a dimerizing partner in kappa B-binding complexes which are capable of transactivation. On the other hand, the I-Rel protein, the presumed human homolog of RelB, was proposed to be an inhibitor whose presence in dimeric complexes interfered with their kappa B binding and therefore interfered also with transactivation. We demonstrate that human RelB (I-Rel) forms with p50 and p52 (p50B) kappa B-binding heterodimeric complexes which potently transactivate kappa B-dependent constructs in transfection studies. It is concluded that human RelB (I-Rel) and murine RelB can both function as transactivators and that no significant species-specific differences exist.	UNIV LIEGE,METASTASIS RES LAB,B-4000 LIEGE,BELGIUM	University of Liege	BOURS, V (corresponding author), NIAID,IMMUNOREGULAT LAB,BETHESDA,MD 20892, USA.		Dejardin, Emmanuel/AAE-9076-2021					BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BALLARD DW, 1992, P NATL ACAD SCI USA, V89, P1875, DOI 10.1073/pnas.89.5.1875; Bours V, 1992, Curr Top Microbiol Immunol, V182, P411; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; BROWNELL E, 1989, ONCOGENE, V4, P935; DOBRZANSKI P, 1993, MOL CELL BIOL, V13, P1572, DOI 10.1128/MCB.13.3.1572; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; FRANZOSO G, 1992, NATURE, V359, P339, DOI 10.1038/359339a0; FRANZOSO G, 1993, EMBO J, V12, P3893, DOI 10.1002/j.1460-2075.1993.tb06067.x; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GRILLI M, 1993, INT REV CYTOL, V148, P1; ISRAEL DI, 1989, NUCLEIC ACIDS RES, V17, P4589, DOI 10.1093/nar/17.12.4589; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; MERCURIO F, 1992, DNA CELL BIOL, V11, P523, DOI 10.1089/dna.1992.11.523; MEYER R, 1991, P NATL ACAD SCI USA, V88, P966, DOI 10.1073/pnas.88.3.966; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; RIVIERE Y, 1991, NATURE, V350, P625, DOI 10.1038/350625a0; RUBEN SM, 1992, GENE DEV, V6, P745, DOI 10.1101/gad.6.5.745; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; STEPHENS RM, 1983, P NATL ACAD SCI-BIOL, V80, P6229, DOI 10.1073/pnas.80.20.6229; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464	30	28	28	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1994	9	6					1699	1702						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NL815	8183565				2022-12-25	WOS:A1994NL81500022
J	ONYIA, JE; HALLADAY, DL; MESSINA, JL				ONYIA, JE; HALLADAY, DL; MESSINA, JL			IDENTIFICATION OF BETA-ACTIN SEQUENCES NECESSARY FOR INDUCTION BY PHORBOL ESTERS AND CALCIUM IONOPHORES	ONCOGENE			English	Article							PROTEIN-KINASE-C; EPIDERMAL GROWTH-FACTOR; SERUM RESPONSE ELEMENT; ACETYLTRANSFERASE GENE-EXPRESSION; SIGNAL-TRANSDUCTION PATHWAYS; 3' UNTRANSLATED REGIONS; FACTOR-ALPHA GENE; CHLORAMPHENICOL ACETYLTRANSFERASE; TRANSCRIPTIONAL REGULATION; MESSENGER-RNAS	Transcription of the cytoskeletal beta-actin gene is rapidly induced by phorbol 12-myristate 13-acetate (PMA) and the calcium ionophore, A23187, in cultured H4IIE hepatoma (H4) cells. PMA directly activates protein kinase C (PKC) and activation of PKC is necessary for the cellular actions of PMA, including induction of beta-actin gene transcription. In the present study, we determined the DNA sequence requirements for induction of the beta-actin gene by PMA and A23187. Constructs containing progressive deletions of normal and mutated human beta-actin 5' sequences fused to the reporter gene, bacterial chloramphenicol acetyltransferase, were analysed in transient transfections of H4 cells. We delineated the PMA response DNA element of the human beta-actin gene to the proximal CCArGG box (-62 to -53) in the 5' flanking region. In contrast, A23187 did not induce expression of transfected gene constructs containing this CCArGG box. Additionally, we demonstrated that CCArGG boxes from two other PMA-induced genes in H4 cells, c-fos and gamma-actin, could confer PMA inducibility to a heterologous promoter. This CCArGG box specifically interacts with one or more proteins present in nuclear extracts of H4 cells. These results indicate that in cultured cells, PMA-dependent induction of the beta-actin gene is mediated through the proximal CCArGG box. This suggests that the CCArGG box is a target for PKC action and may be involved in the control of other PKC regulated genes.	SUNY HLTH SCI CTR,DEPT PHYSIOL,SYRACUSE,NY; SUNY HLTH SCI CTR,CELL & MOLEC BIOL PROGRAM,SYRACUSE,NY	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center					NIDDK NIH HHS [DK40456] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040456] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BLUMBERG PM, 1981, CRC CR REV TOXICOL, V8, P199, DOI 10.3109/10408448109109658; BUSCHER M, 1988, ONCOGENE, V3, P301; CHAVRIER P, 1989, MOL CELL BIOL, V9, P787, DOI 10.1128/MCB.9.2.787; CHIU R, 1987, NATURE, V329, P648, DOI 10.1038/329648a0; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; CLARKE M, 1977, ANNU REV BIOCHEM, V46, P797, DOI 10.1146/annurev.bi.46.070177.004053; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; DANILITION SL, 1991, NUCLEIC ACIDS RES, V19, P6913, DOI 10.1093/nar/19.24.6913; DEPONTIZILLI L, 1988, P NATL ACAD SCI USA, V85, P1389, DOI 10.1073/pnas.85.5.1389; DEY A, 1991, DNA CELL BIOL, V10, P537, DOI 10.1089/dna.1991.10.537; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DIKE LE, 1988, P NATL ACAD SCI USA, V85, P6792, DOI 10.1073/pnas.85.18.6792; DONY C, 1987, NATURE, V328, P711, DOI 10.1038/328711a0; EASTMAN A, 1987, BIOTECHNIQUES, V5, P730; ELDER PK, 1984, P NATL ACAD SCI-BIOL, V81, P7476, DOI 10.1073/pnas.81.23.7476; FISCH TM, 1987, MOL CELL BIOL, V7, P3490, DOI 10.1128/MCB.7.10.3490; FREDERICKSON RM, 1989, NUCLEIC ACIDS RES, V17, P253, DOI 10.1093/nar/17.1.253; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GOLDFELD AE, 1991, J EXP MED, V174, P73, DOI 10.1084/jem.174.1.73; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; HYDER SM, 1991, GENE, V105, P281, DOI 10.1016/0378-1119(91)90164-7; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; IMBRA RJ, 1986, NATURE, V323, P555, DOI 10.1038/323555a0; KAWAMOTO T, 1989, NUCLEIC ACIDS RES, V17, P523, DOI 10.1093/nar/17.2.523; KONIG H, 1991, NUCLEIC ACIDS RES, V19, P3607, DOI 10.1093/nar/19.13.3607; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LIU ZJ, 1991, GENE, V108, P211, DOI 10.1016/0378-1119(91)90436-F; LIU ZJ, 1990, MOL CELL BIOL, V10, P3432, DOI 10.1128/MCB.10.7.3432; LOHSE P, 1988, NUCLEIC ACIDS RES, V16, P2787, DOI 10.1093/nar/16.7.2787; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MAGNUSON MA, 1987, J BIOL CHEM, V262, P14917; MALIK RK, 1991, J BIOL CHEM, V266, P8576; MCKNIGHT GS, 1979, J BIOL CHEM, V254, P9050; Messina J. L., 1990, HDB EXPT PHARM, V92, P399; MESSINA JL, 1992, EXP CELL RES, V200, P532, DOI 10.1016/0014-4827(92)90206-N; MESSINA JL, 1989, ENDOCRINOLOGY, V124, P754, DOI 10.1210/endo-124-2-754; MESSINA JL, 1992, J BIOL CHEM, V267, P9223; MESSINA JL, 1992, MOL ENDOCRINOL, V6, P112, DOI 10.1210/me.6.1.112; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; NG SY, 1989, NUCLEIC ACIDS RES, V17, P601, DOI 10.1093/nar/17.2.601; NG SY, 1985, MOL CELL BIOL, V5, P2720, DOI 10.1128/MCB.5.10.2720; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; ORITA S, 1989, GENE, V75, P13; PONTE P, 1983, MOL CELL BIOL, V3, P1783, DOI 10.1128/MCB.3.10.1783; PONTE P, 1984, NUCLEIC ACIDS RES, V12, P1687, DOI 10.1093/nar/12.3.1687; PRYWES R, 1986, CELL, V47, P777, DOI 10.1016/0092-8674(86)90520-9; QUITSCHKE WW, 1989, J BIOL CHEM, V264, P7539; RENAN MJ, 1986, BIOSCIENCE REP, V6, P819, DOI 10.1007/BF01117105; RENAN MJ, 1985, BIOSCIENCE REP, V5, P739, DOI 10.1007/BF01119872; RESENDEZ E, 1985, MOL CELL BIOL, V5, P1212, DOI 10.1128/MCB.5.6.1212; RIDDLE VGH, 1979, P NATL ACAD SCI USA, V76, P1298, DOI 10.1073/pnas.76.3.1298; RIVERA V M, 1990, New Biologist, V2, P751; ROBIN P, 1991, BIOCHEM BIOPH RES CO, V181, P353, DOI 10.1016/S0006-291X(05)81426-3; ROESLER WJ, 1990, TRENDS ENDOCRIN MET, V1, P347, DOI 10.1016/1043-2760(90)90082-E; RUEDELHUBER T, 1984, NATURE, V312, P700; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SHAKHOV AN, 1990, J EXP MED, V171, P35, DOI 10.1084/jem.171.1.35; SIEGFRIED Z, 1989, ONCOGENE, V4, P3; STUMPO DJ, 1988, J BIOL CHEM, V263, P1611; SUBRAMANIAM M, 1989, NATURE, V340, P64, DOI 10.1038/340064a0; SUGIYAMA H, 1988, GENE, V65, P135; TOLEDANO MB, 1990, P NATL ACAD SCI USA, V87, P1830, DOI 10.1073/pnas.87.5.1830; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; Treisman R, 1990, Semin Cancer Biol, V1, P47; VISVADER J, 1988, P NATL ACAD SCI USA, V85, P9474, DOI 10.1073/pnas.85.24.9474; WEEDS A, 1982, NATURE, V296, P811, DOI 10.1038/296811a0; WEINSTOCK RS, 1988, ENDOCRINOLOGY, V123, P366, DOI 10.1210/endo-123-1-366; WEINSTOCK RS, 1993, AM J PHYSIOL, V264, pE519, DOI 10.1152/ajpendo.1993.264.4.E519; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; YAFFE D, 1985, NUCLEIC ACIDS RES, V13, P3723, DOI 10.1093/nar/13.10.3723	75	11	12	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1994	9	6					1713	1722						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NL815	8183567				2022-12-25	WOS:A1994NL81500024
J	JAISWAL, AK				JAISWAL, AK			HUMAN NAD(P)H-QUINONE OXIDOREDUCTASE(2) - GENE STRUCTURE, ACTIVITY, AND TISSUE-SPECIFIC EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YA-SUBUNIT GENE; ELECTROPHILE-RESPONSIVE ELEMENT; PLANAR AROMATIC-COMPOUNDS; QUINONE REDUCTASE; OXIDATIVE STRESS; TRANSCRIPTIONAL REGULATION; INDUCIBLE EXPRESSION; OXIDOREDUCTASE GENE; DT-DIAPHORASE; NAD(P)H	Human NAD(P)H:quinone oxidoreductase, (NQO(2)) gene, 1336 base pairs (bp) of the 5'-flanking region and 165 bp of the 3'-flanking region, have been sequenced. NQO(2) gene is 20 kilobase pairs in length and has seven exons interrupted by six introns as compared to the previously cloned NQO(1) gene which contains six exons. 187 bp of the first exon in the NQO(2) gene are noncoding and are absent in the NQO(1) gene. 92 bp of the second exon in the NQO(2) gene corresponded to the first exon of the NQO(1) gene and so on. The sizes and nucleotide sequences of exons 3-6 are highly conserved between NQO(2) and NQO(1) genes. The last exon in the NQO(2) gene is 1603 bp shorter than the last exon of the NQO(1) gene and encodes for 58 amino acids as compared to 101 amino acids encoded by the NQO(1) gene. This makes NQO(2) protein 43 amino acids shorter than the NQO(1) protein. The high degree of conservation between NQO(2) and NQO(1) gene organization and sequence confirmed that NQO(2) gene encodes for a second member of the NQO gene family in human. Nucleotide sequence analysis of the 5'-flanking region of the NQO(2) gene revealed presence of four SP1 binding sites at positions -214, -170, -106, and -75, a single copy of the antioxidant response element (ARE) at nucleotide -936, and three copies of xenobiotic response element (XRE) at positions -708, -557, and -51. ARE and XRE elements have previously been found in the promoters of the NQO(1) and glutathione S-transferase Ya subunit genes and mediate increases in their expression in response to polycyclic aromatic compounds, phenolic antioxidants, and 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), respectively. The NQO(2) cDNA-derived protein in monkey kidney COS1 cells efficiently catalyzed nitroreduction of anti-tumor compound CB10-200, an analog of nitrophenylaziridine. Northern blot analysis indicates that NQO(2) gene is expressed in human heart, brain, lung, liver, and skeletal muscle but does not express in placenta. In contrast, the NQO(1) gene was expressed in all human tissues. Large variations were noticed for expression of the NQO(2) and NQO(1) genes among various tissues. 1336 bp of the 5'-flanking region of the NQO(2) gene containing ARE and XRE was found sufficient to increase expression of the CAT gene in response to beta-naphthoflavone and TCDD in transfected human hepatoblastoma (Hep-G2) cells.			JAISWAL, AK (corresponding author), FOX CHASE CANC CTR,DEPT PHARMACOL,PHILADELPHIA,PA 19111, USA.				NIGMS NIH HHS [GM 47466] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047466, R29GM047466] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANSUBEL FM, 1989, CURRENT PROTOCOLS MO; BAYNEY RM, 1989, J BIOL CHEM, V264, P21793; BELINSKY M, 1993, CANCER METAST REV, V12, P103, DOI 10.1007/BF00689804; BHAT GJ, 1990, CELL, V61, P885, DOI 10.1016/0092-8674(90)90199-O; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DAVIES LG, 1980, BASIC METHODS MOL BI, P244; DELONG MJ, 1987, CARCINOGENESIS, V8, P1549, DOI 10.1093/carcin/8.10.1549; DENNINGER PL, 1983, ANAL BIOCHEM, V129, P216; EDWARDS YH, 1980, BIOCHEM J, V187, P429, DOI 10.1042/bj1870429; ERNSTER L, 1987, CHEM SCRIPTA, V27A, P1; FAVREAU LV, 1991, J BIOL CHEM, V266, P4556; FRILING RS, 1990, P NATL ACAD SCI USA, V87, P6258, DOI 10.1073/pnas.87.16.6258; FRILING RS, 1992, P NATL ACAD SCI USA, V89, P668, DOI 10.1073/pnas.89.2.668; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; JAISWAL AK, 1990, BIOCHEMISTRY-US, V29, P1899, DOI 10.1021/bi00459a034; JAISWAL AK, 1988, J BIOL CHEM, V263, P13572; JAISWAL AK, 1991, BIOCHEMISTRY-US, V30, P10647, DOI 10.1021/bi00108a007; KHAN AH, 1971, CHEM-BIOL INTERACT, V4, P11, DOI 10.1016/0009-2797(71)90029-9; KNOX RJ, 1988, BIOCHEM PHARMACOL, V37, P4671, DOI 10.1016/0006-2952(88)90336-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI Y, 1992, J BIOL CHEM, V267, P15097; LI Y, 1992, BIOCHEM BIOPH RES CO, V188, P992, DOI 10.1016/0006-291X(92)91329-O; LIND C, 1982, ARCH BIOCHEM BIOPHYS, V216, P178, DOI 10.1016/0003-9861(82)90202-8; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MONKS TJ, 1992, TOXICOL APPL PHARM, V112, P2, DOI 10.1016/0041-008X(92)90273-U; NEBERT DW, 1987, ANNU REV BIOCHEM, V56, P945, DOI 10.1146/annurev.biochem.56.1.945; NGUYEN T, 1992, J BIOL CHEM, V267, P13535; PARKER BA, 1979, J VIROL, V31, P360, DOI 10.1128/JVI.31.2.360-369.1979; POELLINGER L, 1992, TRENDS PHARMACOL SCI, V13, P241, DOI 10.1016/0165-6147(92)90076-I; PRESTERA T, 1993, P NATL ACAD SCI USA, V90, P2965, DOI 10.1073/pnas.90.7.2965; RILEY RJ, 1992, BIOCHEM PHARMACOL, V43, P1657, DOI 10.1016/0006-2952(92)90694-E; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; RUSHMORE TH, 1993, J BIOL CHEM, V268, P11475; SAL GD, 1989, BIOTECHNIQUES, V7, P514; SCHULE R, 1988, SCIENCE, V242, P1418, DOI 10.1126/science.3201230; SEGERS J, 1985, PROTIDES BIOL FLUIDS, V33, P589; SHAW PM, 1991, EUR J BIOCHEM, V195, P171, DOI 10.1111/j.1432-1033.1991.tb15691.x; STORZ G, 1990, SCIENCE, V248, P189, DOI 10.1126/science.2183352; TAKACS B, 1979, IMMUNOLOGICAL METHOD, P69; TALALAY P, 1988, P NATL ACAD SCI USA, V85, P1157; TALALAY P, 1992, CANCER BIOL THERAPEU, P197; THOR H, 1982, J BIOL CHEM, V257, P2419; WHITLOCK JP, 1990, ANNU REV PHARMACOL, V30, P251; WONG GG, 1985, SCIENCE, V228, P810, DOI 10.1126/science.3923623	46	99	109	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14502	14508						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	8182056				2022-12-25	WOS:A1994NM06500032
J	CLARET, FX; CHAPEL, S; GARCES, J; TSAIPFLUGFELDER, M; BERTHOLET, C; SHAPIRO, DJ; WITTEK, R; WAHLI, W				CLARET, FX; CHAPEL, S; GARCES, J; TSAIPFLUGFELDER, M; BERTHOLET, C; SHAPIRO, DJ; WITTEK, R; WAHLI, W			2 FUNCTIONAL FORMS OF THE XENOPUS-LAEVIS ESTROGEN-RECEPTOR TRANSLATED FROM A SINGLE MESSENGER-RNA SPECIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER RIBONUCLEIC-ACIDS; 5' FLANKING SEQUENCE; MAMMARY-TUMOR VIRUS; CELL-FREE SYSTEM; INVITRO TRANSCRIPTION; GLUCOCORTICOID RECEPTOR; VACCINIA VIRUS; PROGESTERONE-RECEPTOR; RESPONSIVE ELEMENT; LATE GENE	Steroid receptors are nuclear proteins that regulate gene transcription in a ligand-dependent manner. Overexpression of the Xenopus estrogen receptor in a vaccinia virus derived expression system revealed that the receptor localized exclusively in the nucleus of the infected cells, irrespective of the presence or absence of the ligand. Furthermore, two forms of the receptor were produced, a full-length and a N-terminal truncated version, which are translated from a single mRNA species by the use of two AUG within the same reading frame. These 66- and 61-kDa receptors were also observed after in vitro translation of the mRNA as well as in primary Xenopus hepatocytes. Both forms are potent estrogen dependent transcriptional activators in transient transfection experiments, as well as in in vitro transcription assays.	UNIV LAUSANNE,INST BIOL ANIM,CH-1015 LAUSANNE,SWITZERLAND; UNIV ILLINOIS,DEPT BIOCHEM,URBANA,IL 61801	University of Lausanne; University of Illinois System; University of Illinois Urbana-Champaign			Wahli, Walter/B-1398-2009; Claret, Francois X/R-2104-2016; Wahli, Walter/I-3194-2019	Wahli, Walter/0000-0002-5966-9089; Claret, Francois X/0000-0003-4629-6495; 				ALNEMRI ES, 1991, J BIOL CHEM, V266, P3925; BAGCHI MK, 1990, NATURE, V345, P547, DOI 10.1038/345547a0; BAGCHI MK, 1990, J BIOL CHEM, V265, P5129; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BERTHOLET C, 1986, EMBO J, V5, P1951, DOI 10.1002/j.1460-2075.1986.tb04449.x; BERTHOLET C, 1985, P NATL ACAD SCI USA, V82, P2096, DOI 10.1073/pnas.82.7.2096; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN M, 1990, J BIOL CHEM, V265, P11238; CARSONJURICA MA, 1990, ENDOCR REV, V11, P201, DOI 10.1210/edrv-11-2-201; CORTHESY B, 1989, MOL CELL BIOL, V9, P5548, DOI 10.1128/MCB.9.12.5548; CORTHESY B, 1990, P NATL ACAD SCI USA, V87, P7878, DOI 10.1073/pnas.87.20.7878; CORTHESY B, 1988, SCIENCE, V239, P1137, DOI 10.1126/science.2830672; DEBOER W, 1982, ENDOCRINOLOGY, V110, P1217, DOI 10.1210/endo-110-4-1217; DENTON RR, 1992, J BIOL CHEM, V267, P7263; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; ELLISTON JF, 1992, J BIOL CHEM, V267, P5193; ELLISTON JF, 1990, MOL CELL BIOL, V10, P6607, DOI 10.1128/MCB.10.12.6607; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; FREEDMAN LP, 1989, SCIENCE, V245, P298, DOI 10.1126/science.2473529; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GREEN S, 1986, NATURE, V320, P134, DOI 10.1038/320134a0; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; GREENE GL, 1986, SCIENCE, V231, P1150, DOI 10.1126/science.3753802; HAM J, 1988, NUCLEIC ACIDS RES, V16, P5263, DOI 10.1093/nar/16.12.5263; HAYWARD MA, 1982, AM J PHYSIOL, V243, pC1, DOI 10.1152/ajpcell.1982.243.1.C1; HAYWARD MA, 1980, J BIOL CHEM, V255, P1308; HINNEBUSCH AG, 1990, TRENDS BIOCHEM SCI, V15, P148, DOI 10.1016/0968-0004(90)90215-W; KALFF M, 1990, NATURE, V344, P360, DOI 10.1038/344360a0; KING WJ, 1984, NATURE, V307, P745, DOI 10.1038/307745a0; KLEINHITPASS L, 1988, NUCLEIC ACIDS RES, V16, P647, DOI 10.1093/nar/16.2.647; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KRUST A, 1986, EMBO J, V5, P891, DOI 10.1002/j.1460-2075.1986.tb04300.x; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEES JA, 1989, NUCLEIC ACIDS RES, V17, P5477, DOI 10.1093/nar/17.14.5477; MARILLEY D, 1994, IN PRESS MOL CELL EN; MARTINEZ E, 1987, EMBO J, V6, P3719, DOI 10.1002/j.1460-2075.1987.tb02706.x; MARTINEZ E, 1989, EMBO J, V8, P3781, DOI 10.1002/j.1460-2075.1989.tb08555.x; MARTINEZ E, 1991, MOL CELL BIOL, V11, P2937, DOI 10.1128/MCB.11.6.2937; MAY FEB, 1980, DEV BIOL, V77, P419, DOI 10.1016/0012-1606(80)90485-6; MOSS B, 1991, J BIOL CHEM, V266, P1355; NARDULLI AM, 1993, MOL ENDOCRINOL, V7, P331, DOI 10.1210/me.7.3.331; OMALLEY B, 1990, MOL ENDOCRINOL, V4, P363, DOI 10.1210/mend-4-3-363; PAKDEL F, 1989, MOL ENDOCRINOL, V3, P44, DOI 10.1210/mend-3-1-44; PATEL DD, 1987, EMBO J, V6, P3787, DOI 10.1002/j.1460-2075.1987.tb02714.x; PATEL DD, 1988, P NATL ACAD SCI USA, V85, P9431, DOI 10.1073/pnas.85.24.9431; PICARD D, 1990, CELL REGUL, V1, P291, DOI 10.1091/mbc.1.3.291; PRATT WB, 1992, J STEROID BIOCHEM, V41, P223, DOI 10.1016/0960-0760(92)90348-M; REESE JC, 1991, NUCLEIC ACIDS RES, V19, P6595, DOI 10.1093/nar/19.23.6595; ROSEL JL, 1986, J VIROL, V60, P436, DOI 10.1128/JVI.60.2.436-449.1986; Sambrook J, 1989, MOL CLONING LABORATO; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; SHEMSHEDINI L, 1992, J BIOL CHEM, V267, P1834; SLUYSER M, 1990, CANCER RES, V50, P451; SMITH DF, 1993, MOL ENDOCRINOL, V7, P4, DOI 10.1210/me.7.1.4; SRINIVASAN G, 1992, MOL ENDOCRINOL, V6, P857, DOI 10.1210/me.6.6.857; STANLEY KK, 1984, EMBO J, V3, P1429, DOI 10.1002/j.1460-2075.1984.tb01988.x; TOULAS C, 1992, HORM RES, V38, P73, DOI 10.1159/000182493; TSAI SY, 1990, J BIOL CHEM, V265, P17055; TZUKERMAN M, 1991, MOL ENDOCRINOL, V5, P1983, DOI 10.1210/mend-5-12-1983; WAHLI W, 1991, FASEB J, V5, P2243, DOI 10.1096/fasebj.5.9.1860615; WALKER P, 1984, NUCLEIC ACIDS RES, V12, P8611, DOI 10.1093/nar/12.22.8611; WEBB P, 1992, MOL ENDOCRINOL, V6, P157, DOI 10.1210/me.6.2.157; WEILER IJ, 1987, MOL ENDOCRINOL, V1, P355, DOI 10.1210/mend-1-5-355; WELSHONS WV, 1984, NATURE, V307, P747, DOI 10.1038/307747a0; WESTLEY B, 1979, BIOCHEM BIOPH RES CO, V88, P1167, DOI 10.1016/0006-291X(79)91531-6; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; WRIGHT CVE, 1983, EMBO J, V2, P973, DOI 10.1002/j.1460-2075.1983.tb01530.x	73	23	25	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					14047	14055						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188685				2022-12-25	WOS:A1994NL60600051
J	BURNS, CM; SAKAGUCHI, K; APPELLA, E; ASHWELL, JD				BURNS, CM; SAKAGUCHI, K; APPELLA, E; ASHWELL, JD			CD45 REGULATION OF TYROSINE PHOSPHORYLATION AND ENZYME-ACTIVITY OF SRC FAMILY KINASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ANTIGEN RECEPTOR; LEUKOCYTE-COMMON ANTIGEN; PROTEIN-KINASE; SIGNAL TRANSDUCTION; ZETA-CHAIN; PHOSPHOTYROSINE PHOSPHATASE; CATALYTIC ACTIVITY; SURFACE-ANTIGENS; MICE LACKING; T-CELLS	Previous analyses have suggested that the CD45 tyrosine phosphatase activates src family tyrosine kinases p56(lck) and p59(fyn) by dephosphorylating regulatory COOH-terminal residues. We have examined the status of p56(lck) and p59(fyn) in murine and human CD45(-) T cell lines. Surprisingly, despite the fact that p56(lck) and p59(fyn) were spontaneously hyperphosphorylated, the tyrosine kinase activity of both enzymes was increased in CD45(-) versus CD45(+) cells. In vitro exposure of hyperphosphorylated p56(lck) to CD45 decreased enzyme activity to near-basal levels. Lck from CD45(-) cells was hyperphosphorylated on the cyanogen bromide digestion fragment that contains the negative regulatory residue Tyr-505, and the identity of this site of phosphorylation was confirmed by trypsin digestion followed by high performance liquid chromatography. Loss of CD45 results, therefore, in a paradoxical hyperphosphorylation of the COOH-terminal tyrosine and increased src family kinase enzymatic activity.	NCI, CELL BIOL LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	BURNS, CM (corresponding author), NCI, BIOL RESPONSE MODIFIERS PROGRAM, IMMUNE CELL BIOL LAB, BETHESDA, MD 20892 USA.			Sakaguchi, Kazuyasu/0000-0002-8434-4171				ABRAHAM N, 1990, MOL CELL BIOL, V10, P5197, DOI 10.1128/MCB.10.10.5197; AMREIN KE, 1988, P NATL ACAD SCI USA, V85, P4247, DOI 10.1073/pnas.85.12.4247; APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; BERGMAN M, 1992, EMBO J, V11, P2919, DOI 10.1002/j.1460-2075.1992.tb05361.x; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BURNS CM, 1993, CURR BIOL, V3, P97, DOI 10.1016/0960-9822(93)90164-J; CHALUPNY NJ, 1991, EMBO J, V10, P1201, DOI 10.1002/j.1460-2075.1991.tb08061.x; CHAN AC, 1991, P NATL ACAD SCI USA, V88, P9166, DOI 10.1073/pnas.88.20.9166; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CHENG SH, 1991, J VIROL, V65, P170, DOI 10.1128/JVI.65.1.170-179.1991; CHO HJ, 1991, BIOCHEMISTRY-US, V30, P6210, DOI 10.1021/bi00239a019; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; DANIELIAN S, 1992, EUR J IMMUNOL, V22, P2915, DOI 10.1002/eji.1830221124; DEANS JP, 1992, EUR J IMMUNOL, V22, P661, DOI 10.1002/eji.1830220308; EISEMAN E, 1992, NATURE, V355, P78; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KIESSLING R, 1975, EUR J IMMUNOL, V5, P112, DOI 10.1002/eji.1830050208; KITAS EA, 1990, J ORG CHEM, V55, P4181, DOI 10.1021/jo00300a041; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KORETZKY GA, 1990, NATURE, V346, P66, DOI 10.1038/346066a0; KORETZKY GA, 1991, P NATL ACAD SCI USA, V88, P2037, DOI 10.1073/pnas.88.6.2037; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; MCFARLAND EDC, 1993, P NATL ACAD SCI USA, V90, P1402, DOI 10.1073/pnas.90.4.1402; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; MUSTELIN T, 1989, P NATL ACAD SCI USA, V86, P6302, DOI 10.1073/pnas.86.16.6302; MUSTELIN T, 1992, EUR J IMMUNOL, V22, P1173, DOI 10.1002/eji.1830220510; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; MUSTELIN T, 1990, ONCOGENE, V5, P809; OSTERGAARD HL, 1990, J EXP MED, V172, P347, DOI 10.1084/jem.172.1.347; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; PINGEL JT, 1989, CELL, V58, P1055, DOI 10.1016/0092-8674(89)90504-7; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SHIROO M, 1992, EMBO J, V11, P4887, DOI 10.1002/j.1460-2075.1992.tb05595.x; SIEH M, 1993, EMBO J, V12, P315, DOI 10.1002/j.1460-2075.1993.tb05659.x; SPRINGER T, 1978, EUR J IMMUNOL, V8, P539, DOI 10.1002/eji.1830080802; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; TROWBRIDGE IS, 1991, J BIOL CHEM, V266, P23517; TSYGANKOV AY, 1992, J BIOL CHEM, V267, P18259; VEILLETTE A, 1990, ONCOGENE, V5, P1455; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VEILLETTE A, 1989, ONCOGENES, P121; VOLAREVIC S, 1992, J EXP MED, V176, P835, DOI 10.1084/jem.176.3.835; WANGE RL, 1992, J BIOL CHEM, V267, P11685; WEAVER CT, 1991, MOL CELL BIOL, V11, P4415, DOI 10.1128/MCB.11.9.4415	49	95	95	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13594	13600						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175795				2022-12-25	WOS:A1994NK18400078
J	JAFFE, AB; TORANALLERAND, CD; GREENGARD, P; GANDY, SE				JAFFE, AB; TORANALLERAND, CD; GREENGARD, P; GANDY, SE			ESTROGEN REGULATES METABOLISM OF ALZHEIMER AMYLOID-BETA PRECURSOR PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HUMAN-BREAST-CANCER; CELL-LINES; DISEASE; GROWTH; PREVALENCE; DEMENTIA; PEPTIDE; PHOSPHORYLATION; IDENTIFICATION; SECRETION	We have investigated the possible effect of estrogen on the metabolism of the Alzheimer amyloid precursor protein (APP). Using a cell line that contains high levels of estrogen receptors, we have found that treatment with physiological concentrations of 17 beta-estradiol is associated with accumulation in the conditioned medium of an amino-terminal cleavage product of APP (soluble APP or protease nexin-2), indicative of non-amyloidogenic processing. There were no obvious changes in the levels of intracellular immature or mature APP holoproteins, suggesting that estrogen may increase the secretory metabolism of APP.	CORNELL UNIV,COLL MED,DEPT NEUROL & NEUROSCI,NEW YORK,NY 10021; ROCKEFELLER UNIV,MOLEC & CELLULAR NEUROSCI LAB,NEW YORK,NY 10021; COLUMBIA UNIV,COLL PHYS & SURG,DEPT ANAT & CELL BIOL,NEW YORK,NY 10032	Cornell University; Rockefeller University; Columbia University					NATIONAL INSTITUTE ON AGING [P01AG009464, P01AG010491, R01AG011508, R55AG011508] Funding Source: NIH RePORTER; NIA NIH HHS [AG09464, AG 10491, AG 11508] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALLERAND CDT, 1991, NEW BIOL STEROID HOR, P311; ALLERAND CDT, 1992, P NATL ACAD SCI USA, P4668; ALLERAND CDT, 1992, BRAIN RES, V576, P25; ARONSON MK, 1990, NEUROLOGY, V40, P1102, DOI 10.1212/WNL.40.7.1102; BACHMAN DL, 1992, NEUROLOGY, V42, P115, DOI 10.1212/WNL.42.1.115; BARCLAY LL, 1985, NEUROLOGY, V35, P834, DOI 10.1212/WNL.35.6.834; BATES SE, 1988, MOL ENDOCRINOL, V2, P543, DOI 10.1210/mend-2-6-543; BUXBAUM JD, 1990, P NATL ACAD SCI USA, V87, P6003, DOI 10.1073/pnas.87.15.6003; BUXBAUM JD, 1992, P NATL ACAD SCI USA, V89, P10075, DOI 10.1073/pnas.89.21.10075; CAPORASO GL, 1992, P NATL ACAD SCI USA, V89, P3055, DOI 10.1073/pnas.89.7.3055; DICKSON RB, 1986, ENDOCRINOLOGY, V118, P138, DOI 10.1210/endo-118-1-138; DICKSON RB, 1986, CANCER RES, V46, P1707; DICKSON RB, 1986, SCIENCE, V232, P1540, DOI 10.1126/science.3715461; DROUVA SV, 1990, ENDOCRINOLOGY, V126, P536, DOI 10.1210/endo-126-1-536; DUARA R, 1993, NEUROLOGY, V43, P1377, DOI 10.1212/WNL.43.7.1377; ENGEL LW, 1978, CANCER RES, V38, P3352; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; FEINGOLD KR, 1990, CECILS ESSENTIALS ME, P478; FRATIGLIONI L, 1991, NEUROLOGY, V41, P1886, DOI 10.1212/WNL.41.12.1886; FUKUYAMA R, 1993, MOL BRAIN RES, V17, P17, DOI 10.1016/0169-328X(93)90067-Y; GANDY S, 1994, NEUROBIOL AGING, V15, P253, DOI 10.1016/0197-4580(94)90125-2; GILLESPIE SL, 1992, BIOCHEM BIOPH RES CO, V187, P1285, DOI 10.1016/0006-291X(92)90442-N; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; HAASS C, 1993, CELL, V75, P1039, DOI 10.1016/0092-8674(93)90312-E; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HENDERSON VW, 1994, IN PRESS ARCH NEUROL; KAMEL F, 1988, AM J PHYSIOL-ENDOC M, V255, P314; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KATZMAN R, 1989, ANN NEUROL, V25, P317, DOI 10.1002/ana.410250402; KIM KS, 1990, NEUROSCI RES COMMUN, V7, P113; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDERS J P, 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P19; LIPPMAN ME, 1988, J STEROID BIOCHEM, V30, P53, DOI 10.1016/0022-4731(88)90076-3; MAEDA T, 1993, LAB INVEST, V68, P472; MAIZELS ET, 1992, J BIOL CHEM, V267, P17061; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MCGONIGAL G, 1993, BRIT MED J, V306, P680, DOI 10.1136/bmj.306.6879.680; MIRANDA RC, 1993, MOL CELL NEUROSCI, V4, P510, DOI 10.1006/mcne.1993.1063; MOLSA PK, 1982, ACTA NEUROL SCAND, V65, P541; NITSCH RM, 1992, SCIENCE, V258, P304, DOI 10.1126/science.1411529; RAMABHADRAN TV, 1993, J BIOL CHEM, V268, P2009; REFOLO LM, 1989, BIOCHEM BIOPH RES CO, V164, P664, DOI 10.1016/0006-291X(89)91511-8; ROCCA WA, 1990, NEUROLOGY, V40, P626, DOI 10.1212/WNL.40.4.626; RUEDL C, 1990, J STEROID BIOCHEM, V37, P195, DOI 10.1016/0960-0760(90)90327-H; SCHUBERT D, 1989, NEURON, V3, P689, DOI 10.1016/0896-6273(89)90237-7; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SEUBERT P, 1993, NATURE, V361, P260, DOI 10.1038/361260a0; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; Singh M., 1993, Society for Neuroscience Abstracts, V19, P1254; SINHA S, 1992, NEURODEGENERATION, V1, P169; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; SKOOG I, 1993, NEW ENGL J MED, V328, P153, DOI 10.1056/NEJM199301213280301; SLUNT HH, 1994, J BIOL CHEM, V269, P2637; STAM FC, 1986, PATHOL RES PRACT, V181, P558, DOI 10.1016/S0344-0338(86)80149-2; SULKAVA R, 1985, NEUROLOGY, V35, P1025, DOI 10.1212/WNL.35.7.1025; Tomlinson B.E., 1992, GREENFIELDS NEUROPAT, P1284; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANNOSTRAND WE, 1987, J BIOL CHEM, V262, P8508; WASCO W, 1993, NAT GENET, V5, P95, DOI 10.1038/ng0993-95; WASCO W, 1992, P NATL ACAD SCI USA, V89, P10758, DOI 10.1073/pnas.89.22.10758; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; YAN YC, 1990, P NATL ACAD SCI USA, V87, P2405, DOI 10.1073/pnas.87.7.2405; YU ESH, 1989, J GERONTOL, V44, pS97, DOI 10.1093/geronj/44.3.S97; ZHANG MY, 1990, ANN NEUROL, V27, P428, DOI 10.1002/ana.410270412	64	316	325	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13065	13068						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175728				2022-12-25	WOS:A1994NK18400003
J	KEPHART, DD; WANG, BQ; BURTON, ZF; PRICE, DH				KEPHART, DD; WANG, BQ; BURTON, ZF; PRICE, DH			FUNCTIONAL-ANALYSIS OF DROSOPHILA FACTOR-5 (TFIIF), A GENERAL TRANSCRIPTION FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; INITIATION-FACTOR; PREINITIATION COMPLEX; ELONGATION COMPLEXES; SUBUNIT; BINDS; DNA; IDENTIFICATION; FRACTIONATION; PURIFICATION	Factor 5 is a Drosophila RNA polymerase II initiation factor that also affects the elongation phase of transcription. We have used a cDNA encoding the large subunit of factor 5 (F5a) to produce recombinant F5a (rF5a). Antibodies directed against peptides deduced from the sequence of the F5a cDNA recognized rF5a and the large subunit of factor 5 purified from Kc cells. A chimeric human/fly factor composed of the small subunit of human TFIIF (RAP30) and rF5a stimulated elongation by Drosophila RNA polymerase II when assayed using a dC-tailed template. In addition, the chimeric human/fly factor functioned during initiation in either the Drosophila or human system. Therefore, the structure of the large subunit of TFIIF is sufficiently conserved from human to fly to allow functional interaction with both the small subunit of TFIIF and RNA polymerase II from either species. Analysis of deletion mutants of F5a indicated that almost all of the protein was required for initiation while only the NH2-terminal region was required for stimulating transcriptional elongation. A comparison of our results with those obtained with RAP74 suggest that the carboxyl terminal region of the protein may be involved in interactions with RNA polymerase II or other factors during initiation.	UNIV IOWA,DEPT BIOCHEM,IOWA CITY,IA 52242; MICHIGAN STATE UNIV,DEPT BIOCHEM,E LANSING,MI 48824; MICHIGAN STATE UNIV,AGR EXPT STN,E LANSING,MI 48824	University of Iowa; Michigan State University; Michigan State University; Michigan State University AgBioResearch			Price, David H/F-6173-2010	Price, David/0000-0002-5597-385X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035500, R01GM040708] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM40708, GM35500] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASO T, 1992, NATURE, V355, P461, DOI 10.1038/355461a0; BENGAL E, 1991, MOL CELL BIOL, V11, P1195, DOI 10.1128/MCB.11.3.1195; BURTON ZF, 1988, MOL CELL BIOL, V8, P1602, DOI 10.1128/MCB.8.4.1602; CHANG CH, 1993, J BIOL CHEM, V268, P20482; CONAWAY JW, 1989, J BIOL CHEM, V264, P2357; CONAWAY RC, 1990, J BIOL CHEM, V265, P7559; CORTES P, 1992, MOL CELL BIOL, V12, P413, DOI 10.1128/MCB.12.1.413; Drapkin R, 1993, CURR OPIN CELL BIOL, V5, P469, DOI 10.1016/0955-0674(93)90013-G; FINKELSTEIN A, 1992, NATURE, V355, P464, DOI 10.1038/355464a0; FLORES O, 1989, J BIOL CHEM, V264, P8913; FLORES O, 1990, J BIOL CHEM, V265, P5629; FLORES O, 1988, J BIOL CHEM, V263, P10812; FLORES O, 1991, P NATL ACAD SCI USA, V88, P9999, DOI 10.1073/pnas.88.22.9999; FLORES O, 1992, J BIOL CHEM, V267, P2786; FYRBERG EA, 1980, CELL, V19, P365, DOI 10.1016/0092-8674(80)90511-5; GONG DW, 1992, NUCLEIC ACIDS RES, V20, P6414, DOI 10.1093/nar/20.23.6414; HOEY T, 1990, CELL, V61, P1179, DOI 10.1016/0092-8674(90)90682-5; KEPHART DD, 1992, MOL CELL BIOL, V12, P2067, DOI 10.1128/MCB.12.5.2067; KEPHART DD, 1993, NUCLEIC ACIDS RES, V21, P1319, DOI 10.1093/nar/21.5.1319; KILLEEN MT, 1992, MOL CELL BIOL, V12, P30, DOI 10.1128/MCB.12.1.30; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARSHALL NF, 1992, MOL CELL BIOL, V12, P2078, DOI 10.1128/MCB.12.5.2078; MCCRACKEN S, 1991, SCIENCE, V253, P900, DOI 10.1126/science.1652156; PARKER CS, 1984, CELL, V36, P357, DOI 10.1016/0092-8674(84)90229-0; PRICE DH, 1989, MOL CELL BIOL, V9, P1465, DOI 10.1128/MCB.9.4.1465; PRICE DH, 1984, CELL, V38, P423, DOI 10.1016/0092-8674(84)90497-5; PRICE DH, 1987, J BIOL CHEM, V262, P3244; SCOPES RK, 1974, ANAL BIOCHEM, V59, P277, DOI 10.1016/0003-2697(74)90034-7; SOPTA M, 1985, J BIOL CHEM, V260, P353; SOPTA M, 1989, NATURE, V341, P410, DOI 10.1038/341410a0; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TYREE CM, 1993, GENE DEV, V7, P1254, DOI 10.1101/gad.7.7a.1254; WAMPLER SL, 1990, J BIOL CHEM, V265, P21223; WAMPLER SL, 1992, GENE DEV, V6, P1542, DOI 10.1101/gad.6.8.1542; YONAHA M, 1993, NUCLEIC ACIDS RES, V21, P273, DOI 10.1093/nar/21.2.273	35	44	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13536	13543						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175788				2022-12-25	WOS:A1994NK18400071
J	KIM, U; GARNER, TL; SANFORD, T; SPEICHER, D; MURRAY, JM; NISHIKURA, K				KIM, U; GARNER, TL; SANFORD, T; SPEICHER, D; MURRAY, JM; NISHIKURA, K			PURIFICATION AND CHARACTERIZATION OF DOUBLE-STRANDED-RNA ADENOSINE-DEAMINASE FROM BOVINE NUCLEAR EXTRACTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNWINDING MODIFYING ACTIVITY; BIASED HYPERMUTATION; POLYACRYLAMIDE GELS; MEASLES VIRUSES; MAMMALIAN-CELLS; REV PROTEIN; BINDING; SEQUENCE; INVITRO; INOSINE	The double-stranded RNA (dsRNA) adenosine deaminase (DRADA) deaminates adenosine residues to inosines and creates I-U mismatched base pairs in dsRNAs. Its involvement in RNA editing of glutamate-gated ion channel gene transcripts in mammalian brains has been proposed as one of the biological functions for this recently identified cellular enzyme. We purified a mixture of three forms, 93, 88, and 83 kDa, of bovine DRADA proteins, all likely to be active enzymes. We determined that DRADA has a native molecular mass of approximately 100 kDa, suggesting that the enzyme exists as a monomer. The purified enzyme was not inhibited by 2'-deoxycoformycin, a transition state analog inhibitor of adenosine deaminase and AMP deaminase, suggesting that the catalytic mechanism of DRADA might be different from that of other deaminases. DRADA binds specifically to dsRNA with a dissociation constant of 0.23 nM for a synthetic dsRNA, and the Michaelis constant is 0.85 nM. These values indicate that DRADA has a much higher affinity for its substrate than other deaminases such as adenosine deaminase and AMP deaminase. DRADA may need this extremely high affinity to catalyze efficiently the modification of relatively rare substrate RNAs in the cell nucleus.	UNIV PENN, SCH MED, WISTAR INST ANAT & BIOL, PHILADELPHIA, PA 19104 USA; UNIV PENN, SCH DENT MED, DEPT CELL & DEV BIOL, PHILADELPHIA, PA 19104 USA	The Wistar Institute; University of Pennsylvania; University of Pennsylvania					NATIONAL CANCER INSTITUTE [T32CA009171, P30CA010815] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040536] Funding Source: NIH RePORTER; NCI NIH HHS [CA09171, CA10815] Funding Source: Medline; NIGMS NIH HHS [GM40536] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGARWAL RP, 1975, BIOCHEM PHARMACOL, V24, P693, DOI 10.1016/0006-2952(75)90245-2; AGARWAL RP, 1977, BIOCHEM PHARMACOL, V26, P359, DOI 10.1016/0006-2952(77)90192-7; BASILIO C, 1962, P NATL ACAD SCI USA, V48, P613, DOI 10.1073/pnas.48.4.613; BASS BL, 1988, CELL, V55, P1089, DOI 10.1016/0092-8674(88)90253-X; BASS BL, 1987, CELL, V48, P607, DOI 10.1016/0092-8674(87)90239-X; BASS BL, 1989, CELL, V56, P331, DOI 10.1016/0092-8674(89)90234-1; BLUM B, 1990, CELL, V60, P189, DOI 10.1016/0092-8674(90)90735-W; BURK RR, 1983, METHOD ENZYMOL, V91, P247; CATIGNOL A, 1993, MOL CELL BIOL, V13, P2193; CATTANEO R, 1989, VIROLOGY, V173, P415, DOI 10.1016/0042-6822(89)90554-0; CATTANEO R, 1988, CELL, V55, P255, DOI 10.1016/0092-8674(88)90048-7; CHANG Z, 1991, BIOCHEMISTRY-US, V30, P2273, DOI 10.1021/bi00222a033; DALY TJ, 1989, NATURE, V342, P816, DOI 10.1038/342816a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GARCIA ZC, 1992, ARTERIOSCLER THROMB, V12, P172, DOI 10.1161/01.ATV.12.2.172; GREEVE J, 1991, NUCLEIC ACIDS RES, V19, P3569, DOI 10.1093/nar/19.13.3569; GROSSHANS J, 1993, BIOCHIM BIOPHYS ACTA, V1161, P28, DOI 10.1016/0167-4838(93)90191-S; HEUKESHOVEN J, 1985, ELECTROPHORESIS, V6, P103, DOI 10.1002/elps.1150060302; HIGUCHI M, 1993, CELL, V75, P1361, DOI 10.1016/0092-8674(93)90622-W; HODGES P, 1993, RNA EDITING ALTERATI, P125; Kim U, 1993, Semin Cell Biol, V4, P285, DOI 10.1006/scel.1993.1034; KIMELMAN D, 1989, CELL, V59, P687, DOI 10.1016/0092-8674(89)90015-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMB RA, 1989, NATURE, V337, P19, DOI 10.1038/337019a0; Lomant A J, 1975, Prog Nucleic Acid Res Mol Biol, V15, P185, DOI 10.1016/S0079-6603(08)60120-8; MALIM MH, 1991, CELL, V65, P241, DOI 10.1016/0092-8674(91)90158-U; MARGOLIASH E, 1962, J BIOL CHEM, V237, P3397; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; NISHIKURA K, 1991, EMBO J, V10, P3523, DOI 10.1002/j.1460-2075.1991.tb04916.x; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OHARA PJ, 1984, CELL, V36, P915, DOI 10.1016/0092-8674(84)90041-2; POLSON AG, 1991, BIOCHEMISTRY-US, V30, P11507, DOI 10.1021/bi00113a004; REBAGLIATI MR, 1987, CELL, V48, P599, DOI 10.1016/0092-8674(87)90238-8; RIGGS AD, 1968, J MOL BIOL, V34, P365, DOI 10.1016/0022-2836(68)90261-1; ROY S, 1990, GENE DEV, V4, P1365, DOI 10.1101/gad.4.8.1365; SMITH HC, 1991, P NATL ACAD SCI USA, V88, P1489, DOI 10.1073/pnas.88.4.1489; SOMMER B, 1991, CELL, V67, P11, DOI 10.1016/0092-8674(91)90568-J; THAKKAR JK, 1993, BIOCHEM J, V290, P335, DOI 10.1042/bj2900335; WAGNER RW, 1990, MOL CELL BIOL, V10, P5586, DOI 10.1128/MCB.10.10.5586; WAGNER RW, 1989, P NATL ACAD SCI USA, V86, P2647, DOI 10.1073/pnas.86.8.2647; WAGNER RW, 1988, MOL CELL BIOL, V8, P770, DOI 10.1128/MCB.8.2.770; WANG AC, 1971, J MOL BIOL, V62, P591, DOI 10.1016/0022-2836(71)90158-6; WILKINSON G, 1961, BIOCHEM J, V80, P324, DOI 10.1042/bj0800324; WILSON DK, 1991, SCIENCE, V252, P1278, DOI 10.1126/science.1925539; WOO PWK, 1974, J HETEROCYCLIC CHEM, V11, P641, DOI 10.1002/jhet.5570110438; YANG C, 1992, BIOCHEMISTRY-US, V31, P4168, DOI 10.1021/bi00132a003; ZAPP ML, 1991, P NATL ACAD SCI USA, V88, P7734, DOI 10.1073/pnas.88.17.7734	47	106	114	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13480	13489						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175781				2022-12-25	WOS:A1994NK18400064
J	YASUHARA, T; NAKAI, T; OHASHI, A				YASUHARA, T; NAKAI, T; OHASHI, A			AMINOPEPTIDASE-Y, A NEW AMINOPEPTIDASE FROM SACCHAROMYCES-CEREVISIAE - PURIFICATION, PROPERTIES, LOCALIZATION, AND PROCESSING BY PROTEASE-B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST VACUOLE LYSOSOME; PROTEINASE YSCB; PRECURSOR; ENZYMES; DEGRADATION; BIOGENESIS; MATURATION; ACTIVATION; CATALYSTS; HYDROLASE	A novel aminopeptidase, termed aminopeptidase Y, was purified from yeast, Saccharomyces cerevisiae, as two molecular forms of 70 and 75 kDa, which were identical immunologically, catalytically and in N-terminal sequence up to 14 residues. They contained 0.81 and 0.84 mol of zinc atom/mol of protein, respectively. N-G1ycanase generated a single 53-kDa species from both forms, and endoglycosidase H gave a 54-kDa species. Immunoblotting after subcellular fractionation showed that aminopeptidase Y is localized in the vacuole/lysosome-soluble compartment as the 70-kDa form. Aminopeptidase Y hydrolyzed all amino acid-4-methylcoumaryl-7-amides (MCA) examined, especially Lys- and Arg-MCA Dipeptidyl-MCAs were far more rapidly hydrolyzed (Lys-Ala-MCA/Lys-MCA = 350-fold, Arg-Arg-MCA/Arg-MCA = 150-fold). Hydrolysis of amino acid-MCAs or dipeptides was markedly enhanced by Co2+, whereas that of dipeptidyl-MCAs, tripeptides, and larger peptides was inhibited. Rabbit anti-aminopeptidase Y antiserum adsorbed over half the aminopeptidase activities in vacuolar extract from wild-type yeast cells. ABYS1 mutant cells from which the genes of four vacuolar proteases had been deleted contained aminopeptidase Y as a 74-kDa preform. This was converted to the mature form (70 kDa) by vacuolar extract of wild-type cells and by purified yeast vacuolar protease B.	MEIJI INST HLTH SCI,ODAWARA 250,JAPAN									ACHSTETTER T, 1982, BIOCHEM BIOPH RES CO, V109, P341, DOI 10.1016/0006-291X(82)91726-0; AMMERER G, 1986, MOL CELL BIOL, V6, P2490, DOI 10.1128/MCB.6.7.2490; Ben-Bassat A., 1987, NATURE, V326, P315; CHANG YH, 1990, J BIOL CHEM, V265, P19892; CHIANG HL, 1991, NATURE, V350, P313, DOI 10.1038/350313a0; DAUM G, 1982, J BIOL CHEM, V257, P3028; DICE JF, 1990, TRENDS BIOCHEM SCI, V15, P305, DOI 10.1016/0968-0004(90)90019-8; FREY J, 1979, EUR J BIOCHEM, V97, P169, DOI 10.1111/j.1432-1033.1979.tb13099.x; HAEGGSTROM JZ, 1990, BIOCHEM BIOPH RES CO, V173, P431, DOI 10.1016/S0006-291X(05)81076-9; HANSEN RJ, 1977, BIOCHIM BIOPHYS ACTA, V496, P103, DOI 10.1016/0304-4165(77)90119-2; HEMMINGS BA, 1981, P NATL ACAD SCI-BIOL, V78, P435, DOI 10.1073/pnas.78.1.435; HIRSCH HH, 1992, EUR J BIOCHEM, V203, P641, DOI 10.1111/j.1432-1033.1992.tb16594.x; HUBERWALCHLI V, 1979, ARCH MICROBIOL, V120, P141, DOI 10.1007/BF00409100; JONES EW, 1991, J BIOL CHEM, V266, P7963; JONES EW, 1984, ANNU REV GENET, V18, P233, DOI 10.1146/annurev.ge.18.120184.001313; LABBE P, 1977, ANAL BIOCHEM, V81, P416, DOI 10.1016/0003-2697(77)90712-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MASON TL, 1973, J BIOL CHEM, V248, P1346; MATILE P, 1978, ANNU REV PLANT PHYS, V29, P193, DOI 10.1146/annurev.pp.29.060178.001205; MCDONALD JK, 1977, PROTEINASES MAMMALIA, P311; MECHLER B, 1982, BIOCHEM BIOPH RES CO, V107, P770, DOI 10.1016/0006-291X(82)90590-3; MECHLER B, 1987, EMBO J, V6, P2157, DOI 10.1002/j.1460-2075.1987.tb02483.x; METZ G, 1976, BIOCHIM BIOPHYS ACTA, V429, P933, DOI 10.1016/0005-2744(76)90338-7; NEBES VL, 1991, J BIOL CHEM, V266, P22851; NISHIZAWA M, 1994, J BIOL CHEM, V269, P13651; OHASHI A, 1980, J BIOL CHEM, V255, P7740; OHSUMI Y, 1981, J BIOL CHEM, V256, P2079; RIORDAN JF, 1984, METHOD ENZYMAT AN, V5, P44; SAHEKI T, 1975, BIOCHIM BIOPHYS ACTA, V384, P203, DOI 10.1016/0005-2744(75)90109-6; SAHEKI T, 1974, EUR J BIOCHEM, V42, P621, DOI 10.1111/j.1432-1033.1974.tb03377.x; SPORMANN DO, 1992, J BIOL CHEM, V267, P8021; Strobel H W, 1978, Methods Enzymol, V52, P89; TEICHERT U, 1989, J BIOL CHEM, V264, P16037; WEINER S, 1981, J CHROMATOGR, V213, P501, DOI 10.1016/S0021-9673(00)80501-4; WIEMKEN A, 1979, ARCH MICROBIOL, V123, P23, DOI 10.1007/BF00403499; YASUHARA T, 1990, J BIOCHEM-TOKYO, V107, P273, DOI 10.1093/oxfordjournals.jbchem.a123038	36	46	47	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13644	13650						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175799				2022-12-25	WOS:A1994NK18400085
J	KONG, XM; MANCHESTER, J; SALMONS, S; LAWRENCE, JC				KONG, XM; MANCHESTER, J; SALMONS, S; LAWRENCE, JC			GLUCOSE TRANSPORTERS IN SINGLE SKELETAL-MUSCLE FIBERS - RELATIONSHIP TO HEXOKINASE AND REGULATION BY CONTRACTILE ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								Glucose transport and phosphorylation are the first steps in the utilization of extracellular glucose by skeletal muscle. We have examined the relationships between proteins mediating these steps in single fibers of identified type dissected from rabbit skeletal muscle. The level of the glucose transporter isoform GLUT4, measured by immunoblotting, varied among fibers by a factor of 20 (slow oxidative > fast oxidative glycolytic > fast glycolytic). In fibers from the tibialis anterior muscle, GLUT4 was correlated (r(2) = 0.75) with the activity of malate dehydrogenase, an enzyme representative of oxidative energy metabolism. In these fibers a strong correlation (r(2) = 0.70) was also observed between GLUT4 and hexokinase activity. GLUT1 levels were barely detectable, regardless of fiber type. To investigate the possible role of muscle activity in controlling the expression of transporters, tibialis anterior muscles were activated by chronic electrical stimulation of the peroneal nerves. GLUT1 levels increased after 1 day of stimulation to a plateau that was severalfold higher than the level in non-stimulated cells. Hexokinase activity and the GLUT4 level changed in parallel: both were increased by approximately 2.5-fold after 1 day and by 14-fold after 21 days. Thus, while both GLUT1 and GLUT4 were regulated by muscle activity, only GLUT4 expression was coordinated with the expression of hexokinase.	WASHINGTON UNIV, SCH MED, DEPT MOLEC BIOL & PHARMACOL, ST LOUIS, MO 63110 USA; UNIV LIVERPOOL, SCH MED, DEPT HUMAN ANAT & CELL BIOL, LIVERPOOL L69 3BX, ENGLAND	Washington University (WUSTL); University of Liverpool					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041180] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028312] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR41180] Funding Source: Medline; NIDDK NIH HHS [DK28312] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARON AD, 1988, AM J PHYSIOL, V255, pE769, DOI 10.1152/ajpendo.1988.255.6.E769; BERGER M, 1975, BIOCHEM J, V146, P231, DOI 10.1042/bj1460231; BLOCK NE, 1991, J CLIN INVEST, V88, P1546, DOI 10.1172/JCI115465; BORNEMANN A, 1992, DIABETES, V41, P215, DOI 10.2337/diabetes.41.2.215; CASTELLO A, 1993, J BIOL CHEM, V268, P14998; CHI MMY, 1986, AM J PHYSIOL, V251, pC633, DOI 10.1152/ajpcell.1986.251.4.C633; CLOSE RI, 1972, PHYSIOL REV, V52, P129, DOI 10.1152/physrev.1972.52.1.129; CRANE RK, 1954, J BIOL CHEM, V210, P597; DANIEL PM, 1975, J PHYSIOL-LONDON, V247, P273, DOI 10.1113/jphysiol.1975.sp010931; DEFRONZO RA, 1981, DIABETES, V30, P1000, DOI 10.2337/diab.30.12.1000; FRIEDMAN JE, 1991, DIABETES, V40, P150, DOI 10.2337/diabetes.40.1.150; GOODYEAR LJ, 1991, AM J PHYSIOL, V261, pE556, DOI 10.1152/ajpendo.1991.261.5.E556; GROSSBARD L, 1966, J BIOL CHEM, V241, P3546; HANDBERG A, 1992, AM J PHYSIOL, V262, pE721, DOI 10.1152/ajpendo.1992.262.5.E721; HARLOW E, 1988, ANTIBODIES; HENRIKSEN EJ, 1991, J APPL PHYSIOL, V70, P2322, DOI 10.1152/jappl.1991.70.5.2322; HENRIKSEN EJ, 1990, AM J PHYSIOL, V259, pE593, DOI 10.1152/ajpendo.1990.259.4.E593; HENRIKSSON J, 1988, AM J PHYSIOL, V255, pC543, DOI 10.1152/ajpcell.1988.255.4.C543; HENRIKSSON J, 1986, AM J PHYSIOL, V251, pC614, DOI 10.1152/ajpcell.1986.251.4.C614; HINTZ CS, 1984, J HISTOCHEM CYTOCHEM, V32, P655, DOI 10.1177/32.6.6202737; HINTZ CS, 1982, AM J PHYSIOL, V242, pC218, DOI 10.1152/ajpcell.1982.242.3.C218; JAMES DE, 1988, NATURE, V333, P183, DOI 10.1038/333183a0; KASANICKI MA, 1990, DIABETES CARE, V13, P219, DOI 10.2337/diacare.13.3.219; KLIP A, 1992, J CELL BIOCHEM, V48, P51, DOI 10.1002/jcb.240480109; KLIP A, 1990, DIABETES CARE, V13, P228, DOI 10.2337/diacare.13.3.228; LAWRENCE JC, 1986, J BIOL CHEM, V261, P8556; LAWRENCE JC, 1990, J BIOL CHEM, V265, P2324; LOWRY OH, 1992, FLEXIBLE SYSTEM ENZY; LUECK JD, 1974, J BIOL CHEM, V249, P1341; MARETTE A, 1992, AM J PHYSIOL, V263, pC443, DOI 10.1152/ajpcell.1992.263.2.C443; NEUFER PD, 1992, CAN J PHYSIOL PHARM, V70, P1286, DOI 10.1139/y92-178; PARK CR, 1968, J GEN PHYSIOL, V52, pS296, DOI 10.1085/jgp.52.1.296; PESSIN JE, 1992, ANNU REV PHYSIOL, V54, P911, DOI 10.1146/annurev.ph.54.030192.004403; PETER JB, 1972, BIOCHEMISTRY-US, V11, P2627, DOI 10.1021/bi00764a013; PETTE D, 1992, REV PHYSIOL BIOCH P, V120, P115, DOI 10.1007/BFb0036123; PETTE D, 1975, PFLUG ARCH EUR J PHY, V361, P1, DOI 10.1007/BF00587333; PETTE D, 1973, PFLUG ARCH EUR J PHY, V338, P257, DOI 10.1007/BF00587391; PRINTZ RL, 1993, J BIOL CHEM, V268, P5209; REICHMANN H, 1985, PFLUGERS ARCH, V412, P1; RODNICK KJ, 1992, J BIOL CHEM, V267, P6278; RODNICK KJ, 1992, AM J PHYSIOL, V262, pC9, DOI 10.1152/ajpcell.1992.262.1.C9; SALMONS S, 1969, J PHYSIOL-LONDON, V201, P535, DOI 10.1113/jphysiol.1969.sp008771; SALMONS S, 1991, MED BIOL ENG COMPUT, V29, P554, DOI 10.1007/BF02442330; SIMONEAU JA, 1988, PFLUG ARCH EUR J PHY, V412, P86, DOI 10.1007/BF00583735; SIMPSON IA, 1986, ANNU REV BIOCHEM, V55, P1059, DOI 10.1146/annurev.biochem.55.1.1059; WEBER FE, 1990, EUR J BIOCHEM, V191, P85, DOI 10.1111/j.1432-1033.1990.tb19096.x; WEBER FE, 1988, FEBS LETT, V238, P71, DOI 10.1016/0014-5793(88)80227-8; ZIEL FH, 1988, DIABETES, V37, P885, DOI 10.2337/diabetes.37.7.885	48	63	65	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12963	12967						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175714				2022-12-25	WOS:A1994NH71600089
J	KRYSTEK, SR; PATEL, PS; ROSE, PM; FISHER, SM; KIENZLE, BK; LACH, DA; LIU, ECK; LYNCH, JS; NOVOTNY, J; WEBB, ML				KRYSTEK, SR; PATEL, PS; ROSE, PM; FISHER, SM; KIENZLE, BK; LACH, DA; LIU, ECK; LYNCH, JS; NOVOTNY, J; WEBB, ML			MUTATION OF PEPTIDE BINDING-SITE IN TRANSMEMBRANE REGION OF A G-PROTEIN-COUPLED RECEPTOR ACCOUNTS FOR ENDOTHELIN RECEPTOR SUBTYPE SELECTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							BETA-ADRENERGIC-RECEPTOR; VASOCONSTRICTOR PEPTIDE; 3-DIMENSIONAL STRUCTURE; RAT ENDOTHELIN; LIGAND-BINDING; DOMAIN; IDENTIFICATION; ANTAGONISTS; CLONING; BACTERIORHODOPSIN	The molecular basis for endothelin (ET) isopeptide selectivity between ET(A) and ET(B) receptors was studied by examining ligand binding to several site-specific mutants of the human ET(A) receptor. Based on a computer-built three-dimensional model of the ET(A) receptor, five non-conserved amino acids, clustered around the putative ligand binding site, were targeted for mutation to alanine. Expression of the wild-type and mutant ET(A) receptors in COS-7 cells revealed that the binding profile of one of the ET(A) mutants, Tyr(129) --> Ala, was characteristic of the ET(B) receptor. In the Tyr(129) --> Ala ET(A) receptor mutant the affinity of two ET(B)-selective agonists, endothelin-3 and sarafotoxin S6c, was increased 10-200-fold, whereas that for two ET(A)-selective antagonists, BQ-123 and BMS-182874, was reduced 350-2,000-fold. Thus, mutation of a single amino acid in the second transmembrane region of the wild-type ET(A) receptor results in subtype conversion. In addition, these data represent the first example of peptide interactions with a transmembrane region of a G protein-coupled receptor and indicate that Tyr(129), located in the second transmembrane region of the ET(A) receptor, is a critical component for determination of endothelin receptor subtype-selective ligand binding.	BRISTOL MYERS SQUIBB,PHARMACEUT RES INST,DEPT CARDIOVASC BIOCHEM,PRINCETON,NJ 08543; BRISTOL MYERS SQUIBB,PHARMACEUT RES INST,DEPT MACROMOLEC MODELING,PRINCETON,NJ 08543; BRISTOL MYERS SQUIBB,PHARMACEUT RES INST,DEPT METAB DIS,PRINCETON,NJ 08543; BRISTOL MYERS SQUIBB,PHARMACEUT RES INST,DEPT MICROBIAL MOLEC BIOL,PRINCETON,NJ 08543	Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb								ADACHI M, 1992, FEBS LETT, V311, P179, DOI 10.1016/0014-5793(92)81393-Z; ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; BARLOW DJ, 1988, J MOL BIOL, V201, P601, DOI 10.1016/0022-2836(88)90641-9; BEINBORN M, 1993, NATURE, V362, P348, DOI 10.1038/362348a0; BRUCCOLERI RE, 1993, MOL SIMULAT, V10, P151, DOI 10.1080/08927029308022163; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CLOZEL M, 1993, NATURE, V365, P759, DOI 10.1038/365759a0; CRONET P, 1993, PROTEIN ENG, V6, P59, DOI 10.1093/protein/6.1.59; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; ENGLEMAN DM, 1986, ANN REV BIOPHYS CHEM, V15, P321; FINDLAY J, 1990, TRENDS PHARMACOL SCI, V11, P492, DOI 10.1016/0165-6147(90)90050-I; FONG TM, 1993, NATURE, V362, P350; GUAN XM, 1992, MOL PHARMACOL, V41, P695; HAYZER DJ, 1992, AM J MED SCI, V304, P231, DOI 10.1097/00000441-199210000-00002; HUGGINS JP, 1993, EUR J PHARM-MOLEC PH, V245, P203, DOI 10.1016/0922-4106(93)90098-T; IHARA M, 1992, LIFE SCI, V50, P247, DOI 10.1016/0024-3205(92)90331-I; ISHIKAWA T, 1988, AM J PHYSIOL, V255, pH970, DOI 10.1152/ajpheart.1988.255.4.H970; MALONEYHUSS K, 1992, J MOL BIOL, V225, P859, DOI 10.1016/0022-2836(92)90406-A; MARTIN ER, 1989, BIOCHEM BIOPH RES CO, V162, P130, DOI 10.1016/0006-291X(89)91972-4; MASAKI T, 1991, CIRCULATION, V84, P1457, DOI 10.1161/01.CIR.84.4.1457; Nayler W G, 1990, Trends Pharmacol Sci, V11, P96, DOI 10.1016/0165-6147(90)90188-E; OKSENBERG D, 1992, NATURE, V360, P161, DOI 10.1038/360161a0; PARDO L, 1992, P NATL ACAD SCI USA, V89, P4009, DOI 10.1073/pnas.89.9.4009; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; RIEK P, 1991, FASEB J, V5, pA396; RUBANYI GM, 1991, FASEB J, V5, P2713, DOI 10.1096/fasebj.5.12.1916094; SACHAIS BS, 1993, J BIOL CHEM, V268, P2319; SAKAMOTO A, 1993, J BIOL CHEM, V268, P8547; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SECREST RJ, 1989, LIFE SCI, V45, P1365, DOI 10.1016/0024-3205(89)90023-4; SIMONSON MS, 1990, J CLIN INVEST, V85, P790, DOI 10.1172/JCI114505; STEIN PD, 1994, J MED CHEM, V37, P329, DOI 10.1021/jm00029a001; STRADER CD, 1989, FASEB J, V3, P1825, DOI 10.1096/fasebj.3.7.2541037; SURYANARAYANA S, 1991, J BIOL CHEM, V266, P15488; TOTA MR, 1990, J BIOL CHEM, V265, P16891; TRUMPPKALLMEYER S, 1992, J MED CHEM, V35, P3448, DOI 10.1021/jm00097a002; VONHEIJNE G, 1991, J MOL BIOL, V218, P499, DOI 10.1016/0022-2836(91)90695-3; WADSWORTH HL, 1990, SCIENCE, V249, P1423, DOI 10.1126/science.2169649; WARNER TD, 1989, EUR J PHARMACOL, V159, P325, DOI 10.1016/0014-2999(89)90167-2; WEBB ML, 1993, MOL PHARMACOL, V44, P959; WEBER H, 1994, MOL ENDOCRINOL, V8, P148, DOI 10.1210/me.8.2.148; YANAGISAWA M, 1989, TRENDS PHARMACOL SCI, V10, P374; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; YANAGISAWA M, 1988, P NATL ACAD SCI USA, V85, P6964, DOI 10.1073/pnas.85.18.6964	47	78	79	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12383	12386						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175640				2022-12-25	WOS:A1994NH71600001
J	PORRAS, A; MUSZYNSKI, K; RAPP, UR; SANTOS, E				PORRAS, A; MUSZYNSKI, K; RAPP, UR; SANTOS, E			DISSOCIATION BETWEEN ACTIVATION OF RAF-1 KINASE AND THE 42-KDA MITOGEN-ACTIVATED PROTEIN-KINASE 90-KDA-S6 KINASE (MAPK/RSK) CASCADE IN THE INSULIN/RAS PATHWAY OF ADIPOCYTIC DIFFERENTIATION OF 3T3-L1 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE; SIGNAL TRANSDUCTION; XENOPUS OOCYTES; RAS; SERINE; PHOSPHORYLATION; EXPRESSION; STIMULATION; P21RAS; RECEPTOR	Insulin treatment of untransfected 3T3 L1 cells quickly induced activation of a cytosolic 42-kDa mitogen-activated protein kinase (MAPK) and a 90-kDa S6 kinase (RSK). The activation of these cytosolic kinases was also mimicked by Res expression (in the absence of insulin) in the same cells transfected with inducible ras oncogenes. Furthermore, insulin-induced activation of MAPK and RSK could be blocked by expression of a transfected inducible dominant negative Ras mutant (Asn-17). These results indicate that Ras proteins are obligatory intermediates in the activation of the cytosolic MAPK/RSK cascade by insulin. Insulin treatment of 3T3 L1 cells or expression of transfected res oncogenes resulted also in hyperphosphorylation of cellular Raf-l. Insulin-induced Raf hyperphosphorylation was inhibited by expression of an inducible dominant negative Res mutant (Asn-17). We also showed that expression of transfected raf oncogenes induces adipocytic differentiation, as detected by expression of the specific adipocytic marker aP2. In addition, insulin-induced differentiation was significantly blocked by expression of a dominant negative raf mutant. Interestingly, however, the expression of transfected raf oncogenes did not induce MAPK or RSK activation, and the insulin-induced activation of these kinases was not blocked by expression of transfected dominant negative raf mutants. These results are consistent with Raf kinases acting downstream of Ras, but not upstream of MAPK and RSK in insulin-signaling pathways leading to 3T3 L1 differentiation.	NCI,MOLEC & CELLULAR BIOL LAB,BETHESDA,MD 20892; NCI,FREDERICK CANC RES & DEV CTR,VIRAL CARCINOGENESIS LAB,FREDERICK,MD 21701	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick			Porras, Almudena/N-2121-2015	Porras, Almudena/0000-0002-6495-3308				APP H, 1991, MOL CELL BIOL, V11, P913, DOI 10.1128/MCB.11.2.913; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BENITO M, 1991, SCIENCE, V253, P565, DOI 10.1126/science.1857988; BERNLOHR DA, 1984, P NATL ACAD SCI-BIOL, V81, P5468, DOI 10.1073/pnas.81.17.5468; BLACKSHEAR PJ, 1990, J BIOL CHEM, V265, P12131; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; CICIRELLI MF, 1988, J BIOL CHEM, V263, P2009; COOK JS, 1988, P NATL ACAD SCI USA, V85, P2949, DOI 10.1073/pnas.85.9.2949; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; CUADRADO A, 1993, ONCOGENE, V8, P2443; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DICKSON B, 1992, NATURE, V360, P600, DOI 10.1038/360600a0; DOWNWARD J, 1990, TRENDS BIOCHEM SCI, V15, P469, DOI 10.1016/0968-0004(90)90300-Z; FEIG LA, 1993, SCIENCE, V260, P767, DOI 10.1126/science.8484117; HEIDECKER G, 1992, ADV CANCER RES, V58, P53, DOI 10.1016/S0065-230X(08)60290-0; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; IZUMI T, 1991, J BIOL CHEM, V266, P7933; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KOVACINA KS, 1990, J BIOL CHEM, V265, P12115; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; MARSHALL MS, 1993, TRENDS BIOCHEM SCI, V18, P250, DOI 10.1016/0968-0004(93)90175-M; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; NEBREDA AR, 1993, ONCOGENE, V8, P467; NORI M, 1992, MOL CELL BIOL, V12, P936, DOI 10.1128/MCB.12.3.936; POMERANCE M, 1992, J BIOL CHEM, V267, P16155; PORRAS A, 1992, J BIOL CHEM, V267, P21124; PRICE DJ, 1990, P NATL ACAD SCI USA, V87, P7944, DOI 10.1073/pnas.87.20.7944; RAPP UR, 1991, ONCOGENE, V6, P495; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; ROBBINS DJ, 1992, P NATL ACAD SCI USA, V89, P6924, DOI 10.1073/pnas.89.15.6924; ROBERTS TM, 1992, NATURE, V360, P534, DOI 10.1038/360534a0; SANTOS E, 1989, FASEB J, V3, P2151, DOI 10.1096/fasebj.3.10.2666231; SATOH T, 1992, J BIOL CHEM, V267, P24149; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SMITH PJ, 1988, J BIOL CHEM, V263, P9402; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TOSCANI A, 1990, J BIOL CHEM, V265, P5722; TROPPMAIR J, 1992, ONCOGENE, V7, P1867; TSUDA L, 1993, CELL, V72, P407, DOI 10.1016/0092-8674(93)90117-9; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WILLIAMS NG, 1993, P NATL ACAD SCI USA, V90, P5772, DOI 10.1073/pnas.90.12.5772; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	59	81	81	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12741	12748						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175686				2022-12-25	WOS:A1994NH71600058
J	VIGERS, GPK; CAFFES, P; EVANS, RJ; THOMPSON, RC; EISENBERG, SP; BRANDHUBER, BJ				VIGERS, GPK; CAFFES, P; EVANS, RJ; THOMPSON, RC; EISENBERG, SP; BRANDHUBER, BJ			X-RAY STRUCTURE OF INTERLEUKIN-1 RECEPTOR ANTAGONIST AT 2.0-ANGSTROM RESOLUTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTORS; 3-DIMENSIONAL STRUCTURE; PROTEIN-STRUCTURE; CRYSTAL-STRUCTURE; REFINEMENT; INHIBITOR; SPECTROSCOPY; 1-ALPHA; BINDS; CELL	Interleukin-1 receptor antagonist (IL-1ra) is a natural competitive antagonist of IL-1. In order to further elucidate the mechanism by which IL-1ra binds without activating the IL-1 receptor, we have solved the crystal structure of IL-1ra at 2.0-Angstrom resolution. IL-1ra has the same overall beta-trefoil fold as IL-1 alpha and IL-1 beta and has a very similar hydrophobic core. However, there are a number of structural differences between the molecules, including significant differences at the open end of the beta-barrel, which has been identified in IL-1 beta as a receptor binding site.	SYNERGEN INC,BOULDER,CO 80301					Vigers, Guy/0000-0003-4451-8453				BOMSZTYK K, 1989, P NATL ACAD SCI USA, V86, P8034, DOI 10.1073/pnas.86.20.8034; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P46, DOI 10.1107/S0108767389009633; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CHIZZONITE R, 1989, P NATL ACAD SCI USA, V86, P8029, DOI 10.1073/pnas.86.20.8029; CLORE GM, 1991, BIOCHEMISTRY-US, V30, P2315, DOI 10.1021/bi00223a005; COLOTTA F, 1993, SCIENCE, V261, P472, DOI 10.1126/science.8332913; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; DINARELLO CA, 1991, IMMUNOL TODAY, V12, P404, DOI 10.1016/0167-5699(91)90142-G; DRIPPS DJ, 1991, J BIOL CHEM, V266, P10331; DRIPPS DJ, 1991, J BIOL CHEM, V266, P20311; EISENBERG SP, 1991, P NATL ACAD SCI USA, V88, P5232, DOI 10.1073/pnas.88.12.5232; EISENBERG SP, 1990, NATURE, V343, P341, DOI 10.1038/343341a0; Eisenberg Stephen P., 1993, Lymphokine and Cytokine Research, V12, P376; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; ERIKSSON AE, 1991, P NATL ACAD SCI USA, V88, P3441, DOI 10.1073/pnas.88.8.3441; EVANS R J, 1991, Journal of Cellular Biochemistry Supplement, V15, P172; FINZEL BC, 1989, J MOL BIOL, V209, P779, DOI 10.1016/0022-2836(89)90606-2; FITZGERALD PMD, 1967, J APPL CRYSTALLOGR, V23, P544; GRAVES BJ, 1990, BIOCHEMISTRY-US, V29, P2679, DOI 10.1021/bi00463a009; HABAZETTL J, 1992, NATURE, V359, P855, DOI 10.1038/359855a0; HANNUM CH, 1990, NATURE, V343, P336, DOI 10.1038/343336a0; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; JU G, 1991, P NATL ACAD SCI USA, V88, P2658, DOI 10.1073/pnas.88.7.2658; LABRIOLATOMPKINS E, 1991, P NATL ACAD SCI USA, V88, P11182, DOI 10.1073/pnas.88.24.11182; MURZIN AG, 1992, J MOL BIOL, V223, P531, DOI 10.1016/0022-2836(92)90668-A; ONESTI S, 1991, J MOL BIOL, V217, P153, DOI 10.1016/0022-2836(91)90618-G; PRIESTLE JP, 1989, P NATL ACAD SCI USA, V86, P9667, DOI 10.1073/pnas.86.24.9667; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; SATO M, 1992, J APPL CRYSTALLOGR, V25, P348, DOI 10.1107/S0021889891012955; SHAANAN B, 1992, SCIENCE, V257, P961, DOI 10.1126/science.1502561; STOCKMAN BJ, 1992, BIOCHEMISTRY-US, V31, P5237, DOI 10.1021/bi00138a001; VARLEY P, 1993, SCIENCE, V260, P1110, DOI 10.1126/science.8493553; VEERAPANDIAN B, 1992, BIOPHYS J, V62, P112, DOI 10.1016/S0006-3495(92)81796-4; ZEMKE KJ, 1991, FEBS LETT, V279, P240, DOI 10.1016/0014-5793(91)80158-Y; ZHANG JD, 1991, P NATL ACAD SCI USA, V88, P3446, DOI 10.1073/pnas.88.8.3446; ZHU X, 1991, SCIENCE, V251, P90, DOI 10.1126/science.1702556	37	66	70	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12874	12879						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175703				2022-12-25	WOS:A1994NH71600077
J	DINTZIS, SM; VELCULESCU, VE; PFEFFER, SR				DINTZIS, SM; VELCULESCU, VE; PFEFFER, SR			RECEPTOR EXTRACELLULAR DOMAINS MAY CONTAIN TRAFFICKING INFORMATION - STUDIES OF THE 300-KDA MANNOSE 6-PHOSPHATE RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; FACTOR-II RECEPTOR; EGF RECEPTOR; CYTOPLASMIC DOMAIN; LIPOPROTEIN RECEPTOR; MEDIATED ENDOCYTOSIS; KINASE-ACTIVITY; BINDING-SITE; AMINO-ACIDS; CELLS	The 300-kDa mannose 6-phosphate receptor cycles between the trans Golgi network and late endosomes, and between the plasma membrane and early endosomes, to deliver lysosomal enzymes to prelysosomes. Mannose 6-phosphate receptor trafficking requires structural determinants present in the cytoplasmic domain. However, when this domain was joined with the extracellular and transmembrane domains of the epidermal growth factor receptor, it was not sufficient to direct this chimera to late endosomes and the trans Golgi network (Dintzis, S. M., and Pfeffer, S. R. (1990) EMBO J. 9, 77-84). These findings suggested a role for extracellular and/or transmembrane domains in mannose 6-phosphate receptor trafficking. We describe here the construction and expression of chimeric receptors comprised of mannose 6-phosphate receptor extracellular and transmembrane sequences joined with cytoplasmic domain sequences derived from the human epidermal growth factor receptor or the human low density lipoprotein receptor. The chimeras were stable proteins which were efficiently endocytosed and competent to bind a mannose 6-phosphate-containing ligand. Antibody binding assays and indirect immunofluorescence showed that the chimeras containing the mannose 6-phosphate receptor extracellular domain colocalized with mannose 6-phosphate receptors in intracellular compartments, These experiments suggest that the presence of the mannose 6-phosphate receptor extracellular domain may interfere with the rapid recycling of receptors from early endosomes to the cell surface and detain receptors within endosomes.	STANFORD UNIV,SCH MED,DEPT BIOCHEM,STANFORD,CA 94305	Stanford University			Velculescu, Victor/ABF-4846-2020	Velculescu, Victor/0000-0003-1195-438X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007365] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM07365] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRETSCHER MS, 1988, EMBO J, V7, P4087, DOI 10.1002/j.1460-2075.1988.tb03302.x; BROWN MS, 1979, P NATL ACAD SCI USA, V76, P3330, DOI 10.1073/pnas.76.7.3330; CANFIELD WM, 1991, J BIOL CHEM, V266, P5682; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DAVIS CG, 1987, J BIOL CHEM, V262, P4075; DINTZIS SM, 1990, EMBO J, V9, P77, DOI 10.1002/j.1460-2075.1990.tb08082.x; DUNN KW, 1989, J CELL BIOL, V109, P3303, DOI 10.1083/jcb.109.6.3303; FELDER S, 1990, CELL, V61, P623, DOI 10.1016/0092-8674(90)90474-S; FELDER S, 1992, J CELL BIOL, V117, P203, DOI 10.1083/jcb.117.1.203; GARTUNG C, 1985, EMBO J, V4, P1725, DOI 10.1002/j.1460-2075.1985.tb03842.x; GEUZE HJ, 1983, CELL, V32, P277, DOI 10.1016/0092-8674(83)90518-4; GEUZE HJ, 1988, J CELL BIOL, V107, P2491, DOI 10.1083/jcb.107.6.2491; GEUZE HJ, 1985, J CELL BIOL, V101, P2253, DOI 10.1083/jcb.101.6.2253; GEUZE HJ, 1984, J CELL BIOL, V98, P2047, DOI 10.1083/jcb.98.6.2047; GRIFFITHS G, 1988, CELL, V52, P329, DOI 10.1016/S0092-8674(88)80026-6; GRIFFITHS G, 1989, J CELL BIOL, V109, P2703, DOI 10.1083/jcb.109.6.2703; GRUENBERG J, 1989, ANNU REV CELL BIOL, V5, P453; HARLOW E, 1988, ANTIBODIES; HHARE JF, 1990, J BIOL CHEM, V265, P21758; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; HONEGGER AM, 1990, J CELL BIOL, V110, P1541, DOI 10.1083/jcb.110.5.1541; JING SQ, 1990, J CELL BIOL, V110, P283, DOI 10.1083/jcb.110.2.283; JOHNSON KF, 1992, J CELL BIOL, V119, P249, DOI 10.1083/jcb.119.2.249; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KOVAL M, 1989, J CELL BIOL, V108, P2169, DOI 10.1083/jcb.108.6.2169; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOBEL P, 1987, P NATL ACAD SCI USA, V84, P2233, DOI 10.1073/pnas.84.8.2233; LOBEL P, 1989, CELL, V57, P787, DOI 10.1016/0092-8674(89)90793-9; LOBEL P, 1988, J BIOL CHEM, V263, P2563; LOMBARDI D, 1993, EMBO J, V12, P677, DOI 10.1002/j.1460-2075.1993.tb05701.x; MATTER K, 1993, CELL, V74, P1053, DOI 10.1016/0092-8674(93)90727-8; MAYOR S, 1993, J CELL BIOL, V121, P1257, DOI 10.1083/jcb.121.6.1257; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; PFEFFER SR, 1987, J CELL BIOL, V105, P229, DOI 10.1083/jcb.105.1.229; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; SAHAGIAN GG, 1984, BIOL CELL, V51, P207, DOI 10.1111/j.1768-322X.1984.tb00300.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; VANDENHOFF MJB, 1992, NUCLEIC ACIDS RES, V20, P2902, DOI 10.1093/nar/20.11.2902; YAMAMOTO T, 1984, CELL, V39, P27, DOI 10.1016/0092-8674(84)90188-0; YAMASHIRO DJ, 1987, J CELL BIOL, V105, P2723, DOI 10.1083/jcb.105.6.2723; YAMASHIRO DJ, 1984, CELL, V37, P789, DOI 10.1016/0092-8674(84)90414-8	43	45	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					12159	12166						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163521				2022-12-25	WOS:A1994NG37700074
J	PRINS, BA; HU, RM; NAZARIO, B; PEDRAM, A; FRANK, HJL; WEBER, MA; LEVIN, ER				PRINS, BA; HU, RM; NAZARIO, B; PEDRAM, A; FRANK, HJL; WEBER, MA; LEVIN, ER			PROSTAGLANDIN E(2) AND PROSTACYCLIN INHIBIT THE PRODUCTION AND SECRETION OF ENDOTHELIN FROM CULTURED ENDOTHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; NITRIC-OXIDE; VASCULAR ENDOTHELIUM; GENE-EXPRESSION; CYCLIC-GMP; RAT; PROLIFERATION; RELEASE; STIMULATION; RECEPTOR	Endothelin-1 (ET-1) is the most potent endogenous vasoconstrictor yet identified. This peptide plays an important role in the regulation of arterial tone, in part through its interaction with endogenous vasodilator compounds. To understand the interactions of endothelin with the vasoactive prostaglandins (PGs), we determined the effects of prostaglandin E(2) (PGE(2)), prostacyclin (PGI(2)), and thromboxane A(2) on ET-1 synthesis and secretion from cultured bovine aortic endothelial cells and on ET-1 action in aortic smooth muscle cells. Both PGE(2) and PGI(2) (vasodilator prostaglandins) caused an similar to 40% inhibition of basal ET-1 secretion and a 50% inhibition of serum-stimulated ET-1 secretion in a dose-related and time course fashion. In contrast, the vasoconstrictor prostaglandin, thromboxane A(2), had no effect on ET-1 secretion. PGE(2) and PGI(2) similarly inhibited the basal production of new ET-1 protein (translation) by 40-50% and inhibited the basal steady-state mRNA expression of ET-1 in bovine aortic endothelial cells by 60-70%. Both prostaglandins also caused an similar to 55% inhibition of ET-1 transcription, as shown by chloramphenicol acetyltransferase reporter studies. PGE(2) and PGI(2) strongly stimulated cGMP generation; both the PG stimulation of cGMP and the inhibition of ET-1 secretion and translation were reversed by LY83583, a general inhibitor of cGMP generation. The PG-induced inhibition of ET-1 Secretion and translation was also reversed by KT5823, an inhibitor of cGMP-dependent protein kinase, but not by (R(p))-adenosine cyclic 3':5'-monophosphate, an inhibitor of protein kinase A activation. PGE(2) and PGI(2) also inhibited both basal and ET-1-stimulated DNA synthesis in aortic smooth muscle cells by similar to 45% through a cGMP-dependent mechanism. Therefore, two endogenous PGs, known to be important vasodilators in vivo, significantly inhibit the transcription, translation, secretion, and action of ET-1. We propose that the vasodilator action of the PGs results, in part, from their ability to inhibit the production of this potent vasoconstrictor.	LONG BEACH VET HOSP,MED SERV 111I,LONG BEACH,CA 90822; UNIV CALIF IRVINE,DEPT MED,IRVINE,CA 92717; UNIV CALIF IRVINE,DEPT PHARMACOL,IRVINE,CA 92717	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Long Beach Healthcare System; University of California System; University of California Irvine; University of California System; University of California Irvine			Levin, Ellis/J-5402-2013		NHLBI NIH HHS [1RO1HL50161] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050161] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERTI F, 1990, PROSTAGLANDINS, V40, P337, DOI 10.1016/0090-6980(90)90099-H; BOULANGER C, 1990, J CLIN INVEST, V85, P587, DOI 10.1172/JCI114477; CHOU SY, 1990, AM J PHYSIOL, V259, pF645, DOI 10.1152/ajprenal.1990.259.4.F645; DORN GW, 1992, J BIOL CHEM, V267, P24897; FILEP JG, 1991, BIOCHEM BIOPH RES CO, V177, P171, DOI 10.1016/0006-291X(91)91964-E; GELFAND R, 1991, AM J PHYSIOL, V261, pR453; GLASS DB, 1977, J CYCLIC NUCL PROT, V3, P37; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HIRATA Y, 1989, ATHEROSCLEROSIS, V78, P225, DOI 10.1016/0021-9150(89)90227-X; HU RM, 1993, DIABETES, V42, P351, DOI 10.2337/diabetes.42.2.351; HU RM, 1992, J BIOL CHEM, V267, P17384; KASE H, 1987, BIOCHEM BIOPH RES CO, V142, P436, DOI 10.1016/0006-291X(87)90293-2; KOMURO I, 1988, FEBS LETT, V238, P249, DOI 10.1016/0014-5793(88)80489-7; LEE ME, 1990, J BIOL CHEM, V265, P10446; LEVIN ER, 1992, J NEUROCHEM, V58, P659, DOI 10.1111/j.1471-4159.1992.tb09768.x; LUSCHER TF, 1993, J HYPERTENS, V11, P7; MIURA K, 1991, J PHARMACOL EXP THER, V256, P11; MIURA K, 1989, EUR J PHARMACOL, V170, P91, DOI 10.1016/0014-2999(89)90139-8; NEUSER D, 1990, ARTERY, V17, P311; NOLAND TD, 1992, AM J PHYSIOL, V263, pC1208, DOI 10.1152/ajpcell.1992.263.6.C1208; NOVERAL JP, 1992, AM J PHYSIOL, V263, pL317, DOI 10.1152/ajplung.1992.263.3.L317; ODONNELL ME, 1986, J BIOL CHEM, V261, P5461; OLIVER FJ, 1991, J BIOL CHEM, V266, P23251; RADOMSKI MW, 1987, BIOCHEM BIOPH RES CO, V148, P1482, DOI 10.1016/S0006-291X(87)80299-1; RAE GA, 1989, J CARDIOVASC PHARM, V13, pS89, DOI 10.1097/00005344-198900135-00022; REYNOLDS EE, 1990, J PHARMACOL EXP THER, V252, P915; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P718; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SCHMIDT MJ, 1985, J PHARMACOL EXP THER, V232, P764; SHUBEITA HE, 1990, J BIOL CHEM, V265, P20555; SIMONSON MS, 1993, PHYSIOL REV, V73, P375, DOI 10.1152/physrev.1993.73.2.375; SINZINGER H, 1987, PROSTAGLANDINS, V33, P915, DOI 10.1016/0090-6980(87)90118-3; SMITH DL, 1984, PROSTA LEUKOTR MED, V16, P1, DOI 10.1016/0262-1746(84)90080-5; THIEMERMANN C, 1989, J CARDIOVASC PHARM, V13, pS138, DOI 10.1097/00005344-198900135-00034; VANE JR, 1990, NEW ENGL J MED, V323, P27; WANG YX, 1992, HYPERTENSION, V19, P255, DOI 10.1161/01.HYP.19.2_Suppl.II255; WARNER TD, 1989, J CARDIOVASC PHARM, V13, pS85, DOI 10.1097/00005344-198900135-00021; WARNER TD, 1992, AM J PHYSIOL, V262, pH1600, DOI 10.1152/ajpheart.1992.262.5.H1600; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; ZIV I, 1992, STROKE, V23, P1014, DOI 10.1161/01.STR.23.7.1014	40	142	148	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					11938	11944						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163494				2022-12-25	WOS:A1994NG37700042
J	ZARAINHERZBERG, A; MARQUES, J; SUKOVICH, D				ZARAINHERZBERG, A; MARQUES, J; SUKOVICH, D			THYROID-HORMONE RECEPTOR MODULATES THE EXPRESSION OF THE RABBIT CARDIAC SARCO(ENDO)PLASMIC RETICULUM CA2+-ATPASE GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM; MESSENGER-RNA; CA-2+-ATPASE GENE; RESPONSE ELEMENT; CHLORAMPHENICOL ACETYLTRANSFERASE; MOLECULAR-CLONING; SKELETAL-MUSCLE; CA-2+ ATPASE; GROWTH; ACID	We have analyzed the effect of thyroid hormone (T3) on SERCA2 gene expression using fetal chicken primary cardiac myocytes and C2C12 skeletal muscle cells in culture. Northern blot analysis of both cell types demonstrated that T3 induced a 3-fold accumulation of SERCA2 mRNA compared with cells grown in medium lacking T3. We have engineered deletion constructs containing various lengths of the 5'-flanking region from the rabbit SERCA2 gene which we have cloned previously (Zarain-Herzberg, A., MacLennan, D. H., and Periasamy, M. (1990) J. Biol. Chem. 265, 4670-4677). A stable transfectant in C2C12 containing a chimeric SERCA2/CAT gene construct including -254 base pairs (bp) of SERCA2 5'-flanking region showed increased transcription activity upon the addition of 50 nm T3. We have analyzed the expression of several deletion constructs spanning 1,102 bp of the 5'-upstream sequence of the SERCA2 gene by functional expression assays. Transient coexpression of the T3 receptor alpha1 with various SERCA2/CAT deletion constructs showed trans-activation of chimeric constructs containing more than -267 bp, indicating that a thyroid hormone-responsive element was localized, at least in part, to the region -267 to -72 bp. T3 receptor-DNA binding assays demonstrated binding of the rat T3 receptor al to a fragment containing a proposed T3 response element located between position -254 and -72 in the 5'-flanking region of the SERCA2 gene.	DUPONT MERCK PHARMACEUT CO, CARDIOVASC SCI, EXPTL STN, WILMINGTON, DE 19880 USA	DuPont	ZARAINHERZBERG, A (corresponding author), UNIV MANITOBA, ST BONIFACE GEN HOSP,RES CTR,DEPT PHYSIOL, DIV CARDIOVASC SCI, 351 TACHE AVE, WINNIPEG R2H 2A6, MB, CANADA.			Periasamy, Muthu/0000-0001-8834-5975	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL028001] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL28001] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALPERT NR, 1987, PATHOPHYSIOLOGY HEAR, P99; ARAI M, 1991, CIRC RES, V69, P266, DOI 10.1161/01.RES.69.2.266; ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; BEATO M, 1991, FASEB J, V5, P2044, DOI 10.1096/fasebj.5.7.2010057; BLAU HM, 1983, CELL, V32, P1171, DOI 10.1016/0092-8674(83)90300-8; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; BRANDL CJ, 1987, J BIOL CHEM, V262, P3768; BRENT GA, 1991, ANNU REV PHYSIOL, V53, P17, DOI 10.1146/annurev.ph.53.030191.000313; BRENT GA, 1989, MOL ENDOCRINOL, V3, P1996, DOI 10.1210/mend-3-12-1996; BURK SE, 1989, J BIOL CHEM, V264, P18561; CASANOVA J, 1985, J BIOL CHEM, V260, P1744; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK WA, 1976, DEV BIOL, V52, P263, DOI 10.1016/0012-1606(76)90245-1; DESVERGNE B, 1991, J BIOL CHEM, V266, P1008; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FLORINI JR, 1987, MUSCLE NERVE, V10, P577, DOI 10.1002/mus.880100702; GLASS CK, 1987, NATURE, V329, P738, DOI 10.1038/329738a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; IZUMO S, 1988, NATURE, V334, P539, DOI 10.1038/334539a0; KOENIG RJ, 1987, P NATL ACAD SCI USA, V84, P5670, DOI 10.1073/pnas.84.16.5670; KOHTZ DS, 1989, J CELL BIOL, V108, P1067, DOI 10.1083/jcb.108.3.1067; KORCZAK B, 1988, J BIOL CHEM, V263, P4813; LAVIN TN, 1988, J BIOL CHEM, V263, P9418; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; LYTTON J, 1988, J BIOL CHEM, V263, P15024; LYTTON J, 1989, J BIOL CHEM, V264, P7059; LYTTON J, 1991, HEART CARDIOVASCULAR, V2, P1203; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MAHDAVI V, 1984, P NATL ACAD SCI-BIOL, V81, P2626, DOI 10.1073/pnas.81.9.2626; NAGAI R, 1989, P NATL ACAD SCI USA, V86, P2966, DOI 10.1073/pnas.86.8.2966; NORDEEN SK, 1987, DNA-J MOLEC CELL BIO, V6, P173, DOI 10.1089/dna.1987.6.173; PETTY KJ, 1990, J BIOL CHEM, V265, P7395; ROHRER D, 1988, J BIOL CHEM, V263, P6941; ROHRER DK, 1991, J BIOL CHEM, V266, P8638; ROSE JK, 1991, BIOTECHNIQUES, V10, P520; Sambrook J, 1989, MOL CLONING LABORATO; SAMUELS HH, 1979, ENDOCRINOLOGY, V105, P80, DOI 10.1210/endo-105-1-80; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAYEN MR, 1992, MOL CELL ENDOCRINOL, V87, P87, DOI 10.1016/0303-7207(92)90236-Y; WEST BL, 1987, MOL CELL BIOL, V7, P1193, DOI 10.1128/MCB.7.3.1193; ZARAINHERZBERG A, 1990, J BIOL CHEM, V265, P4670; ZILZ ND, 1990, J BIOL CHEM, V265, P8136	42	52	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1460	1467						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8166809				2022-12-25	WOS:A1994MR22000105
J	HOMMA, K; KURATA, S; NATORI, S				HOMMA, K; KURATA, S; NATORI, S			PURIFICATION, CHARACTERIZATION, AND CDNA CLONING OF PROCATHEPSIN-L FROM THE CULTURE-MEDIUM OF NIH-SAPE-4, AN EMBRYONIC-CELL LINE OF SARCOPHAGA-PEREGRINA (FLESH FLY), AND ITS INVOLVEMENT IN THE DIFFERENTIATION OF IMAGINAL DISKS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNOSE 6-PHOSPHATE RECEPTOR; LYSOSOMAL-ENZYMES; GROWTH-FACTOR; MURINE FIBROBLASTS; MOLECULAR-CLONING; CATHEPSIN-L; PROTEIN; TRANSFORMATION; SEQUENCE; SECRETION	A cysteine proteinase that preferentially hydrolyzes carbobenzyloxy-Phe-Arg-RICA (MCA, methylcoumaryl-7-amide) was purified from the culture medium of NIH-Sape-4 cells. The molecular mass of this enzyme was easily changed from 50 to 35 kDa, without appreciable loss of enzyme activity. From the analysis of its cDNA, this enzyme was concluded to be a procathepsin L of Sarcophaga. Only procathepsin L was found in the medium, while the mature 35-kDa cathepsin L was found exclusively in the cells, indicating that the cells have a mechanism to secrete procathepsin L selectively. An antibody against procathepsin L was found to inhibit the differentiation of imaginal discs cultured in vitro in the presence of 20-hydroxyecdysone. In fact imaginal discs were shown to secrete procathepsin L into the culture medium. These results suggest that procathepsin L is an essential proteinase for differentiation of imaginal discs. Northern blotting analysis revealed that unfertilized eggs contain a significant amount of mRNA for the procathepsin L as a maternal mRNA.	UNIV TOKYO,FAC PHARMACEUT SCI,BUNKYO KU,TOKYO 113,JAPAN	University of Tokyo								APPEL LF, 1993, P NATL ACAD SCI USA, V90, P4937, DOI 10.1073/pnas.90.11.4937; Barrett A. J., 1977, PROTEINASES MAMMALIA, P181; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; BROWN WJ, 1984, CELL, V36, P295, DOI 10.1016/0092-8674(84)90223-X; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CHIANG CP, 1986, J BIOL CHEM, V261, P478; DOHERTY PJ, 1985, MOL CELL BIOL, V5, P466, DOI 10.1128/MCB.5.3.466; DONG JM, 1989, J BIOL CHEM, V264, P7377; DONG JM, 1990, J BIOL CHEM, V265, P4210; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; FEKETE E, 1975, W ROUXS ARCH DEV BIO, V173, P123; FESSLER LI, 1993, DEVELOPMENT, V117, P1061; FRICK KK, 1985, MOL CELL BIOL, V5, P2582, DOI 10.1128/MCB.5.10.2582; GAL S, 1985, J CELL BIOL, V100, P535, DOI 10.1083/jcb.100.2.535; GAL S, 1988, BIOCHEM J, V253, P303, DOI 10.1042/bj2530303; GOTTESMAN MM, 1978, P NATL ACAD SCI USA, V75, P2767, DOI 10.1073/pnas.75.6.2767; HANADA K, 1978, AGR BIOL CHEM TOKYO, V42, P523, DOI 10.1080/00021369.1978.10863014; HANAHAN D, 1980, GENE, V10, P63, DOI 10.1016/0378-1119(80)90144-4; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; ISHIDOH K, 1987, FEBS LETT, V223, P69, DOI 10.1016/0014-5793(87)80511-2; KAWAGUCHI N, 1991, DEV BIOL, V144, P86, DOI 10.1016/0012-1606(91)90481-H; KOMANO H, 1987, BIOCHEM J, V248, P217, DOI 10.1042/bj2480217; KOMANO H, 1980, J BIOL CHEM, V255, P2919; KORNFELD S, 1987, FASEB J, V1, P462, DOI 10.1096/fasebj.1.6.3315809; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAYCOCK MV, 1991, FEBS LETT, V292, P115, DOI 10.1016/0014-5793(91)80847-V; LAZZARINO D, 1990, J BIOL CHEM, V265, P11864; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCCAULEY R, 1973, MOL CELL BIOCHEM, V1, P73, DOI 10.1007/BF01659940; MITSUHAS.J, 1964, CONTRIB BOYCE THOMPS, V22, P435; MORITA T, 1977, J BIOCHEM-TOKYO, V82, P1495, DOI 10.1093/oxfordjournals.jbchem.a131840; OKAYAMA H, 1982, MOL CELL BIOL, V2, P161, DOI 10.1128/MCB.2.2.161; PINOHEISS S, 1989, DEV BIOL, V132, P282, DOI 10.1016/0012-1606(89)90225-X; POODRY CA, 1971, ROUX ARCH DEV BIOL, V168, P1, DOI 10.1007/BF00582000; SAHAGIAN GG, 1982, J BIOL CHEM, V257, P1145; SAKSELA O, 1988, ANNU REV CELL BIOL, V4, P93, DOI 10.1146/annurev.cb.04.110188.000521; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAWADA H, 1983, EXPERIENTIA, V39, P377, DOI 10.1007/BF01963132; SCHER CD, 1983, MOL CELL BIOL, V3, P70, DOI 10.1128/MCB.3.1.70; SGARAMELLA V, 1972, J MOL BIOL, V72, P427, DOI 10.1016/0022-2836(72)90155-6; TROEN BR, 1987, BIOCHEM J, V246, P731, DOI 10.1042/bj2460731; UMEZAWA H, 1970, J ANTIBIOT, V23, P259, DOI 10.7164/antibiotics.23.259; VONFIGURA K, 1986, ANNU REV BIOCHEM, V55, P167, DOI 10.1146/annurev.biochem.55.1.167	44	77	81	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					15258	15264						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195162				2022-12-25	WOS:A1994NP73800061
J	OVERVOORDE, PJ; GRIMES, HD				OVERVOORDE, PJ; GRIMES, HD			TOPOGRAPHICAL ANALYSIS OF THE PLASMA MEMBRANE-ASSOCIATED SUCROSE BINDING-PROTEIN FROM SOYBEAN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHASE-SEPARATION; TRITON X-114; HETEROLOGOUS EXPRESSION; SUGAR-TRANSPORT; COTTON FIBER; IDENTIFICATION; PROTOPLASTS; SPINACH; YEAST; CELLS	Plasma membranes of soybean cells actively engaged in sucrose transport have a sucrose binding protein (SBP) that does not appear to be an integral membrane protein. Experiments were undertaken to analyze the topographical association of this protein with the membrane. Treatment of purified plasma membrane vesicles with either 1 M KCl or KI released less than 35% of the sucrose binding protein from the membrane whereas treatment with either 4 M urea or 0.1 M Na2CO3, pH 11.5, disassociated between 50 and 70%, respectively, of this protein from the membrane. SDS, at either 0.5x, 1x, or 10x of its critical micelle concentration, effectively solubilized the sucrose binding protein. The nonionic detergents Triton X-100 and CHAPS, at either 0.5x, 1x, or 10x of their critical micelle concentration, solubilized between 65 and 75% of this protein. When either native plasma membrane-associated or in vitro-transcribed and -translated SBP were subjected to Triton X-114 phase separation, 80% partitioned into the detergent-poor aqueous phase. These results indicate that the SBP is a peripheral membrane protein but also suggest that there is a population of this protein that is tethered to the membrane.	WASHINGTON STATE UNIV,DEPT BOT,PULLMAN,WA 99164	Washington State University			Grimes, Howard D/C-6490-2017	Grimes, Howard D/0000-0002-8956-8609				ALCARAZ G, 1984, J BIOL CHEM, V259, P4922; BLATT MR, 1993, ANNU REV PLANT PHYS, V44, P543, DOI 10.1146/annurev.pp.44.060193.002551; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BUSH DR, 1993, ANNU REV PLANT PHYS, V44, P513, DOI 10.1146/annurev.pp.44.060193.002501; DELMER DP, 1991, PLANT PHYSIOL, V95, P556, DOI 10.1104/pp.95.2.556; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2602; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GALLAGHER SR, 1982, PLANT PHYSIOL, V70, P1335, DOI 10.1104/pp.70.5.1335; GIAQUINTA RT, 1983, ANNU REV PLANT PHYS, V34, P347, DOI 10.1146/annurev.pp.34.060183.002023; GRIMES HD, 1992, PLANT CELL, V4, P1561, DOI 10.1105/tpc.4.12.1561; GRIMES HD, 1988, PLANT PHYSIOL, V88, P444, DOI 10.1104/pp.88.2.444; GRIMES HD, 1991, J PLANT PHYSIOL, V139, P45, DOI 10.1016/S0176-1617(11)80163-X; GRIMES HD, 1986, BIOCHIM BIOPHYS ACTA, V862, P165, DOI 10.1016/0005-2736(86)90480-3; Hatefi Y, 1974, Methods Enzymol, V31, P770; HITZ WD, 1985, PLANT PHYSIOL, V77, P291, DOI 10.1104/pp.77.2.291; Hodges T K, 1974, Methods Enzymol, V32, P392; HOOGEVEEN JT, 1970, J MEMBRANE BIOL, V3, P156, DOI 10.1007/BF01868013; KJELLBOM P, 1984, PHYSIOL PLANTARUM, V62, P501, DOI 10.1111/j.1399-3054.1984.tb02791.x; KJELLBOM P, 1989, PLANT PHYSIOL BIOCH, V27, P169; KUMAR BV, 1985, BIOCHEM BIOPH RES CO, V131, P883, DOI 10.1016/0006-291X(85)91322-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSSON C, 1984, FEBS LETT, V171, P271, DOI 10.1016/0014-5793(84)80502-5; LI LK, 1993, PLANT PHYSIOL, V101, P1149, DOI 10.1104/pp.101.4.1149; LI LK, 1993, PLANT PHYSIOL, V101, P1143, DOI 10.1104/pp.101.4.1143; MAIDEN MCJ, 1987, NATURE, V325, P641, DOI 10.1038/325641a0; OKUDA K, 1993, PLANT PHYSIOL, V101, P1131, DOI 10.1104/pp.101.4.1131; PATE JS, 1972, ANN REV PLANT PHYSIO, V23, P173, DOI 10.1146/annurev.pp.23.060172.001133; PRYDE JG, 1986, BIOCHEM J, V233, P525, DOI 10.1042/bj2330525; RABILLOUD T, 1988, ELECTROPHORESIS, V9, P288, DOI 10.1002/elps.1150090608; RIESMEIER JW, 1992, EMBO J, V11, P4705, DOI 10.1002/j.1460-2075.1992.tb05575.x; RIPP KG, 1988, PLANT PHYSIOL, V88, P1435, DOI 10.1104/pp.88.4.1435; RUCK A, 1993, PLANT J, V4, P41, DOI 10.1046/j.1365-313X.1993.04010041.x; SANDELIUS AS, 1986, PLANT SCI, V48, P1; SANDSTROM RP, 1987, PLANT PHYSIOL, V85, P693, DOI 10.1104/pp.85.3.693; SAUER N, 1993, PLANT J, V4, P601, DOI 10.1046/j.1365-313X.1993.04040601.x; SAUER N, 1990, EMBO J, V9, P3045, DOI 10.1002/j.1460-2075.1990.tb07500.x; SCHMITT MR, 1984, PLANT PHYSIOL, V75, P941, DOI 10.1104/pp.75.4.941; SINGER SJ, 1972, SCIENCE, V175, P720, DOI 10.1126/science.175.4023.720; STECK T L, 1973, Journal of Supramolecular Structure, V1, P220, DOI 10.1002/jss.400010307; TANNER MJA, 1971, BIOCHEM J, V125, P1109, DOI 10.1042/bj1251109; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VONSCHAEWEN A, 1990, EMBO J, V9, P3033, DOI 10.1002/j.1460-2075.1990.tb07499.x	42	25	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					15154	15161						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195152				2022-12-25	WOS:A1994NP73800047
J	SCHWARZ, MA; LAZO, JS; YALOWICH, JC; REYNOLDS, I; KAGAN, VE; TYURIN, V; KIM, YM; WATKINS, SC; PITT, BR				SCHWARZ, MA; LAZO, JS; YALOWICH, JC; REYNOLDS, I; KAGAN, VE; TYURIN, V; KIM, YM; WATKINS, SC; PITT, BR			CYTOPLASMIC METALLOTHIONEIN OVEREXPRESSION PROTECTS NIH 3T3 CELLS FROM TERT-BUTYL HYDROPEROXIDE TOXICITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED-MAMMALIAN-CELLS; SINGLE-STRAND BREAKS; OXIDATIVE STRESS; GLUTATHIONE DEPLETION; RAT HEPATOCYTES; FREE-RADICALS; DNA; CADMIUM; SUPEROXIDE; INHIBITION	Metallothioneins (MT) are ubiquitous low molecular weight metal-binding proteins that may act as antioxidants. We examined the sensitivity of NIH 3T3 cells transfected with a plasmid containing mouse metallothionein-I gene (NIH3T3/MT) to the membrane permeant oxidant, tert-butyl hydroperoxide (tBH). NIH3T3/MT cells had a 4-fold increase in intracellular metallothionein as compared to cells transfected with a plasmid containing an inverted gene (NIH3T3/TM). Newly expressed metallothionein appeared to be localized to the cytoplasm as determined by immunofluorescence and confocal microscopy. NIH3T3/MT cells were 6 times more resistant than NIH3T3/TM cells to the cytotoxic effects of tBH. The antioxidant activity of NIH3T3/MT cells was greater than NIH3T3/TM cells, since exposure to tBH resulted in significantly less: (a) thiobarbituric acid-reactive substances and (b) fluorescence after loading cells with the oxidant-sensitive dye, 2'7'-dichlorodihydrofluorescein diacetate. Furthermore, homogenates of NIH3T3/MT cells were more capable of scavenging in vitro generated phenoxyl radicals as quantified by electron spin resonance detection. In contrast, overexpression of cytoplasmic MT did not protect against tBH-induced DNA damage, suggesting that subcellular location of MT is important for its function and that DNA damage is not a key determinant of cytotoxicity. These data provide direct support for an antioxidant role for MT, since physiologically relevant elevations in cytoplasmic MT interfere with tBH-induced cytotoxic peroxidation.	UNIV PITTSBURGH,SCH MED,DEPT ANESTHESIOL & CRIT CARE MED,PITTSBURGH,PA 15261; UNIV PITTSBURGH,SCH MED,DEPT ENVIRONM & OCCUPAT HLTH,PITTSBURGH,PA 15261; UNIV PITTSBURGH,SCH MED,DEPT SURG,PITTSBURGH,PA 15261; UNIV PITTSBURGH,SCH MED,DEPT CELL BIOL & PHYSIOL,PITTSBURGH,PA 15261	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	SCHWARZ, MA (corresponding author), UNIV PITTSBURGH,SCH MED,DEPT PHARMACOL,PITTSBURGH,PA 15261, USA.		Watkins, Simon/ABG-2590-2021	Watkins, Simon/0000-0003-4092-1552; Yalowich, Jack/0000-0001-5414-573X; Reynolds, Ian/0000-0003-3028-5070; Tyurin, Vladimir/0000-0002-3474-1697	NATIONAL CANCER INSTITUTE [R01CA061299] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032154] Funding Source: NIH RePORTER; NCI NIH HHS [CA 61299] Funding Source: Medline; NHLBI NIH HHS [HL32154] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABEL J, 1989, TOXICOL LETT, V47, P191, DOI 10.1016/0378-4274(89)90075-1; BAKKA A, 1982, EXPERIENTIA, V38, P381, DOI 10.1007/BF01949406; BASS DA, 1983, J IMMUNOL, V130, P1910; BAUMAN JW, 1991, TOXICOL APPL PHARM, V110, P347, DOI 10.1016/S0041-008X(05)80017-1; BEUGE JA, 1978, METHOD ENZYMOL, V52, P302; CHUBATSU LS, 1992, CHEM-BIOL INTERACT, V82, P99, DOI 10.1016/0009-2797(92)90017-F; CHUBATSU LS, 1993, BIOCHEM J, V291, P193, DOI 10.1042/bj2910193; COLEMAN JB, 1989, MOL PHARMACOL, V36, P193; COPPEN DE, 1988, P SOC EXP BIOL MED, V189, P100; EATON DL, 1982, TOXICOL APPL PHARM, V66, P134, DOI 10.1016/0041-008X(82)90068-0; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FORNACE AJ, 1988, MOL CELL BIOL, V88, P4716; GUTTERIDGE JMC, 1982, INT J BIOCHEM, V14, P649, DOI 10.1016/0020-711X(82)90050-7; HAMER DH, 1986, ANNU REV BIOCHEM, V55, P913, DOI 10.1146/annurev.biochem.55.1.913; HART BA, 1990, TOXICOL APPL PHARM, V103, P255, DOI 10.1016/0041-008X(90)90228-M; KAINA B, 1990, P NATL ACAD SCI USA, V87, P2710, DOI 10.1073/pnas.87.7.2710; KARIN M, 1985, CELL, V41, P9, DOI 10.1016/0092-8674(85)90051-0; KOHN KW, 1976, BIOCHEMISTRY-US, V15, P4629, DOI 10.1021/bi00666a013; KUO SM, 1994, TOXICOL APPL PHARM, V125, P104, DOI 10.1006/taap.1994.1054; MASAKI N, 1989, ARCH BIOCHEM BIOPHYS, V269, P390, DOI 10.1016/0003-9861(89)90122-7; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; MELLOFILHO AC, 1988, BIOCHEM J, V266, P475; MORTON KA, 1992, J BIOL CHEM, V267, P2880; Mossmann T., 1983, J IMMUNOL METHODS, V65, P55; MULLER T, 1991, ARCH TOXICOL, V65, P20; OCHI T, 1989, CHEM-BIOL INTERACT, V72, P335, DOI 10.1016/0009-2797(89)90008-2; OCHI T, 1988, TOXICOLOGY, V50, P257, DOI 10.1016/0300-483X(88)90043-1; SATO M, 1993, FREE RADICAL BIO MED, V14, P325, DOI 10.1016/0891-5849(93)90029-T; SCHROEDER JJ, 1990, P NATL ACAD SCI USA, V87, P3137, DOI 10.1073/pnas.87.8.3137; SHOEMAKER RH, 1985, CANCER RES, V45, P2145; STOYANOVSKY D, 1993, FREE RADICAL RES COM, V19, P371, DOI 10.3109/10715769309056527; TAMAI KT, 1993, P NATL ACAD SCI USA, V90, P8013, DOI 10.1073/pnas.90.17.8013; THOMAS JP, 1986, BIOCHIM BIOPHYS ACTA, V884, P448, DOI 10.1016/0304-4165(86)90195-9; THORNALLEY PJ, 1985, BIOCHIM BIOPHYS ACTA, V827, P36, DOI 10.1016/0167-4838(85)90098-6; TSUJIKAWA K, 1991, FEBS LETT, V283, P239, DOI 10.1016/0014-5793(91)80597-V; Zar JH., 1999, BIOSTAT ANAL	36	165	166	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					15238	15243						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195159				2022-12-25	WOS:A1994NP73800058
J	WEMMIE, A; WU, AL; HARSHMAN, KD; PARKER, CS; MOYEROWLEY, WS				WEMMIE, A; WU, AL; HARSHMAN, KD; PARKER, CS; MOYEROWLEY, WS			TRANSCRIPTIONAL ACTIVATION MEDIATED BY THE YEAST AP-1 PROTEIN IS REQUIRED FOR NORMAL CADMIUM TOLERANCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID CONTROL; SACCHAROMYCES-CEREVISIAE; DRUG-RESISTANCE; YAP1 ENCODES; DNA; BINDING; GENE; JUN; GCN4; FOS	The yeast YAP1 gene encodes a transcriptional regulatory protein that utilizes a basic region-leucine zipper (bZip) DNA-binding domain to recognize its cognate DNA element. A synthetic reporter gene containing a SV40 AP-1 response element (ARE) cloned upstream of a TRP5 promoter-lacZ gene fusion shows yAP-1-dependent transactivation in vivo. Recent work has shown that changes in the gene dosage of this factor can dramatically alter the ability of a cell to tolerate a host of toxic agents including cadmium, cycloheximide, and sulfometuron methyl. We have focused on the YAP1-dependent cadmium resistance as cells that lack a functional YAP1 gene are hypersensitive to this metal. Deletion mapping experiments define two domains in the carboxyl-terminal region of the yAP-1 protein that are required for normal cadmium tolerance and ARE-TRP5-lacZ expression. Single amino acid substitutions in the bZip domain of yAP-1 indicate that this region is required for normal DNA binding and in vivo function of the protein. Replacement of a non-canonical asparagine with leucine in the yAP-1 leucine zipper leads to production of a defective protein. A substitution mutation in the basic domain converts this mutant protein into a dominant negative factor. The ability of yAP-1 to act as a positive regulator of transcription is required for its biological action.	UNIV IOWA,PROGRAM MOLEC BIOL,IOWA CITY,IA 52242; UNIV IOWA,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242; CALTECH,DIV CHEM,PASADENA,CA 91125	University of Iowa; University of Iowa; California Institute of Technology			Moye-Rowley, Scott/AFL-7135-2022	Moye-Rowley, Scott/0000-0002-7163-1120; Wemmie, John/0000-0001-7531-9065	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049825] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM49825] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGRE P, 1989, SCIENCE, V246, P922, DOI 10.1126/science.2530632; BALZI E, 1991, BIOCHIM BIOPHYS ACTA, V1073, P241, DOI 10.1016/0304-4165(91)90128-4; BOSSIER P, 1993, J BIOL CHEM, V268, P23640; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; CURRAN T, 1988, COLD SPRING HARB SYM, V53, P769, DOI 10.1101/SQB.1988.053.01.087; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; HARLOW E, 1988, ANTIBODIES LABORATOR; HARSHMAN KD, 1988, CELL, V53, P321, DOI 10.1016/0092-8674(88)90393-5; HERTLE K, 1991, CURR GENET, V19, P429, DOI 10.1007/BF00312733; HILL DE, 1986, SCIENCE, V234, P451, DOI 10.1126/science.3532321; HINNEBUSCH AG, 1984, P NATL ACAD SCI-BIOL, V81, P6442, DOI 10.1073/pnas.81.20.6442; HINNEBUSCH AG, 1983, P NATL ACAD SCI-BIOL, V80, P5374, DOI 10.1073/pnas.80.17.5374; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JANUSKA AP, 1988, GENETIKA+, V24, P773; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; LEPPERT G, 1990, GENETICS, V125, P13; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MOYEROWLEY WS, 1989, GENE DEV, V3, P283, DOI 10.1101/gad.3.3.283; MOYEROWLEY WS, 1988, COLD SPRING HARB SYM, V53, P711, DOI 10.1101/SQB.1988.053.01.081; NEHLIN JO, 1992, NUCLEIC ACIDS RES, V20, P5271, DOI 10.1093/nar/20.20.5271; RANSONE LJ, 1989, GENE DEV, V3, P770, DOI 10.1101/gad.3.6.770; RANSONE LJ, 1990, ANNU REV CELL BIOL, V6, P539, DOI 10.1146/annurev.cellbio.6.1.539; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; SCHNELL N, 1991, EUR J BIOCHEM, V200, P487, DOI 10.1111/j.1432-1033.1991.tb16209.x; SHATZMAN AR, 1987, METHOD ENZYMOL, V152, P661; Sherman F, 1979, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; SMEAL T, 1989, GENE DEV, V3, P2091, DOI 10.1101/gad.3.12b.2091; THIREOS G, 1984, P NATL ACAD SCI-BIOL, V81, P5096, DOI 10.1073/pnas.81.16.5096; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; VINCENT AC, 1992, MOL CELL BIOL, V12, P5394, DOI 10.1128/MCB.12.12.5394; WIEDERRECHT G, 1987, CELL, V48, P507, DOI 10.1016/0092-8674(87)90201-7; WU AL, 1993, J BIOL CHEM, V268, P18850; ZIFF EB, 1990, TRENDS GENET, V6, P69, DOI 10.1016/0168-9525(90)90081-G	36	77	79	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14690	14697						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	8182076				2022-12-25	WOS:A1994NM06500061
J	FANG, KS; BARKER, K; SUDOL, M; HANAFUSA, H				FANG, KS; BARKER, K; SUDOL, M; HANAFUSA, H			A TRANSMEMBRANE PROTEIN-TYROSINE-PHOSPHATASE CONTAINS SPECTRIN-LIKE REPEATS IN ITS EXTRACELLULAR DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEMATOPOIETIC-CELLS; V-MYB; CDNA; RECEPTOR; SEQUENCE; EXPRESSION; CLONING; HOMOLOGY; FAMILY; SRC	We report the first chicken transmembrane protein-tyrosine phosphatase, ChPTP lambda, isolated from a brain cDNA library and preB cells. ChPTP lambda has transcripts of about 5.6 kilobases and is abundant in spleen, intestine, and fibroblasts transformed by oncogenic ras or erbA/B. It has five alternative splicing products varying near their amino termini, and the largest one contains 1237 amino acids. The extracellular domain of ChPTP lambda has several features including a Ser/Thr/Pro-rich region, one fibronectin type III module, and spectrin-like repeats (the first case that spectrin-like repeats were found in the non-cytoplasmic compartment). These repeats were also found in other phosphatases, including CD45 and yeast acid phosphatases PHO5 and PHO3. Antibodies to ChPTP lambda recognized several protein species whose M(r) range from 170,000 to 210,000. ChPTP lambda exhibited phosphotyrosine-specific phosphatase activity. Since CD45 also has these features in the extracellular domain and the two protein-tyrosine phosphatases share 70% similarity in the intracellular domains, we propose that ChPTP lambda and CD45 belong to the same gene family.	ROCKEFELLER UNIV,MOLEC BIOL LAB,NEW YORK,NY 10021	Rockefeller University					NATIONAL CANCER INSTITUTE [R35CA044356] Funding Source: NIH RePORTER; NCI NIH HHS [CA44356, CA01605] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BABA TW, 1985, VIROLOGY, V144, P139, DOI 10.1016/0042-6822(85)90312-5; BAJWA W, 1984, NUCLEIC ACIDS RES, V12, P7721, DOI 10.1093/nar/12.20.7721; BARON MD, 1987, J BIOL CHEM, V262, P17623; BARTHELS D, 1987, EMBO J, V6, P907, DOI 10.1002/j.1460-2075.1987.tb04837.x; BEUG H, 1981, VIROLOGY, V115, P295, DOI 10.1016/0042-6822(81)90112-4; BEUG H, 1982, J CELL PHYSL S, V1, P195; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BOYD D, 1987, P NATL ACAD SCI USA, V84, P8525, DOI 10.1073/pnas.84.23.8525; BRADYKALNAY SM, 1993, J CELL BIOL, V122, P961, DOI 10.1083/jcb.122.4.961; BROWNSHIMER S, 1990, P NATL ACAD SCI USA, V87, P5148, DOI 10.1073/pnas.87.13.5148; CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; CHERNOFF J, 1990, P NATL ACAD SCI USA, V87, P2735, DOI 10.1073/pnas.87.7.2735; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOL DE, 1989, P NATL ACAD SCI USA, V86, P5257, DOI 10.1073/pnas.86.14.5257; COOPER JA, 1990, SRC FAMILY PROTEIN T; DARNELL JE, 1986, MOL CELL BIOL, P947; DAVISON MD, 1988, CELL, V52, P159, DOI 10.1016/0092-8674(88)90503-X; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; FLICKINGER TW, 1992, MOL CELL BIOL, V12, P883, DOI 10.1128/MCB.12.2.883; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; FUKUI Y, 1991, ONCOGENE, V6, P407; GU MX, 1991, P NATL ACAD SCI USA, V88, P5867, DOI 10.1073/pnas.88.13.5867; HANAFUSA H, 1969, P NATL ACAD SCI USA, V63, P318, DOI 10.1073/pnas.63.2.318; HARLOW E, 1988, ANTIBODIES LAB MANUA, P92; HORNE WC, 1992, J CELL BIOL, V119, P1003, DOI 10.1083/jcb.119.4.1003; INTRONA M, 1990, CELL, V63, P1287, DOI 10.1016/0092-8674(90)90424-D; KORNFELD S, 1983, EXP CELL RES, V143, P383, DOI 10.1016/0014-4827(83)90065-4; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; KRUEGER NX, 1992, P NATL ACAD SCI USA, V89, P7417, DOI 10.1073/pnas.89.16.7417; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAX I, 1988, MOL CELL BIOL, V8, P1970, DOI 10.1128/MCB.8.5.1970; LEVY JB, 1993, J BIOL CHEM, V268, P10573; MAIN AL, 1992, CELL, V71, P671, DOI 10.1016/0092-8674(92)90600-H; MARCHESI VT, 1985, ANNU REV CELL BIOL, V1, P531, DOI 10.1146/annurev.cellbio.1.1.531; METZ T, 1991, GENE DEV, V5, P369, DOI 10.1101/gad.5.3.369; MOSINGER B, 1992, P NATL ACAD SCI USA, V89, P499, DOI 10.1073/pnas.89.2.499; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; ROSEN OM, 1987, SCIENCE, V237, P1452, DOI 10.1126/science.2442814; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SAMBROOK J, 1989, MOL CLONING LABORATO, P197; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; TAITKAMRADT AG, 1986, MOL CELL BIOL, V6, P1855, DOI 10.1128/MCB.6.6.1855; THOMAS ML, 1989, ANNU REV IMMUNOL, V7, P336; WINKELMANN JC, 1990, J BIOL CHEM, V265, P11827; WOODFORDTHOMAS TA, 1992, J CELL BIOL, V117, P401, DOI 10.1083/jcb.117.2.401; YANG Q, 1991, P NATL ACAD SCI USA, V88, P5949, DOI 10.1073/pnas.88.14.5949; YI TL, 1992, MOL CELL BIOL, V12, P836, DOI 10.1128/MCB.12.2.836	52	26	27	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					14056	14063						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188686				2022-12-25	WOS:A1994NL60600052
J	HENGSTSCHLAGER, M; KNOFLER, M; MULLNER, EW; OGRIS, E; WINTERSBERGER, E; WAWRA, E				HENGSTSCHLAGER, M; KNOFLER, M; MULLNER, EW; OGRIS, E; WINTERSBERGER, E; WAWRA, E			DIFFERENT REGULATION OF THYMIDINE KINASE DURING THE CELL-CYCLE OF NORMAL VERSUS DNA TUMOR VIRUS-TRANSFORMED COILS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM-STIMULATED CELLS; MESSENGER-RNA; GENE; EXPRESSION; INDUCTION; ENZYME; FIBROBLASTS; PROTEIN; LEVEL	We compared the cell cycle regulation of thymidine kinase (TK) after centrifugal elutriation in normal human and mouse cells (primary cells, diploid fibroblasts) with its expression in cells transformed with different DNA tumor viruses. Normal cells showed a rise of TK enzyme activity near the G(1)/S boundary, which peaked in S phase, and in G(2) returned approximately to the level of G(1). Conversely, in cells derived from viral transformation, TK activity remained high throughout S and G(2) phases, although it was induced to a comparable extent at the onset of DNA replication. In addition, transformed cells exhibited much more enzyme activity during all phases of the cell cycle. The observed differences in expression were due neither to different rates of protein turnover nor to differences in enzyme stability. Enzyme activity was always totally paralleled by the protein level. In all normal cells, the pattern of TK mRNA variation during the cell cycle was similar to that of enzyme activity. In all transformed lines, however, mRNA levels were higher and did not fluctuate throughout the cell cycle. Recently we showed (Ogris et al., 1993) that the E2F binding site present in the TK promoter is a target for transactivation of the TK gene by polyoma virus large T antigen. Using cells expressing this antigen under the control of a hormone-inducible promoter, we were able to switch TK cell cycle expression from the normal to the transformed status. Obviously, DNA tumor viruses suppress transcriptional down-regulation of the endogenous DNA precursor pathway enzyme TK during the eukaryotic cell cycle, maybe to improve conditions for their own replication.	UNIV VIENNA, VIENNA BIOCTR, INST MOLEC BIOL, A-1030 VIENNA, AUSTRIA	University of Vienna; Vienna Biocenter (VBC); Institute of Molecular Biotechnology (IMBA)				Ogris, Egon/0000-0001-5950-9264				ADLER R, 1974, CELL, V2, P113, DOI 10.1016/0092-8674(74)90100-7; BELLO LJ, 1974, EXP CELL RES, V89, P263, DOI 10.1016/0014-4827(74)90790-3; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; CHIBA P, 1989, BRIT J HAEMATOL, V72, P145; COPPOCK DL, 1987, MOL CELL BIOL, V7, P2925, DOI 10.1128/MCB.7.8.2925; Favaloro J, 1980, Methods Enzymol, V65, P718; GROSS MK, 1988, NUCLEIC ACIDS RES, V16, P11625, DOI 10.1093/nar/16.24.11625; GROSS MK, 1989, P NATL ACAD SCI USA, V86, P4987, DOI 10.1073/pnas.86.13.4987; GROUDINE M, 1984, NUCLEIC ACIDS RES, V12, P1427, DOI 10.1093/nar/12.3.1427; GUDAS JM, 1988, P NATL ACAD SCI USA, V85, P4705, DOI 10.1073/pnas.85.13.4705; HAMEL PA, 1992, TRENDS GENET, V8, P180, DOI 10.1016/0168-9525(92)90221-O; HENGSTSCHLAGER M, 1993, FEBS LETT, V321, P237, DOI 10.1016/0014-5793(93)80116-C; HENGSTSCHLAGER M, 1993, CYTOMETRY, V14, P39, DOI 10.1002/cyto.990140108; HORWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775; ITO M, 1990, J BIOL CHEM, V265, P6954; JOHNSON LF, 1982, EXP CELL RES, V138, P79, DOI 10.1016/0014-4827(82)90093-3; KAUFFMAN MG, 1991, MOL CELL BIOL, V11, P2538, DOI 10.1128/MCB.11.5.2538; KNOFLER M, 1993, J BIOL CHEM, V268, P11409; LIEBERMAN HB, 1988, MOL CELL BIOL, V8, P5280, DOI 10.1128/MCB.8.12.5280; LITTLEFIELD JW, 1966, BIOCHIM BIOPHYS ACTA, V114, P398, DOI 10.1016/0005-2787(66)90319-4; MCKENNA PG, 1982, GENET RES, V40, P207, DOI 10.1017/S0016672300019078; MUDRAK I, 1994, MOL CELL BIOL, V14, P1886, DOI 10.1128/MCB.14.3.1886; OGRIS E, 1993, J VIROL, V67, P1765, DOI 10.1128/JVI.67.4.1765-1771.1993; OGRIS E, 1992, J VIROL, V66, P53, DOI 10.1128/JVI.66.1.53-61.1992; PEARSON BE, 1991, MOL CELL BIOL, V11, P2081, DOI 10.1128/MCB.11.4.2081; PIPER AA, 1980, BIOCHIM BIOPHYS ACTA, V633, P400, DOI 10.1016/0304-4165(80)90198-1; REICHARD P, 1988, ANNU REV BIOCHEM, V57, P349, DOI 10.1146/annurev.bi.57.070188.002025; SHERLEY JL, 1988, J BIOL CHEM, V263, P8350; SHOWS TB, 1979, CYTOGENET CELL GENET, V25, P96, DOI 10.1159/000131404; STEWART CJ, 1987, MOL CELL BIOL, V7, P1156, DOI 10.1128/MCB.7.3.1156; STUART P, 1985, MOL CELL BIOL, V5, P1490, DOI 10.1128/MCB.5.6.1490; THOMPSON CB, 1985, NATURE, V314, P363, DOI 10.1038/314363a0; WAWRA E, 1981, J VIROL, V38, P973, DOI 10.1128/JVI.38.3.973-981.1981; [No title captured]	34	119	130	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					13836	13842						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188661				2022-12-25	WOS:A1994NL60600021
J	LILLY, PJ; DEVREOTES, PN				LILLY, PJ; DEVREOTES, PN			IDENTIFICATION OF CRAC, A CYTOSOLIC REGULATOR REQUIRED FOR GUANINE-NUCLEOTIDE STIMULATION OF ADENYLYL-CYCLASE IN DICTYOSTELIUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAMP RECEPTOR; SACCHAROMYCES-CEREVISIAE; ALPHA-SUBUNITS; PROTEIN; DISCOIDEUM; GENE; SEQUENCE; TRANSDUCTION; PURIFICATION; EXPRESSION	As previously reported, guanine nucleotide regulation of adenylyl cyclase activity in the Dictyostelium mutant synag 7 can be restored in vitro by addition of a high speed supernatant prepared from wild-type cells (Theibert, A., and Devreotes, P. N. (1986) J. Biol. Chem. 261, 15121-15125). We have designated this activity CRAC, for cytosolic regulator of adenylyl cyclase. Trypsinization of partially purified material demonstrated that this activity contains a protein. We report here a 50,000-fold purification of this protein using Q and S Sepharose fast flow and P11 cellulose chromatography, followed by sucrose gradient centrifugation and separation on SDS-polyacrylamide gel electrophoresis. Purification of wild-type and mutant supernatants in parallel allowed identification of an 88-kDa protein required for reconstituting activity. A polyclonal antibody was raised against this protein; it stains a band in unfractionated wild-type, but not mutant, supernatants. Immunoblots of fractions from each purification step show that activity and the immunostaining band cochromatograph. We have determined a short N-terminal sequence of the 88-kDa CRAC polypeptide, which matches a portion of the deduced N terminus of a gene, dagA, isolated from a mutant similar to synag 7. Expression of the dagA cDNA in synag 7 cells restores both the 88 kDa band and CRAC activity.	JOHNS HOPKINS UNIV,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21205	Johns Hopkins University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028007, R37GM028007] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 28007] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKALYAR HA, 1990, SCIENCE, V250, P1403, DOI 10.1126/science.2255909; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; BIRNBAUMER L, 1992, CELL, V71, P1069, DOI 10.1016/S0092-8674(05)80056-X; DEVREOTES P, 1989, SCIENCE, V245, P1054, DOI 10.1126/science.2672337; DEVREOTES P, 1987, METHOD CELL BIOL, V28, P299; FIELD J, 1990, CELL, V61, P319, DOI 10.1016/0092-8674(90)90812-S; GAO BN, 1991, P NATL ACAD SCI USA, V88, P10178, DOI 10.1073/pnas.88.22.10178; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HADWIGER JA, 1992, GENE DEV, V6, P38, DOI 10.1101/gad.6.1.38; HARLOW E, 1988, ANTIBODIES LABORATOR; HUNKAPILLER MW, 1986, METHODS PROTEIN MICR; JOHNSON RL, 1993, GENE DEV, V7, P273, DOI 10.1101/gad.7.2.273; KATAOKA T, 1985, CELL, V43, P493, DOI 10.1016/0092-8674(85)90179-5; KESBEKE F, 1988, J CELL BIOL, V107, P521, DOI 10.1083/jcb.107.2.521; KLEIN P, 1987, J BIOL CHEM, V262, P352; KLEIN PS, 1988, SCIENCE, V241, P1467, DOI 10.1126/science.3047871; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; KUMAGAI A, 1991, J BIOL CHEM, V266, P1220; LILLY P, 1993, GENE DEV, V7, P986, DOI 10.1101/gad.7.6.986; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; OKAICHI K, 1992, MOL BIOL CELL, V3, P725; OLMSTED JB, 1981, J BIOL CHEM, V256, P1955; PITT GS, 1992, CELL, V69, P305, DOI 10.1016/0092-8674(92)90411-5; PUPILLO M, 1989, P NATL ACAD SCI USA, V86, P4892, DOI 10.1073/pnas.86.13.4892; PUPILLO M, 1988, COLD SPRING HARB SYM, V53, P657, DOI 10.1101/SQB.1988.053.01.075; PUPILLO M, 1992, MOL BIOL CELL, V3, P1229, DOI 10.1091/mbc.3.11.1229; Salomon Y, 1979, Adv Cyclic Nucleotide Res, V10, P35; SAXE CL, 1991, GENE DEV, V5, P1, DOI 10.1101/gad.5.1.1; SNAARJAGALSKA BE, 1988, J CELL SCI, V91, P287; SUN TJ, 1991, GENE DEV, V5, P572, DOI 10.1101/gad.5.4.572; TANAKA K, 1991, P NATL ACAD SCI USA, V88, P468, DOI 10.1073/pnas.88.2.468; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; THEIBERT A, 1986, J BIOL CHEM, V261, P5121; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANHAASTERT PJM, 1991, EUR J BIOCHEM, V195, P289; WATTS DJ, 1970, BIOCHEM J, V119, P171, DOI 10.1042/bj1190171; WIGLER M, 1988, COLD SPRING HARB SYM, V53, P649, DOI 10.1101/SQB.1988.053.01.074; WU LJ, 1991, BIOCHEM BIOPH RES CO, V179, P1141, DOI 10.1016/0006-291X(91)91690-E	38	58	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					14123	14129						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188693				2022-12-25	WOS:A1994NL60600061
J	FENG, Y; FORGAC, M				FENG, Y; FORGAC, M			INHIBITION OF VACUOLAR H+-ATPASE BY DISULFIDE BOND FORMATION BETWEEN CYSTEINE-254 AND CYSTEINE-532 IN SUBUNIT-A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; TRANSLOCATING ADENOSINE-TRIPHOSPHATASE; NADP-MALATE-DEHYDROGENASE; NUCLEOTIDE BINDING-SITES; BETA-SUBUNIT; CHROMAFFIN GRANULES; ESCHERICHIA-COLI; ALPHA-SUBUNIT; THIOREDOXIN; PROTEINS	We have previously demonstrated that the coated vesicle vacuolar H+-ATPase (V-ATPase) can be inactivated by formation of intramolecular disulfide bonds (Feng, Y., and Forgac, M. (1992) J. Biol. Chem. 267, 19769-19772). The disulfide bond responsible for inactivation can be distinguished from other disulfide bonds that form by the fact that formation of the inactivating disulfide bond is blocked by ATP or high ionic strength. By taking advantage of these properties, we selectively labeled the ATPase at the relevant cysteine residues with fluorescein maleimide. After analyzing the proteolytic fragments that contain the labeled cysteine residues, we found that cysteine 254 and cysteine 532 in subunit A of the bovine V-ATPase are the residues that form the disulfide bond resulting in inactivation of the enzyme. Cysteine 254 and cysteine 532 correspond to 2 of the 3 cysteine residues that are conserved in all available V-ATPase A subunit sequences. Cysteine 254 is located in the consensus motif, G(X)(4)GKT, corresponding to residues 250-257, which is conserved in many nucleotide binding proteins. Cysteine 532 is located in a region not previously shown to be in proximity to the nucleotide binding site. Modification of cysteine 254 by disulfide bond formation with cysteine 532 or thio-disulfide exchange with cystine does not impair binding of 2-azido[P-32]ATP to the A subunit. The inhibition is therefore likely caused by disruption of the catalytic function of the ATPase on formation of the disulfide bond. A possible role in regulating intracellular acidification by reversible sulfhydryl oxidation and reduction is discussed.	TUFTS UNIV,SCH MED,DEPT CELLULAR & MOLEC PHYSIOL,BOSTON,MA 02111	Tufts University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034478, R01GM034478] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM034478, GM-34478] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABBOTT MS, 1984, J BIOL CHEM, V259, P2271; AHLE S, 1988, EMBO J, V7, P919, DOI 10.1002/j.1460-2075.1988.tb02897.x; ANDERSON RGW, 1984, P NATL ACAD SCI-BIOL, V81, P4838, DOI 10.1073/pnas.81.15.4838; ANDERSON RGW, 1985, CELL, V40, P635, DOI 10.1016/0092-8674(85)90212-0; ARAI H, 1987, BIOCHEMISTRY-US, V26, P6632, DOI 10.1021/bi00395a011; BOWMAN EJ, 1988, J BIOL CHEM, V263, P13994; CLANCEY CJ, 1987, J BIOL CHEM, V262, P13545; CROSS RL, 1987, P NATL ACAD SCI USA, V84, P5715, DOI 10.1073/pnas.84.16.5715; DECOTTIGNIES P, 1988, J BIOL CHEM, V263, P11780; DENDA K, 1988, J BIOL CHEM, V263, P6012; DROUX M, 1987, CR ACAD SCI III-VIE, V305, P335; FENG Y, 1992, J BIOL CHEM, V267, P5817; FENG Y, 1992, J BIOL CHEM, V267, P19769; FLING SP, 1986, ANAL BIOCHEM, V155, P83, DOI 10.1016/0003-2697(86)90228-9; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; GEUZE HJ, 1983, CELL, V32, P277, DOI 10.1016/0092-8674(83)90518-4; HALLIWELL B, 1978, PLANTA, V139, P9, DOI 10.1007/BF00390803; HAMMEL KE, 1983, P NATL ACAD SCI-BIOL, V80, P3681, DOI 10.1073/pnas.80.12.3681; HIRATA R, 1990, J BIOL CHEM, V265, P6726; HIRSCH S, 1988, P NATL ACAD SCI USA, V85, P3004, DOI 10.1073/pnas.85.9.3004; INATOMI KI, 1989, J BIOL CHEM, V264, P10954; KEEN JH, 1987, J BIOL CHEM, V262, P3864; KIM HJ, 1990, BIOCHEMISTRY-US, V29, P1107, DOI 10.1021/bi00457a002; LAW MY, 1983, BIOCHEM J, V210, P899, DOI 10.1042/bj2100899; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARCUS F, 1988, P NATL ACAD SCI USA, V85, P5379, DOI 10.1073/pnas.85.15.5379; MARQUEZSTERLING N, 1991, EUR J CELL BIOL, V56, P19; MELESE T, 1985, J BIOL CHEM, V260, P5398; MOOS M, 1988, J BIOL CHEM, V263, P6005; MORIYAMA Y, 1987, J BIOL CHEM, V262, P14723; MYERS M, 1993, J BIOL CHEM, V268, P9184; MYERS M, 1993, J CELL PHYSIOL, V156, P35, DOI 10.1002/jcp.1041560106; NELSON H, 1990, J BIOL CHEM, V265, P20390; OMOTE H, 1992, J BIOL CHEM, V267, P20571; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PORTER MA, 1988, J BIOL CHEM, V263, P123; PUOPOLO K, 1992, J BIOL CHEM, V267, P3696; PUOPOLO K, 1991, J BIOL CHEM, V266, P24564; REBEILLE F, 1986, ARCH BIOCHEM BIOPHYS, V249, P164, DOI 10.1016/0003-9861(86)90571-0; ROBINSON MS, 1987, J CELL BIOL, V104, P887, DOI 10.1083/jcb.104.4.887; RUNSWICK MJ, 1983, J BIOL CHEM, V258, P3081; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SCHWARTZ AL, 1985, EMBO J, V4, P899, DOI 10.1002/j.1460-2075.1985.tb03716.x; SENIOR AE, 1992, J BIOL CHEM, V267, P21471; VANHILLE B, 1993, J BIOL CHEM, V268, P7075; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WANG SY, 1988, J BIOL CHEM, V263, P17638; ZIMNIAK L, 1988, J BIOL CHEM, V263, P9102	48	138	143	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13224	13230						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175752				2022-12-25	WOS:A1994NK18400029
J	TADDIE, JA; HURLEY, TR; HARDWICK, BS; SEFTON, BM				TADDIE, JA; HURLEY, TR; HARDWICK, BS; SEFTON, BM			ACTIVATION OF B-CELLS AND T-CELLS BY THE CYTOPLASMIC DOMAINS OF THE B-CELL ANTIGEN RECEPTOR PROTEINS IG-ALPHA AND IG-BETA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MURINE LYMPHOCYTES-B; TYROSINE PHOSPHORYLATION; MEMBRANE IMMUNOGLOBULIN; SIGNAL TRANSDUCTION; CROSS-LINKING; SRC-FAMILY; COMPLEX; GENE; COMPONENTS; EXPRESSION	In addition to membrane immunoglobulin (mIg), the B-cell antigen receptor contains Ig-alpha/Ig-beta heterodimers that link mIg to intracellular signaling molecules. To compare the ability of the cytoplasmic domains of Ig-alpha and Ig-beta to transduce signals in B- and T-cells, we con constructed chimeric genes encoding the extracellular and transmembrane domains of human CD8 alpha and the cytoplasmic domain of murine Ig-alpha (CD8/Ig-alpha) or Ig-beta (CD8/Ig-beta). In murine B-cell hybridoma LK 35.2 cells, antibody-mediated cross-linking of mIg, CD8/Ig-alpha, or CD8/Ig-beta induced similar increases in intracellular calcium levels and protein tyrosine phosphorylation. Substitution of alanine for the conserved leucine, but not the conserved isoleucine, residue within the putative activation motif of CD8/Ig-beta destroyed signaling ability. In murine T-cell hybridoma DO-11.10 cells, cross-linking of the T-cell antigen receptor, CD8/Ig-alpha, or CD8/Ig-beta stimulated equivalent protein tyrosine phosphorylation and interleukin-2 production. Thus, the cytoplasmic domains of Ig-a! and Ig-p are equally capable of initiating early signaling events downstream of B- and T cell antigen receptors as well as evoking a complete biological effector response in lymphocytes.	UNIV CALIF SAN DIEGO, DEPT BIOMED SCI, SAN DIEGO, CA 92093 USA	University of California System; University of California San Diego	TADDIE, JA (corresponding author), SALK INST, MOLEC BIOL & VIROL LAB, POB 85800, SAN DIEGO, CA 92186 USA.				NCI NIH HHS [CA14195, CA17289] Funding Source: Medline; NIAID NIH HHS [AI08685] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA014195, R01CA017289] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [F32AI008685] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BURKHARDT AL, 1994, MOL CELL BIOL, V14, P1095, DOI 10.1128/MCB.14.2.1095; CAMBIER JC, 1992, CURR OPIN IMMUNOL, V4, P257, DOI 10.1016/0952-7915(92)90074-O; CAMPBELL KS, 1991, P NATL ACAD SCI USA, V88, P3982, DOI 10.1073/pnas.88.9.3982; CAMPBELL MA, 1992, MOL CELL BIOL, V12, P2315, DOI 10.1128/MCB.12.5.2315; CAMPBELL MA, 1990, EMBO J, V9, P2125, DOI 10.1002/j.1460-2075.1990.tb07381.x; CARTER RH, 1991, P NATL ACAD SCI USA, V88, P2745, DOI 10.1073/pnas.88.7.2745; CLARK MR, 1992, SCIENCE, V258, P123, DOI 10.1126/science.1439759; DENNERT G, 1980, NATURE, V287, P47, DOI 10.1038/287047a0; FLASWINKEL H, 1994, EMBO J, V13, P83, DOI 10.1002/j.1460-2075.1994.tb06237.x; GOLD MR, 1991, P NATL ACAD SCI USA, V88, P3436, DOI 10.1073/pnas.88.8.3436; GOLD MR, 1990, NATURE, V345, P810, DOI 10.1038/345810a0; GRUPP SA, 1993, J BIOL CHEM, V268, P25776; HEMPEL WM, 1992, J IMMUNOL, V148, P3021; HERMANSON GG, 1988, P NATL ACAD SCI USA, V85, P6890, DOI 10.1073/pnas.85.18.6890; HOFFMAN RA, 1980, P NATL ACAD SCI-BIOL, V77, P4914, DOI 10.1073/pnas.77.8.4914; HOMBACH J, 1990, NATURE, V343, P760, DOI 10.1038/343760a0; HOMBACH J, 1990, EUR J IMMUNOL, V20, P2795, DOI 10.1002/eji.1830201239; HURLEY TR, 1989, ONCOGENE, V4, P265; HURLEY TR, 1993, MOL CELL BIOL, V13, P1651, DOI 10.1128/MCB.13.3.1651; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; IRVING BA, 1993, J EXP MED, V177, P1093, DOI 10.1084/jem.177.4.1093; KAPPLER J, 1982, P NATL ACAD SCI-BIOL, V79, P3604, DOI 10.1073/pnas.79.11.3604; KIM KM, 1993, EUR J IMMUNOL, V23, P911, DOI 10.1002/eji.1830230422; KOLANUS W, 1992, EMBO J, V11, P4861, DOI 10.1002/j.1460-2075.1992.tb05592.x; LANDAU NR, 1992, J VIROL, V66, P5110, DOI 10.1128/JVI.66.8.5110-5113.1992; LAW DA, 1993, CURR BIOL, V3, P645, DOI 10.1016/0960-9822(93)90062-S; LAW DA, 1992, MOL IMMUNOL, V29, P917, DOI 10.1016/0161-5890(92)90130-P; LEAHY DJ, 1992, CELL, V68, P1145, DOI 10.1016/0092-8674(92)90085-Q; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; LETOURNEUR F, 1991, P NATL ACAD SCI USA, V88, P8905, DOI 10.1073/pnas.88.20.8905; LITTMAN DR, 1985, CELL, V40, P237, DOI 10.1016/0092-8674(85)90138-2; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; RETH M, 1992, ANNU REV IMMUNOL, V10, P97, DOI 10.1146/annurev.iy.10.040192.000525; ROMEO C, 1991, CELL, V64, P1037, DOI 10.1016/0092-8674(91)90327-U; ROSE JK, 1981, J VIROL, V39, P519, DOI 10.1128/JVI.39.2.519-528.1981; SAKAGUCHI N, 1988, EMBO J, V7, P3457, DOI 10.1002/j.1460-2075.1988.tb03220.x; SANCHEZ M, 1993, J EXP MED, V178, P1049, DOI 10.1084/jem.178.3.1049; SHIMONKEVITZ R, 1983, J EXP MED, V158, P303, DOI 10.1084/jem.158.2.303; VENKITARAMAN AR, 1991, NATURE, V352, P777, DOI 10.1038/352777a0; WEGENER AMK, 1992, CELL, V68, P83, DOI 10.1016/0092-8674(92)90208-T; WILLIAMS GT, 1994, P NATL ACAD SCI USA, V91, P474, DOI 10.1073/pnas.91.2.474; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	45	32	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13529	13535						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175787				2022-12-25	WOS:A1994NK18400070
J	SANZ, MA; PEREZ, L; CARRASCO, L				SANZ, MA; PEREZ, L; CARRASCO, L			SEMLIKI FOREST VIRUS 6K PROTEIN MODIFIES MEMBRANE-PERMEABILITY AFTER INDUCIBLE EXPRESSION IN ESCHERICHIA-COLI-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFECTED HELA-CELLS; POLIOVIRUS NONSTRUCTURAL PROTEINS; VALENT CATION-TRANSPORT; VIRAL-INFECTION; MAMMALIAN-CELLS; CHICK-CELLS; TRANSLATION; RELEASE; INHIBITION; SYSTEM	Semliki Forest virus encodes a small protein, known as 6K, that is associated with cellular membranes in the infected cells. This protein has been cloned and expressed in an inducible manner using pET vectors in Escherichia coli cells. Two different plasmids have been utilized; either the 6K gene is placed directly under the T7 promoter (pET3-6K) or the iac operator is located between the T7 promoter and the 6K gene (pET11-6K). In both systems, efficient synthesis of the 6K protein is achieved by induction with isopropyl-1-thio-beta-D-galactopyranoside plus rifampicin. The synthesis of the 6K protein is very toxic for E. coli causing increased membrane permeability and cell lysis as shown by alterations in permeability to either choline or hygromycin B. These results indicate that the togavirus 6K is a membrane-active protein that shows structural and functional similarities to poliovirus 3A protein. The function that the 6K protein could play during the virus replication cycle is discussed in the light of these findings.	UNIV AUTONOMA MADRID,CSIC,CTR NACL BIOTECNOL,E-28049 MADRID,SPAIN	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	SANZ, MA (corresponding author), UNIV AUTONOMA MADRID,CSIC,CTR BIOL MOLEC,CANTO BLANCO,E-28049 MADRID,SPAIN.		Carrasco, Luis/H-3001-2017; Carrasco, Luis/E-2435-2012; Sanz, Miguel A/H-1914-2015; sanz-gomez, miguel/Y-6244-2019	Carrasco, Luis/0000-0003-3833-8835; Sanz, Miguel A/0000-0001-6573-883X; sanz-gomez, miguel/0000-0002-5761-9010; Perez Garcia-Estan, Luis/0000-0003-4078-8763				ALONSO MA, 1982, EMBO J, V1, P913, DOI 10.1002/j.1460-2075.1982.tb01271.x; ALONSO MA, 1980, EUR J BIOCHEM, V109, P535, DOI 10.1111/j.1432-1033.1980.tb04825.x; BARTH BU, 1992, J VIROL, V66, P7560, DOI 10.1128/JVI.66.12.7560-7564.1992; CARRASCO L, 1978, NATURE, V272, P694, DOI 10.1038/272694a0; CARRASCO L, 1977, FEBS LETT, V76, P11, DOI 10.1016/0014-5793(77)80110-5; CARRASCO L, 1989, PHARMACOL THERAPEUT, V40, P171, DOI 10.1016/0163-7258(89)90096-X; CARRASCO L, 1983, PHARMACOL THERAPEUT, V23, P109, DOI 10.1016/0163-7258(83)90028-1; CARRASCO L, 1987, MECHANISM VIRAL TOXI, P1; Carrasco L., 1993, REGULATION GENE EXPR; CARRASCO L, 1979, MODERN TRENDS HUMAN, P277; CARRASCO L, 1983, ANTIBIOTICS, V6, P1980; COLLINS PL, 1993, J GEN VIROL, V74, P1445, DOI 10.1099/0022-1317-74-7-1445; CONTRERAS A, 1979, J VIROL, V29, P114, DOI 10.1128/JVI.29.1.114-122.1979; DUBENDORFF JW, 1991, J MOL BIOL, V219, P45, DOI 10.1016/0022-2836(91)90856-2; GAEDIGKNITSCHKO K, 1990, VIROLOGY, V175, P274, DOI 10.1016/0042-6822(90)90209-A; GAEDIGKNITSCHKO K, 1990, VIROLOGY, V175, P282, DOI 10.1016/0042-6822(90)90210-I; GAROFF H, 1980, NATURE, V288, P236, DOI 10.1038/288236a0; GARRY RF, 1979, VIROLOGY, V96, P108, DOI 10.1016/0042-6822(79)90177-6; HOLSEY C, 1990, J CELL PHYSIOL, V142, P586, DOI 10.1002/jcp.1041420319; HOLSINGER LJ, 1991, VIROLOGY, V183, P32, DOI 10.1016/0042-6822(91)90115-R; IRURZUN A, 1993, J GEN VIROL, V74, P1063, DOI 10.1099/0022-1317-74-6-1063; LACAL JC, 1982, EUR J BIOCHEM, V127, P359, DOI 10.1111/j.1432-1033.1982.tb06880.x; LAMA J, 1992, J BIOL CHEM, V267, P15932; LAMA J, 1992, BIOCHEM BIOPH RES CO, V188, P972, DOI 10.1016/0006-291X(92)91327-M; LAMA J, 1992, GENE, V117, P185, DOI 10.1016/0378-1119(92)90728-8; LILJESTROM P, 1991, J VIROL, V65, P4107; LILJESTROM P, 1991, J VIROL, V65, P147; LOPEZRIVAS A, 1987, J GEN VIROL, V68, P335, DOI 10.1099/0022-1317-68-2-335; LUSA S, 1991, VIROLOGY, V185, P843, DOI 10.1016/0042-6822(91)90556-Q; MALDARELLI F, 1993, J VIROL, V67, P5056, DOI 10.1128/JVI.67.8.5056-5061.1993; MUNOZ A, 1985, VIROLOGY, V146, P203, DOI 10.1016/0042-6822(85)90004-2; NAIR CN, 1984, J GEN VIROL, V65, P1135, DOI 10.1099/0022-1317-65-6-1135; PEREZ L, 1993, VIROLOGY, V194, P28, DOI 10.1006/viro.1993.1231; PINTO LH, 1992, CELL, V69, P517, DOI 10.1016/0092-8674(92)90452-I; Sambrook J, 1989, MOL CLONING LABORATO; SCHLESINGER MJ, 1993, VIROLOGY, V193, P424, DOI 10.1006/viro.1993.1139; SCHLESINGER S, 1993, VIROLOGY, P697; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STUDIER FW, 1991, J MOL BIOL, V219, P37, DOI 10.1016/0022-2836(91)90855-Z; ULUG ET, 1984, VIROLOGY, V132, P118, DOI 10.1016/0042-6822(84)90096-5; ULUG ET, 1989, VIROLOGY, V172, P42, DOI 10.1016/0042-6822(89)90105-0; ULUG ET, 1987, MECHANISMS VIRAL TOX, P91	42	70	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					12106	12110						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163515				2022-12-25	WOS:A1994NG37700066
J	HAWES, BE; LUTTRELL, LM; EXUM, ST; LEFKOWITZ, RJ				HAWES, BE; LUTTRELL, LM; EXUM, ST; LEFKOWITZ, RJ			INHIBITION OF G-PROTEIN-COUPLED RECEPTOR SIGNALING BY EXPRESSION OF CYTOPLASMIC DOMAINS OF THE RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; ALPHA-1-ADRENERGIC RECEPTOR; PHOSPHOLIPASE-C; ALPHA-SUBUNITS; PHOSPHATIDYLINOSITOL HYDROLYSIS; BETA-2-ADRENERGIC RECEPTOR; MOLECULAR-CLONING; ADENYLYL CYCLASE; ACTIVATION; BINDING	The third intracellular domain (3i) of G protein-coupled receptors plays a major role in the activation of G proteins. Alterations in this region of the receptor can affect receptor/G protein coupling efficiency and specificity. We recently reported (Luttrell, L. M., Cotecchia, S., Ostrowski, J., Kendall, H., Lefkowitz, R. J. (1993) Science 259, 1453-1457) that coexpression of the 3i domain of the alpha(1B) adrenergic receptor (AR) (alpha(1B)3i) specifically inhibited alpha(1B)AR-mediated inositol phosphate production, with no effect on D-1A dopamine receptor (D(1A)DR)-mediated cAMP production. Similarly, expression of the 3i domain of D(1A)DR (D(1A)3i) inhibited D(1A)DR-mediated cAMP production but did not affect alpha(1B)AR-mediated inositol phosphate accumulation. This suggests that peptides derived from a G protein-coupled receptor might serve as antagonists of receptor/G protein interactions. The present studies were performed to test the generality as well as the specificity of this phenomenon. The effect of expression of the second intracellular domain (2i), the 3i domain, and the fourth intracellular domain (4i) of alpha(1B)AR on second messenger generation mediated by the alpha(1B)AR, the M(1) muscarinic cholinergic receptor (M(1)AChR), and the D(1A)DR was examined. Although the alpha(1B)2i domain had no effect on receptor/G protein coupling for any receptor tested, the alpha(1B)3i domain inhibited signaling mediated by alpha(1B)AR and M(1)AChR but not by D(1A)DR, while the alpha(1B)4i domain inhibited signaling mediated by each of the receptors. To investigate the generality of 3i domain-induced inhibition of receptor activity further, the 3i domains of two G(q)-coupled receptors (alpha(1B)AR and M(1)AChR) and two G(i)-coupled receptors (alpha(2A)AR and M(2)AChR) were tested for effects on the second messenger generation mediated by each of the four receptors. In each case, the homologous 3i domain caused significant inhibition (40-60%), while the 3i domain of the receptor coupled to the same G protein also decreased receptor/G protein coupling. In contrast, receptor/G protein coupling appeared unaffected by expression of 3i domains derived from receptors coupled to different G proteins. The alpha(1B)3i domain-provoked inhibition of homologous receptor signaling was surmountable at high receptor density, and assays using a phorbol response element/reporter gene construct detected a weak enhancement of basal second messenger generation in cells expressing the alpha(1B)3i domain alone. These data demonstrate that disruption of receptor/G protein coupling by 3i domain peptides 1) can be generalized to both G(q)- and G(i)-coupled receptors and 2) Likely results from the ability of these peptides to act as competitive weak partial agonists at the receptor/G protein interface.	DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT MED,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710	Duke University; Howard Hughes Medical Institute; Duke University; Duke University			Lefkowitz, Robert/AAW-2649-2021	Luttrell, Louis/0000-0003-2805-6949	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016037, R37HL016037] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL16037] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASHKENAZI A, 1987, SCIENCE, V238, P672, DOI 10.1126/science.2823384; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; CHEUNG AH, 1991, FEBS LETT, V279, P277, DOI 10.1016/0014-5793(91)80167-2; COTECCHIA S, 1988, P NATL ACAD SCI USA, V85, P7159, DOI 10.1073/pnas.85.19.7159; COTECCHIA S, 1992, J BIOL CHEM, V267, P1633; COTECCHIA S, 1990, J BIOL CHEM, V265, P63; COTECCHIA S, 1990, P NATL ACAD SCI USA, V87, P2896, DOI 10.1073/pnas.87.8.2896; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DALMAN HM, 1991, J BIOL CHEM, V266, P11025; DEARRY A, 1990, NATURE, V347, P72, DOI 10.1038/347072a0; DIDSBURY JR, 1991, P NATL ACAD SCI USA, V88, P11564, DOI 10.1073/pnas.88.24.11564; DIXON RAF, 1988, COLD SPRING HARB SYM, V53, P487, DOI 10.1101/SQB.1988.053.01.056; DOHLMAN HG, 1988, BIOCHEMISTRY-US, V27, P1813, DOI 10.1021/bi00406a002; EATON DL, 1986, BIOCHEMISTRY-US, V25, P8343, DOI 10.1021/bi00374a001; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; GUTOWSKI S, 1991, J BIOL CHEM, V266, P20519; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; KOBILKA BK, 1987, SCIENCE, V238, P650, DOI 10.1126/science.2823383; KONIG B, 1989, P NATL ACAD SCI USA, V86, P6878, DOI 10.1073/pnas.86.18.6878; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KUROSE H, 1993, MOL PHARMACOL, V43, P444; LUTTRELL LM, 1993, SCIENCE, V259, P1453, DOI 10.1126/science.8383880; MUKAI H, 1992, J BIOL CHEM, V267, P16237; ODOWD BF, 1988, J BIOL CHEM, V263, P15985; OKAMOTO T, 1991, CELL, V67, P723, DOI 10.1016/0092-8674(91)90067-9; OKAMOTO T, 1992, J BIOL CHEM, V267, P8342; PEI G, 1994, IN PRESS P NATL ACAD; PERALTA EG, 1987, EMBO J, V6, P3923, DOI 10.1002/j.1460-2075.1987.tb02733.x; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; STRADER CD, 1987, J BIOL CHEM, V262, P16439; STRADER CD, 1987, CELL, V49, P855, DOI 10.1016/0092-8674(87)90623-4; TAYLOR S, 1990, NATURE, V350, P516; TAYLOR SJ, 1990, J BIOL CHEM, V265, P17150; WU DQ, 1992, J BIOL CHEM, V267, P25798; WU DQ, 1992, J BIOL CHEM, V267, P1811	39	89	90	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15776	15785						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	8195232				2022-12-25	WOS:A1994NP51300060
J	LAVOIE, BD; CHACONAS, G				LAVOIE, BD; CHACONAS, G			A 2ND HIGH-AFFINITY HU BINDING-SITE IN THE PHAGE-MU TRANSPOSOSOME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRATION HOST FACTOR; STRAND TRANSFER-REACTION; HISTONE-LIKE PROTEINS; ESCHERICHIA-COLI; DNA-BINDING; TRANSPOSITIONAL ENHANCER; BACTERIOPHAGE-LAMBDA; ATTACHMENT-SITE; COMPLEXES; INVITRO	The bacteriophage Mu in vitro transposition reaction proceeds through several higher order nucleoprotein intermediates (transpososomes). One of the requirements for complex assembly is the Escherichia coli sequence-independent DNA-binding protein, HU. This protein has an affinity for Mu transpososomes, which is at least 100 times greater than for supercolied DNA (Lavoie and Chaconas, 1990). We have recently identified one such high affinity binding site at the Mu left end by converting HU into a chemical nuclease (Lavoie and Chaconas, 1993). Using immunoelectron microscopy, we now report high affinity HU binding to a region(s) distinct from the previously characterized left end site. HU can be removed from this region by a 0.5 M NaCl wash and subsequently reassembled into the complex with high efficiency. Furthermore, chemical modification of the Mu A protein in the Type 1 complex does not block HU reassembly into the transpososome; the high affinity HU binding observed is therefore unlikely to result from A-HU interactions. These findings are corroborated by the ability of eukaryotic HMG-1 to functionally replace HU in transpososome formation and to efficiently assemble into HU-depleted complexes. We propose that HU recognition of an altered DNA structure, rather than protein-protein interactions, mediates high affinity HU binding to Mu transpososomes.			LAVOIE, BD (corresponding author), UNIV WESTERN ONTARIO, DEPT BIOCHEM, LONDON N6A 5C1, ON, CANADA.							ADZUMA K, 1988, STRUCTURE EXPRESSION, V3, P97; BAKER TA, 1992, GENE DEV, V6, P2221, DOI 10.1101/gad.6.11.2221; BAKER TA, 1993, CELL, V74, P723, DOI 10.1016/0092-8674(93)90519-V; BAKER TA, 1991, CELL, V65, P1003, DOI 10.1016/0092-8674(91)90552-A; BHATTACHARYYA A, 1991, J MOL BIOL, V221, P1191, DOI 10.1016/0022-2836(91)90928-Y; BIANCHI ME, 1989, SCIENCE, V243, P1056, DOI 10.1126/science.2922595; BOOCOCK MR, 1992, TRENDS GENET, V8, P151, DOI 10.1016/0168-9525(92)90206-J; CRAIGIE R, 1984, CELL, V39, P387, DOI 10.1016/0092-8674(84)90017-5; CRAIGIE R, 1987, CELL, V51, P493, DOI 10.1016/0092-8674(87)90645-3; DING ZM, 1993, NUCLEIC ACIDS RES, V21, P4281, DOI 10.1093/nar/21.18.4281; DRLICA K, 1987, MICROBIOL REV, V51, P310; DUCKETT DR, 1988, CELL, V55, P79, DOI 10.1016/0092-8674(88)90011-6; FUNNELL BE, 1987, J BIOL CHEM, V262, P10327; GOODMAN SD, 1992, P NATL ACAD SCI USA, V89, P11910, DOI 10.1073/pnas.89.24.11910; Haniford DB, 1992, CURR OPIN GENET DEV, V2, P698, DOI 10.1016/S0959-437X(05)80129-7; HAYKINSON MJ, 1993, EMBO J, V12, P2503, DOI 10.1002/j.1460-2075.1993.tb05905.x; HODGESGARCIA Y, 1989, J BIOL CHEM, V264, P14621; HWANG DS, 1992, J BIOL CHEM, V267, P23083; Kleinschmidt A.K.=, 1968, METHODS ENZYMOL, V12, P361; KUO CF, 1991, EMBO J, V10, P1585, DOI 10.1002/j.1460-2075.1991.tb07679.x; LANDSMAN D, 1993, BIOESSAYS, V15, P539, DOI 10.1002/bies.950150807; LAVOIE BD, 1993, GENE DEV, V7, P2510, DOI 10.1101/gad.7.12b.2510; LAVOIE BD, 1991, EMBO J, V10, P3051, DOI 10.1002/j.1460-2075.1991.tb07856.x; LAVOIE BD, 1990, J BIOL CHEM, V265, P1623; LEUNG PC, 1989, NATURE, V338, P656, DOI 10.1038/338656a0; LILLEY DMJ, 1992, NATURE, V357, P282, DOI 10.1038/357282a0; MIZUUCHI K, 1992, ANNU REV BIOCHEM, V61, P1011; MIZUUCHI M, 1992, CELL, V70, P303, DOI 10.1016/0092-8674(92)90104-K; MIZUUCHI M, 1991, P NATL ACAD SCI USA, V88, P9031, DOI 10.1073/pnas.88.20.9031; MIZUUCHI M, 1989, CELL, V58, P399, DOI 10.1016/0092-8674(89)90854-4; MURCHIE AIH, 1989, NATURE, V341, P763, DOI 10.1038/341763a0; NASH HA, 1990, TRENDS BIOCHEM SCI, V15, P222, DOI 10.1016/0968-0004(90)90034-9; NASH HA, 1987, J BACTERIOL, V169, P4124, DOI 10.1128/jb.169.9.4124-4127.1987; PAULL TT, 1993, GENE DEV, V7, P1521, DOI 10.1101/gad.7.8.1521; PETTIJOHN DE, 1988, J BIOL CHEM, V263, P12793; PONTIGGIA A, 1993, MOL MICROBIOL, V7, P343, DOI 10.1111/j.1365-2958.1993.tb01126.x; SCHMID MB, 1990, CELL, V63, P451, DOI 10.1016/0092-8674(90)90438-K; SERRANO M, 1993, TRENDS BIOCHEM SCI, V18, P202, DOI 10.1016/0968-0004(93)90187-R; SULLIVAN KM, 1987, J MOL BIOL, V193, P397, DOI 10.1016/0022-2836(87)90227-0; SURETTE MG, 1989, J BIOL CHEM, V264, P3028; SURETTE MG, 1989, EMBO J, V8, P3483, DOI 10.1002/j.1460-2075.1989.tb08513.x; SURETTE MG, 1992, CELL, V68, P1101, DOI 10.1016/0092-8674(92)90081-M; SURETTE MG, 1987, CELL, V49, P253, DOI 10.1016/0092-8674(87)90566-6; WESTMORELAND BC, 1969, SCIENCE, V163, P1343, DOI 10.1126/science.163.3873.1343; WHITE SW, 1989, PROTEINS, V5, P281, DOI 10.1002/prot.340050405; WU ZG, 1992, J BIOL CHEM, V267, P9552; ZHONG M, 1993, J MOL BIOL, V230, P766, DOI 10.1006/jmbi.1993.1199; ZOU A, 1991, J BIOL CHEM, V266, P20476	48	46	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15571	15576						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	8195202				2022-12-25	WOS:A1994NP51300030
J	RALSTON, E; BEUSHAUSEN, S; PLOUG, T				RALSTON, E; BEUSHAUSEN, S; PLOUG, T			EXPRESSION OF THE SYNAPTIC VESICLE PROTEINS VAMPS/SYNAPTOBREVIN-1 AND VAMPS/SYNAPTOBREVIN-2 IN NONNEURAL TISSUES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							INTEGRAL MEMBRANE-PROTEIN; RAT SKELETAL-MUSCLE; GLUCOSE TRANSPORTER; SYSTEMIC DELIVERY; FUSION PROTEIN; INSULIN; GENES; IDENTIFICATION; SYNAPTOBREVIN; LOCALIZATION	The VAMPs/synaptobrevins (Vp/Sybs) are small integral membrane proteins. Two isoforms, Vp/Syb 1 and Vp/Syb 2, are considered to be specific to neural tissue. They are associated with synaptic vesicles and are believed to play an important role in neurotransmitter release. A third isoform, cellubrevin, has recently been found in non-neural tissues. We now report that the distribution of Vp/Syb 1 and Vp/Syb 2 is wider than previously thought. RNA transcripts for both Vp/Syb 1 and Vp/Syb 2 were found in rat skeletal muscle and in several other rat non-neural tissues, and antibodies specific for Vp/Syb 2 detected a protein in the endoplasmic reticulum-Golgi area of skeletal muscle. Thus Vp/Sybs 1 and 2 are not restricted to the nervous system but appear to be co-expressed with cellubrevin in many different tissues. This redundancy of Vp/Sybs in a single cell may be required to control the specificity of vesicle-target interaction in the several pathways of intracellular vesicle traffic that are operative within each cell.	NIDDK,EXPTL DIABET METAB & NUTR SECT,DIABET BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	RALSTON, E (corresponding author), NINCDS,NEUROBIOL LAB,BETHESDA,MD 20892, USA.			Ploug, Thorkil/0000-0002-5375-6595				ARCHER BT, 1990, J BIOL CHEM, V265, P17267; BARR E, 1991, SCIENCE, V254, P1507, DOI 10.1126/science.1962212; BAUMERT M, 1989, EMBO J, V8, P379, DOI 10.1002/j.1460-2075.1989.tb03388.x; BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BENNETT MK, 1993, P NATL ACAD SCI USA, V90, P2559, DOI 10.1073/pnas.90.7.2559; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BORNEMANN A, 1992, DIABETES, V41, P215, DOI 10.2337/diabetes.41.2.215; CAIN CC, 1992, J BIOL CHEM, V267, P11681; CALAKOS N, 1994, SCIENCE, V263, P1146, DOI 10.1126/science.8108733; DAN Y, 1992, NATURE, V359, P733, DOI 10.1038/359733a0; DHAWAN J, 1991, SCIENCE, V254, P1509, DOI 10.1126/science.1962213; ELFERINK LA, 1989, J BIOL CHEM, V264, P11061; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; JAHN R, 1993, J NEUROCHEM, V61, P12, DOI 10.1111/j.1471-4159.1993.tb03533.x; KELLY AM, 1969, J CELL BIOL, V42, P154, DOI 10.1083/jcb.42.1.154; LEUBE RE, 1987, EMBO J, V6, P3261, DOI 10.1002/j.1460-2075.1987.tb02644.x; MALHOTRA V, 1988, CELL, V54, P221, DOI 10.1016/0092-8674(88)90554-5; MATTHEW WD, 1981, J CELL BIOL, V91, P257, DOI 10.1083/jcb.91.1.257; MCMAHON HT, 1993, NATURE, V364, P346, DOI 10.1038/364346a0; OYLER GA, 1989, J CELL BIOL, V109, P3039, DOI 10.1083/jcb.109.6.3039; PLOUG T, 1992, AM J PHYSIOL, V262, pE700, DOI 10.1152/ajpendo.1992.262.5.E700; PLOUG T, 1990, AM J PHYSIOL, V259, pE778, DOI 10.1152/ajpendo.1990.259.6.E778; Ploug T., 1993, Molecular Biology of the Cell, V4, p429A; RALSTON E, 1993, J CELL BIOL, V120, P399, DOI 10.1083/jcb.120.2.399; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SUDHOF TC, 1989, NEURON, V2, P1475, DOI 10.1016/0896-6273(89)90193-1; TRIMBLE WS, 1990, J NEUROSCI, V10, P1380; TRIMBLE WS, 1988, P NATL ACAD SCI USA, V85, P4538, DOI 10.1073/pnas.85.12.4538; WEIDMAN PJ, 1989, J CELL BIOL, V108, P1589, DOI 10.1083/jcb.108.5.1589; YAMASHIRO DJ, 1984, CELL, V37, P789, DOI 10.1016/0092-8674(84)90414-8	33	60	65	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15403	15406						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	8195178				2022-12-25	WOS:A1994NP51300002
J	GUPTA, K; CHEVRETTE, M; GRAY, DA				GUPTA, K; CHEVRETTE, M; GRAY, DA			THE UNP PROTOONCOGENE ENCODES A NUCLEAR-PROTEIN	ONCOGENE			English	Note							RETINOBLASTOMA GENE-PRODUCT; LARGE T-ANTIGEN; TRE ONCOGENE; NUCLEOTIDE-SEQUENCES; CELLULAR PROTEINS; BINDING; ADENOVIRUS-E1A; CLONING; RECOMBINATION; EXPRESSION	The mouse Unp gene is related to TRE17, a human oncogene, but is not its mouse homolog. Unp is a ubiquitously expressed gene producing two related mRNAs. The protein product of Unp is localized in the nucleus. Expression of Unp from a highly active promoter results in tumorigenic transformation of NIH3T3 cells injected into athymic mice. Unp therefore encodes a novel nuclear oncoprotein.	UNIV OTTAWA,DEPT BIOCHEM,OTTAWA K1H 8M5,ON,CANADA; UNIV OTTAWA,DEPT MED,OTTAWA K1H 8M5,ON,CANADA	University of Ottawa; University of Ottawa			/U-3554-2018	/0000-0002-8634-4984				CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DARNELL J, 1986, MOL CELL BIOL, P319; DEFEOJONES D, 1991, NATURE, V352, P251, DOI 10.1038/352251a0; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; GALLIONE CJ, 1981, J VIROL, V39, P529, DOI 10.1128/JVI.39.2.529-535.1981; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUPTA K, 1993, ONCOGENE, V8, P2307; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUEBNER K, 1988, ONCOGENE, V3, P449; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; MCBURNEY MW, 1991, NUCLEIC ACIDS RES, V19, P5755, DOI 10.1093/nar/19.20.5755; NAKAMURA T, 1992, ONCOGENE, V7, P733; NAKAMURA T, 1988, ONCOGENE RES, V2, P357; NEVINS JR, 1992, SCIENCE, V258, P424; ONNO M, 1992, ONCOGENE, V7, P2519; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; Sambrook J, 1989, MOL CLONING LABORATO; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; TANG ZH, 1993, EMBO J, V12, P3427, DOI 10.1002/j.1460-2075.1993.tb06017.x; VARA JA, 1986, NUCLEIC ACIDS RES, V14, P4617, DOI 10.1093/nar/14.11.4617; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993	24	66	69	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1994	9	6					1729	1731						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NL815	8183569				2022-12-25	WOS:A1994NL81500026
J	EXLEY, M; VARTICOVSKI, L; PETER, M; SANCHO, J; TERHORST, C				EXLEY, M; VARTICOVSKI, L; PETER, M; SANCHO, J; TERHORST, C			ASSOCIATION OF PHOSPHATIDYLINOSITOL 3-KINASE WITH A SPECIFIC SEQUENCE OF THE T-CELL RECEPTOR XI-CHAIN IS DEPENDENT ON T-CELL ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; MEDIATED SIGNAL TRANSDUCTION; TCR ZETA-CHAIN; ANTIGEN RECEPTOR; MICE LACKING; CD3 COMPLEX; DOMAIN; PHOSPHORYLATION; BINDING; STIMULATION	The T cell antigen receptor (TCR) CDS complex contains several distinct but related signal transduction modules termed ''Reth motifs'': one each in the cytoplasmic domains of CD3-gamma, -delta, and -epsilon chains and three in the CD3-zeta polypeptide (zeta(A), zeta(B), and zeta(C)). Cross-linking of individual motifs expressed in chimeric molecules leads to early and late T cell activation events. Although the activated T cell receptor associates with nonreceptor tyrosine kinases, the sites of interaction with kinases and other potential effector molecules have not been fully mapped. Here we show that phosphatidylinositol 3-kinase (PI 3-kinase) preferentially associated with the zeta chain membrane proximal motif zeta(A). Maximal PI 3-kinase/zeta(A) association occurred following TCR.CD3 activation and was dependent upon phosphorylation of both tyrosine residues in zeta(A). The association of PI 3-kinase was specific for zeta(A) and could be ranked zeta(A) >> zeta(C) > zeta(B). Phosphorylation of the zeta(A) motif on tyrosine residues occurred in response to TCR.CD3 cross-linking in vivo. These results indicate that T cell activation leads to assembly of an intracellular signaling complex: recruitment of a tyrosine kinase, phosphorylation of zeta(A), and association of PI 3-kinase. These data also support a model in which different Reth motifs of the TCR.CD3 complex recruit distinct signal transduction molecules. Thus, the subdomains of the T cell antigen receptor zeta chain may serve different roles during T cell maturation and antigen-driven activation.	HARVARD UNIV, BETH ISRAEL HOSP, SCH MED, DIV IMMUNOL, BOSTON, MA 02215 USA; TUFTS UNIV, ST ELIZABETHS HOSP, SCH MED, DEPT BIOMED RES, BOSTON, MA 02135 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Tufts University			Sancho, Jaime/O-3228-2013; Sancho, Jaime/K-5989-2019	Sancho, Jaime/0000-0003-3852-7951; Sancho, Jaime/0000-0003-3852-7951; Exley, Mark/0000-0002-5088-1032; Varticovski, Lyuba/0000-0002-5105-9008; Peter, Marcus Ernst/0000-0003-3216-036X	NATIONAL CANCER INSTITUTE [R29CA053094, R01CA053094] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI015066, R56AI015066] Funding Source: NIH RePORTER; NCI NIH HHS [NCI CA53094] Funding Source: Medline; NIAID NIH HHS [AI15066] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; ASHWELL JD, 1990, ANNU REV IMMUNOL, V8, P139, DOI 10.1146/annurev.immunol.8.1.139; BANIYASH M, 1988, J BIOL CHEM, V263, P18225; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1993, J BIOL CHEM, V268, P9478; CHAN AC, 1991, P NATL ACAD SCI USA, V88, P9166, DOI 10.1073/pnas.88.20.9166; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CLARK MR, 1992, SCIENCE, V258, P123, DOI 10.1126/science.1439759; DASGUPTA JD, 1992, J EXP MED, V175, P285, DOI 10.1084/jem.175.1.285; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; EXLEY M, 1991, SEMIN IMMUNOL, V3, P287; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; GARDNER P, 1989, CELL, V59, P15, DOI 10.1016/0092-8674(89)90865-9; GAUEN LKT, 1992, MOL CELL BIOL, V12, P5438, DOI 10.1128/MCB.12.12.5438; HALL CG, 1993, SCIENCE, V261, P915, DOI 10.1126/science.8346442; HE TC, 1993, BLOOD, V82, P3530; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; IRVING BA, 1993, J EXP MED, V177, P1093, DOI 10.1084/jem.177.4.1093; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KANAGAWA O, 1991, J IMMUNOL, V147, P1307; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; KOYASU S, 1992, J BIOL CHEM, V267, P3375; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; PANAYOTU G, 1992, NATURE, V358, P684; PARK DJ, 1991, P NATL ACAD SCI USA, V88, P5453, DOI 10.1073/pnas.88.12.5453; PETER ME, 1992, EMBO J, V11, P933, DOI 10.1002/j.1460-2075.1992.tb05132.x; PONZETTO C, 1993, MOL CELL BIOL, V13, P4600, DOI 10.1128/MCB.13.8.4600; PRASAD KVS, 1993, P NATL ACAD SCI USA, V90, P7366, DOI 10.1073/pnas.90.15.7366; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; REMILLARD B, 1991, J BIOL CHEM, V266, P14167; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; ROMEO C, 1992, CELL, V68, P889, DOI 10.1016/0092-8674(92)90032-8; ROMEO C, 1991, CELL, V64, P1037, DOI 10.1016/0092-8674(91)90327-U; RUDD CE, 1990, IMMUNOL TODAY, V11, P400, DOI 10.1016/0167-5699(90)90159-7; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SANCHO J, 1993, J IMMUNOL, V150, P3230; SANCHO J, 1993, EUR J IMMUNOL, V23, P1636, DOI 10.1002/eji.1830230736; SANCHO J, 1992, J BIOL CHEM, V267, P7871; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; THOMPSON PA, 1992, ONCOGENE, V7, P719; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; VEILLETTE A, 1992, IMMUNOL TODAY, V8, P61; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WARD SG, 1992, EUR J IMMUNOL, V22, P45, DOI 10.1002/eji.1830220108; WEGENER AMK, 1992, CELL, V68, P83, DOI 10.1016/0092-8674(92)90208-T; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; WEISSMAN AM, 1988, P NATL ACAD SCI USA, V85, P9709, DOI 10.1073/pnas.85.24.9709; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	53	115	118	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					15140	15146						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195151				2022-12-25	WOS:A1994NP73800045
J	TEZUKA, K; NEMOTO, K; TEZUKA, Y; SATO, T; IKEDA, Y; KOBORI, M; KAWASHIMA, H; EGUCHI, H; HAKEDA, Y; KUMEGAWA, M				TEZUKA, K; NEMOTO, K; TEZUKA, Y; SATO, T; IKEDA, Y; KOBORI, M; KAWASHIMA, H; EGUCHI, H; HAKEDA, Y; KUMEGAWA, M			IDENTIFICATION OF MATRIX METALLOPROTEINASE-9 IN RABBIT OSTEOCLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE-RESORPTION; CATHEPSIN-L; CYSTEINE-PROTEINASES; POLYMORPHONUCLEAR LEUKOCYTES; COLLAGENOLYTIC CATHEPSIN; IV COLLAGENASE; RAT-LIVER; DEGRADATION; GELATINASE; TISSUE	Osteoclasts are multinucleate giant cells that play key roles in bone resorption. To identify genes predominantly expressed in osteoclasts, we screened a cDNA library of osteoclasts with cDNA probes of osteoclasts and alveolar macrophages. Clones specifically hybridizing to the osteoclast probe were isolated and sequenced. The nucleotide sequence of one such clone, F17, was found to share significant similarity with the sequences of human and mouse matrix metalloproteinase 9 (MMP-9) cDNA By isolation and sequencing of the full-length cDNA, F17 was revealed to encode the rabbit counterpart of MMP-9. By Northern blotting, messenger RNA for MMP-9 was found to be highly and predominantly expressed in isolated osteoclasts when compared with its level in alveolar macrophages and other tissues. By gelatin zymography, gelatinase activity was detected in conditioned medium of isolated osteoclasts, suggesting that MMP-9 is secreted by isolated osteoclasts. Expression of MMP-9 was also observed in in vivo osteoclasts in metacarpal bones of newborn rabbits by in situ hybridization. These facts suggest that MMP-9 is one of the major proteases produced by osteoclasts and possibly plays a role in osteoclastic bone resorption.	MEIKAI UNIV,SCH DENT,DEPT ORAL ANAT,SAKADO,SAITAMA 35002,JAPAN; ST MARIANNA UNIV,SCH MED,DEPT INTERNAL MED 3,KAWASAKI,KANAGAWA 216,JAPAN; YAMANOUCHI PHARMACEUT CO LTD,MOLEC MED RES LABS,TSUKUBA,IBARAKI 305,JAPAN; TEIJIN LTD,INST BIOMED RES,HINO,TOKYO 191,JAPAN	Meikai University; Saint Marianna University; Astellas Pharmaceuticals; Teijin Limited			Tezuka, Ken-ichi/B-3836-2012					BARON R, 1989, ANAT RECORD, V224, P317, DOI 10.1002/ar.1092240220; BARON R, 1985, J CELL BIOL, V101, P2210, DOI 10.1083/jcb.101.6.2210; BLAIR HC, 1993, BIOCHEM J, V290, P873, DOI 10.1042/bj2900873; BURLEIGH MC, 1974, BIOCHEM J, V137, P387, DOI 10.1042/bj1370387; DELAISSE JM, 1987, BONE, V8, P305, DOI 10.1016/8756-3282(87)90007-X; DELAISSE JM, 1991, BIOCHEM J, V279, P167, DOI 10.1042/bj2790167; ETHERINGTON DJ, 1972, BIOCHEM J, V127, P685, DOI 10.1042/bj1270685; ETHERINGTON DJ, 1987, COLLAGEN REL RES, V7, P185; EVANS P, 1978, EUR J BIOCHEM, V83, P87, DOI 10.1111/j.1432-1033.1978.tb12071.x; EVERTS V, 1988, CALCIFIED TISSUE INT, V43, P172, DOI 10.1007/BF02571316; EVERTS V, 1992, J CELL PHYSIOL, V150, P221, DOI 10.1002/jcp.1041500202; HIBBS MS, 1987, J CLIN INVEST, V80, P1644, DOI 10.1172/JCI113253; HIBBS MS, 1985, J BIOL CHEM, V260, P2493; HILL PA, 1993, BIOCHIM BIOPHYS ACTA, V1177, P71, DOI 10.1016/0167-4889(93)90159-M; KAKEGAWA H, 1993, FEBS LETT, V321, P247, DOI 10.1016/0014-5793(93)80118-E; KIRSCHKE H, 1989, BIOCHEM J, V264, P467, DOI 10.1042/bj2640467; KIRSCHKE H, 1982, BIOCHEM J, V201, P367, DOI 10.1042/bj2010367; MACIEWICZ RA, 1987, COLLAGEN REL RES, V7, P295; MACIEWICZ RA, 1988, BIOCHEM J, V256, P433, DOI 10.1042/bj2560433; MURPHY G, 1989, BIOCHEM J, V258, P463, DOI 10.1042/bj2580463; MURPHY G, 1982, BIOCHEM J, V203, P209, DOI 10.1042/bj2030209; MURPHY G, 1991, BIOCHEM J, V277, P277, DOI 10.1042/bj2770277; NAKAJIMAIIJIMA S, 1985, P NATL ACAD SCI USA, V82, P6133, DOI 10.1073/pnas.82.18.6133; OKAMURA T, 1993, CALCIFIED TISSUE INT, V52, P325, DOI 10.1007/BF00296659; RIFKIN BR, 1991, BIOCHEM BIOPH RES CO, V179, P63, DOI 10.1016/0006-291X(91)91334-9; SENIOR RM, 1991, J BIOL CHEM, V266, P7870; SHIMIZU H, 1990, J BONE MINER RES, V5, P411, DOI 10.1002/jbmr.5650050415; SOPATA I, 1974, BIOCHIM BIOPHYS ACTA, V370, P510, DOI 10.1016/0005-2744(74)90112-0; TANAKA H, 1993, BIOCHEM BIOPH RES CO, V190, P732, DOI 10.1006/bbrc.1993.1110; TEZUKA K, 1994, J BIOL CHEM, V269, P1106; TEZUKA K, 1992, BIOCHEM BIOPH RES CO, V186, P911, DOI 10.1016/0006-291X(92)90832-6; WILHELM SM, 1989, J BIOL CHEM, V264, P17213	32	142	146	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					15006	15009						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195136				2022-12-25	WOS:A1994NP73800027
J	LEE, YH; ALBERTA, JA; GONZALEZ, FJ; WAXMAN, DJ				LEE, YH; ALBERTA, JA; GONZALEZ, FJ; WAXMAN, DJ			MULTIPLE, FUNCTIONAL DBP SITES ON THE PROMOTER OF THE CHOLESTEROL 7-ALPHA-HYDROXYLASE P450 GENE, CYP7 - PROPOSED ROLE IN DIURNAL REGULATION OF LIVER GENE-EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENRICHED TRANSCRIPTIONAL ACTIVATOR; BILE-ACID BIOSYNTHESIS; MESSENGER-RNA LEVELS; RAT-LIVER; CIRCADIAN-RHYTHM; BINDING-PROTEIN; ALPHA-HYDROXYLASE; MOLECULAR-CLONING; HEPATOMA-CELLS; ENZYME	Hepatic cytochrome P450 cholesterol 7 alpha-hydroxylase, CYP7, is regulated in vivo at the protein and the mRNA level in response to multiple physiological factors, including liver cholesterol synthesis, bile acid feedback inhibition, and diurnal rhythm. In the present study we investigated whether the liver transcription factor DBP (albumin promoter D-site binding protein), which undergoes a striking diurnal rhythm in rat liver (DBP levels during evening/morning similar to 100:1), contributes to the diurnal regulation of CYP7 gene expression. DNase I footprinting analysis using bacterially expressed DEP and a cloned 5'-flanking DNA segment of the rat CYP7 gene revealed five distinct DBP-binding sites, designated A-E, distributed between nucleotides (nts) -41 and -295 relative to the CYP7 transcription start site. CYP7-directed gene transcription in HepG2 cells transfected with a 5'-CYP7 promoter-chloramphenicol acetyltransferase reporter was activated up to 12-fold upon cotransfection of a DBP expression vector, whereas an HNF-1 alpha expression vector did not stimulate CYP7 gene activity. 5'-Deletion analyses and site-specific mutagenesis revealed that this stimulating effect of DBP can in part be ascribed to its functional interaction with DBP binding sites B (nts -115/-125), C (nts -172/-195), and D (nts -214/-230). C/EBP beta (LAP), another liver enriched basic-leucine zipper transcription factor, bound to these same sites but effected a more modest increase in CYP7-directed gene transcription (up to 3-4-fold) when expressed in HepG2 cells. Competition for CYP7 promoter-binding sites between C/EBP, which undergoes less than or equal to 2-fold diurnal change in rat liver, and the diurnally regulated DBP is proposed to determine the relative rates of basal versus diurnally regulated CYP7 gene transcription and thus may be a primary mechanism for setting the 3-6-fold amplitude that characterizes the circadian rhythm of liver CYP7 expression. Moreover, since DBP is first expressed in rat liver 3-4 weeks after birth, these findings may account for both the enhanced expression and the onset of the diurnal pattern of CYP7 enzyme levels at this stage of development.	NCI,MOLEC CARCINOGENESIS LAB,BETHESDA,MD 20892; HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School				Waxman, David/0000-0001-7982-9206	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033765] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK33765] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSSON S, 1989, J BIOL CHEM, V264, P16249; CLARKE CF, 1984, J BIOL CHEM, V259, P439; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; DROLET DW, 1991, GENE DEV, V5, P1739, DOI 10.1101/gad.5.10.1739; DUANE WC, 1979, AM J PHYSIOL, V236, pR175, DOI 10.1152/ajpregu.1979.236.3.R175; DUANE WC, 1983, J CLIN INVEST, V72, P1930, DOI 10.1172/JCI111157; FEARS R, 1986, CHOLESTEROL 7 ALPHA, P1; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; GIELEN J, 1975, EUR J BIOCHEM, V55, P41, DOI 10.1111/j.1432-1033.1975.tb02136.x; GIELEN JE, 1976, ARCH TOXICOL, V36, P255, DOI 10.1007/BF00340533; GONZALEZ F J, 1992, Keio Journal of Medicine, V41, P68; GONZALEZ FJ, 1990, DNA CELL BIOL, V9, P771, DOI 10.1089/dna.1990.9.771; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREGORI C, 1993, NUCLEIC ACIDS RES, V21, P897, DOI 10.1093/nar/21.4.897; HASSAN AS, 1992, BIOCHEM PHARMACOL, V44, P1475, DOI 10.1016/0006-2952(92)90553-U; JAVITT NB, 1990, FASEB J, V4, P161, DOI 10.1096/fasebj.4.2.2153592; JELINEK DF, 1990, BIOCHEMISTRY-US, V29, P7781, DOI 10.1021/bi00486a001; JELINEK DF, 1990, J BIOL CHEM, V265, P8190; JOHNSON PF, 1990, CELL GROWTH DIFFER, V1, P47; LAI E, 1991, TRENDS BIOCHEM SCI, V16, P427, DOI 10.1016/0968-0004(91)90169-V; LAVERY DJ, 1993, GENE DEV, V7, P1871, DOI 10.1101/gad.7.10.1871; LEE YH, 1994, IN PRESS MOL CELL BI; LI YC, 1990, J BIOL CHEM, V265, P12012; MCGUIRE DM, 1985, J BIOL CHEM, V260, P5435; MEIER AH, 1975, ENDOCRINOLOGY, V98, P1475; MENDEL DB, 1991, J BIOL CHEM, V266, P677; MITROPOULOS KA, 1973, BIOCHIM BIOPHYS ACTA, V326, P428, DOI 10.1016/0005-2760(73)90143-4; MOLOWA DT, 1992, BIOCHEMISTRY-US, V31, P2539, DOI 10.1021/bi00124a014; MUELLER CR, 1990, CELL, V61, P279, DOI 10.1016/0092-8674(90)90808-R; MYANT NB, 1977, J LIPID RES, V18, P135; NELSON DR, 1993, DNA CELL BIOL, V12, P1, DOI 10.1089/dna.1993.12.1; NISHIMOTO M, 1993, BIOCHIM BIOPHYS ACTA, V1172, P147, DOI 10.1016/0167-4781(93)90281-H; NISHIMOTO M, 1991, J BIOL CHEM, V266, P6467; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; NOSHIRO M, 1989, FEBS LETT, V257, P97, DOI 10.1016/0014-5793(89)81795-8; NOSHIRO M, 1990, FEBS LETT, V268, P137, DOI 10.1016/0014-5793(90)80992-R; NOSHIRO M, 1990, J BIOL CHEM, V265, P10036; PANDAK WM, 1991, J BIOL CHEM, V266, P3416; PICKETTS DJ, 1993, NAT GENET, V3, P175, DOI 10.1038/ng0293-175; ROESLER WJ, 1992, J BIOL CHEM, V267, P21235; RUSSELL DW, 1992, BIOCHEMISTRY-US, V31, P4737, DOI 10.1021/bi00135a001; SPADY DK, 1992, J BIOL CHEM, V267, P5584; STRAVITZ RT, 1993, J BIOL CHEM, V268, P13987; SUNDSETH SS, 1990, J BIOL CHEM, V265, P15090; SVENSSON EC, 1992, J BIOL CHEM, V267, P3466; UENO T, 1990, MOL CELL BIOL, V10, P4495, DOI 10.1128/MCB.10.9.4495; VANOOIJ C, 1992, MOL CELL BIOL, V12, P3023, DOI 10.1128/MCB.12.7.3023; VLAHCEVIC ZR, 1991, HEPATOLOGY, V13, P590, DOI 10.1002/hep.1840130331; WAXMAN DJ, 1986, ARCH BIOCHEM BIOPHYS, V247, P335, DOI 10.1016/0003-9861(86)90592-8; WAXMAN DJ, 1985, BIOCHEMISTRY-US, V24, P4409, DOI 10.1021/bi00337a023; WAXMAN DJ, 1992, J STEROID BIOCHEM, V43, P1055, DOI 10.1016/0960-0760(92)90333-E; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; WUARIN J, 1990, CELL, V63, P1257, DOI 10.1016/0092-8674(90)90421-A; YANO M, 1992, MOL CELL BIOL, V12, P2847, DOI 10.1128/MCB.12.6.2847	54	80	81	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14681	14689						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	8182075				2022-12-25	WOS:A1994NM06500060
J	ZHANG, L; GUARENTE, L				ZHANG, L; GUARENTE, L			HAP1 IS NUCLEAR BUT IS BOUND TO A CELLULAR FACTOR IN THE ABSENCE OF HEME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; UPSTREAM ACTIVATION SITES; TRANSCRIPTIONAL ACTIVATION; GLUCOCORTICOID RECEPTOR; DNA-BINDING; SEQUENCE; GENE; IDENTIFICATION; DOMAIN; SIGNAL	The activity of the yeast transcriptional activator HAP1 is controlled by heme. Previously, it has been shown that a heme-responsive domain containing multiple repeats of a conserved motif blocks DNA binding in the absence of heme. In this report, we show that HAP1 is sequestered in a high molecular weight complex in the absence of heme. Titration of the high molecular weight complex by addition of a non-DNA-binding form of HAP1 allows the protein to form dimeric complexes in the absence of heme in vitro and acquires partial transcriptional activity in vivo. The results indicate that one or more cellular factor(s) complexes with HAP1 and represses its activity in the absence of heme. Deletion of the heme domain prevents sequestration of HAP1 in the high molecular weight complex. We discuss these findings in a model that postulates that the heme domain of HAP1 can interact with other cellular factors to regulate HAP1.	MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA	Massachusetts Institute of Technology (MIT)			Zhang, Li/L-5206-2013	Zhang, Li/0000-0001-9242-0763	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030454] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM30454] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		DRYGAS ME, 1989, J BIOL CHEM, V264, P17897; DUMONT ME, 1987, EMBO J, V6, P235, DOI 10.1002/j.1460-2075.1987.tb04744.x; FORSBURG SL, 1989, ANNU REV CELL BIOL, V5, P153, DOI 10.1146/annurev.cb.05.110189.001101; FYTLOVICH S, 1993, EMBO J, V12, P1209, DOI 10.1002/j.1460-2075.1993.tb05762.x; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; GRONEMEYER H, 1991, ANNU REV GENET, V25, P89, DOI 10.1146/annurev.ge.25.120191.000513; GUARENTE L, 1984, CELL, V36, P503, DOI 10.1016/0092-8674(84)90243-5; HALDI M, 1989, J BIOL CHEM, V264, P17107; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; KIM KS, 1989, NATURE, V342, P200, DOI 10.1038/342200a0; LATHROP JT, 1993, SCIENCE, V259, P522, DOI 10.1126/science.8424176; PFEIFER K, 1989, CELL, V56, P291, DOI 10.1016/0092-8674(89)90903-3; PFEIFER K, 1987, CELL, V49, P19, DOI 10.1016/0092-8674(87)90751-3; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; PICARD D, 1990, NATURE, V348, P166, DOI 10.1038/348166a0; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P565; RENOIR JM, 1990, J BIOL CHEM, V265, P10740; ROSE MD, 1988, METHODS YEAST GENETI; ROTENBERG MO, 1991, ARCH BIOCHEM BIOPHYS, V290, P336, DOI 10.1016/0003-9861(91)90549-X; SCHENA M, 1988, SCIENCE, V241, P965, DOI 10.1126/science.3043665; SZE JY, 1992, SCIENCE, V258, P1143, DOI 10.1126/science.1439822; TURCOTTE B, 1992, GENE DEV, V6, P2001, DOI 10.1101/gad.6.10.2001; VERDIERE J, 1988, J MOL BIOL, V204, P277, DOI 10.1016/0022-2836(88)90575-X; ZHANG L, 1993, P NATL ACAD SCI USA, V90, P2851, DOI 10.1073/pnas.90.7.2851	24	55	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14643	14647						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	8182072				2022-12-25	WOS:A1994NM06500054
J	MACHLEIDT, T; WIEGMANN, K; HENKEL, T; SCHUTZE, S; BAEUERLE, P; KRONKE, M				MACHLEIDT, T; WIEGMANN, K; HENKEL, T; SCHUTZE, S; BAEUERLE, P; KRONKE, M			SPHINGOMYELINASE ACTIVATES PROTEOLYTIC I-KAPPA-B-ALPHA DEGRADATION IN A CELL-FREE SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; DORSAL-VENTRAL PATTERN; SERINE-PROTEASE; SIGNAL TRANSDUCTION; PHOSPHOLIPASE-C; CYTO-TOXICITY; NF-KB; DROSOPHILA; RECEPTORS; INHIBITOR	Tumor necrosis factor (TNF) is one of the most potent physiological inducers of the nuclear transcription factor kappa B (NF-kappa B). A key event in the activation of NF-kappa B is the rapid release of the inhibitory subunit I kappa B-alpha. Various inhibitors of serine-like proteases are shown to block TNF-mediated NF-kappa B activation as well as the disappearance of I kappa B-alpha immunoreactivity in primary murine T lymphocytes and in various human leukemic cell lines. The protease inhibitors did not block TNF induced activation of either phosphatidylcholine specific phospholipase C or acidic sphingomyelinase (SMase), indicating that the putative protease operates rather downstream of TNF signal transduction processes. I kappa B-alpha degradation could be directly induced by addition of sphingomyelinase or synthetic ceramide to a cell free system, indicating a stringent coupling of SMase to the NF-kappa B activation pathway. SMase-induced I kappa B-alpha degradation was suppressed by the protease inhibitor dichloroisocoumarin. Together, the data suggest that a TNF-responsive sphingomyelinase triggers the rapid degradation of I kappa B-alpha through a serine-like protease, which appears to be crucial to the control of NF-kappa B activation.	TECH UNIV MUNICH, INST MIKROBIOL & HYG, D-81675 MUNICH, GERMANY; UNIV FREIBURG, INST BIOCHEM, D-79014 FREIBURG, GERMANY	Technical University of Munich; University of Freiburg			Schütze, Stefan/C-8596-2011					BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BEUTLER B, 1988, ANNU REV BIOCHEM, V57, P505, DOI 10.1146/annurev.bi.57.070188.002445; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; CHASAN R, 1989, CELL, V56, P391, DOI 10.1016/0092-8674(89)90242-0; CHEN P, 1993, CELL, V74, P357, DOI 10.1016/0092-8674(93)90426-Q; DELOTTO R, 1986, NATURE, V323, P688, DOI 10.1038/323688a0; DJABALLAH H, 1992, EUR J BIOCHEM, V209, P629, DOI 10.1111/j.1432-1033.1992.tb17329.x; DOBROWSKY RT, 1993, J BIOL CHEM, V268, P15523; GERVAIX A, 1991, J IMMUNOL, V147, P1912; GOVIND S, 1991, TRENDS GENET, V7, P119, DOI 10.1016/0168-9525(91)90456-Z; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HARPER JW, 1985, BIOCHEMISTRY-US, V24, P1831, DOI 10.1021/bi00329a005; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HECHT P M, 1992, Trends in Cell Biology, V2, P197, DOI 10.1016/0962-8924(92)90246-J; HEGUY A, 1992, J BIOL CHEM, V267, P2605; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; KAWAKAMI K, 1988, P NATL ACAD SCI USA, V85, P4700, DOI 10.1073/pnas.85.13.4700; KIDD S, 1992, CELL, V71, P623, DOI 10.1016/0092-8674(92)90596-5; KRONKE M, 1982, J EXP MED, V156, P41, DOI 10.1084/jem.156.1.41; KRONKE M, 1991, TUMOR NECROSIS FACTO, P189; KRUPPA G, 1992, J IMMUNOL, V148, P3152; LENARDO MJ, 1988, P NATL ACAD SCI USA, V85, P8825, DOI 10.1073/pnas.85.23.8825; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; MACHLEIDT T, 1993, PATHOPHYSIOLOGY PHAR, P89; MATHIAS S, 1991, P NATL ACAD SCI USA, V88, P10009, DOI 10.1073/pnas.88.22.10009; OLD LJ, 1987, NATURE, V326, P330, DOI 10.1038/326330a0; ONG EB, 1965, J BIOL CHEM, V240, P694; QUINTERN LE, 1991, METHOD ENZYMOL, V197, P536; ROTHE J, 1992, IMMUNOL RES, V11, P81, DOI 10.1007/BF02918612; RUGGIERO V, 1987, CELL IMMUNOL, V107, P317, DOI 10.1016/0008-8749(87)90240-1; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SCHUTZE S, 1991, J EXP MED, V174, P975, DOI 10.1084/jem.174.5.975; SUFFYS P, 1988, EUR J BIOCHEM, V178, P257, DOI 10.1111/j.1432-1033.1988.tb14451.x; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; VARSHAVSKY A, 1992, CELL, V69, P725, DOI 10.1016/0092-8674(92)90285-K; WIEGMANN K, 1992, J BIOL CHEM, V267, P17997	41	100	101	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					13760	13765						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188652				2022-12-25	WOS:A1994NL60600010
J	NISHIMURA, N; NAKAMURA, H; TAKAI, Y; SANO, K				NISHIMURA, N; NAKAMURA, H; TAKAI, Y; SANO, K			MOLECULAR-CLONING AND CHARACTERIZATION OF 2 RAB GDI SPECIES FROM RAT-BRAIN - BRAIN-SPECIFIC AND UBIQUITOUS TYPES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; NUCLEOTIDE-RELEASING FACTOR; GDP/GTP EXCHANGE PROTEIN; SMG P25A; DISSOCIATION INHIBITOR; GERANYLGERANYL TRANSFERASE; ACTIVATING PROTEIN; REGULATORY PROTEIN; CELLS; PURIFICATION	Rab GDP dissociation inhibitor (GDI) is a regulatory protein for Rab proteins that controls not only the GDP/GTP exchange reaction of Rab proteins but also their translocation between the cytosol and cell membranes. Recently, rab GDI cDNAs have been isolated from human, bovine, rat, and Drosophila, and these Rab GDI proteins indicated an important role in the regulation of intracellular vesicle traffic. In this study, we have isolated two different rab GDI cDNAs, designated rat rab GDI alpha and beta, from a rat brain cDNA library using bovine rab GDI cDNA as a probe. Rat rab GDI alpha and beta show 99 and 86% amino acid identity with bovine rab GDI, respectively, indicating that rat rab GDI alpha is a rat counterpart of bovine rab GDI. Both rat Rab GDI alpha and beta proteins expressed in Escherichia coli showed a similar degree of activity of regulating the GDP/GTP exchange reaction to that of bovine Rab GDI using Rab3A and Rab11 as substrates. Northern blot analysis revealed that rab GDI alpha mRNA was expressed abundantly in brain but much less in other tissues, whereas rat rab GDI beta mRNA was ubiquitously expressed. Reverse transcription-polymerase chain reaction analysis revealed that astrocytes expressed rat rab GDI beta gene but not rat rab GDI alpha gene. These results indicate that Rab GDI alpha is involved in sorting of highly specialized vesicles in brain such as neurosecretory vesicles, whereas Rab GDI beta plays a general role in vesicular trafficking in diverse types of cells.	KOBE UNIV,SCH MED,DEPT PEDIAT,CHUO KU,KOBE 650,JAPAN; KOBE UNIV,SCH MED,DEPT BIOCHEM,KOBE 650,JAPAN	Kobe University; Kobe University								ANDRES DA, 1993, CELL, V73, P1091, DOI 10.1016/0092-8674(93)90639-8; ANTONY C, 1992, J CELL SCI, V103, P785; ARAKI S, 1991, MOL CELL BIOL, V11, P1438, DOI 10.1128/MCB.11.3.1438; ARAKI S, 1990, J BIOL CHEM, V265, P13007; BURSTEIN ES, 1991, J BIOL CHEM, V266, P2689; BURSTEIN ES, 1992, P NATL ACAD SCI USA, V89, P1154, DOI 10.1073/pnas.89.4.1154; BURTON J, 1993, NATURE, V361, P464, DOI 10.1038/361464a0; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; DARCHEN F, 1990, P NATL ACAD SCI USA, V87, P5692, DOI 10.1073/pnas.87.15.5692; Dayhoff M. O., 1978, ATLAS PROTEIN SEQ S3, V5, P345; DIDSBURY J, 1989, J BIOL CHEM, V264, P16378; FARNSWORTH CC, 1991, P NATL ACAD SCI USA, V88, P6196, DOI 10.1073/pnas.88.14.6196; Goedbloed J., 1942, OPHTHALMOLOGICA, V104, P308; GROEBE DR, 1990, NUCLEIC ACIDS RES, V18, P4033, DOI 10.1093/nar/18.13.4033; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HUBNER LA, 1993, J CELLBIOL, V123, P34; Innis MA, 1990, PCR PROTOCOLS GUIDE; KHOSRAVIFAR R, 1991, P NATL ACAD SCI USA, V88, P6264, DOI 10.1073/pnas.88.14.6264; KIKUCHI A, 1988, J BIOL CHEM, V263, P2897; KITTS PA, 1990, NUCLEIC ACIDS RES, V18, P5667, DOI 10.1093/nar/18.19.5667; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LOMBARDI D, 1993, EMBO J, V12, P677, DOI 10.1002/j.1460-2075.1993.tb05701.x; MATSUI Y, 1990, MOL CELL BIOL, V10, P4116, DOI 10.1128/MCB.10.8.4116; MIZOGUCHI A, 1990, J BIOL CHEM, V265, P11872; MOTOIKE T, 1993, NEUROSCI LETT, V156, P87, DOI 10.1016/0304-3940(93)90446-R; MOTOIKE T, 1991, NEUROSCI LETT, V134, P109, DOI 10.1016/0304-3940(91)90519-Y; MOYA M, 1993, NATURE, V361, P460, DOI 10.1038/361460a0; Pfeffer S R, 1992, Trends Cell Biol, V2, P41, DOI 10.1016/0962-8924(92)90161-F; PLUNTER H, 1991, J CELL BIOL, V115, P31; REGAZZI R, 1992, J BIOL CHEM, V267, P17512; RON D, 1988, EMBO J, V7, P2465, DOI 10.1002/j.1460-2075.1988.tb03093.x; RUBINFELD B, 1991, CELL, V65, P1033, DOI 10.1016/0092-8674(91)90555-D; Sambrook J, 1989, MOL CLONING LABORATO; SANO K, 1989, BIOCHEM BIOPH RES CO, V158, P377, DOI 10.1016/S0006-291X(89)80058-0; SASAKI T, 1991, MOL CELL BIOL, V11, P2909, DOI 10.1128/MCB.11.5.2909; SASAKI T, 1990, J BIOL CHEM, V265, P2333; SCHERLE P, 1993, P NATL ACAD SCI USA, V90, P7568, DOI 10.1073/pnas.90.16.7568; SEABRA MC, 1992, CELL, V70, P1049, DOI 10.1016/0092-8674(92)90253-9; SEABRA MC, 1992, J BIOL CHEM, V267, P14497; SHIRATAKI H, 1993, MOL CELL BIOL, V13, P2061, DOI 10.1128/MCB.13.4.2061; SHIRATAKI H, 1992, J BIOL CHEM, V267, P10946; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SIMONS K, 1993, NEURON, V11, P789, DOI 10.1016/0896-6273(93)90109-5; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; TISDALE EJ, 1992, J CELL BIOL, V119, P749, DOI 10.1083/jcb.119.4.749; UEDA T, 1991, BIOCHEMISTRY-US, V30, P909, DOI 10.1021/bi00218a005; ULLRICH O, 1993, J BIOL CHEM, V268, P18143; VANDERSLUIJS P, 1991, P NATL ACAD SCI USA, V88, P6313, DOI 10.1073/pnas.88.14.6313; VONMOLLARD GF, 1990, P NATL ACAD SCI USA, V87, P1988, DOI 10.1073/pnas.87.5.1988; ZAHNER JE, 1993, MOL CELL BIOL, V13, P217, DOI 10.1128/MCB.13.1.217; Zerial M, 1993, CURR OPIN CELL BIOL, V5, P613, DOI 10.1016/0955-0674(93)90130-I	51	80	84	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					14191	14198						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188702				2022-12-25	WOS:A1994NL60600071
J	OHSAKO, S; HAYASHI, Y; BUNICK, D				OHSAKO, S; HAYASHI, Y; BUNICK, D			MOLECULAR-CLONING AND SEQUENCING OF CALNEXIN-T - AN ABUNDANT MALE GERM CELL-SPECIFIC CALCIUM-BINDING PROTEIN OF THE ENDOPLASMIC-RETICULUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE SARCOPLASMIC-RETICULUM; AMINO-ACID-SEQUENCE; MONOCLONAL-ANTIBODIES; ESCHERICHIA-COLI; RECEPTOR-ALPHA; SPERMIOGENESIS; MEMBRANE; RAT; CALRETICULIN; GLYCOPROTEIN	A mouse testis cDNA expression library was screened using a monoclonal antibody (1C9) that recognized an abundant testis-specific 101-kDa endoplasmic reticulum-associated protein. The screening resulted in the isolation of a 2.3-kilobase cDNA clone (A2/6). The sequence encoded 611 amino acids with a calculated mass of 69,454 Da, that was 60% similar to mouse calnexin. A high affinity calcium binding domain, present in both calnexin and calreticulin, and one transmembrane domain similar to that of calnexin were found in the A2/6 protein domain. Northern blot analysis of total RNA from seven different tissues showed hybridization only to testis RNA. Southern blot analysis indicated that A2/6 was a single copy gene. The calculated molecular mass for A2/6 was unexpectedly lower than the 101-kDa protein recognized by 1C9 on Western blot analysis of total testis protein. However, Escherichia coli and in vitro translation products of A2/6 cDNA yielded a similar 100-kDa protein. Finally, using the recombinant protein, calcium binding activity was detected by a Ca-45(2+) overlay assay. These results suggest that spermatogenic cell endoplasmic reticulum has a unique calcium binding protein, calnexin-t, which appears to be a calnexin variant.	UNIV ILLINOIS, DEPT VET BIOSCI, URBANA, IL 61801 USA; UNIV TOKYO, DEPT VET ANAT, BUNKYO KU, TOKYO 113, JAPAN	University of Illinois System; University of Illinois Urbana-Champaign; University of Tokyo								AHLUWALIA N, 1992, J BIOL CHEM, V267, P10914; ANDREADIS A, 1987, ANNU REV CELL BIOL, V3, P207, DOI 10.1146/annurev.cellbio.3.1.207; BAKSH S, 1991, J BIOL CHEM, V266, P21458; CALA SE, 1993, J BIOL CHEM, V268, P2969; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLERMONT Y, 1978, AM J ANAT, V151, P191, DOI 10.1002/aja.1001510204; CLERMONT Y, 1985, ANAT REC, V213, P33, DOI 10.1002/ar.1092130106; Cohen P, 1988, CALMODULIN MOL ASPEC, V5; DABORA SL, 1988, CELL, V54, P27, DOI 10.1016/0092-8674(88)90176-6; DODEMONT H, 1990, EMBO J, V9, P4083, DOI 10.1002/j.1460-2075.1990.tb07630.x; FAWCETT DW, 1971, DEV BIOL, V26, P220, DOI 10.1016/0012-1606(71)90124-2; FLIEGEL L, 1987, P NATL ACAD SCI USA, V84, P1167, DOI 10.1073/pnas.84.5.1167; FLIEGEL L, 1989, J BIOL CHEM, V264, P21522; GARCIABUSTOS J, 1991, BIOCHIM BIOPHYS ACTA, V1071, P83, DOI 10.1016/0304-4157(91)90013-M; GEISER JR, 1991, CELL, V65, P949, DOI 10.1016/0092-8674(91)90547-C; GILCHRIST JSC, 1993, J BIOL CHEM, V268, P4291; HAKE LE, 1993, J BIOL CHEM, V268, P4788; HARRISON RAP, 1988, J REPROD FERTIL, V82, P777, DOI 10.1530/jrf.0.0820777; HAWN TR, 1993, J BIOL CHEM, V268, P7692; HEIZMANN CW, 1987, CELL CALCIUM, V8, P1, DOI 10.1016/0143-4160(87)90034-0; HESS RA, 1990, BIOL REPROD, V43, P525, DOI 10.1095/biolreprod43.3.525; HOFMANN SL, 1989, J BIOL CHEM, V264, P18083; HUANG LQ, 1993, J BIOL CHEM, V268, P6560; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBERER E, 1989, P NATL ACAD SCI USA, V86, P6047, DOI 10.1073/pnas.86.16.6047; LEBLOND CP, 1952, AM J ANAT, V90, P167, DOI 10.1002/aja.1000900202; LIU DY, 1993, BIOL REPROD, V48, P340, DOI 10.1095/biolreprod48.2.340; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; MAZZARELLA RA, 1987, J BIOL CHEM, V262, P8875; MILNER RE, 1992, MOL CELL BIOCHEM, V112, P1; MORI H, 1980, J CELL BIOL, V84, P340, DOI 10.1083/jcb.84.2.340; NAKAMOTO T, 1989, CELL TISSUE RES, V257, P279, DOI 10.1007/BF00261831; OHSAKO S, 1991, J VET MED SCI, V53, P969, DOI 10.1292/jvms.53.969; OHSAKO S, 1994, ANAT REC, V238, P335, DOI 10.1002/ar.1092380308; OU WJ, 1992, J BIOL CHEM, V267, P23789; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; RUSSELL LD, 1991, AM J ANAT, V192, P97, DOI 10.1002/aja.1001920202; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH MJ, 1989, EMBO J, V8, P3581, DOI 10.1002/j.1460-2075.1989.tb08530.x; SUZUKI CK, 1991, J CELL BIOL, V114, P189, DOI 10.1083/jcb.114.2.189; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; WADA I, 1991, J BIOL CHEM, V266, P19599; WALKER RA, 1993, ANNU REV BIOCHEM, V62, P429; WANG ZY, 1992, P NATL ACAD SCI USA, V89, P11814, DOI 10.1073/pnas.89.24.11814; WHITE FH, 1992, INT J PEPT PROT RES, V39, P265; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194	53	38	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					14140	14148						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188695				2022-12-25	WOS:A1994NL60600063
J	REIF, K; BUDAY, L; DOWNWARD, J; CANTRELL, DA				REIF, K; BUDAY, L; DOWNWARD, J; CANTRELL, DA			SH3 DOMAINS OF THE ADAPTER MOLECULE GRB2 COMPLEX WITH 2 PROTEINS IN T-CELLS - THE GUANINE-NUCLEOTIDE EXCHANGE PROTEIN SOS AND A 75-KDA PROTEIN THAT IS A SUBSTRATE FOR T-CELL ANTIGEN RECEPTOR-ACTIVATED TYROSINE KINASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PATHWAYS; P21RAS	In T lymphocytes activated via the T cell antigen receptor (TCR), the SH2- and SH3-containing adapter molecule Grb2 forms a complex with the Ras guanine nucleotide exchange protein Sos and tyrosine phosphoproteins. The interaction of Sos with Grb2 is mediated via the Grb2 SH3 domains. In this study, it is shown that a 75-kDa protein is also complexed with the Grb2 SH3 domains in T cells, but not in Rat-1 fibroblasts. The identity of the p75 protein is not known, but immunoblot analysis with phosphotyrosine antibodies indicated that it is rapidly tyrosine-phosphorylated in TCR-activated T cells. This characteristic clearly distinguishes p75 from Sos since Sos is not a phosphotyrosine protein. In vitro binding studies indicated that the p75 phosphotyrosine protein binds to a glutathione S-transferase fusion protein of intact Grb2, but not to a Grb2 fusion protein mutated in its SH3 domains. p75 can also bind to the single COOH-terminal Grb2 SH3 domain, whereas Sos has an in vitro binding preference for the NH2-terminal Grb2 SH3 domain. Collectively, these data indicate that in T cells, two proteins can complex with the Grb2 SH3 domains: Sos and a p75 molecule that is tyrosine-phosphorylated in TCR-activated cells. The significance of p75 association with Grb2 is not clear, but by analogy with Sos, p75 is a potential candidate for a Grb2 effector protein. Data are presented showing that the interaction of the Grb2 SH2 domains with tyrosine phosphoproteins may be regulated by conformational restraints imposed by different molecules complexing with the Grb2 SH3 domains. It is thus possible to speculate that the interaction of either p75 or Sos with the Grb2 SH3 domain may influence the interaction of the Grb2 SH2 domain with tyrosine phosphoproteins.	IMPERIAL CANC RES FUND,LYMPHOCYTE ACTIVAT LABS,LONDON WC2A 3PX,ENGLAND; IMPERIAL CANC RES FUND,SIGNAL TRANSDUCT LAB,LONDON WC2A 3PX,ENGLAND	Cancer Research UK; Cancer Research UK				Reif, Karin/0000-0001-5490-8389; Downward, Julian/0000-0002-2331-4729				BEVERLEY PCL, 1981, EUR J IMMUNOL, V11, P329, DOI 10.1002/eji.1830110412; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BUDAY L, 1994, J BIOL CHEM, V269, P9019; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CANTRELL DA, 1984, SCIENCE, V224, P1312, DOI 10.1126/science.6427923; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; DOWNWARD J, 1992, IMMUNOL TODAY, V13, P89, DOI 10.1016/0167-5699(92)90148-Z; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; IZQUIERDO M, 1992, MOL CELL BIOL, V12, P3305, DOI 10.1128/MCB.12.7.3305; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SCOLNIK EY, 1993, EMBO J, V12, P1929; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B	18	87	92	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					14081	14087						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188688				2022-12-25	WOS:A1994NL60600055
J	WITCHER, DR; MCPHERSON, PS; KAHL, SD; LEWIS, T; BENTLEY, P; MULLINNIX, MJ; WINDASS, JD; CAMPBELL, KP				WITCHER, DR; MCPHERSON, PS; KAHL, SD; LEWIS, T; BENTLEY, P; MULLINNIX, MJ; WINDASS, JD; CAMPBELL, KP			PHOTOAFFINITY-LABELING OF THE RYANODINE RECEPTOR CA2+ RELEASE CHANNEL WITH AN AZIDO DERIVATIVE OF RYANODINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MUSCLE SARCOPLASMIC-RETICULUM; JUNCTIONAL TERMINAL CISTERNAE; FAST SKELETAL-MUSCLE; CALCIUM RELEASE; CA2+ RELEASE; FUNCTIONAL EXPRESSION; PHOSPHORYLATION SITE; MOLECULAR-CLONING; FEET STRUCTURES; CARDIAC-MUSCLE	Ryanodine receptors/Ca2+ release channels play an important role in regulating the intracellular free calcium concentrations in both muscle and nonmuscle cells. Ryanodine, a neutral plant alkaloid, specifically binds to and modulates these Ca2+ release channels. In the work described here, we characterize the interaction of a tritium- labeled, photoactivable derivative of ryanodine (H-3-labeled 10 O-[3-(4-azidobenzamido)propionyl]ryanodine ([H-3]ABRy)) with the ryanodine receptor of skeletal, cardiac, and brain membranes. Scatchard analysis demonstrates that this ligand binds to a single class of high affinity sites in skeletal muscle triads. Furthermore, competition binding assays of [[H-3]ryanodine with skeletal, cardiac, and brain membranes in the presence of increasing concentrations of unlabeled ABRy illustrate that this azido derivative of ryanodine is able to specifically displace [H-3]ryanodine from its binding site(s). Analysis of the effects of Ca2+, ATP, and KCI on [H-3]ABRy binding in triad membranes shows a similar modulation of binding to that seen in these membranes with [H-3]ryanodine. Photoaffinity labeling of triads with [H-3]ABRy resulted in specific and covalent incorporation of [H-3]ABRy into a 565-kDa protein that was shown to be the skeletal muscle ryanodine receptor. Digestion of the labeled ryanodine receptor revealed a [H-3]ABRy-labeled 76-kDa tryptic fragment that was identified with an antibody directed against the COOH-terminal of the receptor. These results demonstrate that the 76-kDa COOH- terminal tryptic fragment contains the high affinity binding site for ryanodine.	UNIV IOWA, COLL MED, HOWARD HUGHES MED INST, DEPT PHYSIOL & BIOPHYS, IOWA CITY, IA 52242 USA; UNIV IOWA, COLL MED, PROGRAM NEUROSCI, IOWA CITY, IA 52242 USA; ZENECA AGROCHEM, JEALOTTS HILL RES STN, BRACKNELL RG12 6EY, BERKS, ENGLAND	Howard Hughes Medical Institute; University of Iowa; University of Iowa				Kahl, Steven/0000-0001-7085-9556; Campbell, Kevin/0000-0003-2066-5889				CHEN SRW, 1993, BIOCHEMISTRY-US, V32, P3743, DOI 10.1021/bi00065a029; CHEN SRW, 1992, J BIOL CHEM, V267, P23318; CHEN SRW, 1993, J BIOL CHEM, V268, P22642; ELLISMAN MH, 1990, NEURON, V5, P135, DOI 10.1016/0896-6273(90)90304-X; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; FLEISCHER S, 1985, P NATL ACAD SCI USA, V82, P7256, DOI 10.1073/pnas.82.21.7256; GIANNINI G, 1992, SCIENCE, V257, P91, DOI 10.1126/science.1320290; HAKAMATA Y, 1992, FEBS LETT, V312, P229, DOI 10.1016/0014-5793(92)80941-9; HILKERT R, 1992, ARCH BIOCHEM BIOPHYS, V292, P1, DOI 10.1016/0003-9861(92)90043-V; IMAGAWA T, 1987, J BIOL CHEM, V262, P16636; INUI M, 1987, J BIOL CHEM, V262, P15637; INUI M, 1987, J BIOL CHEM, V262, P1740; KAHL SD, 1994, ANAL BIOCHEM, V218, P55, DOI 10.1006/abio.1994.1140; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; LATTANZIO FA, 1987, J BIOL CHEM, V262, P2711; MCPHERSON PS, 1993, J BIOL CHEM, V268, P19785; MCPHERSON PS, 1993, J BIOL CHEM, V268, P13765; MCPHERSON PS, 1991, NEURON, V7, P17, DOI 10.1016/0896-6273(91)90070-G; MEISSNER G, 1986, BIOCHEMISTRY-US, V25, P236, DOI 10.1021/bi00349a033; MEISSNER G, 1987, J BIOL CHEM, V262, P3065; MEISSNER G, 1986, J BIOL CHEM, V261, P6300; MICHALAK M, 1988, BIOCHIM BIOPHYS ACTA, V939, P587, DOI 10.1016/0005-2736(88)90106-X; NAKAI J, 1990, FEBS LETT, V271, P169, DOI 10.1016/0014-5793(90)80399-4; OTSU K, 1990, J BIOL CHEM, V265, P13472; PENNER R, 1989, FEBS LETT, V259, P217, DOI 10.1016/0014-5793(89)81532-7; PESSAH IN, 1985, BIOCHEM BIOPH RES CO, V128, P449, DOI 10.1016/0006-291X(85)91699-7; PESSAH IN, 1986, J BIOL CHEM, V261, P8643; ROUSSEAU E, 1986, BIOPHYS J, V50, P1009, DOI 10.1016/S0006-3495(86)83543-3; ROUSSEAU E, 1988, ARCH BIOCHEM BIOPHYS, V267, P75, DOI 10.1016/0003-9861(88)90010-0; SALAMA G, 1992, CELL CALCIUM, V13, P635, DOI 10.1016/0143-4160(92)90074-3; SHARP AH, 1987, J BIOL CHEM, V262, P12309; SMITH JS, 1989, CIRC RES, V64, P352, DOI 10.1161/01.RES.64.2.352; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; WITCHER DR, 1992, J BIOL CHEM, V267, P4963; WITCHER DR, 1993, SCIENCE, V261, P486, DOI 10.1126/science.8392754; WITCHER DR, 1991, J BIOL CHEM, V266, P11144; ZAIDI NF, 1989, J BIOL CHEM, V264, P21737; ZARKA A, 1993, EUR J BIOCHEM, V213, P147, DOI 10.1111/j.1432-1033.1993.tb17744.x; ZORZATO F, 1990, J BIOL CHEM, V265, P2244	40	60	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13076	13079						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175731				2022-12-25	WOS:A1994NK18400006
J	KATAYAMA, T; KORNBERG, A				KATAYAMA, T; KORNBERG, A			HYPERACTIVE INITIATION OF CHROMOSOMAL REPLICATION IN-VIVO AND IN-VITRO BY A MUTANT INITIATOR PROTEIN, DNAACOS, OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								DnaA protein initiates genomic replication in Escherichia coli. A cold sensitive dnaAcos mutant caused excessive initiation at a restrictive temperature without an increase in the level of DnaA protein. The chromosomal origin (oriC) was essential for the lethality caused by the dnaAcos product. Increased initiation activity was neutralized by multiple copies of oriC on a plasmid (pBR322). OriC plasmids were replicated efficiently in vitro in a crude extract prepared from a dnaAcos mutant, with a specific activity for the DnaAcos protein 8-fold greater than that for the DnaA(+) protein in a wildtype extract. OriC dependent replication in the dnaAcos extract was inhibited by rifampicin and by gyrase inhibitors as was replication in the dnaA(+) extract. As a control, replication of single-stranded phage phi X174 DNA, which did not require DnaA protein, was similar in extracts prepared from dnaA(+) and dnaAcos cells. Thus, initiation at oriC by DnaAcos protein appears to be highly activated both in vivo and in vitro.			KATAYAMA, T (corresponding author), STANFORD UNIV, SCH MED, DEPT BIOCHEM, STANFORD, CA 94305 USA.			Katayama, Tsutomu/0000-0001-9994-1684				ATLUNG T, 1987, MOL GEN GENET, V206, P51, DOI 10.1007/BF00326535; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAMHILL D, 1988, CELL, V52, P743, DOI 10.1016/0092-8674(88)90412-6; BRAUN RE, 1987, J BACTERIOL, V169, P3898, DOI 10.1128/jb.169.9.3898-3903.1987; FULLER RS, 1984, CELL, V38, P889, DOI 10.1016/0092-8674(84)90284-8; FULLER RS, 1983, P NATL ACAD SCI-BIOL, V80, P5817, DOI 10.1073/pnas.80.19.5817; FULLER RS, 1981, P NATL ACAD SCI-BIOL, V78, P7370, DOI 10.1073/pnas.78.12.7370; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HANSEN FG, 1992, MOL GEN GENET, V234, P14, DOI 10.1007/BF00272340; HIROTA Y, 1970, J MOL BIOL, V53, P369, DOI 10.1016/0022-2836(70)90072-0; HORWICH AL, 1993, CELL, V74, P909, DOI 10.1016/0092-8674(93)90470-B; HWANG DS, 1988, J BIOL CHEM, V263, P10625; KATAYAMA T, 1991, MOL GEN GENET, V226, P491, DOI 10.1007/BF00260663; KELLENBERGERGUJER G, 1978, MOL GEN GENET, V162, P9, DOI 10.1007/BF00333845; KOGOMA T, 1986, J BACTERIOL, V166, P361, DOI 10.1128/jb.166.2.361-363.1986; Kornberg A., 1992, DNA REPLICATION; LAMINET AA, 1990, EMBO J, V9, P2315, DOI 10.1002/j.1460-2075.1990.tb07403.x; LANDOULSI A, 1990, CELL, V63, P1053, DOI 10.1016/0092-8674(90)90508-C; LARK KG, 1972, J MOL BIOL, V64, P47, DOI 10.1016/0022-2836(72)90320-8; LARK KG, 1969, J MOL BIOL, V42, P221, DOI 10.1016/0022-2836(69)90039-4; LEE EH, 1991, P NATL ACAD SCI USA, V88, P3029, DOI 10.1073/pnas.88.8.3029; LOBNEROLESEN A, 1989, CELL, V57, P881, DOI 10.1016/0092-8674(89)90802-7; MCMACKEN R, 1987, ESCHERICHIA COLI SAL, V2, P564; Miller J.H., 1972, EXPT MOL GENETICS; MURAKAMI Y, 1987, J BACTERIOL, V169, P1724, DOI 10.1128/jb.169.4.1724-1730.1987; OKA A, 1980, MOL GEN GENET, V178, P9, DOI 10.1007/BF00267207; PIERUCCI O, 1987, J BACTERIOL, V169, P1871, DOI 10.1128/jb.169.5.1871-1877.1987; SAKAKIBARA Y, 1982, MOL GEN GENET, V186, P87, DOI 10.1007/BF00422917; Sambrook J, 1989, MOL CLONING LABORATO; SCHAEFER C, 1989, EMBO J, V8, P1609, DOI 10.1002/j.1460-2075.1989.tb03545.x; SCHAEFER C, 1991, MOL GEN GENET, V226, P34, DOI 10.1007/BF00273584; SCHAUS N, 1981, J BACTERIOL, V145, P904, DOI 10.1128/JB.145.2.904-913.1981; SEKIMIZU K, 1988, J BIOL CHEM, V263, P7136; SMITH DW, 1985, EMBO J, V4, P1319, DOI 10.1002/j.1460-2075.1985.tb03779.x; TIPPESCHINDLER R, 1979, MOL GEN GENET, V168, P185, DOI 10.1007/BF00431444; VONMEYENBURG K, 1987, ESCHERICHIA COLI SAL, V2, P1555; XU YC, 1988, MOL GEN GENET, V211, P138, DOI 10.1007/BF00338404; ZYSKIND JW, 1992, CELL, V69, P5, DOI 10.1016/0092-8674(92)90112-P	39	60	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12698	12703						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175680				2022-12-25	WOS:A1994NH71600052
J	METTERS, KM; SAWYER, N; NICHOLSON, DW				METTERS, KM; SAWYER, N; NICHOLSON, DW			MICROSOMAL GLUTATHIONE-S-TRANSFERASE IS THE PREDOMINANT LEUKOTRIENE C-4 BINDING-SITE IN CELLULAR MEMBRANES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								Dimethyl sulfoxide differentiated U937 (dU937) cells express high affinity G-protein-coupled receptors for leukotriene (LT)D-4 and LTB(4) and, as described here, specific binding sites for LTC(4). The specific binding of [H-3]LTC(4) was of low affinity (K-D = 26 nM) and high abundance (B-max = 33 pmol/mg of protein), as compared to LTD(4) and LTB(4) receptors. In addition, although [H-3]LTC(4), specific binding was enhanced by divalent cations, it was not inhibited by nonhydrolyzable GTP analogs. [H-3]LTC(4) specific binding to dU937 cell membranes does not have, therefore, the characteristics of binding to a G-protein-coupled receptor. Competition for [H-3]LTC(4) specific binding to dU937 cell membranes by leukotrienes and related analogs, including N-methylated LTC(4), as well as glutathione, suggested a dependence on the presence of an arachidonic acid backbone, although varying degrees of saturation were well tolerated, and that the glutathione moiety of LTC(4) in particular was important in determining affinity. The possibility that [H-3]LTC(4) specific binding was to a member of the glutathione S-transferase (GST) family of enzymes, such as LTC(4) synthase, cytosolic GST, or microsomal GST, was therefore investigated. [H-3]LTC(4) specific binding sites could be separated from LTC(4) synthase and cytosolic GSTs by differential detergent solubilization, but cofractionated with microsomal GST during solubilization and subsequent anion exchange chromatography. In membranes that were depleted of LTC(4) synthase and cytosolic GSTs, I-125-azido-LTC(4) (a photoaffinity probe based on LTC(4)) specifically photolabeled in a cation dependent manner a 17-kDa polypeptide that was comparable in mass to the microsomal GST polypeptide. Furthermore, [H-3]LTC(4) bound specifically to purified human microsomal GST with the same characteristics as to the endogenous dU937-cell membrane specific binding sites. The principal [H-3]LTC(4) specific binding site present in dU937 cells, therefore, is not a G-protein-coupled receptor, LTC(4) synthase, or cytosolic GSTs, but is microsomal GST. Finally, the 1:3 stoichiometry of [H-3]LTC(4) specific binding to purified microsomal GST is consistent with the enzyme functioning as a homotrimer.			METTERS, KM (corresponding author), MERCK FROSST CTR THERAPEUT RES, DEPT BIOCHEM & MOLEC BIOL, DORVAL H9R 4P8, PQ, CANADA.							BALLERMANN BJ, 1985, CIRC RES, V56, P324, DOI 10.1161/01.RES.56.3.324; BAUD L, 1987, IMMUNOLOGY, V62, P53; BOYER TD, 1986, J BIOL CHEM, V261, P6963; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CHAU LY, 1986, J IMMUNOL, V137, P1985; CHIONO M, 1992, J PHARMACOL EXP THER, V262, P1248; CIVELLI M, 1987, J PHARMACOL EXP THER, V242, P1019; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CLARK MA, 1985, EUR J PHARMACOL, V116, P207, DOI 10.1016/0014-2999(85)90155-4; FITZ TA, 1990, PROSTAG OTH LIPID M, V40, P417, DOI 10.1016/0090-6980(90)90106-6; FORDHUTCHINSON AW, 1991, TRENDS PHARMACOL SCI, V12, P68, DOI 10.1016/0165-6147(91)90500-R; FORDHUTCHINSON AW, 1990, CRIT REV IMMUNOL, V10, P1; FREY EA, 1993, EUR J PHARM-MOLEC PH, V244, P239, DOI 10.1016/0922-4106(93)90149-4; GHIGLIERIBERTEZ C, 1986, BIOCHIM BIOPHYS ACTA, V879, P97, DOI 10.1016/0005-2760(86)90271-7; GOFFINET A, 1987, EUR J PHARMACOL, V140, P343, DOI 10.1016/0014-2999(87)90291-3; GOFFINET AM, 1989, EUR J PHARMACOL, V161, P99, DOI 10.1016/0014-2999(89)90186-6; HABIG WH, 1974, J BIOL CHEM, V249, P7130; HERMAN CA, 1992, J EXP ZOOL, V262, P1, DOI 10.1002/jez.1402620102; HOGABOOM GK, 1985, MOL PHARMACOL, V27, P236; ISHIKAWA T, 1992, TRENDS BIOCHEM SCI, V17, P463, DOI 10.1016/0968-0004(92)90489-V; JONES TR, 1989, CAN J PHYSIOL PHARM, V67, P17, DOI 10.1139/y89-004; KRELL RD, 1990, AM REV RESPIR DIS, V141, P978, DOI 10.1164/ajrccm/141.4_Pt_1.978; KRILIS S, 1984, P NATL ACAD SCI-BIOL, V81, P4529, DOI 10.1073/pnas.81.14.4529; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAM BK, 1989, J BIOL CHEM, V264, P12885; LEFKOWITZ RJ, 1983, ANNU REV BIOCHEM, V52, P159, DOI 10.1146/annurev.bi.52.070183.001111; LEWIS RA, 1990, NEW ENGL J MED, V323, P645; LUI YX, 1990, PROSTAGLANDINS, V40, P431; LUNDQVIST G, 1992, J BIOL CHEM, V159, P103; MCLELLAN LI, 1989, BIOCHEM J, V258, P87, DOI 10.1042/bj2580087; METTERS KM, 1993, J BIOL CHEM, V268, P6487; METTERS KM, 1991, EUR J PHARMACOL, V194, P51, DOI 10.1016/0014-2999(91)90123-8; MODAT G, 1987, PROSTAGLANDINS, V33, P531, DOI 10.1016/0090-6980(87)90276-0; MONG S, 1985, J PHARMACOL EXP THER, V234, P316; MONG S, 1991, LIPOXYGENASES THEIR, P185; MORGENSTERN R, 1982, EUR J BIOCHEM, V128, P243; MOSIALOU E, 1990, CHEM-BIOL INTERACT, V74, P275, DOI 10.1016/0009-2797(90)90044-N; MULLER A, 1988, BRIT J DERMATOL, V119, P275, DOI 10.1111/j.1365-2133.1988.tb03218.x; NICHOLSON DW, 1992, EUR J BIOCHEM, V209, P725, DOI 10.1111/j.1432-1033.1992.tb17341.x; NICHOLSON DW, 1992, J BIOL CHEM, V267, P17849; NORMAN P, 1987, EUR J PHARMACOL, V143, P323, DOI 10.1016/0014-2999(87)90456-0; OWEN WF, 1987, J IMMUNOL, V138, P532; PENDLEY CE, 1989, PROSTAG OTH LIPID M, V38, P237, DOI 10.1016/0090-6980(89)90086-5; PHAN SH, 1988, BIOCHEMISTRY-US, V27, P2846, DOI 10.1021/bi00408a028; PICKETT CB, 1989, ANNU REV BIOCHEM, V58, P743, DOI 10.1146/annurev.bi.58.070189.003523; PIPER PJ, 1984, PHYSIOL REV, V64, P744, DOI 10.1152/physrev.1984.64.2.744; PONG SS, 1983, J BIOL CHEM, V258, P9616; ROSENTHAL HE, 1967, ANAL BIOCHEM, V20, P525, DOI 10.1016/0003-2697(67)90297-7; ROVATI GE, 1985, BIOCHEM PHARMACOL, V34, P2831, DOI 10.1016/0006-2952(85)90003-6; Samuelsson B, 1985, Adv Prostaglandin Thromboxane Leukot Res, V15, P1; SAMUELSSON B, 1983, SCIENCE, V220, P568, DOI 10.1126/science.6301011; SARAU HM, 1989, ADV PROSTAG THROMB L, V19, P180; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHALLING M, 1986, EUR J PHARMACOL, V122, P251, DOI 10.1016/0014-2999(86)90110-X; SHARP JD, 1991, J BIOL CHEM, V266, P14850; SHIMIZU T, 1988, INT J BIOCHEM, V20, P661, DOI 10.1016/0020-711X(88)90160-7; SLIPETZ DM, 1993, EUR J PHARM-MOLEC PH, V244, P161, DOI 10.1016/0922-4106(93)90022-2; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SUN FF, 1986, J BIOL CHEM, V261, P8540; TATE SS, 1978, P NATL ACAD SCI USA, V75, P4806, DOI 10.1073/pnas.75.10.4806; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSUCHIDA S, 1992, CRIT REV BIOCHEM MOL, V27, P337, DOI 10.3109/10409239209082566; WOODGETT JR, 1986, EUR J BIOCHEM, V161, P177, DOI 10.1111/j.1432-1033.1986.tb10139.x	63	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12816	12823						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175695				2022-12-25	WOS:A1994NH71600069
J	MOLLICONE, R; REGUIGNE, I; FLETCHER, A; AZIZ, A; RUSTAM, M; WESTON, BW; KELLY, RJ; LOWE, JB; ORIOL, R				MOLLICONE, R; REGUIGNE, I; FLETCHER, A; AZIZ, A; RUSTAM, M; WESTON, BW; KELLY, RJ; LOWE, JB; ORIOL, R			MOLECULAR-BASIS FOR PLASMA ALPHA(1,3)-FUCOSYL-TRANSFERASE GENE DEFICIENCY (FUT6)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA(1,3)FUCOSYLTRANSFERASE GENE; DETERMINES EXPRESSION; HUMAN-SERUM; LEWIS-X; CLONING; BLOOD; SPECIFICITY; EPITOPES; ENZYMES; TISSUES	While most humans express an alpha(1,3)-fucosyltransferase in plasma, 9% of individuals on the isle of Java (Indonesia) do not express this enzyme. Ninety five percent of these plasma alpha(1,3) fucosyltransferase-deficient individuals have Lewis negative phenotype on red cells, suggesting strong linkage disequilibrium between these two traits. To define the molecular basis for this plasma deficiency and to determine which of two candidate hu man alpha(1,3)-fucosyltransferase genes encode this enzyme (FUT5 and FUT6), we cloned and analyzed alleles at these two loci from an Indonesian individual deficient in plasma alpha(1,3)-fucosyltransferase activity. Single base pair changes were identified in the coding region of each gene, relative to previously published wild type alleles. These changes in turn yield three codon changes in FUT5 and three in FUT6 The codon changes in the FUT5 gene do not yield detectable diminutions in (alpha(1,3)fucosyltransferase activity when tested by expression in transfected COS-1 cells, and none of the FUT5 alleles co segregate with plasma alpha(1,3)-fucosyltransferase deficiency in Indonesian pedigrees. By contrast, two of the codon changes in the FUT6 alleles inactivate this gene when tested by expression in transfected COS-1 cells. One of these inactivating changes is a missense mutation (Glu-247 --> Lys) within the enzyme's catalytic domain. The other inactivating mutation represents a nonsense mutation (Tyr-315 --> stop) that truncates the COOH terminus of the enzyme by 45 amino acids. The Glu-247 --> Lys missense mutation is present in double dose in the nine plasma alpha(1,3)-fucosyltransferase deficient individuals tested, whereas the nonsense mutation at tyrosine 315 is present in double dose in just one of these persons. These results demonstrate that the (alpha(1,3)fucosyltransferase activity in human plasma is encoded by the FUT6 gene and that the missense mutation within codon 247 of this gene is responsible for deficiency of this activity in these Indonesian families.	NEW S WALES RED CROSS,BLOOD TRANSFUS SERV,SYDNEY,NSW 2000,AUSTRALIA; INDONESIAN RED CROSS SOC,CENT BLOOD TRANSFUS SERV,JAKARTA 10002,INDONESIA; UNIV N CAROLINA,DEPT PEDIAT,DIV HEMATOL ONCOL,RALEIGH,NC 27599; UNIV N CAROLINA,LINEBERGER COMPREHENS CANC CTR,RALEIGH,NC 27599; UNIV MICHIGAN,HOWARD HUGHES MED INST,ANN ARBOR,MI 48109	Australian Red Cross Blood Service; University of North Carolina; University of North Carolina; Howard Hughes Medical Institute; University of Michigan System; University of Michigan	MOLLICONE, R (corresponding author), INSERM,U178,16 AV PAUL VAILLANT COURIER,F-94807 VILLEJUIF,FRANCE.		/L-2667-2019		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047455] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47455] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALL SP, 1991, ANN HUM GENET, V55, P225, DOI 10.1111/j.1469-1809.1991.tb00417.x; Battey, 1986, BASIC METHODS MOL BI; Berger S. L., 1987, GUIDE MOL CLONING TE; BEVILACQUA MP, 1993, ANNU REV IMMUNOL, V11, P767, DOI 10.1146/annurev.iy.11.040193.004003; BREGUET G, 1982, HUM HERED, V32, P52, DOI 10.1159/000153259; BROADBERRY RE, 1991, HUM HERED, V41, P290, DOI 10.1159/000154015; CAILLARD T, 1988, EXP CLIN IMMUNOGENET, V5, P15; CANDELIER JJ, 1993, LAB INVEST, V69, P449; CHANDANAYINGYONG D, 1967, TRANSFUSION, V7, P269, DOI 10.1111/j.1537-2995.1967.tb05516.x; CHENEVIXTRENCH G, 1990, AM J HUM GENET, V46, P635; EASTON EW, 1993, BLOOD, V81, P2978; GOELZ SE, 1990, CELL, V63, P1349, DOI 10.1016/0092-8674(90)90430-M; HENRY SM, 1993, VOX SANG, V65, P62, DOI 10.1111/j.1423-0410.1993.tb04527.x; JOHNSON PH, 1988, BIOCHEM SOC T, V17, P133; KOSZDIN KL, 1992, BIOCHEM BIOPH RES CO, V187, P152, DOI 10.1016/S0006-291X(05)81472-X; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; KUMAR R, 1991, J BIOL CHEM, V266, P21777; LARSEN RD, 1989, P NATL ACAD SCI USA, V86, P8227, DOI 10.1073/pnas.86.21.8227; LEPENDU J, 1982, AM J HUM GENET, V34, P402; Lowe J B, 1991, Semin Cell Biol, V2, P289; LOWE JB, 1991, J BIOL CHEM, V266, P17467; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MOLLICONE R, 1992, CARBOHYD RES, V228, P265, DOI 10.1016/S0008-6215(00)90564-0; MOLLICONE R, 1990, EUR J BIOCHEM, V191, P169, DOI 10.1111/j.1432-1033.1990.tb19107.x; MOURANT AE, 1976, DISTRIBUTION HUMAN B, P191; NAKAMURA Y, 1988, Genomics, V3, P67, DOI 10.1016/0888-7543(88)90161-9; NISHIHARA S, 1993, BIOCHEM BIOPH RES CO, V190, P42, DOI 10.1006/bbrc.1993.1008; ORIOL R, 1992, APMIS, V100, P28; ORIOL R, 1981, AM J HUM GENET, V33, P421; ORIOL R, 1991, GLYCOCONJUGATE J, V8, P147; REGUIGNE I, 1993, CYTOGENET CELL GENET, V66, P104; SARNESTO A, 1992, J BIOL CHEM, V267, P2745; SIMMONS R T, 1951, Med J Aust, V1, P173; VENTURA M, 1988, HUM HERED, V38, P36, DOI 10.1159/000153752; VONANDRIAN UH, 1993, J CLIN INVEST, V91, P2893, DOI 10.1172/JCI116535; VOS GH, 1967, ACTA GENET STAT MED, V17, P495; WESTON BW, 1992, J BIOL CHEM, V267, P4152; WESTON BW, 1992, J BIOL CHEM, V267, P24575	38	75	77	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12662	12671						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175676				2022-12-25	WOS:A1994NH71600047
J	WU, XJ; SAKATA, N; LUI, E; GINSBERG, HN				WU, XJ; SAKATA, N; LUI, E; GINSBERG, HN			EVIDENCE FOR A LACK OF REGULATION OF THE ASSEMBLY AND SECRETION OF APOLIPOPROTEIN B-CONTAINING LIPOPROTEIN FROM HEPG2 CELLS BY CHOLESTERYL ESTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEINS; G2 CELLS; INTRACELLULAR DEGRADATION; ENDOPLASMIC-RETICULUM; RAT HEPATOCYTES; OLEIC-ACID; METABOLISM; TRANSPORT; REDUCTASE; HEP-G2	Although some previous studies have suggested that triglyceride, a major core lipid, plays a key role in the assembly and secretion of apolipoprotein B-containing lipoproteins from HepG2 cells, other reports have indicated the importance of cholesteryl ester, another core lipid. We attempted to better define the roles of triglyceride and cholesteryl ester in the assembly and secretion of apolipoprotein B-containing lipoproteins from HepG2 cells by determining the effects of Sandoz 58-035, a potent acyl-CoA acyltransferase inhibitor, which significantly inhibits cholesteryl synthesis, and Triacsin D, a potent fatty acyl-CoA synthetase inhibitor, which significantly inhibits triglyceride synthesis, on the secretion of apolipoprotein B-containing lipoproteins. Sandoz 58-035 (2 mu g/ml) decreased very low density lipoproteins (VLDL)-stimulated cellular cholesteryl ester content by 60-80%, and blocked oleate-stimulated cholesteryl ester synthesis by 100%, but did not decrease VLDL- or oleate-stimulated apolipoprotein B secretion. Triacsin D (12.5 mu M), which significantly inhibited VLDL and oleate stimulation of triglyceride synthesis, without affecting cholesteryl ester synthesis, blocked the stimulation of apolipoprotein B secretion by both agents. In HepG2 cells transfected with 3-hydroxy-methylglutaryl-CoA reductase cDNA, cholesteryl ester synthesis and mass were increased by 100%, but apolipoprotein B secretion was unaffected. Sandoz 58-035 decreased cholesteryl ester synthesis significantly but did not decrease apolipoprotein B secretion from this cell line. When these transfected cells were incubated with oleate, apolipoprotein B secretion increased; Triacsin D blocked this effect. Finally, sphingomyelinase treatment (which shifts cholesterol from plasma membranes to intracellular pools) increased cholesteryl ester synthesis 4-5-fold, but apolipoprotein E secretion was unaffected. Changes in cellular cholesteryl ester synthesis or mass did not affect the intracellular degradation of newly synthesized apolipoprotein B, but changes in triglyceride synthesis were always associated with corresponding changes in the intracellular degradation of apolipoprotein B. In conclusion, neither long term nor short term changes in cholesteryl ester synthesis or mass regulate the assembly and secretion of apolipoprotein B-containing lipoprotein from HepG2 cells.	COLUMBIA UNIV,COLL PHYS & SURG,DEPT MED,NEW YORK,NY 10032	Columbia University			Sakata, Nobuhiro/ACN-9770-2022		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036000, P50HL021006] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 36000, HL 21006] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BORCHARDT RA, 1987, J BIOL CHEM, V262, P16394; BOREN J, 1990, J BIOL CHEM, V265, P10556; BOREN J, 1992, J BIOL CHEM, V267, P9858; BOSTROM K, 1988, J BIOL CHEM, V263, P4434; CIANFLONE K, 1992, ARTERIOSCLER THROMB, V12, P271, DOI 10.1161/01.ATV.12.3.271; CIANFLONE KM, 1990, J LIPID RES, V31, P2045; CRAIG WY, 1988, J BIOL CHEM, V263, P13880; DASHTI N, 1992, J BIOL CHEM, V267, P7160; DIXON JL, 1993, J LIPID RES, V34, P167; DIXON JL, 1991, J BIOL CHEM, V266, P5080; EVANS AJ, 1992, J BIOL CHEM, V267, P10743; FUNGWE TV, 1992, J LIPID RES, V33, P179; FURUKAWA S, 1992, J BIOL CHEM, V267, P22630; GLAUMANN H, 1975, J CELL BIOL, V64, P356, DOI 10.1083/jcb.64.2.356; HASHIMOTO S, 1980, J BIOL CHEM, V255, P8678; HIGGINS JA, 1984, J LIPID RES, V25, P1295; KHAN B, 1989, BIOCHEM J, V259, P807; KHAN BV, 1990, BIOCHIM BIOPHYS ACTA, V1044, P297, DOI 10.1016/0005-2760(90)90073-7; KOSYKH VA, 1991, LIPIDS, V26, P799, DOI 10.1007/BF02536161; KOSYKH VA, 1988, FEBS LETT, V232, P103, DOI 10.1016/0014-5793(88)80395-8; KRAUSE BR, 1993, J LIPID RES, V34, P279; LUSKEY KL, 1985, J BIOL CHEM, V260, P271; MOBERLY JB, 1990, BIOCHIM BIOPHYS ACTA, V1042, P70, DOI 10.1016/0005-2760(90)90058-6; PULLINGER CR, 1989, J LIPID RES, V30, P1065; RASH JM, 1981, BIOCHIM BIOPHYS ACTA, V666, P294, DOI 10.1016/0005-2760(81)90120-X; RIBEIRO A, 1991, BIOCHIM BIOPHYS ACTA, V1086, P279, DOI 10.1016/0005-2760(91)90171-D; SAKATA N, 1993, J BIOL CHEM, V268, P22967; SAKATA N, 1992, CIRCULATION, V86, P208; Sambrook J, 1989, MOL CLONING LABORATO; SATO R, 1990, J BIOL CHEM, V265, P11880; SATO R, 1990, BIOCHIM BIOPHYS ACTA, V1042, P36, DOI 10.1016/0005-2760(90)90053-Z; SCHNITZERPOLOKOFF R, 1991, COMP BIOCHEM PHYS A, V99, P665, DOI 10.1016/0300-9629(91)90147-5; SLISKOVIC DR, 1991, TRENDS PHARMACOL SCI, V12, P191; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; TANAKA M, 1993, J BIOL CHEM, V268, P12713; VANCE JE, 1991, J LIPID RES, V32, P1971; YAO ZM, 1988, J BIOL CHEM, V263, P2998	37	109	109	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					12375	12382						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163541				2022-12-25	WOS:A1994NG37700105
J	ODONOVAN, A; SCHERLY, D; CLARKSON, SG; WOOD, RD				ODONOVAN, A; SCHERLY, D; CLARKSON, SG; WOOD, RD			ISOLATION OF ACTIVE RECOMBINANT XPG PROTEIN, A HUMAN DNA-REPAIR ENDONUCLEASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							COMPLEMENTATION GROUP-G; PIGMENTOSUM GROUP-F; XERODERMA-PIGMENTOSUM; DAMAGED DNA; EXCISION-REPAIR; SACCHAROMYCES-CEREVISIAE; SCHIZOSACCHAROMYCES-POMBE; (A)BC EXCINUCLEASE; 5' INCISION; BINDING	Complementation group G of xeroderma pigmentosum (XP-G) is one of the most rare and phenotypically heterogeneous forms of this inherited disorder. XP-G patients vary from having a very mild defect in DNA repair to being severely affected, and a few cases are also associated with the neurological complications of Cockayne's syndrome. The XPG gene encodes an acidic protein with a predicted molecular mass of 133 kDa that confers normal UV resistance when expressed in XP-G cells. Here we report the isolation of full-length XPG as a soluble protein expressed from a recombinant baculovirus. The purified polypeptide corrects the DNA nucleotide excision repair defect of XP-G cell extracts in vitro, and it acts as a magnesium-dependent single-stranded DNA endonuclease. This is the first direct evidence for a human protein with properties that implicate it in the incision step of nucleotide excision repair.	IMPERIAL CANC RES FUND,CLARE HALL LABS,S MIMMS EN6 3LD,HERTS,ENGLAND; CTR MED UNIV GENEVA,DEPT GENET & MICROBIOL,CH-1211 GENEVA 4,SWITZERLAND	University of Geneva			Wood, Richard/M-6319-2018	Wood, Richard/0000-0002-9495-6892				ARLETT CF, 1980, CARCINOGENESIS, V1, P745, DOI 10.1093/carcin/1.9.745; BIGGERSTAFF M, 1993, EMBO J, V12, P3685, DOI 10.1002/j.1460-2075.1993.tb06043.x; CARR AM, 1993, NUCLEIC ACIDS RES, V21, P1345, DOI 10.1093/nar/21.6.1345; CLEAVER JE, 1991, PHOTOCHEM PHOTOBIOL, V54, P393, DOI 10.1111/j.1751-1097.1991.tb02033.x; HABRAKEN Y, 1993, NATURE, V366, P365, DOI 10.1038/366365a0; HANAWALT PC, 1991, MUTAT RES, V247, P203, DOI 10.1016/0027-5107(91)90016-H; HANSSON J, 1989, J BIOL CHEM, V264, P21788; HWANG BJ, 1993, BIOCHEMISTRY-US, V32, P1657, DOI 10.1021/bi00057a033; ICHIHASHI M, 1985, J INVEST DERMATOL, V85, P284, DOI 10.1111/1523-1747.ep12276776; JONES CJ, 1993, BIOCHEMISTRY-US, V32, P12096, DOI 10.1021/bi00096a021; KEIJZER W, 1979, MUTAT RES, V62, P183, DOI 10.1016/0027-5107(79)90231-8; LIN JJ, 1992, J BIOL CHEM, V267, P17693; LIN JJ, 1992, J BIOL CHEM, V267, P17688; MACINNES MA, 1993, MOL CELL BIOL, V13, P6393, DOI 10.1128/MCB.13.10.6393; MALITSCHEK B, 1991, BIOTECHNIQUES, V11, P177; NORRIS PG, 1987, BRIT J DERMATOL, V116, P861, DOI 10.1111/j.1365-2133.1987.tb04906.x; ODONOVAN A, 1993, NATURE, V363, P185, DOI 10.1038/363185a0; OREILLY DR, 1992, BACULOVIRUS EXPRESSI, P185; REARDON JT, 1993, J BIOL CHEM, V268, P21301; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SCHERLY D, 1993, NATURE, V363, P182, DOI 10.1038/363182a0; SUNG P, 1993, J BIOL CHEM, V268, P26391; SUNG P, 1993, NATURE, V365, P852, DOI 10.1038/365852a0; SVOBODA DL, 1993, J BIOL CHEM, V268, P1931; TAKAO M, 1993, NUCLEIC ACIDS RES, V21, P4111, DOI 10.1093/nar/21.17.4111; TOMKINSON AE, 1993, NATURE, V362, P860, DOI 10.1038/362860a0; TREIBER DK, 1992, NUCLEIC ACIDS RES, V20, P5805, DOI 10.1093/nar/20.21.5805; VANHOFFEN A, 1993, NUCLEIC ACIDS RES, V21, P5890, DOI 10.1093/nar/21.25.5890; VANVUUREN AJ, 1993, EMBO J, V12, P3693, DOI 10.1002/j.1460-2075.1993.tb06044.x; VERMEULEN W, 1993, AM J HUM GENET, V53, P185; WEEDA G, 1993, SEMIN CANCER BIOL, V4, P105	31	77	78	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					15965	15968						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206890				2022-12-25	WOS:A1994NQ72900003
J	OSAWA, Y; FELLOWS, CS; MEYER, CA; WOODS, A; CASTORO, JA; COTTER, RJ; WILKINS, CL; HIGHET, RJ				OSAWA, Y; FELLOWS, CS; MEYER, CA; WOODS, A; CASTORO, JA; COTTER, RJ; WILKINS, CL; HIGHET, RJ			STRUCTURE OF THE NOVEL HEME ADDUCT FORMED DURING THE REACTION OF HUMAN HEMOGLOBIN WITH BRCCL3 IN RED-CELL LYSATES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MASS-SPECTROMETRY; PROSTHETIC HEME; MYOGLOBIN; METABOLISM; BENZO<A>PYRENE; MECHANISM; BINDING; OXIDASE; MOUSE; RATS	It was previously shown that the reductive debromination of BrCCl3 to trichloromethyl radical by human hemoglobin leads to formation of dissociable altered heme products, two of which are identical to those formed from myoglobin and one which is novel. In this study, we have elucidated the structure of this novel adduct with the use of mass spectrometry, as well as H-1 and C-13 NMR as a substitution product of a -C(Cl)=CCl2 moiety for a beta-hydrogen atom on the prosthetic heme's ring I vinyl group. From studies with the use of C-13-enriched BrCCl3, it was determined that the added carbon atoms were derived from 2 eq of BrCCl3. A mechanism that involves multiple reductive events and a radical cation heme intermediate is proposed. Consistent with this mechanism, cellular reductants were found to selectively enhance the amount of this novel dissociable heme adduct. These studies reveal fine differences between myoglobin and hemoglobin in the accessibility of reactive intermediates to the ring I vinyl group, as well as the potential importance of cellular reductants on the course of heme alteration.	NHLBI,BIOPHYS CHEM LAB,BETHESDA,MD 20892; UNIV CALIF RIVERSIDE,DEPT CHEM,RIVERSIDE,CA 92521; JOHNS HOPKINS UNIV,SCH MED,MIDDLE ATLANTIC MASS SPECT LAB,BALTIMORE,MD 21205	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University of California System; University of California Riverside; Johns Hopkins University	OSAWA, Y (corresponding author), NHLBI,CHEM PHARMACOL LAB,BETHESDA,MD 20892, USA.		Fellows, Christine/C-1433-2008; Wilkins, Charles L/H-8274-2014	Wilkins, Charles L/0000-0001-6471-6313	NIGMS NIH HHS [GM-44606] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044606] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anders MW, 1985, BIOACTIVATION FOREIG, P283; AXWORTHY DB, 1988, CHEM-BIOL INTERACT, V68, P99, DOI 10.1016/0009-2797(88)90009-9; BRYANT MS, 1987, CANCER RES, V47, P602; CASTRO JA, 1992, RAPID COMMUN MASS SP, V6, P239, DOI 10.1002/rcm.1290060403; FALK JE, 1964, PORPHYRINS METALLOPO, P72; FARMER PB, 1987, ARCH TOXICOL, V60, P251, DOI 10.1007/BF01234663; GORELICK NJ, 1989, CARCINOGENESIS, V10, P1579, DOI 10.1093/carcin/10.9.1579; HAUGEN DA, 1989, CHEM RES TOXICOL, V2, P379, DOI 10.1021/tx00012a005; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; Kalinowski H.-O., 1988, CARBON 13 NMR SPECTR, P131; KAUR S, 1989, J BIOL CHEM, V264, P16981; KINDT JT, 1992, J BIOL CHEM, V267, P8739; KOSTER C, 1992, J AM CHEM SOC, V114, P7572, DOI 10.1021/ja00045a045; KUBIC VL, 1981, CHEM-BIOL INTERACT, V34, P201, DOI 10.1016/0009-2797(81)90131-9; NAYLOR S, 1990, CHEM RES TOXICOL, V3, P111, DOI 10.1021/tx00014a005; OSAWA Y, 1990, J BIOL CHEM, V265, P10340; OSAWA Y, 1991, P NATL ACAD SCI USA, V88, P7081, DOI 10.1073/pnas.88.16.7081; OSAWA Y, 1991, J BIOL CHEM, V266, P3208; OSAWA Y, 1993, BIOCHEM PHARMACOL, V46, P2299, DOI 10.1016/0006-2952(93)90621-3; OSAWA Y, 1989, CHEM RES TOXICOL, V2, P131, DOI 10.1021/tx00009a001; OSAWA Y, 1993, J BIOL CHEM, V268, P2953; OSAWA Y, 1989, J AM CHEM SOC, V111, P4462, DOI 10.1021/ja00194a048; OSAWA Y, 1992, SYNTHESIS AND APPLICATIONS OF ISOTOPICALLY LABELLED COMPOUNDS 1991, P415; REYNOLDS WF, 1989, MAGN RESON CHEM, V27, P162, DOI 10.1002/mrc.1260270214; SABBIONI G, 1990, ARCH TOXICOL, V64, P451, DOI 10.1007/BF01977626; SABBIONI G, 1990, CARCINOGENESIS, V11, P111, DOI 10.1093/carcin/11.1.111; SHELTON JB, 1984, J LIQ CHROMATOGR, V7, P1969, DOI 10.1080/01483918408068849; SKIPPER PL, 1989, CHEM RES TOXICOL, V2, P280, DOI 10.1021/tx00011a002; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; SUN JD, 1989, TOXICOL APPL PHARM, V100, P86, DOI 10.1016/0041-008X(89)90093-8; WATERMAN MR, 1978, METHOD ENZYMOL, V52, P460; Winslow R.M, 1992, HEMOGLOBIN BASED RED; WINSLOW RM, 1989, RED CELL, P305; WINTERBOURN CC, 1990, SEMIN HEMATOL, V27, P41	34	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15481	15487						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	8195191				2022-12-25	WOS:A1994NP51300016
J	MIZUNO, K; OKANO, I; OHASHI, K; NUNOUE, K; KUMA, K; MIYATA, T; NAKAMURA, T				MIZUNO, K; OKANO, I; OHASHI, K; NUNOUE, K; KUMA, K; MIYATA, T; NAKAMURA, T			IDENTIFICATION OF A HUMAN CDNA-ENCODING A NOVEL PROTEIN-KINASE WITH 2 REPEATS OF THE LIM DOUBLE ZINC-FINGER MOTIF	ONCOGENE			English	Article							CYSTEINE-RICH PROTEIN; TYROSINE KINASE; CONSERVED FEATURES; CATALYTIC DOMAIN; ACTIVIN RECEPTOR; SERINE KINASE; INSULIN GENE; FAMILY; SEQUENCE; MEMBER	By low-stringency screening of a human hepatoma HepG2 cell cDNA library, using the genomic fragment of chick c-sea receptor tyrosine kinase as a probe, we isolated overlapping cDNAs encoding a novel protein kinase, which we termed LIM-kinase (LIMK). The predicted open reading frame encodes a 647-amino-acid polypeptide containing a putative protein kinase structure in the C-terminal half. In addition, LIMK has two repeats of cysteine-rich LIM/double zinc finger motif at the most N-terminus. To our knowledge, this is the first protein kinase seen to contain the LIM motif(s) in the molecule. Although the protein kinase domain of LIMK has highly conserved sequence elements of protein kinases, phylogenetic analysis revealed that LIMK cannot be classified into any subfamily of known protein kinases. Northern blot analysis revealed that the single species of LIMK mRNA of 3.3 kb was expressed in various human epithelial and hematopoietic cell lines. In rat tissues, LIMK mRNA was expressed in the brain, at the highest level. LIM is suggested to be involved in protein-protein interactions by binding to another LIM motif. As the LIM domain is frequently present in the homeodomain-containing transcriptional regulators and oncogenic nuclear proteins, LIMK may be involved in developmental or oncogenic processes through interactions with these LIM-containing proteins.	KYOTO UNIV, FAC SCI, DEPT BIOPHYS, KYOTO 60601, JAPAN; OSAKA UNIV, SCH MED, BIOMED RES CTR, OSAKA 565, JAPAN	Kyoto University; Osaka University	MIZUNO, K (corresponding author), KYUSHU UNIV, FAC SCI, DEPT BIOL, FUKUOKA 812, JAPAN.		Mizuno, Kensaku/G-8631-2015	Ohashi, Kazumasa/0000-0001-7617-403X				BIRKENMEIER EH, 1986, P NATL ACAD SCI USA, V83, P2516, DOI 10.1073/pnas.83.8.2516; BOEHM T, 1990, EMBO J, V9, P857, DOI 10.1002/j.1460-2075.1990.tb08183.x; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN B, 1992, GENE DEV, V6, P715, DOI 10.1101/gad.6.5.715; FEATHERSTONE C, 1991, NATURE, V349, P808, DOI 10.1038/349808a0; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; FIRMBACHKRAFT I, 1990, ONCOGENE, V5, P1328; FREYD G, 1990, NATURE, V344, P876, DOI 10.1038/344876a0; GERMAN MS, 1992, GENE DEV, V6, P2165, DOI 10.1101/gad.6.11.2165; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HARRISON SC, 1991, NATURE, V353, P715, DOI 10.1038/353715a0; HOWELL BW, 1991, MOL CELL BIOL, V11, P568, DOI 10.1128/MCB.11.1.568; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LIEBHABER SA, 1990, NUCLEIC ACIDS RES, V18, P3871, DOI 10.1093/nar/18.13.3871; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MCGUIRE EA, 1992, MOL CELL BIOL, V12, P4186, DOI 10.1128/MCB.12.9.4186; MCGUIRE EA, 1991, BLOOD, V77, P599; MCGUIRE EA, 1989, MOL CELL BIOL, V9, P2124, DOI 10.1128/MCB.9.5.2124; NAKAMURA T, 1992, J BIOL CHEM, V267, P18924; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OHASHI K, 1994, ONCOGENE, V9, P699; OKANO I, 1993, FEBS LETT, V333, P51, DOI 10.1016/0014-5793(93)80373-3; RABBITTS TH, 1990, NATURE, V346, P418, DOI 10.1038/346418a0; SADLER I, 1992, J CELL BIOL, V119, P1573, DOI 10.1083/jcb.119.6.1573; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEGER R, 1991, P NATL ACAD SCI USA, V88, P6142, DOI 10.1073/pnas.88.14.6142; TAIRA M, 1992, GENE DEV, V6, P356, DOI 10.1101/gad.6.3.356; TAN JL, 1990, MOL CELL BIOL, V10, P3578, DOI 10.1128/MCB.10.7.3578; TANAKA A, 1987, MOL CELL BIOL, V7, P1978, DOI 10.1128/MCB.7.5.1978; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WANG XK, 1992, J BIOL CHEM, V267, P9176; WAY JC, 1988, CELL, V54, P5, DOI 10.1016/0092-8674(88)90174-2; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057	42	181	190	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1994	9	6					1605	1612						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NL815	8183554				2022-12-25	WOS:A1994NL81500011
J	CHASSANDE, O; RENARD, S; BARBRY, P; LAZDUNSKI, M				CHASSANDE, O; RENARD, S; BARBRY, P; LAZDUNSKI, M			HUMAN GENE FOR DIAMINE OXIDASE, AN AMILORIDE BINDING-PROTEIN - MOLECULAR-CLONING, SEQUENCING, AND CHARACTERIZATION OF THE PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL SODIUM-CHANNEL; AMINE OXIDASE; FUNCTIONAL EXPRESSION; ENHANCER ELEMENTS; MAMMALIAN-CELLS; TRANSCRIPTION; MESSENGER; SITE; KERATIN; REGION	The amiloride binding protein (ABP) is detected in many epithelium-rich and/or hematopoietic tissues (Lingueglia, E., Renard, S., Voilley, N., Waldmann, R, Chassande, O., Lazdunski, M., and Barbry, P. (1993) Eur. J. Biochem. 216, 679-687). The protein binds amiloride and some of its derivatives, such as phenamil, benzamil, and ethylpropylamiloride. These properties have previously suggested that ABP might be associated with an amiloride-sensitive Na+ channel. It corresponds in fact to an amiloride-sensitive diamine oxidase (DAO) that catalyzes the degradation of compounds such as putrescine or histamine. The analysis of the organization of the sequence of the human ABP/DAO gene reveals that the 2.4-kilobase messenger RNA is transcribed from two close origins identifying the proximal promoter. After sequencing, some corrections within the initial cDNA sequence have been made. Human ABP/DAO corresponds to a 751-residue polypeptide. The promoter activity of 1800 base pairs upstream of the transcription start sites of the long form has been analyzed. Two bulks of cis-activating sequences have been identified. One of them constitutes the proximal promoter. It contains a palindromic sequence previously described as E-PAL. This motif is essential for the full activity of the promoter and behaves like a composite element. This first molecular cloning of a human gene coding for a diamine oxidase will allow us to further understand its regulation during cell growth and/or embryonic development.	INST PHARMACOL MOLEC & CELLULAIRE,F-06560 VALBONNE,FRANCE				Barbry, Pascal/O-5021-2016	Barbry, Pascal/0000-0001-9632-6483; Renard, Stephane/0000-0002-1374-4960				BACHRACH U, 1985, STRUCTURE FUNCTIONS, P5; BARBRY P, 1987, P NATL ACAD SCI USA, V84, P4836, DOI 10.1073/pnas.84.14.4836; BARBRY P, 1990, HUM GENET, V85, P587, DOI 10.1007/BF00193579; BARBRY P, 1990, P NATL ACAD SCI USA, V87, P7347, DOI 10.1073/pnas.87.19.7347; BEHRENS J, 1991, P NATL ACAD SCI USA, V88, P11495, DOI 10.1073/pnas.88.24.11495; BELIAVSKY A, 1989, NUCLEIC ACIDS RES, V17, P2919; BENOS DJ, 1987, J BIOL CHEM, V262, P10613; BRUINENBERG PG, 1989, BIOCHIM BIOPHYS ACTA, V1008, P157, DOI 10.1016/0167-4781(80)90003-2; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DYNAN WS, 1986, TRENDS GENET, V2, P196, DOI 10.1016/0168-9525(86)90226-X; FRELIN C, 1987, KIDNEY INT, V32, P785, DOI 10.1038/ki.1987.277; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; JANES SM, 1990, SCIENCE, V248, P981, DOI 10.1126/science.2111581; KLEYMAN TR, 1986, J BIOL CHEM, V261, P2839; KLEYMAN TR, 1989, J BIOL CHEM, V264, P11995; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LEASK A, 1990, GENE DEV, V4, P1985, DOI 10.1101/gad.4.11.1985; LINGUEGLIA E, 1993, EUR J BIOCHEM, V216, P679, DOI 10.1111/j.1432-1033.1993.tb18188.x; LOH EY, 1989, SCIENCE, V243, P217, DOI 10.1126/science.2463672; MARCHUK D, 1985, P NATL ACAD SCI USA, V82, P1609, DOI 10.1073/pnas.82.6.1609; MEANS AR, 1991, MOL CELL BIOL, V11, P3960, DOI 10.1128/MCB.11.8.3960; NOVOTNY WF, 1994, J BIOL CHEM, V269, P9921; RANGACHARI PK, 1992, AM J PHYSIOL, V262, pG1, DOI 10.1152/ajpgi.1992.262.1.G1; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; ROSSI A, 1992, FEBS LETT, V301, P253, DOI 10.1016/0014-5793(92)80251-B; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557	30	59	60	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14484	14489						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	8182053				2022-12-25	WOS:A1994NM06500029
J	COREY, JL; DAVIDSON, N; LESTER, HA; BRECHA, N; QUICK, MW				COREY, JL; DAVIDSON, N; LESTER, HA; BRECHA, N; QUICK, MW			PROTEIN-KINASE-C MODULATES THE ACTIVITY OF A CLONED GAMMA-AMINOBUTYRIC-ACID TRANSPORTER EXPRESSED IN XENOPUS-OOCYTES VIA REGULATED SUBCELLULAR REDISTRIBUTION OF THE TRANSPORTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT ADIPOSE CELL; FREE FATTY-ACIDS; GLUCOSE TRANSPORTER; PLASMA-MEMBRANE; PHORBOL ESTERS; INDUCED TRANSLOCATION; INSULIN ACTION; 3T3-L1 CELLS; AFFINITY; PHOSPHORYLATION	We report that activators and inhibitors of protein kinase C (PKC) and protein phosphatases regulate the activity of a cloned rat brain gamma-aminobutyric acid (GABA) transporter (GAT1) expressed in Xenopus oocytes. Four compounds known to activate PKC increased GABA uptake 2-3.5-fold over basal control levels. Inhibition of PKC by bisindolylmaleimide reduced basal GABA uptake 80% and blocked the phorbol 12-myristate 13-acetate (PMA)-induced stimulation of transport. Okadaic acid, a protein phosphatase inhibitor, stimulated transport 2.5-fold; a 4-fold increase in GABA uptake occurred when oocytes were treated with cyclosporin A, a specific inhibitor of protein phosphatase 2B. Modulation resulted in changes to V-max but not to K-m and was influenced by the functional expression level of the transporter protein; as expression level increased, the ability to up-regulate transporter activity decreased. Down-regulation of transporter activity was independent of expression level. Modulation did not occur through phosphorylation of the three consensus PKC sites predicted by the primary protein sequence since their removal had no effect on the susceptibility of the transporter to modulation by PMA or bisindolylmaleimide. Subcellular fractionation of oocyte membranes demonstrated that under basal level conditions, the majority of GAT1 was targeted to a cytoplasmic compartment corresponding to the trans-Golgi or low density vesicles. Stimulation of PKC with PMA resulted in a translocation of transporters from this compartment to the plasma membrane. At higher expression levels of GAT1 protein, a larger portion of GAT1 was found on the plasma membrane during basal level conditions and treatment with bisindolylmaleimide resulted in removal of these transporters from the plasma membrane. At expression levels demonstrated to be resistant to modulation by PMA, PMA-treatment still resulted in translocation of transporters from the cytoplasm to the plasma membrane. Thus, the inability of PMA to increase uptake at high expression of the GAT1 protein is due to saturation at a step subsequent to translocation. These findings 1) demonstrate the presence of a novel regulated secretory pathway in oocytes and 2) suggest a modulatory mechanism for neurotransmitter transporters that could have significant effects upon synaptic function.	UNIV CALIF LOS ANGELES, SCH MED, DEPT ANAT & CELL BIOL, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, SCH MED, INST BRAIN RES, DEPT MED, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, SCH MED, CTR ULCER RES, LOS ANGELES, CA 90024 USA; W LOS ANGELES VET AFFAIRS MED CTR, LOS ANGELES, CA 90073 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; West Los Angeles VA Medical Center	COREY, JL (corresponding author), CALTECH, DIV BIOL, 156-29, PASADENA, CA 91125 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS011756] Funding Source: NIH RePORTER; NINDS NIH HHS [NS-11756] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALDER J, 1992, SCIENCE, V257, P657, DOI 10.1126/science.1353905; Alder J, 1993, Curr Opin Neurobiol, V3, P322, DOI 10.1016/0959-4388(93)90124-H; AMARA SG, 1993, ANNU REV NEUROSCI, V16, P73, DOI 10.1146/annurev.ne.16.030193.000445; ASANO T, 1992, J BIOL CHEM, V267, P19636; BLOK J, 1988, J CELL BIOL, V106, P69, DOI 10.1083/jcb.106.1.69; CALDERHEAD DM, 1990, J BIOL CHEM, V265, P13800; CASADO M, 1991, J NEUROCHEM, V57, P1185, DOI 10.1111/j.1471-4159.1991.tb08278.x; COREY JL, 1992, MOL ENDOCRINOL, V6, P450, DOI 10.1210/me.6.3.450; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; FRIEDMAN J, 1991, CELL, V66, P799, DOI 10.1016/0092-8674(91)90123-G; GILMORE T, 1983, NATURE, V306, P487, DOI 10.1038/306487a0; GOMEZA J, 1991, BIOCHEM J, V275, P435, DOI 10.1042/bj2750435; GUASTELLA J, 1990, SCIENCE, V249, P1303, DOI 10.1126/science.1975955; HARRISON SA, 1990, J BIOL CHEM, V265, P20106; HENSLEY CB, 1989, AM J PHYSIOL, V257, pC637, DOI 10.1152/ajpcell.1989.257.4.C637; KACZMAREK LK, 1988, ADV SEC MESS PHOSPH, V22, P113; KAIN KC, 1991, BIOTECHNIQUES, V10, P366; KAVANAUGH MP, 1992, J BIOL CHEM, V267, P22007; KELLY RB, 1993, NEURON S, V10, P43; KLAUSNER RD, 1980, J BIOL CHEM, V255, P1286; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAGER S, 1993, NEURON, V10, P177, DOI 10.1016/0896-6273(93)90309-F; MUDD LM, 1990, BRAIN RES, V521, P192, DOI 10.1016/0006-8993(90)91542-O; NISHINO H, 1986, BIOCHIM BIOPHYS ACTA, V889, P236, DOI 10.1016/0167-4889(86)90109-6; QUICK MW, 1992, BIOTECHNIQUES, V13, P357; QUICK MW, 1994, METH NEUROSCI, V19, P261; SARANTIS M, 1993, NEURON, V11, P541, DOI 10.1016/0896-6273(93)90158-N; SARDET C, 1990, SCIENCE, V247, P723, DOI 10.1126/science.2154036; SCHAEFFER BE, 1979, BIOCHIM BIOPHYS ACTA, V556, P131, DOI 10.1016/0005-2736(79)90425-5; SCHEUNER D, 1992, J CELL BIOL, V116, P359, DOI 10.1083/jcb.116.2.359; SHIBASAKI Y, 1992, BIOCHEM J, V281, P829, DOI 10.1042/bj2810829; SOLIS JM, 1992, J NEUROSCI, V12, P3466; SUGIMURA T, 1982, GANN, V73, P499; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; SWANN AC, 1984, ARCH BIOCHEM BIOPHYS, V233, P354, DOI 10.1016/0003-9861(84)90456-9; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; WARDZALA LJ, 1978, J BIOL CHEM, V253, P8002; YANG J, 1992, BIOCHEM J, V281, P809, DOI 10.1042/bj2810809; [No title captured]	40	190	193	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14759	14767						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	8182081				2022-12-25	WOS:A1994NM06500071
J	LIU, AYC; BIAN, HJ; HUANG, LE; LEE, YK				LIU, AYC; BIAN, HJ; HUANG, LE; LEE, YK			TRANSIENT COLD SHOCK INDUCES THE HEAT-SHOCK RESPONSE UPON RECOVERY AT 37-DEGREES-C IN HUMAN-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-DIPLOID FIBROBLASTS; TRANSCRIPTIONAL ACTIVATION; CONFORMATIONAL DRIFT; PROMOTER ACTIVITY; BINDING-ACTIVITY; PROTEIN; STRESS; INDUCTION; GENES; EXPRESSION	We evaluated the effects of a transient cold shock followed by recovery and incubation at 37 degrees C on the regulation of heat shock gene expression in the IMR-90 human diploid fibroblasts and HeLa cells in tissue culture. We showed that preincubation of cells at 4 degrees C induced 6he synthesis and accumulation of the heat shock proteins (HSPs) upon recovery at 37 degrees C, and the degree of this induction was directly related to the time that the cells spent at 4 degrees C. Assays on the abundance of the hsp 70 transcript, the hsp 70 gene promoter activity, and the trimerization and activation of heat shock factor (HSF) to bind to its consensus heat shock element (HSE) provided evidence that this induction of the heat shock response in cells recovering from a transient cold shock is attributable to a transcriptional event mediated by the activation of HSF. Further, the induction was a response to the temperature upshift from 4 to 37 degrees C as opposed to the 4 degrees C treatment itself; quantitation of the HSE-binding activity of cells incubated at 4 degrees C without recovery and incubation at 37 degrees C gave no evidence of an activated response. Analysis of the effects of protein synthesis inhibitors demonstrated that neither cycloheximide nor puromycin was effective in blocking 6he induction of HSE-binding activity in cells recovering from a transient cold shock. Experiments on the time course and temperature dependence of this induction of HSE-binding activity showed that the onset, magnitude, and duration of this induction were directly proportional to the severity of the cold stress (measured by time and temperature). We discuss the possible mechanism(s) involved in this induction of the heat shock genes at 37 degrees C by a transient cold shock and the biological implications of this observation.			LIU, AYC (corresponding author), RUTGERS STATE UNIV,DEPT BIOL SCI,PISCATAWAY,NJ 08855, USA.			Huang, Eric/0000-0002-6444-1708; Liu, Alice Y./0000-0002-6984-1671				ABRAVAYA K, 1991, GENE DEV, V5, P2117, DOI 10.1101/gad.5.11.2117; AMBROSIO G, 1993, J BIOL CHEM, V268, P18532; ANANTHAN J, 1986, SCIENCE, V232, P522, DOI 10.1126/science.3083508; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BALER R, 1992, J CELL BIOL, V117, P1151, DOI 10.1083/jcb.117.6.1151; BALER R, 1993, MOL CELL BIOL, V13, P2486, DOI 10.1128/MCB.13.4.2486; BECKMANN RP, 1992, J CELL BIOL, V117, P1137, DOI 10.1083/jcb.117.6.1137; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BOCK PE, 1978, TRENDS BIOCHEM SCI, V3, P100, DOI 10.1016/S0968-0004(78)80013-9; BURTON V, 1988, MOL CELL BIOL, V8, P3550, DOI 10.1128/MCB.8.8.3550; CHANG NT, 1993, J BIOL CHEM, V268, P1436; CHOI HS, 1991, J BIOL CHEM, V266, P11858; CHOI HS, 1990, J BIOL CHEM, V265, P18005; CLOS J, 1993, NATURE, V364, P252, DOI 10.1038/364252a0; EDINGTON BV, 1989, J CELL PHYSIOL, V139, P219, DOI 10.1002/jcp.1041390202; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOLDSTEIN J, 1990, P NATL ACAD SCI USA, V87, P283, DOI 10.1073/pnas.87.1.283; HIGHTOWER LE, 1980, J CELL PHYSIOL, V102, P407, DOI 10.1002/jcp.1041020315; HIGHTOWER LE, 1991, CELL, V66, P191, DOI 10.1016/0092-8674(91)90611-2; KAUL SC, 1992, CELL MOL BIOL, V38, P133; KING L, 1986, BIOCHEMISTRY-US, V25, P3632, DOI 10.1021/bi00360a023; KONDO K, 1992, J BIOL CHEM, V267, P16259; KONDO K, 1991, J BIOL CHEM, V266, P17537; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; LIS J, 1993, CELL, V74, P1, DOI 10.1016/0092-8674(93)90286-Y; LIU AYC, 1989, BIOCHEM BIOPH RES CO, V162, P1302, DOI 10.1016/0006-291X(89)90815-2; LIU AYC, 1989, J BIOL CHEM, V264, P12037; LIU AYC, 1991, J CELL PHYSIOL, V149, P560, DOI 10.1002/jcp.1041490327; LOVEN DP, 1988, MED HYPOTHESES, V26, P39, DOI 10.1016/0306-9877(88)90111-9; MORIMOTO RI, 1993, SCIENCE, V259, P1409, DOI 10.1126/science.8451637; NAGLE WA, 1990, CRYOBIOLOGY, V27, P439, DOI 10.1016/0011-2240(90)90021-U; NOVER L, 1987, ENZYME MICROB TECH, V9, P130, DOI 10.1016/0141-0229(87)90066-4; NOVER L, 1990, HEAT SHOCK RESPONSE; NOVER L, 1984, HEAT SHOCK RESPONSE; OSTLUND RE, 1980, J CELL BIOL, V85, P386, DOI 10.1083/jcb.85.2.386; OURY TD, 1993, J BIOL CHEM, V268, P15394; PAIN RH, 1987, TEMPERATURE ANIMAL C, P21; PEPPEL K, 1990, BIOTECHNIQUES, V9, P711; PEROTTI M, 1990, FEBS LETT, V259, P331, DOI 10.1016/0014-5793(90)80040-P; RABINDRAN SK, 1991, P NATL ACAD SCI USA, V88, P6906, DOI 10.1073/pnas.88.16.6906; RABINDRAN SK, 1993, SCIENCE, V259, P230, DOI 10.1126/science.8421783; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; SCHUETZ TJ, 1991, P NATL ACAD SCI USA, V88, P6911, DOI 10.1073/pnas.88.16.6911; Watson P, 1987, TEMPERATURE ANIMAL C, P311; WEBER G, 1986, BIOCHEMISTRY-US, V25, P3626, DOI 10.1021/bi00360a022; WESTWOOD JT, 1993, MOL CELL BIOL, V13, P3481, DOI 10.1128/MCB.13.6.3481; WILLIAMS GT, 1989, MOL CELL BIOL, V9, P2574, DOI 10.1128/MCB.9.6.2574; WU B, 1985, MOL CELL BIOL, V5, P330, DOI 10.1128/MCB.5.2.330; ZIMARINO V, 1990, MOL CELL BIOL, V10, P752, DOI 10.1128/MCB.10.2.752	49	88	107	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14768	14775						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	8182082				2022-12-25	WOS:A1994NM06500072
J	ESCRIOU, V; LAPORTE, F; GARIN, J; BRANDOLIN, G; VIGNAIS, PV				ESCRIOU, V; LAPORTE, F; GARIN, J; BRANDOLIN, G; VIGNAIS, PV			PURIFICATION AND PHYSICAL-PROPERTIES OF A NOVEL TYPE OF CYTOCHROME-B FROM RABBIT PERITONEAL NEUTROPHILS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN POLYMORPHONUCLEAR LEUKOCYTES; LEUKOTRIENE-B4 OMEGA-HYDROXYLASE; CHRONIC GRANULOMATOUS-DISEASE; GENERATING NADPH OXIDASE; RESPIRATORY BURST; MICROBICIDAL OXIDASE; PHAGOCYTIC-CELLS; REDUCTASE; PROTEIN; SYSTEM	The main redox component of the O-2(-) generating oxidase complex in neutrophils is believed to be a b-type cytochrome, named cytochrome b(558). In the course of purification of cytochrome b(558) from rabbit peritoneal neutrophils, another hemoprotein with an apparent molecular mass of 30 kDa, referred to as p-30, was isolated. Although the spectrum of p-30 was virtually identical to that of cytochrome b(558), its redox potential, E(m7) = -4 +/- 10 mV, was much less negative than that of cytochrome b(558) (-270 +/- 5 mV). The alkaline pyridine hemochrome from purified p-30 was typical of a b-type cytochrome. The 20 N-terminal amino acid residues and some tryptic peptides isolated from p-30 did not show any significant sequence homology to the human phagocyte cytochrome b(558) or to mitochondrial and microsomal cytochromes, except for the N-terminal region which displayed some homology to that of rat liver P-450. After subcellular fractionation, p-30 was found to be located in the plasma membrane and the granule fractions, similarly to cytochrome b(558). Upon neutrophil activation, part of p-30 was transferred from granules to the plasma membrane.	CEN, DEPT BIOL MOLEC & STRUCT, CHIM PROT LAB, F-38041 GRENOBLE, FRANCE		ESCRIOU, V (corresponding author), CEN, BIOCHIM LAB, CNRS, URA 1130, 85X, F-38041 GRENOBLE, FRANCE.			Escriou, Virginie/0000-0001-5686-9301				BABIOR BM, 1981, METHODS HEMATOLOGY, V3, P1; BABIOR BM, 1992, ADV ENZYMOL RAMB, V65, P49; BADWEY JA, 1983, BLOOD, V62, P152; BERTON G, 1985, BIOCHIM BIOPHYS ACTA, V810, P164, DOI 10.1016/0005-2728(85)90132-X; BORREGAARD N, 1983, J CELL BIOL, V97, P52, DOI 10.1083/jcb.97.1.52; BOULAY F, 1990, BIOCHEMISTRY-US, V29, P11123, DOI 10.1021/bi00502a016; BRANDOLIN G, 1974, FEBS LETT, V46, P149, DOI 10.1016/0014-5793(74)80356-X; DOUSSIERE J, 1993, BIOCHEMISTRY-US, V32, P8880, DOI 10.1021/bi00085a020; DUONG LT, 1982, J BIOL CHEM, V257, P8561; Fuhrhop J. H., 1975, PORPHYRINS METALLOPO, P804; HANSFORD RG, 1976, BILL HDB 1, P144; HARLOW E, 1988, ANTIBODIES LABORATOR; HOGEBOOM GH, 1955, METHOD ENZYMOL, V1, P16, DOI 10.1016/0076-6879(55)01007-0; ISOGAI Y, 1991, J BIOL CHEM, V266, P13481; KLEINBERG ME, 1989, J IMMUNOL, V143, P4152; KNOLLER S, 1991, J BIOL CHEM, V266, P2795; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPORTE F, 1991, EUR J BIOCHEM, V196, P59, DOI 10.1111/j.1432-1033.1991.tb15785.x; LAUQIN JGM, 1976, FEBS LETT, V87, P306; LAUQUIN G, 1973, BIOCHIM BIOPHYS ACTA, V305, P534, DOI 10.1016/0005-2728(73)90074-1; LIGHT DR, 1981, BIOCHEMISTRY-US, V20, P1468, DOI 10.1021/bi00509a010; MEIER B, 1993, BIOCHEM J, V289, P481, DOI 10.1042/bj2890481; MEIER B, 1991, BIOCHEM J, V275, P241, DOI 10.1042/bj2750241; MOREL F, 1993, BIOCHIM BIOPHYS ACTA, V1182, P101, DOI 10.1016/0925-4439(93)90159-X; MOREL F, 1985, EUR J BIOCHEM, V152, P669, DOI 10.1111/j.1432-1033.1985.tb09247.x; MOREL F, 1991, EUR J BIOCHEM, V201, P523, DOI 10.1111/j.1432-1033.1991.tb16312.x; MOREL F, 1987, ADV BIOSCI, V66, P301; MUIRWOOD P, 1974, FEBS LETT, V44, P22, DOI 10.1016/0014-5793(74)80297-8; NICHOLLS DG, 1992, BIOENERGETICS, V2, P131; PARKOS CA, 1987, J CLIN INVEST, V80, P732, DOI 10.1172/JCI113128; PARKOS CA, 1988, P NATL ACAD SCI USA, V85, P3319, DOI 10.1073/pnas.85.10.3319; PERIN MS, 1988, EMBO J, V7, P2697, DOI 10.1002/j.1460-2075.1988.tb03123.x; QUINN MT, 1992, J BIOL CHEM, V267, P7303; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; ROTROSEN D, 1993, J BIOL CHEM, V268, P14256; ROTROSEN D, 1992, SCIENCE, V256, P1459, DOI 10.1126/science.1318579; ROTROSEN D, 1990, J BIOL CHEM, V265, P8745; ROYERPOKORA B, 1986, NATURE, V322, P32, DOI 10.1038/322032a0; SEGAL AW, 1987, NATURE, V326, P88, DOI 10.1038/326088a0; SEGAL AW, 1992, BIOCHEM J, V284, P781, DOI 10.1042/bj2840781; SHAK S, 1985, J CLIN INVEST, V76, P1218, DOI 10.1172/JCI112077; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SUMIMOTO H, 1988, EUR J BIOCHEM, V172, P315, DOI 10.1111/j.1432-1033.1988.tb13889.x; SZCZESNASKORUPA E, 1988, P NATL ACAD SCI USA, V85, P738, DOI 10.1073/pnas.85.3.738; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	45	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					14007	14014						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188680				2022-12-25	WOS:A1994NL60600045
J	SEIFERT, RA; COATS, SA; RAINES, EW; ROSS, R; BOWENPOPE, DF				SEIFERT, RA; COATS, SA; RAINES, EW; ROSS, R; BOWENPOPE, DF			PLATELET-DERIVED GROWTH-FACTOR (PDGF) RECEPTOR ALPHA-SUBUNIT MUTANT AND RECONSTITUTED CELL-LINES DEMONSTRATE THAT TRANSFORMING GROWTH-FACTOR-BETA CAN BE MITOGENIC THROUGH PDGF A-CHAIN-DEPENDENT AND A-CHAIN-INDEPENDENT PATHWAYS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA; BIFUNCTIONAL REGULATOR; DNA-SYNTHESIS; FIBROBLASTS; EXPRESSION; CULTURES; ESTABLISHES; SECRETION; GENE	Mitogenic stimulation of connective tissue cells by transforming growth factor-beta (TGF-beta) has two unusual properties; entry into S-phase is delayed compared with that induced by other mitogens, and the dose response is biphasic, with low concentrations stimulating and high concentrations inhibiting or having no effect. A hypothesis that provides an explanation for both of these properties is that TGF-beta stimulates proliferation indirectly by inducing synthesis of platelet-derived growth factor (PDGF) A-chain, which in turn stimulates proliferation via autocrine activation of the PDGF receptor alpha-subunit (PHGFR alpha). High concentrations of TGF-beta reduce PDGFR alpha expression and break the autocrine loop. We tested this hypothesis by determining whether TGF-beta and interleukin-1 alpha can induce DNA synthesis in connective tissue (3T3) cells derived from the Patch mouse line in which the PDGFR alpha gene is deleted. We found that these cells do respond mitogenically to TGF-beta and interleukin-1 alpha, indicating that PDGF A-chain induction is not the sole mechanism of mitogenic stimulation. Reestablishing PDGFR alpha expression via transfection with a human PDGFR alpha construct enhanced the response to TGF-beta. Neutralizing anti-PDGF antiserum reduced TGF-beta stimulation of PDGFR alpha-expressing 3T3 cells by about 35%. We conclude that induction of PDGF A-chain/ PDGFR alpha autocrine stimulation does contribute to the ability of TGF-beta to stimulate connective tissue cells, but that there is, in addition, a PDGF-independent pathway.			SEIFERT, RA (corresponding author), UNIV WASHINGTON,DEPT PATHOL SJ60,SEATTLE,WA 98195, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL018645] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL18645] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BATTEGAY EJ, 1990, CELL, V63, P515, DOI 10.1016/0092-8674(90)90448-N; BAZENET CE, 1994, ONCOGENE, V9, P517; BETSHOLTZ C, 1986, NATURE, V320, P695, DOI 10.1038/320695a0; CENTRELLA M, 1987, J BIOL CHEM, V262, P2869; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; GOLDSMITH KT, 1991, AM J PHYSIOL, V261, pL378, DOI 10.1152/ajplung.1991.261.6.L378; HARVEY AK, 1991, EXP CELL RES, V195, P376, DOI 10.1016/0014-4827(91)90387-A; HILL DJ, 1986, J CELL PHYSIOL, V128, P322, DOI 10.1002/jcp.1041280226; LEOF EB, 1986, P NATL ACAD SCI USA, V83, P2453, DOI 10.1073/pnas.83.8.2453; MAJACK RA, 1987, J CELL BIOL, V105, P465, DOI 10.1083/jcb.105.1.465; MAJACK RA, 1990, J CELL BIOL, V111, P239, DOI 10.1083/jcb.111.1.239; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MOSES HL, 1985, CANCER CELL, V3, P65; PAULSSON Y, 1993, J CELL PHYSIOL, V157, P97, DOI 10.1002/jcp.1041570113; Paulsson Y, 1988, GROWTH FACTORS, V1, P19, DOI 10.3109/08977198809000243; PERTOVAARA L, 1993, GROWTH FACTORS, V9, P81, DOI 10.3109/08977199308991584; RAINES EW, 1989, SCIENCE, V243, P393, DOI 10.1126/science.2783498; REDINI F, 1993, ARTHRITIS RHEUM, V36, P44; ROBERTS AB, 1985, P NATL ACAD SCI USA, V82, P119, DOI 10.1073/pnas.82.1.119; SEIFERT RA, 1993, J BIOL CHEM, V268, P4473; SEIFERT RA, 1989, J BIOL CHEM, V264, P8771; SHIPLEY GD, 1985, P NATL ACAD SCI USA, V82, P4147, DOI 10.1073/pnas.82.12.4147; SMITH EA, 1991, P NATL ACAD SCI USA, V88, P4811, DOI 10.1073/pnas.88.11.4811; SOMA Y, 1989, J CELL PHYSIOL, V140, P246, DOI 10.1002/jcp.1041400209; SPORN MB, 1980, NEW ENGL J MED, V303, P878, DOI 10.1056/NEJM198010093031511; STEPHENSON DA, 1991, P NATL ACAD SCI USA, V88, P6, DOI 10.1073/pnas.88.1.6; STORY MT, 1993, PROSTATE, V22, P183, DOI 10.1002/pros.2990220302; YOSHIDA K, 1992, BRAIN RES, V569, P14, DOI 10.1016/0006-8993(92)90364-F	28	41	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					13951	13955						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188675				2022-12-25	WOS:A1994NL60600038
J	KRYCH, M; CLEMENZA, L; HOWDESHELL, D; HAUHART, R; HOURCADE, D; ATKINSON, JP				KRYCH, M; CLEMENZA, L; HOWDESHELL, D; HAUHART, R; HOURCADE, D; ATKINSON, JP			ANALYSIS OF THE FUNCTIONAL DOMAINS OF COMPLEMENT RECEPTOR-TYPE-1 (C3B/C4B RECEPTOR, CD35) BY SUBSTITUTION MUTAGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPSTEIN-BARR-VIRUS; CONTROL PROTEIN MODULE; C3B C4B RECEPTOR; 3RD COMPONENT; VACCINIA VIRUS; LIGAND-BINDING; SECONDARY STRUCTURE; FACTOR-H; SITES; CR-1	The complement receptor type 1 (CR1; CD35), carrying 30 short consensus repeats (SCRs), has two sites. Site 1 contains SCR-1 and SCR-2 and binds C4b. Site 2 contains SCR-8 and SCR-9 and was reported to bind mainly C3b (Klickstein, L. B., Bartow, T. J., Miletic, V., Rabson, L. D., Smith, J. A, and Fearon, D. T. (1988) J. Exp. Med. 168, 1699-1717). For the functional analysis we used two constructs, each with one site. CR1-4, composed of eight and one-half initial SCRs, carries site 1, binds C4b, and is cofactor for C4b cleavage. CR1-4(8,9), obtained from CR1-4 by converting site 1 to site 2, binds iC3/C3b and, unexpectedly, C4b. It is a cofactor for cleavage of both ligands. Its cofactor activity for C4b cleavage is greater than that of site 1. Analysis of the mutants constructed by interchanging homologous peptides between the two sites identified no sequences necessary for cofactor activity other than those required for binding. In site 2, peptides important for both ligands were found. Some modifications of either site led to higher activity for both ligands. Thus the activity of complement regulators can be increased by changing a few amino acids within SCRs, an important step toward the generation of more effective inhibitors of complement activation. Knowledge of the active sites of CR1 should be applicable to other SCR-containing proteins and should provide insights into the evolution of these proteins.	WASHINGTON UNIV, SCH MED, DEPT MED, ST LOUIS, MO 63110 USA	Washington University (WUSTL)				Atkinson, John/0000-0002-2514-3441				ADAMS EM, 1991, J IMMUNOL, V147, P3005; ALSENZ J, 1992, DEV COMP IMMUNOL, V16, P63, DOI 10.1016/0145-305X(92)90052-E; BARLOW PN, 1992, BIOCHEMISTRY-US, V31, P3626, DOI 10.1021/bi00129a011; BARLOW PN, 1991, BIOCHEMISTRY-US, V30, P997, DOI 10.1021/bi00218a016; BARLOW PN, 1992, 18TH INT C IMM BUD, P168; BECHERER JD, 1988, J BIOL CHEM, V263, P14586; BECHERER JD, 1989, CURRENT TOPICS MICRO; CAMPBELL ID, 1991, PHILOS T R SOC B, V332, P165, DOI 10.1098/rstb.1991.0045; CAREL JC, 1990, J BIOL CHEM, V265, P12293; CARROLL MC, 1983, P NATL ACAD SCI-BIOL, V80, P264, DOI 10.1073/pnas.80.1.264; COYNE KE, 1992, J IMMUNOL, V149, P2906; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DEBRUIJN MHL, 1985, P NATL ACAD SCI USA, V82, P708; DOMDEY H, 1982, P NATL ACAD SCI-BIOL, V79, P7619, DOI 10.1073/pnas.79.24.7619; DYKMAN TR, 1983, P NATL ACAD SCI-BIOL, V80, P1698, DOI 10.1073/pnas.80.6.1698; DYKMAN TR, 1983, J EXP MED, V157, P2160, DOI 10.1084/jem.157.6.2160; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; HOGG N, 1984, EUR J IMMUNOL, V14, P236, DOI 10.1002/eji.1830140307; HOURCADE D, 1989, ADV IMMUNOL, V45, P381, DOI 10.1016/S0065-2776(08)60697-5; HOURCADE D, 1988, J EXP MED, V168, P1255, DOI 10.1084/jem.168.4.1255; JANATOVA J, 1989, BIOCHEMISTRY-US, V28, P4754, DOI 10.1021/bi00437a036; KALLI KR, 1991, J EXP MED, V174, P1451, DOI 10.1084/jem.174.6.1451; KLICKSTEIN LB, 1988, J EXP MED, V168, P1699, DOI 10.1084/jem.168.5.1699; KOTWAL GJ, 1988, NATURE, V335, P176, DOI 10.1038/335176a0; KOTWAL GJ, 1990, SCIENCE, V250, P827, DOI 10.1126/science.2237434; KRYCH M, 1991, P NATL ACAD SCI USA, V88, P4353, DOI 10.1073/pnas.88.10.4353; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LOWELL CA, 1989, J EXP MED, V170, P1931, DOI 10.1084/jem.170.6.1931; MARTIN DR, 1991, J EXP MED, V174, P1299, DOI 10.1084/jem.174.6.1299; MCKENZIE R, 1992, J INFECT DIS, V166, P1245, DOI 10.1093/infdis/166.6.1245; MCNEARNEY TA, 1987, J EXP MED, V166, P1525, DOI 10.1084/jem.166.5.1525; MEDOF ME, 1984, J EXP MED, V159, P1669, DOI 10.1084/jem.159.6.1669; MOLINA H, 1991, J BIOL CHEM, V266, P12173; MULLIGAN MS, 1992, J IMMUNOL, V148, P1479; NORMAN DG, 1991, J MOL BIOL, V219, P717, DOI 10.1016/0022-2836(91)90666-T; O'SHEA JJ, 1985, J IMMUNOL, V134, P2580; OGATA RT, 1993, J IMMUNOL, V150, P2273; PERKINS SJ, 1988, BIOCHEMISTRY-US, V27, P4004, DOI 10.1021/bi00411a017; PRUITT SK, 1991, TRANSPLANTATION, V52, P868, DOI 10.1097/00007890-199111000-00022; REID KBM, 1989, IMMUNOL TODAY, V10, P177, DOI 10.1016/0167-5699(89)90317-4; REILLY BD, 1993, J IMMUNOL, V150, pA224; SEIDELDUGAN C, 1990, J VIROL, V64, P1897, DOI 10.1128/JVI.64.5.1897-1906.1990; WEISMAN HF, 1990, SCIENCE, V249, P146, DOI 10.1126/science.2371562; YEH CG, 1991, J IMMUNOL, V146, P250	44	90	94	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13273	13278						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175757				2022-12-25	WOS:A1994NK18400036
J	LI, JZ; ROBERTS, RM				LI, JZ; ROBERTS, RM			INTERFERON-TAU AND INTERFERON-ALPHA INTERACT WITH THE SAME RECEPTORS IN BOVINE ENDOMETRIUM - USE OF A READILY IODINATABLE FORM OF RECOMBINANT INTERFERON-TAU FOR BINDING-STUDIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OVINE TROPHOBLAST PROTEIN-1; PREGNANCY RECOGNITION HORMONE; CONCEPTUS SECRETORY PROTEINS; COMMON RECEPTORS; SHEEP; EXPRESSION; SEQUENCE; GENES; PURIFICATION; INDUCTION	Trophoblasts of ruminant species secrete multiple forms of a novel Type I interferon (IFN-tau) for a few days preceding implantation. These IFN-tau are structurally distinct from IFN-alpha, -beta, and -omega, but it remains unclear whether they have any distinguishing biological properties. It has been of interest, therefore, to study their interaction with Type I IFN receptors. However, a recombinant bovine IFN-tau (boIFN-tau 1) prepared for such use is rapidly inactivated during chemical iodination with I-125, presumably because a critical tyrosine becomes modified. Here we describe the synthesis of a novel IFN-tau 1 in which Leu(169) and Leu(171) in the carboxyl terminus have been replaced by 2 tyrosine residues. The recombinant product (rboIFN-tau 1Y2) can be readily iodinated without significant loss of antiviral and antiproliferative activities, provided that reaction time with I-125 is minimized. Both rboIFN-tau 1Y2 and rboIFN-alpha 1 compete with each other for binding to bovine endometrial cell membranes and Madin-Darby bovine kidney cells. Dissociation constants of both IFN are quite similar (K-d = 3.7 x 10(-10) and 3.5 x 10(-10) M, respectively). Cross-linking studies reveal a single size class of receptor polypeptide on endometrium and Madin-Darby canine kidney cells whose molecular weight is reduced from similar to 130,000 to similar to 70,000 by treatment with N-glycosidase. These studies with a single recombinant form of boIFN-tau avoid the difficulties that arise from use of a mixture of naturally occurring isoforms. They provide further evidence for the presence of a receptor common to both IFN-tau and IFN-alpha in bovine tissues and no indication for a unique IFN-tau-binding polypeptide in endometrium.	UNIV MISSOURI,DEPT BIOCHEM,COLUMBIA,MO 65211; UNIV MISSOURI,DEPT ANIM SCI,COLUMBIA,MO 65211	University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD021896, R37HD021896] Funding Source: NIH RePORTER; NICHD NIH HHS [HD21896] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AGUET M, 1984, VIROLOGY, V132, P211, DOI 10.1016/0042-6822(84)90105-3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANCA AA, 1987, J INTERFERON RES, V7, P77, DOI 10.1089/jir.1987.7.77; BRANCA AA, 1981, NATURE, V294, P768, DOI 10.1038/294768a0; CAPON DJ, 1985, MOL CELL BIOL, V5, P768, DOI 10.1128/MCB.5.4.768; CROSS JC, 1991, P NATL ACAD SCI USA, V88, P3817, DOI 10.1073/pnas.88.9.3817; EMINI EA, 1985, J VIROL, V55, P836, DOI 10.1128/JVI.55.3.836-839.1985; FILLION C, 1991, J REPROD IMMUNOL, V19, P237, DOI 10.1016/0165-0378(91)90038-R; FINCHER KB, 1986, J REPROD FERTIL, V76, P425, DOI 10.1530/jrf.0.0760425; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GODKIN JD, 1982, J REPROD FERTIL, V65, P141, DOI 10.1530/jrf.0.0650141; GODKIN JD, 1984, ENDOCRINOLOGY, V114, P120, DOI 10.1210/endo-114-1-120; HANNIGAN GE, 1983, BIOCHEM BIOPH RES CO, V110, P537, DOI 10.1016/0006-291X(83)91183-X; HANSEN TR, 1989, J INTERFERON RES, V9, P215, DOI 10.1089/jir.1989.9.215; IMAKAWA K, 1987, NATURE, V330, P377, DOI 10.1038/330377a0; IMAKAWA K, 1989, MOL ENDOCRINOL, V3, P127, DOI 10.1210/mend-3-1-127; JANIN J, 1978, J MOL BIOL, V125, P357, DOI 10.1016/0022-2836(78)90408-4; KLEMANN SW, 1990, MOL ENDOCRINOL, V4, P1506, DOI 10.1210/mend-4-10-1506; KLEMANN SW, 1990, NUCLEIC ACIDS RES, V18, P6724, DOI 10.1093/nar/18.22.6724; KNICKERBOCK JJ, 1986, PROSTAG OTH LIPID M, V31, P777, DOI 10.1016/0090-6980(86)90180-2; KNICKERBOCKER JJ, 1989, BIOL REPROD, V40, P361, DOI 10.1095/biolreprod40.2.361; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEAMAN DW, 1992, J INTERFERON RES, V12, P1, DOI 10.1089/jir.1992.12.1; LEAMAN DW, 1994, IN PRESS MOL ENDOCRI; LI BL, 1989, P NATL ACAD SCI USA, V86, P558, DOI 10.1073/pnas.86.2.558; MITSUI Y, 1993, PHARMACOL THERAPEUT, V58, P93, DOI 10.1016/0163-7258(93)90068-O; MOGENSEN KE, 1986, METHOD ENZYMOL, V119, P267; MOUCHELVIELH E, 1992, FEBS LETT, V313, P255, DOI 10.1016/0014-5793(92)81204-Y; MUNSON PJ, 1983, METHOD ENZYMOL, V92, P543; NEDDEN DLZ, 1986, METHOD ENZYMOL, V119, P276; OLSEN MK, 1989, J BIOTECHNOL, V9, P179, DOI 10.1016/0168-1656(89)90107-7; PONTZER CH, 1991, CANCER RES, V51, P5304; PONTZER CH, 1988, BIOCHEM BIOPH RES CO, V152, P801, DOI 10.1016/S0006-291X(88)80109-8; ROBERTS RM, 1989, J INTERFERON RES, V9, P175, DOI 10.1089/jir.1989.9.175; ROBERTS RM, 1992, ENDOCR REV, V13, P432, DOI 10.1210/er.13.3.432; ROBERTS RM, 1989, BIOL REPROD, V40, P449, DOI 10.1095/biolreprod40.3.449; SARKAR FH, 1986, METHOD ENZYMOL, V119, P263; SENDA T, 1992, EMBO J, V11, P3193, DOI 10.1002/j.1460-2075.1992.tb05396.x; STEWART CL, 1992, NATURE, V359, P76, DOI 10.1038/359076a0; UZE G, 1985, EMBO J, V4, P64; VALLET JL, 1988, J REPROD FERTIL, V84, P493, DOI 10.1530/jrf.0.0840493; YONEHARA S, 1983, J BIOL CHEM, V258, P9046	42	90	93	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13544	13550						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175789				2022-12-25	WOS:A1994NK18400072
J	YAN, ZF; WINAWER, S; FRIEDMAN, E				YAN, ZF; WINAWER, S; FRIEDMAN, E			2 DIFFERENT SIGNAL-TRANSDUCTION PATHWAYS CAN BE ACTIVATED BY TRANSFORMING GROWTH-FACTOR-BETA-1 IN EPITHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE THREONINE KINASE; ERK-1 GENE-PRODUCT; PROTEIN-KINASE; MAP KINASE; EXPRESSION CLONING; PHOSPHORYLATION; RAS; RECEPTOR; FACTOR-BETA-1; CASCADE	Signal transduction initiated by transforming growth factor beta 1 (TGF beta 1) was studied in two sublines of the same colon carcinoma cell line, which respond in opposite ways to TGF beta 1, by proliferation or by growth inhibition. TGF beta 1 activates ras proteins within 5 min of addition when it acts to inhibit growth but not when it acts as a mitogen. In both cases TGF beta 1 also rapidly modulates the activities of three protein kinases, detected by their in gel kinase activity on the mitogen-activated protein kinase (MAP kinase) substrate, myelin basic protein (MBP), When TGF beta 1 acts as a mitogen for U9 cells, it increases the activity of MBP kinases of 57, 105, and 130 kDa within 10 min of the addition without detectably activating ras proteins. When TGF beta 1 inhibits the growth of HD3 cells, it activates ras proteins and the 57-kDa MBP kinase within 5 min but inhibits the activity of the 105- and 130-kDa MBP kinases. In HD3 cells ras activation occurred in two signal transduction pathways, one from TGF beta 1 leading to growth inhibition and one from epidermal growth factor (EGF) leading to proliferation. In addition to ras proteins, EGF activates a different set of MBP kinases in HD3 cells than does TGF beta 1, MBP kinases of 85, 57, and 44 kDa. The latter is likely to be the 44-kDa MAP kinase extracellular signal-regulated kinase (erk) 1, because EGF treatment of HD3 cells activates erk1 by increasing its phosphotyrosine level. Therefore, in two closely related epithelial cell lines TGF beta 1 activates two different signal transduction pathways, one ras-dependent and one ras-independent, and modulates the activities of a set of MBP kinases.	MEM SLOAN KETTERING CANC CTR,DEPT MED,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center					NCI NIH HHS [R01 CA50645, IT32CA09628, CA45783] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA045783, T32CA009628, R01CA050645] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHN NG, 1991, J BIOL CHEM, V266, P4220; ALESSANDRINI A, 1992, P NATL ACAD SCI USA, V89, P8200, DOI 10.1073/pnas.89.17.8200; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BUDAY L, 1993, MOL CELL BIOL, V13, P1903, DOI 10.1128/MCB.13.3.1903; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CHEN RH, 1993, SCIENCE, V260, P1335, DOI 10.1126/science.8388126; CREWS CM, 1992, P NATL ACAD SCI USA, V89, P8205, DOI 10.1073/pnas.89.17.8205; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GIBBS JB, 1993, J BIOL CHEM, V268, P7617; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GONZALEZ FA, 1992, FEBS LETT, V304, P170, DOI 10.1016/0014-5793(92)80612-K; HAFEZ MM, 1990, CELL GROWTH DIFFER, V1, P617; HAFEZ MM, 1992, CELL GROWTH DIFFER, V3, P753; HSU S, 1994, IN PRESS CELL GROWTH; ITOH T, 1993, P NATL ACAD SCI USA, V90, P975, DOI 10.1073/pnas.90.3.975; KYRIAKIS JM, 1990, J BIOL CHEM, V265, P17355; LEE H, 1993, J BIOL CHEM, V268, P8181; LEE HS, 1993, J BIOL CHEM, V268, P5255; LENGECARTER CA, 1993, SCIENCEE, V260, P315; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LINNEKIN D, 1992, J BIOL CHEM, V267, P23993; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MULDER KM, 1992, J BIOL CHEM, V267, P5029; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAY LB, 1988, J BIOL CHEM, V263, P12721; ROBBINS DJ, 1992, P NATL ACAD SCI USA, V89, P6924, DOI 10.1073/pnas.89.15.6924; ROSSOMANDO A, 1992, P NATL ACAD SCI USA, V89, P5221, DOI 10.1073/pnas.89.12.5221; ROSSOMANDO AJ, 1989, P NATL ACAD SCI USA, V86, P6940, DOI 10.1073/pnas.86.18.6940; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SCHROY P, 1990, CANCER RES, V50, P261; SEGER R, 1991, P NATL ACAD SCI USA, V88, P6142, DOI 10.1073/pnas.88.14.6142; SHIBUYA EK, 1992, P NATL ACAD SCI USA, V89, P9831, DOI 10.1073/pnas.89.20.9831; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; THOMAS G, 1993, CELL, V68, P3; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; WANG HCR, 1992, MOL BIOL CELL, V3, P1329, DOI 10.1091/mbc.3.12.1329; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; WILLIAMS NG, 1993, P NATL ACAD SCI USA, V90, P5772, DOI 10.1073/pnas.90.12.5772; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WU J, 1993, P NATL ACAD SCI USA, V90, P173, DOI 10.1073/pnas.90.1.173; WU J, 1991, P NATL ACAD SCI USA, V88, P9508, DOI 10.1073/pnas.88.21.9508; YAN ZF, 1992, ONCOGENE, V7, P801	56	147	150	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13231	13237						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175753				2022-12-25	WOS:A1994NK18400030
J	MACH, L; MORT, JS; GLOSSL, J				MACH, L; MORT, JS; GLOSSL, J			MATURATION OF HUMAN PROCATHEPSIN-B - PROENZYME ACTIVATION AND PROTEOLYTIC PROCESSING OF THE PRECURSOR TO THE MATURE PROTEINASE, IN-VITRO, ARE PRIMARILY UNIMOLECULAR PROCESSES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATHEPSIN-B; CYSTEINE PROTEINASES; RAT MACROPHAGES; IDENTIFICATION; BIOSYNTHESIS; INVITRO; LOCALIZATION; ENDOPROTEASE; FIBROBLASTS; PEPSINOGEN	Recombinant latent human procathepsin B produced in yeast was purified to near homogeneity. The purified recombinant proenzyme is activated in vitro under acidic conditions resulting in rapid conversion into the mature form of the proteinase. Activation as well as proteolytic maturation of the recombinant cathepsin B precursor were shown to be primarily concentration-independent processes indicating a unimolecular (i.e. intramolecular) mechanism. Only one cleavage site was identified, yielding a mature polypeptide with the same amino-terminal sequence as that found in recombinant active human cathepsin B obtained from yeast culture media. The same peptide bond is cleaved during processing of a nonactivatable mutant of procathepsin B by the purified mature enzyme (i.e. intermolecular processing). Thus, the complete proregion is liberated during procathepsin B processing. This peptide may then act as a reversible inhibitor and stabilizer of the mature proteinase, and it appears likely that cathepsin B-propeptide complexes occur transiently during proteolytic maturation.	AGR UNIV VIENNA,ZENTRUM ANGEW GENET,A-1180 VIENNA,AUSTRIA; SHRINERS HOSP CRIPPLED CHILDREN,JOINT DIS LAB,MONTREAL H3G 1A6,PQ,CANADA; MCGILL UNIV,DEPT SURG,MONTREAL H3A 2T6,PQ,CANADA	University of Natural Resources & Life Sciences, Vienna; McGill University; McGill University			Glössl, Josef/H-8208-2013	Glössl, Josef/0000-0002-5042-8828; Mach, Lukas/0000-0001-9013-5408				Achstetter T, 1985, Yeast, V1, P139, DOI 10.1002/yea.320010203; ALJANABI J, 1972, J BIOL CHEM, V247, P4628; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; BROMME D, 1993, J BIOL CHEM, V268, P4832; BUTTLE DJ, 1992, BIOCHEM J, V287, P657, DOI 10.1042/bj2870657; DELAISSE JM, 1991, BIOCHEM J, V279, P167, DOI 10.1042/bj2790167; DUNN AD, 1991, J BIOL CHEM, V266, P20198; DUNN BM, 1986, BIOCHEM J, V237, P899, DOI 10.1042/bj2370899; FOX T, 1992, BIOCHEMISTRY-US, V31, P12571, DOI 10.1021/bi00165a005; GAL S, 1985, J CELL BIOL, V100, P535, DOI 10.1083/jcb.100.2.535; GERMAIN D, 1992, FEBS LETT, V299, P283, DOI 10.1016/0014-5793(92)80132-Z; GIESELMANN V, 1983, J CELL BIOL, V97, P1, DOI 10.1083/jcb.97.1.1; GUAGLIARDI LE, 1990, NATURE, V343, P133, DOI 10.1038/343133a0; HANEWINKEL H, 1987, J BIOL CHEM, V262, P12351; HARA K, 1988, FEBS LETT, V231, P229, DOI 10.1016/0014-5793(88)80737-3; JAMES MNG, 1986, NATURE, V319, P33, DOI 10.1038/319033a0; KARRER KM, 1993, P NATL ACAD SCI USA, V90, P3063, DOI 10.1073/pnas.90.7.3063; KAWABATA T, 1993, J BIOCHEM-TOKYO, V113, P389, DOI 10.1093/oxfordjournals.jbchem.a124056; KEPPLER D, 1988, BIOL CHEM H-S, V369, P185; KOMINAMI E, 1988, FEBS LETT, V231, P225, DOI 10.1016/0014-5793(88)80736-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEDUC R, 1992, J BIOL CHEM, V267, P14304; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACH L, 1993, BIOCHEM J, V293, P437, DOI 10.1042/bj2930437; MACH L, 1992, BIOCHEM J, V282, P577, DOI 10.1042/bj2820577; MASON RW, 1992, BIOCHEM BIOPH RES CO, V189, P1659, DOI 10.1016/0006-291X(92)90268-P; MASON RW, 1987, BIOCHEM J, V248, P449, DOI 10.1042/bj2480449; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MCDONALD JK, 1988, BIOCHEM BIOPH RES CO, V151, P827; MCINTYRE GF, 1991, J BIOL CHEM, V266, P15438; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; MORT JS, 1986, BIOCHEM J, V233, P57, DOI 10.1042/bj2330057; NISHIMURA Y, 1988, ARCH BIOCHEM BIOPHYS, V261, P64, DOI 10.1016/0003-9861(88)90104-X; NISHIMURA Y, 1988, ARCH BIOCHEM BIOPHYS, V262, P159, DOI 10.1016/0003-9861(88)90178-6; PAGANO M, 1989, CR ACAD SCI III-VIE, V309, P7; POWER SD, 1986, P NATL ACAD SCI USA, V83, P3096, DOI 10.1073/pnas.83.10.3096; RIJNBOUTT S, 1992, J BIOL CHEM, V267, P15665; RIJNBOUTT S, 1991, J BIOL CHEM, V266, P23586; ROEDERER M, 1987, J CELL PHYSIOL, V131, P200, DOI 10.1002/jcp.1041310209; ROWAN AD, 1992, J BIOL CHEM, V267, P15993; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHAW E, 1980, BIOCHEM J, V186, P385, DOI 10.1042/bj1860385; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VERNET T, 1991, J BIOL CHEM, V266, P21451; WIEDERANDERS B, 1992, J BIOL CHEM, V267, P13708	45	164	165	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					13030	13035						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175723				2022-12-25	WOS:A1994NH71600099
J	RAY, A; PREFONTAINE, KE; RAY, P				RAY, A; PREFONTAINE, KE; RAY, P			DOWN-MODULATION OF INTERLEUKIN-6 GENE-EXPRESSION BY 17-BETA-ESTRADIOL IN THE ABSENCE OF HIGH-AFFINITY DNA-BINDING BY THE ESTROGEN-RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								The mechanism of repression of the interleukin-6 (IL-6) promoter by 17 beta-estradiol (E(2)) was investigated in cells transfected with wild-type (wt) or mutant estrogen receptor (ER) expression vectors. In transient transfection experiments, IL-1-induced activation of the IL-6 promoter was efficiently inhibited by wt ER. However, estrogen receptors carrying mutations within or overlapping with the DNA binding domain did not repress IL-6 promoter activity. A mutant receptor lacking the N-terminal transactivator function-1 but retaining the C-terminal transactivator function-2 also repressed activation of the IL-6 promoter. Our recent experiments indicate the requirement for both the nuclear factor (NF)-IL6 and the NF-kappa B sites in the IL-6 promoter for activation by IL-1. We now show that activation of the IL-6 promoter, elicited by a combination of NF-IL6 and the p65 subunit of NF-kappa B, can be inhibited by the wt receptor but not by a receptor containing a mutation in its DNA binding domain. Although a deletion within the DNA binding domain of ER abolished the repressor function of the receptor, a chimeric receptor ER-GR CAS1, in which the DNA binding domain of ER was swapped with the complementary region from the glucocorticoid receptor, retained the inhibitory effects on the IL-6 promoter. This was in contrast to the absolute dependence of ER on its own DNA binding domain for activation of typical estrogen response element-containing promoters, as reported previously by other investigators. Furthermore, the repression of the IL-6 promoter by a combination of ER and E(2), unlike activation of estrogen response elements by the same combination, did not appear to be mediated via high affinity binding of the receptor to the promoter. In functional experiments, the transactivator function of ER was totally inhibited by overexpression of p65 and to a lesser extent by that of NF-IL6. These results indicate that ER may repress gene expression in the absence of high affinity DNA binding.			RAY, A (corresponding author), YALE UNIV, SCH MED,DEPT INTERNAL MED, PULM & CRIT CARE MED SECT,333 CEDAR ST, POB 208057, NEW HAVEN, CT 06520 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031137] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI/CA 31137] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADLER S, 1988, CELL, V52, P685, DOI 10.1016/0092-8674(88)90406-0; AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689; BAEUERLE PA, 1991, TRANSCRIPTION, P409; BALLARD DW, 1992, P NATL ACAD SCI USA, V89, P1875, DOI 10.1073/pnas.89.5.1875; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; BRUGGEMEIER U, 1991, CELL, V64, P565, DOI 10.1016/0092-8674(91)90240-Y; DESBOIS C, 1991, CELL, V67, P731, DOI 10.1016/0092-8674(91)90068-A; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; DOUCAS V, 1991, EMBO J, V10, P2237, DOI 10.1002/j.1460-2075.1991.tb07760.x; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; GIRASOLE G, 1992, J CLIN INVEST, V89, P883, DOI 10.1172/JCI115668; GREEN S, 1986, NATURE, V320, P134, DOI 10.1038/320134a0; HOLLENBERG SM, 1987, CELL, V49, P39, DOI 10.1016/0092-8674(87)90753-7; ISSHIKI H, 1990, MOL CELL BIOL, V10, P2757, DOI 10.1128/MCB.10.6.2757; JILKA RL, 1992, SCIENCE, V257, P88, DOI 10.1126/science.1621100; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KAWAKAMI K, 1988, P NATL ACAD SCI USA, V85, P4700, DOI 10.1073/pnas.85.13.4700; KLEINHITPASS L, 1986, CELL, V46, P1053, DOI 10.1016/0092-8674(86)90705-1; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; KUTOH E, 1992, MOL CELL BIOL, V12, P4960, DOI 10.1128/MCB.12.11.4960; LEES JA, 1989, NUCLEIC ACIDS RES, V17, P5477, DOI 10.1093/nar/17.14.5477; LIBERMANN TA, 1990, MOL CELL BIOL, V10, P2327, DOI 10.1128/MCB.10.5.2327; LUCAS PC, 1992, ANNU REV BIOCHEM, V61, P1131; MATHEW S, 1993, ONCOGENE, V8, P191; MCDONNELL DP, 1992, P NATL ACAD SCI USA, V89, P10563, DOI 10.1073/pnas.89.22.10563; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; NARAYANAN R, 1993, MOL CELL BIOL, V13, P3802, DOI 10.1128/MCB.13.6.3802; NISHIO Y, 1993, MOL CELL BIOL, V13, P1854, DOI 10.1128/MCB.13.3.1854; PERKINS ND, 1992, P NATL ACAD SCI USA, V89, P1529, DOI 10.1073/pnas.89.5.1529; RAY A, 1988, P NATL ACAD SCI USA, V85, P6701, DOI 10.1073/pnas.85.18.6701; RAY A, 1990, MOL CELL BIOL, V10, P5736, DOI 10.1128/MCB.10.11.5736; RAY A, 1991, P NATL ACAD SCI USA, V88, P7086, DOI 10.1073/pnas.88.16.7086; RAY A, 1989, MOL CELL BIOL, V9, P5537, DOI 10.1128/MCB.9.12.5537; RUBEN SM, 1992, MOL CELL BIOL, V12, P444, DOI 10.1128/MCB.12.2.444; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SABBAH M, 1991, P NATL ACAD SCI USA, V88, P390, DOI 10.1073/pnas.88.2.390; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; SCHULE R, 1988, SCIENCE, V242, P1418, DOI 10.1126/science.3201230; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SCOTT GK, 1991, J CLIN INVEST, V88, P700, DOI 10.1172/JCI115356; SEHGAL PB, 1990, P SOC EXP BIOL MED, V195, P183; TABIBZADEH SS, 1989, J IMMUNOL, V142, P3134; TASSET D, 1990, CELL, V62, P1177, DOI 10.1016/0092-8674(90)90394-T; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; TORA L, 1988, EMBO J, V7, P3771, DOI 10.1002/j.1460-2075.1988.tb03261.x; TORA L, 1989, EMBO J, V8, P1981, DOI 10.1002/j.1460-2075.1989.tb03604.x; URBAN MB, 1991, EMBO J, V10, P1817, DOI 10.1002/j.1460-2075.1991.tb07707.x; WALTER P, 1985, P NATL ACAD SCI USA, V82, P7889, DOI 10.1073/pnas.82.23.7889; WEBSTER NJG, 1988, CELL, V54, P199, DOI 10.1016/0092-8674(88)90552-1; WIELAND S, 1991, EMBO J, V10, P2513, DOI 10.1002/j.1460-2075.1991.tb07791.x; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; ZHANG XK, 1991, MOL CELL BIOL, V11, P6016, DOI 10.1128/MCB.11.12.6016; ZHANG Y, 1990, MOL CELL BIOL, V10, P3818, DOI 10.1128/MCB.10.7.3818	59	273	283	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12940	12946						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175711				2022-12-25	WOS:A1994NH71600086
J	MIFFLIN, LC; COHEN, RE				MIFFLIN, LC; COHEN, RE			CHARACTERIZATION OF DENATURED PROTEIN INDUCERS OF THE HEAT-SHOCK (STRESS) RESPONSE IN XENOPUS-LAEVIS OOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYNAMIC LIGHT-SCATTERING; MUTANT ACTIN GENES; ABNORMAL PROTEINS; DEPENDENT PROTEOLYSIS; ESCHERICHIA-COLI; UBIQUITIN; DEGRADATION; ATP; NUCLEAR; TRANSCRIPTION	In addition to thermal stress, a large variety of physical and chemical treatments are known to induce heat shock gene expression. Denatured protein, thought to result from the stress condition, has been postulated to act as the common signal. Accordingly, of three pairs of native and denatured proteins injected into Xenopus laevis oocytes, only the denatured derivatives induced expression of a reporter gene from a heat shock promoter (Ananthan, J., Goldberg, A. L., and Voellmy, R. (1986) Science 232, 522-525). These observations are extended here. Protein denaturation per se is shown to be insufficient for heat shock induction; although reduced and carboxymethylated bovine serum albumin (rcm-BSA) and alpha-crystallin elicited a stress response, many other denatured proteins had no effect. Methylation of protein lysines, done to prevent ubiquitination, suppressed heat shock induction by rcm-BSA, but enhanced induction by alpha-crystallin. Thus, the potential for a protein to be ubiquitinated is independent of its ability to induce the stress response. Instead, aggregation distinguished the proteins that were effective stress inducers, and the formation of large aggregates correlated with the magnitude of the response. This correlation may derive in part from decreased in vivo degradation rates of the inducer proteins. An apparent requirement for stress response induction that the inducer proteins be injected directly into the oocyte nucleus may relate to this issue of in vivo stability. The dependence of the stress response on the amount of injected protein is nonlinear and of a form consistent with the titration of a factor that otherwise suppresses heat shock gene expression.	UNIV IOWA,DEPT BIOCHEM,IOWA CITY,IA 52242; UNIV CALIF LOS ANGELES,DEPT CHEM & BIOCHEM,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024	University of Iowa; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles					NIGMS NIH HHS [R01 GM37666, GM07185] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037666] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANANTHAN J, 1986, SCIENCE, V232, P522, DOI 10.1126/science.3083508; BECKMANN RP, 1992, J CELL BIOL, V117, P1137, DOI 10.1083/jcb.117.6.1137; BIRNBOIM HC, 1983, METHOD ENZYMOL, V100, P243; BOND U, 1985, MOL CELL BIOL, V5, P949, DOI 10.1128/MCB.5.5.949; BOND U, 1988, J BIOL CHEM, V263, P2384; CIECHANOVER A, 1984, CELL, V37, P57, DOI 10.1016/0092-8674(84)90300-3; CRAIG EA, 1991, TRENDS BIOCHEM SCI, V16, P135, DOI 10.1016/0968-0004(91)90055-Z; DEJONG WW, 1993, MOL BIOL EVOL, V10, P103; DUBOIS MF, 1991, J BIOL CHEM, V266, P9707; EVANS AC, 1985, BIOCHEMISTRY-US, V24, P2915, DOI 10.1021/bi00333a015; FELDHERR CM, 1984, J CELL BIOL, V99, P2216, DOI 10.1083/jcb.99.6.2216; FERBER S, 1986, J BIOL CHEM, V261, P3128; FINLEY D, 1987, CELL, V48, P1035, DOI 10.1016/0092-8674(87)90711-2; FINLEY D, 1984, CELL, V37, P43, DOI 10.1016/0092-8674(84)90299-X; GOFF SA, 1985, CELL, V41, P587, DOI 10.1016/S0092-8674(85)80031-3; GURDON JB, 1983, METHOD ENZYMOL, V101, P370; HARRINGTON WF, 1959, BIOCHIM BIOPHYS ACTA, V31, P427, DOI 10.1016/0006-3002(59)90017-4; HAZRA AK, 1984, ANAL BIOCHEM, V137, P437, DOI 10.1016/0003-2697(84)90110-6; HIGHTOWER LE, 1980, J CELL PHYSIOL, V102, P407, DOI 10.1002/jcp.1041020315; HIGHTOWER LE, 1991, CELL, V66, P191, DOI 10.1016/0092-8674(91)90611-2; HILL CP, 1993, P NATL ACAD SCI USA, V90, P4136, DOI 10.1073/pnas.90.9.4136; HIROMI Y, 1986, CELL, V44, P293, DOI 10.1016/0092-8674(86)90763-4; HIRS CHW, 1967, METHOD ENZYMOL, V11, P199; JENTOFT N, 1979, J BIOL CHEM, V254, P4359; JONES BN, 1981, J LIQ CHROMATOGR, V4, P565, DOI 10.1080/01483918108059956; KING ML, 1987, DEV BIOL, V119, P532, DOI 10.1016/0012-1606(87)90056-X; LEWIS MJ, 1985, EMBO J, V4, P3137, DOI 10.1002/j.1460-2075.1985.tb04056.x; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; LIS JT, 1988, UBIQUITIN SYSTEM, P56; MAYER A, 1989, SCIENCE, V244, P1480, DOI 10.1126/science.2544030; MEHLIN H, 1992, CELL, V69, P605, DOI 10.1016/0092-8674(92)90224-Z; MIFFLINLC, 1994, J BIOL CHEM, V269, P15718; Miller JH., 1972, EXPT MOL GENETICS; MITRAKI A, 1989, BIO-TECHNOL, V7, P690, DOI 10.1038/nbt0789-690; NICOLI DF, 1991, AM LAB, V23, P32; NOVER L, 1989, MOL CELL BIOL, V9, P1298, DOI 10.1128/MCB.9.3.1298; NOVER L, 1984, HEAT SHOCK RESPONSE, P8; OKAMOTO H, 1986, EMBO J, V5, P589, DOI 10.1002/j.1460-2075.1986.tb04251.x; PARSELL DA, 1989, GENE DEV, V3, P1226, DOI 10.1101/gad.3.8.1226; PELHAM HRB, 1984, EMBO J, V3, P3095, DOI 10.1002/j.1460-2075.1984.tb02264.x; PINTO M, 1991, J BIOL CHEM, V266, P13941; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; SCHLESINGER MJ, 1990, J BIOL CHEM, V265, P12111; SEERY TAP, 1989, POLYMER, V30, P1197, DOI 10.1016/0032-3861(89)90036-0; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; SHI YG, 1992, MOL CELL BIOL, V12, P2186, DOI 10.1128/MCB.12.5.2186; TANAKA K, 1983, J CELL BIOL, V96, P1580, DOI 10.1083/jcb.96.6.1580; VOELLMY R, 1982, P NATL ACAD SCI-BIOL, V79, P1776, DOI 10.1073/pnas.79.6.1776; WILKINSON KD, 1981, J BIOL CHEM, V256, P9235	49	40	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15710	15717						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	8195223				2022-12-25	WOS:A1994NP51300051
J	YU, HR; MUKHOPADHYAY, D; MISRA, TK				YU, HR; MUKHOPADHYAY, D; MISRA, TK			PURIFICATION AND CHARACTERIZATION OF A NOVEL ORGANOMETALLIC RECEPTOR PROTEIN REGULATING THE EXPRESSION OF THE BROAD-SPECTRUM MERCURY-RESISTANT OPERON OF PLASMID PDU1358	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GEL-ELECTROPHORESIS; MER PROMOTER; DNA-SEQUENCE; GENE; BINDING; TRANSCRIPTION; ACTIVATION; BACTERIA; SYSTEM; TN501	The narrow spectrum mercury-resistant (mer) operons of transposons Tn21 and Tn501 are inducible by inorganic mercury salts. The major regulatory gene merR is transcribed divergently from the other mer genes, which are cotranscribed. The MerR protein represses its own expression, as well as the expression of the other mer genes in the absence of the inducers. The synthesis of the polycistronic ner message is stimulated by MerR in the presence of the inducers. The MerR(BS) protein encoded by the broad spectrum mer operon of plasmid pDU1358 was characterized as a novel organomercurial receptor, distinguishing it from the narrow spectrum MerR(NS) proteins, described above. Several organomercurial compounds directly effected cellular activation of the mer operon transcription via the receptor protein MerR(BS) but not by MerR(NS). The merR gene from pDU1358 was cloned under the tac promoter, and the overexpressed MerR(BS) protein was soluble in buffer solutions containing 0.5 M NaCl at pH 7.5, but precipitated when NaCl concentration was reduced to 0.1 M (MerR(BS) concentrations at or above 0.1 mg/ml). MerR(BS) was purified to near homogeneity by selective precipitation and solubilization by varying the salt concentration in buffer solutions, followed by Sephadex G-75 column chromatography. Both MerR(BS) and Tn21-encoded MerR(NS) bound with DNA fragments containing the pDU1358 mer operator sequence with comparable affinities. In vitro run-off transcription studies revealed that MerR(BS) activated mer operon expression in the presence of Hg2+ or phenylmercuric acetate. Phenylmercuric acetate did not induce mer operon expression when the MerR(NS) was used in the assay.	UNIV ILLINOIS, COLL MED, DEPT MICROBIOL & IMMUNOL, CHICAGO, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital					NIGMS NIH HHS [GM-36722] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM036722] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANSARI AZ, 1992, NATURE, V355, P87, DOI 10.1038/355087a0; BARNES WM, 1983, NUCLEIC ACIDS RES, V11, P349, DOI 10.1093/nar/11.2.349; BHRIAIN NNN, 1983, J BACTERIOL, V155, P690, DOI 10.1128/JB.155.2.690-703.1983; FARINHA MA, 1990, J BACTERIOL, V172, P3496, DOI 10.1128/jb.172.6.3496-3499.1990; FRANTZ B, 1990, BIOCHEMISTRY-US, V29, P4747, DOI 10.1021/bi00472a001; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GRIFFIN HG, 1987, P NATL ACAD SCI USA, V84, P3112, DOI 10.1073/pnas.84.10.3112; HELTZEL A, 1987, J BACTERIOL, V169, P3379, DOI 10.1128/jb.169.7.3379-3384.1987; HELTZEL A, 1990, BIOCHEMISTRY-US, V29, P9572, DOI 10.1021/bi00493a011; KLOTZ IM, 1986, INTRO BIOMOLECULAR E, P103; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUND PA, 1986, J GEN MICROBIOL, V132, P465; Miller JH., 1972, EXPT MOL GENETICS; MISRA TK, 1992, PLASMID, V27, P4, DOI 10.1016/0147-619X(92)90002-R; MUKHOPADHYAY D, 1991, J BIOL CHEM, V266, P18538; NUCIFORA G, 1989, J BACTERIOL, V171, P4241, DOI 10.1128/JB.171.8.4241-4247.1989; OHALLORAN T, 1987, SCIENCE, V235, P211, DOI 10.1126/science.3798107; OHALLORAN TV, 1993, SCIENCE, V261, P715, DOI 10.1126/science.8342038; OHALLORAN TV, 1989, CELL, V56, P119, DOI 10.1016/0092-8674(89)90990-2; PARKHILL J, 1990, NUCLEIC ACIDS RES, V18, P5157, DOI 10.1093/nar/18.17.5157; Ralston D M, 1990, Adv Inorg Biochem, V8, P1; Sambrook J, 1989, MOL CLONING LABORATO; SILVER S, 1992, MICROBIOL REV, V56, P195, DOI 10.1128/MMBR.56.1.195-228.1992; SUMMERS AO, 1992, J BACTERIOL, V174, P3097, DOI 10.1128/jb.174.10.3097-3101.1992; WALTS AE, 1988, J AM CHEM SOC, V110, P1950, DOI 10.1021/ja00214a047	26	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15697	15702						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	8195221				2022-12-25	WOS:A1994NP51300049
J	HIGMAN, MA; CHRISTEN, LA; NILES, EG				HIGMAN, MA; CHRISTEN, LA; NILES, EG			THE MESSENGER-RNA (GUANINE-7-)METHYLTRANSFERASE DOMAIN OF THE VACCINIA VIRUS MESSENGER-RNA CAPPING ENZYME - EXPRESSION IN ESCHERICHIA-COLI AND STRUCTURAL AND KINETIC COMPARISON TO THE INTACT CAPPING ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA GUANYLYLTRANSFERASE; TRANSCRIPTION INITIATION-FACTOR; CAP STRUCTURES; EARLY GENES; VIRIONS; PURIFICATION; ASSOCIATION; POLYMERASE; SEQUENCE; COMPLEX	The mRNA (guanine-7-)methyltransferase active site of the heterodimeric vaccinia virus mRNA capping enzyme was previously localized to the carboxyl-terminal third of the large subunit, D1R, associated with the small subunit, D12L (Cong, P., and Shuman, S. (1992) J. Biol. Chem. 267, 16424-16429; Higman, M. A., Bourgeois, N., and Niles, E. G. (1992) J. Biol. Chem. 267, 16430-16437). A plasmid was constructed which directs the coexpression of the carboxyl terminus of the D1R subunit from amino acids 498 to 844 and the D12L subunit in Escherichia coli. The mRNA (guanine-7-)methyltransferase catalytic activity in the isolated domain was found to be kinetically equivalent to that present in the intact enzyme. Through mobility shift and ultraviolet photolinkage analyses, both domains were shown to bind RNA in a saturable fashion. RNA binding was localized predominantly to the large subunit, but a low level of linkage of RNA to D12L was also observed. A low, but reproducible, level of mRNA (guanine-7-)methyltransferase activity was detected in the isolated D1R(498-844) subunit demonstrating that the active site resides solely within the large subunit of the capping enzyme. This activity is enhanced 30- to 50-fold by the association of the D12L subunit.	SUNY BUFFALO, SCH MED & BIOMED SCI, DEPT BIOCHEM, BUFFALO, NY 14214 USA; SUNY BUFFALO, SCH MED & BIOMED SCI, CTR ADV MOLEC BIOL & IMMUNOL, BUFFALO, NY 14214 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo					NIAID NIH HHS [AI28824] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028824] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARBOSA E, 1978, J BIOL CHEM, V253, P7692; BAROUDY BM, 1980, J BIOL CHEM, V255, P4372; BROYLES SS, 1988, J BIOL CHEM, V263, P10754; CAREY J, 1991, METHOD ENZYMOL, V208, P103; CONG PJ, 1993, J BIOL CHEM, V268, P7256; CONG PJ, 1992, J BIOL CHEM, V267, P16424; Dawson R.M.C., 1986, DATA BIOCH RES, P399; FURUICHI Y, 1989, METHOD ENZYMOL, V180, P164; GOEBEL SJ, 1990, VIROLOGY, V179, P247, DOI 10.1016/0042-6822(90)90294-2; GUO PX, 1990, P NATL ACAD SCI USA, V87, P4023, DOI 10.1073/pnas.87.11.4023; HAMM J, 1990, CELL, V63, P109, DOI 10.1016/0092-8674(90)90292-M; HARRIS N, 1993, P NATL ACAD SCI USA, V90, P2860, DOI 10.1073/pnas.90.7.2860; HIGMAN MA, 1992, J BIOL CHEM, V267, P16430; HIGMAN MA, 1994, J BIOL CHEM, V269, P14982; KATES J, 1970, J MOL BIOL, V50, P19, DOI 10.1016/0022-2836(70)90101-4; KATES JR, 1967, P NATL ACAD SCI USA, V57, P314, DOI 10.1073/pnas.57.2.314; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUO Y, 1993, J BIOL CHEM, V268, P21253; MARTIN SA, 1975, J BIOL CHEM, V250, P9330; MARTIN SA, 1976, J BIOL CHEM, V251, P7313; MARTIN SA, 1975, J BIOL CHEM, V250, P9322; MORGAN JR, 1984, J VIROL, V51, P283, DOI 10.1128/JVI.51.2.283-297.1984; MOSS B, 1975, J BIOL CHEM, V250, P4722; NILES EG, 1993, J BIOL CHEM, V268, P24986; NILES EG, 1986, VIROLOGY, V153, P96, DOI 10.1016/0042-6822(86)90011-5; NILES EG, 1989, VIROLOGY, V172, P513, DOI 10.1016/0042-6822(89)90194-3; ROHRMANN G, 1986, CELL, V46, P1029, DOI 10.1016/0092-8674(86)90702-6; SCHNIERLE BS, 1992, P NATL ACAD SCI USA, V89, P2897, DOI 10.1073/pnas.89.7.2897; SHUMAN S, 1990, J BIOL CHEM, V265, P11960; SHUMAN S, 1987, J BIOL CHEM, V262, P12372; SHUMAN S, 1989, J BIOL CHEM, V264, P21356; SHUMAN S, 1990, J BIOL CHEM, V265, P11967; SHUMAN S, 1980, J BIOL CHEM, V255, P1588; SHUMAN S, 1989, J BIOL CHEM, V264, P9690; SONENBERG N, 1988, PROG NUCLEIC ACID RE, V35, P173, DOI 10.1016/S0079-6603(08)60614-5; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TUTAS DJ, 1977, J BIOL CHEM, V252, P3092; VENKATESAN S, 1980, J BIOL CHEM, V255, P903; VOS JC, 1991, EMBO J, V10, P2553, DOI 10.1002/j.1460-2075.1991.tb07795.x; YUEN L, 1987, P NATL ACAD SCI USA, V84, P6069, DOI 10.1073/pnas.84.17.6069; [No title captured]	41	58	92	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					14974	14981						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195132				2022-12-25	WOS:A1994NP73800023
J	SCALONI, A; BARRA, D; JONES, WM; MANNING, JM				SCALONI, A; BARRA, D; JONES, WM; MANNING, JM			HUMAN ACYLPEPTIDE HYDROLASE - STUDIES ON ITS THIOL-GROUPS AND MECHANISM OF ACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYLAMINOACYL-PEPTIDE HYDROLASE; ACID-RELEASING ENZYME; PROLYL OLIGOPEPTIDASE; PARA-NITROPHENYL; RAT-LIVER; SEQUENCE-ANALYSIS; SERINE PROTEASES; ENDOPEPTIDASE; PURIFICATION; SPECIFICITY	The presence of a cysteine residue(s) near the active site of acylpeptide hydrolase was suggested by inactivation of the enzyme with sulfhydryl-modifying agents and by the substantial protection against inactivation afforded by the competitive inhibitor acetylmethionine. 5,5'-dithiobis-(2-nitrobenzoate) titrations of the native and the denatured enzyme together with analysis for cysteic acid after performic acid oxidation showed that the enzyme contained 12 free SH groups and three disulfide bonds/monomer. Chemical modification with radiolabeled iodoacetamide led to the labeling of Cys-30 and Cys-64 suggesting that one or both of these Cys residues are close to the active site. Modification of one or both of them probably inhibits the enzyme either because of a distortion of the active site or because the adducts present a barrier to the efficient diffusion of substrates into and products out of the active site. Studies on the mechanism of action of acylpeptide hydrolase have employed p-nitrophenyl-N-propyl carbamate as a potent active site-directed inhibitor. Enzyme inactivation, which follows pseudo first-order kinetics, is diminished by the competitive inhibitor acetylmethionine. The inhibited enzyme slowly regains activity at a rate that is increased in the presence of the nucleophile hydroxylamine. A general mechanism involving an acyl enzyme intermediate is supported by evidence for the formation of acetyl-alanyl hydroxamate during hydrolysis of acetyl-alanine p-nitroanilide in the presence of hydroxylamine. The effects on V-max and K-m during this reaction indicate that hydrolysis of the acyl-enzyme intermediate is rate limiting.	ROCKEFELLER UNIV,NEW YORK,NY 10021; UNIV ROMA LA SAPIENZA,DIPARTIMENTO SCI BIOCHIM A ROSAI FANELLI,I-00185 ROME,ITALY; CNR,CTR BIOL MOLEC,I-00185 ROME,ITALY	Rockefeller University; Sapienza University Rome; Consiglio Nazionale delle Ricerche (CNR)			Barra, Donatella/D-1236-2011	Scaloni, Andrea/0000-0001-9362-8515	NCRR NIH HHS [507-RR-07065] Funding Source: Medline; NHLBI NIH HHS [HL-18819] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL018819, R01HL018819] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENDER ML, 1960, J AM CHEM SOC, V82, P3336, DOI 10.1021/ja01498a027; Cleland W W, 1979, Methods Enzymol, V63, P103; DAVID F, 1993, J BIOL CHEM, V268, P17247; ERLANDSSON R, 1991, ONCOGENE, V6, P1293; FEESE M, 1993, J MOL BIOL, V233, P546, DOI 10.1006/jmbi.1993.1531; FERSHT A, 1985, ENZYME STRUCTURE MEC, P195; HOSIE L, 1987, J BIOL CHEM, V262, P260; HUPEJENSEN B, 1987, LIPIDS, V22, P559; INWARD PW, 1965, J BIOL CHEM, V240, P1986; JONES WM, 1991, P NATL ACAD SCI USA, V88, P2194, DOI 10.1073/pnas.88.6.2194; JONES WM, 1988, BIOCHIM BIOPHYS ACTA, V953, P357, DOI 10.1016/0167-4838(88)90045-3; JONES WM, 1985, BIOCHEM BIOPH RES CO, V126, P933, DOI 10.1016/0006-291X(85)90275-X; KETTNER CA, 1984, J BIOL CHEM, V259, P5106; KOBAYASHI K, 1987, J BIOL CHEM, V262, P11435; KOBAYASHI K, 1989, J BIOL CHEM, V264, P8892; KRISHNA RG, 1992, PROTEIN SCI, V1, P582, DOI 10.1002/pro.5560010504; KRISHNA RG, 1991, ANAL BIOCHEM, V199, P45, DOI 10.1016/0003-2697(91)90267-W; KUHR RJ, 1976, CARBAMATE INSECTICID, P71; MITTA M, 1989, J BIOCHEM-TOKYO, V106, P548, DOI 10.1093/oxfordjournals.jbchem.a122891; NAYLOR SL, 1989, GENOMICS, V4, P355, DOI 10.1016/0888-7543(89)90342-X; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; POLGAR L, 1992, FEBS LETT, V311, P281, DOI 10.1016/0014-5793(92)81120-B; POLGAR L, 1992, BIOCHEM J, V283, P647, DOI 10.1042/bj2830647; POLGAR L, 1991, EUR J BIOCHEM, V197, P441, DOI 10.1111/j.1432-1033.1991.tb15930.x; POLGAR L, 1992, BIOCHEMISTRY-US, V31, P10769, DOI 10.1021/bi00159a018; POLGAR L, 1992, BIOCHEMISTRY-US, V31, P7729, DOI 10.1021/bi00148a038; POLGAR L, 1989, MECHANISMS PROTEASE, P87; RADHAKRISHNA G, 1989, J BIOL CHEM, V264, P11076; RAWLINGS ND, 1991, BIOCHEM J, V279, P907, DOI 10.1042/bj2790907; SCALONI A, 1992, J BIOL CHEM, V267, P3811; SCALONI A, 1992, J LAB CLIN MED, V120, P546; SCOFIELD RE, 1977, BIOCHEMISTRY-US, V16, P2492, DOI 10.1021/bi00630a027; SHARMA KK, 1993, EUR J BIOCHEM, V216, P631, DOI 10.1111/j.1432-1033.1993.tb18183.x; SHIN HC, 1992, BIOCHEMISTRY-US, V31, P811, DOI 10.1021/bi00118a025; STONE SR, 1991, BIOCHEM J, V276, P837, DOI 10.1042/bj2760837; SUTTON LD, 1986, BIOCHEM BIOPH RES CO, V134, P386, DOI 10.1016/0006-291X(86)90575-9; TAN FL, 1993, J BIOL CHEM, V268, P16631; TSUNASAWA S, 1975, J BIOCHEM, V77, P89; UMEZAWA H, 1980, J ANTIBIOT, V33, P1594, DOI 10.7164/antibiotics.33.1594	39	34	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					15076	15084						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195144				2022-12-25	WOS:A1994NP73800037
J	HOU, D; CENCIARELLI, C; JENSEN, JP; NGUYEN, HB; WEISSMAN, AM				HOU, D; CENCIARELLI, C; JENSEN, JP; NGUYEN, HB; WEISSMAN, AM			ACTIVATION-DEPENDENT UBIQUITINATION OF A T-CELL ANTIGEN RECEPTOR SUBUNIT ON MULTIPLE INTRACELLULAR LYSINES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHORT-LIVED PROTEIN; ZETA-CHAIN; TYROSINE PHOSPHORYLATION; SIGNAL TRANSDUCTION; MONOCLONAL-ANTIBODY; CYTOPLASMIC TAIL; DOMAIN; KINASE; POLYPEPTIDE; DEGRADATION	The T cell antigen receptor zeta chain and other T cell antigen receptor components are ubiquitinated on receptor occupancy. A systematic mutagenesis of the zeta subunit was undertaken to determine the sites of ubiquitination. Ubiquitination was found to occur in the cytoplasmic domain of zeta with multiple lysines serving as sites for mono- and polyubiquitination. The mutation of all potential sites of ubiquitination did not inhibit receptor tyrosine phosphorylation or the ubiquitination of other T cell antigen receptor subunits. Lysines introduced into nonnative positions in the zeta molecule were also able to serve as sites for ubiquitination. These findings demonstrate that once a T cell antigen receptor is targeted for ubiquitination, there is little specificity with regard to the lysine residues that are modified.	NCI, BIOL RESPONSE MODIFIERS PROGRAM, IMMUNE CELL BIOL LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								ASHWELL JD, 1990, ANNU REV IMMUNOL, V8, P139, DOI 10.1146/annurev.immunol.8.1.139; BACHMAIR A, 1989, CELL, V56, P1019, DOI 10.1016/0092-8674(89)90635-1; BANIYASH M, 1988, J BIOL CHEM, V263, P18225; CENCIARELLI C, 1992, SCIENCE, V257, P795, DOI 10.1126/science.1323144; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; FINLEY D, 1991, ANNU REV CELL BIOL, V7, P25, DOI 10.1146/annurev.cb.07.110191.000325; FRANK SJ, 1990, SCIENCE, V249, P174, DOI 10.1126/science.2371564; FRANK SJ, 1992, J BIOL CHEM, V267, P13656; GAUEN LKT, 1992, MOL CELL BIOL, V12, P5438, DOI 10.1128/MCB.12.12.5438; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; HAAS AL, 1985, J BIOL CHEM, V260, P2464; HEDRICK SM, 1982, CELL, V30, P141, DOI 10.1016/0092-8674(82)90020-4; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HOCHSTRASSER M, 1991, P NATL ACAD SCI USA, V88, P4606, DOI 10.1073/pnas.88.11.4606; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; IRVING BA, 1993, J EXP MED, V177, P1093, DOI 10.1084/jem.177.4.1093; JABBEN M, 1989, J BIOL CHEM, V264, P4998; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KAPPLER J, 1982, P NATL ACAD SCI-BIOL, V79, P3604, DOI 10.1073/pnas.79.11.3604; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; LETOURNEUR F, 1991, P NATL ACAD SCI USA, V88, P8905, DOI 10.1073/pnas.88.20.8905; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; MORI S, 1992, J BIOL CHEM, V267, P6429; MORI S, 1993, J BIOL CHEM, V268, P577; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; NAKAMURA T, 1992, ONCOGENE, V7, P733; ORLOFF DG, 1989, J BIOL CHEM, V264, P14812; PAOLINI R, 1993, EMBO J, V12, P779, DOI 10.1002/j.1460-2075.1993.tb05712.x; PAPA FR, 1993, NATURE, V366, P313, DOI 10.1038/366313a0; QIAN DP, 1993, J BIOL CHEM, V268, P4488; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; RIVERA J, 1988, MOL IMMUNOL, V25, P647, DOI 10.1016/0161-5890(88)90100-9; ROMEO C, 1992, CELL, V68, P889, DOI 10.1016/0092-8674(92)90032-8; ROMEO C, 1991, CELL, V64, P1037, DOI 10.1016/0092-8674(91)90327-U; SAMELSON LE, 1986, CELL, V46, P1083, DOI 10.1016/0092-8674(86)90708-7; SIEGELMAN M, 1986, SCIENCE, V231, P823, DOI 10.1126/science.3003913; SOMMER T, 1993, NATURE, V365, P176, DOI 10.1038/365176a0; SUSSMAN JJ, 1988, CELL, V52, P85, DOI 10.1016/0092-8674(88)90533-8; VANDERIJN M, 1990, J IMMUNOL, V145, P1477; VARSHAVSKY A, 1992, CELL, V69, P725, DOI 10.1016/0092-8674(92)90285-K; VOLAREVIC S, 1990, P NATL ACAD SCI USA, V87, P7085, DOI 10.1073/pnas.87.18.7085; WANG JYJ, 1985, MOL CELL BIOL, V5, P3640, DOI 10.1128/MCB.5.12.3640; WANGE RL, 1992, J BIOL CHEM, V267, P11685; WEGENER AMK, 1992, CELL, V68, P83, DOI 10.1016/0092-8674(92)90208-T; WEISSMAN AM, 1988, SCIENCE, V239, P1018, DOI 10.1126/science.3278377; WEISSMAN AM, 1989, EMBO J, V8, P3651, DOI 10.1002/j.1460-2075.1989.tb08539.x; WEISSMAN AM, 1994, IN PRESS CHEM IMMUNO; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0	50	103	104	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					14244	14247						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188707				2022-12-25	WOS:A1994NL60600078
J	SUNADA, Y; BERNIER, SM; KOZAK, CA; YAMADA, Y; CAMPBELL, KP				SUNADA, Y; BERNIER, SM; KOZAK, CA; YAMADA, Y; CAMPBELL, KP			DEFICIENCY OF MEROSIN IN DYSTROPHIC DY MICE AND GENETIC-LINKAGE OF LAMININ M-CHAIN GENE TO DY LOCUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MUSCULAR-DYSTROPHY; GLYCOPROTEIN COMPLEX; SKELETAL-MUSCLE; MOUSE CHROMOSOME-10; SCHWANN-CELLS; PROTEINS; ACTIN; EXPRESSION; BINDING; DOMAIN	Merosin is the predominant laminin isoform in the basal lamina of striated muscle and peripheral nerve, and consists of M, B1 or S, and B2 chains. Here we have demonstrated that merosin is a native ligand for alpha-dystroglycan, an extracellular component of the dystrophin-glycoprotein complex. We have also mapped the mouse M chain gene, Lamm, to the same region of mouse chromosome 10 to which the dystrophia muscularis (dy) locus has been mapped; The dy mutation represents a severe neuromuscular disease resembling human muscular dystrophy. Analysis of merosin expression of dystrophic dy mice revealed a specific deficiency of merosin in skeletal muscle, cardiac muscle, and peripheral nerve. Our results indicate that merosin deficiency may be the primary defect in dy mice and suggest that a disruption of the link between alpha-dystroglycan and merosin may be involved in the pathogenesis of muscle degeneration and peripheral neuropathy in dy mice.	UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242; NIDR,DEV BIOL LAB,BETHESDA,MD 20892; NIAID,MOLEC MICROBIOL LAB,BETHESDA,MD 20892	Howard Hughes Medical Institute; University of Iowa; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)				Campbell, Kevin/0000-0003-2066-5889				ADAMSON MC, 1991, VIROLOGY, V183, P778, DOI 10.1016/0042-6822(91)91010-E; BRADLEY WG, 1973, J NEUROL SCI, V18, P227, DOI 10.1016/0022-510X(73)90009-9; CAMPBELL KP, 1989, NATURE, V338, P259, DOI 10.1038/338259a0; EHRIG K, 1990, P NATL ACAD SCI USA, V87, P3264, DOI 10.1073/pnas.87.9.3264; ENGVALL E, 1992, EXP CELL RES, V198, P115, DOI 10.1016/0014-4827(92)90156-3; ENGVALL E, 1990, CELL REGUL, V1, P731, DOI 10.1091/mbc.1.10.731; ERVASTI JM, 1991, J BIOL CHEM, V266, P9161; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; ERVASTI JM, 1990, NATURE, V345, P315, DOI 10.1038/345315a0; ERVASTI JM, 1993, J CELL BIOL, V122, P809, DOI 10.1083/jcb.122.4.809; FABBRIZIO E, 1993, BIOCHEMISTRY-US, V32, P10457, DOI 10.1021/bi00090a023; FARDEAU M, 1993, CR ACAD SCI III-VIE, V316, P799; Green EL, 1981, GENETICS PROBABILITY, P77; HEMMINGS L, 1992, J CELL BIOL, V116, P1369, DOI 10.1083/jcb.116.6.1369; Hillyard A. L., 1993, Mouse Genome, V91, P15; IBRAGHIMOVBESKROVNAYA O, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; KOZAK CA, 1990, GENOMICS, V8, P519, DOI 10.1016/0888-7543(90)90039-W; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEIVO I, 1988, P NATL ACAD SCI USA, V85, P1544, DOI 10.1073/pnas.85.5.1544; LEVINE BA, 1992, FEBS LETT, V298, P44, DOI 10.1016/0014-5793(92)80019-D; MADRID RE, 1975, NATURE, V257, P319, DOI 10.1038/257319a0; MARDON G, 1990, MOL CELL BIOL, V10, P681, DOI 10.1128/MCB.10.2.681; MATSUMURA K, 1993, FEBS LETT, V334, P281, DOI 10.1016/0014-5793(93)80695-Q; MATSUMURA K, 1992, NATURE, V359, P320, DOI 10.1038/359320a0; OHLENDIECK K, 1991, J CELL BIOL, V112, P135, DOI 10.1083/jcb.112.1.135; OHLENDIECK K, 1993, NEUROLOGY, V43, P795, DOI 10.1212/WNL.43.4.795; OHLENDIECK K, 1991, J CELL BIOL, V115, P1685, DOI 10.1083/jcb.115.6.1685; PASSOSBUENO MR, 1993, HUM MOL GENET, V2, P1945, DOI 10.1093/hmg/2.11.1945; PAULSSON M, 1991, J BIOL CHEM, V266, P17545; PETERSON AC, 1984, J CELL BIOL, V99, P1831, DOI 10.1083/jcb.99.5.1831; ROBERDS SL, 1993, J BIOL CHEM, V268, P23739; TAYLOR BA, 1993, MAMM GENOME, V4, pS154, DOI 10.1007/BF00360836; TIMPL R, 1989, EUR J BIOCHEM, V180, P487, DOI 10.1111/j.1432-1033.1989.tb14673.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VUOLTEENAHO R, 1994, J CELL BIOL, V124, P381, DOI 10.1083/jcb.124.3.381; WAY M, 1992, FEBS LETT, V301, P243, DOI 10.1016/0014-5793(92)80249-G	36	285	288	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					13729	13732						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188645				2022-12-25	WOS:A1994NL60600002
J	VANDERVORM, ER; KUIPERS, A; KIELKOPFRENNER, S; KRANS, HMJ; MOLLER, W; MAASSEN, JA				VANDERVORM, ER; KUIPERS, A; KIELKOPFRENNER, S; KRANS, HMJ; MOLLER, W; MAASSEN, JA			A MUTATION IN THE INSULIN-RECEPTOR THAT IMPAIRS PRORECEPTOR PROCESSING BUT NOT INSULIN BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-SUBUNIT; CELL-SURFACE; PROLINE MUTATION; TRANSPORT; GENE; SITE; SUBSTITUTION; RESISTANCE; AUTOPHOSPHORYLATION; CLEAVAGE	Here we report the identification of a new mutation in the alpha-chain of the insulin receptor, changing Trp(412) into Ser using DNA from consanguineous parents who gave birth to a child with leprechaunism. The mutant receptor was expressed stably in CHO and transiently in COS-1 cells. It was found that the Ser(412) mutant is not cleaved into alpha- and beta-subunits and remains as a 210-kDa proreceptor at an intracellular site. This property of the mutant receptor is in line with the observed decreased insulin binding to the parental fibroblasts. Cross-linkinging experiments show that the Ser(412) proreceptor is able to bind insulin with an affinity comparable to that of the wild-type alpha-chain. Despite its capacity to bind insulin, the mutant receptor is not autophosphorylated. We postulate that the patient was homozygous for the Trp(412)--> Ser mutation and that the mutation was responsible for the leprechaun phenotype. This is the first description of a transport defective receptor with the mutation outside the tetrabasic processing site and a functional insulin binding domain. The ability of the Ser(412) mutant to bind insulin in cross-linking experiments suggests that the impaired transport of the proreceptor to the cell surface is the primary cause for the binding defect to intact cells.	LEIDEN STATE UNIV,SYLVIUS LABS,DEPT BIOCHEM MED,2333 AL LEIDEN,NETHERLANDS; UNIV TUBINGEN,DEPT CLIN GENET,W-7400 TUBINGEN,GERMANY; ACAD HOSP LEIDEN,DEPT ENDOCRINOL & METAB DIS,2300 RC LEIDEN,NETHERLANDS	Leiden University; Leiden University - Excl LUMC; Eberhard Karls University of Tubingen; Leiden University; Leiden University Medical Center (LUMC)								ANDERSEN AS, 1992, J BIOL CHEM, V267, P13681; BECKER AB, 1990, ANNU REV MED, V41, P99; COLLIER E, 1993, BIOCHEMISTRY-US, V32, P7818, DOI 10.1021/bi00081a029; KADOWAKI T, 1988, SCIENCE, V240, P787, DOI 10.1126/science.2834824; KADOWAKI T, 1991, J BIOL CHEM, V266, P21224; KADOWAKI T, 1990, J BIOL CHEM, V265, P19143; KJELDSEN T, 1991, P NATL ACAD SCI USA, V88, P4404, DOI 10.1073/pnas.88.10.4404; KLINKHAMER MP, 1989, EMBO J, V8, P2503, DOI 10.1002/j.1460-2075.1989.tb08387.x; LANE MD, 1985, BIOCHIMIE, V67, P1069, DOI 10.1016/S0300-9084(85)80104-8; MAASSEN JA, 1988, DIABETOLOGIA, V31, P612, DOI 10.1007/BF00264769; MAASSEN JA, 1991, BIOCHEMISTRY-US, V30, P10778, DOI 10.1021/bi00108a024; QUON MJ, 1992, BIOCHEMISTRY-US, V31, P9947, DOI 10.1021/bi00156a013; SCHUMACHER MC, 1992, DIABETES, V41, P416, DOI 10.2337/diabetes.41.4.416; SUGIBAYASHI M, 1992, METABOLISM, V41, P820, DOI 10.1016/0026-0495(92)90161-3; TAYLOR SI, 1992, ENDOCR REV, V13, P566, DOI 10.1210/er.13.3.566; VANDERVORM ER, 1992, J BIOL CHEM, V267, P66; WILLIAMS JF, 1990, J BIOL CHEM, V265, P8463; YIP CC, 1992, J CELL BIOCHEM, V48, P19, DOI 10.1002/jcb.240480105; YIP CC, 1988, BIOCHEM BIOPH RES CO, V157, P321, DOI 10.1016/S0006-291X(88)80050-0; ZHANG B, 1991, P NATL ACAD SCI USA, V88, P9858, DOI 10.1073/pnas.88.21.9858	20	20	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					14297	14302						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188715				2022-12-25	WOS:A1994NL60600086
J	LECOMTE, M; LANEUVILLE, O; JI, C; DEWITT, DL; SMITH, WL				LECOMTE, M; LANEUVILLE, O; JI, C; DEWITT, DL; SMITH, WL			ACETYLATION OF HUMAN PROSTAGLANDIN ENDOPEROXIDE SYNTHASE-2 (CYCLOOXYGENASE-2) BY ASPIRIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTI-INFLAMMATORY DRUGS; H SYNTHASE; G/H SYNTHASE; HEME-BINDING; POLYACRYLAMIDE GELS; COMPLEMENTARY-DNA; MESSENGER-RNA; ACID; GENE; PURIFICATION	Aspirin (acetylsalicylate) treatment of human (h) prostaglandin endoperoxide H synthase (PGHS)-1 expressed in cos-1 cells caused a time-dependent inactivation of oxygenase activity. Aspirin treatment of hPGHS-2 produced an enzyme which retained oxygenase activity but formed exclusively 15-hydroxy-5,8,11,13-eicosatetraenoic acid (15 HETE) instead of PGH(2). The 15-HETE was exclusively of the 15R configuration. The K-m values for arachidonate of native and aspirin-treated hPGHS-2 were about the same suggesting that arachidonate binds to both aspirin-treated and native hPGHS-2 in a similar manner. If, as expected, the formation of 15R-HETE proceeds through abstraction of the 13proS hydrogen from arachidonate, O-2, insertion must occur from the same side as the hydrogen abstraction; with all other lipoxy-genases and cyclooxygenases, O-2 addition is antarafacial. When microsomal hPGHS-2 was incubated with [acetyl-C-14]aspirin, the enzyme was acetylated. An S516A mutant of hPGHS-2, which retains enzyme activity, was not acetylated. This indicates that Ser-516 is the site of aspirin acetylation of PGHS-2; this residue is homologous to the ''active site'' serine of PGHS-1. An S516N mutant of hPGHS-2 was catalytically active; in contrast, an S516Q mutant lacked cyclooxygenase but retained peroxidase activity. Because in the case of PGHS-1 a smaller asparagine substitution is sufficient to eliminate cyclooxygenase activity, we conclude that the active site of PGHS-2 is slightly larger than that of PGHS-1. An S516M mutant of hPGHS-2 was obtained which resembled aspirin-acetylated hPGHS-2 in that this mutant made 15R-HETE as its major product; however, unlike the aspirin-acetylated hPGHS-2, the K-m value of the S516M mutant for arachidonate was 100 times that of native hPGHS-2.	MICHIGAN STATE UNIV,DEPT BIOCHEM,E LANSING,MI 48824; VANDERBILT UNIV,DEPT BIOCHEM,NASHVILLE,TN 37232	Michigan State University; Vanderbilt University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK022042, R01DK022042, R01DK042509] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK22042, DK42509] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRASH AR, 1986, METHOD ENZYMOL, V58, P187; DEWITT DL, 1988, P NATL ACAD SCI USA, V85, P1412, DOI 10.1073/pnas.85.5.1412; DEWITT DL, 1990, J BIOL CHEM, V265, P5192; DEWITT DL, 1993, ARCH BIOCHEM BIOPHYS, V306, P94, DOI 10.1006/abbi.1993.1485; FENG L, 1993, ARCH BIOCHEM BIOPHYS, V307, P361, DOI 10.1006/abbi.1993.1601; FLETCHER BS, 1992, J BIOL CHEM, V267, P4338; FUNK CD, 1991, FASEB J, V5, P2304, DOI 10.1096/fasebj.5.9.1907252; FUTAKI N, 1994, PROSTAGLANDINS, V47, P55, DOI 10.1016/0090-6980(94)90074-4; FUTAKI N, 1993, GEN PHARMACOL, V24, P105, DOI 10.1016/0306-3623(93)90018-S; HAMBERG M, 1967, J BIOL CHEM, V242, P5329; HAMBERG M, 1980, BIOCHEM BIOPH RES CO, V95, P1090, DOI 10.1016/0006-291X(80)91584-3; HAMBERG M, 1967, J BIOL CHEM, V242, P5336; HAMBERG M, 1967, J BIOL CHEM, V242, P5344; HEMLER M, 1976, J BIOL CHEM, V251, P5575; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; HOLTZMAN MJ, 1992, J BIOL CHEM, V267, P21438; HUMES JL, 1981, P NATL ACAD SCI-BIOL, V78, P2053, DOI 10.1073/pnas.78.4.2053; JONES DA, 1993, J BIOL CHEM, V268, P9049; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KENNEDY BP, 1993, BIOCHEM BIOPH RES CO, V197, P494, DOI 10.1006/bbrc.1993.2506; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; KUJUBU DA, 1993, J BIOL CHEM, V268, P5425; KUJUBU DA, 1992, J BIOL CHEM, V267, P7991; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANEUVILLE O, 1994, IN PRESS J PHARM EXP; LASKEY RA, 1975, EUR J BIOCHEM, V56, P335, DOI 10.1111/j.1432-1033.1975.tb02238.x; LIN AH, 1989, J BIOL CHEM, V264, P17379; MAAS RL, 1983, P NATL ACAD SCI-BIOL, V80, P2884, DOI 10.1073/pnas.80.10.2884; MARNETT LJ, 1988, J BIOL CHEM, V263, P16532; MARSHALL PJ, 1988, ARCH BIOCHEM BIOPHYS, V266, P162, DOI 10.1016/0003-9861(88)90246-9; MEADE EA, 1993, J BIOL CHEM, V268, P6610; MERLIE JP, 1988, J BIOL CHEM, V263, P3550; MIYAMOTO T, 1976, J BIOL CHEM, V251, P2629; MIZUNO K, 1982, PROSTAGLANDINS, V23, P743; OLIW EH, 1993, ARCH BIOCHEM BIOPHYS, V305, P288, DOI 10.1006/abbi.1993.1425; OSULLIVAN MG, 1992, BIOCHEM BIOPH RES CO, V187, P1123, DOI 10.1016/0006-291X(92)91313-F; OTTO JC, 1993, J BIOL CHEM, V268, P18234; ROME LH, 1975, P NATL ACAD SCI USA, V72, P4863, DOI 10.1073/pnas.72.12.4863; ROTH GJ, 1983, BIOCHEMISTRY-US, V22, P4672, DOI 10.1021/bi00289a010; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIMOKAWA T, 1991, J BIOL CHEM, V266, P6168; SHIMOKAWA T, 1990, J BIOL CHEM, V265, P20073; SHIMOKAWA T, 1992, J BIOL CHEM, V267, P12387; SIMONSON MS, 1991, MOL ENDOCRINOL, V5, P441, DOI 10.1210/mend-5-3-441; SIROIS J, 1992, J BIOL CHEM, V267, P11586; SIROIS J, 1993, J BIOL CHEM, V268, P21931; SMITH WL, 1989, BIOCHEM J, V259, P315, DOI 10.1042/bj2590315; SMITH WL, 1982, METHOD ENZYMOL, V86, P213; SMITH WL, 1994, CURR OPIN INVEST DR, V3, P1; SPECTOR AA, 1988, PROG LIPID RES, V27, P271, DOI 10.1016/0163-7827(88)90009-4; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANDEROUDERAA FJ, 1977, BIOCHIM BIOPHYS ACTA, V487, P315, DOI 10.1016/0005-2760(77)90008-X; WOLLARD PM, 1989, PROSTAGLANDINS, V38, P465, DOI 10.1016/0090-6980(89)90129-9; WONG WYL, 1991, MOL ENDOCRINOL, V5, P1269, DOI 10.1210/mend-5-9-1269; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692; YOKOYAMA C, 1988, FEBS LETT, V231, P347, DOI 10.1016/0014-5793(88)80847-0	57	325	333	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13207	13215						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175750				2022-12-25	WOS:A1994NK18400027
J	MUKAIDA, N; MORITA, M; ISHIKAWA, Y; RICE, N; OKAMOTO, S; KASAHARA, T; MATSUSHIMA, K				MUKAIDA, N; MORITA, M; ISHIKAWA, Y; RICE, N; OKAMOTO, S; KASAHARA, T; MATSUSHIMA, K			NOVEL MECHANISM OF GLUCOCORTICOID-MEDIATED GENE REPRESSION - NUCLEAR FACTOR-KAPPA-B IS TARGET FOR GLUCOCORTICOID-MEDIATED INTERLEUKIN-8 GENE REPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; TRANSCRIPTION FACTOR; MAMMALIAN-CELLS; CYCLOSPORINE-A; LYMPHOCYTES-T; MESSENGER-RNA; DNA-BINDING; C-JUN; RECEPTOR; EXPRESSION	A glucocorticoid, dexamethasone, inhibited the production of a leukocyte chemotactic cytokine, interleukin 8 (IL-8), as well as mRNA expression by a glioblastoma cell line, T98G, stimulated with interleukin 1 (IL-1). Dexamethasone also inhibited IL-8 promoter-driven chloramphenicol acetyltransferase (CAT) activities induced by IL-1, suggesting that dexamethasone inhibited IL-8 production mainly at the transcriptional level. Moreover, CAT assay revealed that the nuclear factor-kappa B (NF-kappa B) binding site was the crucial cis-element required for conferring IL-1 responsiveness in conjunction with the CCAAT enhancer binding protein/nuclear factor-IL-6 (NF-IL6) and/or the AP-1 binding site(s). Mutation of either the AP-1 or NF-IL6 binding site did not abolish IL-8 gene repression by dexamethasone, suggesting that these sites were not targets for dexamethasone. Trimerized kappa B sequence in the IL-8 gene was enough for conferring the induction by IL-1 and inhibition by dexamethasone of CAT activity. Finally, dexamethasone diminished the IL-l-induced formation of NF-kappa B complexes, which were identified immunochemically to consist of p50 and p65, without reducing the amount of translocated factors. Collectively, dexamethasone interfered with the binding of the most essential transcription factor, NF-kappa B, to its cognate cis-element, thereby suppressing the transcription of IL-8 gene.	JICHI MED SCH, DEPT NEUROL, MINAMI KAWACHI, TOCHIGI 32904, JAPAN; JICHI MED SCH, DEPT MED BIOL & PARASITOL, MINAMI KAWACHI, TOCHIGI 32904, JAPAN; NCI, FREDERICK CANC RES & DEV CTR, ABL BASIC RES PROGRAM, FREDERICK, MD 21702 USA	Jichi Medical University; Jichi Medical University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	MUKAIDA, N (corresponding author), KANAZAWA UNIV, CANC RES INST, DEPT PHARMACOL, KANAZAWA 920, JAPAN.		Mukaida, Naofumi/D-7623-2011	Mukaida, Naofumi/0000-0002-4193-1851	NCI NIH HHS [NCI N01-CO-74101] Funding Source: Medline; OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADLER S, 1988, CELL, V52, P685, DOI 10.1016/0092-8674(88)90406-0; AKERBLOM IE, 1988, SCIENCE, V241, P350, DOI 10.1126/science.2838908; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BAGGIOLINI M, 1989, J CLIN INVEST, V84, P1045, DOI 10.1172/JCI114265; BEUTLER B, 1986, SCIENCE, V232, P977, DOI 10.1126/science.3754653; BROWNELL E, 1989, ONCOGENE, V4, P935; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CICCARONE VC, 1990, J IMMUNOL, V144, P725; DETMERS PA, 1990, J EXP MED, V171, P1155, DOI 10.1084/jem.171.4.1155; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DROUIN J, 1989, MOL CELL BIOL, V9, P5305, DOI 10.1128/MCB.9.12.5305; ENDO H, 1991, LYMPHOKINE CYTOK RES, V10, P245; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; FURIE MB, 1991, BLOOD, V78, P2089; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HARADA A, 1993, INT IMMUNOL, V5, P681, DOI 10.1093/intimm/5.6.681; HUBER AR, 1991, SCIENCE, V254, P99, DOI 10.1126/science.1718038; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KO YC, 1992, J IMMUNOL METHODS, V149, P227, DOI 10.1016/0022-1759(92)90254-Q; KOCH AE, 1992, SCIENCE, V258, P1798, DOI 10.1126/science.1281554; LARSEN CG, 1991, BIOCHEM BIOPH RES CO, V176, P1020, DOI 10.1016/0006-291X(91)90384-J; LARSEN CG, 1989, SCIENCE, V243, P1464, DOI 10.1126/science.2648569; LECLAIR KP, 1992, P NATL ACAD SCI USA, V89, P8145, DOI 10.1073/pnas.89.17.8145; LEE SW, 1988, P NATL ACAD SCI USA, V85, P1204, DOI 10.1073/pnas.85.4.1204; LUCIBELLO FC, 1990, EMBO J, V9, P2827, DOI 10.1002/j.1460-2075.1990.tb07471.x; MAHE Y, 1991, J BIOL CHEM, V266, P13759; MATSUSAKA T, 1993, P NATL ACAD SCI USA, V90, P10193, DOI 10.1073/pnas.90.21.10193; MATSUSHIMA K, 1988, J EXP MED, V167, P1883, DOI 10.1084/jem.167.6.1883; MIMS CA, 1986, PATHOGENESIS INFECTI; MUKAIDA N, 1992, IMMUNOLOGY, V75, P674; MUKAIDA N, 1990, J BIOL CHEM, V265, P21128; MUKAIDA N, 1989, J IMMUNOL, V143, P1366; MUKAIDA N, 1991, J IMMUNOL, V146, P1212; NISHIO Y, 1993, MOL CELL BIOL, V13, P1854, DOI 10.1128/MCB.13.3.1854; OKAMOTO SI, 1994, J BIOL CHEM, V269, P8582; OLIVEIRA IC, 1992, P NATL ACAD SCI USA, V89, P9049, DOI 10.1073/pnas.89.19.9049; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SEKIDO N, 1993, NATURE, V365, P654, DOI 10.1038/365654a0; STANDIFORD TJ, 1990, J IMMUNOL, V145, P1435; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; TAI PKK, 1992, SCIENCE, V256, P1315, DOI 10.1126/science.1376003; VACCA A, 1992, J EXP MED, V175, P637, DOI 10.1084/jem.175.3.637; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; YASUMOTO K, 1992, J BIOL CHEM, V267, P22506; YEM AW, 1992, J BIOL CHEM, V267, P2868; ZIPFEL PF, 1991, BIOCHEM BIOPH RES CO, V181, P179, DOI 10.1016/S0006-291X(05)81398-1	48	408	417	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13289	13295						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175759				2022-12-25	WOS:A1994NK18400038
J	NISHIKIMI, M; FUKUYAMA, R; MINOSHIMA, S; SHIMIZU, N; YAGI, K				NISHIKIMI, M; FUKUYAMA, R; MINOSHIMA, S; SHIMIZU, N; YAGI, K			CLONING AND CHROMOSOMAL MAPPING OF THE HUMAN NONFUNCTIONAL GENE FOR L-GULONO-GAMMA-LACTONE OXIDASE, THE ENZYME FOR L-ASCORBIC-ACID BIOSYNTHESIS MISSING IN MAN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUINEA-PIGS; KEY ENZYME; LOCALIZATION	Man is among the exceptional higher animals that are unable to synthesize L-ascorbic acid because of their deficiency in L-gulono-gamma-lactone oxidase, the enzyme catalyzing the terminal step in L-ascorbic acid biosynthesis. In the present study, we isolated a segment of the nonfunctional L-gulono-gamma-lactone oxidase gene from a human genomic library, and mapped it on chromosome 8p21.1 by spot blot hybridization using flow-sorted human chromosomes and fluorescence in situ hybridization. Sequencing analysis indicated that the isolated segment represented a 3'-part of the gene, where the regions corresponding to exons VII, IX, X, and XII of the rat L-gulono-gamma-lactone oxidase gene remain with probable deletion of the regions corresponding to exons VIII and XI. In the identified exon regions were found various anomalous nucleotide changes, such as deletion and insertion of nucleotide(s) and nonconformance to the GT/AG rule at intron/exon boundaries. When the conceptual amino acid sequences deduced from the four exon sequences were compared with the corresponding rat sequences, there were a large number of nonconservative substitutions and also two stop codons. These findings indicate that the human nonfunctional L-gulono-gamma-lactone oxidase gene has accumulated a large number of mutations without selective pressure since it ceased to function during evolution.	KEIO UNIV,SCH MED,DEPT MOLEC BIOL,TOKYO 160,JAPAN	Keio University	NISHIKIMI, M (corresponding author), INST APPL BIOCHEM,YAGI MEM PK,MITAKE,GIFU 50501,JAPAN.							BURNS JJ, 1976, METABOLIC PATHWAYS, V1, P394; Dayhoff M. O., 1978, ATLAS PROTEIN SEQ S3, V5, P345; DEININGER PL, 1986, TRENDS GENET, V2, P76, DOI 10.1016/0168-9525(86)90183-6; FUKUYAMA R, 1991, GENOMICS, V11, P410, DOI 10.1016/0888-7543(91)90149-9; KOSHIZAKA T, 1988, J BIOL CHEM, V263, P1619; MARTENSSON J, 1992, P NATL ACAD SCI USA, V89, P11566, DOI 10.1073/pnas.89.23.11566; MINOSHIMA S, 1990, CYTOMETRY, V11, P539, DOI 10.1002/cyto.990110413; MINOSHIMA S, 1991, CYTOGENET CELL GENET, V57, P30, DOI 10.1159/000133108; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NAKAJIMA Y, 1969, HISTOCHEMISTRY, V18, P293; NEVIN NC, 1990, J MED GENET, V27, P135, DOI 10.1136/jmg.27.2.135; NISHIKIMI M, 1977, TRENDS BIOCHEM SCI, V2, P111, DOI 10.1016/0968-0004(77)90175-X; NISHIKIMI M, 1992, J BIOL CHEM, V267, P21967; NISHIKIMI M, 1988, ARCH BIOCHEM BIOPHYS, V267, P842, DOI 10.1016/0003-9861(88)90093-8; RALEIGH EA, 1988, NUCLEIC ACIDS RES, V16, P1563, DOI 10.1093/nar/16.4.1563; SAKAI K, 1992, GENOMICS, V14, P175, DOI 10.1016/S0888-7543(05)80301-5; WINKLER BS, 1987, BIOCHIM BIOPHYS ACTA, V925, P258, DOI 10.1016/0304-4165(87)90190-5	17	343	355	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13685	13688						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175804				2022-12-25	WOS:A1994NK18400091
J	ZLOTNICK, A; REDDY, VS; DASGUPTA, R; SCHNEEMANN, A; RAY, WJ; RUECKERT, RR; JOHNSON, JE				ZLOTNICK, A; REDDY, VS; DASGUPTA, R; SCHNEEMANN, A; RAY, WJ; RUECKERT, RR; JOHNSON, JE			CAPSID ASSEMBLY IN A FAMILY OF ANIMAL VIRUSES PRIMES AN AUTOPROTEOLYTIC MATURATION THAT DEPENDS ON A SINGLE ASPARTIC-ACID RESIDUE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLEAVAGE; PROTEINS	Maturation of noninfectious nodavirus provirions occurs by autoproteolytic cleavage of most of the 180 copies of the alpha-protein that make up, the icosahedral capsid. This maturation, which is much slower than viral assembly, produces an infectious particle that is more stable than the provirion and makes viral uncoating thermodynamically distinct from assembly, allowing assembly and (a time delayed) uncoating to occur under similar conditions. The results of structural, computational, and molecular genetic studies suggest that maturation depends both on intrasubunit strain, produced during assembly, and on a critical aspartic acid residue. This residue lies in a hydrophobic pocket that is stabilized by intersubunit contacts. It is close to the scissile bond and exhibits an environmentally elevated pK(a). The apparent involvement of a single acidic residue in the hydrolytic cleavage of a peptide bond contrasts with the involvement of 2 such residues in acid proteases.	PURDUE UNIV,DEPT BIOL SCI,W LAFAYETTE,IN 47907; UNIV WISCONSIN,INST MOLEC VIROL,MADISON,WI 53706	Purdue University System; Purdue University; Purdue University West Lafayette Campus; University of Wisconsin System; University of Wisconsin Madison				Zlotnick, Adam/0000-0001-9945-6267	NIAID NIH HHS [AI22813] Funding Source: Medline; NIGMS NIH HHS [GM34220, GM08296] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI022813] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034220, T32GM008296, R37GM034220] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BISHOP NE, 1993, VIROLOGY, V197, P616, DOI 10.1006/viro.1993.1636; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; CASPAR DLD, 1962, COLD SPRING HARB SYM, V27, P1, DOI 10.1101/sqb.1962.027.001.005; CHENG RH, 1994, IN PRESS STRUCTURE; CREIGHTON TE, 1984, PROTEIN STRUCTURE MO, P449; FISHER AJ, 1993, NATURE, V361, P176, DOI 10.1038/361176a0; GALLAGHER TM, 1988, J VIROL, V62, P3399, DOI 10.1128/JVI.62.9.3399-3406.1988; GILSON MK, 1988, J COMPUT CHEM, V9, P327, DOI 10.1002/jcc.540090407; HENDRY DA, 1991, VIRUSES INVERTEBRATE, P227; HOSUR MV, 1987, PROTEINS, V2, P167, DOI 10.1002/prot.340020302; HOSUR MV, 1984, VIROLOGY, V133, P119, DOI 10.1016/0042-6822(84)90430-6; JONES TA, 1982, COMPUTATIONAL CRYSTA, P307; KAESBERG P, 1990, J MOL BIOL, V214, P423, DOI 10.1016/0022-2836(90)90191-N; KAESBERG P, 1987, MOL BIOL POSITIVE ST, P207; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATTHEW JB, 1985, CRC CR REV BIOCH MOL, V18, P91, DOI 10.3109/10409238509085133; MORI KI, 1992, VIROLOGY, V187, P368, DOI 10.1016/0042-6822(92)90329-N; RUECKERT RR, 1990, VIROLOGY, P507; SCHNEEMANN A, 1992, J VIROL, V66, P6728, DOI 10.1128/JVI.66.11.6728-6734.1992; SHARP KA, 1990, ANNU REV BIOPHYS BIO, V19, P301, DOI 10.1146/annurev.bb.19.060190.001505; SMITH TJ, 1993, J APPL CRYSTALLOGR, V26, P496, DOI 10.1107/S0021889892013153; WERY JP, 1994, J MOL BIOL, V235, P565, DOI 10.1006/jmbi.1994.1014; YANG AS, 1993, PROTEINS, V15, P252, DOI 10.1002/prot.340150304	24	85	85	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13680	13684						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175803				2022-12-25	WOS:A1994NK18400090
J	ZOU, LL; HAGEN, SG; STRAIT, KA; OPPENHEIMER, JH				ZOU, LL; HAGEN, SG; STRAIT, KA; OPPENHEIMER, JH			IDENTIFICATION OF THYROID-HORMONE RESPONSE ELEMENTS IN RODENT PCP-2, A DEVELOPMENTALLY-REGULATED GENE OF CEREBELLAR PURKINJE-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOID X-RECEPTOR; TRANS-ACTIVATION; ENHANCES BINDING; ACID; EXPRESSION; PROTEIN; RAT; SEQUENCE; LEADER; TESTIS	In a previous study, we have shown that in vivo expression of the cerebellar Purkinje cell-specific gene Pcp-2 is regulated by thyroid hormone (T-3) during neonatal development. In addition, transient cotransfection studies using thyroid hormone receptors (TRs) and a Pcp-2-lacZ construct pointed to direct regulation of Pcp-2 gene expression by T-3. Therefore, we have initiated the following series of studies to define more precisely the location of the thyroid hormone regulatory elements in the Pcp-2 gene. By transfection and in vitro receptor binding analyses, we have identified two thyroid hormone response elements, A1 (-295/-268) and B1 (+207/+227). A1 contains a central half site flanked by two similar half-sites. B1 contains two pairs of alternate half-sites. When these elements were ligated to the modified mouse mammary tumor virus promoter (Delta MMTV), both induced a 8-14-fold expression of the reporter gene, but only in the presence of T-3. Gel mobility assays demonstrated that both A1 and B1 bind TRs in the presence of thyroid hormone receptor auxiliary proteins or the retinoid X beta receptor. Mutations of the G residues to T within the individual half-site sequences of A1 caused a variable decrease in the transactivation of the MMTV-CAT construct and a corresponding reduction in TR binding in vitro. Thus, mutational analysis of A1 pointed to the interaction of the flanking half-site motifs with the central AGGTCA half-site. Interestingly, lengthening of the A1 sequence at its 3'-end caused a progressive dampening of the T-3 response. The results suggest that the neighboring sequence may function as a silencer of the A1 element. Since thyroid hormone regulation of Pcp-2 is manifest only during the first 2 weeks after birth, we hypothesize that A1 and B1 act as T-3-dependent response elements operative only during early neonatal Purkinje cell development and that their function is suppressed by a neighboring silencer element operative when expression of Pcp-2 becomes hormone-independent.	UNIV MINNESOTA,DEPT MED,DIABET ENDOCRINOL & METAB SECT,THYROID RES UNIT,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,DEPT CELL BIOL & NEUROANAT,MINNEAPOLIS,MN 55455	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities					NIDDK NIH HHS [DK-RO1-19812] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019812] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWNING KS, 1988, J BIOL CHEM, V263, P9630; BURNSIDE J, 1990, J BIOL CHEM, V265, P2500; DeLong GR, 1989, IODINE BRAIN, P231; FARSETTI A, 1991, J BIOL CHEM, V266, P23226; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; GLASS CK, 1987, NATURE, V329, P738, DOI 10.1038/329738a0; JOBLING SA, 1987, NATURE, V325, P622, DOI 10.1038/325622a0; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; LEGRAND J, 1967, ARCH ANAT MICROSC MO, V56, P291; Legrand J, 1986, THYROID HORMONE META, P503; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MURRAY MB, 1989, MOL ENDOCRINOL, V3, P1434, DOI 10.1210/mend-3-9-1434; OPPENHEIMER JH, 1974, ENDOCRINOLOGY, V95, P897, DOI 10.1210/endo-95-3-897; PARK HY, 1993, MOL ENDOCRINOL, V7, P319, DOI 10.1210/me.7.3.319; SAP J, 1990, EMBO J, V9, P887, DOI 10.1002/j.1460-2075.1990.tb08186.x; SCHUELER PA, 1990, MOL ENDOCRINOL, V4, P227, DOI 10.1210/mend-4-2-227; STRAIT KA, 1990, J BIOL CHEM, V265, P10514; STRAIT KA, 1992, MOL ENDOCRINOL, V6, P1874, DOI 10.1210/me.6.11.1874; THOMPSON CC, 1989, P NATL ACAD SCI USA, V86, P3494, DOI 10.1073/pnas.86.10.3494; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; VANDAELE S, 1991, GENE DEV, V5, P1136, DOI 10.1101/gad.5.7.1136; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	26	56	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13346	13352						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175765				2022-12-25	WOS:A1994NK18400046
J	ESCALANTE, R; SASTRE, L				ESCALANTE, R; SASTRE, L			STRUCTURE OF ARTEMIA-FRANCISCANA SARCO/ENDOPLASMIC RETICULUM CA-ATPASE GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PIG SMOOTH-MUSCLE; CA-2+ PUMP; SARCOPLASMIC-RETICULUM; MOLECULAR-CLONING; CA-2+-ATPASE GENE; CRUSTACEAN ARTEMIA; SKELETAL-MUSCLE; MYOD FAMILY; EXPRESSION; IDENTIFICATION	Genomic clones coding for the Artemia franciscana sarco(endo)plasmic reticulum Ca-ATPase have been isolated. The restriction map of the overlapping clones covers a region of 65 kilobases of DNA, Nucleotide sequence of mRNA coding regions shows that the gene is divided into 18 exons separated by 17 introns. Compared with the structure of the rabbit sarco(endo)plasmic reticulum Ca-ATPase 1 gene, 12 of the introns are in the same position, 8 introns present in the rabbit gene are absent from A. franciscana, 4 introns present in A. franciscana are not found in rabbit, and the position of 1 intron is shifted one base between both genes. Southern blot analysis strongly suggests that this is the only sarco(endo)plasmic reticulum Ca-ATPase gene present in A. franciscana. Primer extension and nuclease S1 protection experiments have shown the existence of two main regions of transcription initiation separated by 30 nucleotides. Transcription is initiated in both regions at two or three consecutive bases. A hexanucleotide that includes the initiation sites is repeated in both transcription initiation regions. The nucleotide sequence of the promoter region shows the existence of several putative regulatory sites, including some that are muscle-specific such as one CArG box, 3 MEF-2, and 8 putative binding sites for muscle transcription factors of the MyoD family.	CSIC,INST INVEST BIOMED,E-28029 MADRID,SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)			Escalante, Ricardo/G-8272-2015	Escalante, Ricardo/0000-0001-8547-531X; Sastre, Leandro/0000-0003-3613-5938				BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; BRANDL CJ, 1987, J BIOL CHEM, V262, P3768; BURK SE, 1989, J BIOL CHEM, V264, P18561; CAMPBELL AM, 1991, J BIOL CHEM, V266, P16050; CAVALIERSMITH T, 1991, TRENDS GENET, V7, P145, DOI 10.1016/0168-9525(91)90102-V; CRUCES J, 1981, BIOCHEM BIOPH RES CO, V98, P404, DOI 10.1016/0006-291X(81)90854-8; DORIT RL, 1990, SCIENCE, V250, P1377, DOI 10.1126/science.2255907; EGGERMONT JA, 1991, BIOCHIM BIOPHYS ACTA, V1088, P448, DOI 10.1016/0167-4781(91)90143-A; EGGERMONT JA, 1989, BIOCHEM J, V260, P757, DOI 10.1042/bj2600757; EGGERMONT JA, 1990, BIOCHEM J, V266, P901; ESCALANTE R, 1993, J BIOL CHEM, V268, P14090; GIL I, 1987, NUCLEIC ACIDS RES, V15, P6007, DOI 10.1093/nar/15.15.6007; GILBERT W, 1978, NATURE, V271, P501, DOI 10.1038/271501a0; GUNTESKIHAMBLIN AM, 1988, J BIOL CHEM, V263, P15032; KORCZAK B, 1988, J BIOL CHEM, V263, P4813; LIAUD MF, 1990, P NATL ACAD SCI USA, V87, P8918, DOI 10.1073/pnas.87.22.8918; LYTTON J, 1988, J BIOL CHEM, V263, P15024; LYTTON J, 1989, J BIOL CHEM, V264, P7059; MAGYAR A, 1990, BIOCHEM BIOPH RES CO, V173, P872, DOI 10.1016/S0006-291X(05)80867-8; Maxam A M, 1980, Methods Enzymol, V65, P499; MICHELSON AM, 1990, GENE DEV, V4, P2086, DOI 10.1101/gad.4.12a.2086; MINTY A, 1986, MOL CELL BIOL, V6, P2125, DOI 10.1128/MCB.6.6.2125; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; Palmer JD, 1991, CURR OPIN GENET DEV, V1, P470, DOI 10.1016/S0959-437X(05)80194-7; PALMERO I, 1989, J MOL BIOL, V210, P737, DOI 10.1016/0022-2836(89)90106-X; POLLOCK R, 1991, GENE DEV, V5, P2327, DOI 10.1101/gad.5.12a.2327; SUKOVICH DA, 1993, NUCLEIC ACIDS RES, V21, P2723, DOI 10.1093/nar/21.11.2723; TRIEZENBERG SJ, 1993, CURRENT PROTOCOLS MO; VARADI A, 1993, FEBS LETT, V258, P203; ZARAINHERZBERG A, 1990, J BIOL CHEM, V265, P4670	30	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					13005	13012						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175720				2022-12-25	WOS:A1994NH71600096
J	FLAHERTY, KM; WILBANKS, SM; DELUCAFLAHERTY, C; MCKAY, DB				FLAHERTY, KM; WILBANKS, SM; DELUCAFLAHERTY, C; MCKAY, DB			STRUCTURAL BASIS OF THE 70-KILODALTON HEAT-SHOCK COGNATE PROTEIN ATP HYDROLYTIC ACTIVITY .2. STRUCTURE OF THE ACTIVE-SITE WITH ADP OR ATP BOUND TO WILD-TYPE AND MUTANT ATPASE FRAGMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAY-DIFFRACTION DATA; AUTOPHOSPHORYLATION; RESOLUTION	The ATPase fragment of the bovine 70-kDa heat shock cognate protein is an attractive construct in which to study its mechanism of ATP hydrolysis. The three-dimensional structure suggests several residues that might participate in the ATPase reaction. Four acidic residues (Asp-10, Glu-175, Asp-199, and Asp-206) have been individually mutated to both the cognate amine (asparagine/glutamine) and to serine, and the effects of the mutations on the kinetics of the ATPase activity (Wilbanks, S. M., DeLuca-Flaherty, C., and McKay, D. B. (1994) J. Biol. Chem. 269, 12893-12898) and the structure of the mutant ATPase fragments have been determined, typically to similar to 2.4 Angstrom resolution. Additionally, the structures of the wild type protein complexed with MgADP and P-i, MgAMPPNP (5'-adenylyl-beta,gamma-imidodiphosphate) and CaAMPPNP have been refined to 2.1, 2.4, and 2.4 Angstrom, respectively. Combined, these structures provide models for the prehydrolysis, MgATP-bound state and the post-hydrolysis, MgADP-bound state of the ATPase fragment. These models suggest a pathway for the hydrolytic reaction in which 1) the gamma phosphate of bound ATP reorients to form a beta,gamma-bidentate phosphate complex with the Mig(2+) ion, allowing 2) in-line nucleophilic attack on the gamma phosphate by a H2O molecule or OH- ion, with 3) subsequent release of inorganic phosphate.	STANFORD UNIV,SCH MED,DEPT CELL BIOL,BECKMAN LABS STRUCT BIOL,STANFORD,CA 94305	Stanford University				Wilbanks, Sigurd/0000-0001-7565-8913	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039928] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-39928] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLURED VS, 1986, P NATL ACAD SCI USA, V83, P1320, DOI 10.1073/pnas.83.5.1320; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CHAPPELL TG, 1987, J BIOL CHEM, V262, P746; DELUCAFLAHERTY C, 1988, J MOL BIOL, V200, P749, DOI 10.1016/0022-2836(88)90487-1; FERSHT A, 1985, ENZYME STRUCTURE MEC, P235; FLAHERTY KM, 1991, P NATL ACAD SCI USA, V88, P5041, DOI 10.1073/pnas.88.11.5041; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; FLETTERICK RJ, 1975, P NATL ACAD SCI USA, V72, P38, DOI 10.1073/pnas.72.1.38; GAUT JR, 1993, J BIOL CHEM, V268, P12691; GLUSKER JP, 1991, ADV PROTEIN CHEM, V42, P1; HANSON JC, 1979, ACTA CRYSTALLOGR A, V35, P616, DOI 10.1107/S0567739479001443; HURLEY JH, 1993, SCIENCE, V259, P673, DOI 10.1126/science.8430315; JONES TA, 1986, EMBO J, V5, P819, DOI 10.1002/j.1460-2075.1986.tb04287.x; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; LEUSTEK T, 1991, ARCH BIOCHEM BIOPHYS, V289, P256, DOI 10.1016/0003-9861(91)90469-Y; LEUSTEK T, 1992, CELL MOL BIOL, V38, P1; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; OBRIEN MC, 1993, J BIOL CHEM, V268, P24323; SCHLOSSMAN DM, 1984, J CELL BIOL, V99, P723, DOI 10.1083/jcb.99.2.723; STEIGEMANN W, 1974, THESIS TU MUNCHEN; WILBANKS SM, 1994, J BIOL CHEM, V269, P12893; ZYLICZ M, 1983, P NATL ACAD SCI-BIOL, V80, P6431, DOI 10.1073/pnas.80.21.6431	22	139	146	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12899	12907						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175707				2022-12-25	WOS:A1994NH71600081
J	GAMBAROTTA, G; PISTOI, S; GIORDANO, S; COMOGLIO, PM; SANTORO, C				GAMBAROTTA, G; PISTOI, S; GIORDANO, S; COMOGLIO, PM; SANTORO, C			STRUCTURE AND INDUCIBLE REGULATION OF THE HUMAN MET PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								The MET oncogene, encoding the tyrosine kinase receptor for the hepatocyte growth factor/scatter factor, is expressed in epithelial cells and overexpressed in a significant proportion of human epithelial cancers, suggesting the occurrence of transcriptional alteration(s). To identify the MET promoter, we isolated recombinant cDNA clones encompassing the entire 5'- noncoding sequence of MET messenger RNAs. Using probes derived from this region, we cloned the entire genomic region spanning the first MET exon and the flanking regulatory sequences. The first exon, containing the entire untranslated sequence, is present in the MET mRNAs of 7.1, 5.9, and 4.6 kilobases, showing that the expression of the multiple transcripts is regulated by a single promoter. The start site of transcription was determined by primes extension and by rapid amplification of cDNA ends. We show that a 300-base pair fragment, containing sequences upstream from the start site, efficiently drives the expression of a reporter gene in transfected epithelial cells. This promoter fragment also contains the cis-acting elements responsible for phorbol-ester induction.	INTERUNIV CONSORTIUM BIOTECHNOL, LN CIB, I-34012 TRIESTE, ITALY; UNIV TURIN, SCH MED, DEPT BIOMED SCI & ONCOL, I-10126 TURIN, ITALY; UNIV TURIN, SCH MED, DEPT GENET BIOL & MED CHEM, I-10126 TURIN, ITALY	University of Turin; University of Turin			Gambarotta, Giovanna/I-8473-2012; santoro, claudio/G-6819-2012; Giordano, Silvia/J-9858-2018	Gambarotta, Giovanna/0000-0002-8380-5925; Giordano, Silvia/0000-0003-1854-1086; Comoglio, Paolo/0000-0002-7056-5328				ADNANE J, 1991, ONCOGENE, V6, P659; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ARAKI E, 1987, J BIOL CHEM, V262, P16186; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BOCCACCIO C, 1994, J BIOL CHEM, V269, P12846; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; COHEN JA, 1989, ONCOGENE, V4, P81; DIRENZO MF, 1991, ONCOGENE, V6, P1997; DIRENZO MF, 1992, ONCOGENE, V7, P2549; DON RH, 1991, NUCLEIC ACIDS RES, V19, P4008, DOI 10.1093/nar/19.14.4008; FABER PW, 1993, J BIOL CHEM, V268, P9296; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; GIORDANO S, 1993, P NATL ACAD SCI USA, V90, P649, DOI 10.1073/pnas.90.2.649; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; GUTMAN A, 1991, TRENDS GENET, V7, P49, DOI 10.1016/0168-9525(91)90231-E; HOLLYWOOD DP, 1993, EMBO J, V12, P2369, DOI 10.1002/j.1460-2075.1993.tb05891.x; HUDSON LG, 1990, J BIOL CHEM, V265, P4389; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; INNIS JW, 1991, J BIOL CHEM, V266, P21765; ISHII S, 1985, P NATL ACAD SCI USA, V82, P4920, DOI 10.1073/pnas.82.15.4920; ITOH F, 1992, ONCOGENE, V7, P1201; JACOBS JP, 1970, NATURE, V227, P168, DOI 10.1038/227168a0; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; KING CR, 1989, CANCER RES, V49, P4185; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; KUNIYASU H, 1993, INT J CANCER, V55, P72, DOI 10.1002/ijc.2910550114; KUNIYASU H, 1992, BIOCHEM BIOPH RES CO, V189, P227, DOI 10.1016/0006-291X(92)91548-5; KURY FD, 1990, ONCOGENE, V5, P1403; LIBERMANN TA, 1985, J CELL SCI, P161; LIU C, 1992, ONCOGENE, V7, P181; LU SH, 1988, INT J CANCER, V42, P502, DOI 10.1002/ijc.2910420406; MARTIN ME, 1988, P NATL ACAD SCI USA, V85, P5839, DOI 10.1073/pnas.85.16.5839; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MOTOYAMA T, 1986, ACTA PATHOL JAPON, V36, P65; NALDINI L, 1991, ONCOGENE, V6, P501; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; NATALI PG, 1993, BRIT J CANCER, V68, P746, DOI 10.1038/bjc.1993.422; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; PONZETTO C, 1991, ONCOGENE, V6, P553; PRAT M, 1991, INT J CANCER, V49, P323, DOI 10.1002/ijc.2910490302; REGECAMBRIN G, 1992, CANCER GENET CYTOGEN, V64, P170, DOI 10.1016/0165-4608(92)90350-H; RODRIGUES GA, 1991, MOL CELL BIOL, V11, P2962, DOI 10.1128/MCB.11.6.2962; Sambrook J, 1989, MOL CLONING LABORATO; SANTORO C, 1986, NUCLEIC ACIDS RES, V14, P2863, DOI 10.1093/nar/14.7.2863; SCHULZ AS, 1993, ONCOGENE, V8, P509; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; WASYLYK C, 1989, EMBO J, V8, P3371, DOI 10.1002/j.1460-2075.1989.tb08500.x; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0	56	55	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12852	12857						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175700				2022-12-25	WOS:A1994NH71600074
J	PRADO, GN; THOMAS, KM; SUZUKI, H; LAROSA, GJ; WILKINSON, N; FOLCO, E; NAVARRO, J				PRADO, GN; THOMAS, KM; SUZUKI, H; LAROSA, GJ; WILKINSON, N; FOLCO, E; NAVARRO, J			MOLECULAR CHARACTERIZATION OF A NOVEL RABBIT INTERLEUKIN-8 RECEPTOR ISOTYPE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							NEUTROPHIL CHEMOTACTIC FACTOR; CLONING; IL-8	Interleukin-8 (IL-8) mediates the transendothelial migration and activation of neutrophils to the site of inflammation. Two human IL-8 receptor isotype (A and B) and one rabbit IL-8 receptor isotype (A) cDNAs have been previously cloned and characterized on the basis of their pharmacological profile. Human and rabbit IL-8 receptor subtype A binds IL-8 and structurally related peptide melanoma growth-stimulating activity (MGSA) and neutrophil-activating peptide-2 (NAP-2) according to the following affinity binding profile: IL-8 >>> MGSA > NAP-2, whereas the human IL-8 receptor subtype B profile is IL-8 = MGSA > NAP-2 (LaRosa, G., Thomas, K. M., Kaufmann, M., Mark, R., White, M., Taylor, L., Gray, G., Witt, D., and Navarro, J. (1992) J. Biol. Chem. 267, 25402-25406). In this study, we isolated a cDNA clone (5B1a) from a rabbit neutrophil Library encoding a G-protein-coupled receptor of the interleukin-8 receptor family. The 5B1a clone encodes a 358-amino acid protein exhibiting 80% amino acid identity to the human IL-8 receptor B, 74% to the rabbit IL-8 receptor A, and 73% to the human IL-8 receptor A Tissue distribution by Northern blot analysis reveals that the 5B1a mRNA is expressed preferentially in neutrophils. In contrast to previously described IL-8 receptors, the 5B1a receptor exhibited specific I-125-IL-8 binding with a novel affinity binding profile of IL-8 >> NAP-2 > MGSA. The corresponding apparent K-i values for IL-8, NAP-2, and MGSA were 4, 120, and 320 nM, respectively. IL-8 induced intracellular calcium mobilization and desensitization in Chinese hamster ovary cells stably transfected with 5B1a, indicating that this cDNA encodes a functional IL-8 receptor. Sequence analysis of the 5B1a protein with other IL-8 receptor subtypes within the framework of their pharmacological profile reveals putative structural motifs that may correspond to the ligand binding site of the IL-8 receptor.	UNIV TEXAS,MED BRANCH,SEALY CTR MOLEC SCI,DEPT PHYSIOL & BIOPHYS,GALVESTON,TX 77555	University of Texas System; University of Texas Medical Branch Galveston				Navarro, Javier/0000-0001-7098-4373	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039602] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01 AR 39602] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALTENBERG GA, 1992, J GEN PHYSIOL, V99, P241, DOI 10.1085/jgp.99.2.241; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DOHLMAN HG, 1987, BIOCHEMISTRY-US, V26, P2657, DOI 10.1021/bi00384a001; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; KUNKEL SL, 1991, EXP LUNG RES, V17, P17, DOI 10.3109/01902149109063278; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAROSA GJ, 1992, J BIOL CHEM, V267, P25402; LEE J, 1992, J IMMUNOL, V148, P1261; MATSUSHIMA K, 1988, J EXP MED, V167, P1883, DOI 10.1084/jem.167.6.1883; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; SCHRODER JM, 1986, J INVEST DERMATOL, V87, P53, DOI 10.1111/1523-1747.ep12523566; SEITZ M, 1991, J CLIN INVEST, V87, P463, DOI 10.1172/JCI115018; THOMAS KM, 1991, J BIOL CHEM, V266, P14839; THOMAS KM, 1990, J BIOL CHEM, V265, P20061; YOSHIMURA T, 1987, P NATL ACAD SCI USA, V84, P9233, DOI 10.1073/pnas.84.24.9233	16	20	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12391	12394						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175642				2022-12-25	WOS:A1994NH71600003
J	BATES, S; PARRY, D; BONETTA, L; VOUSDEN, K; DICKSON, C; PETERS, G				BATES, S; PARRY, D; BONETTA, L; VOUSDEN, K; DICKSON, C; PETERS, G			ABSENCE OF CYCLIN-D CDK COMPLEXES IN CELLS LACKING FUNCTIONAL RETINOBLASTOMA PROTEIN	ONCOGENE			English	Article							LARGE TUMOR-ANTIGEN; HUMAN BREAST-CANCER; GENE-PRODUCT; DEPENDENT KINASES; RB GENE; P53; LINES; ASSOCIATION; PHOSPHORYLATION; EXPRESSION	Cyclins D1, D2 and D3 are thought to function in the G1 phase of the cell division cycle by regulating the activity of cyclin-dependent protein kinases. All three D-type cyclins can be shown to associate with two specific kinases, cdk4 and cdk6, providing at least six possible combinations. To establish whether different cell types require different subsets of these complexes and whether they are altered in tumours where D-cyclin expression is perturbed, we surveyed a series of tumour cell lines and compared them where possible to non-tumorigenic counterparts. Although complexes involving cdk4 or cdk6 were readily observed in many of the cell lines, no complexes were detectable in human cells harbouring, DNA tumour virus oncoproteins or in which the retinblastoma gene product (pRb) is mutated or missing. These data suggest that as well as being a potential substrate for D-cyclin-kinases, functional pRb contributes to the formation or stability of the complexes, at least in human cells.	IMPERIAL CANC RES FUND, LONDON WC2A 3PX, ENGLAND; ST MARYS HOSP, SCH MED, LUDWIG INST CANC RES, LONDON W2 1PG, ENGLAND	Cancer Research UK; Imperial College London; Ludwig Institute for Cancer Research								AKIYAMA T, 1992, P NATL ACAD SCI USA, V89, P7900, DOI 10.1073/pnas.89.17.7900; BARTEK J, 1991, P NATL ACAD SCI USA, V88, P3520, DOI 10.1073/pnas.88.9.3520; BARTEK J, 1990, ONCOGENE, V5, P893; BATES S, 1994, ONCOGENE, V9, P71; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; CROOK T, 1992, LANCET, V339, P1070, DOI 10.1016/0140-6736(92)90662-M; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FANTL V, 1994, IN PRESS CANCER SURV, V18; FAUST JB, 1992, CANCER RES, V52, P2460; GOLDFARB M, 1991, ONCOGENE, V6, P65; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HALL FL, 1993, ONCOGENE, V8, P1377; HARPER JW, 1993, CELL, V75, P805; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; HIEBERT SW, 1993, MOL CELL BIOL, V13, P3384, DOI 10.1128/MCB.13.6.3384; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; KATO J, 1993, GENE DEV, V7, P331; KHATIB ZA, 1993, CANCER RES, V53, P5535; LAMMIE GA, 1991, CANCER CELL-MON REV, V3, P413; LAMMIE GA, 1991, ONCOGENE, V6, P439; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; LEHMAN TA, 1993, CARCINOGENESIS, V14, P833, DOI 10.1093/carcin/14.5.833; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; LUKAS J, 1994, ONCOGENE, V9, P707; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MORGAN C, 1987, J CELL PHYSIOL, V130, P420, DOI 10.1002/jcp.1041300316; MOTOKURA T, 1993, BIOCHIM BIOPHYS ACTA, V1155, P63, DOI 10.1016/0304-419X(93)90022-5; Nigg EA, 1993, CURR OPIN CELL BIOL, V5, P187, DOI 10.1016/0955-0674(93)90101-U; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; OOKAWA K, 1993, ONCOGENE, V8, P2175; PALMERO I, 1993, ONCOGENE, V8, P1049; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SCHUURING E, 1992, ONCOGENE, V7, P355; SOULE HD, 1990, CANCER RES, V50, P6075; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; TSAI LH, 1993, ONCOGENE, V8, P1593; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WREDE D, 1991, MOL CARCINOGEN, V4, P171, DOI 10.1002/mc.2940040302; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	55	195	203	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1994	9	6					1633	1640						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NL815	8183557				2022-12-25	WOS:A1994NL81500014
J	OGAWA, S; TOYOSHIMA, H; KOZUTSUMI, H; HAGIWARA, K; SAKAI, R; TANAKA, T; HIRANO, N; MANO, H; YAZAKI, Y; HIRAI, H				OGAWA, S; TOYOSHIMA, H; KOZUTSUMI, H; HAGIWARA, K; SAKAI, R; TANAKA, T; HIRANO, N; MANO, H; YAZAKI, Y; HIRAI, H			THE C-TERMINAL SH3 DOMAIN OF THE MOUSE C-CRK PROTEIN NEGATIVELY REGULATES TYROSINE-PHOSPHORYLATION OF CRK ASSOCIATED P130 IN RAT 3Y1 CELLS	ONCOGENE			English	Article							PHOSPHOTYROSINE-CONTAINING PROTEINS; GUANINE-NUCLEOTIDE EXCHANGE; V-CRK; SIGNAL TRANSDUCTION; PHOSPHOLIPASE-C; ONCOGENE PRODUCT; ADAPTER PROTEIN; SARCOMA-VIRUS; RECEPTOR; KINASE	We have isolated the mouse c-crk cDNA from a mouse liver cDNA library. It encodes 304 amino acids and consists mainly of SH2/SH3 regions. In Northern blot analysis, the mouse c-crk mRNA is expressed ubiquitously in every tissue and organ, suggesting that the c-Crk protein may be a common signal transducing molecule among tissues. In contrast to the v-Crk protein, which has a single SH3 domain, the c-Crk protein contains two, the more N-terminal SH3(1) domain and the C-terminal SH3(2) domain. To elucidate functions of these SH3 domains, we have constructed two c-crk mutants, B-cuk and D-crk which lack the SH3(2) and the SH3(1) domain, respectively. These mutants were expressed in rat 3Y1 cells, and examined for their transforming ability in terms of morphological phenotypes and for tyrosine phosphorylation profiles of cells expressing the mutant proteins. Morphological alteration and increased tyrosine phosphorylation of 130-140 kDa proteins, the major component of which is the Crk-associated p130, were observed in cells expressing B-Crk as well as those expressing v-Crk, but little in cells expressing c-Crk even at a similar level of expression. Although a highly tyrosine-phosphorylated form of the p130 was coimmunoprecipitated with c-Crk as well as B-Crk, the relative level of tyrosine phosphorylation of the p130, which is normalized to the amount of Crk protein immunoprecipitated, was 10 to 20 times higher in B-Crk-expressing cells than in c-Crk- or D-Crk-expressing cells. The present results indicate that the SH3(2) domain of mouse c-Crk protein negatively regulates tyrosine phosphorylation of the p130, and that lack of the SH3(2) domain in B-Crk and v-Crk may contribute, at least partly, to their morphological alteration or transforming ability through increasing tyrosine phosphorylation of the p130.	UNIV TOKYO,FAC MED,DEPT INTERNAL MED 3,TOKYO 113,JAPAN; JICHI MED SCH,DEPT MOLEC BIOL,MINAMI KAWACHI,TOCHIGI,JAPAN	University of Tokyo; Jichi Medical University				Sakai, Ryuichi/0000-0001-6833-1103				BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DRUBIN DG, 1990, NATURE, V343, P288, DOI 10.1038/343288a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; EMORI Y, 1989, J BIOL CHEM, V264, P21885; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FRANZ WM, 1989, EMBO J, V8, P137, DOI 10.1002/j.1460-2075.1989.tb03358.x; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GISH GD, 1992, CELL, V71, P359; HIRAI H, 1990, MOL CELL BIOL, V10, P1307, DOI 10.1128/MCB.10.4.1307; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; KATO JY, 1986, MOL CELL BIOL, V6, P4155, DOI 10.1128/MCB.6.12.4155; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; LETO TL, 1990, SCIENCE, V248, P727, DOI 10.1126/science.1692159; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MATSUDA M, 1993, J BIOL CHEM, V268, P4441; MATSUDA M, 1991, MOL CELL BIOL, V11, P1607, DOI 10.1128/MCB.11.3.1607; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; MAYER BJ, 1990, J VIROL, V64, P3581, DOI 10.1128/JVI.64.8.3581-3589.1990; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MAYER BJ, 1990, P NATL ACAD SCI USA, V87, P2638, DOI 10.1073/pnas.87.7.2638; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PAWSON T, 1988, ONCOGENE, V3, P491; POTTS MW, 1987, J VIROL, V60, P494; Potts W M, 1988, Oncogene Res, V3, P343; REICHMAN CT, 1992, CELL GROWTH DIFFER, V3, P451; RODAWAY ARF, 1989, NATURE, V342, P624, DOI 10.1038/342624a0; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SABE H, 1992, MOL CELL BIOL, V12, P4706, DOI 10.1128/MCB.12.10.4706; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; STAHL ML, 1988, NATURE, V332, P113; SUH PG, 1988, P NATL ACAD SCI USA, V85, P5419, DOI 10.1073/pnas.85.15.5419; TRAHEY M, 1988, SCIENCE, V242, P1692; TSUCHIE H, 1989, ONCOGENE, V4, P1281; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WASENIUS VM, 1989, J CELL BIOL, V108, P79, DOI 10.1083/jcb.108.1.79	42	50	52	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1994	9	6					1669	1678						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NL815	8183562				2022-12-25	WOS:A1994NL81500019
J	TSUBOI, S; MATSUMOTO, H; YAMAZAKI, A				TSUBOI, S; MATSUMOTO, H; YAMAZAKI, A			PHOSPHORYLATION OF AN INHIBITORY SUBUNIT OF CGMP PHOSPHODIESTERASE IN RANA-CATESBIANA ROD PHOTORECEPTORS .2. A POSSIBLE MECHANISM FOR THE TURNOFF OF CGMP PHOSPHODIESTERASE WITHOUT GTP HYDROLYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-GMP PHOSPHODIESTERASE; OUTER SEGMENTS; G-PROTEIN; BINDING PROTEIN; TRANSDUCIN; DEPHOSPHORYLATION; PHOSPHATASES; DEACTIVATION; ACTIVATION; KINETICS	In amphibian rod photoreceptor membranes, P gamma, an inhibitory subunit of cGMP phosphodiesterase, is phosphorylated by a protein kinase when P gamma is complexed with the guanosine 5'-O-(3-thiotriphosphate)-bound alpha subunit of transducin (GTP gamma S T alpha). Five different experiments support the conclusion that the phosphorylated P gamma loses its interaction with GTP gamma S.T alpha. These observations include 1) detection of the inhibitory effect of the GTP gamma S.T alpha.P gamma complex on cGMP phosphodiesterase activity after P gamma in the complex is phosphorylated in a system reconstituted from isolated components, 2) no stimulating effect of GTP gamma S.T alpha on the phosphorylated P gamma-inhibited cGMP phosphodiesterase in the reconstituted system, 3) physical release of phosphorylated P gamma from GTP gamma S.T alpha in the reconstituted system, 4) no inhibitory effect of phosphorylated P gamma on both GTP hydrolysis by T alpha and GTP gamma S/GDP exchange on T alpha in the reconstituted system, and 5) no enhanced activity of cGMP phosphodiesterase by GTP gamma S.T alpha in rod outer segment membranes after incubation of the membranes with the kinase preparation in the presence of ATP. Together with our data that P gamma released with GTP.T alpha is not phosphorylated, and that phosphorylated P gamma inhibits more effectively cGMP phosphodiesterase activity than nonphosphorylated Py (Tsuboi, S., Matsumoto, H., Jackson, K. W., Tsujimoto, K., Williams, T., and Yamazaki, A (1994) J. Biol. Chem. 269, 15016-15023), these observations suggest that, after P gamma is released with GTP.T alpha from catalytic subunits of cGMP phosphodiesterase, P gamma complexed with GTP.T alpha is phosphorylated by a kinase. Then, the phosphorylated P gamma is released from GTP.T alpha and binds to active cGMP phosphodiesterase to inhibit the cGMP hydrolysis. It is suggested that in some G-protein-dependent signal transduction systems G-protein-activated effector may be phosphorylated with a specific kinase and that phosphorylation of the effector results in the turnoff of signal transduction without GTP hydrolysis.	WAYNE STATE UNIV, SCH MED, KRESGE EYE INST, DEPT OPHTHALMOL, DETROIT, MI 48201 USA; WAYNE STATE UNIV, SCH MED, KRESGE EYE INST, DEPT PHARMACOL, DETROIT, MI 48201 USA; UNIV OKLAHOMA, HLTH SCI CTR, DEPT BIOCHEM & MOLEC BIOL, OKLAHOMA CITY, OK 73190 USA	Wayne State University; Wayne State University; University of Oklahoma System; University of Oklahoma Health Sciences Center					NATIONAL EYE INSTITUTE [R01EY009631, R01EY007546] Funding Source: NIH RePORTER; NEI NIH HHS [EY 06595, EY 07546, EY 09631] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANGLESON JK, 1992, INVEST OPHTH VIS SCI, V33, P1103; ANTONNY B, 1993, BIOCHEMISTRY-US, V32, P8646, DOI 10.1021/bi00084a036; ARSHAVSKY VY, 1992, J BIOL CHEM, V267, P24501; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLACK JW, 1983, NATURE, V305, P50, DOI 10.1038/305050a0; COHEN P, 1989, FEBS LETT, V250, P596, DOI 10.1016/0014-5793(89)80803-8; ERICKSON MA, 1992, SCIENCE, V257, P1255, DOI 10.1126/science.1519062; FOWLES C, 1989, BIOCHEMISTRY-US, V28, P9385, DOI 10.1021/bi00450a020; HARGRAVE PA, 1992, INT REV CYTOL, V137B, P49; HAYASHI F, 1991, P NATL ACAD SCI USA, V88, P4333, DOI 10.1073/pnas.88.10.4333; HURLEY JB, 1982, J BIOL CHEM, V257, P1094; HURLEY JB, 1987, ANNU REV PHYSIOL, V49, P793; MILLER WH, 1990, INVEST OPHTH VIS SCI, V31, P1664; MORRISON DF, 1989, J BIOL CHEM, V264, P11671; OTTOBRUC A, 1993, BIOCHEMISTRY-US, V32, P8636, DOI 10.1021/bi00084a035; PALCZEWSKI K, 1989, J BIOL CHEM, V264, P15770; PUGH EN, 1993, BIOCHIM BIOPHYS ACTA, V1141, P111, DOI 10.1016/0005-2728(93)90038-H; SITARAMAYYA A, 1988, BIOCHEMISTRY-US, V27, P4880, DOI 10.1021/bi00413a044; STRYER L, 1986, ANNU REV CELL BIOL, V2, P391, DOI 10.1146/annurev.cb.02.110186.002135; TING TD, 1991, BIOCHEMISTRY-US, V30, P8996, DOI 10.1021/bi00101a013; TSUBOI S, 1994, J BIOL CHEM, V269, P15016; UMBARGER KO, 1992, J BIOL CHEM, V267, P19494; YAMAZAKI A, 1982, P NATL ACAD SCI-BIOL, V79, P3702, DOI 10.1073/pnas.79.12.3702; YAMAZAKI A, 1983, J BIOL CHEM, V258, P8188; YAMAZAKI A, 1990, J BIOL CHEM, V265, P11539; YAMAZAKI A, 1993, J BIOL CHEM, V268, P8899; YAMAZAKI A, 1987, J BIOL CHEM, V262, P9316; YAMAZAKI A, 1992, ADV SEC MESS PHOSPH, V25, P135; YAU KW, 1989, ANNU REV NEUROSCI, V12, P289, DOI 10.1146/annurev.ne.12.030189.001445	29	37	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					15024	15029						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195139				2022-12-25	WOS:A1994NP73800030
J	DEMARTINO, JA; VANRIPER, G; SICILIANO, SJ; MOLINEAUX, CJ; KONTEATIS, ZD; ROSEN, H; SPRINGER, MS				DEMARTINO, JA; VANRIPER, G; SICILIANO, SJ; MOLINEAUX, CJ; KONTEATIS, ZD; ROSEN, H; SPRINGER, MS			THE AMINO-TERMINUS OF THE HUMAN C5A RECEPTOR IS REQUIRED FOR HIGH-AFFINITY C5A BINDING AND FOR RECEPTOR ACTIVATION BY C5A BUT NOT C5A ANALOGS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; INTERLEUKIN-8 RECEPTOR; ANAPHYLATOXIN C5A; MOLECULAR-CLONING; LIGAND-BINDING; IDENTIFICATION; EXPRESSION; ANTIBODIES; SITE; MECHANISM	The binding domain of the human C5a receptor consists of two distinct and physically separable subsites. One of these sites binds the C-terminal 8 amino acids of C5a and is as yet undefined, while the second site lies in the N terminus of the receptor and interacts with the core of C5a. Two deletion mutants were prepared to probe the importance of this second site. Removal of residues 2-22 decreased the binding affinity for C5a by 600-fold, while extending the deletion through residue 30 caused a further 75-fold decrease. Thus, the N terminus is responsible for at least 45% of the total energy for the binding of C5a. The five aspartic acids present in the deleted segments appear to be critical residues, as their conversion to alanines accounts for most of the affinity lost in the two truncations. Despite its importance for binding, the N terminus is not necessary for signal transduction, as a C-terminal peptide analog of C5a was able to stimulate G protein activation and to generate a Ca2+ flux through a receptor lacking residues 2-22. However, intact C5a was a very poor activator of this truncated receptor. These results imply that interaction between the N terminus of the receptor and C5a produces a conformational change in C5a that allows it's C terminus to properly interact with and activate the receptor.	MERCK SHARP & DOHME LTD,RES LABS,DEPT IMMUNOL RES,RAHWAY,NJ 07065; MERCK SHARP & DOHME LTD,RES LABS,DEPT BIOCHEM & MOLEC PATHOL,RAHWAY,NJ 07065; MERCK SHARP & DOHME LTD,RES LABS,DEPT ANALYT BIOCHEM,RAHWAY,NJ 07065	Merck & Company; Merck & Company; Merck & Company								BOULAY F, 1991, BIOCHEMISTRY-US, V30, P2993, DOI 10.1021/bi00226a002; DEMARTINO JA, 1991, ANTIBODY IMMUNOCONJ, V4, P829; DIXON RAF, 1987, NATURE, V326, P73, DOI 10.1038/326073a0; FINDLAY JBC, 1986, BIOCHEM J, V238, P625, DOI 10.1042/bj2380625; GAYLE RB, 1993, J BIOL CHEM, V268, P7283; GERARD C, 1992, J IMMUNOL, V149, P2600; GERARD NP, 1991, NATURE, V349, P614, DOI 10.1038/349614a0; GOLDSTEIN IM, 1988, INFLAMMATION BASIC P, P55; HUGLI TE, 1984, SPRINGER SEMIN IMMUN, V7, P193; KAWAI M, 1991, J MED CHEM, V34, P2068, DOI 10.1021/jm00111a022; KAWAI M, 1990, WO9009162 WORLD INTE; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KUPPER RW, 1992, BIOCHEM J, V282, P429, DOI 10.1042/bj2820429; LAROSA GJ, 1992, J BIOL CHEM, V267, P25402; MOLLISON KW, 1989, P NATL ACAD SCI USA, V86, P292, DOI 10.1073/pnas.86.1.292; MORGAN EL, 1993, J IMMUNOL, V151, P377; OPPERMANN M, 1993, J IMMUNOL, V151, P3785; PERRET JJ, 1992, BIOCHEM J, V288, P911, DOI 10.1042/bj2880911; ROLLINS TE, 1988, J BIOL CHEM, V263, P520; SCARBOROUGH RM, 1992, J BIOL CHEM, V267, P13146; SICILIANO SJ, 1994, P NATL ACAD SCI USA, V91, P1214, DOI 10.1073/pnas.91.4.1214; SIRAGANIAN RP, 1982, FED PROC, V41, P30; STRADER CD, 1989, FASEB J, V3, P1825, DOI 10.1096/fasebj.3.7.2541037; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; XIE YB, 1990, J BIOL CHEM, V265, P21411; ZUIDERWEG ERP, 1989, BIOCHEMISTRY-US, V28, P172, DOI 10.1021/bi00427a025	26	105	108	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14446	14450						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	8182049				2022-12-25	WOS:A1994NM06500024
J	HERTZOG, PJ; HWANG, SY; HOLLAND, KA; TYMMS, MJ; IANNELLO, R; KOLA, I				HERTZOG, PJ; HWANG, SY; HOLLAND, KA; TYMMS, MJ; IANNELLO, R; KOLA, I			A GENE ON HUMAN-CHROMOSOME-21 LOCATED IN THE REGION 21Q22.2 TO 21Q22.3 ENCODES A FACTOR NECESSARY FOR SIGNAL-TRANSDUCTION AND ANTIVIRAL RESPONSE TO TYPE-I INTERFERONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA RECEPTOR GENE; TYROSINE KINASE; MESSENGER-RNA; HUMAN-CELLS; PROTEIN; BINDING; EXPRESSION; SUBTYPES; FAMILY; ASSAYS	The type I interferons (IFNs) are a family of multifunctional cytokines which includes the 15 IFN alpha subtypes and IFN beta. These IFNs compete for binding to cell surface receptors. However, murine cells transfected with a cDNA for a human IFN alpha receptor (IFNAR) developed an antiviral response only to human IFN alpha B, but not to human IFN alpha 2 nor -beta(1). In this study we show, using a panel of CHO human chromosome 21 hybrid cell lines which all express IFNAR, that only those containing the region 21q22.2 to 21q22.3 transduce signals for IFN responses. Two such hybrid cell lines responded to IFNs alpha 2, -alpha B and -beta by induction of 2'-5' oligoadenylate synthetase and resistance to viral infection. Other hybrid cell lines, that lacked the region 21q22.2-3, failed to transduce signals as above; even though they expressed IFNAR and bound human IFN alpha 2, -alpha B, and -beta. These data demonstrate that a gene(s) located in the region 21q22.2-3 encodes a factor(s) which is necessary for signaling but does not influence ligand binding. This factor is not the cofactor required for IFN gamma signaling which is located in the region 21p to 21q22.1(2).			HERTZOG, PJ (corresponding author), MONASH MED CTR,INST REPROD & DEV,MOLEC EMBRYOL & BIRTH DEFECTS LAB,CLAYTON,VIC 3168,AUSTRALIA.		Kola, Ismail/C-5254-2013; Hertzog, Paul/I-7053-2013	Hertzog, Paul/0000-0002-1373-8472				BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6931; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHUMAKOV I, 1992, NATURE, V359, P380, DOI 10.1038/359380a0; COLAMONICI OR, 1993, J BIOL CHEM, V268, P10895; DEHAAN JB, 1992, MOL BRAIN RES, V13, P179, DOI 10.1016/0169-328X(92)90025-7; FIRMBACHKRAFT I, 1990, ONCOGENE, V5, P1329; FISH EN, 1983, BIOCHEM BIOPH RES CO, V112, P537, DOI 10.1016/0006-291X(83)91498-5; FU XY, 1992, P NATL ACAD SCI USA, V89, P7840, DOI 10.1073/pnas.89.16.7840; GARDINER K, 1990, EMBO J, V9, P25, DOI 10.1002/j.1460-2075.1990.tb08076.x; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; Hemmi S., 1993, Journal of Interferon Research, V13, pS55; HERTZOG PJ, 1988, CLIN IMMUNOL IMMUNOP, V48, P192, DOI 10.1016/0090-1229(88)90083-9; JUNG V, 1990, J BIOL CHEM, V265, P1827; LANGER JA, 1990, SOMAT CELL MOLEC GEN, V16, P231, DOI 10.1007/BF01233359; LANGER JA, 1988, IMMUNOL TODAY, V9, P393, DOI 10.1016/0167-5699(88)91241-8; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; LOVELAND BE, 1992, BIOCHEM INT, V27, P501; LUTFALLA G, 1990, J INTERFERON RES, V10, P515, DOI 10.1089/jir.1990.10.515; MOGENSEN KE, 1986, METHOD ENZYMOL, V119, P267; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MUNSON PJ, 1983, METHOD ENZYMOL, V92, P543; NICOLA NA, 1991, CELL, V67, P1, DOI 10.1016/0092-8674(91)90564-F; OROURKE EC, 1984, MOL CELL BIOL, V4, P2745, DOI 10.1128/MCB.4.12.2745; OVERALL ML, 1992, MOL IMMUNOL, V29, P391, DOI 10.1016/0161-5890(92)90027-U; PATTERSON D, 1993, GENOMICS, V15, P177, DOI 10.1006/geno.1993.1026; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; PLATANIAS LC, 1993, J IMMUNOL, V150, P3382; PRITCHARD MA, 1992, MAMM GENOME, V3, P36, DOI 10.1007/BF00355839; ROBERTS RM, 1991, GROWTH FACTORS REPRO, P235; SHULMAN L, 1980, NATURE, V288, P98, DOI 10.1038/288098a0; Soh Jaemong, 1993, Journal of Interferon Research, V13, pS55; Staeheli P, 1990, Adv Virus Res, V38, P147, DOI 10.1016/S0065-3527(08)60862-3; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WEIL J, 1980, J INTERFERON RES, V1, P111, DOI 10.1089/jir.1980.1.111; WEISSMANN C, 1986, PROG NUCLEIC ACID RE, V33, P251, DOI 10.1016/S0079-6603(08)60026-4	37	35	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					14088	14093						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188689				2022-12-25	WOS:A1994NL60600056
J	NAGANO, M; KELLY, PA				NAGANO, M; KELLY, PA			TISSUE DISTRIBUTION AND REGULATION OF RAT PROLACTIN RECEPTOR GENE-EXPRESSION - QUANTITATIVE-ANALYSIS BY POLYMERASE CHAIN-REACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-HORMONE; MESSENGER-RNA; MOLECULAR-CLONING; ADRENAL-MEDULLA; MULTIPLE FORMS; MAMMARY-GLAND; BINDING-SITES; FEMALE RATS; LIVER; CELLS	The rat prolactin receptor (PRLR) exists as two forms, short and long. We have developed a quantitative polymerase chain reaction (Q-PCR) in order to measure the absolute number of mRNA molecules encoding both forms of PRLR in 16 tissues of adult female rats at two stages of the estrous cycle (proestrus and diestrus I) and in the mammary gland of 20-day pregnant and 7-day lactating rats. Using this technique, it was possible to detect as few as 500 molecules of a target mRNA per mu g of total RNA. All tissues examined expressed the two forms of receptor transcripts, ranging from 1.8 x 10(3) molecules/mu g of total RNA in the skeletal muscle to 2.9 x 10(7) molecules/mu g of total RNA in the ovary. Fourteen tissues expressed the long form mRNA predominantly, the thymus and the kidney expressed both forms equally, and the liver expressed the short form predominantly. In the liver, the level of mRNA expression of the short form was similar to 2-fold higher in proestrus than in diestrus. In the ovary, uterus, and cerebral cortex, the expression of the long form transcript was higher in proestrus than in diestrus: 4-fold in the ovary, 2.8-fold in the uterus, and 1.4-fold in the cerebral cortex. In contrast, the hypothalamus and the pituitary expressed 1.6-fold more long form transcript in diestrus than in proestrus. These results indicate that PRLR mRNA is ubiquitously but variably expressed in a tissue-specific manner and is clearly regulated by the hormonal environment associated with the stage of the estrous cycle, pregnancy, and lactation.	FAC MED NECKER ENFANTS MALAD, INSERM, U344, F-75015 PARIS, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite			Kelly, Paul/A-7951-2008					ALBERTSON BD, 1987, ENDOCR RES, V13, P317, DOI 10.1080/07435808709035461; ALI S, 1991, J BIOL CHEM, V266, P20110; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BOUTIN JM, 1988, CELL, V53, P69, DOI 10.1016/0092-8674(88)90488-6; BOUTIN JM, 1989, MOL ENDOCRINOL, V3, P1455, DOI 10.1210/mend-3-9-1455; BUCK K, 1992, ENDOCRINOLOGY, V130, P1108, DOI 10.1210/en.130.3.1108; BUTCHER RL, 1974, ENDOCRINOLOGY, V94, P1704, DOI 10.1210/endo-94-6-1704; CHEUNG CY, 1990, BIOGENIC AMINES, V7, P315; CHIU S, 1992, ENDOCRINOLOGY, V130, P1747, DOI 10.1210/en.130.3.1747; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARKE DL, 1993, ENDOCRINOLOGY, V133, P224, DOI 10.1210/en.133.1.224; CLARKE DL, 1993, ENDOCRINOLOGY, V133, P2594, DOI 10.1210/en.133.6.2594; COSMAN D, 1993, CYTOKINE, V5, P95, DOI 10.1016/1043-4666(93)90047-9; DAVIS JA, 1989, MOL ENDOCRINOL, V3, P674, DOI 10.1210/mend-3-4-674; DUSANTERFOURT I, 1992, ENDOCRINOLOGY, V130, P2877, DOI 10.1210/en.130.5.2877; EDERY M, 1989, P NATL ACAD SCI USA, V86, P2112, DOI 10.1073/pnas.86.6.2112; FERNANDEZRUIZ J, 1987, NEUROENDOCRINOLOGY, V45, P208, DOI 10.1159/000124727; GLOWINSKI J, 1966, J NEUROCHEM, V13, P655, DOI 10.1111/j.1471-4159.1966.tb09873.x; HERNANDEZ ML, 1991, J ENDOCRINOL INVEST, V14, P201, DOI 10.1007/BF03346789; HOEFFLER JP, 1987, ENDOCRINOLOGY, V120, P1679, DOI 10.1210/endo-120-4-1679; HOLT JA, 1976, ENDOCRINOLOGY, V98, P1005, DOI 10.1210/endo-98-4-1005; HU ZZ, 1991, BIOCHEM BIOPH RES CO, V181, P219, DOI 10.1016/S0006-291X(05)81405-6; JAHN GA, 1991, ENDOCRINOLOGY, V128, P2976, DOI 10.1210/endo-128-6-2976; JOLICOEUR C, 1989, MOL ENDOCRINOL, V3, P895, DOI 10.1210/mend-3-6-895; KELLY PA, 1975, ENDOCRINOLOGY, V97, P1408, DOI 10.1210/endo-97-6-1408; KELLY PA, 1993, RECENT PROG HORM RES, V48, P123; KELLY PA, 1991, ENDOCR REV, V12, P235, DOI 10.1210/edrv-12-3-235; KELLY PA, 1990, HORMONES, P191; KHARROUBI AT, 1984, ENDOCRINOLOGY, V115, P1283, DOI 10.1210/endo-115-4-1283; LESUEUR L, 1991, P NATL ACAD SCI USA, V88, P824, DOI 10.1073/pnas.88.3.824; MARSHALL S, 1978, ENDOCRINOLOGY, V102, P869, DOI 10.1210/endo-102-3-869; MEITES J, 1988, INT CONGR SER, V819, P123; MICK CCW, 1985, ENDOCRINOLOGY, V116, P2049, DOI 10.1210/endo-116-5-2049; MURPHY LD, 1990, BIOCHEMISTRY-US, V29, P10351, DOI 10.1021/bi00497a009; Nicoll C.S., 1972, LACTOGENIC HORMONES, P299; NICOLL CS, 1988, INT CONGR SER, V819, P349; NIELSEN JH, 1982, ENDOCRINOLOGY, V110, P600, DOI 10.1210/endo-110-2-600; OUHTIT A, 1993, ENDOCRINOLOGY, V133, P135, DOI 10.1210/en.133.1.135; OUHTIT A, 1993, BIOL REPROD, V49, P528, DOI 10.1095/biolreprod49.3.528; OUHTIT A, 1994, IN PRESS AM J PHYSL; PELLEGRINI I, 1992, MOL ENDOCRINOL, V6, P1023, DOI 10.1210/me.6.7.1023; PIPPARD C, 1986, J ENDOCRINOL, V108, P95, DOI 10.1677/joe.0.1080095; RICHARDS JS, 1976, ENDOCRINOLOGY, V99, P1571, DOI 10.1210/endo-99-6-1571; ROBERTSON MT, 1986, ENDOCRINOLOGY, V119, P2439, DOI 10.1210/endo-119-6-2439; ROZAKISADCOCK M, 1991, J BIOL CHEM, V266, P16472; RUSSELL DH, 1988, INT CONGR SER, V819, P155; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCOTT P, 1992, MOL CELL ENDOCRINOL, V89, P47, DOI 10.1016/0303-7207(92)90210-W; SHIROTA M, 1990, MOL ENDOCRINOL, V4, P1136, DOI 10.1210/mend-4-8-1136; SOARES MJ, 1991, ENDOCR REV, V12, P402, DOI 10.1210/edrv-12-4-402; SORENSON RL, 1987, ENDOCRINOLOGY, V121, P1447, DOI 10.1210/endo-121-4-1447; TANAKA M, 1992, BIOCHEM BIOPH RES CO, V188, P490, DOI 10.1016/0006-291X(92)91082-2; TAYA K, 1981, ENDOCRINOLOGY, V108, P2324, DOI 10.1210/endo-108-6-2324; VANDERSCHOOT P, 1983, J ENDOCRINOL, V97, P83, DOI 10.1677/joe.0.0970083; VILLALBA M, 1991, ENDOCRINOLOGY, V129, P2857, DOI 10.1210/endo-129-6-2857; WALSH RJ, 1987, ENDOCRINOLOGY, V120, P1846, DOI 10.1210/endo-120-5-1846; WANG AM, 1989, P NATL ACAD SCI USA, V86, P9717, DOI 10.1073/pnas.86.24.9717; ZHANG R, 1990, BIOCHEM BIOPH RES CO, V168, P415, DOI 10.1016/0006-291X(90)92337-Y	60	246	251	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13337	13345						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175764				2022-12-25	WOS:A1994NK18400045
J	SU, TT; MCCLURE, WR				SU, TT; MCCLURE, WR			SELECTIVE BINDING OF ESCHERICHIA-COLI RNA-POLYMERASE TO TOPOISOMERS OF MINICIRCLES CARRYING THE TAC16 AND TAC17 PROMOTERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC RECOMBINATION; GEL-ELECTROPHORESIS; TRANSCRIPTION INITIATION; ACTIVATOR PROTEIN; DNA MINICIRCLES; INVITRO; INVIVO; HELIX; PURIFICATION; INHIBITION	We have studied the effect of DNA supercoliing on open complex formation by Escherichia coli RNA polymerase at the TAC16 and TAC17 promoters. A two dimensional gel retardation assay was used to measure the relative rate of association between RNA polymerase and the TAC promoters on individual topoisomers. Plasmid DNAs usually have several promoters that complicate the analysis of RNA polymerase binding to only one of them. We avoided this problem by using minicircles of DNA carrying only a single promoter. These were generated in vivo by the site-specific recombination system of bacteriophage lambda. Both the TAC16 and TAC17 promoters exhibited a biphasic response to negative supercoliing. Between superhelical densities of 0 and -0.04, increases in the negative linking difference favored binding. Beyond -0.04, either no effect on binding (TAC16) or a slight inhibition of binding (TAC17) was observed for increases in the negative linking difference. The unwinding at the rate-limiting step was calculated for both TAC promoters at moderate superhelical densities. This unwinding was found to be a fraction (about 20-30%) of the total unwinding measured by topoisomerase I relaxation (about one turn). In addition, the 1-base pair difference in spacer length between the TAC16 and TAC17 promoters resulted in different extents of activation and inhibition by negative supercoliing.	CARNEGIE MELLON UNIV, DEPT BIOL SCI, PITTSBURGH, PA 15213 USA	Carnegie Mellon University					NIGMS NIH HHS [GM30375] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030375] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADRIAN M, 1990, EMBO J, V9, P4551, DOI 10.1002/j.1460-2075.1990.tb07907.x; AMOUYAL M, 1987, J MOL BIOL, V195, P795, DOI 10.1016/0022-2836(87)90485-2; BACKMAN K, 1984, BIO-TECHNOL, V2, P1045, DOI 10.1038/nbt1284-1045; BAUER W, 1968, J MOL BIOL, V33, P141, DOI 10.1016/0022-2836(68)90286-6; BAUER W, 1970, Journal of Molecular Biology, V47, P419, DOI 10.1016/0022-2836(70)90312-8; BEARD P, 1984, EUR J BIOCHEM, V143, P39, DOI 10.1111/j.1432-1033.1984.tb08336.x; BERTRANDBURGGRAF E, 1990, EMBO J, V9, P2265, DOI 10.1002/j.1460-2075.1990.tb07397.x; BERTRANDBURGGRAF E, 1984, NUCLEIC ACIDS RES, V12, P7741, DOI 10.1093/nar/12.20.7741; BLISKA JB, 1987, J MOL BIOL, V194, P205, DOI 10.1016/0022-2836(87)90369-X; BLUMENTHAL T, 1973, BIOCHEM BIOPH RES CO, V55, P680, DOI 10.1016/0006-291X(73)91198-4; BOFFINI A, 1991, NUCLEIC ACIDS RES, V19, P1369, DOI 10.1093/nar/19.7.1369; BOROWIEC JA, 1987, J MOL BIOL, V195, P89, DOI 10.1016/0022-2836(87)90329-9; BOROWIEC JA, 1985, J MOL BIOL, V184, P587, DOI 10.1016/0022-2836(85)90305-5; BRAHMS JG, 1985, J MOL BIOL, V181, P455, DOI 10.1016/0022-2836(85)90419-X; Buc H., 1992, NUCLEIC ACIDS MOL BI, V6, P23, DOI [10.1007/978-3-642-77356-3_2, DOI 10.1007/978-3-642-77356-3_2]; BURGESS RR, 1975, BIOCHEMISTRY-US, V14, P4634, DOI 10.1021/bi00692a011; CALLADINE CR, 1988, J MOL BIOL, V201, P127, DOI 10.1016/0022-2836(88)90444-5; CHAMBERLIN MJ, 1974, ANNU REV BIOCHEM, V43, P721, DOI 10.1146/annurev.bi.43.070174.003445; COUREY AJ, 1988, J MOL BIOL, V202, P35, DOI 10.1016/0022-2836(88)90516-5; DAVIDSON N, 1972, J MOL BIOL, V66, P307, DOI 10.1016/0022-2836(72)90482-2; DEPEW RE, 1975, P NATL ACAD SCI USA, V72, P4275, DOI 10.1073/pnas.72.11.4275; DOUCRASY S, 1989, NUCLEIC ACIDS RES, V17, P5173, DOI 10.1093/nar/17.13.5173; DRLICA K, 1984, MICROBIOL REV, V48, P273, DOI 10.1128/MMBR.48.4.273-289.1984; DUNN JJ, 1983, J MOL BIOL, V166, P477, DOI 10.1016/S0022-2836(83)80282-4; GAMPER HB, 1982, CELL, V29, P81, DOI 10.1016/0092-8674(82)90092-7; GILBERTOGONZALEZ R, 1980, BIOCHEMISTRY-US, V19, P4299, DOI 10.1021/bi00559a023; HAWLEY DK, 1982, J MOL BIOL, V157, P493, DOI 10.1016/0022-2836(82)90473-9; HOROWITZ DS, 1984, J MOL BIOL, V173, P75, DOI 10.1016/0022-2836(84)90404-2; KELLER W, 1975, P NATL ACAD SCI USA, V72, P4876, DOI 10.1073/pnas.72.12.4876; KLENIN KV, 1991, J MOL BIOL, V217, P413, DOI 10.1016/0022-2836(91)90745-R; LEE CH, 1981, P NATL ACAD SCI-BIOL, V78, P2838, DOI 10.1073/pnas.78.5.2838; LILLEY D, 1986, NATURE, V320, P14, DOI 10.1038/320014a0; LOWE PA, 1979, BIOCHEMISTRY-US, V18, P1344, DOI 10.1021/bi00574a034; Maniatis T., 1982, MOL CLONING LABORATO, P86; MCCLURE WR, 1985, ANNU REV BIOCHEM, V54, P171, DOI 10.1146/annurev.bi.54.070185.001131; MEIKLEJOHN AL, 1989, J MOL BIOL, V207, P661, DOI 10.1016/0022-2836(89)90236-2; MULLIGAN ME, 1985, J BIOL CHEM, V260, P3529; MULLIGAN ME, 1984, NUCLEIC ACIDS RES, V12, P789, DOI 10.1093/nar/12.1Part2.789; NORDHEIM A, 1988, NUCLEIC ACIDS RES, V16, P21, DOI 10.1093/nar/16.1.21; PETTIJOHN DE, 1980, P NATL ACAD SCI-BIOL, V77, P1331, DOI 10.1073/pnas.77.3.1331; RAHMOUNI AR, 1989, SCIENCE, V246, P358, DOI 10.1126/science.2678475; SCHWARTZ M, 1988, THESIS C MELLON U PI; SHORE D, 1983, J MOL BIOL, V170, P957, DOI 10.1016/S0022-2836(83)80198-3; SINDEN RR, 1980, CELL, V21, P773, DOI 10.1016/0092-8674(80)90440-7; VINOGRAD J, 1968, J MOL BIOL, V33, P173, DOI 10.1016/0022-2836(68)90287-8; WANG JC, 1982, COLD SPRING HARB SYM, V47, P85, DOI 10.1101/SQB.1983.047.01.011	46	16	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13511	13521						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175785				2022-12-25	WOS:A1994NK18400068
J	ARRIBAS, J; ARIZTI, P; CASTANO, JG				ARRIBAS, J; ARIZTI, P; CASTANO, JG			ANTIBODIES AGAINST THE C2 COOH-TERMINAL REGION DISCRIMINATE THE ACTIVE AND LATENT FORMS OF THE MULTICATALYTIC PROTEINASE COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM DODECYL-SULFATE; ATP-DEPENDENT PROTEASES; RAT HEPATOMA-CELLS; ESCHERICHIA-COLI; POLYACRYLAMIDE GELS; SKELETAL-MUSCLE; RNA-POLYMERASE; CDNA CLONING; COMPONENT; LIVER	The mouse cDNA homologues of the rat C2, C9, and C5 subunits of the multicatalytic proteinase have been cloned and expressed in bacteria. The respective recombinant proteins were purified and used to produce specific anti-subunit antibodies. Immunoblotting of two-dimensional gels of purified rat liver multicatalytic proteinase showed that the C2 (32-kDa) and C9 (29-kDa) polypeptides are resolved into three and two isoelectric variants, respectively, likely due to post-translational modifications, i.e. phosphorylation, and the presence of two anti-C5 reacting polypeptides (25.5 and 23 kDa). Epitope mapping of the anti-C2-specific antibody with different constructs of the recombinant C2 protein allowed us to determine that one major epitope of this anti-C2 antibody is located within the last 9-11 amino acids of the C2 polypeptide. Affinity purified antibodies directed against the C2 COOH-terminal were able to discriminate the active and latent forms of the multicatalytic proteinase, supporting the conclusion that the C2 protein found in the active form of the enzyme is a polypeptide of 28 kDa, produced by the loss, at least, of the last 9-13 amino acids (DEPAEKADEPMEH) of the intact C2 (32-kDa) component. By in vitro treatment of the latent form of the enzyme with elastase, we show the conversion of the C2 (32-kDa) component to a 28-kDa protein with loss of recognition by the anti-C2 COOH-terminal affinity purified antibodies, but this limited degradation of the C2 component did not have any significant effect on the proteolytic activity (assayed with myelin basic protein and fluorogenic peptides) of the multicatalytic proteinase. It is suggested that the proteolytic cleavage of the C2 COOH-terminal region may be involved in the regulation of the interaction of the multicatalytic proteinase with other cellular proteins and/or in the translocation of the complex to the nucleus.	UNIV AUTONOMA MADRID,FAC MED,DEPT BIOQUIM,E-28029 MADRID,SPAIN; UNIV AUTONOMA MADRID,FAC MED,CSIC,INST INVEST BIOMED,E-28029 MADRID,SPAIN	Autonomous University of Madrid; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)			Arribas, Joaquin/M-4482-2014	Arribas, Joaquin/0000-0002-0504-0664				ARRIBAS J, 1993, J BIOL CHEM, V268, P21165; ARRIBAS J, 1990, J BIOL CHEM, V265, P13969; ARRIBAS J, 1991, J EXP MED, V173, P423, DOI 10.1084/jem.173.2.423; BROWN MG, 1993, J IMMUNOL, V151, P1193; CASTANO JG, 1986, CELL, V46, P377, DOI 10.1016/0092-8674(86)90658-6; CHU-PING M, 1992, Journal of Biological Chemistry, V267, P10515; DAHLMANN B, 1985, BIOCHEM J, V228, P171, DOI 10.1042/bj2280171; DEMENA IR, 1993, BIOCHEM J, V296, P93, DOI 10.1042/bj2960093; DESA CM, 1986, J MOL BIOL, V187, P479, DOI 10.1016/0022-2836(86)90328-1; FALKENBURG PE, 1989, J BIOL CHEM, V264, P6660; FRUH K, 1992, J BIOL CHEM, V267, P22131; FUJIWARA T, 1989, BIOCHEMISTRY-US, V28, P7332, DOI 10.1021/bi00444a028; GOLDBERG AL, 1992, EUR J BIOCHEM, V203, P9, DOI 10.1111/j.1432-1033.1992.tb19822.x; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; HEINEMEYER W, 1991, EMBO J, V10, P555, DOI 10.1002/j.1460-2075.1991.tb07982.x; HOFFMAN L, 1992, J BIOL CHEM, V267, P22362; ISHIURA S, 1985, FEBS LETT, V189, P119, DOI 10.1016/0014-5793(85)80854-1; KANAYAMA H, 1991, CANCER RES, V51, P6677; KLEIN U, 1990, J CELL BIOL, V111, P2275, DOI 10.1083/jcb.111.6.2275; KLEINSCHMIDT JA, 1983, EUR J CELL BIOL, V32, P143; KUMATORI A, 1990, P NATL ACAD SCI USA, V87, P7071, DOI 10.1073/pnas.87.18.7071; KUMATORI A, 1990, FEBS LETT, V264, P279, DOI 10.1016/0014-5793(90)80267-M; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANIATIS T, 1986, MOL CLONING; MAURIZI MR, 1990, J BIOL CHEM, V265, P12536; MCGUIRE MJ, 1989, BIOCHIM BIOPHYS ACTA, V995, P181, DOI 10.1016/0167-4838(89)90078-2; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; ORLOWSKI M, 1990, BIOCHEMISTRY-US, V29, P10289, DOI 10.1021/bi00497a001; ORLOWSKI M, 1981, BIOCHEM BIOPH RES CO, V101, P814; PAL JK, 1988, J CELL SCI, V90, P555; PEREIRA ME, 1992, J BIOL CHEM, V267, P7949; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; RIVETT AJ, 1993, BIOCHEM J, V291, P1; RIVETT AJ, 1989, J BIOL CHEM, V264, P12215; RIVETT AJ, 1991, BIOCHEM J, V278, P171, DOI 10.1042/bj2780171; SAITOH Y, 1989, BIOCHEM BIOPH RES CO, V162, P334, DOI 10.1016/0006-291X(89)92000-7; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIMBARA N, 1992, J BIOL CHEM, V267, P18100; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TAMURA T, 1990, FEBS LETT, V264, P91, DOI 10.1016/0014-5793(90)80773-C; TANAKA K, 1989, BIOCHEM BIOPH RES CO, V164, P1253, DOI 10.1016/0006-291X(89)91804-4; TANAKA K, 1990, FEBS LETT, V271, P41, DOI 10.1016/0014-5793(90)80367-R; TANAKA K, 1992, NEW BIOL, V4, P173; TANAKA K, 1988, J MOL BIOL, V203, P985, DOI 10.1016/0022-2836(88)90123-4; TANAKA K, 1988, J BIOL CHEM, V263, P16209; TANAKA K, 1986, J BIOL CHEM, V261, P5197; TOMEK W, 1988, FEBS LETT, V239, P155, DOI 10.1016/0014-5793(88)80564-7; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WELTMAN D, 1992, J BIOL CHEM, V267, P6977; WILK S, 1983, J NEUROCHEM, V40, P842, DOI 10.1111/j.1471-4159.1983.tb08056.x; YANG Y, 1992, P NATL ACAD SCI USA, V89, P4928, DOI 10.1073/pnas.89.11.4928; YU B, 1993, J BIOL CHEM, V268, P2029; ZWICKL P, 1991, FEBS LETT, V278, P217, DOI 10.1016/0014-5793(91)80120-R; ZWICKL P, 1992, BIOCHEMISTRY-US, V31, P964, DOI 10.1021/bi00119a004	55	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12858	12864						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175701				2022-12-25	WOS:A1994NH71600075
J	GUO, GG; GU, MZ; ETLINGER, JD				GUO, GG; GU, MZ; ETLINGER, JD			240-KDA PROTEASOME INHIBITOR (CF-2) IS IDENTICAL TO DELTA-AMINOLEVULINIC-ACID DEHYDRATASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note								The 240-kDa proteasome inhibitor has been reported to be an ATP-stabilized component (CF-2) of the 26 S proteasome complex. We now report that this inhibitory factor is indistinguishable from delta-aminolevulinic acid dehydratase (ALAD), the second enzyme in the pathway of heme synthesis, based upon the following observations: 1) common sequence of the first 14 N-terminal amino acids; 2) identical migration on native and SDS-polyacrylamide gel electrophoresis; 3) identical isoelectric points of pH 7.1; 4) cross-reactivity of specific polyclonal antibodies; 5) similar dehydratase and proteasome inhibitor specific activities in both proteins; and 6) the presence of both activities in recombinant ALAD. The dual role of this protein as CF-2 in the ATP/ ubiquitin-dependent pathway and in heme synthesis may be an example of ''gene sharing'' and explains the unexpected abundance of ALAD noted in earlier studies.	NEW YORK MED COLL, DEPT CELL BIOL & ANAT, VALHALLA, NY 10595 USA; SUNY HLTH SCI CTR, DEPT ANAT & CELL BIOL, BROOKLYN, NY 11203 USA	New York Medical College; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center								ANDERSON PM, 1979, J BIOL CHEM, V254, P6924; ASTRIN KH, 1987, ANN NY ACAD SCI, V514, P23, DOI 10.1111/j.1749-6632.1987.tb48757.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DRISCOLL J, 1992, P NATL ACAD SCI USA, V89, P4986, DOI 10.1073/pnas.89.11.4986; DRISCOLL J, 1990, J BIOL CHEM, V265, P4789; ETLINGER JD, 1980, J BIOL CHEM, V255, P4563; EYTAN E, 1989, P NATL ACAD SCI USA, V86, P7751, DOI 10.1073/pnas.86.20.7751; GANOTH D, 1988, J BIOL CHEM, V263, P12412; GOLDBERG AL, 1992, NATURE, V357, P375, DOI 10.1038/357375a0; HAAS AL, 1981, P NATL ACAD SCI-BIOL, V78, P6845, DOI 10.1073/pnas.78.11.6845; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; Hochstrasser Mark, 1992, Current Opinion in Cell Biology, V4, P1024, DOI 10.1016/0955-0674(92)90135-Y; JORDAN PM, 1986, METHOD ENZYMOL, V123, P427; Kornberg A., 1992, DNA REPLICATION, VSecond, P113; LI XC, 1991, BIOCHEMISTRY-US, V30, P9709, DOI 10.1021/bi00104a020; LI XCS, 1992, BIOCHEMISTRY-US, V31, P11963, DOI 10.1021/bi00163a001; LUDEMANN R, 1993, J BIOL CHEM, V268, P17413; MOLDAVE K, 1985, ANNU REV BIOCHEM, V54, P1109, DOI 10.1146/annurev.biochem.54.1.1109; MURAKAMI K, 1986, P NATL ACAD SCI USA, V83, P7588, DOI 10.1073/pnas.83.20.7588; NARISAWA K, 1966, BIOCHIM BIOPHYS ACTA, V123, P596, DOI 10.1016/0005-2787(66)90226-7; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PIATIGORSKY J, 1992, J BIOL CHEM, V267, P4277; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; RIVETT AJ, 1993, BIOCHEM J, V291, P1; Sassa S, 1981, Adv Hum Genet, V11, P121; SHEMIN D, 1972, ENZYMES, P323; TANAKA K, 1992, NEW BIOL, V4, P173; TSUKAMOTO I, 1980, INT J BIOCHEM, V12, P751; WEITMAN D, 1992, J BIOL CHEM, V267, P6977; WETMUR JG, 1986, GENE, V43, P123, DOI 10.1016/0378-1119(86)90015-6; WETMUR JG, 1986, P NATL ACAD SCI USA, V83, P7703, DOI 10.1073/pnas.83.20.7703; WU WH, 1974, P NATL ACAD SCI USA, V71, P1767, DOI 10.1073/pnas.71.5.1767	32	80	81	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12399	12402						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175643				2022-12-25	WOS:A1994NH71600005
J	RENARD, S; LINGUEGLIA, E; VOILLEY, N; LAZDUNSKI, M; BARBRY, P				RENARD, S; LINGUEGLIA, E; VOILLEY, N; LAZDUNSKI, M; BARBRY, P			BIOCHEMICAL-ANALYSIS OF THE MEMBRANE TOPOLOGY OF THE AMILORIDE-SENSITIVE NA+ CHANNEL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN KINASE-C; CELLS; DEGRADATION	A key protein component of the amiloride-sensitive sodium channel has been cloned from rat colon and human lung. It may represent the first member of a new family of ionic channels expressed from nematode to human. The biochemical properties of the rat protein, a 699 amino acids long polypeptide, have been analyzed. Four polyclonal antibodies raised against distinct parts of the channel immunoprecipitated a glycosylated protein of 96 kDa after cRNA expression in oocytes as well as after in vitro translation. When expressed alone into oocytes, the protein was not stable; most of it remains stacked into the endoplasmic reticulum. This results in a very low yield of complete maturation of the protein at the cell surface after expression from the pure cRNA. To determine the membrane topology of the protein, in vitro translation by a rabbit reticulocyte lysate was performed followed by insertion into canine pancreatic microsomes and protease digestion. Analysis revealed a model with only two transmembrane alpha helices and a large extracellular domain of about 500 amino acids, The NH2 and COOH termini are cytoplasmic. Protease digestion results suggest the possible presence of a structural element that could have a function similar to that of the H5 segment in K+ channels. The model indicates that there is no cytoplasmic site for protein kinase A phosphorylation. The well known regulation of the channel activity by hormones that activate this kinase such as vasopressin might thus be situated on another channel component.	SOPHIA ANTIPOLIS,INST PHARMACOL MOLEC & CELLULAIRE,F-06560 VALBONNE,FRANCE				Barbry, Pascal/O-5021-2016; LINGUEGLIA, Eric/F-5509-2013	Barbry, Pascal/0000-0001-9632-6483; LINGUEGLIA, Eric/0000-0003-3902-3405; Renard, Stephane/0000-0002-1374-4960				AMARA JF, 1989, J CELL BIOL, V109, P3315, DOI 10.1083/jcb.109.6.3315; BONIFACINO JS, 1990, CELL, V63, P503, DOI 10.1016/0092-8674(90)90447-M; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; CHALFIE M, 1993, NATURE, V361, P504, DOI 10.1038/361504a0; CRAMER WA, 1992, FASEB J, V6, P3397, DOI 10.1096/fasebj.6.15.1464373; DRISCOLL M, 1991, NATURE, V349, P588, DOI 10.1038/349588a0; DURELL SR, 1992, BIOPHYS J, V62, P238, DOI 10.1016/S0006-3495(92)81809-X; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; HAMILTON KL, 1986, MEMBRANE BIOCHEM, V6, P149, DOI 10.3109/09687688609065447; HARLOW E, 1988, ANTIBODIES LAB MANUA, P92; HEDGPETH J, 1983, CELL, V34, P759; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LING BN, 1989, AM J PHYSIOL, V256, pF1094, DOI 10.1152/ajprenal.1989.256.6.F1094; LINGUEGLIA E, 1993, FEBS LETT, V318, P95, DOI 10.1016/0014-5793(93)81336-X; PALMER LG, 1986, P NATL ACAD SCI USA, V83, P2767, DOI 10.1073/pnas.83.8.2767; PALMER LG, 1992, ANNU REV PHYSIOL, V54, P51, DOI 10.1146/annurev.ph.54.030192.000411; PARKER JMR, 1986, BIOCHEMISTRY-US, V25, P5425, DOI 10.1021/bi00367a013; PONGS O, 1992, PHYSIOL REV, V72, P569; ROTH J, 1987, BIOCHIM BIOPHYS ACTA, V906, P405, DOI 10.1016/0304-4157(87)90018-9; TARENTINO AL, 1978, METHOD ENZYMOL, V83, P399; VERRIER B, 1989, EUR J BIOCHEM, V183, P499, DOI 10.1111/j.1432-1033.1989.tb21077.x; VIGNE P, 1989, J BIOL CHEM, V264, P7663; VOILLEY N, 1994, P NATL ACAD SCI USA, V91, P247, DOI 10.1073/pnas.91.1.247; YANASE M, 1986, AM J PHYSIOL, V250, pC517, DOI 10.1152/ajpcell.1986.250.3.C517; YELLEN G, 1991, SCIENCE, V251, P939, DOI 10.1126/science.2000494	27	217	219	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12981	12986						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175716				2022-12-25	WOS:A1994NH71600092
J	WERNER, H; RAUSCHER, FJ; SUKHATME, VP; DRUMMOND, IA; ROBERTS, CT; LEROITH, D				WERNER, H; RAUSCHER, FJ; SUKHATME, VP; DRUMMOND, IA; ROBERTS, CT; LEROITH, D			TRANSCRIPTIONAL REPRESSION OF THE INSULIN-LIKE GROWTH-FACTOR-I RECEPTOR (IGF-I-R) GENE BY THE TUMOR-SUPPRESSOR WT1 INVOLVES BINDING TO SEQUENCES BOTH UPSTREAM AND DOWNSTREAM OF THE IGF-I-R GENE-TRANSCRIPTION START SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC FINGER PROTEIN; WILMS-TUMOR; PROMOTER REGION; MESSENGER-RNA; EXPRESSION; LOCUS; INITIATOR; CLONING; KIDNEY	The insulin-like growth factor-I receptor (IGF-I-R) has been implicated in the etiology and/or progression of Wilms' tumor, a pediatric malignancy of the kidney that is often associated with deletion or mutation of the WT1 tumor suppressor gene. The expression of the IGF-I-R gene is increased in Wilms' tumor as compared with normal kidney tissue. Furthermore, the levels of IGF-I-R mRNA in individual tumors have been shown to be inversely correlated to the levels of WT1 mRNA, suggesting that the expression of the IGF-I R gene is under the negative control of WT1. The activity of an IGF-I R promoter/luciferase construct in Chinese hamster ovary cells was reduced by cotransfection of a WT1 expression vector. An analysis of various reporter constructs containing different portions of the IGF-I-R 5'-flanking and 5'-untranslated regions suggested that the effect of WT1 depends on the number of WT1 binding sites present, with sites located both upstream and downstream of the IGF-I-R transcription start site involved in mediating this effect. Using the purified zinc finger domain of WT1 in gel retardation and DNase I footprinting assays, we mapped five sites in the 5'-flanking and six sites in the 5'-untranslated regions that were involved in WT1 binding. In addition, the initiator element of the IGF-I-R gene contains a sequence that binds WT1. Thus, the repression of IGF-I-R promoter activity by the WT1 tumor suppressor gene product involves multiple interactions of its zinc finger domain with WT1 binding sites located both 5' and 3' of the transcription initiation site.	WISTER INST ANAT & BIOL,PHILADELPHIA,PA 19104; BETH ISRAEL HOSP,DIV RENAL,BOSTON,MA 02215; HARVARD UNIV,SCH MED,BOSTON,MA 02215	The Wistar Institute; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	WERNER, H (corresponding author), NIDDKD,DIABET BRANCH,BLDG 10,ROOM 8S-239,BETHESDA,MD 20892, USA.		Sukhatme, Vikas/W-2776-2019; Roberts, Charles/K-6953-2017	Roberts, Charles/0000-0003-1756-5772	NCI NIH HHS [CA 10817, CA 47983, CA 52009] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA052009, P01CA047983] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BICKMORE WA, 1992, SCIENCE, V257, P235, DOI 10.1126/science.1321494; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; COOKE DW, 1991, BIOCHEM BIOPH RES CO, V177, P1113, DOI 10.1016/0006-291X(91)90654-P; DICICCOBLOOM E, 1988, P NATL ACAD SCI USA, V85, P4066, DOI 10.1073/pnas.85.11.4066; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; GANSLER T, 1988, AM J PATHOL, V130, P431; GANSLER T, 1989, AM J PATHOL, V135, P961; GASHLER AL, 1992, P NATL ACAD SCI USA, V89, P10984, DOI 10.1073/pnas.89.22.10984; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; HASELBACHER GK, 1987, P NATL ACAD SCI USA, V84, P1104, DOI 10.1073/pnas.84.4.1104; HUANG A, 1990, SCIENCE, V250, P991, DOI 10.1126/science.2173145; LEROITH D, 1991, TRENDS ENDOCRIN MET, V2, P134, DOI 10.1016/1043-2760(91)90003-6; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MAHESWARAN S, 1993, P NATL ACAD SCI USA, V90, P5100, DOI 10.1073/pnas.90.11.5100; MAMULA PW, 1992, DNA CELL BIOL, V11, P43, DOI 10.1089/dna.1992.11.43; MORRIS JF, 1991, ONCOGENE, V6, P2339; PAIK S, 1989, LAB INVEST, V61, P522; PIETRZKOWSKI Z, 1992, CELL GROWTH DIFFER, V3, P199; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; REEVE AE, 1985, NATURE, V317, P258, DOI 10.1038/317258a0; ROSE EA, 1990, CELL, V60, P495, DOI 10.1016/0092-8674(90)90600-J; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SUKHATME VP, 1992, KIDNEY INT, V41, P550, DOI 10.1038/ki.1992.79; WANG ZY, 1993, J BIOL CHEM, V268, P9172; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; WERNER H, 1992, MOL ENDOCRINOL, V6, P1545, DOI 10.1210/me.6.10.1545; WERNER H, 1990, BIOCHEM BIOPH RES CO, V169, P1021, DOI 10.1016/0006-291X(90)91996-6; WERNER H, 1993, P NATL ACAD SCI USA, V90, P5828, DOI 10.1073/pnas.90.12.5828; Werner H, 1991, INSULIN LIKE GROWTH, P17; ZENZIEGREGORY B, 1993, MOL CELL BIOL, V13, P3841, DOI 10.1128/MCB.13.7.3841	31	145	149	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12577	12582						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175666				2022-12-25	WOS:A1994NH71600034
J	ASANO, M; TAMIYAKOIZUMI, K; HOMMA, Y; TAKENAWA, T; NIMURA, Y; KOJIMA, K; YOSHIDA, S				ASANO, M; TAMIYAKOIZUMI, K; HOMMA, Y; TAKENAWA, T; NIMURA, Y; KOJIMA, K; YOSHIDA, S			PURIFICATION AND CHARACTERIZATION OF NUCLEAR PHOSPHOLIPASE-C SPECIFIC FOR PHOSPHOINOSITIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SWISS 3T3 CELLS; PROTEIN-KINASE-C; RAT-LIVER NUCLEI; BOVINE BRAIN; HUMAN-PLATELETS; PHOSPHATIDYLINOSITOL; MATRIX; FORMS; MEMBRANE; DIACYLGLYCEROL	A phosphoinositide-specific phospholipase C (PLC) was solubilized from the isolated nuclei of rat ascites hepatoma AH7974 cells by ultrasonication in 2 M KCl. The extract was then subjected to five steps of column chromatographies in the order of Sephacryl S-300, phosphocellulose, Mono Q, Mono S, and Superose 6. Four forms of PLC (tentatively designated as N1, N2, N3, and N4) were purified 440-1400-fold. N1, N2, N3, and N4 showed apparent molecular masses of 85, 83, 80, and 88 kDa, respectively, on SDS polyacrylamide gel electrophoresis. N1 cross-reacted with the antibody against the delta 1 isoform, while the other three forms did not crossreact with any of the antibodies against PLC-delta(1), -gamma(1), -gamma(2), and -beta(1). They hydrolyzed phosphatidylinositol (PI), phosphatidylinositol 4-monophosphate (PIP), and phosphatidylinositol 4,5-bisphosphate (PIP2) but did not show any activities against phosphatidylcholine and phosphatidylethanolamine. They showed the same optimal pH: pH 6.5 for PI hydrolysis and pH 7.0 for both PIP and PIP2 hydrolyses. They absolutely required Ca2+ for activity, with optimal concentrations of 10(-3)-10(-5) M for PIP and 10(-4)-10(-5) M for PIP2. For PI hydrolysis, N1, N2, and N3 required a Ca2+ concentration higher than 10(-2) M whereas N4 revealed significant activity even at 10(-5) M Ca2+ concentrations. Two forms of plasma membrane PLC and three forms of cytosolic PLC were purified from AH7974 cells by the same procedure as for nuclear PLC. Comparative study with these three groups revealed that all of the purified PLC isoforms shared similar enzymological properties except N4, which showed an exceptionally high affinity to Mono S column and was active at low concentrations of Ca2+ for PI as substrate. Furthermore, when PLC isoforms of nuclei from adult resting rat liver were compared with those from regenerating rat liver after partial hepatectomy, a PLC isoform corresponding to N4 of AH7974 cells was found only in regenerating liver nuclei. From these results, it was suggested that the nuclei of growing liver cells possessed a unique form of PLC (N4).	NAGOYA UNIV, SCH MED,DIS MECHANISM & CONTROL RES INST, CANC CELL BIOL LAB,SHOWA KU, NAGOYA, AICHI 466, JAPAN; NAGOYA UNIV, SCH MED, DEPT SURG 1, SHOWA KU, NAGOYA, AICHI 466, JAPAN; TOKYO METROPOLITAN GERIATR HOSP & INST GERONTOL, DEPT BIOSIGNAL RES, TOKYO 173, JAPAN; UNIV TOKYO, INST MED SCI, DEPT MOLEC ONCOL, MINATO KU, TOKYO 108, JAPAN	Nagoya University; Nagoya University; Tokyo Metropolitan Institute of Gerontology; University of Tokyo								BALDASSARE JJ, 1989, BIOCHEMISTRY-US, V28, P6010, DOI 10.1021/bi00440a043; BANNO Y, 1987, BIOCHEM J, V248, P95, DOI 10.1042/bj2480095; BANNO Y, 1990, BIOCHEM BIOPH RES CO, V167, P396, DOI 10.1016/0006-291X(90)92035-X; BANSAL VS, 1990, ANNU REV CELL BIOL, V6, P41, DOI 10.1146/annurev.cellbio.6.1.41; BEREZNEY R, 1979, EUR J CELL BIOL, V20, P139; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAPITANI S, 1990, BIOCHIM BIOPHYS ACTA, V1044, P193, DOI 10.1016/0005-2760(90)90303-F; COCCO L, 1988, BIOCHEM BIOPH RES CO, V154, P1266, DOI 10.1016/0006-291X(88)90276-8; COCCO L, 1980, BIOCHEM BIOPH RES CO, V96, P890, DOI 10.1016/0006-291X(80)91439-4; COCKCROFT S, 1992, BIOCHEM J, V288, P1; DIVECHA N, 1993, BIOCHEM J, V289, P617, DOI 10.1042/bj2890617; DIVECHA N, 1991, EMBO J, V10, P3207, DOI 10.1002/j.1460-2075.1991.tb04883.x; HOFMANN SL, 1982, J BIOL CHEM, V257, P6461; HOMMA Y, 1988, J BIOL CHEM, V263, P6592; HOMMA Y, 1990, BIOCHEM J, V269, P13, DOI 10.1042/bj2690013; HOMMA Y, 1989, BIOCHEM BIOPH RES CO, V164, P406, DOI 10.1016/0006-291X(89)91734-8; KATAN M, 1988, CELL, V54, P171, DOI 10.1016/0092-8674(88)90549-1; KATAN M, 1987, EUR J BIOCHEM, V168, P413, DOI 10.1111/j.1432-1033.1987.tb13435.x; KURIKI H, 1992, J BIOCHEM-TOKYO, V111, P283, DOI 10.1093/oxfordjournals.jbchem.a123750; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE KY, 1987, P NATL ACAD SCI USA, V84, P5540, DOI 10.1073/pnas.84.16.5540; MAJERUS PW, 1986, SCIENCE, V234, P1519, DOI 10.1126/science.3024320; MAJERUS PW, 1990, CELL, V63, P459, DOI 10.1016/0092-8674(90)90442-H; MANZOLI FA, 1977, CANCER RES, V37, P843; MARTELLI AM, 1992, NATURE, V358, P242, DOI 10.1038/358242a0; MAZZONI M, 1992, BIOCHEM BIOPH RES CO, V187, P114, DOI 10.1016/S0006-291X(05)81466-4; MORRIS AJ, 1990, J BIOL CHEM, V265, P13501; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OGAWA Y, 1968, J BIOCHEM-TOKYO, V64, P255, DOI 10.1093/oxfordjournals.jbchem.a128887; PAWELCZYK T, 1993, BIOCHEM J, V291, P693, DOI 10.1042/bj2910693; PAYRASTRE B, 1992, J BIOL CHEM, V267, P5078; REBECCHI MJ, 1987, J BIOL CHEM, V262, P12526; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; RYU SH, 1987, P NATL ACAD SCI USA, V84, P6649, DOI 10.1073/pnas.84.19.6649; RYU SH, 1987, J BIOL CHEM, V262, P12511; RYU SH, 1986, BIOCHEM BIOPH RES CO, V141, P137, DOI 10.1016/S0006-291X(86)80345-X; SPANGLER M, 1975, CANCER RES, V35, P3131; TAKENAWA T, 1989, INT CONGR SER, V811, P207; TAMIYAKOIZUMI K, 1989, BIOCHIM BIOPHYS ACTA, V1002, P182, DOI 10.1016/0005-2760(89)90285-3; WANG P, 1986, J BIOCHEM-TOKYO, V100, P1015, DOI 10.1093/oxfordjournals.jbchem.a121780	41	55	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					12360	12366						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163540				2022-12-25	WOS:A1994NG37700103
J	MCDONNELL, DP; GOLDMANN, ME				MCDONNELL, DP; GOLDMANN, ME			RU486 EXERTS ANTIESTROGENIC ACTIVITIES THROUGH A NOVEL PROGESTERONE-RECEPTOR-A FORM-MEDIATED MECHANISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ENDOMETRIUM	The human progesterone receptor (hPR) exists in two distinct forms in most cells, hPR-A and hPR-B. Both receptor isoforms exhibit distinct biological functions and demonstrate a cell- and promoter-specific ability to regulate gene transcription. Interestingly, in cell contexts where PR-A is transcriptionally inactive, it acts as a progesterone-dependent inhibitor of estrogen receptor function. Coexpression of the human estrogen receptor with the A form (but not the B form) of the human progesterone receptor resulted in a ligand-dependent inhibition of estrogen receptor-mediated gene transcription. The antiprogestins RU486 (Mifepristone) and ZK98299 (Onapristone) and related antiprogestins were ah effective ''noncompetitive'' inhibitors of the estrogen receptor in this assay as none of these compounds interacted directly with the estrogen receptor. This observation may explain in part the observed tissue-specific antiestrogenic effects of RU486 and further indicates that the antiestrogenic activities of antiprogestins may be intrinsic to their biological function. This important new information defines novel activities of progesterone receptor ligands and may alter the way in which we define progesterone receptor modulators for future clinical applications. In addition, these data reveal that the A form of the progesterone receptor plays a key role in modulating estrogen receptor function in cells where both receptors are expressed.	LIGAND PHARMACEUT INC, DEPT NEW LEADS DISCOVERY, LA JOLLA, CA 92037 USA	Ligand Pharmaceuticals	MCDONNELL, DP (corresponding author), LIGAND PHARMACEUT INC, DEPT MOLEC BIOL, 11149 N TORREY PINES RD, LA JOLLA, CA 92037 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK043267] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 43267-01] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERGER TS, 1992, J STEROID BIOCHEM, V41, P733, DOI 10.1016/0960-0760(92)90414-E; FEIL PD, 1988, ENDOCRINOLOGY, V123, P2506, DOI 10.1210/endo-123-5-2506; FUQUA SAW, 1991, CANCER RES, V51, P105; GORDON T, 1977, AM J MED, V62, P707, DOI 10.1016/0002-9343(77)90874-9; GOTTARDIS MM, 1988, CANCER RES, V48, P5183; HIRVONEN E, 1981, NEW ENGL J MED, V304, P560, DOI 10.1056/NEJM198103053041002; HORWITZ KB, 1983, ENDOCRINOLOGY, V113, P2195, DOI 10.1210/endo-113-6-2195; MARKIEWICZ L, 1990, J STEROID BIOCHEM, V35, P535, DOI 10.1016/0022-4731(90)90196-Y; PHILIBERT D, 1991, FRONT HORM RES, V19, P1; SCHRADER WT, 1972, J BIOL CHEM, V247, P51; SLAYDEN OD, 1993, ENDOCRINOLOGY, V132, P1845, DOI 10.1210/en.132.4.1845; SLAYDEN OD, 1994, IN PRESS J CLIN ENDO; TZUKERMAN MT, 1994, MOL ENDOCRINOL, V8, P21, DOI 10.1210/me.8.1.21; VEGETO E, 1993, MOL ENDOCRINOL, V7, P1244, DOI 10.1210/me.7.10.1244; WAKELING AE, 1991, CANCER RES, V51, P3867; WOLF JP, 1989, FERTIL STERIL, V52, P1055	16	183	196	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					11945	11949						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163495				2022-12-25	WOS:A1994NG37700043
J	BARTOLI, F; LIN, HK; GHOMASHCHI, F; GELB, MH; JAIN, MK; APITZCASTRO, R				BARTOLI, F; LIN, HK; GHOMASHCHI, F; GELB, MH; JAIN, MK; APITZCASTRO, R			TIGHT-BINDING INHIBITORS OF 85-KDA PHOSPHOLIPASE A(2) BUT NOT 14-KDA PHOSPHOLIPASE A(2) INHIBIT RELEASE OF FREE ARACHIDONATE IN THROMBIN-STIMULATED HUMAN PLATELETS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPETITIVE INHIBITORS; INTERFACIAL CATALYSIS; PHOSPHATIDIC-ACID; CYTOSOLIC PHOSPHOLIPASE-A2; SUBSTRATE SPECIFICITIES; RABBIT PLATELETS; PHOSPHORYLATION; PURIFICATION; METABOLISM; CELLS	An analogue of arachidonic acid in which the COOH group is replaced by a trifluoromethyl ketone group (COCF3) has recently been shown to be a tight binding inhibitor of the 85-kDa cytosolic phospholipase A, that is found in platelets and other cells (Street, I. P., Lin, H.-K., Laliberte, F., Ghomashchi, F. G., Wang, Z., Perrier, H., Tremblay, N. M., Huang, Z., Weech, P. K., and Gelb, M. H. (1993) Biochemistry 32, 5935-5940). This trifluoromethyl ketone inhibits most of the arachidonate release from the phospholipid pool in thrombin-stimulated human platelets at concentrations of 0-40 mu M with 4 x 10(8) platelets/ml. A structure-function analysis of related compounds reveals a good correlation between the inhibition of the purified phospholipase A(2) and the blockage of arachidonate release in platelets. A number of recently described potent inhibitors of the 14-bDa phospholipase A(2) that is secreted from activated platelets have no effect on the level of free arachidonate production. Furthermore, the addition of a large amount of recombinant 14-kDa phospholipase A(2) to platelets does not produce free arachidonate, and it does not alter the amount of arachidonate released following platelet activation with thrombin. These studies provide strong pharmacological evidence for the role of the cytosolic phospholipase A(2) in producing most, if not all, of the liberated arachidonate in thrombin stimulated human platelets, and they show that tight binding membrane-residing inhibitors of the cytosolic phospholipase A(2) can block the eicosanoid cascade in living cells.	UNIV WASHINGTON,DEPT CHEM,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT BIOCHEM,SEATTLE,WA 98195; INST VENEZOLANO INVEST CIENT,TROMBOSIS EXPTL LAB,CARACAS,VENEZUELA; UNIV DELAWARE,DEPT CHEM & BIOCHEM,NEWARK,DE 19716	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Venezuelan Institute Science Research; University of Delaware				gelb, michael/0000-0001-7000-5219	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036235, R37HL036235, R23HL036235] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029703] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL36235] Funding Source: Medline; NIGMS NIH HHS [GM562, GM29703] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AARSMAN AJ, 1989, J LIPID MEDIATOR, V1, P49; ALMEHDI AB, 1993, BIOCHIM BIOPHYS ACTA, V1167, P56, DOI 10.1016/0005-2760(93)90217-W; APITZCASTRO R, 1991, BIOCHIM BIOPHYS ACTA, V1094, P269, DOI 10.1016/0167-4889(91)90086-D; APITZCASTRO R, 1983, THROMB RES, V32, P155, DOI 10.1016/0049-3848(83)90027-0; APITZCASTRO R, 1981, THROMB RES, V23, P347, DOI 10.1016/0049-3848(81)90195-X; APITZCASTRO RJ, 1979, BIOCHEM BIOPH RES CO, V91, P63, DOI 10.1016/0006-291X(79)90583-7; BARBOUR SE, 1993, J BIOL CHEM, V268, P21875; BAYBURT T, 1993, BIOCHEMISTRY-US, V32, P573, DOI 10.1021/bi00053a024; BELL RL, 1979, P NATL ACAD SCI USA, V76, P3238, DOI 10.1073/pnas.76.7.3238; BENNION C, 1992, J MED CHEM, V35, P2939, DOI 10.1021/jm00094a003; BERG OG, 1991, BIOCHEMISTRY-US, V30, P7283, DOI 10.1021/bi00243a034; BILLAH MM, 1981, J BIOL CHEM, V256, P5399; BILLS TK, 1977, J CLIN INVEST, V60, P1, DOI 10.1172/JCI108745; BILLS TK, 1976, BIOCHIM BIOPHYS ACTA, V424, P303, DOI 10.1016/0005-2760(76)90198-3; BLACKWELL GJ, 1977, BRIT J PHARMACOL, V59, P353, DOI 10.1111/j.1476-5381.1977.tb07500.x; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BROEKMAN MJ, 1981, J BIOL CHEM, V256, P8271; BROEKMAN MJ, 1986, J LIPID RES, V27, P884; BROEKMAN MJ, 1980, J CLIN INVEST, V66, P275, DOI 10.1172/JCI109854; CHAU LY, 1983, BIOCHEM BIOPH RES CO, V113, P241, DOI 10.1016/0006-291X(83)90457-6; CHAU LY, 1988, BIOCHIM BIOPHYS ACTA, V963, P436, DOI 10.1016/0005-2760(88)90312-8; CHILTON FH, 1989, BIOCHEM J, V258, P327, DOI 10.1042/bj2580327; CLAPHAM DE, 1990, BIOCHEM PHARMACOL, V39, P813, DOI 10.1016/0006-2952(90)90194-P; DIEZ E, 1992, J BIOL CHEM, V267, P18342; FISHER AB, 1992, BIOCHEM J, V288, P407, DOI 10.1042/bj2880407; HAMBERG M, 1974, P NATL ACAD SCI USA, V71, P3400, DOI 10.1073/pnas.71.9.3400; HANEL AM, 1993, BIOCHEMISTRY-US, V32, P5949, DOI 10.1021/bi00074a005; HULKOWER KI, 1992, BIOCHEM BIOPH RES CO, V184, P712, DOI 10.1016/0006-291X(92)90648-5; IRVINE RF, 1982, BIOCHEM J, V204, P3, DOI 10.1042/bj2040003; Jain M K, 1992, Mediators Inflamm, V1, P85, DOI 10.1155/S0962935192000164; JAIN MK, 1992, J MED CHEM, V35, P3584, DOI 10.1021/jm00097a018; KANNAGI R, 1979, ARCH BIOCHEM BIOPHYS, V196, P534, DOI 10.1016/0003-9861(79)90305-9; KARPATKI.S, 1969, J CLIN INVEST, V48, P1073, DOI 10.1172/JCI106063; KIM DK, 1991, BIOCHEM BIOPH RES CO, V174, P189, DOI 10.1016/0006-291X(91)90504-Z; KRAMER RM, 1989, J BIOL CHEM, V264, P5768; KRAMER RM, 1993, J BIOL CHEM, V268, P26796; LEHMAN JJ, 1993, J BIOL CHEM, V268, P20713; LEMAHIEU RA, 1993, J MED CHEM, V36, P3029, DOI 10.1021/jm00072a025; LIN HK, 1993, J AM CHEM SOC, V115, P3932, DOI 10.1021/ja00063a012; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MAGOLDA RL, 1989, J CELL BIOCHEM, V40, P371, DOI 10.1002/jcb.240400313; MAUCO G, 1984, BIOCHEM J, V224, P933, DOI 10.1042/bj2240933; MCKEAN ML, 1981, J BIOL CHEM, V256, P1522; MOUNIER C, 1993, EUR J BIOCHEM, V216, P169, DOI 10.1111/j.1432-1033.1993.tb18129.x; MURAKAMI M, 1989, BIOCHIM BIOPHYS ACTA, V1005, P270; NEAGOS GR, 1993, AM J PHYSIOL, V264, pL261, DOI 10.1152/ajplung.1993.264.3.L261; PURDON AD, 1985, J BIOL CHEM, V260, P2700; QIU ZH, 1993, J BIOL CHEM, V268, P24506; RANSAC S, 1990, BIOCHIM BIOPHYS ACTA, V1043, P57, DOI 10.1016/0005-2760(90)90110-J; RIENDEAU D, 1994, J BIOL CHEM, V269, P15619; SHATTIL SJ, 1986, BLOOD, V68, P1224; SHOENE NW, 1975, FED PROC, V34, P257; STREET IP, 1993, BIOCHEMISTRY-US, V32, P5935, DOI 10.1021/bi00074a003; TAKAYAMA K, 1991, FEBS LETT, V282, P326, DOI 10.1016/0014-5793(91)80506-X; VENABLE ME, 1993, J LIPID RES, V34, P691; WHEELERJONES CPD, 1992, BIOCHEM J, V281, P465, DOI 10.1042/bj2810465; WIJKANDER J, 1991, EUR J BIOCHEM, V202, P873, DOI 10.1111/j.1432-1033.1991.tb16445.x; WINKLER JD, 1991, BIOCHIM BIOPHYS ACTA, V1081, P339, DOI 10.1016/0005-2760(91)90291-O; XING MZ, 1992, J BIOL CHEM, V267, P25966; YU L, 1990, J BIOL CHEM, V265, P2657; ZWAAL RFA, 1982, SUBCELL BIOCH, V9, P299	62	190	193	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15625	15630						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	8195211				2022-12-25	WOS:A1994NP51300039
J	MOYRET, C; THEILLET, C; PUIG, PL; MOLES, JP; THOMAS, G; HAMELIN, R				MOYRET, C; THEILLET, C; PUIG, PL; MOLES, JP; THOMAS, G; HAMELIN, R			RELATIVE EFFICIENCY OF DENATURING GRADIENT GEL-ELECTROPHORESIS AND SINGLE-STRAND CONFORMATION POLYMORPHISM IN THE DETECTION OF MUTATIONS IN EXON-5 TO EXON-8 OF THE P53 GENE	ONCOGENE			English	Note							POLYMERASE CHAIN-REACTION; LI-FRAUMENI SYNDROME; POINT MUTATIONS; DNA FRAGMENTS; BREAST-CANCER; LUNG-CANCER; OCCUR; SUBSTITUTIONS; EXPRESSION; DELETIONS	p53 is the most commonly mutated gene in a large variety of human tumors including familial cancers. Because p53 mutations have in a number of human cancer types, been related to a negative outcome of the disease and the importance of pre-symptomatic diagnosis in cancer-prone families, screening for p53 mutations is becoming more and more widely used. In order to avoid sequencing of the complete coding sequence, several prescreening methods have been developed and applied to the p53 gene. Among them, Single Strand Conformation Polymorphism (SSCP) and Denaturing Gradient Gel Electrophoresis (DGGE) appear to be highly sensitive. In this work, we used 52 different p53 variants to compare the two methods. In our conditions, DGGE is more sensitive than SSCP since 100% of the variants were detected. SSCP detected 90% of the variants, but efficiency of the method can still be improved by additional optimization experiments.	INST CURIE,GENET TUMEURS LAB,F-75231 PARIS,FRANCE; INST GENET MOLEC MONTPELLIER,CNRS,F-34033 MONTPELLIER 01,FRANCE	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS)			Molès, Jean-Pierre/M-2286-2017; Theillet, Charles/O-7634-2018	Molès, Jean-Pierre/0000-0002-6863-6350; Theillet, Charles/0000-0001-5555-2759				BAKER SJ, 1990, CANCER RES, V50, P7717; CONDIE A, 1993, HUM MUTAT, V2, P58, DOI 10.1002/humu.1380020111; FISCHER SG, 1983, P NATL ACAD SCI-BIOL, V80, P1579, DOI 10.1073/pnas.80.6.1579; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HAMELIN R, 1994, GASTROENTEROLOGY, V106, P42, DOI 10.1016/S0016-5085(94)94217-X; HAMELIN R, 1993, ONCOGENE, V8, P2213; HAMELIN R, 1994, INT J CANCER, V57; HORIO Y, 1993, CANCER RES, V53, P1; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MARTIN HM, 1992, INT J CANCER, V50, P859, DOI 10.1002/ijc.2910500604; MAZARS GR, 1992, ONCOGENE, V7, P1015; MAZARS R, 1992, CANCER RES, V52, P3918; MAZARS R, 1991, ONCOGENE, V6, P1685; MOLES JP, 1993, ONCOGENE, V8, P583; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PORTIER M, 1992, ONCOGENE, V7, P2539; SANTIBANEZKOREF MF, 1991, LANCET, V338, P1490, DOI 10.1016/0140-6736(91)92303-J; SHEFFIELD VC, 1989, P NATL ACAD SCI USA, V86, P232, DOI 10.1073/pnas.86.1.232; SHEFFIELD VC, 1993, GENOMICS, V16, P325, DOI 10.1006/geno.1993.1193; SPINARDI L, 1991, NUCLEIC ACIDS RES, V19, P4009, DOI 10.1093/nar/19.14.4009; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; TOMINAGA O, 1993, ONCOGENE, V8, P2653	25	95	96	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1994	9	6					1739	1743						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NL815	8183571				2022-12-25	WOS:A1994NL81500028
J	CHANDRA, M; DASILVA, EF; SORENSON, MM; FERRO, JA; PEARLSTONE, JR; NASH, BE; BORGFORD, T; KAY, CM; SMILLIE, LB				CHANDRA, M; DASILVA, EF; SORENSON, MM; FERRO, JA; PEARLSTONE, JR; NASH, BE; BORGFORD, T; KAY, CM; SMILLIE, LB			THE EFFECTS OF N-HELIX DELETION AND MUTANT F29W ON THE CA2+ BINDING AND FUNCTIONAL-PROPERTIES OF CHICKEN SKELETAL-MUSCLE TROPONIN-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THIN FILAMENT; CONFORMATIONAL TRANSITION; CALCIUM-BINDING; DIRECTED MUTAGENESIS; MOLECULAR MECHANISM; VERTEBRATE MUSCLE; CA-2+ DEPENDENCE; TERMINAL HELIX; RABBIT PSOAS; CONTRACTION	To assess the structural and functional significance of the N helix (residues 3-13) of avian recombinant troponin C (rTnC), we have constructed NHdel, in which residues 1-11 have been deleted, both in rTnC and in the spectral probe mutant F29W (Pearlstone, J. R., Borgford, T., Chandra, M., Oikawa, K., Kay, C. M., Herzberg, O., Moult, J., Herklotz, A., Reinach, F. C., and Smillie, L.B. (1992) Biochemistry 31, 6545-6553). Comparison of the far- and near-UV CD spectra (+/-Ca2+) of F29W and F29W/ NHdel and titration of the Ca2+-induced ellipticity and fluorescence changes indicates that the deletion has little effect on the global fold of the molecule but reduces the Ca2+ affinity of the N domain, but not the C domain, by 1.6-1.8-fold. Comparisons of the mutants NHdel, F29W, and F29W/NHdel with rTnC have been made using several functional assays. In reconstituted troponin-tropomyosin actomyosin subfragment 1 and myofibrillar ATPase systems, both F29W and NHdel have significantly reduced Ca2+-activated enzymic activities. These effects are cumulative in the double mutant F29W/NHdel. On the other hand, maximal isometric tension development in Ca2+-activated reconstituted skinned fibers is not affected with F29W and NHdel, although the Ca2+ sensitivity of NHdel in this system is markedly reduced. We conclude that both mutations, NHdel and F29W, are functionally deleterious, possibly affecting interactions of the N domain with troponin I and/or T.	UNIV ALBERTA,DEPT BIOCHEM,MRC CANADA,PROT STRUCT & FUNCT GRP,EDMONTON T6G 2H7,AB,CANADA; FED UNIV RIO DE JANEIRO,CCS,ICB,DEPT BIOQUIM MED,BR-21941590 RIO JANEIRO,BRAZIL	University of Alberta; Universidade Federal do Rio de Janeiro			Ferro, Jesus Aparecido A/C-8251-2013	Ferro, Jesus Aparecido A/0000-0002-3966-1303; Fidalgo da Silva, Elizabeth/0000-0003-3540-9335				BARANY M, 1967, J GEN PHYSIOL, V50, P197, DOI 10.1085/jgp.50.6.197; BRANDT PW, 1984, J MOL BIOL, V180, P379, DOI 10.1016/S0022-2836(84)80010-8; BRANDT PW, 1990, J MOL BIOL, V212, P473, DOI 10.1016/0022-2836(90)90326-H; CHANDRA M, 1994, BIOCHEMISTRY-US, V33, P2961, DOI 10.1021/bi00176a028; Cohen P, 1988, CALMODULIN; COOKE R, 1988, J PHYSIOL-LONDON, V395, P77, DOI 10.1113/jphysiol.1988.sp016909; COX JA, 1981, BIOCHEM J, V195, P205, DOI 10.1042/bj1950205; DASILVA ACR, 1993, EUR J BIOCHEM, V213, P599; DASILVA EF, 1993, J BIOL CHEM, V268, P26220; DOBROWOLSKI Z, 1991, J BIOL CHEM, V266, P5703; DOBROWOLSKI Z, 1991, BIOCHEMISTRY-US, V30, P7089, DOI 10.1021/bi00243a008; EASTWOOD AB, 1979, TISSUE CELL, V11, P553, DOI 10.1016/0040-8166(79)90062-4; FUJIMORI K, 1990, NATURE, V345, P182, DOI 10.1038/345182a0; GEORGE SE, 1993, J BIOL CHEM, V268, P25213; GLYN H, 1985, J PHYSIOL-LONDON, V365, P259, DOI 10.1113/jphysiol.1985.sp015770; GOLDMAN YE, 1987, ANNU REV PHYSIOL, V49, P629; GOLOSINSKA K, 1991, J BIOL CHEM, V266, P15797; GRABAREK Z, 1990, NATURE, V345, P132, DOI 10.1038/345132a0; GRABAREK Z, 1992, J MUSCLE RES CELL M, V13, P383, DOI 10.1007/BF01738034; GULATI J, 1993, J BIOL CHEM, V268, P11685; GULATI J, 1992, J BIOL CHEM, V267, P25073; HARTREE EF, 1972, ANAL BIOCHEM, V48, P422, DOI 10.1016/0003-2697(72)90094-2; HEINONEN JK, 1981, ANAL BIOCHEM, V113, P313, DOI 10.1016/0003-2697(81)90082-8; HERZBERG O, 1985, NATURE, V313, P653, DOI 10.1038/313653a0; HERZBERG O, 1986, J BIOL CHEM, V261, P2638; HERZBERG O, 1985, BIOCHEMISTRY-US, V24, P5298, DOI 10.1021/bi00341a004; HERZBERG O, 1988, J MOL BIOL, V203, P761, DOI 10.1016/0022-2836(88)90208-2; JOHNSON JD, 1978, J BIOL CHEM, V253, P3775; KERRICK WGL, 1991, J MUSCLE RES CELL M, V12, P53, DOI 10.1007/BF01781174; KNIGHT PJ, 1982, METHOD ENZYMOL, V85, P9; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUSHMERICK MJ, 1982, FED PROC, V41, P2232; LEAVIS PC, 1984, CRC CR REV BIOCH MOL, V16, P235, DOI 10.3109/10409238409108717; LEVY RM, 1976, BIOCHIM BIOPHYS ACTA, V430, P352, DOI 10.1016/0005-2728(76)90091-8; LI MX, 1994, BIOCHEMISTRY-US, V33, P917, DOI 10.1021/bi00170a010; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCCUBBIN WD, 1982, BIOCHEMISTRY-US, V21, P5948, DOI 10.1021/bi00266a034; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; MORIMOTO S, 1987, J BIOCHEM-TOKYO, V101, P291, DOI 10.1093/oxfordjournals.jbchem.a121913; MOSS RL, 1992, CIRC RES, V70, P865, DOI 10.1161/01.RES.70.5.865; NAGAI K, 1984, NATURE, V309, P810, DOI 10.1038/309810a0; PARMACEK MS, 1991, CIRCULATION, V84, P991, DOI 10.1161/01.CIR.84.3.991; PEARLSTONE JR, 1992, BIOCHEMISTRY-US, V31, P9703, DOI 10.1021/bi00155a025; PEARLSTONE JR, 1992, BIOCHEMISTRY-US, V31, P6545, DOI 10.1021/bi00143a026; PFERRER S, 1988, BIOPHYS J, V53, P127, DOI 10.1016/S0006-3495(88)83074-1; POTTER JD, 1982, CALCIUM CELL FUNCTIO, V2, P145; PUTKEY JA, 1991, J BIOL CHEM, V266, P14881; REINACH FC, 1988, J BIOL CHEM, V263, P2371; SATYSHUR KA, 1988, J BIOL CHEM, V263, P1628; SHENG Z, 1991, J BIOL CHEM, V266, P5711; SIEMANKOWSKI RF, 1985, P NATL ACAD SCI USA, V82, P658, DOI 10.1073/pnas.82.3.658; SMITH L, 1993, BIOPHYS J, V64, pA134; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; SUNDARALINGAM M, 1985, SCIENCE, V227, P945, DOI 10.1126/science.3969570; TOBACMAN LS, 1987, BIOCHEMISTRY-US, V26, P492, DOI 10.1021/bi00376a022; TOBACMAN LS, 1990, J BIOL CHEM, V265, P931; WANG ZY, 1992, P NATL ACAD SCI USA, V89, P11814, DOI 10.1073/pnas.89.24.11814; ZOLLER MJ, 1982, NUCLEIC ACIDS RES, V10, P6487, DOI 10.1093/nar/10.20.6487; ZOT AS, 1987, ANNU REV BIOPHYS BIO, V16, P535; ZOT AS, 1987, J BIOL CHEM, V262, P1966; ZOT HG, 1982, J BIOL CHEM, V257, P7678; ZOT HG, 1986, J BIOL CHEM, V261, P5883	62	45	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					14988	14994						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195134				2022-12-25	WOS:A1994NP73800025
J	CORTAY, JC; NEGRE, D; SCARABEL, M; RAMSEIER, TM; VARTAK, NB; REIZER, J; SAIER, MH; COZZONE, AJ				CORTAY, JC; NEGRE, D; SCARABEL, M; RAMSEIER, TM; VARTAK, NB; REIZER, J; SAIER, MH; COZZONE, AJ			IN-VITRO ASYMMETRIC BINDING OF THE PLEIOTROPIC REGULATORY PROTEIN, FRUR, TO THE ACE OPERATOR CONTROLLING GLYOXYLATE SHUNT ENZYME SYNTHESIZES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FRUCTOSE PHOSPHOTRANSFERASE SYSTEM; LAC REPRESSOR PROTEIN; ESCHERICHIA-COLI; SALMONELLA-TYPHIMURIUM; NUCLEOTIDE-SEQUENCE; AFFINITY-CHROMATOGRAPHY; GENETIC-REGULATION; OPERON EXPRESSION; DNA INTERACTIONS; ACETATE OPERON	The fruR gene of Escherichia coli, which encodes the regulatory protein FruR, was cloned in the pT7-5 expression vector so as to overproduce a protein tagged with 6 histidine residues. By using a one-step chromatographic procedure, FruR was purified to near homogeneity. Analysis of the protein under both denaturing and nondenaturing conditions indicated that it is a tetramer with a molecular mass of about 150 kilodaltons. The positions of interference between FruR and the operator of the acetate operon were examined. The number and nature of the nucleotides essential for FruR binding were determined by several different techniques: base methylation with dimethyl sulfate, base removal by formic acid and hydrazine, uracil interference, and hydroxyl radical footprinting. It was observed that FruR asymmetrically binds to a 16-base pair DNA sequence located 170 base pairs upstream from the transcriptional start point of the ace operon.	CNRS,INST BIOL & CHIM PROT,F-69367 LYON,FRANCE; UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093	Centre National de la Recherche Scientifique (CNRS); University of California System; University of California San Diego				Cortay, Jean-Claude/0000-0003-3676-8436; NEGRE, Didier/0000-0003-4769-0814	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI014176, R01AI021702] Funding Source: NIH RePORTER; NIAID NIH HHS [NIAID 5R01AI 21702, NIAID 2R01AI 14176] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALBERTI S, 1993, EMBO J, V12, P3227, DOI 10.1002/j.1460-2075.1993.tb05992.x; ALLEN TD, 1991, J BIOL CHEM, V266, P6113; BLATTNER FR, 1977, SCIENCE, V196, P161, DOI 10.1126/science.847462; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUNELLE A, 1987, P NATL ACAD SCI USA, V84, P6673, DOI 10.1073/pnas.84.19.6673; BYRNE C, 1988, NUCLEIC ACIDS RES, V19, P9342; CHAKERIAN AE, 1991, J BIOL CHEM, V266, P1371; CHIN AM, 1989, J BACTERIOL, V171, P2424, DOI 10.1128/jb.171.5.2424-2434.1989; CHIN AM, 1987, J BACTERIOL, V169, P897, DOI 10.1128/jb.169.2.897-899.1987; CHUNG T, 1988, J BACTERIOL, V170, P386, DOI 10.1128/jb.170.1.386-392.1988; CORTAY JC, 1989, BIOCHIMIE, V71, P1043, DOI 10.1016/0300-9084(89)90109-0; CORTAY JC, 1991, EMBO J, V10, P675, DOI 10.1002/j.1460-2075.1991.tb07996.x; DEVCHAND PR, 1993, NUCLEIC ACIDS RES, V21, P3437, DOI 10.1093/nar/21.15.3437; DICKSON RC, 1975, SCIENCE, V187, P27, DOI 10.1126/science.1088926; DUCLOS B, 1989, NUCLEIC ACIDS RES, V17, P2856, DOI 10.1093/nar/17.7.2856; FARABAUGH PJ, 1978, NATURE, V274, P765, DOI 10.1038/274765a0; FELDHEIM DA, 1990, J BACTERIOL, V172, P5459, DOI 10.1128/jb.172.9.5459-5469.1990; GARNAK M, 1978, SCIENCE, V203, P1111; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GEERSE RH, 1989, MOL GEN GENET, V216, P517, DOI 10.1007/BF00334399; GEERSE RH, 1989, MOL GEN GENET, V218, P348, DOI 10.1007/BF00331288; GOEDDEL DV, 1987, J MOL BIOL, V123, P661; HEMDAN ES, 1989, P NATL ACAD SCI USA, V86, P1811, DOI 10.1073/pnas.86.6.1811; HOUMAN F, 1990, CELL, V62, P1153, DOI 10.1016/0092-8674(90)90392-R; JAHREIS K, 1991, MOL GEN GENET, V226, P332, DOI 10.1007/BF00273623; KAMMANN M, 1989, NUCLEIC ACIDS RES, V17, P5404, DOI 10.1093/nar/17.13.5404; LAPORTE DC, 1982, NATURE, V300, P458, DOI 10.1038/300458a0; LECLERC G, 1990, J BACTERIOL, V172, P4696, DOI 10.1128/jb.172.8.4696-4700.1990; MAHADEVAN S, 1987, CELL, V50, P485, DOI 10.1016/0092-8674(87)90502-2; MALOY SR, 1982, J BACTERIOL, V149, P173, DOI 10.1128/JB.149.1.173-180.1982; Maniatis T., 1982, MOL CLONING; Maxam A M, 1980, Methods Enzymol, V65, P499; NEGRE D, 1992, J MOL BIOL, V228, P23, DOI 10.1016/0022-2836(92)90488-6; NIMMO GA, 1984, EUR J BIOCHEM, V141, P401, DOI 10.1111/j.1432-1033.1984.tb08205.x; PORATH J, 1975, NATURE, V258, P598, DOI 10.1038/258598a0; PU WT, 1992, NUCLEIC ACIDS RES, V20, P771, DOI 10.1093/nar/20.4.771; RAMSEIER TM, 1993, J MOL BIOL, V234, P28, DOI 10.1006/jmbi.1993.1561; REZNIKOFF WS, 1992, J BACTERIOL, V174, P655, DOI 10.1128/jb.174.3.655-658.1992; ROLAND KL, 1985, J BACTERIOL, V163, P991, DOI 10.1128/JB.163.3.991-999.1985; SAIER MH, 1990, BACTERIAL ENERGETICS, P273; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; STUDIER WF, 1990, METHOD ENZYMOL, V185, P60, DOI DOI 10.1016/0076-6879(90)85008-C; SUNNARBORG A, 1990, J BACTERIOL, V172, P2642, DOI 10.1128/jb.172.5.2642-2649.1990; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TULLIUS TD, 1987, METHOD ENZYMOL, V155, P537; WEICKERT MJ, 1993, J BACTERIOL, V175, P251, DOI 10.1128/JB.175.1.251-258.1993; WEICKERT MJ, 1992, J BIOL CHEM, V267, P15869; WICK KL, 1991, J BIOL CHEM, V266, P6106	48	67	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					14885	14891						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195118				2022-12-25	WOS:A1994NP73800009
J	TAUCHI, T; FENG, GS; SHEN, R; SONG, HY; DONNER, D; PAWSON, T; BROXMEYER, HE				TAUCHI, T; FENG, GS; SHEN, R; SONG, HY; DONNER, D; PAWSON, T; BROXMEYER, HE			SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE SYP IS A TARGET OF P210BCR-ABL TYROSINE KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; GUANINE-NUCLEOTIDE EXCHANGE; FACTOR RECEPTOR-BETA; P210 BCR-ABL; SIGNAL TRANSDUCTION; SH3 DOMAINS; PHOSPHOLIPASE-C; ADAPTER PROTEIN; GRB2; RAS	The phosphorylation of proteins at tyrosine residues is critical in cellular signal transduction and neoplastic transformation. These mechanisms are regulated by the activities of both protein-tyrosine kinases and protein-tyrosine phosphatases. Recent studies have identified a novel protein-tyrosine phosphatase, termed Syp, that is widely expressed in various tissues. Syp encodes a cytoplasmic phosphatase that contains two Src homology 2 (SH2) domains. Since SH2 domains have been shown to target the association of signal transducing molecules to activated tyrosine kinases, experiments were performed to determine whether Syp might form specific complexes with p210bcr-abl, a fusion protein believed to be involved in the pathogenesis of chronic myelogenous leukemia and, thus, possibly alter or mediate p210bcr-abl tyrosine kinase activity. We found that Syp was highly and constitutively tyrosine phosphorylated in three different murine cell lines transfected with a p210bcr-abl expression vector. Furthermore, p210bcr-abl, Syp, and Grb2 formed stable complexes in BCR-ABL expressing cells. Complex formation between p210bcr-abl and Syp was mediated in vitro by the NH2-terminal SH2 domain of Syp. Last, p210bcr-abl tyrosine kinase was effectively dephosphorylated by Syp in vitro. These results suggest an interaction between Syp and BCR-ABL protein, which might play a role in cellular transformation of BCR-ABL.	INDIANA UNIV, SCH MED, WALTHER ONCOL CTR, DEPT MED HEMATOL ONCOL, INDIANAPOLIS, IN 46202 USA; INDIANA UNIV, SCH MED, WALTHER ONCOL CTR, DEPT BIOCHEM & MOLEC BIOL, INDIANAPOLIS, IN 46202 USA; INDIANA UNIV, SCH MED, DEPT PHYSIOL & BIOPHYS, INDIANAPOLIS, IN 46202 USA; INDIANA UNIV, SCH MED, DEPT MICROBIOL & IMMUNOL, INDIANAPOLIS, IN 46202 USA; MT SINAI HOSP, SAMUEL LUNENFELD RES INST, DIV MOLEC & DEV BIOL, TORONTO M5G 1X5, ON, CANADA	Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute			Pawson, Tony J/E-4578-2013		NATIONAL CANCER INSTITUTE [R37CA036464] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049202, R01HL046549] Funding Source: NIH RePORTER; NCI NIH HHS [R37 CA36464] Funding Source: Medline; NHLBI NIH HHS [R01 HL49202, R01 HL46549] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHMAD S, 1993, P NATL ACAD SCI USA, V90, P2197, DOI 10.1073/pnas.90.6.2197; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DRUKER B, 1992, BLOOD, V79, P2215; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FEEDMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FENG GS, 1994, IN PRESS ONCOGENE; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; KLOETZER W, 1985, VIROLOGY, V140, P230, DOI 10.1016/0042-6822(85)90361-7; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P13434; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MANDANAS RA, 1993, BLOOD, V82, P1838; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PAWSON T, 1988, ONCOGENE, V3, P491; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PENDERGAST AM, 1991, P NATL ACAD SCI USA, V88, P5927, DOI 10.1073/pnas.88.13.5927; PENDERGAST AM, 1993, MOL CELL BIOL, V13, P1728, DOI 10.1128/MCB.13.3.1728; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; PUIL L, 1994, IN PRESS EMBO J; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; SUGIMOTO S, 1993, J BIOL CHEM, V268, P22771; SUH PG, 1988, P NATL ACAD SCI USA, V85, P5419, DOI 10.1073/pnas.85.15.5419; TAUCHI T, 1994, J EXP MED, V179, P167, DOI 10.1084/jem.179.1.167; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; YI TL, 1993, MOL CELL BIOL, V13, P3350, DOI 10.1128/MCB.13.6.3350; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	43	92	96	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					15381	15387						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195176				2022-12-25	WOS:A1994NP73800078
J	KRISANS, SK; ERICSSON, J; EDWARDS, PA; KELLER, GA				KRISANS, SK; ERICSSON, J; EDWARDS, PA; KELLER, GA			FARNESYL-DIPHOSPHATE SYNTHASE IS LOCALIZED IN PEROXISOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER PEROXISOMES; STEROL CARRIER PROTEIN-2; IMMUNOELECTRON MICROSCOPY; CHOLESTEROL-SYNTHESIS; FIREFLY LUCIFERASE; ACETOACETYL-COA; ACETYL-COA; CELLS; PRENYLTRANSFERASE; METABOLISM	In this study, we have investigated the subcellular localization of farnesyl-diphosphate synthase (FPP synthase). FPP synthase produces FPP, which is utilized in the synthesis of squalene, cholesterol, farnesylated and geranylgeranylated proteins, dolichols, coenzyme Q, and the isoprenoid moiety of heme a. This enzyme is found in the 100,000 x g supernatant fraction of cells or tissues and has been considered to be a cytoplasmic protein. In this study, analysis of FPP synthase activity and protein in fractionated rat liver together with immunofluorescent and immunoelectron microscopy studies demonstrated unequivocally that FPP synthase is largely localized in peroxisomes. These data, in combination with the previous observation that mevalonate kinase is predominantly localized in peroxisomes, suggest that peroxisomes are the major site of synthesis of FPP from mevalonate. We also demonstrate that in liver tissue obtained from patients with peroxisomal deficiency diseases (Zellweger syndrome and neonatal adrenoleukodystrophy), the activities of five enzymes involved in isoprenoid synthesis, namely mevalonate kinase, phosphomevalonate kinase, mevalonate-diphosphate decarboxylase, isopentenyl-diphosphate isomerase, and FPP synthase, are significantly reduced, consistent with a peroxisomal localization of these enzymes.	UNIV CALIF LOS ANGELES,SCH MED,DEPT BIOL CHEM,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DIV CARDIOL,LOS ANGELES,CA 90024; UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California San Diego	KRISANS, SK (corresponding author), SAN DIEGO STATE UNIV,DEPT BIOL,SAN DIEGO,CA 92182, USA.		Ericsson, Johan/AAA-6664-2020	Ericsson, Johan/0000-0003-1186-6574	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL030568] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044350, R01DK032852] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 30568] Funding Source: Medline; NIDDK NIH HHS [DK 44350, DK 32852] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASHBY MN, 1989, J BIOL CHEM, V264, P635; BIARDI L, 1994, J BIOL CHEM, V269, P1197; BRUENGER E, 1986, ARCH BIOCHEM BIOPHYS, V248, P620, DOI 10.1016/0003-9861(86)90516-3; CLARKE CF, 1987, MOL CELL BIOL, V7, P3138, DOI 10.1128/MCB.7.9.3138; ERICSSON J, 1992, J BIOL CHEM, V267, P18708; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GOULD SJ, 1990, J CELL BIOL, V110, P27, DOI 10.1083/jcb.110.1.27; HODGE VJ, 1991, BIOCHEM BIOPH RES CO, V181, P537, DOI 10.1016/0006-291X(91)91222-X; HOVIK R, 1991, J LIPID RES, V32, P993; JOLY A, 1993, J BIOL CHEM, V268, P26983; KELLER GA, 1987, P NATL ACAD SCI USA, V84, P3264, DOI 10.1073/pnas.84.10.3264; KELLER GA, 1986, J CELL BIOL, V103, P875, DOI 10.1083/jcb.103.3.875; KELLER GA, 1984, P NATL ACAD SCI-BIOL, V81, P5744, DOI 10.1073/pnas.81.18.5744; KELLER GA, 1989, J CELL BIOL, V108, P1353, DOI 10.1083/jcb.108.4.1353; KELLER GA, 1985, P NATL ACAD SCI USA, V82, P770, DOI 10.1073/pnas.82.3.770; KRISANS SK, 1992, AM J RESP CELL MOL, V7, P358, DOI 10.1165/ajrcmb/7.4.358; KRISANS SK, 1988, J CELL BIOL, V107, P122; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lazarow P. B., 1989, METABOLIC BASIS INHE, P1479; MCLEAN IW, 1974, J HISTOCHEM CYTOCHEM, V22, P1077, DOI 10.1177/22.12.1077; NOLAND BJ, 1980, J BIOL CHEM, V255, P4282; RILLING HC, 1985, STEROLS BILE ACIDS, P17; SPURGEON SL, 1981, BIOSYNTHESIS ISOPREN, V1, P2; STAMELLOS KD, 1992, J BIOL CHEM, V267, P5560; SUBRAMANI S, 1993, ANNU REV CELL BIOL, V9, P445, DOI 10.1146/annurev.cb.09.110193.002305; SUZUKI Y, 1990, CELL STRUCT FUNCT, V15, P301, DOI 10.1247/csf.15.301; THOMPSON SL, 1990, J BIOL CHEM, V265, P5731; TOKUYASU KT, 1973, J CELL BIOL, V57, P551, DOI 10.1083/jcb.57.2.551	28	100	101	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					14165	14169						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188698				2022-12-25	WOS:A1994NL60600067
J	SAKURAI, T; ABE, Y; KASUYA, Y; TAKUWA, N; SHIBA, R; YAMASHITA, T; ENDO, T; GOTO, K				SAKURAI, T; ABE, Y; KASUYA, Y; TAKUWA, N; SHIBA, R; YAMASHITA, T; ENDO, T; GOTO, K			ACTIVIN-A STIMULATES MITOGENESIS IN SWISS 3T3 FIBROBLASTS WITHOUT ACTIVATION OF MITOGEN-ACTIVATED PROTEIN-KINASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE THREONINE KINASE; FSH-RELEASING PROTEIN; C-MYC-GENE; GROWTH-FACTOR; MAP KINASE; EXPRESSION CLONING; MESSENGER-RNA; PHOSPHORYLATION; RECEPTOR; CELLS	Activin A stimulated DNA synthesis and transient c-fos expression in quiescent Swiss 3T3 fibroblasts. The activin A-induced DNA synthesis was dose dependent with a half-maximal effect obtained at 0.3 nM. The maximal response obtained at 10 nM was comparable with that induced by 5 ng/ml basic fibroblast growth factor. Swiss 3T3 fibroblasts expressed abundant high affinity binding sites for I-125-labeled activin A with a K-d value of 0.63 nM and the number of binding sites at 24,000/cell. Northern blot analysis revealed that Swiss 3T3 fibroblasts express a high level of type II activin receptor mRNA. In an attempt to elucidate the mechanism of mitogenic action of activin A, we examined the effect of activin A on mitogen-activated protein kinase activation. Unexpectedly, however, activin A did not induce kinase activation under conditions in which basic fibroblast growth factor and endothelin-1 at similar or even less potent mitogenic concentrations did. Furthermore, activin A did not induce phosphorylation of the Erk2 species of mitogen-activated protein kinase. These observations strongly suggest that the activation of mitogen-activated protein kinase is not a necessary step for activin A-induced DNA synthesis in Swiss 3T3 fibroblasts.	UNIV TOKYO,FAC MED,DEPT PHYSIOL,BUNKYO KU,TOKYO 113,JAPAN; UNIV TOKYO,DEPT INTERNAL MED 4,BUNKYO KU,TOKYO 112,JAPAN; CHIBA UNIV,FAC SCI,DEPT BIOL,CHIBA 263,JAPAN	University of Tokyo; University of Tokyo; Chiba University	SAKURAI, T (corresponding author), UNIV TSUKUBA,INST BASIC MED SCI,DEPT PHARMACOL,TENNODAI 1-1-1,TSUKUBA,IBARAKI 305,JAPAN.		Abe, Yoichiro/J-5576-2013; Shiba, Reiko/R-3091-2019; Abe, Yoichiro/AAN-8801-2020	Abe, Yoichiro/0000-0001-6163-8794; Abe, Yoichiro/0000-0001-6163-8794; TAKUWA, Noriko/0000-0002-4278-2704; Kasuya, Yoshitoshi/0000-0003-0614-5836				ATTISANO L, 1992, CELL, V68, P97, DOI 10.1016/0092-8674(92)90209-U; ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; ETO Y, 1987, BIOCHEM BIOPH RES CO, V142, P1095, DOI 10.1016/0006-291X(87)91528-2; GEORGI LL, 1990, CELL, V61, P635, DOI 10.1016/0092-8674(90)90475-T; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GONZALEZMANCHON C, 1989, ENDOCRINOLOGY, V125, P1666, DOI 10.1210/endo-125-3-1666; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; GREEN JBA, 1990, NATURE, V347, P391, DOI 10.1038/347391a0; HEDGER MP, 1989, MOL CELL ENDOCRINOL, V61, P133, DOI 10.1016/0303-7207(89)90198-6; KAIBUCHI K, 1986, J BIOL CHEM, V261, P1187; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KOHNO M, 1992, BIOCHEM J, V287, P917, DOI 10.1042/bj2870917; KOJIMA I, 1989, BIOCHEM BIOPH RES CO, V159, P1107, DOI 10.1016/0006-291X(89)92223-7; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; MATHEWS LS, 1992, SCIENCE, V255, P1702, DOI 10.1126/science.1313188; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; PALUMBO AP, 1986, EXP CELL RES, V167, P276, DOI 10.1016/0014-4827(86)90226-0; POSADA J, 1992, SCIENCE, V255, P212, DOI 10.1126/science.1313186; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; ROBERTS TM, 1992, NATURE, V360, P534, DOI 10.1038/360534a0; SAKURAI T, 1992, BIOCHEM BIOPH RES CO, V186, P342, DOI 10.1016/S0006-291X(05)80813-7; SAWCHENKO PE, 1988, NATURE, V334, P868; SCHUBERT D, 1990, NATURE, V344, P868, DOI 10.1038/344868a0; SMITH JC, 1990, NATURE, V345, P729, DOI 10.1038/345729a0; SOKOL S, 1991, NATURE, V351, P409, DOI 10.1038/351409a0; STEH A, 1991, J BIOL CHEM, V266, P23521; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; TAKUWA N, 1989, J BIOL CHEM, V264, P7856; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; VALE W, 1986, NATURE, V321, P776, DOI 10.1038/321776a0; Vale W., 1990, HDB EXPT PHARM, P211; VANDENEIJNDENVANRAAIJ AJM, 1990, NATURE, V345, P732, DOI 10.1038/345732a0; VANSTRAATEN F, 1983, P NATL ACAD SCI-BIOL, V80, P3183; YU J, 1987, NATURE, V330, P765, DOI 10.1038/330765a0	37	27	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					14118	14122						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188692				2022-12-25	WOS:A1994NL60600060
J	SCRUTTON, NS; PACKMAN, LC; MATHEWS, FS; ROHLFS, RJ; HILLE, R				SCRUTTON, NS; PACKMAN, LC; MATHEWS, FS; ROHLFS, RJ; HILLE, R			ASSEMBLY OF REDOX CENTERS IN THE TRIMETHYLAMINE DEHYDROGENASE OF BACTERIUM W(3)A(1) - PROPERTIES OF THE WILD-TYPE ENZYME AND A C30A MUTANT EXPRESSED FROM A CLONED GENE IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR FLAVOPROTEIN; COVALENTLY BOUND COENZYME; 6-HYDROXY-D-NICOTINE OXIDASE; SEQUENCE DETERMINATION; BACILLUS-SUBTILIS; FLAVIN; IDENTIFICATION; FLAVINYLATION; CLONING; CLUSTER	In trimethylamine dehydrogenase, the enzyme-bound FMN is covalently linked to Cys-30 by a 6-S cysteinyl FMN bond. The role played by this bond in catalysis has been investigated using a recombinant wild-type trimethylamine dehydrogenase and a Cys-30 to Ala-30 mutant, both expressed from a cloned gene (tmd) in the heterologous host Escherichia coli. The recombinant wild-type and C30A enzymes were found to be quantitatively associated with the 4Fe-4S center and ADP which are both present in the enzyme isolated from bacterium W(3)A(1). In contrast to the enzyme isolated from bacterium W(3)A(1), however, both recombinant proteins contained less than stoichiometric amounts of flavin and were refractory to reconstitution by FMN. The FMN in the recombinant wild-type enzyme was shown to be covalently linked to the protein, and the enzyme possessed catalytic properties similar to its counterpart isolated from bacterium W(3)A(1). It is envisaged that flavinylation proceeds via a nucleophilic attack by the thiolate of Cys-30 at C-6 of the isoalloxazine ring of enzyme-bound FMN. The C30A mutant was found to bind FMN noncovalently and to also catalyze the demethylation of trimethylamine. The major effect of removing the 6-S-cysteinyl FMN bond is to raise the apparent K-m for trimethylamine by 2 orders of magnitude and to diminish the apparent k(cat) for the reaction by only a factor of 2. Therefore, the 6-S-cysteinyl FMN bond is not essential for catalysis, but it is required for efficient functioning of the enzyme at micromolar concentrations of substrate.	WASHINGTON UNIV,SCH MED,DEPT BIOCHEM,ST LOUIS,MO 63110; OHIO STATE UNIV,DEPT MED BIOCHEM,COLUMBUS,OH 43210	Washington University (WUSTL); University System of Ohio; Ohio State University	SCRUTTON, NS (corresponding author), UNIV CAMBRIDGE,CTR MOLEC RECOGNIT,CAMBRIDGE CB2 1QW,ENGLAND.							BARBER MJ, 1991, J BIOL CHEM, V267, P6611; BIGGIN MD, 1983, P NATL ACAD SCI-BIOL, V80, P3963, DOI 10.1073/pnas.80.13.3963; BOYD G, 1992, FEBS LETT, V308, P271, DOI 10.1016/0014-5793(92)81291-S; BRANDSCH R, 1987, FEBS LETT, V224, P121, DOI 10.1016/0014-5793(87)80433-7; BRANDSCH R, 1991, J BIOL CHEM, V266, P19056; BROOKFIELD DE, 1991, FEBS LETT, V295, P13, DOI 10.1016/0014-5793(91)81373-G; CECCHINI G, 1988, FASEB J, V2, P354; CRICKMORE N, 1992, MOL MICROBIOL, V6, P1533, DOI 10.1111/j.1365-2958.1992.tb00874.x; DAWSON RMC, 1984, DATA BIOCH RES, P105; FLINTA C, 1986, EUR J BIOCHEM, V154, P193, DOI 10.1111/j.1432-1033.1986.tb09378.x; GROSS NH, 1984, METHOD ENZYMOL, V106, P261; HILL CL, 1977, P NATL ACAD SCI USA, V74, P547, DOI 10.1073/pnas.74.2.547; KASPRZAK AA, 1983, BIOCHEM J, V211, P535, DOI 10.1042/bj2110535; KASPRZAK AA, 1983, J BACTERIOL, V156, P348, DOI 10.1128/JB.156.1.348-353.1983; KENNEY WC, 1978, FEBS LETT, V85, P137, DOI 10.1016/0014-5793(78)81265-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEGRICE SFJ, 1986, MOL GEN GENET, V204, P229, DOI 10.1007/BF00425503; LEHMAN TC, 1990, ANAL BIOCHEM, V186, P280, DOI 10.1016/0003-2697(90)90080-S; LIM LW, 1988, J BIOL CHEM, V263, P3075; LIM LW, 1986, J BIOL CHEM, V261, P5140; MASSEY V, 1966, J BIOL CHEM, V241, P3417; MAUCH L, 1989, FEBS LETT, V257, P86, DOI 10.1016/0014-5793(89)81792-2; MORAN CP, 1982, MOL GEN GENET, V186, P339, DOI 10.1007/BF00729452; PERRETT D, 1991, BIOMED CHROMATOGR, V5, P207, DOI 10.1002/bmc.1130050506; PHILLIPS DC, 1978, J MOL BIOL, V119, P329, DOI 10.1016/0022-2836(78)90440-0; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SINGER TP, 1984, METHOD ENZYMOL, V106, P369; STEENKAMP DJ, 1978, BIOCHEM J, V169, P361, DOI 10.1042/bj1690361; STEENKAMP DJ, 1976, BIOCHIM BIOPHYS ACTA, V429, P705, DOI 10.1016/0005-2744(76)90319-3; STEENKAMP DJ, 1978, J BIOL CHEM, V253, P4086; STEENKAMP DJ, 1978, J BIOL CHEM, V253, P2818; STEVENSON RC, 1986, BIOCHIM BIOPHYS ACTA, V869, P81, DOI 10.1016/0167-4838(86)90313-4; VANONI MA, 1992, BIOCHEMISTRY-US, V31, P4613, DOI 10.1021/bi00134a011; VISCO C, 1985, J BIOL CHEM, V260, P6133	35	43	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					13942	13950						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188674				2022-12-25	WOS:A1994NL60600037
J	SHIMONAKA, M; YAMAGUCHI, Y				SHIMONAKA, M; YAMAGUCHI, Y			PURIFICATION AND BIOLOGICAL CHARACTERIZATION OF EPITAXIN, A FIBROBLAST-DERIVED MOTILITY FACTOR FOR EPITHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCYTE GROWTH-FACTOR; SCATTER FACTOR; CARCINOMA CELLS; FACTOR-BETA; MIGRATION; EXPRESSION; RECEPTOR; IDENTIFICATION; CHEMOTAXIS; CYTOKINES	We have identified a motility factor in conditioned medium of human fibroblasts that stimulates the migration of HepG2 cells in the Boyden chamber assay. This factor, termed epitaxin, was purified to homogeneity by ammonium sulfate precipitation, hydrophobic interaction chromatography on phenyl-Sepharose, and a series of reverse phase high performance liquid chromatography. Under a nonreducing condition, purified epitaxin migrated as a 36-kDa band, and the biological activity was recovered from the area in the gel coinciding with this band. Purified epitaxin stimulates the motility of HepG2 cells in the concentrations above 1 ng/ml with half-maximal activity at 4.2 ng/ml, and its mode of action is mainly chemotactic. Epitaxin slightly stimulates DNA synthesis of HepG2 cells, while scatter factor/hepatocyte growth factor which also stimulates the motility of HepG2 cells showed a growth-inhibitory effect. Epitaxin increases the motility of a wide variety of epithelially derived tumor cell lines, but none of the tested fibroblast lines responded to epitaxin. These results define epitaxin as a novel fibroblast-derived factor that affects the migration, and possibly the invasion, of epithelially derived tumor cells.	LA JOLLA CANC RES FDN,CANC RES CTR,LA JOLLA,CA 92037	Sanford Burnham Prebys Medical Discovery Institute					NATIONAL CANCER INSTITUTE [R01CA057366] Funding Source: NIH RePORTER; NCI NIH HHS [CA-57366] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ATNIP KD, 1987, BIOCHEM BIOPH RES CO, V146, P996, DOI 10.1016/0006-291X(87)90746-7; CHAN AML, 1991, SCIENCE, V254, P1382, DOI 10.1126/science.1720571; ELBADRY OM, 1990, CELL GROWTH DIFFER, V1, P325; GHERARDI E, 1989, P NATL ACAD SCI USA, V86, P5844, DOI 10.1073/pnas.86.15.5844; GREY AM, 1989, P NATL ACAD SCI USA, V86, P2438, DOI 10.1073/pnas.86.7.2438; GROTENDORST GR, 1981, P NATL ACAD SCI-BIOL, V78, P3669, DOI 10.1073/pnas.78.6.3669; HART IR, 1989, BIOCHIM BIOPHYS ACTA, V989, P65, DOI 10.1016/0304-419X(89)90035-8; KAKUNAGA T, 1978, P NATL ACAD SCI USA, V75, P1334, DOI 10.1073/pnas.75.3.1334; KOYAMA N, 1993, J BIOL CHEM, V268, P13301; LEAVITT J, 1982, CELL, V28, P259, DOI 10.1016/0092-8674(82)90344-0; LIOTTA LA, 1991, CANCER RES, V51, pS5054; LIOTTA LA, 1986, P NATL ACAD SCI USA, V83, P3302, DOI 10.1073/pnas.83.10.3302; MOSCATELLI D, 1986, P NATL ACAD SCI USA, V83, P2091, DOI 10.1073/pnas.83.7.2091; NAKAMURA T, 1986, P NATL ACAD SCI USA, V83, P6489, DOI 10.1073/pnas.83.17.6489; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; OTT MO, 1984, EMBO J, V3, P2505, DOI 10.1002/j.1460-2075.1984.tb02164.x; POSTLETHWAITE AE, 1987, J EXP MED, V165, P251, DOI 10.1084/jem.165.1.251; ROSEN EM, 1991, CANCER RES, V51, P5315; SHIOTA G, 1992, P NATL ACAD SCI USA, V89, P373, DOI 10.1073/pnas.89.1.373; SILLETTI S, 1991, CANCER RES, V51, P3507; STOKER M, 1991, BIOCHIM BIOPHYS ACTA, V1072, P81, DOI 10.1016/0304-419X(91)90008-9; STOKER M, 1989, J CELL PHYSIOL, V139, P565, DOI 10.1002/jcp.1041390316; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; STONE KL, 1989, PRACTICAL GUIDE PROT; STRACKE ML, 1992, J BIOL CHEM, V267, P2524; STRACKE ML, 1988, BIOCHEM BIOPH RES CO, V153, P1076, DOI 10.1016/S0006-291X(88)81338-X; TAJIMA H, 1992, EXP CELL RES, V202, P423, DOI 10.1016/0014-4827(92)90095-P; TAMM I, 1989, J EXP MED, V170, P1649, DOI 10.1084/jem.170.5.1649; VALLES AM, 1990, P NATL ACAD SCI USA, V87, P1124, DOI 10.1073/pnas.87.3.1124; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; WEIDNER KM, 1991, P NATL ACAD SCI USA, V88, P7001, DOI 10.1073/pnas.88.16.7001; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0; YOSHIDA K, 1970, INT J CANCER, V6, P123, DOI 10.1002/ijc.2910060116; ZIGMOND SH, 1973, J EXP MED, V137, P387, DOI 10.1084/jem.137.2.387	34	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					14284	14289						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188713				2022-12-25	WOS:A1994NL60600084
J	BHAT, BG; WANG, P; COLEMAN, RA				BHAT, BG; WANG, P; COLEMAN, RA			HEPATIC MONOACYLGLYCEROL ACYLTRANSFERASE IS REGULATED BY SN-1,2-DIACYLGLYCEROL AND BY SPECIFIC LIPIDS IN TRITON X-100 PHOSPHOLIPID-MIXED MICELLES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; MIXED MICELLES; RAT INTESTINE; SUCKLING RAT; ACTIVATION; ENZYMES; ACIDS; PHOSPHOLIPASE-A2; DIACYLGLYCEROL; BIOSYNTHESIS	The lipid cofactor requirement of hepatic monoacylglycerol acyltransferase (MGAT) (EC 2.3.1.22) was studied in Triton X-100/lipid-mixed micelles. Anionic phospholipids and anionic lysophospholipids stimulated MGAT activity, whereas fatty acids and sphingosine inhibited enzyme activity. Phosphatidic acid was a potent activator, stimulating MGAT 11-fold at 4.2 mol %. Kinetic studies revealed that phosphatidic acid, with an apparent K-alpha of 0.26 mol %, was a better activator than phos- phatidylserine, phosphatidylinositol, or cardiolipin. Of the anionic lysophospholipids, lysophosphatidic acid was a better activator than lysophosphatidylserine, stimulating maximally at less than 3 mol %. Oleate was a more potent inhibitor (K-i, 2.4 mol %) than sphingosine (K-i, 18.3 mol %). The dependence of MGAT on sn-2-monoacylglycerol was not cooperative in the absence or presence of anionic phospholipids, oleic acid, or sphingosine. The apparent K-m for sn-2-monoC18:1-glycerol was 1.24 mol % in the presence of maximally activating phospholipid and 0.19 mol % when phospholipid was omitted. MGAT's product sn-1,2-diacylglycerol was a weaker activator than the anionic phospholipids, but the effects of diacylglycerol and phospholipid were additive. Activation by sn-1,2-diC18:1-glycerol was highly cooperative with a Hill coefficient of 3.6. Activation was specific for the sn-1,2-stereoisomer; neither 1,3-diacylglycerol nor the ether analogs of sn-1,2- or 1,3-diacylglycerol were activators. Since several of the lipid modulators of MGAT activity are intracellular second messengers, these data suggest the possibility that regulatory links exist between signal transduction and the synthesis of complex lipids via the monoacylglycerol pathway.	UNIV N CAROLINA,DEPT PEDIAT,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill	BHAT, BG (corresponding author), UNIV N CAROLINA,DEPT NUTR,CB 7400,CHAPEL HILL,NC 27599, USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD019068] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 19068] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BELL RM, 1991, J BIOL CHEM, V266, P4661; BHAT BG, 1993, ARCH BIOCHEM BIOPHYS, V300, P663, DOI 10.1006/abbi.1993.1092; BISHOP WR, 1986, J BIOL CHEM, V261, P6993; COLEMAN RA, 1984, J BIOL CHEM, V259, P8934; COLEMAN RA, 1986, J LIPID RES, V27, P158; COLEMAN RA, 1986, J BIOL CHEM, V261, P224; CORNELL RB, 1991, BIOCHEMISTRY-US, V30, P5873, DOI 10.1021/bi00238a010; DEEMS RA, 1975, J BIOL CHEM, V250, P9013; DODDS PF, 1991, LIFE SCI, V49, P629, DOI 10.1016/0024-3205(91)90110-W; FERNANDOWARNAKULASURIYA GJP, 1981, J LIPID RES, V22, P668; FLETCHER MJ, 1968, CLIN CHIM ACTA, V22, P393, DOI 10.1016/0009-8981(68)90041-7; GRIGOR MR, 1982, BIOCHIM BIOPHYS ACTA, V712, P464, DOI 10.1016/0005-2760(82)90273-9; HANNUN YA, 1986, J BIOL CHEM, V261, P7184; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HATA Y, 1989, BIOCHEM J, V262, P947, DOI 10.1042/bj2620947; HJELMSTAD RH, 1991, J BIOL CHEM, V266, P4357; HJELMSTAD RH, 1991, BIOCHEMISTRY-US, V30, P1731, DOI 10.1021/bi00221a001; JOHNSTON JM, 1977, LIPID METABOLISM MAM, P151; LEE MH, 1989, J BIOL CHEM, V264, P14797; LEHNER R, 1992, BIOCHIM BIOPHYS ACTA, V1125, P171, DOI 10.1016/0005-2760(92)90042-T; Lineweaver H, 1934, J AM CHEM SOC, V56, P658, DOI 10.1021/ja01318a036; LITCHENBERG D, 1983, BIOCHIM BIOPHYS ACTA, V737, P285; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MERRILL AH, 1982, J LIPID RES, V23, P1368; MOORHOUSE KG, 1990, BIOCHEM PHARMACOL, V39, P1529, DOI 10.1016/0006-2952(90)90517-O; MOSTAFA N, 1993, BIOCHIM BIOPHYS ACTA, V1169, P189, DOI 10.1016/0005-2760(93)90205-N; NEURINGER M, 1988, ANNU REV NUTR, V8, P517, DOI 10.1146/annurev.nu.08.070188.002505; POLHEIM D, 1973, J LIPID RES, V14, P415; QUINN MT, 1991, BIOCHIM BIOPHYS ACTA, V1082, P293, DOI 10.1016/0005-2760(91)90205-V; RAELEE M, 1990, J BIOL CHEM, V265, P7221; ROBSON RJ, 1983, ACCOUNTS CHEM RES, V16, P251, DOI 10.1021/ar00091a003; SANDERMANN H, 1991, BIOCHIM BIOPHYS ACTA, V1069, P235, DOI 10.1016/0005-2736(91)90130-Z; Segel IH., 1975, ENZYME KINETICS, P1, DOI 10.1016/0014-5793(75)80457-1; SINCLAIR AJ, 1972, J NEUROCHEM, V19, P1753, DOI 10.1111/j.1471-4159.1972.tb06219.x; THUREN T, 1990, BIOCHIM BIOPHYS ACTA, V1046, P178, DOI 10.1016/0005-2760(90)90186-2; WALSH JP, 1986, J BIOL CHEM, V261, P6239; WU WI, 1993, J BIOL CHEM, V268, P13830; XIA T, 1993, J NUTR BIOCHEM, V4, P313, DOI 10.1016/0955-2863(93)90102-3; XIA T, 1993, AM J PHYSIOL, V265, pR414, DOI 10.1152/ajpregu.1993.265.2.R414; YU L, 1990, J BIOL CHEM, V265, P2657	41	35	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13172	13178						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175745				2022-12-25	WOS:A1994NK18400022
J	JI, ZS; LAUER, SJ; FAZIO, S; BENSADOUN, A; TAYLOR, JM; MAHLEY, RW				JI, ZS; LAUER, SJ; FAZIO, S; BENSADOUN, A; TAYLOR, JM; MAHLEY, RW			ENHANCED BINDING AND UPTAKE OF REMNANT LIPOPROTEINS BY HEPATIC LIPASE-SECRETING HEPATOMA-CELLS IN CULTURE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; RECEPTOR-RELATED PROTEIN; TRIGLYCERIDE LIPASE; MONOCLONAL-ANTIBODIES; LOCALIZATION; DEFICIENCY; INVIVO; PLASMA; LIVER; ABNORMALITIES	Rat hepatoma McA-RH7777 cells transfected with a human hepatic lipase (HL) cDNA synthesized and secreted 50-80 ng of human HL/mg of cell protein at 4 h, similar to 50% of which was bound to cell-surface heparan sulfate proteoglycans (HSPG). The newly synthesized HL possessed enzymatic activity. When rabbit beta-very low density lipoproteins (beta-VLDL) and canine chylomicrons or chylomicron remnants were incubated with HL-secreting cells, remnant binding and uptake were enhanced 3-fold compared with nontransfected cells. Furthermore, fluorescence microscopy showed enhanced uptake of 1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine-labeled beta-VLDL by the HL-transfected cells. When I-125-beta-VLDL were added to conditioned medium from HL-secreting cells, the HL in the media enhanced the binding and uptake of the remnant lipoproteins by nontransfected cells about 3-fold. Likewise, surface-bound HL (without HL in the medium) also was able to mediate the enhanced binding of the remnants. This HL-enhanced binding was shown to be mediated by an interaction with cell-surface HSPG. Heparinase treatment to remove cell-surface HSPG or chlorate treatment to prevent HSPG sulfation of the HL-secreting cells abolished all the HL-mediated enhanced binding and uptake. Furthermore, heparinase pretreatment of nontransfected cells prevented the enhanced binding and uptake of beta-VLDL incubated with conditioned medium from HL-secreting cells. As binding was not enhanced in the absence of HSPG, an HL-HSPG initial interaction appears essential. Addition of apolipoprotein (apo) E to the beta-VLDL did not facilitate HL-mediated binding and uptake; in fact, beta-VLDL from apoE-null mice demonstrated a similar degree of enhanced binding as did rabbit beta-VLDL with or without added apoE. On the other hand, beta-VLDL from transgenic mice overexpressing binding-defective apoE(Arg(142) --> Cys) did not display any enhanced binding and uptake by the HL-secreting cells, and it appears that the apoE(Arg(142) -->( Cys) actually inhibited the HL-mediated interaction. This mutant form of apoE is associated with a dominant mode of expression of type III hyperlipoproteinemia in contrast to the more commonly occurring recessive disorder. Impaired HL interaction with the apoE(Arg(142) --> Cys) beta-VLDL may contribute to remnant lipoprotein accumulation in the plasma of patients with this mutant form of apoE. Thus, HL contributes to the enhanced cell association of specific types of remnant lipoproteins by initiating their binding to cell-surface HSPG.	UNIV CALIF SAN FRANCISCO, GLADSTONE INST CARDIOVASC DIS, CARDIOVASC RES INST, SAN FRANCISCO, CA 94141 USA; UNIV CALIF SAN FRANCISCO, DEPT PATHOL, SAN FRANCISCO, CA 94141 USA; UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA 94141 USA; UNIV CALIF SAN FRANCISCO, DEPT PHYSIOL, SAN FRANCISCO, CA 94141 USA; CORNELL UNIV, DIV NUTR SCI, ITHACA, NY 14853 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Cornell University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041633] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL41633] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AUWERX JH, 1990, AM J HUM GENET, V46, P470; BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; BRASAEMLE DL, 1993, J LIPID RES, V34, P455; BRECKENRIDGE WC, 1982, ATHEROSCLEROSIS, V45, P161, DOI 10.1016/0021-9150(82)90136-8; BROWN MS, 1991, CURR OPIN LIPIDOL, V2, P65; CARLSON LA, 1986, ACTA MED SCAND, V219, P435; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CHENG CF, 1985, J BIOL CHEM, V260, P720; CHOI SSY, 1991, J CLIN INVEST, V88, P1173, DOI 10.1172/JCI115419; CISAR LA, 1989, BIOCHIM BIOPHYS ACTA, V1004, P196, DOI 10.1016/0005-2760(89)90268-3; CISAR LA, 1985, J LIPID RES, V26, P380; DAGGY BP, 1986, BIOCHIM BIOPHYS ACTA, V877, P252, DOI 10.1016/0005-2760(86)90302-4; DAVIS RC, 1992, J BIOL CHEM, V267, P21499; Ehnholm C, 1986, Methods Enzymol, V129, P716; FAZIO S, 1993, J CLIN INVEST, V92, P1497, DOI 10.1172/JCI116728; GOLDBERG IJ, 1982, J CLIN INVEST, V70, P1184, DOI 10.1172/JCI110717; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; HAMILTON RL, 1990, J LIPID RES, V31, P1589; HEGELE RA, 1991, J CLIN ENDOCR METAB, V72, P730, DOI 10.1210/jcem-72-3-730; Herz Joachim, 1993, Current Opinion in Lipidology, V4, P107, DOI 10.1097/00041433-199304000-00006; HIDE WA, 1992, J LIPID RES, V33, P167; HIXENBAUGH EA, 1989, J BIOL CHEM, V264, P4222; HUMPHRIES DE, 1989, METHOD ENZYMOL, V179, P428; HUSSAIN MM, 1989, J BIOL CHEM, V264, P9571; IKEDA Y, 1990, J LIPID RES, V31, P1911; JANSEN H, 1980, FEBS LETT, V112, P30, DOI 10.1016/0014-5793(80)80119-0; JI ZS, 1994, J BIOL CHEM, V269, P13421; JI ZS, 1994, J BIOL CHEM, V269, P2764; JI ZS, 1993, J BIOL CHEM, V268, P10160; KHAN MY, 1991, ANAL BIOCHEM, V196, P373; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; KUUSI T, 1979, BIOCHEM J, V181, P245, DOI 10.1042/bj1810245; KUUSI T, 1979, FEBS LETT, V104, P384, DOI 10.1016/0014-5793(79)80858-3; Mahley R. W., 1991, CURR OPIN LIPIDOL, V2, P170; MAHLEY RW, 1989, METABOLIC BASIS INHE, V1, P1195; MAHLEY RW, 1994, IN PRESS ANN NY ACAD; PIEDRAHITA JA, 1992, P NATL ACAD SCI USA, V89, P4471, DOI 10.1073/pnas.89.10.4471; PITAS RE, 1980, J BIOL CHEM, V255, P5454; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; RALL SC, 1992, J INTERN MED, V231, P653, DOI 10.1111/j.1365-2796.1992.tb01254.x; Sambrook J, 1989, MOL CLONING LABORATO; SIMONET WS, 1993, J BIOL CHEM, V268, P8221; THUREN T, 1991, J BIOL CHEM, V266, P4853; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172	45	122	123	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13429	13436						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175774				2022-12-25	WOS:A1994NK18400057
J	BITO, H; MORI, M; SAKANAKA, C; TAKANO, T; HONDA, Z; GOTOH, Y; NISHIDA, E; SHIMIZU, T				BITO, H; MORI, M; SAKANAKA, C; TAKANO, T; HONDA, Z; GOTOH, Y; NISHIDA, E; SHIMIZU, T			FUNCTIONAL COUPLING OF SSTR4, A MAJOR HIPPOCAMPAL SOMATOSTATIN RECEPTOR, TO ADENYLATE-CYCLASE INHIBITION, ARACHIDONATE RELEASE, AND ACTIVATION OF THE MITOGEN-ACTIVATED PROTEIN-KINASE CASCADE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEAMINE-INDUCED DEPLETION; CENTRAL-NERVOUS-SYSTEM; MAP KINASE; RAT-BRAIN; TYROSINE PHOSPHORYLATION; SIGNAL TRANSDUCTION; ACID METABOLITES; SENILE DEMENTIA; K+ CHANNEL; CLONING	Somatostatin has a modulatory role in regulating the membrane conductance in hippocampal neurons. To examine the signal transducing molecules involved in this process, we isolated the cDNA encoding the dominant rat hippocampal somatostatin receptor, SSTR4. Distribution of SSTR4 in the adult central nervous system was restricted to the hippocampus, cerebral cortex, striatum, hypothalamus, and thalamus, as determined by Northern blot analysis and in situ hybridization. In SSTR4-expressing Chinese hamster ovary cells, SSTR4 was functionally coupled not only to inhibition of adenylate cyclase, but also to activation of both arachidonate release and mitogen-activated protein (MAP) kinase cascade, with similar ED(50) values. All of these pathways, including both MAP kinase kinase and MAP kinase activation, were completely blocked by pretreatment with pertussis toxin. On the other hand, neither inositol 1,4,5-trisphosphate synthesis nor intracellular Ca2+ mobilization was induced upon SSTR4 stimulation. These data indicate that the hippocampal functions of somatostatin might be mediated through diverse but selective second messenger systems activated via SSTR4 and reveal an unsuspected coupling of a neuronal SSTR subtype to a mitogenic signaling pathway. SSTR4, in addition, provides a useful system to study the Ca2+-independent, G(i)-dependent (pertussis toxin-sensitive) pathway of MAP kinase activation.	UNIV TOKYO,FAC MED,DEPT BIOCHEM,BUNKYO KU,TOKYO 113,JAPAN; KYOTO UNIV,INST VIRUS RES,DEPT MOLEC BIOL & GENET,SAKYO KU,KYOTO 606,JAPAN	University of Tokyo; Kyoto University			Bito, Haruhiko/A-8635-2008	Bito, Haruhiko/0000-0001-6315-9594				BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060; BADING H, 1991, SCIENCE, V253, P912, DOI 10.1126/science.1715095; BELL GI, 1993, TRENDS NEUROSCI, V16, P34, DOI 10.1016/0166-2236(93)90050-V; BITO H, 1992, NEURON, V9, P285, DOI 10.1016/0896-6273(92)90167-C; BRAZEAU P, 1973, SCIENCE, V179, P77, DOI 10.1126/science.179.4068.77; BREDER CD, 1992, J NEUROSCI, V12, P3920; BROWNSTEIN M, 1975, ENDOCRINOLOGY, V96, P1456, DOI 10.1210/endo-96-6-1456; BRUNO JF, 1992, P NATL ACAD SCI USA, V89, P11151, DOI 10.1073/pnas.89.23.11151; CHAO MV, 1992, CELL, V68, P995, DOI 10.1016/0092-8674(92)90068-N; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOPER PE, 1981, NEUROLOGY, V31, P64; DAVIES P, 1980, NATURE, V288, P279, DOI 10.1038/288279a0; DENOBLE VJ, 1989, BRAIN RES, V482, P42, DOI 10.1016/0006-8993(89)90540-4; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DODD J, 1978, NATURE, V273, P674, DOI 10.1038/273674a0; DUMUIS A, 1988, NATURE, V336, P68, DOI 10.1038/336068a0; EPELBAUM J, 1986, PROG NEUROBIOL, V27, P63, DOI 10.1016/0301-0082(86)90012-2; GUPTA SK, 1992, MOL BIOL CELL, V3, P123, DOI 10.1091/mbc.3.1.123; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; HAROUTUNIAN V, 1987, BRAIN RES, V403, P234, DOI 10.1016/0006-8993(87)90060-6; HONDA Z, 1994, J BIOL CHEM, V269, P2307; JOELS M, 1990, REGUL PEPTIDES, V28, P215, DOI 10.1016/0167-0115(90)90019-S; KIM D, 1989, NATURE, V357, P537; KLUXEN FW, 1992, P NATL ACAD SCI USA, V89, P4618, DOI 10.1073/pnas.89.10.4618; KOSAKO H, 1993, EMBO J, V12, P787, DOI 10.1002/j.1460-2075.1993.tb05713.x; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KURACHI Y, 1989, NATURE, V337, P555, DOI 10.1038/337555a0; LALLEMAIN G, 1991, CELL REGUL, V2, P675, DOI 10.1091/mbc.2.8.675; LI LL, 1992, P NATL ACAD SCI USA, V89, P6147; LI XJ, 1992, J BIOL CHEM, V267, P21307; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; MARIN P, 1991, P NATL ACAD SCI USA, V88, P9016, DOI 10.1073/pnas.88.20.9016; MATSUDA S, 1993, J BIOL CHEM, V268, P3277; MAYERHOF W, 1992, P NATL ACAD SCI USA, V89, P10267; MAYERHOF W, 1991, DNA CELL BIOL, V10, P689; MCGEE R, 1988, J MEMBRANE BIOL, V102, P21, DOI 10.1007/BF01875350; MILLER B, 1992, NATURE, V355, P722, DOI 10.1038/355722a0; MOORE SD, 1988, SCIENCE, V239, P278, DOI 10.1126/science.2892268; NAKAMURA M, 1992, FEBS LETT, V314, P125, DOI 10.1016/0014-5793(92)80957-I; NEMEROFF CB, 1983, SCIENCE, V221, P972, DOI 10.1126/science.6136092; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; OCARROLL AM, 1992, MOL PHARMACOL, V42, P939; OHMICHI M, 1992, J BIOL CHEM, V267, P14604; PAN MG, 1992, SCIENCE, V256, P1215, DOI 10.1126/science.256.5060.1215; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; PELECH SL, 1992, SCIENCE, V257, P1355, DOI 10.1126/science.1382311; PIOMELLI D, 1987, NATURE, V328, P38, DOI 10.1038/328038a0; PITTMAN QJ, 1981, BRAIN RES, V221, P402, DOI 10.1016/0006-8993(81)90791-5; RAYMOND LA, 1993, TRENDS NEUROSCI, V16, P147, DOI 10.1016/0166-2236(93)90123-4; RAYNOR K, 1992, J PHARMACOL EXP THER, V260, P841; REICHLIN S, 1983, NEW ENGL J MED, V309, P1495, DOI 10.1056/NEJM198312153092406; REICHLIN S, 1983, NEW ENGL J MED, V309, P1556, DOI 10.1056/NEJM198312223092506; RENSDOMIANO S, 1992, MOL PHARMACOL, V42, P28; RENSDOMIANO S, 1992, J NEUROCHEM, V58, P1987, DOI 10.1111/j.1471-4159.1992.tb10938.x; ROSSOR MN, 1980, NEUROSCI LETT, V20, P373, DOI 10.1016/0304-3940(80)90177-9; RUIZTORRES P, 1993, BIOCHEM BIOPH RES CO, V195, P1057, DOI 10.1006/bbrc.1993.2151; SATOH T, 1992, J BIOL CHEM, V267, P24149; SCHERER RW, 1990, J GEN PHYSIOL, V96, P735, DOI 10.1085/jgp.96.4.735; SCHETTINI G, 1989, BRAIN RES, V492, P65, DOI 10.1016/0006-8993(89)90889-5; SCHWEITZER P, 1990, NATURE, V346, P464, DOI 10.1038/346464a0; SCHWEITZER P, 1993, J NEUROSCI, V13, P2033; SHIGEMOTO R, 1992, J COMP NEUROL, V322, P121, DOI 10.1002/cne.903220110; SHIMIZU T, 1990, J NEUROCHEM, V55, P1, DOI 10.1111/j.1471-4159.1990.tb08813.x; SHIRAKABE K, 1992, J BIOL CHEM, V267, P16685; TAPIAARANCIBIA L, 1992, EUR J PHARM-MOLEC PH, V225, P253, DOI 10.1016/0922-4106(92)90027-S; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TOBE K, 1991, J BIOL CHEM, V266, P24793; VALE W, 1977, ANNU REV PHYSIOL, V39, P473, DOI 10.1146/annurev.ph.39.030177.002353; VANETTI M, 1992, FEBS LETT, V311, P290, DOI 10.1016/0014-5793(92)81122-3; WANG HL, 1989, P NATL ACAD SCI USA, V86, P9616, DOI 10.1073/pnas.86.23.9616; WHITE RE, 1991, NATURE, V351, P570, DOI 10.1038/351570a0; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YAMADA Y, 1992, P NATL ACAD SCI USA, V89, P251, DOI 10.1073/pnas.89.1.251; YAMADA Y, 1992, MOL ENDOCRINOL, V6, P2136, DOI 10.1210/me.6.12.2136; YASUDA K, 1992, J BIOL CHEM, V267, P20422	77	97	100	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12722	12730						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175684				2022-12-25	WOS:A1994NH71600056
J	FREY, M; ROTHE, M; WAGNER, AFV; KNAPPE, J				FREY, M; ROTHE, M; WAGNER, AFV; KNAPPE, J			ADENOSYLMETHIONINE-DEPENDENT SYNTHESIS OF THE GLYCYL RADICAL IN PYRUVATE FORMATE-LYASE BY ABSTRACTION OF THE GLYCINE C-2 PRO-S HYDROGEN-ATOM - STUDIES OF [H-2]GLYCINE-SUBSTITUTED ENZYME AND PEPTIDES HOMOLOGOUS TO THE GLYCINE-734 SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; ACTIVATING ENZYME; HYPOPHOSPHITE	The active form of pyruvate formate-lyase (PFL) from Escherichia coli contains a glycyl radical in position 734 of the polypeptide chain which is produced post-translationally by pyruvate formate-lyase-activating enzyme (PFL activase) using S-adenosylmethionine (AdoMet) and dihydroflavodoxin as co-substrates (Wagner, A. F.V., Frey, M., Neugebauer, F.A., Schafer, W., and Knappe, J. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 996-1000). Studying radical synthesis with [2-H-2]glycine-labeled PFL, we have now found stoichiometric incorporation of a H-2 atom into the 5'-deoxyadenosine (dAdo) co product via mass and NMR spectroscopic analyses. Furthermore, a series of peptides homologous to the Gly-734 site of PFL have been synthesized for analyzing recognition determinants of PFL activase. Peptides that proved active as substrates (monitored by [C-14]dAdo formation from [C-14]AdoMet) were also competitive inhibitors of PFL conversion to the radical form. In the sequence of the standard peptide Arg-Val-Ser-Gly-Tyr-Ala-Val, which corresponds to amino acid residues 731-737 of PFL, the Gly residue was replaceable by D-Ala (actually display ing enhanced efficiency), whereas a normal Ala totally abolished the interaction with PFL activase. Our results show that the radical in pyruvate formate-lyase is produced by stereospecific abstraction of the pro-S hydrogen of glycine 734 by the 5'-dAdo radical generated in the active center of PFL activase, Gly-734 is probably located in a beta-turn segment of the protein.	UNIV HEIDELBERG,INST BIOL CHEM,D-69120 HEIDELBERG,GERMANY	Ruprecht Karls University Heidelberg			Frey, Manfred/AAN-3224-2020					CASTRO B, 1977, J CHEM RES, V182, P2118; CONRADT H, 1984, ARCH BIOCHEM BIOPHYS, V228, P133, DOI 10.1016/0003-9861(84)90054-7; FRANK R, 1988, MODERN METHODS PROTE, V3, P42; FREY PA, 1993, FASEB J, V7, P662, DOI 10.1096/fasebj.7.8.8500691; Grimshaw J., 1981, CHEM SULPHONIUM GROU, P141; JAMES MNG, 1983, J MOL BIOL, V163, P299, DOI 10.1016/0022-2836(83)90008-6; KNAPPE J, 1990, FEMS MICROBIOL LETT, V75, P383, DOI 10.1111/j.1574-6968.1990.tb04108.x; KNAPPE J, 1984, P NATL ACAD SCI-BIOL, V81, P1332, DOI 10.1073/pnas.81.5.1332; KNAPPE J, 1993, BIOCHEM SOC T, V21, P731, DOI 10.1042/bst0210731; MULLIEZ E, 1993, J BIOL CHEM, V268, P2296; PLAGA W, 1988, EUR J BIOCHEM, V178, P445, DOI 10.1111/j.1432-1033.1988.tb14468.x; REICHARD P, 1993, SCIENCE, V260, P1773, DOI 10.1126/science.8511586; RODEL W, 1988, EUR J BIOCHEM, V177, P153, DOI 10.1111/j.1432-1033.1988.tb14356.x; SUN XY, 1993, P NATL ACAD SCI USA, V90, P577, DOI 10.1073/pnas.90.2.577; Tabor H., 1971, METHODS ENZYMOLOGY B, V17B, P393; UNKRIG V, 1989, EUR J BIOCHEM, V184, P723, DOI 10.1111/j.1432-1033.1989.tb15072.x; VETTER H, 1971, HOPPESEYLERS Z PHYSL, V352, P443; WAGNER AFV, 1992, P NATL ACAD SCI USA, V89, P996, DOI 10.1073/pnas.89.3.996; WANG Y, 1977, CARBOHYD RES, V59, P449, DOI 10.1016/S0008-6215(00)83184-5	19	149	149	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12432	12437						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175649				2022-12-25	WOS:A1994NH71600012
J	SHI, HP; TENG, CT				SHI, HP; TENG, CT			CHARACTERIZATION OF A MITOGEN-RESPONSE UNIT IN THE MOUSE LACTOFERRIN GENE PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								Lactoferrin is present in a variety of tissues and biological fluids; however, the amount differs significantly due to differential expressions. We have previously demonstrated that the mouse lactoferrin gene is regulated by estrogen through an estrogen-response DNA element located at -349, upstream from the transcription start site (+1). In this report, we characterized by deletion and mutation analyses a cluster of mitogen-response elements located between -80 and -40 of the mouse lactoferrin promoter. We demonstrated that the chimeric chloramphenicol acetyltransferase reporter constructs (the -103 to +1 sequence of the mouse lactoferrin gene) containing the mitogen-response unit of the lactoferrin gene were stimulated by cAMP, forskolin, 12-O-tetradecanoylphorbol-13-acetate, and epidermal growth factor/recombinant transforming growth factor-alpha (EGF/TGF-alpha) in a time- and dose-dependent manner. The sequence at position -52 to -40 (mLF-CRE) of the gene conferred transcriptional activation in the presence of forskolin, cyclic AMP, and 12-O-tetradecanoylphorbol-13-acetate in transiently transfected human endometrium carcinoma RL95-2 cells, whereas the region at -80 to -60 responded to EGF/TGF-alpha stimulation. Overexpression of the catalytic unit of protein kinase C or protein kinase A in the RL95-2 cells elevated the chloramphenicol acetyltransferase activity of the reporter construct 5-6-fold. The mobility shift assay suggested that AP1 and CREB or related proteins participated in complex formation with the mLF-CRE, whereas different proteins bound to the EGF/TGF-alpha-response element.	NIEHS, REPROD & DEV TOXICOL LAB, RES TRIANGLE PK, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)								ANDERSON BF, 1990, NATURE, V344, P784, DOI 10.1038/344784a0; ARNOLD RR, 1982, INFECT IMMUN, V35, P792, DOI 10.1128/IAI.35.3.792-799.1982; BAKER EN, 1991, INT J BIOL MACROMOL, V13, P122, DOI 10.1016/0141-8130(91)90036-T; BELLAMY W, 1992, BIOCHIM BIOPHYS ACTA, V1121, P130, DOI 10.1016/0167-4838(92)90346-F; BOWMAN BH, 1988, ADV GENET, V25, P1; BROXMEYER HE, 1987, BLOOD CELLS, V13, P31; BROXMEYER HE, 1989, IRON IMMUNITY CANCER, P199; CUNNINGHAM GA, 1992, BIOCHEM BIOPH RES CO, V189, P1725, DOI 10.1016/0006-291X(92)90277-R; DAVIDSON LA, 1988, AM J PHYSIOL, V254, pG580, DOI 10.1152/ajpgi.1988.254.4.G580; ELSHOLTZ HP, 1986, SCIENCE, V234, P1552, DOI 10.1126/science.3491428; ESAGUY N, 1991, INFECT IMMUN, V59, P1117, DOI 10.1128/IAI.59.3.1117-1125.1991; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; GREEN MR, 1978, ENDOCRINOLOGY, V103, P1510, DOI 10.1210/endo-103-4-1510; HANGOC G, 1991, EXP HEMATOL, V19, P697; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; IGNARTROWBRIDGE DM, 1993, MOL ENDOCRINOL, V7, P992, DOI 10.1210/me.7.8.992; IMAI E, 1993, J BIOL CHEM, V268, P5353; ISHIGURO H, 1993, J BIOL CHEM, V268, P17987; JOHANSON B, 1960, ACTA CHEM SCAND, V14, P510, DOI 10.3891/acta.chem.scand.14-0510; KALMAR JR, 1988, INFECT IMMUN, V56, P2552, DOI 10.1128/IAI.56.10.2552-2557.1988; KIM KS, 1993, J BIOL CHEM, V268, P15689; KLEINHITPASS L, 1989, MOL CELL BIOL, V9, P43, DOI 10.1128/MCB.9.1.43; LAMPREAVE F, 1990, INT J BIOL MACROMOL, V12, P2, DOI 10.1016/0141-8130(90)90073-J; LEGRAND D, 1992, BIOCHEMISTRY-US, V31, P9243, DOI 10.1021/bi00153a018; LEGRAND D, 1990, BIOCHEM J, V266, P575; LEWIS EJ, 1987, MOL CELL BIOL, V7, P3332, DOI 10.1128/MCB.7.9.3332; LIU YH, 1993, MOL CELL BIOL, V13, P1836, DOI 10.1128/MCB.13.3.1836; LIU YH, 1991, J BIOL CHEM, V266, P21880; LIU YH, 1992, MOL ENDOCRINOL, V6, P355, DOI 10.1210/me.6.3.355; LU L, 1991, INT J HEMATOL, V54, P117; Masson P. L., 1966, PROTIDES BIOL FLUIDS, V14, P115; MASSON PL, 1966, CLIN CHIM ACTA, V14, P735, DOI 10.1016/0009-8981(66)90004-0; MASSON PL, 1969, J EXP MED, V130, P643, DOI 10.1084/jem.130.3.643; MERCHANT JL, 1991, MOL CELL BIOL, V11, P2686, DOI 10.1128/MCB.11.5.2686; NELSON KG, 1991, P NATL ACAD SCI USA, V88, P21, DOI 10.1073/pnas.88.1.21; NICHOLS BL, 1987, PEDIATR RES, V21, P563, DOI 10.1203/00006450-198706000-00011; OUYANG Q, 1993, MOL CELL BIOL, V13, P1796, DOI 10.1128/MCB.13.3.1796; PARK I, 1985, P NATL ACAD SCI USA, V82, P3149, DOI 10.1073/pnas.82.10.3149; PENTECOST BT, 1987, J BIOL CHEM, V262, P10134; ROESLER WJ, 1989, J BIOL CHEM, V264, P9657; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAWATZKI G, 1989, BLOOD CELLS, V15, P371; SCHILD C, 1993, EMBO J, V12, P423, DOI 10.1002/j.1460-2075.1993.tb05674.x; SHIRSAT NV, 1992, GENE, V110, P229, DOI 10.1016/0378-1119(92)90653-7; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; SORENSEN MARGRETHE, 1939, Comptes rendus des Travaux du Laboratoire Carlsberg, V23, P55; TENG CT, 1986, BIOCHEM J, V240, P413, DOI 10.1042/bj2400413; TENG CT, 1989, ENDOCRINOLOGY, V124, P992, DOI 10.1210/endo-124-2-992; TENG CT, 1992, MOL ENDOCRINOL, V6, P1969, DOI 10.1210/me.6.11.1969; WANG LH, 1987, J BIOL CHEM, V262, P16080; WANG LH, 1989, NATURE, V340, P163, DOI 10.1038/340163a0; ZIMECKI M, 1991, IMMUNOL LETT, V30, P119, DOI 10.1016/0165-2478(91)90099-V; ZIMECKI M, 1987, ARCH IMMUNOL THER EX, V35, P351	55	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12973	12980						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175715				2022-12-25	WOS:A1994NH71600091
J	MIFFLIN, LC; COHEN, RE				MIFFLIN, LC; COHEN, RE			HSC70 MODERATES THE HEAT-SHOCK (STRESS) RESPONSE IN XENOPUS-LAEVIS OOCYTES AND BINDS TO DENATURED PROTEIN INDUCERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN-CELLS; SACCHAROMYCES-CEREVISIAE; MOLECULAR CHAPERONES; HSP70; GENE; DROSOPHILA; ATP; TRANSCRIPTION; LOCALIZATION; POLYPEPTIDES	Injections of hsc70 protein into Xenopus oocytes lowered the stress response to both a thermal shock and to co-injected protein inducers. Binding of hsc70 to native and modified forms of bovine serum albumin (BSA) were tested by two assays. In one, nitrocellulose-bound proteins were incubated with hsc70, cross-linked with glutaraldehyde, and then bound hsc70 was probed with a monoclonal anti-hsc70 antibody. In the second, peroxidase-conjugated hsc70 was employed as a more direct probe for binding to proteins displayed on nitrocellulose membranes. hsc70 binding to the BSA derivatives correlated with their abilities to induce a stress response upon microinjection into oocytes. Reduced and carboxymethylated (rcm) BSA, the most potent stress inducer tested, was bound most tightly by hsc70, whereas hsc70 had moderate affinity for N-methylated rcm-BSA and very little affinity for the native protein. No binding was observed with iodinated BSA. The results suggest a mechanism whereby the cell employs hsc70 or other proteins of the hsp70 family both to trigger the response to an environmental stress and to provide a feedback mechanism to attenuate the response.	UNIV IOWA,DEPT BIOCHEM,IOWA CITY,IA 52242; UNIV CALIF LOS ANGELES,DEPT CHEM & BIOCHEM,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024	University of Iowa; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles					NIGMS NIH HHS [GM07185, R01 GM37666] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037666] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAVAYA K, 1992, GENE DEV, V6, P1153, DOI 10.1101/gad.6.7.1153; ANANTHAN J, 1986, SCIENCE, V232, P522, DOI 10.1126/science.3083508; ANGELIDIS CE, 1991, EUR J BIOCHEM, V199, P35, DOI 10.1111/j.1432-1033.1991.tb16088.x; ARRIGO AP, 1980, DEV BIOL, V78, P86, DOI 10.1016/0012-1606(80)90320-6; AVRAMEAS S, 1978, SCAND J IMMUNOL   S7, V8, P7; BALER R, 1992, J CELL BIOL, V117, P1151, DOI 10.1083/jcb.117.6.1151; BECKMANN RP, 1992, J CELL BIOL, V117, P1137, DOI 10.1083/jcb.117.6.1137; BOORSTEIN WR, 1990, MOL CELL BIOL, V10, P3262, DOI 10.1128/MCB.10.6.3262; BRAELL WA, 1984, J CELL BIOL, V99, P734, DOI 10.1083/jcb.99.2.734; BROWN CR, 1993, J CELL BIOL, V120, P1101, DOI 10.1083/jcb.120.5.1101; CRAIG EA, 1984, CELL, V38, P841, DOI 10.1016/0092-8674(84)90279-4; CRAIG EA, 1991, TRENDS BIOCHEM SCI, V16, P135, DOI 10.1016/0968-0004(91)90055-Z; DIDOMENICO BJ, 1982, CELL, V31, P593, DOI 10.1016/0092-8674(82)90315-4; DUBOIS MF, 1991, J BIOL CHEM, V266, P9707; GEORGOPOULOS C, 1993, ANNU REV CELL BIOL, V9, P601, DOI 10.1146/annurev.cb.09.110193.003125; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HIGHTOWER LE, 1980, J CELL PHYSIOL, V102, P407, DOI 10.1002/jcp.1041020315; HIGHTOWER LE, 1991, CELL, V66, P191, DOI 10.1016/0092-8674(91)90611-2; HORWITZ J, 1993, INVEST OPHTH VIS SCI, V34, P10; JAKOB U, 1993, J BIOL CHEM, V268, P1517; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWIS MJ, 1985, EMBO J, V4, P3137, DOI 10.1002/j.1460-2075.1985.tb04056.x; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; MIFFLIN LC, 1994, J BIOL CHEM, V269, P15710; MITRAKI A, 1989, BIO-TECHNOL, V7, P690, DOI 10.1038/nbt0789-690; PALLEROS DR, 1991, P NATL ACAD SCI USA, V88, P5719, DOI 10.1073/pnas.88.13.5719; PELHAM HRB, 1984, EMBO J, V3, P3095, DOI 10.1002/j.1460-2075.1984.tb02264.x; PELHAM HRB, 1990, STRESS PROTEINS BIOL, P287; Penefsky H S, 1979, Methods Enzymol, V56, P527; SADIS S, 1990, BIOCHEMISTRY-US, V29, P8199, DOI 10.1021/bi00488a001; SCHLESINGER MJ, 1990, J BIOL CHEM, V265, P12111; SHERMAN MY, 1992, EMBO J, V11, P71; SHI YG, 1992, MOL CELL BIOL, V12, P2186, DOI 10.1128/MCB.12.5.2186; SOLOMON JM, 1991, NEW BIOL, V3, P1106; STONE DE, 1990, MOL CELL BIOL, V10, P1622, DOI 10.1128/MCB.10.4.1622; VALAZQUEZ JM, 1980, CELL, V20, P679; VOELLMY R, 1982, P NATL ACAD SCI-BIOL, V79, P1776, DOI 10.1073/pnas.79.6.1776; WELCH WJ, 1984, J BIOL CHEM, V259, P4501; WELCH WJ, 1986, J CELL BIOL, V103, P2035, DOI 10.1083/jcb.103.5.2035; Welch WJ, 1990, STRESS PROTEINS BIOL, P223	41	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15718	15723						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	8195224				2022-12-25	WOS:A1994NP51300052
J	ROTTAPEL, R; TURCK, CW; CASTERAN, N; LIU, XG; BIRNBAUM, D; PAWSON, T; DUBREUIL, P				ROTTAPEL, R; TURCK, CW; CASTERAN, N; LIU, XG; BIRNBAUM, D; PAWSON, T; DUBREUIL, P			SUBSTRATE SPECIFICITIES AND IDENTIFICATION OF A PUTATIVE BINDING-SITE FOR PI3K IN THE CARBOXY TAIL OF THE MURINE FLT3 RECEPTOR TYROSINE KINASE	ONCOGENE			English	Article							EPIDERMAL GROWTH-FACTOR; GUANINE-NUCLEOTIDE EXCHANGE; PHOSPHOLIPASE-C-GAMMA; GTPASE-ACTIVATING PROTEIN; FACTOR-I RECEPTOR; VAV PROTOONCOGENE PRODUCT; GAP-ASSOCIATED PROTEINS; GRB2 ADAPTER PROTEIN; PDGF BETA-RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE	Flt3 is a receptor tyrosine kinase (RTK) structurally related to the CSF-1R encoded by the c-fms locus, Kit and the PDGFR which is restricted in its expression to hematopoietic precursor populations and several distinct cell types within the central nervous system. Although the ligand for Flt3 has recently been identified, the developmental function of Flt3 within these tissues has not yet been described. In order to examine the signalling properties of this receptor, we previously constructed a chimeric molecule containing the extracellular domain of CSF-1R fused to the transmembrane and cytoplasmic domain of mouse Flt3 (FF3). The ability of the FF3 to directly associate with or tyrosine phosphorylate specific cytoplasmic signalling molecules in vivo was examined. GAP, Vav, She, and to a lessor extent PLC gamma become tyrosine-phosphorylated but no in vivo association with the receptor was detectable. FF3 associates with PI3K activity and the SH2 domains of p85 and Grb-2. Phosphopeptide competition experiments suggest that the PI3K binding site is located outside of the kinase insert in the carboxy tail of the receptor.	UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, SAN FRANCISCO, CA 94143 USA; UNIV TORONTO, MT SINAI HOSP, SAMUEL LUNENFELD RES INST, DIV MOLEC & DEV BIOL, TORONTO M5G 1X5, ON, CANADA; UNIV TORONTO, DEPT MOLEC GENET, TORONTO M5G 1X5, ON, CANADA; INSERM, U119, MOLEC ONCOL LAB, F-13009 MARSEILLE, FRANCE	Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; Institut National de la Sante et de la Recherche Medicale (Inserm)	ROTTAPEL, R (corresponding author), INSERM, U119, MOLEC HEMATOL LAB, 27 BD LEI ROURE, F-13009 MARSEILLE, FRANCE.		Dubreuil, Patrice/V-4816-2019; Pawson, Tony J/E-4578-2013; dubreuil, patrice/F-5346-2011	Dubreuil, Patrice/0000-0003-1155-1150; dubreuil, patrice/0000-0003-1155-1150; Rottapel, Robert/0000-0002-6024-5558; Liu, X. Johne/0000-0003-3381-5030				ADAMS JM, 1992, ONCOGENE, V7, P611; ALAI M, 1992, J BIOL CHEM, V267, P18021; AUGUSTINE JA, 1991, MOL CELL BIOL, V11, P4431, DOI 10.1128/MCB.11.9.4431; BJORGE JD, 1990, P NATL ACAD SCI USA, V87, P3816, DOI 10.1073/pnas.87.10.3816; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BUSTELO XR, 1993, CELL GROWTH DIFFER, V4, P297; BUSTELO XR, 1992, SCIENCE, V256, P1196, DOI 10.1126/science.256.5060.1196; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; COREY S, 1993, EMBO J, V12, P2681, DOI 10.1002/j.1460-2075.1993.tb05929.x; COUGHLIN SR, 1989, SCIENCE, V243, P1191; DAMEN JE, 1993, BLOOD, V81, P3204; DOSIL M, 1993, MOL CELL BIOL, V13, P6572, DOI 10.1128/MCB.13.10.6572; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; ELLIS C, 1991, ONCOGENE, V6, P895; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GALLAND F, 1992, ONCOGENE, V7, P585; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; Jones Gwenith, 1992, Progress in Growth Factor Research, V4, P97, DOI 10.1016/0955-2235(92)90025-D; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAZLAUSKAS A, 1990, EMBO J, V9, P3279, DOI 10.1002/j.1460-2075.1990.tb07527.x; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LIU XQ, 1993, MOL CELL BIOL, V13, P5225, DOI 10.1128/MCB.13.9.5225; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; LYMAN S, 1993, CELL, V75; LYMAN SD, 1993, ONCOGENE, V8, P815; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MAROC N, 1993, ONCOGENE, V8, P909; MATTHEWS W, 1991, CELL, V65, P1143, DOI 10.1016/0092-8674(91)90010-V; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NISHIBE S, 1990, P NATL ACAD SCI USA, V87, P424, DOI 10.1073/pnas.87.1.424; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; ORRURTREGER A, 1992, DEVELOPMENT, V115, P1045; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PAWSON T, 1990, TRENDS GENET, V6, P350, DOI 10.1016/0168-9525(90)90276-C; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PONZETTO C, 1993, MOL CELL BIOL, V13, P4600, DOI 10.1128/MCB.13.8.4600; PRASAD KVS, 1993, P NATL ACAD SCI USA, V90, P7366, DOI 10.1073/pnas.90.15.7366; PRINGLE NP, 1992, DEVELOPMENT, V115, P535; REEDIJK M, 1990, MOL CELL BIOL, V10, P5601, DOI 10.1128/MCB.10.11.5601; RETTENMIER CW, 1987, MOL CELL BIOL, V7, P2378, DOI 10.1128/MCB.7.7.2378; RONNSTRAND L, 1992, EMBO J, V11, P3911, DOI 10.1002/j.1460-2075.1992.tb05484.x; ROSNET O, 1991, ONCOGENE, V6, P1641; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; ROTTAPEL R, 1991, MOL CELL BIOL, V11, P3043, DOI 10.1128/MCB.11.6.3043; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; SCHATTEMAN GC, 1992, DEVELOPMENT, V115, P123; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; SEGATTO O, 1993, ONCOGENE, V8, P2105; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; SHERR CJ, 1990, BLOOD, V75, P1; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SUEN KL, 1993, MOL CELL BIOL, V13, P5500, DOI 10.1128/MCB.13.9.5500; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; TUVESON DA, 1993, SCIENCE, V260, P986, DOI 10.1126/science.7684160; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VALIUS M, 1993, MOL CELL BIOL, V13, P133, DOI 10.1128/MCB.13.1.133; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; WAHL M, 1991, BIOESSAYS, V13, P107, DOI 10.1002/bies.950130303; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1568, DOI 10.1073/pnas.86.5.1568; WONG G, 1992, CELL, V69, P551, DOI 10.1016/0092-8674(92)90455-L; YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	85	71	72	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1994	9	6					1755	1765						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NL815	8183574				2022-12-25	WOS:A1994NL81500031
J	SAIDO, TC; YOKOTA, M; MARUYAMA, K; YAMAOHARIGAYA, W; TANI, E; IHARA, Y; KAWASHIMA, S				SAIDO, TC; YOKOTA, M; MARUYAMA, K; YAMAOHARIGAYA, W; TANI, E; IHARA, Y; KAWASHIMA, S			SPATIAL-RESOLUTION OF THE PRIMARY BETA-AMYLOIDOGENIC PROCESS-INDUCED IN POSTISCHEMIC HIPPOCAMPUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-E POLYMORPHISM; ALZHEIMERS-DISEASE; PROTEIN-PRECURSOR; GERBIL HIPPOCAMPUS; MU-CALPAIN; ISCHEMIA; PEPTIDE; BRAIN; CELLS; PROTEOLYSIS	Proteolytic modifications of amyloid precursor protein (APP) play key roles in the development of Alzheimer's disease. However, each specific in vivo process has not yet been fully resolved in spatial terms because the orthodox approach employing electrophoretic analysis requires homogenization of samples and thus provides limited information on the localization of the process. To acquire such spatial information for the primary process involved in beta-amyloidogenesis, we have designed and developed a novel antibody exclusively specific to APP fragments possessing the exact amino terminus of the major beta-amyloid (A beta) peptide. Use of this antibody revealed that cleavage of APP at the amino terminal position of the A beta sequence is a normal steady-state process in gerbil hippocampus. Furthermore, nonfatal transient (10 min) forebrain ischemia followed by reperfusion enhanced the initial beta-amyloidogenic reaction mainly in pyramidal cells of CA1 sector and of dentate gyrus prior to and along with delayed neuronal degeneration. The APP fragments accumulated in cell bodies and dendrites of the neurons. These results suggest that beta-amyloidogenesis may involve a process that is also activated in postischemic brain and that ischemia-like conditions may contribute to pathogenic A beta accumulation.	HYOGO MED UNIV,DEPT NEUROSURG,NISHINOMIYA,HYOGO,JAPAN; UNIV TOKYO,SCH MED,INST BRAIN RES,BUNKYO KU,TOKYO 113,JAPAN	Hyogo College of Medicine; University of Hyogo; University of Tokyo	SAIDO, TC (corresponding author), TOKYO METROPOLITAN INST MED SCI,DEPT MOLEC BIOL,BUNKYO KU,3-18-22 HONK OMAGOME,TOKYO 113,JAPAN.		Saido, Takaomi C/N-5472-2015; Sado, Takaomi/AAN-2759-2021	Saido, Takaomi C/0000-0003-1970-6903; Sado, Takaomi/0000-0003-1970-6903				ABE K, 1991, NEUROSCI LETT, V125, P172, DOI 10.1016/0304-3940(91)90020-T; ANDERSON JP, 1991, NEUROSCI LETT, V128, P126, DOI 10.1016/0304-3940(91)90775-O; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.ne.13.030190.001131; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; CUMMING AM, 1984, CLIN GENET, V25, P310; DAVIGNON J, 1988, ARTERIOSCLEROSIS, V8, P1, DOI 10.1161/01.ATV.8.1.1; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; KALARIA RN, 1993, NEUROREPORT, V4, P211, DOI 10.1097/00001756-199302000-00025; KANEMARU K, 1990, AM J PATHOL, V137, P677; KANG J, 1987, NATURE, V197, P192; KIRINO T, 1982, BRAIN RES, V239, P57, DOI 10.1016/0006-8993(82)90833-2; LANSBURY PT, 1992, BIOCHEMISTRY-US, V31, P6865, DOI 10.1021/bi00145a001; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MARUYAMA K, 1991, BIOCHEM BIOPH RES CO, V179, P1670, DOI 10.1016/0006-291X(91)91767-7; MARUYAMA K, 1990, NATURE, V347, P566, DOI 10.1038/347566a0; MORI H, 1992, J BIOL CHEM, V267, P17082; NISHIMOTO I, 1993, NATURE, V362, P75, DOI 10.1038/362075a0; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; ROHER AE, 1993, J BIOL CHEM, V268, P3072; SAIDO TC, 1993, J BIOL CHEM, V268, P7422; SAIDO TC, 1993, J BIOL CHEM, V268, P25239; SAIDO TC, 1992, J BIOCHEM, V111, P81, DOI 10.1093/oxfordjournals.jbchem.a123723; SCHMIDTKASTNER R, 1991, NEUROSCIENCE, V40, P599, DOI 10.1016/0306-4522(91)90001-5; SELKOE DJ, 1993, TRENDS NEUROSCI, V16, P403, DOI 10.1016/0166-2236(93)90008-A; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SEUBERT P, 1989, BRAIN RES, V492, P366, DOI 10.1016/0006-8993(89)90921-9; SEUBERT P, 1993, NATURE, V361, P260, DOI 10.1038/361260a0; SHIN RW, 1991, LAB INVEST, V64, P693; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SIMAN R, 1990, FIDDIA RES F S SER, V4, P125; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; UTERMANN G, 1987, AM HEART J, V113, P433, DOI 10.1016/0002-8703(87)90610-7; YAMADA T, 1987, BIOCHEM BIOPH RES CO, V149, P665, DOI 10.1016/0006-291X(87)90419-0; YOKOTA M, 1992, BRAIN RES, V587, P123, DOI 10.1016/0006-8993(92)91436-I; YOSHIDA S, 1986, J NEUROCHEM, V47, P744	39	81	103	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					15253	15257						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195161				2022-12-25	WOS:A1994NP73800060
J	KOO, P; NAGAI, MK; FARBER, E				KOO, P; NAGAI, MK; FARBER, E			MULTIPLE SITES OF CONTROL OF GLUTATHIONE-S-TRANSFERASE P1-1 IN RAT-LIVER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED PROTEIN METHYLATION; PERSISTENT HEPATOCYTE NODULES; MESSENGER-RNA; CHEMICAL HEPATOCARCINOGENESIS; LEAD NITRATE; IDENTIFICATION; ACID; GENE; CELLS; POLYRIBOSOMES	Glutathione transferase P1-1, normally very low in adult rat liver, is induced by a single intravenous dose of lead nitrate. In this transient induction, there are at least three sites of regulation or control. These are transcription, post transcription, and post-translation. The increase in transcription is evident both by nuclear runoff analysis and by measurement of mRNA levels. The other two sites of control were seen in actinomycin D-treated animals in which RNA synthesis was inhibited by over 80%. Treatment with actinomycin D increases the stability of the mRNA and also somehow inhibits the conversion of a glutathione transferase protein to an enzymatically active form. These three sites offer possibilities for the study of mechanisms of control for this interesting enzyme that may play a role in chemical carcinogenesis and in drug resistance.	UNIV TORONTO, DEPT PATHOL, TORONTO M5S 1A8, ON, CANADA; UNIV TORONTO, DEPT BIOCHEM, TORONTO M5S 1A8, ON, CANADA	University of Toronto; University of Toronto								AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; CAMERON RG, 1989, CANCER LETT, V47, P163, DOI 10.1016/0304-3835(89)90086-4; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Columbano A, 1984, Toxicol Pathol, V12, P89; COLUMBANO A, 1983, AM J PATHOL, V110, P83; DING VDH, 1990, CANCER RES, V50, P256; FARBER E, 1987, CHEM SCRIPTA, V27A, P131; FARBER E, 1990, BIOCHEM PHARMACOL, V39, P1837, DOI 10.1016/0006-2952(90)90599-G; FAUSTO N, 1984, MOL CELL BIOCHEM, V59, P131; FRIEDMAN JM, 1984, J MOL BIOL, V179, P37, DOI 10.1016/0022-2836(84)90305-X; GARRITY PA, 1990, MOL CELL BIOL, V10, P5646, DOI 10.1128/MCB.10.11.5646; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HABIG WH, 1974, J BIOL CHEM, V249, P7130; HAYES JD, 1990, GLUTATHIONE S TRANSF; KUZMICH S, 1989, Proceedings of the American Association for Cancer Research Annual Meeting, V30, P513; LI Y, 1989, ONCOGENE, V4, P795; Maniatis T., 1982, MOL CLONING; MANNERVIK B, 1985, P NATL ACAD SCI USA, V82, P7202, DOI 10.1073/pnas.82.21.7202; MANNERVIK B, 1992, BIOCHEM J, V282, P305, DOI 10.1042/bj2820305; MCKNIGHT GS, 1979, J BIOL CHEM, V254, P9050; MEYER DJ, 1985, FEBS LETT, V184, P139, DOI 10.1016/0014-5793(85)80670-0; MOORE MA, 1987, CARCINOGENESIS, V8, P483, DOI 10.1093/carcin/8.3.483; NEAL TL, 1988, BIOCHEM BIOPH RES CO, V156, P368, DOI 10.1016/S0006-291X(88)80850-7; OKUDA A, 1987, J BIOL CHEM, V262, P3858; PRINCEN HMG, 1982, BIOCHIM BIOPHYS ACTA, V699, P121, DOI 10.1016/0167-4781(82)90145-2; PYERIN W, 1987, BIOCHEM BIOPH RES CO, V142, P885, DOI 10.1016/0006-291X(87)91496-3; ROOMI MW, 1986, CARCINOGENESIS, V7, P1643, DOI 10.1093/carcin/7.10.1643; RUSHMORE TH, 1987, BIOCHEM BIOPH RES CO, V143, P98, DOI 10.1016/0006-291X(87)90635-8; RUSHMORE TH, 1988, CANCER RES, V48, P2805; Sambrook J, 1989, MOL CLONING LABORATO; SARGENT TD, 1979, P NATL ACAD SCI USA, V76, P3256, DOI 10.1073/pnas.76.7.3256; SATO K, 1989, ADV CANCER RES, V52, P205; SATO K, 1984, GANN, V75, P199; SCHIBLER U, 1983, CELL, V33, P501, DOI 10.1016/0092-8674(83)90431-2; SHINOZUKA H, 1970, LAB INVEST, V23, P253; SIEGEL FL, 1990, GLUTATHIONE S-TRANSFERASES AND DRUG RESISTANCE, P47; SIEGEL FL, 1985, ARCH BIOCHEM BIOPHYS, V237, P347, DOI 10.1016/0003-9861(85)90286-3; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SUGUOKA Y, 1985, NUCLEIC ACIDS RES, V13, P6049, DOI 10.1093/nar/13.17.6049; VILLATREVINO S, 1966, J BIOL CHEM, V241, P4670; WILLIAMS JB, 1986, J BIOL CHEM, V261, P5524	43	16	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14601	14606						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	8182066				2022-12-25	WOS:A1994NM06500047
J	REN, JM; SEMENKOVICH, CF; GULVE, EA; GAO, JP; HOLLOSZY, JO				REN, JM; SEMENKOVICH, CF; GULVE, EA; GAO, JP; HOLLOSZY, JO			EXERCISE INDUCES RAPID INCREASES IN GLUT4 EXPRESSION, GLUCOSE-TRANSPORT CAPACITY, AND INSULIN-STIMULATED GLYCOGEN-STORAGE IN MUSCLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT SKELETAL-MUSCLE; PLASMA-MEMBRANE; APPARENT TRANSLOCATION; ENDURANCE PERFORMANCE; POTENTIAL MECHANISM; PHORBOL ESTER; SOLEUS MUSCLE; PROTEIN; LOCALIZATION; ACTIVATION	GLUT4 glucose transporter content and glucose transport capacity are closely correlated in skeletal muscle. In this study, we tested the hypothesis that a rapid increase in GLUT4 expression occurs as part of the early adaptive response of muscle to exercise and serves to enhance glycogen storage. Rats exercised by swimming had a similar to 2-fold increase in GLUT4 mRNA and a 50% increase in GLUT4 protein expression in epitrochlearis muscle 16 h after one prolonged exercise session. After a 2nd day of exercise, muscle GLUT4 protein was increased further to similar to 2-fold while there was no additional increase in GLUT4 mRNA. Muscle hexokinase activity also doubled in response to 2 days of exercise. Glucose transport activity maximally stimulated with insulin, contractions, or hypoxia was increased roughly in proportion to the adaptive increase in GLUT4 protein in epitrochlearis muscles. Treatment with insulin prior to subcellular fractionation of muscle resulted in a similar to 2-fold greater increase in GLUT4 content of a plasma membrane fraction in the 2-day swimmers than in controls. When epitrochlearis muscles were incubated with glucose and insulin, glycogen accumulation over 3 h was twice as great in muscles from 2-day swimmers as in control muscles. Our results show that a rapid increase in GLUT4 expression is an early adaptive response of muscle to exercise. This adaptation appears to be mediated by pretranslational mechanisms. We hypothesize that the physiological role of this adaptation is to enhance replenishment of muscle glycogen stores.	WASHINGTON UNIV, SCH MED, DEPT MED, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT CELL BIOL & PHYSIOL, ST LOUIS, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)				Semenkovich, Clay/0000-0003-1163-1871	NHLBI NIH HHS [HL47436] Funding Source: Medline; NIA NIH HHS [AG00078] Funding Source: Medline; NIDDK NIH HHS [DK18986] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL047436] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK018986] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALDWIN KM, 1975, PFLUG ARCH EUR J PHY, V354, P203, DOI 10.1007/BF00584644; BERGSTROM J, 1967, ACTA PHYSIOL SCAND, V71, P140, DOI 10.1111/j.1748-1716.1967.tb03720.x; BORNEMANN A, 1992, DIABETES, V41, P215, DOI 10.2337/diabetes.41.2.215; BROZINICK JT, 1993, AM J PHYSIOL, V265, pE419, DOI 10.1152/ajpendo.1993.265.3.E419; CARTEE GD, 1991, J APPL PHYSIOL, V70, P1593, DOI 10.1152/jappl.1991.70.4.1593; CARTEE GD, 1989, AM J PHYSIOL, V256, pE494, DOI 10.1152/ajpendo.1989.256.4.E494; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COGGAN AR, 1992, J APPL PHYSIOL, V73, P1873, DOI 10.1152/jappl.1992.73.5.1873; COGGAN AR, 1990, J APPL PHYSIOL, V68, P990, DOI 10.1152/jappl.1990.68.3.990; CONSTABLE SH, 1984, AM J PHYSIOL, V247, pR880, DOI 10.1152/ajpregu.1984.247.5.R880; COSTILL DL, 1977, J APPL PHYSIOL, V43, P695, DOI 10.1152/jappl.1977.43.4.695; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; DOUEN AG, 1990, J BIOL CHEM, V265, P13427; ETGEN GJ, 1993, J BIOL CHEM, V268, P20164; FELL RD, 1982, J APPL PHYSIOL, V52, P434, DOI 10.1152/jappl.1982.52.2.434; FOSTER C, 1979, MED SCI SPORT EXER, V11, P1; FRIEDMAN JE, 1990, FEBS LETT, V268, P13, DOI 10.1016/0014-5793(90)80960-Q; GOODYEAR LJ, 1992, DIABETES, V41, P1091, DOI 10.2337/diabetes.41.9.1091; GULVE EA, 1993, AM J PHYSIOL, V264, pE319, DOI 10.1152/ajpendo.1993.264.3.E319; HANSEN PA, 1994, J APPL PHYSIOL, V76, P979, DOI 10.1152/jappl.1994.76.2.979; HENRIKSEN EJ, 1991, J APPL PHYSIOL, V70, P2322, DOI 10.1152/jappl.1991.70.5.2322; HENRIKSEN EJ, 1989, J BIOL CHEM, V264, P21536; HENRIKSEN EJ, 1990, AM J PHYSIOL, V259, pE593, DOI 10.1152/ajpendo.1990.259.4.E593; HIRSHMAN MF, 1990, J BIOL CHEM, V265, P987; HIRSHMAN MF, 1988, FEBS LETT, V238, P235, DOI 10.1016/0014-5793(88)80486-1; HOLLOSZY JO, 1979, AM J PHYSIOL, V236, pR180, DOI 10.1152/ajpregu.1979.236.3.R180; HOLLOSZY JO, 1976, ANNU REV PHYSIOL, V38, P273, DOI 10.1146/annurev.ph.38.030176.001421; HOLLOSZY JO, 1967, J BIOL CHEM, V242, P2278; HOLMAN GD, 1990, J BIOL CHEM, V265, P18172; HOUMARD JA, 1993, AM J PHYSIOL, V264, pE896, DOI 10.1152/ajpendo.1993.264.6.E896; HURLEY BF, 1986, J APPL PHYSIOL, V60, P562, DOI 10.1152/jappl.1986.60.2.562; JAMES DE, 1989, NATURE, V338, P83, DOI 10.1038/338083a0; KARLSSON J, 1971, J APPL PHYSIOL, V31, P203, DOI 10.1152/jappl.1971.31.2.203; KERN M, 1990, BIOCHEM J, V270, P397, DOI 10.1042/bj2700397; KIPNIS DM, 1959, J BIOL CHEM, V234, P171; KLIP A, 1990, DIABETES CARE, V13, P228, DOI 10.2337/diacare.13.3.228; KLIP A, 1987, FEBS LETT, V224, P224, DOI 10.1016/0014-5793(87)80452-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWIS SF, 1989, EXERCISE SPORT SCI R, V17, P67; Lowenstein JM, 1969, METHOD ENZYMOL, P3, DOI [10.1016/0076-6879(69)13005-0, DOI 10.1016/0076-6879(69)13005-0]; LUND S, 1993, FEBS LETT, V330, P312, DOI 10.1016/0014-5793(93)80895-2; MARETTE A, 1992, AM J PHYSIOL, V263, pC443, DOI 10.1152/ajpcell.1992.263.2.C443; MARTIN WH, 1993, AM J PHYSIOL, V265, pE708, DOI 10.1152/ajpendo.1993.265.5.E708; MEGENEY LA, 1993, AM J PHYSIOL, V264, pE583, DOI 10.1152/ajpendo.1993.264.4.E583; MOLE PA, 1971, J CLIN INVEST, V50, P2323, DOI 10.1172/JCI106730; MUECKLER M, 1990, DIABETES, V39, P6, DOI 10.2337/diabetes.39.1.6; PASSONNEAU JV, 1974, ANAL BIOCHEM, V60, P405, DOI 10.1016/0003-2697(74)90248-6; PETER JB, 1968, SCIENCE, V160, P200, DOI 10.1126/science.160.3824.200; PLOUG T, 1990, AM J PHYSIOL, V259, pE778, DOI 10.1152/ajpendo.1990.259.6.E778; REN JM, 1993, AM J PHYSIOL, V264, pC146, DOI 10.1152/ajpcell.1993.264.1.C146; REN JM, 1993, J BIOL CHEM, V268, P16113; RODNICK KJ, 1992, J BIOL CHEM, V267, P6278; RODNICK KJ, 1992, AM J PHYSIOL, V262, pC9, DOI 10.1152/ajpcell.1992.262.1.C9; ROGERS MA, 1988, DIABETES CARE, V11, P613, DOI 10.2337/diacare.11.8.613; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; UYEDA K, 1965, J BIOL CHEM, V240, P4682; WALLBERGHENRIKSSON H, 1988, J APPL PHYSIOL, V65, P909, DOI 10.1152/jappl.1988.65.2.909; WARDZALA LJ, 1981, J BIOL CHEM, V256, P7090; WEBER FE, 1990, EUR J BIOCHEM, V191, P85, DOI 10.1111/j.1432-1033.1990.tb19096.x; YOUNG DA, 1986, J BIOL CHEM, V261, P6049	61	319	331	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14396	14401						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	8182045				2022-12-25	WOS:A1994NM06500017
J	BIZZARRI, C; SHIOI, A; TEITELBAUM, SL; OHARA, J; HARWALKAR, VA; ERDMANN, JM; LACEY, DL; CIVITELLI, R				BIZZARRI, C; SHIOI, A; TEITELBAUM, SL; OHARA, J; HARWALKAR, VA; ERDMANN, JM; LACEY, DL; CIVITELLI, R			INTERLEUKIN-1 INHIBITS BONE-RESORPTION AND ACUTELY INCREASES CYTOSOLIC CA2+ IN MURINE OSTEOCLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY STIMULATING FACTOR; EXTRACELLULAR CALCIUM; RAT OSTEOCLASTS; CELLS; CALCITONIN; PURIFICATION; MECHANISMS; ACTIVATION; RECEPTORS; CHANNELS	Interleukin-4 (IL-4) is an immune cytokine recently shown to inhibit bone resorption. To determine whether IL-4 directly acts on osteoclasts, we have analyzed its effect on cytosolic calcium concentration [Ca2+](i) and bone resorptive function of murine osteoclastic cells generated from bone marrow/stromal cell co-cultures. IL-4 exposure induced an immediate and sustained increase in [Ca2+](i) that remained elevated for at least 10 min. This IL-4 effect was dose-dependent, with the maximal effect (209 +/- 15% of baseline, n = 16) at 200 units/ml and an apparent ED(0.5) of 60 units/ml. The IL-4-induced [Ca2+](i). rise required extracellular Ca2+ influx, since the response was prevented by LaCl3, and voltage-gated Ca2+ channel blockers, although the IL-4 effect was more sensitive to nicardipine and nifedipine than to diltiazem. Depolarization by high extracellular K+ concentration also raised [Ca2+](i), and, under these conditions, osteoclasts failed to respond to IL-4. On the other hand, when intracellular Ca2+ stores were depleted by thapsigargin, IL-4 still induced an increase in [Ca2+](i), although smaller in amplitude and transient. Calcitonin also produced [Ca2+](i) increases in osteoclasts, yet it only slightly desensitized these cells to IL-4. Furthermore, IL-4 was much less effective on osteoclasts pretreated (5-10 min) with either forskolin or 8-bromo-cAMP. Both IL-4 and calcitonin were effective even when [Ca2+](i) had been increased by exposure to high extracellular Ca2+. Finally, IL-4 dose dependently inhibited the bone resorptive activity of mature osteoclasts. Therefore, IL-4 signal transduction in osteoclasts involves a rapid and sustained elevation of [Ca2+](i) mediated by a voltage dependent Ca2+ influx, in combination with Ca2+ release from intracellular stores. Modulation of osteoclast [Ca2+](i) represents a potential mechanism by which IL-4 inhibits bone resorption.	WASHINGTON UNIV, JEWISH HOSP ST LOUIS, MED CTR, DIV ENDOCRINOL & BONE & MINERAL DIS, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, JEWISH HOSP ST LOUIS, MED CTR, DEPT PATHOL, ST LOUIS, MO 63110 USA; UNIV COLORADO, HLTH SCI CTR, DIV GASTROENTEROL, DENVER, CO 80262 USA; CONSORZIO BIOLAQ LAQUILA, I-67100 LAQUILA, ITALY	Barnes-Jewish Hospital; Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL); University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver			Civitelli, Roberto/AAA-8260-2019	Civitelli, Roberto/0000-0003-4076-4315; Teitelbaum, Steven/0000-0002-4054-6679	NIAMS NIH HHS [AR42356, AR32087, AR41255] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042356, P01AR032087, R01AR041255, R29AR041255] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BLAIR HC, 1986, J CELL BIOL, V102, P1164, DOI 10.1083/jcb.102.4.1164; BOULAY JL, 1992, J BIOL CHEM, V267, P20525; BRYAN J, 1985, J CELL BIOL, V101, P1236, DOI 10.1083/jcb.101.4.1236; CATTERALL WA, 1988, J BIOL CHEM, V263, P3535; CHAMBERS TJ, 1991, VITAM HORM, V46, P41; CHAMBERS TJ, 1985, J PATHOL, V145, P297, DOI 10.1002/path.1711450403; CHAPONNIER C, 1986, J CELL BIOL, V103, P1473, DOI 10.1083/jcb.103.4.1473; CIVITELLI R, 1990, ENDOCRINOLOGY, V127, P2253, DOI 10.1210/endo-127-5-2253; CIVITELLI R, 1991, J TISSUE CULTURE MET, V13, P217; EISNER DA, 1985, AM J PHYSIOL, V248, pC189, DOI 10.1152/ajpcell.1985.248.3.C189; FUJIMORI A, 1991, ENDOCRINOLOGY, V128, P3032, DOI 10.1210/endo-128-6-3032; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HOWARD M, 1982, J EXP MED, V155, P914, DOI 10.1084/jem.155.3.914; KASONO K, 1993, BONE MINER, V21, P179, DOI 10.1016/S0169-6009(08)80229-2; KOJIMA I, 1985, J BIOL CHEM, V260, P9177; LACEY DL, 1987, J IMMUNOL, V138, P1680; LACEY DL, 1993, J CELL BIOCHEM, V53, P122, DOI 10.1002/jcb.240530205; LACEY DL, 1992, J BONE MINER RES, V7, pS95; MALGAROLI A, 1989, J BIOL CHEM, V264, P14342; MARCHISIO PC, 1984, J CELL BIOL, V99, P1696, DOI 10.1083/jcb.99.5.1696; MARCHISIO PC, 1987, EXP CELL RES, V169, P202, DOI 10.1016/0014-4827(87)90238-2; MIYAUCHI A, 1990, J CELL BIOL, V111, P2543, DOI 10.1083/jcb.111.6.2543; MOONGA BS, 1992, J ENDOCRINOL, V132, P241, DOI 10.1677/joe.0.1320241; MUNDY GR, 1984, NEW ENGL J MED, V310, P1718; OHARA J, 1987, J IMMUNOL, V139, P1127; OHARA J, 1989, YEAR IMMUNOLOGY IMMU, P126; PAREKH AB, 1993, NATURE, V364, P814, DOI 10.1038/364814a0; RABIN EM, 1985, P NATL ACAD SCI USA, V82, P2935, DOI 10.1073/pnas.82.9.2935; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; REID IR, 1987, AM J PHYSIOL, V253, pE45, DOI 10.1152/ajpendo.1987.253.1.E45; SHANKAR VS, 1993, J CELL PHYSIOL, V155, P120, DOI 10.1002/jcp.1041550116; SHIOI A, 1991, J CELL BIOCHEM, V47, P272, DOI 10.1002/jcb.240470313; STANLEY ER, 1977, J BIOL CHEM, V252, P4305; TAKAHASHI N, 1988, ENDOCRINOLOGY, V123, P1504, DOI 10.1210/endo-123-3-1504; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; TETI A, 1989, J CLIN INVEST, V84, P773, DOI 10.1172/JCI114235; THOMSON BM, 1987, J IMMUNOL, V138, P775; THOMSON BM, 1986, J EXP MED, V164, P104, DOI 10.1084/jem.164.1.104; UDAGAWA N, 1989, ENDOCRINOLOGY, V125, P1805, DOI 10.1210/endo-125-4-1805; WATANABE K, 1990, BIOCHEM BIOPH RES CO, V172, P1035, DOI 10.1016/0006-291X(90)91550-C; WATANABE K, 1991, J BONE MINER RES, V6, pS288; ZAIDI M, 1993, CELL CALCIUM, V14, P271, DOI 10.1016/0143-4160(93)90048-B; ZAIDI M, 1992, BIOCHEM BIOPH RES CO, V188, P1332, DOI 10.1016/0006-291X(92)91377-3; ZAMBONINZALLONE A, 1988, J BONE MINER RES, V3, P517	45	41	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					13817	13824						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188659				2022-12-25	WOS:A1994NL60600019
J	MULLER, KM; EBENSPERGER, C; TAMPE, R				MULLER, KM; EBENSPERGER, C; TAMPE, R			NUCLEOTIDE-BINDING TO THE HYDROPHILIC C-TERMINAL DOMAIN OF THE TRANSPORTER ASSOCIATED WITH ANTIGEN-PROCESSING (TAP)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; CLASS-II REGION; TRANSMEMBRANE CONDUCTANCE REGULATOR; PUTATIVE PEPTIDE TRANSPORTER; MULTIDRUG-RESISTANCE; CYSTIC-FIBROSIS; ATP HYDROLYSIS; MALTOSE TRANSPORT; SALMONELLA-TYPHIMURIUM; STRUCTURAL MODEL	The gene products of tap1 and tap2 encoded in the major histocompatibility complex (MHC) class II:region belong to the ATP binding cassette superfamily of transporters. They are thought to form a heterodimer for the delivery of peptides into the lumen of the endoplasmic reticulum; peptides are required for correct assembly and presentation of the MHC class I molecule peptide complex at the cell surface. To elucidate the ATP binding properties of these proteins in vitro, we expressed the hydrophilic C terminal part of human transporter associated with antigen processing (TAP1) (nucleotide binding domain (NBD)-TAP1, amino acids 452-748) and TAP2 (NBD- TAP2, amino acids 399-686) fused to a His(6) tag in Escherichia coli. The recombinant proteins accumulated exclusively in inclusion bodies and were solubilized under denaturing conditions. After purification by immobilized metal ion affinity chromatography, we were able to refold the domains for functional studies. NBD-TAP1 bound to C-8-ATP-agarose and was specifically eluted with ATP or EDTA. Photoaffinity labeling of NBD-TAP1 with the ATP analogues 8-azido-[gamma-P-32]ATP and 3'-0-[(4-azido-3,5-[I-125]diiodo-2-hydroxybenzoyl)-beta-alanyl]-ATP was specific. The addition of 50 mu M ATP inhibited photoaffinity labeling by 8-azido-ATP down to 8% of controls. Efficiency of inhibition decreased as follows: ATP > GTP > ADP > CTP > AMP. Photolabeling of NBD-TAP2 was not observed. ATP hydrolysis by NBD-TAP1 was not detected. Until now strong but only indirect data of the TAP function existed. The described experiments demonstrate ATP binding to an isolated domain of the antigenic peptide transporter, TAP, and therefore support the theory of ATP-dependent peptide translocation.	MAX PLANCK INST BIOCHEM, D-82152 MARTINSRIED, GERMANY; TECH UNIV MUNICH, LEHRSTUHL BIOPHYS E22, D-85748 GARCHING, GERMANY	Max Planck Society; Technical University of Munich			Tampé, Robert/H-2953-2015	Tampé, Robert/0000-0002-0403-2160				ALSHAWI MK, 1993, J BIOL CHEM, V268, P4197; AMBUDKAR SV, 1992, P NATL ACAD SCI USA, V89, P8472, DOI 10.1073/pnas.89.18.8472; AMES GFL, 1992, INT REV CYTOL, V137A, P1; ANDROLEWICZ MJ, 1993, P NATL ACAD SCI USA, V90, P9130, DOI 10.1073/pnas.90.19.9130; ATTAYA M, 1992, NATURE, V355, P647, DOI 10.1038/355647a0; BAHRAM S, 1991, P NATL ACAD SCI USA, V88, P10094, DOI 10.1073/pnas.88.22.10094; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BISHOP L, 1989, P NATL ACAD SCI USA, V86, P6953, DOI 10.1073/pnas.86.18.6953; CORNWELL MM, 1987, FASEB J, V1, P51, DOI 10.1096/fasebj.1.1.2886389; DEAN DA, 1989, P NATL ACAD SCI USA, V86, P9134, DOI 10.1073/pnas.86.23.9134; DEVERSON EV, 1990, NATURE, V348, P738, DOI 10.1038/348738a0; ECKERSKORN C, 1988, ELECTROPHORESIS, V9, P830, DOI 10.1002/elps.1150091208; GERMAIN RN, 1993, ANNU REV IMMUNOL, V11, P403, DOI 10.1146/annurev.immunol.11.1.403; HAMADA H, 1988, J BIOL CHEM, V263, P1454; HARTMAN J, 1992, J BIOL CHEM, V267, P6455; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HOBSON AC, 1984, P NATL ACAD SCI-BIOL, V81, P7333, DOI 10.1073/pnas.81.23.7333; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; KELLY A, 1992, NATURE, V355, P641, DOI 10.1038/355641a0; KLEIJMEER MJ, 1992, NATURE, V357, P342, DOI 10.1038/357342a0; KOPPELMAN B, 1992, P NATL ACAD SCI USA, V89, P3908, DOI 10.1073/pnas.89.9.3908; KORONAKIS V, 1993, MOL MICROBIOL, V8, P1163, DOI 10.1111/j.1365-2958.1993.tb01661.x; KUCHLER K, 1993, J CELL BIOL, V120, P1203, DOI 10.1083/jcb.120.5.1203; LEVY F, 1991, CELL, V67, P265, DOI 10.1016/0092-8674(91)90178-2; MIMURA CS, 1991, P NATL ACAD SCI USA, V88, P84, DOI 10.1073/pnas.88.1.84; MOMBURG F, 1992, NATURE, V360, P174, DOI 10.1038/360174a0; MONACO JJ, 1990, SCIENCE, V250, P1723, DOI 10.1126/science.2270487; MORBACH S, 1993, J BIOL CHEM, V268, P18617; NEEFJES JJ, 1993, SCIENCE, V261, P769, DOI 10.1126/science.8342042; POWIS SH, 1992, P NATL ACAD SCI USA, V89, P1463, DOI 10.1073/pnas.89.4.1463; POWIS SJ, 1991, NATURE, V354, P528, DOI 10.1038/354528a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARKADI B, 1992, J BIOL CHEM, V267, P4854; SCHNEIDER E, 1991, MOL MICROBIOL, V5, P1375, DOI 10.1111/j.1365-2958.1991.tb00784.x; SHEPHERD JC, 1993, CELL, V74, P577, DOI 10.1016/0092-8674(93)80058-M; SHIMABUKU AM, 1992, J BIOL CHEM, V267, P4308; SPIES T, 1991, NATURE, V351, P323, DOI 10.1038/351323a0; SPIES T, 1992, NATURE, V355, P644, DOI 10.1038/355644a0; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; TEEM JL, 1993, CELL, V73, P335, DOI 10.1016/0092-8674(93)90233-G; THOMAS PJ, 1991, SCIENCE, V251, P555, DOI 10.1126/science.1703660; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WALTER C, 1992, J BIOL CHEM, V267, P8863; YANG Y, 1992, J BIOL CHEM, V267, P11669; YEWDELL JW, 1992, ADV IMMUNOL, V52, P1, DOI 10.1016/S0065-2776(08)60875-5	46	59	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					14032	14037						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188683				2022-12-25	WOS:A1994NL60600049
J	WAKITA, T; WANDS, JR				WAKITA, T; WANDS, JR			SPECIFIC-INHIBITION OF HEPATITIS-C VIRUS EXPRESSION BY ANTISENSE OLIGODEOXYNUCLEOTIDES - IN-VITRO MODEL FOR SELECTION OF TARGET SEQUENCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; NON-B-HEPATITIS; 5' UNTRANSLATED REGION; NON-A; TRANSLATION ARREST; VIRAL-RNA; OLIGONUCLEOTIDES; COMPLEMENTARY; REPLICATION; GENOME	The effect of sense and antisense oligodeoxynucleotides (ODNs) on hepatitis C virus (HCV) gene expression was studied to determine the role of the highly conserved 5'-untranslated region in the life cycle of the virus. It was found that antisense ODNs complementary to nucleotides (nt) 38-65, 134-175, and 312-339 in the 5' noncoding region and 341-377 in the core open reading frame efficiently blocked HCV RNA translation. Overlapping ODNs that differed by only several nucleotides showed substantially different inhibition of HCV RNA translation. Fine sequence specificity testing at nt positions 351-377 revealed that ODNs as small as a 12-mer (nt 351-363) retained a high degree (80%) of inhibitory activity compared to ODNs of longer sequences. These results suggest that there are three highly specific domains in the 5' noncoding region and a sequence immediately downstream of the HCV core initiation codon that may be critical for translation of HCV RNA. This study also provides an experimental approach for the selection of target HCV RNA sequences susceptible to antisense effects, as well as for definition of functional regions of the genome necessary for viral replication.	MASSACHUSETTS GEN HOSP,CTR CANC,MOLEC HEPATOL LAB,BOSTON,MA 02114; HARVARD UNIV,SCH MED,BOSTON,MA 02114	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School					NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA008169, R37AA002666, R01AA002666] Funding Source: NIH RePORTER; NCI NIH HHS [CA-357111] Funding Source: Medline; NIAAA NIH HHS [AA-08169, AA-02666] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ALTMANN M, 1993, TRENDS BIOCHEM SCI, V18, P429, DOI 10.1016/0968-0004(93)90143-B; BLAKE KR, 1985, BIOCHEMISTRY-US, V24, P6132, DOI 10.1021/bi00343a015; BLUM HE, 1991, LANCET, V337, P1230, DOI 10.1016/0140-6736(91)92907-J; BROWN EA, 1992, NUCLEIC ACIDS RES, V20, P5041, DOI 10.1093/nar/20.19.5041; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOO QL, 1991, P NATL ACAD SCI USA, V88, P2451, DOI 10.1073/pnas.88.6.2451; DELANGEL RM, 1989, P NATL ACAD SCI USA, V86, P8299; GOODARZI G, 1990, J GEN VIROL, V71, P3021, DOI 10.1099/0022-1317-71-12-3021; GUPTA KC, 1987, J BIOL CHEM, V262, P7492; HAEUPTLE MT, 1986, NUCLEIC ACIDS RES, V14, P1427, DOI 10.1093/nar/14.3.1427; HAN JH, 1991, P NATL ACAD SCI USA, V88, P1711, DOI 10.1073/pnas.88.5.1711; HIJIKATA M, 1991, P NATL ACAD SCI USA, V88, P5547, DOI 10.1073/pnas.88.13.5547; HOOFNAGLE JH, 1986, NEW ENGL J MED, V315, P1575, DOI 10.1056/NEJM198612183152503; ICHAUSPE G, 1991, P NATL ACAD SCI USA, V88, P10292; KABANOV AV, 1990, FEBS LETT, V259, P327, DOI 10.1016/0014-5793(90)80039-L; KATO N, 1990, P NATL ACAD SCI USA, V87, P9524, DOI 10.1073/pnas.87.24.9524; KIYOSAWA K, 1990, HEPATOLOGY, V12, P671, DOI 10.1002/hep.1840120409; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; LEMAITRE M, 1987, P NATL ACAD SCI USA, V84, P648, DOI 10.1073/pnas.84.3.648; LETSINGER RL, 1989, P NATL ACAD SCI USA, V86, P6553, DOI 10.1073/pnas.86.17.6553; LIEBHABER SA, 1984, J BIOL CHEM, V259, P5597; LISZIEWICZ J, 1992, P NATL ACAD SCI USA, V89, P11209, DOI 10.1073/pnas.89.23.11209; MATSUKURA M, 1987, P NATL ACAD SCI USA, V84, P7706, DOI 10.1073/pnas.84.21.7706; MIROSHNICHENKO NA, 1988, FEBS LETT, V234, P65, DOI 10.1016/0014-5793(88)81304-8; OFFENSPERGER WB, 1993, EMBO J, V12, P1257, DOI 10.1002/j.1460-2075.1993.tb05767.x; OKAMOTO H, 1992, VIROLOGY, V188, P331, DOI 10.1016/0042-6822(92)90762-E; OKAMOTO H, 1991, J GEN VIROL, V72, P2697, DOI 10.1099/0022-1317-72-11-2697; PATERSON BM, 1977, P NATL ACAD SCI USA, V74, P4370, DOI 10.1073/pnas.74.10.4370; PELHAM HRB, 1976, EUR J BIOCHEM, V67, P247, DOI 10.1111/j.1432-1033.1976.tb10656.x; SHIH DS, 1987, J VIROL, V61, P2033, DOI 10.1128/JVI.61.6.2033-2037.1987; SHIMIZU YK, 1993, P NATL ACAD SCI USA, V90, P6037, DOI 10.1073/pnas.90.13.6037; SMITH CC, 1986, P NATL ACAD SCI USA, V83, P2787, DOI 10.1073/pnas.83.9.2787; STEIN CA, 1993, SCIENCE, V261, P1004, DOI 10.1126/science.8351515; TAKAMIZAWA A, 1991, J VIROL, V65, P1105, DOI 10.1128/JVI.65.3.1105-1113.1991; TSUKIYAMAKOHARA K, 1992, J VIROL, V66, P1476, DOI 10.1128/JVI.66.3.1476-1483.1992; UHLMANN E, 1990, CHEM REV, V90, P543, DOI 10.1021/cr00102a001; WALDER RY, 1988, P NATL ACAD SCI USA, V85, P5011, DOI 10.1073/pnas.85.14.5011; WANG CY, 1993, J VIROL, V67, P3338, DOI 10.1128/JVI.67.6.3338-3344.1993; YOSHIOKA K, 1992, HEPATOLOGY, V16, P293, DOI 10.1002/hep.1840160203; ZAMECNIK PC, 1986, P NATL ACAD SCI USA, V83, P4143, DOI 10.1073/pnas.83.12.4143	41	123	132	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					14205	14210						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188703				2022-12-25	WOS:A1994NL60600073
J	KUMAR, V; HEINEMANN, FS; OZOLS, J				KUMAR, V; HEINEMANN, FS; OZOLS, J			PURIFICATION AND CHARACTERIZATION OF AVIAN OLIGOSACCHARYLTRANSFERASE - COMPLETE AMINO-ACID-SEQUENCE OF THE 50-KDA SUBUNIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROUGH ENDOPLASMIC-RETICULUM; SITE-BINDING-PROTEIN; RIBOPHORINS-I; GLYCOSYLATION; MEMBRANE; TRANSFERASE; GLYCOPROTEINS; TOPOLOGY	We have purified oligosaccharyltransferase from hen oviduct microsomes some 850-fold. Oligosaccharyltransferase activity copurified with a a 200-kDa complex consisting of two 65-kDa polypeptides and a 50-kDa polypeptide. N-terminal sequence analysis indicated that the 50-kDa subunit was the avian form of OST48, a canine pancreatic microsomal protein associated with oligosaccharyltransferase. As the first step toward reconstitution of the oligosaccharyltransferase complex, the 50-kDa subunit was purified to homogeneity under nondenaturing conditions. The complete amino acid sequence of the 50-kDa subunit was determined by sequence analysis of peptides isolated by a combination of gel filtration and high performance liquid chromatography from chemical and enzymatic digests. The protein consists of 412 residues in a single polypeptide chain. The amino acid sequence of the 50-kDa subunit of avian oligosaccharyltransferase is 92% identical to the sequence of canine OST48 protein and about 25% identical to WBP1 protein from the yeast Saccharomyces cerevisiae. The yeast WBP1 protein has been shown in vitro, as well as in vivo, to be essential for the oligosaccharyltransferase activity.	UNIV CONNECTICUT, CTR HLTH, DEPT BIOCHEM, FARMINGTON, CT 06030 USA; HOAG MEM HOSP, DEPT PATHOL, NEWPORT BEACH, CA 92663 USA	University of Connecticut					NIGMS NIH HHS [GM-26351] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026351] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUBERT JP, 1982, BIOCHEM BIOPH RES CO, V104, P1550, DOI 10.1016/0006-291X(82)91428-0; BAKER RK, 1986, J CELL BIOCHEM, V32, P193, DOI 10.1002/jcb.240320305; BULLEID NJ, 1990, EMBO J, V9, P3527, DOI 10.1002/j.1460-2075.1990.tb07561.x; CRIMAUDO C, 1987, EMBO J, V6, P75, DOI 10.1002/j.1460-2075.1987.tb04721.x; DAS RC, 1980, P NATL ACAD SCI-BIOL, V77, P3811, DOI 10.1073/pnas.77.7.3811; GEETHAHABIB M, 1988, CELL, V54, P1053, DOI 10.1016/0092-8674(88)90120-1; HART GW, 1979, J BIOL CHEM, V254, P9747; HEESEN ST, 1992, EMBO J, V11, P2071, DOI 10.1002/j.1460-2075.1992.tb05265.x; HEESEN ST, 1993, EMBO J, V12, P279, DOI 10.1002/j.1460-2075.1993.tb05654.x; HEESEN ST, 1991, EUR J CELL BIOL, V56, P8; KAPLAN HA, 1987, BIOCHIM BIOPHYS ACTA, V906, P161, DOI 10.1016/0304-4157(87)90010-4; KELLEHER DJ, 1992, CELL, V69, P55, DOI 10.1016/0092-8674(92)90118-V; KREIBICH G, 1978, J CELL BIOL, V77, P464, DOI 10.1083/jcb.77.2.464; MARCANTONIO EE, 1984, J CELL BIOL, V99, P2254, DOI 10.1083/jcb.99.6.2254; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; NOIVA R, 1991, P NATL ACAD SCI USA, V88, P1986, DOI 10.1073/pnas.88.5.1986; OZOLS J, 1990, METHOD ENZYMOL, V182, P587; OZOLS J, 1989, BIOCHIM BIOPHYS ACTA, V997, P121, DOI 10.1016/0167-4838(89)90143-X; OZOLS J, 1993, P NATL ACAD SCI USA, V90, P5302, DOI 10.1073/pnas.90.11.5302; SANDERSON CM, 1990, J CELL BIOL, V111, P2861, DOI 10.1083/jcb.111.6.2861; SHARMA C, 1981, EUR J BIOCHEM, V116, P101, DOI 10.1111/j.1432-1033.1981.tb05306.x; SILBERSTEIN S, 1992, J BIOL CHEM, V267, P23658; WELPLY JK, 1986, ARCH BIOCHEM BIOPHYS, V246, P808, DOI 10.1016/0003-9861(86)90337-1; WELPLY JK, 1985, J BIOL CHEM, V260, P6459; ZIMMERMAN JW, 1993, J BIOL CHEM, V268, P16746	25	44	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13451	13457						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175777				2022-12-25	WOS:A1994NK18400060
J	SUTTER, TR; TANG, YM; HAYES, CL; WO, YYP; JABS, EW; LI, X; YIN, H; CODY, CW; GREENLEE, WF				SUTTER, TR; TANG, YM; HAYES, CL; WO, YYP; JABS, EW; LI, X; YIN, H; CODY, CW; GREENLEE, WF			COMPLETE CDNA SEQUENCE OF A HUMAN DIOXIN-INDUCIBLE MESSENGER-RNA IDENTIFIES A NEW GENE SUBFAMILY OF CYTOCHROME-P450 THAT MAPS TO CHROMOSOME-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCES; AH-RECEPTOR; DIFFERENTIAL EXPRESSION; AROMATIC-HYDROCARBONS; NUCLEOTIDE-SEQUENCE; MESSENGER-RNAS; DNA; LIVER; PROTEIN; CLONING	Previously, levels of a novel human mRNA detected by a recombinant cDNA designated clone 1, were shown to be increased 50-fold in response to treatment of a keratinocyte cell line with 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), in part as a function of increased rates of gene transcription (Sutter, T. R., Guzman, K., Dold, K. M., and Greenlee, W. F. (1991) Science 254, 415-418). Here we report the complete corresponding 5.1-kilobase cDNA sequence. A single open reading frame that predicts a protein of 543 amino acid residues was determined by computer-assisted analysis of the cDNA sequence. This predicted protein identifies a new gene subfamily of cytochrome P450, cytochrome P4501B1 (CYP1B1), that maps to human chromosome 2. Southern blot analysis of genomic DNA indicates that the human CYP1B subfamily is likely to contain only this single gene. Northern blot analysis of RNA isolated from primary cultures of normal human epidermal keratinocytes showed similar to 100-fold increased levels of the CYP1B1 mRNA after treatment with 10 nM TCDD for 24 h. Low levels of constitutive CYP1B1 mRNA were detected in 15 different human tissue samples. These results indicate that CYP1B1 is expressed in many normal human tissues and advance our understanding of the complexity of a gene family of cytochromes P450 whose expression is altered by TCDD.	JOHNS HOPKINS MED INST, DEPT ENVIRONM HLTH SCI, BALTIMORE, MD 21205 USA; JOHNS HOPKINS MED INST, DEPT PEDIAT, BALTIMORE, MD 21205 USA; JOHNS HOPKINS MED INST, DEPT MED, BALTIMORE, MD 21205 USA; JOHNS HOPKINS MED INST, DEPT SURG, BALTIMORE, MD 21205 USA; PURDUE UNIV, SCH PHARM & PHARMACAL SCI, DEPT PHARMACOL & TOXICOL, W LAFAYETTE, IN 47907 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Purdue University System; Purdue University; Purdue University West Lafayette Campus				Jabs, Ethylin/0000-0001-8983-5466; Sutter, Carrie/0000-0002-6088-6320	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [P01HG000373] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES003819, R29ES006071] Funding Source: NIH RePORTER; NHGRI NIH HHS [HG00373] Funding Source: Medline; NIEHS NIH HHS [ES06071, ES03819] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BAIROCH A, 1992, NUCLEIC ACIDS RES, V20, P2013, DOI 10.1093/nar/20.suppl.2013; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHUNG BC, 1987, P NATL ACAD SCI USA, V84, P407, DOI 10.1073/pnas.84.2.407; CONNEY AH, 1982, CANCER RES, V42, P4875; DAYHOFF MO, 1979, ATLAS PROTEIN SEQ S3, V5, P353; DRWINGA HL, 1993, GENOMICS, V16, P311, DOI 10.1006/geno.1993.1190; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FUJIIKURIYAMA Y, 1992, FASEB J, V6, P706, DOI 10.1096/fasebj.6.2.1537460; GOLDSTEIN JA, 1984, MOL PHARMACOL, V25, P185; GONZALEZ FJ, 1988, PHARMACOL REV, V40, P243; GREENLEE WF, 1994, IN PRESS RECENT PROG; GUENGERICH FP, 1992, FASEB J, V6, P745, DOI 10.1096/fasebj.6.2.1537465; HANAHAN D, 1980, GENE, V10, P63, DOI 10.1016/0378-1119(80)90144-4; HEILMANN LJ, 1988, DNA-J MOLEC CELL BIO, V7, P379, DOI 10.1089/dna.1.1988.7.379; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; JAISWAL A K, 1987, Journal of Experimental Pathology (New York), V3, P1; JAISWAL AK, 1985, SCIENCE, V228, P80, DOI 10.1126/science.3838385; KAGAWA N, 1987, J BIOCHEM-TOKYO, V101, P1471, DOI 10.1093/oxfordjournals.jbchem.a122017; KAWAJIRI K, 1993, CRIT REV ONCOL HEMAT, V14, P77, DOI 10.1016/1040-8428(93)90007-Q; KELLY RB, 1970, J BIOL CHEM, V245, P39; KIMURA S, 1989, AM J HUM GENET, V45, P889; KIMURA S, 1986, MOL CELL BIOL, V6, P1471, DOI 10.1128/MCB.6.5.1471; KIMURA S, 1984, J BIOL CHEM, V259, P705; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; NEBERT DW, 1991, MOL ENDOCRINOL, V5, P1203, DOI 10.1210/mend-5-9-1203; NEBERT DW, 1991, METHOD ENZYMOL, V206, P3; NEBERT DW, 1989, INT J BIOCHEM, V21, P243, DOI 10.1016/0020-711X(89)90182-1; NELSON DR, 1993, DNA CELL BIOL, V12, P1, DOI 10.1089/dna.1993.12.1; OKEY AB, 1990, PHARMACOL THERAPEUT, V45, P241, DOI 10.1016/0163-7258(90)90030-6; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; POLAND A, 1982, ANNU REV PHARMACOL, V22, P517, DOI 10.1146/annurev.pa.22.040182.002505; POMPON D, 1988, EUR J BIOCHEM, V177, P285, DOI 10.1111/j.1432-1033.1988.tb14375.x; POTTENGER LH, 1991, ARCH BIOCHEM BIOPHYS, V286, P488, DOI 10.1016/0003-9861(91)90070-Y; REYES H, 1992, SCIENCE, V256, P1193, DOI 10.1126/science.256.5060.1193; RIFKIND AB, 1983, NATURE, V303, P524, DOI 10.1038/303524a0; SAFE SH, 1986, ANNU REV PHARMACOL, V26, P371, DOI 10.1146/annurev.pa.26.040186.002103; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SESARDIC D, 1990, CARCINOGENESIS, V11, P1183, DOI 10.1093/carcin/11.7.1183; SHEN ES, 1992, J BIOL CHEM, V267, P6815; SOGAWA K, 1985, J BIOL CHEM, V260, P5026; SUTTER TR, 1991, SCIENCE, V254, P415, DOI 10.1126/science.1925598; SUTTER TR, 1992, CHEMOSPHERE, V25, P223, DOI 10.1016/0045-6535(92)90519-W; SUTTER TR, 1990, J BIOL CHEM, V265, P16428; SUTTER TR, 1991, BANB REPORT, V35, P379; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; WAHLE E, 1992, ANNU REV BIOCHEM, V61, P419; WHITLOCK JP, 1993, CHEM RES TOXICOL, V6, P754, DOI 10.1021/tx00036a003; WILHELMSSON A, 1990, EMBO J, V9, P69, DOI 10.1002/j.1460-2075.1990.tb08081.x; YABUSAKI Y, 1984, NUCLEIC ACIDS RES, V12, P2929, DOI 10.1093/nar/12.6.2929; YAMANO S, 1989, BIOCHEMISTRY-US, V28, P7340, DOI 10.1021/bi00444a029	53	457	476	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13092	13099						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175734				2022-12-25	WOS:A1994NK18400010
J	WARD, CR; STOREY, BT; KOPF, GS				WARD, CR; STOREY, BT; KOPF, GS			SELECTIVE ACTIVATION OF G(I1), AND G(I2), IN MOUSE SPERM BY THE ZONA-PELLUCIDA, THE EGGS EXTRACELLULAR-MATRIX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING REGULATORY PROTEIN; ACROSOME REACTION; ALPHA-SUBUNITS; MAMMALIAN SPERM; FERTILIZATION INVITRO; GAMETE INTERACTIONS; RECEPTOR ACTIVITY; TYROSINE KINASE; IDENTIFICATION; GI	Mammalian sperm acrosomal exocytosis as induced by the egg's zona pellucida (ZP) appears to be a G protein-mediated event. Previously, we demonstrated that ZP3, the acrosome reaction-inducing component of mouse ZP, activates one or more G(i) subtypes in isolated sperm membranes (Ward, C. R., Storey, B. T., and Kopf, G. S. (1992) J. Biol. Chen. 267, 14061-14067). To determine the identity of the G(i) subtype(s) activated in the sperm, we examined ligand-dependent decreases in pertussis toxin-catalyzed in vitro [P-32]ADP-ribosylation of the different G(i alpha) subtypes that were identified by immunoprecipitation using G(i alpha)-specific antisera. Membranes treated with solubilized ZP or mastoparan and subsequently [P-32]ADP-ribosylated using pertussis toxin displayed 35 and 56% decreases, respectively, in [P-32]ADP-ribosylation when compared with controls. These changes were quantitatively similar to the percentage increases in S-35-labeled guanosine 5'-O-(thiotriphosphate) binding in membranes treated with equivalent concentrations of ZP or mastoparan (Ward et al., 1992). Immunoprecipitation with G(i alpha) subtype-specific antisera and subsequent autoradiography revealed that mastoparan activated G(i1), G(i2), and G(i3) in the membranes. ZP, in contrast, selectively activated G(i1) and G(i2). These data demonstrate that the egg's extracellular matrix has the ability to activate selectively sperm membrane G(i) subtypes.			WARD, CR (corresponding author), UNIV PENN, SCH MED, DEPT OBSTET & GYNECOL, DIV REPROD BIOL, JOHN MORGAN BLDG 339, PHILADELPHIA, PA 19104 USA.				NICHD NIH HHS [HD00972, HD06274, HD07725] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD006274] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AARONS D, 1984, BIOL REPROD, V31, P811, DOI 10.1095/biolreprod31.4.811; BIRNBAUMER L, 1991, BIOL REPROD, V44, P207, DOI 10.1095/biolreprod44.2.207; BLEIL JD, 1990, P NATL ACAD SCI USA, V87, P5563, DOI 10.1073/pnas.87.14.5563; BLEIL JD, 1980, CELL, V20, P873, DOI 10.1016/0092-8674(80)90334-7; BLEIL JD, 1986, J CELL BIOL, V102, P1363, DOI 10.1083/jcb.102.4.1363; BLEIL JD, 1983, DEV BIOL, V95, P317, DOI 10.1016/0012-1606(83)90032-5; Bookbinder L. H., 1993, Molecular Biology of the Cell, V4, p247A; CARLSON KE, 1989, J BIOL CHEM, V264, P13298; ENDO Y, 1987, DEV BIOL, V119, P210, DOI 10.1016/0012-1606(87)90222-3; ENDO Y, 1988, DEV BIOL, V129, P12, DOI 10.1016/0012-1606(88)90157-1; FAUNDES D F, 1991, Journal of Cell Biology, V115, p141A; FLORMAN HM, 1985, CELL, V41, P313, DOI 10.1016/0092-8674(85)90084-4; FLORMAN HM, 1982, DEV BIOL, V91, P121, DOI 10.1016/0012-1606(82)90015-X; FLORMAN HM, 1989, DEV BIOL, V135, P133, DOI 10.1016/0012-1606(89)90164-4; FREISSMUTH M, 1991, J BIOL CHEM, V266, P17778; GLASSNER M, 1991, DEV BIOL, V146, P438, DOI 10.1016/0012-1606(91)90245-X; GOMPERTS BD, 1988, COLD SPRING HARB SYM, V53, P983, DOI 10.1101/SQB.1988.053.01.113; GORDON JH, 1988, FEBS LETT, V235, P201, DOI 10.1016/0014-5793(88)81262-6; HIGASHIJIMA T, 1988, J BIOL CHEM, V263, P6491; HIGASHIJIMA T, 1990, J BIOL CHEM, V265, P14176; HINSCH KD, 1994, IN PRESS FEBS LETT; HUFF RM, 1986, J BIOL CHEM, V261, P1105; JONES J, 1989, FEBS LETT, V243, P409, DOI 10.1016/0014-5793(89)80172-3; KALAB P, 1994, IN PRESS J BIOL CHEM, V269; KARNIK NS, 1992, DEV BIOL, V152, P393, DOI 10.1016/0012-1606(92)90146-8; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KINLOCH RA, 1991, J CELL BIOL, V115, P655, DOI 10.1083/jcb.115.3.655; KOPF GS, 1991, METHOD ENZYMOL, V195, P257; KOPF GS, 1986, J BIOL CHEM, V261, P7327; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAW SF, 1993, J BIOL CHEM, V268, P10721; LAW SF, 1991, J BIOL CHEM, V266, P17885; LEE MA, 1992, MOL REPROD DEV, V31, P78, DOI 10.1002/mrd.1080310114; LEYTON L, 1989, J CELL BIOL, V108, P2163, DOI 10.1083/jcb.108.6.2163; LEYTON L, 1989, CELL, V57, P1123, DOI 10.1016/0092-8674(89)90049-4; LEYTON L, 1992, P NATL ACAD SCI USA, V89, P11692, DOI 10.1073/pnas.89.24.11692; LEYTON L, 1989, DEV BIOL, V132, P174, DOI 10.1016/0012-1606(89)90215-7; MACEK MB, 1991, DEV BIOL, V147, P440, DOI 10.1016/0012-1606(91)90301-I; MILLER DJ, 1992, NATURE, V357, P589, DOI 10.1038/357589a0; MORISHITA R, 1990, FEBS LETT, V271, P231, DOI 10.1016/0014-5793(90)80413-D; MUNSHI R, 1991, J BIOL CHEM, V266, P22285; OKAMOTO T, 1990, CELL, V62, P709, DOI 10.1016/0092-8674(90)90116-V; RUBENSTEIN RC, 1991, BIOCHEMISTRY-US, V30, P10769, DOI 10.1021/bi00108a023; SALING PM, 1979, J CELL BIOL, V83, P544, DOI 10.1083/jcb.83.3.544; SENOGLES SE, 1990, J BIOL CHEM, V265, P4507; SHUR BD, 1988, J BIOL CHEM, V263, P17706; Storey B. T., 1991, A comparative overview of mammalian fertilization., P167; STOREY BT, 1991, ANN NY ACAD SCI, V637, P459, DOI 10.1111/j.1749-6632.1991.tb27330.x; WANGE RL, 1991, J BIOL CHEM, V266, P11409; WARD CR, 1992, J BIOL CHEM, V267, P14061; WASSARMAN PM, 1988, ANNU REV BIOCHEM, V57, P415, DOI 10.1146/annurev.bi.57.070188.002215; WILLIAMS AG, 1990, BLOOD, V76, P721; ZIMMERBERG J, 1987, BIOSCIENCE REP, V7, P251, DOI 10.1007/BF01121447	53	62	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13254	13258						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175755				2022-12-25	WOS:A1994NK18400033
J	ZACHARIAS, C; VANECHTENDECKERT, G; PLEWE, M; SCHMIDT, RR; SANDHOFF, K				ZACHARIAS, C; VANECHTENDECKERT, G; PLEWE, M; SCHMIDT, RR; SANDHOFF, K			A TRUNCATED EPOXY GLUCOSYLCERAMIDE UNCOUPLES GLYCOSPHINGOLIPID BIOSYNTHESIS BY DECREASING LACTOSYLCERAMIDE SYNTHASE ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRIMARY CULTURED NEURONS; SERINE PALMITOYLTRANSFERASE; GLUCOCEREBROSIDE SYNTHETASE; SPHINGOLIPID BIOSYNTHESIS; GANGLIOSIDES; GOLGI; TOPOLOGY; GLYCOSYLTRANSFERASE; SPHINGANINE; MODULATION	Introduction of an epoxide function at the C4 position of the glucose moiety of a truncated glucosylceramide (GlcCer) yields two stereoisomeric products namely a gluco- and a galacto-derivative. The effects of both analogues on the [C-14]serine incorporation into glycosphingolipids as well as on lactosylceramide (LacCer) synthase activity of primary cultured neurons derived from the telencephalon of 8-day-old chick embryos were investigated. Whereas the galacto-derivative had no effect either on the pattern of labeled glycosphingolipids or on LacCer synthase activity, pretreatment (24 h) of neurons with the gluco derivative caused a concentration dependent (IC50 = 8 mu M) and irreversible decrease of the specific activity of LacCer synthase. As a consequence the biosynthetic glycosphingolipid pattern of cultured neurons treated with the glucoanalogue changed as follows: the radioactive label of all glycosphingolipids biosynthetically derived from GlcCer was decreased while labeling of GlcCer increased significantly. The inhibitory effect of the gluco derivative on LacCer synthase activity was much less pronounced in vitro. Thus 250 mu M analogue caused only about 30% inhibition of enzymatic activity.	UNIV BONN,INST ORGAN CHEM & BIOCHEM,D-53121 BONN,GERMANY; UNIV KONSTANZ,FAK CHEM,W-7750 CONSTANCE,GERMANY	University of Bonn; University of Konstanz								BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHATTERJEE S, 1988, J BIOL CHEM, V263, P13017; CHATTERJEE S, 1991, BIOCHEM BIOPH RES CO, V181, P554, DOI 10.1016/0006-291X(91)91225-2; CHATTERJEE S, 1993, BIOCHIM BIOPHYS ACTA, V1167, P339, DOI 10.1016/0005-2760(93)90238-5; COSTE H, 1986, BIOCHIM BIOPHYS ACTA, V858, P6, DOI 10.1016/0005-2736(86)90285-3; DEUTSCHER SL, 1986, J BIOL CHEM, V261, P96; DREYFUS H, 1980, NEUROSCIENCE, V5, P1647, DOI 10.1016/0306-4522(80)90028-7; FENDERSON BA, 1992, EXP CELL RES, V198, P362, DOI 10.1016/0014-4827(92)90392-L; FUTERMAN AH, 1991, BIOCHEM J, V280, P295, DOI 10.1042/bj2800295; INOKUCHI JI, 1987, J LIPID RES, V28, P565; JECKEL D, 1992, J CELL BIOL, V117, P259, DOI 10.1083/jcb.117.2.259; JECKEL D, 1990, FEBS LETT, V261, P155, DOI 10.1016/0014-5793(90)80659-7; KARRENBAUER A, 1990, CELL, V63, P259, DOI 10.1016/0092-8674(90)90159-C; LEDEEN RW, 1982, METHOD ENZYMOL, V83, P139; MANDON EC, 1992, J BIOL CHEM, V267, P11144; PLEWE M, 1992, LIEBIGS ANN CHEM, P699; RADIN NS, 1991, TRENDS GLYCOSCI GLYC, V3, P200; ROTHER J, 1992, BIOCHEM BIOPH RES CO, V189, P14, DOI 10.1016/0006-291X(92)91518-U; SARMIENTOS F, 1986, EUR J BIOCHEM, V160, P527, DOI 10.1111/j.1432-1033.1986.tb10071.x; SCHACHTER H, 1980, BIOCH GLYCOPROTEINS, P85; SHAPIRO D, 1958, J AM CHEM SOC, V80, P1194, DOI 10.1021/ja01538a044; SVENNERHOLM L, 1984, CELLULAR PATHOLOGICA, V126, P21; TRINCHERA M, 1991, J BIOL CHEM, V266, P20907; VANECHTEN G, 1993, J BIOL CHEM, V268, P5341; VANECHTEN G, 1989, J NEUROCHEM, V52, P207; VANECHTEN G, 1990, J BIOL CHEM, V265, P9333; VUNNAM RR, 1980, CHEM PHYS LIPIDS, V26, P265; WANG E, 1991, J BIOL CHEM, V266, P14486; ZELLER CB, 1992, AM J PHYSIOL, V262, pC1341, DOI 10.1152/ajpcell.1992.262.6.C1341; ZWEERINK MM, 1992, J BIOL CHEM, V267, P25032	30	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13313	13317						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175761				2022-12-25	WOS:A1994NK18400041
J	LIST, HJ; PATZEL, V; ZEIDLER, U; SCHOPEN, A; RUHL, G; STOLLWERK, J; KLOCK, G				LIST, HJ; PATZEL, V; ZEIDLER, U; SCHOPEN, A; RUHL, G; STOLLWERK, J; KLOCK, G			METHYLATION SENSITIVITY OF THE ENHANCER FROM THE HUMAN PAPILLOMAVIRUS TYPE-16	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CERVICAL-CARCINOMA CELLS; TYROSINE AMINOTRANSFERASE GENE; UPSTREAM REGULATORY REGION; LONG TERMINAL REPEAT; CPG BINDING-PROTEIN; NUCLEAR FACTOR-I; DNA METHYLATION; TRANSCRIPTION FACTOR; PROMOTER REGION; MESSENGER-RNA	The human papillomavirus type 16 is associated with anogenital cancer. Transcription of the viral transforming genes E6 and E7 is under the control of an epithelial cell type-specific enhancer. In the enhancer core, we have identified a regulatory element that is recognized by a novel nuclear factor named MSPF (methylation-sensitive papillomavirus transcription factor). Mutating the MSPF binding site strongly affects the enhancer activity. The MSPF recognition sequence 5'-ATGCGNNNNCGCCT-3' contains two CpG dinucleotides, potential targets for B cytidine methylation. DNA recognition by MSPF is strictly methylation-sensitive, since introduction of 5-methylcytidine into either CpG abolishes complex formation. Moreover, CpG methylation of the MSPF binding site suppresses the activity of the enhancer and of the MSPF enhanson subfragment in vivo. In the cervical carcinoma cell line CaSki, which has integrated multiple transcriptionally inactive human papilloma virus 16 genomes, a few of the viral genomes are methylated at the MSPF binding site. These findings suggest that viral transcription can be suppressed by methylation of the regulatory region, an event that prevents binding of the cellular transcription factor MSPF.	TH DARMSTADT, INST BIOCHEM, D-64287 DARMSTADT, GERMANY	Technical University of Darmstadt								BAKER CC, 1987, J VIROL, V61, P962, DOI 10.1128/JVI.61.4.962-971.1987; BECK TW, 1990, MOL CELL BIOL, V10, P3325, DOI 10.1128/MCB.10.7.3325; BEDNARIK DP, 1991, NEW BIOL, V3, P969; BOSHART M, 1984, EMBO J, V3, P1151, DOI 10.1002/j.1460-2075.1984.tb01944.x; BOSHART M, 1992, GENE, V110, P129, DOI 10.1016/0378-1119(92)90456-Y; BOYES J, 1991, CELL, V64, P1123, DOI 10.1016/0092-8674(91)90267-3; BOYES J, 1992, EMBO J, V11, P327, DOI 10.1002/j.1460-2075.1992.tb05055.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSSLINGER M, 1983, CELL, V34, P197, DOI 10.1016/0092-8674(83)90150-2; CEDAR H, 1988, CELL, V53, P3, DOI 10.1016/0092-8674(88)90479-5; CHAILLET JR, 1991, CELL, V66, P77, DOI 10.1016/0092-8674(91)90140-T; CHAN WK, 1990, NUCLEIC ACIDS RES, V18, P763, DOI 10.1093/nar/18.4.763; CHAN WK, 1989, J VIROL, V63, P3261, DOI 10.1128/JVI.63.8.3261-3269.1989; CHOI YC, 1991, J BIOL CHEM, V266, P20504; CHONG T, 1990, NUCLEIC ACIDS RES, V18, P465, DOI 10.1093/nar/18.3.465; CHONG T, 1991, J VIROL, V65, P5933, DOI 10.1128/JVI.65.11.5933-5943.1991; CRIPE T P, 1990, New Biologist, V2, P450; CRIPE TP, 1987, EMBO J, V6, P3745, DOI 10.1002/j.1460-2075.1987.tb02709.x; DESROSIERS RC, 1979, P NATL ACAD SCI USA, V76, P3839, DOI 10.1073/pnas.76.8.3839; DOEBERITZ MV, 1988, CANCER RES, V48, P3780; DURST M, 1983, P NATL ACAD SCI-BIOL, V80, P3812, DOI 10.1073/pnas.80.12.3812; DURST M, 1987, ONCOGENE, V1, P251; DYNAN WS, 1989, CELL, V58, P1, DOI 10.1016/0092-8674(89)90393-0; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; GISSMANN L, 1987, CANCER CELL, V5, P275; GLOSS B, 1989, NUCLEIC ACIDS RES, V17, P3519, DOI 10.1093/nar/17.9.3519; GLOSS B, 1987, EMBO J, V6, P3735, DOI 10.1002/j.1460-2075.1987.tb02708.x; GLOSS B, 1989, J VIROL, V63, P1142, DOI 10.1128/JVI.63.3.1142-1152.1989; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRANGE T, 1991, NUCLEIC ACIDS RES, V19, P131, DOI 10.1093/nar/19.1.131; HAUSEN HZ, 1991, SCIENCE, V254, P1167, DOI 10.1126/science.1659743; HERMANN R, 1989, J MOL BIOL, V210, P411, DOI 10.1016/0022-2836(89)90340-9; HOLLER M, 1988, GENE DEV, V2, P1127, DOI 10.1101/gad.2.9.1127; IGUCHIARIGA SMM, 1989, GENE DEV, V3, P612, DOI 10.1101/gad.3.5.612; ISHII S, 1985, P NATL ACAD SCI USA, V82, P4920, DOI 10.1073/pnas.82.15.4920; ISHIJI T, 1992, EMBO J, V11, P2271, DOI 10.1002/j.1460-2075.1992.tb05286.x; JAHNER D, 1982, NATURE, V298, P623, DOI 10.1038/298623a0; JANTZEN HM, 1987, CELL, V49, P29, DOI 10.1016/0092-8674(87)90752-5; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; MCCANCE DJ, 1988, P NATL ACAD SCI USA, V85, P7169, DOI 10.1073/pnas.85.19.7169; MIKSICEK R, 1986, CELL, V46, P283, DOI 10.1016/0092-8674(86)90745-2; NELSON M, 1991, NUCLEIC ACIDS RES, V19, P2045, DOI 10.1093/nar/19.suppl.2045; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; POTEAT HT, 1990, J VIROL, V64, P1264, DOI 10.1128/JVI.64.3.1264-1270.1990; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; RAZIN A, 1991, MICROBIOL REV, V55, P451, DOI 10.1128/MMBR.55.3.451-458.1991; ROMANCZUK H, 1990, J VIROL, V64, P2849, DOI 10.1128/JVI.64.6.2849-2859.1990; ROSL F, 1988, EMBO J, V7, P1321, DOI 10.1002/j.1460-2075.1988.tb02947.x; ROSL F, 1991, EMBO J, V10, P1337, DOI 10.1002/j.1460-2075.1991.tb07653.x; ROSL F, 1993, J GEN VIROL, V74, P791, DOI 10.1099/0022-1317-74-5-791; Sambrook J, 1989, MOL CLONING LABORATO; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHNEIDERMAUNOURY S, 1987, J VIROL, V61, P3295, DOI 10.1128/JVI.61.10.3295-3298.1987; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; SEEDORF K, 1985, VIROLOGY, V145, P181, DOI 10.1016/0042-6822(85)90214-4; SIBBET GJ, 1990, J GEN VIROL, V71, P2699, DOI 10.1099/0022-1317-71-11-2699; SMOTKIN D, 1989, J VIROL, V63, P1441, DOI 10.1128/JVI.63.3.1441-1447.1989; SPANOPOULOU E, 1991, MOL CELL BIOL, V11, P2216, DOI 10.1128/MCB.11.4.2216; STOREY A, 1988, EMBO J, V7, P1815, DOI 10.1002/j.1460-2075.1988.tb03013.x; SUTTER D, 1980, P NATL ACAD SCI-BIOL, V77, P253, DOI 10.1073/pnas.77.1.253; VANWIJNEN AJ, 1992, MOL CELL BIOL, V12, P3273, DOI 10.1128/MCB.12.7.3273; WATT F, 1988, GENE DEV, V2, P1136, DOI 10.1101/gad.2.9.1136; WEIH F, 1988, NUCLEIC ACIDS RES, V16, P1628, DOI 10.1093/nar/16.4.1628; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YISRAELI J, 1986, CELL, V46, P409, DOI 10.1016/0092-8674(86)90661-6; ZURHAUSEN H, 1977, BEHRING I MITT, V61, P23	70	28	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					11902	11911						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163489				2022-12-25	WOS:A1994NG37700037
J	HAMMES, A; OBERDORF, S; STREHLER, EE; STAUFFER, T; CARAFOLI, E; VETTER, H; NEYSES, L				HAMMES, A; OBERDORF, S; STREHLER, EE; STAUFFER, T; CARAFOLI, E; VETTER, H; NEYSES, L			DIFFERENTIATION-SPECIFIC ISOFORM MESSENGER-RNA EXPRESSION OF THE CALMODULIN-DEPENDENT PLASMA-MEMBRANE CA2+-ATPASE	FASEB JOURNAL			English	Article						PLASMA MEMBRANE CA2+ PUMP; CA2+ TRANSPORT; ISOFORMS; ALTERNATIVE SPLICING; DIFFERENTIATION; MUSCLE CELLS; NEURONAL CELLS; MYOGENIN; MYOGENIC DETERMINATION	CA2+ PUMP; MOLECULAR-CLONING; CA-2+-TRANSPORTING ATPASE; SKELETAL-MUSCLE; MESSENGER-RNAS; CALCIUM-PUMP; RAT-HEART; DOMAIN; CELL; BINDING	The functional significance of the isoform diversity of the calmodulin-dependent plasma membrane Ca2+-ATPase (PMCA) is largely unknown. To determine whether the mRNA synthesis of different isoforms of the enzyme is regulated in a differentiation-specific manner, we investigated the expression of isoform-specific mRNAs in muscle and neuronal cells during differentiation by reverse transcription PCR. In the rat, the ubiquitous PMCA splicing variants 1b and 4b formed the typical PMCA isoform pattern of L6 myoblasts, the heart-derived cell line H9c2(2-1), two different fibroblast cell lines (FR and NRK-49F), smooth muscle, and endothelial cells. In addition to these two enzymes, novel expression of the splicing variants 1c, 1d, and 4a was induced during myogenic differentiation of L6 and H9c2(2-1) cells. A similar isoform subtype switch could be detected during differentiation of the neuronal PC-12 cells induced by nerve growth factor (NGF). The isoform-specific mRNAs 1c, 1d, and 4a were not expressed in cells other than myocytes and neurons, and therefore may be specific for excitable cells. The mRNA for isoform 1d was heart- and skeletal muscle-specific. To determine whether expression of a differentiation-specific PMCA mRNA pattern is under control of a myogenic determination factor, myogenin was constitutively expressed in rat fibroblasts. These cells converted to multinucleated myotubes, which displayed the PMCA isoform-specific mRNAs 1c, 1d, and 4a, typical of differentiated muscle cells. We conclude that: 1) the distribution of the various PMCA isoform-specific mRNAs and their splicing variants is cell type- and development-specific 2) expression of the myogenic determination factor myogenin is sufficient to direct alternative splicing generating muscle-specific PMCA mRNA species; and 3) PMCA isoforms and/or splicing variants may play a role in determining functions of terminally differentiated muscle and neuronal cells and possibly during the differentiation process itself.	UNIV BONN, MED POLICLIN, W-5300 BONN 1, GERMANY; ETH ZENTRUM, INST BIOCHEM, CH-8092 ZURICH, SWITZERLAND; MAYO CLIN & MAYO FDN, DEPT BIOCHEM & MOLEC BIOL, ROCHESTER, MN 55905 USA	University of Bonn; Swiss Federal Institutes of Technology Domain; ETH Zurich; Mayo Clinic			Carafoli, Ernesto/K-5192-2016; Neyses, Ludwig/AGY-7446-2022	Carafoli, Ernesto/0000-0002-7826-0094; Hammes-Lewin, Annette/0000-0003-1663-8378				ADAMO HP, 1992, BIOCHEM J, V283, P355, DOI 10.1042/bj2830355; BRANDT P, 1992, J BIOL CHEM, V267, P4376; BREITBART RE, 1987, ANNU REV BIOCHEM, V56, P467, DOI 10.1146/annurev.bi.56.070187.002343; BURK SE, 1992, J BIOL CHEM, V267, P19683; CARAFOLI E, 1992, J BIOL CHEM, V267, P2115; CARAFOLI E, 1991, PHYSIOL REV, V71, P129, DOI 10.1152/physrev.1991.71.1.129; CARONI P, 1980, P NATL ACAD SCI-BIOL, V77, P6354, DOI 10.1073/pnas.77.11.6354; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CORTHESYTHEULAZ I, 1991, AM J PHYSIOL, V261, pC124, DOI 10.1152/ajpcell.1991.261.1.C124; DESMEDT H, 1991, J BIOL CHEM, V266, P7092; Emerson CP, 1990, CURR OPIN CELL BIOL, V2, P1065, DOI 10.1016/0955-0674(90)90157-A; ENYEDI A, 1991, J BIOL CHEM, V266, P8952; EWTON DZ, 1981, DEV BIOL, V86, P31, DOI 10.1016/0012-1606(81)90312-2; FLORINI JR, 1991, ANNU REV PHYSIOL, V53, P201, DOI 10.1146/annurev.ph.53.030191.001221; GREEB J, 1989, J BIOL CHEM, V264, P18569; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HESCHELER J, 1991, CIRC RES, V69, P1476, DOI 10.1161/01.RES.69.6.1476; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; KEETON TP, 1993, J BIOL CHEM, V268, P2740; KESSLER F, 1992, BIOCHEMISTRY-US, V31, P11785, DOI 10.1021/bi00162a016; KIMES BW, 1976, EXP CELL RES, V98, P367, DOI 10.1016/0014-4827(76)90447-X; KNOLL G, 1991, J CELL BIOL, V113, P1295, DOI 10.1083/jcb.113.6.1295; MANGIACAPRA FJ, 1992, MOL ENDOCRINOL, V6, P2038, DOI 10.1210/me.6.12.2038; MANIATIS T, 1991, SCIENCE, V251, P33, DOI 10.1126/science.1824726; NEYSES L, 1985, J BIOL CHEM, V260, P283; NICOLL DA, 1990, SCIENCE, V250, P562, DOI 10.1126/science.1700476; OLSON EN, 1993, CIRC RES, V72, P1, DOI 10.1161/01.RES.72.1.1; POWELL T, 1988, BIOL ADULT CARDIAC M, P9; RICHLER C, 1970, DEV BIOL, V23, P1, DOI 10.1016/S0012-1606(70)80004-5; ROSE H, 1986, PFLUG ARCH EUR J PHY, V407, P116, DOI 10.1007/BF00580731; ROSS R, 1971, J CELL BIOL, V50, P172, DOI 10.1083/jcb.50.1.172; Sambrook J, 1989, MOL CLONING LABORATO; SCHATZMANN HJ, 1966, EXPERIENTIA, V22, P364, DOI 10.1007/BF01901136; SHULL GE, 1988, J BIOL CHEM, V263, P8646; SHULL GE, 1986, BIOCHEMISTRY-US, V25, P8125, DOI 10.1021/bi00373a001; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; Strehler E E, 1990, Semin Cell Biol, V1, P283; STREHLER EE, 1989, P NATL ACAD SCI USA, V86, P6908, DOI 10.1073/pnas.86.18.6908; Wang K K, 1992, Trends Cell Biol, V2, P46, DOI 10.1016/0962-8924(92)90162-G; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; WUYTACK F, 1992, 8TH INT S CALC BIND; YAFFE D, 1968, P NATL ACAD SCI USA, V61, P477, DOI 10.1073/pnas.61.2.477; ZURINI M, 1984, J BIOL CHEM, V259, P618	43	74	75	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR 1	1994	8	6					428	435		10.1096/fasebj.8.6.8168693	http://dx.doi.org/10.1096/fasebj.8.6.8168693			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	NH250	8168693				2022-12-25	WOS:A1994NH25000010
J	MINTHWORBY, CA				MINTHWORBY, CA			TRANSCRIPTIONAL REGULATION OF THE HUMAN NEUROPEPTIDE-Y GENE BY NERVE GROWTH-FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR AP-2; CHLORAMPHENICOL ACETYLTRANSFERASE; PC12 CELLS; DEVELOPMENTAL REGULATION; EXPRESSION; BINDING; SEQUENCES; PROMOTER; DIFFERENTIATION; EMBRYOGENESIS	Neuropeptide Y (NPY) is the most ubiquitously expressed peptide in the mammalian nervous system. Transcription of the NPY gene in PC12 cells is regulated by a number of agents, including the neurotrophic peptide nerve growth factor (NGF). In this paper, we define the cis-acting promoter elements which respond to NGF and characterize the trans-acting factors which interact with these sequences. The NGF-responsive elements of the NPY gene lie between nucleotides -87 and -36. At least four proteins interact with this promoter region. One of these proteins interacts with a CT-rich sequence centered at position -51, which closely abuts a binding site for transcription factor AP-2 centered at position -63. Two newly characterized factors bind between positions -87 and -58. These proteins are expressed in a tissue-specific manner and, together with the other binding activities, modulate the transcriptional activity of the NPY gene. These results suggest that the concerted interplay of these proteins, in response to NGF, increases the transcriptional activity of the NPY gene.			MINTHWORBY, CA (corresponding author), UNIV MICHIGAN, DEPT BIOL CHEM, ANN ARBOR, MI 48109 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS028496] Funding Source: NIH RePORTER; NINDS NIH HHS [NINDS NS28496] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALLEN JM, 1987, MOL BRAIN RES, V3, P39, DOI 10.1016/0169-328X(87)90042-8; ANDRISANI OM, 1988, MOL CELL BIOL, V8, P1947, DOI 10.1128/MCB.8.5.1947; BERG JM, 1992, P NATL ACAD SCI USA, V89, P11109, DOI 10.1073/pnas.89.23.11109; CHANGELIAN PS, 1989, P NATL ACAD SCI USA, V86, P377, DOI 10.1073/pnas.86.1.377; COMB M, 1990, NUCLEIC ACIDS RES, V18, P3975, DOI 10.1093/nar/18.13.3975; COURTOIS SJ, 1990, NUCLEIC ACIDS RES, V18, P57, DOI 10.1093/nar/18.1.57; CRABB DW, 1989, METHOD ENZYMOL, V168, P690; CROSBY SD, 1991, MOL CELL BIOL, V11, P3835, DOI 10.1128/MCB.11.8.3835; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P33; GIDONI D, 1984, NATURE, V312, P409, DOI 10.1038/312409a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAY TS, 1986, LIFE SCI, V38, P389, DOI 10.1016/0024-3205(86)90061-5; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; IBANEZ CF, 1992, CELL, V69, P329, DOI 10.1016/0092-8674(92)90413-7; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; KIMURA A, 1986, CELL, V44, P261, DOI 10.1016/0092-8674(86)90760-9; KINGSLEY C, 1991, MOL CELL BIOL, V12, P4251; LEE SL, 1988, J BIOL CHEM, V263, P16604; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; LOEB DM, 1991, CELL, V66, P961, DOI 10.1016/0092-8674(91)90441-Z; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MINTH CD, 1990, J BIOL CHEM, V265, P12933; MINTH CD, 1986, J BIOL CHEM, V261, P1974; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; NIELSEN DA, 1989, ANAL BIOCHEM, V179, P19, DOI 10.1016/0003-2697(89)90193-0; RUDKIN BB, 1989, EMBO J, V8, P3319, DOI 10.1002/j.1460-2075.1989.tb08493.x; SABOL SL, 1990, MOL ENDOCRINOL, V4, P384, DOI 10.1210/mend-4-3-384; SILVA CM, 1987, P NATL ACAD SCI USA, V84, P1744, DOI 10.1073/pnas.84.7.1744; WINNING RS, 1991, NUCLEIC ACIDS RES, V19, P3709, DOI 10.1093/nar/19.13.3709	32	45	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15460	15468						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	8195188				2022-12-25	WOS:A1994NP51300013
J	SHIOTA, M; FUJIMOTO, J; SEMBA, T; SATOH, H; YAMAMOTO, T; MORI, S				SHIOTA, M; FUJIMOTO, J; SEMBA, T; SATOH, H; YAMAMOTO, T; MORI, S			HYPERPHOSPHORYLATION OF A NOVEL 80 KDA PROTEIN-TYROSINE KINASE SIMILAR TO LTK IN A HUMAN KI-1 LYMPHOMA CELL-LINE, AMS3	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTORS; C-ERBB-2 ONCOGENE; HODGKINS-DISEASE; BREAST-CANCER; BLADDER-CANCER; GENE-PRODUCT; PHOSPHORYLATION; EXPRESSION; TRANSLOCATION; AMPLIFICATION	Ki-l lymphoma is a subtype of human malignant lymphoma characterized by the expression of CD30 (Ki-1) and a peculiar morphology. It is occasionally accompanied by a unique reciprocal chromosomal translocation t(2;5)(p23;q35). A Ki-l lymphoma cell line, AMS3, was established by maintaining biopsied tumor cells in SCID (severe combined immunodeficiency) mice. To investigate abnormalities of the signal transduction in Ki-l lymphomas, AMS3 lysate was immunoprecipitated with anti-phosphotyrosine monoclonal antibody, 25.2G4, and the immunoprecipitates were subjected to kinase assay and immune-blotting with 25.2G4. A unique phosphotyrosine-containing protein of MW 80 000, designated p80, was found only in AMS3 cells and not in other cell lines or mononuclear cells from healthy donors. Subsequent amino acid sequence analysis of its tryptic digests showed that p80 was a hitherto undescribed tyrosine phosphoprotein similar to Ltk (leukocyte tyrosine kinase). Furthermore, physical interaction of p80 with CD30 was suggested from immunoprecipitation experiments with AMS3 lysates.	APPL BIOSYST JAPAN,URAYASU,CHIBA 279,JAPAN	Thermo Fisher Scientific; Applied Biosystems	SHIOTA, M (corresponding author), UNIV TOKYO,INST MED SCI,DEPT PATHOL,MINATO KU,4-6-1 SHIROKAMEDAI,TOKYO 108,JAPAN.							ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BEN-NERIAH Y, 1988, NATURE, V333, P672, DOI 10.1038/333672a0; BERNARDS A, 1990, EMBO J, V9, P2279, DOI 10.1002/j.1460-2075.1990.tb07399.x; BOSMA GC, 1983, NATURE, V301, P527, DOI 10.1038/301527a0; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DURKOP H, 1992, CELL, V68, P421, DOI 10.1016/0092-8674(92)90180-K; EBSTEIN SA, 1990, GENES CHROMOSOME CAN, V2, P27; GROSS JL, 1983, P NATL ACAD SCI-BIOL, V80, P2276, DOI 10.1073/pnas.80.8.2276; HASSE VH, 1991, ONCOGENE, V6, P2319; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; ITOH T, 1993, CANCER, V72, P2684; KADIN ME, 1986, BLOOD, V68, P1042; KANEKO Y, 1989, BLOOD, V73, P806; KANEKO Y, 1990, Current Opinion in Oncology, V2, P816, DOI 10.1097/00001622-199010000-00003; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; KROLEWSKI JJ, 1991, EMBO J, V10, P2911, DOI 10.1002/j.1460-2075.1991.tb07841.x; KROLEWSKI JJ, 1990, ONCOGENE, V5, P277; LEDER P, 1983, SCIENCE, V222, P765, DOI 10.1126/science.6356357; MARU Y, 1990, ONCOGENE RES, V5, P199; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORIYAMA M, 1991, J UROLOGY, V145, P423, DOI 10.1016/S0022-5347(17)38356-8; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; NEAL DE, 1985, LANCET, V1, P366; PALLAS D, 1982, CELL, V30, P407, DOI 10.1016/0092-8674(82)90238-0; PENNY RJ, 1991, CANCER, V68, P362, DOI 10.1002/1097-0142(19910715)68:2<362::AID-CNCR2820680226>3.0.CO;2-C; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SAINSBURY JRC, 1987, LANCET, V1, P1398; SAINSBURY JRC, 1985, LANCET, V1, P364; SATOH H, 1993, CYTOGENET CELL GENET, V62, P49, DOI 10.1159/000133443; SCHWAB U, 1982, NATURE, V299, P65, DOI 10.1038/299065a0; SCHWARTING R, 1989, BLOOD, V74, P1678; SLAMON DJ, 1989, SCIENCE, V244, P7047; STEIN H, 1985, BLOOD, V66, P848; TAKAHASHI E, 1993, GENOMICS, V17, P234, DOI 10.1006/geno.1993.1310; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; YAMORI T, 1991, CANCER RES, V51, P5859; YOKOTA J, 1988, ONCOGENE, V2, P283; YOKOTA J, 1986, LANCET, V1, P765; ZHOU DJ, 1987, CANCER RES, V47, P6123	44	201	219	1	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1994	9	6					1567	1574						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NL815	8183550				2022-12-25	WOS:A1994NL81500006
J	COLOMBO, MI; MAYORGA, LS; NISHIMOTO, I; ROSS, EM; STAHL, PD				COLOMBO, MI; MAYORGA, LS; NISHIMOTO, I; ROSS, EM; STAHL, PD			G(S) REGULATION OF ENDOSOME FUSION SUGGESTS A ROLE FOR SIGNAL-TRANSDUCTION PATHWAYS IN ENDOCYTOSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEINS; TRIMERIC-G-PROTEINS; MEDIATED ENDOCYTOSIS; ADRENERGIC-RECEPTORS; INVITRO; PHOSPHORYLATION; IDENTIFICATION; STIMULATION; TRANSPORT; KINASE	Work from several laboratories indicates that guanine nucleotide-binding proteins (GTP-binding proteins) are required for intracellular vesicular transport. In a previous report we presented evidence indicating that one or more heterotrimeric G proteins regulate fusion between endosomes (Colombo, M. I., Mayorga, L. S., Casey, P.J., and Stahl, P D. (1992) Science 255, 1695-1697). We now report on experiments showing that G(s) plays a role in endosome fusion. We have used several reagents known to modulate G(s) function including (i) peptides corresponding to the cytoplasmic domains of G protein-coupled receptors and peptides that mimic interaction of receptors with G proteins, (ii) anti-G protein antibodies, and (iii) cholera toxin. Synthetic peptides corresponding to the third cytoplasmic loop of the beta 2-adrenergic receptor which putatively interact with G(alpha s) inhibited endosomal fusion. The inhibitory effect of these peptides was prevented by a short preincubation of endosomes with guanosine-5'-3-O-(thio)triphosphate or by phosphorylating the peptide with cAMP-dependent protein kinase. The involvement of G(s) in endosome recognition and/or the fusion process was assessed by testing an antibody against the COOH terminus of G(alpha s). Anti-G(alpha s) IgG completely abolished fusion between endosomes. Lastly, preincubation of endosomal vesicles with cholera toxin abrogated fusion in the presence of NAD, whereas no effect was observed in the absence of the cofactor. Taken together these findings indicate a role for G(s) in either the mechanism or the regulation of fusion among endosomes. These results raise the possibility that signal transduction through cytoplasmic domains of receptors may participate in the regulation of endocytic trafficking.	WASHINGTON UNIV,SCH MED,DEPT CELL BIOL & PHYSIOL,ST LOUIS,MO 63108; UNIV TOKYO,SCH MED,DEPT INTERNAL MED 4,TOKYO 112,JAPAN; UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75235	Washington University (WUSTL); University of Tokyo; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Stahl, Philip/D-6315-2012	Mayorga, Luis S/0000-0002-5995-0671	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI020015, R01AI020015] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042259] Funding Source: NIH RePORTER; NIAID NIH HHS [AI20015] Funding Source: Medline; NIGMS NIH HHS [GM42259] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALCH W E, 1992, Current Biology, V2, P157, DOI 10.1016/0960-9822(92)90276-G; Barr F A, 1992, Trends Cell Biol, V2, P91, DOI 10.1016/0962-8924(92)90001-4; BENOVIC JL, 1985, J BIOL CHEM, V260, P7094; BOMSEL M, 1992, MOL BIOL CELL, V3, P1317, DOI 10.1091/mbc.3.12.1317; BOURNE HR, 1988, CELL, V53, P669, DOI 10.1016/0092-8674(88)90081-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURGOYNE RD, 1992, TRENDS BIOCHEM SCI, V17, P87; CARTER LL, 1993, J CELL BIOL, V120, P37, DOI 10.1083/jcb.120.1.37; COLOMBO MI, 1992, SCIENCE, V255, P1695, DOI 10.1126/science.1348148; COLOMBO MI, 1992, METHOD ENZYMOL, V219, P32; COLOMBO MI, 1994, IN PRESS MOL MEMBR C; DIAZ R, 1988, J BIOL CHEM, V263, P6093; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOUD B, 1991, Current Opinion in Cell Biology, V3, P626, DOI 10.1016/0955-0674(91)90033-U; HARAGUCHI K, 1991, P NATL ACAD SCI USA, V88, P5964, DOI 10.1073/pnas.88.14.5964; HIGASHIJIMA T, 1988, J BIOL CHEM, V263, P6491; KOBILKA B, 1992, ANNU REV NEUROSCI, V15, P87, DOI 10.1146/annurev.ne.15.030192.000511; LENHARD JM, 1992, J BIOL CHEM, V267, P13047; LENHARD JM, 1994, IN PRESS ARCH BIOH B; LEYTE A, 1992, EMBO J, V11, P4795, DOI 10.1002/j.1460-2075.1992.tb05585.x; MAYORGA LS, 1989, SCIENCE, V244, P1475, DOI 10.1126/science.2499930; MAYORGA LS, 1989, CELL REGUL, V1, P113, DOI 10.1091/mbc.1.1.113; MURAYAMA T, 1993, BIOCHEMISTRY-US, V32, P561, DOI 10.1021/bi00053a022; NISHIMOTO I, 1993, NATURE, V362, P75, DOI 10.1038/362075a0; OKAMOTO T, 1991, CELL, V67, P723, DOI 10.1016/0092-8674(91)90067-9; OKAMOTO T, 1990, CELL, V62, P709, DOI 10.1016/0092-8674(90)90116-V; Pfeffer S R, 1992, Trends Cell Biol, V2, P41, DOI 10.1016/0962-8924(92)90161-F; PIMPLIKAR SW, 1993, NATURE, V362, P456, DOI 10.1038/362456a0; SCHWANINGER R, 1992, J CELL BIOL, V119, P1077, DOI 10.1083/jcb.119.5.1077; STRYER L, 1986, ANNU REV CELL BIOL, V2, P391, DOI 10.1146/annurev.cb.02.110186.002135; WESSLINGRESNICK M, 1990, J BIOL CHEM, V265, P16751; WONG SKF, 1990, J BIOL CHEM, V265, P6219	32	55	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					14919	14923						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195123				2022-12-25	WOS:A1994NP73800014
J	GALLO, KA; MARK, MR; SCADDEN, DT; WANG, ZY; GU, QM; GODOWSKI, PJ				GALLO, KA; MARK, MR; SCADDEN, DT; WANG, ZY; GU, QM; GODOWSKI, PJ			IDENTIFICATION AND CHARACTERIZATION OF SPRK, A NOVEL SRC-HOMOLOGY-3 DOMAIN-CONTAINING PROLINE-RICH KINASE WITH SERINE/THREONINE KINASE-ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; RECEPTOR TYROSINE KINASES; DEPENDENT PROTEIN-KINASE; LEUCINE ISOLEUCINE-ZIPPER; GROWTH-FACTOR RECEPTOR; LIGAND-BINDING SITE; SH3 DOMAINS; INSULIN-RECEPTOR; SECONDARY-STRUCTURE; SIGNALING PROTEINS	Protein kinases play important roles in the growth and differentiation of cells. We have isolated cDNA clones from the human megakaryocytic cell line CMK11-5 that encode a novel protein kinase, which we call SPRK (src-homology 3 (SH3) domain containing proline-rich kinase). The gene sequence predicts an 847-amino acid protein kinase with a unique domain arrangement. An amino-terminal glycine-rich region is followed by an SH3 domain and a kinase domain that is similar to both tyrosine and serine/threonine kinases. Adjacent to the kinase domain are two closely spaced leucine/isoleucine zipper motifs and a stretch of basic amino acids that resembles karyophilic nuclear localization signals. The COOH-terminal half of SPRK is basic, and proline accounts for 24% of the COOH-terminal 216 amino acids. The sprk gene is widely expressed as a 4-kilobase transcript in adult and fetal human tissues. Transfection of 293 cells with a vector encoding an epitope-tagged SPRK results in the expression of a 95-kDa protein. The epitope-tagged SPRK becomes phosphorylated on serine and threonine residues in an in vitro kinase assay, whereas SPRK variants with point mutations in the predicted ATP-binding site fail to become phosphorylated. These data indicate that SPRK has serine/threonine kinase activity. The SH3 domain of SPRK is interrupted by a unique 5-amino acid insert whose location in the SH3 consensus sequence is the same as that of the inserts found in the SH3 domains of neuronal SRC and of the p85 subunit of phosphatidylinositol 3-kinase.	GENENTECH INC, DEPT CELL GENET, San Francisco, CA 94080 USA; GENENTECH INC, DEPT MOLEC BIOL, San Francisco, CA 94080 USA; HARVARD UNIV, NEW ENGLAND DEACONESS HOSP,SCH MED,DEPT MED, DIV HEMATOL ONCOL, BOSTON, MA 02215 USA	Roche Holding; Genentech; Roche Holding; Genentech; Harvard University; Harvard Medical School								ADACHI M, 1991, EXP HEMATOL, V19, P923; ATKINSON RA, 1991, BIOCHEMISTRY-US, V30, P9387, DOI 10.1021/bi00103a001; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BOOKER GW, 1993, CELL, V73, P813, DOI 10.1016/0092-8674(93)90259-S; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; COZZONE AJ, 1993, J CELL BIOCHEM, V51, P7, DOI 10.1002/jcb.240510103; DEERY WJ, 1993, J CELL BIOL, V122, P21, DOI 10.1083/jcb.122.1.21; DOROW DS, 1993, EUR J BIOCHEM, V213, P701, DOI 10.1111/j.1432-1033.1993.tb17810.x; FENG DF, 1990, METHOD ENZYMOL, V183, P375; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GIBBS CS, 1991, J BIOL CHEM, V266, P8923; GODOWSKI PJ, 1989, P NATL ACAD SCI USA, V86, P8083, DOI 10.1073/pnas.86.20.8083; GORDON JI, 1991, J BIOL CHEM, V266, P8647; GORMAN C, 1990, DNA CLONING PRACTICA, P143; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; KNIGHTON DR, 1993, P NATL ACAD SCI USA, V90, P5001, DOI 10.1073/pnas.90.11.5001; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOYAMA S, 1993, CELL, V72, P945, DOI 10.1016/0092-8674(93)90582-B; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LANDGRAF W, 1990, BIOCHEMISTRY-US, V29, P9921, DOI 10.1021/bi00494a024; LEE J, 1994, GENE, V138, P247, DOI 10.1016/0378-1119(94)90817-6; LEVY JB, 1987, MOL CELL BIOL, V7, P4142, DOI 10.1128/MCB.7.11.4142; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LINDBERG RA, 1992, TRENDS BIOCHEM SCI, V17, P114, DOI 10.1016/0968-0004(92)90248-8; MARK MR, 1992, J BIOL CHEM, V267, P26166; MARTINEZ R, 1987, SCIENCE, V237, P411, DOI 10.1126/science.2440106; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; MOTOJIMA K, 1993, FEBS LETT, V319, P75, DOI 10.1016/0014-5793(93)80040-2; MUSACCHIO A, 1992, NATURE, V359, P851, DOI 10.1038/359851a0; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PUGSLEY AP, 1989, PROTEIN TARGETING, P202; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SUVA LJ, 1987, SCIENCE, V237, P893, DOI 10.1126/science.3616618; TAYLOR SS, 1993, TRENDS BIOCHEM SCI, V18, P84, DOI 10.1016/0968-0004(93)80001-R; WENG ZG, 1993, J BIOL CHEM, V268, P14956; WIELAND T, 1993, J BIOL CHEM, V268, P18111; YONEMOTO W, 1993, J BIOL CHEM, V268, P18626; YU HT, 1992, SCIENCE, V258, P1665, DOI 10.1126/science.1280858; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	59	112	119	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					15092	15100						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195146				2022-12-25	WOS:A1994NP73800039
J	PRIGLINGER, U; GEIGER, M; BIELEK, E; VANYEK, E; BINDER, BR				PRIGLINGER, U; GEIGER, M; BIELEK, E; VANYEK, E; BINDER, BR			BINDING OF URINARY PROTEIN-C INHIBITOR TO CULTURED HUMAN EPITHELIAL KIDNEY TUMOR-CELLS (TCL-598) - THE ROLE OF GLYCOSAMINOGLYCANS PRESENT ON THE LUMINAL CELL-SURFACE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR; EXTRACELLULAR-MATRIX; ENDOTHELIAL-CELLS; SEMINAL PLASMA; UROKINASE; KALLIKREIN; ANTIGEN; HEPARIN	Binding of urinary protein C inhibitor (PCI) to cultured human epithelial kidney tumor cells (TCL-598) was studied. Binding was dose-dependent, time-dependent, and saturable. Heparin interfered in a dose-dependent way with PCI binding to TCL-598 as did heparan sulfate and to a lesser degree also dermatan sulfate. Pre- treatment of TCL-598 with protamine sulfate inhibited subsequent binding of PCI in a dose-dependent manner and >100 mu g/ml protamine sulfate reduced binding of PCI to <10% of the control. Binding of I-125-pCI was specific, and bound (125)-pCI was recovered from the cells by heparin treatment or detached together with intact cells by EDTA treatment, migrated on sodium dodecyl sulfate-polyacrylamide gel electrophoresis with the same mobility (M(r) = 57,000) as unbound I-125-pCI. Furthermore, cell-bound PCI was functionally active as judged from its ability to inhibit the amidolytic activity of urokinase, and its inhibitory activity was stimulated approximate to 3-4-fold as compared to fluid-phase PCI. Immunogold electron microscopy revealed that PCI-antigen presented to the cells from the luminal side bound exclusively to that surface in native as well as in prefixed cells. This binding of PCI was abolished in the presence of heparin (50 mu g/ml) and after pretreatment of the cells either with protamine sulfate (400 mu g/ml) or with heparinase III (0.5 unit/ml). A slight decrease in PCI binding was seen after pretreatment of the cells with chondroitinase ABC and chondroitinase AC. In contrast, binding of PCI to extracellular matrices of TCL-598 was decreased to approximate to 70% after chondroitinase ABC treatment of the extracellular matrices, whereas both heparinase III or chondroitinase AC treatment only reduced matrix-bound PCI to approximate to 95%. These data suggest that heparan sulfate-containing proteoglycans are predominantly involved in binding of PCI to the luminal side of TCL-598, while dermatan sulfate-containing proteoglycans, the overall predominant PCI-binding proteoglycans in TCL extracts, are responsible for PCI binding to the extracellular matrix. Heparan sulfate, however, exposed to an environment containing PCI under physiological conditions, might localize PCI and modulate its target enzyme specificity in vivo.	UNIV VIENNA,DEPT MED PHYSIOL,CLIN & EXPTL PHYSIOL LAB,A-1090 VIENNA,AUSTRIA; UNIV VIENNA,DEPT HISTOL & EMBRYOL,A-1090 VIENNA,AUSTRIA	University of Vienna; University of Vienna				Geiger, Margarethe/0000-0003-2021-5319				ECKE S, 1992, J BIOL CHEM, V267, P7048; ECKE S, 1992, ANN NY ACAD SCI, V667, P84, DOI 10.1111/j.1749-6632.1992.tb51601.x; ECKE S, 1992, ANN HEMATOL S, V64, pA46; ESPANA F, 1991, THROMB RES, V64, P309, DOI 10.1016/0049-3848(91)90002-E; GEIGER M, 1988, Fibrinolysis, V2, P183, DOI 10.1016/0268-9499(88)90011-2; GEIGER M, 1989, BLOOD, V74, P722; GEIGER M, 1991, J BIOL CHEM, V266, P11851; Ishikawa E, 1980, J Immunoassay, V1, P385, DOI 10.1080/01971528008058479; KNUDSEN BS, 1987, J CLIN INVEST, V80, P1082, DOI 10.1172/JCI113164; KOHNO T, 1984, BIO-TECHNOL, V2, P628, DOI 10.1038/nbt0784-628; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURELL M, 1992, J CLIN INVEST, V89, P1094, DOI 10.1172/JCI115689; LEVIN EG, 1987, J CELL BIOL, V105, P2543, DOI 10.1083/jcb.105.6.2543; LITTLE JR, 1967, METHODS IMMUNOLOGY I, V2, P343; MARLAR RA, 1980, J CLIN INVEST, V66, P1186, DOI 10.1172/JCI109952; MEIJERS JCM, 1988, BIOCHEMISTRY-US, V27, P4231, DOI 10.1021/bi00412a005; MIMURO J, 1987, BLOOD, V70, P721; NAKANE PK, 1974, J HISTOCHEM CYTOCHEM, V22, P1081; Patterson M K Jr, 1979, Methods Enzymol, V58, P141; PRATT CW, 1992, J BIOL CHEM, V267, P8789; PRIGLINGER U, 1992, FIBRINOLYSIS S2, V6, P6; RESCH I, 1991, NT C KININ 91 MUNICH, P199; STERN D, 1985, J CLIN INVEST, V75, P272, DOI 10.1172/JCI111685; SUZUKI K, 1989, THROMB HAEMOSTASIS, V61, P337; SUZUKI K, 1987, J BIOL CHEM, V262, P611; SUZUKI K, 1984, J BIOCHEM, V95, P187, DOI 10.1093/oxfordjournals.jbchem.a134583; SUZUKI K, 1983, J BIOL CHEM, V258, P163; WHINNA HC, 1993, J BIOL CHEM, V268, P3920	28	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14705	14710						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	8182078				2022-12-25	WOS:A1994NM06500063
J	SASAKI, K; KURATA, K; FUNAYAMA, K; NAGATA, M; WATANABE, E; OHTA, S; HANAI, N; NISHI, T				SASAKI, K; KURATA, K; FUNAYAMA, K; NAGATA, M; WATANABE, E; OHTA, S; HANAI, N; NISHI, T			EXPRESSION CLONING OF A NOVEL ALPHA-1,3-FUCOSYL-TRANSFERASE THAT IS INVOLVED IN BIOSYNTHESIS OF THE SIALYL-LEWIS-X CARBOHYDRATE DETERMINANTS IN LEUKOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA(1,3)FUCOSYLTRANSFERASE GENE; ELAM-1-DEPENDENT CELL-ADHESION; E-SELECTIN LIGAND; SERUM-FREE MEDIUM; MONOCLONAL-ANTIBODIES; FUCOSYL-TRANSFERASE; P-SELECTIN; GLYCOPROTEIN LIGAND; MOLECULAR-CLONING; BINDING-ACTIVITY	The sialyl Lewis x (NeuAc alpha 2-3Gal beta 1-4(Fuc alpha 1-3)Glc-NAc) determinants serve as ligands in the selectin-mediated adhesion of leukocytes to activated endothelium or platelets. In our efforts to identify glycosyltransferases involved in the biosynthesis of those ligands, we achieved expression cloning of a novel human alpha 1,3-fucosyltransferase termed Fuc-TVII from a THP-1 cDNA library by enrichment of the Namalwa cells highly expressing that determinant with a fluorescence-activated cell sorter. Expression of the COOH-terminal catalytic domain of Fuc-TVII showed an alpha 1,3-fucosyltransferase activity for a type II oligosaccharide with a terminal alpha 2,3-linked sialic acid among various accepters, consistent with that in vivo acceptor specificity. Alignment of the primary sequences of five alpha 1,3-fucosyltransferase and assignment of the chromosomal location of Fuc-TVII gene, together with that acceptor specificity, indicate that Fuc-TVII consists of a unique class of the alpha 1,3-fucosyltransferase family. Determination of the expression levels of these alpha 1,3-fucosyltransferases in various cells revealed that both Fuc-TVII and a myeloid fucosyltransferase Fuc-TIV were significantly expressed in myeloid Lineage cells. Fuc-TVII-transfected Namalwa cells exhibited significant binding to E-selectin in contrast to little binding of the Fuc-TIV-transfected cells. These results suggest that Fuc-TVII may participate in the biosynthesis of the selectin ligands.	KYOWA HAKKO KOGYO CO LTD,TOKYO RES LABS,MACHIDA,TOKYO 194,JAPAN	Kyowa Kirin Ltd								BERG EL, 1992, BIOCHEM BIOPH RES CO, V184, P1048, DOI 10.1016/0006-291X(92)90697-J; BERG EL, 1991, J BIOL CHEM, V266, P14869; BEVILACQUA MP, 1993, J CLIN INVEST, V91, P379, DOI 10.1172/JCI116210; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; EASTON EW, 1993, BLOOD, V81, P2978; FEIZI T, 1985, NATURE, V314, P53, DOI 10.1038/314053a0; FOXALL C, 1992, J CELL BIOL, V117, P895, DOI 10.1083/jcb.117.4.895; Fukuda M., 1992, CELL SURFACE CARBOHY; FUKUSHI Y, 1984, J BIOL CHEM, V259, P511; FUKUSHIMA K, 1984, CANCER RES, V44, P5279; FURUYA A, 1992, ANTICANCER RES, V12, P27; GILLILAND G, 1990, P NATL ACAD SCI USA, V87, P2725, DOI 10.1073/pnas.87.7.2725; GOELZ SE, 1990, CELL, V63, P1349, DOI 10.1016/0092-8674(90)90430-M; GONWA TA, 1983, J IMMUNOL, V130, P706; HAKOMORI S, 1991, CURR OPIN IMMUNOL, V3, P646, DOI 10.1016/0952-7915(91)90091-E; HAKOMORI S, 1984, ANNU REV IMMUNOL, V2, P103, DOI 10.1146/annurev.iy.02.040184.000535; HANAI N, 1990, ANTICANCER RES, V10, P1579; HANDA K, 1991, BIOCHEM BIOPH RES CO, V181, P1223, DOI 10.1016/0006-291X(91)92069-V; HOLMES EH, 1993, ARCH BIOCHEM BIOPHYS, V301, P190, DOI 10.1006/abbi.1993.1132; HOSOI S, 1991, CYTOTECHNOLOGY, V5, pS17, DOI 10.1007/BF00573878; JOHNSON PH, 1987, BIOCHEM SOC T, V15, P396, DOI 10.1042/bst0150396; KITAGAWA H, 1993, BIOCHEM BIOPH RES CO, V194, P375, DOI 10.1006/bbrc.1993.1830; KONDO A, 1990, AGR BIOL CHEM TOKYO, V54, P2169, DOI 10.1080/00021369.1990.10870232; KOSZDIN KL, 1992, BIOCHEM BIOPH RES CO, V187, P152, DOI 10.1016/S0006-291X(05)81472-X; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; KUMAR R, 1991, J BIOL CHEM, V266, P21777; LAM KS, 1991, NATURE, V354, P82, DOI 10.1038/354082a0; LARKIN M, 1992, J BIOL CHEM, V267, P13661; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; LEVINOVITZ A, 1993, J CELL BIOL, V121, P449, DOI 10.1083/jcb.121.2.449; LOBB RR, 1991, J IMMUNOL, V147, P124; LOWE JB, 1991, J BIOL CHEM, V266, P17467; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; MARGOLSKEE RF, 1988, MOL CELL BIOL, V8, P2837, DOI 10.1128/MCB.8.7.2837; MATSUSHITA Y, 1991, EXP CELL RES, V196, P20, DOI 10.1016/0014-4827(91)90451-Y; MEIER W, 1993, BIOCHEM J, V294, P25, DOI 10.1042/bj2940025; MIYAJI H, 1990, CYTOTECHNOLOGY, V4, P173, DOI 10.1007/BF00365098; MIYAJI H, 1990, CYTOTECHNOLOGY, V3, P133, DOI 10.1007/BF00143675; MOLLICONE R, 1990, EUR J BIOCHEM, V191, P169, DOI 10.1111/j.1432-1033.1990.tb19107.x; MUROI K, 1992, BLOOD, V79, P713; NAKAMURA K, 1994, CANCER RES, V54, P1511; NORGARD KE, 1993, J BIOL CHEM, V268, P12764; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; POLLEY MJ, 1991, P NATL ACAD SCI USA, V88, P6224, DOI 10.1073/pnas.88.14.6224; SAKO D, 1993, CELL, V75, P1179, DOI 10.1016/0092-8674(93)90327-M; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASAKI K, 1993, J BIOL CHEM, V268, P22782; Sato S, 1983, J TISSUE CULT METHOD, V8, P167; SHITARA K, 1987, CANCER RES, V47, P1267; TAKADA A, 1991, BIOCHEM BIOPH RES CO, V179, P713, DOI 10.1016/0006-291X(91)91875-D; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; WESTON BW, 1992, J BIOL CHEM, V267, P4152; WESTON BW, 1992, J BIOL CHEM, V267, P24575	55	325	348	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14730	14737						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	8182079				2022-12-25	WOS:A1994NM06500067
J	JAMES, GL; GOLDSTEIN, JL; PATHAK, RK; ANDERSON, RGW; BROWN, MS				JAMES, GL; GOLDSTEIN, JL; PATHAK, RK; ANDERSON, RGW; BROWN, MS			PXF, A PRENYLATED PROTEIN OF PEROXISOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSTTRANSLATIONAL MODIFICATION; HUMAN-FIBROBLASTS; RAT-BRAIN; FARNESYLTRANSFERASE; EXPRESSION; CLONING; P21RAS; ALPHA; ACID; ISOPRENYLATION	CAAX farnesyltransferase attaches a farnesyl group to proteins that terminate in the sequence CAAX, where C is cysteine, A is an aliphatic amino acid, and X is typically methionine or serine. A limited number of substrates for the CAAX farnesyltransferase have been identified in cultured cells. These include p21(ras) proteins and the nuclear lamins A and B. We describe here the use of a CAAX farnesyltransferase inhibitor, together with a hamster cell line that exhibits efficient uptake of [H-3]mevalonate, as a means of identifying novel farnesylated proteins. One candidate protein was purified and its attached prenyl group identified as farnesyl. The predicted amino acid sequence of this protein, deduced from a cloned cDNA, terminates with the tetrapeptide Cys-Leu-Ile-Met, which conforms to the consensus sequence for recognition by farnesyltransferase. This farnesylated protein, designated PxF, is localized to the outer surface of peroxisomes as determined by indirect immunofluorescence and electron microscopy.	UNIV TEXAS,SOUTHWESTERN MED CTR,DEPT CELL BIOL,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	JAMES, GL (corresponding author), UNIV TEXAS,SOUTHWESTERN MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235, USA.				NHLBI NIH HHS [HL 20948] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ANDRES DA, 1993, CELL, V73, P1091, DOI 10.1016/0092-8674(93)90639-8; ARMSTRONG SA, 1993, J BIOL CHEM, V268, P12221; BEISIEGEL U, 1981, J BIOL CHEM, V256, P4071; BROWN MS, 1993, NATURE, V366, P14, DOI 10.1038/366014a0; BROWN MS, 1978, J BIOL CHEM, V253, P1121; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CHEN WJ, 1991, P NATL ACAD SCI USA, V88, P11368, DOI 10.1073/pnas.88.24.11368; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; FARNSWORTH C C, 1990, Methods (Orlando), V1, P231, DOI 10.1016/S1046-2023(05)80322-6; FAUST J, 1987, J BIOL CHEM, V262, P1996; FERNANDEZ J, 1992, ANAL BIOCHEM, V201, P255, DOI 10.1016/0003-2697(92)90336-6; GARCIA CK, 1994, CELL, V76, P865, DOI 10.1016/0092-8674(94)90361-1; Glomset J. A., 1991, CURR OPIN LIPIDOL, V2, P118; GOULD SJ, 1990, J CELL BIOL, V110, P27, DOI 10.1083/jcb.110.1.27; GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HEILMEYER LMG, 1992, P NATL ACAD SCI USA, V89, P9554, DOI 10.1073/pnas.89.20.9554; INGLESE J, 1992, J BIOL CHEM, V267, P1422; JAMES GL, 1993, SCIENCE, V260, P1937, DOI 10.1126/science.8316834; KIM CM, 1992, J BIOL CHEM, V267, P23113; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lazarow P. B., 1989, METABOLIC BASIS INHE, P1479; MALTESE WA, 1990, FASEB J, V4, P3319, DOI 10.1096/fasebj.4.15.2123808; MOORES SL, 1991, J BIOL CHEM, V266, P14603; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; NOVIKOFF AB, 1969, J HISTOCHEM CYTOCHEM, V17, P675, DOI 10.1177/17.10.675; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PATHAK RK, 1989, J HISTOCHEM CYTOCHEM, V37, P69, DOI 10.1177/37.1.2491753; REESE JH, 1991, MOL CELL BIOCHEM, V104, P109; REISS Y, 1992, J BIOL CHEM, V267, P6403; REISS Y, 1991, P NATL ACAD SCI USA, V88, P732, DOI 10.1073/pnas.88.3.732; REISS Y, 1991, J BIOL CHEM, V266, P10672; RILLING HC, 1993, ARCH BIOCHEM BIOPHYS, V301, P210, DOI 10.1006/abbi.1993.1135; Sambrook J, 1989, MOL CLONING LABORATO; SCHMIDT RA, 1984, J BIOL CHEM, V259, P175; SULSTON J, 1992, NATURE, V356, P37, DOI 10.1038/356037a0; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; THIERINGER R, 1993, J BIOL CHEM, V268, P12631; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; ZOELLER RA, 1989, J BIOL CHEM, V264, P21872	44	94	97	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					14182	14190						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188701				2022-12-25	WOS:A1994NL60600070
J	LEID, M				LEID, M			LIGAND-INDUCED ALTERATION OF THE PROTEASE SENSITIVITY OF RETINOID-X RECEPTOR-ALPHA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE; CONFORMATIONAL-CHANGES; SIGNALING PATHWAYS; NUCLEAR RECEPTORS; RXR-ALPHA; ACID; BINDING; DIVERSITY; DOMAIN; GENES	Ligand-induced structural alterations of retinoid X receptor (RXR) appear to facilitate receptor homodimerization, to enhance DNA binding of RXR homodimeric complexes, and to dictate the transcriptional activation properties of RXR complexes bound to response elements located in the promoter region of 9-cis-retinoic acid responsive genes. The technique of limited proteolysis was used to address 9-cis-retinoic acid-induced RXR conformational change and to identify receptor region(s) which undergo structural alteration upon ligand binding. Proteolytic digestion of 9-cis-retinoic acid-liganded, but not unliganded, RXR gave rise to a fragment of 31 kilodaltons (PF31), which contained a large portion of the RXR ligand binding domain. The potency with which 9-cis-retinoic acid induced formation of PE31 was nearly identical to that with which the ligand enhanced DNA binding of a RXR homodimeric complex to a response element composed of the directly repeated hexanucleotide, PuGGTCA, separated by 1 base pair. The amino-terminal limit of PF31 mapped to Ser(229) of mouse RXR alpha, which lies roughly in the middle of the spacer region separating the DNA and ligand binding domains of the receptor. These results suggest that a fairly large region of the receptor protein undergoes a structural alteration upon ligand binding which may directly alter the multiple functions of the RXR ligand binding domain.	OREGON STATE UNIV, PROGRAM MOLEC & CELLULAR BIOL, CORVALLIS, OR 97331 USA	Oregon State University	LEID, M (corresponding author), OREGON STATE UNIV, COLL PHARM, CTR GENE RES & BIOTECHNOL, DEPT BIOCHEM & BIOPHYS, CORVALLIS, OR 97331 USA.							ALLAN GF, 1992, J BIOL CHEM, V267, P19513; ALLAN GF, 1992, P NATL ACAD SCI USA, V89, P11750, DOI 10.1073/pnas.89.24.11750; ALLENBY G, 1993, P NATL ACAD SCI USA, V90, P30, DOI 10.1073/pnas.90.1.30; AUFLIEGNER M, 1993, MOL CELL BIOL, V13, P5725, DOI 10.1128/MCB.13.9.5725; BARDOT O, 1993, BIOCHEM BIOPH RES CO, V192, P37, DOI 10.1006/bbrc.1993.1378; BARETTINO D, 1993, EMBO J, V12, P1343, DOI 10.1002/j.1460-2075.1993.tb05779.x; BEEKMAN JM, 1993, MOL ENDOCRINOL, V7, P1266, DOI 10.1210/me.7.10.1266; BHAT MK, 1993, BIOCHEM BIOPH RES CO, V195, P385, DOI 10.1006/bbrc.1993.2055; BOGENHAGEN DF, 1993, MOL CELL BIOL, V13, P5149, DOI 10.1128/MCB.13.9.5149; BUGGE TH, 1992, EMBO J, V11, P1409, DOI 10.1002/j.1460-2075.1992.tb05186.x; DE LUCA LM, 1991, FASEB J, V5, P2924; DREYER C, 1993, BIOL CELL, V77, P67, DOI 10.1016/S0248-4900(05)80176-5; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FRITSCH M, 1992, BIOCHEMISTRY-US, V31, P5303, DOI 10.1021/bi00138a009; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; HOROWITZ ZD, 1989, MOL ENDOCRINOL, V3, P148, DOI 10.1210/mend-3-1-148; ISSEMANN I, 1993, BIOCHIMIE, V75, P251, DOI 10.1016/0300-9084(93)90084-6; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; KLIEWER SA, 1992, P NATL ACAD SCI USA, V89, P1448, DOI 10.1073/pnas.89.4.1448; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; KUROKAWA R, 1993, GENE DEV, V7, P1423, DOI 10.1101/gad.7.7b.1423; LEHMANN JM, 1992, SCIENCE, V258, P1944, DOI 10.1126/science.1335166; LEID M, 1993, ANN NY ACAD SCI, V684, P19, DOI 10.1111/j.1749-6632.1993.tb32268.x; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LU XP, 1993, MOL CELL BIOL, V13, P6509, DOI 10.1128/MCB.13.10.6509; MADER S, 1993, EMBO J, V12, P5029, DOI 10.1002/j.1460-2075.1993.tb06196.x; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; PERLMANN T, 1993, GENE DEV, V7, P1411, DOI 10.1101/gad.7.7b.1411; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; WEISSHART K, 1993, P NATL ACAD SCI USA, V90, P1028, DOI 10.1073/pnas.90.3.1028; WIDOM RL, 1992, MOL CELL BIOL, V12, P3380, DOI 10.1128/MCB.12.8.3380; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG XK, 1992, NATURE, V358, P587, DOI 10.1038/358587a0; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	39	63	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					14175	14181						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188700				2022-12-25	WOS:A1994NL60600069
J	MORRISON, JR; SILVESTRE, MJ; PITTMAN, RC				MORRISON, JR; SILVESTRE, MJ; PITTMAN, RC			CHOLESTERYL ESTER TRANSFER BETWEEN HIGH-DENSITY-LIPOPROTEIN AND PHOSPHOLIPID-BILAYERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SELECTIVE UPTAKE; RAT-LIVER; PLASMA-MEMBRANES; PHOSPHATIDYLCHOLINE; MECHANISM; CELLS; EXCHANGE; VESICLES; SOLUBILIZATION; LOCALIZATION	High density lipoprotein associated cholesteryl esters (HDL CE) are taken up by many cells without parallel uptake of HDL apoproteins, a pathway we have termed ''selective uptake.'' The first step in this pathway, the reversible incorporation of HDL CE into the plasma membrane, is the subject of the present study. To examine the role of membrane proteins, the rate of HDL CE incorporation into isolated rat liver plasma membrane was compared with the rate of incorporation into synthetic membranes devoid of protein. Both membrane systems exhibited saturable uptake of CE, and at rates that were similar (t(1/2) approximate to 2 h, measured with 50 mu g of HDL protein). Addition of unlabeled HDL to ''chase'' CE tracer from the biological and synthetic membranes revealed two kinetically distinct CE pools (t(1/2) approximate to 0.5 h and t(1/2) approximate to 30 h). Both biological and synthetic membranes accepted similar amounts of CE into both pools, with a maximum incorporation of 2-4 mol % relative to membrane phospholipids. CE transfer between HDL and membranes was kinetically second order, in contrast to the first-order transfer of unesterified cholesterol. There was no evidence for direct participation of any apolipoprotein in CE uptake; CE in HDL or in protein-free microemulsions of similar particle size transferred to membranes at similar rates. To examine the possibility that CE transfer requires transient fusion of the HDL amphipathic coat with the membrane outer leaflet, radiolabeled cardiolipin was incorporated into either HDL particles or into synthetic membranes as an amphipathic coat marker that does not diffuse through the aqueous phase; transfer between HDL and membranes was not observed. Thus, CE are transferred between HDL and cell membranes in a collision mediated process that does not involve amphipathic coat fusion and is not dependent on either membrane protein or apolipoproteins.	UNIV CALIF SAN DIEGO,DEPT MED 0682,LA JOLLA,CA 92093	University of California System; University of California San Diego								BARTLETT GR, 1959, J BIOL CHEM, V234, P466; Fleischer S, 1974, Methods Enzymol, V31, P6; GLASS C, 1985, J BIOL CHEM, V260, P744; GOORMAGHTIGH E, 1986, ANAL BIOCHEM, V159, P122, DOI 10.1016/0003-2697(86)90316-7; GREEN SR, 1991, J LIPID RES, V32, P457; HAMILTON JA, 1982, J BIOL CHEM, V257, P7318; HAMILTON JA, 1981, P NATL ACAD SCI-BIOL, V78, P6878, DOI 10.1073/pnas.78.11.6878; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HELLINGS JA, 1974, EUR J BIOCHEM, V47, P601, DOI 10.1111/j.1432-1033.1974.tb03731.x; HOMAN R, 1988, BIOCHIM BIOPHYS ACTA, V938, P155, DOI 10.1016/0005-2736(88)90155-1; JOHNSON WJ, 1991, BIOCHIM BIOPHYS ACTA, V1085, P273, DOI 10.1016/0005-2760(91)90132-2; JONES JD, 1989, BIOCHEMISTRY-US, V28, P129, DOI 10.1021/bi00427a019; JONES JD, 1990, BIOCHEMISTRY-US, V29, P1593, DOI 10.1021/bi00458a034; KADOWAKI H, 1992, J LIPID RES, V33, P1689; KADOWAKI H, 1993, J LIPID RES, V34, P180; KNECHT TP, 1989, BIOCHIM BIOPHYS ACTA, V1002, P365, DOI 10.1016/0005-2760(89)90351-2; LEBLOND L, 1993, J BIOL CHEM, V268, P1670; LETIZIA JY, 1991, BIOCHEMISTRY-US, V30, P866, DOI 10.1021/bi00217a041; LIS LJ, 1982, BIOPHYS J, V37, P657; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCLEAN LR, 1981, BIOCHEMISTRY-US, V20, P2893, DOI 10.1021/bi00513a028; MCPHERSON GA, 1985, KINETIC EBDA LIGAND; MILLER KW, 1983, BIOCHEMISTRY-US, V22, P443, DOI 10.1021/bi00271a030; MORRISON JR, 1992, J BIOL CHEM, V267, P13205; PHILLIPS MC, 1987, BIOCHIM BIOPHYS ACTA, V906, P223, DOI 10.1016/0304-4157(87)90013-X; Pittman R C, 1986, Methods Enzymol, V129, P612; PITTMAN RC, 1987, J BIOL CHEM, V262, P2443; PITTMAN RC, 1987, J BIOL CHEM, V262, P2435; RAND RP, 1989, BIOCHIM BIOPHYS ACTA, V988, P351, DOI 10.1016/0304-4157(89)90010-5; RAY TK, 1970, BIOCHIM BIOPHYS ACTA, V196, P1, DOI 10.1016/0005-2736(70)90159-8; RINNINGER F, 1989, J BIOL CHEM, V264, P6111; RINNINGER F, 1988, J LIPID RES, V29, P1179; RINNINGER F, 1987, J LIPID RES, V28, P1313; SPARROW CP, 1990, BIOCHIM BIOPHYS ACTA, V1043, P203, DOI 10.1016/0005-2760(90)90297-B; TALL AR, 1986, METHOD ENZYMOL, V128, P647; TULSIANI DRP, 1977, J BIOL CHEM, V252, P3227; VANHOEVEN RP, 1972, J MEMBRANE BIOL, V9, P105, DOI 10.1007/BF01868047; WALSH MT, 1986, METHOD ENZYMOL, V128, P582; WEDER HG, 1984, LIPOSOME TECHNOLOGY, V1; WETTERAU JR, 1984, J BIOL CHEM, V259, P863; [No title captured]	41	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					13911	13918						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188670				2022-12-25	WOS:A1994NL60600032
J	ZHANG, ZJ; ZHAO, SM; BAI, G; LEE, EYC				ZHANG, ZJ; ZHAO, SM; BAI, G; LEE, EYC			CHARACTERIZATION OF DELETION MUTANTS OF THE CATALYTIC SUBUNIT OF PROTEIN PHOSPHATASE-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER PHOSPHORYLASE PHOSPHATASE; SERINE THREONINE PHOSPHATASES; RABBIT SKELETAL-MUSCLE; MOLECULAR-WEIGHT; MICROCYSTIN-LR; OKADAIC ACID; INHIBITOR; TYPE-1; PURIFICATION; FAMILY	Deletion mutagenesis was used to define the core region of the catalytic subunit of rabbit muscle protein phosphatase-1. Deletions in the N terminus were found to lead to loss of expression. Deletions of up to 33 residues from the C-terminal region were tolerated, and the truncated enzymes were fully active. Deletion of an additional 21 residues led to loss of expression. Mutants which had had 33 and 25 residues deleted maintained specific activities that were comparable to those of the wild type enzyme. The response of these two deletion mutants to okadaic acid, microcystin, and inhibitor-2 was determined, Only slightly lower IC50 values were observed in all cases, showing that the C terminus itself does not play a major role in the binding of these inhibitors. The deletion mutants formed stable complexes with inhibitor a as shown by gel filtration. These studies provide unambiguous evidence that the extreme C-terminal region of protein phosphatase-1 is not directly involved in catalytic function or in the binding of inhibitor-2, microcystin, or okadaic acid, and they also establish that the first similar to 300 residues of the sequence constitute a sufficient core for protein phosphatase-1 catalytic functions.	UNIV MIAMI, SCH MED, DEPT BIOCHEM & MOLEC BIOL R629, MIAMI, FL 33101 USA	University of Miami					NIDDK NIH HHS [DK18512] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK018512] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALESSI DR, 1993, EUR J BIOCHEM, V213, P1055, DOI 10.1111/j.1432-1033.1993.tb17853.x; BAI G, 1990, J BIOL CHEM, V265, P7843; BAI G, 1988, FASEB J, V2, P3013; BALLOU LM, 1983, BIOCHEMISTRY-US, V22, P3393, DOI 10.1021/bi00283a014; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BOLLEN M, 1992, CRIT REV BIOCHEM MOL, V27, P227, DOI 10.3109/10409239209082564; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANDT H, 1975, BIOCHEM BIOPH RES CO, V63, P950, DOI 10.1016/0006-291X(75)90661-0; BRANDT H, 1974, BIOCHEM BIOPH RES CO, V61, P598, DOI 10.1016/0006-291X(74)90999-1; BRANDT H, 1975, J BIOL CHEM, V250, P8038; BROWNER MF, 1989, P NATL ACAD SCI USA, V86, P1443, DOI 10.1073/pnas.86.5.1443; CHEN MX, 1992, FEBS LETT, V306, P54, DOI 10.1016/0014-5793(92)80836-6; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN PTW, 1990, FEBS LETT, V268, P355, DOI 10.1016/0014-5793(90)81285-V; DEGUZMAN A, 1988, METHOD ENZYMOL, V159, P356; DOMBRADI V, 1990, EUR J BIOCHEM, V194, P739, DOI 10.1111/j.1432-1033.1990.tb19464.x; DOONAN JH, 1989, CELL, V57, P987, DOI 10.1016/0092-8674(89)90337-1; GRATECOS D, 1977, BIOCHEMISTRY-US, V16, P4812, DOI 10.1021/bi00641a009; HONKANEN RE, 1990, J BIOL CHEM, V265, P19401; HUANG FL, 1976, EUR J BIOCHEM, V70, P419, DOI 10.1111/j.1432-1033.1976.tb11032.x; ISHIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P871, DOI 10.1016/0006-291X(89)92189-X; JOHANSEN JW, 1987, BIOCHIM BIOPHYS ACTA, V928, P63, DOI 10.1016/0167-4889(87)90086-3; KHANDELWAL RL, 1976, J BIOL CHEM, V251, P4850; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee E Y, 1976, Adv Enzyme Regul, V14, P467, DOI 10.1016/0065-2571(76)90026-1; Lee E Y, 1980, Adv Cyclic Nucleotide Res, V13, P95; MACKINTOSH C, 1990, FEBS LETT, V264, P187, DOI 10.1016/0014-5793(90)80245-E; MACKINTOSH RW, 1990, FEBS LETT, V276, P156, DOI 10.1016/0014-5793(90)80531-M; MERLEVEDE W, 1984, CURR TOP CELL REGUL, V23, P177; OHKURA H, 1989, CELL, V57, P997, DOI 10.1016/0092-8674(89)90338-3; RESINK TJ, 1983, EUR J BIOCHEM, V133, P455, DOI 10.1111/j.1432-1033.1983.tb07485.x; SASAKI K, 1990, JPN J CANCER RES, V81, P1272, DOI 10.1111/j.1349-7006.1990.tb02690.x; SCHLENDER KK, 1989, BIOCHEM BIOPH RES CO, V159, P72, DOI 10.1016/0006-291X(89)92406-6; SHENOLIKAR S, 1991, ADV SEC MESS PHOSPH, V23, P1; SILBERMAN SR, 1984, J BIOL CHEM, V259, P2913; SMITH RD, 1993, PLANT MOL BIOL, V21, P307, DOI 10.1007/BF00019946; VILLAMORUZZI E, 1991, FEBS LETT, V293, P67, DOI 10.1016/0014-5793(91)81154-Z; VILLAMORUZZI E, 1984, J BIOL CHEM, V259, P5857; ZHANG Z, 1993, ADV PROTEIN PHOSPHAT, V7, P183; ZHANG Z, 1994, IN PRESS ARCH BIOCH; ZHANG ZJ, 1992, J BIOL CHEM, V267, P1484; ZHANG ZJ, 1993, ARCH BIOCHEM BIOPHYS, V303, P402, DOI 10.1006/abbi.1993.1301	43	25	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					13766	13770						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188653				2022-12-25	WOS:A1994NL60600011
J	NANTEL, F; MARULLO, S; KRIEF, S; STROSBERG, AD; BOUVIER, M				NANTEL, F; MARULLO, S; KRIEF, S; STROSBERG, AD; BOUVIER, M			CELL-SPECIFIC DOWN-REGULATION OF THE BETA(3)-ADRENERGIC RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC RECEPTORS; MESSENGER-RNA; BETA-2-ADRENERGIC RECEPTOR; BETA-3-ADRENERGIC RECEPTOR; DISTINCT PATHWAYS; ADENYLYL CYCLASE; AGONIST EXPOSURE; DESENSITIZATION; PHOSPHORYLATION; INTERNALIZATION	Previous studies have shown that beta(3) adrenergic receptors, in contrast to the beta(1) and beta(2) subtypes, do not undergo desensitization following short term activation (minutes) with agonists. Longer activation (hours) has been shown to induce desensitization of the beta(3)-adrenergic receptor in some, but not all, cases, suggesting that cell- or species-specific mechanisms may be involved. We investigated the contribution of the cell type to the pattern of beta(3)-adrenergic receptor long term desensitization by studying, in parallel, two cell lines (Chinese hamster fibroblasts and murine Ltk(-) cells) expressing the human beta(3)-adrenergic receptor. Sustained agonist-promoted down-regulation of the beta(3)-adrenergic receptor could be induced in Ltk(-) cells, whereas only a transient and weak reduction of receptor number was observed in Chinese hamster fibroblasts. The half-life of the beta(3)-adrenergic receptor was not affected by the agonist activation in either cell line, indicating that in contrast to the beta(2)-adrenergic receptor, degradation of preexisting receptor protein does not contribute to down-regulation. Sustained reduction of receptor RNA levels, monitored by reverse transcriptase polymerase chain reaction, was exclusively shown in Ltk(-) cells and probably accounted for most of the observed down-regulation. Differences in the ability of the receptor to stimulate adenylyl cyclase activity in the two cell lines may be responsible for the distinct patterns of beta(3)-adrenergic receptor down-regulation.	CNRS,UPR 0415,F-75014 PARIS,FRANCE; UNIV MONTREAL,DEPT BIOCHIM,MONTREAL H3C 3J7,PQ,CANADA; UNIV MONTREAL,RECH SYST NERVEUX AUTONOME GRP,MONTREAL H3C 3J7,PQ,CANADA; UNIV PARIS 07,INST COCHIN GENET MOLEC,F-75014 PARIS,FRANCE	Centre National de la Recherche Scientifique (CNRS); Universite de Montreal; Universite de Montreal; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite			Bouvier, Michel/H-2758-2014; Marullo, Stefano/C-6142-2008	Bouvier, Michel/0000-0003-1128-0100; Marullo, Stefano/0000-0001-9604-9973; Krief, Stephane/0000-0002-5543-731X				ARCH JRS, 1984, NATURE, V309, P163, DOI 10.1038/309163a0; BARBER R, 1992, FASEB J, V6, P78; BECKERANDRE M, 1989, NUCLEIC ACIDS RES, V17, P9437, DOI 10.1093/nar/17.22.9437; BENOVIC JL, 1988, ANNU REV CELL BIOL, V4, P405, DOI 10.1146/annurev.cb.04.110188.002201; BENOVIC JL, 1989, SCIENCE, V246, P235, DOI 10.1126/science.2552582; BOUVIER M, 1989, J BIOL CHEM, V264, P16786; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAVO EL, 1984, NEW ENGL J MED, V311, P1298, DOI 10.1056/NEJM198411153112007; CARPENE C, 1993, J PHARMACOL EXP THER, V265, P237; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DOSS RC, 1981, J BIOL CHEM, V256, P2281; EMORINE LJ, 1991, BIOCHEM PHARMACOL, V41, P853, DOI 10.1016/0006-2952(91)90188-B; EMORINE LJ, 1989, SCIENCE, V245, P1118, DOI 10.1126/science.2570461; FREDERICH RC, 1983, J CYCLIC NUCL PROT, V9, P103; GRANNEMAN JG, 1992, J PHARMACOL EXP THER, V261, P638; GRANNEMAN JG, 1992, ENDOCRINOLOGY, V130, P109, DOI 10.1210/en.130.1.109; HADCOCK JR, 1988, P NATL ACAD SCI USA, V85, P5021, DOI 10.1073/pnas.85.14.5021; HADCOCK JR, 1989, J BIOL CHEM, V264, P13956; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HAUSDORFF WP, 1989, J BIOL CHEM, V264, P12657; HOMBURGER V, 1984, J CELL PHYSIOL, V121, P589, DOI 10.1002/jcp.1041210318; HOUGH C, 1990, BIOCHEM BIOPH RES CO, V170, P46, DOI 10.1016/0006-291X(90)91238-N; KRIEF S, 1994, J BIOL CHEM, V269, P6664; KRIEF S, 1993, J CLIN INVEST, V91, P344, DOI 10.1172/JCI116191; KTISTAKIS NT, 1990, J CELL BIOL, V111, P1393, DOI 10.1083/jcb.111.4.1393; LIGGETT SB, 1993, P NATL ACAD SCI USA, V90, P3665, DOI 10.1073/pnas.90.8.3665; LONNQVIST F, 1993, BRIT J PHARMACOL, V110, P929; MCGREGOR AM, 1990, CLIN ENDOCRINOL, V33, P683, DOI 10.1111/j.1365-2265.1990.tb03905.x; MORISHIMA I, 1980, MOL PHARMACOL, V18, P370; NANTEL F, 1993, MOL PHARMACOL, V43, P548; REVELLI JP, 1992, BIOCHEM J, V286, P743, DOI 10.1042/bj2860743; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; Simon W, 1972, MATH TECHNIQUES PHYS; SUZUKI T, 1992, MOL PHARMACOL, V41, P542; SVOBODA P, 1993, BIOCHEM J, V295, P655, DOI 10.1042/bj2950655; THOMAS RF, 1992, P NATL ACAD SCI USA, V89, P4490, DOI 10.1073/pnas.89.10.4490; UNELIUS L, 1993, AM J PHYSIOL, V265, pC1340, DOI 10.1152/ajpcell.1993.265.5.C1340; VALIQUETTE M, 1990, P NATL ACAD SCI USA, V87, P5089, DOI 10.1073/pnas.87.13.5089; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530; ZHOU XM, 1991, J BIOL CHEM, V266, P7462	40	57	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13148	13155						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175742				2022-12-25	WOS:A1994NK18400018
J	JOHNSON, RP; CRAIG, SW				JOHNSON, RP; CRAIG, SW			AN INTRAMOLECULAR ASSOCIATION BETWEEN THE HEAD AND TAIL DOMAINS OF VINCULIN MODULATES TALIN BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								Three independent lines of evidence demonstrate an interaction between the head and tail domains of vinculin. First, both the purified 30-kDa tail fragment and a fusion protein containing tail domain, vinculin residues 884-1066, protect purified 95-kDa head domain from cleavage by protease V8 in a specific, dose dependent manner. Second, direct binding studies between the 95-kDa head and the V884-1066 fusion protein and carboxyl-terminal truncations of the fusion protein indicate a tight interaction (K-d similar to 50 nM) that requires vinculin residues 1013-1043. Finally, cross-linking of vinculin demonstrates cross-linkable head tail complexes in the intact protein, which are almost exclusively intramolecular. Talin and the tail domain compete for binding to the vinculin head domain. Therefore, we propose that the loss of the intramolecular interaction of head and tail accounts for the increased affinity for talin of the head domain compared with intact vinculin. The observation that a head-tail interaction in the molecule affects the ability of vinculin to interact with another adherens junction component suggests that modulation of head-tail binding is a way to control recruitment of vinculin into an adherens junction.	JOHNS HOPKINS UNIV, SCH MED, DEPT BIOL CHEM, BALTIMORE, MD 21205 USA	Johns Hopkins University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041605, R56GM041605] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41605] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARSTEAD RJ, 1989, J BIOL CHEM, V264, P10177; BARSTEAD RJ, 1991, J CELL BIOL, V114, P715, DOI 10.1083/jcb.114.4.715; BURRIDGE K, 1984, NATURE, V308, P744, DOI 10.1038/308744a0; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; COUTU MD, 1988, P NATL ACAD SCI USA, V85, P8535, DOI 10.1073/pnas.85.22.8535; DEPASQUALE JA, 1987, J CELL BIOL, V105, P2803, DOI 10.1083/jcb.105.6.2803; EIMER W, 1993, J MOL BIOL, V229, P146, DOI 10.1006/jmbi.1993.1014; ENYEDI A, 1989, J BIOL CHEM, V264, P12313; EVANS RR, 1984, J BIOL CHEM, V259, P3916; FERAMISCO JR, 1980, J BIOL CHEM, V255, P1194; FERNANDEZ JLR, 1992, J CELL BIOL, V119, P427, DOI 10.1083/jcb.119.2.427; FERNANDEZ JLR, 1992, CELL MOTIL CYTOSKEL, V22, P127, DOI 10.1002/cm.970220206; FRORATH B, 1992, BIOTECHNIQUES, V12, P558; GEIGER B, 1990, CELL DIFFER DEV, V32, P343, DOI 10.1016/0922-3371(90)90049-3; GEIGER B, 1985, J CELL BIOL, V101, P1523, DOI 10.1083/jcb.101.4.1523; GEIGER B, 1980, P NATL ACAD SCI-BIOL, V77, P4127, DOI 10.1073/pnas.77.7.4127; GEIGER B, 1979, CELL, V18, P193, DOI 10.1016/0092-8674(79)90368-4; GILMORE AP, 1992, J CELL SCI, V103, P719; GILMORE AP, 1993, J CELL BIOL, V122, P337, DOI 10.1083/jcb.122.2.337; GIMONA M, 1988, EMBO J, V7, P2329, DOI 10.1002/j.1460-2075.1988.tb03076.x; GROESCH ME, 1990, CELL MOTIL CYTOSKEL, V15, P41, DOI 10.1002/cm.970150107; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; HYNES RO, 1992, CELL, V68, P303, DOI 10.1016/0092-8674(92)90472-O; ISENBERG G, 1982, J MOL BIOL, V158, P231, DOI 10.1016/0022-2836(82)90431-4; ITO S, 1983, J BIOL CHEM, V258, P4626; JOCKUSCH BM, 1981, COLD SPRING HARB SYM, V46, P613, DOI 10.1101/SQB.1982.046.01.057; JOHNSON R P, 1990, Journal of Cell Biology, V111, p300A; JOHNSON RP, 1992, MOL BIOL CELL, V3, pA266; KLASSE PJ, 1993, NATURE, V365, P395, DOI 10.1038/365395a0; KWIATKOWSKI DJ, 1989, J CELL BIOL, V108, P1717, DOI 10.1083/jcb.108.5.1717; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANESS PF, 1983, J BIOL CHEM, V258, P4055; MARUYAMA K, 1965, J BIOCHEM-TOKYO, V58, P13, DOI 10.1093/oxfordjournals.jbchem.a128158; MATSUZAKI F, 1990, J CELL BIOL, V110, P1239, DOI 10.1083/jcb.110.4.1239; MEGE RM, 1988, P NATL ACAD SCI USA, V85, P7274, DOI 10.1073/pnas.85.19.7274; MILAM LM, 1985, J MOL BIOL, V184, P543, DOI 10.1016/0022-2836(85)90301-8; MOLONY L, 1987, J BIOL CHEM, V262, P7790; MOLONY L, 1985, J CELL BIOCHEM, V29, P31, DOI 10.1002/jcb.240290104; OHALLORAN T, 1986, METHOD ENZYMOL, V134, P69; PLOPPER G, 1993, BIOCHEM BIOPH RES CO, V193, P571, DOI 10.1006/bbrc.1993.1662; PRICE GJ, 1989, BIOCHEM J, V259, P453, DOI 10.1042/bj2590453; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Sambrook J, 1989, MOL CLONING LABORATO; SAMUELS M, 1993, J CELL BIOL, V121, P909, DOI 10.1083/jcb.121.4.909; Schaller Michael D., 1993, Trends in Cell Biology, V3, P258, DOI 10.1016/0962-8924(93)90053-4; SINGER II, 1982, J CELL SCI, V56, P1; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SODERLING TR, 1990, J BIOL CHEM, V265, P1823; STRASSER P, 1993, FEBS LETT, V317, P189, DOI 10.1016/0014-5793(93)81274-4; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSUKITA S, 1991, J CELL BIOL, V113, P867, DOI 10.1083/jcb.113.4.867; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; VOLBERG T, 1992, EMBO J, V11, P1733, DOI 10.1002/j.1460-2075.1992.tb05225.x; WACHSSTOCK DH, 1987, BIOCHEM BIOPH RES CO, V146, P554, DOI 10.1016/0006-291X(87)90564-X; WAY M, 1989, J CELL BIOL, V109, P593, DOI 10.1083/jcb.109.2.593; WESTMEYER A, 1990, EMBO J, V9, P2071, DOI 10.1002/j.1460-2075.1990.tb07374.x; WILLIAMS CL, 1993, J CELL BIOL, V121, P643, DOI 10.1083/jcb.121.3.643; WOODS A, 1992, J CELL SCI, V101, P277	64	201	202	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12611	12619						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175670				2022-12-25	WOS:A1994NH71600040
J	MULHERON, JG; CASANAS, SJ; ARTHUR, JM; GARNOVSKAYA, MN; GETTYS, TW; RAYMOND, JR				MULHERON, JG; CASANAS, SJ; ARTHUR, JM; GARNOVSKAYA, MN; GETTYS, TW; RAYMOND, JR			HUMAN 5-HT1A RECEPTOR EXPRESSED IN INSECT CELLS ACTIVATES ENDOGENOUS G(O)-LIKE G-PROTEIN(S)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								Insect cell expression systems are used to characterize signaling components such as G protein-coupled receptors. As such, one must know whether endogenous G proteins couple to non-native receptors. We examined G protein linkages after infection of Sporodoptera frugiperda (Sf9) cells with a baculovirus encoding the 5-HT1A receptor. Receptor expression was confirmed by immunoblot. Some of the receptors were functional, showing guanine nucleotide-sensitive binding to the specific agonist ligand [H-3]8-hydroxy-2-(di-n-propylamino)-1,2,3,4- tetranaphthalene). Peak expression (approximate to 150 fmol/mg of membrane protein) was attained approximate to 72-96 h post-infection. 5-HT-increased covalent binding of [P-32]GTP-azidoanilide to a 40 kDa band, which was identified as a G protein by nucleotide blocking, Mg2+ dependence, and immunoblot and immunoprecipitation studies. The band comigrated with 1) pertussis toxin substrate(s), and 2) a band recognized by two G(o alpha) antisera and one common to heterotrimeric G protein alpha-subunits, but not by sera specific for G(s alpha) or G(i alpha). Labeled species could be precipitated with a G(o alpha) antiserum. 5-HT-increased labeling of the band was prevented by preincubation with pertussis toxin. These studies suggest that the 5-HT1A receptor couples effectively to native insect cell G(o) like proteins.	DUKE UNIV, MED CTR, DEPT MED NEPHROL, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT MED GASTROENTEROL, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT CELL BIOL, DURHAM, NC 27710 USA; VET AFFAIRS MED CTR, MED SERV, NEPHROL SECT, DURHAM, NC 27710 USA	Duke University; Duke University; Duke University; US Department of Veterans Affairs; Veterans Health Administration (VHA)			Gettys, Thomas W/N-1964-2017	Gettys, Thomas W/0000-0001-7125-7995; Arthur, John/0000-0003-4342-4762; Garnovskaya, Maria/0000-0002-6216-038X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK042486] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030927] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK42486] Funding Source: Medline; NINDS NIH HHS [NS30927] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BERSTEIN G, 1992, CELL, V70, P411, DOI 10.1016/0092-8674(92)90165-9; BERTIN B, 1992, J BIOL CHEM, V267, P8200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCHNER E, 1991, J NEUROGENET, V7, P153, DOI 10.3109/01677069109167432; CASEY PJ, 1990, J BIOL CHEM, V265, P2383; DELLACQUA ML, 1993, J BIOL CHEM, V268, P5676; ELLISTON JF, 1992, J BIOL CHEM, V267, P5193; FARGIN A, 1988, NATURE, V335, P358, DOI 10.1038/335358a0; FARGIN A, 1991, CELL SIGNAL, V3, P547, DOI 10.1016/0898-6568(91)90031-O; FLORIO VA, 1989, J BIOL CHEM, V264, P3909; GERHARDT MA, 1991, MOL PHARMACOL, V40, P707; GETTYS TW, 1991, J BIOL CHEM, V266, P15949; GRABER SG, 1992, J BIOL CHEM, V267, P1271; GRABER SG, 1992, J BIOL CHEM, V267, P13123; GUAN XM, 1992, J BIOL CHEM, V267, P21995; HEN R, 1992, TRENDS PHARMACOL SCI, V13, P160, DOI 10.1016/0165-6147(92)90054-A; KOBILKA BK, 1987, NATURE, V329, P75, DOI 10.1038/329075a0; KOPF GS, 1991, METHOD ENZYMOL, V195, P257; KWATRA MM, 1993, J BIOL CHEM, V268, P9161; LABRECQUE J, 1992, FEBS LETT, V304, P157, DOI 10.1016/0014-5793(92)80609-K; LAW SF, 1993, J BIOL CHEM, V268, P10721; MOUILLAC B, 1992, J BIOL CHEM, V267, P21733; MUMBY S, 1988, J BIOL CHEM, V263, P2020; MUMBY SM, 1991, METHOD ENZYMOL, V195, P215; OFFERMANNS S, 1991, METHOD ENZYMOL, V195, P286; OFFERMANNS S, 1991, J BIOL CHEM, V266, P3365; OKERBLOM C, 1993, BIOCHIM BIOPHYS ACTA, V1176, P269, DOI 10.1016/0167-4889(93)90055-T; PARKER EM, 1991, J BIOL CHEM, V266, P519; PROVOST NM, 1988, J BIOL CHEM, V263, P12070; QUEHENBERGER O, 1992, J BIOL CHEM, V267, P19757; RAYMOND JR, 1989, MOL PHARMACOL, V36, P15; RAYMOND JR, 1993, BIOCHEMISTRY-US, V32, P11064, DOI 10.1021/bi00092a016; RAYMOND JR, 1992, N-S ARCH PHARMACOL, V346, P127, DOI 10.1007/BF00165293; RAYMOND JR, 1993, AM J PHYSIOL, V264, pF9, DOI 10.1152/ajprenal.1993.264.1.F9; RAYMOND JR, 1992, MOL BIOL RECEPTORS C, P113; REILANDER H, 1991, FEBS LETT, V282, P441, DOI 10.1016/0014-5793(91)80532-8; RICHARDSON RM, 1992, J BIOL CHEM, V267, P22249; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAUDOU F, 1992, EMBO J, V11, P7, DOI 10.1002/j.1460-2075.1992.tb05021.x; SUMMERS MD, 1987, TEXAS AGR EXPT STATI, V1555, P1; VASUDEVAN S, 1992, FEBS LETT, V311, P7, DOI 10.1016/0014-5793(92)81354-O	41	96	104	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12954	12962						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175713				2022-12-25	WOS:A1994NH71600088
J	SCHELLER, U; KRAFT, R; SCHRODER, KL; SCHUNCK, WH				SCHELLER, U; KRAFT, R; SCHRODER, KL; SCHUNCK, WH			GENERATION OF THE SOLUBLE AND FUNCTIONAL CYTOSOLIC DOMAIN OF MICROSOMAL CYTOCHROME-P450 52A3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE-SPECIFIC PROTEOLYSIS; YEAST CANDIDA-MALTOSA; MEMBRANE TOPOLOGY; ESCHERICHIA-COLI; LODDEROMYCES ELONGISPORUS; ENDOPLASMIC-RETICULUM; MOLECULAR-CLONING; INSERTION SIGNAL; PURIFICATION; EXPRESSION	The cytosolic domain of microsomal P450 52A3 (P450Cm1) was isolated as a soluble and functionally active protein. The NH2-terminal region that anchors the P450 protein to the endoplasmic reticulum was removed by sequence-specific proteolysis at a designed cleavage site. For that purpose, P450Cm1 was genetically engineered to establish at position 63-66 the sequence Ile-Glu-Gly-Arg, which is recognized by the restriction protease factor Xa. The modified P450 was produced in high yields as an integral membrane protein in Saccharomyces cerevisiae. In the microsomal fraction, it was accessible to factor Xa digestion, releasing a readily soluble, shortened P450 protein. For large scale preparation of the cytosolic domain, the modified P450Cm1 was first purified and then subjected to sequence-specific proteolysis. The highly purified Delta(1-66)P450Cm1 exhibited unchanged spectral characteristics and catalyzed the hydroxylation of n-hexadecane with 85% of the activity determined for full-length wild-type P450Cm1. The method developed for the preparation of the cytosolic domain of P450Cm1 may be more generally applicable to facilitate structure-function studies on membrane-bound P450 forms.			SCHELLER, U (corresponding author), MAX DELBRUCK CTR MOLEC MED,ROBERT ROSSLE STR 10,D-13122 BERLIN,GERMANY.							BLACK SD, 1992, FASEB J, V6, P680, DOI 10.1096/fasebj.6.2.1537456; Broach J. R., 1983, EXPT MANIPULATION GE, P83; CLARK BJ, 1992, J BIOL CHEM, V267, P24568; CULLIN C, 1992, BIOCHEM BIOPH RES CO, V184, P1490, DOI 10.1016/S0006-291X(05)80051-8; DELEMOSCHIARANDINI C, 1987, J CELL BIOL, V104, P209, DOI 10.1083/jcb.104.2.209; Higuchi R., 1989, PCR TECHNOLOGY, P61; HONECK H, 1982, BIOCHEM BIOPH RES CO, V106, P1318, DOI 10.1016/0006-291X(82)91257-8; HSU LC, 1993, J BIOL CHEM, V268, P14682; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSON JR, 1991, P NATL ACAD SCI USA, V88, P9141, DOI 10.1073/pnas.88.20.9141; LI YC, 1991, J BIOL CHEM, V266, P19186; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Michel H., 1991, CRYSTALLIZATION MEMB, P73; NAGAI K, 1987, METHOD ENZYMOL, V153, P461; NAGAI K, 1984, NATURE, V309, P810, DOI 10.1038/309810a0; NELSON DR, 1993, DNA CELL BIOL, V12, P1, DOI 10.1089/dna.1993.12.1; NELSON DR, 1988, J BIOL CHEM, V263, P6038; OHKUMA M, 1991, DNA CELL BIOL, V10, P271, DOI 10.1089/dna.1991.10.271; OMURA T, 1964, J BIOL CHEM, V239, P2370; Omura T., 1993, CYTOCHROME P 450, P1; PERNECKY SJ, 1993, P NATL ACAD SCI USA, V90, P2651, DOI 10.1073/pnas.90.7.2651; POULOS TL, 1987, J MOL BIOL, V195, P687, DOI 10.1016/0022-2836(87)90190-2; RAVICHANDRAN KG, 1993, SCIENCE, V261, P731, DOI 10.1126/science.8342039; RIEGE P, 1981, BIOCHEM BIOPH RES CO, V98, P527, DOI 10.1016/0006-291X(81)90872-X; SAKAGUCHI M, 1987, EMBO J, V6, P2425, DOI 10.1002/j.1460-2075.1987.tb02521.x; SANGLARD D, 1989, GENE, V76, P121, DOI 10.1016/0378-1119(89)90014-0; SCHUNCK WH, 1989, BIOCHEM BIOPH RES CO, V161, P843, DOI 10.1016/0006-291X(89)92677-6; SCHUNCK WH, 1991, EUR J CELL BIOL, V55, P336; SZCZESNASKORUPA E, 1989, J CELL BIOL, V108, P1237, DOI 10.1083/jcb.108.4.1237; TAKAGI M, 1989, AGR BIOL CHEM TOKYO, V53, P2217, DOI 10.1080/00021369.1989.10869646; VOGEL F, 1992, EUR J CELL BIOL, V57, P285; WIEDMANN B, 1993, BIOCHIM BIOPHYS ACTA, V1153, P267; YABUSAKI Y, 1988, DNA-J MOLEC CELL BIO, V7, P701, DOI 10.1089/dna.1988.7.701	33	34	46	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12779	12783						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175690				2022-12-25	WOS:A1994NH71600063
J	DECROLY, E; VANDENBRANDEN, M; RUYSSCHAERT, JM; COGNIAUX, J; JACOB, GS; HOWARD, SC; MARSHALL, G; KOMPELLI, A; BASAK, A; JEAN, F; LAZURE, C; BENJANNET, S; CHRETIEN, M; DAY, R; SEIDAH, NG				DECROLY, E; VANDENBRANDEN, M; RUYSSCHAERT, JM; COGNIAUX, J; JACOB, GS; HOWARD, SC; MARSHALL, G; KOMPELLI, A; BASAK, A; JEAN, F; LAZURE, C; BENJANNET, S; CHRETIEN, M; DAY, R; SEIDAH, NG			THE CONVERTASES FURIN AND PC1 CAN BOTH CLEAVE THE HUMAN-IMMUNODEFICIENCY-VIRUS (HIV)-1 ENVELOPE GLYCOPROTEIN GP160 INTO GP120 (HIV-I SU) AND GP41 (HIV-I TM)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEOLYTIC CLEAVAGE; INFLUENZA-VIRUS; ENDOPROTEOLYTIC CLEAVAGE; MUTATIONAL ANALYSIS; HTLV-III/LAV; GENE ENCODES; PRO-PROTEIN; TYPE-1; ACTIVATION; SEQUENCE	Intracellular proteolytic processing of human immunodeficiency virus envelope glycoprotein precursor (gp160) is an essential step for virus infectivity. Northern blot analysis provided evidence that furin and PC1, but not PC2, are expressed in the CD4(+) human lymphoblastoid H9 cell line, suggesting the possible participation of these convertases in human immunodeficiency virus (HIV) gp160 proteolytic processing. Purified PC1 and furin cleaved specifically in vitro gp160 into gp120 (HIV-I SU) and gp41 (HIV-I TM). NH2-terminal sequence analysis of the produced gp41 (HIV-I TM) demonstrated that the cleavage occurred within the sequence Arg-Glu-Lys-Arg down arrow Ala-Val-Gly-Ile, which is identical to the bond cleaved in vivo. Transition state analog peptides were designed and tested in vitro for their ability to inhibit the PC1- or furin mediated gp160 cleavage. The best inhibitor was decanoyl-Arg-Lys-Arg-Arg-Psi[CH2NH]-Phe-Leu-Gly-Phe-NH2.	CLIN RES INST MONTREAL, BIOCHEM NEUROENDOCRINOL LAB, MONTREAL H2W 1R7, PQ, CANADA; CLIN RES INST MONTREAL, PEPTIDE METAB & STRUCT LAB, MONTREAL H2W 1R7, PQ, CANADA; CLIN RES INST MONTREAL, MOLEC ENDOCRINOL LAB, MONTREAL H2W 1R7, PQ, CANADA; FREE UNIV BRUSSELS, CHIM PHYS MACROMOLEC INTERFACES LAB, B-1050 BRUSSELS, BELGIUM; INST PASTEUR, B-1180 BRUSSELS, BELGIUM; MONSANTO CO, MONSANTO CORP RES, GLYCOSCI, ST LOUIS, MO 63167 USA; WASHINGTON UNIV, SCH MED, CTR MOLEC DESIGN, ST LOUIS, MO 63130 USA	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Monsanto; Washington University (WUSTL)			Seidah, Nabil/I-3596-2013	Seidah, Nabil/0000-0001-6503-9342; DECROLY, Etienne/0000-0002-6046-024X; Marshall, Garland/0000-0002-3098-0332				ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; BENJANNET S, 1993, BIOCHEM J, V294, P735, DOI 10.1042/bj2940735; BENJANNET S, 1992, J BIOL CHEM, V267, P11417; BLOOMQUIST BT, 1991, MOL ENDOCRINOL, V5, P2014, DOI 10.1210/mend-5-12-2014; BOSCH V, 1990, J VIROL, V64, P2337, DOI 10.1128/JVI.64.5.2337-2344.1990; BRASSEUR R, 1990, BIOCHIM BIOPHYS ACTA, V1029, P267, DOI 10.1016/0005-2736(90)90163-I; BRESNAHAN PA, 1990, J CELL BIOL, V111, P2851, DOI 10.1083/jcb.111.6.2851; DAY R, 1992, MOL ENDOCRINOL, V6, P485, DOI 10.1210/me.6.3.485; DEWAR RL, 1989, J VIROL, V63, P2452, DOI 10.1128/JVI.63.6.2452-2456.1989; FAVERO J, 1990, INT J IMMUNOPHARMACO, V12, P769, DOI 10.1016/0192-0561(90)90041-K; FENOUILLET E, 1992, VIROLOGY, V187, P825, DOI 10.1016/0042-6822(92)90487-A; FREED EO, 1989, J VIROL, V63, P4670, DOI 10.1128/JVI.63.11.4670-4675.1989; FTOUHI N, 1994, IN PRESS DNA CELL BI; GARTEN W, 1989, VIROLOGY, V172, P25, DOI 10.1016/0042-6822(89)90103-7; GOTOH B, 1992, J VIROL, V66, P6391, DOI 10.1128/JVI.66.11.6391-6397.1992; GUO HG, 1990, VIROLOGY, V174, P217, DOI 10.1016/0042-6822(90)90070-8; HALLENBERGER S, 1992, NATURE, V360, P358, DOI 10.1038/360358a0; HAROUSE JM, 1989, J VIROL, V63, P2527, DOI 10.1128/JVI.63.6.2527-2533.1989; HAROUSE JM, 1991, SCIENCE, V253, P320, DOI 10.1126/science.1857969; HATSUZAWA K, 1992, J BIOL CHEM, V267, P16094; JEAN F, 1993, BIOCHEM J, V292, P891, DOI 10.1042/bj2920891; KIDO H, 1993, J BIOL CHEM, V268, P13406; KIEFER MC, 1991, DNA CELL BIOL, V10, P757, DOI 10.1089/dna.1991.10.757; KIRCHMAIR R, 1992, NEUROSCI LETT, V143, P143, DOI 10.1016/0304-3940(92)90252-3; KLENK HD, 1975, VIROLOGY, V68, P426, DOI 10.1016/0042-6822(75)90284-6; KLENK HD, 1984, EMBO J, V3, P2911, DOI 10.1002/j.1460-2075.1984.tb02231.x; KONINGS PNM, 1993, NEUROPEPTIDES, V25, P19, DOI 10.1016/0143-4179(93)90064-H; LEIS J, 1988, J VIROL, V62, P1808, DOI 10.1128/JVI.62.5.1808-1809.1988; LUSSON J, 1993, P NATL ACAD SCI USA, V90, P6691, DOI 10.1073/pnas.90.14.6691; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; MCCUNE JM, 1988, CELL, V53, P55, DOI 10.1016/0092-8674(88)90487-4; MCDOUGAL JS, 1986, SCIENCE, V231, P382, DOI 10.1126/science.3001934; MOORE JP, 1990, AIDS, V4, P307, DOI 10.1097/00002030-199004000-00004; MORIKAWA Y, 1993, J VIROL, V67, P3601, DOI 10.1128/JVI.67.6.3601-3604.1993; MOULARD M, 1994, FEBS LETT, V338, P281, DOI 10.1016/0014-5793(94)80284-X; ODA K, 1991, BIOCHEM BIOPH RES CO, V179, P1181, DOI 10.1016/0006-291X(91)91696-A; OWENS RJ, 1990, VIROLOGY, V179, P827, DOI 10.1016/0042-6822(90)90151-G; PAL R, 1989, P NATL ACAD SCI USA, V86, P3384, DOI 10.1073/pnas.86.9.3384; PAL R, 1988, P NATL ACAD SCI USA, V85, P9283, DOI 10.1073/pnas.85.23.9283; PHILLIPS DM, 1992, VIROLOGY, V186, P261, DOI 10.1016/0042-6822(92)90080-9; POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935; SASAKI Y, 1987, J MED CHEM, V30, P1162, DOI 10.1021/jm00390a008; SCHAFER MKH, 1993, J NEUROSCI, V13, P1258; SCHEID A, 1974, VIROLOGY, V57, P475, DOI 10.1016/0042-6822(74)90187-1; SEIDAH NG, 1991, ENZYME, V45, P271, DOI 10.1159/000468901; SEIDAH NG, 1992, DNA CELL BIOL, V11, P283, DOI 10.1089/dna.1992.11.283; SEIDAH NG, 1991, MOL ENDOCRINOL, V5, P111, DOI 10.1210/mend-5-1-111; STEIN BS, 1990, J BIOL CHEM, V265, P2640; STEINER DF, 1992, J BIOL CHEM, V267, P23435; STIENEKEGROBER A, 1992, EMBO J, V11, P2407, DOI 10.1002/j.1460-2075.1992.tb05305.x; TATENO M, 1989, P NATL ACAD SCI USA, V86, P4287, DOI 10.1073/pnas.86.11.4287; VANDENOUWELAND AMW, 1989, NUCLEIC ACIDS RES, V17, P7101, DOI 10.1093/nar/17.17.7101; VANDEVEN WJM, 1993, CRIT REV ONCOGENESIS, V4, P115; VERONESE FD, 1985, SCIENCE, V229, P1402, DOI 10.1126/science.2994223; VEY M, 1992, VIROLOGY, V188, P408, DOI 10.1016/0042-6822(92)90775-K; WILLEY RL, 1988, P NATL ACAD SCI USA, V85, P9580, DOI 10.1073/pnas.85.24.9580	57	116	123	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					12240	12247						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163529				2022-12-25	WOS:A1994NG37700086
J	ZHONG, ZY; QUON, D; HIGGINS, LS; HIGAKI, J; CORDELL, B				ZHONG, ZY; QUON, D; HIGGINS, LS; HIGAKI, J; CORDELL, B			INCREASED AMYLOID PRODUCTION FROM ABERRANT BETA-AMYLOID PRECURSOR PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL ALZHEIMERS-DISEASE; ENDOPLASMIC-RETICULUM; TERMINAL FRAGMENTS; CYSTIC-FIBROSIS; CULTURED-CELLS; PROTEASE; MUTATION; PEPTIDE; BRAIN; GENE	The 4-kDa beta-amyloid protein that forms fibrillar deposits in Alzheimer's diseased brains is derived from a large precursor, the beta-amyloid precursor protein (beta-APP). Recently, it has been reported that beta-amyloid is normally produced and secreted by cultured mammalian cells. In our studies involving recombinant expression of beta-APP, increased yields of beta-amyloid were associated with expression of aberrant beta-APP molecules. Deletion mutations within the beta-amyloid domain, incorrect beta-APP isoform expression in fibroblasts or neuronal cells, or excess amounts of beta-APP all led to increases in beta-amyloid production. Aberrant beta-APP appears to be diverted from the secretory pathway and then degraded to beta amyloid.	SCIOS NOVA INC,MT VIEW,CA 94043	Scios								BUSCIGLIO J, 1993, P NATL ACAD SCI USA, V90, P2092, DOI 10.1073/pnas.90.5.2092; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; CHARTIERHARLIN MC, 1991, NATURE, V353, P844, DOI 10.1038/353844a0; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; DESTROOPER B, 1993, J CELL BIOL, V121, P295, DOI 10.1083/jcb.121.2.295; GABUZDA D, 1991, J ACQ IMMUN DEF SYND, V4, P34; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HAASS C, 1993, J BIOL CHEM, V268, P3021; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; MANN DMA, 1989, J NEUROL SCI, V89, P169, DOI 10.1016/0022-510X(89)90019-1; MARUYAMA K, 1991, BIOCHEM BIOPH RES CO, V179, P1670, DOI 10.1016/0006-291X(91)91767-7; MOTTE J, 1989, ACTA NEUROPATHOL, V77, P535, DOI 10.1007/BF00687256; NEVE RL, 1988, NEURON, V1, P669, DOI 10.1016/0896-6273(88)90166-3; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; QUON D, 1991, NATURE, V352, P239, DOI 10.1038/352239a0; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; SAHASRABUDHE SR, 1992, J BIOL CHEM, V267, P25602; SAMBAMURTI K, 1992, J NEUROSCI RES, V33, P319, DOI 10.1002/jnr.490330216; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SEUBERT P, 1993, NATURE, V361, P260, DOI 10.1038/361260a0; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; THOMAS PJ, 1992, J BIOL CHEM, V267, P5727; WOLF D, 1990, EMBO J, V9, P2079, DOI 10.1002/j.1460-2075.1990.tb07375.x; ZHHONG Z, 1994, J BIOL CHEM, V269, P627	32	23	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					12179	12184						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163522				2022-12-25	WOS:A1994NG37700077
J	GETTS, RC; STAMATO, TD				GETTS, RC; STAMATO, TD			ABSENCE OF A KU-LIKE DNA END BINDING-ACTIVITY IN THE XRS DOUBLE-STRAND DNA REPAIR-DEFICIENT MUTANT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							RAY SENSITIVE MUTANTS; CHINESE-HAMSTER CELL; RNA POLYMERASE-II; IONIZING-RADIATION; BREAK REPAIR; TRANSCRIPTION FACTOR; AUTOANTIGEN-KU; PROTEIN-KINASE; SCID MUTATION; MECHANISM	Double-strand DNA break repair is important in maintaining the genetic integrity of the genome. Using a mobility shift assay, we find that a protein, or complex of proteins, that is present in mammalian and yeast cells binds to the ends of double-strand DNA and renders the ends resistant to exonuclease digestion. Additionally, a mammalian DNA double-strand repair-deficient mutant, xrs, has no observable DNA end binding activity, while a revertant cell has wild-type activity. In addition, mobility supershift assays using monoclonal antibodies to the human Ku antigen (M(r) 70,000 subunit) reveal that one of the proteins of this end binding activity may be the Ku antigen or a protein with similar antigenic determinants. These observations suggest that this DNA end-binding protein may function in DNA repair.	LANKENAU MED RES CTR,WYNNEWOOD,PA 19096	Lankenau Medical Center; Lankenau Institute for Medical Research								BADING H, 1988, NUCLEIC ACIDS RES, V16, P5241, DOI 10.1093/nar/16.12.5241; BIEDERMANN KA, 1991, P NATL ACAD SCI USA, V88, P1394, DOI 10.1073/pnas.88.4.1394; DEVRIES E, 1989, J MOL BIOL, V208, P65, DOI 10.1016/0022-2836(89)90088-0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DVIR A, 1992, P NATL ACAD SCI USA, V89, P11920, DOI 10.1073/pnas.89.24.11920; FALZON M, 1993, J BIOL CHEM, V268, P10546; FULOP GM, 1990, NATURE, V347, P479, DOI 10.1038/347479a0; GIACCIA A, 1985, SOMAT CELL MOLEC GEN, V11, P485, DOI 10.1007/BF01534842; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; HANAWALT PC, 1979, ANNU REV BIOCHEM, V48, P483; HUTCHINSON F, 1985, PROG NUCLEIC ACID RE, V32, P115, DOI 10.1016/S0079-6603(08)60347-5; KEMP LM, 1984, MUTAT RES, V132, P189, DOI 10.1016/0167-8817(84)90037-3; MAY G, 1991, J BIOL CHEM, V266, P3052; MIMORI T, 1986, J BIOL CHEM, V261, P375; PAILLARD S, 1991, NUCLEIC ACIDS RES, V19, P5619, DOI 10.1093/nar/19.20.5619; Sambrook J, 1989, MOL CLONING LABORATO; SASTRY SS, 1989, BIOCHEMISTRY-US, V28, P5670, DOI 10.1021/bi00439a050; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; STRICKLAND MS, 1988, BIOCHEMISTRY-US, V27, P5755, DOI 10.1021/bi00415a054; TACCIOLI GE, 1993, SCIENCE, V260, P207, DOI 10.1126/science.8469973; THACKER J, 1991, MUTAT RES, V254, P135, DOI 10.1016/0921-8777(91)90004-9; WHITMORE GF, 1989, INT J RADIAT BIOL, V56, P657, DOI 10.1080/09553008914551881; ZDZIENICKA MZ, 1992, RADIAT RES, V131, P309, DOI 10.2307/3578421; ZDZIENICKA MZ, 1988, MUTAT RES, V194, P239	24	220	222	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 10	1994	269	23					15981	15984						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ729	8206892				2022-12-25	WOS:A1994NQ72900007
J	DIRACSVEJSTRUP, AB; SOLDATI, T; SHAPIRO, AD; PFEFFER, SR				DIRACSVEJSTRUP, AB; SOLDATI, T; SHAPIRO, AD; PFEFFER, SR			RAB-GDI PRESENTS FUNCTIONAL RAB9 TO THE INTRACELLULAR-TRANSPORT MACHINERY AND CONTRIBUTES SELECTIVITY TO RAB9 MEMBRANE RECRUITMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GTP-BINDING PROTEINS; VESICULAR TRANSPORT; SACCHAROMYCES-CEREVISIAE; DISSOCIATION INHIBITOR; ENDOCYTIC PATHWAY; GOLGI NETWORK; BOVINE BRAIN; SEC4; ENDOSOMES; CYTOSOL	Rab proteins occur in the cytosol bound to Rab-GDP dissociation inhibitor (GDI). We demonstrate here that cytosolic complexes of Rab9 bound to GDI represent a functional pool of Rab9 protein that can be utilized for transport from late endosomes to the trans Golgi network in vitro. Immunodepletion of GDI and Rab proteins bound to GDI led to the loss of cytosol activity; readdition of pure Rab9-GDI complexes fully restored cytosol activity. Delipidated serum albumin could solubilize prenylated Rab9 protein, but unlike Rab9-GDI complexes, Rab9-serum albumin complexes led to indiscriminate membrane association of Rab9 protein. Rab9 delivered to membranes by serum albumin was functional, but GDI increased the efficiency of Rab9 utilization, presumably because it suppressed Rab9 protein mistargeting. Finally, GDI inhibited transport of proteins from late endosomes to the trans Golgi network, likely because of its capacity to inhibit the membrane recruitment of cytosolic Rab9. These experiments show that GDI contributes to the selectivity of Rab9 membrane recruitment and presents functional Rab9 to the endosome-trans Golgi network transport machinery.	STANFORD UNIV,SCH MED,DEPT BIOCHEM,STANFORD,CA 94305	Stanford University			SOLDATI, Thierry/A-2902-2009; SOLDATI, Thierry/U-6494-2019	SOLDATI, Thierry/0000-0002-2056-7931; SOLDATI, Thierry/0000-0002-2056-7931	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK037332, R01DK037332, R56DK037332] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK37332] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENNWALD P, 1993, NATURE, V362, P560, DOI 10.1038/362560a0; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; CHAVRIER P, 1991, NATURE, V353, P769, DOI 10.1038/353769a0; DUNN B, 1993, NATURE, V362, P533; ELZAR Z, 1994, J BIOL CHEM, V266, P794; GARRETT MD, 1993, FEBS LETT, V331, P233, DOI 10.1016/0014-5793(93)80343-S; GARRETT MD, 1994, EMBO J, V13, P1718, DOI 10.1002/j.1460-2075.1994.tb06436.x; GODA Y, 1991, J CELL BIOL, V112, P823, DOI 10.1083/jcb.112.5.823; GODA Y, 1988, CELL, V55, P399; LOMBARDI D, 1993, EMBO J, V12, P677, DOI 10.1002/j.1460-2075.1993.tb05701.x; Magee Tony, 1992, Trends in Cell Biology, V2, P318, DOI 10.1016/0962-8924(92)90172-J; MATSUI Y, 1990, MOL CELL BIOL, V10, P4116, DOI 10.1128/MCB.10.8.4116; Pfeffer S R, 1992, Trends Cell Biol, V2, P41, DOI 10.1016/0962-8924(92)90161-F; PLUTNER H, 1991, J CELL BIOL, V115, P31, DOI 10.1083/jcb.115.1.31; REGAZZI R, 1992, J BIOL CHEM, V267, P17512; RIEDERER MA, 1994, J CELL BIOL, V125, P573, DOI 10.1083/jcb.125.3.573; SASAKI T, 1990, J BIOL CHEM, V265, P2333; SOLDATI T, 1994, NATURE, V369, P76, DOI 10.1038/369076a0; SOLDATI T, 1993, MOL BIOL CELL, V4, P425, DOI 10.1091/mbc.4.4.425; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; ULLRICH O, 1994, NATURE, V368, P157, DOI 10.1038/368157a0; ULLRICH O, 1993, J BIOL CHEM, V268, P18143; VANDERSLUIJS P, 1992, CELL, V70, P729, DOI 10.1016/0092-8674(92)90307-X; WALWORTH NC, 1992, MOL CELL BIOL, V12, P2017, DOI 10.1128/MCB.12.5.2017; Zerial M, 1993, CURR OPIN CELL BIOL, V5, P613, DOI 10.1016/0955-0674(93)90130-I	26	71	71	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15427	15430						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	8195183				2022-12-25	WOS:A1994NP51300008
J	LU, Q; WALLRATH, LL; EMANUEL, PA; ELGIN, SCR; GILMOUR, DS				LU, Q; WALLRATH, LL; EMANUEL, PA; ELGIN, SCR; GILMOUR, DS			INSENSITIVITY OF THE PRESET HSP26 CHROMATIN STRUCTURE TO A TATA BOX MUTATION IN DROSOPHILA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOSOME-FREE REGIONS; I HYPERSENSITIVE SITES; RNA POLYMERASE-II; HEAT-SHOCK; BINDING PROTEIN; SEQUENCES DOWNSTREAM; CRYSTAL-STRUCTURE; TRANSCRIPTION; GENE; PROMOTER	The role of the TATA element in establishing the chromatin structure and inducible transcription of the Drosophila melanogaster hsp26 gene has been analyzed. An hsp26/lacZ fusion gene with a mutant promoter, in which the TATA box sequence TATAAA was changed to CCCAAA, was introduced into Drosophila by P-element transformation. The mutation had little effect on formation of the preset chromatin structure observed prior to induction. However, the mutation dramatically reduced transcription levels following heat shock. Northern analysis indicated that weak, inducible expression of the mutant promoter occurred within the same period of heat shock as for the normal promoter, suggesting that TFIID was associated with the mutant promoter prior to heat shock. Biochemical analysis showed that the mutant promoter still bound TFIID in vitro, but with 3-5-fold less affinity than the normal promoter. DNase I footprinting revealed that the conformation of the TFIID.DNA complex differed significantly from that of the normal promoter. These results indicate that alterations in the conformation or the stability of the TFIID.DNA complex drastically reduce the level of induction, but do not dramatically affect chromatin structure formation. Formation of the requisite chromatin structure is either independent of, or highly tolerant of, changes in the TFIID.DNA complex.	PENN STATE UNIV,CTR GENE REGULAT,DEPT BIOCHEM & MOLEC BIOL,UNIV PK,PA 16802; WASHINGTON UNIV,DEPT BIOL,ST LOUIS,MO 63130	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Washington University (WUSTL)				Elgin, Sarah C. R./0000-0002-5176-2510; Wallrath, Lori/0000-0002-4391-7199	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047477, F32GM014516, R01GM031532] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47477, GM14516, GM 31532] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BATSON SC, 1993, NUCLEIC ACIDS RES, V21, P3459; BECKER PB, 1991, P NATL ACAD SCI USA, V88, P4109, DOI 10.1073/pnas.88.10.4109; CARTWRIGHT IL, 1986, MOL CELL BIOL, V6, P779, DOI 10.1128/MCB.6.3.779; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; ELGIN SCR, 1988, J BIOL CHEM, V263, P19259; EMANUEL PA, 1993, P NATL ACAD SCI USA, V90, P8449, DOI 10.1073/pnas.90.18.8449; FASCHER KD, 1993, J MOL BIOL, V231, P658, DOI 10.1006/jmbi.1993.1317; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GIARDINA C, 1992, GENE DEV, V6, P2190, DOI 10.1101/gad.6.11.2190; GILMOUR DS, 1986, MOL CELL BIOL, V6, P3984, DOI 10.1128/MCB.6.11.3984; GILMOUR DS, 1988, MOL CELL BIOL, V8, P3204, DOI 10.1128/MCB.8.8.3204; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; GRUNSTEIN M, 1990, TRENDS GENET, V6, P395, DOI 10.1016/0168-9525(90)90299-L; HIRSCHHORN JN, 1992, GENE DEV, V6, P2288, DOI 10.1101/gad.6.12a.2288; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEE H, 1992, GENE DEV, V60, P284; LEE MS, 1992, P NATL ACAD SCI USA, V89, P9166, DOI 10.1073/pnas.89.19.9166; LU Q, 1992, J MOL BIOL, V225, P985, DOI 10.1016/0022-2836(92)90099-6; LU Q, 1993, MOL CELL BIOL, V13, P2808; LU Q, 1993, J CELL BIOCHEM, V54, P1; Lu Qin, 1993, V1, P333; Maniatis T., 1982, MOL CLONING; OBRIEN T, 1993, MOL CELL BIOL, V13, P3456, DOI 10.1128/MCB.13.6.3456; PUGH BF, 1992, J BIOL CHEM, V267, P679; PURNELL BA, 1993, MOL CELL BIOL, V13, P2593, DOI 10.1128/MCB.13.4.2593; PURNELL BA, 1994, GENE DEV, V8, P830, DOI 10.1101/gad.8.7.830; RIGBY PWJ, 1993, CELL, V72, P7, DOI 10.1016/0092-8674(93)90042-O; ROUGVIE AE, 1990, MOL CELL BIOL, V10, P6041, DOI 10.1128/MCB.10.11.6041; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; SCHMIDT MC, 1989, MOL CELL BIOL, V9, P3299, DOI 10.1128/MCB.9.8.3299; SHARP PA, 1992, CELL, V68, P819, DOI 10.1016/0092-8674(92)90023-6; SIMON JA, 1987, NUCLEIC ACIDS RES, V15; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; SYPES MA, 1994, NUCLEIC ACIDS RES, V22, P807, DOI 10.1093/nar/22.5.807; THOMAS GH, 1988, EMBO J, V7, P2191, DOI 10.1002/j.1460-2075.1988.tb03058.x; TSUKIYAMA T, 1994, NATURE, V367, P525, DOI 10.1038/367525a0; VASLET CA, 1980, NATURE, V285, P674, DOI 10.1038/285674a0; VAZQUEZ J, 1993, CHROMOSOMA, V102, P233, DOI 10.1007/BF00352397; WALLRATH LL, 1990, MOL CELL BIOL, V10, P5114, DOI 10.1128/MCB.10.10.5114; WORKMAN JL, 1987, CELL, V51, P613, DOI 10.1016/0092-8674(87)90130-9; WORKMAN JL, 1993, TRENDS BIOCHEM SCI, V18, P90, DOI 10.1016/0968-0004(93)90160-O; WU C, 1984, NATURE, V309, P229, DOI 10.1038/309229a0; ZHOU Q, 1993, GENE DEV, V7, P180, DOI 10.1101/gad.7.2.180	46	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15906	15911						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	8195245				2022-12-25	WOS:A1994NP51300078
J	MAROULAKOU, IG; PAPAS, TS; GREEN, JE				MAROULAKOU, IG; PAPAS, TS; GREEN, JE			DIFFERENTIAL EXPRESSION OF ETS-1 AND ETS-2 PROTOONCOGENES DURING MURINE EMBRYOGENESIS	ONCOGENE			English	Article							LONG TERMINAL REPEAT; DNA-BINDING MOTIF; C-FOS; TRANSCRIPTIONAL ACTIVATION; C-ETS-1 PROTOONCOGENE; PROMOTER SEQUENCES; TRANSFORMING GENE; CELLS; DOMAIN; PROTEINS	ets-l and ets-2 genes have previously been identified by their sequence homology to the v-ets oncogene of the avian erythroblastosis virus, E26. These cellular genes have been shown to function as transcription factors important in lymphoid differentiation and activation and cellular proliferation. In this study, we have broadly analysed the differential expression of ets-l and ets-2 during murine development using in situ hybridization. Our results indicate that these transcription factors are expressed in multiple tissues during critical stages of embryo formation and organogenesis, suggesting that these genes may serve multiple functions during mouse development. The patterns of expression of both genes are quite different as early as day 8.0 of gestation. ets-l expression is clearly observed during a narrow developmental stage in the developing nervous system, including the presumptive hindbrain regions, the neural tube, as well as neural crest and the first and second branchial arches. ets-2 expression is limited to the developing limb buds and distal tail. At later times, ets-l expression is observed in developing vascular structures, including the heart, arteries, capillaries and meninges, whereas ets-2 is highly expressed in developing bone, tooth buds, epithelial layers of the gut, nasal sinus and uterus, and several regions of the developing brain. Both ets-l and ets-2 are expressed in developing lung, gut and skin. High levels of expression in both genes is observed in adult lymphoid tissues, but in different tissue subsets. ets-l is expressed in the adult lung, gut mesenchyme and bone marrow. ets-2 continues to be expressed at low levels in several adult tissues, except in the differentiated brain, where substantial levels of expression are found in particular regions of the mature brain. These results demonstrate that ets-l and ets-2 are differentially regulated, are widely expressed in many tissues during murine embryogenesis and may play important roles in cellular proliferation and differentiation during mouse development.	NCI,MOLEC ONCOL LAB,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								Ascione R., 1993, Genome research in molecular medicine and virology., P199; BHAT NK, 1989, J IMMUNOL, V142, P672; BHAT NK, 1987, P NATL ACAD SCI USA, V84, P3161, DOI 10.1073/pnas.84.10.3161; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; CONLON RA, 1992, DEVELOPMENT, V116, P357; DAVAL JL, 1989, J NEUROCHEM, V52, P1954, DOI 10.1111/j.1471-4159.1989.tb07285.x; FISHER CL, 1991, J IMMUNOL, V146, P1743; FLEISCHMAN LF, 1993, ONCOGENE, V8, P771; FUJIWARA S, 1988, ONCOGENE, V2, P99; FUJIWARA S, 1988, MOL CELL BIOL, V8, P4700, DOI 10.1128/MCB.8.11.4700; GREENBERG JM, 1990, NATURE, V344, P158, DOI 10.1038/344158a0; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; HAGMAN J, 1992, P NATL ACAD SCI USA, V89, P8889, DOI 10.1073/pnas.89.19.8889; HIGASHINO F, 1993, NUCLEIC ACIDS RES, V21, P547, DOI 10.1093/nar/21.3.547; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; JORCYK CL, 1991, ONCOGENE, V6, P523; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KLAMBT C, 1993, DEVELOPMENT, V117, P163; KOIZUMI S, 1990, ONCOGENE, V5, P675; KOLA I, 1993, P NATL ACAD SCI USA, V90, P7588, DOI 10.1073/pnas.90.16.7588; LAUTENBERGER JA, 1992, ONCOGENE, V7, P1713; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LEPRINCE D, 1990, ONCOGENE RES, V5, P255; MAVROTHALASSITIS GJ, 1990, P NATL ACAD SCI USA, V87, P1047, DOI 10.1073/pnas.87.3.1047; NELSEN B, 1993, SCIENCE, V261, P82, DOI 10.1126/science.8316859; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; NUNN MF, 1989, J VIROL, V63, P398, DOI 10.1128/JVI.63.1.398-402.1989; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; OOSTERWEGEL M, 1993, DEVELOPMENT, V118, P439; PAPAS TS, 1989, CURR TOP MICROBIOL, P143; PARMA DL, 1991, INT J DEV NEUROSCI, V9, P613, DOI 10.1016/0736-5748(91)90023-F; PRIBYL LJ, 1988, DEV BIOL, V127, P45, DOI 10.1016/0012-1606(88)90187-X; QUEVA C, 1993, ONCOGENE, V8, P2511; ROWE A, 1992, EXP CELL RES, V202, P199, DOI 10.1016/0014-4827(92)90420-D; SACCHI N, 1991, ONCOGENE, V6, P2149; Sambrook J, 1989, MOL CLONING LABORATO; SETH A, 1993, ONCOGENE, V8, P1783; SETH A, 1992, CELL GROWTH DIFFER, V3, P327; SETH A, 1990, ONCOGENE, V5, P1761; VANDENBUNDER B, 1989, DEVELOPMENT, V106, P265; VIRBASIUS JV, 1991, MOL CELL BIOL, V11, P5631, DOI 10.1128/MCB.11.11.5631; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WATSON D K, 1990, Critical Reviews in Oncogenesis, V1, P409; WATSON DK, 1985, P NATL ACAD SCI USA, V82, P7294, DOI 10.1073/pnas.82.21.7294; WERNERT N, 1992, AM J PATHOL, V140, P119; YOUNG WS, 1990, METHODS ANAL NEURONA, P481	48	191	194	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1994	9	6					1551	1565						15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NL815	8183549				2022-12-25	WOS:A1994NL81500005
J	AMBROZIAK, J; HENRY, SA				AMBROZIAK, J; HENRY, SA			INO2 AND INO4 GENE-PRODUCTS, POSITIVE REGULATORS OF PHOSPHOLIPID BIOSYNTHESIS IN SACCHAROMYCES-CEREVISIAE, FORM A COMPLEX THAT BINDS TO THE INO1 PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOOP-HELIX PROTEINS; DNA-BINDING; YEAST; MYC; MYOD; TRANSFORMATION; RECOGNITION; ACTIVATION; SEQUENCES; SYNTHASE	The INO4 gene encodes a protein required for derepression of a number of structural genes encoding enzymes involved in phospholipid biosynthesis in the yeast Saccharomyces cerevisiae. Ino4p shows structural similarity to the basic helix-loop-helix (bHLH) family of regulatory proteins (Hoshizaki, D. K., Hill, J. E., and Henry, S. A, (1990) J. Biol. Chem. 265, 4736-4745). In this report we demonstrate that Ino4p translated in vitro forms a complex with Ino2p, another positive regulator of phospholipid biosynthesis that contains a bHLH domain. The Ino2p.Ino4p complex binds to a fragment of the INO1 promoter containing two copies of the consensus binding site for the bHLH family of proteins. The complex formed when this DNA fragment is incubated with in vitro translated Ino2p and Ino4p is identical in mobility to the complex formed when this DNA fragment is incubated with whole cell extracts. The binding of DNA by the Ino2p.Ino4p complex is competed by an oligonucleotide containing the consensus binding sequence for bHLH proteins. Neither Ino2p nor Ino4p translated alone is capable of forming a complex with the INO1 promoter fragment. The two products, translated separately and mixed, show only reduced capability to form a complex compared with cotranslated proteins. Immunoprecipitation experiments demonstrate that Ino2p and Ino4p interact in the absence of DNA. Ino2p and Ino4p are, thus, both necessary and sufficient for formation of a complex with the INO1 promoter.	CARNEGIE MELLON UNIV,DEPT BIOL SCI,PITTSBURGH,PA 15213	Carnegie Mellon University			Henry, Susan/K-5464-2014		NIGMS NIH HHS [GM-19629] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM019629, R37GM019629] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel F. M., 1988, CURRENT PROTOCOLS MO; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BAILIS AM, 1987, MOL CELL BIOL, V7, P167, DOI 10.1128/MCB.7.1.167; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; CAI MJ, 1990, CELL, V61, P437, DOI 10.1016/0092-8674(90)90525-J; CARMAN GM, 1989, ANNU REV BIOCHEM, V58, P635, DOI 10.1146/annurev.biochem.58.1.635; CULBERTSON MR, 1975, GENETICS, V80, P23; DANG CV, 1992, P NATL ACAD SCI USA, V89, P599, DOI 10.1073/pnas.89.2.599; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; DONAHUE TF, 1981, GENETICS, V98, P491; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; FISHER F, 1991, ONCOGENE, V6, P1099; HAMMOND C, 1994, IN PRESS CELL MOL BI; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HATHAWAY GM, 1979, J BIOL CHEM, V254, P762; HIRSCH JP, 1986, MOL CELL BIOL, V6, P3320, DOI 10.1128/MCB.6.10.3320; HOSHIZAKI DK, 1990, J BIOL CHEM, V265, P4736; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LOEWY BS, 1984, MOL CELL BIOL, V4, P2479, DOI 10.1128/MCB.4.11.2479; LOPES JM, 1991, NUCLEIC ACIDS RES, V19, P1687, DOI 10.1093/nar/19.7.1687; LOPES JM, 1991, NUCLEIC ACIDS RES, V19, P3987, DOI 10.1093/nar/19.14.3987; MANDEL M, 1970, J MOL BIOL, V53, P159, DOI 10.1016/0022-2836(70)90051-3; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NIKOLOFF DM, 1992, NUCLEIC ACIDS RES, V20, P3253, DOI 10.1093/nar/20.12.3253; NIKOLOFF DM, 1994, J BIOL CHEM, V269, P7402; NIKOLOFF DM, 1991, ANNU REV GENET, V25, P559; OGAWA N, 1990, MOL CELL BIOL, V10, P2224, DOI 10.1128/MCB.10.5.2224; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SERGHINI MA, 1989, NUCLEIC ACIDS RES, V17, P3604, DOI 10.1093/nar/17.9.3604; Sherman F., 1978, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; VORONOVA A, 1990, P NATL ACAD SCI USA, V87, P4722, DOI 10.1073/pnas.87.12.4722	35	162	164	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					15344	15349						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195172				2022-12-25	WOS:A1994NP73800073
J	KAWAMOTO, S				KAWAMOTO, S			EVIDENCE FOR AN INTERNAL REGULATORY REGION IN A HUMAN NONMUSCLE MYOSIN HEAVY-CHAIN GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIHYDROFOLATE-REDUCTASE PROMOTER; AMINO-ACID-SEQUENCES; SMOOTH-MUSCLE; MESSENGER-RNAS; TRANSCRIPTION INITIATION; DIFFERENTIAL EXPRESSION; CELLULAR MYOSIN; NERVOUS-SYSTEM; SV40 ENHANCER; DNA-SEQUENCE	We have isolated genomic clones which encode the promoter and flanking region of human nonmuscle myosin heavy chain (MHC)-A. The sequence of this region shows many features typical of a housekeeping gene; there is no TATA element and no functional CAAT box. The GC content is high, having an average GC content of 74% in the 600 base pairs (bp) surrounding the transcriptional start sites, and multiple GC boxes (putative Sp1 binding sites) are present. A number of nucleotide sites are utilized for the initiation of transcription. Promoter activity was monitored using luciferase as a reporter following transient transfection into NIH 3T3 cells. Analysis of 5' and 3' deletion mutants in the promoter region defines the core promoter as extending from nucleotide -112 to +61, where +1 is a major transcriptional start site. An essential sequence for core promoter activity resides in the 36-bp region from -77 to -112 which includes a single potential AP-2 binding site and a single potential Spl binding site. The region just downstream from the transcriptional start site (between +62 and +257) was found to be involved in cell type-specific activation of nonmuscle MHC-A gene expression. The increase in luciferase activity due to this proximal downstream region is approximately 15-fold in NIH 3T3 cells, but no increase was observed in C2C12 myotubes and neuroblastoma cells. This 196-bp region, which consists of 100 bp from exon 1 and 96 bp from intron 1, functions in a position- and orientation-dependent manner. Quantitation of luciferase mRNA content driven by the MHC-A promoter, using both competitive polymerase chain reaction and RNase protection assays, revealed that the increase seen in luciferase mRNA due to the 196-bp fragment is approximately 5-fold in NIH 3T3 cells. This only accounts for about one-third of the total increase seen in luciferase activity (protein amounts). Thus, this proximal downstream region appears to activate gene expression in MH 3T3 cells via both pretranslational (transcription and/or mRNA stability) and translational mechanisms.			KAWAMOTO, S (corresponding author), NHLBI,MOLEC CARDIOL LAB,BETHESDA,MD 20892, USA.							AUSUBEL FM, 1993, CURR PROTCOLS MOL BI, V1; BABIJ P, 1989, J MOL BIOL, V210, P673, DOI 10.1016/0022-2836(89)90142-3; BABIJ P, 1991, P NATL ACAD SCI USA, V88, P10676, DOI 10.1073/pnas.88.23.10676; BHATIADEY N, 1993, P NATL ACAD SCI USA, V90, P2856, DOI 10.1073/pnas.90.7.2856; BLAKE MC, 1990, MOL CELL BIOL, V10, P6632, DOI 10.1128/MCB.10.12.6632; BOYER TG, 1989, J BIOL CHEM, V264, P5177; BURRIDGE K, 1975, J MOL BIOL, V99, P1, DOI 10.1016/S0022-2836(75)80154-9; CHENEY R E, 1992, Current Opinion in Cell Biology, V4, P27, DOI 10.1016/0955-0674(92)90055-H; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHUNG S, 1989, MOL CELL BIOL, V9, P2075, DOI 10.1128/MCB.9.5.2075; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DYNAN WS, 1986, TRENDS GENET, V2, P196, DOI 10.1016/0168-9525(86)90226-X; EMERSON CP, 1987, ANNU REV BIOCHEM, V56, P695, DOI 10.1146/annurev.bi.56.070187.003403; FARNHAM PJ, 1990, MOL CELL BIOL, V10, P1390, DOI 10.1128/MCB.10.4.1390; FRANKLIN GC, 1991, EMBO J, V10, P1365, DOI 10.1002/j.1460-2075.1991.tb07656.x; Frohman M.A., 1990, PCR PROTOCOLS GUIDE, P28; Gilliland G., 1990, PCR PROTOCOLS GUIDE, P60; GOODSON HV, 1993, P NATL ACAD SCI USA, V90, P659, DOI 10.1073/pnas.90.2.659; HAMADA Y, 1990, BIOCHEM BIOPH RES CO, V170, P53, DOI 10.1016/0006-291X(90)91239-O; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HENTZE MW, 1987, SCIENCE, V238, P1570, DOI 10.1126/science.3685996; HERR W, 1986, CELL, V45, P461, DOI 10.1016/0092-8674(86)90332-6; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HULTMARK D, 1986, CELL, V44, P429, DOI 10.1016/0092-8674(86)90464-2; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KATSURAGAWA Y, 1989, EUR J BIOCHEM, V184, P611, DOI 10.1111/j.1432-1033.1989.tb15057.x; KAWAMOTO S, 1991, J CELL BIOL, V112, P915, DOI 10.1083/jcb.112.5.915; KAWAMOTO S, 1987, J BIOL CHEM, V262, P7282; KETCHUM AS, 1990, P NATL ACAD SCI USA, V87, P6316, DOI 10.1073/pnas.87.16.6316; KIEHART DP, 1989, EMBO J, V8, P913, DOI 10.1002/j.1460-2075.1989.tb03452.x; KUROO M, 1989, J BIOL CHEM, V264, P18272; MAHDAVI V, 1986, MOL BIOL MUSCLE DEV, P345; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; MEANS AL, 1990, MOL CELL BIOL, V10, P653, DOI 10.1128/MCB.10.2.653; SAEZ CG, 1990, P NATL ACAD SCI USA, V87, P1164, DOI 10.1073/pnas.87.3.1164; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHOHET RV, 1989, P NATL ACAD SCI USA, V86, P7726, DOI 10.1073/pnas.86.20.7726; SIMONS M, 1991, CIRC RES, V69, P530, DOI 10.1161/01.RES.69.2.530; SPUDICH JA, 1989, CELL REGUL, V1, P1; STREHLER EE, 1985, J BIOL CHEM, V260, P468; SUN WD, 1992, J MOL BIOL, V224, P1185, DOI 10.1016/0022-2836(92)90482-Y; TAKAHASHI M, 1992, J BIOL CHEM, V267, P17864; TOOTHAKER LE, 1991, BLOOD, V78, P1826; WHALEN RG, 1986, MOL BIOL MUSCLE DEV, P237; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; YANAGISAWA M, 1987, J MOL BIOL, V198, P143, DOI 10.1016/0022-2836(87)90302-0; YANG JQ, 1986, EMBO J, V5, P3553, DOI 10.1002/j.1460-2075.1986.tb04682.x; YUTZEY KE, 1989, MOL CELL BIOL, V9, P1397, DOI 10.1128/MCB.9.4.1397; ZENKE M, 1986, EMBO J, V5, P387, DOI 10.1002/j.1460-2075.1986.tb04224.x	49	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					15101	15110						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195147				2022-12-25	WOS:A1994NP73800040
J	TSUBOI, S; MATSUMOTO, H; JACKSON, KW; TSUJIMOTO, K; WILLIAMS, T; YAMAZAKI, A				TSUBOI, S; MATSUMOTO, H; JACKSON, KW; TSUJIMOTO, K; WILLIAMS, T; YAMAZAKI, A			PHOSPHORYLATION OF AN INHIBITORY SUBUNIT OF CGMP PHOSPHODIESTERASE IN RANA-CATESBIANA ROD PHOTORECEPTORS .1. CHARACTERIZATION OF THE PHOSPHORYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-GMP PHOSPHODIESTERASE; PROTEIN-KINASE-C; LIGHT-INDUCED DEPHOSPHORYLATION; GTP-BINDING PROTEIN; OUTER SEGMENTS; GAMMA-SUBUNIT; DROSOPHILA PHOTORECEPTOR; ACTIVATION MECHANISM; AMINO-ACID; TRANSDUCIN	Interaction between the inhibitory subunit (P gamma) and catalytic subunits of cGMP phosphodiesterase is essential for the regulation of cGMP phosphodiesterase in vertebrate rod photoreceptors. P gamma phosphorylation in vitro has been studied using a kinase which is extracted from amphibian rod outer segments. Various chromatographies of the kinase preparation using ionic exchange, gel filtration, and heparin-Sepharose columns indicate that a kinase with M(r) 70,000 is responsible for the P gamma phosphorylation. The kinase does not require any of the known activators for protein kinases but is inhibited by cGMP in a concentration-dependent manner. Together with analysis by laser-desorption mass spectrometry, measurement of P-32 radioactivity in phosphorylated P gamma indicates that P gamma extracted with GTP-bound transducin alpha subunit is not phosphorylated and that a phosphate is incorporated into more than 80% of the P gamma by the kinase. Phosphoamino acid analysis, sequencing of phosphorylated peptides derived from phosphorylated P gamma, and phosphorylation of synthetic peptides indicate threonine 22 in P gamma is phosphorylated by the kinase. Phosphorylated P gamma has a higher inhibitory activity for active cGMP phosphodiesterase than nonphosphorylated P gamma. These data suggest that threonine 22 in P gamma is phosphorylated by a specific kinase and that the P gamma phosphorylation governs the interaction between P gamma and catalytic subunits of cGMP phosphodiesterase in vertebrate rod photoreceptors.	WAYNE STATE UNIV, SCH MED, KRESGE EYE INST, DEPT OPHTHALMOL, DETROIT, MI 48201 USA; WAYNE STATE UNIV, SCH MED, KRESGE EYE INST, DEPT PHARMACOL, DETROIT, MI 48201 USA; UNIV OKLAHOMA, HLTH SCI CTR, DEPT BIOCHEM & MOLEC BIOL, OKLAHOMA CITY, OK 73190 USA; UNIV OKLAHOMA, HLTH SCI CTR, WILLIAM K WARREN MED RES INST, OKLAHOMA CITY, OK 73190 USA; UNIV OKLAHOMA, HLTH SCI CTR, DEPT MED, OKLAHOMA CITY, OK 73190 USA; UNIV ELECTROCOMMUN, DEPT APPL PHYS & CHEM, CHOFU, TOKYO 182, JAPAN; JASCO INT CO LTD, HACHIOJI, TOKYO 193, JAPAN	Wayne State University; Wayne State University; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Electro-Communications - Japan					NEI NIH HHS [EY 07546, EY 09631, EY 06596] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY009631, R01EY007546] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ARTEMYEV NO, 1992, J BIOL CHEM, V267, P25067; BINDER BM, 1989, J BIOL CHEM, V264, P8857; BOWNDS D, 1972, NATURE-NEW BIOL, V237, P125, DOI 10.1038/newbio237125a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN RL, 1992, BIOCHEMISTRY-US, V31, P5918, DOI 10.1021/bi00140a031; BYK T, 1993, P NATL ACAD SCI USA, V90, P1907, DOI 10.1073/pnas.90.5.1907; CUNNICK JM, 1990, BIOCHEM J, V271, P721, DOI 10.1042/bj2710721; GILLESPIE PG, 1989, P NATL ACAD SCI USA, V86, P4311, DOI 10.1073/pnas.86.11.4311; HAMILTON SE, 1990, J BIOL CHEM, V265, P11259; HAMM H, 1990, J GEN PHYSIOL, V95, P545, DOI 10.1085/jgp.95.3.545; HARGRAVE PA, 1992, INT REV CYTOL, V137B, P49; HAYASHI F, 1991, P NATL ACAD SCI USA, V88, P4333, DOI 10.1073/pnas.88.10.4333; HAYASHI F, 1987, BIOCHEM BIOPH RES CO, V148, P54, DOI 10.1016/0006-291X(87)91075-8; HAYASHI F, 1988, MOL PHYSL RETINAL PR, P405; HURLEY JB, 1987, ANNU REV PHYSIOL, V49, P793; KELLEHER DJ, 1986, J BIOL CHEM, V261, P4749; LEE RH, 1990, J BIOL CHEM, V265, P15867; LEE RH, 1987, BIOCHEMISTRY-US, V26, P3983, DOI 10.1021/bi00387a036; LEE RH, 1984, BIOCHEMISTRY-US, V23, P1972, DOI 10.1021/bi00304a014; LEE RH, 1992, J BIOL CHEM, V267, P25104; LIEBMAN PA, 1980, NATURE, V287, P734, DOI 10.1038/287734a0; LIPKIN VM, 1988, FEBS LETT, V234, P287, DOI 10.1016/0014-5793(88)80100-5; MATSUMOTO H, 1991, BIOCHEM BIOPH RES CO, V177, P1306, DOI 10.1016/0006-291X(91)90683-X; MILLER WH, 1990, INVEST OPHTH VIS SCI, V31, P1664; MORRISON DF, 1987, FEBS LETT, V222, P266, DOI 10.1016/0014-5793(87)80383-6; NEWTON AC, 1991, J BIOL CHEM, V266, P17725; OVCHINNIKOV YA, 1986, FEBS LETT, V201, P237, DOI 10.1016/0014-5793(86)80616-0; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P12949; PALCZEWSKI K, 1991, TRENDS BIOCHEM SCI, V16, P387, DOI 10.1016/0968-0004(91)90157-Q; POLANS AS, 1979, J GEN PHYSIOL, V74, P595, DOI 10.1085/jgp.74.5.595; PUGH EN, 1993, BIOCHIM BIOPHYS ACTA, V1141, P111, DOI 10.1016/0005-2728(93)90038-H; SITARAMAYYA A, 1983, J BIOL CHEM, V258, P1205; STRYER L, 1986, ANNU REV CELL BIOL, V2, P391, DOI 10.1146/annurev.cb.02.110186.002135; TSUBOI S, 1994, J BIOL CHEM, V269, P15024; TUTEJA N, 1990, GENE, V88, P227, DOI 10.1016/0378-1119(90)90035-P; TUTEJA N, 1988, FEBS LETT, V232, P182, DOI 10.1016/0014-5793(88)80413-7; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; YAMADA T, 1990, SCIENCE, V248, P483, DOI 10.1126/science.2158671; YAMAZAKI A, 1982, P NATL ACAD SCI-BIOL, V79, P3702, DOI 10.1073/pnas.79.12.3702; YAMAZAKI A, 1983, J BIOL CHEM, V258, P8188; YAMAZAKI A, 1990, J BIOL CHEM, V265, P11539; YAMAZAKI A, 1987, J BIOL CHEM, V262, P9316; YAMAZAKI A, 1980, J BIOL CHEM, V255, P1619; YAN KW, 1989, ANNU REV NEUROSCI, V12, P289	44	36	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					15016	15023						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195138				2022-12-25	WOS:A1994NP73800029
J	OKAMOTO, T; MURAYAMA, Y; STRITTMATTER, SM; KATADA, T; ASANO, S; OGATA, E; NISHIMOTO, I				OKAMOTO, T; MURAYAMA, Y; STRITTMATTER, SM; KATADA, T; ASANO, S; OGATA, E; NISHIMOTO, I			AN INTRINSIC GUANINE-NUCLEOTIDE EXCHANGE INHIBITOR IN G(I2)ALPHA - SIGNIFICANCE OF G-PROTEIN SELF-SUPPRESSION WHICH ANTAGONIZES RECEPTOR SIGNAL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GTP-BINDING PROTEIN; FACTOR-II RECEPTOR; ALPHA-SUBUNIT; PERTUSSIS-TOXIN; IDENTIFICATION; PURIFICATION; PEPTIDE; REGION; CELLS; BRAIN	The alpha subunit of G(i2) (G(i2)alpha) is a member of the heterotrimeric G protein family, which transduces receptor signals as a proto-oncogene product. We have found a novel self-suppressive region in G(i2)alpha near its C terminus. A polypeptide consisting of residues 338-352 of G(i2)alpha (G(i2)alpha-338-352) antagonizes receptor- and receptor peptide stimulated G(i2)alpha activation, without affecting basal activity. Antagonism by G(i2)alpha-338-352 is attributable to an interaction with activated G(i2)alpha, which is not competitive with receptor polypeptides. Combined with the reports suggesting the presence of self-suppressive domains in a juxta-C-terminal portion of G(i2)alpha and G(o) alpha, this study sup ports the hypothesis that G(i2)alpha-338-352 constitutes an intrinsic guanine nucleotide exchange inhibitor, which in turn antagonizes receptor stimulation, suggesting that G proteins are activated by receptors through relaxation of a self suppressive conformation.	MASSACHUSETTS GEN HOSP, CARDIOVASC RES CTR, BOSTON, MA 02129 USA; MASSACHUSETTS GEN HOSP, DEV BIOL LAB, BOSTON, MA 02129 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02129 USA; HARVARD UNIV, SCH MED, DEPT NEUROL, BOSTON, MA 02129 USA; UNIV TOKYO, SCH MED, DEPT INTERNAL MED 4, BUNKYO KU, TOKYO 112, JAPAN; TOKYO INST TECHNOL, DEPT LIFE SCI, MIDORI KU, YOKOHAMA, KANAGAWA 227, JAPAN; CANC RES INST, TOSHIMA KU, TOKYO 170, JAPAN	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; University of Tokyo; Tokyo Institute of Technology			Strittmatter, Stephen/F-5739-2011	Strittmatter, Stephen/0000-0001-8188-3092				ASANO T, 1989, BIOCHEMISTRY-US, V28, P4749, DOI 10.1021/bi00437a035; BIGAY J, 1985, FEBS LETT, V191, P181, DOI 10.1016/0014-5793(85)80004-1; CHEE WW, 1989, J BIOL CHEM, V264, P5687; DENKER BM, 1992, J BIOL CHEM, V267, P9998; DITTMAN AH, 1994, BIOCHEMISTRY-US, V33, P943, DOI 10.1021/bi00170a013; HAGA K, 1985, J BIOL CHEM, V260, P7927; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; HEIDEMAN W, 1990, G PROTEINS, P17; JOHNSON GL, 1991, J CELL BIOCHEM, V47, P136, DOI 10.1002/jcb.240470207; KATADA T, 1987, FEBS LETT, V213, P353, DOI 10.1016/0014-5793(87)81521-1; KOTANI K, 1992, ONCOGENE, V7, P1699; LARIVIERE G, 1988, CANCER RES, V48, P3405; LESTER BR, 1989, CANCER RES, V49, P5940; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MATSUI Y, 1990, MOL CELL BIOL, V10, P4116, DOI 10.1128/MCB.10.8.4116; MORISHITA R, 1989, BIOCHEM BIOPH RES CO, V161, P1280, DOI 10.1016/0006-291X(89)91381-8; MOXHAM CM, 1993, SCIENCE, V260, P991, DOI 10.1126/science.8493537; MUKAI H, 1992, J BIOL CHEM, V267, P16237; NISHIMOTO I, 1989, J BIOL CHEM, V264, P14029; NISHIMOTO I, 1991, J BIOL CHEM, V266, P12747; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; OKAMOTO T, 1991, CELL, V67, P723, DOI 10.1016/0092-8674(91)90067-9; OKAMOTO T, 1990, CELL, V62, P709, DOI 10.1016/0092-8674(90)90116-V; OKAMOTO T, 1992, J BIOL CHEM, V267, P8342; OKAMOTO T, 1991, P NATL ACAD SCI USA, V88, P8020, DOI 10.1073/pnas.88.18.8020; PACE AM, 1991, P NATL ACAD SCI USA, V88, P7031, DOI 10.1073/pnas.88.16.7031; TAKAHASHI K, 1993, P NATL ACAD SCI USA, V90, P11772, DOI 10.1073/pnas.90.24.11772; WATKINS DC, 1992, SCIENCE, V258, P1373, DOI 10.1126/science.1455234	28	7	7	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					13756	13759						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188651				2022-12-25	WOS:A1994NL60600009
J	TAVERNA, FA; WANG, LY; MACDONALD, JF; HAMPSON, DR				TAVERNA, FA; WANG, LY; MACDONALD, JF; HAMPSON, DR			A TRANSMEMBRANE MODEL FOR AN IONOTROPIC GLUTAMATE-RECEPTOR PREDICTED ON THE BASIS OF THE LOCATION OF ASPARAGINE-LINKED OLIGOSACCHARIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYLCHOLINE-RECEPTOR; FUNCTIONAL EXPRESSION; HIPPOCAMPAL-NEURONS; KAINATE; AMPA; CHANNEL; DESENSITIZATION; PROTEINS; CLONING; SUBUNIT	Several different models have been proposed for the transmembrane structure of receptors for the neurotransmitter L-glutamate. In this study, the sites of N-linked oligosaccharides on GluR6, a member of the kainate class of ionotropic glutamate receptors, were examined. Site directed mutagenesis was utilized to alter the consensus sequence at three potential sites for N-linked glycosylation in the carboxyl-terminal half of the molecule. The presence of a carbohydrate substitution was monitored by shifts in the relative molecular weight of the mutant receptors on immunoblots. Molecular weight shifts were observed for the mutants N515Q and N720Q and for two companion mutants, T517A and T722A, which also eliminate the consensus sequence for N-linked glycosylation. No shift in molecular weight was observed in the the mutant N574Q. These results indicate that asparagines 515 and 720 are glycosylated and thus are likely located extracellularly. In immunocytochemical analyses of GluR6 expressed in baculovirus-infected cells, permeabilization with detergents was required for immunostaining with a carboxyl-terminal antibody, indicating that the carboxyl terminus is located intracellularly. Electrophysiological recordings of the mutant receptors expressed in human embryonic kidney cells demonstrated that the amplitudes of the kainate-activated currents mediated by the N574Q, N720Q, and the T722A mutants were not significantly different from currents mediated by wild type GluR6 receptors, while the currents mediated by the N515Q and T517A mutants were significantly depressed. Based on these findings, we propose a model for the transmembrane topology of GluR6.	UNIV TORONTO,FAC PHARM,TORONTO M5S 2S2,ON,CANADA; UNIV TORONTO,MRC,NERVE CELLS & SYNAPSES GRP,TORONTO M5S 2S2,ON,CANADA; UNIV TORONTO,DEPT PHYSIOL,TORONTO M5S 2S2,ON,CANADA; UNIV TORONTO,DEPT PHARMACOL,TORONTO M5S 2S2,ON,CANADA	University of Toronto; University of Toronto; University of Toronto; University of Toronto								BOULTER J, 1990, SCIENCE, V249, P1033, DOI 10.1126/science.2168579; DINGLEDINE R, 1992, J NEUROSCI, V12, P4080; EGEBJERG J, 1993, P NATL ACAD SCI USA, V90, P755, DOI 10.1073/pnas.90.2.755; EGEBJERG J, 1991, NATURE, V351, P745, DOI 10.1038/351745a0; ESHHAR N, 1993, NEUROSCIENCE, V57, P943, DOI 10.1016/0306-4522(93)90040-M; FINERMOORE J, 1984, P NATL ACAD SCI-BIOL, V81, P155, DOI 10.1073/pnas.81.1.155; GEHLE VM, 1991, MOL BRAIN RES, V11, P17, DOI 10.1016/0169-328X(91)90016-Q; GREGOR P, 1989, NATURE, V342, P689, DOI 10.1038/342689a0; GUY HR, 1986, P NATL ACAD SCI USA, V83, P508, DOI 10.1073/pnas.83.2.508; HOLLMANN M, 1989, NATURE, V342, P643, DOI 10.1038/342643a0; HUETTNER JE, 1990, NEURON, V5, P255, DOI 10.1016/0896-6273(90)90163-A; HULLEBROECK MF, 1992, BRAIN RES, V590, P187, DOI 10.1016/0006-8993(92)91094-U; JAKOI ER, 1992, BRAIN RES, V582, P282, DOI 10.1016/0006-8993(92)90145-Y; KAPLAN HA, 1987, BIOCHIM BIOPHYS ACTA, V906, P161, DOI 10.1016/0304-4157(87)90010-4; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; KOHLER M, 1993, NEURON, V10, P491, DOI 10.1016/0896-6273(93)90336-P; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIS H, 1993, EUR J BIOCHEM, V218, P1, DOI 10.1111/j.1432-1033.1993.tb18347.x; LODISH HF, 1988, TRENDS BIOCHEM SCI, V13, P332, DOI 10.1016/0968-0004(88)90101-6; MAYER ML, 1989, P NATL ACAD SCI USA, V86, P1411, DOI 10.1073/pnas.86.4.1411; MOLNAR E, 1993, NEUROSCIENCE, V53, P307, DOI 10.1016/0306-4522(93)90198-O; MORI H, 1993, NEUROREPORT, V4, P519, DOI 10.1097/00001756-199305000-00014; NAKANISHI N, 1990, NEURON, V5, P569, DOI 10.1016/0896-6273(90)90212-X; OHARA PJ, 1993, NEURON, V11, P41, DOI 10.1016/0896-6273(93)90269-W; PETRALIA RS, 1992, J COMP NEUROL, V318, P329, DOI 10.1002/cne.903180309; PICKERING DS, 1993, J NEUROCHEM, V61, P85, DOI 10.1111/j.1471-4159.1993.tb03540.x; RAYMOND LA, 1993, NATURE, V361, P637, DOI 10.1038/361637a0; ROSS SM, 1994, IN PRESS NEUROSCI LE; SEEBURG PH, 1993, TRENDS NEUROSCI, V16, P359, DOI 10.1016/0166-2236(93)90093-2; SOMMER B, 1991, CELL, V67, P11, DOI 10.1016/0092-8674(91)90568-J; TAKAHASHI K, 1993, J BIOL CHEM, V268, P19341; TAVERNA FA, 1994, EUR J PHARM-MOLEC PH, V266, P181, DOI 10.1016/0922-4106(94)90108-2; TINGLEY WG, 1993, NATURE, V364, P70, DOI 10.1038/364070a0; UCHINO S, 1992, FEBS LETT, V308, P253, DOI 10.1016/0014-5793(92)81286-U; WADA K, 1989, NATURE, V342, P684, DOI 10.1038/342684a0; WANG LY, 1993, SCIENCE, V259, P1173, DOI 10.1126/science.8382377; WENTHOLD RJ, 1994, J BIOL CHEM, V269, P1332; WONG LA, 1993, MOL PHARMACOL, V44, P504; YAMADA KA, 1992, J PHYSIOL-LONDON, V458, P409, DOI 10.1113/jphysiol.1992.sp019424; ZORUMSKICF, 1992, PROG NEUROBIOL NY, V39, P295	40	58	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					14159	14164						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188697				2022-12-25	WOS:A1994NL60600066
J	FINAZZI, D; CASSEL, D; DONALDSON, JG; KLAUSNER, RD				FINAZZI, D; CASSEL, D; DONALDSON, JG; KLAUSNER, RD			ALUMINUM FLUORIDE ACTS ON THE REVERSIBILITY OF ARF1-DEPENDENT COAT PROTEIN-BINDING TO GOLGI MEMBRANES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; TRIMERIC-G-PROTEINS; BREFELDIN-A; GUANINE-NUCLEOTIDE; BETA-COP; GTP; TRANSPORT; VESICLES; ARF; RECONSTITUTION	The GTP dependent interaction of ADP ribosylation factor 1 (ARF1) with Golgi membranes is required for the binding of cytosolic coatomer proteins to those membranes. Whereas both GTP and GTP gamma S can support coatomer binding to membranes, by using partially purified components, GTP driven binding is rapidly reversible (t(1/2) of 2 min) while that driven by GTP gamma S is more stable (t(1/2) of over 30 min). In the presence of GTP, aluminum fluoride, an activator of trimeric G proteins, promotes the stable ARF-dependent binding of coatomer to membranes, even though this reagent does not itself activate ARF. Aluminum fluoride appears to act, like GTP gamma S, to make the binding of coatomer relatively irreversible. It acts to inhibit ARF-GTP hydrolysis catalyzed by the membrane and thus makes the ARF-GTP active state persistent. This effect is not dependent on the presence of any cytosolic component, such as the coatomer. The number of molecules of ARF that can be protected from hydrolysis by aluminum fluoride, however, is only a fraction of the total amount of ARF that can bind to membranes in the presence of GTP gamma S. We propose that this population defines a set of binding sites that are sufficient for coat protein assembly onto the membrane.	NIH,CELL BIOL & METAB BRANCH,BETHESDA,MD 20892; TECHNION ISRAEL INST TECHNOL,DEPT BIOL,IL-32000 HAIFA,ISRAEL; NICHHD,CELL BIOL & METAB BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; Technion Israel Institute of Technology; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)			finazzi, dario/GYV-1567-2022	Finazzi, Dario/0000-0001-5176-2839				ALLAN VJ, 1986, J CELL BIOL, V103, P2229, DOI 10.1083/jcb.103.6.2229; BALCH WE, 1984, CELL, V39, P525, DOI 10.1016/0092-8674(84)90459-8; Barr F A, 1992, Trends Cell Biol, V2, P91, DOI 10.1016/0962-8924(92)90001-4; BARR FA, 1991, FEBS LETT, V294, P239, DOI 10.1016/0014-5793(91)81438-E; BIGAY J, 1985, FEBS LETT, V191, P181, DOI 10.1016/0014-5793(85)80004-1; BOMSEL M, 1992, MOL BIOL CELL, V3, P1317, DOI 10.1091/mbc.3.12.1317; BURGOYNE RD, 1992, TRENDS BIOCHEM SCI, V17, P87; CHABRE M, 1990, TRENDS BIOCHEM SCI, V1, P6; COLOMBO MI, 1992, SCIENCE, V255, P1695, DOI 10.1126/science.1348148; DEMATTEIS MA, 1993, NATURE, V364, P818, DOI 10.1038/364818a0; DENFERT C, 1991, J CELL BIOL, V114, P663, DOI 10.1083/jcb.114.4.663; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; DURONIO RJ, 1990, P NATL ACAD SCI USA, V87, P1506, DOI 10.1073/pnas.87.4.1506; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOUD B, 1991, Current Opinion in Cell Biology, V3, P626, DOI 10.1016/0955-0674(91)90033-U; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; HELMS JB, 1993, J CELL BIOL, V121, P751, DOI 10.1083/jcb.121.4.751; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P752; KAHN RA, 1991, J BIOL CHEM, V266, P15595; KTISTAKIS NT, 1992, NATURE, V356, P344, DOI 10.1038/356344a0; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; MELANCON P, 1993, CURR BIOL, V3, P230, DOI 10.1016/0960-9822(93)90341-K; NAKANO A, 1989, J CELL BIOL, V109, P2677, DOI 10.1083/jcb.109.6.2677; OKA T, 1991, J CELL BIOL, V114, P671, DOI 10.1083/jcb.114.4.671; OSTERMANN J, 1993, CELL, V75, P1015, DOI 10.1016/0092-8674(93)90545-2; PALMER DJ, 1993, J BIOL CHEM, V268, P12083; Pfeffer S R, 1992, Trends Cell Biol, V2, P41, DOI 10.1016/0962-8924(92)90161-F; PIMPLIKAR SW, 1993, NATURE, V362, P456, DOI 10.1038/362456a0; RANDAZZO PA, 1993, J BIOL CHEM, V268, P9555; ROBINSON MS, 1992, CELL, V69, P129, DOI 10.1016/0092-8674(92)90124-U; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; STAMNES MA, 1993, CELL, V73, P999, DOI 10.1016/0092-8674(93)90277-W; STOW JL, 1991, J CELL BIOL, V114, P1113, DOI 10.1083/jcb.114.6.1113; TANIGAWA G, 1993, J CELL BIOL, V123, P1365, DOI 10.1083/jcb.123.6.1365; TEAL SB, 1994, J BIOL CHEM, V269, P3135; TRAUB LM, 1993, J CELL BIOL, V123, P561, DOI 10.1083/jcb.123.3.561; WEISS O, 1989, J BIOL CHEM, V264, P21066; Zerial M, 1993, CURR OPIN CELL BIOL, V5, P613, DOI 10.1016/0955-0674(93)90130-I	41	62	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13325	13330						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175763				2022-12-25	WOS:A1994NK18400043
J	CARRERAS, CW; COSTI, PM; SANTI, DV				CARRERAS, CW; COSTI, PM; SANTI, DV			HETERODIMERIC THYMIDYLATE SYNTHESES WITH C-TERMINAL DELETION ON ONE SUBUNIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNTHASE; SYNTHETASE; MUTANTS; BINDING	We have combined site directed mutagenesis with the technique of reversible unfolding and subunit dissociation to construct heterodimeric thymidylate syntheses that lack the C-terminal valine from only one subunit of the dimer. Removal of this residue either from both subunits of the dimer by mutagenesis (V316Am mutation) or from only one subunit by treatment with carboxypeptidase has been reported to result in an inactive enzyme (Carreras, C. W, Climie, S. C., and Santi, D. V. (1992) Biochemistry 31, 6038-6044; Aull, J. L., Loeble, R. B., and Dunlap, R. B. (1974) J. Biol. Chem. 249, 1167-1172). Arg-178 is an essential active site residue of thymidylate synthese that is donated from the opposing subunit of the dimer. The R178F-V316Am heterodimer was formed by the unfolding and refolding of a mixture of inactive R178F and V316Am mutants. This enzyme has one intact active site and was found to have half of the activity and the same K-m values as wild-type thymidylate synthase that was unfolded and refolded as a control. We have also formed the V316Am-WT heterodimer and report that this heterodimeric enzyme is also active, has a k(cat) value that is approximately half of that of the wild-type thymidylate synthase dimer, and binds substrate and cofactor with K-m values similar to those of the wild-type enzyme.	UNIV CALIF SAN FRANCISCO,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143; UNIV MODENA,DIPARTIMENTO SCI FARMACEUT,I-41100 MODENA,ITALY	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Universita di Modena e Reggio Emilia			Costi, Maria Paola/F-4747-2015	Costi, Maria Paola/0000-0002-0443-5402	NATIONAL CANCER INSTITUTE [R01CA014394, R37CA014394] Funding Source: NIH RePORTER; NCI NIH HHS [CA-14394] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AULL JL, 1974, J BIOL CHEM, V249, P1167; BRUICE TW, 1982, BIOCHEMISTRY-US, V21, P6703, DOI 10.1021/bi00269a014; CARRERAS CW, 1992, BIOCHEMISTRY-US, V31, P6038, DOI 10.1021/bi00141a012; CISNEROS RJ, 1993, J BIOL CHEM, V268, P10102; CLIMIE S, 1990, J BIOL CHEM, V265, P18776; CLIMIE SC, 1992, BIOCHEMISTRY-US, V31, P6032, DOI 10.1021/bi00141a011; FINERMOORE J, 1993, J MOL BIOL, V232, P1101, DOI 10.1006/jmbi.1993.1463; GALIVAN J, 1977, ARCH BIOCHEM BIOPHYS, V184, P346, DOI 10.1016/0003-9861(77)90361-7; GALIVAN JH, 1976, BIOCHEM BIOPH RES CO, V71, P527, DOI 10.1016/0006-291X(76)90819-6; GREENE PJ, 1993, BIOCHEMISTRY-US, V32, P10283, DOI 10.1021/bi00090a002; HARDY LW, 1987, SCIENCE, V235, P448, DOI 10.1126/science.3099389; KEALEY JT, 1992, PROTEIN EXPRES PURIF, V3, P380, DOI 10.1016/S1046-5928(05)80039-7; KOHNO T, 1990, METHOD ENZYMOL, V185, P187; MONTFORT WR, 1990, BIOCHEMISTRY-US, V29, P6964, DOI 10.1021/bi00482a004; PERRY KM, 1993, BIOCHEMISTRY-US, V32, P7116, DOI 10.1021/bi00079a007; PERRY KM, 1992, PROTEIN SCI, V1, P796, DOI 10.1002/pro.5560010611; POGOLOTTI AL, 1986, J MED CHEM, V29, P478, DOI 10.1021/jm00154a009; POOKANJANATAVIP M, 1992, BIOCHEMISTRY-US, V31, P10303, DOI 10.1021/bi00157a018	18	10	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12444	12446						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175650				2022-12-25	WOS:A1994NH71600014
J	HAEBERLE, JR				HAEBERLE, JR			CALPONIN DECREASES THE RATE OF CROSS-BRIDGE CYCLING AND INCREASES MAXIMUM FORCE PRODUCTION BY SMOOTH-MUSCLE MYOSIN IN AN IN-VITRO MOTILITY ASSAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								Mammalian smooth muscles, like invertebrate ''catch'' muscles, dynamically regulate the rate of cross-bridge cycling. During sustained contractions, cross-bridge cycling rates may decrease severalfold, whereas tension remains elevated (''latch-state''). Physiologic studies have shown that decreased cycling rate is frequently, but not always, associated with dephosphorylation of the 20,000 dalton light chain of myosin. Tropomyosin, caldesmon, and calponin are actin binding proteins found in mammalian smooth muscles that modulate actin-activated myosin ATPase activity in vitro and may modulate cross-bridge cycling in situ. Using an in vitro motility assay in combination with a new method for estimating relative changes in the force exerted on actin filaments, the present study demonstrates that the effects of calponin on actin filament motility are: increased actin filament binding to thiophosphorylated smooth muscle myosin, decreased filament velocity from 2.0 to 0.74 mu m/s, and a 3-4-fold increase in the force exerted on stationary actin filaments. Taken together, these observations suggest that calponin inhibits the rate of dissociation of the high-affinity actomyosin complex and, consequently, that it may be an integral component of the latch-state in mammalian smooth muscles.			HAEBERLE, JR (corresponding author), UNIV VERMONT, DEPT PHYSIOL & BIOPHYS, BURLINGTON, VT 05405 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL028001] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040259] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL28001] Funding Source: Medline; NIAMS NIH HHS [AR40259] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ABE M, 1990, J BIOCHEM-TOKYO, V107, P507, DOI 10.1093/oxfordjournals.jbchem.a123075; ADELSTEIN RS, 1980, ANNU REV BIOCHEM, V49, P921, DOI 10.1146/annurev.bi.49.070180.004421; BOREJDO J, 1992, BIOPHYS J, V61, P1267, DOI 10.1016/S0006-3495(92)81935-5; BREMEL RD, 1972, NATURE-NEW BIOL, V238, P97, DOI 10.1038/newbio238097a0; BRENNER B, 1988, P NATL ACAD SCI USA, V85, P3265, DOI 10.1073/pnas.85.9.3265; Brenner B., 1990, MUSCLE MECH BIOLOGIC, P77; CHALOVICH JM, 1990, ANN NY ACAD SCI, V599, P85, DOI 10.1111/j.1749-6632.1990.tb42367.x; CHALOVICH JM, 1992, PHARMACOL THERAPEUT, V55, P95, DOI 10.1016/0163-7258(92)90013-P; DILLON PF, 1981, SCIENCE, V211, P495, DOI 10.1126/science.6893872; ENGANDER SW, 1987, ANAL BIOCHEM, V161, P300; HAEBERLE JR, 1992, J BIOL CHEM, V267, P23001; HAEBERLE JR, 1985, PFLUG ARCH EUR J PHY, V403, P215, DOI 10.1007/BF00584103; HAI CM, 1988, AM J PHYSIOL, V255, pC86, DOI 10.1152/ajpcell.1988.255.1.C86; HARRIS DE, 1993, J BIOL CHEM, V268, P14764; HORIUCHI KY, 1989, BIOCHEMISTRY-US, V28, P9111, DOI 10.1021/bi00449a023; HORIUCHI KY, 1991, BIOCHEM BIOPH RES CO, V176, P1487, DOI 10.1016/0006-291X(91)90455-G; HUXLEY AF, 1957, PROG BIOPHYS MOL BIO, V7, P255, DOI 10.1016/S0096-4174(18)30128-8; KAMM KE, 1985, ANNU REV PHARMACOL, V25, P593, DOI 10.1146/annurev.pharmtox.25.1.593; KENNEY RE, 1990, J BIOL CHEM, V265, P8642; KERRICK WGL, 1991, J MUSCLE RES CELL M, V12, P53, DOI 10.1007/BF01781174; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARSTON SB, 1989, J MUSCLE RES CELL M, V10, P97, DOI 10.1007/BF01739965; MIKI M, 1992, BIOCHEM BIOPH RES CO, V187, P867, DOI 10.1016/0006-291X(92)91277-W; Moreland S, 1986, PFLUEGERS ARCH, V408, P139; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; PERRIE WT, 1970, BIOCHEM J, V119, P31, DOI 10.1042/bj1190031; PORZIO MA, 1977, BIOCHIM BIOPHYS ACTA, V490, P27, DOI 10.1016/0005-2795(77)90102-7; SELLERS JR, 1981, J BIOL CHEM, V256, P3137; SELLERS JR, 1985, J BIOL CHEM, V260, P5815; SHIRINSKY VP, 1992, J BIOL CHEM, V267, P15886; SIEGMAN MJ, 1984, PFLUG ARCH EUR J PHY, V401, P385, DOI 10.1007/BF00584340; SMILLIE LB, 1982, METHOD ENZYMOL, V85, P234; SOMLYO AV, 1988, J GEN PHYSIOL, V91, P165, DOI 10.1085/jgp.91.2.165; TAKAHASHI K, 1987, LIFE SCI, V41, P291, DOI 10.1016/0024-3205(87)90151-2; VANBUREN P, 1994, P NATL ACAD SCI USA, V91, P202, DOI 10.1073/pnas.91.1.202; VANBUREN P, 1993, BIOPHYS J, V64, pA230; WARSHAW DM, 1990, J CELL BIOL, V111, P453, DOI 10.1083/jcb.111.2.453; WELLS C, 1985, NATURE, V313, P696, DOI 10.1038/313696a0; WORK SS, 1992, ANAL BIOCHEM, V202, P275, DOI 10.1016/0003-2697(92)90106-H	39	121	123	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12424	12431						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175648				2022-12-25	WOS:A1994NH71600011
J	RAULO, E; CHERNOUSOV, MA; CAREY, DJ; NOLO, R; RAUVALA, H				RAULO, E; CHERNOUSOV, MA; CAREY, DJ; NOLO, R; RAUVALA, H			ISOLATION OF A NEURONAL CELL-SURFACE RECEPTOR OF HEPARIN-BINDING GROWTH-ASSOCIATED MOLECULE (HB-GAM) - IDENTIFICATION AS N-SYNDECAN (SYNDECAN-3)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								HB-GAM (heparin binding growth-associated molecule; pleiotrophin) is a secretory, extracellular matrix-associated protein that is strongly expressed in developing nervous tissues and belongs to a novel family of differentiation/growth factors. It promotes axonal growth from perinatal rat brain neurons and is suggested to be mitogenic for some cell types and to display cell-transforming activity. Since the receptors of HB-GAM in cells are unknown, we have started isolation of putative cell surface receptors from brain neurons and from perinatal rat brain. For this purpose, recombinant HB-GAM was produced with the aid of a baculovirus vector and used as an affinity matrix in receptor isolation. A detergent-solubilized component from cultured brain neurons and from brain was identified that binds specifically to HB-GAM and migrates on sodium dodecyl sulfate-polyacrylamide gel electrophoresis as a broad smear with an apparent molecular mass of about 200 kDa. This cell surface component was found to contain heparan sulfate chains, which are bound to a core protein with an apparent molecular mass of 120 kDa. Gel electrophoretic characteristics, immunochemical analysis, and partial peptide sequencing revealed that the cell surface component isolated as an HB-GAM receptor is N-syndecan (syndecan-3). In a solid phase binding assay, N-syndecan was found to bind to HB-GAM in a similar manner as to basic fibroblast growth factor (K-D = 0.6 nM). Immunofluorescence microscopy indicated that in brain neurons, N-syndecan occurs at the surface of the cell soma and of the neurites that grow along HB-GAM-coated substrates. Anti-N-syndecan antibodies added to culture media had an inhibitory effect on HB-GAM-induced neurite outgrowth. We suggest that N-syndecan mediates the neurite outgrowth-promoting signal from HB-GAM to the cytoskeleton of growing neurites.	SIGFRIED & JANET WEIS CTR RES, DANVILLE, PA 17822 USA; UNIV HELSINKI, DEPT MED CHEM, SF-00014 HELSINKI, FINLAND	University of Helsinki	RAULO, E (corresponding author), UNIV HELSINKI, INST BIOTECHNOL, MOLEC NEUROBIOL LAB, SF-00014 HELSINKI, FINLAND.			Raulo, Erkki/0000-0001-9113-3770; Rauvala, Heikki/0000-0001-7809-9811	NINDS NIH HHS [NS21925] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021925] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAUMANN M, 1990, ANAL BIOCHEM, V190, P198, DOI 10.1016/0003-2697(90)90181-8; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; CAREY DJ, 1992, J CELL BIOL, V117, P191, DOI 10.1083/jcb.117.1.191; CHAUHAN AK, 1993, P NATL ACAD SCI USA, V90, P679, DOI 10.1073/pnas.90.2.679; CHERNOUSOV MA, 1993, J BIOL CHEM, V268, P16810; ELENIUS K, 1990, J BIOL CHEM, V265, P17837; FANG WJ, 1992, J BIOL CHEM, V267, P25889; GOULD SE, 1992, P NATL ACAD SCI USA, V89, P3271, DOI 10.1073/pnas.89.8.3271; HAMPTON BS, 1992, MOL BIOL CELL, V3, P85, DOI 10.1091/mbc.3.1.85; JALKANEN S, 1987, J CELL BIOL, V105, P983, DOI 10.1083/jcb.105.2.983; KADOMATSU K, 1988, BIOCHEM BIOPH RES CO, V151, P1312, DOI 10.1016/S0006-291X(88)80505-9; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; Kretschmer P J, 1991, Growth Factors, V5, P99, DOI 10.3109/08977199109000275; KUO MD, 1992, BIOCHEM BIOPH RES CO, V182, P188, DOI 10.1016/S0006-291X(05)80129-9; KUO MD, 1990, J BIOL CHEM, V265, P18749; LETOURNEAU PC, 1991, NERVE GROWTH CONE, P535; LI YS, 1990, SCIENCE, V250, P1690, DOI 10.1126/science.2270483; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; MATSUBARA S, 1990, J BIOL CHEM, V265, P9441; MERENMIES J, 1990, J BIOL CHEM, V265, P16721; MILNER PG, 1989, BIOCHEM BIOPH RES CO, V165, P1096, DOI 10.1016/0006-291X(89)92715-0; MOHAN PS, 1992, BIOCHEM BIOPH RES CO, V182, P689, DOI 10.1016/0006-291X(92)91787-Q; MOLLER HJ, 1993, ANAL BIOCHEM, V209, P169, DOI 10.1006/abio.1993.1098; NURCOMBE V, 1992, DEVELOPMENT, V116, P1175; PARKKINEN J, 1993, J BIOL CHEM, V268, P19726; RAULO E, 1992, J BIOL CHEM, V267, P11408; RAUVALA H, 1989, EMBO J, V8, P2933, DOI 10.1002/j.1460-2075.1989.tb08443.x; RAUVALA H, 1988, J CELL BIOL, V107, P2293, DOI 10.1083/jcb.107.6.2293; RAUVALA H, 1987, J BIOL CHEM, V262, P16625; RAUVALA H, 1994, DEV BRAIN RES, V79, P157, DOI 10.1016/0165-3806(94)90121-X; SAUNDERS S, 1989, J CELL BIOL, V108, P1547, DOI 10.1083/jcb.108.4.1547; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; TEZUKA K, 1990, BIOCHEM BIOPH RES CO, V173, P246, DOI 10.1016/S0006-291X(05)81048-4; VIGNY M, 1989, EUR J BIOCHEM, V186, P733, DOI 10.1111/j.1432-1033.1989.tb15267.x; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; WELLSTEIN A, 1992, J BIOL CHEM, V267, P2582	36	262	268	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12999	13004						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175719				2022-12-25	WOS:A1994NH71600095
J	YOO, SH				YOO, SH			PH-DEPENDENT INTERACTION OF CHROMOGRANIN-A WITH INTEGRAL MEMBRANE-PROTEINS OF SECRETORY VESICLE INCLUDING 260-KDA PROTEIN REACTIVE TO INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR ANTIBODY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONFORMATIONAL CHANGE; CHROMAFFIN GRANULES; NERVOUS-TISSUE; INSP3 RECEPTOR; EXPRESSION; CA-2+; CA2+	Chromogranin A is a high capacity, low affinity Ca2+-binding protein suggested to be responsible for the Ca2+ storage function of the secretory vesicle, which has been identified as a major inositol 1,4,5-trisphosphate (IP3)-sensitive intracellular Ca2+ store of adrenal medullary chromaffin cells. Moreover, chromogranin A has recently been shown to interact with the vesicle membrane at the intravesicular pH of 5.5 and to be released from it at a near physiological pH of 7.5 (Yoo, S. H. (1993) Biochemistry 32, 8213-8219). In the present study, chromogranin A is shown to interact with several integral membrane proteins of secretory vesicles at pH 5.5 but not at pH 7.5. One of the chromogranin A-interacting membrane proteins had a mass of 260 kDa and reacted with the IP3 receptor antibody. This result suggested not only the existence of the IP3 receptor in the vesicle membrane but also the existence of direct communication between chromogranin A and the IP3 receptor. In addition, the pH-dependent interaction of chromogranin A with integral membrane proteins implies an important role for chromogranin A in the sorting process of the vesicle membrane proteins during vesicle biogenesis in the trans-Golgi network.			YOO, SH (corresponding author), NIDOCD,CELLULAR BIOL LAB,BETHESDA,MD 20892, USA.							ANDERSON RGW, 1985, CELL, V40, P635, DOI 10.1016/0092-8674(85)90212-0; BLONDEL O, 1993, J BIOL CHEM, V268, P11356; BULENDA D, 1985, BIOCHEMISTRY-US, V24, P760; CASEY RP, 1977, BIOCHEMISTRY-US, V16, P972, DOI 10.1021/bi00624a025; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; DANIELS AJ, 1978, NEUROSCIENCE, V3, P573, DOI 10.1016/0306-4522(78)90022-2; FERRIS CD, 1989, NATURE, V342, P87, DOI 10.1038/342087a0; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; HUTTNER WB, 1991, MARKERS NEURAL ENDOC, P93; JOHNSON RG, 1976, J BIOL CHEM, V251, P2189; KALINOSKI DL, 1992, BIOCHEM J, V281, P449, DOI 10.1042/bj2810449; KHAN AA, 1992, SCIENCE, V257, P815, DOI 10.1126/science.1323146; MAEDA N, 1990, EMBO J, V9, P61, DOI 10.1002/j.1460-2075.1990.tb08080.x; MATTER N, 1993, J BIOL CHEM, V268, P732; MIGNERY GA, 1990, J BIOL CHEM, V265, P12679; MIGNERY GA, 1989, NATURE, V342, P192, DOI 10.1038/342192a0; OCONNOR DT, 1984, J BIOL CHEM, V259, P3237; ORCI L, 1986, J CELL BIOL, V103, P2273, DOI 10.1083/jcb.103.6.2273; REIFFEN FU, 1986, FEBS LETT, V195, P327, DOI 10.1016/0014-5793(86)80187-9; ROSS CA, 1989, NATURE, V339, P468, DOI 10.1038/339468a0; SIMON JP, 1989, BIOCHEM J, V262, P1; SNYDER SH, 1988, CELL CALCIUM, V10, P337; SUDHOF TC, 1991, EMBO J, V10, P3199, DOI 10.1002/j.1460-2075.1991.tb04882.x; TODDERUD G, 1990, SCIENCE, V249, P296, DOI 10.1126/science.2374928; WINKLER H, 1986, NEUROSCIENCE, V18, P261, DOI 10.1016/0306-4522(86)90154-5; WINKLER H, 1992, NEUROSCIENCE, V49, P497, DOI 10.1016/0306-4522(92)90222-N; YOO SH, 1992, J BIOL CHEM, V267, P11236; YOO SH, 1990, BIOCHIM BIOPHYS ACTA, V1040, P66, DOI 10.1016/0167-4838(90)90146-7; YOO SH, 1990, J BIOL CHEM, V265, P14414; YOO SH, 1993, FEBS LETT, V334, P373, DOI 10.1016/0014-5793(93)80715-7; YOO SH, 1991, J BIOL CHEM, V266, P7740; YOO SH, 1990, J BIOL CHEM, V265, P13446; YOO SH, 1993, BIOCHEMISTRY-US, V32, P8213, DOI 10.1021/bi00083a023	33	69	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					12001	12006						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163503				2022-12-25	WOS:A1994NG37700052
J	AXELROD, A; GIBBS, VC; GOEDDEL, DV				AXELROD, A; GIBBS, VC; GOEDDEL, DV			THE INTERFERON-GAMMA RECEPTOR EXTRACELLULAR DOMAIN - NONIDENTICAL REQUIREMENTS FOR LIGAND-BINDING AND SIGNALING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IFN-GAMMA; EXPRESSION; CELLS; CHROMOSOME-21; CLONING; CDNA; IDENTIFICATION; SENSITIVITY; TRANSDUCER; AFFINITY	The human interferon-gamma receptor (hIFN-gamma R) extracellular domain interacts in a species-specific manner with both its ligand and an accessory factor encoded on human chromosome 21. Mutant interferon-gamma receptors were constructed by homolog-scanning mutagenesis, replacing segments of the human extracellular domain with the corresponding murine sequence. Replacement of hIFN-gamma R amino acids 1-100, 100-132, 134-183, or 183-245 abolished binding to human interferon-gamma (hIFN-gamma). However, replacement of hIFN-gamma R amino acids 134-209, 183-209, 134-153, 153-167, or 167-183 or deletion of residues 156-165 affected hIFN-gamma binding only partially or not at all. Receptors that bound hIFN-gamma were tested for their ability to signal a functional response, induction of major histocompatibility complex class I antigen expression. Replacement of residues 134-209 greatly reduced the ability of the receptor to signal. This signaling defect could not be attributed solely to a reduction in affinity for ligand and could not be localized to any subregion.	GENENTECH INC,DEPT MOLEC BIOL,S SAN FRANCISCO,CA 94080; UNIV CALIF SAN FRANCISCO,VET ADM MED CTR,DEPT SURG,SAN FRANCISCO,CA 94121	Roche Holding; Genentech; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA)								AGUET M, 1988, CELL, V55, P273, DOI 10.1016/0092-8674(88)90050-5; Ausubel FM., 1988, CURRENT PROTOCOLS MO; BASS SH, 1991, P NATL ACAD SCI USA, V88, P4498, DOI 10.1073/pnas.88.10.4498; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; CAO Y, 1990, Technique (Philadelphia), V2, P109; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; COOK JR, 1992, P NATL ACAD SCI USA, V89, P11317, DOI 10.1073/pnas.89.23.11317; CUNNINGHAM BC, 1989, SCIENCE, V243, P1330, DOI 10.1126/science.2466339; DALTON DK, 1993, SCIENCE, V259, P1739, DOI 10.1126/science.8456300; DEVOS AM, 1992, SCIENCE, V248, P739; DIGHE AS, 1993, J BIOL CHEM, V268, P10645; EALICK SE, 1991, SCIENCE, V252, P698, DOI 10.1126/science.1902591; FARRAR MA, 1991, J BIOL CHEM, V266, P19626; FARRAR MA, 1993, ANNU REV IMMUNOL, V11, P571, DOI 10.1146/annurev.iy.11.040193.003035; FARRAR MA, 1992, P NATL ACAD SCI USA, V89, P11706, DOI 10.1073/pnas.89.24.11706; FOUNTOULAKIS M, 1990, J BIOL CHEM, V265, P13268; FOUNTOULAKIS M, 1991, J BIOL CHEM, V266, P14970; FOUNTOULAKIS M, 1992, EUR J BIOCHEM, V208, P7811; GIBBS VC, 1991, MOL CELL BIOL, V11, P5860, DOI 10.1128/MCB.11.12.5860; GRAY PW, 1989, P NATL ACAD SCI USA, V86, P8497, DOI 10.1073/pnas.86.21.8497; GREENLUND AC, 1993, J BIOL CHEM, V268, P18103; GRIGGS ND, 1992, J IMMUNOL, V149, P517; HEMMI S, 1989, P NATL ACAD SCI USA, V86, P9901, DOI 10.1073/pnas.86.24.9901; HEMMI S, 1992, P NATL ACAD SCI USA, V89, P2737, DOI 10.1073/pnas.89.7.2737; HIBINO Y, 1991, J BIOL CHEM, V266, P6948; HUANG S, 1993, SCIENCE, V259, P1742, DOI 10.1126/science.8456301; IMLER JL, 1992, EMBO J, V11, P2047, DOI 10.1002/j.1460-2075.1992.tb05262.x; JANSSEN JWG, 1986, CYTOMETRY, V7, P411, DOI 10.1002/cyto.990070504; JUNG V, 1987, P NATL ACAD SCI USA, V84, P4151, DOI 10.1073/pnas.84.12.4151; KUMAR CS, 1989, J BIOL CHEM, V264, P17939; LUTFALLA G, 1993, GENOMICS, V16, P366, DOI 10.1006/geno.1993.1199; MUNRO S, 1989, P NATL ACAD SCI USA, V86, P8248; RAZIUDDIN A, 1984, P NATL ACAD SCI-BIOL, V81, P5504, DOI 10.1073/pnas.81.17.5504; SHEEHAN KCF, 1988, J IMMUNOL, V140, P4231; STUBER D, 1993, BIOCHEMISTRY-US, V32, P2423; THOREAU E, 1991, FEBS LETT, V282, P26, DOI 10.1016/0014-5793(91)80437-8; WANG HM, 1992, J BIOL CHEM, V267, P979; YAWATA H, 1993, EMBO J, V12, P1705, DOI 10.1002/j.1460-2075.1993.tb05815.x; YON J, 1989, NUCLEIC ACIDS RES, V17, P4895, DOI 10.1093/nar/17.12.4895	39	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 3	1994	269	22					15533	15539						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP513	8195198				2022-12-25	WOS:A1994NP51300024
J	WINKLER, C; WITTBRODT, J; LAMMERS, R; ULLRICH, A; SCHARTL, M				WINKLER, C; WITTBRODT, J; LAMMERS, R; ULLRICH, A; SCHARTL, M			LIGAND-DEPENDENT TUMOR-INDUCTION IN MEDAKAFISH EMBRYOS BY A XMRK RECEPTOR TYROSINE KINASE TRANSGENE	ONCOGENE			English	Article							TRANSIENT EXPRESSION; ORYZIAS-LATIPES; XIPHOPHORUS; MICE; MELANOMA; ONCOGENE; PROMOTER; GENE; OVEREXPRESSION; NEOPLASIA	Xmrk encodes a subclass I receptor tyrosine kinase (RTK) which has been cloned from the melanoma-inducing locus Tn of the poeciliid fish Xiphophorus. To demonstrate a high oncogenic potential in vivo we transferred the gene into early embryos of the closely related medakafish. Ectopic expression of the Xmrk oncogene under the control of a strong, constitutive promoter (CMVTk) led to the induction of embryonic tumors with high incidence, after short latency periods, and with a specific pattern of affected tissues. We demonstrate ligand-dependent transformation in vivo using a chimeric receptor consisting of the extracellular and transmembrane domains of the human EGF receptor (HER) and the cytoplasmatic domain of Xmrk. Expression of the chimeric receptor alone does not lead to kinase activation or induction of tumors. Coexpression of the chimera with its corresponding ligand, human transforming growth factor alpha (hTGF alpha), however, results in the activation of the chimeric RTK. In injected fish embryos the induction of the neoplastic growth is observed with similar incidence and tissue distribution as in embryos carrying the native Xmrk oncogene suggesting that the ligand as well as factors downstream of the RTK are required for tumor formation. In this study we show single-step induction of tumors by ectopic expression of RTKs in vivo substantiating the significance of autocrine stimulation in RTK induced tumors in vertebrates.	UNIV WURZBURG,BIOCTR,DEPT PHYSIOL CHEM 1,D-97074 WURZBURG,GERMANY; UNIV BASEL,BIOCTR,DEPT CELL BIOL,CH-4056 BASEL,SWITZERLAND; MAX PLANCK INST BIOCHEM,DEPT MOLEC BIOL,D-82152 MARTINSRIED,GERMANY	University of Wurzburg; University of Basel; Max Planck Society			Wittbrodt, Joachim/D-4735-2014; Winkler, Christoph/G-4822-2012	Wittbrodt, Joachim/0000-0001-8550-7377; Schartl, Manfred/0000-0001-9882-5948; Winkler, Christoph/0000-0003-4688-6241				ADAM D, 1993, SCIENCE, V259, P816, DOI 10.1126/science.8430335; ADAM D, 1991, ONCOGENE, V6, P73; AHUJA MR, 1976, PROG EXP TUMOR RES, V20, P380; CHONG SSC, 1989, THEOR APPL GENET, V78, P369, DOI 10.1007/BF00265299; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; FRIEDENREICH H, 1990, NUCLEIC ACIDS RES, V18, P3299, DOI 10.1093/nar/18.11.3299; FRIEND SH, 1993, SCIENCE, V259, P774, DOI 10.1126/science.8430329; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; JHAPPAN C, 1990, CELL, V61, P1137, DOI 10.1016/0092-8674(90)90076-Q; Kirchen R. V, 1976, JAPANESE MEDAKA ITS; LAX I, 1989, EMBO J, V8, P421, DOI 10.1002/j.1460-2075.1989.tb03393.x; MARCEY D, 1986, NATURE, V321, P380, DOI 10.1038/321380a0; MATSUI Y, 1990, CELL, V61, P1147, DOI 10.1016/0092-8674(90)90077-R; MICHIELS F, 1989, EMBO J, V8, P1559, DOI 10.1002/j.1460-2075.1989.tb03540.x; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; ROSSANT J, 1992, GENE DEV, V6, P1, DOI 10.1101/gad.6.1.1; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; TAKAGI H, 1992, CANCER RES, V52, P5171; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VELU TJ, 1987, SCIENCE, V238, P1408, DOI 10.1126/science.3500513; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; WEINBERG RA, 1989, CANCER RES, V49, P3713; WINKLER C, 1991, MOL GEN GENET, V226, P129, DOI 10.1007/BF00273596; Winkler Christoph, 1992, Molecular Marine Biology and Biotechnology, V1, P326; WITTBRODT J, 1992, EMBO J, V11, P4239, DOI 10.1002/j.1460-2075.1992.tb05518.x; WITTBRODT J, 1989, NATURE, V341, P415, DOI 10.1038/341415a0; YAMAMOTO TO, 1961, INT REV CYTOL, V12, P361	27	50	50	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1994	9	6					1517	1525						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NL815	8183545				2022-12-25	WOS:A1994NL81500001
J	ANDERSON, PM; KORTE, JJ; HOLCOMB, TA; CHO, YG; SON, CM; SUNG, YC				ANDERSON, PM; KORTE, JJ; HOLCOMB, TA; CHO, YG; SON, CM; SUNG, YC			FORMATION OF INTERSUBUNIT DISULFIDE BONDS AND PROPERTIES OF THE SINGLE HISTIDINE AND CYSTEINE RESIDUES IN EACH SUBUNIT RELATIVE TO THE DECAMERIC STRUCTURE OF CYANASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; CARBONIC-ANHYDRASE	Reaction of the single cysteine residue in each subunit of cyanase with certain SH reagents gives an active decameric derivative that dissociates reversibly to an inactive dimer derivative (Anderson, P. M., Johnson, W. V., Korte, J. J., Xiong, X., Sung, Y.-c., and Fuchs, J. A. (1988) J. Biol. Chem. 263, 5674-5680). Reaction of mixed disulfide dimer derivatives of cyanase with dithiothreitol at 0 degrees C results in formation of a disulfide bond between the subunits in the dimer. The disulfide dimer was inactive and did not associate to a decamer; the intersubunit disulfide bond could not be formed when the dimers were associated as a decamer. The two SH groups apparently are in close proximity to each other in the dissociated dimer but not when the dimer is associated to a decamer. Substitution of glycine for the cysteine residue or of tyrosine, asparagine, glycine, valine, or leucine for the single histidine residue in each subunit gave mutant enzymes that were active. However, H113N, H113Y, and C83G were unstable at low temperature and/or ionic strength, dissociating reversibly to an inactive dimer. Efficient reassociation required the presence of bicarbonate or cyanate analog. The results are consistent with a proposed single site per subunit model explaining apparent half site binding of substrates and the requirement of decameric structure for activity.	POHANG INST SCI & TECHNOL,DEPT LIFE SCI,POHANG 790600,SOUTH KOREA	Pohang University of Science & Technology (POSTECH)	ANDERSON, PM (corresponding author), UNIV MINNESOTA,DEPT BIOCHEM & MOLEC BIOL,10 UNIV DR,DULUTH,MN 55812, USA.				NIGMS NIH HHS [GM33842] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033842] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON PM, 1987, BIOCHEMISTRY-US, V26, P3938, DOI 10.1021/bi00387a029; ANDERSON PM, 1988, J BIOL CHEM, V263, P5674; ANDERSON PM, 1980, BIOCHEMISTRY-US, V19, P2882, DOI 10.1021/bi00554a010; ANDERSON PM, 1986, BIOCHEMISTRY-US, V25, P1621, DOI 10.1021/bi00355a026; CHIN CCQ, 1983, J BIOL CHEM, V258, P276; CLELAND WW, 1964, BIOCHEMISTRY-US, V3, P480, DOI 10.1021/bi00892a002; GUILLOTON MB, 1992, J BIOL CHEM, V267, P3731; GUILLOTON MB, 1993, J BACTERIOL, V175, P1443, DOI 10.1128/JB.175.5.1443-1451.1993; Habeeb A F, 1972, Methods Enzymol, V25, P457, DOI 10.1016/S0076-6879(72)25041-8; IYER KS, 1973, J BIOL CHEM, V248, P707; JOHNSON WV, 1987, J BIOL CHEM, V262, P9021; KUNKEL TA, 1985, P NATL ACAD SCI USA, V80, P3963; KYUNG HK, 1987, J MOL BIOL, V198, P137; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LITTLE RM, 1987, J BIOL CHEM, V262, P10120; OTWINOWSKI Z, 1991, 4 P INT M CRYST BIOL, P54; RIDDLES PW, 1983, METHOD ENZYMOL, V91, P49; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SUNG YC, 1987, J BACTERIOL, V169, P5224, DOI 10.1128/jb.169.11.5224-5230.1987; TAUSSIG A, 1965, CAN J BIOCHEM CELL B, V43, P1063, DOI 10.1139/o65-119	20	8	8	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					15036	15045						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195141				2022-12-25	WOS:A1994NP73800032
J	ONO, S; MINAMI, N; ABE, H; OBINATA, T				ONO, S; MINAMI, N; ABE, H; OBINATA, T			CHARACTERIZATION OF A NOVEL COFILIN ISOFORM THAT IS PREDOMINANTLY EXPRESSED IN MAMMALIAN SKELETAL-MUSCLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN DEPOLYMERIZING FACTOR; BINDING PROTEINS; PORCINE BRAIN; NUCLEOTIDE-SEQUENCE; NUCLEAR TRANSPORT; HUMAN VILLIN; CHICKEN; CDNA; NITROCELLULOSE; POLYMERIZATION	Cofilin is an actin-modulating protein of 20 kDa, which is widely distributed throughout muscle and nonmuscle cells. By means of immunoblotting combined with two-dimensional gel electrophoresis, we found that two cofilin variants, muscle type (M-type) and nonmuscle type (NM-type), exist in mammals, while a single isoform exists in chickens. During in vitro myogenesis of mouse C2 cells, expression of the M-type cofilin was upregulated. To better understand the nature of the M-type cofilin, we cloned cDNAs encoding M-type cofilin from the cDNA library of C2 myotubes and determined the entire sequence. The deduced peptide sequence contained a nuclear localization signal and a putative actin-binding sequence as reported in NM-type cofilin. The sequence showed 81% identity in the amino acid residues with the mouse NM-type cofilin sequence and, interestingly, higher homology (96% identity) with that of chicken cofilin. The mRNA encoding M-type cofilin, though it contains two variants that differ in the size of their 3'-non coding sequences, was detected predominantly in heart, skeletal muscle, C2 myotubes, and testis by Northern blotting, while the mRNA for NM-type cofilin was seen in a variety of non-muscle tissues. The presence of the muscle type isoform of cofilin strongly suggests that cofilin is deeply involved in the regulation of actin function not only in non-muscle cells but also in muscle cells.	CHIBA UNIV, FAC SCI, GRAD SCH SCI & TECHNOL, INAGE KU, CHIBA 263, JAPAN; CHIBA UNIV, FAC SCI, DEPT BIOL, INAGE KU, CHIBA 263, JAPAN	Chiba University; Chiba University			Ono, Shoichiro/A-6475-2015	Ono, Shoichiro/0000-0002-4763-0398				ABE H, 1990, BIOCHEMISTRY-US, V29, P7420, DOI 10.1021/bi00484a010; ABE H, 1989, J BIOCHEM-TOKYO, V106, P696, DOI 10.1093/oxfordjournals.jbchem.a122919; ABE H, 1993, EXP CELL RES, V206, P1, DOI 10.1006/excr.1993.1113; ABE H, 1989, J BIOCHEM-TOKYO, V106, P172, DOI 10.1093/oxfordjournals.jbchem.a122810; ADAMS ME, 1990, BIOCHEMISTRY-US, V29, P7414, DOI 10.1021/bi00484a009; ARPIN M, 1988, J CELL BIOL, V107, P1759, DOI 10.1083/jcb.107.5.1759; BAMBURG JR, 1980, FEBS LETT, V121, P178, DOI 10.1016/0014-5793(80)81292-0; BAMBURG JR, 1987, J CELL BIOL, V105, P2817, DOI 10.1083/jcb.105.6.2817; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2302; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEBLAS AL, 1983, ANAL BIOCHEM, V133, P214, DOI 10.1016/0003-2697(83)90245-2; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; HAYAKAWA K, 1993, J BIOCHEM-TOKYO, V114, P582, DOI 10.1093/oxfordjournals.jbchem.a124220; IIDA K, 1992, CELL STRUCT FUNCT, V17, P39, DOI 10.1247/csf.17.39; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAEKAWA S, 1984, J BIOCHEM-TOKYO, V95, P377, DOI 10.1093/oxfordjournals.jbchem.a134618; MATSUZAKI F, 1988, J BIOL CHEM, V263, P11564; MIKAWA T, 1981, J BIOCHEM-TOKYO, V89, P1951, DOI 10.1093/oxfordjournals.jbchem.a133397; MORGAN TE, 1993, J CELL BIOL, V122, P623, DOI 10.1083/jcb.122.3.623; MORIYAMA K, 1992, J BIOL CHEM, V267, P7240; MORIYAMA K, 1990, NUCLEIC ACIDS RES, V18, P3053, DOI 10.1093/nar/18.10.3053; MORIYAMA K, 1990, J BIOL CHEM, V265, P5771; NISHIDA E, 1984, BIOCHEMISTRY-US, V23, P5307, DOI 10.1021/bi00317a032; NISHIDA E, 1985, BIOCHEMISTRY-US, V24, P6624, DOI 10.1021/bi00344a049; NISHIDA E, 1987, P NATL ACAD SCI USA, V84, P5262, DOI 10.1073/pnas.84.15.5262; OBINATA T, 1993, INT REV CYTOL, V143, P153; OBINATA T, 1991, INT CONGR SER, P235; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; OGAWA K, 1990, NUCLEIC ACIDS RES, V18, P7169, DOI 10.1093/nar/18.23.7169; OHSHIMA S, 1989, J BIOCHEM-TOKYO, V105, P855, DOI 10.1093/oxfordjournals.jbchem.a122765; OHTA Y, 1989, J BIOL CHEM, V264, P16143; ONO S, 1993, J MUSCLE RES CELL M, V14, P195, DOI 10.1007/BF00115454; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; PRINGAULT E, 1991, P NATL ACAD SCI USA, V88, P10811, DOI 10.1073/pnas.88.23.10811; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHINAGAWA Y, 1993, ZOOL SCI, V10, P611; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WAY M, 1990, NATURE, V344, P292, DOI 10.1038/344292a0; YONEZAWA N, 1991, J BIOL CHEM, V266, P17218; YONEZAWA N, 1989, EUR J BIOCHEM, V183, P235, DOI 10.1111/j.1432-1033.1989.tb14918.x; YONEZAWA N, 1985, J BIOL CHEM, V260, P4410; YONEZAWA N, 1987, CELL STRUCT FUNCT, V12, P443, DOI 10.1247/csf.12.443; YONEZAWA N, 1991, J BIOL CHEM, V266, P10485	45	93	104	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					15280	15286						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195165				2022-12-25	WOS:A1994NP73800064
J	OSSORIO, PN; DUBREMETZ, JF; JOINER, KA				OSSORIO, PN; DUBREMETZ, JF; JOINER, KA			A SOLUBLE SECRETORY PROTEIN OF THE INTRACELLULAR PARASITE TOXOPLASMA-GONDII ASSOCIATES WITH THE PARASITOPHOROUS VACUOLE MEMBRANE THROUGH HYDROPHOBIC INTERACTIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROCYTE SURFACE-ANTIGEN; INDUCED PHASE-SEPARATION; HOST-CELL INVASION; PLASMODIUM-FALCIPARUM; MONOCLONAL-ANTIBODIES; DENSE GRANULES; TRITON X-114; INFECTED ERYTHROCYTES; LOCALIZATION; RHOPTRIES	The obligate intracellular parasite Toxoplasma gondii resides within a specialized, nonfusogenic vacuole termed the parasitophorous vacuole. We are exploring the hypothesis that parasite proteins contained in dense core granules and secreted into the vacuole after cell invasion contribute to the modification of the parasitophorous vacuole membrane (PVM). The dense granule protein GRA3 associates preferentially with the PVM. Here we show that GRA3 liberated from dense granules is a soluble protein. Following secretion, one-third or more of GRA3 in the parasitophorous vacuole becomes stably associated with the vacuole membrane as judged by sucrose flotation gradients and Triton X-114 phase partitioning experiments. GRA3 cannot be removed from the membrane by extraction with sodium carbonate at pH 11.0, nor can it be labeled in infected cells with [1-C-14]acetate. In sucrose velocity sedimentation gradients, GRA3 from vacuolar membranes solubilized in Triton X-100 sediments as an oligomer. Membrane-associated GRA3 cross-links to itself, migrating as a ladder of bands in SDS-polyacrylamide gel electrophoresis. No other parasite or cell proteins co-precipitate with cross-linked GRA3. We conclude that a portion of GRA3 secreted from the parasite as a soluble protein directly inserts into the vacuole membrane in an oligomeric form. This is the first report in Toxoplasma or related parasites of a protein which inserts into the vacuole membrane for some purpose other than to lyse that membrane.	INSERM, U42, F-59650 VILLENEUVE DASCQ, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm)	OSSORIO, PN (corresponding author), YALE UNIV, SCH MED, DEPT INTERNAL MED, INFECT DIS SECT, NEW HAVEN, CT 06510 USA.		Joiner, Keith/AAH-1059-2021	Joiner, Keith/0000-0003-3062-823X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030060] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI 30060] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ACHBAROU A, 1991, PARASITOLOGY, V103, P321, DOI 10.1017/S0031182000059837; ALEY SB, 1984, J EXP MED, V160, P1585, DOI 10.1084/jem.160.5.1585; ANDREWS NW, 1990, CELL, V61, P1277, DOI 10.1016/0092-8674(90)90692-8; ANDREWS NW, 1991, PARASITOL TODAY, V7, P335, DOI 10.1016/0169-4758(91)90212-7; BALCH WE, 1985, ARCH BIOCHEM BIOPHYS, V240, P413, DOI 10.1016/0003-9861(85)90046-3; BERNHEIMER AW, 1986, BIOCHIM BIOPHYS ACTA, V864, P123, DOI 10.1016/0304-4157(86)90018-3; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BROWN GV, 1985, J EXP MED, V162, P774, DOI 10.1084/jem.162.2.774; CHANAT E, 1991, J CELL BIOL, V115, P1505, DOI 10.1083/jcb.115.6.1505; COPPEL RL, 1988, MOL BIOCHEM PARASIT, V31, P223, DOI 10.1016/0166-6851(88)90152-1; COUVREUR G, 1988, PARASITOLOGY, V97, P1, DOI 10.1017/S0031182000066695; CULVENOR JG, 1991, INFECT IMMUN, V59, P1183, DOI 10.1128/IAI.59.3.1183-1187.1991; DEMPSEY CE, 1990, BIOCHIM BIOPHYS ACTA, V1031, P143, DOI 10.1016/0304-4157(90)90006-X; DUBREMETZ JF, 1993, PARASITOL RES, V79, P402, DOI 10.1007/BF00931830; ETZION Z, 1989, EUR J CELL BIOL, V48, P174; FOLEY M, 1990, MOL BIOCHEM PARASIT, V38, P69, DOI 10.1016/0166-6851(90)90206-2; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; FURTADO GC, 1992, INFECT IMMUN, V60, P2337, DOI 10.1128/IAI.60.6.2337-2342.1992; GORMLEY JA, 1992, J CELL BIOL, V119, P1481, DOI 10.1083/jcb.119.6.1481; GUNTHER K, 1991, MOL BIOCHEM PARASIT, V46, P149, DOI 10.1016/0166-6851(91)90208-N; HIGH N, 1992, EMBO J, V11, P1991, DOI 10.1002/j.1460-2075.1992.tb05253.x; HOOPER NM, 1991, BIOCHEM J, V280, P745, DOI 10.1042/bj2800745; JOINER KA, 1990, SCIENCE, V249, P641, DOI 10.1126/science.2200126; JONES TC, 1972, J EXP MED, V136, P1173, DOI 10.1084/jem.136.5.1173; KARA UAK, 1988, INFECT IMMUN, V56, P903, DOI 10.1128/IAI.56.4.903-909.1988; KIMATA I, 1987, J CELL SCI, V88, P231; LAKEY JH, 1992, FEBS LETT, V307, P26, DOI 10.1016/0014-5793(92)80895-N; LECORDIER L, 1993, MOL BIOCHEM PARASIT, V59, P143, DOI 10.1016/0166-6851(93)90015-P; LERICHE MA, 1991, MOL BIOCHEM PARASIT, V45, P249, DOI 10.1016/0166-6851(91)90092-K; LERICHE MA, 1990, PARASITOL RES, V76, P559, DOI 10.1007/BF00932560; LI WL, 1991, MOL BIOCHEM PARASIT, V49, P157, DOI 10.1016/0166-6851(91)90138-V; LINDER E, 1992, PARASITOL RES, V78, P175, DOI 10.1007/BF00931663; LUSTIGMAN S, 1990, MOL BIOCHEM PARASIT, V38, P261, DOI 10.1016/0166-6851(90)90029-L; LYCKE E, 1968, J BACTERIOL, V96, P785, DOI 10.1128/JB.96.3.785-788.1968; MAHER PA, 1985, P NATL ACAD SCI USA, V82, P958, DOI 10.1073/pnas.82.4.958; MERCIER C, 1993, MOL BIOCHEM PARASIT, V58, P71, DOI 10.1016/0166-6851(93)90092-C; NAGEL SD, 1989, J BIOL CHEM, V264, P5569; NICHOLS BA, 1983, J ULTRA MOL STRUCT R, V83, P85, DOI 10.1016/S0022-5320(83)90067-9; NIEHRS C, 1992, EUR J CELL BIOL, V58, P35; OJCIUS DM, 1991, TRENDS BIOCHEM SCI, V16, P225, DOI 10.1016/0968-0004(91)90090-I; OSSORIO PN, 1992, MOL BIOCHEM PARASIT, V50, P1, DOI 10.1016/0166-6851(92)90239-G; PARKER MW, 1990, TRENDS BIOCHEM SCI, V15, P126, DOI 10.1016/0968-0004(90)90205-P; PEITSCH M C, 1991, Current Opinion in Cell Biology, V3, P710, DOI 10.1016/0955-0674(91)90045-Z; PEITSCH MC, 1990, MOL IMMUNOL, V27, P589, DOI 10.1016/0161-5890(90)90001-G; POISNER AM, 1982, SECRETORY GRANULE; PORCHETHENNERE E, 1983, PROTISTOLOGICA, V19, P357; PORTNOY DA, 1992, INFECT IMMUN, V60, P1263, DOI 10.1128/IAI.60.4.1263-1267.1992; PRYDE JG, 1986, BIOCHEM J, V233, P525, DOI 10.1042/bj2330525; PRYDE JG, 1986, TRENDS BIOCHEM SCI, V11, P160, DOI 10.1016/0968-0004(86)90132-5; SAMYELLOWE TY, 1990, MOL BIOCHEM PARASIT, V39, P91, DOI 10.1016/0166-6851(90)90011-A; SCHWAB JC, 1994, P NATL ACAD SCI USA, V91, P509, DOI 10.1073/pnas.91.2.509; SCHWARTZMAN JD, 1986, INFECT IMMUN, V51, P760, DOI 10.1128/IAI.51.3.760-764.1986; SCHWARTZMAN JD, 1989, EXP PARASITOL, V68, P74, DOI 10.1016/0014-4894(89)90010-6; Sibley L. D., 1989, Intracellular parasitism., P245; SIBLEY LD, 1985, NATURE, V315, P416, DOI 10.1038/315416a0; SIBLEY LD, 1988, EUR J CELL BIOL, V47, P81; SIBLEY LD, 1986, J CELL BIOL, V103, P867, DOI 10.1083/jcb.103.3.867; SIMMONS D, 1987, EMBO J, V6, P485, DOI 10.1002/j.1460-2075.1987.tb04779.x; SUETTERLIN BW, 1991, MOL BIOCHEM PARASIT, V46, P113, DOI 10.1016/0166-6851(91)90205-K; TOKUNAGA H, 1992, BIOCHIM BIOPHYS ACTA, V1105, P125, DOI 10.1016/0005-2736(92)90170-Q; TOOZE SA, 1991, FEBS LETT, V285, P220, DOI 10.1016/0014-5793(91)80805-D; WALLACE BA, 1986, P NATL ACAD SCI USA, V83, P9423, DOI 10.1073/pnas.83.24.9423	62	69	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					15350	15357						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195173				2022-12-25	WOS:A1994NP73800074
J	MCMASTER, CR; BELL, RM				MCMASTER, CR; BELL, RM			PHOSPHATIDYLCHOLINE BIOSYNTHESIS VIA THE CDP-CHOLINE PATHWAY IN SACCHAROMYCES-CEREVISIAE - MULTIPLE MECHANISMS OF REGULATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENCODING CHOLINEPHOSPHATE CYTIDYLYLTRANSFERASE; PHOSPHATIDYLSERINE SYNTHASE ACTIVITY; DEPENDENT PROTEIN-KINASE; EPT1 GENE-PRODUCTS; PHOSPHOLIPID BIOSYNTHESIS; COORDINATE REGULATION; YEAST MUTANT; SN-1,2-DIACYLGLYCEROL CHOLINEPHOSPHOTRANSFERASE; PHOSPHATIDYLETHANOLAMINE METHYLTRANSFERASE; PHOSPHATIDATE PHOSPHATASE	Multiple mechanisms of regulation in the CDP-choline pathway for phosphatidylcholine (PC) synthesis were revealed by exploring the effects of choline and inositol on this pathway in Saccharomyces cerevisiae. At exogenous choline concentrations below 100 mu M, phosphocholine cytidylyltransferase was rate-limiting; at higher choline concentrations the conversion of choline to phosphocholine by choline kinase became rate-limiting. Choline and inositol were found to regulate choline uptake; this established another regulatory mechanism by which PC synthesis is regulated in yeast. Inositol addition did not immediately affect labeled choline uptake or its incorporation into PC in actively dividing cells; however, preculturing the cells in the presence of choline decreased the rate of choline uptake, and this effect was amplified by the concomitant addition of inositol and choline. Additionally, a growth phase dependent effect of inositol supplementation was observed. Inositol addition to stationary phase cells resulted in an increase in choline uptake and subsequent PC production in these cells. This increase was shown to be due to an increase in the rate of choline transport into the cell. In the presence of inositol, choline transport is the main regulatory mechanism controlling flux through the CDP-choline pathway in S. cerevisiae. Inositol supplementation resulted in changes in the levels of enzyme activity detected in vitro. However, the effects observed in vivo correlated exclusively with changes in choline uptake. Choline transporter assays were consistent with these results. Since both the CPT1 and EPT1 gene products catalyze the cholinephosphotransferase reaction in vitro (Hjelmstad, R. H., and Bell, R. M. (1991) J. Biol. Chem. 266, 4357-4365), the effect of inositol on these two separate routes for PC biosynthesis was investigated. The data revealed that only cells harboring a functional CPT1 gene synthesized PC in vivo. These cells (ept1-Delta 1::URA3) also displayed an identical mode of regulation in response to inositol as did cells containing an intact EPT1 gene (wild type) indicating there is no requirement for an alternate functional CDP-aminoalcohol pathway for inositol to regulate PC synthesis via the CDP-choline pathway.	DUKE UNIV, MED CTR, DEPT MOLEC CANC BIOL, DURHAM, NC 27710 USA	Duke University				McMaster, Christopher/0000-0003-0822-5776	NIGMS NIH HHS [GM20015] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMES BN, 1960, J BIOL CHEM, V235, P769; ATKINSON K, 1980, J BIOL CHEM, V255, P6653; ATKINSON KD, 1980, J BACTERIOL, V141, P558, DOI 10.1128/JB.141.2.558-564.1980; BAILIS AM, 1992, NUCLEIC ACIDS RES, V20, P1411, DOI 10.1093/nar/20.6.1411; BAILIS AM, 1987, MOL CELL BIOL, V7, P167, DOI 10.1128/MCB.7.1.167; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; CARMAN GM, 1989, ANNU REV BIOCHEM, V58, P635, DOI 10.1146/annurev.biochem.58.1.635; CARSON MA, 1984, J BIOL CHEM, V259, P6267; CARSON MA, 1982, J BIOL CHEM, V257, P8115; CLEVES AE, 1991, CELL, V64, P789, DOI 10.1016/0092-8674(91)90508-V; EXTON JH, 1990, J BIOL CHEM, V265, P1; GAYNOR PM, 1991, BIOCHIM BIOPHYS ACTA, V1090, P326, DOI 10.1016/0167-4781(91)90197-T; GREENBERG ML, 1988, MOL CELL BIOL, V8, P4773, DOI 10.1128/MCB.8.11.4773; Henry S. A., 1982, MOL BIOL YEAST SACCH, P101; HJELMSTAD RH, 1988, J BIOL CHEM, V263, P19748; HJELMSTAD RH, 1991, J BIOL CHEM, V266, P4357; HJELMSTAD RH, 1987, J BIOL CHEM, V262, P3909; HJELMSTAD RH, 1991, J BIOL CHEM, V266, P5094; HJELMSTAD RH, 1990, J BIOL CHEM, V265, P1755; HOMANN MJ, 1987, J BACTERIOL, V169, P533, DOI 10.1128/jb.169.2.533-539.1987; HOMANN MJ, 1985, J BACTERIOL, V163, P1265, DOI 10.1128/JB.163.3.1265-1266.1985; HOMANN MJ, 1987, J BACTERIOL, V169, P3276, DOI 10.1128/jb.169.7.3276-3280.1987; HOSAKA K, 1981, EUR J BIOCHEM, V116, P1, DOI 10.1111/j.1432-1033.1981.tb05292.x; HOSAKA K, 1990, J BACTERIOL, V172, P2005, DOI 10.1128/jb.172.4.2005-2012.1990; HOSAKA K, 1989, J BIOL CHEM, V264, P2053; HOSAKA K, 1992, J BIOCHEM-TOKYO, V111, P352, DOI 10.1093/oxfordjournals.jbchem.a123761; HOSAKA K, 1987, EUR J BIOCHEM, V162, P7, DOI 10.1111/j.1432-1033.1987.tb10533.x; HOSAKA K, 1980, J BACTERIOL, V143, P176, DOI 10.1128/JB.143.1.176-181.1980; HOSHIZAKI DK, 1990, J BIOL CHEM, V265, P4736; HOUTS GE, 1979, J VIROL, V29, P517, DOI 10.1128/JVI.29.2.517-522.1979; JOHNSON JE, 1992, BIOCHEM J, V285, P815, DOI 10.1042/bj2850815; KELLEY MJ, 1988, J BIOL CHEM, V263, P18078; KENNEDY EP, 1956, J BIOL CHEM, V222, P193; KINNEY AJ, 1990, J BACTERIOL, V172, P1133, DOI 10.1128/jb.172.2.1133-1136.1990; KLIG LS, 1985, J BACTERIOL, V162, P1135, DOI 10.1128/JB.162.3.1135-1141.1985; KOVAC L, 1980, EUR J BIOCHEM, V111, P491, DOI 10.1111/j.1432-1033.1980.tb04965.x; LAMPING E, 1991, J BACTERIOL, V173, P6432, DOI 10.1128/jb.173.20.6432-6437.1991; LESTER RL, 1968, J BIOL CHEM, V243, P4889; LETTS VA, 1985, J BACTERIOL, V163, P560, DOI 10.1128/JB.163.2.560-567.1985; LOEWY BS, 1984, MOL CELL BIOL, V4, P2479, DOI 10.1128/MCB.4.11.2479; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCGRAW P, 1989, GENETICS, V122, P317; MORLOCK KR, 1988, J BACTERIOL, V170, P3561, DOI 10.1128/jb.170.8.3561-3566.1988; NIKAWA J, 1990, J BIOL CHEM, V265, P15996; NIKAWA J, 1983, EUR J BIOCHEM, V131, P223, DOI 10.1111/j.1432-1033.1983.tb07253.x; NIKAWA J, 1982, J BACTERIOL, V150, P441, DOI 10.1128/JB.150.2.441-446.1982; NIKAWA J, 1981, BIOCHIM BIOPHYS ACTA, V665, P420, DOI 10.1016/0005-2760(81)90254-X; NIKAWA J, 1991, J BIOL CHEM, V266, P11184; NIKAWA JI, 1986, J BACTERIOL, V166, P328, DOI 10.1128/jb.166.1.328-330.1986; NIKOLOFF DM, 1991, ANNU REV GENET, V25, P559; PALTAUF F, 1992, MOL CELLULAR BIOL YE, P415; PELECH SL, 1984, BIOCHIM BIOPHYS ACTA, V779, P217, DOI 10.1016/0304-4157(84)90010-8; PELECH SL, 1989, TRENDS BIOCHEM SCI, V14, P28, DOI 10.1016/0968-0004(89)90086-8; POOLE MA, 1986, J BACTERIOL, V168, P668, DOI 10.1128/jb.168.2.668-672.1986; QUINLAN JJ, 1992, J BIOL CHEM, V267, P18013; Rose M. D., 1990, METHODS YEAST GENETI, P140; STEINER MR, 1970, BIOCHEMISTRY-US, V9, P63, DOI 10.1021/bi00803a009; SUMMERS EF, 1988, GENETICS, V120, P909; TSUKAGOSHI Y, 1987, EUR J BIOCHEM, V169, P477, DOI 10.1111/j.1432-1033.1987.tb13635.x; TSUKAGOSHI Y, 1991, J BACTERIOL, V173, P2134, DOI 10.1128/jb.173.6.2134-2136.1991; VANCE DE, 1984, TRENDS BIOCHEM SCI, V9, P17, DOI 10.1016/0968-0004(84)90041-0; VANCE DE, 1989, PHOSPHATIDYLCHOLINE, P33; WAECHTER CJ, 1969, J BIOL CHEM, V244, P3419; White DA, 1973, FORM FUNCTION PHOSPH, P441; WHITE MJ, 1991, ADV MICROB PHYSIOL, V32, P1, DOI 10.1016/S0065-2911(08)60004-1; WHITE MJ, 1991, J BIOL CHEM, V266, P863; YAMASHITA S, 1980, EUR J BIOCHEM, V104, P611, DOI 10.1111/j.1432-1033.1980.tb04465.x; YAMASHITA S, 1982, EUR J BIOCHEM, V128, P589; ZELINSKI TA, 1980, J BIOL CHEM, V255, P1423; ZINSER E, 1991, J BACTERIOL, V173, P2026, DOI 10.1128/jb.173.6.2026-2034.1991	70	72	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14776	14783						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	8182083				2022-12-25	WOS:A1994NM06500073
J	SIMONEN, M; JAMSA, E; MAKAROW, M				SIMONEN, M; JAMSA, E; MAKAROW, M			THE ROLE OF THE CARRIER PROTEIN AND DISULFIDE FORMATION IN THE FOLDING OF BETA-LACTAMASE FUSION PROTEINS IN THE ENDOPLASMIC-RETICULUM OF YEAST	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PREPRO-ALPHA-FACTOR; SACCHAROMYCES-CEREVISIAE; GROWTH-FACTOR; S-CEREVISIAE; SECRETION; GENE; EXPRESSION; SEQUENCE; INVITRO; ENCODES	We have studied the relationship between folding and secretion competence of hsp150-beta-lactamase fusion proteins in Saccharomyces cerevisiae. hsp150 is a secretory protein of yeast, and beta-lactamase was chosen, since its folding can be monitored by assaying its enzymatic activity. The hsp150 pre-pro-protein consists of a signal peptide, subunit I, a repetitive region, and a unique C terminus. Fusion of beta-lactamase to the C terminus of hsp150 produced Cla-bla protein, which was secretion-competent but inactive. The Pst-bla protein, where p-lactamase was fused to subunit I, was also inactive and mostly secreted, but part of it remained in the pre-Golgi compartment. When beta-lactamase was fused to the C terminus of the repetitive region, the fusion protein (Kpn-bla) was translocated to the endoplasmic reticulum, acquired disulfide bonds, and adopted an enzymatically active conformation. Kpn-bla was secreted to the medium without decrease of specific activity or retention in the cell. Folding of Kpn-bla to an active and transport competent form required co-translational disulfide for formation, since treatment of cells with dithiothreitol resulted in endoplasmic reticulum-retained inactive Kpn-bla. When dithiothreitol was removed, Kpn-bla resumed transport competence but remained inactive. Reduction of prefolded Kpn-bla did not inhibit enzymatic activity or transport. The repetitive hsp150 carrier may have use in heterologous protein production by conferring secretion competence to foreign proteins in yeast.			SIMONEN, M (corresponding author), UNIV HELSINKI, INST BIOTECHNOL, VALIMOTIE 7, SF-00380 HELSINKI, FINLAND.		Jokitalo, Eija/C-8375-2009	Jokitalo, Eija/0000-0002-4159-6934				ALBERINI CM, 1990, NATURE, V347, P485, DOI 10.1038/347485a0; AMMERER G, 1983, METHOD ENZYMOL, V101, P192; BECKER DM, 1991, METHOD ENZYMOL, V194, P182; BIELEFELD M, 1992, CURR GENET, V21, P265, DOI 10.1007/BF00351680; BOTSTEIN D, 1979, GENE, V8, P17, DOI 10.1016/0378-1119(79)90004-0; BRAAKMAN I, 1992, EMBO J, V11, P1717, DOI 10.1002/j.1460-2075.1992.tb05223.x; BRAKE AJ, 1984, P NATL ACAD SCI-BIOL, V81, P4642, DOI 10.1073/pnas.81.15.4642; CHANG A, 1993, P NATL ACAD SCI USA, V90, P5808, DOI 10.1073/pnas.90.12.5808; DESILVA AM, 1990, J CELL BIOL, V111, P857, DOI 10.1083/jcb.111.3.857; FILHO SA, 1986, BIOTECHNOLOGY, V4, P311; GELLERFORS P, 1989, J BIOL CHEM, V264, P11444; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GUNTHER R, 1991, J BIOL CHEM, V266, P24557; HOLLENBERG CP, 1983, GENE EXPRESSION YEAS, P73; HURTLEY SM, 1989, J CELL BIOL, V108, P2117, DOI 10.1083/jcb.108.6.2117; JAMSA E, 1994, YEAST, V10, P355, DOI 10.1002/yea.320100308; JULIUS D, 1984, CELL, V36, P309, DOI 10.1016/0092-8674(84)90224-1; KASSENBROCK CK, 1988, NATURE, V333, P90, DOI 10.1038/333090a0; LAMINET AA, 1989, EMBO J, V8, P1469, DOI 10.1002/j.1460-2075.1989.tb03530.x; LODISH HF, 1992, J BIOL CHEM, V267, P12753; LOISON G, 1988, BIO-TECHNOL, V6, P72, DOI 10.1038/nbt0188-72; NORMINGTON K, 1989, CELL, V57, P1223, DOI 10.1016/0092-8674(89)90059-7; OCALLAGHAN CH, 1972, ANTIMICROB AGENTS CH, V1, P283, DOI 10.1128/AAC.1.4.283; RIEDERER MA, 1991, J BACTERIOL, V173, P3539, DOI 10.1128/jb.173.11.3539-3546.1991; ROGGENKAMP R, 1985, J BIOL CHEM, V260, P1508; ROMANOS MA, 1992, YEAST, V8, P423, DOI 10.1002/yea.320080602; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; ROTHBLATT JA, 1987, EMBO J, V6, P3455, DOI 10.1002/j.1460-2075.1987.tb02669.x; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; RUSSO P, 1992, P NATL ACAD SCI USA, V89, P3671, DOI 10.1073/pnas.89.9.3671; RUSSO P, 1993, MOL GEN GENET, V239, P273, DOI 10.1007/BF00281628; RUSSO P, 1992, P NATL ACAD SCI USA, V89, P8857, DOI 10.1073/pnas.89.18.8857; SAKAI A, 1991, BIO-TECHNOL, V9, P1382, DOI 10.1038/nbt1291-1382; Sambrook J, 1989, MOL CLONING LABORATO; SATO T, 1989, GENE, V83, P355, DOI 10.1016/0378-1119(89)90122-4; SCHERENS B, 1991, YEAST, V7, P185, DOI 10.1002/yea.320070212; TACHIBANA C, 1992, MOL CELL BIOL, V12, P4601, DOI 10.1128/MCB.12.10.4601; THIM L, 1986, P NATL ACAD SCI USA, V83, P6766, DOI 10.1073/pnas.83.18.6766; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885	39	26	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					13887	13892						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188666				2022-12-25	WOS:A1994NL60600028
J	GE, RW; RHEE, M; MALIK, S; KARATHANASIS, SK				GE, RW; RHEE, M; MALIK, S; KARATHANASIS, SK			TRANSCRIPTIONAL REPRESSION OF APOLIPOPROTEIN AI GENE-EXPRESSION BY ORPHAN RECEPTOR ARP-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; ENHANCER-BINDING-PROTEIN; ZINC FINGER PROTEIN; E MESSENGER-RNA; I GENE; RETINOIC ACID; LIVER; SUPERFAMILY; CELLS; DIFFERENTIATION	Expression of the apolipoprotein AI (apoAI) gene in the liver is controlled by a liver specific enhancer. The function of this enhancer depends on synergistic interactions between transcription factors bound to at least three sites (designated A, B, and C) located within this enhancer. We have previously shown that an apoAI gene reporter construct containing the entire enhancer is expressed efficiently in a hepatoma cell line and that its activity is repressed by the orphan receptor ARP-1. Moreover, repression by ARP-1 is overcome by the retinoid X receptor RXR alpha in the presence of retinoic acid. In this study, we show that ARP-1 represses the apoAI prometer by binding to site A of the apoAI liver specific enhancer, the repression being a promoter context-specific event. Mapping analysis of ARP-1 indicated that its DNA binding domain is essential but not sufficient for repression. Two separate repression domains located at the amino- and carboxyl terminal halves of ARP-1 were found to individually complement the DNA binding domain for efficient repression. We also demonstrate the reversibility of ARP-1 repression by transcription factors C/EBP and Egr-1, which might also be involved in apoAI gene expression. Significantly, repression by ARP-1 was found to be a prerequisite for C/EBP-mediated transactivation. We interpret our results in terms of a model in which ARP-1 repression via its interaction with site A is an obligatory intermediate step in switching from one activated state of the apoAI gene to another.	AMER CYANAMID CO,LEDERLE LABS,DEPT CARDIOVASC MOLEC BIOL,PEARL RIVER,NY 10965; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,HOWARD HUGHES MED INST,DEPT MED,DIV GENET,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Howard Hughes Medical Institute			Ge, Ruowen/D-8352-2012	Ge, Ruowen/0000-0002-0750-7336; Rhee, Myungchull/0000-0002-4595-7573				BANIAHMAD A, 1992, EMBO J, V11, P1015, DOI 10.1002/j.1460-2075.1992.tb05140.x; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; COONEY AJ, 1993, J BIOL CHEM, V268, P4152; ELSHOURBAGY NA, 1985, P NATL ACAD SCI USA, V82, P203, DOI 10.1073/pnas.82.1.203; ELSHOURBAGY NA, 1985, P NATL ACAD SCI USA, V82, P8242, DOI 10.1073/pnas.82.23.8242; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Fausto N, 1990, CURR OPIN CELL BIOL, V2, P1036, DOI 10.1016/0955-0674(90)90153-6; FONDELL JD, 1993, GENE DEV, V7, P1400, DOI 10.1101/gad.7.7b.1400; FRIEDMAN JM, 1984, J MOL BIOL, V179, P37, DOI 10.1016/0022-2836(84)90305-X; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; ING NH, 1992, J BIOL CHEM, V267, P17617; KARATHANASIS SK, 1992, MONOGR HUM GENET, V14, P140; LADIAS JAA, 1991, SCIENCE, V251, P561, DOI 10.1126/science.1899293; MIETUSSNYDER M, 1992, MOL CELL BIOL, V12, P1708, DOI 10.1128/MCB.12.4.1708; MISCHOULON D, 1992, MOL CELL BIOL, V12, P2553, DOI 10.1128/MCB.12.6.2553; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; ORO AE, 1988, CELL, V55, P1109, DOI 10.1016/0092-8674(88)90255-3; PAPAZAFIRI P, 1991, J BIOL CHEM, V266, P5790; POWER RF, 1991, SCIENCE, V252, P1546, DOI 10.1126/science.2047861; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; ROTTMAN JN, 1991, MOL CELL BIOL, V11, P3814, DOI 10.1128/MCB.11.7.3814; SASTRY KN, 1988, MOL CELL BIOL, V8, P605, DOI 10.1128/MCB.8.2.605; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; STUNNENBERG HG, 1993, BIOESSAYS, V15, P309, DOI 10.1002/bies.950150504; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; WIDOM RL, 1991, MOL CELL BIOL, V11, P677, DOI 10.1128/MCB.11.2.677; WIDOM RL, 1992, MOL CELL BIOL, V12, P3380, DOI 10.1128/MCB.12.8.3380; ZANNIS VI, 1985, BIOCHEMISTRY-US, V24, P4450, DOI 10.1021/bi00337a028	29	63	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13185	13192						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175747				2022-12-25	WOS:A1994NK18400024
J	KOJIMA, M; OHYAMA, Y; MIYAMOTO, K; MINAMINO, N; KANGAWA, K; MATSUO, H				KOJIMA, M; OHYAMA, Y; MIYAMOTO, K; MINAMINO, N; KANGAWA, K; MATSUO, H			CLONING AND CHARACTERIZATION OF A NOVEL NATRIURETIC PEPTIDE IN FROG (RANA-CATESBEIANA)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE-ANALYSIS; PORCINE BRAIN; RAT-BRAIN; RECEPTOR; CNP; EXPRESSION; PRECURSOR; FAMILY	C-type natriuretic peptide (CNP) is one of three members of the natriuretic peptide family. In the course of cloning frog CNP precursor cDNA, we found cDNA clones encoding a novel natriuretic peptide precursor. This novel natriuretic peptide precursor is a 118-residue peptide, carrying a 22-residue signal peptide at the N terminus and a 17-residue ring structure characteristic of the natriuretic peptide family at the C terminus. The precursor is highly homologous to mammalian CNP precursors. Its C-terminal Cys codon is directly followed by a termination codon. This feature is characteristic of CNP precursor cDNAs. The cGMP-stimulating activity of the novel natriuretic peptide was at the same level with those of frog CNP and mammalian CNPs, when rat CNP receptor was used in the cGMP assay system. Thus, this novel natriuretic peptide is structurally and functionally a member of the C-type natriuretic peptide. We designated the peptide as frog CNP II, and the previously described CNP as frog CNP I. By Northern blot analysis, expression of this novel CNP mRNA was found in brain, heart, lung, and stomach. On the other hand, frog CNP mRNA was mainly expressed in brain, where mammalian CNP mRNA is exclusively expressed. The distribution of the two frog CNPs suggests a complex system for regulating electrolyte and water balance in frog.	NATL CARDIOVASC CTR,RES INST,DEPT BIOCHEM,SUITA,OSAKA 565,JAPAN	National Cerebral & Cardiovascular Center - Japan								ARIMURA JJ, 1991, BIOCHEM BIOPH RES CO, V174, P142, DOI 10.1016/0006-291X(91)90497-U; CHRISMAN TD, 1993, J BIOL CHEM, V268, P3698; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; KOJIMA M, 1990, FEBS LETT, V276, P209, DOI 10.1016/0014-5793(90)80544-S; KOJIMA M, 1989, BIOCHEM BIOPH RES CO, V159, P1420, DOI 10.1016/0006-291X(89)92268-7; KOMATSU Y, 1991, ENDOCRINOLOGY, V129, P1104, DOI 10.1210/endo-129-2-1104; MINAMINO N, 1993, BIOCHEM BIOPH RES CO, V197, P326, DOI 10.1006/bbrc.1993.2479; MINAMINO N, 1990, BIOCHEM BIOPH RES CO, V170, P973, DOI 10.1016/0006-291X(90)92187-5; OHYAMA Y, 1992, BIOCHEM BIOPH RES CO, V183, P743, DOI 10.1016/0006-291X(92)90546-W; OHYAMA Y, 1992, BIOCHEM BIOPH RES CO, V189, P336, DOI 10.1016/0006-291X(92)91563-6; ROSENZWEIG A, 1991, ANNU REV BIOCHEM, V60, P229, DOI 10.1146/annurev.biochem.60.1.229; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SAITO Y, 1989, BIOCHEM BIOPH RES CO, V158, P360, DOI 10.1016/S0006-291X(89)80056-7; SCHULZ S, 1989, CELL, V58, P1155, DOI 10.1016/0092-8674(89)90513-8; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SUDOH T, 1990, BIOCHEM BIOPH RES CO, V168, P863, DOI 10.1016/0006-291X(90)92401-K; TALLERICOMELNYK T, 1992, BIOCHEM BIOPH RES CO, V189, P610, DOI 10.1016/0006-291X(92)92244-R; WILCOX JN, 1991, MOL CELL BIOL, V11, P3454, DOI 10.1128/MCB.11.7.3454; YOSHIHARA A, 1990, BIOCHEM BIOPH RES CO, V173, P591, DOI 10.1016/S0006-291X(05)80076-2	19	37	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13136	13140						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175740				2022-12-25	WOS:A1994NK18400016
J	BARAGI, VM; FLISZAR, CJ; CONROY, MC; YE, QZ; SHIPLEY, JM; WELGUS, HG				BARAGI, VM; FLISZAR, CJ; CONROY, MC; YE, QZ; SHIPLEY, JM; WELGUS, HG			CONTRIBUTION OF THE C-TERMINAL DOMAIN OF METALLOPROTEINASES TO BINDING BY TISSUE INHIBITOR OF METALLOPROTEINASES - C-TERMINAL TRUNCATED STROMELYSIN AND MATRILYSIN EXHIBIT EQUALLY COMPROMISED BINDING AFFINITIES AS COMPARED TO FULL-LENGTH STROMELYSIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKIN FIBROBLAST COLLAGENASE; HUMAN 72-KDA GELATINASE; MATRIX METALLOPROTEINASE; IV COLLAGENASE; PURIFICATION; ACTIVATION; EXPRESSION; TIMP-2; PUMP-1; FAMILY	In this study, we have used high resolution gel-filtration chromatography and measurements of K-i to compare the capacity of full-length native stromelysin, C-terminal truncated stromelysin (Phe(100)-Pro(273)), and matrilysin (the only metalloproteinase spontaneously lacking a C-terminal hemopexin-like domain) to bind to the tissue inhibitor of metalloproteinases (TIMP). While prostromelysin failed to bind TIMP, active stromelysin bound to the inhibitor avidly, exhibiting an affinity for TIMP (K-i = 8.3 x 10(-10) M) essentially identical to that of active interstitial collagenase as determined by compe tition experiments. C-terminal truncated stromelysin also formed a higher M(r) complex with TIMP which survived gel filtration. However, when truncated stromelysin was forced to compete with its full-length parent molecule for limiting amounts of TIMP, the full-length enzyme preferentially bound to the inhibitor. Indeed, binding studies indicated a K-i of 5.95 x 10(-9) M for the truncated variant's interaction with TIMP, only 14% as tight as that of full length stromelysin. We also examined the interaction between TIMP and matrilysin, the only metalloproteinase which naturally lacks a C-terminal domain. Promatrilysin failed to bind the inhibitor. However, active matrilysin readily bound TIMP, forming a complex that resisted separation by gel filtration. When active matrilysin was forced to compete with truncated stromelysin for limiting amounts of TIMP, both enzymes appeared to complex the inhibitor with nearly equivalent efficacy. Indeed, active matrilysin exhibited a K-i for TIMP of 4.5 x 10(-9) M, essentially identical to that of truncated stromelysin. These data indicate that, as is true for collagenase, the C-terminal domain of stromelysin contributes significantly to its capacity to bind the physiologic inhibitor, TIMP. Furthermore, since stromelysin readily processes in vitro to a C-terminal truncated form, this enzyme species, as well as the full length metalloproteinase matrilysin, may resist inhibition by TIMP in areas of active inflammation in vivo.	WARNER LAMBERT PARKE DAVIS,PARKE DAVIS PHARMACEUT RES,DEPT BIOCHEM,ANN ARBOR,MI 48105; WASHINGTON UNIV,JEWISH HOSP ST LOUIS,SCH MED,DEPT MED,DIV DERMATOL,ST LOUIS,MO 63110; WASHINGTON UNIV,JEWISH HOSP ST LOUIS,SCH MED,DEPT MED,DIV RESP & CRIT CARE,ST LOUIS,MO 63110	Pfizer; Barnes-Jewish Hospital; Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL)	BARAGI, VM (corresponding author), WARNER LAMBERT PARKE DAVIS,PARKE DAVIS PHARMACEUT RES,DEPT IMMUNOPATHOL,2800 PLYMOUTH RD,ANN ARBOR,MI 48105, USA.		Ye, Qizhuang/B-3147-2009		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL029594] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR035805] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL29594] Funding Source: Medline; NIAMS NIH HHS [AR35805] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BUSIEK DF, 1992, J BIOL CHEM, V267, P9087; COLLIER IE, 1992, J BIOL CHEM, V267, P6776; DECLERCK YA, 1991, J BIOL CHEM, V266, P3893; FRIDMAN R, 1992, J BIOL CHEM, V267, P15398; GOLDBERG GI, 1992, J BIOL CHEM, V267, P4583; GOLDBERG GI, 1989, P NATL ACAD SCI USA, V86, P8207, DOI 10.1073/pnas.86.21.8207; HOWARD EW, 1991, J BIOL CHEM, V266, P13070; HOWARD EW, 1991, J BIOL CHEM, V266, P17972; KOKLITIS PA, 1991, BIOCHEM J, V276, P217, DOI 10.1042/bj2760217; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARTI HP, 1992, BIOCHEM J, V285, P899, DOI 10.1042/bj2850899; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; MCDONNELL S, 1991, MOL CARCINOGEN, V4, P527, DOI 10.1002/mc.2940040617; MIYAZAKI K, 1990, CANCER RES, V50, P7758; MULLER D, 1988, BIOCHEM J, V253, P187, DOI 10.1042/bj2530187; MURPHY G, 1992, BIOCHEM J, V283, P637, DOI 10.1042/bj2830637; MURPHY G, 1992, J BIOL CHEM, V267, P9612; MURPHY G, 1991, BIOCHEM J, V277, P277, DOI 10.1042/bj2770277; NAGASE H, 1990, BIOCHEMISTRY-US, V29, P5783, DOI 10.1021/bi00476a020; OKADA Y, 1988, BIOCHEM J, V254, P731, DOI 10.1042/bj2540731; OSHEA M, 1992, BIOCHEMISTRY-US, V31, P10146, DOI 10.1021/bi00157a002; QUANTIN B, 1989, BIOCHEMISTRY-US, V28, P5327, DOI 10.1021/bi00439a004; RODGERS WH, 1993, AM J OBSTET GYNECOL, V168, P253, DOI 10.1016/S0002-9378(12)90922-9; SHAPIRO SD, 1992, J BIOL CHEM, V267, P4664; SIRES UI, 1993, J BIOL CHEM, V268, P2069; STETLERSTEVENSON WG, 1989, J BIOL CHEM, V264, P17374; STRICKLIN GP, 1983, J BIOL CHEM, V258, P2252; TSAO T, 1990, J BIOL CHEM, V265, P5188; WEINGARTEN H, 1985, ANAL BIOCHEM, V147, P437, DOI 10.1016/0003-2697(85)90294-5; WELGUS HG, 1985, COLLAGEN REL RES, V5, P167; WELGUS HG, 1986, J CLIN INVEST, V77, P1675, DOI 10.1172/JCI112485; WILHELM SM, 1987, P NATL ACAD SCI USA, V84, P6725, DOI 10.1073/pnas.84.19.6725; WILLENBROCK F, 1993, BIOCHEMISTRY-US, V32, P4330, DOI 10.1021/bi00067a023; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; WOESSNER JF, 1988, J BIOL CHEM, V263, P16918; YE QZ, 1992, BIOCHEMISTRY-US, V31, P11231, DOI 10.1021/bi00160a038	36	67	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12692	12697						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175679				2022-12-25	WOS:A1994NH71600051
J	MILLERMARTINI, DM; HUA, S; HOROWITZ, PM				MILLERMARTINI, DM; HUA, S; HOROWITZ, PM			CYSTEINE-254 CAN COOPERATE WITH ACTIVE-SITE CYSTEINE-247 IN REACTIVATION OF 5,5'-DITHIOBIS(2-NITROBENZOIC ACID)-INACTIVATED RHODANESE AS DETERMINED BY SITE-DIRECTED MUTAGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE LIVER RHODANESE; ENZYME; CATALYSIS; COVALENT; STATES	Sulfhydryl substitution mutants of rhodanese (thiosulfate:cyanide sulfurtransferase; EC 2.8.1.1) were used to determine whether the 4 cysteine residues in the native structure could cooperate in reactions. The sulfhydryl reactivity of persulfide-containing (ES) rhodanese was not significantly changed when cysteine residues at positions 63, 254, and 263 were replaced by serine, either individually or in combination. However, the sulfhydryl reactivity of persulfide-free (E) rhodanese was enhanced when Cys-254 was mutated. One sulfhydryl group, presumably the active site Cys-247, reacted rapidly in the E forms of these proteins with 5,5'-dithiobis(2-nitrobenzoic acid) (DTNB) or 4,4'-dipyridyl disulfide (4-PDS). After reaction with DTNB or 4-PDS, proteins with Cys-254 retained >95% of their original activities as compared with Ser-254-containing proteins, which retained <6% of their activities. Cyanide treatment could release thionitrobenzoate from rhodanese-thionitrobenzoate complexes with an approximate 1:1 stoichiometry. After this treatment, only the wild-type and C263S enzymes were fully active. Cyanide-treated rhodanese-thionitrobenzoate complexes of the C254S and C254S/C263S mutants could be fully reactivated using an exogenously added thiol, beta-mercaptoethanol. These results are consistent with the formation of a Cys-247-thiocyano derivative that is inactive but capable of being reactivated by intramolecular transfer of cyanide to Cys-254. In the absence of Cys 254, beta-mercaptoethanol can serve as the transferring sulfhydryl group.	UNIV TEXAS,HLTH SCI CTR,DEPT BIOCHEM,SAN ANTONIO,TX 78284	University of Texas System; University of Texas Health San Antonio					NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES005729] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025177] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES05729] Funding Source: Medline; NIGMS NIH HHS [GM25177] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHOW SF, 1985, J BIOL CHEM, V260, P2763; CHUNG AE, 1971, BIOCHEMISTRY-US, V10, P2872, DOI 10.1021/bi00791a012; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HEINRIKSON RL, 1983, FRONTIERS BIOCH BIOP, P163; HOL WGJ, 1983, FUND APPL TOXICOL, V3, P370, DOI 10.1016/S0272-0590(83)80007-4; HOL WGJ, 1987, BIOL MACROMOL, P483; HOROWITZ P, 1983, J BIOL CHEM, V258, P7894; HOROWITZ PM, 1989, J BIOL CHEM, V264, P3311; HOROWITZ PM, 1988, J BIOL CHEM, V263, P10278; HOROWITZ PM, 1987, J BIOL CHEM, V262, P14544; HOROWITZ PM, 1992, BIOCATALYST DESIGN S, V516, P167; ISLAM TA, 1994, J BIOL CHEM, V269, P7908; JOCELYN PC, 1972, BIOCH SH GROUP, P116; KOHANSKI RA, 1990, J PROTEIN CHEM, V9, P369, DOI 10.1007/BF01024612; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEMIRE BD, 1989, J BIOL CHEM, V264, P20206; MILLER DM, 1992, BIOCHIM BIOPHYS ACTA, V1121, P286, DOI 10.1016/0167-4838(92)90158-A; MILLER DM, 1991, J BIOL CHEM, V266, P4686; MILLERMARTINI DM, 1994, J BIOL CHEM, V269, P3423; MINTEL R, 1966, J BIOL CHEM, V241, P3386; OGATA K, 1990, J BIOL CHEM, V265, P8087; OGATA K, 1988, J BIOL CHEM, V264, P2718; PENSA B, 1977, BIOCHIM BIOPHYS ACTA, V484, P368, DOI 10.1016/0005-2744(77)90092-4; PLOEGMAN JH, 1978, NATURE, V273, P124, DOI 10.1038/273124a0; PLOEGMAN JH, 1973, THESIS U GRONINGEN; RUSSELL J, 1978, J BIOL CHEM, V253, P8102; SORBO B, 1973, ACTA CHEM SCAND, V7, P1123; WANG SF, 1968, J BIOL CHEM, V243, P5465; WEILAND KL, 1991, BIOCHEM J, V275, P227, DOI 10.1042/bj2750227; WENG L, 1978, J BIOL CHEM, V253, P8109; WESTLEY J, 1983, FUND APPL TOXICOL, V3, P377, DOI 10.1016/S0272-0590(83)80008-6; WESTLEY J, 1973, ADV ENZYMOL RAMB, V39, P327; Westley J., 1977, BIOORG CHEM, V1, P371; WOOD JL, 1982, ADV EXP MED BIOL, V148, P327	34	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12414	12418						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175646				2022-12-25	WOS:A1994NH71600009
J	ZIEGLER, FD; GEMMILL, TR; TRIMBLE, RB				ZIEGLER, FD; GEMMILL, TR; TRIMBLE, RB			GLYCOPROTEIN-SYNTHESIS IN YEAST - EARLY EVENTS IN N-LINKED OLIGOSACCHARIDE PROCESSING IN SCHIZOSACCHAROMYCES-POMBE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANION-EXCHANGE CHROMATOGRAPHY; SACCHAROMYCES-CEREVISIAE; ACETYLGLUCOSAMINIDASE-H; PROTEIN GLYCOSYLATION; H-1-NMR SPECTROSCOPY; PURIFICATION; INVERTASE; BIOSYNTHESIS; MANNOSIDASE; MICROSOMES	Oligosaccharide-lipid precursors and glycoprotein N-linked oligosaccharides isolated from the fission yeast, Schizosaccharomyces pombe, were compared with those from the budding yeast, Saccharomyces cerevisiae. Bio-Gel P-4 chromatography of oligosaccharide intermediates showed that Glc(3)Man(9)GlcNAc(2)-PP-dol synthesis, transfer of glycan to protein, and glucose removal to yield Man(9)GlcNAc(2) proceeded in S. pombe as in S. cerevisiae. Two series of oligosaccharides were released from S. pombe glycoproteins by endo-beta-N-acetylglu cosaminidase H; large ''mannan-like'' structures and smaller precursor or ''core-filling'' species. Unexpectedly, the smallest S. pombe N-linked glycan was Man(9)GlcNAc, confirmed by 500 MHz H-1 NMR spectroscopy to be the lipid-linked isomer. No endoplasmic reticulum Man(9)-alpha 1,2-mannosidase activity was detected in S. pombe, thus identifying Man(9)GlcNAc as the minimum precursor for oligosaccharide elongation in contrast to the Man(8)GlcNA(2), intermediate identified in S. cerevisiae (Byrd, J.C., Tarentino, A.L., Maley, F., Atkinson, P.H., and Trimble, R.B. (1982) J. Biol. Chem. 257, 14657-14666). S. pombe Hex(10)GlcNAc was at least four isomers by high pH anion-exchange chromatography with pulsed amperometric detection. Compositional analyses identified two of the major species as GalMan(9)GlcNac and GlcMan(9)GlcNAc, the latter of which suggests that glycan trimming may be attenuated in the S. pombe endoplasmic reticulum. Hex(13)GlcNAc from S. pombe was homogeneous by mass spectrometry but yielded 12 species by high pH anion-exchange chromatography. Compositional analyses, alpha-galactosidase digestion, and lectin affinity chromatography on Griffonia simplicifolia lectin I-agarose indicated these to be a family of Gal(x) Man(13-x)GlcNAc isomers (X = 1-4 residues). The absence of Man(9)GlcNAc(2), to Man(8)GlcNAc(2), trimming in S. pombe and elongation of the lipid precursor of Man(9)GlcNAc with both Man and Gal to form ''galactomannans'' provides a novel system for N-linked glycoprotein processing studies.	NEW YORK STATE DEPT HLTH,WADSWORTH CTR LABS & RES,ALBANY,NY 12201; SUNY ALBANY,SCH PUBL HLTH,DEPT BIOMED SCI,ALBANY,NY 12201	State University of New York (SUNY) System; Wadsworth Center; State University of New York (SUNY) System; State University of New York (SUNY) Albany					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023900] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM23900] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALLOU CE, 1990, METHOD ENZYMOL, V185, P440; BYRD JC, 1982, J BIOL CHEM, V257, P4657; CHAPPELL TG, 1989, J CELL BIOL, V109, P2693, DOI 10.1083/jcb.109.6.2693; DIBENEDETTO G, 1972, BIOCHIM BIOPHYS ACTA, V286, P363, DOI 10.1016/0304-4165(72)90272-3; DIBENEDETTO G, 1975, BIOCHEMISTRY-US, V14, P2847, DOI 10.1021/bi00684a009; DORLAND L, 1981, J BIOL CHEM, V256, P7708; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; HARDY MR, 1988, ANAL BIOCHEM, V170, P54, DOI 10.1016/0003-2697(88)90089-9; HERSCOVICS A, 1993, FASEB J, V7, P540, DOI 10.1096/fasebj.7.6.8472892; HIRSCHBERG CB, 1987, ANNU REV BIOCHEM, V56, P63, DOI 10.1146/annurev.bi.56.070187.000431; JELINEKKELLY S, 1988, J BIOL CHEM, V263, P14757; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KUKURUZINSKA MA, 1987, ANNU REV BIOCHEM, V56, P915, DOI 10.1146/annurev.biochem.56.1.915; LEHLE L, 1980, EUR J BIOCHEM, V109, P589, DOI 10.1111/j.1432-1033.1980.tb04832.x; Li Y.-T., 1972, METHOD ENZYMOL, V28, P702; MORENO S, 1985, ARCH MICROBIOL, V142, P370, DOI 10.1007/BF00491906; MORENO S, 1990, BIOCHEM J, V267, P697, DOI 10.1042/bj2670697; PARODI AJ, 1982, J BIOL CHEM, V257, P7641; PUCCIA R, 1993, BIOCHEM J, V290, P21, DOI 10.1042/bj2900021; RANDERATH K, 1964, J CHROMATOGR, V16, P111, DOI 10.1016/S0021-9673(01)82445-6; SCHWEDEN J, 1986, EUR J BIOCHEM, V157, P563, DOI 10.1111/j.1432-1033.1986.tb09703.x; SCHWEINGRUBER AM, 1986, EUR J BIOCH, V158; TANNER W, 1987, BIOCHIM BIOPHYS ACTA, V906, P81, DOI 10.1016/0304-4157(87)90006-2; TOWNSEND R R, 1991, Glycobiology, V1, P139, DOI 10.1093/glycob/1.2.139; TOWNSEND RR, 1991, CARBOHYD RES, V215, P211, DOI 10.1016/0008-6215(91)84021-6; TRIMBLE RB, 1991, J BIOL CHEM, V266, P22807; TRIMBLE RB, 1984, ANAL BIOCHEM, V141, P515, DOI 10.1016/0003-2697(84)90080-0; TRIMBLE RB, 1980, J BIOL CHEM, V255, P232; TRIMBLE RB, 1986, J BIOL CHEM, V261, P9815; TRIMBLE RB, 1980, J BIOL CHEM, V255, P1892; TRIMBLE RB, 1992, GLYCOBIOLOGY, V2, P57, DOI 10.1093/glycob/2.1.57; TRUMBLY RJ, 1985, J BIOL CHEM, V260, P5683; Verostek M. F., 1992, Glycobiology, V2, P458; VEROSTEK MF, 1993, J BIOL CHEM, V268, P12095; ZIEGLER F D, 1991, Glycobiology, V1, P605, DOI 10.1093/glycob/1.6.605	35	52	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12527	12535						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175662				2022-12-25	WOS:A1994NH71600027
J	BURKE, J; PETTITT, JM; HUMPHRIS, D; GLEESON, PA				BURKE, J; PETTITT, JM; HUMPHRIS, D; GLEESON, PA			MEDIAL-GOLGI RETENTION OF N-ACETYLGLUCOSAMINYLTRANSFERASE-I - CONTRIBUTION FROM ALL DOMAINS OF THE ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GALACTOSIDE ALPHA-2,6-SIALYLTRANSFERASE; NH2-TERMINAL SIGNAL ANCHOR; MEMBRANE-SPANNING DOMAIN; TRANSMEMBRANE DOMAIN; IMMUNOELECTRON MICROSCOPY; GLYCOPROTEIN-SYNTHESIS; GENOMIC ORGANIZATION; RAT-LIVER; PROTEIN; LOCALIZATION	We have previously shown that the transmembrane domain and flanking residues of beta-1,2-N-acetylglucosaminyltransferase I (GnTI) can localize a hybrid molecule to medial-Golgi cisternae (Burke, J., Pettitt, J. M., Schachter, H., Sarkar, M., and Gleeson, P.A. (1992) J. Biol. Chem. 267, 24433-24440). Here, we have further examined the contribution of the cytoplasmic tail, transmembrane domain, and the catalytically active, luminal domain of GnTI in medial-Golgi localization, by analyzing the localization of hybrid molecules stably expressed in murine cells. In contrast to wild-type GnTI, which was efficiently localized to the medial-Golgi and not detected at the cell surface, hybrid molecules containing any two of the three domains of GnTI were localized to the medial-Golgi and were also present at low levels at the cell surface. Hybrid molecules containing only the transmembrane domain or the luminal domain of GnTI showed partial Golgi retention together with an increased level of cell surface expression compared with molecules containing two GnTI domains. The cytoplasmic tail independently was unable to retain reporter sequences to the Golgi but increased the ability of constructs containing either the luminal or transmembrane domain of GnTI to localize to the Golgi apparatus. Therefore, all three domains of GnTI contribute significantly to medial-Golgi localization. Furthermore, GnTI hybrid molecules showing increased cell surface expression were more readily extracted in a low salt buffer, suggesting that Golgi localized GnTI differs in physicochemical properties from cell surface GnTI. Based on an aggregation model of localization, we propose that Golgi retention of these hybrid molecules is mediated by the interaction of their GnTI domains with the corresponding domains of endogenous glycosyltransferase aggregates within the Golgi membranes of the transfected cell.	MONASH UNIV,ALFRED HOSP,SCH MED,DEPT PATHOL & IMMUNOL,MELBOURNE,VIC 3181,AUSTRALIA	Florey Institute of Neuroscience & Mental Health; Monash University				Gleeson, Paul/0000-0002-5336-6503				AOKI D, 1992, P NATL ACAD SCI USA, V89, P4319, DOI 10.1073/pnas.89.10.4319; BENDIAK B, 1987, J BIOL CHEM, V262, P5775; BIRD P, 1987, J CELL BIOL, V105, P2905, DOI 10.1083/jcb.105.6.2905; BRETSCHER MS, 1993, SCIENCE, V261, P1280, DOI 10.1126/science.8362242; BURKE J, 1992, J BIOL CHEM, V267, P24433; COLLEY KJ, 1989, J BIOL CHEM, V264, P17619; COLLEY KJ, 1992, J BIOL CHEM, V267, P7784; CROWE JS, 1991, NUCLEIC ACIDS RES, V19, P184, DOI 10.1093/nar/19.1.184; DAGOSTARO G, 1989, EUR J BIOCHEM, V183, P211, DOI 10.1111/j.1432-1033.1989.tb14915.x; DUNPHY WG, 1985, CELL, V40, P463, DOI 10.1016/0092-8674(85)90161-8; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; JOZIASSE DH, 1992, GLYCOBIOLOGY, V2, P271, DOI 10.1093/glycob/2.4.271; KOOY J, 1992, J BIOL CHEM, V267, P20255; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LAMMERS G, 1988, BIOCHEM J, V256, P623, DOI 10.1042/bj2560623; Machamer C E, 1991, Trends Cell Biol, V1, P141, DOI 10.1016/0962-8924(91)90001-P; MACHAMER CE, 1993, MOL BIOL CELL, V4, P695, DOI 10.1091/mbc.4.7.695; MASIBAY AS, 1993, J BIOL CHEM, V268, P9908; MASIBAY AS, 1992, MOL BIOL REP, V116, P99; MCCLELLAND A, 1984, CELL, V39, P267, DOI 10.1016/0092-8674(84)90004-7; MELLMAN I, 1992, CELL, V68, P829, DOI 10.1016/0092-8674(92)90027-A; MOORE MW, 1988, CELL, V54, P777, DOI 10.1016/S0092-8674(88)91043-4; MULLIGAN RC, 1981, P NATL ACAD SCI-BIOL, V78, P2072, DOI 10.1073/pnas.78.4.2072; MUNRO S, 1991, EMBO J, V10, P3577, DOI 10.1002/j.1460-2075.1991.tb04924.x; NILSSON T, 1993, FEBS LETT, V330, P1, DOI 10.1016/0014-5793(93)80906-B; NILSSON T, 1993, J CELL BIOL, V120, P5, DOI 10.1083/jcb.120.1.5; NILSSON T, 1991, EMBO J, V10, P3567, DOI 10.1002/j.1460-2075.1991.tb04923.x; NISHIKAWA Y, 1988, J BIOL CHEM, V263, P8270; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; ROTH J, 1985, CELL, V43, P287, DOI 10.1016/0092-8674(85)90034-0; ROTH J, 1982, J CELL BIOL, V92, P223; ROTH MG, 1988, INFLUENZA VIRUSES, P219; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; RUSSO RN, 1992, J BIOL CHEM, V267, P9241; Sambrook J, 1989, MOL CLONING LABORATO; SARKAR M, 1991, P NATL ACAD SCI USA, V88, P234, DOI 10.1073/pnas.88.1.234; Schachter H, 1991, CURR OPIN STRUC BIOL, V1, P755, DOI 10.1016/0959-440X(91)90175-S; SHAPER JH, 1992, CURR OPIN STRUC BIOL, V2, P701; SLUSAREWICZ P, 1994, IN PRESS J CELL BIOL; STROUS GJ, 1986, CRC CR REV BIOCH MOL, V21, P119, DOI 10.3109/10409238609113610; SUGANUMA T, 1991, J HISTOCHEM CYTOCHEM, V39, P299, DOI 10.1177/39.3.1899684; SWIFT AM, 1991, J CELL BIOL, V115, P19, DOI 10.1083/jcb.115.1.19; TAATJES DJ, 1988, J BIOL CHEM, V263, P6302; TANG BL, 1992, J BIOL CHEM, V267, P10122; TEASDALE RD, 1992, J BIOL CHEM, V267, P4084; VANDENEIJNDEN DH, 1993, CURR OPIN STRUC BIOL, V3, P711, DOI 10.1016/0959-440X(93)90054-O; VANDRIEL IR, 1987, J BIOL CHEM, V262, P4882; VISCHER P, 1981, EUR J BIOCHEM, V117, P275, DOI 10.1111/j.1432-1033.1981.tb06334.x; WEINSTEIN J, 1987, J BIOL CHEM, V262, P17735; WEISZ OA, 1993, J CELL BIOL, V122, P1185, DOI 10.1083/jcb.122.6.1185; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; WONG SH, 1992, J CELL BIOL, V117, P245, DOI 10.1083/jcb.117.2.245	52	57	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 22	1994	269	16					12049	12059						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NG377	8163508				2022-12-25	WOS:A1994NG37700058
J	GANJU, P; SHIGEMOTO, K; BRENNAN, J; ENTWISTLE, A; REITH, AD				GANJU, P; SHIGEMOTO, K; BRENNAN, J; ENTWISTLE, A; REITH, AD			THE ECK RECEPTOR TYROSINE KINASE IS IMPLICATED IN PATTERN-FORMATION DURING GASTRULATION, HINDBRAIN SEGMENTATION AND LIMB DEVELOPMENT	ONCOGENE			English	Article							HEPATOCYTE GROWTH-FACTOR; MOUSE MUTANT EMBRYOS; GERM-CELL SURVIVAL; NEURAL CREST; REPEATED EPILATION; PROTEIN-KINASE; CHICK-EMBRYO; SCATTER FACTOR; MET RECEPTOR; KIT RECEPTOR	Members of the protein superfamily of transmembrane receptor tyrosine kinases are key components of intercellular signal transduction pathways that elicit appropriate cellular responses to environmental cues during development of multicellular organisms. In a search for additional receptor tyrosine kinases expressed during mouse embryogenesis we cloned the murine homolog of Eck, a member of the Eph subfamily, that maps to the distal region of mouse chromosome 4. Specific antisera defined Eck in murine embryonic cells as a glycoprotein of 130 kDa with an intrinsic autophosphorylation activity. Immunohistochemical staining and laser scanning microscopy revealed a dynamic and tightly regulated distribution of Eck receptor protein in the developing mouse embryo. During gastrulation, a high transient distribution of Eck was seen in mesodermal cells aggregating in the midline as notochordal plate. A similar restriction of Eck receptor protein was apparent along the rostrocaudal axis of the developing neural tube. In hindbrain neuroepithelia, Eck protein localised specifically to cells of rhombomere 4 and was also seen transiently in cells populating second and third branchial arches and neurogenic facial crest VII-VIII and IX-X. Receptor distribution also implicated Eck in development of the proximodistal axis of the limb, expression being restricted to distal regions of limb bud mesenchyme. At later stages, additional sites of Eck protein expression were seen in the cartilaginous model of the skeleton, tooth primordia, infundibular component of the pituitary and various fetal tissue epithelia. Taken together, our data suggest pleiotropic functions for the Eck receptor, initially in distinctive aspects of pattern formation and subsequently in development of several fetal tissues, and reveal possible allelism with known mouse developmental mutant loci.	LUDWIG INST CANC RES, LONDON W1P 8BT, ENGLAND	Ludwig Institute for Cancer Research				Brennan, Jane/0000-0003-3222-5485				BEDDINGTON RSP, 1992, DEVELOPMENT, P157; BEDDINGTON RSP, 1993, CURR OPIN GENET DEV, V3, P655, DOI 10.1016/0959-437X(93)90103-V; BLUMEJENSEN P, 1991, EMBO J, V10, P4121, DOI 10.1002/j.1460-2075.1991.tb04989.x; BOHME B, 1993, ONCOGENE, V8, P2857; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; CHAKRAVARTI S, 1991, MAMM GENOME, V1, P270, DOI 10.1007/BF00352338; CHAN J, 1991, ONCOGENE, V6, P1057; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CORDONCARDO C, 1991, CELL, V66, P173, DOI 10.1016/0092-8674(91)90149-S; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; DOLCI S, 1991, NATURE, V352, P809, DOI 10.1038/352809a0; END P, 1992, EUR J BIOCHEM, V209, P1041, DOI 10.1111/j.1432-1033.1992.tb17380.x; ENTWISTLE A, 1992, J MICROSC-OXFORD, V168, P219, DOI 10.1111/j.1365-2818.1992.tb03265.x; ENTWISTLE A, 1992, J MICROSC-OXFORD, V165, P347, DOI 10.1111/j.1365-2818.1992.tb01492.x; ENTWISTLE A, 1990, T ROY MICR, V1, P405; ENTWISTLE A, 1990, T ROY MICR, V1, P361; FAUST C, 1993, CURR OPIN GENET DEV, V3, P491, DOI 10.1016/0959-437X(93)90125-9; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; FRASER S, 1990, NATURE, V344, P431, DOI 10.1038/344431a0; GILARDIHEBENSTREIT P, 1992, ONCOGENE, V7, P2499; GLASS DJ, 1991, CELL, V66, P405, DOI 10.1016/0092-8674(91)90629-D; GODIN I, 1991, NATURE, V352, P807, DOI 10.1038/352807a0; GREENWALD I, 1992, CELL, V68, P271, DOI 10.1016/0092-8674(92)90470-W; GUENET JL, 1979, J HERED, V70, P90, DOI 10.1093/oxfordjournals.jhered.a109223; GUTHRIE S, 1991, DEVELOPMENT, V112, P221; GUTHRIE S, 1992, NATURE, V356, P157, DOI 10.1038/356157a0; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HASIMOTO K, 1987, DEVELOPMENT, V100, P587; HEMPSTEAD BL, 1992, NEURON, V9, P883, DOI 10.1016/0896-6273(92)90241-5; HERRMANN BG, 1992, CIBA F SYMP, V165, P78; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; JAT PS, 1991, P NATL ACAD SCI USA, V88, P5096, DOI 10.1073/pnas.88.12.5096; JOHNSON GD, 1982, J IMMUNOL METHODS, V55, P231, DOI 10.1016/0022-1759(82)90035-7; JURAND A, 1974, J EMBRYOL EXP MORPH, V32, P1; KLEIN R, 1992, NEURON, V8, P947, DOI 10.1016/0896-6273(92)90209-V; KOMADA M, 1993, ONCOGENE, V8, P2381; KRUMLAUF R, 1993, TRENDS GENET, V9, P106, DOI 10.1016/0168-9525(93)90203-T; KURATANI SC, 1993, DEVELOPMENT, V117, P105; LAWSON KA, 1991, DEVELOPMENT, V113, P891; LHOTAK V, 1991, MOL CELL BIOL, V11, P2496, DOI 10.1128/MCB.11.5.2496; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; LOEB DM, 1991, CELL, V66, P961, DOI 10.1016/0092-8674(91)90441-Z; LUMSDEN A, 1989, NATURE, V337, P424, DOI 10.1038/337424a0; LUMSDEN A, 1991, DEVELOPMENT, V113, P1281; MEISLER MH, 1992, TRENDS GENET, V8, P341, DOI 10.1016/0168-9525(92)90278-C; MEREDITH R, 1964, MOUSE NEWS LETT, V31, P25; MONTMINY M, 1993, SCIENCE, V261, P1694, DOI 10.1126/science.8397444; MORGAN BA, 1993, CURR OPIN GENET DEV, V3, P668, DOI 10.1016/0959-437X(93)90105-X; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; NICHOLS DH, 1981, J EMBRYOL EXP MORPH, V64, P105; NIETO MA, 1992, DEVELOPMENT, V116, P1137; NODEN DM, 1988, DEVELOPMENT, V103, P121; OBERMEIER A, 1993, EMBO J, V12, P933, DOI 10.1002/j.1460-2075.1993.tb05734.x; PASQUALE EB, 1991, CELL REGUL, V2, P523, DOI 10.1091/mbc.2.7.523; PASQUALE EB, 1992, J NEUROSCI, V12, P3956; PESCE M, 1993, DEVELOPMENT, V118, P1089; REITH AD, 1990, GENE DEV, V4, P390, DOI 10.1101/gad.4.3.390; REITH AD, 1991, GENE DEV, V5, P1115, DOI 10.1101/gad.5.7.1115; REITH AD, 1991, EMBO J, V10, P2451, DOI 10.1002/j.1460-2075.1991.tb07784.x; REITH AD, 1993, ONCOGENE, V8, P45; REITH AD, 1991, GENOME ANAL, V3, P105; REZNIKOFF CA, 1973, CANCER RES, V33, P3231; SAJJADI FG, 1993, ONCOGENE, V8, P1807; SALZGEBER B, 1984, J CRAN GENET DEV BIO, V4, P95; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SELLECK MAJ, 1992, DEVELOPMENT, V114, P403; SERBEDZIJA GN, 1992, DEVELOPMENT, V116, P297; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SQUINTO SP, 1991, CELL, V65, P885, DOI 10.1016/0092-8674(91)90395-F; SUMMERBELL D, 1973, NATURE, V244, P492, DOI 10.1038/244492a0; TABIN CJ, 1991, CELL, V66, P199, DOI 10.1016/0092-8674(91)90612-3; TASSIN MT, 1983, J CRAN GENET DEV BIO, V3, P289; TAYLOR BA, 1977, J VIROL, V23, P106, DOI 10.1128/JVI.23.1.106-109.1977; VERWOERD CDA, 1979, ADV ANATOMY EMBRYOLO, V58; WESTERMARK B, 1990, P NATL ACAD SCI USA, V87, P128, DOI 10.1073/pnas.87.1.128; WICKS IP, 1992, P NATL ACAD SCI USA, V89, P1611, DOI 10.1073/pnas.89.5.1611; WILCOX FH, 1981, J HERED, V72, P387, DOI 10.1093/oxfordjournals.jhered.a109537; WILKINSON DG, 1993, BIOESSAYS, V15, P499, DOI 10.1002/bies.950150802; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; ZAKUT R, 1993, ONCOGENE, V8, P2221	80	91	98	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1994	9	6					1613	1624						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NL815	8183555				2022-12-25	WOS:A1994NL81500012
J	OHTANIFUJITA, N; FUJITA, T; TAKAHASHI, R; ROBBINS, PD; DRYJA, TP; SAKAI, T				OHTANIFUJITA, N; FUJITA, T; TAKAHASHI, R; ROBBINS, PD; DRYJA, TP; SAKAI, T			A SILENCER ELEMENT IN THE RETINOBLASTOMA TUMOR-SUPPRESSOR GENE	ONCOGENE			English	Article							TRANSCRIPTION FACTOR E2F; SITE-DIRECTED MUTAGENESIS; POLYMERASE CHAIN-REACTION; LARGE T-ANTIGEN; CELL-CYCLE; SUSCEPTIBILITY GENE; E2F-BINDING SITE; BINDING PROTEIN; CARCINOMA-CELLS; REPORTER GENE	We have previously identified two positive regulatory elements in the retinoblastoma gene (RB) promoter. One is an ATF site and the other we have called a retinoblastoma binding factor 1 site. In addition, a consensus E2F site is located directly 3' to the ATF site. Here we demonstrate with gel shift assays that E2F and E2F-dependent complexes can bind in vitro to the E2F site of the RB promoter (RB-E2F site). Moreover, we demonstrate that deletion of the RB-E2F site results in stimulation of RB promoter activity in transient transfection assays in several cell lines. Specific point mutations in the E2F site that inhibit the binding of E2F and its complexes also stimulate the RB promoter activity, suggesting that a factor(s) that can bind to the RB-E2F site could be a silencer. RB promoter activity was also stimulated two- to four-fold by mutation of the E2F site in the RB-negative cell lines, J82 and HTB9. Taken together, our results show that the E2F site in the promoter of the RB tumor-suppressor gene acts as a silencer element and that the silencer effect of the E2F site is not necessarily dependent on the presence of the RB protein.	KYOTO PREFECTURAL UNIV MED,DEPT PREVENT MED,KAMIKYO KU,KYOTO 602,JAPAN; KYOTO UNIV,FAC MED,DEPT PATHOL 2,KYOTO 606,JAPAN; UNIV PITTSBURGH,SCH MED,DEPT MOLEC GENET & BIOCHEM,PITTSBURGH,PA 15261; HARVARD UNIV,SCH MED,MASSACHUSETTS EYE & EAR INFIRM,DEPT OPHTHALMOL,BOSTON,MA 02114	Kyoto Prefectural University of Medicine; Kyoto University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Harvard University; Harvard Medical School; Massachusetts Eye & Ear Infirmary								BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; BIGNON YJ, 1993, GENE DEV, V7, P1654, DOI 10.1101/gad.7.9.1654; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHITTENDEN T, 1993, MOL CELL BIOL, V13, P3975, DOI 10.1128/MCB.13.7.3975; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; COPPOLA JA, 1990, ONCOGENE, V5, P1731; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; ENDO T, 1992, J BIOCHEM-TOKYO, V112, P427, DOI 10.1093/oxfordjournals.jbchem.a123916; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; GIRLING R, 1993, NATURE, V362, P83, DOI 10.1038/362083a0; GOODRICH DW, 1993, BIOCHIM BIOPHYS ACTA, V1155, P43, DOI 10.1016/0304-419X(93)90021-4; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; KADONAGA JT, 1988, SCIENCE, V242, P1566, DOI 10.1126/science.3059495; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MISTCHENKO AS, 1993, INT J CANCER, V53, P87, DOI 10.1002/ijc.2910530117; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; OHTANIFUJITA N, 1993, ONCOGENE, V8, P1063; OSIFCHIN NE, 1994, J BIOL CHEM, V269, P6383; OUELLETTE MM, 1992, ONCOGENE, V7, P1075; RICHON VM, 1992, CELL GROWTH DIFFER, V3, P413; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; SAKAI T, 1991, AM J HUM GENET, V48, P880; SAKAI T, 1991, NATURE, V353, P83, DOI 10.1038/353083a0; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SCHWARZ JK, 1993, EMBO J, V12, P1013, DOI 10.1002/j.1460-2075.1993.tb05742.x; SLACK RS, 1993, ONCOGENE, V8, P1585; TAKAHASHI R, 1991, P NATL ACAD SCI USA, V88, P5257, DOI 10.1073/pnas.88.12.5257; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; YEE AS, 1989, MOL CELL BIOL, V9, P578, DOI 10.1128/MCB.9.2.578; YOKOTA J, 1988, ONCOGENE, V3, P471; ZAMANIAN M, 1992, EMBO J, V11, P2603, DOI 10.1002/j.1460-2075.1992.tb05325.x; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	55	23	23	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1994	9	6					1703	1711						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NL815	8183566				2022-12-25	WOS:A1994NL81500023
J	MATTAR, S; SCHARF, B; KENT, SBH; RODEWALD, K; OESTERHELT, D; ENGELHARD, M				MATTAR, S; SCHARF, B; KENT, SBH; RODEWALD, K; OESTERHELT, D; ENGELHARD, M			THE PRIMARY STRUCTURE OF HALOCYANIN, AN ARCHAEAL BLUE COPPER PROTEIN, PREDICTS A LIPID ANCHOR FOR MEMBRANE FIXATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; ESCHERICHIA-COLI; SIGNAL PEPTIDE; NATRONOBACTERIUM-PHARAONIS; OUTER-MEMBRANE; GENE STRUCTURE; CLEAVAGE SITE; OPSIN GENE; LIPOPROTEIN; ARCHAEBACTERIUM	Halocyanin, a small blue copper protein, was isolated from the haloalkaliphilic archaeon Natronobacterium pharaonis. The NH2 terminus was not accessible to Edman degradation. About 70% of the amino acid sequence was determined by protein sequence analysis. The sequence information of two peptides was used for cloning and sequencing the halocyanin gene (hcy). The open reading frame codes for 489 base pairs, which account for a protein with 163 amino acids and a molecular mass of 17,223 Da. The discrepancy between this value and the molecular mass of 15,456 +/- 1.5 Da for the copper-free protein determined by electrospray mass spectrometry can be explained by a post-translational processing of the gene product. The NH2-terminal sequence of the open reading frame contains a motif that is characteristic for prokaryotic lipoproteins. Assuming a similar processing for halocyanin, Cys at position 25 of the primary transcript would be modified by a diphytanyl (glycerol)diether. Subsequently, the precursor is cleaved by a signal peptidase II-like protease and then acetylated at its NH2-terminal alpha-amino group. These modifications would yield a protein with a calculated molecular mass of 15,456 Ha. A comparison of the primary structure of halocyanin with a number of other blue copper proteins places it into the plastocyanin-related group.	MAX PLANCK INST MOLEK PHYSIOL, D-44139 DORTMUND, GERMANY; MAX PLANCK INST BIOCHEM, D-82152 MARTINSRIED, GERMANY; SCRIPPS RES INST, LA JOLLA, CA 92037 USA	Max Planck Society; Max Planck Society; Scripps Research Institute								ADMAN ET, 1991, ADV PROTEIN CHEM, V42, P145; BERGMAN C, 1977, BIOCHEM BIOPH RES CO, V77, P1052, DOI 10.1016/S0006-291X(77)80084-3; BETLACH M, 1984, NUCLEIC ACIDS RES, V12, P7949, DOI 10.1093/nar/12.20.7949; BLANCK A, 1987, EMBO J, V6, P265, DOI 10.1002/j.1460-2075.1987.tb04749.x; BOUVIER J, 1991, J BACTERIOL, V173, P5523, DOI 10.1128/jb.173.17.5523-5531.1991; BRISCHWEIN M, 1993, BIOCHEMISTRY-US, V32, P13710, DOI 10.1021/bi00212a041; BROWN JW, 1989, CRIT REV MICROBIOL, V16, P287, DOI 10.3109/10408418909105479; BULUWELA L, 1989, NUCLEIC ACIDS RES, V17, P452, DOI 10.1093/nar/17.1.452; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; COLMAN PM, 1978, NATURE, V272, P319, DOI 10.1038/272319a0; DASSARMA S, 1984, P NATL ACAD SCI-BIOL, V81, P125, DOI 10.1073/pnas.81.1.125; DEROSA M, 1986, MICROBIOL REV, V50, P70, DOI 10.1128/MMBR.50.1.70-80.1986; DUFFAUD GD, 1985, CURR TOP MEMBR TRANS, V24, P65; FUJITA VS, 1984, P NATL ACAD SCI-BIOL, V81, P4260, DOI 10.1073/pnas.81.14.4260; GIAM CZ, 1984, EUR J BIOCHEM, V141, P331, DOI 10.1111/j.1432-1033.1984.tb08196.x; GOTSCHLICH EC, 1987, FEMS MICROBIOL LETT, V43, P253; HANTKE K, 1973, EUR J BIOCHEM, V34, P284, DOI 10.1111/j.1432-1033.1973.tb02757.x; HASE T, 1977, FEBS LETT, V77, P308, DOI 10.1016/0014-5793(77)80257-3; HAYASHI S, 1990, J BIOENERG BIOMEMBR, V22, P451, DOI 10.1007/BF00763177; HOLMES DS, 1981, ANAL BIOCHEM, V114, P193, DOI 10.1016/0003-2697(81)90473-5; HOLTKE HJ, 1992, BIOTECHNIQUES, V12, P104; INOUYE S, 1983, EMBO J, V2, P87, DOI 10.1002/j.1460-2075.1983.tb01386.x; LANYI JK, 1990, J BIOL CHEM, V265, P1253; LANYI JK, 1974, BACTERIOL REV, V38, P272, DOI 10.1128/MMBR.38.3.272-290.1974; LODWICK D, 1991, SYST APPL MICROBIOL, V14, P352, DOI 10.1016/S0723-2020(11)80309-7; MATTAR S, 1993, THESIS RUHR U BOCHUM; MCMANUS JD, 1992, J BIOL CHEM, V267, P6531; POLLITT S, 1986, J BIOL CHEM, V261, P1835; REITER WD, 1988, NUCLEIC ACIDS RES, V16, P1, DOI 10.1093/nar/16.1.1; RYDEN L, 1984, COPPER PROTEINS COPP, V1, P157; RYDEN L, 1988, OXIDASES RELATED RED, P349; RYDEN LG, 1993, J MOL EVOL, V36, P41, DOI 10.1007/BF02407305; Sambrook J, 1989, MOL CLONING LABORATO; SCHARF B, 1993, BIOCHEMISTRY-US, V32, P12894, DOI 10.1021/bi00210a043; SCHARF B, 1992, THESIS RUHR U BOCHUM; SOLIMAN GSH, 1982, ZBL BAKT MIK HYG I C, V3, P318, DOI 10.1016/S0721-9571(82)80045-8; SOPPA J, 1994, SYST APPL MICROBIOL, V16, P725; STEINER M, 1983, THESIS LUDWIG MAXIMI; STRITTMATTER W, 1986, J EXP MED, V164, P2038, DOI 10.1084/jem.164.6.2038; SYKES AG, 1991, ADV INORG CHEM, V36, P377, DOI 10.1016/S0898-8838(08)60044-6; THOMM M, 1988, NUCLEIC ACIDS RES, V16, P151, DOI 10.1093/nar/16.1.151; TINDALL BJ, 1984, SYST APPL MICROBIOL, V5, P41; TOBARI J, 1981, BIOCHEM BIOPH RES CO, V101, P502, DOI 10.1016/0006-291X(81)91288-2; TOKUNAGA M, 1982, P NATL ACAD SCI-BIOL, V79, P2255, DOI 10.1073/pnas.79.7.2255; VOGELSANG H, 1983, METHOD ENZYMOL, V97, P226; WEYER KA, 1987, BIOCHEMISTRY-US, V26, P2909, DOI 10.1021/bi00384a036; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576; Zillig W., 1992, ORIGIN EVOLUTION CEL, P163	48	79	85	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					14939	14945						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195126				2022-12-25	WOS:A1994NP73800017
J	VILLALBA, M; BATANERO, E; MONSALVE, RI; DELAPENA, MAG; LAHOZ, C; RODRIGUEZ, R				VILLALBA, M; BATANERO, E; MONSALVE, RI; DELAPENA, MAG; LAHOZ, C; RODRIGUEZ, R			CLONING AND EXPRESSION OF OLE-E-I, THE MAJOR ALLERGEN FROM OLIVE TREE POLLEN - POLYMORPHISM ANALYSIS AND TISSUE-SPECIFICITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								Ole e I, the major allergen from the olive tree (Olea europaea), is one of the main causes of allergy in Mediterranean countries and some areas of North America. The cloning and sequencing of several cDNAs coding for the olive allergen have been achieved. cDNA has been synthesized from total pollen RNA and amplified by using the polymerase chain reaction. The nucleotide sequence data demonstrate the existence of microheterogeneities in at least 37 positions out of the 145 amino acids of Ole e I, thus explaining the high degree of polymorphism exhibited by the natural protein. One of the sequenced cDNAs encoding a full-length isoform was inserted into the plasmid vector pGEX-2T and overexpressed. The recombinant Ole e I has been produced in Escherichia coli as a fusion protein with glutathione S-transferase of Schistosoma japonicum. This chimeric protein was purified by affinity chromatography on a glutathione-Sepharose 4B column and digested with thrombin to release the recombinant allergen. Both the fusion protein and the recombinant Ole e I were recognized in Western blot analysis by rabbit polyclonal and mouse monoclonal antisera raised against native Ole e I as well as by the IgE of olive pollen-sensitive human sera. This indicates that the recombinant production of individual isoforms may be useful for the improvement of reagents to be used in diagnosis and therapy of IgE-mediated disorders. In addition, Ole e I mRNA has been observed to be pollen-specific as shown in a Northern blot analysis.	UNIV COMPLUTENSE MADRID,FAC QUIM,DEPT BIOQUIM & BIOL MOLEC,E-28040 MADRID,SPAIN; FDN JIMENEZ DIAZ,DEPT IMMUNOL,E-28040 MADRID,SPAIN	Complutense University of Madrid			Gonzalez, Manuel A/A-3404-2013; RODRIGUEZ, ROSALIA/K-4993-2014; Villalba, Mayte/K-5365-2014	RODRIGUEZ, ROSALIA/0000-0002-4280-3691; VILLALBA, MAYTE/0000-0002-0042-9953; Monsalve, Rafael/0000-0002-6838-4472					0	119	125	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 27	1994	269	21					15217	15222						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NP738	8195158				2022-12-25	WOS:A1994NP73800055
J	INAGAKI, Y; TRUTER, S; RAMIREZ, F				INAGAKI, Y; TRUTER, S; RAMIREZ, F			TRANSFORMING GROWTH-FACTOR-BETA STIMULATES ALPHA-2(I) COLLAGEN GENE-EXPRESSION THROUGH A CIS-ACTING ELEMENT THAT CONTAINS AN SP1-BINDING SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN-CELLS; TRANSCRIPTIONAL ACTIVATION; EXTRACELLULAR-MATRIX; FUNCTIONAL-ANALYSIS; DNA-SEQUENCES; REPORTER GENE; PROMOTER; FACTOR-BETA-1; INHIBITION; SP1	Transforming growth factor-beta 1 (TGF-beta) is a strong and rapid inducer of several genes coding for extracellular matrix components, such as type I collagen. Fire report here that TGF-beta stimulates transcription of the human alpha 2(I) collagen gene (COL1A2) promoter by increasing the affinity of an Sp1-containing protein complex for its cognate DNA-binding site. Cell transfection experiments mapped the TGF-beta-responsive element (TbRE) of the COL1A2 promoter to a 131 bp region that contains at least two cis-acting elements. Insertion of the TbRE upstream of the thymidine kinase promoter conferred TGF-beta inducibility to the otherwise unresponsive thymidine kinase promoter. Footprinting assays revealed that the TbRE contains two neighboring protein-bound sequences, termed Box 3A and Box B. Within Box 3A is an Sp1 recognition sequence whose structural integrity is required for nuclear protein binding in vitro, and for promoter inducibility in vivo. Gel mobility shift assays documented increased binding to the TbRE of nuclear proteins hom TGF-beta-treated cells compared with those from TGF-beta-untreated fibroblasts. There was, however, no binding increase with Box 3A alone or with an Sp1 oligonucleotide. Thus, the results strongly suggest a functional interaction between Sp1 and other components of the TbRE complex in mediating TGF-beta stimulation of COL1A2 gene expression.	CUNY MT SINAI SCH MED,BROOKDALE CTR MOLEC BIOL,NEW YORK,NY 10029	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR038648, R37AR038648] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR-38648] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BARNARD JA, 1990, BIOCHIM BIOPHYS ACTA, V1032, P79, DOI 10.1016/0304-419X(90)90013-Q; BOAST S, 1990, J BIOL CHEM, V265, P13351; BORDER WA, 1992, J CLIN INVEST, V90, P1, DOI 10.1172/JCI115821; BROEKELMANN TJ, 1991, P NATL ACAD SCI USA, V88, P6642, DOI 10.1073/pnas.88.15.6642; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; COUREY AJ, 1992, TRANSCRIPTIONAL REGU, P743; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DICKSON LA, 1985, NUCLEIC ACIDS RES, V13, P3427, DOI 10.1093/nar/13.10.3427; DIEGELMANN RF, 1988, COLLAGEN BIOCH BIOME, P113; GIDONI D, 1984, NATURE, V312, P409, DOI 10.1038/312409a0; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Hay E.D., 1991, CELL BIOL EXTRACELLU, P419; HIGUCHI RB, 1988, NUCLEIC ACIDS RES, V10, P7351; IGNOTZ RA, 1987, J BIOL CHEM, V262, P6443; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KAHARI VM, 1990, J CLIN INVEST, V86, P1489, DOI 10.1172/JCI114866; KARSENTY G, 1988, J BIOL CHEM, V263, P13909; KERR LD, 1990, CELL, V61, P267, DOI 10.1016/0092-8674(90)90807-Q; KIM SJ, 1989, J BIOL CHEM, V264, P19373; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MORRIS GF, 1986, P NATL ACAD SCI USA, V83, P1; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; NIEDERREITHER K, 1992, J CELL BIOL, V119, P1361, DOI 10.1083/jcb.119.5.1361; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; RITZENTHALER JD, 1993, J BIOL CHEM, V268, P13625; RIZZINO A, 1988, DEV BIOL, V130, P411, DOI 10.1016/0012-1606(88)90337-5; ROBERTS AB, 1990, ANN NY ACAD SCI, V580, P225, DOI 10.1111/j.1749-6632.1990.tb17931.x; ROSSI P, 1988, CELL, V52, P405, DOI 10.1016/S0092-8674(88)80033-3; Sambrook J, 1989, MOL CLONING LABORATO; SARTORELLI V, 1990, GENE DEV, V4, P1811, DOI 10.1101/gad.4.10.1811; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; SLACK JL, 1993, AM J MED GENET, V45, P140, DOI 10.1002/ajmg.1320450203; SPORN MB, 1992, J CELL BIOL, V119, P1017, DOI 10.1083/jcb.119.5.1017; TRUTER S, 1992, J BIOL CHEM, V267, P25389; VANDERREST M, 1991, FASEB J, V5, P2814, DOI 10.1096/fasebj.5.13.1916105	39	273	282	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14828	14834						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	8182090				2022-12-25	WOS:A1994NM06500080
J	POLOTSKAYA, A; ZHAO, YM; LILLY, MB; KRAFT, AS				POLOTSKAYA, A; ZHAO, YM; LILLY, MB; KRAFT, AS			MAPPING THE INTRACYTOPLASMIC REGIONS OF THE ALPHA-GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR-RECEPTOR NECESSARY FOR CELL-GROWTH REGULATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; GM-CSF RECEPTOR; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; BETA-SUBUNIT; EXPRESSION CLONING; MOLECULAR-CLONING; INTERLEUKIN-3; RECONSTITUTION; ERYTHROPOIETIN	The granulocyte-macrophage colony-stimulating factor (GM CSF) receptor is composed of an alpha subunit which binds GM-CSF and a beta subunit, which together form the high affinity receptor. By transfecting the human alpha subunit into murine Ba/F3 cells, we have been able to investigate the role of the short 54-amino acid intracytoplasmic portion (amino acid 346-400) of this subunit in mediating cell growth. We have shown that the intracytoplasmic amino acids 346-382 are necessary for GM CSF-mediated cell growth. In contrast, amino acids 382-400 can be removed without effect. The stable transfection of the human beta subunit into the cell lines containing the mutant alpha subunits did not affect the growth characteristics of these cells. The ability of GMCSF to stimulate cell growth of the Ba/F3 cells alpha subunit transfectants was correlated with the ability of this hormone to translocate protein kinase C to the particulate fraction. In contrast, the ability of GM-CSF addition to increase phosphorylation of the human beta subunit did not correlate with cell growth and required the entire intracytoplasmic domain of the alpha subunit. These results demonstrate an important role for the intracytoplasmic portion of the alpha subunit in mediating both signal transduction and cell cycle commitment stimulated by GM-CSF.	UNIV ALABAMA,DIV HEMATOL ONCOL,BIRMINGHAM,AL 35294; UNIV WASHINGTON,DIV MED ONCOL,SEATTLE,WA 98108; VET ADM MED CTR,SEATTLE,WA 98108	University of Alabama System; University of Alabama Birmingham; University of Washington; University of Washington Seattle; US Department of Veterans Affairs; Veterans Health Administration (VHA)					NATIONAL CANCER INSTITUTE [R55CA045672, R01CA045672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044741] Funding Source: NIH RePORTER; NCI NIH HHS [CA45672] Funding Source: Medline; NIDDK NIH HHS [DK44741] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADUNYAH SE, 1991, J BIOL CHEM, V266, P5670; ANTMAN KS, 1988, NEW ENGL J MED, V319, P593, DOI 10.1056/NEJM198809083191001; ARECES LB, 1993, P NATL ACAD SCI USA, V90, P3963, DOI 10.1073/pnas.90.9.3963; CARROLL MP, 1990, J BIOL CHEM, V265, P19812; CLARK SC, 1987, SCIENCE, V236, P1229, DOI 10.1126/science.3296190; DOMAIN J, 1993, BLOOD, V82, P1445; DURONIO V, 1992, J BIOL CHEM, V267, P21856; EDER M, 1993, EMBO J, V12, P1647, DOI 10.1002/j.1460-2075.1993.tb05810.x; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; JUBINSKY PT, 1993, BLOOD, V81, P587; KANAKURA Y, 1990, BLOOD, V76, P706; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KITAMURA T, 1991, P NATL ACAD SCI USA, V88, P5082, DOI 10.1073/pnas.88.12.5082; LILLY M, 1992, ONCOGENE, V7, P727; LINNEKIN D, 1992, J BIOL CHEM, V267, P23993; MIYAZAWA K, 1991, EXP HEMATOL, V19, P1110; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; NISHIMURA M, 1992, BLOOD, V80, P1045; OKUDA K, 1992, BLOOD, V79, P2880; PARK LS, 1986, J BIOL CHEM, V261, P4177; POLOTSKAYA A, 1993, CELL GROWTH DIFFER, V4, P523; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; SATOH T, 1992, J BIOL CHEM, V267, P2537; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SCHATZMUNDING M, 1992, EUR J BIOCHEM, V204, P705, DOI 10.1111/j.1432-1033.1992.tb16685.x; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SORENSEN PHB, 1989, BLOOD, V73, P406; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; WELHAM MJ, 1992, J IMMUNOL, V149, P1683; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; WONG GG, 1985, SCIENCE, V228, P810, DOI 10.1126/science.3923623	32	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 20	1994	269	20					14607	14613						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NM065	8182067				2022-12-25	WOS:A1994NM06500048
J	KIM, JH; JOHANSEN, FE; ROBERTSON, N; CATINO, JJ; PRYWES, R; KUMAR, CC				KIM, JH; JOHANSEN, FE; ROBERTSON, N; CATINO, JJ; PRYWES, R; KUMAR, CC			SUPPRESSION OF RAS TRANSFORMATION BY SERUM RESPONSE FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							C-FOS PROMOTER; ALPHA-ACTIN PROMOTER; PROTEIN KINASE-C; TRANSCRIPTIONAL ACTIVATION; GENE-EXPRESSION; FIBROBLAST CELLS; ELEMENT PATHWAY; CASEIN KINASE; CDNA; PHOSPHORYLATION	Serum response factor (SRF) is a nuclear transcription factor that binds to the serum response element (SRE) found in the promoter regions of a number of growth factor-inducible genes, as well as muscle-specific genes. The smooth muscle alpha-actin promoter contains two SRE sequences that can bind to SRF. Its expression is repressed in Ras-transformed fibroblast cells and derepressed in revertant cells. In this study, we demonstrate that SRF can activate alpha-actin expression in Ras-transformed cells and that overexpression of SRF in Res-transformed cells can revert their transformed phenotype. The ability of SRF to bind to the SRE was required for this effect, since mutations that inhibit DNA binding abolish SRF's ability to activate alpha-actin expression and suppress transformation by the ras oncogene. These results show that SRF, thought to be involved in stimulation of cell growth through activation of growth factor-inducible genes, can actually have the opposite effect and suggest a novel mechanism for suppression of transformation by Ras.	SCHERING PLOUGH CORP,RES INST,DEPT TUMOR BIOL,KENILWORTH,NJ 07033; COLUMBIA UNIV,DEPT BIOL SCI,NEW YORK,NY 10027	Merck & Company; Schering Plough Corporation; Columbia University			Kim, Jae-Hong/B-2530-2009	Kim, Jae-Hong/0000-0002-8019-0208				BRAVO R, 1980, EXP CELL RES, V127, P249, DOI 10.1016/0014-4827(80)90430-9; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; FERNANDEZ JLR, 1992, J CELL BIOL, V119, P427, DOI 10.1083/jcb.119.2.427; Franza BR, 1984, CANC CELLS, V1, P137; FUKUMOTO Y, 1990, J BIOL CHEM, V265, P774; GAUTHIERROUVIERE C, 1990, EMBO J, V9, P171, DOI 10.1002/j.1460-2075.1990.tb08093.x; GAUTHIERROUVIERE C, 1991, EMBO J, V10, P2921, DOI 10.1002/j.1460-2075.1991.tb07842.x; GIUS D, 1990, MOL CELL BIOL, V10, P4243, DOI 10.1128/MCB.10.8.4243; GLUCK U, 1993, P NATL ACAD SCI USA, V90, P383, DOI 10.1073/pnas.90.2.383; GUTMAN A, 1991, MOL CELL BIOL, V11, P5381, DOI 10.1128/MCB.11.10.5381; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; JAMAL S, 1990, NATURE, V344, P463, DOI 10.1038/344463a0; JOHANSEN FE, 1993, MOL CELL BIOL, V13, P4640, DOI 10.1128/MCB.13.8.4640; KAIBUCHI K, 1989, J BIOL CHEM, V264, P20855; KIM JH, 1993, BIOCHEM BIOPH RES CO, V190, P1115, DOI 10.1006/bbrc.1993.1165; KONIG H, 1989, EMBO J, V8, P2559, DOI 10.1002/j.1460-2075.1989.tb08394.x; KUMAR CC, 1992, CANCER RES, V52, P6877; KUMAR CC, 1992, CELL GROWTH DIFFER, V3, P1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEAVITT J, 1978, J BIOL CHEM, V253, P2497; LEAVITT J, 1986, MOL CELL BIOL, V6, P2721, DOI 10.1128/MCB.6.7.2721; LEE TC, 1992, P NATL ACAD SCI USA, V89, P9814, DOI 10.1073/pnas.89.20.9814; LUCIBELLO FC, 1989, CELL, V59, P999, DOI 10.1016/0092-8674(89)90756-3; MANAK JR, 1993, ONCOGENE, V8, P703; MINTY A, 1986, MOL CELL BIOL, V6, P2125, DOI 10.1128/MCB.6.6.2125; NODA M, 1983, P NATL ACAD SCI-BIOL, V80, P5602, DOI 10.1073/pnas.80.18.5602; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; POLLACK R, 1984, ADV VIRAL ONCOL, V4, P3; PRASAD GL, 1993, P NATL ACAD SCI USA, V90, P7039, DOI 10.1073/pnas.90.15.7039; QURESHI SA, 1991, J BIOL CHEM, V266, P10802; RIVERA V M, 1990, New Biologist, V2, P751; RIVERA VM, 1990, GENE DEV, V4, P255, DOI 10.1101/gad.4.2.255; SASSONECORSI P, 1989, MOL CELL BIOL, V9, P3174, DOI 10.1128/MCB.9.8.3174; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SCHONTHAL A, 1989, ONCOGENE, V4, P629; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; STACEY DW, 1987, MOL CELL BIOL, V7, P523, DOI 10.1128/MCB.7.1.523; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; Treisman R, 1990, Semin Cancer Biol, V1, P47; VARDROMME M, 1992, J CELL BIOL, V118, P1489	40	46	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					13740	13743						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188648				2022-12-25	WOS:A1994NL60600005
J	SANDBRINK, R; MASTERS, CL; BEYREUTHER, K				SANDBRINK, R; MASTERS, CL; BEYREUTHER, K			SIMILAR ALTERNATIVE SPLICING OF A NONHOMOLOGOUS DOMAIN IN BETA-A4-AMYLOID PROTEIN PRECURSOR-LIKE PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID-BETA-PROTEIN; ALZHEIMERS-DISEASE; MESSENGER-RNA; HUMAN-BRAIN; CDNA; EXPRESSION; PEPTIDE; CELLS; GENE; IDENTIFICATION	The beta A4 amyloid protein precursor (APP) is a transmembrane glycoprotein that is the source of the characteristic beta A4-amyloid deposits found in Alzheimer brains. It is expressed in several isoforms generated by alternative splicing of exons 7, 8, and 15, of which the leukocyte derived APP mRNAs lacking exon 15 are significantly expressed in non-neuronal tissues, but not in neurons. The recent finding of APP-like proteins prompted us to analyze alternative splicing of the nearest relative of APP, the amyloid protein precursor homologue (APPH) or amyloid precursor-like protein 2 (APLP2). We were able to show that there are two alternatively spliced inserts, i.e. the Kunitz protease inhibitor domain and a 12-amino-acid-encoding region on the NH2-terminal side of the transmembrane domain, which is part of the region of highest divergence between APP and APLP2/ APPH. Analysis of the tissue specific differential expression of the resulting four APLP2/APPH mRNA isoforms revealed that isoforms lacking the latter, non-homologous insert are highly expressed in non-neuronal tissues, but only weakly in neurons. While this resembles the tissue-specific alternative splicing of exon 15 of APP, expression of the Kunitz protease inhibitor-encoding exon of APLP2/APPH is abundant in both neuronal and non-neuronal tissues and thus differs from APP. Because of the similar regulation of alternative splicing of exon 15 of APP and the described APLP2/APPH insert, and because of structural similarities of the sequences and the predicted secondary structures, a functional homology of alternatively spliced isoforms of APP and APLP2/ APPH is suggested.	UNIV MELBOURNE,DEPT PATHOL,PARKVILLE,VIC 3052,AUSTRALIA	University of Melbourne	SANDBRINK, R (corresponding author), UNIV HEIDELBERG,CTR MOLEC BIOL HEIDELBERG,NEUENHEIMER FELD 282,D-69120 HEIDELBERG,GERMANY.							CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK MJ, 1985, EMBO J, V4, P113, DOI 10.1002/j.1460-2075.1985.tb02324.x; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOLDE TE, 1990, NEURON, V4, P253, DOI 10.1016/0896-6273(90)90100-T; GOLDGABER D, 1987, SCIENCE, V235, P877, DOI 10.1126/science.3810169; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; KANG J, 1990, BIOCHEM BIOPH RES CO, V166, P1192, DOI 10.1016/0006-291X(90)90992-V; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; KONIG G, 1992, J BIOL CHEM, V267, P10804; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MONNING U, 1992, J BIOL CHEM, V267, P23950; NEVE RL, 1988, NEURON, V1, P669, DOI 10.1016/0896-6273(88)90166-3; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANDBRINK R, 1994, J BIOL CHEM, V269, P1510; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; SPRECHER CA, 1993, BIOCHEMISTRY-US, V32, P4481, DOI 10.1021/bi00068a002; TANZI RE, 1987, SCIENCE, V235, P880, DOI 10.1126/science.2949367; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; VIDAL F, 1992, BIOCHEM BIOPH RES CO, V189, P1336, DOI 10.1016/0006-291X(92)90220-F; WASCO W, 1993, NAT GENET, V5, P95, DOI 10.1038/ng0993-95; WASCO W, 1992, P NATL ACAD SCI USA, V89, P10758, DOI 10.1073/pnas.89.22.10758; YAN YC, 1990, P NATL ACAD SCI USA, V87, P2405, DOI 10.1073/pnas.87.7.2405; YOSHIKAI S, 1990, GENE, V87, P257, DOI 10.1016/0378-1119(90)90310-N	28	64	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 13	1994	269	19					14227	14234						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL606	8188705				2022-12-25	WOS:A1994NL60600076
J	REDOWICZ, MJ; MARTIN, B; ZOLKIEWSKI, M; GINSBURG, A; KORN, ED				REDOWICZ, MJ; MARTIN, B; ZOLKIEWSKI, M; GINSBURG, A; KORN, ED			EFFECTS OF PHOSPHORYLATION AND NUCLEOTIDES ON THE CONFORMATION OF MYOSIN-II FROM ACANTHAMOEBA-CASTELLANII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN-ACTIVATED ATPASE; AMINO-ACID-SEQUENCE; HEAVY-CHAIN; ASPARTATE TRANSCARBAMOYLASE; MG2+-ATPASE ACTIVITY; FILAMENT FORMATION; SITES; SUBFRAGMENT-1; TAIL; PURIFICATION	The actin-activated Mg2+-ATPase activity of filamentous Acanthamoeba myosin II is inactivated by phosphorylation of a short non-helical tailpiece at the C-terminal end of each heavy chain even though the catalytic sites are in the N-terminal globular head. Consistent with this effect, phosphorylation at the tip of the tail alters the conformation of the head as shown by a shift in the principal site of cleavage by endoproteinase Arg-C (Ganguly, C., Martin, B., Bubb, M., and Kern, E. D. (1992) J. Biol. Chem. 267, 20905-20908). We now show that the sedimentation coefficient of monomeric phospho-myosin II is 1.3-4.6% lower than that of dephospho-myosin II, which suggests that phosphorylation produces a less compact conformation with a small increase in frictional coefficient. As shown by changes in papain digestion patterns, bound nucleotide also affects the conformation of the head region of monomeric phospho- and dephospho-myosin II, the conformation of the head region of filamentous phospho- and dephospho-myosin II, and the conformation of the C-terminal region of the tail of filamentous phospho-myosin II, Conformational differences between the dephospho- and phospho-forms of myosin II in the presence of nucleotide, as detected by susceptibility to proteolysis, therefore, appear to be greater in filaments than in monomers. These results provide additional evidence for communication between the N-terminal heads and C-terminal tails of Acanthamoeba myosin II.	NHLBI,CELL BIOL LAB,BETHESDA,MD 20892; NHLBI,BIOCHEM LAB,BETHESDA,MD 20892; NIMH,CLIN NEUROSCI BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)			Korn, Edward D/F-9929-2012; Redowicz, Maria Jolanta/AAM-8020-2020; Redowicz, Maria Jolanta/R-4083-2016	Redowicz, Maria Jolanta/0000-0001-5834-471X				ABRAHAMS JP, 1993, EMBO J, V12, P1775, DOI 10.1002/j.1460-2075.1993.tb05825.x; APPLEGATE D, 1984, BIOCHEMISTRY-US, V23, P4779, DOI 10.1021/bi00315a038; ATKINSON MAL, 1987, J BIOL CHEM, V262, P15809; ATKINSON MAL, 1986, J BIOL CHEM, V261, P1844; ATKINSON MAL, 1986, J BIOL CHEM, V261, P3382; AUDEMARD E, 1988, J MUSCLE RES CELL M, V9, P197, DOI 10.1007/BF01773891; COLLINS JH, 1982, J BIOL CHEM, V257, P4529; COLLINS JH, 1980, J BIOL CHEM, V255, P8011; COLLINS JH, 1982, BIOCHEMISTRY-US, V21, P6910, DOI 10.1021/bi00269a045; COLLINS JH, 1981, J BIOL CHEM, V256, P2586; COTE GP, 1984, J BIOL CHEM, V259, P2781; COTE GP, 1981, J BIOL CHEM, V256, P2811; GANGULY C, 1992, J BIOL CHEM, V267, P20905; GANGULY C, 1990, J BIOL CHEM, V265, P9993; GANGULY C, 1992, J BIOL CHEM, V267, P20900; HAMMER JA, 1987, J CELL BIOL, V105, P913, DOI 10.1083/jcb.105.2.913; HOWLETT GJ, 1977, BIOCHEMISTRY-US, V16, P5077, DOI 10.1021/bi00642a021; HOZUMI T, 1983, BIOCHEMISTRY-US, V22, P799, DOI 10.1021/bi00273a014; KUZNICKI J, 1985, J BIOL CHEM, V260, P1967; MARUTA H, 1977, J BIOL CHEM, V252, P6501; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MORNET D, 1985, J MOL BIOL, V183, P479, DOI 10.1016/0022-2836(85)90015-4; MORNET D, 1989, J MUSCLE RES CELL M, V10, P10, DOI 10.1007/BF01739853; MUHLRAD A, 1990, EUR J BIOCHEM, V192, P663, DOI 10.1111/j.1432-1033.1990.tb19273.x; MUHLRAD A, 1981, ARCH BIOCHEM BIOPHYS, V209, P304, DOI 10.1016/0003-9861(81)90285-X; OKAMOTO Y, 1980, J BIOCHEM, V88, P361, DOI 10.1093/oxfordjournals.jbchem.a132981; POLLARD TD, 1978, J BIOL CHEM, V253, P4798; RAU DC, 1993, J BIOL CHEM, V268, P4612; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; ROULET A, 1993, EUR J BIOCHEM, V216, P89, DOI 10.1111/j.1432-1033.1993.tb18120.x; SHRAKE A, 1980, J BIOL CHEM, V255, P581; SINARD JH, 1989, J CELL BIOL, V109, P1537, DOI 10.1083/jcb.109.4.1537; SINARD JH, 1989, J CELL BIOL, V109, P1529, DOI 10.1083/jcb.109.4.1529; UENO H, 1984, J MOL BIOL, V180, P667, DOI 10.1016/0022-2836(84)90032-9; WERNER WE, 1989, J MOL BIOL, V206, P231, DOI 10.1016/0022-2836(89)90536-6; WIJMENGA SS, 1987, J BIOL CHEM, V262, P15803; YAMAMOTO K, 1989, J MOL BIOL, V209, P703, DOI 10.1016/0022-2836(89)90601-3	38	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 6	1994	269	18					13558	13563						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NK184	8175791				2022-12-25	WOS:A1994NK18400074
J	LEUNG, T; HOW, BE; MANSER, E; LIM, L				LEUNG, T; HOW, BE; MANSER, E; LIM, L			CEREBELLAR BETA-2-CHIMAERIN, A GTPASE-ACTIVATING PROTEIN FOR P21 RAS-RELATED RAC IS SPECIFICALLY EXPRESSED IN GRANULE CELLS AND HAS A UNIQUE N-TERMINAL SH2 DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROFIBROMATOSIS TYPE-1; NEURONAL DIFFERENTIATION; MOLECULAR-CLONING; GENE ENCODES; BCR; CHIMAERIN; PRODUCT; RHO	beta-Chimaerin, a 30-kDa GTPase-activating protein (GAP) for the p21 Ras-related Rac, is expressed specifically in late stage spermatocytes (Leung, T., How, B.-E., Manser, E., and Lim, L. (1993) J. Biol. Chem. 268, 3813-3816). Using antibodies raised against beta-chimaerin, we detected a major 46-kDa RacGAP in the rat cerebellum. With beta-chimaerin cDNA as a probe and using polymerase chain reaction, cDNAs from both human and rat cerebellum were isolated. The human and rat cDNAs encoded sequences containing cysteine-rich and GAP domains identical to those of testis beta-chimaerin. The cDNAs also encoded an additional N-terminal SH2 (Src homology 2) domain, probably derived from the beta-chimaerin gene by alternate splicing. This SH2 domain of the predicted 54-kDa protein was strikingly similar to that of alpha 2-chimaerin, including replacement by glutamic acid of the invariant tryptophan present at the start of other SH2 domains. The SH2 domains of alpha- and beta-chimaerin thus represent a subset of SH2 domains. The cerebellar beta-chimaerin (beta 2-) is expressed mainly in granule cells and exhibits postnatal developmental increases. beta 2-Chimaerin was enriched in particulate/synaptosomal fractions. In the mouse weaver mutant lacking mature granule cells, there is a corresponding decrease in beta 2-chimaerin, which could well serve as a marker of granule cell differentiation.	INST NEUROL,LONDON WC1N 1PJ,ENGLAND	University of London; University College London	LEUNG, T (corresponding author), NATL UNIV SINGAPORE,INST MOLEC & CELL BIOL,10 KENT RIDGE CRESCENT,SINGAPORE 0511,SINGAPORE.		Manser, Edward/ABD-2301-2020					ARSHAVSKY VY, 1992, NATURE, V357, P416, DOI 10.1038/357416a0; BERNSTEIN G, 1992, CELL, V70, P411; BIBBINS KB, 1993, MOL CELL BIOL, V13, P7278, DOI 10.1128/MCB.13.12.7278; BOLLAG G, 1991, NATURE, V351, P576, DOI 10.1038/351576a0; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; GAO WQ, 1992, CELL, V68, P841, DOI 10.1016/0092-8674(92)90028-B; GOLUBIC M, 1991, EMBO J, V10, P2897, DOI 10.1002/j.1460-2075.1991.tb07839.x; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HALL C, 1993, MOL CELL BIOL, V13, P4986, DOI 10.1128/MCB.13.8.4986; HALL C, 1990, J MOL BIOL, V211, P11, DOI 10.1016/0022-2836(90)90006-8; HEISTERKAMP N, 1993, J BIOL CHEM, V268, P16903; LEUNG T, 1993, J BIOL CHEM, V268, P3813; LEUNG TKC, 1982, J NEUROCHEM, V39, P1496, DOI 10.1111/j.1471-4159.1982.tb12599.x; LEUNG TKC, 1992, GENOMICS, V12, P74, DOI 10.1016/0888-7543(92)90409-L; LI WJ, 1989, ONCOGENE, V4, P127; LIM HH, 1992, BIOCHEM J, V287, P415, DOI 10.1042/bj2870415; MANSER E, 1992, J BIOL CHEM, V267, P16025; MANSER E, 1993, NATURE, V363, P364, DOI 10.1038/363364a0; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARTIN GA, 1992, SCIENCE, V255, P192, DOI 10.1126/science.1553544; MARU Y, 1991, CELL, V67, P459, DOI 10.1016/0092-8674(91)90521-Y; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; NISHI T, 1991, ONCOGENE, V6, P1555; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SELF AJ, 1993, ONCOGENE, V8, P655; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; SETTLEMAN J, 1992, NATURE, V359, P153, DOI 10.1038/359153a0; TAN EC, 1993, J BIOL CHEM, V268, P27291; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0	33	63	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12888	12892						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175705				2022-12-25	WOS:A1994NH71600079
J	MACH, L; MORT, JS; GLOSSL, J				MACH, L; MORT, JS; GLOSSL, J			NONCOVALENT COMPLEXES BETWEEN THE LYSOSOMAL PROTEINASE CATHEPSIN-B AND ITS PROPEPTIDE ACCOUNT FOR STABLE, EXTRACELLULAR, HIGH-MOLECULAR-MASS FORMS OF THE ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE PROTEINASES; POLYACRYLAMIDE GELS; MAMMARY-GLAND; CYSTATIN-C; SECRETION; INHIBITORS; PROTEOGLYCAN; PURIFICATION; DEGRADATION; FIBROBLASTS	Although the lysosomal cysteine proteinase cathepsin B is alkaline pH-labile, active, stable high molecular mass forms have been reported previously from the culture medium of human and murine mammary tumor explants and the sputum of patients with purulent bronchiectasis. A similar, catalytically active, high molecular mass form of recombinant human cathepsin B produced in yeast has now been found to represent a noncovalent complex between the 30-kDa single chain enzyme and its 6-kDa propeptide formed during autocatalytic maturation of the proenzyme (see accompanying article; Mach, L., Mort, J. S., and Glossl, J. (1994) J. Biol. Chem. 269, 13030-13035). Incubation of the complex under acidic conditions resulted in dissociation and degradation of the inhibitory propeptide leading to increased enzymatic activity, as also observed for partially purified cathepsin B isoenzymes from purulent sputum and mammary tumor explant media. The stabilization of the processed proteinase as a noncovalent complex with its proregion provides an important mechanism whereby extracellular cathepsin B can lie dormant until regional acidification mediates its activity.	AGR UNIV VIENNA,ZENTRUM ANGEW GENET,A-1180 VIENNA,AUSTRIA; SHRINERS HOSP CRIPPLED CHILDREN,JOINT DIS LAB,MONTREAL H3G 1A6,PQ,CANADA; MCGILL UNIV,DEPT SURG,MONTREAL H3A 2T6,PQ,CANADA	University of Natural Resources & Life Sciences, Vienna; McGill University; McGill University			Glössl, Josef/H-8208-2013	Glössl, Josef/0000-0002-5042-8828; Mach, Lukas/0000-0001-9013-5408				ABRAHAMSON M, 1991, BIOCHEM J, V273, P621, DOI 10.1042/bj2730621; ABRAHAMSON M, 1986, J BIOL CHEM, V261, P1282; ACHKAR C, 1990, J BIOL CHEM, V265, P13650; ANASTASI A, 1983, BIOCHEM J, V211, P129, DOI 10.1042/bj2110129; BARRETT AJ, 1987, TRENDS BIOCHEM SCI, V12, P193, DOI 10.1016/0968-0004(87)90092-2; BARRETT AJ, 1973, BIOCHEM J, V131, P809, DOI 10.1042/bj1310809; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; BUCK MR, 1992, BIOCHEM J, V282, P273, DOI 10.1042/bj2820273; BUTTLE DJ, 1992, BIOCHEM J, V287, P657, DOI 10.1042/bj2870657; BUTTLE DJ, 1988, BIOCHEM J, V254, P693, DOI 10.1042/bj2540693; BUTTLE DJ, 1991, BIOCHEM J, V276, P325, DOI 10.1042/bj2760325; DELAISSE JM, 1991, BIOCHEM J, V279, P167, DOI 10.1042/bj2790167; FOX T, 1992, BIOCHEMISTRY-US, V31, P12571, DOI 10.1021/bi00165a005; GUAGLIARDI LE, 1990, NATURE, V343, P133, DOI 10.1038/343133a0; HANEWINKEL H, 1987, J BIOL CHEM, V262, P12351; HASNAIN S, 1992, J BIOL CHEM, V267, P4713; KEPPLER D, 1988, CANCER RES, V48, P6855; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LENARCIC B, 1988, BIOCHEM BIOPH RES CO, V154, P765, DOI 10.1016/0006-291X(88)90206-9; MACH L, 1994, J BIOL CHEM, V269, P13030; MACH L, 1993, BIOCHEM J, V293, P437, DOI 10.1042/bj2930437; MACH L, 1992, BIOCHEM J, V282, P577, DOI 10.1042/bj2820577; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MERRIL CR, 1982, ELECTROPHORESIS, V3, P17, DOI 10.1002/elps.1150030104; MORT JS, 1986, BIOCHEM J, V233, P57, DOI 10.1042/bj2330057; MORT JS, 1984, ARTHRITIS RHEUM, V27, P509, DOI 10.1002/art.1780270505; POOLE AR, 1978, NATURE, V273, P545, DOI 10.1038/273545a0; QIAN F, 1989, CANCER RES, V49, P4870; RECKLIES AD, 1985, BIOCHEM BIOPH RES CO, V131, P402, DOI 10.1016/0006-291X(85)91816-9; RECKLIES AD, 1982, CANCER RES, V42, P1026; RECKLIES AD, 1982, BIOCHEM J, V207, P633, DOI 10.1042/bj2070633; RECKLIES AD, 1985, CANCER RES, V45, P2302; ROWAN AD, 1992, J BIOL CHEM, V267, P15993; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHAW E, 1980, BIOCHEM J, V186, P385, DOI 10.1042/bj1860385; TOOZE J, 1991, EUR J CELL BIOL, V56, P187; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TURK B, 1993, BIOCHEMISTRY-US, V32, P375, DOI 10.1021/bi00052a046	38	56	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					13036	13040						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175724				2022-12-25	WOS:A1994NH71600100
J	SUNG, CK; SANCHEZMARGALET, V; GOLDFINE, ID				SUNG, CK; SANCHEZMARGALET, V; GOLDFINE, ID			ROLE OF P85 SUBUNIT OF PHOSPHATIDYLINOSITOL-3-KINASE AS AN ADAPTER MOLECULE LINKING THE INSULIN-RECEPTOR, P62, AND GTPASE-ACTIVATING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								After insulin stimulation of rat HTC hepatoma cells overexpressing normal human insulin receptors (IR), an antiserum to the p85 subunit of phosphatidylinositol-3-kinase (PIK) (alpha-p85) immunoprecipitated three major tyrosine-phosphorylated proteins: IR, insulin receptor substrate-1 (IRS-l), and a new 62-kDa protein (p62). Studies with antibodies to GTPase activating protein (alpha-GAP) and p62 GAP-associated protein suggested that p62 was the same as (or closely related to) p62 GAP-associated protein. In order to understand how p62 interacts with p85, we employed: 1) antibodies to the p110 subunit of PIK (alpha-p110); and 2) antiserum to IRS-1. To determine which subunit of PIK (p110 or p85) p62 associates with, we first immunoprecipitated insulin-treated cell lysates with alpha-p110 and subsequently immunoprecipitated with alpha-p85 followed by Western blotting analysis with anti-phosphotyrosine antibody (alpha-PY). In response to insulin, most of the tyrosine-phosphorylated p62 was complexed to p85 alone rather than with the PIK heterodimer. Moreover, p62 was absent in alpha-IRS-1 immunoprecipitates. These data suggest that: 1) p62 GAP-associated protein is tyrosine phosphorylated after insulin stimulation of cells; 2) p62 and IRS-1 form separate complexes with p85; 3) p62-GAP complex may be linked to p85 that is not bound to p110; 4) p85 may serve as an adaptor molecule in insulin receptor signaling, interacting with and regulating other intracellular proteins via SH2 domains.			SUNG, CK (corresponding author), UNIV CALIF SAN FRANCISCO, MT ZION MED CTR, DEPT MED, DIV DIABET & ENDOCRINE RES, 1600 DIVISADERO ST, SAN FRANCISCO, CA 94120 USA.		Sánchez-Margalet, Victor/AAB-9986-2021	Sánchez-Margalet, Victor/0000-0001-8638-8680	NIDDK NIH HHS [DK44834] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044834] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1993, J BIOL CHEM, V268, P9478; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; ENDEMANN G, 1990, J BIOL CHEM, V265, P396; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FEIG LA, 1993, SCIENCE, V260, P767, DOI 10.1126/science.8484117; GOLDFINE ID, 1987, ENDOCR REV, V8, P235, DOI 10.1210/edrv-8-3-235; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; KAHN CR, 1993, 53RD BANT LECT ANN A; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KELLY KL, 1993, J BIOL CHEM, V268, P4391; KORN LJ, 1987, SCIENCE, V236, P840, DOI 10.1126/science.3554510; KOZMA L, 1993, P NATL ACAD SCI USA, V90, P4460, DOI 10.1073/pnas.90.10.4460; LAVAN BE, 1993, J BIOL CHEM, V268, P5921; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; MARENGERE LEM, 1992, J BIOL CHEM, V267, P22779; MARX J, 1992, SCIENCE, V257, P484, DOI 10.1126/science.1636083; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MEDEMA RH, 1992, MOL CELL BIOL, V12, P3425, DOI 10.1128/MCB.12.8.3425; MYERS MG, 1993, DIABETES, V42, P643, DOI 10.2337/diabetes.42.5.643; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PORRAS A, 1992, J BIOL CHEM, V267, P21124; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUNG CK, 1992, BIOCHEM BIOPH RES CO, V189, P1024, DOI 10.1016/0006-291X(92)92306-I; SUNG CK, 1989, J BIOL CHEM, V264, P18951; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WIGLER MH, 1990, NATURE, V346, P696, DOI 10.1038/346696a0; WONG G, 1992, CELL, V69, P551, DOI 10.1016/0092-8674(92)90455-L; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YONEZAWA K, 1992, J BIOL CHEM, V267, P440; ZHANG B, 1992, J BIOL CHEM, V267, P18320; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	41	93	93	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 29	1994	269	17					12503	12507						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NH716	8175658				2022-12-25	WOS:A1994NH71600023
